<DOC>
<DOCNO>WT23-B18-1</DOCNO>
<DOCOLDNO>IA013-000139-B020-201</DOCOLDNO>
<DOCHDR>
http://www.thoracic.org:80/ca1.html 206.138.195.144 19970217070241 text/html 5864
HTTP/1.0 200 OK
Date: Monday, 17-Feb-97 06:57:56 GMT
Server: NCSA/1.3
MIME-version: 1.0
Content-type: text/html
Last-modified: Thursday, 13-Feb-97 14:55:47 GMT
Content-length: 5682
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//SQ//DTD HTML 2.0 HoTMetaL + extensions//EN">
<HTML>
<HEAD>
<TITLE>American Thoracic Society - State Thoracic Societies: California</TITLE></HEAD>
<BODY BACKGROUND="images/back.jpg">
<CENTER><IMG ALIGN="LEFT" SRC="images/smlogo.gif"><BR><IMG
SRC="images/cts1.gif" ALIGN="BOTTOM"></CENTER>
<CENTER></CENTER>
<HR SIZE="5" NOSHADE="NOSHADE" WIDTH="100%">
<P></P>
<CENTER>
<TABLE BORDER="2">
<TR ALIGN="CENTER" VALIGN="MIDDLE">
<TD><SMALL><A HREF="ca.html#top">BACK TO CTS MENU</A></SMALL></TD></TR></TABLE></CENTER>
<P></P>
<HR>
<CENTER>
<H2><A NAME="cme">CME Programs</A></H2></CENTER>
<CENTER>
<H2>VOLUNTARY EDUCATION AND SITE VISIT CONSULTATION PROGRAM FOR PULMONARY
FUNCTION LABORATORIES</H2></CENTER>
<BLOCKQUOTE>
<P>The California Thoracic Society (CTS) is pleased to offer an educational
program for hospital-based pulmonary function laboratories in this state. </P>
<P><B>THE GOAL:</B>  The major goal of this program is to enhance patient care
via quality control for measurements of spirometry, flow-volume loops, and
diffusing capacity.  Recognizing the expanding role of federal regulatory
agencies in monitoring quality control aspects of health care, the CTS is
offering this voluntary program now -- both to help some programs in upgrading
existing quality control measures and to provide recognition for those programs
which are already performing satisfactorily.</P>
<P><B>THE PROGRAM:</B>  Enrollment in the program simply requires a completed
application form including the authorized administrator's approval, and payment
of the fee. When we receive your enrollment, we will send you a Syllabus
containing reprints of key articles, which form the basis of currently accepted
procedures for quality control.  You will also receive a questionnaire to advise
us regarding specific quality control measures for each test.  Once you have had
a chance to review these materials and make any desired changes in your
procedures, notify us to schedule your laboratory for the PFT Site Visit. The
Visit is conducted by a team of two experts designated by the CTS and it is
about four hours long.  The primary goal of the Site Visit, is to review your
procedures and suggest ways to improve them. A written confidential report is
provided.  CME, RCP, and/or BRN credits are awarded to those involved in full
site visit participation. CTS provides a frameable certificate of completion,
after receiving your written response to the reported recommendations.</P>
<P><B>FEE:</B>  Enrollment in the full program is $450 (plus air fare when
needed in exceptional circumstances).</P>
<P><B>REGISTER FOR THE PULMONARY FUNCTION TESTING EDUCATION AND SITE VISIT
CONSULTATION PROGRAM BY PRINTING AND RETURNING THIS COMPLETED FORM WITH YOUR
CHECK TO:</B></P>
<CENTER>
<H2> Colleen Richardson, CAE<BR> California Thoracic Society<BR>202 Fashion
Lane, Ste. 219<BR>Tustin, California 92780<BR>Phone: (714) 730-1944<BR>Fax:
(714) 730-4057<BR>E-mail: <A HREF="mailto:ctslung@aol.com">ctslung@aol.com</A></H2></CENTER></BLOCKQUOTE>
<BLOCKQUOTE>
<P><B>Name:</B> __________________________________________________________</P>
<P><B>Telephone:</B> (___)_____-_______</P>
<P><B>Fax: </B> (___)_____-_______</P>
<P><B>Address:</B>__________________________________________________________</P>
<P><B>Zip:</B>__________________________________________________________</P>
<P><B>Authorizing Administrator's Signature:</B>__________________________________________________________</P></BLOCKQUOTE>
<P></P>
<HR SIZE="4" WIDTH="80%">
<CENTER><A HREF="about.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/about.gif" ALT="About Society"></A>
<A HREF="ssg.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/ss.gif" ALT="Society Structure"></A>
<A HREF="calendar.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/calendar.gif" ALT="ATS Calendar"></A>
<A HREF="gpi.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/pi.gif" ALT="Gen Public Info"></A>
<A HREF="ms.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/memserv.gif" ALT="Memb Serv"></A>
<BR>
<A HREF="pub.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/pubs.gif" ALT="Publications"></A>
<A HREF="press.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/press.gif" ALT="Press"></A>
<A HREF="index.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/home.gif" ALT="Home Page"></A>
<A HREF="search.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/search.gif" ALT="Search"></A>
<A HREF="assemb.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/assemb.gif" ALT="Assemblies"></A>
<A HREF="research.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/research.gif" ALT="Research"></A>
<BR>
<A HREF="mep.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/meded.gif" ALT="Med Education"></A>
<A HREF="wr.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/wr.gif" ALT="Wash Report"></A>
<A HREF="ic.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/ic.gif" ALT="Int'l Conference"></A>
<A HREF="source.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/link.gif" ALT="Web Links"></A>
<A HREF="store.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/store.gif" ALT="Store"></A> 
<A HREF="sig.html"><IMG SRC="images/special.gif" ALT="Special" HSPACE=1 VSPACE=1 BORDER=0 HEIGHT=35 WIDTH=84></A>
</CENTER>
<HR SIZE="4" WIDTH="80%">
<CENTER><FONT SIZE="+2"><B><I>American Thoracic Society</I></B></FONT><BR>
1740 Broadway<BR> New York, NY 10019<BR> VOICE:  212-315-8700<BR> Copyright &copy;
1996 American Lung Association.<BR> The American Thoracic  Society is the
medical section <BR>of the American Lung Association.<BR> 
</CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-2</DOCNO>
<DOCOLDNO>IA013-000139-B020-229</DOCOLDNO>
<DOCHDR>
http://www.thoracic.org:80/ca2.html 206.138.195.144 19970217070249 text/html 8836
HTTP/1.0 200 OK
Date: Monday, 17-Feb-97 06:58:07 GMT
Server: NCSA/1.3
MIME-version: 1.0
Content-type: text/html
Last-modified: Thursday, 13-Feb-97 14:56:06 GMT
Content-length: 8654
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//SQ//DTD HTML 2.0 HoTMetaL + extensions//EN">
<HTML>
<HEAD>
<TITLE>American Thoracic Society - State Thoracic Societies: California</TITLE></HEAD>
<BODY BACKGROUND="images/back.jpg">
<CENTER><IMG ALIGN="LEFT" SRC="images/smlogo.gif"><BR><IMG
SRC="images/cts1.gif" ALIGN="BOTTOM"></CENTER>
<CENTER></CENTER>
<HR SIZE="5" NOSHADE="NOSHADE" WIDTH="100%">
<P></P>
<CENTER>
<TABLE BORDER="2">
<TR ALIGN="CENTER" VALIGN="MIDDLE">
<TD><SMALL><A HREF="ca.html#top">BACK TO CTS MENU</A></SMALL></TD></TR></TABLE></CENTER>
<P></P>
<HR>
<CENTER>
<H2>RECENT MEMBERSHIP SERVICES FROM CTS </H2></CENTER>
<P><B><FONT SIZE="+1">ADVANCING PATIENT ACCESS TO CARE, INCLUDING PULMONARY
SPECIALTY CARE IN THE MANAGED CARE ENVIRONMENT: </FONT></B></P>
<UL>
<LI> CTS successfully supported legislation which prohibits HMOs from
establishing financial incentive arrangements that inappropriately limit or deny
medical care.</LI>
<LI> CTS critiqued pulmonary care guidelines used by managed care providers and
recommended  changes.
</LI>
<LI> CTS endorsed three resolutions to CMA's Annual Meeting along with the
California Access to  Specialty Care Coalition. We were successful in gaining
CMA support for: 
</LI></UL>
<BLOCKQUOTE>
<UL>
<LI>	preserving direct patient access to a physician of his/her choice, </LI>
<LI> developing and supporting legislation which would enhance patient choice
of provider and continuity of care,</LI>
<LI> requiring managed care entities to provide contracting physicians with the
fee schedule for their services, upon request.</LI></UL></BLOCKQUOTE>
<P></P>
<UL>
<LI>CTS encouraged Medicare/CMRI use of pneumococcal pneumonia vaccine prior to
discharge  of patients hospitalized for pneumonia. </LI>
<LI> CTS continues to foster public policy improvements to achieve access to
health care for Californians to provide universality, quality assessment and
assurance, cost containment,  comprehensiveness of benefits, equitable and
progressive financing, adequacy of choice, and accountable administration.
</LI>
<LI> CTS offered specific pulmonary input in support of Medicare, GME,
Medicaid, and medical  malpractice reforms.
</LI>
<LI> CTS secured the pulmonary physicians' right to run ABG laboratories.</LI>
<LI> CTS backed the Medi-Cal payment of Respiratory Care Practitioners as home
care providers. 
</LI>
<LI> CTS has a representative to the Medicare Carrier Advisory Committee. We
clarified the  appropriate Alpha-1 antiprotease inhibitor indication for the
northern Local Medicare Medical  Review Policy.
</LI>
<LI> CTS has lobbyists in Sacramento working full time to promote lung health
issues.
</LI></UL>
<P><B><FONT SIZE="+1">FOSTERING RESEARCH: </FONT></B></P>
<UL>
<LI> CTS advocated increased federal allocations for CDC, NIH and NIOSH
research grants and  continued support for medical education.
</LI>
<LI> CTS promoted Lung Volume Reduction Surgery limitations by the federal
Agency for Health Care  Policy &amp; Research until it is evaluated in the
context of COPD management including  rehabilitation. 
</LI>
<LI> CTS supports the ALA of California Research Program (ALACRP) through
advocacy, peer  review, and donating the CTS surplus each fiscal year. This
program awards grants to support  lung disease research.
</LI></UL>
<P><B><FONT SIZE="+1">PROMOTING STAUNCH TOBACCO CONTROLS: </FONT></B></P>
<UL>
<LI> CTS advocates FDA control for the sale, distribution and marketing of
tobacco products.
</LI>
<LI>CTS played a major role in restoring Prop 99 funds to education and
research which the  governor had been misusing by:
</LI></UL>
<BLOCKQUOTE>
<UL>
<LI>authoring and successfully negotiating the 1996 CMA House of Delegates
Resolution,</LI>
<LI>contributing to and partnering with the Coalition to Save Prop 99, raising
awareness and   lobbying for the necessary public and Capitol support.</LI></UL></BLOCKQUOTE>
<P><B><FONT SIZE="+1">PATIENT AND PROFESSIONAL SERVICES: </FONT></B></P>
<UL>
<LI> CTS conducted its annual scientific conference with CME-BRN credits in
January 1996 with  topics including management of end-stage lung disease, sleep
disorders, lung transplantation  and tuberculosis.
</LI>
<LI> CTS sponsored 12 regional CME-BRN seminars, organized and promoted a TB
speaker's bureau  for ALA Affiliate/Branch access, and provides a Calendar of
Pulmonary and Critical Care Events.
</LI>
<LI> CTS continues to prompt the DoHS and DMV to better define &quot;sleepiness&quot;
for loss of  consciousness reporting regulations.
</LI>
<LI> CTS offers a clearinghouse for professional guidelines and scientifically
approved patient literature.</LI>
<LI> CTS responded to over 200 specific requests from medical professionals and
patients related  to specific aspects of lung disease.
</LI>
<LI> CTS members receive two issues of <I>CTS News </I>yearly with the latest
information on lung health,  along with four <I>President's Memos</I>.
</LI>
<LI> Nurse members prepare a semiannual newsletter <I>CTS Pulmonary Nursing
Airways</I>.</LI>
<LI> CTS prepared and distributed three posters, public service print ads, and
patient education  prescription pads featuring the toll free 800 number for easy
connection to anyone's ALA.  These items efficiently provide accurate patient
information and peer support.  
</LI>
<LI> CTS published and distributed the 1996 Membership Directory, which
enhances networking and  referral possibilities.
</LI>
<LI> CTS pioneered the pulmonary proficiency testing programs for ABG and
cooximetry, and has  CLIA approval for the service.</LI>
<LI> CTS initiated the PFT Site Visit Consultation Program, which 30 labs have
experienced and  reported to be a highly productive encounter.
</LI>
<LI> CTS is developing natural disaster fact sheets for lung care.
</LI>
<LI> CTS has initiated a member survey regarding opiates and hospice use and a
CTS statement on  hospice care for lung patients.
</LI>
<LI> CTS has a web site and an e-mail address (<A HREF="mailto:ctslung@aol.com">CTSLUNG@AOL.COM</A>)
for easy communication with members. 
</LI>
<LI> CTS developed a jump list for lung care resources on the Internet.
</LI></UL>
<CENTER>
<P><B><FONT SIZE="+1" COLOR="#FF0000">CTS STANDS READY TO RESPOND TO OUR
MEMBERS NEEDS.  WE ENCOURAGE COMMENTS, SUGGESTIONS, REQUESTS, AND OFFERS TO
SHARE INFORMATION AND BECOME INVOLVED!</FONT></B></P>
<P>REACH CTS AT:  <A HREF="mailto:ctslung@aol.com">CTSLUNG@AOL.COM</A><BR> 
FAX:  714/730-4057<BR>  VOICE: 714/730-1944</P></CENTER>
<P></P>
<HR SIZE="4" WIDTH="80%">
<CENTER><A HREF="about.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/about.gif" ALT="About Society"></A>
<A HREF="ssg.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/ss.gif" ALT="Society Structure"></A>
<A HREF="calendar.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/calendar.gif" ALT="ATS Calendar"></A>
<A HREF="gpi.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/pi.gif" ALT="Gen Public Info"></A>
<A HREF="ms.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/memserv.gif" ALT="Memb Serv"></A>
<BR>
<A HREF="pub.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/pubs.gif" ALT="Publications"></A>
<A HREF="press.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/press.gif" ALT="Press"></A>
<A HREF="index.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/home.gif" ALT="Home Page"></A>
<A HREF="search.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/search.gif" ALT="Search"></A>
<A HREF="assemb.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/assemb.gif" ALT="Assemblies"></A>
<A HREF="research.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/research.gif" ALT="Research"></A>
<BR>
<A HREF="mep.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/meded.gif" ALT="Med Education"></A>
<A HREF="wr.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/wr.gif" ALT="Wash Report"></A>
<A HREF="ic.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/ic.gif" ALT="Int'l Conference"></A>
<A HREF="source.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/link.gif" ALT="Web Links"></A>
<A HREF="store.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/store.gif" ALT="Store"></A> 
<A HREF="sig.html"><IMG SRC="images/special.gif" ALT="Special" HSPACE=1 VSPACE=1 BORDER=0 HEIGHT=35 WIDTH=84></A>
</CENTER>
<HR SIZE="4" WIDTH="80%">
<CENTER><FONT SIZE="+2"><B><I>American Thoracic Society</I></B></FONT><BR>
1740 Broadway<BR> New York, NY 10019<BR> VOICE:  212-315-8700<BR> Copyright &copy;
1996 American Lung Association.<BR> The American Thoracic  Society is the
medical section <BR>of the American Lung Association.<BR> 
</CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-3</DOCNO>
<DOCOLDNO>IA013-000139-B020-269</DOCOLDNO>
<DOCHDR>
http://www.thoracic.org:80/ca3.html 206.138.195.144 19970217070301 text/html 12137
HTTP/1.0 200 OK
Date: Monday, 17-Feb-97 06:58:15 GMT
Server: NCSA/1.3
MIME-version: 1.0
Content-type: text/html
Last-modified: Thursday, 13-Feb-97 14:56:34 GMT
Content-length: 11954
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//SQ//DTD HTML 2.0 HoTMetaL + extensions//EN">
<HTML>
<HEAD>
<TITLE>American Thoracic Society - State Thoracic Societies: California</TITLE></HEAD>
<BODY BACKGROUND="images/back.jpg">
<CENTER><IMG ALIGN="LEFT" SRC="images/smlogo.gif"><BR><IMG
SRC="images/cts1.gif" ALIGN="BOTTOM"></CENTER>
<CENTER></CENTER>
<HR SIZE="5" NOSHADE="NOSHADE" WIDTH="100%">
<P></P>
<CENTER>
<TABLE BORDER="2">
<TR ALIGN="CENTER" VALIGN="MIDDLE">
<TD><SMALL><A HREF="ca.html">BACK TO CTS MENU</A></SMALL></TD></TR></TABLE></CENTER>
<P></P>
<HR>
<CENTER>
<H1>CURRENT STATEMENTS</H1></CENTER>
<CENTER>
<H4>PRINT THIS FORM AND<BR>FAX YOUR REQUEST TO CTS, <BR>FAX : (714) 730-4057.</H4></CENTER>
<CENTER>
<TABLE BORDER="2" ALIGN="CENTER">
<TR>
<TD COLSPAN="3"><FONT SIZE="-1">NAME:</FONT>___________________________________________________________</TD></TR>
<TR>
<TD COLSPAN="3"><FONT SIZE="-1">ADDRESS:</FONT>________________________________________________________</TD></TR>
<TR>
<TD><FONT SIZE="-1">CITY:</FONT>_______________________</TD>
<TD><FONT SIZE="-1">STATE:</FONT>__________</TD>
<TD><FONT SIZE="-1">ZIP:</FONT>__________</TD></TR></TABLE></CENTER>
<P><B>                                                                        
                                                                                
                                                            </B></P>
<CENTER>
<TABLE BORDER="2" ALIGN="CENTER">
<TR>
<TD COLSPAN="2" ALIGN="CENTER"><B><FONT SIZE="+1">PROFESSIONAL ITEMS</FONT></B></TD></TR>
<TR>
<TD>
<TABLE BORDER="1" ALIGN="LEFT">
<TR>
<TD><FONT COLOR="#FFFFFF">__</FONT></TD></TR></TABLE></TD>
<TD><FONT SIZE="-1"> Blood and Blood Product Transfusions and Fiberoptic
Bronchoscopy (1991; 1996)</FONT></TD></TR>
<TR>
<TD>
<TABLE BORDER="1" ALIGN="LEFT">
<TR>
<TD><FONT COLOR="#FFFFFF">__</FONT></TD></TR></TABLE></TD>
<TD><FONT SIZE="-1">California Lung Health:  1995 Selected Statistics</FONT></TD></TR>
<TR>
<TD>
<TABLE BORDER="1" ALIGN="LEFT">
<TR>
<TD><FONT COLOR="#FFFFFF">__</FONT></TD></TR></TABLE></TD>
<TD><FONT SIZE="-1">Clinical Privileges for Mechanical Ventilator Management
(1993; 1996)</FONT></TD></TR>
<TR>
<TD>
<TABLE BORDER="1" ALIGN="LEFT">
<TR>
<TD><FONT COLOR="#FFFFFF">__</FONT></TD></TR></TABLE></TD>
<TD><FONT SIZE="-1">Criteria for Pulmonary Related DRG Categories (1985; 1996)</FONT></TD></TR>
<TR>
<TD>
<TABLE BORDER="1" ALIGN="LEFT">
<TR>
<TD><FONT COLOR="#FFFFFF">__</FONT></TD></TR></TABLE></TD>
<TD><FONT SIZE="-1">Extracorporeal Membrane Oxygenation (ECMO) for the
Treatment of Reversible, Life-Threatening Cardiac and Respiratory Failure (1991;
1996)</FONT></TD></TR>
<TR>
<TD>
<TABLE BORDER="1" ALIGN="LEFT">
<TR>
<TD><FONT COLOR="#FFFFFF">__</FONT></TD></TR></TABLE></TD>
<TD><FONT SIZE="-1">&quot;A Guide to Occupational Respiratory Disease in
California&quot; (1993) $6.00 plus tax for CTS or CMA members, order from CMA,
PO Box 7690, San Francisco, CA 94120-7690</FONT></TD></TR>
<TR>
<TD>
<TABLE BORDER="1" ALIGN="LEFT">
<TR>
<TD><FONT COLOR="#FFFFFF">__</FONT></TD></TR></TABLE></TD>
<TD><FONT SIZE="-1">Indications for Laser Bronchoscopy  (1991; 1996)
</FONT></TD></TR>
<TR>
<TD>
<TABLE BORDER="1" ALIGN="LEFT">
<TR>
<TD><FONT COLOR="#FFFFFF">__</FONT></TD></TR></TABLE></TD>
<TD><FONT SIZE="-1">Laser Surgery for Snoring (1996)</FONT></TD></TR>
<TR>
<TD>
<TABLE BORDER="1" ALIGN="LEFT">
<TR>
<TD><FONT COLOR="#FFFFFF">__</FONT></TD></TR></TABLE></TD>
<TD><FONT SIZE="-1">Management of Asthma During Pregnancy (1991)</FONT></TD></TR>
<TR>
<TD>
<TABLE BORDER="1" ALIGN="LEFT">
<TR>
<TD><FONT COLOR="#FFFFFF">__</FONT></TD></TR></TABLE></TD>
<TD><FONT SIZE="-1">Medical Director for Respiratory Care at Alternative (out
of hospital) Sites (1990; 1996)</FONT></TD></TR>
<TR>
<TD>
<TABLE BORDER="1" ALIGN="LEFT">
<TR>
<TD><FONT COLOR="#FFFFFF">__</FONT></TD></TR></TABLE></TD>
<TD><FONT SIZE="-1">Medical Director of Respiratory Care Services and
Pulmonary Function Labs Responsibilities (1985; 1996)</FONT></TD></TR>
<TR>
<TD>
<TABLE BORDER="1" ALIGN="LEFT">
<TR>
<TD><FONT COLOR="#FFFFFF">__</FONT></TD></TR></TABLE></TD>
<TD><FONT SIZE="-1">Out-of-Hospital Ventilator Care (1985; 1996)</FONT>
</TD></TR>
<TR>
<TD>
<TABLE BORDER="1" ALIGN="LEFT">
<TR>
<TD><FONT COLOR="#FFFFFF">__</FONT></TD></TR></TABLE></TD>
<TD><FONT SIZE="-1">Patient Information &quot;Prescription Pads&quot; (1994)</FONT>
</TD></TR>
<TR>
<TD>
<TABLE BORDER="1" ALIGN="LEFT">
<TR>
<TD><FONT COLOR="#FFFFFF">__</FONT></TD></TR></TABLE></TD>
<TD><FONT SIZE="-1">Nicotine Replacement Treatment Strategies to Enhance
Smoking Cessation (1997)</FONT></TD></TR>
<TR>
<TD>
<TABLE BORDER="1" ALIGN="LEFT">
<TR>
<TD><FONT COLOR="#FFFFFF">__</FONT></TD></TR></TABLE></TD>
<TD><FONT SIZE="-1">Principles of Pulmonary Rehabilitation (1991; 1996)
</FONT></TD></TR>
<TR>
<TD>
<TABLE BORDER="1" ALIGN="LEFT">
<TR>
<TD><FONT COLOR="#FFFFFF">__</FONT></TD></TR></TABLE></TD>
<TD><FONT SIZE="-1">Pulmonary Physiology Laboratory Personnel Qualifications
(1987; 1996)
</FONT></TD></TR>
<TR>
<TD>
<TABLE BORDER="1" ALIGN="LEFT">
<TR>
<TD><FONT COLOR="#FFFFFF">__</FONT></TD></TR></TABLE></TD>
<TD><FONT SIZE="-1">Pulmonary Rehabilitation Coordinator: Pulmonary Clinical
Nurse Specialist (1992; 1996)</FONT>
</TD></TR>
<TR>
<TD>
<TABLE BORDER="1" ALIGN="LEFT">
<TR>
<TD><FONT COLOR="#FFFFFF">__</FONT></TD></TR></TABLE></TD>
<TD><FONT SIZE="-1">Quality Assurance for Home Oxygen Therapy (1985; 1996)</FONT>
</TD></TR>
<TR>
<TD>
<TABLE BORDER="1" ALIGN="LEFT">
<TR>
<TD><FONT COLOR="#FFFFFF">__</FONT></TD></TR></TABLE></TD>
<TD><FONT SIZE="-1">Responsibilities of the Medical Director of the Pulmonary
Physiology Lab(1983; 1996)</FONT></TD></TR>
<TR>
<TD>
<TABLE BORDER="1" ALIGN="LEFT">
<TR>
<TD><FONT COLOR="#FFFFFF">__</FONT></TD></TR></TABLE></TD>
<TD><FONT SIZE="-1">Thoracoscopy (1993; 1996)</FONT></TD></TR>
<TR>
<TD>
<TABLE BORDER="1" ALIGN="LEFT">
<TR>
<TD><FONT COLOR="#FFFFFF">__</FONT></TD></TR></TABLE></TD>
<TD><FONT SIZE="-1">Travel at High Altitude Information for Physicians (1989)</FONT></TD></TR>
<TR>
<TD>
<TABLE BORDER="1" ALIGN="LEFT">
<TR>
<TD><FONT COLOR="#FFFFFF">__</FONT></TD></TR></TABLE></TD>
<TD><FONT SIZE="-1">Using Narcotics to Relieve Dyspnea (1993; 1996)</FONT>
</TD></TR>
<TR>
<TD COLSPAN="2" ALIGN="CENTER"><FONT SIZE="+1"><B>POSTERS</B></FONT></TD></TR>
<TR>
<TD>
<TABLE BORDER="1" ALIGN="LEFT">
<TR>
<TD><FONT COLOR="#FFFFFF">__</FONT></TD></TR></TABLE></TD>
<TD><FONT SIZE="-1"> Lungs Are For Life (1994)</FONT></TD></TR>
<TR>
<TD>
<TABLE BORDER="1" ALIGN="LEFT">
<TR>
<TD><FONT COLOR="#FFFFFF">__</FONT></TD></TR></TABLE></TD>
<TD><FONT SIZE="-1">When You Can't Breathe (Clouds) (1995)
</FONT></TD></TR>
<TR>
<TD>
<TABLE BORDER="1" ALIGN="LEFT">
<TR>
<TD><FONT COLOR="#FFFFFF">__</FONT></TD></TR></TABLE></TD>
<TD><FONT SIZE="-1">When You Can't Breathe (Clouds and Border) (1995)</FONT></TD></TR>
<TR>
<TD COLSPAN="2" ALIGN="CENTER"><B><FONT SIZE="+1">LUNG PREVENTION AND PATIENT
ITEMS</FONT><BR></B> <FONT SIZE="-1">(QUANTITIES OF THESE ITEMS ARE AVAILABLE
FOR<BR>DISTRIBUTION FROM YOUR LOCAL AMERICAN LUNG ASSOCIATION</FONT></TD></TR>
<TR>
<TD>
<TABLE BORDER="1" ALIGN="LEFT">
<TR>
<TD><FONT COLOR="#FFFFFF">__</FONT></TD></TR></TABLE></TD>
<TD><FONT SIZE="-1">Air Pollution: A Cloud Over Your Child's Health (1992)
</FONT></TD></TR>
<TR>
<TD>
<TABLE BORDER="1" ALIGN="LEFT">
<TR>
<TD><FONT COLOR="#FFFFFF">__</FONT></TD></TR></TABLE></TD>
<TD><FONT SIZE="-1">Beginning an Exercise Program: Guidelines for Adults with
Asthma (1995)</FONT>
</TD></TR>
<TR>
<TD>
<TABLE BORDER="1" ALIGN="LEFT">
<TR>
<TD><FONT COLOR="#FFFFFF">__</FONT></TD></TR></TABLE></TD>
<TD><FONT SIZE="-1">The Choice is Yours (1994)
</FONT></TD></TR>
<TR>
<TD>
<TABLE BORDER="1" ALIGN="LEFT">
<TR>
<TD><FONT COLOR="#FFFFFF">__</FONT></TD></TR></TABLE></TD>
<TD><FONT SIZE="-1"> Durable Power of Attorney for Health Care (1990)
</FONT></TD></TR>
<TR>
<TD>
<TABLE BORDER="1" ALIGN="LEFT">
<TR>
<TD><FONT COLOR="#FFFFFF">__</FONT></TD></TR></TABLE></TD>
<TD><FONT SIZE="-1">Fiberoptic Bronchoscopy Information Guide (1995)
</FONT></TD></TR>
<TR>
<TD>
<TABLE BORDER="1" ALIGN="LEFT">
<TR>
<TD><FONT COLOR="#FFFFFF">__</FONT></TD></TR></TABLE></TD>
<TD><FONT SIZE="-1">Fire Disaster: Planning for Lung Health (1996)</FONT></TD></TR>
<TR>
<TD>
<TABLE BORDER="1" ALIGN="LEFT">
<TR>
<TD><FONT COLOR="#FFFFFF">__</FONT></TD></TR></TABLE></TD>
<TD><FONT SIZE="-1">How to Use Inhalers - For Delivering Asthma Medications
(1985; 1992)</FONT>
</TD></TR>
<TR>
<TD>
<TABLE BORDER="1" ALIGN="LEFT">
<TR>
<TD><FONT COLOR="#FFFFFF">__</FONT></TD></TR></TABLE></TD>
<TD><FONT SIZE="-1">Pneumothorax Fact Sheet (1987; 1992)
</FONT></TD></TR>
<TR>
<TD>
<TABLE BORDER="1" ALIGN="LEFT">
<TR>
<TD><FONT COLOR="#FFFFFF">__</FONT></TD></TR></TABLE></TD>
<TD><FONT SIZE="-1">Pulmonary Function Testing - A Guide for Patients (1983)
</FONT></TD></TR>
<TR>
<TD>
<TABLE BORDER="1" ALIGN="LEFT">
<TR>
<TD><FONT COLOR="#FFFFFF">__</FONT></TD></TR></TABLE></TD>
<TD><FONT SIZE="-1">Pulmonary Rehabilitation Programs - Questions &amp;
Answers for Lung Patients (1987)
</FONT></TD></TR>
<TR>
<TD>
<TABLE BORDER="1" ALIGN="LEFT">
<TR>
<TD><FONT COLOR="#FFFFFF">__</FONT></TD></TR></TABLE></TD>
<TD><FONT SIZE="-1">Radon Fact Sheet for California (1991)</FONT></TD></TR>
<TR>
<TD>
<TABLE BORDER="1" ALIGN="LEFT">
<TR>
<TD><FONT COLOR="#FFFFFF">__</FONT></TD></TR></TABLE></TD>
<TD><FONT SIZE="-1">Safe Flying for Patients with Lung Disease (1983; 1992)</FONT></TD></TR>
<TR>
<TD>
<TABLE BORDER="1" ALIGN="LEFT">
<TR>
<TD><FONT COLOR="#FFFFFF">__</FONT></TD></TR></TABLE></TD>
<TD><FONT SIZE="-1">Tender Lung Care:  Positive Steps for Healthy Lungs (1988;
1992)</FONT></TD></TR></TABLE></CENTER>
<CENTER>
<P>(All items reviewed for accuracy FY '95-'96)</P></CENTER>
<P></P>
<HR SIZE="4" WIDTH="80%">
<CENTER><A HREF="about.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/about.gif" ALT="About Society"></A>
<A HREF="ssg.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/ss.gif" ALT="Society Structure"></A>
<A HREF="calendar.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/calendar.gif" ALT="ATS Calendar"></A>
<A HREF="gpi.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/pi.gif" ALT="Gen Public Info"></A>
<A HREF="ms.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/memserv.gif" ALT="Memb Serv"></A>
<BR>
<A HREF="pub.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/pubs.gif" ALT="Publications"></A>
<A HREF="press.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/press.gif" ALT="Press"></A>
<A HREF="index.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/home.gif" ALT="Home Page"></A>
<A HREF="search.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/search.gif" ALT="Search"></A>
<A HREF="assemb.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/assemb.gif" ALT="Assemblies"></A>
<A HREF="research.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/research.gif" ALT="Research"></A>
<BR>
<A HREF="mep.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/meded.gif" ALT="Med Education"></A>
<A HREF="wr.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/wr.gif" ALT="Wash Report"></A>
<A HREF="ic.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/ic.gif" ALT="Int'l Conference"></A>
<A HREF="source.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/link.gif" ALT="Web Links"></A>
<A HREF="store.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/store.gif" ALT="Store"></A> 
<A HREF="sig.html"><IMG
SRC="images/special.gif" ALT="Special" HSPACE="1" VSPACE="1" BORDER="0" HEIGHT="35" WIDTH="84"></A>
</CENTER>
<HR SIZE="4" WIDTH="80%">
<CENTER><FONT SIZE="+2"><B><I>American Thoracic Society</I></B></FONT><BR>
1740 Broadway<BR> New York, NY 10019<BR> VOICE:  212-315-8700<BR> Copyright &copy;
1996 American Lung Association.<BR> The American Thoracic  Society is the
medical section <BR>of the American Lung Association.<BR> 
</CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-4</DOCNO>
<DOCOLDNO>IA013-000139-B020-300</DOCOLDNO>
<DOCHDR>
http://www.thoracic.org:80/chic_3.html 206.138.195.144 19970217070313 text/html 3948
HTTP/1.0 200 OK
Date: Monday, 17-Feb-97 06:58:31 GMT
Server: NCSA/1.3
MIME-version: 1.0
Content-type: text/html
Last-modified: Wednesday, 18-Dec-96 16:01:32 GMT
Content-length: 3765
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//SQ//DTD HTML 2.0 HoTMetaL + extensions//EN">
<HTML>
<HEAD>
<TITLE>American Thoracic Society - State Thoracic Societies: Chicago, Illinois</TITLE></HEAD>
<BODY BACKGROUND="images/back.jpg">
<CENTER><IMG ALIGN="LEFT" SRC="images/smlogo.gif"><BR>
<H1>2d Annual Meeting<BR> North American Region IUATLD</H1></CENTER>
<HR SIZE="5" NOSHADE="NOSHADE" WIDTH="100%">
<P></P>
<CENTER>
<TABLE BORDER="2">
<TR ALIGN="CENTER" VALIGN="MIDDLE">
<TD><SMALL><A HREF="chic.html">BACK TO CTS MAIN MENU</A></SMALL></TD></TR></TABLE></CENTER>
<P></P>
<HR>
<P><BR><BR></P><IMG SRC="images/iuatld.jpg" ALIGN="LEFT" BORDER="0">
<BLOCKQUOTE>
<P><FONT SIZE="+1"><B>2d Annual Meeting North American Region International
Union Against Tuberculosis and Lung Disease &quot;The Role of the Public and
Private Sectors in Global Tuberculosis Control&quot;</B></FONT></P>
<H2>February 27 - March 2, 1997</H2>
<H2>Hotel Inter-Continental</H2>
<H2>Chicago, Illinois</H2>
<P><B><FONT SIZE="+1">Posters are invited on four topics:<BR>TB Control: 
Public/Private Sector Collaboration,<BR>TB Control Strategies in the
Underserved,<BR>International TB Collaborative Research, <BR>TB Education
Strategies:  Teaching Tools for Special Groups.</FONT></B></P>
<P><B><FONT SIZE="+1">CMEs and Nursing CEUs applied for.</FONT></B></P>
<P><BR><BR></P>
<BLOCKQUOTE>
<P><B>For more information contact: </B></P>
<P>Kitty McAndrews<BR>Associate Director of Professional Education<BR>American
Lung Association of Metropolitan Chicago<BR>1440 W. Washington<BR>Chicago, IL 
60607<BR>Telephone:  312.243.2000<BR>FAX: 312.243.3954<BR><A
HREF="mailto:kmcandre@alamc.org">E-mail: kmcandre@alamc.org</A></P></BLOCKQUOTE></BLOCKQUOTE>
<P></P>
<HR SIZE="4" WIDTH="80%">
<CENTER><A HREF="about.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/about.gif" ALT="About Society"></A>
<A HREF="ssg.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/ss.gif" ALT="Society Structure"></A>
<A HREF="calendar.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/calendar.gif" ALT="ATS Calendar"></A>
<A HREF="gpi.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/pi.gif" ALT="Gen Public Info"></A>
<A HREF="ms.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/memserv.gif" ALT="Memb Serv"></A>
<BR>
<A HREF="pub.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/pubs.gif" ALT="Publications"></A>
<A HREF="press.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/press.gif" ALT="Press"></A>
<A HREF="index.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/home.gif" ALT="Home Page"></A>
<A HREF="search.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/search.gif" ALT="Search"></A>
<A HREF="assemb.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/assemb.gif" ALT="Assemblies"></A>
<A HREF="research.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/research.gif" ALT="Research"></A>
<BR>
<A HREF="mep.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/meded.gif" ALT="Med Education"></A>
<A HREF="wr.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/wr.gif" ALT="Wash Report"></A>
<A HREF="ic.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/ic.gif" ALT="Int'l Conference"></A>
<A HREF="source.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/link.gif" ALT="Web Links"></A>
<A HREF="store.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/store.gif" ALT="Store"></A> 
</CENTER>
<HR SIZE="4" WIDTH="80%">
<CENTER><FONT SIZE="+2"><B><I>American Thoracic Society</I></B></FONT><BR>
1740 Broadway<BR> New York, NY 10019<BR> VOICE:  212-315-8700<BR> Copyright &copy;
1996 American Lung Association.<BR> The American Thoracic  Society is the
medical section <BR>of the American Lung Association.<BR> 
</CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-5</DOCNO>
<DOCOLDNO>IA013-000139-B020-331</DOCOLDNO>
<DOCHDR>
http://www.thoracic.org:80/blueinfo.html 206.138.195.144 19970217070325 text/html 5218
HTTP/1.0 200 OK
Date: Monday, 17-Feb-97 06:58:38 GMT
Server: NCSA/1.3
MIME-version: 1.0
Content-type: text/html
Last-modified: Friday, 20-Dec-96 20:23:52 GMT
Content-length: 5038
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//SQ//DTD HTML 2.0 HoTMetaL + extensions//EN">
<HTML>
<HEAD><TITLE>American Thoracic Society - AJRCCM Information</TITLE></HEAD> 
<BODY BACKGROUND="images/back.jpg">
<CENTER><IMG ALIGN="LEFT" SRC="images/smlogo.gif"><BR><H1>AJRCCM Contact
Information</H1></CENTER>
<HR SIZE="5" NOSHADE="NOSHADE" WIDTH="100%">
<P><BR><BR></P>
<CENTER>

<B>CONTACT INFORMATION MENU</B>
<BR><BR><TABLE BORDER="2"><TR ALIGN="CENTER" VALIGN="MIDDLE"><TD
COLSTART="1"><SMALL><A HREF="general.html">MAIN CONTACT PAGE</A></SMALL></TD><TD
COLSTART="2"><SMALL>AJRCCM CONTACT PAGE</SMALL></TD><TD COLSTART="3"><SMALL><A
HREF="redinfo.html">AJRCMB CONTACT PAGE</A></SMALL></TD></TR></TABLE></CENTER>
<P></P>
<HR SIZE="5" WIDTH="70%">  
<H3>AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE:</H3> 
<H2><IMG ALIGN="ABSMIDDLE" SRC="images/shdbull.gif"><B><A
HREF="bluecont.html">Submission of Manuscripts</A></B></H2> 
<H2><IMG ALIGN="ABSMIDDLE" SRC="images/shdbull.gif"><B><A HREF="bluesup.html">Submission
of Supplement Issues</A></B></H2>
<P><B>Copyrights/Permissions:</B><BR> All requests must be submmited in
writing (prefavorably on letterhead), must  indicate the name and reference of
the material being requested, and in what  manner this material will be used.
Full bibliographic information is required  and a photocopy of the requested
materal would be helpful. To obtain  permission or for further information,
please contact Christina Shepherd,  Managing Editor, ATS Editorial Office, 1740
Broadway, New York, NY  10019-4374. Phone (212)315-6441; FAX (212)315-6455. 
E-Mail: <A HREF="mailto:cshepherd@lungusa.org">cshepherd@lungusa.org</A>.</P>
<P><B>Editorial Production:</B><BR> 1740 Broadway, New York, NY 10019-4374. 
Phone (212)315-6440; FAX (212)315-6455. E-Mail:
<A HREF="mailto:cshepherd@lungusa.org">cshepherd@lungusa.org</A>.</P>
<P><B>Display Advertising:</B><BR> Please contact Cunningham Associates; 180 
Old Tappan Road, Old Tappan, NJ 07675. Phone (201)767-4170; FAX  (201)767-8065.</P>
<P><B>Classified Advertising (Announcements and Professional Recruitment):</B><BR>
Membership and Subscriptions, ATS, 1740 Broadway, New York,  NY 10019-4374.
Phone (212)315-8771; FAX (212)315-6455.  E-Mail:
<A HREF="mailto:jreyes@lungusa.org">jreyes@lungusa.org</A>.</P>
<H2><IMG ALIGN="ABSMIDDLE" SRC="images/shdbull.gif"><B><A
HREF="subscrib.html">Subscriptions</A></B></H2>
<P><B>Reprints/Offprints:</B><BR> ATS Editorial Office, 1740 Broadway, New
York, NY 10019-4374.  Phone: (212)315-6440; FAX: (212)315-6455. E-Mail: 
<A HREF="mailto:mmobley@lungusa.org">mmobley@lungusa.org</A>.</P>
<H2><IMG ALIGN="ABSMIDDLE" SRC="images/shdbull.gif"><B><A
HREF="bluecont.html">Instructions for Contributors</A></B></H2>
<H2><IMG ALIGN="ABSMIDDLE" SRC="images/shdbull.gif"><B><A HREF="art.html">Submitting
Best Quality Art</A></B></H2>
<HR SIZE="4" WIDTH="80%"> 
<CENTER>
<A HREF="about.html"><IMG VSPACE="1" HSPACE="1" BORDER="0" 
SRC="images/about.gif" ALT="About Society"></A>
<A HREF="ssg.html"><IMG VSPACE="1" HSPACE="1" BORDER="0" 
SRC="images/ss.gif" ALT="Society Structure"></A>
<A HREF="calendar.html"><IMG VSPACE="1" HSPACE="1" BORDER="0" 
SRC="images/calendar.gif" ALT="ATS Calendar"></A>
<A HREF="gpi.html"><IMG VSPACE="1" HSPACE="1" BORDER="0" 
SRC="images/pi.gif" ALT="Gen Public Info"></A>
<A HREF="ms.html"><IMG VSPACE="1" HSPACE="1" BORDER="0" 
SRC="images/memserv.gif" ALT="Memb Serv"></A>
<BR>
<A HREF="pub.html"><IMG VSPACE="1" HSPACE="1" BORDER="0" 
SRC="images/pubs.gif" ALT="Publications"></A>
<A HREF="press.html"><IMG VSPACE="1" HSPACE="1" BORDER="0" 
SRC="images/press.gif" ALT="Press"></A>
<A HREF="index.html"><IMG VSPACE="1" HSPACE="1" BORDER="0" 
SRC="images/home.gif" ALT="Home Page"></A>
<A HREF="search.html"><IMG VSPACE="1" HSPACE="1" BORDER="0" 
SRC="images/search.gif" ALT="Search"></A>
<A HREF="assemb.html"><IMG VSPACE="1" HSPACE="1" BORDER="0" 
SRC="images/assemb.gif" ALT="Assemblies"></A>
<A HREF="research.html"><IMG VSPACE="1" HSPACE="1" BORDER="0" 
SRC="images/research.gif" ALT="Research"></A>
<BR>
<A HREF="mep.html"><IMG VSPACE="1" HSPACE="1" BORDER="0" 
SRC="images/meded.gif" ALT="Med Education"></A>
<A HREF="wr.html"><IMG VSPACE="1" HSPACE="1" BORDER="0" 
SRC="images/wr.gif" ALT="Wash Report"></A>
<A HREF="ic.html"><IMG VSPACE="1" HSPACE="1" BORDER="0" 
SRC="images/ic.gif" ALT="Int'l Conference"></A>
<A HREF="source.html"><IMG VSPACE="1" HSPACE="1" BORDER="0" 
SRC="images/link.gif" ALT="Web Links"></A>
<A HREF="store.html"><IMG VSPACE="1" HSPACE="1" BORDER="0" 
SRC="images/store.gif" ALT="Store"></A> 
<A HREF="sig.html"><IMG SRC="images/special.gif" ALT="Special" HSPACE=1 VSPACE=1 BORDER=0 HEIGHT=35 WIDTH=84></A>
</CENTER>
<HR SIZE="4" WIDTH="80%"> 
<CENTER><FONT SIZE="+2"><B><I>American Thoracic Society</I></B></FONT><BR>
1740 Broadway<BR> New York, NY 10019<BR> VOICE:  212-315-8700<BR> Copyright &#169;
1996 American Lung Association.<BR> The American Thoracic  Society is the
medical section <BR>of the American Lung Association.<BR> 
</CENTER>
</BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-6</DOCNO>
<DOCOLDNO>IA013-000139-B020-361</DOCOLDNO>
<DOCHDR>
http://www.thoracic.org:80/redinfo.html 206.138.195.144 19970217070334 text/html 5430
HTTP/1.0 200 OK
Date: Monday, 17-Feb-97 06:58:50 GMT
Server: NCSA/1.3
MIME-version: 1.0
Content-type: text/html
Last-modified: Friday, 20-Dec-96 20:24:32 GMT
Content-length: 5250
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//SQ//DTD HTML 2.0 HoTMetaL + extensions//EN">
<HTML>
<HEAD><TITLE>American Thoracic Society - AJRCMB Contact Information</TITLE></HEAD>
<BODY BACKGROUND="images/back.jpg">
<CENTER><IMG ALIGN="LEFT" SRC="images/smlogo.gif"><BR><H1>AJRCMB Contact
Information</H1></CENTER>
<HR SIZE="5" NOSHADE="NOSHADE" WIDTH="100%">
<P><BR><BR></P>
<CENTER>

<B>CONTACT INFORMATION MENU</B>
<BR><BR><TABLE BORDER="2"><TR ALIGN="CENTER" VALIGN="MIDDLE"><TD
COLSTART="1"><SMALL><A HREF="general.html">MAIN CONTACT PAGE</A></SMALL></TD><TD
COLSTART="2"><SMALL><A HREF="blueinfo.html">AJRCCM CONTACT PAGE</A></SMALL></TD><TD
 COLSTART="3"><SMALL>AJRCMB CONTACT PAGE</SMALL></TD></TR></TABLE></CENTER>
<P></P>
<HR SIZE="5" WIDTH="70%">  
<H3>AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY:</H3> 
<H2><IMG ALIGN="ABSMIDDLE" SRC="images/shdbull.gif"><B><A HREF="redcont.html">Submission
of Manuscripts</A></B></H2> 
<P><B>Submission of Supplement Issues:</B><BR> Christina Shepherd, Managing
Editor, ATS Editorial Office, 1740 Broadway,  New York, NY 10019-4374. Phone
(212)315-6440; FAX (212) 315-6455.  E-Mail:
<A HREF="mailto:cshepherd@lungusa.org">cshepherd@lungusa.org</A>.  (See
Instructions for Submission of Supplement Issues)</P> 
<P><B>Copyrights/Permissions:</B><BR> All requests must be submmited in
writing (prefavorably on letterhead), must  indicate the name and reference of
the material being requested, and in what  manner this material will be used.
Full bibliographic information is  required and a photocopy of the requested
materal would be helpful. To obtain permission or for  further information,
please contact Christina Shepherd, Managing Editor, ATS  Editorial Office, 1740
Broadway, New York, NY 10019-4374. Phone  (212)315-6441; FAX (212)315-6455.
E-Mail: 
<A HREF="mailto:cshepherd@lungusa.org">cshepherd@lungusa.org</A>.</P> 
<P><B>Editorial Production:</B><BR> 1740 Broadway, New York, NY 10019-4374. 
Phone: (212)315-6440; FAX (212)315-6455. E-Mail: 
<A HREF="mailto:cshepherd@lungusa.org">cshepherd@lungusa.org</A>.</P>
<P><B>Display advertising:</B><BR> Please contact Cunningham Associates; 180 
Old Tappan Road, Old Tappan, NJ 07675. Phone (201)767-4170; FAX  (201)767-8065.</P>
<P><B>Classified Advertising (Announcements and Professional Recruitment):</B><BR>
Membership and Subscriptions, ATS, 1740 Broadway, New York,  NY 10019-4374.
Phone (212)315-8771; FAX (212)315-6455.   E-Mail:
<A HREF="mailto:jreyes@lungusa.org">jreyes@lungusa.org</A>.</P>
<H2><IMG ALIGN="ABSMIDDLE" SRC="images/shdbull.gif"><B><A
HREF="subscrib.html">Subscriptions</A></B></H2>
<P><B>Reprints/Offprints:</B><BR> ATS Editorial Office, 1740 Broadway, New
York, NY 10019-4374.  Phone: (212)315-6440; FAX: (212)315-6455. E-Mail: 
<A HREF="mailto:mmobley@lungusa.org">mmobley@lungusa.org</A>.</P>
<H2><IMG ALIGN="ABSMIDDLE" SRC="images/shdbull.gif"><B><A HREF="redcont.html">Instructions
for Contributors</A></B></H2>
<H2><IMG ALIGN="ABSMIDDLE" SRC="images/shdbull.gif"><B><A HREF="art.html">Submitting
Best Quality Art</A></B></H2>
<HR SIZE="4" WIDTH="80%"> 
<CENTER>
<A HREF="about.html"><IMG VSPACE="1" HSPACE="1" BORDER="0" 
SRC="images/about.gif" ALT="About Society"></A>
<A HREF="ssg.html"><IMG VSPACE="1" HSPACE="1" BORDER="0" 
SRC="images/ss.gif" ALT="Society Structure"></A>
<A HREF="calendar.html"><IMG VSPACE="1" HSPACE="1" BORDER="0" 
SRC="images/calendar.gif" ALT="ATS Calendar"></A>
<A HREF="gpi.html"><IMG VSPACE="1" HSPACE="1" BORDER="0" 
SRC="images/pi.gif" ALT="Gen Public Info"></A>
<A HREF="ms.html"><IMG VSPACE="1" HSPACE="1" BORDER="0" 
SRC="images/memserv.gif" ALT="Memb Serv"></A>
<BR>
<A HREF="pub.html"><IMG VSPACE="1" HSPACE="1" BORDER="0" 
SRC="images/pubs.gif" ALT="Publications"></A>
<A HREF="press.html"><IMG VSPACE="1" HSPACE="1" BORDER="0" 
SRC="images/press.gif" ALT="Press"></A>
<A HREF="index.html"><IMG VSPACE="1" HSPACE="1" BORDER="0" 
SRC="images/home.gif" ALT="Home Page"></A>
<A HREF="search.html"><IMG VSPACE="1" HSPACE="1" BORDER="0" 
SRC="images/search.gif" ALT="Search"></A>
<A HREF="assemb.html"><IMG VSPACE="1" HSPACE="1" BORDER="0" 
SRC="images/assemb.gif" ALT="Assemblies"></A>
<A HREF="research.html"><IMG VSPACE="1" HSPACE="1" BORDER="0" 
SRC="images/research.gif" ALT="Research"></A>
<BR>
<A HREF="mep.html"><IMG VSPACE="1" HSPACE="1" BORDER="0" 
SRC="images/meded.gif" ALT="Med Education"></A>
<A HREF="wr.html"><IMG VSPACE="1" HSPACE="1" BORDER="0" 
SRC="images/wr.gif" ALT="Wash Report"></A>
<A HREF="ic.html"><IMG VSPACE="1" HSPACE="1" BORDER="0" 
SRC="images/ic.gif" ALT="Int'l Conference"></A>
<A HREF="source.html"><IMG VSPACE="1" HSPACE="1" BORDER="0" 
SRC="images/link.gif" ALT="Web Links"></A>
<A HREF="store.html"><IMG VSPACE="1" HSPACE="1" BORDER="0" 
SRC="images/store.gif" ALT="Store"></A> 
<A HREF="sig.html"><IMG SRC="images/special.gif" ALT="Special" HSPACE=1 VSPACE=1 BORDER=0 HEIGHT=35 WIDTH=84></A>
</CENTER>
<HR SIZE="4" WIDTH="80%"> 
<CENTER><FONT SIZE="+2"><B><I>American Thoracic Society</I></B></FONT><BR>
1740 Broadway<BR> New York, NY 10019<BR> VOICE:  212-315-8700<BR> Copyright &#169;
1996 American Lung Association.<BR> The American Thoracic  Society is the
medical section <BR>of the American Lung Association.<BR> 
</CENTER>
</BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-7</DOCNO>
<DOCOLDNO>IA013-000139-B021-7</DOCOLDNO>
<DOCHDR>
http://www.thoracic.org:80/news1096.html 206.138.195.144 19970217070343 text/html 38855
HTTP/1.0 200 OK
Date: Monday, 17-Feb-97 06:59:00 GMT
Server: NCSA/1.3
MIME-version: 1.0
Content-type: text/html
Last-modified: Friday, 20-Dec-96 20:24:17 GMT
Content-length: 38674
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//SQ//DTD HTML 2.0 HoTMetaL + extensions//EN">
<HTML>
<HEAD>
<TITLE>American Thoracic Society - ATS News Archive: September 1996</TITLE></HEAD>
<BODY BACKGROUND="images/back.jpg">
<CENTER><IMG SRC="images/news2.gif" ALIGN="BOTTOM"></CENTER>
<P></P>
<HR SIZE="5" NOSHADE="NOSHADE" WIDTH="100%">
<P></P>
<CENTER>
<TABLE BORDER="2">
<TR>
<TD><B><A HREF="newsarch.html"><SMALL>BACK TO ATS NEWS ARCHIVE</SMALL></A></B></TD></TR></TABLE></CENTER>
<P></P>
<HR SIZE="5" WIDTH="70%">
<CENTER>
<H1><B>October 1996: Vol. 22, No. 10</B></H1></CENTER>
<TABLE>
<TR ALIGN="CENTER" VALIGN="MIDDLE">
<TD>
<H4>In This Issue</H4></TD>
<TD>
<H4>Announcements</H4></TD></TR>
<TR>
<TD>
<BLOCKQUOTE>
<P><IMG SRC="images/bullet1.gif" ALIGN="TOP"> <A HREF="news1096.html#ats1">ATS
Leadership Retreat Summary</A> 
</P>
<P><IMG SRC="images/bullet1.gif" ALIGN="TOP"> <A HREF="news1096.html#ats2">Assembly
Reports</A>
<BR>
</P>
<P><IMG SRC="images/bullet1.gif" ALIGN="TOP"> <A HREF="news1096.html#ats3">Who's
Who in ATS</A>
</P></BLOCKQUOTE>
<BLOCKQUOTE>
<P><IMG SRC="images/bullet1.gif" ALIGN="TOP"> <A HREF="news1096.html#ats4">ATS
Chapter News</A></P>
<P><IMG SRC="images/bullet1.gif" ALIGN="TOP"> <A HREF="news1096.html#ats5">AARC
and JRCRTE Form Respiratory Care Accreditation Agency (RCAA)</A>
</P>
<P><IMG SRC="images/bullet1.gif" ALIGN="TOP"> <A HREF="news1096.html#ats6">WHO
Report on TB Deaths</A>
</P>
<P><IMG SRC="images/bullet1.gif" ALIGN="TOP"> <A HREF="news1096.html#ats7">Committee
on Manpower for Pulmonary and Critical Care Societies (COMPACCS)</A><BR>
</P></BLOCKQUOTE>
<BLOCKQUOTE>
<P><IMG SRC="images/bullet1.gif" ALIGN="TOP">	<A HREF="news1096.html#ats8">Two
Asthma Research Centers Chosen</A></P></BLOCKQUOTE>
<HR SIZE="5" WIDTH="70%"></TD>
<TD>
<BLOCKQUOTE>
<P><IMG SRC="images/bullet1.gif" ALIGN="TOP"> <A HREF="news1096.html#ats9">2nd
State of the Art Review Course in Pulmonary Medicine and Critical Care</A> </P>
<P><IMG SRC="images/bullet1.gif" ALIGN="TOP"> <A HREF="news1096.html#ats10">State
of the Art Review Pulmonary Medicine and Critical Care</A></P>
<P><IMG SRC="images/bullet1.gif" ALIGN="TOP"><A HREF="news1096.html#ats11">Disability
Income Plan Now Available for ATS Members</A></P></BLOCKQUOTE>
<HR SIZE="5" WIDTH="70%">
<BLOCKQUOTE>
<P><IMG SRC="images/bullet1.gif" ALIGN="TOP"> <A HREF="news1096.html#ats12">Masthead</A></P></BLOCKQUOTE>
<HR SIZE="5" WIDTH="70%"></TD></TR></TABLE>
<P></P>
<CENTER>
<TABLE BORDER="3">
<TR ALIGN="JUSTIFY" VALIGN="MIDDLE">
<TD ALIGN="CENTER"><IMG SRC="images/boehring.gif" ALIGN="MIDDLE">  
<BR><BR>   This publication is supported by a grant from Boehringer Ingelheim
Pharmaceuticals, Inc., Ridgefield, CT.  
</TD></TR></TABLE></CENTER>
<HR SIZE="4" WIDTH="80%">
<CENTER>
<H1><A NAME="ats1">ATS Leadership Retreat Summary</A></H1></CENTER>
<P>The ATS Leadership Retreat was held on February 28-29, 1996 in Orlando,
Florida. The purpose was  to bring together ATS members in leadership positions
to discuss future directions of the Society and the ALA-ATS relationship. A
plenary  session was held to review the key areas of ATS activity. The attendees
then divided into small groups to develop recommendations on the following: role
of the medical section, scientific and education programs, advocacy, research,
ATS in the world community, clinical practice and critical care, and finances.
Each small group had a leader whose role was to guide the discussion and present
a summary to the attendees.  Three overall themes emerged from the proceedings:
the ATS continues to grow and develop as the premier national and international
professional society in pulmonary and critical care medicine; the organizational
alignment of ALA and ATS has been, and continues to be, a major strength for
both organizations; periodic review of the ATS and ALA relationship is required
to accommodate changing needs of both organizations. A synopsis of the
discussion for each of the areas follows:
</P>
<P>Role of the Medical Section: It is believed that the current structure, in
which the ATS serves as the Medical Section of the ALA, is basically sound and
appropriate. In this role, ATS should work with ALA to: ensure equal access for
all people with lung disease to quality health care; translate science for
public education; partner with ALA  in research advocacy and revenue generation
such as research fund raising for the ALA; offer broadly based consensus
opinions on all medical/scientific documents and policies; provide training for
ALA staff and volunteers; provide broad-based peer review of research grants in
the ALA Research programs; serve as an information/education referral resource
for medical/scientific issues that rise through the ALA; provide direction by
having ATS leadership serve on the ALA Board of Directors.
</P>
<P>Scientific and Education Programs: The goals identified in this area are:
develop and maintain the highest standards of training for health care
practitioners in respiratory and critical care medicine; develop and maintain
the highest standards for research and clinical practice. Several mechanisms
were recommended, including the utilization of newer technologies (e.g., CD-ROM)
for educational activities such as CME programs, the International Conference,
and regional meetings.
</P>
<P>Advocacy: The primary goal is to support advocacy for the highest quality of
care by working through volunteers, patients and their families, and ATS
members.  Advocacy should be directed toward government and regulatory agencies
at all levels. To implement this goal, the ATS should: develop a mechanism for
monitoring developments in the managed care field; alert its members to upcoming
issues; respond promptly to practice and regulatory changes that may impact
adversely on the delivery of pulmonary and critical care; develop a mechanism
for gathering and responding promptly to comments and complaints from its
membership regarding problems in the delivery of appropriate pulmonary and
critical care; be a better advocate for critical care in general.
</P>
<P>Research: The ATS should promote the highest quality research to facilitate
the discovery of new knowledge. To achieve this goal, the following mechanisms
were stated:
<BR>foster the provision of more funds for investigator-initiated research,
including funds for young investigators and support for all stages of a
researcher's career; facilitate  information transfer via journals, conferences,
and courses; provide networking through the Internet to promote communication
among researchers internationally to identify areas of common interest; develop
a research advocacy network: involve ATS members, lung disease patients and
their families, and the interested public; help set research priorities within
the ALA by identifying unique opportunities; develop joint research activities
with industry (consider developing a research network to facilitate
industry-sponsored projects); focus on advocacy for increasing research funds
for the NIH, the major source of funding for pulmonary research; develop
mechanisms to encourage the public to donate more money to the ALA for research:
cooperate with the ALA to solicit funds that are specifically earmarked for
research with defined dollar targets in order to increase ALA expenditures for
research comparable to other voluntary health organizations.
</P>
<P>ATS in the World Community: The ATS should promote prevention and treatment
of lung disease and critical illness throughout the world. To accomplish this,
ATS should: support the ATS-ERS relationship consisting of joint membership,
joint ventures such as the development of statements and other projects and
representations on each others' Board of Directors; develop relationships with
other transnational thoracic societies and continue to maintain the identity of
the ATS or consider development of a North American ATS; increase communication
with international members of the ATS and international organizations through
the ATS News and the World Wide Web; continue to support educational programs
such as the International Respiratory Epidemiology Course.
</P>
<P>Clinical Practice and Critical Care: The ATS should work to advance the role
of the pulmonary/critical care physician in the health care delivery system. A
goal of the Society is to play a major role in assuring that Americans have
access to high-quality, cost-effective pulmonary/critical care services, while
assuring fair reimbursement for such services. To achieve this, the ATS should
establish a managed care task force charged with monitoring and responding as
appropriate to managed care issues affecting pulmonary and critical care.
Additional mechanisms include: foster both the performance of health services
outcome research in pulmonary/critical care medicine and the dissemination of
information in this area; highlight the organization as a critical care society:
several initiatives were put forth in this area, including the sponsorship of
educational sessions for primary care physicians, and educational programs for
the public emphasizing pulmonary and critical care medicine; explore the
offering of retraining to pulmonary physicians so they can enhance their
employability: topics for consideration include geriatric pulmonary disease,
sleep medicine, home care and rehabilitation; form a task force on fair
reimbursement; gather all available data on outcomes of care from generalists as
well as specialists.
</P>
<P>Finances: To fulfill our mission as a professional scientific society and
medical section of the ALA, the ATS must have autonomy and control over its
expenses and revenue. Such control would include an independent auditing and
accounting system, control over its surplus, allowance for multi-year projects,
a system that is accountable to the ATS leadership, flexibility to establish its
own fiscal year, a separate financial officer, and overall control of personnel.
</P>
<P>The ATS recognizes that these requirements may necessitate the creation of a
separate corporate entity. Regardless of the structure that is recommended, it
is important to maintain alignment with the ALA. It is also important to
acknowledge that money, per se, is not the central issue; rather it is the need
to have the autonomy required to enable us to be responsible and responsive to
the ATS membership.
<BR><IMG SRC="images/slug1.gif" ALIGN="BOTTOM"></P>
<HR SIZE="4" WIDTH="80%">
<CENTER>
<H1><A NAME="ats2">Assembly Reports</A></H1></CENTER>
<H2> Behavioral Science
</H2>
<P></P>
<P>During the past year, the Assembly on Behavioral Science has continued to
define and strengthen participation in the Society. Members adopted a mission
statement at the 1996 ATS International Conference in New Orleans.  The
statement emphasizes facilitating and promoting interest, knowledge, research,
and application related to behavioral and social factors in lung health among
ATS members, other researchers, and policy makers. The agenda of presentations
at the 1996 International Conference, and plans for the 1997 meeting, reflect
our intention to facilitate research that is rigorous and addresses the breadth
of important lung health topics. Through ATS project funding, we have initiated
work on a web page on the ATS home page devoted to Quality of Life measures and
related resources. Assembly representatives participated in a recent conference
on Quality of Life assessment sponsored by the ATS Corporate Relations
Committee. The Long Range Planning Committee is conducting quarterly conference
calls in order to develop a plan that will guide and integrate assembly
activities. Members are developing a formal statement on the role of behavioral
science research in lung disease prevention and treatment. We have initiated
communication with the European Respiratory Society in order to foster
collaboration and support European researchers. As we plan for the year to come,
we invite suggestions for ATS-funded projects or workshops on behavioral aspects
of lung health. For more information, contact Judy Corn in the ATS office at
(212) 315-8709 (phone).
</P>
<P></P>
<P>Esther M. Sumartojo, Chair
</P>
<P></P>
<H2>Critical Care
</H2>
<P></P>
<P>The Assembly on Critical Care is sponsoring or co-sponsoring several events
over the upcoming academic year. The project having the most significant
involvement of the Assembly is a two-day workshop on Tools for Measuring Outcome
in Critical Care. This is a separate meeting which will be held in early April,
1997 in Toronto, Canada. The purpose of this meeting is to begin to develop
standardized outcome measures for randomized clinical trials as well as for
outcomes research. In addition, issues related to the relevance of outcomes
research versus randomized clinical trials in assessing treatment modalities in
critical care medicine will be discussed. It is expected that a workshop report
will be produced detailing the major issues and the areas of consensus. A
follow-up workshop (Part II), which is planned for sometime later in 1997, will
explore the most promising issues raised in part I in more detail. If you are
interested in working on this project, please contact Gordon R. Bernard, M.D. at
(615) 322-2386 (phone). 
</P>
<P></P>
<P>Gordon R. Bernard, Chair
</P>
<P></P>
<H2>Nursing
</H2>
<P></P>
<P>The Assembly on Nursing has been funded to develop respiratory nursing
research priorities for the year 2000. An ad hoc committee has been created
within the Assembly and one of the first tasks of the committee was to survey
the membership for input. Assembly members received a survey questionnaire about
future research priorities and were asked to respond to the chair of the
committee by mid-September 1996. If a member has not responded, the committee is
still interested in receiving that input and will accept any late submissions.
After compiling the survey data, the committee will continue their work via
conference calls and a two-day meeting scheduled in early 1997.
</P>
<P>We are also moving forward with the creation of a Pulmonary Rehabilitation
Section within the Assembly on Nursing. The necessary numbers of membership
signatures have been obtained and the Assembly will vote on the creation of the
Section at the International Conference in San Francisco next May. Sue Lareau,
M.S., R.N., and Richard ZuWallack, M.D., co-convened a meeting in New Orleans in
May 1996 to begin preliminary work to establish this important group. ATS
members from other assemblies are encouraged to join this interdisciplinary
group of clinicians and researchers.
</P>
<P></P>
<P>Mary Ellen Wewers, Chair
</P>
<P></P>
<H2>Pediatrics
</H2>
<P></P>
<P>The Assembly on Pediatrics  has three on-going projects-the Infant Pulmonary
Function Working Group, the Statement on Bronchopulmonary Dysplasia group, and a
new group developing a consensus statement on Care of the Child with a Chronic
Tracheostomy. In addition, Ricki Zinman is developing a group on Technology
Dependent Children. Twenty-four people attended the first meeting of this group.
If you are interested in participating, let Ricki know. 
</P>
<P>The following people were elected to positions in the Assembly: Dennis
Strokes, Chair-Elect; Chris Green, Program Chair 1998; Michael Wall, Long Range
Planning Committee; Frank Accurso and Gerald Loughlin, Nominating Committee.
</P>
<P>The Long Range Planning Committee will meet in early November. If there are
topics you wish this committee to address, please contact Julian Allen, Chair.
</P>
<P>The International Pediatric Respiratory Congress Meeting will be held March
16-19, 1997 in Sydney, Australia. A call for abstracts will be sent out soon.
</P>
<P>The pediatric workforce document prepared by Greg Redding will be presented
to the ATS Board in November. This document has been extensively reviewed and,
when approved, will be published in the American Journal of Respiratory and
Critical Care Medicine.
</P>
<P></P>
<P>Michelle M. Cloutier, Chair
</P>
<P></P>
<H2>Pulmonary Circulation 
</H2>
<P></P>
<P>The deadline for abstracts for the 1997 International Conference  is rapidly
approaching-Friday, November 1. Suggested symposia include: drug-induced
pulmonary vascular disease, interactions between the liver and the lung
circulation, and new horizons for treatment of pulmonary hypertension. Contact
Nick Hill at (401) 444-3560 (phone) for further information.
</P>
<P>Marlene Rabinovitch and I will co-chair a workshop at the 1997 conference
entitled &quot;Differences and Similarities between the Pulmonary and Systemic
Circulations Related to Reactivity and Progression and Regression of Vascular
Disease.&quot; The workshop follows closely on an initiative to stimulate
interactions between the systemic and pulmonary circulations and will be held
Saturday, May 17 in San Francisco. 
</P>
<P>The first meeting to discuss a position paper on the &quot;Diagnosis and
Treatment of Pulmonary Thromboembolism&quot; took place in New Orleans with Vic
Tapson, Acting Chair. The members of the committee decided that the paper should
center on diagnostic approaches to pulmonary thromboembolism and important areas
for future research. The next meeting is in October. A committee chaired by
Harold Palevsky also met to discuss a position paper &quot;Diagnosis and
Treatment of Primary Pulmonary Hypertension.&quot; Future position papers
include the increased risk for development of chronic pulmonary hypertension in
patients taking appetite suppressants, including the recently approved
dexfenfluramine. For more information, contact Norbert Voelkel at (303) 270-4211
(phone).
</P>
<P>The Long Range Planning Committee will meet in November. Suggested topics
for discussion should be sent to Charles Hales at (617) 726-8854 (phone).
</P>
<P>The AHA/ATS - sponsored conference &quot;The Pathogenesis and Treatment of
Pulmonary Edema&quot; will be held at the Lost Valley Conference Center,
Colorado, September 5-8.
</P>
<P></P>
<P>Barbara O. Meyrick, Chair
</P>
<P></P>
<H2>Respiratory, Neurobiology, and Sleep
</H2>
<P></P>
<P>In spite of the budgetary constraints on all of us that have resulted either
from the shrinking clinical revenues or from tighter NIH budgets, I believe our
Assembly and our membership are passing through an exciting and challenging
time. At no time in the past has the scientific community at large been more
able to do as much as today to understand the basic mechanisms of sleep,
respiration, and the conditions and diseases that can afflict these systems.
Within our Assembly, we have started a number of new programs in the past few
years. We are still faced, however, with quite a few challenges in the next few
years.
</P>
<P>Three of these challenges are pressing and important to address.  First, the
ATS and our Assembly should collaborate with the ASDA and other societies to
continue to help and advise the NIH, not only on &quot;hot&quot; research areas,
but also on how to possibly implement research and training programs. The second
challenge is to foster the basic sciences pertaining to our interests and to
continue to create an exciting intellectual environment for young residents,
postdoctoral fellows, and graduates and undergraduate students and get them
interested in questions that are important to solve.  Finally, it is very
important for us at this juncture to entice young MD and PhD members to join our
Assembly. We will need as part of our long-range planning to set in motion a
program to do just that. Invited speakers at symposia, travel awards, and other
such efforts for the International Conference will also be of help in attracting
new members.
</P>
<P>I am looking forward to another exciting year working with Richard Parisi
chairing our Program Committee and Judy Neubauer chairing our Long Range
Planning. We would appreciate the input of the membership any time. Please
participate and make your voice heard!
</P>
<P></P>
<P>Gabriel G. Haddad, Chair
</P>
<P></P>
<H2>Respiratory Structure and Function
</H2>
<P></P>
<P>The Assembly on Respiratory Structure and Function has been very active
during the summer months. The ATS position paper on &quot;Lung Volume Reduction
Surgery,&quot; jointly sponsored by RSF and CP assemblies, will be published in
the American Journal of Respiratory and Critical Care Medicine in October. The
Airway Narrowing Workshop, held in Quebec between August 23 and 25, was very
successful, and a position paper on &quot;Transduction of Inflammation into a
Physiological Response&quot; is in preparation. The committee that is preparing
the joint ATS/ERS statement on &quot;Respiratory Muscle Function Testing&quot;
will meet for a second time in early September in Stockholm. The committee
preparing the ATS position paper on &quot;High Resolution CT Scanning in the
Diagnosis of Lung Disease&quot; will meet in early October in Vancouver. Members
of the Assembly are also involved in two projects for the Committee on
Proficiency Standards for Clinical Pulmonary Function Laboratories. The first is
a Guideline Statement for Bronchial Challenge Testing and the second is a
Generic Laboratory Procedure Manual for Pulmonary Function Laboratories.</P>
<P></P>
<P>Gary C. Sieck, Chair
<BR><IMG SRC="images/slug1.gif" ALIGN="BOTTOM">
</P>
<HR SIZE="4" WIDTH="80%">
<CENTER>
<H1><A NAME="ats3">Who's Who in ATS</A></H1></CENTER>
<H2><IMG SRC="images/mellins.gif" ALIGN="MIDDLE"> <B><BIG>ROBERT B. MELLINS,
M.D.</BIG></B></H2>
<P> Robert B. Mellins is Professor of  Pediatrics and Director of the Pediatric
Pulmonary Division,  Columbia University, New York.  He received his M.D. degree
from Johns Hopkins.  After house staff training at Johns Hopkins, Cornell, and
Columbia, he entered the private pediatrics practice for four years.  He then
returned to the Columbia-Presbyterian Medical Center as a research fellow in
pulmonary medicine and subsequently was appointed Director of the Pediatric
Intensive Care Unit. In 1972, he established the Pediatric Pulmonary Division,
and for the past 24 years has had an active training program for pediatric
pulmonary research fellows supported by a training grant from the NHLBI.  His
research interests have included studies of the mechanical behavior of the lung
under dynamic conditions, the effect of maturation and sleep on respiratory
control, the development of the lung, transvascular exchange of fluid in the
lung and pulmonary edema, cardiopulmonary function of the lung during exercise,
pulmonary complications of HIV infection in children, asthma, and behavioral
science as it applies to the prevention and control of lung disease.  He played
a major role in having a serious research experience included as part of the
requirements of the Pediatric Pulmonary Boards.
</P>
<P>Dr. Mellins  is a member of the American Pediatric Society, the Society for
Pediatric Research, the American Physiological Society, the American Society for
Pharmacology and Experimental Therapeutics, the American Thoracic Society, the
American Academy of Allergy, Asthma and Immunology, the American College of
Chest Physicians, and has just completed service as  President of the Fleischner
Society.  He is Principal Investigator or Program Director of several NHLBI-
supported projects on asthma in minority populations and chairs the Steering
Committee of an NHLBI-sponsored multicenter study of pulmonary and
cardiovascular complications of HIV infection in children.
</P>
<P>His honors and awards include AOA from Johns Hopkins, First Prize in the New
England Journal of Medicine Essay Competition, NIH Career Development Award,
First Deans Distinguished Lecturer in the Clinical Sciences and the Stevens
Triennial Award for Research from Columbia, and a Medical Education Award from
the American Academy of Pediatrics. Earlier this year he was the recipient of a
Distinguished Achievement Award from the ATS and the Will Ross Medal from the
ALA.
</P>
<P>	He first became a member of the ATS in 1970 and played an active role in
the establishment of several scientific assemblies, including the Assembly on
Pediatrics (which he also chaired) and the Assembly on Behavioral Science. He
has served as a member of the editorial board and as an associate editor of the
American Review of Respiratory Disease.  He helped initiate the Annual Research
Fund Dinner and raised the funds to support the Dalsemar Research Scholar Award.
He was President of the ATS for 1982-1983. He has been a volunteer for the
American Lung Association since 1970. In addition to serving on the ALA Board
and Council, he was Vice President of the ALA for 1987-1989 and is currently
President of the ALA of New York.
</P>
<P>	Dr. Mellins serves on the boards of a number of public-spirited
organizations, including the A.P. Gold Foundation to foster humanism in
medicine, the L.A. Jonas Foundation to help disadvantaged but potentially
outstanding young men and women and promote a philosophy of service, and the
Symphony of the United Nations to foster international good will through music.

<BR>
<IMG SRC="images/slug1.gif" ALIGN="BOTTOM"></P>
<HR SIZE="4" WIDTH="80%">
<CENTER>
<H1><A NAME="ats4">ATS Chapter News</A></H1></CENTER>
<P>The combined meeting of New Jersey Thoracic Society (NJTS) and the Pulmonary
Research Group (PRG) was held June 20 and 21, 1996. The afternoon symposium on
the Pathology and Treatment of COPD was organized by the PRG, a loose
affiliation of scientists from industry and academia who have an interest in
novel ideas and progress on various areas of basic research. Topics ranged from
&quot;Emphysema-Progress and Prospects&quot; to &quot;Role of Neutrophil
Elastase in Pulmonary Disease: Pharmacology of Elastase Inhibitors.&quot; The
slide and poster session, organized by the NJTS, included papers on experimental
pulmonary hypertension, the effects of hypoxia on brainstem neurons, and the
outcome of lung transplantation.
</P>
<P>One of NJTS's goals is the promotion of research directed toward the
understanding and treatment of lung diseases within the state of New Jersey. As
part of its mission, it is important to provide a forum for the exchange of
ideas and research findings between practicing clinical scientists and
pharmaceutical research organizations. With the help of organizations of
researchers from pharmaceutical and academic research (PRG), the planning
committee of the NJTS achieved this forum. PRG provided a series of speakers
focusing on a clinical endpoint. The nationally and internationally known
speakers from academia and industry discussed the known clinical picture of a
specific lung disease or treatment modality. After, the NJTS highlighted the
most recent research in lung disease carried out in the state. The result was a
presentation of the state of the art in lung disease treatment and current
research, benefitting clinician and basic researcher.<BR><IMG
SRC="images/slug1.gif" ALIGN="BOTTOM"></P>
<HR SIZE="4" WIDTH="80%">
<CENTER>
<H1><A NAME="ats5">AARC and JRCRTE Form Respiratory Care Accreditation Agency</A></H1></CENTER>
<P>The American Association for Respiratory Care (AARC) and the Joint Review
Committee for Respiratory Therapy Education (JRCRTE) have announced the new
committee on accreditation:
</P>
<P>A new committee on accreditation will be formed January 1, 1998; the new
committee will be independent of the ARRC and other sponsors; the committee will
be sponsored by the AARC, ACCP, ATS, and ASA upon approval by each organization;
the committee will be composed of 6 RCPs, 6 physicians, 2 deans, and 1-3 public
members as required by the US Department of Education; the AARC and JRCRTE will
form a transition group comprised of RCPs and physicians who will be on the new
committee; the committee will initially adopt the JRCRTE Essentials and will
prepare proposed revisions for approval; the committee leadership will meet with
the AARC at least annually to discuss accreditation and professional direction;
the committee will be committed to streamlining the accreditation process with a
goal of minimized duplication through consideration of elements of accreditation
granted by other entities; the AARC will provide the committee with access to
its programs and publications.
<BR><IMG SRC="images/slug1.gif" ALIGN="BOTTOM"></P>
<HR SIZE="4" WIDTH="80%">
<CENTER>
<H1><A NAME="ats6">WHO Report on TB Deaths</A></H1></CENTER>
<P>According to the World Health Organization, more people died from
tuberculosis in 1995 than in any other year in history. Nearly 3 million people
died from TB in 1995, compared with the worst years of the epidemic around 1900,
when an estimated 2.1 million people died annually. According to a WHO report
entitled &quot;Groups at Risk,&quot; TB is now the leading infectious killer of
youth and adults, the principal killer of HIV-positive people, and the killer of
more women than all causes of maternal mortality combined. Nearly half the
world's refugees may be infected with TB.</P>
<P>The WHO endorses a strategy treatment called &quot;DOTS,&quot; directly
observed treatment, short-course. DOTS can cure nearly 95% of TB patients, using
medicines that cost less than $11 in some parts of the world. This treatment
places the responsibility for curing patients with TB on the health care
workers, not the patients.  With the DOTS strategy, health care workers watch
their patients swallow medication and track each patient's progress, ensuring
that contagious people are cured. 
</P>
<P>According to WHO, only 10% of the TB patients in the world are being treated
by DOTS regimen, and the longer countries wait to employ DOTS programs
worldwide, the more costly TB treatment will become and the less likely the
disease will be stopped.
<BR><IMG SRC="images/slug1.gif" ALIGN="BOTTOM">
</P>
<HR SIZE="4" WIDTH="80%">
<H1><A NAME="ats7">Committee on Manpower for Pulmonary and Critical Care
Societies (COMPACCS)</A></H1>
<P>The American Thoracic Society, the American College of Chest Physicians, the
Society of Critical Care Medicine, and the Program Directors responsible for
training pulmonary and critical care physicians created COMPACCS, which has
designed a study to examine the current and future manpower needs for pulmonary
and critical care in the US. The project will measure society's current clinical
demand for care and match it with current physician supply. The study will also
project how these clinical demands will change the future and thereby influence
the demand for specialty care in these disciplines.
</P>
<P>COMPACCS will mail two survey instruments in the fall. The first, for
intensive care unit directors, will capture the practice of critical care across
the representative sample of ICUs. The second survey, sent to selected members
of the three COMPACCS societies, asks physicians about their clinical activities
in both pulmonary and critical care medicine to provide a &quot;snapshot&quot;
of their current practice. These data will provide the foundation of modeling
future clinical demands for pulmonary and critical care physicians.
<BR><IMG SRC="images/slug1.gif" ALIGN="BOTTOM"></P>
<HR SIZE="4" WIDTH="80%">
<H1><A NAME="ats8">Two Asthma Research Centers Chosen</A></H1>
<P>After an extensive cooperative ALA/ATS peer review selection, two centers
have been chosen for funding for the Asthma Research Initiative - the National
Jewish Center for Immunology and Respiratory Medicine, Denver, Colorado, and the
Cardiovascular Research and Training Institute at the University of Utah, Salt
Lake City, Utah. Each center will receive $500,000 a year for up to five years.
Funding will begin October 1, 1996.
</P>
<P>Research led by Richard J. Martin at the National Jewish Center will
concentrate on infections as the underlying cause of asthma; whereas the
researchers led by Thomas M. McIntryre at the Cardiovascular Research and
Training Institute Institute will focus on the role of inflammation in asthma.<BR><IMG
SRC="images/slug1.gif" ALIGN="BOTTOM">
</P>
<HR SIZE="4" WIDTH="80%">
<CENTER>
<H2><I><B><BLINK><A NAME="ats9">ANNOUNCEMENT:</A></BLINK></B></I></H2></CENTER>
<CENTER>
<H1><A NAME="ats9">The
<FONT SIZE="8">Second</FONT> ATS State of the Art Review Course in  Pulmonary
Medicine and Critical Care</A></H1></CENTER>
<H3>John Hansen - Flaschen, MD, Chairman
</H3>
<P>Hyatt Regency La Jolla at Aventine, San Diego, CA February 1-4, 1997 
</P>
<P>Encompassing both pulmonary medicine and critical care, this state of the
art course is designed for the practicing subspecialist as well as physicians in
training.
</P>
<P>Four days of didactic presentations, discussion, and interaction of 33
faculty and 250 participants have been planned to provide the latest knowledge
and experience in the current clinical practice of pulmonary medicine and
critical care.
</P>
<P>Participation will be limited to 250 persons. To be placed on the mailing
list for the preliminary program and registration materials, please return the
attached coupon to ATS.
</P>
<P></P>
<P></P>
<UL>
<LI>	Registration fee for ATS members: $550
</LI>
<LI>	Fellows: $300. Fee for non-members: $675.
</LI>
<LI>	CME Category I credit will be awarded 
</LI></UL>
<P><BR><IMG SRC="images/slug1.gif" ALIGN="BOTTOM"> </P>
<HR SIZE="4" WIDTH="80%">
<CENTER>
<H1><A NAME="ats10">State of the Art Review Pulmonary Medicine and Critical
Care</A></H1></CENTER>
<H3>Hyatt Regency La Jolla at Aventine,  San Diego, CA
</H3>
<P>February 1-4, 1997  Please send me the preliminary program and registration
materials for the course:
</P>
<H5>(Please print/type carefully)</H5>
<PRE>
<HR SIZE="1" NOSHADE="NOSHADE"> Name			
<HR SIZE="1" NOSHADE="NOSHADE"> Address		
<HR SIZE="1" NOSHADE="NOSHADE"> City 		
<HR SIZE="1" NOSHADE="NOSHADE"> State 	
<HR SIZE="1" NOSHADE="NOSHADE"> Zip Code		
<HR SIZE="1" NOSHADE="NOSHADE"> Country	
<HR SIZE="1" NOSHADE="NOSHADE"> Telephone 	
<HR SIZE="1" NOSHADE="NOSHADE"> Fax		
<HR SIZE="1" NOSHADE="NOSHADE"> E-mail	
<HR SIZE="1" NOSHADE="NOSHADE"> 
</PRE>
<P>Please return to: CME Office, American Thoracic Society 1740 Broadway, New
York, NY 10019-4374<BR>Phone: (212) 315-8621 Fax: (212) 315-6498
<BR><IMG SRC="images/slug1.gif" ALIGN="BOTTOM">
</P>
<P></P>
<HR SIZE="4" WIDTH="80%">
<CENTER>
<H1><A NAME="ats11">Disability Income Plan Now Available for ATS Members</A></H1></CENTER>
<P>All ATS members and spouses under age 60 who have been actively working (at
least 30 hours per week) for the last 90 days and have not been hospitalized in
the last 6 months are eligible to apply for the ATS Disability Income Plan, with
monthly benefits up to $3,000.
</P>
<P>For more information, contact the ATS Insurance Administrator, Albert H.
Wohlers &amp;AMP Co., 1440 N. Northwest Highway, Park Ridge, IL60068-1400;
800/503-9230. Members can reach Wohlers &amp;AMP Company by two e-mail
addresses: The <B>customer service department </B>can be reached at
<A HREF="mailto:cusv@ahw.com">cusv@ahw.com</A>. For members who seek <B>information</B>
(brochures or applications for plans), use the <A HREF="mailto:info@ahw.com">info@ahw.com</A>
address. When using the Internet to contact the Wohlers Company, it is important
for members to include the following information: name, complete address, date
of birth, spouse date of birth, telephone number, and name of association.
<BR><IMG SRC="images/slug1.gif" ALIGN="BOTTOM">
</P>
<HR SIZE="4" WIDTH="80%">
<CENTER>
<H1><A NAME="ats12">Masthead</A></H1></CENTER>
<BLOCKQUOTE>
<CENTER>
<P><B>President</B><BR> Philip C. Hopewell, MD</P>
<P><B>President-Elect</B><BR> Talmadge E. King, Jr., MD</P>
<P><B>Vice-President</B><BR> Edward R. Block, MD</P>
<P><B>Secretary-Treasurer</B> <BR>Jeffrey Glassroth, MD</P>
<P><B>Past-President</B><BR> Leonard D. Hudson, MD</P>
<P><B>Executive Director</B><BR> Marilyn Hansen</P>
<P><B>Managing Editor</B><BR> Christina Shepherd</P>
<P><B>ATS News Editor</B><BR> Kristine Garland</P> 
</CENTER></BLOCKQUOTE>
<CENTER>
<TABLE>
<TR>
<TD ALIGN="CENTER">
<P>Vol. 22  No.10  October 1996. ATS News (usps 103-750, issn 0892-8916) is
published monthly at 1740 Broadway, New York, NY 10019-4374. Copyright 1996 by
the American Lung Association. The American Thoracic Society is the medical
section of the American Lung Association.</P>
<P>Internet: http://www.thoracic.org.
</P>
<HR><IMG SRC="images/boehring.gif" ALIGN="BOTTOM"> 
<BR> This publication is supported by a grant from Boehringer Ingelheim
Pharmaceuticals, Inc., Ridgefield, CT. 
</TD></TR></TABLE></CENTER>
<P><BR><BR> 
</P>
<HR SIZE="4" WIDTH="80%">
<CENTER><A HREF="about.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/about.gif" ALT="About Society"></A>
<A HREF="ssg.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/ss.gif" ALT="Society Structure"></A>
<A HREF="calendar.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/calendar.gif" ALT="ATS Calendar"></A>
<A HREF="gpi.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/pi.gif" ALT="Gen Public Info"></A>
<A HREF="ms.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/memserv.gif" ALT="Memb Serv"></A>
<BR>
<A HREF="pub.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/pubs.gif" ALT="Publications"></A>
<A HREF="press.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/press.gif" ALT="Press"></A>
<A HREF="index.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/home.gif" ALT="Home Page"></A>
<A HREF="search.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/search.gif" ALT="Search"></A>
<A HREF="assemb.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/assemb.gif" ALT="Assemblies"></A>
<A HREF="research.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/research.gif" ALT="Research"></A>
<BR>
<A HREF="mep.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/meded.gif" ALT="Med Education"></A>
<A HREF="wr.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/wr.gif" ALT="Wash Report"></A>
<A HREF="ic.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/ic.gif" ALT="Int'l Conference"></A>
<A HREF="source.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/link.gif" ALT="Web Links"></A>
<A HREF="store.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/store.gif" ALT="Store"></A> 
<A HREF="sig.html"><IMG SRC="images/special.gif" ALT="Special" HSPACE=1 VSPACE=1 BORDER=0 HEIGHT=35 WIDTH=84></A>
</CENTER>
<HR SIZE="4" WIDTH="80%">
<CENTER><FONT SIZE="+2"><B><I>American Thoracic Society</I></B></FONT><BR>
1740 Broadway<BR> New York, NY 10019<BR> VOICE:  212-315-8700<BR> Copyright &copy;
1996 American Lung Association.<BR> The American Thoracic  Society is the
medical section <BR>of the American Lung Association.<BR> 
</CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-8</DOCNO>
<DOCOLDNO>IA013-000139-B021-49</DOCOLDNO>
<DOCHDR>
http://www.thoracic.org:80/news1196.html 206.138.195.144 19970217070354 text/html 36101
HTTP/1.0 200 OK
Date: Monday, 17-Feb-97 06:59:08 GMT
Server: NCSA/1.3
MIME-version: 1.0
Content-type: text/html
Last-modified: Monday, 10-Feb-97 16:30:38 GMT
Content-length: 35920
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 3.2//EN">
<HTML>
<HEAD>
   <TITLE>American Thoracic Society - ATS News</TITLE>
   <META NAME="GENERATOR" CONTENT="Mozilla/3.0Gold (Win16; U) [Netscape]">
</HEAD>
<BODY BACKGROUND="images/back.jpg">

<CENTER><P><IMG SRC="images/newslogo.gif" HEIGHT=124 WIDTH=466 ALIGN=BOTTOM>
</P></CENTER>

<P>
<HR SIZE="5" NOSHADE="NOSHADE" WIDTH="100%"></P>

<CENTER><TABLE BORDER=2 >
<TR>
<TD><B><A HREF="newsarch.html">BACK TO ATS NEWS ARCHIVE</A></B></TD>
</TR>
</TABLE></CENTER>

<CENTER><P>
<HR SIZE="5" WIDTH="70%"></P></CENTER>

<CENTER><P><B><FONT SIZE=+2>November 1996<BR>
</FONT><FONT SIZE=-1>Vol. 22, No. 11</FONT></B><BR>
</P></CENTER>

<TABLE>
<TR ALIGN="CENTER" VALIGN="MIDDLE">
<TD>
<H4>In This Issue</H4>
</TD>

<TD>
<H4>Announcements</H4>
</TD>
</TR>

<TR>
<TD>
<BLOCKQUOTE>
<P><IMG SRC="images/bullet1.gif" HEIGHT=11 WIDTH=11 ALIGN=TOP> <A HREF="#ats1">American
Thoracic Society Supports the Recommendations of the Advisory Committee
on Immunization Practices (ACIP) for Prevention and Control of Influenza</A>
</P>

<P><IMG SRC="images/bullet1.gif" HEIGHT=11 WIDTH=11 ALIGN=TOP> <A HREF="#ats2">Assembly
Report</A> <BR>
</P>

<P><IMG SRC="images/bullet1.gif" HEIGHT=11 WIDTH=11 ALIGN=TOP> <A HREF="#ats3">1997
ALA/ATS International Conference<BR>
May 16-21, 1997, San Francisco, California</A> </P>
</BLOCKQUOTE>

<BLOCKQUOTE>
<P><IMG SRC="images/bullet1.gif" HEIGHT=11 WIDTH=11 ALIGN=TOP> <A HREF="#ats4">Who's
Who in ATS</A></P>

<P><IMG SRC="images/bullet1.gif" HEIGHT=11 WIDTH=11 ALIGN=TOP> <A HREF="#ats5">Airways
Narrowing Workshop Held in Val-Morin, Quebec</A> </P>

<P><IMG SRC="images/bullet1.gif" HEIGHT=11 WIDTH=11 ALIGN=TOP> <A HREF="#ats9">From
Washington</A> </P>

<P><IMG SRC="images/bullet1.gif" HEIGHT=11 WIDTH=11 ALIGN=TOP> <A HREF="#ats10">Meetings,
Conferences, and Courses (COMPACCS)</A><BR>
</P>
</BLOCKQUOTE>

<BLOCKQUOTE>
<P><IMG SRC="images/bullet1.gif" HEIGHT=11 WIDTH=11 ALIGN=TOP> <A HREF="#ats11">Recent
News Releases</A></P>
</BLOCKQUOTE>

<P>
<HR SIZE="5" WIDTH="70%"></P>
</TD>

<TD><IMG SRC="images/bullet1.gif" HEIGHT=11 WIDTH=11 ALIGN=TOP> <A HREF="#ats8">Helping
Smokers Quit</A> 
<P><IMG SRC="images/bullet1.gif" HEIGHT=11 WIDTH=11 ALIGN=TOP> <A HREF="#ats6">Second
Call for Nominations</A></P>

<P><IMG SRC="images/bullet1.gif" HEIGHT=11 WIDTH=11 ALIGN=TOP><A HREF="#ats7">The
Virtual Hospital</A></P>

<P><IMG SRC="images/bullet1.gif" HEIGHT=11 WIDTH=11 ALIGN=TOP><A HREF="#ats12">ABIM-1997
Certification Exam Dates</A></P>

<P><IMG SRC="images/bullet1.gif" HEIGHT=11 WIDTH=11 ALIGN=TOP><A HREF="#ats13">Pneumonia:
All You Need To Know</A></P>

<P>
<HR SIZE="5" WIDTH="70%"></P>

<P><IMG SRC="images/bullet1.gif" HEIGHT=11 WIDTH=11 ALIGN=TOP> <A HREF="#credits">Masthead</A></P>

<P>
<HR SIZE="5" WIDTH="70%"></P>
</TD>
</TR>
</TABLE>

<CENTER><TABLE BORDER=3 >
<TR ALIGN="JUSTIFY" VALIGN="MIDDLE">
<TD ALIGN="CENTER"><IMG SRC="images/boehring.gif" HEIGHT=34 WIDTH=125 ALIGN=CENTER>
<BR>
<BR>
This publication is supported by a grant from Boehringer Ingelheim Pharmaceuticals,
Inc., Ridgefield, CT. </TD>
</TR>
</TABLE></CENTER>

<CENTER><TABLE>
<TR ALIGN="CENTER" VALIGN="MIDDLE">
<TD><B>We welcome suggestions from the readership for new columns, story
ideas, and nominations for Who's Who in ATS. Contact the Managing Editor
at 212-315-6440 (phone); 212-315-6455 (FAX); <A HREF="mailto:cshepherd@lungusa.org">cshepherd@lungusa.org</A>.</B></TD>
</TR>
</TABLE></CENTER>

<P>
<HR SIZE="4" WIDTH="80%"></P>

<H1><A NAME="ats1"></A>American Thoracic Society Supports the Recommendations
of the Advisory Committee on Immunization Practices (ACIP) for Prevention
and Control of Influenza</H1>

<P>It is the position of the American Thoracic Society that pulmonary physicians
and other physicians, particularly those involved with the care of patients
with all varieties of lung disorders, should make the prevention of influenza
through vaccine and/or amantadine a high priority for their patients. We
urge all physicians to review carefully the CDC document &quot;Prevention
and Control of Influenza: Recommendations of the Advisory Committee on
Immunization Practices (ACIP),&quot; MMWR 1996;45 (No.RR-5) in order to
plan appropriate preventive programs for high-risk patients.</P>

<P>Excerpts of the ACIP recommendations for the use of influenza vaccine
include the following:</P>

<P>Influenza vaccine is strongly recommended for any person greater than
or equal to 6 months of age who, because of age or underlying medical condition,
is at increased risk for complications of influenza. </P>

<P>Health-care workers and others (including household members) in close
contact with persons in high-risk groups should be vaccinated. </P>

<P>The trivalent influenza vaccine prepared for the 1996&shy;97 season
will include A/Texas/36/91-like (H1N1), A/Wuhan/359/95-like (H3N2) [new],
and B/Beijing/184/93-like hemagglutinin antigens. </P>

<P>For both A/Wuhan/359/95-like and B/Beijing/184/93-like antigens, U.S.
manufacturers will use the antigenically equivalent strains A/Nanchang/933/95
(H3N2) and B/Harbin/07/94 because of their growth properties. </P>

<P>The window for organized campaigns has been expanded to October 1 -
November 15. </P>

<P>To receive a complete copy of &quot;Prevention and Control of Influenza:
Recommendations of the Advisory Committee on Immunization Practices (ACIP),&quot;
MMWR 1996;.45 (No. RR-5) please contact the Centers for Disease Control
and Prevention, Division of Viral and Rickettsial Diseases, Influenza Branch,
Influenza Epidemiology Section (A-32), 1600 Clifton Road, N.E., Atlanta,
Georgia 30333. Phone: 404/ 639-3865 or 404/ 639-3747. Fax: 404/ 639-3866.
Electronic copy is also available from CDC's World Wide Web server at <A HREF="http://www.cdc.gov/">http://www.cdc.gov</A>
or from CDC's file transfer protocol server at <A HREF="ftp://cdc.gov/">ftp.cdc.gov</A>.<BR>
<IMG SRC="images/slug1.gif" HEIGHT=26 WIDTH=60></P>

<P><B><FONT SIZE=+2>TABLE 1. Influenza vacine* dosage, by age group-United
States, 1996-97 season</FONT></B></P>

<TABLE BORDER=2 >
<TR ALIGN="CENTER" VALIGN="TOP">
<TD><B>Age group</B></TD>

<TD><B>Product</B></TD>

<TD><B>Dosage</B></TD>

<TD><B>No. of doses</B></TD>

<TD><B>Route</B></TD>
</TR>

<TR ALIGN="CENTER" VALIGN="TOP">
<TD>6-35 mos</TD>

<TD>Split virus only</TD>

<TD>.025 ml</TD>

<TD>1 or 2</TD>

<TD>IM</TD>
</TR>

<TR ALIGN="CENTER" VALIGN="TOP">
<TD>3-8 yrs</TD>

<TD>Split virus only</TD>

<TD>0.50 ml</TD>

<TD>1 or 2</TD>

<TD>IM</TD>
</TR>

<TR ALIGN="CENTER" VALIGN="TOP">
<TD>9-12 yrs</TD>

<TD>Split virus only</TD>

<TD>0.50 ml</TD>

<TD>1</TD>

<TD>IM</TD>
</TR>

<TR ALIGN="CENTER" VALIGN="TOP">
<TD>12 yrs</TD>

<TD>Whole or split virus only</TD>

<TD>0.50 ml</TD>

<TD>1</TD>

<TD>IM</TD>
</TR>
</TABLE>

<P>
<HR SIZE="4" WIDTH="80%"></P>

<H1><A NAME="ats2"></A>Assembly Report</H1>

<P>The Assembly on Allergy, Immunology, and Inflammation has been active
in the election and selection of individuals for leadership positions,
the definition of new research opportunities in allergy, immunology, and
inflammation, and in the formulation of educational programs. Dr. Toews
has attended all ATS Board meetings. </P>

<P>The assembly is committed to involving as many members as possible.
Sally Wenzel, M.D., was elected Program Committee Chair Elect at the Annual
Meeting in New Orleans. Thomas R. Martin, M.D., the present Chair of the
Program Committee, has appointed six new members to the Program Committee
for the 1997 ATS meeting. New members include Robert Baughman, M.D., Greg
Downey, M.D., Carolyn Rochester, M.D., Margaret Gyetko, M.D., Monica Kraft,
M.D., and Jeff Hasday, M.D. Jeff Curtis, M.D., has been appointed as the
Chair of the Long Range Planning Committee. Dr. Curtis has appointed Mary
Lipscomb, M.D., and Mark Liu, M.D., to the Long Range Planning Committee.
The assembly is grateful that these capable individuals are willing to
serve in these important assembly positions. </P>

<P>The identification of new research opportunities is an ongoing task
for the assembly. A workshop that considered research possibilities in
mucosal immunology met in Ann Arbor from June 24 to June 25, 1996. Thirteen
attendees from the United States, Canada, and Britain enjoyed two days
of vigorous, stimulating discussion. We thank Jack Gauldie, Ph.D., for
his hard work organizing this important workshop. The assembly welcomes
suggestions for future workshops. </P>

<P>Thomas B. Casale, M.D., and the Asthma Advisory Committee members are
completing work on a group of regional asthma postgraduate courses for
primary care physicians. Planning for this postgraduate course has involved
assembly members from RCMB, RSF, Clinical Problems, EOH, Pediatrics, Behavioral
Sciences, Nursing, and Allergy, Immunology, and Inflammation. It is anticipated
that seven regional asthma courses will be offered during 1997. This joint
project is an example of the ATS functioning at its best. This effort,
which involves members from numerous assemblies within the ATS, is an important
first initiative to provide state-of-the-art information regarding the
diagnosis and treatment of asthma to primary care physicians. Planning
for the ATS meeting in 1997 is moving forward briskly. Dr. Martin and the
Program Committee are in the process of developing symposia and postgraduate
courses that will highlight important new findings. </P>

<P>The ATS Board of Directors and the Long Range Planning Committee will
both meet in November 1996. Drs. Toews and Curtis welcome input from the
membership. Additionally, we would be pleased to hear from members who
are interested in being more involved in the tasks of the assembly. Dr.
Toews welcomes your input by phone at 313/936-5010 or by e-mail at <A HREF="mailto:gtoews@uvl.im.med.umich.edu">gtoews@uvl.im.med.umich.edu</A>.
Dr. Curtis welcomes your input by phone at 313/769-7980 or by e-mail at
<A HREF="mailto:jlcurtis@medmail.med.umich.edu">jlcurtis@medmail.med.umich.edu</A>.<BR>
<IMG SRC="images/slug1.gif" HEIGHT=26 WIDTH=60></P>

<P>
<HR SIZE="4" WIDTH="80%"></P>

<H1><A NAME="ats3"></A>1997 ALA/ATS International Conference<BR>
May 16-21, 1997, San Francisco, California</H1>

<P>The annual American Lung Association/American Thoracic Society International
Conference is the largest lung-related conference in the world. In 1997,
the meeting will be held in San Francisco, California, May 16-21 and will
offer the latest and most significant developments in clinical science,
basic science, the behavioral aspects of respiratory disease, and public
health education. </P>

<P>Session topics will include asthma, tobacco control, managed care, lung
reduction surgery, critical care, tuberculosis, pediatric pulmonology,
sleep apnea, environmental and occupational lung disease, nursing studies,
cell biology, lung structure and function, and lung health in diverse communities.
These topics will be featured in general symposia, clinical tracks, seminars,
poster sessions, and slide presentations. </P>

<P>The ATS will also offer postgraduate courses on the Friday (May 16)
and Saturday (May 17) prior to the International Conference. Among the
topics covered in these courses are infant lung function testing, asthma,
lung epithelium, indoor air, cell biology, clinical exercise testing, and
pulmonary hypertension. </P>

<P>The Advance Program, which will contain the registration form, will
be available in January and will be mailed automatically to ATS members.
Look for more information about the Conference sessions in next month's
issue of the ATS News.<BR>
<IMG SRC="images/slug1.gif" HEIGHT=26 WIDTH=60></P>

<P>
<HR SIZE="4" WIDTH="80%"></P>

<H1><A NAME="ats4"></A>Who's Who in ATS</H1>

<H2>Eileen Hanafin Breslin, RN, DNSC, FAAN </H2>

<P><IMG SRC="images/breslin.jpg" HEIGHT=148 WIDTH=113 ALIGN=BOTTOM> Eileen
Breslin is the immediate past Chair of the Assembly on Nursing. Her activities
in ATS included serving on the Board of Directors (1994&shy;1996) and chairing
the Scientific Conference Committee of the Assembly on Nursing (1992&shy;1994).
She is currently serving on the Research Review Committee, Task Force on
Women in ATS, and the Dyspnea Consensus Group. Dr. Breslin received her
diploma in Nursing from St. Elizabeth&sup1;s School of Nursing, Boston,
her BSN from California State University, Hayward, and MSN and DNSc from
University of California, San Francisco. She completed a postdoctoral fellowship
in nursing and respiratory muscle physiology at Boston University and Boston
College. Following her postdoctoral work, Dr. Breslin became Director for
the Center for Nursing Research at the University of California, Davis
Medical Center, Sacramento. She is Assistant Adjunct Professor in the School
of Medicine, Pulmonary and Critical Care Division and Director of Pulmonary
Rehabilitation. Dr. Breslin&sup1;s major areas of study are in the area
of respiratory muscle function, symptom management, and the application
of respiratory physiology in the rehabilitation of pulmonary and neurology
patients. She is Principal Investigator of the study &sup3;Dyspnea, Respiratory
Control, and Rehabilitation Therapeutics in Neuromuscular Disease,&sup2;
sponsored by the National Institute of Disability and Rehabilitation Research.
In this study, she is evaluating the effects of rehabilitation strategies
on respiratory muscle EMG activity and dyspnea in normal subjects and patients
with COPD and neuromuscular diseases. Her work will contribute to the understanding
of respiratory muscle performance in relationship to breathing pattern
and dyspnea. ATS has benefited from Dr. Breslin&sup1;s scientific approach
to analyzing health care issues and forecasting the need for clinical and
research programs. Her research will contribute to the knowledge of respiratory
muscle activity and breathing patterns in patients with respiratory impairment.<BR>
<IMG SRC="images/slug1.gif" HEIGHT=26 WIDTH=60></P>

<P>
<HR SIZE="4" WIDTH="80%"></P>

<H1><A NAME="ats5"></A>Airways Narrowing Workshop Held in Val-Morin, Quebec</H1>

<P><IMG SRC="images/airways.jpg" HEIGHT=131 WIDTH=202 ALIGN=BOTTOM>Drs.
Charlie Irvin (ATS) and Vito Brusasco (ERS) of the Assembly on Respiratory
Structure and Function co-chaired a workshop on Airways Narrowing held
August 23&shy;25, 1996 in Val-Morin, Quebec, Canada. The outcome of this
project will be to produce a joint ATS/ERS Statement that will be copublished
in the ERJ and AJRCCM. Photo: (from left to right) Julian Solway, Ole Pederson,
Peter Macklem, James Martin, Jeffrey Fredberg, Solbert Permutt, Vito Busasco,
Stephanie Shore, Charles Irvin, Ricardo Pellegrino, Joseph Rodarte, Robert
Tepper, Peter Sterk, Jason Bates. Also present at the workshop were David
Eidelman, Marc Hershenson, and Marc Ludwig.<BR>
<IMG SRC="images/slug1.gif" HEIGHT=26 WIDTH=60></P>

<P>
<HR SIZE="4" WIDTH="80%"></P>

<H1><A NAME="ats6"></A>Second Call for Nominations</H1>

<P>The ATS Nominating Committee will prepare recommendations to submit
to the membership for the office of Secretary-Treasurer for the 1997-1998
year. This person will progress through the Society and become President
in 2000. Suggestions from ATS members should be sent to: Nominating Committee,
American Thoracic Society, 1740 Broadway, New York, NY 10019-4374, by 1
December 1996. In making recommendations for ATS officers, you might find
it helpful to keep the following leadership considerations in mind: organizational
ability, prestige, willingness to devote time to the Society, past contributions
to the Society, diplomacy, and ability to communicate effectively. Please
respond in the space below. </P>

<H5>Nomination for Secretary&shy;Treasurer</H5>

<P>
<HR></P>

<P>If you wish to send detailed information on your reason for any or all
of your nominees, the Committee would be most appreciative. Nomination
sent by : </P>

<P>
<HR></P>

<P>Please return to: CME Office, American Thoracic Society 1740 Broadway,
New York, NY 10019-4374 Phone: (212) 315-8621 Fax: (212) 315-6498<BR>
<IMG SRC="images/slug1.gif" HEIGHT=26 WIDTH=60></P>

<P>
<HR SIZE="4" WIDTH="80%"></P>

<H1><A NAME="ats7"></A>The Virtual Hospital</H1>

<P><A HREF="post2.html"><IMG SRC="images/whitevhl.gif" BORDER=0 HEIGHT=144 WIDTH=457 ALIGN=BOTTOM></A></P>

<P>The Radiology for Chest Physicians Conference from the May 1996 International
Conference is now available on the World Wide Web for 3 hours of category
1 CME credit . It is accessible through the Virtual Hospital, selected
from the ATS homepage at <A HREF="post2.html">http://www.thoracic.org/post2.html</A>.<BR>
<IMG SRC="images/slug1.gif" HEIGHT=26 WIDTH=60></P>

<P>
<HR SIZE="4" WIDTH="80%"></P>

<H1><A NAME="ats8"></A>Helping Smokers Quit</H1>

<P>The Agency for Health Care Policy and Research has developed a pocket
guide for primary care physicians and a quick reference guide for smoking
cessation specialists. For a free copy of either guide, contact AHCPR at:
</P>

<P><B>AHCPR Publications Clearinghouse<BR>
PO Box 8547<BR>
Silver Spring, MD 20907<BR>
phone: 800/358-9295<BR>
fax: 301/594-2800</B><BR>
</P>

<P>(wait for automated voice instructions. Press 0, then enter 960693 for
the primary care clinician guide or 960694 for the smoking cessation specialist
guide); web site: <A HREF="http://www.ahcpr.gov/">http://www.ahcpr.gov/</A>.<BR>
<IMG SRC="images/slug1.gif" HEIGHT=26 WIDTH=60></P>

<P>
<HR SIZE="4" WIDTH="80%"></P>

<H1><A NAME="ats9"></A>From Washington</H1>

<H2>Gary Ewart</H2>

<P><IMG SRC="images/monument.gif" HEIGHT=174 WIDTH=120> On September 30,
hours before the start of the new fiscal year, Congress and the Administration
came to an agreement on federal spending for fiscal year 1997. To avoid
another round of federal shutdowns, Congress passed and the President signed,
a year-long spending bill that combines six appropriations bills that had
not yet been enacted. The spending measure included an additional $6.5
billion in spending for various Administration priorities. Highlights of
the bill include: an increase in funding for the National Institutes of
Health (NIH), Centers for Disease Control and Prevention (CDC), and the
Agency for Health Care Policy and Research (AHCPR). Congress also included
funding for a new clinical center at NIH. Please see the chart below for
program specifics. In separate action, the Congress and the Administration
completed work on the 1997 Veteran's Administration-Housing and Urban Development
and Independent Agencies Appropriations bill. The measure provided a $5
million increase for VA medical research programs (total = $262 million)
and a $170 million increase for EPA funding (total = $6.7 billion).<BR>
<IMG SRC="images/slug1.gif" HEIGHT=26 WIDTH=60></P>

<CENTER><P><B><FONT SIZE=+2>FY97 NIH Institute Funding For Selected Institutes<BR>
(in thousands of dollars)</FONT></B> </P></CENTER>

<TABLE BORDER=2 >
<TR ALIGN="CENTER" VALIGN="TOP">
<TD><B>Institute</B></TD>

<TD><B>FY96</B></TD>

<TD><B>President's FY97 Request</B></TD>

<TD><B>House Bill</B></TD>

<TD><B>Senate Bill </B></TD>

<TD><B>FY97*</B></TD>
</TR>

<TR ALIGN="CENTER" VALIGN="TOP">
<TD>NHLBI</TD>

<TD>1,354,946</TD>

<TD>1,378,670</TD>

<TD>1,438,265</TD>

<TD>1,403,557</TD>

<TD>1,433,001</TD>
</TR>

<TR ALIGN="CENTER" VALIGN="TOP">
<TD>NIAID</TD>

<TD>1,168,483</TD>

<TD>1,208,730</TD>

<TD>1,256,149</TD>

<TD>1,229,009</TD>

<TD>1,257,234</TD>
</TR>

<TR ALIGN="CENTER" VALIGN="TOP">
<TD>NIEHS</TD>

<TD>288,378</TD>

<TD>295,142</TD>

<TD>308,258</TD>

<TD>300,853</TD>

<TD>308,819</TD>
</TR>

<TR ALIGN="CENTER" VALIGN="TOP">
<TD>NCRR</TD>

<TD>390,298</TD>

<TD>377,599</TD>

<TD>416,523</TD>

<TD>395,852</TD>

<TD>415,145</TD>
</TR>

<TR ALIGN="CENTER" VALIGN="TOP">
<TD>Fogarty</TD>

<TD>25,327</TD>

<TD>25,547</TD>

<TD>26,707</TD>

<TD>26,707</TD>

<TD>26,586</TD>
</TR>

<TR ALIGN="CENTER" VALIGN="TOP">
<TD>Directors's Office</TD>

<TD>260,072</TD>

<TD>251,513</TD>

<TD>275,423</TD>

<TD>276,625</TD>

<TD>287,206</TD>
</TR>

<TR ALIGN="CENTER" VALIGN="TOP">
<TD>Building/<BR>
Facility</TD>

<TD>146,151</TD>

<TD>390,261</TD>

<TD>200,000</TD>

<TD>180,000</TD>

<TD>200,000</TD>
</TR>

<TR ALIGN="CENTER" VALIGN="TOP">
<TD>NIH</TD>

<TD>11,927,562</TD>

<TD>12,376,561</TD>

<TD>12,747,203</TD>

<TD>12,414,580</TD>

<TD>12,747,203</TD>
</TR>
</TABLE>

<CENTER><P>*Total figures include transfers to Office of AIDS Research
</P></CENTER>

<P><BR>
<BR>
</P>

<CENTER><P><B><FONT SIZE=+2>Selected Public Health Service Programs<BR>
(in thousands of dollars)</FONT></B> </P></CENTER>

<TABLE BORDER=2 >
<TR ALIGN="CENTER" VALIGN="TOP">
<TD><B>Institute</B></TD>

<TD><B>FY96</B></TD>

<TD><B>President's FY97 Request</B></TD>

<TD><B>House </B></TD>

<TD><B>Senate</B></TD>

<TD><B>FY97*</B></TD>
</TR>

<TR ALIGN="RIGHT" VALIGN="TOP">
<TD>Black Lung Clinics</TD>

<TD>3,811</TD>

<TD>0</TD>

<TD>3,900</TD>

<TD>4,000</TD>

<TD>4,000</TD>
</TR>

<TR ALIGN="RIGHT" VALIGN="TOP">
<TD>CDC*</TD>

<TD>2,111,916</TD>

<TD>2,245,758</TD>

<TD>2,187,018</TD>

<TD>2,209,948</TD>

<TD>2,303,698</TD>
</TR>

<TR ALIGN="RIGHT" VALIGN="TOP">
<TD>TB</TD>

<TD>119,303</TD>

<TD>***</TD>

<TD>119,303</TD>

<TD>119,303</TD>

<TD>119,303</TD>
</TR>

<TR ALIGN="RIGHT" VALIGN="TOP">
<TD>Infectious Disease</TD>

<TD>62,153</TD>

<TD>87,820</TD>

<TD>82,153</TD>

<TD>86,153</TD>

<TD>87,820</TD>
</TR>

<TR ALIGN="RIGHT" VALIGN="TOP">
<TD>Injury Control Center</TD>

<TD>43,198</TD>

<TD>43,198</TD>

<TD>40,598</TD>

<TD>40,598</TD>

<TD>43,198</TD>
</TR>

<TR ALIGN="RIGHT" VALIGN="TOP">
<TD>NIOSH</TD>

<TD>128,623</TD>

<TD>136,584</TD>

<TD>128,623</TD>

<TD>136,584</TD>

<TD>141,584</TD>
</TR>

<TR ALIGN="RIGHT" VALIGN="TOP">
<TD>AHCPR</TD>

<TD>125,169</TD>

<TD>143,780</TD>

<TD>125,169</TD>

<TD>143,587</TD>

<TD>143,587</TD>
</TR>
</TABLE>

<CENTER><P>* CDC totals include fund for Crime Bill progams. *** The Administration's
request for TB funding was included in a joint sexually transmitted disease-TB
block grant. </P></CENTER>

<P><BR>
<BR>
</P>

<CENTER><TABLE BORDER=2 >
<TR ALIGN="CENTER" VALIGN="TOP">
<TD><B><FONT SIZE=+2>EPA Program</FONT></B></TD>

<TD><B><FONT SIZE=+2>FY97</FONT></B></TD>
</TR>

<TR ALIGN="CENTER" VALIGN="TOP">
<TD>Science and Technology</TD>

<TD>$542 million</TD>
</TR>

<TR ALIGN="CENTER" VALIGN="TOP">
<TD>Programs and Management</TD>

<TD>$1.71 billion</TD>
</TR>

<TR ALIGN="CENTER" VALIGN="TOP">
<TD>Superfund</TD>

<TD>$1.394 billion</TD>
</TR>

<TR ALIGN="CENTER" VALIGN="TOP">
<TD>Leaking Underground Storage Tanks</TD>

<TD>$60 million</TD>
</TR>

<TR ALIGN="CENTER" VALIGN="TOP">
<TD>Clean Water</TD>

<TD>$625 million</TD>
</TR>

<TR ALIGN="CENTER" VALIGN="TOP">
<TD>Drinking Water</TD>

<TD>$1.275 billion</TD>
</TR>

<TR ALIGN="CENTER" VALIGN="TOP">
<TD>State Grants</TD>

<TD>$674 million</TD>
</TR>

<TR ALIGN="CENTER" VALIGN="TOP">
<TD>Building and Facilities</TD>

<TD>$872 million</TD>
</TR>
</TABLE></CENTER>

<P>
<HR SIZE="4" WIDTH="80%"></P>

<H1><A NAME="ats10"></A>Meetings, Conferences, and Courses</H1>

<P>36th Annual Durrance-Waring Mid-Winter Chest Conference: February 19-22,
1997, Aspen, Colorado. This conference is designed for pulmonologists,
thoracic surgeons, critical care specialists, and general internists. CME
credits are available. For information call 303-388-4327. </P>

<P>The Thoracic Society of Australia and New Zealand Annual Scientific
Meeting: April 6-10, 1997, Wellington Festival and Convention Centre, Wellington,
New Zealand. Plenary sessions will focus on updates for the practicing
clinician; combined sessions with the Australasian Society of Clinical
Immunology and Allergy and with the Australasian Sleep Association will
be offered as well. Abstract deadline is November 29, 1996. For information
contact the Thoracic Society of Australia and New Zealand, 1997 Annual
Scientific Meeting, c/o Conference Consultants and Management Limited,
PO Box 6175, Wellington, New Zealand. Phone: 64-4-472-7420; Fax: 64-4-472-7426.
</P>

<P>Thomas L. Petty Aspen Lung Conference - 40th Annual Meeting: Biology
and Pathobiology of the Lung Circulation: June 4-7, 1997, Aspen Colorado.
The Conference will explore the normal functions of the lung vascular cells
and how they respond to shear stress, hypoxia, to inflammatory cells and
their mediators. Abstract deadline is February 3, 1997. For information
contact Norbert F. Voelkel, M.D., Box C272, University of Colorado Health
Sciences Center, 4200 E. 9th Avenue, Denver, CO 80262. Phone: 303-315-7767;
Fax: 303-315-5632. </P>

<P>1st International Congress of Thorax Surgery: July 1-8, 1997, Athens,
Greece. For information contact the Congress Secretariat, Triaena Congress,
24, Har. Trikoupi Str, 10679 Athens, Greece. Phone: 30-1-3609511; Fax 30-1-3607962.
<BR>
<IMG SRC="images/slug1.gif" HEIGHT=26 WIDTH=60></P>

<P>
<HR SIZE="4" WIDTH="80%"></P>

<H1><A NAME="ats11"></A>Recent News Releases</H1>

<H2>Tuberculin Test Reactions Higher in Health Care Workers</H2>

<P>For clinical personnel at two Canadian hospitals, the prevalence of
significant tuberculosis reactions and of documented test conversions was
unexpectedly high, according to the results of a study published in the
October issue of the American Journal of Respiratory and Critical Care
Medicine. Richard I. Menzies, M.D., of the Montreal Chest Institute, Montreal,
Canada, along with 3 associates, tested 522 workers at two Montreal hospitals.
Participants completed questionnaires, then underwent two-step tuberculin
testing. Of the group, 196 (38%) were tuberculin reactors; 23 (4%) had
documented conversions. Prior to the use of antibiotics, tuberculosis represented
a major occupational hazard for health care workers. During training, 81%
to 100% of these workers had documented tuberculin conversions, and the
incidence of active tuberculosis was 35 to 50 times higher for this group.
However, from 1950 to the early 1980&sup1;s, the incidence of active TB
declined steadily in North America. Many North American hospitals admitted
few, if any, TB patients. As a result, hospital workers had conversion
rates not significantly different from those of the general population.
However, since 1985, the resurgence of TB, along with the HIV epidemic,
have resurrected concerns about TB infection in health care workers, according
to the investigators.</P>

<P>In this study, the number of tuberculin reactions was higher at one
hospital among clinical as opposed to nonclinical personnel. At the other
hospital, the prevalence was greater among staff on the surgical units
as compared to the intensive care and medical wards. In the study, initial
tuberculin reaction was associated with older age, foreign birth, male
gender, and BCG vaccine&shy;the immunizing agent against TB prepared from
Calmette-Guerin bacillus. After adjustment for these factors, clinical
personnel were 2.6 times more likely to have an initial positive tuberculin
reaction than non-clinical workers. The estimated annual risk of infection
among exposed workers ranged from 1.6% to 2.7%, according to the researchers.
At one of the hospitals, the prevalence of tuberculosis infection was highest
among surgical nurses, and coincided with a low air change rate in surgical
patient care areas and a substantial delay in diagnosing one patient with
active tuberculosis. As a result of the study, administrators at both hospitals
changed their infection control procedures.</P>

<H2>Mechanism of Improved Lung Function Following LVRS Surgery</H2>

<P>Writing in the October issue of the American Journal of Respiratory
and Critical Care Medicine, Arthur F. Gelb, M.D., of the Pulmonary Division,
Department of Medicine, Lakewood Regional Medical Center, Lakewood, California,
along with 3 associates, demonstrated marked improvement in the lung function
of 12 patients after lung volume reduction surgery (LVRS). The researchers
removed diseased tissue in the 12 symptomatic patients who had highly advanced
chronic obstructive pulmonary disease (COPD). The investigators checked
lung function prior to surgery and at the end of 6 months. Of the dozen
patients, who averaged approximately 68 years old, 10 were men. All had
severe COPD symptoms that had not improved despite treatment with antibiotics,
aerosol and systemic bronchodilators, corticosteroids, and physical conditioning
training. Using thorascopic surgery, the investigators excised tissue destroyed
by emphysema, reducing volume by 15% to 20% in each lung. The researchers
point out that their study demonstrated marked clinical and physiologic
improvement in lung function after surgery in this group of carefully selected
patients. They believe that the improvement in lung function resulted from
the lungs' increased elastic recoil properties, causing secondary increases
in airway diameter. They wrote: &quot;The increased lung elastic recoil
in the remaining lung provides driving pressure and improves airway stability
during expiratory airflow.&quot; The researchers plan long-term follow-up.<BR>
<IMG SRC="images/slug1.gif" HEIGHT=26 WIDTH=60></P>

<P>
<HR SIZE="4" WIDTH="80%"></P>

<H1><A NAME="ats12"></A>ABIM-1997 Certification Exam Dates</H1>

<P>The American Board of Internal Medicine Certification Examination in
Critical Care Medicine, 1997 Certification Examination in Pulmonary Disease:
Registration Period: <B>January 1, 1997-April 1, 1997</B>. Beginning in
1997, the Board will offer all of its subspecialty certification examinations
annually in November. Examination Date: <B>November 19, 1997</B>. </P>

<P>The American Board of Internal Medicine 1997 Recertification Examinations
in Internal Medicine, its subspecialties, and added qualifications: Registration
Period: Ongoing and continuous since July 1, 1995. Examination Date: <B>November
19, 1997</B>. </P>

<P>The Board&sup1;s new comprehensive Recertification Program consists
of an at-home, open-book, Self-Evaluation Process (SEP) and a proctored
final examination that will be administered annually in November. To be
eligible for the November final examination, diplomates must return all
their required at-home open-book SEP Modules to the Board office by <B>August
1, 1997</B> and must submit their Recertification final examination application
by <B>September 1, 1997</B>. 1997 Certification Examination for Added Qualification
in Adolescent Medicine: Registration Period: <B>January 1, 1997-April 1,
1997</B>. Examination Date: November 18, 1997. For more information and
application forms, contact: Registration Section, American Board of Internal
Medicine, 3624 Market Street, Philadelphia, PA 19104-2675. Phone: 800/441-2246
or 215/243-1500; Fax: 215/243-1590; e-mail: <A HREF="mailto:request@abim.org">request@abim.org</A>.<BR>
<IMG SRC="images/slug1.gif" HEIGHT=26 WIDTH=60></P>

<P>
<HR SIZE="4" WIDTH="80%"></P>

<H1><A NAME="ats13"></A>Pneumonia: All You Need To Know</H1>

<P>&quot;Pneumonia: All You Need To Know&quot;, will be featured on an
upcoming edition of The Cutting Edge Medical Report. Co-hosted by Dr. Michael
Neiderman, a respiratory disease specialist at Winthrop University Hospital
in Mineola, New York, this timely program will examine the different types
of pneumonia that exist and will discuss the treatments that are currently
being used and developed. This program is produced in conjunction with
the American Thoracic Society and is made possible through unrestricted
educational grants from Bayer, Zeneca Pharmaceuticals, and Pfizer, Inc.
The Cutting Edge Medical Report, a production of Information Television
Network, is a 30-minute TV magazine dedicated to showcasing the lastest
developments in medical technology. For more information on air dates and
times, and how to obtain a video copy of the program, call 1-800-INFO-ITV
(463-6488). <A HREF="http://www.itvisus.com/">http://www.itvisus.com</A>.<BR>
<IMG SRC="images/slug1.gif" HEIGHT=26 WIDTH=60></P>

<P>
<HR SIZE="4" WIDTH="80%"></P>

<H1><A NAME="credits"></A>Masthead</H1>

<BLOCKQUOTE>
<CENTER><P><B>President<BR>
</B>Philip C. Hopewell, MD</P></CENTER>

<CENTER><P><B>President-Elect<BR>
</B>Talmadge E. King, Jr., MD</P></CENTER>

<CENTER><P><B>Vice-President<BR>
</B>Edward R. Block, MD</P></CENTER>

<CENTER><P><B>Secretary-Treasurer</B> <BR>
Jeffrey Glassroth, MD</P></CENTER>

<CENTER><P><B>Past-President<BR>
</B>Leonard D. Hudson, MD</P></CENTER>

<CENTER><P><B>Executive Director<BR>
</B>Marilyn Hansen</P></CENTER>

<CENTER><P><B>Managing Editor<BR>
</B>Christina Shepherd</P></CENTER>

<CENTER><P><B>ATS News Editor<BR>
</B>Kristine Garland</P></CENTER>
</BLOCKQUOTE>

<CENTER><P>Vol. 22 No.11 November 1996. ATS News (usps 103-750, issn 0892-8916)
is published monthly at 1740 Broadway, New York, NY 10019-4374. Copyright
1996 by the American Lung Association. The American Thoracic Society is
the medical section of the American Lung Association.</P></CENTER>

<CENTER><P>Internet: http://www.thoracic.org. </P></CENTER>

<CENTER><P>
<HR SIZE="4" WIDTH="80%"></P></CENTER>

<CENTER><P><IMG SRC="images/boehring.gif" HEIGHT=34 WIDTH=125 ALIGN=BOTTOM>
<BR>
</P></CENTER>

<CENTER><P>This publication is supported by a grant from Boehringer Ingelheim
Pharmaceuticals, Inc., Ridgefield, CT. <BR>
<BR>
</P></CENTER>

<CENTER><P>
<HR SIZE="4" WIDTH="80%"><A HREF="about.html"><IMG SRC="file:///D|/ATSWEB/images/about.gif" ALT="About Society" HSPACE=1 VSPACE=1 BORDER=0 HEIGHT=35 WIDTH=84></A><A HREF="ssg.html"><IMG SRC="file:///D|/ATSWEB/images/ss.gif" ALT="Society Structure" HSPACE=1 VSPACE=1 BORDER=0 HEIGHT=35 WIDTH=84></A>
<A HREF="calendar.html"><IMG SRC="file:///D|/ATSWEB/images/calendar.gif" ALT="ATS Calendar" HSPACE=1 VSPACE=1 BORDER=0 HEIGHT=35 WIDTH=84></A>
<A HREF="gpi.html"><IMG SRC="file:///D|/ATSWEB/images/pi.gif" ALT="Gen Public Info" HSPACE=1 VSPACE=1 BORDER=0 HEIGHT=35 WIDTH=84></A>
<A HREF="ms.html"><IMG SRC="file:///D|/ATSWEB/images/memserv.gif" ALT="Memb Serv" HSPACE=1 VSPACE=1 BORDER=0 HEIGHT=35 WIDTH=84></A>
<BR>
<A HREF="pub.html"><IMG SRC="file:///D|/ATSWEB/images/pubs.gif" ALT="Publications" HSPACE=1 VSPACE=1 BORDER=0 HEIGHT=35 WIDTH=84></A>
<A HREF="press.html"><IMG SRC="file:///D|/ATSWEB/images/press.gif" ALT="Press" HSPACE=1 VSPACE=1 BORDER=0 HEIGHT=35 WIDTH=84></A>
<A HREF="index.html"><IMG SRC="file:///D|/ATSWEB/images/home.gif" ALT="Home Page" HSPACE=1 VSPACE=1 BORDER=0 HEIGHT=35 WIDTH=84></A>
<A HREF="search.html"><IMG SRC="file:///D|/ATSWEB/images/search.gif" ALT="Search" HSPACE=1 VSPACE=1 BORDER=0 HEIGHT=35 WIDTH=84></A>
<A HREF="assemb.html"><IMG SRC="file:///D|/ATSWEB/images/assemb.gif" ALT="Assemblies" HSPACE=1 VSPACE=1 BORDER=0 HEIGHT=35 WIDTH=84></A>
<A HREF="research.html"><IMG SRC="file:///D|/ATSWEB/images/research.gif" ALT="Research" HSPACE=1 VSPACE=1 BORDER=0 HEIGHT=35 WIDTH=84></A>
<BR>
<A HREF="mep.html"><IMG SRC="file:///D|/ATSWEB/images/meded.gif" ALT="Med Education" HSPACE=1 VSPACE=1 BORDER=0 HEIGHT=35 WIDTH=84></A>
<A HREF="wr.html"><IMG SRC="file:///D|/ATSWEB/images/wr.gif" ALT="Wash Report" HSPACE=1 VSPACE=1 BORDER=0 HEIGHT=35 WIDTH=84></A>
<A HREF="ic.html"><IMG SRC="file:///D|/ATSWEB/images/ic.gif" ALT="Int'l Conference" HSPACE=1 VSPACE=1 BORDER=0 HEIGHT=35 WIDTH=84></A>
<A HREF="source.html"><IMG SRC="file:///D|/ATSWEB/images/link.gif" ALT="Web Links" HSPACE=1 VSPACE=1 BORDER=0 HEIGHT=35 WIDTH=84></A>
<A HREF="store.html"><IMG SRC="file:///D|/ATSWEB/images/store.gif" ALT="Store" HSPACE=1 VSPACE=1 BORDER=0 HEIGHT=35 WIDTH=84></A>
<A HREF="sig.html"><IMG SRC="file:///D|/ATSWEB/images/special.gif" ALT="Special" HSPACE=1 VSPACE=1 BORDER=0 HEIGHT=35 WIDTH=84></A>

<HR SIZE="4" WIDTH="80%"><B><I><FONT SIZE=+2>American Thoracic Society<BR>
</FONT></I></B>1740 Broadway<BR>
New York, NY 10019<BR>
VOICE: 212-315-8700<BR>
Copyright &copy; 1996 American Lung Association.<BR>
The American Thoracic Society is the medical section <BR>
of the American Lung Association.<BR>
</P></CENTER>

</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-9</DOCNO>
<DOCOLDNO>IA013-000139-B021-83</DOCOLDNO>
<DOCHDR>
http://www.thoracic.org:80/news1296.html 206.138.195.144 19970217070406 text/html 36972
HTTP/1.0 200 OK
Date: Monday, 17-Feb-97 06:59:22 GMT
Server: NCSA/1.3
MIME-version: 1.0
Content-type: text/html
Last-modified: Monday, 10-Feb-97 16:29:44 GMT
Content-length: 36791
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 3.2//EN">
<HTML>
<HEAD>
   <TITLE>American Thoracic Society - ATS News</TITLE>
   <META NAME="GENERATOR" CONTENT="Mozilla/3.0Gold (Win16; U) [Netscape]">
</HEAD>
<BODY BACKGROUND="images/back.jpg">

<CENTER><P><IMG SRC="images/newslogo.gif" HEIGHT=124 WIDTH=466 ALIGN=BOTTOM>
</P></CENTER>

<P>
<HR SIZE="5" NOSHADE="NOSHADE" WIDTH="100%"></P>

<CENTER><TABLE BORDER=2 >
<TR>
<TD><B><A HREF="newsarch.html">BACK TO NEWS ARCHIVES</A></B></TD>
</TR>
</TABLE></CENTER>

<CENTER><P>
<HR SIZE="5" WIDTH="70%"></P></CENTER>

<CENTER><P><B><FONT SIZE=+2>December 1996<BR>
</FONT><FONT SIZE=-1>Vol. 22, No. 12</FONT></B><BR>
</P></CENTER>

<TABLE>
<TR ALIGN="CENTER" VALIGN="MIDDLE">
<TD>
<H4>In This Issue</H4>
</TD>

<TD>
<H4>Announcements</H4>
</TD>
</TR>

<TR>
<TD VALIGN="TOP">
<BLOCKQUOTE>
<P><IMG SRC="images/bullet1.gif" HEIGHT=11 WIDTH=11 ALIGN=TOP> <A HREF="#ats1">1997
ALA/ATS International Conference Preview</A> </P>

<P><IMG SRC="images/bullet1.gif" HEIGHT=11 WIDTH=11 ALIGN=TOP> <A HREF="#ats2">ATS
Wants Your Vote</A> <BR>
</P>

<P><IMG SRC="images/bullet1.gif" HEIGHT=11 WIDTH=11 ALIGN=TOP> <A HREF="#ats3">Who's
Who</A> </P>
</BLOCKQUOTE>

<BLOCKQUOTE>
<P><IMG SRC="images/bullet1.gif" HEIGHT=11 WIDTH=11 ALIGN=TOP> <A HREF="#ats4">Fellowship
Awards</A></P>

<P><IMG SRC="images/bullet1.gif" HEIGHT=11 WIDTH=11 ALIGN=TOP> <A HREF="#ats5">Meetings,
Conferences, and Courses</A> </P>

<P><IMG SRC="images/bullet1.gif" HEIGHT=11 WIDTH=11 ALIGN=TOP> <A HREF="#ats7">AMA
Ballot</A> </P>

<P><IMG SRC="images/bullet1.gif" HEIGHT=11 WIDTH=11 ALIGN=TOP> <A HREF="#ats8">Convention
Camp</A></P>
</BLOCKQUOTE>

<P>
<HR SIZE="5" WIDTH="70%"></P>
</TD>

<TD VALIGN="TOP">
<BLOCKQUOTE>
<P><IMG SRC="images/bullet1.gif" HEIGHT=11 WIDTH=11 ALIGN=TOP> <A HREF="#ats9">Award
Announcements</A></P>
</BLOCKQUOTE>

<P>
<HR SIZE="5" WIDTH="70%"></P>

<BLOCKQUOTE>
<P><IMG SRC="images/bullet1.gif" HEIGHT=11 WIDTH=11 ALIGN=TOP> <A HREF="#credits">Masthead</A></P>
</BLOCKQUOTE>

<P>
<HR SIZE="5" WIDTH="70%"></P>
</TD>
</TR>
</TABLE>

<CENTER><TABLE BORDER=3 >
<TR ALIGN="JUSTIFY" VALIGN="MIDDLE">
<TD ALIGN="CENTER"><IMG SRC="images/boehring.gif" HEIGHT=34 WIDTH=125 ALIGN=CENTER>
<BR>
<BR>
This publication is supported by a grant from Boehringer Ingelheim Pharmaceuticals,
Inc., Ridgefield, CT. </TD>
</TR>
</TABLE></CENTER>

<CENTER><TABLE>
<TR ALIGN="CENTER" VALIGN="MIDDLE">
<TD><B>We welcome suggestions from the readership for new columns, story
ideas, and nominations for Who's Who in ATS. Contact the Managing Editor
at 212-315-6440 (phone); 212-315-6455 (FAX); <A HREF="mailto:cshepherd@lungusa.org">cshepherd@lungusa.org</A>.</B></TD>
</TR>
</TABLE></CENTER>

<P>
<HR SIZE="4" WIDTH="80%"></P>

<H1><A NAME="ats1"></A>1997 ALA/ATS International Conference Preview<BR>
</H1>

<TABLE>
<TR ALIGN="CENTER" VALIGN="TOP">
<TD COLSPAN="2" ALIGN="LEFT" VALIGN="TOP"><IMG SRC="images/interart.jpg" HEIGHT=227 WIDTH=181 ALIGN=LEFT>

<P>The 1997 American Lung Association/American Thoracic Society International
Conference will take place May 16-21 in San Francisco, California. This
issue contains a preview of some of the sessions and postgraduate courses
being offered at the conference. Watch for the Advance Program, which will
contain complete details on sessions, workshops and courses as well as
instructions on how to register through mail, fax, telephone and the Internet!
</P>

<P>Postgraduate Courses </P>

<P>Postgraduate courses will be offered prior to the Conference. Seven
courses will be held on Friday, May 16 and eleven courses will be held
on Saturday, May 17. The list of these courses along with their target
audiences follows. Advance registration and payment of a registration fee
are required for these courses. </P>

<P><BR>
FRIDAY, MAY 16 </P>

<P>PG1 Sarcoidosis as a Systemic Disease. Target Audience: Residents, clinicians,
and physicians in pulmonary medicine. </P>

<P>PG2 Indoor Air: Symptoms, Evaluation, Diseases and Management. Target
Audience: Pulmonary and occupational medicine clinicians and trainees who
are in an individual, group, corporate, or government practice. Also of
interest to allergists, pediatric pulmonologists, and behavioral medicine
specialists. </P>

<P>PG3 Quantitative Morphology. Target Audience: Basic scientists who need
to quantify changes in lung morphology. </P>

<P>PG4 Pulmonary Rehabilitation: Update 1997. Target Audience: Clinicians,
nurses, physicians, physiologists, respiratory therapists, and physical
therapists with a basic understanding of pulmonary rehabilitation. </P>

<P>PG5 Lung Function Testing in Infants: Theory and Practice. Target Audience:
Neonatologists, pediatric pulmonologists, pediatricians and pulmonary function
technicians. </P>

<P>PG6 Pediatric Asthma: A to Z. Target Audience: Health care providers
that care for children and adolescents with asthma and individuals interested
in the basic science of airway hyperreactivity. </P>

<P>PG7 Culture of Primary Lung Epithelium. Target Audience: Active lung
biology investigators, fellows, postdoctoral, and graduate students. </P>

<P>SATURDAY, MAY 17 </P>

<P>PG8 Update on Asthma Management Issues. Target Audience: Physicians
and health care workers involved in the care of asthmatics and the biology
of the disease. </P>

<P>PG9 Interventional Pulmonology. Target Audience: Fellows and clinicians
interested in treating tracheobronchial disorders and pleural diseases.
</P>

<P>PG10 Back to the Future: Emerging Models of Pulmonary and Critical Care
Practice. Target Audience: Practicing clinicians and clinically oriented
academicians with interests in pulmonary and critical care medicine. </P>

<P>PG11 Outcomes Evaluation, Measurement and Design: Research and Clinical
Perspectives. Target Audience: Clinicians and researchers. </P>

<P>PG12 Cell Biology of the Lung. Target Audience: Lung cell biologists,
physiologists, and clinical and basic scientists. </P>

<P>PG13 Advanced Molecular Biology Techniques. Target Audience: Cell and
molecular biologists, post-doctoral fellows, and those with an interest
in molecular biology. </P>

<P>PG14 Basic Science Techniques and Methods in Neurobiology. Target Audience:
Physiologists, basic and clinical scientists, and post-doctoral students
and fellows. </P>

<P>PG15 Pulmonary Pathology for the Pulmonologist. Target Audience: Pulmonary
fellows preparing for the boards, junior faculty and pulmonary practitioners
desiring to gain clinicopathologic/ radiologic insights. </P>

<P>PG16 Interpretation of Clinical Exercise Testing for the Clinician.
Target Audience: Physicians, respiratory trainees, exercise physiologists,
directors of pulmonary function laboratories, and respiratory therapists.
</P>

<P>PG17 Technologic Advances in the Diagnosis and Management of Pediatric
Respiratory Disease. Target Audience: Pediatric pulmonologists, neonatologists,
intensivists and health care personnel who care for children with respiratory
disease. </P>

<P>PG18 Emerging Therapeutic Trends for Pulmonary Hypertension. Target
Audience: Practicing pulmonary, critical care specialists, and interested
nurses and therapists. </P>

<P>Conference Sessions </P>

<P>The Conference sessions will officially begin on Sunday, May 18 and
run through Wednesday, May 21. The following is a list of ATS Symposia,
ALA Symposia, joint ALA/ATS Symposia, Clinical Topics in Pulmonary Medicine
track sessions, and Critical Care track sessions. The acronyms in parentheses
represent the sponsoring Assemblies. </P>

<P>SUNDAY, MAY 18 </P>

<P>ATS Clinical Topics in Pulmonary Medicine Track/Critical Care Track:
</P>

<P>8:15 am-10:15 am<BR>
A1 Clinical Year in Review 1 (CP) </P>

<P>8:15 am-11:00 am<BR>
A2 Controversies in Lung Reduction Surgery for Diffuse Emphysema (CP)<BR>
A3 Evaluating Exercise Intolerance (CP/RSF)<BR>
A4 Effects of Mechanical Ventilation on Lung Injury and Repair (CC/RSF)
</P>

<P>ALA Symposia and ALA/ATS Joint Symposia: </P>

<P>8:15 am-9:45 am<BR>
A5 Tobacco Education: Peer Teaching Models that Work (ALA/PED/BS) </P>

<P>8:15 am-11:30 am<BR>
A7 Are You Overlooking Hundreds of Volunteers? The &quot;Alternative&quot;
Volunteer-Seizing the Opportunity/Preparing for the Risk<BR>
A8 Integrated Communications for Greater Visibility and Resource Development<BR>
A9 Comprehensive Fund Raising Program </P>

<P>10:00 am-11:30 am<BR>
A10 Thumbs Up! Thumbs Down! Tobacco Use in the Movies, TV and Music Videos<BR>
A11 Policy Marketing: Adding Revenue Generation to Your Advocacy Program
</P>

<P>ATS Symposia: </P>

<P>8:15 am-11:00 am<BR>
A12 The Practical Politics of International Tobacco Control: A Primer on
Effective Strategies to Change Smoking Behavior at the Community Level
(BS/EOH/CP/ALA)<BR>
A13 Molecular Mechanisms of Leukocyte Adhesion and Migration in Lung Inflammation
(AII)<BR>
A14 Implementation and Utilization of Clinical Practice Guidelines for
Lung Disease (NRSG/CC/CP)<BR>
A15 Host Response Mechanisms to Microbial Pathogens (RCMB/AII/MTPI)<BR>
A16 The Roles of Infections and Irritants in the Pathogenesis of Asthma
(EOH/AII/MTPI/PED/RCMB/ALA) ATS Clinical Topics in Pulmonary Medicine Track/Critical
Care Track: </P>

<P>1:30 pm&shy;4:15 pm<BR>
A51 Acute Pulmonary Embolism: Evolving Management Strategies (CP)<BR>
A52 Criteria for Lung Transplantation (CP/MTPI)<BR>
A53 Controversies in Critical Care Medicine (CC)<BR>
</P>

<P>ALA Symposia and ALA/ATS Joint Symposia:<BR>
</P>

<P>A54 Asthma Education and Cultural Diversity (ALA/AII/NRSG)<BR>
A55 From Pussycats to Tigers: Putting Teeth into Tobacco Control Advocacy
Programs (ALA/EOH)<BR>
A56 Affiliated Volunteers: They Are Energized and Motivated &shy;Are You
Prepared for Them?<BR>
A57 Major/Planned Board Giving: Asthma Research Initiative as an Approach<BR>
A58 Community and Media Partnerships </P>

<P>ATS Symposia: </P>

<P>A59 Apoptosis and Cell Cycle Regulation (RCMB)<BR>
A60 Molecular Mechanisms Underlying the Effects of Nitric Oxide and Reactive
Oxidants on Airway and Chest Wall Muscles (RSF)<BR>
A61 The Intersection of Lipid and Polypeptide Mediators: From Strangers
to Bedfellows (AII)<BR>
A62 Brainstem Serotonergic Systems: Role in Sleep and Respiration (RNS)<BR>
A63 ATS/ERS Joint Symposium/Treatment of COPD: A Futuristic Approach </P>

<P>MONDAY, MAY 19 </P>

<P>ATS Clinical Topics in Pulmonary Medicine Track/Critical Care Track:<BR>
</P>

<P>8:15 am-10:15 am<BR>
B1 Clinical Year in Review 2 (CP) </P>

<P>8:15 am-11:00 am<BR>
B2 Lung Cancer in 1996: More Questions Than Answers (CP)<BR>
B3 Evidence Based Medicine and Outcomes Assessment in Pulmonary Disease
Management (CP/BS)<BR>
B4 Patient-Ventilator Interaction (CC)<BR>
</P>

<P>ALA Symposia and ALA/ATS Joint Symposia: </P>

<P>8:15 am-9:45 am<BR>
B5 Understanding Asthma and Indoor Air Quality/Open Airways for Schools:
Train the Trainer Part (1)<BR>
B6 Childhood Asthma: Insights into Pathogenesis (ALA/AII/PED)<BR>
B7 Determining Customer Preferences and Their Effects on Program Design<BR>
</P>

<P>8:15 am-11:30 am<BR>
B8 Grantsmanship and Corporate Partnerships<BR>
B9 Learn About: Lung Diseases<BR>
</P>

<P>10:00 am-11:30 am<BR>
B10 Achieving Healthy Indoor Air (ALA/EOH)<BR>
B11 The Shadow Meets Mr. Tobacco (ALA/PED)<BR>
</P>

<P>10:00 am-4:15 pm<BR>
B12 Open Airways for Schools: Train the Trainer Part (2) </P>

<P>ATS Symposia: </P>

<P>8:15 am-11:00 am<BR>
B13 Appetite-Suppressant and Toxin-Induced Pulmonary Hypertension (PC/BS)<BR>
B14 Current Issues in Pulmonary Rehabilitation (NRSG/CP/BS)<BR>
B15 Proteinases: Beyond Matrix Destruction (RCMB)<BR>
B16 Transcription Factors in Inflammatory Lung Disease (AII/RCMB)<BR>
B17 The Changing Spectrum of HIV-Related Pulmonary Disease (MTPI)<BR>
</P>

<P>ATS Clinical Topics in Pulmonary Medicine Track/Critical Care Track:
</P>

<P>1:30 pm&shy;4:15 pm<BR>
B51 Malignant Pleural Mesothelioma (CP/EOH)<BR>
B52 Clinical Decision Making: An International Approach (CP)<BR>
B53 Using Outcomes Research to Optimize the Management of Critically Ill
Patients and Intensive Care Unit (CC)<BR>
</P>

<P>ALA Symposia: </P>

<P>B54 Passion and Power in Leadership<BR>
B55 Media Advocacy: 365 Days a Year </P>

<P>ATS Symposia: </P>

<P>B57 Combined Therapies for the Treatment of Severe Respiratory Failure
in Neonates (PED)<BR>
B58 Occupational and Environmental Asthma: The Latest in Diagnosis and
Management (EOH/AII/CP/ALA/ERS/AAAAI/EAACI)<BR>
B59 New Perspectives on the Pathogenesis and Treatment of Sepsis (CC)<BR>
B60 Cellular and Molecular Implications of Mechanical Forces in the Lung
(AII/RSF/CC/RCMB)<BR>
B61 The Pulmonary Physician as Primary Care Provider </P>

<P>TUESDAY, MAY 20 </P>

<P>ATS Clinical Topics in Pulmonary Medicine Track/Critical Care Track:
</P>

<P>8:15 am-10:15 am<BR>
C1 Clinical Year in Review 3 (CP)<BR>
</P>

<P>8:15 am-11:00 am<BR>
C2 Bronchoscopy for the 21st Century (CP)<BR>
C3 Interstitial Lung Disease: Pathology Update with Clinical and Radiological
Correlations (CP)<BR>
C4 Nutrition, the Gut and Critical Illness (CC)<BR>
</P>

<P>ALA Symposia and ALA/ATS Joint Symposia: </P>

<P>8:15 am-9:45 am<BR>
C5 Report from ALA Funded Research Centers<BR>
C6 Adding Value to Your Database Assets<BR>
</P>

<P>8:15 am-11:30 am C7 ALA Nationwide Marketing Plan<BR>
C8 Lung Healthy Communities<BR>
C9 Virtual Leadership: Managing from a Distance<BR>
</P>

<P>10:00 am-11:30 am<BR>
C10 What's New in Asthma Research and Treatment<BR>
C11 Clean Air Act Update (ALA/EOH)<BR>
</P>

<P>ATS Symposia: </P>

<P>8:15 am-11:00 am<BR>
C13 How Can Clinicians Foster Self-Management in Their Patients?<BR>
(BS/PED/NRSG/CP/ALA)<BR>
C14 TB &shy;Year in Review (MTPI)<BR>
C15 Clinical Outcome Measures in Sleep Apnea (RNS/NRSG)<BR>
C16 Normal and Abnormal Control of Ventilation in Infancy and Childhood
(PED/RNS)<BR>
C17 Particulate Pollution and Biologic Plausibility: Can Studies in the
Laboratory Substantiate the Epidemiology? (EOH) </P>

<P>ATS Clinical Topics in Pulmonary Medicine Track/Critical Care Track:
</P>

<P>3:15 pm-6:00 pm<BR>
C51 Lymphangioleiomyomatosis (LAM): New Insights into Biology and Management
(CP)<BR>
C52 Update on Hemoptysis (CP)<BR>
C53 Clinical Cases in Critical Care 1 (CC)<BR>
</P>

<P>ATS Symposia </P>

<P>C54 National Asthma Education and Prevention Program: Expert Panel Guidelines
Update Report (DLD)<BR>
C55 Respiratory Mechanics During Mechanical Ventilation: Clinical Application
(CC)<BR>
C56 Novel Signaling Pathways in Vascular Biology (PC/RCMB)<BR>
C57 Airway Smooth Muscle in Asthma (RSF/AII)<BR>
C58 Pulmonary Physician as Primary Care Provider </P>

<P>WEDNESDAY, MAY 21 </P>

<P>ATS Clinical Topics in Pulmonary Medicine Track/Critical Care Track:
</P>

<P>8:15 am-10:15 am<BR>
D1 Clinical Year in Review 4 (CP) </P>

<P>8:15 am-11:00 am<BR>
D2 Clinical Pediatric Chest Rounds (PED/CP)<BR>
D3 Radiology and Clinical Correlation for the Chest Physician (CCR)<BR>
D4 Inhaled Therapies in Respiratory Failure (CC)<BR>
</P>

<P>ATS Symposia: </P>

<P>D5 The Physiology of Respiratory Muscles<BR>
D6 Matrix and Cellular Interactions in Airway Smooth Muscle Remodeling
(AII/RCMB)<BR>
D7 Stress and Asthma: Emerging Lines of Evidence (BS/NRSG/AII/CP/EOH/ALA)<BR>
D8 Update on Non-Tuberculous Mycobacterial (NTM) Pulmonary Diseases (MTPI)<BR>
D9 Potential Therapeutic Targets in Airway Inflammation (AII/RCMB) </P>

<P>ATS Clinical Topics in Pulmonary Medicine Track/Critical Care Track:
</P>

<P>1:30 pm-4:15 pm<BR>
D51 Community-Acquired Pneumonia: The Out-Patient Interface (CP/MTPI)<BR>
D52 Pulmonary Involvement in Non-Pulmonary Disorders (CP)<BR>
D53 Investigating the Injured Lung (CC)<BR>
</P>

<P>ATS Symposia: </P>

<P>D54 Genetic Basis of Pulmonary Disease (PED/RCMB)<BR>
D55 Asthma Disease State Management in the Managed Care Environment (NRSG/BS/ALA)<BR>
D56 Clinical Cases in Critical Care 2 (CC)<BR>
D57 Infectious and Economical Issues Arising from Ventilator Circuits (CC)
</P>

<P>Assemblies and Other Sponsoring Organizations </P>

<P>AII - Allergy, Immunology and Inflammation; BS - Behavioral Science;
CC - Critical Care; CP - Clinical Problems; EOH - Environmental and Occupational
Health; MTPI - Microbiology, Tuberculosis and Pulmonary Infections; NRSG
- Nursing; PC - Pulmonary Circulation; PED - Pediatrics; RCMB - Respiratory
Cell and Molecular Biology; RNS - Respiratory Neurobiology and Sleep; RSF
- Respiratory Structure and Function; CCR - Council of Chapter Representatives;
ALA - American Lung Association; ERS - European Respiratory Society; AAAAI
- American Academy of Allergy, Asthma and Immunology; EAACI - European
Academy of Allergy and Clinical Immunology<BR>
<IMG SRC="images/slug1.gif" HEIGHT=26 WIDTH=60></P>
</TD>
</TR>
</TABLE>

<P>
<HR SIZE="4" WIDTH="80%"></P>

<H1><A NAME="ats2"></A>ATS Wants Your Vote</H1>

<TABLE>
<TR ALIGN="CENTER" VALIGN="TOP">
<TD COLSPAN="2" ALIGN="LEFT" VALIGN="TOP">At its 1996 annual meeting, the
American Medical Association adopted proportional representation for national
specialty societies in the AMA's policy-making body, the House of Delegates.
Specialty society representation is dependent upon the number of members
of a specialty society (e.g., ATS) who select that society to represent
them in the AMA. At present, ATS has two members (a delegate and an alternate)
at the AMA House of Delegates, namely Joseph Sokolowski, Jr. and Gibbe
Parsons. In order for ATS to continue to represent the pulmonary/critical
care community, it is important that ATS members who are AMA members select
the American Thoracic Society. If you are an AMA member, you will receive
a ballot. If you are not an AMA member, but wish to be initiated, please
call 1-800-AMA-3211 for a membership application and a ballot (copy of
ballot on page 6). The deadline for this ballot process is December 20,
1996. New delegates should be seated at the AMA&sup1;s next annual meeting
in June 1997. For your convenience, you have the option of casting your
vote by dialing 1-888-200-5309 (toll-free). You will be asked to enter
your 11-digit AMA membership number and the three-digit code for your selection
from the ballot. You may also return you ballot by mail to AMA/Specialty
Society Allocation Ballot, c/o the Blackstone Group, 360 North Michigan
Avenue, Chicago, IL 60601-9527.<BR>
<IMG SRC="images/slug1.gif" HEIGHT=26 WIDTH=60></TD>
</TR>
</TABLE>

<P>
<HR SIZE="4" WIDTH="80%"></P>

<H1><A NAME="ats3"></A>Who's Who in ATS</H1>

<TABLE>
<TR ALIGN="CENTER" VALIGN="TOP">
<TD COLSPAN="2" ALIGN="LEFT" VALIGN="TOP">
<H2>Phyllis Armelle Dennery, M.D.</H2>

<P><IMG SRC="images/phyllis.jpg" HEIGHT=152 WIDTH=111 ALIGN=BOTTOM>Dr.
Dennery received her M.D. from Howard University College of Medicine, Washington,
D.C. in 1984 and went on to a residency in pediatrics at Children's Hospital
National Medical Center, Washington, D.C. in 1987. She was nominated and
elected to Who's Who among Black Americans while at Children's Hospital.
In 1989, Dr. Dennery became certified by the American Board of Pediatrics
and certified by the subboard of neonatal-perinatal medicine in 1989. In
1989, she was among those chosen to be included in the second edition of
the International Leaders in Achievement. She completed her postdoctoral
fellowship in neonatology at Case Western Reserve, Cleveland, Ohio in 1990
and was appointed Assistant Professor of Pediatrics at Stanford University,
CA. In 1992 and 1993, she was an Andrew W. Mellon Fellow. In 1994, she
was nominated to Who's Who in the West. In 1996, she was nominated to Who's
Who in the World and Who's Who Amongst American Women. She is the recipient
of the 1997 Ross Young Investigator Award from the Western Society for
Pediatric Research. Dr. Dennery is a member of the American Thoracic Society,
the Oxygen Society, the Western Society for Pediatric Research, the Society
for Pediatric Research, the Society for Developmental Biology, the American
Association for the Advancement of Science, the Perinatal Research Society,
and the European Respiratory Society. Dr. Dennery has been active on several
ATS committees: the Membership Committee, (chair, May 1995 to present),
the Pediatric Assembly Scientific Committee, and the Nominating Committee.
She is involved in the ATS Task Force on Minorities and the ATS Task Force
on Women. Her research interests include mechanisms in oxidative injury
in developing organisms, the role of heme oxygenase and bilirubin in neonatal
endogenous antioxidant defense, and the maturational regulation of heme
oxygenase in oxidant stress. Her clinical interests include neonatal respiratory
failure and bronchopulmonary dysplasia.<BR>
<IMG SRC="images/slug1.gif" HEIGHT=26 WIDTH=60></P>
</TD>
</TR>
</TABLE>

<P>
<HR SIZE="4" WIDTH="80%"></P>

<H1><A NAME="ats4"></A>Fellowship Awards</H1>

<TABLE>
<TR ALIGN="CENTER" VALIGN="TOP">
<TD COLSPAN="2" ALIGN="LEFT" VALIGN="TOP">National Research CouncilFord
Foundation Postdoctoral Fellowships for Minorities. Deadline for submission
of applications January 3, 1997. For inquiries concerning application materials
and program administration, contact: the Fellowship Office TJ 2039, National
Research Council, 2101 Constitution Avenue, Washington, D.C. 20418. Tel.:
202/334-2872. E-mail: infofell@nas.edu<BR>
<IMG SRC="images/slug1.gif" HEIGHT=26 WIDTH=60></TD>
</TR>
</TABLE>

<P>
<HR SIZE="4" WIDTH="80%"></P>

<H1><A NAME="ats5"></A>Meetings, Conferences, and Courses</H1>

<TABLE>
<TR ALIGN="CENTER" VALIGN="TOP">
<TD COLSPAN="2" ALIGN="LEFT" VALIGN="TOP">New York State Thoracic Society
Annual Scientific Assembly--January 24-25, 1997, Hotel Thayer, West Point,
NY. Contact:518/453-0172, ext. 314 or 309. 
<P>Internationl Paediatric Respiratory Congress--March 16-19, 1997, Sydney
Convention and Exhibition Centre, Darling Harbour, Sydney. Contact: Congress
Secretariat, International Paediatric Respiratory Congress, ICMS Australasia,
GPO Box 2609 Sydney NSW 2001. tel.: 61-2-92411478; fax: 61-2-92513552.
</P>

<P>The Home and Community Care of the Chronically Ill or Medically Complex
Child--April 2-4, 1997, Newport Doubletree Hotel, Newport, Rhode Island.
Contact: Dorothy Page, MSN, FNP, National Association of Pediatric Home
and Community Care, c/o University of Massachusetts Medical Center, Department
of Pediatric Pulmonology, 55 Lake Avenue North, Worcester, MA 01655; tel.:
508/856-1908; fax: 508/856-2609. </P>

<P>Critical Care '97 11th Annual Review and Update--April 30-May 4, 1997,
Hyatt Regency, Washington, D.C. 41.25 credit hours in category 1 of the
Physician's Recognition Award of the AMA. Contact: Center for Bio-Medical
Communications, Inc., tel: 201/385-8080; fax: 201/385-5650. E-mail cbcbiomed@aol.com.
</P>

<P>18th Annual Congress of the European Society of Mycobacteriology--June
17-18, 1997, Cordoba, Spain. Contact: Congress Secretariat of ESM-97, Vincit
International Agency, Plaza de Espana no. 18, Torre de Madrid, Planta no.
10, 28008 Madrid, Spain. Tel.: 34-1-5590426; fax: 34-1-5592505. </P>

<P>2nd International Symposium on Mycobacteria of Clinical Interest--June
19-20, 1997, Cordoba, Spain. Contact: Congress Secretariat of ISM97 Vincit
International Agency, Plaza de Espana no. 18, Torre de Madrid, Planta no.
10, 28008 Madrid, Spain. Tel.: 34-1-5590426; fax: 34-1-5592505.<BR>
<IMG SRC="images/slug1.gif" HEIGHT=26 WIDTH=60></P>
</TD>
</TR>
</TABLE>

<P>
<HR SIZE="4" WIDTH="80%"></P>

<H1><A NAME="ats7"></A>AMA Ballot</H1>

<TABLE>
<TR ALIGN="CENTER" VALIGN="TOP">
<TD COLSPAN="2" ALIGN="LEFT" VALIGN="TOP">Call 1-888-200-5309 to vote by
phone for the one specialty society which you would like to represent you
in the AMA House of Delegates. 
<P>Aerospace MedicalAssociation........024 </P>

<P>American Academy of Allergy, Asthma, &amp; Immunology........036 </P>

<P>American Academy of Child &amp; Adolescent Psychiatry........040 </P>

<P>American Academy of Dermatology........048 </P>

<P>American Academy of Facial Plastic &amp; Reconstructive Surgery........480
</P>

<P>American Academy of Family Physicians........060 </P>

<P>American Academy of Insurance Medicine........756 </P>

<P>American Academy of Neurology........084 </P>

<P>American Academy of Ophthalmology........115 </P>

<P>American Academy of Orthopaedic Surgeons........120 </P>

<P>American Academy of Otolaryngic Allergy........126 </P>

<P>American Academy of Otolaryngology-Head &amp; Neck Surgery........125
</P>

<P>American Academy of Pain Medicine........128 </P>

<P>American Academy of Pediatrics........132 </P>

<P>American Academy of Physical Medicine &amp; Rehabilitation........144
</P>

<P>American Association ofClinical Endocrinologists........151 </P>

<P>American Association of Clinical Urologists........152 </P>

<P>American Association of Electrodiagnostic Medicine........175 </P>

<P>American Association of Neurological Surgeons........852 </P>

<P>American Association of Plastic Surgeons........216 </P>

<P>American Association of Public Health Physicians........220 </P>

<P>American Association for Thoracic Surgery........168 </P>

<P>American College of Allergy, Asthma, &amp; Immunology........252 </P>

<P>American College of Cardiology........264 </P>

<P>American College of Chest Physicians........276 </P>

<P>American College of Emergency Physicians........285 </P>

<P>American College of Gastroenterology........288 </P>

<P>American College of Legal Medicine........290 </P>

<P>American College of Medical Genetics........291 </P>

<P>American College of Medical Quality........338 </P>

<P>American College of Nuclear Medicine........298 </P>

<P>American College of Nuclear Physicians........299 </P>

<P>American College of Obstetricians &amp; Gynecologists........300 </P>

<P>American College of Occupational &amp; Environmental Medicine........305
</P>

<P>American College of Physician Executives........065 </P>

<P>American College of Physicians........312 </P>

<P>American College of Preventive Medicine........318 </P>

<P>American College of Radiation Oncology........325 </P>

<P>American College of Radiology........324 </P>

<P>American College of Rheumatology........576 </P>

<P>American College of Surgeons........336 </P>

<P>American Gastroenterological Association........384 </P>

<P>American Geriatrics Society........390 </P>

<P>American Institute of Ultrasound in Medicine........485 </P>

<P>American Medical Directors Assn.........421 </P>

<P>American Medical Group Assn.........394 </P>

<P>American Orthopaedic Assn.........466 </P>

<P>American Orthopaedic Foot and Ankle Society........580 </P>

<P>American Pediatric Surgical Assn.........493 </P>

<P>American Psychiatric Association........516 </P>

<P>American Roentgen Ray Society........588 </P>

<P>American Sleep Disorders Assn.........592 </P>

<P>American Society of Abdominal Surgeons........630 </P>

<P>American Society of Addiction Medicine........425 </P>

<P>American Society of Anesthesiologists........636 </P>

<P>American Society of Cataract &amp; Refractive Surgery........398 </P>

<P>American Society of Clinical Oncology........590 </P>

<P>American Society of Clinical Pathologists........648 </P>

<P>American Society of Colon and Rectal Surgeons........504 </P>

<P>American Society of Cytopathology........650 </P>

<P>American Society for Dermatologic Surgery........661 </P>

<P>American Society for Gastrointestinal Endoscopy........615 </P>

<P>American Society of Hematology........652 </P>

<P>American Society of Internal Medicine........654 </P>

<P>American Society of Maxillofacial Surgeons........655 </P>

<P>American Society of Neuroimaging........657 </P>

<P>American Society of Neuroradiology........631 </P>

<P>American Society of Plastic and Reconstructive Surgeons........672 </P>

<P>American Society for Reproductive Medicine........368 </P>

<P>American Society for Surgery of the Hand........624 </P>

<P>American Society for Therapeutic Radiology and Oncology........675 </P>

<P>American Thoracic Society........696 </P>

<P>American Triological Association........420 </P>

<P>American Urological Association........708 </P>

<P>Association of Military Surgeons of the U.S.........720 </P>

<P>Association of University Radiologists........764 </P>

<P>College of American Pathologists........828 </P>

<P>Congress of Neurological Surgeons........840 </P>

<P>Contact Lens Assn. of Ophthalmologists........842 </P>

<P>Int&sup1;l College of Surgeons-US Section........888 </P>

<P>Int&sup1;l Society for Cardiovascular Surgery........885 </P>

<P>National Association of Medical Examiners........905 </P>

<P>North American Spine Society........906 </P>

<P>Radiological Society of North America........912 </P>

<P>Renal Physicians Association........952 </P>

<P>Society of American Gastrointestinal Endoscopic Surgeons........653
</P>

<P>Society of Cardiovascular &amp; Interventional Radiology........917
</P>

<P>Society of Critical Care Medicine........916 </P>

<P>Society for Investigative Dermatology........911 </P>

<P>Society of Medical Consultants to theArmed Forces........913 </P>

<P>Society of Nuclear Medicine........920 </P>

<P>Society of Thoracic Surgeons........950 </P>

<P>The Endocrine Society 960 U.S. &amp; Canadian Academy of Pathology........876
<BR>
<IMG SRC="images/slug1.gif" HEIGHT=26 WIDTH=60></P>
</TD>
</TR>
</TABLE>

<P>
<HR SIZE="4" WIDTH="80%"></P>

<H1><A NAME="ats8"></A>Convention Camp</H1>

<TABLE>
<TR ALIGN="CENTER" VALIGN="TOP">
<TD COLSPAN="2" ALIGN="LEFT" VALIGN="TOP">Give your children the most exciting,
entertaining experience they've ever had! 
<P>Bring them with you to the 1997 ALA/ATS International Conference in
San Francisco. </P>

<P>While you're attending meetings and tour programs, your children can
enjoy their own Convention Camp, organized by ACCENT on Children's Arrangements,
Inc. a national company specializing in children's activities. Convention
Camp is a complete morning to early evening entertainment program packed
with activities for children ages six months to 12 years. </P>

<P><IMG SRC="images/girlboy.jpg" HEIGHT=142 WIDTH=233 ALIGN=RIGHT> </P>

<P>Scheduled activities are themed so that children experience the diversity
of San Francisco. Children will enjoy arts &amp; crafts projects, learn
about the history of San Francisco and much, much more. With a high ratio
of caregiver to child (1:2 for children 6 mos - 30 mos.; 1:4 for children
30 mos - 4 years; 1:6 for ages 4 - 6; 1:8 for children 6 - 12), campers
receive lots of personal attention. </P>

<P><IMG SRC="images/smgirl.jpg" HEIGHT=237 WIDTH=175 ALIGN=LEFT> </P>

<P><BR>
<BR>
Space for this terrific children's entertainment package is limited, so
you'll want to register early at the special advance registration rate
of $25.00 per child per day (1-10 hours). There is also a one-time registration
fee of $30.00 per child. The program cost includes morning and afternoon
snacks and juice, entertainment and craft materials. Arrangements for lunch
will be made at the time of registration. </P>

<P><IMG SRC="images/smboy.jpg" HEIGHT=165 WIDTH=237 ALIGN=RIGHT> </P>

<P><BR>
<BR>
<BR>
<BR>
<BR>
<BR>
<BR>
<BR>
<BR>
To enroll your children, look for the registration form in the advanced
program to be mailed in January 1997 or contact: ACCENT on Children's Arrangements,
Inc. 938 Lafayette, Suite 201 New Orleans, LA 70113 Questions? Call 504/524-1227
</P>

<P>*The ALA/ATS reserves the right to cancel this program should a minimum
number of children not be met. You will be notified by May 5 and receive
a full refund. </P>

<P>The ALA/ATS will not be liable for any cost involving this cancellation.
<BR>
<IMG SRC="images/slug1.gif" HEIGHT=26 WIDTH=60></P>
</TD>
</TR>
</TABLE>

<P>
<HR SIZE="4" WIDTH="80%"></P>

<H1><A NAME="ats9"></A>Award Announcements</H1>

<TABLE>
<TR ALIGN="CENTER" VALIGN="TOP">
<TD COLSPAN="2" ALIGN="LEFT" VALIGN="TOP">Dr. Kristin Fraser is the winner
of the Cameron C. Gray Fellowship Award for 1997-1998 from the Ontario
Thoracic Society. This annual award is given to support the salary of a
second or third year resident who is in one of the university training
programs in the Province of Ontario. Dr. Fraser is currently in her second
year of the Respiratory Training Programme at the University of Toronto.

<P>ATS member Dr. David J. Pierson received the 1996 Forrest M. Bird Achievement
Award. The Bird award recognizes scientific contributions to the respiratory
care profession. Dr. Pierson has written six books; 75 research papers
and case reports; 185 reviews, editorials, chapters, and position statements;
60 research abstracts; and 15 audiovisual programs related to research
and training the respiratory care field.<BR>
<IMG SRC="images/slug1.gif" HEIGHT=26 WIDTH=60></P>
</TD>
</TR>
</TABLE>

<P>
<HR SIZE="4" WIDTH="80%"></P>

<H1><A NAME="credits"></A>Masthead</H1>

<TABLE>
<TR ALIGN="CENTER" VALIGN="TOP">
<TD COLSPAN="2" ALIGN="LEFT" VALIGN="TOP">
<BLOCKQUOTE>
<CENTER><P><B>President<BR>
</B>Philip C. Hopewell, MD</P></CENTER>

<CENTER><P><B>President-Elect<BR>
</B>Talmadge E. King, Jr., MD</P></CENTER>

<CENTER><P><B>Vice-President<BR>
</B>Edward R. Block, MD</P></CENTER>

<CENTER><P><B>Secretary-Treasurer</B> <BR>
Jeffrey Glassroth, MD</P></CENTER>

<CENTER><P><B>Past-President<BR>
</B>Leonard D. Hudson, MD</P></CENTER>

<CENTER><P><B>Executive Director<BR>
</B>Marilyn Hansen</P></CENTER>

<CENTER><P><B>Managing Editor<BR>
</B>Christina Shepherd</P></CENTER>

<CENTER><P><B>ATS News Editor<BR>
</B>Kristine Garland</P></CENTER>
</BLOCKQUOTE>
</TD>
</TR>
</TABLE>

<CENTER><P>Vol. 22 No.12 December 1996. ATS News (usps 103-750, issn 0892-8916)
is published monthly at 1740 Broadway, New York, NY 10019-4374. Copyright
1996 by the American Lung Association. The American Thoracic Society is
the medical section of the American Lung Association.</P></CENTER>

<CENTER><P>Internet: http://www.thoracic.org. </P></CENTER>

<CENTER><P>
<HR SIZE="4" WIDTH="80%"></P></CENTER>

<CENTER><P><IMG SRC="images/boehring.gif" HEIGHT=34 WIDTH=125 ALIGN=BOTTOM>
<BR>
</P></CENTER>

<CENTER><P>This publication is supported by a grant from Boehringer Ingelheim
Pharmaceuticals, Inc., Ridgefield, CT. <BR>
<BR>

<HR SIZE="4" WIDTH="80%"><A HREF="about.html"><IMG SRC="file:///D|/ATSWEB/images/about.gif" ALT="About Society" HSPACE=1 VSPACE=1 BORDER=0 HEIGHT=35 WIDTH=84></A><A HREF="ssg.html"><IMG SRC="file:///D|/ATSWEB/images/ss.gif" ALT="Society Structure" HSPACE=1 VSPACE=1 BORDER=0 HEIGHT=35 WIDTH=84></A>
<A HREF="calendar.html"><IMG SRC="file:///D|/ATSWEB/images/calendar.gif" ALT="ATS Calendar" HSPACE=1 VSPACE=1 BORDER=0 HEIGHT=35 WIDTH=84></A>
<A HREF="gpi.html"><IMG SRC="file:///D|/ATSWEB/images/pi.gif" ALT="Gen Public Info" HSPACE=1 VSPACE=1 BORDER=0 HEIGHT=35 WIDTH=84></A>
<A HREF="ms.html"><IMG SRC="file:///D|/ATSWEB/images/memserv.gif" ALT="Memb Serv" HSPACE=1 VSPACE=1 BORDER=0 HEIGHT=35 WIDTH=84></A>
<BR>
<A HREF="pub.html"><IMG SRC="file:///D|/ATSWEB/images/pubs.gif" ALT="Publications" HSPACE=1 VSPACE=1 BORDER=0 HEIGHT=35 WIDTH=84></A>
<A HREF="press.html"><IMG SRC="file:///D|/ATSWEB/images/press.gif" ALT="Press" HSPACE=1 VSPACE=1 BORDER=0 HEIGHT=35 WIDTH=84></A>
<A HREF="index.html"><IMG SRC="file:///D|/ATSWEB/images/home.gif" ALT="Home Page" HSPACE=1 VSPACE=1 BORDER=0 HEIGHT=35 WIDTH=84></A>
<A HREF="search.html"><IMG SRC="file:///D|/ATSWEB/images/search.gif" ALT="Search" HSPACE=1 VSPACE=1 BORDER=0 HEIGHT=35 WIDTH=84></A>
<A HREF="assemb.html"><IMG SRC="file:///D|/ATSWEB/images/assemb.gif" ALT="Assemblies" HSPACE=1 VSPACE=1 BORDER=0 HEIGHT=35 WIDTH=84></A>
<A HREF="research.html"><IMG SRC="file:///D|/ATSWEB/images/research.gif" ALT="Research" HSPACE=1 VSPACE=1 BORDER=0 HEIGHT=35 WIDTH=84></A>
<BR>
<A HREF="mep.html"><IMG SRC="file:///D|/ATSWEB/images/meded.gif" ALT="Med Education" HSPACE=1 VSPACE=1 BORDER=0 HEIGHT=35 WIDTH=84></A>
<A HREF="wr.html"><IMG SRC="file:///D|/ATSWEB/images/wr.gif" ALT="Wash Report" HSPACE=1 VSPACE=1 BORDER=0 HEIGHT=35 WIDTH=84></A>
<A HREF="ic.html"><IMG SRC="file:///D|/ATSWEB/images/ic.gif" ALT="Int'l Conference" HSPACE=1 VSPACE=1 BORDER=0 HEIGHT=35 WIDTH=84></A>
<A HREF="source.html"><IMG SRC="file:///D|/ATSWEB/images/link.gif" ALT="Web Links" HSPACE=1 VSPACE=1 BORDER=0 HEIGHT=35 WIDTH=84></A>
<A HREF="store.html"><IMG SRC="file:///D|/ATSWEB/images/store.gif" ALT="Store" HSPACE=1 VSPACE=1 BORDER=0 HEIGHT=35 WIDTH=84></A>
<A HREF="sig.html"><IMG SRC="file:///D|/ATSWEB/images/special.gif" ALT="Special" HSPACE=1 VSPACE=1 BORDER=0 HEIGHT=35 WIDTH=84></A>

<HR SIZE="4" WIDTH="80%"><B><I><FONT SIZE=+2>American Thoracic Society<BR>
</FONT></I></B>1740 Broadway<BR>
New York, NY 10019<BR>
VOICE: 212-315-8700<BR>
Copyright &copy; 1996 American Lung Association.<BR>
The American Thoracic Society is the medical section <BR>
of the American Lung Association.<BR>
</P></CENTER>

</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-10</DOCNO>
<DOCOLDNO>IA013-000139-B021-144</DOCOLDNO>
<DOCHDR>
http://www.thoracic.org:80/orderfrm.html 206.138.195.144 19970217070425 text/html 15481
HTTP/1.0 200 OK
Date: Monday, 17-Feb-97 06:59:40 GMT
Server: NCSA/1.3
MIME-version: 1.0
Content-type: text/html
Last-modified: Friday, 20-Dec-96 20:24:20 GMT
Content-length: 15300
</DOCHDR>
<HTML>
<HEAD><TITLE>American Thoracic Society - Statements and Position Papers Request Form</TITLE></HEAD>
<BODY BACKGROUND="images/back.jpg">

<H2>AMERICAN THORACIC SOCIETY
STATEMENTS AND POSITION PAPERS REQUEST FORM</H2>

<H3>MICROBIOLOGY, TUBERCULOSIS AND PULMONARY INFECTIONS</H3>
<B>Price of set: $35.00 MEMBERS, $40.00 NON-MEMBERS</B>
<PRE>

<B>	Hospital-acquired Pneumonia in Adults:  Diagnosis, 
	Assessment of Severity, Initial Antimicrobial Therapy, and  
	Preventative Strategies:  A Consensus Statement</B>
	AJRCCM Vol. 153 pp. 1711-1725, NO 5  (May 1996)
	$6.00
	QTY:	________________________
	TOTAL:	________________________

<B>	Fungal Infections in HIV-Infected Persons</B>
	AJRCCM, Vol.152:2 (August 1995)
	$4.00
	QTY:	________________________
	TOTAL:	________________________

<B> 	Treatment of Tuberculosis and Tuberculosis Infection in Adults & 
	Children
</B>	AJRCCM, Vol. 149:5 (May 1994)
	$6.00	
	QTY:	________________________
	TOTAL:	________________________

<B> 	Guidelines for the Initial Management of Adults with Community-
	acquired Pneumonia:
	Diagnosis, Assessment of Severity and Initial Antimicrobial Therapy
</B>	ARRD, Vol. 148:5 (November 1993)
	$6.00
	QTY:	________________________
	TOTAL:	________________________

<B> 	Control of Tuberculosis in the United States				
</B>	ARRD, Vol. 146:6 (December 1992)
	$6.00
	QTY:	________________________
	TOTAL:	________________________

<B> 	Diagnosis & Treatment of Diseases Due to the Nontuberculous 
	Mycobacteria	
</B>	ARRD, Vol. 142:4 (October 1990)
	$4.00
	QTY:	________________________
	TOTAL:	________________________

<B> 	Diagnostic Standards and Classification of Tuberculosis
</B>	ARRD, Vol. 142:3 (September 1990)
	$6.00
	QTY:	________________________
	TOTAL:	________________________

<B> 	Clinical Usefulness of Skin Testing in Histoplasmosis, 
	Coccidioidomycosis and Blastomycosis
</B>	ARRD, Vol. 138:4 (October 1988)
	$4.00
	QTY:	________________________
	TOTAL:	________________________

<B> 	Chemotherapy of the Pulmonary Mycoses
</B>	ARRD, Vol. 138:4 (October 1988)
	$6.00
	QTY:	________________________
	TOTAL:	________________________

<B> 	Future Research in Tuberculosis: Prospects and Priorities for 
	Elimination
</B>	ARRD, Vol. 136:3 (September 1986)
	$4.00
	QTY:	________________________
	TOTAL:	________________________

<B> 	Mycobacteriosis and the Acquired Immunodeficiency Syndrome
</B>	ARRD, Vol. 136:2 (August 1987)
	$4.00
	QTY:	________________________
	TOTAL:	________________________

<B> 	Laboratory Diagnosis of Mycotic and Specific Fungal Infections
</B>	ARRD, Vol. 132:6 (December 1985)
	$4.00
	QTY:	________________________
	TOTAL:	________________________

<B> 	Levels of Laboratory Services for Mycobacterial Disease / The 
	Levels of Service Concept in Mycobacteriology
</B>	ARRD, Vol. 128:1 (July 1983) / ATS NEWS, Summer 1983
	$4.00
	QTY:	________________________
	TOTAL:	________________________
</PRE>

<H3>PULMONARY FUNCTION TESTING</H3>
<B>Price of set: $27.00 MEMBERS, $32.00 NON-MEMBERS</B>
<PRE>
<B> 	Recommendations for Standard Technique in Single Breath Carbon 
	Monoxide Diffusing Capacity (Transfer Factor) DLCO
</B>	AJRCCM, Vol 152, No 6 (December 1995)
	$6.00
	QTY:	________________________	
	TOTAL:	________________________

<B> 	Standardization of Spirometry - 1994 Update
</B>	AJRCCM, Vol. 152:3 (September 1995)
	$6.00
	QTY:	________________________	
	TOTAL:	________________________

<B> 	Respiratory Function Measurement in Infants: Symbols, Abbreviations,
	and Units (SI Units)
</B>	AJRCCM, Vol. 151:6 (June 1995)
	$6.00
	QTY:	________________________
	TOTAL:	________________________

<B> 	Respiratory Function Measurement in Infants: Measurement Conditions
</B>	AJRCCM, Vol. 151:6 (June 1995)
	$6.00
	QTY:	________________________	
	TOTAL:	________________________

<B> 	Respiratory Mechanics in Infants: Physiologic Evaluation in Health 
	and Disease
</B>	ARRD, Vol. 147:2 (February 1993)
	$6.00
	QTY:	________________________
	TOTAL:	________________________

<B> 	Lung Function Testing: Selection of Reference Values and 
	Interpretive Strategies
</B>	ARRD, Vol. 144:5 (November 1991)
	$6.00
	QTY:	________________________
	TOTAL:	________________________

<B> 	Quality Assurance in Pulmonary Function Laboratories
</B>	ARRD, Vol. 134:3 (September 1986)
	$4.00
	QTY:	________________________
	TOTAL:	________________________

<B> 	Pulmonary Function Laboratory Personnel Qualifications
</B>	ARRD, Vol. 134:3 (September 1986)
	$4.00
	QTY:	________________________
	TOTAL:	________________________

<B> 	Computer Guidelines for Pulmonary Laboratories
</B>	ARRD, Vol. 134:3 (September 1986)
	$4.00
	QTY:	________________________
	TOTAL:	________________________
</PRE>

<H3>RESPIRATORY DISEASE</H3>
<B>Price of set: $41.00 MEMBERS, $48.00 NON-MEMBERS</B>
<PRE>
<B> 	Lung Volume Reduction Surgery
</B>	$6.00
	QTY:	________________________
	TOTAL:	________________________

<B> 	Standards and Indications for Cardiopulmonary Sleep Studies in 
	Children
</B>	AJRCCM, Vol 153, No 2 (February 1996)
	$6.00
	QTY:	________________________
	TOTAL:	________________________

<B> 	Future Directions for Research on Disease of the Lung
</B>	AJRCCM, Vol 152, No 5 (November 1995)
	$6.00
	QTY:	________________________
	TOTAL:	________________________

<B> 	Standards for the Diagnosis and Care of Patients with Chronic 
	Obstructive Pulmonary Disease (COPD)
</B>	AJRCCM, Vol 152, No 5 (November 1995)
	$10.00
	QTY:	________________________
	TOTAL:	________________________

<B> 	Indications and Standards for the Use of Nasal Continous Positive 
	Airway Pressure (CPAP) in Sleep Apnea Syndromes
</B>	AJRCCM, Vol. 150:6 (December 1994)
	$6.00
	QTY:	________________________
	TOTAL:	________________________

<B> 	Sleep Apnea: Sleepiness, and Driving Risk
</B>	AJRCCM, Vol. 145:5 (November 1994)
	$6.00
	QTY:	________________________
	TOTAL:	________________________

<B> 	Lung Transplantation
</B>	ARRD, Vol. 147:3 (March 1993)
	$6.00
	QTY:	________________________
	TOTAL:	________________________

<B> 	Flexible Endoscopy of the Pediatric Airway
</B>	ARRD, Vol. 145:1 (January 1992)
	$4.00
	QTY:	________________________
	TOTAL:	________________________

<B> 	Withdrawing and Withholding Life-Sustaining Therapy
</B>	ARRD, Vol. 144:3 (September 1991)
	$4.00
	QTY:	________________________
	TOTAL:	________________________

<B> 	Standards of Nursing Care for Adult Patients With Pulmonary 
	Dysfunction
</B>	ARRD, Vol. 144:1 (July 1991)
	$4.00
	QTY:	________________________
	TOTAL:	________________________

<B> 	Research Priorities in Respiratory Nursing
</B>	ARRD, Vol. 142:6 (December 1990)
	$4.00
	QTY:	________________________
	TOTAL:	________________________

<B> 	Clinical Role of Bronchoalveolar Lavage in Adults with Pulmonary 
	Disease
</B>	ARRD, Vol. 142:2 (August 1990)
	$4.00
	QTY:	________________________
	TOTAL:	________________________

<B> 	Home Mechanical Ventilation of Pediatric Patients
</B>	ARRD, Vol. 141:1 (January 1990)
	$4.00
	QTY:	________________________
	TOTAL:	________________________

<B> 	Guidelines for the Approach to the Patient With Severe Hereditary 
	Alpha-1-Antitrypsin Deficiency
</B>	ARRD, Vol. 140:5 (November 1989)
	$4.00
	QTY:	________________________
	TOTAL:	________________________

<B> 	Guidelines for Percutaneous Transthoracic Needle Biopsy
</B>	ARRD, Vol. 140:1 (July 1989)
	$4.00
	QTY:	________________________
	TOTAL:	________________________

<B> 	Guidelines for Thoracentesis and Needle Biopsy of the Pleura
</B>	ARRD, Vol. 140:1 (July 1989)
	$4.00
	QTY:	________________________
	TOTAL:	________________________

<B> 	Guidelines for Fiberoptic Bronchoscopy in Adults
</B>	ARRD, Vol. 136:4 (October 1987)
	$4.00
	QTY:	________________________
	TOTAL:	________________________

<B> 	Skills of the Health Care Team Involved  in Out-of-Hospital Care 
	for Patients with COPD
</B>	ARRD, Vol. 135:5 (May 1986)
	$6.00
	QTY:	________________________
	TOTAL:	________________________

<B> 	Training of Pulmonary Physicians in Sleep Disorders
</B>	$1.00
	QTY:	________________________
	TOTAL:	________________________
</PRE>

<H3>ENVIRONMENTAL AND OCCUPATIONAL HEALTH</H3>
<B>Price of set: $21.00 MEMBERS, $24.00 NON-MEMBERS</B>
<PRE>
<B> 	Respiratory Protection Guidelines
</B>	$6.00
	QTY:	________________________
	TOTAL:	________________________

<B> 	Cigarette Smoking and Health
</B>	AJRCCM, Vol 153, No 2 (February 1996)
	$6.00
	QTY:	________________________
	TOTAL:	________________________

<B> 	Guidelines for the Evaluation of Impairment/Disability in Patients 
	with Asthma
</B>	ARRD, Vol. 147:4 (April 1993)
	$6.00
	QTY:	________________________
	TOTAL:	________________________

<B> 	Fact Sheet:"Facts About Second Hand Smoke"
</B>	ATS News, December 1993
	$1.00
	QTY:	________________________
	TOTAL:	________________________

<B> 	The Report on the ATS Workshop on the Health Effects of Atmospheric
	Acids and their Precursors
</B>	ARRD, Vol. 144:2 (August 1991)
	$6.00
	QTY:	________________________
	TOTAL:	________________________

<B> 	Health Effects of Tremolite
</B>	ARRD, Vol. 142:6 (December 1990)
	$4.00
	QTY:	________________________
	TOTAL:	________________________

<B> 	Environmental Controls and Lung Disease
</B>	ARRD, Vol. 142:4 (October 1990)
	$6.00
	QTY:	________________________
	TOTAL:	________________________

<B> 	The Diagnosis of Nonmalignant Disease Related to Asbestos
</B>	ARRD, Vol. 134:2 (August 1986)
	$4.00
	QTY:	________________________
	TOTAL:	________________________

<B> 	Guidelines as to What Constitutes an Adverse Respiratory Effect, 
	With Special Reference to Epidemiologic Studies of Air
	Pollution (and associated editorial in same issue)
</B>	ARRD, Vol. 134:4 (April 1985)
	$4.00
	QTY:	________________________
	TOTAL:	________________________

<B> 	Public Responsibility in Asbestos - Associated Diseases
</B>	ATS NEWS, Fall 1983
	$4.00
	QTY:	________________________
	TOTAL:	________________________

<B> 	Disability Legislation for Occupational Lung Disease
</B>	ATS NEWS, Summer 1981
	$4.00
	QTY:	________________________
	TOTAL:	________________________
</PRE>

<H3>OTHER INTERESTS</H3>
<B>Price of set: $26.00 MEMBERS, 30.00 NON-MEMBERS</B>
<PRE>
<B> 	Role of Pulmonary and Critical Care Medicine Physician in the 
	American Health Care System
</B>	AJRCCM, Vol 152, No 6 (December 1995)
	$6.00
	QTY:	________________________
	TOTAL:	________________________

<B> 	Animals in Medical Research
</B>	ARRD, Vol. 144:4 (October 1991)
	$4.00
	QTY:	________________________
	TOTAL:	________________________

<B> 	Physicians and the Pharmaceutical Industry
</B>	ARRD, Vol. 142:3 (September 1990)
	$4.00
	QTY:	________________________
	TOTAL:	________________________

<B> 	Medical Director of Respiratory Care
</B>	ARRD, Vol. 138:4 (October 1988)
	$4.00
	QTY:	________________________
	TOTAL:	________________________

<B> 	The Potential for Conflict of Interest of Members of the American 
	Thoracic Society
</B>	ARRD, Vol. 137:2 (February 1988)
	$4.00
	QTY:	________________________
	TOTAL:	________________________

<B> 	Essentials of a Pulmonary Consultation
</B>	ARRD, Vol. 136:4 (October 1987)
	$4.00
	QTY:	________________________
	TOTAL:	________________________

<B> 	Aspiration Hazards to the Developing Lung
</B>	ARRD, Vol. 131:5 (May 1985)
	$1.00
	QTY:	________________________
	TOTAL:	________________________

<B> 	Pulmonary Manpower
</B>	ARRD, Vol. 127:5 May 1993)
	$4.00
	QTY:	________________________
	TOTAL:	________________________

<B> 	The Tuberculin Skin Test, A Historical Perspective
</B>	ARRD, Vol. 124:3 (September 1981)
	$4.00
	QTY:	________________________
	TOTAL:	________________________

<B> 	Licensure of Respiratory Therapy Technical Personnel
</B>	ATS NEWS, Summer 1981
	$4.00
	QTY:	________________________
	TOTAL:	________________________

<B> 	American Thoracic Society Mission Statement
</B>	$1.00
	QTY:	________________________
	TOTAL:	________________________

<B> 	American Thoracic Society Strategic Plan
</B>	$1.00
	QTY:	________________________
	TOTAL:	________________________

<B> 	Report of the Workshop on Development of New Treatments for 
	Tuberculosis
</B>	$6.00
	QTY:	________________________
	TOTAL:	________________________
</PRE>

<H3>ATS RESPONSES TO FEDERAL AGENCIES AND NATIONAL ORGANIZATIONS /
HEALTH CARE POLICY POSITIONS</H3>
<B>Price of set: $5.00 MEMBERS, $6.00 NON-MEMBERS. FREE SET WITH ANY ORDER 
OVER $10.00</B>
<PRE>
<B> 	HCFA: Medicare Coverage of Lung Transplants - March 6, 1995
</B>	$1.00
	QTY:	________________________
	TOTAL:	________________________

<B> 	1995 Physcian Payment Review Commission Draft Report - March 2, 1995
</B>	$1.00
	QTY:	________________________
	TOTAL:	________________________

<B> 	DMERC: Reimbursement for Nebulizer Use - February 2, 1995
</B>	$1.00
	QTY:	________________________
	TOTAL:	________________________

<B> 	OSHA: Respiratory Protection Guidelines - February 2, 1995
</B>	$1.00
	QTY:	________________________
	TOTAL:	________________________

<B> 	HCFA: Relative Values for Critcal Care and PFT Codes - 
	February 1, 1995
</B>	$1.00
	QTY:	________________________
	TOTAL:	________________________

<B> 	HCFA: Draft Quality Indicators for Pneumonia - September 29, 1994
</B>	$1.00
	QTY:	________________________
	TOTAL:	________________________

<B> 	FDA: Over-the-Counter Marketing of Anti-Asthma Drug Products - 
	September 26, 1994
</B>	$1.00
	QTY:	________________________
	TOTAL:	________________________

<B> 	HFCA: Intermittent Positive Pressure Breathing Machine Therapy - 
	August 15, 1994
</B>	$1.00
	QTY:	________________________
	TOTAL:	________________________

<B> 	EPA: Indoor Air Quality - July 29, 1994
</B>	$1.00
	QTY:	________________________
	TOTAL:	________________________

<B> 	NIOSH: Respiratory Protective Devices - July 20, 1994
</B>	$1.00
	QTY:	________________________
	TOTAL:	________________________

</PRE>

<H3>COMPLETE ATS SET =$100.00 MEMBERS, $135.00 NON-MEMBERS</H3>
<PRE><B>
PRODUCT TOTAL:					________________________

SHIPPING & HANDLING PER 
COMPLETE SET $10.00 (INTERNATIONAL ONLY):	________________________

ORDER TOTAL:					________________________
</B>
(Please type or print clearly)
<B>
NAME:_______________________________________________

ADDRESS:_________________________________________________________________
_________________________________________________________________________

CITY:________________STATE:_____ZIP:_____________COUNTRY:________________

TELEPHONE #:______________________________________________________
FAX#:_____________________________________________________________
</B></PRE>

<H3>METHOD OF PAYMENT, <I>(CHECK ONE BOX)</I></H3>
<PRE>
<B> CHECK:</B> Make check (U.S. Dollars drawn on a  U.S. or Canadian bank only) 
	payable to: AMERICAN THORACIC SOCIETY
<B> CREDIT CARD</B>
	MASTERCARD  	VISA  	AMERICAN EXPRESS  
<B>
_____________________________________________________
AMOUNT
_____________________________________________________
ACCOUNT NUMBER
_____________________________________________________
EXPIRATION DATE
_____________________________________________________
SIGNATURE
</B>
Send to: American Thoracic Society, 1740 Broadway, 
New York, N.Y. 10019-4374, 
T. 212/ 315-8863, F. 212/ 315-6498
* PLEASE ALLOW 4-6 WEEKS FOR DELIVERY *
</PRE>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-11</DOCNO>
<DOCOLDNO>IA013-000139-B021-170</DOCOLDNO>
<DOCHDR>
http://www.thoracic.org:80/sponsors.html 206.138.195.144 19970217070435 text/html 2514
HTTP/1.0 200 OK
Date: Monday, 17-Feb-97 06:59:52 GMT
Server: NCSA/1.3
MIME-version: 1.0
Content-type: text/html
Last-modified: Tuesday, 24-Sep-96 14:30:29 GMT
Content-length: 2333
</DOCHDR>
<HTML>
<HEAD><TITLE>American Thoracic Society - Sponsorship</TITLE></HEAD>

<BODY BACKGROUND="images/back.jpg">

<CENTER><IMG ALIGN=LEFT SRC="images/smlogo.gif"><BR><H1>Sponsorship</H1></CENTER>
<HR SIZE=5 NOSHADE WIDTH=100%>
<BR><BR>
<H1>Coming Soon</H1>
<HR SIZE="4" WIDTH="80%"> 
<CENTER>
<A HREF="about.html"><IMG VSPACE="1" HSPACE="1" BORDER="0" 
SRC="images/about.gif" ALT="About Society"></A>
<A HREF="ssg.html"><IMG VSPACE="1" HSPACE="1" BORDER="0" 
SRC="images/ss.gif" ALT="Society Structure"></A>
<A HREF="calendar.html"><IMG VSPACE="1" HSPACE="1" BORDER="0" 
SRC="images/calendar.gif" ALT="ATS Calendar"></A>
<A HREF="gpi.html"><IMG VSPACE="1" HSPACE="1" BORDER="0" 
SRC="images/pi.gif" ALT="Gen Public Info"></A>
<A HREF="ms.html"><IMG VSPACE="1" HSPACE="1" BORDER="0" 
SRC="images/memserv.gif" ALT="Memb Serv"></A>
<BR>
<A HREF="pub.html"><IMG VSPACE="1" HSPACE="1" BORDER="0" 
SRC="images/pubs.gif" ALT="Publications"></A>
<A HREF="press.html"><IMG VSPACE="1" HSPACE="1" BORDER="0" 
SRC="images/press.gif" ALT="Press"></A>
<A HREF="index.html"><IMG VSPACE="1" HSPACE="1" BORDER="0" 
SRC="images/home.gif" ALT="Home Page"></A>
<A HREF="search.html"><IMG VSPACE="1" HSPACE="1" BORDER="0" 
SRC="images/search.gif" ALT="Search"></A>
<A HREF="assemb.html"><IMG VSPACE="1" HSPACE="1" BORDER="0" 
SRC="images/assemb.gif" ALT="Assemblies"></A>
<A HREF="research.html"><IMG VSPACE="1" HSPACE="1" BORDER="0" 
SRC="images/research.gif" ALT="Research"></A>
<BR>
<A HREF="mep.html"><IMG VSPACE="1" HSPACE="1" BORDER="0" 
SRC="images/meded.gif" ALT="Med Education"></A>
<A HREF="wr.html"><IMG VSPACE="1" HSPACE="1" BORDER="0" 
SRC="images/wr.gif" ALT="Wash Report"></A>
<A HREF="ic.html"><IMG VSPACE="1" HSPACE="1" BORDER="0" 
SRC="images/ic.gif" ALT="Int'l Conference"></A>
<A HREF="source.html"><IMG VSPACE="1" HSPACE="1" BORDER="0" 
SRC="images/link.gif" ALT="Web Links"></A>
<A HREF="store.html"><IMG VSPACE="1" HSPACE="1" BORDER="0" 
SRC="images/store.gif" ALT="Store"></A> 
</CENTER>
<HR SIZE="4" WIDTH="80%"> 
<CENTER><FONT SIZE="+2"><B><I>American Thoracic Society</I></B></FONT><BR>
1740 Broadway<BR> New York, NY 10019<BR> VOICE:  212-315-8700<BR> Copyright &#169;
1996 American Lung Association.<BR> The American Thoracic  Society is the
medical section <BR>of the American Lung Association.<BR> 
</CENTER>
</BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-12</DOCNO>
<DOCOLDNO>IA013-000139-B021-205</DOCOLDNO>
<DOCHDR>
http://www.thoracic.org:80/ncycle1.html 206.138.195.144 19970217070445 text/html 6949
HTTP/1.0 200 OK
Date: Monday, 17-Feb-97 07:00:00 GMT
Server: NCSA/1.3
MIME-version: 1.0
Content-type: text/html
Last-modified: Friday, 20-Dec-96 20:24:15 GMT
Content-length: 6769
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//SQ//DTD HTML 2.0 HoTMetaL + extensions//EN">
<HTML>
<HEAD>
<TITLE>American Thoracic Society - New Projects - Review Cycle #1</TITLE></HEAD>
<BODY BGCOLOR="#FFFFFF" BACKGROUND="images/back.jpg">
<CENTER><IMG ALIGN="LEFT" SRC="images/smlogo.gif"><BR>
<H1>Application for Assembly Project Funding<BR>Review Cycle #1<BR>1997-1998</H1></CENTER>
<CENTER><IMG SRC="images/ybar.jpg" ALIGN="MIDDLE"></CENTER>
<P><BR></P>
<CENTER><IMG SRC="images/buttn10g.gif" ALIGN="LEFT" BORDER="0"><BR>
<H1><BLINK>DEADLINE<BR>OCTOBER 1, 1996</BLINK></H1></CENTER>
<P></P>
<P><B>Date:</B><BR>_______________________________________________</P>
<P><BR><B>Assembly Affiliation:</B><BR>_______________________________________________</P>
<P><BR><B>Name:</B><BR>___________________________________________________________________________________________</P>
<P><BR><IMG SRC="images/g1.gif" ALIGN="MIDDLE"> <B>Proposed Name of Project:</B><BR>___________________________________________________________________________________________</P>
<P><BR><IMG SRC="images/g2.gif" ALIGN="MIDDLE"> <B>Rationale:</B> Please
document the need for the Project (a &quot;Case Statement&quot;) and its
significance to the ATS membership in the space provided:</P>
<P>___________________________________________________________________________________________<BR>___________________________________________________________________________________________<BR>___________________________________________________________________________________________<BR>___________________________________________________________________________________________<BR>___________________________________________________________________________________________<BR>___________________________________________________________________________________________<BR>___________________________________________________________________________________________<BR>___________________________________________________________________________________________<BR>___________________________________________________________________________________________<BR>___________________________________________________________________________________________<BR>___________________________________________________________________________________________</P>
<P><IMG SRC="images/g3.gif" ALIGN="MIDDLE"> <B>Specific objectives of the
project:</B></P>
<P>A)_________________________________________________________________________________________</P>
<P>B)_________________________________________________________________________________________</P>
<P>C)_________________________________________________________________________________________</P>
<P>D)_________________________________________________________________________________________</P>
<P><BR><IMG SRC="images/g4.gif" ALIGN="MIDDLE"> <B>Outcome of the Project:</B><BR>___________________________________________________________________________________________</P>
<P>___________________________________________________________________________________________</P>
<P>___________________________________________________________________________________________</P>
<P>___________________________________________________________________________________________</P>
<P>___________________________________________________________________________________________</P>
<P>___________________________________________________________________________________________</P>
<P><BR><IMG SRC="images/g5.gif" ALIGN="MIDDLE"> <B>Check the Assemblies that
should be involved in this Project:<BR><BR></B></P>
<CENTER><IMG SRC="images/aii.gif" ALIGN="MIDDLE">
<IMG SRC="images/bs.gif" ALIGN="MIDDLE"><IMG SRC="images/cc.gif" ALIGN="MIDDLE">
<IMG SRC="images/cp.gif" ALIGN="MIDDLE"></CENTER>
<CENTER>
<P><BR><BR></P>
<IMG SRC="images/eoh.gif" ALIGN="MIDDLE">
<IMG SRC="images/mtpi.gif" ALIGN="MIDDLE">
<IMG SRC="images/nur.gif" ALIGN="MIDDLE">
<IMG SRC="images/pc.gif" ALIGN="MIDDLE">
<BR>
<IMG SRC="images/ped.gif" ALIGN="MIDDLE">
<IMG SRC="images/rcmb.gif" ALIGN="MIDDLE">
<IMG SRC="images/rns.gif" ALIGN="MIDDLE">
<IMG SRC="images/rsf.gif" ALIGN="MIDDLE"> 
</CENTER>
<P><B>COPIES OF COMPLETED PROJECT FORMS WILL  BE AUTOMATICALLY FORWARDED TO
THE CHAIRMAN OF YOUR ASSEMBLY AND YOUR LONG RANGE PLANNING COMMITTEE FOR THEIR
INFORMATION.</B></P>
<P><B>Please send to:</B></P>
<CENTER>
<P><B>JUDY CORN<BR>AMERICAN THORACIC SOCIETY<BR>1740 BROADWAY<BR>NEW YORK,
NY 10019-4374<BR>TEL: (212) 315 - 8709<BR>FAX: (212) 315 - 6498<BR>E-MAIL:
<A HREF="mailto:jcorn@lungusa.org">jcorn@lungusa.org</A></B></P></CENTER>
<P><BR><BR> 
</P>
<HR SIZE="4" WIDTH="80%">
<CENTER><A HREF="about.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/about.gif" ALT="About Society"></A>
<A HREF="ssg.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/ss.gif" ALT="Society Structure"></A>
<A HREF="calendar.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/calendar.gif" ALT="ATS Calendar"></A>
<A HREF="gpi.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/pi.gif" ALT="Gen Public Info"></A>
<A HREF="ms.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/memserv.gif" ALT="Memb Serv"></A>
<BR>
<A HREF="pub.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/pubs.gif" ALT="Publications"></A>
<A HREF="press.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/press.gif" ALT="Press"></A>
<A HREF="index.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/home.gif" ALT="Home Page"></A>
<A HREF="search.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/search.gif" ALT="Search"></A>
<A HREF="assemb.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/assemb.gif" ALT="Assemblies"></A>
<A HREF="research.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/research.gif" ALT="Research"></A>
<BR>
<A HREF="mep.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/meded.gif" ALT="Med Education"></A>
<A HREF="wr.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/wr.gif" ALT="Wash Report"></A>
<A HREF="ic.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/ic.gif" ALT="Int'l Conference"></A>
<A HREF="source.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/link.gif" ALT="Web Links"></A>
<A HREF="store.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/store.gif" ALT="Store"></A> 
<A HREF="sig.html"><IMG SRC="images/special.gif" ALT="Special" HSPACE=1 VSPACE=1 BORDER=0 HEIGHT=35 WIDTH=84></A>
</CENTER>
<HR SIZE="4" WIDTH="80%">
<CENTER><FONT SIZE="+2"><B><I>American Thoracic Society</I></B></FONT><BR>
1740 Broadway<BR> New York, NY 10019<BR> VOICE:  212-315-8700<BR> Copyright &copy;
1996 American Lung Association.<BR> The American Thoracic  Society is the
medical section <BR>of the American Lung Association.<BR> 
</CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-13</DOCNO>
<DOCOLDNO>IA013-000139-B021-244</DOCOLDNO>
<DOCHDR>
http://www.thoracic.org:80/recycle1.html 206.138.195.144 19970217070457 text/html 5515
HTTP/1.0 200 OK
Date: Monday, 17-Feb-97 07:00:12 GMT
Server: NCSA/1.3
MIME-version: 1.0
Content-type: text/html
Last-modified: Friday, 20-Dec-96 20:24:30 GMT
Content-length: 5335
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//SQ//DTD HTML 2.0 HoTMetaL + extensions//EN">
<HTML>
<HEAD><TITLE>American Thoracic Society - New Projects - Review Cycle #1</TITLE></HEAD>
<BODY BGCOLOR="#FFFFFF" BACKGROUND="images/back.jpg">
<CENTER><IMG ALIGN="LEFT" SRC="images/smlogo.gif"><BR><H1>Application for
Assembly Project Funding<BR>Review Cycle #1<BR>1997-1998</H1></CENTER>
<CENTER><IMG SRC="images/ybar.jpg" ALIGN="MIDDLE"></CENTER>
<P><BR></P>
<CENTER><IMG SRC="images/buttn11g.gif" ALIGN="MIDDLE"><BR><H1><BLINK>DEADLINE<BR>OCTOBER
1, 1996</BLINK></H1></CENTER>
<P></P>
<P><B>Date:</B><BR>_______________________________________________</P>
<P><BR><B>Assembly Affiliation:</B><BR>_______________________________________________</P>
<P><BR><B>Name:</B><BR>___________________________________________________________________________________________</P>
<P><BR><IMG SRC="images/g1.gif" ALIGN="MIDDLE"> <B>Proposed Name of Project:</B><BR>___________________________________________________________________________________________</P>
<P><BR><IMG SRC="images/g2.gif" ALIGN="MIDDLE"> <B>Progress Report:</B>
(Briefly state progress you;ve made to date and your plans in the coming year):</P>
<P>___________________________________________________________________________________________<BR>___________________________________________________________________________________________<BR>___________________________________________________________________________________________<BR>___________________________________________________________________________________________<BR>___________________________________________________________________________________________<BR>___________________________________________________________________________________________<BR>___________________________________________________________________________________________<BR>___________________________________________________________________________________________<BR>___________________________________________________________________________________________<BR>___________________________________________________________________________________________<BR>___________________________________________________________________________________________</P>
<P><IMG SRC="images/g3.gif" ALIGN="MIDDLE"> <B>Outcome of the project:</B></P>
<P>___________________________________________________________________________________________</P>
<P>___________________________________________________________________________________________</P>
<P>___________________________________________________________________________________________</P>
<P>___________________________________________________________________________________________</P>
<P><B>COPIES OF COMPLETED PROJECT FORMS WILL  BE AUTOMATICALLY FORWARDED TO
THE CHAIRMAN OF YOUR ASSEMBLY AND YOUR LONG RANGE PLANNING COMMITTEE FOR THEIR
INFORMATION.</B></P>
<P><B>Please send to:</B></P>
<CENTER><P><B>JUDY CORN<BR>AMERICAN THORACIC SOCIETY<BR>1740 BROADWAY<BR>NEW
YORK, NY 10019-4374<BR>TEL: (212) 315 - 8709<BR>FAX: (212) 315 - 6498<BR>E-MAIL:
<A HREF="mailto:jcorn@lungusa.org">jcorn@lungusa.org</A></B></P></CENTER>
<P><BR><BR> 
</P>
<HR SIZE="4" WIDTH="80%"> 
<CENTER>
<A HREF="about.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/about.gif" ALT="About Society"></A>
<A HREF="ssg.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/ss.gif" ALT="Society Structure"></A>
<A HREF="calendar.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/calendar.gif" ALT="ATS Calendar"></A>
<A HREF="gpi.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/pi.gif" ALT="Gen Public Info"></A>
<A HREF="ms.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/memserv.gif" ALT="Memb Serv"></A>
<BR>
<A HREF="pub.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/pubs.gif" ALT="Publications"></A>
<A HREF="press.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/press.gif" ALT="Press"></A>
<A HREF="index.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/home.gif" ALT="Home Page"></A>
<A HREF="search.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/search.gif" ALT="Search"></A>
<A HREF="assemb.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/assemb.gif" ALT="Assemblies"></A>
<A HREF="research.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/research.gif" ALT="Research"></A>
<BR>
<A HREF="mep.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/meded.gif" ALT="Med Education"></A>
<A HREF="wr.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/wr.gif" ALT="Wash Report"></A>
<A HREF="ic.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/ic.gif" ALT="Int'l Conference"></A>
<A HREF="source.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/link.gif" ALT="Web Links"></A>
<A HREF="store.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/store.gif" ALT="Store"></A> 
<A HREF="sig.html"><IMG SRC="images/special.gif" ALT="Special" HSPACE=1 VSPACE=1 BORDER=0 HEIGHT=35 WIDTH=84></A>
</CENTER>
<HR SIZE="4" WIDTH="80%"> 
<CENTER><FONT SIZE="+2"><B><I>American Thoracic Society</I></B></FONT><BR>
1740 Broadway<BR> New York, NY 10019<BR> VOICE:  212-315-8700<BR> Copyright &#169;
1996 American Lung Association.<BR> The American Thoracic  Society is the
medical section <BR>of the American Lung Association.<BR> 
</CENTER>
</BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-14</DOCNO>
<DOCOLDNO>IA013-000139-B021-279</DOCOLDNO>
<DOCHDR>
http://www.thoracic.org:80/ncycle2.html 206.138.195.144 19970217070508 text/html 17440
HTTP/1.0 200 OK
Date: Monday, 17-Feb-97 07:00:23 GMT
Server: NCSA/1.3
MIME-version: 1.0
Content-type: text/html
Last-modified: Friday, 20-Dec-96 20:24:16 GMT
Content-length: 17259
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//SQ//DTD HTML 2.0 HoTMetaL + extensions//EN">
<HTML>
<HEAD><TITLE>American Thoracic Society - New Projects - Review Cycle #2</TITLE></HEAD>
<BODY BGCOLOR="#FFFFFF" BACKGROUND="images/back.jpg">
<CENTER><IMG ALIGN="LEFT" SRC="images/smlogo.gif"><BR><H1>Application for
Assembly Project Funding<BR>Review Cycle <BIG>#2</BIG><BR>1997-1998</H1></CENTER>
<CENTER><IMG SRC="images/ybar.jpg" ALIGN="MIDDLE"></CENTER>
<P><BR></P>
<CENTER><IMG SRC="images/buttn10g.gif" ALIGN="BOTTOM"><BR><H1><BLINK>DEADLINE<BR>DECEMBER
15, 1996</BLINK></H1></CENTER>
<P></P>
<P><B>Date:</B><BR>_______________________________________________</P>
<P><BR><B>Assembly Affiliation:</B><BR>_______________________________________________</P>
<P><BR><B>Name:</B><BR>___________________________________________________________________________________________</P>
<P><BR><IMG SRC="images/g1.gif" ALIGN="MIDDLE"> <B>Proposed Name of Project:</B><BR>___________________________________________________________________________________________</P>
<P><BR><IMG SRC="images/g2.gif" ALIGN="MIDDLE"> <B>Rationale:</B> Please
document the need for the Project (a &quot;Case Statement&quot;) and its
significance to the ATS membership in the space provided:</P>
<P>___________________________________________________________________________________________<BR>___________________________________________________________________________________________<BR>___________________________________________________________________________________________<BR>___________________________________________________________________________________________<BR>___________________________________________________________________________________________<BR>___________________________________________________________________________________________<BR>___________________________________________________________________________________________<BR>___________________________________________________________________________________________<BR>___________________________________________________________________________________________<BR>___________________________________________________________________________________________<BR>___________________________________________________________________________________________</P>
<P><IMG SRC="images/g3.gif" ALIGN="MIDDLE"> <B>Specific objectives of the
project (use additional sheets as necessary):</B></P>
<P>A)_________________________________________________________________________________________</P>
<P>B)_________________________________________________________________________________________</P>
<P>C)_________________________________________________________________________________________</P>
<P>D)_________________________________________________________________________________________</P>
<P><BR><IMG SRC="images/g4.gif" ALIGN="MIDDLE"> <B>Identify potential
participants and their areas of expertise:</B><BR></P>
<CENTER><TABLE BORDER="5"><TR ALIGN="CENTER" VALIGN="TOP"><TD COLSTART="1"><B>NAME</B></TD>
<TD COLSTART="2" COLSPAN="2"><B>ADDRESS</B></TD><TD COLSTART="4"><B>EXPERTISE</B></TD></TR>
<TR><TD COLSTART="1">__________________<BR>__________________</TD><TD
COLSTART="2" COLSPAN="2">___________________________________________________<BR>___________________________________________________</TD>
<TD COLSTART="4">__________________<BR>__________________</TD></TR><TR><TD
COLSTART="1">__________________<BR>__________________</TD><TD
COLSTART="2" COLSPAN="2">___________________________________________________<BR>___________________________________________________</TD>
<TD COLSTART="4">__________________<BR>__________________</TD></TR><TR><TD
COLSTART="1">__________________<BR>__________________</TD><TD
COLSTART="2" COLSPAN="2">___________________________________________________<BR>___________________________________________________</TD>
<TD COLSTART="4">__________________<BR>__________________</TD></TR><TR><TD
COLSTART="1">__________________<BR>__________________</TD><TD
COLSTART="2" COLSPAN="2">___________________________________________________<BR>___________________________________________________</TD>
<TD COLSTART="4">__________________<BR>__________________</TD></TR><TR><TD
COLSTART="1">__________________<BR>__________________</TD><TD
COLSTART="2" COLSPAN="2">___________________________________________________<BR>___________________________________________________</TD>
<TD COLSTART="4">__________________<BR>__________________</TD></TR><TR><TD
COLSTART="1">__________________<BR>__________________</TD><TD
COLSTART="2" COLSPAN="2">___________________________________________________<BR>___________________________________________________</TD>
<TD COLSTART="4">__________________<BR>__________________</TD></TR><TR><TD
COLSTART="1">__________________<BR>__________________</TD><TD
COLSTART="2" COLSPAN="2">___________________________________________________<BR>___________________________________________________</TD>
<TD COLSTART="4">__________________<BR>__________________</TD></TR><TR><TD
COLSTART="1">__________________<BR>__________________</TD><TD
COLSTART="2" COLSPAN="2">___________________________________________________<BR>___________________________________________________</TD>
<TD COLSTART="4">__________________<BR>__________________</TD></TR><TR><TD
COLSTART="1">__________________<BR>__________________</TD><TD
COLSTART="2" COLSPAN="2">___________________________________________________<BR>___________________________________________________</TD>
<TD COLSTART="4">__________________<BR>__________________</TD></TR></TABLE></CENTER>
<P><BR><IMG SRC="images/g5.gif" ALIGN="MIDDLE"> <B>Check the Assemblies that
should be involved in this Project:<BR><BR></B></P>
<CENTER>
<SMALL><IMG SRC="images/aii.gif" ALIGN="MIDDLE">
<IMG SRC="images/bs.gif" ALIGN="MIDDLE"><IMG SRC="images/cc.gif" ALIGN="MIDDLE">
<IMG SRC="images/cp.gif" ALIGN="MIDDLE"></SMALL></CENTER> 
<CENTER><P><BR><BR></P>
<SMALL><IMG SRC="images/eoh.gif" ALIGN="MIDDLE">
<IMG SRC="images/mtpi.gif" ALIGN="MIDDLE">
<IMG SRC="images/nur.gif" ALIGN="MIDDLE">
<IMG SRC="images/pc.gif" ALIGN="MIDDLE">
<BR><IMG SRC="images/ped.gif" ALIGN="MIDDLE"><IMG
SRC="images/rcmb.gif" ALIGN="MIDDLE">
<IMG SRC="images/rns.gif" ALIGN="MIDDLE">
<IMG SRC="images/rsf.gif" ALIGN="MIDDLE"> 
</SMALL></CENTER>
<P><BR><IMG SRC="images/g6.gif" ALIGN="MIDDLE"> <B>List of other
professional organizations that should be involved in this project:
<BR><BR></B></P>
<CENTER><TABLE BORDER="4"><TR ALIGN="CENTER" VALIGN="TOP"><TD
COLSTART="1" COLSPAN="2">ORGANIZATION</TD><TD COLSTART="3">CONTACT PERSON(S)</TD></TR>
<TR><TD COLSTART="1" COLSPAN="2">______________________________________________</TD>
<TD COLSTART="3">________________________________</TD></TR><TR><TD
COLSTART="1" COLSPAN="2">______________________________________________</TD><TD
COLSTART="3">________________________________</TD></TR><TR><TD
COLSTART="1" COLSPAN="2">______________________________________________</TD><TD
COLSTART="3">________________________________</TD></TR><TR><TD
COLSTART="1" COLSPAN="2">______________________________________________</TD><TD
COLSTART="3">________________________________</TD></TR><TR><TD
COLSTART="1" COLSPAN="2">______________________________________________</TD><TD
COLSTART="3">________________________________</TD></TR></TABLE></CENTER>
<P><BR><A NAME="ats1"><IMG SRC="images/g7.gif" ALIGN="MIDDLE"></A> <B>Develop
a timetable for the completion of the project using the chart below.</B></P>
<CENTER><P> (Please refer to the <A HREF="stmttime.html">Timetable for
Development of Statements and Position Papers</A>):
<BR><BR></P></CENTER>
<CENTER><TABLE BORDER="4"><TR ALIGN="CENTER" VALIGN="TOP"><TD COLSTART="1"><SMALL><B>Function</B></SMALL></TD>
<TD COLSTART="2"><SMALL><B>Proposed Dates(s)</B></SMALL></TD><TD
COLSTART="3" COLSPAN="2"><SMALL><B>Suggested Location (if applicable)</B></SMALL></TD>
<TD COLSTART="5"><SMALL><B>Suggested # of Participants</B></SMALL></TD></TR><TR><TD
 COLSTART="1" ALIGN="CENTER" VALIGN="MIDDLE"><B><SMALL>Planning Meeting</SMALL></B></TD>
<TD COLSTART="2">_________________</TD><TD COLSTART="3" COLSPAN="2">____________________________</TD>
<TD COLSTART="5">_____________________</TD></TR><TR><TD
COLSTART="1" ALIGN="CENTER" VALIGN="MIDDLE"><B><SMALL>Meeting 1</SMALL></B></TD><TD
 COLSTART="2">_________________</TD><TD COLSTART="3" COLSPAN="2">____________________________</TD>
<TD COLSTART="5">_____________________</TD></TR><TR><TD
COLSTART="1" ALIGN="CENTER" VALIGN="MIDDLE"><B><SMALL>Meeting 2</SMALL></B></TD><TD
 COLSTART="2">_________________</TD><TD COLSTART="3" COLSPAN="2">____________________________</TD>
<TD COLSTART="5">_____________________</TD></TR><TR><TD
COLSTART="1" ALIGN="CENTER" VALIGN="MIDDLE"><B><SMALL>Meeting 3</SMALL></B></TD><TD
 COLSTART="2">_________________</TD><TD COLSTART="3" COLSPAN="2">____________________________</TD>
<TD COLSTART="5">_____________________</TD></TR><TR><TD
COLSTART="1" ALIGN="CENTER" VALIGN="MIDDLE"><B><SMALL>Workshop</SMALL></B></TD><TD
 COLSTART="2">_________________</TD><TD COLSTART="3" COLSPAN="2">____________________________</TD>
<TD COLSTART="5">_____________________</TD></TR><TR><TD
COLSTART="1" ALIGN="CENTER"><B><SMALL>Conference Call 1</SMALL></B></TD><TD
COLSTART="2">_________________</TD><TD COLSTART="3" COLSPAN="2">____________________________</TD>
<TD COLSTART="5">_____________________</TD></TR><TR><TD
COLSTART="1" ALIGN="CENTER"><B><SMALL>Conference Call 2</SMALL></B></TD><TD
COLSTART="2">_________________</TD><TD COLSTART="3" COLSPAN="2">____________________________</TD>
<TD COLSTART="5">_____________________</TD></TR><TR><TD
COLSTART="1" ALIGN="CENTER"><SMALL><B>Conference Call 3</B></SMALL></TD><TD
COLSTART="2">_________________</TD><TD COLSTART="3" COLSPAN="2">____________________________</TD>
<TD COLSTART="5">_____________________</TD></TR><TR><TD
COLSTART="1" ALIGN="CENTER"><SMALL><B>Mailing</B></SMALL></TD><TD
COLSTART="2">_________________</TD><TD COLSTART="3" COLSPAN="2">____________________________</TD>
<TD COLSTART="5">_____________________</TD></TR><TR><TD
COLSTART="1" ALIGN="CENTER"><SMALL><B>Committee Review</B></SMALL></TD><TD
COLSTART="2">_________________</TD><TD COLSTART="3" COLSPAN="2">____________________________</TD>
<TD COLSTART="5">_____________________</TD></TR><TR><TD
COLSTART="1" ALIGN="CENTER"><SMALL><B>Outside Expert Review</B></SMALL></TD><TD
COLSTART="2">_________________</TD><TD COLSTART="3" COLSPAN="2">____________________________</TD>
<TD COLSTART="5">_____________________</TD></TR><TR><TD
COLSTART="1" ALIGN="CENTER"><SMALL><B>Board of Directors Review</B></SMALL></TD><TD
 COLSTART="2">_________________</TD><TD COLSTART="3" COLSPAN="2">____________________________</TD>
<TD COLSTART="5">_____________________</TD></TR><TR><TD
COLSTART="1" ALIGN="CENTER"><SMALL><B>Other</B></SMALL></TD><TD COLSTART="2">_________________</TD>
<TD COLSTART="3" COLSPAN="2">____________________________</TD><TD COLSTART="5">_____________________</TD></TR></TABLE></CENTER>
<P><BR><IMG SRC="images/g8.gif" ALIGN="MIDDLE"> <B>Comments:</B></P>
<P>___________________________________________________________________________________________<BR>___________________________________________________________________________________________<BR>___________________________________________________________________________________________<BR>___________________________________________________________________________________________<BR>___________________________________________________________________________________________<BR>___________________________________________________________________________________________<BR>___________________________________________________________________________________________<BR>___________________________________________________________________________________________<BR>___________________________________________________________________________________________<BR>___________________________________________________________________________________________<BR>___________________________________________________________________________________________</P>
<P><BR><IMG SRC="images/g9.gif" ALIGN="MIDDLE"> <B>Develop a budget.
Document all major expenses.</B></P>
<CENTER><P><B><A HREF="recycle2.html#ats1">Click here for Budget Guidelines</A></B></P></CENTER>
<CENTER><TABLE BORDER="4"><TR ALIGN="CENTER" VALIGN="MIDDLE"><TD COLSTART="1"><B>Year
1: July 1, 1997 - June 30. 1998</B></TD><TD COLSTART="2"><B>Year 2: July 1,
1998 - June 30. 1999</B></TD></TR><TR><TD COLSTART="1">__________________________________</TD>
<TD COLSTART="2">__________________________________</TD></TR><TR><TD
COLSTART="1">__________________________________</TD><TD COLSTART="2">__________________________________</TD></TR>
<TR><TD COLSTART="1">__________________________________</TD><TD COLSTART="2">__________________________________</TD></TR>
<TR><TD COLSTART="1">__________________________________</TD><TD COLSTART="2">__________________________________</TD></TR>
<TR><TD COLSTART="1">__________________________________</TD><TD COLSTART="2">__________________________________</TD></TR>
<TR><TD COLSTART="1">__________________________________</TD><TD COLSTART="2">__________________________________</TD></TR>
<TR><TD COLSTART="1">__________________________________</TD><TD COLSTART="2">__________________________________</TD></TR>
<TR><TD COLSTART="1">__________________________________</TD><TD COLSTART="2">__________________________________</TD></TR>
<TR><TD COLSTART="1">__________________________________</TD><TD COLSTART="2">__________________________________</TD></TR>
<TR><TD COLSTART="1">__________________________________</TD><TD COLSTART="2">__________________________________</TD></TR>
<TR><TD COLSTART="1">__________________________________</TD><TD COLSTART="2">__________________________________</TD></TR>
<TR><TD COLSTART="1">__________________________________</TD><TD COLSTART="2">__________________________________</TD></TR>
<TR><TD COLSTART="1">__________________________________</TD><TD COLSTART="2">__________________________________</TD></TR>
<TR><TD COLSTART="1">__________________________________</TD><TD COLSTART="2">__________________________________</TD></TR>
<TR><TD COLSTART="1">__________________________________</TD><TD COLSTART="2">__________________________________</TD></TR>
<TR ALIGN="CENTER" VALIGN="MIDDLE"><TD COLSTART="1"><B>TOTAL Budget Requested
(Year 1)<BR>$_____________________</B></TD><TD COLSTART="2"><B>TOTAL Budget
Requested (Year 2)<BR>$_____________________</B></TD></TR></TABLE></CENTER> 
<P><B>COPIES OF COMPLETED PROJECT FORMS WILL  BE AUTOMATICALLY FORWARDED TO
THE CHAIRMAN OF YOUR ASSEMBLY AND YOUR LONG RANGE PLANNING COMMITTEE FOR THEIR
INFORMATION.</B></P>
<P><B>Please send to:</B></P>
<CENTER><P><B>JUDY CORN<BR>AMERICAN THORACIC SOCIETY<BR>1740 BROADWAY<BR>NEW
YORK, NY 10019-4374<BR>TEL: (212) 315 - 8709<BR>FAX: (212) 315 - 6498<BR>E-MAIL:
<A HREF="mailto:jcorn@lungusa.org">jcorn@lungusa.org</A></B></P></CENTER>
<P><BR><BR> 
</P>
<HR SIZE="4" WIDTH="80%"> 
<CENTER>
<A HREF="about.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/about.gif" ALT="About Society"></A>
<A HREF="ssg.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/ss.gif" ALT="Society Structure"></A>
<A HREF="calendar.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/calendar.gif" ALT="ATS Calendar"></A>
<A HREF="gpi.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/pi.gif" ALT="Gen Public Info"></A>
<A HREF="ms.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/memserv.gif" ALT="Memb Serv"></A>
<BR>
<A HREF="pub.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/pubs.gif" ALT="Publications"></A>
<A HREF="press.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/press.gif" ALT="Press"></A>
<A HREF="index.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/home.gif" ALT="Home Page"></A>
<A HREF="search.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/search.gif" ALT="Search"></A>
<A HREF="assemb.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/assemb.gif" ALT="Assemblies"></A>
<A HREF="research.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/research.gif" ALT="Research"></A>
<BR>
<A HREF="mep.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/meded.gif" ALT="Med Education"></A>
<A HREF="wr.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/wr.gif" ALT="Wash Report"></A>
<A HREF="ic.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/ic.gif" ALT="Int'l Conference"></A>
<A HREF="source.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/link.gif" ALT="Web Links"></A>
<A HREF="store.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/store.gif" ALT="Store"></A> 
<A HREF="sig.html"><IMG SRC="images/special.gif" ALT="Special" HSPACE=1 VSPACE=1 BORDER=0 HEIGHT=35 WIDTH=84></A>
</CENTER>
<HR SIZE="4" WIDTH="80%"> 
<CENTER><FONT SIZE="+2"><B><I>American Thoracic Society</I></B></FONT><BR>
1740 Broadway<BR> New York, NY 10019<BR> VOICE:  212-315-8700<BR> Copyright &#169;
1996 American Lung Association.<BR> The American Thoracic  Society is the
medical section <BR>of the American Lung Association.<BR> 
</CENTER>
</BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-15</DOCNO>
<DOCOLDNO>IA013-000139-B021-307</DOCOLDNO>
<DOCHDR>
http://www.thoracic.org:80/recycle2.html 206.138.195.144 19970217070551 text/html 5365
HTTP/1.0 200 OK
Date: Monday, 17-Feb-97 07:00:34 GMT
Server: NCSA/1.3
MIME-version: 1.0
Content-type: text/html
Last-modified: Friday, 20-Dec-96 20:24:30 GMT
Content-length: 5185
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//SQ//DTD HTML 2.0 HoTMetaL + extensions//EN">
<HTML>
<HEAD><TITLE>American Thoracic Society - New Projects - Review Cycle #1</TITLE></HEAD>
<BODY BGCOLOR="#FFFFFF" BACKGROUND="images/back.jpg">
<CENTER><IMG ALIGN="LEFT" SRC="images/smlogo.gif"><BR><H1>Application for
Assembly Project Funding<BR><BIG>RENEWAL BUDGET FORM</BIG><BR>Review Cycle<BIG>
#2</BIG><BR> 1997-1998</H1></CENTER>
<CENTER><IMG SRC="images/ybar.jpg" ALIGN="MIDDLE"></CENTER>
<P><BR></P>
<CENTER><IMG SRC="images/buttn11g.gif" ALIGN="MIDDLE"><BR><H1><BLINK>DEADLINE<BR>DECEMBER
15, 1996</BLINK></H1></CENTER>
<P></P>
<P><B>Date:</B><BR>_______________________________________________</P>
<P><BR><B>Assembly Affiliation:</B><BR>_______________________________________________</P>
<P><BR><B>Name:</B><BR>___________________________________________________________________________________________</P>
<P><BR><IMG SRC="images/g1.gif" ALIGN="MIDDLE"> <B>Name of Project:</B><BR>___________________________________________________________________________________________</P>
<CENTER><A NAME="ats1"><IMG SRC="images/budget.jpg" ALIGN="BOTTOM"></A></CENTER>
<P><IMG SRC="images/g2.gif" ALIGN="MIDDLE"> <B>Develop a budget. Document all
major expenses.</B></P>
<CENTER><TABLE BORDER="4"><TR ALIGN="CENTER" VALIGN="MIDDLE"><TD
COLSTART="1" COLSPAN="2"><B>Year 1: July 1, 1997 - June 30. 1998</B></TD></TR><TR>
<TD COLSTART="1" COLSPAN="2">__________________________________________________________________________________</TD></TR>
<TR><TD COLSTART="1" COLSPAN="2">__________________________________________________________________________________</TD></TR>
<TR><TD COLSTART="1" COLSPAN="2">__________________________________________________________________________________</TD></TR>
<TR><TD COLSTART="1" COLSPAN="2">__________________________________________________________________________________</TD></TR>
<TR><TD COLSTART="1" COLSPAN="2">__________________________________________________________________________________</TD></TR>
<TR><TD COLSTART="1" COLSPAN="2">__________________________________________________________________________________</TD></TR>
<TR><TD COLSTART="1" COLSPAN="2">__________________________________________________________________________________</TD></TR>
<TR><TD COLSTART="1" COLSPAN="2">__________________________________________________________________________________</TD></TR>
<TR ALIGN="CENTER" VALIGN="MIDDLE"><TD COLSTART="1" COLSPAN="2"><B>TOTAL
Budget Requested (Year 1)<BR>$_____________________</B></TD></TR></TABLE></CENTER>
<P><B>COPIES OF COMPLETED PROJECT FORMS WILL  BE AUTOMATICALLY FORWARDED TO
THE CHAIRMAN OF YOUR ASSEMBLY AND YOUR LONG RANGE PLANNING COMMITTEE FOR THEIR
INFORMATION.</B></P>
<P><B>Please send to:</B></P>
<CENTER><P><B>JUDY CORN<BR>AMERICAN THORACIC SOCIETY<BR>1740 BROADWAY<BR>NEW
YORK, NY 10019-4374<BR>TEL: (212) 315 - 8709<BR>FAX: (212) 315 - 6498<BR>E-MAIL:
<A HREF="mailto:jcorn@lungusa.org">jcorn@lungusa.org</A></B></P></CENTER>
<P><BR><BR> 
</P>
<HR SIZE="4" WIDTH="80%"> 
<CENTER>
<A HREF="about.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/about.gif" ALT="About Society"></A>
<A HREF="ssg.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/ss.gif" ALT="Society Structure"></A>
<A HREF="calendar.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/calendar.gif" ALT="ATS Calendar"></A>
<A HREF="gpi.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/pi.gif" ALT="Gen Public Info"></A>
<A HREF="ms.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/memserv.gif" ALT="Memb Serv"></A>
<BR>
<A HREF="pub.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/pubs.gif" ALT="Publications"></A>
<A HREF="press.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/press.gif" ALT="Press"></A>
<A HREF="index.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/home.gif" ALT="Home Page"></A>
<A HREF="search.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/search.gif" ALT="Search"></A>
<A HREF="assemb.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/assemb.gif" ALT="Assemblies"></A>
<A HREF="research.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/research.gif" ALT="Research"></A>
<BR>
<A HREF="mep.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/meded.gif" ALT="Med Education"></A>
<A HREF="wr.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/wr.gif" ALT="Wash Report"></A>
<A HREF="ic.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/ic.gif" ALT="Int'l Conference"></A>
<A HREF="source.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/link.gif" ALT="Web Links"></A>
<A HREF="store.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/store.gif" ALT="Store"></A> 
<A HREF="sig.html"><IMG SRC="images/special.gif" ALT="Special" HSPACE=1 VSPACE=1 BORDER=0 HEIGHT=35 WIDTH=84></A>
</CENTER>
<HR SIZE="4" WIDTH="80%"> 
<CENTER><FONT SIZE="+2"><B><I>American Thoracic Society</I></B></FONT><BR>
1740 Broadway<BR> New York, NY 10019<BR> VOICE:  212-315-8700<BR> Copyright &#169;
1996 American Lung Association.<BR> The American Thoracic  Society is the
medical section <BR>of the American Lung Association.<BR> 
</CENTER>
</BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-16</DOCNO>
<DOCOLDNO>IA013-000139-B021-347</DOCOLDNO>
<DOCHDR>
http://www.thoracic.org:80/post3.html 206.138.195.144 19970217070609 text/html 4207
HTTP/1.0 200 OK
Date: Monday, 17-Feb-97 07:01:24 GMT
Server: NCSA/1.3
MIME-version: 1.0
Content-type: text/html
Last-modified: Friday, 20-Dec-96 20:24:23 GMT
Content-length: 4027
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//SQ//DTD HTML 2.0 HoTMetaL + extensions//EN">
<HTML>
<HEAD><TITLE>American Thoracic Society - Postgraduate Course on Clinical
Management and Control of Tuberculosis</TITLE></HEAD> 
<BODY BACKGROUND="images/back.jpg">
<CENTER><IMG ALIGN="LEFT" SRC="images/smlogo.gif"><BR><H1>Postgraduate
Course on Clinical Management and Control of Tuberculosis</H1></CENTER>
<HR SIZE="5" NOSHADE="NOSHADE" WIDTH="100%"> 
<P><BR><BR>
</P>
<CENTER><TABLE BORDER="2"><TR><TD COLSTART="1" ALIGN="CENTER" VALIGN="MIDDLE"><SMALL><A
HREF="oed.html#top">BACK TO MENU</A></SMALL></TD></TR></TABLE></CENTER>
<P></P>
<HR SIZE="5" WIDTH="70%">
<P></P>
<P><B>Postgraduate Course on Clinical Management and Control of Tuberculosis</B></P>
<H2>Held in: </H2>
<P>Denver, Colorado</P>
<H2>Presented by:</H2>
<P> National Jewish Center for Immunology and Respiratory Medicine, in
collaboration with Denver Health Department and University of Colorado School of
Medicine.</P>
<P>Early Registration Advised.</P>
<P>Applications Will Be Processed On A First-Come, First-Served Basis</P>
<H2>Dates:</H2>
<P>October 21-25, 1996</P>
<P>February 10-14, 1997</P>
<P>April 14-18, 1997</P>
<H2>Tuition:</H2>
<P>$560.00 physicians/nurses<BR>$280.00 fellows/residents</P>
<P></P>
<P><B>Nonrefundable deposit of $100 or total payment must accompany
application.</B></P>
<H2>Mail to:</H2>
<CENTER>National Jewish Center for Immunology and Respiratory Medicine<BR>TB
Course Office<BR>1400 Jackson St., K624<BR>Denver, CO 80206</CENTER>
<H2>For Further Information, Please Contact:</H2>
<CENTER>National Jewish Center for Immunology and Respiratory Medicine<BR>TB
Course Office<BR>1400 Jackson St., K624<BR>Denver, CO 80206<BR>Telephone:
303-398-1700<BR>Fax: 303-398-1806<BR>Email: <A HREF="mailto:queenc@njc.org">queenc@njc.org</A></CENTER>
<P><BR><BR> 
</P>
<HR SIZE="4" WIDTH="80%"> 
<CENTER>
<A HREF="about.html"><IMG VSPACE="1" HSPACE="1" BORDER="0" 
SRC="images/about.gif" ALT="About Society"></A>
<A HREF="ssg.html"><IMG VSPACE="1" HSPACE="1" BORDER="0" 
SRC="images/ss.gif" ALT="Society Structure"></A>
<A HREF="calendar.html"><IMG VSPACE="1" HSPACE="1" BORDER="0" 
SRC="images/calendar.gif" ALT="ATS Calendar"></A>
<A HREF="gpi.html"><IMG VSPACE="1" HSPACE="1" BORDER="0" 
SRC="images/pi.gif" ALT="Gen Public Info"></A>
<A HREF="ms.html"><IMG VSPACE="1" HSPACE="1" BORDER="0" 
SRC="images/memserv.gif" ALT="Memb Serv"></A>
<BR>
<A HREF="pub.html"><IMG VSPACE="1" HSPACE="1" BORDER="0" 
SRC="images/pubs.gif" ALT="Publications"></A>
<A HREF="press.html"><IMG VSPACE="1" HSPACE="1" BORDER="0" 
SRC="images/press.gif" ALT="Press"></A>
<A HREF="index.html"><IMG VSPACE="1" HSPACE="1" BORDER="0" 
SRC="images/home.gif" ALT="Home Page"></A>
<A HREF="search.html"><IMG VSPACE="1" HSPACE="1" BORDER="0" 
SRC="images/search.gif" ALT="Search"></A>
<A HREF="assemb.html"><IMG VSPACE="1" HSPACE="1" BORDER="0" 
SRC="images/assemb.gif" ALT="Assemblies"></A>
<A HREF="research.html"><IMG VSPACE="1" HSPACE="1" BORDER="0" 
SRC="images/research.gif" ALT="Research"></A>
<BR>
<A HREF="mep.html"><IMG VSPACE="1" HSPACE="1" BORDER="0" 
SRC="images/meded.gif" ALT="Med Education"></A>
<A HREF="wr.html"><IMG VSPACE="1" HSPACE="1" BORDER="0" 
SRC="images/wr.gif" ALT="Wash Report"></A>
<A HREF="ic.html"><IMG VSPACE="1" HSPACE="1" BORDER="0" 
SRC="images/ic.gif" ALT="Int'l Conference"></A>
<A HREF="source.html"><IMG VSPACE="1" HSPACE="1" BORDER="0" 
SRC="images/link.gif" ALT="Web Links"></A>
<A HREF="store.html"><IMG VSPACE="1" HSPACE="1" BORDER="0" 
SRC="images/store.gif" ALT="Store"></A> 
<A HREF="sig.html"><IMG SRC="images/special.gif" ALT="Special" HSPACE=1 VSPACE=1 BORDER=0 HEIGHT=35 WIDTH=84></A>
</CENTER>
<HR SIZE="4" WIDTH="80%"> 
<CENTER><FONT SIZE="+2"><B><I>American Thoracic Society</I></B></FONT><BR>
1740 Broadway<BR> New York, NY 10019<BR> VOICE:  212-315-8700<BR> Copyright &#169;
1996 American Lung Association.<BR> The American Thoracic  Society is the
medical section <BR>of the American Lung Association.<BR> 
</CENTER>
</BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-17</DOCNO>
<DOCOLDNO>IA013-000139-B021-378</DOCOLDNO>
<DOCHDR>
http://www.thoracic.org:80/post4.html 206.138.195.144 19970217070616 text/html 3556
HTTP/1.0 200 OK
Date: Monday, 17-Feb-97 07:01:34 GMT
Server: NCSA/1.3
MIME-version: 1.0
Content-type: text/html
Last-modified: Friday, 20-Dec-96 20:24:24 GMT
Content-length: 3376
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//SQ//DTD HTML 2.0 HoTMetaL + extensions//EN">
<HTML>
<HEAD>
<TITLE>American Thoracic Society - Tuberculosis 2000</TITLE></HEAD>
<BODY BACKGROUND="images/back.jpg">
<CENTER><IMG ALIGN="LEFT" SRC="images/smlogo.gif"><BR>
<H1>Tuberculosis 2000</H1></CENTER>
<HR SIZE="5" NOSHADE="NOSHADE" WIDTH="100%">
<P><BR><BR>
</P>
<CENTER>
<TABLE BORDER="2">
<TR>
<TD ALIGN="CENTER" VALIGN="MIDDLE"><SMALL><A HREF="oed.html#top">BACK TO MENU</A></SMALL></TD></TR></TABLE></CENTER>
<P></P>
<HR SIZE="5" WIDTH="70%">
<P></P>
<CENTER>
<P><B>The Francis J. Curry National Tuberculosis Center is pleased to
announce:</B></P>
<H1>Tuberculosis 2000</H1>
<H2>Fundamentals of Clinical Tuberculosis and Tuberculosis Control</H2>
<P><B>A 3-part live, interactive satellite course for medical professionals</B></P></CENTER>
<CENTER>
<H2>January 23, 1997 / January 30, 1997 / February 6, 1997</H2>
<P><B>EST 1:00-3:00 pm / CST 12:00-2:00 pm / MST 11:00-1:00 pm / PST
10:00-12:00 pm</B></P></CENTER>
<P><B>To learn more about this course including satellite dish access, send
e-mail to <A HREF="mailto:tb2000@nationaltbcenter.edu">tb2000@nationaltbcenter.edu</A></B></P>
<P><BR><BR> 
</P>
<HR SIZE="5" NOSHADE="NOSHADE" WIDTH="100%">
<CENTER><A HREF="about.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/about.gif" ALT="About Society"></A>
<A HREF="ssg.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/ss.gif" ALT="Society Structure"></A>
<A HREF="calendar.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/calendar.gif" ALT="ATS Calendar"></A>
<A HREF="gpi.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/pi.gif" ALT="Gen Public Info"></A>
<A HREF="ms.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/memserv.gif" ALT="Memb Serv"></A>
<BR>
<A HREF="pub.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/pubs.gif" ALT="Publications"></A>
<A HREF="press.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/press.gif" ALT="Press"></A>
<A HREF="index.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/home.gif" ALT="Home Page"></A>
<A HREF="search.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/search.gif" ALT="Search"></A>
<A HREF="assemb.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/assemb.gif" ALT="Assemblies"></A>
<A HREF="research.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/research.gif" ALT="Research"></A>
<BR>
<A HREF="mep.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/meded.gif" ALT="Med Education"></A>
<A HREF="wr.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/wr.gif" ALT="Wash Report"></A>
<A HREF="ic.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/ic.gif" ALT="Int'l Conference"></A>
<A HREF="source.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/link.gif" ALT="Web Links"></A>
<A HREF="store.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/store.gif" ALT="Store"></A> 
<A HREF="sig.html"><IMG SRC="images/special.gif" ALT="Special" HSPACE=1 VSPACE=1 BORDER=0 HEIGHT=35 WIDTH=84></A>
</CENTER>
<HR SIZE="4" WIDTH="80%">
<CENTER><FONT SIZE="+2"><B><I>American Thoracic Society</I></B></FONT><BR>
1740 Broadway<BR> New York, NY 10019<BR> VOICE:  212-315-8700<BR> Copyright &copy;
1996 American Lung Association.<BR> The American Thoracic  Society is the
medical section <BR>of the American Lung Association.<BR> 
</CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-18</DOCNO>
<DOCOLDNO>IA013-000139-B022-36</DOCOLDNO>
<DOCHDR>
http://www.thoracic.org:80/2nd-1.html 206.138.195.144 19970217070634 text/html 6124
HTTP/1.0 200 OK
Date: Monday, 17-Feb-97 07:01:50 GMT
Server: NCSA/1.3
MIME-version: 1.0
Content-type: text/html
Last-modified: Friday, 03-Jan-97 22:05:54 GMT
Content-length: 5944
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//SQ//DTD HTML 2.0 HoTMetaL + extensions//EN">
<HTML>
<HEAD>
<TITLE>ATS - Second State-Of-The-Art: Course Parameters</TITLE></HEAD>
<BODY BGCOLOR="#FFFFFF" BACKGROUND="images/back.jpg">
<CENTER><IMG ALIGN="LEFT" SRC="images/smlogo.gif"><BR> 
<H1>Course Parameters</H1>
</CENTER>
<HR SIZE="5" NOSHADE="NOSHADE" WIDTH="100%">
<P></P>
<CENTER>
<TABLE BORDER="4" ALIGN="CENTER">
<TR>
<TD><FONT SIZE="-1"><A HREF="2nd-1.html#ats1">Course Description</A></FONT></TD>
<TD><FONT SIZE="-1"><A HREF="2nd-2.html">Saturday, February 1, 1997</A></FONT></TD>
<TD><FONT SIZE="-1"><A HREF="2nd-6.html">Speaker's Index</A></FONT></TD>
<TD><FONT SIZE="-1"><A HREF="2nd-8.html#ats1">Meet the-Professor Seminars</A></FONT></TD></TR>
<TR>
<TD><FONT SIZE="-1"><A HREF="2nd-1.html#ats2">Target Audience</A></FONT></TD>
<TD><FONT SIZE="-1"><A HREF="2nd-3.html">Sunday, February 2, 1997</A></FONT></TD>
<TD><FONT SIZE="-1"><A HREF="2nd-7.html#ats1">Date and Location</A></FONT></TD>
<TD><FONT SIZE="-1"><A HREF="2nd-8.html#ats2">Hotel Accommodations</A></FONT></TD></TR>
<TR>
<TD><FONT SIZE="-1"><A HREF="2nd-1.html#ats3">Course Objectives</A></FONT></TD>
<TD><FONT SIZE="-1"><A HREF="2nd-4.html">Monday, February 3, 1997</A></FONT></TD>
<TD><FONT SIZE="-1"><A HREF="2nd-7.html#ats2">Accreditation</A></FONT></TD>
<TD><FONT SIZE="-1"><A HREF="2nd-8.html#ats3">ATS Membership</A></FONT></TD></TR>
<TR>
<TD><FONT SIZE="-1"><A HREF="2nd-1.html#ats4">Sponsor</A></FONT></TD>
<TD><FONT SIZE="-1"><A HREF="2nd-5.html">Tuesday, February 4, 1997</A></FONT></TD>
<TD><FONT SIZE="-1"><A HREF="2nd-7.html#ats3">Registration Fee</A></FONT></TD>
<TD><FONT SIZE="-1"><A HREF="2nd-9.html">Registration Form</A></FONT></TD></TR></TABLE></CENTER>
<H2><A NAME="ats1">Course Description</A></H2>
<P>The course is designed to provide a comprehensive update on the clinical
management of pulmonary and critical care disorders for <B>250 participants.
</B>The speakers are experienced academic clinicians from across the United
States who are currently contributing to the advancement of their fields.</P>
<P>The four-day program includes 33 <B>lectures </B>and a choice of seven <B><A
HREF="2nd-8.html#ats1">Meet-the-Professor seminars</A>. </B>Lectures provide a
current perspective on topics of practical importance to practitioners.
Meet-the- Professor seminars enable informal exchange with the speakers on
additional topics of current inter est which are related to the day's lectures.</P>
<P>A comprehensive syllabus and related materials will be provided to all
participants. The language of the course is English.</P>
<P></P>
<H2><A NAME="ats2">Target Audience</A></H2>
<P>Practicing physicians and fellows are the target audience for this course.</P>
<P></P>
<H2><A NAME="ats3">Course Objectives</A></H2>
<P>Upon completion of this course, participants will be able to:</P>
<OL>
<LI>apply up-to-date information and evidence-based advice to the clinical
management of current problems in pulmonary medicine and respiratory intensive
care.</LI>
<LI>discuss the essential elements of lectures designed to provide an expert
synthesis on &quot;what's new,&quot; in selected topics across a spectrum of
pulmonary and critical care medicine.</LI>
<LI>interpret the succinct viewpoints on specific topics provided by the
Meet-the-Professor seminars through an extended opportunity for informal
interaction with the lecturers.</LI></OL>
<P></P>
<H2><A NAME="ats4">Sponsor</A></H2>
<P>This course is a continuing medical education program of the American
Thoracic Society, medical section of the American Lung Association, developed
under the auspices of the ATS Postgraduate Education Committee. John
Hansen-Flaschen, MD, is the chairman of the committee.</P>
<P><BR><BR></P>
<HR SIZE="4" WIDTH="80%">
<P></P>
<CENTER><A HREF="about.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/about.gif" ALT="About Society"></A>
<A HREF="ssg.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/ss.gif" ALT="Society Structure"></A>
<A HREF="calendar.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/calendar.gif" ALT="ATS Calendar"></A>
<A HREF="gpi.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/pi.gif" ALT="Gen Public Info"></A>
<A HREF="ms.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/memserv.gif" ALT="Memb Serv"></A>
<BR>
<A HREF="pub.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/pubs.gif" ALT="Publications"></A>
<A HREF="press.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/press.gif" ALT="Press"></A>
<A HREF="index.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/home.gif" ALT="Home Page"></A>
<A HREF="search.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/search.gif" ALT="Search"></A>
<A HREF="assemb.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/assemb.gif" ALT="Assemblies"></A>
<A HREF="research.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/research.gif" ALT="Research"></A>
<BR>
<A HREF="mep.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/meded.gif" ALT="Med Education"></A>
<A HREF="wr.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/wr.gif" ALT="Wash Report"></A>
<A HREF="ic.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/ic.gif" ALT="Int'l Conference"></A>
<A HREF="source.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/link.gif" ALT="Web Links"></A>
<A HREF="store.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/store.gif" ALT="Store"></A> 
<A HREF="sig.html"><IMG
SRC="images/special.gif" ALT="Special" HSPACE="1" VSPACE="1" BORDER="0" HEIGHT="35" WIDTH="84"></A>
</CENTER>
<HR SIZE="4" WIDTH="80%">
<CENTER><FONT SIZE="+2"><B><I>American Thoracic Society</I></B></FONT><BR>
1740 Broadway<BR> New York, NY 10019<BR> VOICE:  212-315-8700<BR> Copyright &copy;
1996 American Lung Association.<BR> The American Thoracic  Society is the
medical section <BR>of the American Lung Association.<BR> 
</CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-19</DOCNO>
<DOCOLDNO>IA013-000139-B022-73</DOCOLDNO>
<DOCHDR>
http://www.thoracic.org:80/2nd-2.html 206.138.195.144 19970217070645 text/html 6722
HTTP/1.0 200 OK
Date: Monday, 17-Feb-97 07:02:00 GMT
Server: NCSA/1.3
MIME-version: 1.0
Content-type: text/html
Last-modified: Friday, 10-Jan-97 17:47:45 GMT
Content-length: 6542
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//SQ//DTD HTML 2.0 HoTMetaL + extensions//EN">
<HTML>
<HEAD>
<TITLE>ATS - Second State-Of-The-Art: Program</TITLE></HEAD>
<BODY BGCOLOR="#FFFFFF" BACKGROUND="images/back.jpg">
<CENTER><IMG ALIGN="LEFT" SRC="images/smlogo.gif"><BR> 
<H1>Program for:<BR>Saturday, February 1, 1997</H1>
</CENTER>
<HR SIZE="5" NOSHADE="NOSHADE" WIDTH="100%">
<P></P>
<CENTER>
<TABLE BORDER="4" ALIGN="CENTER">
<TR>
<TD><FONT SIZE="-1"><A HREF="2nd-1.html#ats1">Course Description</A></FONT></TD>
<TD><FONT SIZE="-1"><A HREF="2nd-2.html">Saturday, February 1, 1997</A></FONT></TD>
<TD><FONT SIZE="-1"><A HREF="2nd-6.html">Speaker's Index</A></FONT></TD>
<TD><FONT SIZE="-1"><A HREF="2nd-8.html#ats1">Meet the-Professor Seminars</A></FONT></TD></TR>
<TR>
<TD><FONT SIZE="-1"><A HREF="2nd-1.html#ats2">Target Audience</A></FONT></TD>
<TD><FONT SIZE="-1"><A HREF="2nd-3.html">Sunday, February 2, 1997</A></FONT></TD>
<TD><FONT SIZE="-1"><A HREF="2nd-7.html#ats1">Date and Location</A></FONT></TD>
<TD><FONT SIZE="-1"><A HREF="2nd-8.html#ats2">Hotel Accommodations</A></FONT></TD></TR>
<TR>
<TD><FONT SIZE="-1"><A HREF="2nd-1.html#ats3">Course Objectives</A></FONT></TD>
<TD><FONT SIZE="-1"><A HREF="2nd-4.html">Monday, February 3, 1997</A></FONT></TD>
<TD><FONT SIZE="-1"><A HREF="2nd-7.html#ats2">Accreditation</A></FONT></TD>
<TD><FONT SIZE="-1"><A HREF="2nd-8.html#ats3">ATS Membership</A></FONT></TD></TR>
<TR>
<TD><FONT SIZE="-1"><A HREF="2nd-1.html#ats4">Sponsor</A></FONT></TD>
<TD><FONT SIZE="-1"><A HREF="2nd-5.html">Tuesday, February 4, 1997</A></FONT></TD>
<TD><FONT SIZE="-1"><A HREF="2nd-7.html#ats3">Registration Fee</A></FONT></TD>
<TD><FONT SIZE="-1"><A HREF="2nd-9.html">Registration Form</A></FONT></TD></TR></TABLE></CENTER>
<P></P>
<CENTER>
<TABLE BORDER="4" ALIGN="CENTER">
<TR>
<TD>7:00 am </TD>
<TD><B>Registration and Continental Breakfast</B></TD></TR>
<TR>
<TD>8:00 am</TD>
<TD><B>Introduction and Welcome </B><BR>John Hansen-Flaschen, MD, Chairman</TD></TR>
<TR>
<TD></TD>
<TD><B>Session I - Michael Donahoe, MD, Moderator</B><BR>(Q&amp;A follow each
lecture)</TD></TR>
<TR>
<TD>8:10 am</TD>
<TD><B> Low Pressure Ventilation and Permissive Hypercapnea for ARDS</B><BR>Roy
Brower, MD</TD></TR>
<TR>
<TD>8:50 am</TD>
<TD><B>Tracheal Gas Insufflation: An Adjunct to Mechanical Ventilation</B><BR>Adelaida
Miro, MD</TD></TR>
<TR>
<TD>9:30 am</TD>
<TD><B>Break</B></TD></TR>
<TR>
<TD>9:40 am</TD>
<TD><B>Noninvasive Ventilation for Acute Respiratory Failure</B><BR>Nicholas
Hill, MD</TD></TR>
<TR>
<TD>10:20 am </TD>
<TD><B>Weaning from Mechanical Ventilation</B><BR>Gerald Criner, MD</TD></TR>
<TR>
<TD>11:00am</TD>
<TD><B>Break</B></TD></TR>
<TR>
<TD>11:10 am</TD>
<TD><B>Choose One of Four Meet-the-Professor Seminars</B>
<OL>
<LI><B>Patient-Ventilator Asynchrony: Causes and Potential Solutions</B><BR>Roy
Brower, MD</LI>
<LI><B>Heart/Lung Interaction in Mechanical Ventilation</B><BR>Adelaida Miro,
MD</LI>
<LI><B>Management of Pulmonary Hypertension in the ICU </B><BR>Nicholas Hill,
MD</LI>
<LI><B>Problems in Ventilator Weaning:</B><BR>Gerald Criner, MD</LI></OL></TD></TR>
<TR>
<TD>12:00pm</TD>
<TD> <B>Lunch</B></TD></TR>
<TR>
<TD></TD>
<TD><B>Session II - Michael Donahoe, MD, Moderator</B><BR>(Q&amp;A follow
each lecture)</TD></TR>
<TR>
<TD>1:00 pm</TD>
<TD><B>Management of the Difficult Airway </B><BR>Jeanine Wiener-Kronish, MD</TD></TR>
<TR>
<TD>1:40 pm</TD>
<TD><B>New Concepts in Line Sepsis </B><BR>Dennis Maki, MD</TD></TR>
<TR>
<TD>2:20 pm </TD>
<TD><B>Break</B></TD></TR>
<TR>
<TD>2:35 pm</TD>
<TD><B>Nutritional Support of Critically Ill Patients</B><BR>Michael Donahoe,
MD</TD></TR>
<TR>
<TD>3:15 pm</TD>
<TD><B>Pitfalls in Hemodynamic Monitoring</B><BR>John Yanos, MD</TD></TR>
<TR>
<TD>3:55 pm</TD>
<TD><B>Break</B></TD></TR>
<TR>
<TD>4:10 pm</TD>
<TD><B>Choose One of Four Meet-the-Professor Seminars</B>
<OL>
<LI><B>Preoperative Pulmonary Evaluation: An Anesthesiology Perspective</B><BR>Jeanine
Wiener-Kronish, MD</LI>
<LI><B>ICU Infections: </B> <B>Case Presentations</B><BR>Dennis Maki, MD</LI>
<LI><B>Disease-specific Nutritional Support in the ICU</B><BR>Michael
Donahoe, MD</LI>
<LI><B>Protocol Therapy in the ICU</B><BR>John Yanos, MD</LI></OL></TD></TR>
<TR>
<TD>5:00 pm</TD>
<TD BGCOLOR="#C0C0C0">All participants are invited to a Cocktail Reception</TD></TR></TABLE></CENTER>
<P><BR><BR></P>
<HR SIZE="4" WIDTH="80%">
<P></P>
<CENTER><A HREF="about.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/about.gif" ALT="About Society"></A>
<A HREF="ssg.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/ss.gif" ALT="Society Structure"></A>
<A HREF="calendar.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/calendar.gif" ALT="ATS Calendar"></A>
<A HREF="gpi.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/pi.gif" ALT="Gen Public Info"></A>
<A HREF="ms.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/memserv.gif" ALT="Memb Serv"></A>
<BR>
<A HREF="pub.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/pubs.gif" ALT="Publications"></A>
<A HREF="press.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/press.gif" ALT="Press"></A>
<A HREF="index.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/home.gif" ALT="Home Page"></A>
<A HREF="search.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/search.gif" ALT="Search"></A>
<A HREF="assemb.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/assemb.gif" ALT="Assemblies"></A>
<A HREF="research.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/research.gif" ALT="Research"></A>
<BR>
<A HREF="mep.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/meded.gif" ALT="Med Education"></A>
<A HREF="wr.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/wr.gif" ALT="Wash Report"></A>
<A HREF="ic.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/ic.gif" ALT="Int'l Conference"></A>
<A HREF="source.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/link.gif" ALT="Web Links"></A>
<A HREF="store.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/store.gif" ALT="Store"></A> 
<A HREF="sig.html"><IMG
SRC="images/special.gif" ALT="Special" HSPACE="1" VSPACE="1" BORDER="0" HEIGHT="35" WIDTH="84"></A>
</CENTER>
<HR SIZE="4" WIDTH="80%">
<CENTER><FONT SIZE="+2"><B><I>American Thoracic Society</I></B></FONT><BR>
1740 Broadway<BR> New York, NY 10019<BR> VOICE:  212-315-8700<BR> Copyright &copy;
1996 American Lung Association.<BR> The American Thoracic  Society is the
medical section <BR>of the American Lung Association.<BR> 
</CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-20</DOCNO>
<DOCOLDNO>IA013-000139-B022-128</DOCOLDNO>
<DOCHDR>
http://www.thoracic.org:80/2nd-3.html 206.138.195.144 19970217070657 text/html 6925
HTTP/1.0 200 OK
Date: Monday, 17-Feb-97 07:02:12 GMT
Server: NCSA/1.3
MIME-version: 1.0
Content-type: text/html
Last-modified: Friday, 03-Jan-97 22:06:59 GMT
Content-length: 6745
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//SQ//DTD HTML 2.0 HoTMetaL + extensions//EN">
<HTML>
<HEAD>
<TITLE>ATS - Second State-Of-The-Art: Program</TITLE></HEAD>
<BODY BGCOLOR="#FFFFFF" BACKGROUND="images/back.jpg">
<CENTER><IMG ALIGN="LEFT" SRC="images/smlogo.gif"><BR> 
<H1>Program for:<BR>Sunday, February 2, 1997</H1>
</CENTER>
<HR SIZE="5" NOSHADE="NOSHADE" WIDTH="100%">
<P></P>
<CENTER>
<TABLE BORDER="4" ALIGN="CENTER">
<TR>
<TD><FONT SIZE="-1"><A HREF="2nd-1.html#ats1">Course Description</A></FONT></TD>
<TD><FONT SIZE="-1"><A HREF="2nd-2.html">Saturday, February 1, 1997</A></FONT></TD>
<TD><FONT SIZE="-1"><A HREF="2nd-6.html">Speaker's Index</A></FONT></TD>
<TD><FONT SIZE="-1"><A HREF="2nd-8.html#ats1">Meet the-Professor Seminars</A></FONT></TD></TR>
<TR>
<TD><FONT SIZE="-1"><A HREF="2nd-1.html#ats2">Target Audience</A></FONT></TD>
<TD><FONT SIZE="-1"><A HREF="2nd-3.html">Sunday, February 2, 1997</A></FONT></TD>
<TD><FONT SIZE="-1"><A HREF="2nd-7.html#ats1">Date and Location</A></FONT></TD>
<TD><FONT SIZE="-1"><A HREF="2nd-8.html#ats2">Hotel Accommodations</A></FONT></TD></TR>
<TR>
<TD><FONT SIZE="-1"><A HREF="2nd-1.html#ats3">Course Objectives</A></FONT></TD>
<TD><FONT SIZE="-1"><A HREF="2nd-4.html">Monday, February 3, 1997</A></FONT></TD>
<TD><FONT SIZE="-1"><A HREF="2nd-7.html#ats2">Accreditation</A></FONT></TD>
<TD><FONT SIZE="-1"><A HREF="2nd-8.html#ats3">ATS Membership</A></FONT></TD></TR>
<TR>
<TD><FONT SIZE="-1"><A HREF="2nd-1.html#ats4">Sponsor</A></FONT></TD>
<TD><FONT SIZE="-1"><A HREF="2nd-5.html">Tuesday, February 4, 1997</A></FONT></TD>
<TD><FONT SIZE="-1"><A HREF="2nd-7.html#ats3">Registration Fee</A></FONT></TD>
<TD><FONT SIZE="-1"><A HREF="2nd-9.html">Registration Form</A></FONT></TD></TR></TABLE></CENTER>
<P></P>
<CENTER>
<TABLE BORDER="4" ALIGN="CENTER">
<TR>
<TD>7:00 am </TD>
<TD><B>Continental Breakfast</B></TD></TR>
<TR>
<TD>8:00 am</TD>
<TD><B>Announcements</B><BR>John Hansen-Flaschen, MD, Chairman</TD></TR>
<TR>
<TD></TD>
<TD><B>Session III - Jesse Hall, MD, Moderator</B><BR>(Q&amp;A follow each
lecture)</TD></TR>
<TR>
<TD>8:10 am</TD>
<TD><B>Acquired Neuromuscular Weakness in the ICU</B><BR>John
Hansen-Flaschen, MD</TD></TR>
<TR>
<TD>8:50 am</TD>
<TD><B>Management of Septic Shock</B><BR>Jesse Hall, MD</TD></TR>
<TR>
<TD>9:30 am</TD>
<TD><B>Break</B></TD></TR>
<TR>
<TD>9:40 am</TD>
<TD><B>Advances in the Treatment of Esophagovariceal Bleeding </B><BR>Jack
Lake, MD</TD></TR>
<TR>
<TD>10:20 am </TD>
<TD><B>New Therapeutic Interventions for Stroke</B><BR>Patrick Lyden, MD</TD></TR>
<TR>
<TD>11:00am</TD>
<TD><B>Break</B></TD></TR>
<TR>
<TD>11:10 am</TD>
<TD><B>Choose One of Four Meet-the-Professor Seminars</B>
<OL>
<LI><B> Sedation of Mechanically Ventilated Patients: Case Studies</B><BR>
John Hansen-Flaschen, MD</LI>
<LI><B>Diagnosis and Treatment of Hypotension in the ICU</B><BR>Jesse Hall,
MD</LI>
<LI><B>Critical Complications of Chronic Liver Disease</B><BR>Jack Lake, MD</LI>
<LI><B>Cerebrovascular Brain Injuries: Supportive Management</B><BR>Patrick
Lyden, MD</LI></OL></TD></TR>
<TR>
<TD>12:00pm</TD>
<TD> <B>Lunch</B></TD></TR>
<TR>
<TD></TD>
<TD><B>Session IV - Joseph Lynch, III, MD, Moderator</B><BR>(Q&amp;A follow
each lecture)</TD></TR>
<TR>
<TD>1:00 pm</TD>
<TD><B>High Resolution CT in the Diagnosis of Interstitial Lung Diseases</B><BR>Ganesh
Raghu, MD </TD></TR>
<TR>
<TD>1:40 pm</TD>
<TD><B>Lung Biopsy for Diagnosis and Staging of Interstitial Lung Diseases
</B><BR>Jeffrey Myers, MD</TD></TR>
<TR>
<TD>2:20 pm </TD>
<TD><B>Break</B></TD></TR>
<TR>
<TD>2:35 pm</TD>
<TD><B>Treatment of Idiopathic Pulmonary Fibrosis</B><BR>Joseph Lynch, III,
MD</TD></TR>
<TR>
<TD>3:15 pm</TD>
<TD><B>The Emerging Spectrum of Bronchiolitis</B><BR>Talmadge King, MD</TD></TR>
<TR>
<TD>3:55 pm</TD>
<TD><B>Break</B></TD></TR>
<TR>
<TD>4:10 pm</TD>
<TD><B>Choose One of Four Meet-the-Professor Seminars</B>
<OL>
<LI><B>Monitoring the Clinical Course of Idiopathic Pulmonary Fibrosis</B><BR>Ganesh
Raghu, MD</LI>
<LI><B>Getting the Most from Lung Biopsies: When is Tissue the Issue?</B>
<BR>Jeffrey Myers, MD</LI>
<LI><B>Individualizing and Stratifying Therapy for Idiopathic Pulmonary
Fibrosis</B><BR>Joseph Lynch, III, MD</LI>
<LI><B>Syndromes that Mimic Pulmonary Fibrosis</B><BR>Talmadge King, MD</LI></OL></TD></TR>
<TR>
<TD>5:00 pm</TD>
<TD>Adjournment</TD></TR>
<TR>
<TD>7:30 pm -<BR>9:00 pm</TD>
<TD><B> Case Presentations I </B><BR>George Robinson, MD, Moderator
<P></P><B>Participants are invited to bring cases for review and discussion</B></TD></TR></TABLE></CENTER>
<P><BR><BR></P>
<HR SIZE="4" WIDTH="80%">
<P></P>
<CENTER><A HREF="about.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/about.gif" ALT="About Society"></A>
<A HREF="ssg.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/ss.gif" ALT="Society Structure"></A>
<A HREF="calendar.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/calendar.gif" ALT="ATS Calendar"></A>
<A HREF="gpi.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/pi.gif" ALT="Gen Public Info"></A>
<A HREF="ms.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/memserv.gif" ALT="Memb Serv"></A>
<BR>
<A HREF="pub.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/pubs.gif" ALT="Publications"></A>
<A HREF="press.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/press.gif" ALT="Press"></A>
<A HREF="index.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/home.gif" ALT="Home Page"></A>
<A HREF="search.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/search.gif" ALT="Search"></A>
<A HREF="assemb.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/assemb.gif" ALT="Assemblies"></A>
<A HREF="research.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/research.gif" ALT="Research"></A>
<BR>
<A HREF="mep.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/meded.gif" ALT="Med Education"></A>
<A HREF="wr.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/wr.gif" ALT="Wash Report"></A>
<A HREF="ic.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/ic.gif" ALT="Int'l Conference"></A>
<A HREF="source.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/link.gif" ALT="Web Links"></A>
<A HREF="store.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/store.gif" ALT="Store"></A> 
<A HREF="sig.html"><IMG
SRC="images/special.gif" ALT="Special" HSPACE="1" VSPACE="1" BORDER="0" HEIGHT="35" WIDTH="84"></A>
</CENTER>
<HR SIZE="4" WIDTH="80%">
<CENTER><FONT SIZE="+2"><B><I>American Thoracic Society</I></B></FONT><BR>
1740 Broadway<BR> New York, NY 10019<BR> VOICE:  212-315-8700<BR> Copyright &copy;
1996 American Lung Association.<BR> The American Thoracic  Society is the
medical section <BR>of the American Lung Association.<BR> 
</CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-21</DOCNO>
<DOCOLDNO>IA013-000139-B022-162</DOCOLDNO>
<DOCHDR>
http://www.thoracic.org:80/2nd-4.html 206.138.195.144 19970217070714 text/html 6833
HTTP/1.0 200 OK
Date: Monday, 17-Feb-97 07:02:27 GMT
Server: NCSA/1.3
MIME-version: 1.0
Content-type: text/html
Last-modified: Friday, 10-Jan-97 17:20:53 GMT
Content-length: 6653
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//SQ//DTD HTML 2.0 HoTMetaL + extensions//EN">
<HTML>
<HEAD>
<TITLE>ATS - Second State-Of-The-Art: Program</TITLE></HEAD>
<BODY BGCOLOR="#FFFFFF" BACKGROUND="images/back.jpg">
<CENTER><IMG ALIGN="LEFT" SRC="images/smlogo.gif"><BR> 
<H1>Program for:<BR>Monday, February 3, 1997</H1>
</CENTER>
<HR SIZE="5" NOSHADE="NOSHADE" WIDTH="100%">
<P></P>
<CENTER>
<TABLE BORDER="4" ALIGN="CENTER">
<TR>
<TD><FONT SIZE="-1"><A HREF="2nd-1.html#ats1">Course Description</A></FONT></TD>
<TD><FONT SIZE="-1"><A HREF="2nd-2.html">Saturday, February 1, 1997</A></FONT></TD>
<TD><FONT SIZE="-1"><A HREF="2nd-6.html">Speaker's Index</A></FONT></TD>
<TD><FONT SIZE="-1"><A HREF="2nd-8.html#ats1">Meet the-Professor Seminars</A></FONT></TD></TR>
<TR>
<TD><FONT SIZE="-1"><A HREF="2nd-1.html#ats2">Target Audience</A></FONT></TD>
<TD><FONT SIZE="-1"><A HREF="2nd-3.html">Sunday, February 2, 1997</A></FONT></TD>
<TD><FONT SIZE="-1"><A HREF="2nd-7.html#ats1">Date and Location</A></FONT></TD>
<TD><FONT SIZE="-1"><A HREF="2nd-8.html#ats2">Hotel Accommodations</A></FONT></TD></TR>
<TR>
<TD><FONT SIZE="-1"><A HREF="2nd-1.html#ats3">Course Objectives</A></FONT></TD>
<TD><FONT SIZE="-1"><A HREF="2nd-4.html">Monday, February 3, 1997</A></FONT></TD>
<TD><FONT SIZE="-1"><A HREF="2nd-7.html#ats2">Accreditation</A></FONT></TD>
<TD><FONT SIZE="-1"><A HREF="2nd-8.html#ats3">ATS Membership</A></FONT></TD></TR>
<TR>
<TD><FONT SIZE="-1"><A HREF="2nd-1.html#ats4">Sponsor</A></FONT></TD>
<TD><FONT SIZE="-1"><A HREF="2nd-5.html">Tuesday, February 4, 1997</A></FONT></TD>
<TD><FONT SIZE="-1"><A HREF="2nd-7.html#ats3">Registration Fee</A></FONT></TD>
<TD><FONT SIZE="-1"><A HREF="2nd-9.html">Registration Form</A></FONT></TD></TR></TABLE></CENTER>
<P></P>
<CENTER>
<TABLE BORDER="4" ALIGN="CENTER">
<TR>
<TD>7:00 am </TD>
<TD><B>Continental Breakfast</B></TD></TR>
<TR>
<TD>8:00 am</TD>
<TD><B>Announcements</B><BR>John Hansen-Flaschen, MD, Chairman</TD></TR>
<TR>
<TD></TD>
<TD><B>Session V - Richard Millman, MD, Moderator</B><BR>(Q&amp;A follow each
lecture)</TD></TR>
<TR>
<TD>8:10 am</TD>
<TD><B>Controversies in Outpatient Management of Asthma</B><BR>Christopher
Fanta, MD</TD></TR>
<TR>
<TD>8:50 am</TD>
<TD><B>Laryngeal Dysfunction: Asthma that Isn't</B><BR>Kenneth Newman, MD</TD></TR>
<TR>
<TD>9:30 am</TD>
<TD><B>Break</B></TD></TR>
<TR>
<TD>9:40 am</TD>
<TD><B>Update on Alpha-1 Antitrypsin Disease</B><BR>Herbert Wiedemann, MD</TD></TR>
<TR>
<TD>10:20 am </TD>
<TD><B>Sleep Apnea: Old and New Treatment Options</B><BR>Richard Millman, MD</TD></TR>
<TR>
<TD>11:00am</TD>
<TD><B>Break</B></TD></TR>
<TR>
<TD>11:10 am</TD>
<TD><B>Choose One of Four Meet-the-Professor Seminars</B>
<OL>
<LI><B> Pseudosteroid-resistant Asthma</B><BR> Christopher Fanta, MD</LI>
<LI><B>Management of Status Asthmaticus</B><BR>Kenneth Newman, MD</LI>
<LI><B>Rare Causes of Chronic Airflow Obstruction</B><BR>Herbert Wiedemann,
MD</LI>
<LI><B>Diagnostic Dilemmas in Sleep Medicine</B><BR>Richard Millman, MD</LI></OL></TD></TR>
<TR>
<TD>12:00pm</TD>
<TD> <B>Lunch</B></TD></TR>
<TR>
<TD></TD>
<TD><B>Session VI - Alan Fein, MD, Moderator</B><BR>(Q&amp;A follow each
lecture)</TD></TR>
<TR>
<TD>1:00 pm</TD>
<TD><B>Severe Pneumonia: the Old and the New</B><BR>Alan Fein, MD</TD></TR>
<TR>
<TD>1:40 pm</TD>
<TD><B>Antibiotics for Pulmonary Infections: New Horizons</B><BR>Ronald
Grossman, MD</TD></TR>
<TR>
<TD>2:20 pm </TD>
<TD><B>Break</B></TD></TR>
<TR>
<TD>2:35 pm</TD>
<TD><B>Ventilator Associated Pneumonia: Clinical Judgment vs Practice
Guidelines</B><BR>Richard Wunderink, MD</TD></TR>
<TR>
<TD>3:15 pm</TD>
<TD><B>Tuberculosis: New Risks and Challenges</B><BR>Jeffrey Glassroth, MD</TD></TR>
<TR>
<TD>3:55 pm</TD>
<TD><B>Break</B></TD></TR>
<TR>
<TD>4:10 pm</TD>
<TD><B>Choose One of Four Meet-the-Professor Seminars</B>
<OL>
<LI><B>Community Acquired Pneumonia: the Outpatient Frontier</B><BR>Alan
Fein, MD</LI>
<LI><B> Lower Airway Infections</B> <BR>Ronald Grossman, MD</LI>
<LI><B>Fever in the Ventilated Patient: Cost-effective Approaches</B><BR>Richard
Wunderink, MD</LI>
<LI><B>Non-tuberculous Mycobacteria Infections in Immunocompetent Hosts</B><BR>Jeffrey
Glassroth, MD</LI></OL></TD></TR>
<TR>
<TD>5:00 pm</TD>
<TD>Adjournment</TD></TR>
<TR>
<TD>7:30 pm -<BR>9:00 pm</TD>
<TD><B> Case Presentations II </B><BR>George Robinson, MD, Moderator
<P></P><B>Participants are invited to bring cases for review and discussion</B></TD></TR></TABLE></CENTER>
<P><BR><BR></P>
<HR SIZE="4" WIDTH="80%">
<P></P>
<CENTER><A HREF="about.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/about.gif" ALT="About Society"></A>
<A HREF="ssg.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/ss.gif" ALT="Society Structure"></A>
<A HREF="calendar.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/calendar.gif" ALT="ATS Calendar"></A>
<A HREF="gpi.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/pi.gif" ALT="Gen Public Info"></A>
<A HREF="ms.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/memserv.gif" ALT="Memb Serv"></A>
<BR>
<A HREF="pub.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/pubs.gif" ALT="Publications"></A>
<A HREF="press.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/press.gif" ALT="Press"></A>
<A HREF="index.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/home.gif" ALT="Home Page"></A>
<A HREF="search.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/search.gif" ALT="Search"></A>
<A HREF="assemb.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/assemb.gif" ALT="Assemblies"></A>
<A HREF="research.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/research.gif" ALT="Research"></A>
<BR>
<A HREF="mep.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/meded.gif" ALT="Med Education"></A>
<A HREF="wr.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/wr.gif" ALT="Wash Report"></A>
<A HREF="ic.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/ic.gif" ALT="Int'l Conference"></A>
<A HREF="source.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/link.gif" ALT="Web Links"></A>
<A HREF="store.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/store.gif" ALT="Store"></A> 
<A HREF="sig.html"><IMG
SRC="images/special.gif" ALT="Special" HSPACE="1" VSPACE="1" BORDER="0" HEIGHT="35" WIDTH="84"></A>
</CENTER>
<HR SIZE="4" WIDTH="80%">
<CENTER><FONT SIZE="+2"><B><I>American Thoracic Society</I></B></FONT><BR>
1740 Broadway<BR> New York, NY 10019<BR> VOICE:  212-315-8700<BR> Copyright &copy;
1996 American Lung Association.<BR> The American Thoracic  Society is the
medical section <BR>of the American Lung Association.<BR> 
</CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-22</DOCNO>
<DOCOLDNO>IA013-000139-B022-202</DOCOLDNO>
<DOCHDR>
http://www.thoracic.org:80/2nd-5.html 206.138.195.144 19970217070728 text/html 6890
HTTP/1.0 200 OK
Date: Monday, 17-Feb-97 07:02:43 GMT
Server: NCSA/1.3
MIME-version: 1.0
Content-type: text/html
Last-modified: Friday, 03-Jan-97 22:08:15 GMT
Content-length: 6710
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//SQ//DTD HTML 2.0 HoTMetaL + extensions//EN">
<HTML>
<HEAD>
<TITLE>ATS - Second State-Of-The-Art: Program</TITLE></HEAD>
<BODY BGCOLOR="#FFFFFF" BACKGROUND="images/back.jpg">
<CENTER><IMG ALIGN="LEFT" SRC="images/smlogo.gif"><BR> 
<H1>Program for:<BR>Tuesday, February 4, 1997</H1>
</CENTER>
<HR SIZE="5" NOSHADE="NOSHADE" WIDTH="100%">
<P></P>
<CENTER>
<TABLE BORDER="4" ALIGN="CENTER">
<TR>
<TD><FONT SIZE="-1"><A HREF="2nd-1.html#ats1">Course Description</A></FONT></TD>
<TD><FONT SIZE="-1"><A HREF="2nd-2.html">Saturday, February 1, 1997</A></FONT></TD>
<TD><FONT SIZE="-1"><A HREF="2nd-6.html">Speaker's Index</A></FONT></TD>
<TD><FONT SIZE="-1"><A HREF="2nd-8.html#ats1">Meet the-Professor Seminars</A></FONT></TD></TR>
<TR>
<TD><FONT SIZE="-1"><A HREF="2nd-1.html#ats2">Target Audience</A></FONT></TD>
<TD><FONT SIZE="-1"><A HREF="2nd-3.html">Sunday, February 2, 1997</A></FONT></TD>
<TD><FONT SIZE="-1"><A HREF="2nd-7.html#ats1">Date and Location</A></FONT></TD>
<TD><FONT SIZE="-1"><A HREF="2nd-8.html#ats2">Hotel Accommodations</A></FONT></TD></TR>
<TR>
<TD><FONT SIZE="-1"><A HREF="2nd-1.html#ats3">Course Objectives</A></FONT></TD>
<TD><FONT SIZE="-1"><A HREF="2nd-4.html">Monday, February 3, 1997</A></FONT></TD>
<TD><FONT SIZE="-1"><A HREF="2nd-7.html#ats2">Accreditation</A></FONT></TD>
<TD><FONT SIZE="-1"><A HREF="2nd-8.html#ats3">ATS Membership</A></FONT></TD></TR>
<TR>
<TD><FONT SIZE="-1"><A HREF="2nd-1.html#ats4">Sponsor</A></FONT></TD>
<TD><FONT SIZE="-1"><A HREF="2nd-5.html">Tuesday, February 4, 1997</A></FONT></TD>
<TD><FONT SIZE="-1"><A HREF="2nd-7.html#ats3">Registration Fee</A></FONT></TD>
<TD><FONT SIZE="-1"><A HREF="2nd-9.html">Registration Form</A></FONT></TD></TR></TABLE></CENTER>
<P></P>
<CENTER>
<TABLE BORDER="4" ALIGN="CENTER">
<TR>
<TD>7:00 am </TD>
<TD><B>Continental Breakfast</B></TD></TR>
<TR>
<TD>8:00 am</TD>
<TD><B>Announcements</B><BR>John Hansen-Flaschen, MD, Chairman</TD></TR>
<TR>
<TD></TD>
<TD><B>Session VII - John Hansen-Flaschen, MD, Moderator</B><BR>(Q&amp;A
follow each lecture)</TD></TR>
<TR>
<TD>8:10 am</TD>
<TD><B>Video Assisted Thoracic Surgery </B><BR>Larry Kaiser, MD</TD></TR>
<TR>
<TD>8:50 am</TD>
<TD><B>Chronic Thromboembolic Pulmonary Hypertension: Diagnosis and Surgical
Therapy</B><BR>Peter Fedullo, MD</TD></TR>
<TR>
<TD>9:30 am</TD>
<TD><B>Break</B></TD></TR>
<TR>
<TD>9:40 am</TD>
<TD><B><B>Lung Reduction Surgery for Emphysema</B></B><BR>Elbert Trulock, MD</TD></TR>
<TR>
<TD>10:20 am </TD>
<TD><B>Promise and Pitfalls of Lung Transplantation</B><BR>Robert Kotloff, MD</TD></TR>
<TR>
<TD>11:00am</TD>
<TD><B>Break</B></TD></TR>
<TR>
<TD>11:10 am</TD>
<TD><B>Choose One of Four Meet-the-Professor Seminars</B>
<OL>
<LI><B> Thoracic Surgery: New Applications</B><BR> Larry Kaiser, MD</LI>
<LI><B>Pulmonary Hypertension: Diagnostic and Therapeutic Approach</B><BR>Peter
Fedullo, MD</LI>
<LI><B>Pulmonary Complications of Lung Transplantation</B><BR>Elbert Trulock,
MD</LI>
<LI><B>Pulmonary Zebras: Misdiagnosis of Uncommon Lung Diseases</B><BR>Robert
Kotloff, MD</LI></OL></TD></TR>
<TR>
<TD>12:00pm</TD>
<TD> <B>Lunch</B></TD></TR>
<TR>
<TD></TD>
<TD><B>Session VIII - Idelle Weisman, MD, Moderator</B><BR>(Q&amp;A follow
each lecture)</TD></TR>
<TR>
<TD>1:00 pm</TD>
<TD><B>Bronchoprovocation Challenge Testing in Clinical Practice </B><BR>James
Fish, MD</TD></TR>
<TR>
<TD>1:40 pm</TD>
<TD><B>Comprehensive Cardiopulmonary Exercise Testing</B><BR>Idelle Weisman,
MD</TD></TR>
<TR>
<TD>2:20 pm </TD>
<TD><B>Break</B></TD></TR>
<TR>
<TD>2:35 pm</TD>
<TD><B>Update on Pulmonary Rehabilitation</B><BR>Andrew Ries, MD</TD></TR>
<TR>
<TD>3:15 pm</TD>
<TD><B>Advances and Controversies in Long Term Oxygen Therapy</B><BR>Walter
0'Donohue, Jr., MD</TD></TR>
<TR>
<TD>3:55 pm</TD>
<TD><B>Break</B></TD></TR>
<TR>
<TD>4:10 pm</TD>
<TD><B>Choose One of Four Meet-the-Professor Seminars</B>
<OL>
<LI><B>Clinical Problems in Asthma Diagnosis</B><BR>James Fish, MD</LI>
<LI><B>Exercise Testing in Patient Management: Case Studies</B> <BR>Idelle
Weisman, MD</LI>
<LI><B>Optimizing Pulmonary Rehabilitation for Individual Patients</B><BR>Andrew
Ries, MD</LI>
<LI><B>Practical Application of  Home Oxygen Therapy: What's Available and How
to Write an Appropriate Prescription</B><BR>Walter 0'Donohue, Jr., MD</LI></OL></TD></TR>
<TR>
<TD>5:00 pm</TD>
<TD>Course Ends</TD></TR>
<TR>
<TD></TD>
<TD BGCOLOR="#C0C0C0"><B>Submission of Evaluation Forms and Awarding of
Catagory 1 Credit Hours</B></TD></TR></TABLE></CENTER>
<P><BR><BR></P>
<HR SIZE="4" WIDTH="80%">
<P></P>
<CENTER><A HREF="about.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/about.gif" ALT="About Society"></A>
<A HREF="ssg.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/ss.gif" ALT="Society Structure"></A>
<A HREF="calendar.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/calendar.gif" ALT="ATS Calendar"></A>
<A HREF="gpi.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/pi.gif" ALT="Gen Public Info"></A>
<A HREF="ms.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/memserv.gif" ALT="Memb Serv"></A>
<BR>
<A HREF="pub.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/pubs.gif" ALT="Publications"></A>
<A HREF="press.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/press.gif" ALT="Press"></A>
<A HREF="index.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/home.gif" ALT="Home Page"></A>
<A HREF="search.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/search.gif" ALT="Search"></A>
<A HREF="assemb.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/assemb.gif" ALT="Assemblies"></A>
<A HREF="research.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/research.gif" ALT="Research"></A>
<BR>
<A HREF="mep.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/meded.gif" ALT="Med Education"></A>
<A HREF="wr.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/wr.gif" ALT="Wash Report"></A>
<A HREF="ic.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/ic.gif" ALT="Int'l Conference"></A>
<A HREF="source.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/link.gif" ALT="Web Links"></A>
<A HREF="store.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/store.gif" ALT="Store"></A> 
<A HREF="sig.html"><IMG
SRC="images/special.gif" ALT="Special" HSPACE="1" VSPACE="1" BORDER="0" HEIGHT="35" WIDTH="84"></A>
</CENTER>
<HR SIZE="4" WIDTH="80%">
<CENTER><FONT SIZE="+2"><B><I>American Thoracic Society</I></B></FONT><BR>
1740 Broadway<BR> New York, NY 10019<BR> VOICE:  212-315-8700<BR> Copyright &copy;
1996 American Lung Association.<BR> The American Thoracic  Society is the
medical section <BR>of the American Lung Association.<BR> 
</CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-23</DOCNO>
<DOCOLDNO>IA013-000139-B022-239</DOCOLDNO>
<DOCHDR>
http://www.thoracic.org:80/2nd-6.html 206.138.195.144 19970217070736 text/html 8411
HTTP/1.0 200 OK
Date: Monday, 17-Feb-97 07:02:53 GMT
Server: NCSA/1.3
MIME-version: 1.0
Content-type: text/html
Last-modified: Friday, 10-Jan-97 17:20:36 GMT
Content-length: 8231
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//SQ//DTD HTML 2.0 HoTMetaL + extensions//EN">
<HTML>
<HEAD>
<TITLE>ATS - Second State-Of-The-Art: Speakers' Index</TITLE></HEAD>
<BODY BGCOLOR="#FFFFFF" BACKGROUND="images/back.jpg">
<CENTER><IMG ALIGN="LEFT" SRC="images/smlogo.gif"><BR> 
<H1>Speakers' Index</H1>
</CENTER>
<HR SIZE="5" NOSHADE="NOSHADE" WIDTH="100%">
<P></P>
<TABLE BORDER="4" ALIGN="LEFT" VALIGN="MIDDLE">
<TR>
<TD><FONT SIZE="-1"><A HREF="2nd-1.html#ats1">Course Description</A></FONT></TD></TR>
<TR>
<TD><FONT SIZE="-1"><A HREF="2nd-1.html#ats2">Target Audience</A></FONT></TD></TR>
<TR>
<TD><FONT SIZE="-1"><A HREF="2nd-1.html#ats3">Course Objectives</A></FONT></TD></TR>
<TR>
<TD><FONT SIZE="-1"><A HREF="2nd-1.html#ats4">Sponsor</A></FONT></TD></TR>
<TR>
<TD><FONT SIZE="-1"><A HREF="2nd-2.html">Saturday, February 1, 1997</A></FONT></TD></TR>
<TR>
<TD><FONT SIZE="-1"><A HREF="2nd-3.html">Sunday, February 2, 1997</A></FONT></TD></TR>
<TR>
<TD><FONT SIZE="-1"><A HREF="2nd-4.html">Monday, February 3, 1997</A></FONT></TD></TR>
<TR>
<TD><FONT SIZE="-1"><A HREF="2nd-5.html">Tuesday, February 4, 1997</A></FONT></TD></TR>
<TR>
<TD><FONT SIZE="-1"><A HREF="2nd-6.html">Speaker's Index</A></FONT></TD></TR>
<TR>
<TD><FONT SIZE="-1"><A HREF="2nd-7.html#ats1">Date and Location</A></FONT></TD></TR>
<TR>
<TD><FONT SIZE="-1"><A HREF="2nd-7.html#ats2">Accreditation</A></FONT></TD></TR>
<TR>
<TD><FONT SIZE="-1"><A HREF="2nd-7.html#ats3">Registration Fee</A></FONT></TD></TR>
<TR>
<TD><FONT SIZE="-1"><A HREF="2nd-8.html#ats1">Meet the-Professor Seminars</A></FONT></TD></TR>
<TR>
<TD><FONT SIZE="-1"><A HREF="2nd-8.html#ats2">Hotel Accommodations</A></FONT></TD></TR>
<TR>
<TD><FONT SIZE="-1"><A HREF="2nd-8.html#ats3">ATS Membership</A></FONT></TD></TR>
<TR>
<TD><FONT SIZE="-1"><A HREF="2nd-9.html">Registration Form</A></FONT></TD></TR></TABLE>
<CENTER>
<TABLE BORDER="4" ALIGN="CENTER">
<TR ALIGN="CENTER" VALIGN="MIDDLE">
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P><B>B</B></P>
<P><FONT SIZE="-1">Brower, R., MD<BR>Johns Hopkins University<BR>School of
Medicine,<BR>Baltimore, MD</FONT></P></TD>
<TD>
<P><B>M</B></P>
<P><FONT SIZE="-1">Maki, D., MD<BR>UW Hospital,<BR>Madison, WI</FONT></P>
<P><FONT SIZE="-1">Millman, R., MD<BR>Rhode Island Hospital,<BR>Providence,
RI</FONT></P>
<P><FONT SIZE="-1">Miro, A., MD<BR>University of Pittsburgh<BR>Medical
Center<BR>Pittsburgh, PA</FONT></P>
<P><FONT SIZE="-1">Myers, J., MD<BR>Mayo Clinic,<BR>Rochester MN</FONT></P></TD></TR>
<TR ALIGN="CENTER" VALIGN="MIDDLE">
<TD>
<P><B>C</B></P>
<P><FONT SIZE="-1">Criner, G., MD<BR>Temple University<BR>Hospital Pulmonary
Division,<BR>Philadelphia, PA</FONT></P></TD>
<TD>
<P><B>N</B></P>
<P><FONT SIZE="-1">Newman, K., MD<BR>University of Cincinnati<BR>Medical
Center<BR>Cincinnati, OH</FONT></P></TD></TR>
<TR ALIGN="CENTER" VALIGN="MIDDLE">
<TD>
<P><B>D</B></P>
<P><FONT SIZE="-1">Donahoe, M., MD<BR>The Lung Center<BR>University of
Pittsburgh,<BR>Pittsburgh, PA</FONT></P></TD>
<TD>
<P><B>O</B></P>
<P><FONT SIZE="-1">O'Donohue, Jr., W., MD<BR>Creighton University Medical
Center<BR>Omaha, NE</FONT></P></TD></TR>
<TR ALIGN="CENTER" VALIGN="MIDDLE">
<TD>
<P><B>F</B></P>
<P><FONT SIZE="-1">Fanta, C., MD<BR>Brigham &amp; Women's Hospital,<BR>Boston,
MA</FONT></P>
<P><FONT SIZE="-1">Fedullo, P, MD<BR> UCSD Medical Center, <BR>San Diego, CA</FONT></P>
<P><FONT SIZE="-1">Fein, A., MD<BR>Winthmp Pulmonary Associates,<BR>Mineola,
NY</FONT></P>
<P><FONT SIZE="-1">Fish, J., MD<BR>Jefferson Medical College,<BR>Philadelphia,
PA</FONT></P></TD>
<TD>
<P><B>R</B></P>
<P><FONT SIZE="-1">Raghu, G., MD<BR>University of Washington<BR>School of
Medicine,<BR>Seattle, WA</FONT></P>
<P><FONT SIZE="-1">Ries, A., MD, M.P.H.<BR>University of California at San
Diego,<BR>San Diego, CA</FONT></P>
<P><FONT SIZE="-1">Robinson, II, G., MD,<BR>York Hospital,<BR> York, PA</FONT></P></TD></TR>
<TR ALIGN="CENTER" VALIGN="MIDDLE">
<TD>
<P><B>G</B></P>
<P><FONT SIZE="-1">Glassroth, J., MD<BR>Allegheny University Hospital,<BR>Philadelphia,
PA</FONT></P>
<P><FONT SIZE="-1">Grossman, R., MD<BR>University of Toronto<BR>Mt. Sinai
Hospital<BR> Toronto, Ontario Canada</FONT></P></TD>
<TD>
<P><B>T</B></P>
<P><FONT SIZE="-1">Trulock, E., MD<BR>Washington University<BR>School of
Medicine,<BR>St. Louis, MO</FONT></P></TD></TR>
<TR ALIGN="CENTER" VALIGN="MIDDLE">
<TD>
<P><B>H</B></P>
<P><FONT SIZE="-1">Hall, J., MD<BR>University of Chicago,<BR>Chicago, IL</FONT></P>
<P><FONT SIZE="-1">Hansen-Flaschen, J., MD<BR>Hospital of the University of
Pennsylvania,<BR>Philadelphia, PA,</FONT></P>
<P><FONT SIZE="-1">Hill, N., MD<BR>Rhode Island Hospital,<BR>Providence, RI,</FONT></P></TD>
<TD>
<P><B>W</B></P>
<P><FONT SIZE="-1">Wiedemann, H., MD<BR>Cleveland Clinic Foundation,<BR>Cleveland,
OH</FONT></P>
<P><FONT SIZE="-1">Weisman, I., MD<BR>William Beaumont Army<BR>Medical
Center<BR>El Paso, TX</FONT></P>
<P><FONT SIZE="-1">Wiener-Kronish, J., MD<BR>University of California<BR>San
Francisco, CA</FONT></P>
<P><FONT SIZE="-1">Wunderink, R., MD<BR>University of Tennessee,<BR>Memphis,
TN</FONT></P></TD></TR>
<TR ALIGN="CENTER" VALIGN="MIDDLE">
<TD>
<P><B>K</B></P>
<P><FONT SIZE="-1">Kaiser L., MD<BR>Hospital of the University of
Pennsylvannia,<BR>Philadelphia, PA</FONT></P>
<P><FONT SIZE="-1">King, Jr., T., MD<BR>National Jewish Center<BR>for
Immunology &amp; Respiratory Medicine,<BR>Denver, CO</FONT></P>
<P><FONT SIZE="-1">Kotloff, R., MD<BR>Hospital of the University of
Pennsylvannia,<BR> Philadelphia, PA</FONT></P></TD>
<TD>
<P><B>Y</B></P>
<P><FONT SIZE="-1">Yanos, J., MD<BR>Medical Center<BR>Columbia, MO</FONT></P></TD></TR>
<TR ALIGN="CENTER" VALIGN="MIDDLE">
<TD>
<P><B>L</B></P>
<P><FONT SIZE="-1">Lake J., MD<BR>University of California,<BR>San
Francisco, CA</FONT></P>
<P><FONT SIZE="-1">Lyden, P, MD<BR>University of California<BR>San Diego
Medical Center<BR>San Diego, CA</FONT></P>
<P><FONT SIZE="-1">Lynch, III, J., MD<BR>University of Michigan Medical
Center<BR>Ann Arbor MI</FONT></P></TD>
<TD BGCOLOR="#C0C0C0"></TD></TR></TABLE></CENTER>
<P><BR><BR></P>
<HR SIZE="4" WIDTH="80%">
<P></P>
<CENTER><A HREF="about.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/about.gif" ALT="About Society"></A>
<A HREF="ssg.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/ss.gif" ALT="Society Structure"></A>
<A HREF="calendar.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/calendar.gif" ALT="ATS Calendar"></A>
<A HREF="gpi.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/pi.gif" ALT="Gen Public Info"></A>
<A HREF="ms.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/memserv.gif" ALT="Memb Serv"></A>
<BR>
<A HREF="pub.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/pubs.gif" ALT="Publications"></A>
<A HREF="press.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/press.gif" ALT="Press"></A>
<A HREF="index.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/home.gif" ALT="Home Page"></A>
<A HREF="search.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/search.gif" ALT="Search"></A>
<A HREF="assemb.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/assemb.gif" ALT="Assemblies"></A>
<A HREF="research.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/research.gif" ALT="Research"></A>
<BR>
<A HREF="mep.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/meded.gif" ALT="Med Education"></A>
<A HREF="wr.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/wr.gif" ALT="Wash Report"></A>
<A HREF="ic.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/ic.gif" ALT="Int'l Conference"></A>
<A HREF="source.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/link.gif" ALT="Web Links"></A>
<A HREF="store.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/store.gif" ALT="Store"></A> 
<A HREF="sig.html"><IMG
SRC="images/special.gif" ALT="Special" HSPACE="1" VSPACE="1" BORDER="0" HEIGHT="35" WIDTH="84"></A>
</CENTER>
<HR SIZE="4" WIDTH="80%">
<CENTER><FONT SIZE="+2"><B><I>American Thoracic Society</I></B></FONT><BR>
1740 Broadway<BR> New York, NY 10019<BR> VOICE:  212-315-8700<BR> Copyright &copy;
1996 American Lung Association.<BR> The American Thoracic  Society is the
medical section <BR>of the American Lung Association.<BR> 
</CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-24</DOCNO>
<DOCOLDNO>IA013-000139-B022-274</DOCOLDNO>
<DOCHDR>
http://www.thoracic.org:80/2nd-7.html 206.138.195.144 19970217070746 text/html 6088
HTTP/1.0 200 OK
Date: Monday, 17-Feb-97 07:03:02 GMT
Server: NCSA/1.3
MIME-version: 1.0
Content-type: text/html
Last-modified: Friday, 10-Jan-97 22:38:24 GMT
Content-length: 5908
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//SQ//DTD HTML 2.0 HoTMetaL + extensions//EN">
<HTML>
<HEAD>
<TITLE>ATS - Second State-Of-The-Art: Course Description</TITLE></HEAD>
<BODY BGCOLOR="#FFFFFF" BACKGROUND="images/back.jpg">
<CENTER><IMG ALIGN="LEFT" SRC="images/smlogo.gif"><BR> 
<H1>Course Description</H1>
</CENTER>
<HR SIZE="5" NOSHADE="NOSHADE" WIDTH="100%">
<P></P>
<CENTER>
<TABLE BORDER="4" ALIGN="CENTER">
<TR>
<TD><FONT SIZE="-1"><A HREF="2nd-1.html#ats1">Course Description</A></FONT></TD>
<TD><FONT SIZE="-1"><A HREF="2nd-2.html">Saturday, February 1, 1997</A></FONT></TD>
<TD><FONT SIZE="-1"><A HREF="2nd-6.html">Speaker's Index</A></FONT></TD>
<TD><FONT SIZE="-1"><A HREF="2nd-8.html#ats1">Meet the-Professor Seminars</A></FONT></TD></TR>
<TR>
<TD><FONT SIZE="-1"><A HREF="2nd-1.html#ats2">Target Audience</A></FONT></TD>
<TD><FONT SIZE="-1"><A HREF="2nd-3.html">Sunday, February 2, 1997</A></FONT></TD>
<TD><FONT SIZE="-1"><A HREF="2nd-7.html#ats1">Date and Location</A></FONT></TD>
<TD><FONT SIZE="-1"><A HREF="2nd-8.html#ats2">Hotel Accommodations</A></FONT></TD></TR>
<TR>
<TD><FONT SIZE="-1"><A HREF="2nd-1.html#ats3">Course Objectives</A></FONT></TD>
<TD><FONT SIZE="-1"><A HREF="2nd-4.html">Monday, February 3, 1997</A></FONT></TD>
<TD><FONT SIZE="-1"><A HREF="2nd-7.html#ats2">Accreditation</A></FONT></TD>
<TD><FONT SIZE="-1"><A HREF="2nd-8.html#ats3">ATS Membership</A></FONT></TD></TR>
<TR>
<TD><FONT SIZE="-1"><A HREF="2nd-1.html#ats4">Sponsor</A></FONT></TD>
<TD><FONT SIZE="-1"><A HREF="2nd-5.html">Tuesday, February 4, 1997</A></FONT></TD>
<TD><FONT SIZE="-1"><A HREF="2nd-7.html#ats3">Registration Fee</A></FONT></TD>
<TD><FONT SIZE="-1"><A HREF="2nd-9.html">Registration Form</A></FONT></TD></TR></TABLE></CENTER>
<H2><A NAME="ats1">Date and Location</A></H2>
<P><B>&quot;Pulmonary Medicine and Critical Care: The Second ATS
State-Of-The-Art Review Course&quot;</B> will be offered on Saturday, February 1
through Tuesday, February 4, 1997 at the Hyatt Regency LaJolla at Aventine, in
San Diego, California. The hotel is located at 3777 LaJolla Village Drive, San
Diego, CA 92122. Tel.# 619/552-1234. Telfax# 619/552-6066.</P>
<H2><A NAME="ats2">Accreditation</A></H2>
<P>The American Thoracic Society is accredited by the Accreditation Council for
Continuing Medical Education (ACCME) to sponsor continuing medical education for
physicians.</P>
<P>The American Thoracic Society designates this continuing medical education
activity for 35 credit hours in Category 1 of the Physicians Recognition Award
of the American Medical Association.</P>
<CENTER>
<H2><B><FONT COLOR="#FF0000">***Participants must complete the entire<BR>course
to receive credit hours.***</FONT></B></H2></CENTER>
<H2><A NAME="ats3">Registration Fee</A></H2>
<P>The registration fee is $550.00 for practicing physicians who are <U>ATS
members</U>.<BR>The fee is $675.00 for Non-Members</P>
<P>The fee for fellows who are <U>ATS associate members</U> is $300.00. The
fee is $400.00 for Fellows who are Non-Members. </P>
<P>Fees include instruction, course syllabus, daily Continental breakfast,
daily lunch, and refreshment breaks.</P>
<P>The participants who register early will be offered their choice of &quot;Meet-the-Professor&quot;
seminars in the date priority of registrations and payments received by ATS.
When 250 participants have been registered, a waiting list of no more than 25
registrants will be maintained after the registration deadline of <B>January
24, 1997. </B>ATS accepts personal checks, Amex, Visa, and Mastercard. Use tele-
fax for the most rapid registration when charging your registration fee to your
credit card. Late registration: add $25.00 to registration fee, all categories.</P>
<P><BR><BR></P>
<HR SIZE="4" WIDTH="80%">
<P></P>
<CENTER><A HREF="about.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/about.gif" ALT="About Society"></A>
<A HREF="ssg.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/ss.gif" ALT="Society Structure"></A>
<A HREF="calendar.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/calendar.gif" ALT="ATS Calendar"></A>
<A HREF="gpi.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/pi.gif" ALT="Gen Public Info"></A>
<A HREF="ms.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/memserv.gif" ALT="Memb Serv"></A>
<BR>
<A HREF="pub.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/pubs.gif" ALT="Publications"></A>
<A HREF="press.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/press.gif" ALT="Press"></A>
<A HREF="index.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/home.gif" ALT="Home Page"></A>
<A HREF="search.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/search.gif" ALT="Search"></A>
<A HREF="assemb.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/assemb.gif" ALT="Assemblies"></A>
<A HREF="research.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/research.gif" ALT="Research"></A>
<BR>
<A HREF="mep.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/meded.gif" ALT="Med Education"></A>
<A HREF="wr.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/wr.gif" ALT="Wash Report"></A>
<A HREF="ic.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/ic.gif" ALT="Int'l Conference"></A>
<A HREF="source.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/link.gif" ALT="Web Links"></A>
<A HREF="store.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/store.gif" ALT="Store"></A> 
<A HREF="sig.html"><IMG
SRC="images/special.gif" ALT="Special" HSPACE="1" VSPACE="1" BORDER="0" HEIGHT="35" WIDTH="84"></A>
</CENTER>
<HR SIZE="4" WIDTH="80%">
<CENTER><FONT SIZE="+2"><B><I>American Thoracic Society</I></B></FONT><BR>
1740 Broadway<BR> New York, NY 10019<BR> VOICE:  212-315-8700<BR> Copyright &copy;
1996 American Lung Association.<BR> The American Thoracic  Society is the
medical section <BR>of the American Lung Association.<BR> 
</CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-25</DOCNO>
<DOCOLDNO>IA013-000139-B022-297</DOCOLDNO>
<DOCHDR>
http://www.thoracic.org:80/2nd-8.html 206.138.195.144 19970217070756 text/html 7176
HTTP/1.0 200 OK
Date: Monday, 17-Feb-97 07:03:12 GMT
Server: NCSA/1.3
MIME-version: 1.0
Content-type: text/html
Last-modified: Wednesday, 15-Jan-97 19:42:22 GMT
Content-length: 6993
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//SQ//DTD HTML 2.0 HoTMetaL + extensions//EN">
<HTML>
<HEAD>
<TITLE>ATS - Second State-Of-The-Art: Accreditation</TITLE></HEAD>
<BODY BGCOLOR="#FFFFFF" BACKGROUND="images/back.jpg">
<CENTER><IMG ALIGN="LEFT" SRC="images/smlogo.gif"><BR> 
<H1>&quot;Meet-the-Professor Seminars&quot;</H1>
</CENTER>
<HR SIZE="5" NOSHADE="NOSHADE" WIDTH="100%">
<P></P>
<TABLE BORDER="4" ALIGN="LEFT" VALIGN="MIDDLE">
<TR>
<TD><FONT SIZE="-1"><A HREF="2nd-1.html#ats1">Course Description</A></FONT></TD></TR>
<TR>
<TD><FONT SIZE="-1"><A HREF="2nd-1.html#ats2">Target Audience</A></FONT></TD></TR>
<TR>
<TD><FONT SIZE="-1"><A HREF="2nd-1.html#ats3">Course Objectives</A></FONT></TD></TR>
<TR>
<TD><FONT SIZE="-1"><A HREF="2nd-1.html#ats4">Sponsor</A></FONT></TD></TR>
<TR>
<TD><FONT SIZE="-1"><A HREF="2nd-2.html">Saturday, February 1, 1997</A></FONT></TD></TR>
<TR>
<TD><FONT SIZE="-1"><A HREF="2nd-3.html">Sunday, February 2, 1997</A></FONT></TD></TR>
<TR>
<TD><FONT SIZE="-1"><A HREF="2nd-4.html">Monday, February 3, 1997</A></FONT></TD></TR>
<TR>
<TD><FONT SIZE="-1"><A HREF="2nd-5.html">Tuesday, February 4, 1997</A></FONT></TD></TR>
<TR>
<TD><FONT SIZE="-1"><A HREF="2nd-6.html">Speaker's Index</A></FONT></TD></TR>
<TR>
<TD><FONT SIZE="-1"><A HREF="2nd-7.html#ats1">Date and Location</A></FONT></TD></TR>
<TR>
<TD><FONT SIZE="-1"><A HREF="2nd-7.html#ats2">Accreditation</A></FONT></TD></TR>
<TR>
<TD><FONT SIZE="-1"><A HREF="2nd-7.html#ats3">Registration Fee</A></FONT></TD></TR>
<TR>
<TD><FONT SIZE="-1"><A HREF="2nd-8.html#ats1">Meet the-Professor Seminars</A></FONT></TD></TR>
<TR>
<TD><FONT SIZE="-1"><A HREF="2nd-8.html#ats2">Hotel Accommodations</A></FONT></TD></TR>
<TR>
<TD><FONT SIZE="-1"><A HREF="2nd-8.html#ats3">ATS Membership</A></FONT></TD></TR>
<TR>
<TD><FONT SIZE="-1"><A HREF="2nd-9.html">Registration Form</A></FONT></TD></TR></TABLE>
<H2><A NAME="ats1">&quot;Meet-the-Professor Seminars&quot;</A></H2>
<P>&quot;Meet-the-Professor Seminars&quot; will be offered each day of the
Course. Registrants should select their choice of seven (7) seminars. Seminars
will be assigned in priority order based upon dated receipt of registration and
payment, until each seminar is filled. Participants will be assigned a regis-
tration number as ATS receives registration forms and payment of the
registration fee.</P>
<P>If a Meet-theProfessor Seminar selected first is filled, a second choice
will be assigned, as designated by the participant, unless space is limited in
that seminar as well. The Course directors reserve the right to make final
seminar assignments.</P>
<P>Refunds of registration fees will be issued upon written notification of
cancellation if received by January 22, 1997 (subject to a $25.00 service
charge). No refunds will be issued thereafter.</P>
<H2><A NAME="ats2">Hotel Accommodations</A></H2>
<P>Overnight accommodations are being held at the site of the Course, the Hyatt
Regency LaJolla at Aventine, 3777 LaJolla Village Drive, San Diego, CA 92122.
The special course room rate is $155.00 single or double, plus tax.<FONT
COLOR="#FF0000"> A block of rooms is being held for participants until <B>January
17, 1997</B>. Reservations received after this date will be accepted by the
hotel based upon availability. The Course's room rate cannot be guaranteed after
that date.</FONT> The San Diego International Airport is located 20 minutes away
from the Hotel.</P>
<HR SIZE="5" NOSHADE="NOSHADE" WIDTH="100%">
<P><B>To make your reservations, please call the Hyatt at 619/552-1234 or <I>fax
</I>reservation request to 619/552-6066. Ask for the ATS State-0f-The-Art Review
Course room rate. Participants are responsible for making room reservations
directly with the Hyatt Regency LaJolla at Aventine. <FONT COLOR="#FF0000">If
the Course rate is no longer available, be sure to negotiate with the hotel for
the best rate possible!</FONT></B></P>
<TABLE BORDER="0" ALIGN="RIGHT">
<TR>
<TD><IMG SRC="images/minicme.gif" ALIGN="RIGHT"></TD></TR></TABLE>
<TABLE BORDER="4" ALIGN="LEFT">
<TR>
<TD>3777 LaJolla Village Drive<BR>San Diego, California 92122<BR>619-552-1234<BR>Telefax
619-552-6066
<UL>
<LI>16-story, 400-room hotel, including 25<BR> suites, Hyatt Business Plan&reg;
 and exclusive<BR> Regency Club&reg; accommodations</LI>
<LI>Part of The Aventine, including five<BR> internationally themed
restaurants and<BR> entertainment lounge</LI></UL></TD></TR></TABLE>
<HR SIZE="5" NOSHADE="NOSHADE" WIDTH="100%">
<P><BR><BR></P>
<P><BR><BR></P>
<P><BR><BR></P>
<P><BR><BR></P>
<P><BR><BR></P>
<P><BR><BR></P>
<P><BR><BR></P>
<P><BR><BR></P>
<H2><A NAME="ats3">ATS Membership</A></H2>
<P>Become an ATS member and register for the course at the ATS member rate.
Click <A HREF="ms.html"><FONT SIZE="+1">HERE</FONT></A> to access ATS
Membership Page.</P>
<P><BR><BR></P>
<HR SIZE="4" WIDTH="80%">
<CENTER><A HREF="about.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/about.gif" ALT="About Society"></A>
<A HREF="ssg.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/ss.gif" ALT="Society Structure"></A>
<A HREF="calendar.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/calendar.gif" ALT="ATS Calendar"></A>
<A HREF="gpi.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/pi.gif" ALT="Gen Public Info"></A>
<A HREF="ms.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/memserv.gif" ALT="Memb Serv"></A>
<BR>
<A HREF="pub.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/pubs.gif" ALT="Publications"></A>
<A HREF="press.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/press.gif" ALT="Press"></A>
<A HREF="index.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/home.gif" ALT="Home Page"></A>
<A HREF="search.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/search.gif" ALT="Search"></A>
<A HREF="assemb.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/assemb.gif" ALT="Assemblies"></A>
<A HREF="research.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/research.gif" ALT="Research"></A>
<BR>
<A HREF="mep.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/meded.gif" ALT="Med Education"></A>
<A HREF="wr.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/wr.gif" ALT="Wash Report"></A>
<A HREF="ic.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/ic.gif" ALT="Int'l Conference"></A>
<A HREF="source.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/link.gif" ALT="Web Links"></A>
<A HREF="store.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/store.gif" ALT="Store"></A> 
<A HREF="sig.html"><IMG
SRC="images/special.gif" ALT="Special" HSPACE="1" VSPACE="1" BORDER="0" HEIGHT="35" WIDTH="84"></A>
</CENTER>
<HR SIZE="4" WIDTH="80%">
<CENTER><FONT SIZE="+2"><B><I>American Thoracic Society</I></B></FONT><BR>
1740 Broadway<BR> New York, NY 10019<BR> VOICE:  212-315-8700<BR> Copyright &copy;
1996 American Lung Association.<BR> The American Thoracic  Society is the
medical section <BR>of the American Lung Association.<BR> 
</CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-26</DOCNO>
<DOCOLDNO>IA013-000139-B022-339</DOCOLDNO>
<DOCHDR>
http://www.thoracic.org:80/2nd-9.html 206.138.195.144 19970217070812 text/html 8128
HTTP/1.0 200 OK
Date: Monday, 17-Feb-97 07:03:25 GMT
Server: NCSA/1.3
MIME-version: 1.0
Content-type: text/html
Last-modified: Wednesday, 15-Jan-97 19:42:42 GMT
Content-length: 7945
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//SQ//DTD HTML 2.0 HoTMetaL + extensions//EN">
<HTML>
<HEAD>
<TITLE>ATS - Second State-Of-The-Art: ATS Registration Form</TITLE></HEAD>
<BODY BGCOLOR="#FFFFFF" BACKGROUND="images/back.jpg">
<CENTER><IMG ALIGN="LEFT" SRC="images/smlogo.gif"><BR> 
<H1>ATS Registration Form</H1>
<P><FONT COLOR="#FF0000" SIZE="-1">(Please print out this form)</FONT></P>
</CENTER>
<HR SIZE="5" NOSHADE="NOSHADE" WIDTH="100%">
<P></P>
<CENTER>
<TABLE BORDER="4" ALIGN="CENTER">
<TR>
<TD ALIGN="CENTER" VALIGN="MIDDLE"><FONT SIZE="-1"><B><A HREF="2nd.html">Back
to Main Page</A></B></FONT></TD></TR></TABLE></CENTER>
<H2 ALIGN="CENTER">&quot;Pulmonary Medicine and Critical Care: The Second ATS
State-Of-The-Art Review Course&quot;</H2>
<P ALIGN="CENTER">February 1-4, 1997 &#183; San Diego, CA . &#183;  Hyatt
Regency LaJolla at Aventine</P>
<HR>
<CENTER>
<TABLE BORDER="0" ALIGN="LEFT">
<TR>
<TD><B>___________________________</B><BR><FONT SIZE="-1">Last Name (please
print or type)</FONT>
<P></P><B>___________________________</B><BR><FONT SIZE="-1">First Name</FONT>
<P></P>[ ] <FONT SIZE="-1">MD</FONT> [ ]<FONT SIZE="-1"> DO</FONT> [ ]
<FONT SIZE="-1">PhD</FONT> [ ] <FONT SIZE="-1">Fellow</FONT> [ ]<FONT
SIZE="-1">Other</FONT>
<P></P><B>___________________________</B><BR><FONT SIZE="-1">Street or P.0.
Box</FONT>
<P></P><B>___________________________</B><BR><FONT SIZE="-1">City/State/Zip</FONT>
<P></P><B>___________________________</B><BR><FONT SIZE="-1">Country</FONT>
<P></P><B>___________________________</B><BR><FONT SIZE="-1">Daytime
Telephone No.</FONT>
<P></P><B>___________________________</B><BR><FONT SIZE="-1">FAX No:</FONT>
<P></P><B>___________________________</B><BR><FONT SIZE="-1">E-mail</FONT></TD></TR></TABLE></CENTER>
<P></P>
<CENTER>
<TABLE BORDER="0" ALIGN="RIGHT">
<TR>
<TD ALIGN="CENTER" VALIGN="MIDDLE"><B>Indicate below your first and second
choice of &quot;Meet the Professor&quot; seminars:</B>
<P></P>
<TABLE BORDER="0" ALIGN="LEFT">
<TR>
<TD>Session I: </TD>
<TD>1st</TD>
<TD>  a._____ b._____ c._____ d._____</TD></TR>
<TR>
<TD></TD>
<TD>2nd</TD>
<TD>  a._____ b._____ c._____ d._____</TD></TR>
<TR>
<TD>Session II:</TD>
<TD>1st</TD>
<TD>  a._____ b._____ c._____ d._____</TD></TR>
<TR>
<TD></TD>
<TD>2nd</TD>
<TD>  a._____ b._____ c._____ d._____</TD></TR>
<TR>
<TD>Session III: </TD>
<TD>1st</TD>
<TD>  a._____ b._____ c._____ d._____</TD></TR>
<TR>
<TD></TD>
<TD>2nd</TD>
<TD>  a._____ b._____ c._____ d._____</TD></TR>
<TR>
<TD>Session IV:</TD>
<TD>1st</TD>
<TD>  a._____ b._____ c._____ d._____</TD></TR>
<TR>
<TD></TD>
<TD>2nd</TD>
<TD>  a._____ b._____ c._____ d._____</TD></TR>
<TR>
<TD>Session V: </TD>
<TD>1st</TD>
<TD>  a._____ b._____ c._____ d._____</TD></TR>
<TR>
<TD></TD>
<TD>2nd</TD>
<TD>  a._____ b._____ c._____ d._____</TD></TR>
<TR>
<TD>Session VI:</TD>
<TD>1st</TD>
<TD>  a._____ b._____ c._____ d._____</TD></TR>
<TR>
<TD></TD>
<TD>2nd</TD>
<TD>  a._____ b._____ c._____ d._____</TD></TR>
<TR>
<TD>Session VII:</TD>
<TD>1st</TD>
<TD>  a._____ b._____ c._____ d._____</TD></TR>
<TR>
<TD></TD>
<TD>2nd</TD>
<TD>  a._____ b._____ c._____ d._____</TD></TR>
<TR>
<TD>Session VIII:</TD>
<TD>1st</TD>
<TD>  a._____ b._____ c._____ d._____</TD></TR>
<TR>
<TD></TD>
<TD>2nd</TD>
<TD>  a._____ b._____ c._____ d._____</TD></TR></TABLE></TD></TR></TABLE></CENTER>
<P><BR><BR></P>
<P><BR><BR></P>
<P><BR><BR></P>
<P><BR><BR></P>
<P><BR><BR></P>
<P><BR><BR></P>
<P><BR><BR></P>
<P><BR><BR></P>
<P><BR><BR></P>
<P><BR><BR></P>
<P><BR><BR></P>
<P><BR><BR></P>
<P><BR><BR></P>
<CENTER>
<TABLE BORDER="0" ALIGN="CENTER">
<TR>
<TD><B>Methods of Payment</B><BR><BR>[ ] <FONT SIZE="-1"><B><U>CreditCard</U></B>:
AMEX, Mastercard and VISA are accepted for registration. You must include your
card number, expiration date, and signature. You may fax your form if you
provide a credit card number and <U>signature</U> to (212)315-6498 at ATS
headquarters. <B><U>Please check one</U>:</B></FONT></TD></TR>
<TR>
<TD>[ ]<FONT SIZE="-1"> MC (16 digits)</FONT><BR>[ ] <FONT SIZE="-1">AMEX
(15 digits)</FONT><BR>[ ] <FONT SIZE="-1">VISA (13 or 16 digits)</FONT></TD></TR>
<TR>
<TD>[ ]<FONT SIZE="-1"><U>Check</U> or <U>Money Order</U>: Make check (U.S.
dollars drawn on U.S. Bank) or money order (U.S. dollars) payable to: <U>American
Thoracic Society</U>.</FONT></TD></TR>
<TR>
<TD><B>_______________________________________</B><BR><FONT SIZE="-1">Card
Number</FONT>
<P></P><B>_______________________________________</B><BR><FONT SIZE="-1">Expiration
Date</FONT>
<P></P><B>_______________________________________</B><BR><FONT SIZE="-1">Signature</FONT></TD></TR>
<TR>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P></P><B>Payment </B><FONT SIZE="-1">Registration fees (Please check one)<BR></FONT><B>Late
Registration: </B><FONT SIZE="-1">After January 24, add $25.00 late fee.</FONT>
<P></P></TD></TR>
<TR>
<TD><B>M.D./Ph.D. </B><FONT SIZE="-1">in Practice</FONT><BR>
<TABLE BORDER="0" ALIGN="LEFT">
<TR>
<TD>* ATS Member:  </TD>
<TD>[ ]  $550.00</TD></TR>
<TR>
<TD>Non-ATS Member:  </TD>
<TD>[ ]  $675.00</TD></TR></TABLE></TD></TR>
<TR>
<TD><B>Fellow</B><BR>
<TABLE BORDER="0" ALIGN="LEFT">
<TR>
<TD><U>ATS</U> <U>Associate</U> <U>Member:</U><BR>Non-ATS Member:  </TD>
<TD>[ ]  $300.00<BR>[ ]  $400.00</TD></TR>
<TR>
<TD COLSPAN="2"><BR><BR>[ ]  I attended the first ATS Review Course in
Washington DC in February 1996<BR><BR>.</TD></TR></TABLE></TD></TR>
<TR>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P><BR></P><B>FAX OR MAIL REGISTRATION FORM AND PAYMENT TO:</B></TD></TR>
<TR>
<TD ALIGN="CENTER" VALIGN="MIDDLE"><B>AMERICAN THORACIC SOCIETY<BR>Continuing
Medical Education Division<BR>1740 Broadway<BR>New York, New York 10019<BR>FAX
# 212/315-6498 &#183; Tel. #212/315-6621 or 8644</B>
<P></P></TD></TR></TABLE></CENTER>
<P></P>
<HR SIZE="4" WIDTH="80%">
<CENTER><A HREF="about.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/about.gif" ALT="About Society"></A>
<A HREF="ssg.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/ss.gif" ALT="Society Structure"></A>
<A HREF="calendar.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/calendar.gif" ALT="ATS Calendar"></A>
<A HREF="gpi.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/pi.gif" ALT="Gen Public Info"></A>
<A HREF="ms.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/memserv.gif" ALT="Memb Serv"></A>
<BR>
<A HREF="pub.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/pubs.gif" ALT="Publications"></A>
<A HREF="press.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/press.gif" ALT="Press"></A>
<A HREF="index.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/home.gif" ALT="Home Page"></A>
<A HREF="search.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/search.gif" ALT="Search"></A>
<A HREF="assemb.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/assemb.gif" ALT="Assemblies"></A>
<A HREF="research.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/research.gif" ALT="Research"></A>
<BR>
<A HREF="mep.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/meded.gif" ALT="Med Education"></A>
<A HREF="wr.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/wr.gif" ALT="Wash Report"></A>
<A HREF="ic.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/ic.gif" ALT="Int'l Conference"></A>
<A HREF="source.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/link.gif" ALT="Web Links"></A>
<A HREF="store.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/store.gif" ALT="Store"></A> 
<A HREF="sig.html"><IMG
SRC="images/special.gif" ALT="Special" HSPACE="1" VSPACE="1" BORDER="0" HEIGHT="35" WIDTH="84"></A>
</CENTER>
<HR SIZE="4" WIDTH="80%">
<CENTER><FONT SIZE="+2"><B><I>American Thoracic Society</I></B></FONT><BR>
1740 Broadway<BR> New York, NY 10019<BR> VOICE:  212-315-8700<BR> Copyright &copy;
1996 American Lung Association.<BR> The American Thoracic  Society is the
medical section <BR>of the American Lung Association.<BR> 
</CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-27</DOCNO>
<DOCOLDNO>IA013-000139-B023-3</DOCOLDNO>
<DOCHDR>
http://www.thoracic.org:80/ic97/clas1.html 206.138.195.144 19970217070820 text/html 2950
HTTP/1.0 200 OK
Date: Monday, 17-Feb-97 07:03:38 GMT
Server: NCSA/1.3
MIME-version: 1.0
Content-type: text/html
Last-modified: Friday, 24-Jan-97 16:15:39 GMT
Content-length: 2770
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//SQ//DTD HTML 2.0 HoTMetaL + extensions//EN">
<HTML>
<HEAD>
<TITLE>CLAS</TITLE></HEAD>
<BODY BGCOLOR="#FFFFFF">
<CENTER><IMG SRC="images/clas.jpg" BORDER="0" WIDTH="53" HEIGHT="55"></CENTER>
<CENTER><BR> 
<H2>CONGRESS OF LUNG ASSOCIATION STAFF (CLAS) MEMBERSHIP MEETING</H2></CENTER>
<HR SIZE="5" NOSHADE="NOSHADE" WIDTH="100%">
<P></P>
<CENTER>
<TABLE BORDER="2">
<TR ALIGN="CENTER" VALIGN="MIDDLE">
<TD ALIGN="CENTER" VALIGN="MIDDLE"><B><SMALL><A HREF="clas.html">BACK TO
CLAS PAGE</A></SMALL></B></TD></TR></TABLE></CENTER>
<P></P>
<HR SIZE="10" WIDTH="85%">
<P></P>
<CENTER>
<P>MONDAY , MAY 19</P></CENTER>
<BLOCKQUOTE>
<P><B>7:00 AM&#151;8:00 AM </B></P></BLOCKQUOTE>
<HR SIZE="4" WIDTH="85%" ALIGN="CENTER" NOSHADE="NOSHADE">
<BLOCKQUOTE>
<P>Shane McDermott, Executive Director of the ALA of Oregon, who is the
1996-1997 CLAS President will preside. Mr. McDermott will pass the presidential
gavel on to Sandra Kessler, Executive Director of the ALA of Florida, at the
close of the meeting. All CLAS members are encouraged to attend.</P>
<P><B>Registration Fee: $15.00 (Breakfast is included.)</B> <I>Advance
registration is required.</I></P>
<P>Please register under Part 4 of the registration form.</P></BLOCKQUOTE>
<P></P>
<HR SIZE="4" WIDTH="80%">
<CENTER>
<P><A HREF=97ala.html><IMG
SRC=images/activity_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97bus.html><IMG
SRC=images/business_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97cal.html><IMG
SRC=images/calendar_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97child.html><IMG
SRC=images/child_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=pg.html><IMG
SRC=images/courses_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=search.html><IMG
SRC=images/search_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=main.html><IMG
SRC=images/home_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97house.html><IMG
SRC=images/house_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=http://itsmtgs.com/ala-ats><IMG
SRC=images/regist_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=sessions.html><IMG
SRC=images/session_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=special.html><IMG
SRC=images/special_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97tours.html><IMG
SRC=images/tour_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97travel.html><IMG
SRC=images/travel_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
</P></CENTER>
<HR SIZE="4" WIDTH="80%">
<CENTER><FONT SIZE="+2"><B><I>American Thoracic Society</I></B></FONT><BR>
1740 Broadway<BR> New York, NY 10019<BR> VOICE:  212-315-8700<BR> Copyright &copy;
1996 American Lung Association.<BR> The American Thoracic  Society is the
medical section <BR>of the American Lung Association.<BR> 
</CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-28</DOCNO>
<DOCOLDNO>IA013-000139-B023-32</DOCOLDNO>
<DOCHDR>
http://www.thoracic.org:80/ic97/clas2.html 206.138.195.144 19970217070829 text/html 3448
HTTP/1.0 200 OK
Date: Monday, 17-Feb-97 07:03:46 GMT
Server: NCSA/1.3
MIME-version: 1.0
Content-type: text/html
Last-modified: Friday, 24-Jan-97 16:15:41 GMT
Content-length: 3268
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//SQ//DTD HTML 2.0 HoTMetaL + extensions//EN">
<HTML>
<HEAD>
<TITLE>ALA PLENARY SESSION</TITLE></HEAD>
<BODY BGCOLOR="#FFFFFF">
<CENTER><IMG SRC="images/clas.jpg" BORDER="0" WIDTH="53" HEIGHT="55"></CENTER>
<CENTER><BR>
<P>BUSINESS MEETINGS</P> 
<H2>CLAS ASSEMBLIES MEMBERSHIP MEETINGS </H2></CENTER>
<HR SIZE="5" NOSHADE="NOSHADE" WIDTH="100%">
<P></P>
<CENTER>
<TABLE BORDER="2">
<TR ALIGN="CENTER" VALIGN="MIDDLE">
<TD ALIGN="CENTER" VALIGN="MIDDLE"><B><SMALL><A HREF="clas.html">BACK TO
CLAS PAGE</A></SMALL></B></TD></TR></TABLE></CENTER>
<P></P>
<HR SIZE="10" WIDTH="85%">
<P></P>
<CENTER>
<P>MONDAY , MAY 19</P></CENTER>
<BLOCKQUOTE>
<P><B>4:30 PM-6:30 PM</B></P></BLOCKQUOTE>
<HR SIZE="4" WIDTH="85%" ALIGN="CENTER" NOSHADE="NOSHADE">
<BLOCKQUOTE>
<P>CLAS Assemblies provide members who share similar job responsibilities and
experiences the opportunity to explore new ideas, problem solve, and build
professional relationships with others throughout the nationwide American Lung
Association. Five assemblies have been formed during the year to represent
members with interest in the following professional areas: Management; Program:
Development; Communications; and Administrative Support.</P>
<P><B>Management Assembly</B><BR><I>Coordinators:</I> E. Miller, Portland,
MEK. Fulton, Monterey, CA D. Berg, Minneapolis, MN</P>
<P><B>CLAS Program Assembly</B><BR><I>Coordinator: </I>S. Jones Sink,
Norristown, PA</P>
<P><B>CLAS Development Assembly</B><BR><I>Coordinator: </I>J. Stephens,
Southfield, MI</P>
<P><B>CLAS Communications Assembly</B><BR><I>Coordinator: </I>C.E. Sikorski,
Cincinnati, OH</P>
<P><B>CLAS Administrative Support Assembly</B><BR><I>Coordinator: </I>S.
Romig, Sacramento, CA</P></BLOCKQUOTE>
<P></P>
<HR SIZE="4" WIDTH="80%">
<CENTER>
<P><A HREF=97ala.html><IMG
SRC=images/activity_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97bus.html><IMG
SRC=images/business_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97cal.html><IMG
SRC=images/calendar_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97child.html><IMG
SRC=images/child_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=pg.html><IMG
SRC=images/courses_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=search.html><IMG
SRC=images/search_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=main.html><IMG
SRC=images/home_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97house.html><IMG
SRC=images/house_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=http://itsmtgs.com/ala-ats><IMG
SRC=images/regist_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=sessions.html><IMG
SRC=images/session_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=special.html><IMG
SRC=images/special_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97tours.html><IMG
SRC=images/tour_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97travel.html><IMG
SRC=images/travel_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
</P></CENTER>
<HR SIZE="4" WIDTH="80%">
<CENTER><FONT SIZE="+2"><B><I>American Thoracic Society</I></B></FONT><BR>
1740 Broadway<BR> New York, NY 10019<BR> VOICE:  212-315-8700<BR> Copyright &copy;
1996 American Lung Association.<BR> The American Thoracic  Society is the
medical section <BR>of the American Lung Association.<BR> 
</CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-29</DOCNO>
<DOCOLDNO>IA013-000139-B023-62</DOCOLDNO>
<DOCHDR>
http://www.thoracic.org:80/ic97/ss001.html 206.138.195.144 19970217070841 text/html 3904
HTTP/1.0 200 OK
Date: Monday, 17-Feb-97 07:03:56 GMT
Server: NCSA/1.3
MIME-version: 1.0
Content-type: text/html
Last-modified: Tuesday, 04-Feb-97 19:35:55 GMT
Content-length: 3723
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//SQ//DTD HTML 2.0 HoTMetaL + extensions//EN">
<HTML>
<HEAD>
<TITLE>ALA Sunrise Session: ss001</TITLE></HEAD>
<BODY BGCOLOR="#FFFFFF">
<CENTER><IMG ALIGN="LEFT" SRC="images/banner0.jpg"></CENTER>
<CENTER><BR>
<P>ALA Sunrise Session</P>
<H2> SS001: VOLUNTEER MANAGEMENT:<BR>ARE YOU IN STEP?
</H2></CENTER>
<HR SIZE="5" NOSHADE="NOSHADE" WIDTH="100%">
<P></P>
<CENTER>
<TABLE BORDER="2">
<TR ALIGN="CENTER" VALIGN="MIDDLE">
<TD ALIGN="CENTER" VALIGN="MIDDLE"><B><SMALL><A HREF="97ala.html">BACK TO
MAIN MENU</A></SMALL></B></TD></TR></TABLE></CENTER>
<P></P>
<HR SIZE="10" WIDTH="85%">
<P></P>
<CENTER>
<P>SUNDAY, MAY 18</P></CENTER>
<P><B>Registration Fee: $15.00 (includes continental breakfast).</B> <I>Attendance
is limited. Advance registration is required and is on a first come, first
served basis.</I></P>
<P><B>7:00 AM&#151;8:00 AM</B></P>
<HR SIZE="4" WIDTH="85%" ALIGN="CENTER" NOSHADE="NOSHADE">
<P><I><B>Target Audience: </B></I>Volunteer management professionals with at
least one year of significant volunteer management experience.</P>
<P><B>OBJECTIVES</B><BR>At the conclusion of this session, the participant
will be able to:</P>
<UL>
<LI>articulate key issues facing the contemporary volunteer manager;</LI>
<LI>identify personal areas of volunteer management competency and weakness;</LI>
<LI>identify leading-edge professional resources to enhance personal and
Association volunteer performance.</LI></UL>
<P>The field of Volunteer Management/Administration has made great strides over
the past decade. The field is currently experiencing another growth spurt,
encouraged in-part by the advent of on-line networking, critical contemporary
issues, a matured cadre of highly seasoned professionals, and the growing
urgency within the not-for-profit sector for volunteer involvement at all levels
of Association operations. This session will address how the volunteer manager,
with a host of additional responsibilities, can keep pace with, prioritize, and
ensure their ability to meet these issues, challenges and changes.</P>
<P><I><B>Chairing: </B></I>D.B. Richards, R.N., M.S., Duncanville, TX</P>
<P><I><B>Speaker:</B></I> S.J. Ellis, Philadelphia, PA</P>
<P></P>
<HR SIZE="4" WIDTH="80%">
<CENTER>
<P><A HREF=97ala.html><IMG
SRC=images/activity_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97bus.html><IMG
SRC=images/business_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97cal.html><IMG
SRC=images/calendar_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97child.html><IMG
SRC=images/child_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=pg.html><IMG
SRC=images/courses_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=search.html><IMG
SRC=images/search_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=main.html><IMG
SRC=images/home_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97house.html><IMG
SRC=images/house_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=http://itsmtgs.com/ala-ats><IMG
SRC=images/regist_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=sessions.html><IMG
SRC=images/session_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=special.html><IMG
SRC=images/special_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97tours.html><IMG
SRC=images/tour_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97travel.html><IMG
SRC=images/travel_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
</P></CENTER>
<HR SIZE="4" WIDTH="80%">
<CENTER><FONT SIZE="+2"><B><I>American Thoracic Society</I></B></FONT><BR>
1740 Broadway<BR> New York, NY 10019<BR> VOICE:  212-315-8700<BR> Copyright &copy;
1996 American Lung Association.<BR> The American Thoracic  Society is the
medical section <BR>of the American Lung Association.<BR> 
</CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-30</DOCNO>
<DOCOLDNO>IA013-000139-B023-89</DOCOLDNO>
<DOCHDR>
http://www.thoracic.org:80/ic97/ss002.html 206.138.195.144 19970217070848 text/html 4028
HTTP/1.0 200 OK
Date: Monday, 17-Feb-97 07:04:06 GMT
Server: NCSA/1.3
MIME-version: 1.0
Content-type: text/html
Last-modified: Tuesday, 04-Feb-97 19:36:07 GMT
Content-length: 3847
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//SQ//DTD HTML 2.0 HoTMetaL + extensions//EN">
<HTML>
<HEAD>
<TITLE>ALA/ATS Joint Sunrise Session: ss002</TITLE></HEAD>
<BODY BGCOLOR="#FFFFFF">
<CENTER><IMG ALIGN="LEFT" SRC="images/banner0.jpg"></CENTER>
<CENTER><BR>
<P>ALA/ATS Joint Sunrise Session</P>
<H2> SS002: EXPLODING CIGAR MYTHS</H2>
<P><B></B></P></CENTER>
<HR SIZE="5" NOSHADE="NOSHADE" WIDTH="100%">
<P></P>
<CENTER>
<TABLE BORDER="2">
<TR ALIGN="CENTER" VALIGN="MIDDLE">
<TD ALIGN="CENTER" VALIGN="MIDDLE"><B><SMALL><A HREF="97ala.html">BACK TO
MAIN MENU</A></SMALL></B></TD></TR></TABLE></CENTER>
<P></P>
<HR SIZE="10" WIDTH="85%">
<P></P>
<CENTER>
<P>SUNDAY MORNING, MAY 18</P></CENTER>
<P><B>Registration Fee: $15.00 (includes continental breakfast). </B><I>Attendance
is limited. Advance registration is required and is on a first come, first
served basis.</I></P>
<P><B><I>American Lung Association/Assembly on Environmental and Occupational
Health</I></B></P>
<P><B>7:00 AM&#151;8:00 AM</B></P>
<HR SIZE="4" WIDTH="85%" ALIGN="CENTER" NOSHADE="NOSHADE">
<P><I><B>Target Audience: </B></I>ALA volunteers and staff, clinicians,
behavioral scientist and ATS members who are interested in learning more about
the new cigar craze and effective strategies for combating it.</P>
<P><B>OBJECTIVES</B><BR>At the conclusion of this session, the participant
will be able to:</P>
<UL>
<LI>define the physiology and health hazards of cigar use;</LI>
<LI>describe the epidemiology of cigar use, including changes in the user
profile since 1990;</LI>
<LI>identify marketing strategies used by the tobacco industry to promote cigar
smoking;</LI>
<LI>define strategies local American Lung Associations can implement to combat
cigar use.</LI></UL>
<P>The cigar-smoking craze seems to be sweeping the nation and making inroads
with populations (athletes, high-income groups) who would otherwise remain
smoke-free. Cigars are not giant cigarettes; they are smoked differently and
present distinct health hazards, and the profile of a cigar user has changed:
Grandpa's not the only one smoking cigars anymore. In this session participants
will learn what is fueling this dangerous trend and what American Lung
Associations can do to extinguish it.</P>
<P><I><B>Chairing: </B></I>D. Kelley, San Diego, CA</P>
<P>Additional faculty to be announced.</P>
<P></P>
<HR SIZE="4" WIDTH="80%">
<CENTER>
<P><A HREF=97ala.html><IMG
SRC=images/activity_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97bus.html><IMG
SRC=images/business_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97cal.html><IMG
SRC=images/calendar_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97child.html><IMG
SRC=images/child_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=pg.html><IMG
SRC=images/courses_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=search.html><IMG
SRC=images/search_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=main.html><IMG
SRC=images/home_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97house.html><IMG
SRC=images/house_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=http://itsmtgs.com/ala-ats><IMG
SRC=images/regist_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=sessions.html><IMG
SRC=images/session_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=special.html><IMG
SRC=images/special_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97tours.html><IMG
SRC=images/tour_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97travel.html><IMG
SRC=images/travel_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
</P></CENTER>
<HR SIZE="4" WIDTH="80%">
<CENTER><FONT SIZE="+2"><B><I>American Thoracic Society</I></B></FONT><BR>
1740 Broadway<BR> New York, NY 10019<BR> VOICE:  212-315-8700<BR> Copyright &copy;
1996 American Lung Association.<BR> The American Thoracic  Society is the
medical section <BR>of the American Lung Association.<BR> 
</CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-31</DOCNO>
<DOCOLDNO>IA013-000139-B023-119</DOCOLDNO>
<DOCHDR>
http://www.thoracic.org:80/ic97/ss003.html 206.138.195.144 19970217070859 text/html 3785
HTTP/1.0 200 OK
Date: Monday, 17-Feb-97 07:04:14 GMT
Server: NCSA/1.3
MIME-version: 1.0
Content-type: text/html
Last-modified: Tuesday, 04-Feb-97 19:36:14 GMT
Content-length: 3604
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//SQ//DTD HTML 2.0 HoTMetaL + extensions//EN">
<HTML>
<HEAD>
<TITLE>ALA Sunrise Session: ss003</TITLE></HEAD>
<BODY BGCOLOR="#FFFFFF">
<CENTER><IMG ALIGN="LEFT" SRC="images/banner0.jpg"></CENTER>
<CENTER><BR>
<P>ALA Sunrise Session</P>
<H2>SS003: SPECIAL EVENTS/WORK PLACE GIVING</H2>
<P><B></B></P></CENTER>
<HR SIZE="5" NOSHADE="NOSHADE" WIDTH="100%">
<P></P>
<CENTER>
<TABLE BORDER="2">
<TR ALIGN="CENTER" VALIGN="MIDDLE">
<TD ALIGN="CENTER" VALIGN="MIDDLE"><B><SMALL><A HREF="97ala.html">BACK TO
MAIN MENU</A></SMALL></B></TD></TR></TABLE></CENTER>
<P></P>
<HR SIZE="10" WIDTH="85%">
<P></P>
<CENTER>
<P>SUNDAY MORNING, MAY 18</P></CENTER>
<P><B>Registration Fee: $15.00 (includes continental breakfast).</B> <I>Attendance
is limited. Advance registration is required and is on a first come, first
served basis.</I></P>
<P><B>7:00 AM&#151;8:00 AM</B></P>
<HR SIZE="4" WIDTH="85%" ALIGN="CENTER" NOSHADE="NOSHADE">
<P><I><B>Target Audience: </B></I>Lung Association volunteers and staff
responsible for special events and/or workplace giving.</P>
<P><B>OBJECTIVES</B><BR>At the conclusion of this session, the participant
will be able to:</P>
<UL>
<LI>understand the special event mission statements, goals, and strategies for
nationwide programs such as the Vehicle Donation Program (VDP), the Golf
Privilege Card (GPC), and the Clean Air Challenge (CAC);</LI>
<LI>use these statements, goals, and strategies to assist in developing special
events for their association;</LI>
<LI>understand how national sponsors can be leveraged to decrease local
expenses and increase local revenues.</LI></UL>
<P>This session will highlight how the special event mission statements, goals,
and strategies are being utilized to develop, implement, and promote special
events. Strategies for incorporating national sponsors will also be addressed.
Roundtables hosted by field and national staff will provide a forum for
attendees to ask questions and share both successes and challenges.</P>
<P><I><B>Chairing: </B></I>R. Burwell, New York, NYT. Heath, New York, NY</P>
<P></P>
<HR SIZE="4" WIDTH="80%">
<CENTER>
<P><A HREF=97ala.html><IMG
SRC=images/activity_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97bus.html><IMG
SRC=images/business_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97cal.html><IMG
SRC=images/calendar_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97child.html><IMG
SRC=images/child_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=pg.html><IMG
SRC=images/courses_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=search.html><IMG
SRC=images/search_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=main.html><IMG
SRC=images/home_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97house.html><IMG
SRC=images/house_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=http://itsmtgs.com/ala-ats><IMG
SRC=images/regist_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=sessions.html><IMG
SRC=images/session_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=special.html><IMG
SRC=images/special_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97tours.html><IMG
SRC=images/tour_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97travel.html><IMG
SRC=images/travel_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
</P></CENTER>
<HR SIZE="4" WIDTH="80%">
<CENTER><FONT SIZE="+2"><B><I>American Thoracic Society</I></B></FONT><BR>
1740 Broadway<BR> New York, NY 10019<BR> VOICE:  212-315-8700<BR> Copyright &copy;
1996 American Lung Association.<BR> The American Thoracic  Society is the
medical section <BR>of the American Lung Association.<BR> 
</CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-32</DOCNO>
<DOCOLDNO>IA013-000139-B023-146</DOCOLDNO>
<DOCHDR>
http://www.thoracic.org:80/ic97/ss004.html 206.138.195.144 19970217070906 text/html 3684
HTTP/1.0 200 OK
Date: Monday, 17-Feb-97 07:04:24 GMT
Server: NCSA/1.3
MIME-version: 1.0
Content-type: text/html
Last-modified: Tuesday, 04-Feb-97 19:36:23 GMT
Content-length: 3503
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//SQ//DTD HTML 2.0 HoTMetaL + extensions//EN">
<HTML>
<HEAD>
<TITLE>ALA Sunrise Session: ss004</TITLE></HEAD>
<BODY BGCOLOR="#FFFFFF">
<CENTER><IMG ALIGN="LEFT" SRC="images/banner0.jpg"></CENTER>
<CENTER><BR>
<P>ALA Sunrise Session</P>
<H2>SS004: INTEGRATED COMMUNICATIONS: INTRODUCTION </H2>
<P><B></B></P></CENTER>
<HR SIZE="5" NOSHADE="NOSHADE" WIDTH="100%">
<P></P>
<CENTER>
<TABLE BORDER="2">
<TR ALIGN="CENTER" VALIGN="MIDDLE">
<TD ALIGN="CENTER" VALIGN="MIDDLE"><B><SMALL><A HREF="97ala.html">BACK TO
MAIN MENU</A></SMALL></B></TD></TR></TABLE></CENTER>
<P></P>
<HR SIZE="10" WIDTH="85%">
<P></P>
<CENTER>
<P>SUNDAY MORNING, MAY 18</P></CENTER>
<P><B>Registration Fee: $15.00 (includes continental breakfast).</B> <I>Attendance
is limited. Advance registration is required and is on a first come, first
served basis.</I></P>
<P><B><I>This session will serve as an introduction to the <A HREF="a8.html">session
A8, &quot; Integrated Communications for Greater Visibility and Resource
Development&quot;</A> which follows from 8:15 - 11:30 a.m.</I></B></P>
<P><B>7:00 AM&#151;8:00 AM</B></P>
<HR SIZE="4" WIDTH="85%" ALIGN="CENTER" NOSHADE="NOSHADE">
<P><I><B>Target Audience: </B></I>Lung Association volunteers and staff.</P>
<P><B>OBJECTIVES</B><BR>At the conclusion of this session, the participant
will be able to:</P>
<UL>
<LI> recognize communication's role throughout all ALA initiatives;</LI>
<LI> identify opportunities for ongoing integration of all ALA activities.</LI></UL>
<P>Through presentation of the &quot;ALA reality&quot; of integrated program,
development, and advocacy initiatives, this session will illustrate the vital
role that communications plays in bringing all ALA functions together under one
umbrella. The strategies and benefits of serving as ALA's &quot;advance team&quot;
within the community will be discussed.</P>
<P><I><B>Speaker:</B></I> J. Perrett, East Hartford, CT</P>
<P>Additional faculty to be announced.</P>
<P></P>
<HR SIZE="4" WIDTH="80%">
<CENTER>
<P><A HREF=97ala.html><IMG
SRC=images/activity_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97bus.html><IMG
SRC=images/business_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97cal.html><IMG
SRC=images/calendar_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97child.html><IMG
SRC=images/child_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=pg.html><IMG
SRC=images/courses_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=search.html><IMG
SRC=images/search_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=main.html><IMG
SRC=images/home_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97house.html><IMG
SRC=images/house_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=http://itsmtgs.com/ala-ats><IMG
SRC=images/regist_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=sessions.html><IMG
SRC=images/session_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=special.html><IMG
SRC=images/special_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97tours.html><IMG
SRC=images/tour_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97travel.html><IMG
SRC=images/travel_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
</P></CENTER>
<HR SIZE="4" WIDTH="80%">
<CENTER><FONT SIZE="+2"><B><I>American Thoracic Society</I></B></FONT><BR>
1740 Broadway<BR> New York, NY 10019<BR> VOICE:  212-315-8700<BR> Copyright &copy;
1996 American Lung Association.<BR> The American Thoracic  Society is the
medical section <BR>of the American Lung Association.<BR> 
</CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-33</DOCNO>
<DOCOLDNO>IA013-000139-B023-170</DOCOLDNO>
<DOCHDR>
http://www.thoracic.org:80/ic97/ss005.html 206.138.195.144 19970217070915 text/html 3712
HTTP/1.0 200 OK
Date: Monday, 17-Feb-97 07:04:32 GMT
Server: NCSA/1.3
MIME-version: 1.0
Content-type: text/html
Last-modified: Tuesday, 04-Feb-97 19:36:34 GMT
Content-length: 3531
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//SQ//DTD HTML 2.0 HoTMetaL + extensions//EN">
<HTML>
<HEAD>
<TITLE>ALA/ATS Joint Sunrise Session: ss005</TITLE></HEAD>
<BODY BGCOLOR="#FFFFFF">
<CENTER><IMG ALIGN="LEFT" SRC="images/banner0.jpg"></CENTER>
<CENTER><BR>
<P>ALA/ATS Joint Sunrise Session</P>
<H2>SS005: A DEBATE: SHOULD ALA RESEARCH FUNDING BE LIMITED TO ASTHMA AND
TOBACCO?</H2>
<P><B></B></P></CENTER>
<HR SIZE="5" NOSHADE="NOSHADE" WIDTH="100%">
<P></P>
<CENTER>
<TABLE BORDER="2">
<TR ALIGN="CENTER" VALIGN="MIDDLE">
<TD ALIGN="CENTER" VALIGN="MIDDLE"><B><SMALL><A HREF="97ala.html">BACK TO
MAIN MENU</A></SMALL></B></TD></TR></TABLE></CENTER>
<P></P>
<HR SIZE="10" WIDTH="85%">
<P></P>
<CENTER>
<P>SUNDAY MORNING, MAY 18</P></CENTER>
<P><B>Registration Fee: $15.00 (includes continental breakfast).</B> <I>Attendance
is limited. Advance registration is required and is on a first come, first
served basis.</I></P>
<P><B>7:00 AM&#151;8:00 AM</B></P>
<HR SIZE="4" WIDTH="85%" ALIGN="CENTER" NOSHADE="NOSHADE">
<P><I><B>Target Audience: </B></I>Lung Association volunteers, and staff,
researchers, behavioral scientists, pulmonologists, and allergists.</P>
<P><B>OBJECTIVES</B><BR>At the conclusion of this session, the participant
will be able to:</P>
<UL>
<LI>understand the facts about current ALA research funding;</LI>
<LI>form an opinion about the future scope of ALA research funding in light of
the ALA strategic plan/core programs.</LI></UL>
<P>During the 1995 ALA Consensus Conference, the leadership of the ALA agreed
to a nationwide strategic plan organized around 6 goals. In addition, a decision
was made to emphasize two areas of work during a three-year planning cycle
(1996-1998): asthma and tobacco control. This session will explore rationale pro
and con the ALA limiting its research monies to asthma and tobacco control.
Results of this session will be shared with the appropriate ALA committees.</P>
<P><I><B>Chairing: </B></I>S.S. Braman, M.D., Providence, RI</P>
<P>Faculty to be announced.</P>
<P></P>
<HR SIZE="4" WIDTH="80%">
<CENTER>
<P><A HREF=97ala.html><IMG
SRC=images/activity_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97bus.html><IMG
SRC=images/business_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97cal.html><IMG
SRC=images/calendar_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97child.html><IMG
SRC=images/child_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=pg.html><IMG
SRC=images/courses_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=search.html><IMG
SRC=images/search_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=main.html><IMG
SRC=images/home_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97house.html><IMG
SRC=images/house_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=http://itsmtgs.com/ala-ats><IMG
SRC=images/regist_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=sessions.html><IMG
SRC=images/session_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=special.html><IMG
SRC=images/special_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97tours.html><IMG
SRC=images/tour_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97travel.html><IMG
SRC=images/travel_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
</P></CENTER>
<HR SIZE="4" WIDTH="80%">
<CENTER><FONT SIZE="+2"><B><I>American Thoracic Society</I></B></FONT><BR>
1740 Broadway<BR> New York, NY 10019<BR> VOICE:  212-315-8700<BR> Copyright &copy;
1996 American Lung Association.<BR> The American Thoracic  Society is the
medical section <BR>of the American Lung Association.<BR> 
</CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-34</DOCNO>
<DOCOLDNO>IA013-000139-B023-195</DOCOLDNO>
<DOCHDR>
http://www.thoracic.org:80/ic97/ss221.html 206.138.195.144 19970217070923 text/html 3768
HTTP/1.0 200 OK
Date: Monday, 17-Feb-97 07:04:41 GMT
Server: NCSA/1.3
MIME-version: 1.0
Content-type: text/html
Last-modified: Friday, 24-Jan-97 16:16:29 GMT
Content-length: 3588
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//SQ//DTD HTML 2.0 HoTMetaL + extensions//EN">
<HTML>
<HEAD>
<TITLE>ALA SUNRISE SESSION: ss221</TITLE></HEAD>
<BODY BGCOLOR="#FFFFFF">
<CENTER><IMG ALIGN="LEFT" SRC="images/banner0.jpg"></CENTER>
<CENTER></CENTER>
<CENTER><BR> 
<P>ALA SUNRISE SESSIONS</P>
<H2><I>SS221.</I> <B>ASTHMA EDUCATOR CERTIFICATE TRAINING: EXAMPLES FROM THE
FIELD </B></H2>
<P></P></CENTER>
<HR SIZE="5" NOSHADE="NOSHADE" WIDTH="100%">
<P><BR><BR></P>
<CENTER>
<TABLE BORDER="2">
<TR ALIGN="CENTER" VALIGN="MIDDLE">
<TD ALIGN="CENTER" VALIGN="MIDDLE"><B><SMALL><A HREF="ic97.html">BACK TO
MAIN MENU</A></SMALL></B></TD></TR></TABLE></CENTER>
<P><BR><BR></P>
<HR SIZE="10" WIDTH="85%">
<P></P>
<BLOCKQUOTE>
<CENTER>
<P>TUESDAY, MAY 20</P></CENTER>
<P><B>Registration Fee: $15.00 (includes continental breakfast).</B> <I>Attendance
is limited. Advance registration is required and on a first come, first served
basis.</I></P>
<P><B>7:00 am-8:00 am</B></P></BLOCKQUOTE>
<HR SIZE="4" WIDTH="85%" ALIGN="CENTER" NOSHADE="NOSHADE">
<BLOCKQUOTE>
<P><I><B>Target Audience</B></I><B>: </B>Lung Association volunteers and
staff.</P>
<P><B>OBJECTIVES</B><BR>At the conclusion of this session, the participant
will be able to:</P>
<UL>
<LI>recognize the American Lung Association's asthma efforts as they relate to
the strategic plan and the Asthma Task Force recommendations;</LI>
<LI>discuss Lung Association interventions;</LI>
<LI>understand the components of current asthma educator certificate programs.</LI></UL>
<P>This session will showcase two Asthma Educator Certificate Programs
currently being offered by constituent and affiliate Lung Associations. In
addition, the relationship to the strategic plan and the recommendations made by
the Asthma Task Force will be explored.</P>
<P><I>7:00</I> A. McIntosh, New York, NY</P>
<P><I>7:20</I> <B>Asthma Educator Certificate Program</B>/R. Pearsall,
Rochester, NY/M.C. Kallay, M.D., F.C.C.P., Rochester, NY</P>
<P><I>7:40</I> <B>Asthma Educators Institute: The Maine Experience</B>/E.
Miller, Augusta, ME</P></BLOCKQUOTE>
<P></P>
<HR SIZE="4" WIDTH="80%">
<CENTER>
<P><A HREF=97ala.html><IMG
SRC=images/activity_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97bus.html><IMG
SRC=images/business_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97cal.html><IMG
SRC=images/calendar_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97child.html><IMG
SRC=images/child_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=pg.html><IMG
SRC=images/courses_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=search.html><IMG
SRC=images/search_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=main.html><IMG
SRC=images/home_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97house.html><IMG
SRC=images/house_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=http://itsmtgs.com/ala-ats><IMG
SRC=images/regist_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=sessions.html><IMG
SRC=images/session_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=special.html><IMG
SRC=images/special_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97tours.html><IMG
SRC=images/tour_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97travel.html><IMG
SRC=images/travel_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
</P></CENTER>
<HR SIZE="4" WIDTH="80%">
<CENTER><FONT SIZE="+2"><B><I>American Thoracic Society</I></B></FONT><BR>
1740 Broadway<BR> New York, NY 10019<BR> VOICE:  212-315-8700<BR> Copyright &copy;
1996 American Lung Association.<BR> The American Thoracic  Society is the
medical section <BR>of the American Lung Association.<BR> 
</CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-35</DOCNO>
<DOCOLDNO>IA013-000139-B023-222</DOCOLDNO>
<DOCHDR>
http://www.thoracic.org:80/ic97/ss222.html 206.138.195.144 19970217070932 text/html 3357
HTTP/1.0 200 OK
Date: Monday, 17-Feb-97 07:04:51 GMT
Server: NCSA/1.3
MIME-version: 1.0
Content-type: text/html
Last-modified: Friday, 24-Jan-97 16:16:29 GMT
Content-length: 3177
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//SQ//DTD HTML 2.0 HoTMetaL + extensions//EN">
<HTML>
<HEAD>
<TITLE>ALA SUNRISE SESSION: ss222</TITLE></HEAD>
<BODY BGCOLOR="#FFFFFF">
<CENTER><IMG ALIGN="LEFT" SRC="images/banner0.jpg"></CENTER>
<CENTER></CENTER>
<CENTER><BR> 
<P>ALA SUNRISE SESSIONS</P>
<H2><I>SS222.</I> <B>LEARN ABOUT: ASTHMA </B></H2>
<P></P></CENTER>
<HR SIZE="5" NOSHADE="NOSHADE" WIDTH="100%">
<P><BR><BR></P>
<CENTER>
<TABLE BORDER="2">
<TR ALIGN="CENTER" VALIGN="MIDDLE">
<TD ALIGN="CENTER" VALIGN="MIDDLE"><B><SMALL><A HREF="ic97.html">BACK TO
MAIN MENU</A></SMALL></B></TD></TR></TABLE></CENTER>
<P><BR><BR></P>
<HR SIZE="10" WIDTH="85%">
<P></P>
<BLOCKQUOTE>
<CENTER>
<P>TUESDAY, MAY 20</P></CENTER>
<P><B>Registration Fee: $15.00 (includes continental breakfast).</B> <I>Attendance
is limited. Advance registration is required and on a first come, first served
basis.</I></P>
<P><B>7:00 am-8:00 am</B></P></BLOCKQUOTE>
<HR SIZE="4" WIDTH="85%" ALIGN="CENTER" NOSHADE="NOSHADE">
<BLOCKQUOTE>
<P><I><B>Target Audience:</B></I><B> </B>Lung Association staff and
volunteers.</P>
<P><B>OBJECTIVES</B><BR>At the conclusion of this session, the participant
will be able to:</P>
<UL>
<LI>describe what asthma is;</LI>
<LI>identify who gets asthma;</LI>
<LI>understand why asthma occurs.</LI></UL>
<P>This session will help promote a better understanding of the nature of
asthma. Discussion will focus on who gets it, what it means, and why it happens.
New information on the processes of asthma will also be shared.</P>
<P><I><B>Chairing: </B></I>S. Wenzel, M.D., Denver, CO</P>
<P><I><B>Speaker:</B></I> K. Young, Jr., M.D., Birmingham, AL</P></BLOCKQUOTE>
<P></P>
<HR SIZE="4" WIDTH="80%">
<CENTER>
<P><A HREF=97ala.html><IMG
SRC=images/activity_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97bus.html><IMG
SRC=images/business_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97cal.html><IMG
SRC=images/calendar_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97child.html><IMG
SRC=images/child_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=pg.html><IMG
SRC=images/courses_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=search.html><IMG
SRC=images/search_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=main.html><IMG
SRC=images/home_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97house.html><IMG
SRC=images/house_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=http://itsmtgs.com/ala-ats><IMG
SRC=images/regist_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=sessions.html><IMG
SRC=images/session_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=special.html><IMG
SRC=images/special_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97tours.html><IMG
SRC=images/tour_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97travel.html><IMG
SRC=images/travel_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
</P></CENTER>
<HR SIZE="4" WIDTH="80%">
<CENTER><FONT SIZE="+2"><B><I>American Thoracic Society</I></B></FONT><BR>
1740 Broadway<BR> New York, NY 10019<BR> VOICE:  212-315-8700<BR> Copyright &copy;
1996 American Lung Association.<BR> The American Thoracic  Society is the
medical section <BR>of the American Lung Association.<BR> 
</CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-36</DOCNO>
<DOCOLDNO>IA013-000139-B023-243</DOCOLDNO>
<DOCHDR>
http://www.thoracic.org:80/ic97/ss223.html 206.138.195.144 19970217070939 text/html 4202
HTTP/1.0 200 OK
Date: Monday, 17-Feb-97 07:04:58 GMT
Server: NCSA/1.3
MIME-version: 1.0
Content-type: text/html
Last-modified: Friday, 24-Jan-97 16:16:30 GMT
Content-length: 4022
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//SQ//DTD HTML 2.0 HoTMetaL + extensions//EN">
<HTML>
<HEAD>
<TITLE>ALA SUNRISE SESSION: ss223</TITLE></HEAD>
<BODY BGCOLOR="#FFFFFF">
<CENTER><IMG ALIGN="LEFT" SRC="images/banner0.jpg"></CENTER>
<CENTER></CENTER>
<CENTER><BR> 
<P>ALA SUNRISE SESSIONS</P>
<H2><I>SS223.</I> <B>BUILDING A HEALTH HOUSE PROGRAM </B></H2>
<P></P></CENTER>
<HR SIZE="5" NOSHADE="NOSHADE" WIDTH="100%">
<P><BR><BR></P>
<CENTER>
<TABLE BORDER="2">
<TR ALIGN="CENTER" VALIGN="MIDDLE">
<TD ALIGN="CENTER" VALIGN="MIDDLE"><B><SMALL><A HREF="ic97.html">BACK TO
MAIN MENU</A></SMALL></B></TD></TR></TABLE></CENTER>
<P><BR><BR></P>
<HR SIZE="10" WIDTH="85%">
<P></P>
<BLOCKQUOTE>
<CENTER>
<P>TUESDAY, MAY 20</P></CENTER>
<P><B>Registration Fee: $15.00 (includes continental breakfast).</B> <I>Attendance
is limited. Advance registration is required and on a first come, first served
basis.</I></P>
<P><B>7:00 am-8:00 am</B></P></BLOCKQUOTE>
<HR SIZE="4" WIDTH="85%" ALIGN="CENTER" NOSHADE="NOSHADE">
<BLOCKQUOTE>
<P><I><B>Target Audience:</B></I><B> </B>Lung Association staff, volunteers,
and pulmonologists.</P>
<P><B>OBJECTIVES</B><BR>At the conclusion of this session, the participant
will be able to:</P>
<UL>
<LI>describe the health, energy, and resource efficiency issues of the Health
House system of building and remodeling homes;</LI>
<LI>understand the options available to ALA to use the Health House Project as
a new delivery system for their Indoor Air Quality message;</LI>
<LI>introduce the public relations and fund raising opportunities available as
a result of developing a Health House project for their association.</LI></UL>
<P>Health House is changing the way homes are being built in America to be
healthier and more energy and resource efficient.</P>
<P>This session will provide an overview of Health House, an Indoor Air Quality
program developed by an American Lung Association affiliate for implementation
by other Lung Associations. Staff involved in the project will discuss the
educational, fund raising, and public relations opportunities this program
provides.</P>
<P><I><B>Chairing: </B></I>D.B. Richards, R.N., M.S., Ducanville, TX</P>
<P><I>7:00</I> <B>Building a Health House Program</B>/G.W. Orr, M.A.,
Minneapolis, MN</P>
<P><I>7:15</I> <B>Health, Energy and Resource Efficiency Issues Related to
Health House</B>/D. Walsh Astry, Minneapolis, MN</P>
<P><I>7:30</I> <B>Public Relation and Fund Raising Opportunities</B>/L.
Wortmann, Minneapolis, MN</P></BLOCKQUOTE>
<P></P>
<HR SIZE="4" WIDTH="80%">
<CENTER>
<P><A HREF=97ala.html><IMG
SRC=images/activity_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97bus.html><IMG
SRC=images/business_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97cal.html><IMG
SRC=images/calendar_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97child.html><IMG
SRC=images/child_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=pg.html><IMG
SRC=images/courses_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=search.html><IMG
SRC=images/search_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=main.html><IMG
SRC=images/home_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97house.html><IMG
SRC=images/house_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=http://itsmtgs.com/ala-ats><IMG
SRC=images/regist_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=sessions.html><IMG
SRC=images/session_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=special.html><IMG
SRC=images/special_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97tours.html><IMG
SRC=images/tour_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97travel.html><IMG
SRC=images/travel_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
</P></CENTER>
<HR SIZE="4" WIDTH="80%">
<CENTER><FONT SIZE="+2"><B><I>American Thoracic Society</I></B></FONT><BR>
1740 Broadway<BR> New York, NY 10019<BR> VOICE:  212-315-8700<BR> Copyright &copy;
1996 American Lung Association.<BR> The American Thoracic  Society is the
medical section <BR>of the American Lung Association.<BR> 
</CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-37</DOCNO>
<DOCOLDNO>IA013-000139-B023-281</DOCOLDNO>
<DOCHDR>
http://www.thoracic.org:80/ic97/ss224.html 206.138.195.144 19970217070951 text/html 3743
HTTP/1.0 200 OK
Date: Monday, 17-Feb-97 07:05:06 GMT
Server: NCSA/1.3
MIME-version: 1.0
Content-type: text/html
Last-modified: Friday, 24-Jan-97 16:16:30 GMT
Content-length: 3563
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//SQ//DTD HTML 2.0 HoTMetaL + extensions//EN">
<HTML>
<HEAD>
<TITLE>ALA SUNRISE SESSION: ss224</TITLE></HEAD>
<BODY BGCOLOR="#FFFFFF">
<CENTER><IMG ALIGN="LEFT" SRC="images/banner0.jpg"></CENTER>
<CENTER></CENTER>
<CENTER><BR> 
<P>ALA SUNRISE SESSIONS</P>
<H2><I>SS224.</I> <B>FINANCIAL PLANNING: TAKE CHARGE OF YOUR FINANCIAL FUTURE
</B></H2>
<P></P></CENTER>
<HR SIZE="5" NOSHADE="NOSHADE" WIDTH="100%">
<P><BR><BR></P>
<CENTER>
<TABLE BORDER="2">
<TR ALIGN="CENTER" VALIGN="MIDDLE">
<TD ALIGN="CENTER" VALIGN="MIDDLE"><B><SMALL><A HREF="ic97.html">BACK TO
MAIN MENU</A></SMALL></B></TD></TR></TABLE></CENTER>
<P><BR><BR></P>
<HR SIZE="10" WIDTH="85%">
<P></P>
<BLOCKQUOTE>
<CENTER>
<P>TUESDAY, MAY 20</P></CENTER>
<P><B>Registration Fee: $15.00 (includes continental breakfast).</B> <I>Attendance
is limited. Advance registration is required and on a first come, first served
basis.</I></P>
<P><B>7:00 am-8:00 am</B></P></BLOCKQUOTE>
<HR SIZE="4" WIDTH="85%" ALIGN="CENTER" NOSHADE="NOSHADE">
<BLOCKQUOTE>
<P><I><B>Target Audience: </B></I>Lung Association staff, volunteers.</P>
<P><B>OBJECTIVES</B><BR>At the conclusion of this session, the participant
will be able to:</P>
<UL>
<LI>begin the personal retirement planning process;</LI>
<LI>understand the importance of interest compounding and tax deferral;</LI>
<LI>take advantage of the benefits of investment diversification;</LI>
<LI>understand the differences between and advantages of tax deferred annuities
(403(b) plans), 401K plans, and IRA's.</LI></UL>
<P>During this session, the essentials of personal financial planning will be
explained. Participants will learn about various available investment vehicles
such as IRA's, tax deferred annuities (403(b)'s), and 401K plans. Stocks, and
how to read an investment fund prospectus, will also be discussed. Questions
will be welcomed!</P>
<P><I><B>Chairing: </B></I>A. Brown, New York, NYS. Cutter, New York, NY</P>
<P><I><B>Speaker: </B></I>N. Kaye, M.B.A., C.F.P., Port Washington, NY</P></BLOCKQUOTE>
<P></P>
<HR SIZE="4" WIDTH="80%">
<CENTER>
<P><A HREF=97ala.html><IMG
SRC=images/activity_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97bus.html><IMG
SRC=images/business_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97cal.html><IMG
SRC=images/calendar_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97child.html><IMG
SRC=images/child_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=pg.html><IMG
SRC=images/courses_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=search.html><IMG
SRC=images/search_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=main.html><IMG
SRC=images/home_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97house.html><IMG
SRC=images/house_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=http://itsmtgs.com/ala-ats><IMG
SRC=images/regist_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=sessions.html><IMG
SRC=images/session_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=special.html><IMG
SRC=images/special_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97tours.html><IMG
SRC=images/tour_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97travel.html><IMG
SRC=images/travel_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
</P></CENTER>
<HR SIZE="4" WIDTH="80%">
<CENTER><FONT SIZE="+2"><B><I>American Thoracic Society</I></B></FONT><BR>
1740 Broadway<BR> New York, NY 10019<BR> VOICE:  212-315-8700<BR> Copyright &copy;
1996 American Lung Association.<BR> The American Thoracic  Society is the
medical section <BR>of the American Lung Association.<BR> 
</CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-38</DOCNO>
<DOCOLDNO>IA013-000139-B023-309</DOCOLDNO>
<DOCHDR>
http://www.thoracic.org:80/ic97/ss225.html 206.138.195.144 19970217070959 text/html 3593
HTTP/1.0 200 OK
Date: Monday, 17-Feb-97 07:05:16 GMT
Server: NCSA/1.3
MIME-version: 1.0
Content-type: text/html
Last-modified: Friday, 24-Jan-97 16:16:31 GMT
Content-length: 3413
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//SQ//DTD HTML 2.0 HoTMetaL + extensions//EN">
<HTML>
<HEAD>
<TITLE>ALA SUNRISE SESSION: ss225</TITLE></HEAD>
<BODY BGCOLOR="#FFFFFF">
<CENTER><IMG ALIGN="LEFT" SRC="images/banner0.jpg"></CENTER>
<CENTER></CENTER>
<CENTER><BR> 
<P>ALA SUNRISE SESSIONS</P>
<H2><I>SS225.</I> <B>INTEGRATING TECHNOLOGY AND STRATEGY</B></H2>
<P></P></CENTER>
<HR SIZE="5" NOSHADE="NOSHADE" WIDTH="100%">
<P><BR><BR></P>
<CENTER>
<TABLE BORDER="2">
<TR ALIGN="CENTER" VALIGN="MIDDLE">
<TD ALIGN="CENTER" VALIGN="MIDDLE"><B><SMALL><A HREF="ic97.html">BACK TO
MAIN MENU</A></SMALL></B></TD></TR></TABLE></CENTER>
<P><BR><BR></P>
<HR SIZE="10" WIDTH="85%">
<P></P>
<BLOCKQUOTE>
<CENTER>
<P>TUESDAY, MAY 20</P></CENTER>
<P><B>Registration Fee: $15.00 (includes continental breakfast).</B> <I>Attendance
is limited. Advance registration is required and on a first come, first served
basis.</I></P>
<P><B>7:00 am-8:00 am</B></P></BLOCKQUOTE>
<HR SIZE="4" WIDTH="85%" ALIGN="CENTER" NOSHADE="NOSHADE">
<BLOCKQUOTE>
<P><I><B>Target Audience:</B></I><B> </B>ALA staff and volunteers.</P>
<P><B>OBJECTIVES</B><BR>At the conclusion of this session, the participant
will be able to:</P>
<UL>
<LI>understand how technology can help an association accomplish its goals;</LI>
<LI>choose technology that is appropriate for the purposes of a specific
association;</LI>
<LI>describe the recommendations of the ALA/ATS Technology Task Force for
nationwide implimentation.</LI></UL>
<P>Merging an association's strategic direction with its technology initiatives
is essential to achieving and sustaining competitive advantage. This session
will demonstrate how to align the two strategies to maximize a Lung
Association's effectiveness. Participants will learn how to make smarter
technology choices which are appropriate to the organization's broader goals.</P>
<P>Faculty to be announced.</P></BLOCKQUOTE>
<P></P>
<HR SIZE="4" WIDTH="80%">
<CENTER>
<P><A HREF=97ala.html><IMG
SRC=images/activity_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97bus.html><IMG
SRC=images/business_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97cal.html><IMG
SRC=images/calendar_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97child.html><IMG
SRC=images/child_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=pg.html><IMG
SRC=images/courses_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=search.html><IMG
SRC=images/search_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=main.html><IMG
SRC=images/home_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97house.html><IMG
SRC=images/house_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=http://itsmtgs.com/ala-ats><IMG
SRC=images/regist_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=sessions.html><IMG
SRC=images/session_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=special.html><IMG
SRC=images/special_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97tours.html><IMG
SRC=images/tour_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97travel.html><IMG
SRC=images/travel_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
</P></CENTER>
<HR SIZE="4" WIDTH="80%">
<CENTER><FONT SIZE="+2"><B><I>American Thoracic Society</I></B></FONT><BR>
1740 Broadway<BR> New York, NY 10019<BR> VOICE:  212-315-8700<BR> Copyright &copy;
1996 American Lung Association.<BR> The American Thoracic  Society is the
medical section <BR>of the American Lung Association.<BR> 
</CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-39</DOCNO>
<DOCOLDNO>IA013-000139-B023-338</DOCOLDNO>
<DOCHDR>
http://www.thoracic.org:80/ic97/a7.html 206.138.195.144 19970217071011 text/html 4695
HTTP/1.0 200 OK
Date: Monday, 17-Feb-97 07:05:24 GMT
Server: NCSA/1.3
MIME-version: 1.0
Content-type: text/html
Last-modified: Friday, 24-Jan-97 16:15:02 GMT
Content-length: 4515
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//SQ//DTD HTML 2.0 HoTMetaL + extensions//EN">
<HTML>
<HEAD>
<TITLE>ALA SYMPOSIUM: a7</TITLE></HEAD>
<BODY BGCOLOR="#FFFFFF">
<CENTER><IMG ALIGN="LEFT" SRC="images/banner0.jpg"></CENTER>
<CENTER><BR>
<P>ALA SYMPOSIUM</P><BR>
<H2>A7: THE &quot;ALTERNATIVE&quot; VOLUNTEER: SEIZING THE OPPORTUNITY</H2></CENTER>
<HR SIZE="5" NOSHADE="NOSHADE" WIDTH="100%">
<P></P>
<CENTER>
<TABLE BORDER="2">
<TR ALIGN="CENTER" VALIGN="MIDDLE">
<TD ALIGN="CENTER" VALIGN="MIDDLE"><B><SMALL><A HREF="ic97.html">BACK TO
MAIN MENU</A></SMALL></B></TD></TR></TABLE></CENTER>
<P></P>
<HR SIZE="10" WIDTH="85%">
<P></P>
<CENTER>
<P>SUNDAY , MAY 18</P></CENTER>
<BLOCKQUOTE>
<P><B>8:15 am-11:30 am</B></P></BLOCKQUOTE>
<HR SIZE="4" WIDTH="85%" ALIGN="CENTER" NOSHADE="NOSHADE">
<BLOCKQUOTE>
<P><I><B>Target Audience: </B></I>Lung Association volunteers and staff
managing or getting ready to manage a Lung Association volunteer program.</P>
<P><B>OBJECTIVES</B><BR>At the conclusion of this session, the participant
will be able to:</P>
<UL>
<LI>identify new sources of &quot;alternative&quot; volunteers within their
community;</LI>
<LI>develop job descriptions for &quot;alternative&quot; volunteers which meet
their prescribed needs and the Association's goals;</LI>
<LI>identify and implement best-practices in volunteer risk management policies
and procedures.</LI></UL>
<P>The American Lung Association defines the registered volunteer as &quot;any
person who donates time or expertise to accomplish a particular organizational
task within an ALA fiscal year, and whose name, address and telephone number are
known.&quot; When we think of a volunteer, we usually think of someone who comes
to our organization of their own &quot;volition&quot; hence, &quot;volunteer.&quot;
Our definitional paradigm is being challenged daily as high schools around the
country begin to &quot;require&quot; community service for graduation, as &quot;alternative
sentences&quot; are bestowed upon convicted criminals and they come to us for
placement, or as those in drug rehabilitation programs seek out opportunities
for re-integration into society. This session will explore the challenges
inherent in this new cadre of potential volunteers and how to partner with them
to meet both their needs and Association goals. This session will also review
risk management systems Associations need to have in place to successfully
recruit these, as well as all other, volunteers.</P>
<P>Susan J. Ellis is founder and president of ENERGIZE, Inc. and is a national
columnist on volunteerism for the Nonprofit Times. She is recognized
internationally as a leader in the volunteer field, and has been conducting
workshops on volunteer management for the past 19 years. She blends her
personal, hands-on management experience with extensive research on
volunteerism.</P>
<P><I><B>Chairing: </B></I>D.B. Richards, R.N., M.S., Ducanville, TX</P>
<P><I><B>Speaker:</B></I> S.J. Ellis, Philadelphia, PA</P></BLOCKQUOTE>
<P></P>
<HR SIZE="4" WIDTH="80%">
<CENTER>
<P><A HREF=97ala.html><IMG
SRC=images/activity_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97bus.html><IMG
SRC=images/business_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97cal.html><IMG
SRC=images/calendar_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97child.html><IMG
SRC=images/child_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=pg.html><IMG
SRC=images/courses_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=search.html><IMG
SRC=images/search_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=main.html><IMG
SRC=images/home_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97house.html><IMG
SRC=images/house_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=http://itsmtgs.com/ala-ats><IMG
SRC=images/regist_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=sessions.html><IMG
SRC=images/session_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=special.html><IMG
SRC=images/special_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97tours.html><IMG
SRC=images/tour_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97travel.html><IMG
SRC=images/travel_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
</P></CENTER>
<HR SIZE="4" WIDTH="80%">
<CENTER><FONT SIZE="+2"><B><I>American Thoracic Society</I></B></FONT><BR>
1740 Broadway<BR> New York, NY 10019<BR> VOICE:  212-315-8700<BR> Copyright &copy;
1996 American Lung Association.<BR> The American Thoracic  Society is the
medical section <BR>of the American Lung Association.<BR> 
</CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-40</DOCNO>
<DOCOLDNO>IA013-000139-B024-8</DOCOLDNO>
<DOCHDR>
http://www.thoracic.org:80/ic97/a56.html 206.138.195.144 19970217071023 text/html 4690
HTTP/1.0 200 OK
Date: Monday, 17-Feb-97 07:05:38 GMT
Server: NCSA/1.3
MIME-version: 1.0
Content-type: text/html
Last-modified: Wednesday, 29-Jan-97 17:22:54 GMT
Content-length: 4507
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//SQ//DTD HTML 2.0 HoTMetaL + extensions//EN">
<HTML>
<HEAD>
<TITLE>ALA SYMPOSIUM: a56</TITLE></HEAD>
<BODY BGCOLOR="#FFFFFF">
<CENTER><IMG ALIGN="LEFT" SRC="images/banner0.jpg"></CENTER>
<CENTER><BR>
<P>ALA SYMPOSIUM</P>
<H2>A56: AFFILIATED VOLUNTEERS: THEY ARE ENERGIZED AND MOTIVATED- ARE YOU
PREPARED FOR THEM? </H2>
<P><BR></P></CENTER>
<HR SIZE="5" NOSHADE="NOSHADE" WIDTH="100%">
<P></P>
<CENTER>
<TABLE BORDER="2">
<TR ALIGN="CENTER" VALIGN="MIDDLE">
<TD ALIGN="CENTER" VALIGN="MIDDLE"><B><SMALL><A HREF="main.html">BACK TO
MAIN MENU</A></SMALL></B></TD></TR></TABLE></CENTER>
<P></P>
<HR SIZE="10" WIDTH="85%">
<P></P>
<CENTER>
<P>SUNDAY , MAY 18</P></CENTER>
<BLOCKQUOTE>
<P><B>1:30 pm-4:15 pm</B></P></BLOCKQUOTE>
<HR SIZE="4" WIDTH="85%" ALIGN="CENTER" NOSHADE="NOSHADE">
<BLOCKQUOTE>
<P><I><B>Target Audience: </B></I>Lung Association volunteers and staff
currently engaged in volunteer recruitment as well as those involved in other
association activities where volunteers can become involved.</P>
<P><B>OBJECTIVES</B><BR>At the conclusion of this session, the participant
will be able to:</P>
<UL>
<LI>articulate a range of corporate needs related to volunteer activities;</LI>
<LI>define secondary education Service Learning;</LI>
<LI>define &quot;family volunteering&quot; and articulate its benefits;</LI>
<LI>identify three current Association activities which can be marketed to the
business, education and family sectors;</LI>
<LI>enhance/expand existing Association activities and volunteer jobs to
include corporate volunteer groups, service learner participants and family
units.</LI></UL>
<P>The tide is rising in organized volunteering within the corporate,
educational, and family sectors. Employers and employees, educators and
students, and care-givers and their charges are increasingly seeking out
projects to better society, meet others, explore mutual interests, and expand
their education as a formal activity of the group with which they are
affiliated. These &quot;affiliated volunteers&quot; - individuals who are
members of an organized group/institution with a prescribed mission- are often
recruited as individuals but are largely untapped or under-recognized as members
of powerful, energizing, and supportive external groups which can be sources of
added benefits for Lung Associations. </P>
<P>Learn how to re-design and market your activities so that they are
attractive to the business community, learner oriented and family friendly. Get
on the bandwagon of organizational success by learning the essentials of
partnering with corporations, educational institutions, and family units to
prevent lung disease and promote lung health.</P>
<P><I><B>Chairing</B></I>: D.B. Richards, R.N., M.S., Ducanville, TX</P>
<P><I><B>Speaker: </B></I>  S.J. Ellis, Philadelphia, PA</P></BLOCKQUOTE>
<P></P>
<HR SIZE="4" WIDTH="80%">
<CENTER>
<P><A HREF="97ala.html"><IMG
SRC="images/activity_but.jpg" BORDER="0" WIDTH="84" HEIGHT="35"></A>
<A HREF="97bus.html"><IMG
SRC="images/business_but.jpg" BORDER="0" WIDTH="84" HEIGHT="35"></A>
<A HREF="97cal.html"><IMG
SRC="images/calendar_but.jpg" BORDER="0" WIDTH="84" HEIGHT="35"></A>
<A HREF="97child.html"><IMG
SRC="images/child_but.jpg" BORDER="0" WIDTH="84" HEIGHT="35"></A><BR>
<A HREF="pg.html"><IMG
SRC="images/courses_but.jpg" BORDER="0" WIDTH="84" HEIGHT="35"></A>
<A HREF="search.html"><IMG
SRC="images/search_but.jpg" BORDER="0" WIDTH="84" HEIGHT="35"></A>
<A HREF="index.html"><IMG
SRC="images/home_but.jpg" BORDER="0" WIDTH="84" HEIGHT="35"></A>
<A HREF="97house.html"><IMG
SRC="images/house_but.jpg" BORDER="0" WIDTH="84" HEIGHT="35"></A>
<A HREF="http://itsmtgs.com/ala-ats"><IMG
SRC="images/regist_but.jpg" BORDER="0" WIDTH="84" HEIGHT="35"></A><BR>
<A HREF="sessions.html"><IMG
SRC="images/session_but.jpg" BORDER="0" WIDTH="84" HEIGHT="35"></A>
<A HREF="special.html"><IMG
SRC="images/special_but.jpg" BORDER="0" WIDTH="84" HEIGHT="35"></A>
<A HREF="97tours.html"><IMG
SRC="images/tour_but.jpg" BORDER="0" WIDTH="84" HEIGHT="35"></A>
<A HREF="97travel.html"><IMG
SRC="images/travel_but.jpg" BORDER="0" WIDTH="84" HEIGHT="35"></A><BR>
</P></CENTER>
<HR SIZE="4" WIDTH="80%">
<CENTER><FONT SIZE="+2"><B><I>American Thoracic Society</I></B></FONT><BR>
1740 Broadway<BR> New York, NY 10019<BR> VOICE:  212-315-8700<BR> Copyright &copy;
1996 American Lung Association.<BR> The American Thoracic  Society is the
medical section <BR>of the American Lung Association.<BR> 
</CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-41</DOCNO>
<DOCOLDNO>IA013-000139-B024-35</DOCOLDNO>
<DOCHDR>
http://www.thoracic.org:80/ic97/c9.html 206.138.195.144 19970217071031 text/html 3896
HTTP/1.0 200 OK
Date: Monday, 17-Feb-97 07:05:48 GMT
Server: NCSA/1.3
MIME-version: 1.0
Content-type: text/html
Last-modified: Friday, 24-Jan-97 16:15:36 GMT
Content-length: 3716
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//SQ//DTD HTML 2.0 HoTMetaL + extensions//EN">
<HTML>
<HEAD>
<TITLE>ALA SYMPOSIUM: c9</TITLE></HEAD>
<BODY BGCOLOR="#FFFFFF">
<CENTER><IMG ALIGN="LEFT" SRC="images/banner0.jpg"></CENTER>
<CENTER><BR>
<P>ALA SYMPOSIUM</P><BR>
<H2>C9: HOW TO CREATE A LEGEND IN THE VIRTUAL WORKPLACE</H2></CENTER>
<HR SIZE="5" NOSHADE="NOSHADE" WIDTH="100%">
<P></P>
<CENTER>
<TABLE BORDER="2">
<TR ALIGN="CENTER" VALIGN="MIDDLE">
<TD ALIGN="CENTER" VALIGN="MIDDLE"><B><SMALL><A HREF="ic97.html">BACK TO
MAIN MENU</A></SMALL></B></TD></TR></TABLE></CENTER>
<P></P>
<HR SIZE="10" WIDTH="85%">
<P></P>
<BLOCKQUOTE>
<CENTER>
<P>TUESDAY , MAY 20</P>
<P><B>8:15 am-11:30 am</B></P></CENTER></BLOCKQUOTE>
<HR SIZE="4" WIDTH="85%" ALIGN="CENTER" NOSHADE="NOSHADE">
<BLOCKQUOTE>
<P><I><B>Target Audience: </B></I>Lung Association volunteers and staff.</P>
<P><B>OBJECTIVES</B><BR>At the conclusion of this session, the participant
will be able to:</P>
<UL>
<LI>describe the elements which make up the &quot;virtual workplace&quot;;</LI>
<LI> identify the benefits of building trust in the &quot;virtual workplace&quot;;</LI>
<LI>develop strategies to accomplish this trust;</LI>
<LI>create an atmosphere of open communication - even from a distance.</LI></UL>
<P>The promise of the virtual workplace is that people can be anywhere, at
anytime and still be in touch. Whether by phone, voice mail, e-mail, or any of
the other high-tech tools of this age, the implication is simple; Press a few
keys, and voila, you're connected. This promise is especially important for
those who work in a widely dispersed organization like the American Lung
Association.</P>
<P>Unfortunately, one possible result is that rich, interactive conversations
are being replaced by impersonal messages adding to a growing sense of isolation
in the workplace. This session will focus on how participants can use technology
while keeping in mind the importance of the human connection. Tools and
techniques to help build warm, trusting relationships with long distance
co-workers will be discussed.</P>
<P><I><B>Chairing: </B></I>J. Kostner, Ph.D., Englewood, CO</P>
<P>Additional faculty to be announced.</P></BLOCKQUOTE>
<P></P>
<HR SIZE="4" WIDTH="80%">
<CENTER>
<P><A HREF=97ala.html><IMG
SRC=images/activity_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97bus.html><IMG
SRC=images/business_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97cal.html><IMG
SRC=images/calendar_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97child.html><IMG
SRC=images/child_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=pg.html><IMG
SRC=images/courses_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=search.html><IMG
SRC=images/search_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=main.html><IMG
SRC=images/home_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97house.html><IMG
SRC=images/house_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=http://itsmtgs.com/ala-ats><IMG
SRC=images/regist_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=sessions.html><IMG
SRC=images/session_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=special.html><IMG
SRC=images/special_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97tours.html><IMG
SRC=images/tour_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97travel.html><IMG
SRC=images/travel_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
</P></CENTER>
<HR SIZE="4" WIDTH="80%">
<CENTER><FONT SIZE="+2"><B><I>American Thoracic Society</I></B></FONT><BR>
1740 Broadway<BR> New York, NY 10019<BR> VOICE:  212-315-8700<BR> Copyright &copy;
1996 American Lung Association.<BR> The American Thoracic  Society is the
medical section <BR>of the American Lung Association.<BR> 
</CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-42</DOCNO>
<DOCOLDNO>IA013-000139-B024-70</DOCOLDNO>
<DOCHDR>
http://www.thoracic.org:80/ic97/b54.html 206.138.195.144 19970217071041 text/html 4354
HTTP/1.0 200 OK
Date: Monday, 17-Feb-97 07:05:57 GMT
Server: NCSA/1.3
MIME-version: 1.0
Content-type: text/html
Last-modified: Friday, 24-Jan-97 16:15:17 GMT
Content-length: 4174
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//SQ//DTD HTML 2.0 HoTMetaL + extensions//EN">
<HTML>
<HEAD>
<TITLE>ALA SYMPOSIUM: b54</TITLE></HEAD>
<BODY BGCOLOR="#FFFFFF">
<CENTER><IMG ALIGN="LEFT" SRC="images/banner0.jpg"></CENTER>
<CENTER><BR>
<P>ALA SYMPOSIUM</P><BR>
<H2>B54: PASSION AND POWER IN LEADERSHIP </H2></CENTER>
<HR SIZE="5" NOSHADE="NOSHADE" WIDTH="100%">
<P></P>
<CENTER>
<TABLE BORDER="2">
<TR ALIGN="CENTER" VALIGN="MIDDLE">
<TD ALIGN="CENTER" VALIGN="MIDDLE"><B><SMALL><A HREF="ic97.html">BACK TO
MAIN MENU</A></SMALL></B></TD></TR></TABLE></CENTER>
<P></P>
<HR SIZE="10" WIDTH="85%">
<P></P>
<BLOCKQUOTE>
<CENTER>
<P>MONDAY , MAY 19</P>
<P><B>1:30 pm-4:15 pm</B></P></CENTER></BLOCKQUOTE>
<HR SIZE="4" WIDTH="85%" ALIGN="CENTER" NOSHADE="NOSHADE">
<BLOCKQUOTE>
<P><I><B>Target Audience: </B></I>Lung Association staff and volunteers.</P>
<P><B>OBJECTIVES</B><BR>At the conclusion of this session, the participant
will be able to:</P>
<UL>
<LI>use their knowledge of the four key strengths of personal differences to
augment the power of individuals and organizations;</LI>
<LI>recognize the compelling forces that drive people to take risks;</LI>
<LI>create an inclusive vision that leads to greater achievement;</LI>
<LI>promote visibility to develop resources and ensure success over time.</LI></UL>
<P>Believe it or not, we live and work in an era of resource abundance, not
scarcity. Government funding, foundation and corporate giving, and private
contributions of both dollars and time are at an all time high. Yet many
organizations are faced with cutbacks, downsizing, and mergers, struggling with
the operational pressures that are as demanding as the increasing community
needs that must be met.</P>
<P>Strong leadership is needed to take full advantage of the abundant resources
necessary to empower our organization and foster our communities. Our leaders
can tap two crucial resources: the passion to make a difference and the power to
connect. This interactive and challenging session will focus on developing
skills in collaboration with others and on integrating these collaborations into
the work of the American Lung Association.</P>
<P>Michael Winer is the founder of Synoptics: Seeing Results Together, which is
dedicated to mobilizing individual, organizational, and community resources to
achieve results through joint efforts. He has worked closely with leaders and
their organizations from all sectors, bringing together diverse talents and
perspectives to achieve common visions.</P>
<P><I><B>Chairing: </B></I>P. Gottier Fena, Bloomington, MN</P>
<P><I><B>Speaker:</B></I>  M. Winer, M.A.A.B.S., St. Paul, MN</P></BLOCKQUOTE>
<P></P>
<HR SIZE="4" WIDTH="80%">
<CENTER>
<P><A HREF=97ala.html><IMG
SRC=images/activity_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97bus.html><IMG
SRC=images/business_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97cal.html><IMG
SRC=images/calendar_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97child.html><IMG
SRC=images/child_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=pg.html><IMG
SRC=images/courses_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=search.html><IMG
SRC=images/search_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=main.html><IMG
SRC=images/home_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97house.html><IMG
SRC=images/house_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=http://itsmtgs.com/ala-ats><IMG
SRC=images/regist_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=sessions.html><IMG
SRC=images/session_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=special.html><IMG
SRC=images/special_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97tours.html><IMG
SRC=images/tour_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97travel.html><IMG
SRC=images/travel_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
</P></CENTER>
<HR SIZE="4" WIDTH="80%">
<CENTER><FONT SIZE="+2"><B><I>American Thoracic Society</I></B></FONT><BR>
1740 Broadway<BR> New York, NY 10019<BR> VOICE:  212-315-8700<BR> Copyright &copy;
1996 American Lung Association.<BR> The American Thoracic  Society is the
medical section <BR>of the American Lung Association.<BR> 
</CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-43</DOCNO>
<DOCOLDNO>IA013-000139-B024-109</DOCOLDNO>
<DOCHDR>
http://www.thoracic.org:80/ic97/f1.html 206.138.195.144 19970217071054 text/html 3200
HTTP/1.0 200 OK
Date: Monday, 17-Feb-97 07:06:09 GMT
Server: NCSA/1.3
MIME-version: 1.0
Content-type: text/html
Last-modified: Friday, 24-Jan-97 16:16:01 GMT
Content-length: 3020
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//SQ//DTD HTML 2.0 HoTMetaL + extensions//EN">
<HTML>
<HEAD>
<TITLE>FORUM: f1</TITLE></HEAD>
<BODY BGCOLOR="#FFFFFF">
<CENTER><IMG ALIGN="LEFT" SRC="images/master.jpg"></CENTER>
<CENTER><BR>
<P>FORUM</P><BR>
<H2>F1: ALA/ATS HEALTH CARE POLICY: <BR>HOW CAN WE HAVE AN EFFECTIVE <BR>VOICE
IN THE DEVELOPMENT OF <BR>HEALTH CARE SYSTEMS? </H2></CENTER>
<HR SIZE="5" NOSHADE="NOSHADE" WIDTH="100%">
<P></P>
<CENTER>
<TABLE BORDER="2">
<TR ALIGN="CENTER" VALIGN="MIDDLE">
<TD ALIGN="CENTER" VALIGN="MIDDLE"><B><SMALL><A HREF="forums.html">BACK TO
FORUMS</A></SMALL></B></TD></TR></TABLE></CENTER>
<P></P>
<HR SIZE="10" WIDTH="85%">
<P></P>
<BLOCKQUOTE>
<CENTER>
<P>SUNDAY , MAY 18</P>
<P><B>7:00 pm-9:00 pm</B></P></CENTER></BLOCKQUOTE>
<HR SIZE="4" WIDTH="85%" ALIGN="CENTER" NOSHADE="NOSHADE">
<BLOCKQUOTE>
<P>The ALA and ATS have completed a new Health Care Policy Statement which will
have relevance to all levels of the organization. Volunteers and staff working
in local and state government relations will find this overview of the health
care policy issues facing us informative and useful. We will look at three broad
areas; access to care, quality of health care and cost effectiveness of health
care. Specific issues such as scope of health care, eliminating barriers, access
to appropriate care, patient-provider relationships, professional and public
education, biomedical research and the financing of health care are all part of
this presentation.</P></BLOCKQUOTE>
<P></P>
<HR SIZE="4" WIDTH="80%">
<CENTER>
<P><A HREF=97ala.html><IMG
SRC=images/activity_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97bus.html><IMG
SRC=images/business_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97cal.html><IMG
SRC=images/calendar_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97child.html><IMG
SRC=images/child_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=pg.html><IMG
SRC=images/courses_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=search.html><IMG
SRC=images/search_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=main.html><IMG
SRC=images/home_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97house.html><IMG
SRC=images/house_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=http://itsmtgs.com/ala-ats><IMG
SRC=images/regist_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=sessions.html><IMG
SRC=images/session_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=special.html><IMG
SRC=images/special_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97tours.html><IMG
SRC=images/tour_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97travel.html><IMG
SRC=images/travel_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
</P></CENTER>
<HR SIZE="4" WIDTH="80%">
<CENTER><FONT SIZE="+2"><B><I>American Thoracic Society</I></B></FONT><BR>
1740 Broadway<BR> New York, NY 10019<BR> VOICE:  212-315-8700<BR> Copyright &copy;
1996 American Lung Association.<BR> The American Thoracic  Society is the
medical section <BR>of the American Lung Association.<BR> 
</CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-44</DOCNO>
<DOCOLDNO>IA013-000139-B024-143</DOCOLDNO>
<DOCHDR>
http://www.thoracic.org:80/ic97/f2.html 206.138.195.144 19970217071103 text/html 2700
HTTP/1.0 200 OK
Date: Monday, 17-Feb-97 07:06:19 GMT
Server: NCSA/1.3
MIME-version: 1.0
Content-type: text/html
Last-modified: Friday, 24-Jan-97 16:16:01 GMT
Content-length: 2520
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//SQ//DTD HTML 2.0 HoTMetaL + extensions//EN">
<HTML>
<HEAD>
<TITLE>FORUM: f2</TITLE></HEAD>
<BODY BGCOLOR="#FFFFFF">
<CENTER><IMG ALIGN="LEFT" SRC="images/master.jpg"></CENTER>
<CENTER><BR>
<P>FORUM</P><BR>
<H2>F2: ATS-ERS STATEMENT ON RESPIRATORY MUSCLES TESTING </H2></CENTER>
<HR SIZE="5" NOSHADE="NOSHADE" WIDTH="100%">
<P></P>
<CENTER>
<TABLE BORDER="2">
<TR ALIGN="CENTER" VALIGN="MIDDLE">
<TD ALIGN="CENTER" VALIGN="MIDDLE"><B><SMALL><A HREF="forums.html">BACK TO
FORUMS</A></SMALL></B></TD></TR></TABLE></CENTER>
<P></P>
<HR SIZE="10" WIDTH="85%">
<P></P>
<BLOCKQUOTE>
<CENTER>
<P>SUNDAY , MAY 18</P>
<P><B>7:30 pm-9:30 pm</B></P></CENTER></BLOCKQUOTE>
<HR SIZE="4" WIDTH="85%" ALIGN="CENTER" NOSHADE="NOSHADE">
<BLOCKQUOTE>
<P>In this forum, an update of the progress made by the 10 working groups
evaluating specific techniques used for clinical testing of respiratory muscle
function will be presented. Feedback from the audience is encouraged.</P></BLOCKQUOTE>
<P></P>
<HR SIZE="4" WIDTH="80%">
<CENTER>
<P><A HREF=97ala.html><IMG
SRC=images/activity_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97bus.html><IMG
SRC=images/business_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97cal.html><IMG
SRC=images/calendar_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97child.html><IMG
SRC=images/child_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=pg.html><IMG
SRC=images/courses_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=search.html><IMG
SRC=images/search_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=main.html><IMG
SRC=images/home_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97house.html><IMG
SRC=images/house_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=http://itsmtgs.com/ala-ats><IMG
SRC=images/regist_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=sessions.html><IMG
SRC=images/session_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=special.html><IMG
SRC=images/special_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97tours.html><IMG
SRC=images/tour_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97travel.html><IMG
SRC=images/travel_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
</P></CENTER>
<HR SIZE="4" WIDTH="80%">
<CENTER><FONT SIZE="+2"><B><I>American Thoracic Society</I></B></FONT><BR>
1740 Broadway<BR> New York, NY 10019<BR> VOICE:  212-315-8700<BR> Copyright &copy;
1996 American Lung Association.<BR> The American Thoracic  Society is the
medical section <BR>of the American Lung Association.<BR> 
</CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-45</DOCNO>
<DOCOLDNO>IA013-000139-B024-174</DOCOLDNO>
<DOCHDR>
http://www.thoracic.org:80/ic97/a5.html 206.138.195.144 19970217071122 text/html 4301
HTTP/1.0 200 OK
Date: Monday, 17-Feb-97 07:06:29 GMT
Server: NCSA/1.3
MIME-version: 1.0
Content-type: text/html
Last-modified: Friday, 24-Jan-97 16:14:57 GMT
Content-length: 4121
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//SQ//DTD HTML 2.0 HoTMetaL + extensions//EN">
<HTML>
<HEAD>
<TITLE>ALA/ATS JOINT SYMPOSIUM: a5</TITLE></HEAD>
<BODY BGCOLOR="#FFFFFF">
<CENTER><IMG ALIGN="LEFT" SRC="images/banner0.jpg"></CENTER>
<CENTER><BR>
<P>ALA/ATS JOINT SYMPOSIUM</P><BR>
<H2>A5: TOBACCO EDUCATION: PEER TEACHING MODELS THAT WORK</H2></CENTER>
<HR SIZE="5" NOSHADE="NOSHADE" WIDTH="100%">
<P></P>
<CENTER>
<TABLE BORDER="2">
<TR ALIGN="CENTER" VALIGN="MIDDLE">
<TD ALIGN="CENTER" VALIGN="MIDDLE"><B><SMALL><A HREF="ic97.html">BACK TO
MAIN MENU</A></SMALL></B></TD></TR></TABLE></CENTER>
<P></P>
<HR SIZE="10" WIDTH="85%">
<P></P>
<CENTER>
<P>SUNDAY , MAY 18</P></CENTER>
<BLOCKQUOTE>
<P><B>American Lung Association/Assemblies on Pediatrics/Behavioral Science</B></P>
<P><B>8:15 am-9:45 am</B></P></BLOCKQUOTE>
<HR SIZE="4" WIDTH="85%" ALIGN="CENTER" NOSHADE="NOSHADE">
<BLOCKQUOTE>
<P><I><B>Target Audience: </B></I>Lung Association volunteers, and staff,
behavioral scientists, nurses and pediatricians.</P>
<P><B>OBJECTIVES</B><BR>At the conclusion of this session, the participant
will be able to:</P>
<UL>
<LI>describe the components of effective and fun peer tobacco education
teaching models;</LI>
<LI>outline methods for recruiting teens to participate in peer tobacco
education programs;</LI>
<LI>organize peer programs that will have the components necessary to result in
tobacco use risk reduction.</LI></UL>
<P>Children are starting to smoke at younger and younger ages. The average
smoker begins at age 13 and is already a daily smoker by 14 1/2. Smoking among
teens has increased to the highest level in 16 years. Past-month smoking for
students in grades 9-12 has increased from 27.5% in 1991 to almost 35% in 1996.
The ALA's core program on youth tobacco-use prevention, currently in
development, will contain a peer education component. This session will offer an
overview of several such programs that are being utilized successfully in Lung
Associations across the country.</P>
<P><I><B>Chairing: </B></I>K. Monaco, Chapel Hill, NCM. Nenno, Washington, DC</P>
<P><I>8:15</I> <B>Introduction</B>/K. Monaco, Chapel Hill, NC/M. Nenno,
Washington, DC</P>
<P><I>8:20</I> <B>High School Heros</B>/R. Jones, M.H.A., St. Louis, MO</P>
<P><I>8:30</I> <B>STARS</B>/L. Nichols, Austin, TX</P>
<P><I>8:45</I> <B>TATU (Teens Against Tobacco Use)</B>/B. Smith, Portland, OR</P>
<P><I>9:00</I> <B>Students Teach Students</B>/E. Tokarz, Tampa, FL</P>
<P><I>9:15</I> <B>No Butts About It</B>/B. Berk, Manchester, NH</P>
<P><I>9:30</I> <B>Project Yuck</B>/K. Groenendyk, Brooklyn, NY</P></BLOCKQUOTE>
<P></P>
<HR SIZE="4" WIDTH="80%">
<CENTER>
<P><A HREF=97ala.html><IMG
SRC=images/activity_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97bus.html><IMG
SRC=images/business_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97cal.html><IMG
SRC=images/calendar_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97child.html><IMG
SRC=images/child_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=pg.html><IMG
SRC=images/courses_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=search.html><IMG
SRC=images/search_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=main.html><IMG
SRC=images/home_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97house.html><IMG
SRC=images/house_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=http://itsmtgs.com/ala-ats><IMG
SRC=images/regist_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=sessions.html><IMG
SRC=images/session_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=special.html><IMG
SRC=images/special_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97tours.html><IMG
SRC=images/tour_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97travel.html><IMG
SRC=images/travel_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
</P></CENTER>
<HR SIZE="4" WIDTH="80%">
<CENTER><FONT SIZE="+2"><B><I>American Thoracic Society</I></B></FONT><BR>
1740 Broadway<BR> New York, NY 10019<BR> VOICE:  212-315-8700<BR> Copyright &copy;
1996 American Lung Association.<BR> The American Thoracic  Society is the
medical section <BR>of the American Lung Association.<BR> 
</CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-46</DOCNO>
<DOCOLDNO>IA013-000139-B024-207</DOCOLDNO>
<DOCHDR>
http://www.thoracic.org:80/ic97/a16.html 206.138.195.144 19970217071130 text/html 4936
HTTP/1.0 200 OK
Date: Monday, 17-Feb-97 07:06:48 GMT
Server: NCSA/1.3
MIME-version: 1.0
Content-type: text/html
Last-modified: Friday, 24-Jan-97 16:14:56 GMT
Content-length: 4756
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//SQ//DTD HTML 2.0 HoTMetaL + extensions//EN">
<HTML>
<HEAD>
<TITLE>ALA/ATS JOINT SYMPOSIUM: a16</TITLE></HEAD>
<BODY BGCOLOR="#FFFFFF">
<CENTER><IMG ALIGN="LEFT" SRC="images/banner0.jpg"></CENTER>
<CENTER><BR>
<P>ALA/ATS JOINT SYMPOSIUM</P><BR>
<H2>A16: THE ROLES OF INFECTIONS AND IRRITANTS IN THE PATHOGENESIS OF ASTHMA</H2></CENTER>
<HR SIZE="5" NOSHADE="NOSHADE" WIDTH="100%">
<P></P>
<CENTER>
<TABLE BORDER="2">
<TR ALIGN="CENTER" VALIGN="MIDDLE">
<TD ALIGN="CENTER" VALIGN="MIDDLE"><B><SMALL><A HREF="ic97.html">BACK TO
MAIN MENU</A></SMALL></B></TD></TR></TABLE></CENTER>
<P></P>
<HR SIZE="10" WIDTH="85%">
<P></P>
<CENTER>
<P>SUNDAY , MAY 18</P></CENTER>
<BLOCKQUOTE>
<P><B>Assemblies on Environmental and Occupational Health/Allergy, Immunology
and Inflammation/Microbiology, Tuberculosis and Pulmonary
Infections/Pediatrics/Respiratory Cell and Molecular Biology/American Lung
Association</B></P>
<P><B>8:15 am-11:00 am</B></P></BLOCKQUOTE>
<HR SIZE="4" WIDTH="85%" ALIGN="CENTER" NOSHADE="NOSHADE">
<BLOCKQUOTE>
<P><I><B>Target Audience: </B></I>Adult pulmonary physicians, pediatric
pulmonary physicians, allergists, basic scientists, Lung Associations volunteers
and staff.</P>
<P><B>OBJECTIVES</B><BR>At the conclusion of this session, the participant
will be able to:</P>
<UL>
<LI>obtain new information on the roles of infections and environmental
irritants in the induction and/or exacerbation of asthma;</LI>
<LI>understand the epidemiologic evidence linking viral infections and
environmental irritants to asthma;</LI>
<LI>understand the responses of the airway epithelium to infectious agents and
chemical irritants.</LI></UL>
<P>This symposium will provide a forum for exchange of new information on the
roles of respiratory tract infections and environmental irritants in the
induction and/or exacerbation of asthma. This new information comes from both
epidemiologic and experimental research. The response of the airway epithelium
to injury from both microbes and chemical irritants is emerging as a potential
key to understanding the development of persistent asthma.</P>
<P><I><B>Chairing: </B></I>J.R. Balmes, M.D., San Francisco, CAM. Kraft,
M.D., Denver, CO</P>
<P><I>8:15</I> <B>Introduction</B>/H.A. Boushey, M.D., San Francisco, CA</P>
<P><I>8:30</I> <B>Role of Viral Infections in Childhood Asthma</B>/F.
Martinez, M.D., Tucson, AZ</P>
<P><I>8:50</I> <B>Role of Irritant Exposures in Asthma</B>/P.D. Blanc, M.D.,
San Francisco, CA</P>
<P><I>9:10</I> <B>Roles of Mycoplasma and Chlamydia Infections in the
Pathogenesis of Asthma</B>/G. Cassel, Ph.D., Birmingham, AL</P>
<P><I>9:30</I> <I>Break</I></P>
<P><I>9:40</I> <B>Effects of Air Pollutants in Asthma</B>/D.B. Peden, M.D.,
Chapel Hill, NC</P>
<P><I>10:00</I> <B>Persistent and Latent Viral Infections in the Pathology of
Asthma</B>/J.C. Hogg, M.D., Vancouver, BC, Canada</P>
<P><I>10:20</I> <B>Epithelial Injury and Repair in the Pathogenesis of Asthma</B>/D.
Sheppard, M.D., San Francisco, CA</P>
<P><I>10:40</I> <B>Infection and Irritant-Induced Asthma: From Epidemiology
to Pathogenetic Mechanisms</B>/S.T. Holgate, M.D., D.Sc., Southampton, England</P>
<P>Discussion after each presentation/5 minutes</P></BLOCKQUOTE>
<P></P>
<HR SIZE="4" WIDTH="80%">
<CENTER>
<P><A HREF=97ala.html><IMG
SRC=images/activity_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97bus.html><IMG
SRC=images/business_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97cal.html><IMG
SRC=images/calendar_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97child.html><IMG
SRC=images/child_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=pg.html><IMG
SRC=images/courses_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=search.html><IMG
SRC=images/search_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=main.html><IMG
SRC=images/home_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97house.html><IMG
SRC=images/house_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=http://itsmtgs.com/ala-ats><IMG
SRC=images/regist_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=sessions.html><IMG
SRC=images/session_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=special.html><IMG
SRC=images/special_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97tours.html><IMG
SRC=images/tour_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97travel.html><IMG
SRC=images/travel_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
</P></CENTER>
<HR SIZE="4" WIDTH="80%">
<CENTER><FONT SIZE="+2"><B><I>American Thoracic Society</I></B></FONT><BR>
1740 Broadway<BR> New York, NY 10019<BR> VOICE:  212-315-8700<BR> Copyright &copy;
1996 American Lung Association.<BR> The American Thoracic  Society is the
medical section <BR>of the American Lung Association.<BR> 
</CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-47</DOCNO>
<DOCOLDNO>IA013-000139-B024-238</DOCOLDNO>
<DOCHDR>
http://www.thoracic.org:80/ic97/a54.html 206.138.195.144 19970217071137 text/html 3465
HTTP/1.0 200 OK
Date: Monday, 17-Feb-97 07:06:56 GMT
Server: NCSA/1.3
MIME-version: 1.0
Content-type: text/html
Last-modified: Friday, 24-Jan-97 16:14:58 GMT
Content-length: 3285
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//SQ//DTD HTML 2.0 HoTMetaL + extensions//EN">
<HTML>
<HEAD>
<TITLE>ALA/ATS JOINT SYMPOSIUM: a54</TITLE></HEAD>
<BODY BGCOLOR="#FFFFFF">
<CENTER><IMG ALIGN="LEFT" SRC="images/banner0.jpg"></CENTER>
<CENTER><BR>
<P>ALA/ATS JOINT SYMPOSIUM</P>
<H2>A54: ASTHMA EDUCATION AND CULTURAL DIVERSITY: A POSTER SESSION</H2>
<P><BR></P></CENTER>
<HR SIZE="5" NOSHADE="NOSHADE" WIDTH="100%">
<P></P>
<CENTER>
<TABLE BORDER="2">
<TR ALIGN="CENTER" VALIGN="MIDDLE">
<TD ALIGN="CENTER" VALIGN="MIDDLE"><B><SMALL><A HREF="ic97.html">BACK TO
MAIN MENU</A></SMALL></B></TD></TR></TABLE></CENTER>
<P></P>
<HR SIZE="10" WIDTH="85%">
<P></P>
<CENTER>
<P>SUNDAY , MAY 18</P></CENTER>
<BLOCKQUOTE>
<P><B>American Lung Association/Assemblies on Allergy, Immunology and
Inflammation/Nursing</B></P>
<P><B>1:30 pm-4:15 pm</B></P></BLOCKQUOTE>
<HR SIZE="4" WIDTH="85%" ALIGN="CENTER" NOSHADE="NOSHADE">
<BLOCKQUOTE>
<P><I><B>Target Audience: </B></I>Lung Association volunteers and staff, and
pulmonologists, allergists and nurses.</P>
<P><B>OBJECTIVES</B><BR>At the conclusion of this session, the participant
will be able to:</P>
<UL>
<LI>identify ALA asthma education programs which reach culturally diverse
populations;</LI>
<LI>discuss program outcomes with fellow ALA colleagues;</LI>
<LI>identify programs being implemented that reach multiple age groups.</LI></UL>
<P>This poster session will explore asthma education programs which reach many
age groups among culturally diverse populations. Representatives from Lung
Associations will present the programs as posters and then lead a panel
discussion with audience participation.</P>
<P>This session is supported by an educational grant from<B>Rhone-Poulenc
Rorer Pharmaceuticals, Inc.</B></P></BLOCKQUOTE>
<P></P>
<HR SIZE="4" WIDTH="80%">
<CENTER>
<P><A HREF=97ala.html><IMG
SRC=images/activity_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97bus.html><IMG
SRC=images/business_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97cal.html><IMG
SRC=images/calendar_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97child.html><IMG
SRC=images/child_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=pg.html><IMG
SRC=images/courses_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=search.html><IMG
SRC=images/search_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=main.html><IMG
SRC=images/home_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97house.html><IMG
SRC=images/house_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=http://itsmtgs.com/ala-ats><IMG
SRC=images/regist_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=sessions.html><IMG
SRC=images/session_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=special.html><IMG
SRC=images/special_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97tours.html><IMG
SRC=images/tour_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97travel.html><IMG
SRC=images/travel_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
</P></CENTER>
<HR SIZE="4" WIDTH="80%">
<CENTER><FONT SIZE="+2"><B><I>American Thoracic Society</I></B></FONT><BR>
1740 Broadway<BR> New York, NY 10019<BR> VOICE:  212-315-8700<BR> Copyright &copy;
1996 American Lung Association.<BR> The American Thoracic  Society is the
medical section <BR>of the American Lung Association.<BR> 
</CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-48</DOCNO>
<DOCOLDNO>IA013-000139-B024-274</DOCOLDNO>
<DOCHDR>
http://www.thoracic.org:80/ic97/a55.html 206.138.195.144 19970217071146 text/html 4248
HTTP/1.0 200 OK
Date: Monday, 17-Feb-97 07:07:02 GMT
Server: NCSA/1.3
MIME-version: 1.0
Content-type: text/html
Last-modified: Friday, 24-Jan-97 16:14:58 GMT
Content-length: 4068
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//SQ//DTD HTML 2.0 HoTMetaL + extensions//EN">
<HTML>
<HEAD>
<TITLE>ALA/ATS JOINT SYMPOSIUM: a55</TITLE></HEAD>
<BODY BGCOLOR="#FFFFFF">
<CENTER><IMG ALIGN="LEFT" SRC="images/banner0.jpg"></CENTER>
<CENTER><BR>
<P>ALA/ATS JOINT SYMPOSIUM</P>
<H2>A55: FROM PUSSYCATS TO TIGERS: PUTTING TEETH INTO TOBACCO CONTROL ADVOCACY
PROGRAMS</H2>
<P><BR></P></CENTER>
<HR SIZE="5" NOSHADE="NOSHADE" WIDTH="100%">
<P></P>
<CENTER>
<TABLE BORDER="2">
<TR ALIGN="CENTER" VALIGN="MIDDLE">
<TD ALIGN="CENTER" VALIGN="MIDDLE"><B><SMALL><A HREF="ic97.html">BACK TO
MAIN MENU</A></SMALL></B></TD></TR></TABLE></CENTER>
<P></P>
<HR SIZE="10" WIDTH="85%">
<P></P>
<CENTER>
<P>SUNDAY , MAY 18</P></CENTER>
<BLOCKQUOTE>
<P><B>American Lung Association/Assembly on Environmental and Occupational
Health</B></P>
<P><B>1:30 pm-4:15 pm</B></P></BLOCKQUOTE>
<HR SIZE="4" WIDTH="85%" ALIGN="CENTER" NOSHADE="NOSHADE">
<BLOCKQUOTE>
<P><I><B>Target Audience: </B></I>Clinicians, behavioral scientists, nurses,
and Lung Association volunteers and staff.</P>
<P><B>OBJECTIVES</B><BR>At the conclusion of this session, the participant
will be able to:</P>
<UL>
<LI>identify the changes in the tobacco industry's tactics made over the past
decade and look ahead to the industry's future agenda;</LI>
<LI>describe how &quot;war correspondents&quot; (the media) perceive the &quot;armies&quot;
(advocates engaged in fighting the tobacco wars) and the &quot;battlegrounds&quot;
(issues) being fought over;</LI>
<LI>discuss the continuum of activities for tobacco control advocacy and the
pros and cons of being a &quot;pussycat&quot; vs. a &quot;tiger&quot; in
different situations;</LI>
<LI>develop a local action plan for tobacco control advocacy customized to
their Association's strengths and to the level of tobacco industry activity in
their area.</LI></UL>
<P>Today more than ever, tobacco control experts recognize that we cannot win
the war on tobacco unless we fight the tobacco industry itself. Tobacco
companies have spent millions of dollars to frame the issues, influence elected
officials, and present themselves as responsible corporate citizens.
Counteracting these efforts often requires Lung Associations to transform
themselves from &quot;pussycats&quot; into &quot;tigers.&quot; This session will
provide insight into how the battles are being fought and what Lung Associations
can do to win them.</P>
<P><I><B>Chairing: </B></I>D. Kelley, San Diego, CAF. Du Melle, Washington,
DC</P>
<P>Additional faculty to be announced</P></BLOCKQUOTE>
<P></P>
<HR SIZE="4" WIDTH="80%">
<CENTER>
<P><A HREF=97ala.html><IMG
SRC=images/activity_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97bus.html><IMG
SRC=images/business_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97cal.html><IMG
SRC=images/calendar_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97child.html><IMG
SRC=images/child_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=pg.html><IMG
SRC=images/courses_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=search.html><IMG
SRC=images/search_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=main.html><IMG
SRC=images/home_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97house.html><IMG
SRC=images/house_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=http://itsmtgs.com/ala-ats><IMG
SRC=images/regist_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=sessions.html><IMG
SRC=images/session_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=special.html><IMG
SRC=images/special_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97tours.html><IMG
SRC=images/tour_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97travel.html><IMG
SRC=images/travel_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
</P></CENTER>
<HR SIZE="4" WIDTH="80%">
<CENTER><FONT SIZE="+2"><B><I>American Thoracic Society</I></B></FONT><BR>
1740 Broadway<BR> New York, NY 10019<BR> VOICE:  212-315-8700<BR> Copyright &copy;
1996 American Lung Association.<BR> The American Thoracic  Society is the
medical section <BR>of the American Lung Association.<BR> 
</CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-49</DOCNO>
<DOCOLDNO>IA013-000139-B024-315</DOCOLDNO>
<DOCHDR>
http://www.thoracic.org:80/ic97/b6.html 206.138.195.144 19970217071156 text/html 4254
HTTP/1.0 200 OK
Date: Monday, 17-Feb-97 07:07:12 GMT
Server: NCSA/1.3
MIME-version: 1.0
Content-type: text/html
Last-modified: Friday, 24-Jan-97 16:15:22 GMT
Content-length: 4074
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//SQ//DTD HTML 2.0 HoTMetaL + extensions//EN">
<HTML>
<HEAD>
<TITLE>ALA/ATS JOINT SYMPOSIUM: b6</TITLE></HEAD>
<BODY BGCOLOR="#FFFFFF">
<CENTER><IMG ALIGN="LEFT" SRC="images/banner0.jpg"></CENTER>
<CENTER><BR>
<P>ALA/ATS JOINT SYMPOSIUM</P><BR>
<H2>B6: CHILDHOOD ASTHMA: INSIGHTS INTO PATHOGENESIS</H2></CENTER>
<HR SIZE="5" NOSHADE="NOSHADE" WIDTH="100%">
<P></P>
<CENTER>
<TABLE BORDER="2">
<TR ALIGN="CENTER" VALIGN="MIDDLE">
<TD ALIGN="CENTER" VALIGN="MIDDLE"><B><SMALL><A HREF="ic97.html">BACK TO
MAIN MENU</A></SMALL></B></TD></TR></TABLE></CENTER>
<P></P>
<HR SIZE="10" WIDTH="85%">
<P></P>
<CENTER>
<P>MONDAY , MAY 19</P></CENTER>
<BLOCKQUOTE>
<P><B>Assemblies on Allergy, Immunology and Inflammation/Pediatrics/American
Lung Association</B></P>
<P><B>8:15 am-9:45 am</B></P></BLOCKQUOTE>
<HR SIZE="4" WIDTH="85%" ALIGN="CENTER" NOSHADE="NOSHADE">
<BLOCKQUOTE>
<P><I><B>Target Audience: </B></I>Lung Association Volunteers and Staff,
pediatricians, basic scientists, clinical scientists, asthma health care
providers.</P>
<P><B>OBJECTIVES</B><BR>At the conclusion of this session, the participant
will be able to:</P>
<UL>
<LI>identify and discuss the risk factors in asthma and the importance of viral
infections;</LI>
<LI>define the characteristics and unique features of airway inflammation in
asthma;</LI>
<LI>describe the implications and special considerations of treatment in
childhood asthma.</LI></UL>
<P>Asthma is a common and important childhood disease. This symposium is
designed to address many of the key features of childhood asthma: risk factors,
viral respiratory infections and inflammatory features. This information will be
used to develop a rational basic therapeutic approach to asthma in childhood and
also to raise the possibility that asthma in children may be unique and a key
opportunity to influence national history of this disease.</P>
<P><I><B>Chairing: </B></I>W.W. Busse, M.D., Madison, WIS. Holgate, M.D.,
D.Sc., F.R.C.P., Southampton, England</P>
<P><I>8:15</I> <B>Risk Factors in the Development of Asthma</B>/F. Martinez,
M.D., Tucson, AZ</P>
<P><I>8:35</I> <B>The Role and Influence of Viral Respiratory Infections in
Childhood Asthma</B>/W.W. Busse, M.D., Madison, WI</P>
<P><I>8:55</I> <B>Characteristics of Airway Inflammation in Childhood Asthma</B>/S.
Holgate, M.D., D.Sc., F.R.C.P., Southampton, England</P>
<P><I>9:15</I> <B>Therapeutic Considerations in Childhood Asthma</B>/R.F.
Lemanske, Jr., M.D., Madison, WI</P>
<P><I>9:45</I> <B>Panel Discussion</B></P></BLOCKQUOTE>
<P></P>
<HR SIZE="4" WIDTH="80%">
<CENTER>
<P><A HREF=97ala.html><IMG
SRC=images/activity_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97bus.html><IMG
SRC=images/business_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97cal.html><IMG
SRC=images/calendar_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97child.html><IMG
SRC=images/child_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=pg.html><IMG
SRC=images/courses_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=search.html><IMG
SRC=images/search_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=main.html><IMG
SRC=images/home_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97house.html><IMG
SRC=images/house_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=http://itsmtgs.com/ala-ats><IMG
SRC=images/regist_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=sessions.html><IMG
SRC=images/session_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=special.html><IMG
SRC=images/special_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97tours.html><IMG
SRC=images/tour_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97travel.html><IMG
SRC=images/travel_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
</P></CENTER>
<HR SIZE="4" WIDTH="80%">
<CENTER><FONT SIZE="+2"><B><I>American Thoracic Society</I></B></FONT><BR>
1740 Broadway<BR> New York, NY 10019<BR> VOICE:  212-315-8700<BR> Copyright &copy;
1996 American Lung Association.<BR> The American Thoracic  Society is the
medical section <BR>of the American Lung Association.<BR> 
</CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-50</DOCNO>
<DOCOLDNO>IA013-000139-B024-345</DOCOLDNO>
<DOCHDR>
http://www.thoracic.org:80/ic97/b10.html 206.138.195.144 19970217071204 text/html 4139
HTTP/1.0 200 OK
Date: Monday, 17-Feb-97 07:07:22 GMT
Server: NCSA/1.3
MIME-version: 1.0
Content-type: text/html
Last-modified: Friday, 24-Jan-97 16:15:10 GMT
Content-length: 3959
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//SQ//DTD HTML 2.0 HoTMetaL + extensions//EN">
<HTML>
<HEAD>
<TITLE>ALA/ATS JOINT SYMPOSIUM: b10</TITLE></HEAD>
<BODY BGCOLOR="#FFFFFF">
<CENTER><IMG ALIGN="LEFT" SRC="images/banner0.jpg"></CENTER>
<CENTER><BR>
<P>ALA/ATS JOINT SYMPOSIUM</P><BR>
<H2>B10: ACHIEVING HEALTHY INDOOR AIR</H2></CENTER>
<HR SIZE="5" NOSHADE="NOSHADE" WIDTH="100%">
<P></P>
<CENTER>
<TABLE BORDER="2">
<TR ALIGN="CENTER" VALIGN="MIDDLE">
<TD ALIGN="CENTER" VALIGN="MIDDLE"><B><SMALL><A HREF="ic97.html">BACK TO
MAIN MENU</A></SMALL></B></TD></TR></TABLE></CENTER>
<P></P>
<HR SIZE="10" WIDTH="85%">
<P></P>
<CENTER>
<P>MONDAY , MAY 19</P></CENTER>
<BLOCKQUOTE>
<P><B>American Lung Association/Assembly on Environmental and Occupational
Health</B></P>
<P><B>10:00 am-11:30 am</B></P></BLOCKQUOTE>
<HR SIZE="4" WIDTH="85%" ALIGN="CENTER" NOSHADE="NOSHADE">
<BLOCKQUOTE>
<P><I><B>Target Audience: </B></I>Epidemiologists, pulmonary toxicologists,
clinicians, allergists, and Lung Association volunteers and staff.</P>
<P><B>OBJECTIVES</B><BR>At the conclusion of this session, the participant
will be able to:</P>
<UL>
<LI> identify key elements of &quot;healthy indoor air&quot;;</LI>
<LI>assess the documented impact of source control, ventilation, air cleaning
and treatment, and problem solving in buildings on indoor air quality;</LI>
<LI>identify individuals in the populations they serve who may be especially
susceptible to indoor air pollutants;</LI>
<LI>provide guidelines to susceptible individuals to help them reduce the risks
of adverse health effects related to indoor air pollution.</LI></UL>
<P>This session will inform ALA/ATS membership of the outcome of the joint
ALA/ATS workshop &quot;Achieving Healthy Indoor Air&quot; convened in November
1995. The workshop was attended by a multi-disciplinary group to assess the
current state-of-the-art in key areas including building design and operation,
ventilation, air cleaning, source control, and problem solving in buildings.</P>
<P>A practical, clinical approach will be emphasized. Participants will be
provided with a summary of recent scientific findings, as well as guidelines to
control indoor air quality to prevent and/or relieve patient symptoms.</P>
<P><I><B>Chairing: </B></I>J.M. Samet, M.D., M.S., Baltimore, MD</P>
<P><I><B>Speakers: </B></I>J.D. Spengler, Ph.D., Boston, MAR. Diamond, Ph.D.,
Berkeley, CAE.A. Nardell, M.D., Cambridge, MA</P></BLOCKQUOTE>
<P></P>
<HR SIZE="4" WIDTH="80%">
<CENTER>
<P><A HREF=97ala.html><IMG
SRC=images/activity_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97bus.html><IMG
SRC=images/business_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97cal.html><IMG
SRC=images/calendar_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97child.html><IMG
SRC=images/child_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=pg.html><IMG
SRC=images/courses_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=search.html><IMG
SRC=images/search_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=main.html><IMG
SRC=images/home_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97house.html><IMG
SRC=images/house_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=http://itsmtgs.com/ala-ats><IMG
SRC=images/regist_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=sessions.html><IMG
SRC=images/session_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=special.html><IMG
SRC=images/special_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97tours.html><IMG
SRC=images/tour_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97travel.html><IMG
SRC=images/travel_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
</P></CENTER>
<HR SIZE="4" WIDTH="80%">
<CENTER><FONT SIZE="+2"><B><I>American Thoracic Society</I></B></FONT><BR>
1740 Broadway<BR> New York, NY 10019<BR> VOICE:  212-315-8700<BR> Copyright &copy;
1996 American Lung Association.<BR> The American Thoracic  Society is the
medical section <BR>of the American Lung Association.<BR> 
</CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-51</DOCNO>
<DOCOLDNO>IA013-000139-B025-1</DOCOLDNO>
<DOCHDR>
http://www.thoracic.org:80/ic97/b11.html 206.138.195.144 19970217071212 text/html 4004
HTTP/1.0 200 OK
Date: Monday, 17-Feb-97 07:07:30 GMT
Server: NCSA/1.3
MIME-version: 1.0
Content-type: text/html
Last-modified: Friday, 24-Jan-97 16:15:10 GMT
Content-length: 3824
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//SQ//DTD HTML 2.0 HoTMetaL + extensions//EN">
<HTML>
<HEAD>
<TITLE>ALA/ATS JOINT SYMPOSIUM: b11</TITLE></HEAD>
<BODY BGCOLOR="#FFFFFF">
<CENTER><IMG ALIGN="LEFT" SRC="images/banner0.jpg"></CENTER>
<CENTER><BR>
<P>ALA/ATS JOINT SYMPOSIUM</P><BR>
<H2>B11: THE SHADOW MEETS MR. TOBACCO</H2></CENTER>
<HR SIZE="5" NOSHADE="NOSHADE" WIDTH="100%">
<P></P>
<CENTER>
<TABLE BORDER="2">
<TR ALIGN="CENTER" VALIGN="MIDDLE">
<TD ALIGN="CENTER" VALIGN="MIDDLE"><B><SMALL><A HREF="ic97.html">BACK TO
MAIN MENU</A></SMALL></B></TD></TR></TABLE></CENTER>
<P></P>
<HR SIZE="10" WIDTH="85%">
<P></P>
<CENTER>
<P>MONDAY , MAY 19</P></CENTER>
<BLOCKQUOTE>
<P><B>American Lung Association/Assembly on Pediatrics</B></P>
<P><B>10:00 am-11:30 am</B></P></BLOCKQUOTE>
<HR SIZE="4" WIDTH="85%" ALIGN="CENTER" NOSHADE="NOSHADE">
<BLOCKQUOTE>
<P><I><B>Target Audience: </B></I>Lung Association volunteers and staff,
pediatric pulmonologists, and behavioral scientist who have an interest in
tobacco and the internet.</P>
<P><B>OBJECTIVES</B><BR>At the conclusion of this session, the participant
will be able to:</P>
<UL>
<LI>explore the power of radio drama as an exciting and effective tobacco use
prevention strategy;</LI>
<LI>describe a wide array of tobacco resources currently on the Internet;</LI>
<LI>experience a unique &quot;virtual&quot; radio station where students can
share their ideas and concerns about tobacco use.</LI></UL>
<P>Every day 3000 children in the United States start smoking, adding up to
more than one million per year. One-third of these children will eventually die
from their addiction. Countering this public health problem requires unique and
real-world based activities that youth will want to participate in. The World
Wide Web and multimedia technologies are revolutionizing the way information and
education are delivered and received. This session will overview the tobacco web
sites on the Internet that students can get involved with. It will also
demonstrate how students can develop radio drama to teach other students about
tobacco's evils.</P>
<P><I><B>Chairing: </B></I>E. Miller, Augusta, ME</P>
<P><I>10:00</I> <B>Introduction</B>/E. Miller, Augusta, ME</P>
<P><I>10:05</I> <B>The Shadow Meets Mr. Tobacco</B>/J. McHugh, Nevada City,
CA</P></BLOCKQUOTE>
<P></P>
<HR SIZE="4" WIDTH="80%">
<CENTER>
<P><A HREF=97ala.html><IMG
SRC=images/activity_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97bus.html><IMG
SRC=images/business_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97cal.html><IMG
SRC=images/calendar_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97child.html><IMG
SRC=images/child_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=pg.html><IMG
SRC=images/courses_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=search.html><IMG
SRC=images/search_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=main.html><IMG
SRC=images/home_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97house.html><IMG
SRC=images/house_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=http://itsmtgs.com/ala-ats><IMG
SRC=images/regist_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=sessions.html><IMG
SRC=images/session_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=special.html><IMG
SRC=images/special_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97tours.html><IMG
SRC=images/tour_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97travel.html><IMG
SRC=images/travel_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
</P></CENTER>
<HR SIZE="4" WIDTH="80%">
<CENTER><FONT SIZE="+2"><B><I>American Thoracic Society</I></B></FONT><BR>
1740 Broadway<BR> New York, NY 10019<BR> VOICE:  212-315-8700<BR> Copyright &copy;
1996 American Lung Association.<BR> The American Thoracic  Society is the
medical section <BR>of the American Lung Association.<BR> 
</CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-52</DOCNO>
<DOCOLDNO>IA013-000139-B025-31</DOCOLDNO>
<DOCHDR>
http://www.thoracic.org:80/ic97/c5.html 206.138.195.144 19970217071238 text/html 3661
HTTP/1.0 200 OK
Date: Monday, 17-Feb-97 07:07:38 GMT
Server: NCSA/1.3
MIME-version: 1.0
Content-type: text/html
Last-modified: Friday, 24-Jan-97 16:15:30 GMT
Content-length: 3481
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//SQ//DTD HTML 2.0 HoTMetaL + extensions//EN">
<HTML>
<HEAD>
<TITLE>ALA/ATS JOINT SYMPOSIUM: c5</TITLE></HEAD>
<BODY BGCOLOR="#FFFFFF">
<CENTER><IMG ALIGN="LEFT" SRC="images/banner0.jpg"></CENTER>
<CENTER><BR>
<P>ALA/ATS JOINT SYMPOSIUM</P><BR>
<H2>C5: REPORT FROM THE ALA FUNDED RESEARCH CENTERS</H2></CENTER>
<HR SIZE="5" NOSHADE="NOSHADE" WIDTH="100%">
<P></P>
<CENTER>
<TABLE BORDER="2">
<TR ALIGN="CENTER" VALIGN="MIDDLE">
<TD ALIGN="CENTER" VALIGN="MIDDLE"><B><SMALL><A HREF="ic97.html">BACK TO
MAIN MENU</A></SMALL></B></TD></TR></TABLE></CENTER>
<P></P>
<HR SIZE="10" WIDTH="85%">
<P></P>
<BLOCKQUOTE>
<CENTER>
<P>TUESDAY , MAY 20</P>
<P><B>8:15 am-9:45 am</B></P></CENTER></BLOCKQUOTE>
<HR SIZE="4" WIDTH="85%" ALIGN="CENTER" NOSHADE="NOSHADE">
<BLOCKQUOTE>
<P><I><B>Target Audience: </B></I>Lung Association volunteers and staff,
pulmonologists, nurses and scientists.</P>
<P><B>OBJECTIVES</B><BR>At the conclusion of this session, the participant
will be able to:</P>
<UL>
<LI>articulate the goals of each of the Asthma Research Centers;</LI>
<LI>describe the focus of each of the research studies</LI></UL>
<P>The American Lung Association recently awarded a $2.5 million research grant
to both the National Jewish Center for Immunology and Respiratory Medicine in
Denver, CO, and the University of Utah's School of Medicine in Salt Lake City,
UT to find a cure for asthma. These National Asthma Research Centers were chosen
through an extensive peer review process by the ALA/ATS Research Coordinating
Committee. </P>
<P>The leaders of the two research teams will report on the focus of their
studies. The Denver Center is exploring the role of infection in the origin of
chronic asthma. The Salt Lake City Center will study several interrelated
aspects of the inflammatory process that underlies asthma.</P>
<P><I><B>Speakers:</B></I> R.J. Martin, M.D., Denver, COT.M. McIntyre, M.D.,
Salt Lake City, UT</P></BLOCKQUOTE>
<P></P>
<HR SIZE="4" WIDTH="80%">
<CENTER>
<P><A HREF=97ala.html><IMG
SRC=images/activity_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97bus.html><IMG
SRC=images/business_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97cal.html><IMG
SRC=images/calendar_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97child.html><IMG
SRC=images/child_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=pg.html><IMG
SRC=images/courses_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=search.html><IMG
SRC=images/search_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=main.html><IMG
SRC=images/home_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97house.html><IMG
SRC=images/house_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=http://itsmtgs.com/ala-ats><IMG
SRC=images/regist_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=sessions.html><IMG
SRC=images/session_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=special.html><IMG
SRC=images/special_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97tours.html><IMG
SRC=images/tour_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97travel.html><IMG
SRC=images/travel_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
</P></CENTER>
<HR SIZE="4" WIDTH="80%">
<CENTER><FONT SIZE="+2"><B><I>American Thoracic Society</I></B></FONT><BR>
1740 Broadway<BR> New York, NY 10019<BR> VOICE:  212-315-8700<BR> Copyright &copy;
1996 American Lung Association.<BR> The American Thoracic  Society is the
medical section <BR>of the American Lung Association.<BR> 
</CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-53</DOCNO>
<DOCOLDNO>IA013-000139-B025-76</DOCOLDNO>
<DOCHDR>
http://www.thoracic.org:80/ic97/c11.html 206.138.195.144 19970217071253 text/html 4024
HTTP/1.0 200 OK
Date: Monday, 17-Feb-97 07:08:09 GMT
Server: NCSA/1.3
MIME-version: 1.0
Content-type: text/html
Last-modified: Friday, 24-Jan-97 16:15:26 GMT
Content-length: 3844
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//SQ//DTD HTML 2.0 HoTMetaL + extensions//EN">
<HTML>
<HEAD>
<TITLE>ALA/ATS JOINT SYMPOSIUM: c11</TITLE></HEAD>
<BODY BGCOLOR="#FFFFFF">
<CENTER><IMG ALIGN="LEFT" SRC="images/banner0.jpg"></CENTER>
<CENTER><BR>
<P>ALA/ATS JOINT SYMPOSIUM</P><BR>
<H2>C11: CLEAN AIR ACT UPDATE</H2></CENTER>
<HR SIZE="5" NOSHADE="NOSHADE" WIDTH="100%">
<P></P>
<CENTER>
<TABLE BORDER="2">
<TR ALIGN="CENTER" VALIGN="MIDDLE">
<TD ALIGN="CENTER" VALIGN="MIDDLE"><B><SMALL><A HREF="ic97.html">BACK TO
MAIN MENU</A></SMALL></B></TD></TR></TABLE></CENTER>
<P></P>
<HR SIZE="10" WIDTH="85%">
<P></P>
<BLOCKQUOTE>
<CENTER>
<P>TUESDAY , MAY 20</P>
<P><B>American Lung Association/<BR>Assembly on Environmental and
Occupational Health</B></P>
<P><B>10:00 am-11:30 am</B></P></CENTER></BLOCKQUOTE>
<HR SIZE="4" WIDTH="85%" ALIGN="CENTER" NOSHADE="NOSHADE">
<BLOCKQUOTE>
<P><I><B>Target Audience: </B></I>Lung Association staff, volunteers,
clinicians, and epidemiologists.</P>
<P><B>OBJECTIVES</B><BR>At the conclusion of this session, the participant
will be able to:</P>
<UL>
<LI>identify and analyze the public health policy implications of recent
proposals to amend the Clean Air Act;</LI>
<LI>explain how forthcoming national air quality standards for ozone and
particulate matter will affect national and local air quality policy and Lung
Association clean air programs;</LI>
<LI>plan and execute local clean air programs that reflect new national
legislative and regulatory policies.</LI></UL>
<P>Anticipating that efforts to amend the Clean Air Act will be well underway
by May 1997, and that the Environmental Protection Agency will be nearing
completion of its efforts to revise national air quality standards for ozone and
particulate matter, this session will describe and critique these major new
clean air policy initiatives. The implications of these forthcoming clean air
policy changes for public health and Lung Association clean air programs will be
discussed. Lung Association public outreach efforts that relate the national
policy changes to local initiatives will be presented and discussed as well.</P>
<P><I><B>Chairing: </B></I>F. Du Melle, Washington, DC</P>
<P><I><B>Speakers:</B></I>  P. Billings, Washington, DC R. White, M.S.T.,
Washington, DC M. Cofer-Wildsmith, St. Louis, MO</P></BLOCKQUOTE>
<P></P>
<HR SIZE="4" WIDTH="80%">
<CENTER>
<P><A HREF=97ala.html><IMG
SRC=images/activity_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97bus.html><IMG
SRC=images/business_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97cal.html><IMG
SRC=images/calendar_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97child.html><IMG
SRC=images/child_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=pg.html><IMG
SRC=images/courses_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=search.html><IMG
SRC=images/search_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=main.html><IMG
SRC=images/home_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97house.html><IMG
SRC=images/house_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=http://itsmtgs.com/ala-ats><IMG
SRC=images/regist_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=sessions.html><IMG
SRC=images/session_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=special.html><IMG
SRC=images/special_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97tours.html><IMG
SRC=images/tour_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97travel.html><IMG
SRC=images/travel_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
</P></CENTER>
<HR SIZE="4" WIDTH="80%">
<CENTER><FONT SIZE="+2"><B><I>American Thoracic Society</I></B></FONT><BR>
1740 Broadway<BR> New York, NY 10019<BR> VOICE:  212-315-8700<BR> Copyright &copy;
1996 American Lung Association.<BR> The American Thoracic  Society is the
medical section <BR>of the American Lung Association.<BR> 
</CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-54</DOCNO>
<DOCOLDNO>IA013-000139-B025-109</DOCOLDNO>
<DOCHDR>
http://www.thoracic.org:80/ic97/a8.html 206.138.195.144 19970217071301 text/html 3311
HTTP/1.0 200 OK
Date: Monday, 17-Feb-97 07:08:18 GMT
Server: NCSA/1.3
MIME-version: 1.0
Content-type: text/html
Last-modified: Friday, 24-Jan-97 16:15:02 GMT
Content-length: 3131
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//SQ//DTD HTML 2.0 HoTMetaL + extensions//EN">
<HTML>
<HEAD>
<TITLE>ALA SYMPOSIUM: a8</TITLE></HEAD>
<BODY BGCOLOR="#FFFFFF">
<CENTER><IMG ALIGN="LEFT" SRC="images/banner0.jpg"></CENTER>
<CENTER><BR>
<P>ALA SYMPOSIUM</P><BR>
<H2>A8: INTEGRATED COMMUNICATIONS FOR GREATER VISIBILITY AND RESOURCE
DEVELOPMENT </H2></CENTER>
<HR SIZE="5" NOSHADE="NOSHADE" WIDTH="100%">
<P></P>
<CENTER>
<TABLE BORDER="2">
<TR ALIGN="CENTER" VALIGN="MIDDLE">
<TD ALIGN="CENTER" VALIGN="MIDDLE"><B><SMALL><A HREF="ic97.html">BACK TO
MAIN MENU</A></SMALL></B></TD></TR></TABLE></CENTER>
<P></P>
<HR SIZE="10" WIDTH="85%">
<P></P>
<CENTER>
<P>SUNDAY , MAY 18</P></CENTER>
<BLOCKQUOTE>
<P><B>8:15 am-11:30 am</B></P></BLOCKQUOTE>
<HR SIZE="4" WIDTH="85%" ALIGN="CENTER" NOSHADE="NOSHADE">
<BLOCKQUOTE>
<P><I><B>Target Audience: </B></I>American Lung Association volunteers and
staff.</P>
<P><B>OBJECTIVES</B><BR>At the conclusion of this session, the participant
will be able to:</P>
<UL>
<LI>analyze local staff responsiblities and understand why and how they
interrelate;</LI>
<LI>identify avenues for streamlining staff activities for more effective,
integrated planning;</LI>
<LI> identify opportunities for increased visibility and resource development
through heightened integrated communications.</LI></UL>
<P>Through presentations and small group case study discussions, participants
will examine the &quot;why&quot; and &quot;how&quot; of integrated planning
while they learn to recognize the importance of communications as the core of
that planning.</P>
<P>Faculty to be announced</P></BLOCKQUOTE>
<P></P>
<HR SIZE="4" WIDTH="80%">
<CENTER>
<P><A HREF=97ala.html><IMG
SRC=images/activity_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97bus.html><IMG
SRC=images/business_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97cal.html><IMG
SRC=images/calendar_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97child.html><IMG
SRC=images/child_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=pg.html><IMG
SRC=images/courses_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=search.html><IMG
SRC=images/search_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=main.html><IMG
SRC=images/home_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97house.html><IMG
SRC=images/house_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=http://itsmtgs.com/ala-ats><IMG
SRC=images/regist_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=sessions.html><IMG
SRC=images/session_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=special.html><IMG
SRC=images/special_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97tours.html><IMG
SRC=images/tour_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97travel.html><IMG
SRC=images/travel_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
</P></CENTER>
<HR SIZE="4" WIDTH="80%">
<CENTER><FONT SIZE="+2"><B><I>American Thoracic Society</I></B></FONT><BR>
1740 Broadway<BR> New York, NY 10019<BR> VOICE:  212-315-8700<BR> Copyright &copy;
1996 American Lung Association.<BR> The American Thoracic  Society is the
medical section <BR>of the American Lung Association.<BR> 
</CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-55</DOCNO>
<DOCOLDNO>IA013-000139-B025-139</DOCOLDNO>
<DOCHDR>
http://www.thoracic.org:80/ic97/a9.html 206.138.195.144 19970217071309 text/html 3621
HTTP/1.0 200 OK
Date: Monday, 17-Feb-97 07:08:27 GMT
Server: NCSA/1.3
MIME-version: 1.0
Content-type: text/html
Last-modified: Friday, 24-Jan-97 16:15:03 GMT
Content-length: 3441
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//SQ//DTD HTML 2.0 HoTMetaL + extensions//EN">
<HTML>
<HEAD>
<TITLE>ALA SYMPOSIUM: a9</TITLE></HEAD>
<BODY BGCOLOR="#FFFFFF">
<CENTER><IMG ALIGN="LEFT" SRC="images/banner0.jpg"></CENTER>
<CENTER><BR>
<P>ALA SYMPOSIUM</P><BR>
<H2>A9: COMPREHENSIVE FUND RAISING PROGRAM </H2></CENTER>
<HR SIZE="5" NOSHADE="NOSHADE" WIDTH="100%">
<P></P>
<CENTER>
<TABLE BORDER="2">
<TR ALIGN="CENTER" VALIGN="MIDDLE">
<TD ALIGN="CENTER" VALIGN="MIDDLE"><B><SMALL><A HREF="ic97.html">BACK TO
MAIN MENU</A></SMALL></B></TD></TR></TABLE></CENTER>
<P></P>
<HR SIZE="10" WIDTH="85%">
<P></P>
<CENTER>
<P>SUNDAY , MAY 18</P></CENTER>
<BLOCKQUOTE>
<P><B>8:15 am-11:30 am</B></P></BLOCKQUOTE>
<HR SIZE="4" WIDTH="85%" ALIGN="CENTER" NOSHADE="NOSHADE">
<BLOCKQUOTE>
<P><I><B>Target Audience: </B></I>American Lung Association Executive
directors, development staff and volunteers.</P>
<P><B>OBJECTIVES</B><BR>At the conclusion of this session, the participant
will be able to:</P>
<UL>
<LI>identify the components of a diversified income base;</LI>
<LI>describe the relationship between these components;</LI>
<LI>assess their own association's potential for moving toward a diversified
income base;</LI>
<LI>prepare a Comprehensive Fund Raising Program Plan.</LI></UL>
<P>This session will explore the strategies necessary to build and maintain a
strong, diversified income base, including elements of annual and major giving.
It represents a process of assessment, evaluation, long-range planning and goal
setting, preparation of the case statement, training, implementation and ongoing
maintenance, review, reassessment, and revision. This process also ties the
diversified income base to all elements of the organization's operation
including program, volunteer development, and communications.</P>
<P><I><B>Chairing: </B></I>S. Borischak, CFRE, New York, NY</P>
<P>Additional faculty to be announced</P></BLOCKQUOTE>
<P></P>
<HR SIZE="4" WIDTH="80%">
<CENTER>
<P><A HREF=97ala.html><IMG
SRC=images/activity_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97bus.html><IMG
SRC=images/business_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97cal.html><IMG
SRC=images/calendar_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97child.html><IMG
SRC=images/child_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=pg.html><IMG
SRC=images/courses_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=search.html><IMG
SRC=images/search_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=main.html><IMG
SRC=images/home_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97house.html><IMG
SRC=images/house_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=http://itsmtgs.com/ala-ats><IMG
SRC=images/regist_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=sessions.html><IMG
SRC=images/session_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=special.html><IMG
SRC=images/special_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97tours.html><IMG
SRC=images/tour_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97travel.html><IMG
SRC=images/travel_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
</P></CENTER>
<HR SIZE="4" WIDTH="80%">
<CENTER><FONT SIZE="+2"><B><I>American Thoracic Society</I></B></FONT><BR>
1740 Broadway<BR> New York, NY 10019<BR> VOICE:  212-315-8700<BR> Copyright &copy;
1996 American Lung Association.<BR> The American Thoracic  Society is the
medical section <BR>of the American Lung Association.<BR> 
</CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-56</DOCNO>
<DOCOLDNO>IA013-000139-B025-172</DOCOLDNO>
<DOCHDR>
http://www.thoracic.org:80/ic97/a10.html 206.138.195.144 19970217071319 text/html 3928
HTTP/1.0 200 OK
Date: Monday, 17-Feb-97 07:08:34 GMT
Server: NCSA/1.3
MIME-version: 1.0
Content-type: text/html
Last-modified: Friday, 24-Jan-97 16:14:53 GMT
Content-length: 3748
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//SQ//DTD HTML 2.0 HoTMetaL + extensions//EN">
<HTML>
<HEAD>
<TITLE>ALA SYMPOSIUM: a10</TITLE></HEAD>
<BODY BGCOLOR="#FFFFFF">
<CENTER><IMG ALIGN="LEFT" SRC="images/banner0.jpg"></CENTER>
<CENTER><BR>
<P>ALA SYMPOSIUM</P><BR>
<H2>A10: THUMBS UP! THUMBS DOWN! TOBACCO USE IN THE MOVIES, TELEVISION, AND
MUSIC VIDEOS </H2></CENTER>
<HR SIZE="5" NOSHADE="NOSHADE" WIDTH="100%">
<P></P>
<CENTER>
<TABLE BORDER="2">
<TR ALIGN="CENTER" VALIGN="MIDDLE">
<TD ALIGN="CENTER" VALIGN="MIDDLE"><B><SMALL><A HREF="ic97.html">BACK TO
MAIN MENU</A></SMALL></B></TD></TR></TABLE></CENTER>
<P></P>
<HR SIZE="10" WIDTH="85%">
<P></P>
<CENTER>
<P>SUNDAY , MAY 18</P></CENTER>
<BLOCKQUOTE>
<P><B>10:00 am-11:30 am</B></P></BLOCKQUOTE>
<HR SIZE="4" WIDTH="85%" ALIGN="CENTER" NOSHADE="NOSHADE">
<BLOCKQUOTE>
<P><I><B>Target Audience: </B></I>Lung Association volunteers and staff.</P>
<P><B>OBJECTIVES</B><BR>At the conclusion of this session, the participant
will be able to:</P>
<UL>
<LI>describe the components of the Thumbs Up! Thumbs Down! curriculum designed
to raise awareness about tobacco use in movies, TV and music videos;</LI>
<LI>teach teens how to conduct an analysis of tobacco use in the movies, TV,
and music videos;</LI>
<LI>publicize effectively the results of the teen evaluation of tobacco use in
the media.</LI></UL>
<P>Cigarette advertising was banned from television in 1970. Federal law
prohibits any cigarette advertising not bearing a required health warning. Yet a
recent study in the American Journal of Public Health showed that current movie
heroes are three times more likely to smoke than the real-life role models of
American society. Tobacco advertising in the movies, TV and music videos is
emerging as an important part of the tobacco industry's marketing mix. The ALA
must vigilantly point out how the tobacco industry may be circumventing FDA
advertising regulations by promoting smoking in movies, TV, and music videos;
and thereby provide one more strategy to prevent teen tobacco use.</P>
<P><I><B>Chairing: </B></I>J. Howard, Sacramento, CA</P>
<P><B>Thumbs Up! Thumbs Down!</B>/T. Gibson, B.A./M. Howard, Sacramento, CA</P>
<P>Additional faculty to be announced</P></BLOCKQUOTE>
<P></P>
<HR SIZE="4" WIDTH="80%">
<CENTER>
<P><A HREF=97ala.html><IMG
SRC=images/activity_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97bus.html><IMG
SRC=images/business_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97cal.html><IMG
SRC=images/calendar_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97child.html><IMG
SRC=images/child_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=pg.html><IMG
SRC=images/courses_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=search.html><IMG
SRC=images/search_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=main.html><IMG
SRC=images/home_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97house.html><IMG
SRC=images/house_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=http://itsmtgs.com/ala-ats><IMG
SRC=images/regist_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=sessions.html><IMG
SRC=images/session_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=special.html><IMG
SRC=images/special_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97tours.html><IMG
SRC=images/tour_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97travel.html><IMG
SRC=images/travel_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
</P></CENTER>
<HR SIZE="4" WIDTH="80%">
<CENTER><FONT SIZE="+2"><B><I>American Thoracic Society</I></B></FONT><BR>
1740 Broadway<BR> New York, NY 10019<BR> VOICE:  212-315-8700<BR> Copyright &copy;
1996 American Lung Association.<BR> The American Thoracic  Society is the
medical section <BR>of the American Lung Association.<BR> 
</CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-57</DOCNO>
<DOCOLDNO>IA013-000139-B025-197</DOCOLDNO>
<DOCHDR>
http://www.thoracic.org:80/ic97/a11.html 206.138.195.144 19970217071329 text/html 3868
HTTP/1.0 200 OK
Date: Monday, 17-Feb-97 07:08:44 GMT
Server: NCSA/1.3
MIME-version: 1.0
Content-type: text/html
Last-modified: Friday, 24-Jan-97 16:14:53 GMT
Content-length: 3688
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//SQ//DTD HTML 2.0 HoTMetaL + extensions//EN">
<HTML>
<HEAD>
<TITLE>ALA SYMPOSIUM: a11</TITLE></HEAD>
<BODY BGCOLOR="#FFFFFF">
<CENTER><IMG ALIGN="LEFT" SRC="images/banner0.jpg"></CENTER>
<CENTER><BR>
<P>ALA SYMPOSIUM</P><BR>
<H2>A11: POLICY MARKETING: ADDING REVENUE GENERATION TO YOUR ADVOCACY PROGRAM
</H2></CENTER>
<HR SIZE="5" NOSHADE="NOSHADE" WIDTH="100%">
<P></P>
<CENTER>
<TABLE BORDER="2">
<TR ALIGN="CENTER" VALIGN="MIDDLE">
<TD ALIGN="CENTER" VALIGN="MIDDLE"><B><SMALL><A HREF="ic97.html">BACK TO
MAIN MENU</A></SMALL></B></TD></TR></TABLE></CENTER>
<P></P>
<HR SIZE="10" WIDTH="85%">
<P></P>
<CENTER>
<P>SUNDAY , MAY 18</P></CENTER>
<BLOCKQUOTE>
<P><B>10:00 am-11:30 am</B></P></BLOCKQUOTE>
<HR SIZE="4" WIDTH="85%" ALIGN="CENTER" NOSHADE="NOSHADE">
<BLOCKQUOTE>
<P><I><B>Target Audience: </B></I>Lung Association executives, government
relations and fund raising staff, advocacy and fund raising volunteers.</P>
<P><B>OBJECTIVES</B><BR>At the conclusion of this session, the participant
will be able to:</P>
<UL>
<LI>describe policy marketing principles;</LI>
<LI>contrast policy marketing outcomes with cause related marketing outcomes;</LI>
<LI>identify local issues appropriate for policy marketing relationships;</LI>
<LI>identify characteristics of successful policy partnerships.</LI></UL>
<P>This session will explain the concept of &quot;policy marketing&quot; and
how national and local policy positions can provide revenue generating
opportunities for Lung Associations. Through presentation and case study, this
session will demonstrate ways in which ALA advocacy activities and public
relations on issues of importance to our mission can form the basis for
partnerships with companies and organizations that share our values -- and how
valuable associating our credibility with the issues can be to those partners.
This will help to leverage ALA's established policy positions, not compromise
them. This session will help participants develop skills in this new way of
marketing their association.</P>
<P><I><B>Chairing: </B></I>F. Du Melle, Washington, DC</P>
<P>Additional faculty to be announced</P></BLOCKQUOTE>
<P></P>
<HR SIZE="4" WIDTH="80%">
<CENTER>
<P><A HREF=97ala.html><IMG
SRC=images/activity_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97bus.html><IMG
SRC=images/business_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97cal.html><IMG
SRC=images/calendar_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97child.html><IMG
SRC=images/child_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=pg.html><IMG
SRC=images/courses_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=search.html><IMG
SRC=images/search_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=main.html><IMG
SRC=images/home_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97house.html><IMG
SRC=images/house_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=http://itsmtgs.com/ala-ats><IMG
SRC=images/regist_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=sessions.html><IMG
SRC=images/session_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=special.html><IMG
SRC=images/special_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97tours.html><IMG
SRC=images/tour_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97travel.html><IMG
SRC=images/travel_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
</P></CENTER>
<HR SIZE="4" WIDTH="80%">
<CENTER><FONT SIZE="+2"><B><I>American Thoracic Society</I></B></FONT><BR>
1740 Broadway<BR> New York, NY 10019<BR> VOICE:  212-315-8700<BR> Copyright &copy;
1996 American Lung Association.<BR> The American Thoracic  Society is the
medical section <BR>of the American Lung Association.<BR> 
</CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-58</DOCNO>
<DOCOLDNO>IA013-000139-B025-226</DOCOLDNO>
<DOCHDR>
http://www.thoracic.org:80/ic97/a57.html 206.138.195.144 19970217071338 text/html 3694
HTTP/1.0 200 OK
Date: Monday, 17-Feb-97 07:08:55 GMT
Server: NCSA/1.3
MIME-version: 1.0
Content-type: text/html
Last-modified: Friday, 24-Jan-97 16:14:59 GMT
Content-length: 3514
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//SQ//DTD HTML 2.0 HoTMetaL + extensions//EN">
<HTML>
<HEAD>
<TITLE>ALA SYMPOSIUM: a57</TITLE></HEAD>
<BODY BGCOLOR="#FFFFFF">
<CENTER><IMG ALIGN="LEFT" SRC="images/banner0.jpg"></CENTER>
<CENTER><BR>
<P>ALA SYMPOSIUM</P>
<H2>A57: MAJOR/PLANNED BOARD GIVING: ASTHMA RESEARCH INITIATIVE AS AN APPROACH
</H2>
<P><BR></P></CENTER>
<HR SIZE="5" NOSHADE="NOSHADE" WIDTH="100%">
<P></P>
<CENTER>
<TABLE BORDER="2">
<TR ALIGN="CENTER" VALIGN="MIDDLE">
<TD ALIGN="CENTER" VALIGN="MIDDLE"><B><SMALL><A HREF="ic97.html">BACK TO
MAIN MENU</A></SMALL></B></TD></TR></TABLE></CENTER>
<P></P>
<HR SIZE="10" WIDTH="85%">
<P></P>
<CENTER>
<P>SUNDAY , MAY 18</P></CENTER>
<BLOCKQUOTE>
<P><B>1:30 pm-4:15 pm</B></P></BLOCKQUOTE>
<HR SIZE="4" WIDTH="85%" ALIGN="CENTER" NOSHADE="NOSHADE">
<BLOCKQUOTE>
<P><I><B>Target Audience: </B></I>Lung Association executives, Board
Presidents, Planned Giving Committee members, Directors of Development.</P>
<P><B>OBJECTIVES</B><BR>At the conclusion of this session, the participant
will be able to:</P>
<UL>
<LI>understand what really motivates donors;</LI>
<LI>recognize trends and developments in the major gifts field;</LI>
<LI>dispel some planned giving myths;</LI>
<LI>address the concerns and challenges facing major gifts fundraisers.</LI></UL>
<P>Through discussion and small group exercises, participants will define major
gifts for their Association, learn how an Association positions itself, and how
to effectively convey marketing ideas to prospects. The value of involving
Presidents, Boards, and volunteers in solicitations and cultivations will be
addressed. Participants will also have some fun with a hypothetical planned
giving donor who wishes to support a Lung Association - if only a way can be
found!</P>
<P><I><B>Chairing: </B></I>S. Donato, Esq., New York, NY</P>
<P><I><B>Speakers: </B></I>R. Fines Fournier, Chicago, ILA. Makar, Boston,
MAJ. Young, Houston, TX</P>
<P>Additional faculty to be announced</P></BLOCKQUOTE>
<P></P>
<HR SIZE="4" WIDTH="80%">
<CENTER>
<P><A HREF=97ala.html><IMG
SRC=images/activity_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97bus.html><IMG
SRC=images/business_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97cal.html><IMG
SRC=images/calendar_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97child.html><IMG
SRC=images/child_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=pg.html><IMG
SRC=images/courses_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=search.html><IMG
SRC=images/search_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=main.html><IMG
SRC=images/home_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97house.html><IMG
SRC=images/house_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=http://itsmtgs.com/ala-ats><IMG
SRC=images/regist_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=sessions.html><IMG
SRC=images/session_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=special.html><IMG
SRC=images/special_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97tours.html><IMG
SRC=images/tour_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97travel.html><IMG
SRC=images/travel_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
</P></CENTER>
<HR SIZE="4" WIDTH="80%">
<CENTER><FONT SIZE="+2"><B><I>American Thoracic Society</I></B></FONT><BR>
1740 Broadway<BR> New York, NY 10019<BR> VOICE:  212-315-8700<BR> Copyright &copy;
1996 American Lung Association.<BR> The American Thoracic  Society is the
medical section <BR>of the American Lung Association.<BR> 
</CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-59</DOCNO>
<DOCOLDNO>IA013-000139-B025-257</DOCOLDNO>
<DOCHDR>
http://www.thoracic.org:80/ic97/a58.html 206.138.195.144 19970217071349 text/html 3549
HTTP/1.0 200 OK
Date: Monday, 17-Feb-97 07:09:04 GMT
Server: NCSA/1.3
MIME-version: 1.0
Content-type: text/html
Last-modified: Friday, 24-Jan-97 16:14:59 GMT
Content-length: 3369
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//SQ//DTD HTML 2.0 HoTMetaL + extensions//EN">
<HTML>
<HEAD>
<TITLE>ALA SYMPOSIUM: a58</TITLE></HEAD>
<BODY BGCOLOR="#FFFFFF">
<CENTER><IMG ALIGN="LEFT" SRC="images/banner0.jpg"></CENTER>
<CENTER><BR>
<P>ALA SYMPOSIUM</P>
<H2>A58: COMMUNITY AND MEDIA PARTNERSHIPS </H2>
<P><BR></P></CENTER>
<HR SIZE="5" NOSHADE="NOSHADE" WIDTH="100%">
<P></P>
<CENTER>
<TABLE BORDER="2">
<TR ALIGN="CENTER" VALIGN="MIDDLE">
<TD ALIGN="CENTER" VALIGN="MIDDLE"><B><SMALL><A HREF="ic97.html">BACK TO
MAIN MENU</A></SMALL></B></TD></TR></TABLE></CENTER>
<P></P>
<HR SIZE="10" WIDTH="85%">
<P></P>
<CENTER>
<P>SUNDAY , MAY 18</P></CENTER>
<BLOCKQUOTE>
<P><B>1:30 pm-4:15 pm</B></P></BLOCKQUOTE>
<HR SIZE="4" WIDTH="85%" ALIGN="CENTER" NOSHADE="NOSHADE">
<BLOCKQUOTE>
<P><I><B>Target Audience: </B></I>Lung Association volunteers and staff.</P>
<P><B>OBJECTIVES</B><BR>At the conclusion of this session, the participant
will be able to:</P>
<UL>
<LI>identify the agenda of potential partners to assess benefits and conflicts;</LI>
<LI>manage the &quot;balancing act&quot; of partnerships while keeping ALA true
to its message and mission;</LI>
<LI>identify opportunities for communications staff to act as resources for
optimum partnership development.</LI></UL>
<P>Community and media partnerships can either enhance or diminish the American
Lung Association's reputation and must be developed and managed effectively.</P>
<P>Through panel presentation and case study discussions, this session will
explore &quot;beyond the basics&quot; of community, media and corporate
partnerships, while examining the &quot;how, when and why&quot;, the issues
involved in managing them, and the communicator's role as networker.</P>
<P><I><B>Speakers:</B></I> A. Weisser, Los Angeles, CAL. Dauphine, New York,
NYV. Robinson, Washington, DC</P></BLOCKQUOTE>
<P></P>
<HR SIZE="4" WIDTH="80%">
<CENTER>
<P><A HREF=97ala.html><IMG
SRC=images/activity_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97bus.html><IMG
SRC=images/business_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97cal.html><IMG
SRC=images/calendar_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97child.html><IMG
SRC=images/child_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=pg.html><IMG
SRC=images/courses_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=search.html><IMG
SRC=images/search_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=main.html><IMG
SRC=images/home_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97house.html><IMG
SRC=images/house_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=http://itsmtgs.com/ala-ats><IMG
SRC=images/regist_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=sessions.html><IMG
SRC=images/session_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=special.html><IMG
SRC=images/special_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97tours.html><IMG
SRC=images/tour_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97travel.html><IMG
SRC=images/travel_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
</P></CENTER>
<HR SIZE="4" WIDTH="80%">
<CENTER><FONT SIZE="+2"><B><I>American Thoracic Society</I></B></FONT><BR>
1740 Broadway<BR> New York, NY 10019<BR> VOICE:  212-315-8700<BR> Copyright &copy;
1996 American Lung Association.<BR> The American Thoracic  Society is the
medical section <BR>of the American Lung Association.<BR> 
</CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-60</DOCNO>
<DOCOLDNO>IA013-000139-B025-292</DOCOLDNO>
<DOCHDR>
http://www.thoracic.org:80/ic97/b5.html 206.138.195.144 19970217071358 text/html 3818
HTTP/1.0 200 OK
Date: Monday, 17-Feb-97 07:09:14 GMT
Server: NCSA/1.3
MIME-version: 1.0
Content-type: text/html
Last-modified: Friday, 24-Jan-97 16:15:15 GMT
Content-length: 3638
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//SQ//DTD HTML 2.0 HoTMetaL + extensions//EN">
<HTML>
<HEAD>
<TITLE>ALA SYMPOSIUM: b5</TITLE></HEAD>
<BODY BGCOLOR="#FFFFFF">
<CENTER><IMG ALIGN="LEFT" SRC="images/banner0.jpg"></CENTER>
<CENTER><BR>
<P>ALA SYMPOSIUM</P><BR>
<H2>B5: UNDERSTANDING ASTHMA AND INDOOR AIR QUALITY/OPEN AIRWAYS FOR SCHOOLS:
TRAIN THE TRAINER (PART 1) </H2></CENTER>
<HR SIZE="5" NOSHADE="NOSHADE" WIDTH="100%">
<P></P>
<CENTER>
<TABLE BORDER="2">
<TR ALIGN="CENTER" VALIGN="MIDDLE">
<TD ALIGN="CENTER" VALIGN="MIDDLE"><B><SMALL><A HREF="ic97.html">BACK TO
MAIN MENU</A></SMALL></B></TD></TR></TABLE></CENTER>
<P></P>
<HR SIZE="10" WIDTH="85%">
<P></P>
<CENTER>
<P>MONDAY , MAY 19</P></CENTER>
<BLOCKQUOTE>
<P><B>This session is Part 1 of a full day workshop on the Open Airway for
Schools: Train the Trainer Program</B></P>
<P><B>8:15 am-9:45 am</B></P></BLOCKQUOTE>
<HR SIZE="4" WIDTH="85%" ALIGN="CENTER" NOSHADE="NOSHADE">
<BLOCKQUOTE>
<P><I><B>Target Audience: </B></I>Lung Association staff and volunteers.</P>
<P><B>OBJECTIVES</B><BR>At the conclusion of this session, the participant
will be able to:</P>
<UL>
<LI>describe the physiology of asthma, as well as the importance of asthma
education in asthma management;</LI>
<LI>distinguish facts from myths about asthma;</LI>
<LI>recognize indoor air pollutants as triggers for asthma episodes;</LI>
<LI>identify the benefits of the &quot;Indoor Air Quality Tools for Schools&quot;
kit and how it fits with ALA's current priorities under the Strategic Plan.</LI></UL>
<P>The physiology of asthma and the importance of education in self management
of the disease will be reviewed. Indoor Air Quality will then be explored as a
crucial contributing factor to asthma episodes. Indoor Air Quality Tools for
Schools will be discussed as a complementary intervention to ALA's Open Airways
for Schools.</P>
<P><I>8:15</I> <B>Introduction</B>/D. Evans, Ph.D., New York, NY</P>
<P><I>8:30</I> <B>Indoor Air Quality in Schools</B>/M. Cofer Wildsmith, M.A.,
St. Louis, MO</P>
<P><I>8:45</I> <B>Understanding Asthma</B>/R.B. Mellins, M.D., New York, NY</P></BLOCKQUOTE>
<P></P>
<HR SIZE="4" WIDTH="80%">
<CENTER>
<P><A HREF=97ala.html><IMG
SRC=images/activity_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97bus.html><IMG
SRC=images/business_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97cal.html><IMG
SRC=images/calendar_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97child.html><IMG
SRC=images/child_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=pg.html><IMG
SRC=images/courses_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=search.html><IMG
SRC=images/search_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=main.html><IMG
SRC=images/home_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97house.html><IMG
SRC=images/house_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=http://itsmtgs.com/ala-ats><IMG
SRC=images/regist_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=sessions.html><IMG
SRC=images/session_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=special.html><IMG
SRC=images/special_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97tours.html><IMG
SRC=images/tour_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97travel.html><IMG
SRC=images/travel_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
</P></CENTER>
<HR SIZE="4" WIDTH="80%">
<CENTER><FONT SIZE="+2"><B><I>American Thoracic Society</I></B></FONT><BR>
1740 Broadway<BR> New York, NY 10019<BR> VOICE:  212-315-8700<BR> Copyright &copy;
1996 American Lung Association.<BR> The American Thoracic  Society is the
medical section <BR>of the American Lung Association.<BR> 
</CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-61</DOCNO>
<DOCOLDNO>IA013-000139-B025-323</DOCOLDNO>
<DOCHDR>
http://www.thoracic.org:80/ic97/b7.html 206.138.195.144 19970217071408 text/html 3620
HTTP/1.0 200 OK
Date: Monday, 17-Feb-97 07:09:23 GMT
Server: NCSA/1.3
MIME-version: 1.0
Content-type: text/html
Last-modified: Friday, 24-Jan-97 16:15:23 GMT
Content-length: 3440
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//SQ//DTD HTML 2.0 HoTMetaL + extensions//EN">
<HTML>
<HEAD>
<TITLE>ALA SYMPOSIUM: b7</TITLE></HEAD>
<BODY BGCOLOR="#FFFFFF">
<CENTER><IMG ALIGN="LEFT" SRC="images/banner0.jpg"></CENTER>
<CENTER><BR>
<P>ALA SYMPOSIUM</P><BR>
<H2>B7: DETERMINING CUSTOMER PREFERENCES AND THEIR EFFECT ON PROGRAM DESIGN
</H2></CENTER>
<HR SIZE="5" NOSHADE="NOSHADE" WIDTH="100%">
<P></P>
<CENTER>
<TABLE BORDER="2">
<TR ALIGN="CENTER" VALIGN="MIDDLE">
<TD ALIGN="CENTER" VALIGN="MIDDLE"><B><SMALL><A HREF="ic97.html">BACK TO
MAIN MENU</A></SMALL></B></TD></TR></TABLE></CENTER>
<P></P>
<HR SIZE="10" WIDTH="85%">
<P></P>
<CENTER>
<P>MONDAY , MAY 19</P></CENTER>
<BLOCKQUOTE>
<P><B>8:15 am-9:45 am</B></P></BLOCKQUOTE>
<HR SIZE="4" WIDTH="85%" ALIGN="CENTER" NOSHADE="NOSHADE">
<BLOCKQUOTE>
<P><I><B>Target Audience: </B></I>Lung Association staff and volunteer
leaders.</P>
<P><B>OBJECTIVES</B><BR>At the conclusion of this session, the participant
will be able to:</P>
<UL>
<LI>get feedback from local community opinion leaders regarding how their
existing programs are perceived;</LI>
<LI>rank programs in terms of their fundability;</LI>
<LI>package and promote their programs based on customer preferences;</LI>
<LI>understand that analyzing marketing without looking at product is a waste
of time.</LI></UL>
<P>In a changing and competitive environment, staff and volunteer leaders of
local associations must know community needs and provide the programs that
fulfill those needs. They should &quot;package&quot; programs to potential
donors using terms that convey the urgency and importance of funding them. This
session will teach participants how to get the feedback from their community
leaders and how to use a system to &quot;rank&quot; their programs in terms of
their fundability.</P>
<P><I><B>Chairing: </B></I>T. Fries, Walnut Creek, CA</P>
<P>Additional faculty to be announced.</P></BLOCKQUOTE>
<P></P>
<HR SIZE="4" WIDTH="80%">
<CENTER>
<P><A HREF=97ala.html><IMG
SRC=images/activity_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97bus.html><IMG
SRC=images/business_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97cal.html><IMG
SRC=images/calendar_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97child.html><IMG
SRC=images/child_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=pg.html><IMG
SRC=images/courses_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=search.html><IMG
SRC=images/search_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=main.html><IMG
SRC=images/home_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97house.html><IMG
SRC=images/house_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=http://itsmtgs.com/ala-ats><IMG
SRC=images/regist_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=sessions.html><IMG
SRC=images/session_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=special.html><IMG
SRC=images/special_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97tours.html><IMG
SRC=images/tour_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97travel.html><IMG
SRC=images/travel_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
</P></CENTER>
<HR SIZE="4" WIDTH="80%">
<CENTER><FONT SIZE="+2"><B><I>American Thoracic Society</I></B></FONT><BR>
1740 Broadway<BR> New York, NY 10019<BR> VOICE:  212-315-8700<BR> Copyright &copy;
1996 American Lung Association.<BR> The American Thoracic  Society is the
medical section <BR>of the American Lung Association.<BR> 
</CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-62</DOCNO>
<DOCOLDNO>IA013-000139-B025-361</DOCOLDNO>
<DOCHDR>
http://www.thoracic.org:80/ic97/b8.html 206.138.195.144 19970217071417 text/html 3655
HTTP/1.0 200 OK
Date: Monday, 17-Feb-97 07:09:34 GMT
Server: NCSA/1.3
MIME-version: 1.0
Content-type: text/html
Last-modified: Friday, 24-Jan-97 16:15:24 GMT
Content-length: 3475
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//SQ//DTD HTML 2.0 HoTMetaL + extensions//EN">
<HTML>
<HEAD>
<TITLE>ALA SYMPOSIUM: b8</TITLE></HEAD>
<BODY BGCOLOR="#FFFFFF">
<CENTER><IMG ALIGN="LEFT" SRC="images/banner0.jpg"></CENTER>
<CENTER><BR>
<P>ALA SYMPOSIUM</P><BR>
<H2>B8: CREATING EFFECTIVE ALLIANCES WITH CORPORATIONS AND/OR FOUNDATIONS</H2></CENTER>
<HR SIZE="5" NOSHADE="NOSHADE" WIDTH="100%">
<P></P>
<CENTER>
<TABLE BORDER="2">
<TR ALIGN="CENTER" VALIGN="MIDDLE">
<TD ALIGN="CENTER" VALIGN="MIDDLE"><B><SMALL><A HREF="ic97.html">BACK TO
MAIN MENU</A></SMALL></B></TD></TR></TABLE></CENTER>
<P></P>
<HR SIZE="10" WIDTH="85%">
<P></P>
<CENTER>
<P>MONDAY , MAY 19</P></CENTER>
<BLOCKQUOTE>
<P><B>8:15 am-11:30 am</B></P></BLOCKQUOTE>
<HR SIZE="4" WIDTH="85%" ALIGN="CENTER" NOSHADE="NOSHADE">
<BLOCKQUOTE>
<P><I><B>Target Audience: </B></I>Lung Association staff and volunteers.</P>
<P><B>OBJECTIVES</B><BR>At the conclusion of this session, the participant
will be able to:</P>
<UL>
<LI>use project analysis to identify, create, and develop revenue generating
strategic alliances;</LI>
<LI>practice the &quot;art&quot; of budget development;</LI>
<LI>describe the dollar value of &quot;good lists&quot;;</LI>
<LI>identify the similarities and differences between grants and corporate
partnerships;</LI>
<LI>initiate grant proposal development.</LI></UL>
<P>This session will show participants how to develop relationships with
funding partners to achieve their Lung Association's mission objectives. Revenue
is always a necessary component, whether the project involves program,
communications, public relations, policy, or events. Participants will learn the
key elements of project analysis as a basis for proposal development. These
include: understanding the mission, developing goals and objectives, choosing
methods, formulating time lines, implementing evaluations, and creating
opportunities for the future.</P>
<P>Faculty to be announced.</P></BLOCKQUOTE>
<P></P>
<HR SIZE="4" WIDTH="80%">
<CENTER>
<P><A HREF=97ala.html><IMG
SRC=images/activity_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97bus.html><IMG
SRC=images/business_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97cal.html><IMG
SRC=images/calendar_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97child.html><IMG
SRC=images/child_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=pg.html><IMG
SRC=images/courses_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=search.html><IMG
SRC=images/search_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=main.html><IMG
SRC=images/home_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97house.html><IMG
SRC=images/house_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=http://itsmtgs.com/ala-ats><IMG
SRC=images/regist_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=sessions.html><IMG
SRC=images/session_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=special.html><IMG
SRC=images/special_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97tours.html><IMG
SRC=images/tour_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97travel.html><IMG
SRC=images/travel_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
</P></CENTER>
<HR SIZE="4" WIDTH="80%">
<CENTER><FONT SIZE="+2"><B><I>American Thoracic Society</I></B></FONT><BR>
1740 Broadway<BR> New York, NY 10019<BR> VOICE:  212-315-8700<BR> Copyright &copy;
1996 American Lung Association.<BR> The American Thoracic  Society is the
medical section <BR>of the American Lung Association.<BR> 
</CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-63</DOCNO>
<DOCOLDNO>IA013-000139-B026-26</DOCOLDNO>
<DOCHDR>
http://www.thoracic.org:80/ic97/b9.html 206.138.195.144 19970217071425 text/html 3252
HTTP/1.0 200 OK
Date: Monday, 17-Feb-97 07:09:44 GMT
Server: NCSA/1.3
MIME-version: 1.0
Content-type: text/html
Last-modified: Friday, 24-Jan-97 16:15:24 GMT
Content-length: 3072
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//SQ//DTD HTML 2.0 HoTMetaL + extensions//EN">
<HTML>
<HEAD>
<TITLE>ALA SYMPOSIUM: b9</TITLE></HEAD>
<BODY BGCOLOR="#FFFFFF">
<CENTER><IMG ALIGN="LEFT" SRC="images/banner0.jpg"></CENTER>
<CENTER><BR>
<P>ALA SYMPOSIUM</P><BR>
<H2>B9: LEARN ABOUT: LUNG DISEASES </H2></CENTER>
<HR SIZE="5" NOSHADE="NOSHADE" WIDTH="100%">
<P></P>
<CENTER>
<TABLE BORDER="2">
<TR ALIGN="CENTER" VALIGN="MIDDLE">
<TD ALIGN="CENTER" VALIGN="MIDDLE"><B><SMALL><A HREF="ic97.html">BACK TO
MAIN MENU</A></SMALL></B></TD></TR></TABLE></CENTER>
<P></P>
<HR SIZE="10" WIDTH="85%">
<P></P>
<CENTER>
<P>MONDAY , MAY 19</P></CENTER>
<BLOCKQUOTE>
<P><B>8:15 am-11:30 am</B></P></BLOCKQUOTE>
<HR SIZE="4" WIDTH="85%" ALIGN="CENTER" NOSHADE="NOSHADE">
<BLOCKQUOTE>
<P><I><B>Target Audience: </B></I>Lung Association volunteers and staff.</P>
<P>This session will help promote a better understanding of a variety of lung
diseases. Participants will have an opportunity to question the experts<B>.</B></P>
<P><I><B>Chairing: </B></I>S.S. Braman, M.D., Providence, RI</P>
<P><I>8:15</I> <B>The Hereditary Emphysema Story</B>/T.J. Ferro, M.D.,
Albany, NY</P>
<P><I>9:00</I> <B>Pulmonary Hypertension: A Lethal Disease Now Treatable</B>/N.S.
Hill, M.D., Providence, RI</P>
<P><I>9:45</I> <I>Break</I></P>
<P><I>10:00</I> <B>Lung Cancer: Can We Cure It?</B>/J.R. Jett, M.D.,
Pittsburgh, PA</P>
<P><I>10:45</I> <B>Sleep Apnea Syndrome: An Epidemiologist's View</B>/S.
Redline, M.D., Cleveland, OH</P>
<P>Discussion after each presentation/15 minutes</P></BLOCKQUOTE>
<P></P>
<HR SIZE="4" WIDTH="80%">
<CENTER>
<P><A HREF=97ala.html><IMG
SRC=images/activity_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97bus.html><IMG
SRC=images/business_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97cal.html><IMG
SRC=images/calendar_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97child.html><IMG
SRC=images/child_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=pg.html><IMG
SRC=images/courses_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=search.html><IMG
SRC=images/search_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=main.html><IMG
SRC=images/home_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97house.html><IMG
SRC=images/house_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=http://itsmtgs.com/ala-ats><IMG
SRC=images/regist_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=sessions.html><IMG
SRC=images/session_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=special.html><IMG
SRC=images/special_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97tours.html><IMG
SRC=images/tour_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97travel.html><IMG
SRC=images/travel_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
</P></CENTER>
<HR SIZE="4" WIDTH="80%">
<CENTER><FONT SIZE="+2"><B><I>American Thoracic Society</I></B></FONT><BR>
1740 Broadway<BR> New York, NY 10019<BR> VOICE:  212-315-8700<BR> Copyright &copy;
1996 American Lung Association.<BR> The American Thoracic  Society is the
medical section <BR>of the American Lung Association.<BR> 
</CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-64</DOCNO>
<DOCOLDNO>IA013-000139-B026-55</DOCOLDNO>
<DOCHDR>
http://www.thoracic.org:80/ic97/b12.html 206.138.195.144 19970217071436 text/html 4226
HTTP/1.0 200 OK
Date: Monday, 17-Feb-97 07:09:51 GMT
Server: NCSA/1.3
MIME-version: 1.0
Content-type: text/html
Last-modified: Friday, 24-Jan-97 16:15:11 GMT
Content-length: 4046
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//SQ//DTD HTML 2.0 HoTMetaL + extensions//EN">
<HTML>
<HEAD>
<TITLE>ALA SYMPOSIUM: b12</TITLE></HEAD>
<BODY BGCOLOR="#FFFFFF">
<CENTER><IMG ALIGN="LEFT" SRC="images/banner0.jpg"></CENTER>
<CENTER><BR>
<P>ALA SYMPOSIUM</P><BR>
<H2>B12: OPEN AIRWAYS FOR SCHOOLS: TRAIN THE TRAINER (PART II)</H2></CENTER>
<HR SIZE="5" NOSHADE="NOSHADE" WIDTH="100%">
<P></P>
<CENTER>
<TABLE BORDER="2">
<TR ALIGN="CENTER" VALIGN="MIDDLE">
<TD ALIGN="CENTER" VALIGN="MIDDLE"><B><SMALL><A HREF="ic97.html">BACK TO
MAIN MENU</A></SMALL></B></TD></TR></TABLE></CENTER>
<P></P>
<HR SIZE="10" WIDTH="85%">
<P></P>
<CENTER>
<P>MONDAY , MAY 19</P></CENTER>
<BLOCKQUOTE>
<P><B>Registration Fee: $20.00 (Includes box lunch.)</B> <I>Pre-registration
is required and on a first come, first served basis.</I></P>
<P><I>Participants must also attend the previous session <A HREF="b5.html">B5
&quot;Understanding Asthma and Indoor Air Quality&quot;</A> beginning at 8:15
a.m. to complete this session.</I></P>
<P>There will be a break at noon so that participants can attend the
<A HREF="plenary.html">Plenary Session</A>.</P>
<P><B>10:00 am-4:15 pm</B></P></BLOCKQUOTE>
<HR SIZE="4" WIDTH="85%" ALIGN="CENTER" NOSHADE="NOSHADE">
<BLOCKQUOTE>
<P><I><B>Target Audience: </B></I>Lung Association staff and volunteers.</P>
<P><B>OBJECTIVES</B><BR>At the conclusion of this session, the participant
will be able to:</P>
<UL>
<LI>describe the materials used throughout the six Open Airways for Schools
sessions and use them to enhance interaction;</LI>
<LI>discuss and demonstrate the interactive teaching methods used to deliver
the Open Airways for Schools program;</LI>
<LI>understand and teach the components of Open Airways for Schools Instructor
Learning workshops for volunteer instructors.</LI></UL>
<P>In an effort to ensure the uniformity of Open Airways for Schools
nationwide, this session teaches ALA staff and volunteers how to prepare Open
Airways for Schools instructors. Developed in conjunction with professionals
from Columbia University, this session incorporates valuable role-play,
feedback, and modeling techniques to enhance the learning process.</P>
<P><I>10:00</I> <B>Materials and Lesson Modeling</B>/D. Evans, Ph.D., New
York, NY/M. Pinkett-Heller, M.P.H., Teaneck, NJ</P>
<P><I>1:00</I> <B>Roleplay and Feeback/</B>A. McIntosh, New York, NY<B>/</B>D.
Evans, Ph.D., New York, NY/D. Naughton, New York, NY/M. Pinkett-Heller, M.P.H.,
Teaneck, NJ/R. Bachiman, New York, NY/W. Iseman, Brooklyn, NY</P></BLOCKQUOTE>
<P></P>
<HR SIZE="4" WIDTH="80%">
<CENTER>
<P><A HREF=97ala.html><IMG
SRC=images/activity_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97bus.html><IMG
SRC=images/business_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97cal.html><IMG
SRC=images/calendar_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97child.html><IMG
SRC=images/child_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=pg.html><IMG
SRC=images/courses_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=search.html><IMG
SRC=images/search_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=main.html><IMG
SRC=images/home_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97house.html><IMG
SRC=images/house_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=http://itsmtgs.com/ala-ats><IMG
SRC=images/regist_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=sessions.html><IMG
SRC=images/session_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=special.html><IMG
SRC=images/special_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97tours.html><IMG
SRC=images/tour_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97travel.html><IMG
SRC=images/travel_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
</P></CENTER>
<HR SIZE="4" WIDTH="80%">
<CENTER><FONT SIZE="+2"><B><I>American Thoracic Society</I></B></FONT><BR>
1740 Broadway<BR> New York, NY 10019<BR> VOICE:  212-315-8700<BR> Copyright &copy;
1996 American Lung Association.<BR> The American Thoracic  Society is the
medical section <BR>of the American Lung Association.<BR> 
</CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-65</DOCNO>
<DOCOLDNO>IA013-000139-B026-92</DOCOLDNO>
<DOCHDR>
http://www.thoracic.org:80/ic97/b55.html 206.138.195.144 19970217071453 text/html 3478
HTTP/1.0 200 OK
Date: Monday, 17-Feb-97 07:10:08 GMT
Server: NCSA/1.3
MIME-version: 1.0
Content-type: text/html
Last-modified: Friday, 24-Jan-97 16:15:17 GMT
Content-length: 3298
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//SQ//DTD HTML 2.0 HoTMetaL + extensions//EN">
<HTML>
<HEAD>
<TITLE>ALA SYMPOSIUM: b55</TITLE></HEAD>
<BODY BGCOLOR="#FFFFFF">
<CENTER><IMG ALIGN="LEFT" SRC="images/banner0.jpg"></CENTER>
<CENTER><BR>
<P>ALA SYMPOSIUM</P><BR>
<H2>B55: MEDIA ADVOCACY: 365 DAYS A YEAR  </H2></CENTER>
<HR SIZE="5" NOSHADE="NOSHADE" WIDTH="100%">
<P></P>
<CENTER>
<TABLE BORDER="2">
<TR ALIGN="CENTER" VALIGN="MIDDLE">
<TD ALIGN="CENTER" VALIGN="MIDDLE"><B><SMALL><A HREF="ic97.html">BACK TO
MAIN MENU</A></SMALL></B></TD></TR></TABLE></CENTER>
<P></P>
<HR SIZE="10" WIDTH="85%">
<P></P>
<BLOCKQUOTE>
<CENTER>
<P>MONDAY , MAY 19</P>
<P><B>1:30 pm-4:15 pm</B></P></CENTER></BLOCKQUOTE>
<HR SIZE="4" WIDTH="85%" ALIGN="CENTER" NOSHADE="NOSHADE">
<BLOCKQUOTE>
<P><I><B>Target Audience: </B></I>Lung Association staff and volunteers.</P>
<P><B>OBJECTIVES</B><BR>At the conclusion of this session, the participant
will be able to:</P>
<UL>
<LI>strategize to incorporate media advocacy into local organizational goals;</LI>
<LI>identify opportunities and rationale for focusing communications activities
on issues-based media efforts.</LI></UL>
<P>Working with the media on issues rather than activities enhances the
American Lung Association's overall visibility and individual relationships with
the media. Media advocacy transcends public policy and conveys our educational
messages more effectively than traditional publicity. The &quot;how, why and
day-to-day realities&quot; of media advocacy as an integral part of ALA's
organizational goals will be discussed in this interactive panel-driven
discussion. The resulting benefits in public policy, revenue generation, and
volunteer and program development will be explored.</P>
<P>Faculty to be announced</P></BLOCKQUOTE>
<P></P>
<HR SIZE="4" WIDTH="80%">
<CENTER>
<P><A HREF=97ala.html><IMG
SRC=images/activity_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97bus.html><IMG
SRC=images/business_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97cal.html><IMG
SRC=images/calendar_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97child.html><IMG
SRC=images/child_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=pg.html><IMG
SRC=images/courses_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=search.html><IMG
SRC=images/search_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=main.html><IMG
SRC=images/home_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97house.html><IMG
SRC=images/house_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=http://itsmtgs.com/ala-ats><IMG
SRC=images/regist_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=sessions.html><IMG
SRC=images/session_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=special.html><IMG
SRC=images/special_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97tours.html><IMG
SRC=images/tour_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97travel.html><IMG
SRC=images/travel_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
</P></CENTER>
<HR SIZE="4" WIDTH="80%">
<CENTER><FONT SIZE="+2"><B><I>American Thoracic Society</I></B></FONT><BR>
1740 Broadway<BR> New York, NY 10019<BR> VOICE:  212-315-8700<BR> Copyright &copy;
1996 American Lung Association.<BR> The American Thoracic  Society is the
medical section <BR>of the American Lung Association.<BR> 
</CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-66</DOCNO>
<DOCOLDNO>IA013-000139-B026-120</DOCOLDNO>
<DOCHDR>
http://www.thoracic.org:80/ic97/c6.html 206.138.195.144 19970217071506 text/html 3796
HTTP/1.0 200 OK
Date: Monday, 17-Feb-97 07:10:23 GMT
Server: NCSA/1.3
MIME-version: 1.0
Content-type: text/html
Last-modified: Friday, 24-Jan-97 16:15:34 GMT
Content-length: 3616
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//SQ//DTD HTML 2.0 HoTMetaL + extensions//EN">
<HTML>
<HEAD>
<TITLE>ALA SYMPOSIUM: c6</TITLE></HEAD>
<BODY BGCOLOR="#FFFFFF">
<CENTER><IMG ALIGN="LEFT" SRC="images/banner0.jpg"></CENTER>
<CENTER><BR>
<P>ALA SYMPOSIUM</P><BR>
<H2>C6: DEVELOPING A DATABASE: ADDING VALUE FOR YOU AND YOUR CORPORATE PARTNERS</H2></CENTER>
<HR SIZE="5" NOSHADE="NOSHADE" WIDTH="100%">
<P></P>
<CENTER>
<TABLE BORDER="2">
<TR ALIGN="CENTER" VALIGN="MIDDLE">
<TD ALIGN="CENTER" VALIGN="MIDDLE"><B><SMALL><A HREF="ic97.html">BACK TO
MAIN MENU</A></SMALL></B></TD></TR></TABLE></CENTER>
<P></P>
<HR SIZE="10" WIDTH="85%">
<P></P>
<BLOCKQUOTE>
<CENTER>
<P>TUESDAY , MAY 20</P>
<P><B>8:15 am-9:45 am</B></P></CENTER></BLOCKQUOTE>
<HR SIZE="4" WIDTH="85%" ALIGN="CENTER" NOSHADE="NOSHADE">
<BLOCKQUOTE>
<P><I><B>Target Audience: </B></I>Lung Association staff and volunteers with
responsibility for or interest in tracking relationships with the public.</P>
<P><B>OBJECTIVES</B><BR>At the conclusion of this session, the participant
will be able to:</P>
<UL>
<LI>understand the components of a database system and how they can be used to
track valuable Association information;</LI>
<LI>define and recognize the value of the relevant data that can be entered
into a database;</LI>
<LI>demonstrate how building a database of Association information can be of
significant benefit in dealing with potential managed care and other corporate
partners.</LI></UL>
<P>This session will help participants learn how to share information regarding
ALA audiences with managed care and other corporate partners. The ALA of
Mid-Ohio will team up with the ALA National Office to demonstrate how easy and
remunerative it is to set up an Association-wide database. By collecting vital
data on all participants and donors, Lung Associations can develop a tracking
system and document volunteer activities while increasing corporate matched
income.</P>
<P><I><B>Chairing: </B></I>R. Burwell, New York, NY</P>
<P><I><B>Speaker: </B></I>J. Page, Columbus, OH</P>
<P>Additional faculty to be announced.</P></BLOCKQUOTE>
<P></P>
<HR SIZE="4" WIDTH="80%">
<CENTER>
<P><A HREF=97ala.html><IMG
SRC=images/activity_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97bus.html><IMG
SRC=images/business_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97cal.html><IMG
SRC=images/calendar_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97child.html><IMG
SRC=images/child_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=pg.html><IMG
SRC=images/courses_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=search.html><IMG
SRC=images/search_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=main.html><IMG
SRC=images/home_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97house.html><IMG
SRC=images/house_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=http://itsmtgs.com/ala-ats><IMG
SRC=images/regist_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=sessions.html><IMG
SRC=images/session_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=special.html><IMG
SRC=images/special_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97tours.html><IMG
SRC=images/tour_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97travel.html><IMG
SRC=images/travel_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
</P></CENTER>
<HR SIZE="4" WIDTH="80%">
<CENTER><FONT SIZE="+2"><B><I>American Thoracic Society</I></B></FONT><BR>
1740 Broadway<BR> New York, NY 10019<BR> VOICE:  212-315-8700<BR> Copyright &copy;
1996 American Lung Association.<BR> The American Thoracic  Society is the
medical section <BR>of the American Lung Association.<BR> 
</CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-67</DOCNO>
<DOCOLDNO>IA013-000139-B026-149</DOCOLDNO>
<DOCHDR>
http://www.thoracic.org:80/ic97/c7.html 206.138.195.144 19970217071514 text/html 3608
HTTP/1.0 200 OK
Date: Monday, 17-Feb-97 07:10:31 GMT
Server: NCSA/1.3
MIME-version: 1.0
Content-type: text/html
Last-modified: Friday, 24-Jan-97 16:15:35 GMT
Content-length: 3428
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//SQ//DTD HTML 2.0 HoTMetaL + extensions//EN">
<HTML>
<HEAD>
<TITLE>ALA SYMPOSIUM: c7</TITLE></HEAD>
<BODY BGCOLOR="#FFFFFF">
<CENTER><IMG ALIGN="LEFT" SRC="images/banner0.jpg"></CENTER>
<CENTER><BR>
<P>ALA SYMPOSIUM</P><BR>
<H2>C7: THE AMERICAN LUNG ASSOCIATION NATIONWIDE MARKETING PLAN</H2></CENTER>
<HR SIZE="5" NOSHADE="NOSHADE" WIDTH="100%">
<P></P>
<CENTER>
<TABLE BORDER="2">
<TR ALIGN="CENTER" VALIGN="MIDDLE">
<TD ALIGN="CENTER" VALIGN="MIDDLE"><B><SMALL><A HREF="ic97.html">BACK TO
MAIN MENU</A></SMALL></B></TD></TR></TABLE></CENTER>
<P></P>
<HR SIZE="10" WIDTH="85%">
<P></P>
<BLOCKQUOTE>
<CENTER>
<P>TUESDAY , MAY 20</P>
<P><B>8:15 am-11:30 am</B></P></CENTER></BLOCKQUOTE>
<HR SIZE="4" WIDTH="85%" ALIGN="CENTER" NOSHADE="NOSHADE">
<BLOCKQUOTE>
<P><I><B>Target Audience: </B></I>Lung Association volunteers and staff.</P>
<P><B>OBJECTIVES</B><BR>At the conclusion of this session, the participant
will be able to:</P>
<UL>
<LI>identify opportunities for integrated planning throughout the organization
to reach ALA's nationwide marketing goals;</LI>
<LI>create local marketing plans for specific ALA programs and
revenue-generating initiatives, based on nationwide marketing goals and
positioning statements;</LI>
<LI>define staff role/responsibility to implementing marketing strategies.</LI></UL>
<P>This session will begin with a presentation of the ALA nationwide marketing
goals, positioning statements, and plans for specific ALA education and revenue
generation initiatives. Group exercises will be employed to critique local ALA
marketing plans currently in development, as well as ALA pilot sites. The
hands-on process of implementing the nationwide marketing plan within the local
community will also be explored.</P>
<P><I><B>Speakers:</B></I> G.J. Stern, Minneapolis, MN J. Bergen, New York,
NY</P>
<P>Additional faculty to be announced.</P></BLOCKQUOTE>
<P></P>
<HR SIZE="4" WIDTH="80%">
<CENTER>
<P><A HREF=97ala.html><IMG
SRC=images/activity_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97bus.html><IMG
SRC=images/business_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97cal.html><IMG
SRC=images/calendar_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97child.html><IMG
SRC=images/child_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=pg.html><IMG
SRC=images/courses_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=search.html><IMG
SRC=images/search_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=main.html><IMG
SRC=images/home_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97house.html><IMG
SRC=images/house_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=http://itsmtgs.com/ala-ats><IMG
SRC=images/regist_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=sessions.html><IMG
SRC=images/session_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=special.html><IMG
SRC=images/special_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97tours.html><IMG
SRC=images/tour_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97travel.html><IMG
SRC=images/travel_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
</P></CENTER>
<HR SIZE="4" WIDTH="80%">
<CENTER><FONT SIZE="+2"><B><I>American Thoracic Society</I></B></FONT><BR>
1740 Broadway<BR> New York, NY 10019<BR> VOICE:  212-315-8700<BR> Copyright &copy;
1996 American Lung Association.<BR> The American Thoracic  Society is the
medical section <BR>of the American Lung Association.<BR> 
</CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-68</DOCNO>
<DOCOLDNO>IA013-000139-B026-177</DOCOLDNO>
<DOCHDR>
http://www.thoracic.org:80/ic97/c8.html 206.138.195.144 19970217071523 text/html 2603
HTTP/1.0 200 OK
Date: Monday, 17-Feb-97 07:10:40 GMT
Server: NCSA/1.3
MIME-version: 1.0
Content-type: text/html
Last-modified: Friday, 24-Jan-97 16:15:35 GMT
Content-length: 2423
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//SQ//DTD HTML 2.0 HoTMetaL + extensions//EN">
<HTML>
<HEAD>
<TITLE>ALA SYMPOSIUM: c8</TITLE></HEAD>
<BODY BGCOLOR="#FFFFFF">
<CENTER><IMG ALIGN="LEFT" SRC="images/banner0.jpg"></CENTER>
<CENTER><BR>
<P>ALA SYMPOSIUM</P><BR>
<H2>C8: LUNG HEALTHY COMMUNITIES </H2></CENTER>
<HR SIZE="5" NOSHADE="NOSHADE" WIDTH="100%">
<P></P>
<CENTER>
<TABLE BORDER="2">
<TR ALIGN="CENTER" VALIGN="MIDDLE">
<TD ALIGN="CENTER" VALIGN="MIDDLE"><B><SMALL><A HREF="ic97.html">BACK TO
MAIN MENU</A></SMALL></B></TD></TR></TABLE></CENTER>
<P></P>
<HR SIZE="10" WIDTH="85%">
<P></P>
<BLOCKQUOTE>
<CENTER>
<P>TUESDAY , MAY 20</P>
<P><B>8:15 am-11:30 am</B></P></CENTER></BLOCKQUOTE>
<HR SIZE="4" WIDTH="85%" ALIGN="CENTER" NOSHADE="NOSHADE">
<BLOCKQUOTE>
<P><I><B>Speakers:</B></I> J. Howard, Sacramento, CAE. Miller, Augusta, ME</P>
<P>Program and additional faculty to be announced.</P></BLOCKQUOTE>
<P></P>
<HR SIZE="4" WIDTH="80%">
<CENTER>
<P><A HREF=97ala.html><IMG
SRC=images/activity_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97bus.html><IMG
SRC=images/business_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97cal.html><IMG
SRC=images/calendar_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97child.html><IMG
SRC=images/child_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=pg.html><IMG
SRC=images/courses_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=search.html><IMG
SRC=images/search_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=main.html><IMG
SRC=images/home_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97house.html><IMG
SRC=images/house_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=http://itsmtgs.com/ala-ats><IMG
SRC=images/regist_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=sessions.html><IMG
SRC=images/session_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=special.html><IMG
SRC=images/special_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97tours.html><IMG
SRC=images/tour_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97travel.html><IMG
SRC=images/travel_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
</P></CENTER>
<HR SIZE="4" WIDTH="80%">
<CENTER><FONT SIZE="+2"><B><I>American Thoracic Society</I></B></FONT><BR>
1740 Broadway<BR> New York, NY 10019<BR> VOICE:  212-315-8700<BR> Copyright &copy;
1996 American Lung Association.<BR> The American Thoracic  Society is the
medical section <BR>of the American Lung Association.<BR> 
</CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-69</DOCNO>
<DOCOLDNO>IA013-000139-B026-215</DOCOLDNO>
<DOCHDR>
http://www.thoracic.org:80/ic97/c10.html 206.138.195.144 19970217071533 text/html 3850
HTTP/1.0 200 OK
Date: Monday, 17-Feb-97 07:10:48 GMT
Server: NCSA/1.3
MIME-version: 1.0
Content-type: text/html
Last-modified: Friday, 24-Jan-97 16:15:26 GMT
Content-length: 3670
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//SQ//DTD HTML 2.0 HoTMetaL + extensions//EN">
<HTML>
<HEAD>
<TITLE>ALA SYMPOSIUM: c10</TITLE></HEAD>
<BODY BGCOLOR="#FFFFFF">
<CENTER><IMG ALIGN="LEFT" SRC="images/banner0.jpg"></CENTER>
<CENTER><BR>
<P>ALA SYMPOSIUM</P><BR>
<H2>C10: WHAT'S NEW IN ASTHMA RESEARCH AND TREATMENT?</H2></CENTER>
<HR SIZE="5" NOSHADE="NOSHADE" WIDTH="100%">
<P></P>
<CENTER>
<TABLE BORDER="2">
<TR ALIGN="CENTER" VALIGN="MIDDLE">
<TD ALIGN="CENTER" VALIGN="MIDDLE"><B><SMALL><A HREF="ic97.html">BACK TO
MAIN MENU</A></SMALL></B></TD></TR></TABLE></CENTER>
<P></P>
<HR SIZE="10" WIDTH="85%">
<P></P>
<BLOCKQUOTE>
<CENTER>
<P>TUESDAY , MAY 20</P>
<P><B>American Lung Association/<BR>Assembly on Allergy, Immunology and
Inflammation</B></P>
<P><B>10:00 am-11:30 am</B></P></CENTER></BLOCKQUOTE>
<HR SIZE="4" WIDTH="85%" ALIGN="CENTER" NOSHADE="NOSHADE">
<BLOCKQUOTE>
<P><I><B>Target Audience: </B></I>Lung Association staff and volunteers.</P>
<P><B>OBJECTIVES</B><BR>At the conclusion of this session, the participant
will be able to:</P>
<UL>
<LI>describe the role of inflammation in asthma and its importance to asthma
treatment;</LI>
<LI>identify new approaches to better delivery of treatment and adherence to
treatment plans;</LI>
<LI>discuss new aspects of asthma drug therapy.</LI></UL>
<P>This session will address new theories and concepts in asthma research and
treatment including current approaches to better treatment through improved
patient-physician-nurse communications and a better understanding of the disease
itself. New information on asthma drug treatments will also be shared.</P>
<P><I><B>Chairing: </B></I>S.E. Wenzel, M.D., Denver, CO</P>
<P><I>10:00</I> <B>Importance of Inflammation in Asthma</B>/R.F. Lemanske,
Jr., M.D., Madison, WI</P>
<P><I>10:20</I> <B>New Approaches to Monitoring, Adherence, Self-Care and
Inhaler Use</B>/S.M. Brugman, M.D., Denver, CO</P>
<P><I>10:35</I> <B>New Approaches to Drug Therapy</B>/C.A. Sorkness,
Pharm.D., Madison, WI</P>
<P><I>10:50</I> <B>Panel Discussion</B></P>
<P>This session is supported by an educational grant from<I><B>Abbott
Laboratories, Inc.</B></I></P></BLOCKQUOTE>
<P></P>
<HR SIZE="4" WIDTH="80%">
<CENTER>
<P><A HREF=97ala.html><IMG
SRC=images/activity_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97bus.html><IMG
SRC=images/business_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97cal.html><IMG
SRC=images/calendar_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97child.html><IMG
SRC=images/child_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=pg.html><IMG
SRC=images/courses_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=search.html><IMG
SRC=images/search_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=main.html><IMG
SRC=images/home_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97house.html><IMG
SRC=images/house_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=http://itsmtgs.com/ala-ats><IMG
SRC=images/regist_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=sessions.html><IMG
SRC=images/session_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=special.html><IMG
SRC=images/special_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97tours.html><IMG
SRC=images/tour_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97travel.html><IMG
SRC=images/travel_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
</P></CENTER>
<HR SIZE="4" WIDTH="80%">
<CENTER><FONT SIZE="+2"><B><I>American Thoracic Society</I></B></FONT><BR>
1740 Broadway<BR> New York, NY 10019<BR> VOICE:  212-315-8700<BR> Copyright &copy;
1996 American Lung Association.<BR> The American Thoracic  Society is the
medical section <BR>of the American Lung Association.<BR> 
</CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-70</DOCNO>
<DOCOLDNO>IA013-000139-B026-247</DOCOLDNO>
<DOCHDR>
http://www.thoracic.org:80/ic97/a1.html 206.138.195.144 19970217071541 text/html 3780
HTTP/1.0 200 OK
Date: Monday, 17-Feb-97 07:10:59 GMT
Server: NCSA/1.3
MIME-version: 1.0
Content-type: text/html
Last-modified: Friday, 24-Jan-97 16:14:53 GMT
Content-length: 3600
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//SQ//DTD HTML 2.0 HoTMetaL + extensions//EN">
<HTML>
<HEAD>
<TITLE>CLINICAL TOPICS IN PULMONARY MEDICINE: a1</TITLE></HEAD>
<BODY BGCOLOR="#FFFFFF">
<CENTER><IMG ALIGN="LEFT" SRC="images/banner0.jpg"></CENTER>
<CENTER><BR>
<P>CLINICAL TOPICS IN PULMONARY MEDICINE</P><BR>
<H2>A1: CLINICAL YEAR IN REVIEW 1</H2></CENTER>
<HR SIZE="5" NOSHADE="NOSHADE" WIDTH="100%">
<P></P>
<CENTER>
<TABLE BORDER="2">
<TR ALIGN="CENTER" VALIGN="MIDDLE">
<TD ALIGN="CENTER" VALIGN="MIDDLE"><B><SMALL><A HREF="ic97.html">BACK TO
MAIN MENU</A></SMALL></B></TD></TR></TABLE></CENTER>
<P></P>
<HR SIZE="10" WIDTH="85%">
<P></P>
<CENTER>
<P>SUNDAY , MAY 18</P></CENTER>
<BLOCKQUOTE>
<P><B>Assembly on Clinical Problems</B></P>
<P><B>8:15 am-10:15 am</B></P></BLOCKQUOTE>
<HR SIZE="4" WIDTH="85%" ALIGN="CENTER" NOSHADE="NOSHADE">
<BLOCKQUOTE>
<P><I><B>Target Audience: </B></I>Clinicians and practitioners.</P>
<P><B>OBJECTIVES</B><BR>At the conclusion of this session, the participant
will be able to:</P>
<UL>
<LI>use newly released asthma medications appropriately;</LI>
<LI>understand current methods for predicting the outcome of ICU care;</LI>
<LI>determine which patients should be formally evaluated for lung
transplantation;</LI>
<LI>know the current status of low molecular weight heparin use.</LI></UL>
<P>This session will review the 3-5 major recent clinically relevant papers in
the designated topic areas, putting them in context and indicating how they have
influenced the speaker's clinical practice.</P>
<P><I><B>Chairing: </B></I>D.H. Ingbar, M.D., Minneapolis, MNR.J. Maunder,
M.D., Portland, ORD.A. White, M.D., New York, NY</P>
<P><I>8:15</I> <B>Asthma and Immunologic Lung Diseases</B>/K.R. Young, M.D.,
Birmingham, AL</P>
<P><I>8:45</I> <B>ICU Organization Outcomes</B>/J. Hall, M.D., Chicago, IL</P>
<P><I>9:15</I> <B>Lung Transplantation</B>/M. Hertz, M.D., Minneapolis, MN</P>
<P><I>9:45</I> <B>Pulmonary Vascular Diseases and Thromboembolism</B>/S.
Idele, M.D., Ph.D., Tyler, TX</P>
<P>Discussion after each presentation/5 minutes</P></BLOCKQUOTE>
<P></P>
<HR SIZE="4" WIDTH="80%">
<CENTER>
<P><A HREF=97ala.html><IMG
SRC=images/activity_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97bus.html><IMG
SRC=images/business_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97cal.html><IMG
SRC=images/calendar_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97child.html><IMG
SRC=images/child_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=pg.html><IMG
SRC=images/courses_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=search.html><IMG
SRC=images/search_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=main.html><IMG
SRC=images/home_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97house.html><IMG
SRC=images/house_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=http://itsmtgs.com/ala-ats><IMG
SRC=images/regist_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=sessions.html><IMG
SRC=images/session_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=special.html><IMG
SRC=images/special_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97tours.html><IMG
SRC=images/tour_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97travel.html><IMG
SRC=images/travel_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
</P></CENTER>
<HR SIZE="4" WIDTH="80%">
<CENTER><FONT SIZE="+2"><B><I>American Thoracic Society</I></B></FONT><BR>
1740 Broadway<BR> New York, NY 10019<BR> VOICE:  212-315-8700<BR> Copyright &copy;
1996 American Lung Association.<BR> The American Thoracic  Society is the
medical section <BR>of the American Lung Association.<BR> 
</CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-71</DOCNO>
<DOCOLDNO>IA013-000139-B026-273</DOCOLDNO>
<DOCHDR>
http://www.thoracic.org:80/ic97/a2.html 206.138.195.144 19970217071550 text/html 4964
HTTP/1.0 200 OK
Date: Monday, 17-Feb-97 07:11:07 GMT
Server: NCSA/1.3
MIME-version: 1.0
Content-type: text/html
Last-modified: Friday, 24-Jan-97 16:14:56 GMT
Content-length: 4784
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//SQ//DTD HTML 2.0 HoTMetaL + extensions//EN">
<HTML>
<HEAD>
<TITLE>CLINICAL TOPICS IN PULMONARY MEDICINE: a2</TITLE></HEAD>
<BODY BGCOLOR="#FFFFFF">
<CENTER><IMG ALIGN="LEFT" SRC="images/banner0.jpg"></CENTER>
<CENTER><BR>
<P>CLINICAL TOPICS IN PULMONARY MEDICINE</P><BR>
<H2>A2: CONTROVERSIES IN LUNG REDUCTION SURGERY FOR DIFFUSE EMPHYSEMA</H2></CENTER>
<HR SIZE="5" NOSHADE="NOSHADE" WIDTH="100%">
<P></P>
<CENTER>
<TABLE BORDER="2">
<TR ALIGN="CENTER" VALIGN="MIDDLE">
<TD ALIGN="CENTER" VALIGN="MIDDLE"><B><SMALL><A HREF="ic97.html">BACK TO
MAIN MENU</A></SMALL></B></TD></TR></TABLE></CENTER>
<P></P>
<HR SIZE="10" WIDTH="85%">
<P></P>
<CENTER>
<P>SUNDAY , MAY 18</P></CENTER>
<BLOCKQUOTE>
<P><B>Assembly on Clinical Problems</B></P>
<P><B>8:15 am-11:00 am</B></P></BLOCKQUOTE>
<HR SIZE="4" WIDTH="85%" ALIGN="CENTER" NOSHADE="NOSHADE">
<BLOCKQUOTE>
<P><I><B>Target Audience: </B></I>Clinicians and researchers with an interest
in the patho-physiology and management of patients with advanced emphysema.</P>
<P><B>OBJECTIVES</B><BR>At the conclusion of this session, the participant
will be able to:</P>
<UL>
<LI>describe important uncertainties concerning lung reduction surgery which
are not yet well defined by available data;</LI>
<LI>define anatomical and physiological predictors of outcome and the potential
consequences of offering surgery to patients deviating from recently adopted
criteria;</LI>
<LI>discuss the potential morbidity and lack of response and understand the
limitations of the two most validated surgical approaches;</LI>
<LI>discuss the merits of a randomized trial and the medical, physiological and
economic parameters which should be addressed.</LI></UL>
<P>This session will address several areas of controversy surrounding the
utility of lung reduction surgery in advanced emphysema which has culminated in
refusal of medicare and other insurance agencies to offer reimbursement. While
data documenting short term clinical efficacy is mounting, controversy still
remains with respect to: the mechanisms of improvement; which patients are the
best candidates, what is the duration of benefit and what is the overall medical
and economic impact of the procedure.</P>
<P><I><B>Chairing: </B></I>F.C. Sciurba, M.D., Pittsburgh, PAM. Brenner,
M.D., Orange, CA</P>
<P><I>8:15</I> <B>Introduction: How Does It Work? Physiologic Mechanisms of
Improvement</B>/F.C. Sciurba, M.D., Pittsburgh, PA</P>
<P><I>8:40</I> <B>How Long Does It Last? How Long Is Long Enough?</B>/S.S.
Lefrak, M.D., St. Louis, MO</P>
<P><I>9:00</I> <B>On Whom Should It Be Performed? Physiologic and Anatomic
Selection Criteria</B>/M. Brenner, M.D., Orange, CA</P>
<P><I>9:20</I> <B>Does Thoracoscopy vs. Median Sternotomy Approach Change
Outcome?</B>/R.M. Kotloff, M.D., Philadelphia, PA</P>
<P><I>9:40</I> <I>Discussion</I></P>
<P><I>9:50</I> <B>How Common Are Morbidity and Lack of Response?</B>/R.
Keenan, M.D., Pittsburgh, PA</P>
<P><I>10:10</I> <B>How Do We Balance Medical and Economic Risks and Benefits?</B>/<I>Speaker
to be announced</I></P>
<P><I>10:30</I> <B>The NIH Clinical Trial, Design and Implementation</B>/<I>Steering
Committee Chairman to be announced</I></P>
<P><I>10:50</I> <B>Panel Discussion</B></P></BLOCKQUOTE>
<P></P>
<HR SIZE="4" WIDTH="80%">
<CENTER>
<P><A HREF=97ala.html><IMG
SRC=images/activity_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97bus.html><IMG
SRC=images/business_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97cal.html><IMG
SRC=images/calendar_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97child.html><IMG
SRC=images/child_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=pg.html><IMG
SRC=images/courses_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=search.html><IMG
SRC=images/search_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=main.html><IMG
SRC=images/home_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97house.html><IMG
SRC=images/house_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=http://itsmtgs.com/ala-ats><IMG
SRC=images/regist_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=sessions.html><IMG
SRC=images/session_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=special.html><IMG
SRC=images/special_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97tours.html><IMG
SRC=images/tour_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97travel.html><IMG
SRC=images/travel_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
</P></CENTER>
<HR SIZE="4" WIDTH="80%">
<CENTER><FONT SIZE="+2"><B><I>American Thoracic Society</I></B></FONT><BR>
1740 Broadway<BR> New York, NY 10019<BR> VOICE:  212-315-8700<BR> Copyright &copy;
1996 American Lung Association.<BR> The American Thoracic  Society is the
medical section <BR>of the American Lung Association.<BR> 
</CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-72</DOCNO>
<DOCOLDNO>IA013-000139-B026-304</DOCOLDNO>
<DOCHDR>
http://www.thoracic.org:80/ic97/a3.html 206.138.195.144 19970217071558 text/html 5786
HTTP/1.0 200 OK
Date: Monday, 17-Feb-97 07:11:16 GMT
Server: NCSA/1.3
MIME-version: 1.0
Content-type: text/html
Last-modified: Friday, 24-Jan-97 16:14:56 GMT
Content-length: 5606
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//SQ//DTD HTML 2.0 HoTMetaL + extensions//EN">
<HTML>
<HEAD>
<TITLE>CLINICAL TOPICS IN PULMONARY MEDICINE: a3</TITLE></HEAD>
<BODY BGCOLOR="#FFFFFF">
<CENTER><IMG ALIGN="LEFT" SRC="images/banner0.jpg"></CENTER>
<CENTER><BR>
<P>CLINICAL TOPICS IN PULMONARY MEDICINE</P><BR>
<H2>A3: EVALUATING EXERCISE INTOLERANCE</H2></CENTER>
<HR SIZE="5" NOSHADE="NOSHADE" WIDTH="100%">
<P></P>
<CENTER>
<TABLE BORDER="2">
<TR ALIGN="CENTER" VALIGN="MIDDLE">
<TD ALIGN="CENTER" VALIGN="MIDDLE"><B><SMALL><A HREF="ic97.html">BACK TO
MAIN MENU</A></SMALL></B></TD></TR></TABLE></CENTER>
<P></P>
<HR SIZE="10" WIDTH="85%">
<P></P>
<CENTER>
<P>SUNDAY , MAY 18</P></CENTER>
<BLOCKQUOTE>
<P><B>Assemblies on Clinical Problems/Respiratory Structure and Function</B></P>
<P><B>8:15 am-11:00 am</B></P></BLOCKQUOTE>
<HR SIZE="4" WIDTH="85%" ALIGN="CENTER" NOSHADE="NOSHADE">
<BLOCKQUOTE>
<P><I><B>Target Audience:</B></I> Pulmonary practitioners, exercise
physiologists, physicians in training, nurses and other allied health
professionals interested in evaluating and treating exercise intolerance in
patients with cardiopulmonary diseases.</P>
<P><B>OBJECTIVES</B><BR>At the conclusion of this session, the participant
will be able to:</P>
<UL>
<LI>understand that exercise limitation is often multifactorial in patients
with cardiopulmonary disorders;</LI>
<LI>describe the clinical utility and limitations of exercise tidal flow-volume
loops and end expiratory lung volume in the diagnosis of ventilatory limitation;</LI>
<LI>describe the importance of deconditioning, and the role of skeletal muscles
and other peripheral factors on exercise limitation in patients with
cardiopulmonary disorders;</LI>
<LI>define the role of dynamic hyperinflation on breathlessness, the
inspiratory muscles and exercise limitation;</LI>
<LI>apply these concepts in a step approach to the clinical evaluation of
unexplained dyspnea, with emphasis on the use of cardiopulmonary exercise
testing.</LI></UL>
<P>This session will provide an update and overview of important issues and
evolving concepts concerning exercise intolerance in patients with
cardiopulmonary disorders. The multifactorial etiology of exercise limitation,
the diagnosis and clinical management of several important contributing factors
including hypoxemia, dynamic hyperinflation, deconditioning and peripheral
factors including skeletal muscle dysfunction will be discussed. The value of
exercise tidal flow-volume loop in the diagnosis of ventilatory limitation and
interpretation of cardiopulmonary exercise test, along with the valuable role of
cardiopulmonary exercise testing on the clinical evaluation of unexplained
dyspnea will be addressed.</P>
<P><I><B>Chairing: </B></I>I.M. Weisman, M.D., El Paso, TXF. Martinez, M.D.,
Ann Arbor, MI</P>
<P><I>8:15</I> <B>Introduction</B>/I.M. Weisman, M.D., El Paso, TX</P>
<P><I>8:20</I> <B>Exercise Intolerance in Patients with Respiratory Disease:
It's Not Just the Lungs!</B>/C.G. Gallagher, M.D., Dublin, Ireland</P>
<P><I>8:40</I> <B>The Role of Hypoxemia in Exercise Intolerance</B>/D.
Marciniuk, M.D., Saskatoon, SK, Canada</P>
<P><I>9:00</I> <B>Breathlessness, Symptom Intensity, Hyperinflation, and
Exercise Limitation in Patients with COPD</B>/D.E. O'Donnell, M.D., Kingston,
ON, Canada</P>
<P><I>9:20</I> <I>Discussion</I></P>
<P><I>9:35</I> <I>Break</I></P>
<P><I>9:45</I> <B>Clinical Utility of Exercise Tidal Flow-Volume Loops in the
Diagnosis of Ventilatory Limitation and in the Interpretation of Cardiopulmonary
Exercise Testing</B>/F. Martinez, M.D., Ann Arbor, MI</P>
<P><I>10:05</I> <B>The Role of Deconditioning and the Contribution of
Skeletal Muscles/Peripheral Factors to Exercise Limitation in Patients with End
Stage Lung Disease and Lung Transplantation</B>/T. Williams, M.B.B.S., Prahran,
Melbourne, Australia</P>
<P><I>10:25</I> <B>Step Approach to the Clinical Evaluation of Unexplained
Dyspnea with Emphasis on the Use of Cardiopulmonary Exercise Testing</B>/I.M.
Weisman, M.D., El Paso, TX</P>
<P><I>10:45</I> <I>Discussion</I></P></BLOCKQUOTE>
<P></P>
<HR SIZE="4" WIDTH="80%">
<CENTER>
<P><A HREF=97ala.html><IMG
SRC=images/activity_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97bus.html><IMG
SRC=images/business_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97cal.html><IMG
SRC=images/calendar_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97child.html><IMG
SRC=images/child_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=pg.html><IMG
SRC=images/courses_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=search.html><IMG
SRC=images/search_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=main.html><IMG
SRC=images/home_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97house.html><IMG
SRC=images/house_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=http://itsmtgs.com/ala-ats><IMG
SRC=images/regist_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=sessions.html><IMG
SRC=images/session_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=special.html><IMG
SRC=images/special_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97tours.html><IMG
SRC=images/tour_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97travel.html><IMG
SRC=images/travel_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
</P></CENTER>
<HR SIZE="4" WIDTH="80%">
<CENTER><FONT SIZE="+2"><B><I>American Thoracic Society</I></B></FONT><BR>
1740 Broadway<BR> New York, NY 10019<BR> VOICE:  212-315-8700<BR> Copyright &copy;
1996 American Lung Association.<BR> The American Thoracic  Society is the
medical section <BR>of the American Lung Association.<BR> 
</CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-73</DOCNO>
<DOCOLDNO>IA013-000139-B026-341</DOCOLDNO>
<DOCHDR>
http://www.thoracic.org:80/ic97/a51.html 206.138.195.144 19970217071611 text/html 4812
HTTP/1.0 200 OK
Date: Monday, 17-Feb-97 07:11:26 GMT
Server: NCSA/1.3
MIME-version: 1.0
Content-type: text/html
Last-modified: Friday, 24-Jan-97 16:14:57 GMT
Content-length: 4632
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//SQ//DTD HTML 2.0 HoTMetaL + extensions//EN">
<HTML>
<HEAD>
<TITLE>CLINICAL TOPICS IN PULMONARY MEDICINE: a51</TITLE></HEAD>
<BODY BGCOLOR="#FFFFFF">
<CENTER><IMG ALIGN="LEFT" SRC="images/banner0.jpg"></CENTER>
<CENTER><BR>
<P>CLINICAL TOPICS IN PULMONARY MEDICINE</P>
<H2>A51: ACUTE PULMONARY EMBOLISM: EVOLVING MANAGEMENT STRATEGIES</H2>
<P><BR></P></CENTER>
<HR SIZE="5" NOSHADE="NOSHADE" WIDTH="100%">
<P></P>
<CENTER>
<TABLE BORDER="2">
<TR ALIGN="CENTER" VALIGN="MIDDLE">
<TD ALIGN="CENTER" VALIGN="MIDDLE"><B><SMALL><A HREF="ic97.html">BACK TO
MAIN MENU</A></SMALL></B></TD></TR></TABLE></CENTER>
<P></P>
<HR SIZE="10" WIDTH="85%">
<P></P>
<CENTER>
<P>SUNDAY , MAY 18</P></CENTER>
<BLOCKQUOTE>
<P><B>Assembly on Clinical Problems</B></P>
<P><B>1:30 pm-4:15 pm</B></P></BLOCKQUOTE>
<HR SIZE="4" WIDTH="85%" ALIGN="CENTER" NOSHADE="NOSHADE">
<BLOCKQUOTE>
<P><I><B>Target Audience:</B></I><B> </B>Clinicians and pulmonologists<B>.</B></P>
<P><B>OBJECTIVES</B><BR>At the conclusion of this session, the participant
will be able to:</P>
<UL>
<LI>understand the advantages and limitation of new diagnostic techniques for
acute deep vein thrombosis and pulmonary embolism;</LI>
<LI> recognize the indications for low-molecular-weight heparin preparations as
well as for the treatment of acute venous thromboembolism, as well as the areas
where data is lacking;</LI>
<LI>use thrombolytic therapy when appropriate and understand the evolving role
of echocardiography in acute PE;</LI>
<LI>weigh the advantages and disadvantages of IVC filter placement.</LI></UL>
<P>Pulmonary embolism continues to offer many challenges in both the diagnostic
and therapeutic realms. New technology needs to be appropriately integrated into
the diagnostic algorithm. The low-molecular-weight heparins are being utilized
for both prophylaxis and treatment. These agents have distinct advantages and
need to be carefully introduced into clinical practice. Thrombolytic therapy
continues to be utilized in select populations of patients. Techniques such as
echocardiography are being explored and may prove effective in guiding the use
of thrombolytic agents. Indications for inferior vena cava filters seem to be
expanding and offer appropriate alternative therapy in certain populations of
patients.</P>
<P><I><B>Chairing: </B></I>V.F. Tapson, M.D., Durham, NCK.M. Moser, M.D., San
Diego, CA</P>
<P><I>1:30</I> <B>The Diagnosis of Venous Thromboembolism: The Role of New
Technologies</B>/H.D. Sostman, M.D., New York, NY</P>
<P><I>2:00</I> <B>Low-Molecular-Weight Heparin for Venous Thromboebolism:
Home Treatment?</B>/V.F. Tapson, M.D., Durham, NC</P>
<P><I>2:30</I> <B>Thrombolytic Therapy in Acute PE: Standard and Novel
Approaches</B>/K.V. Leeper, M.D., Memphis, TN</P>
<P><I>3:00</I> <B>Echocardiography in Acute PE: A Guide to Treatment?</B>/C.
Elliott, M.D., Salt Lake City, UT</P>
<P><I>3:30</I> <B>The IVC Filter: Absolute and Relative Indications</B>/K.M.
Moser, M.D., San Diego, CA</P>
<P><I>4:00</I> <B>Panel Discussion</B></P>
<P>Discussion after each presentation/5 minutes</P></BLOCKQUOTE>
<P></P>
<HR SIZE="4" WIDTH="80%">
<CENTER>
<P><A HREF=97ala.html><IMG
SRC=images/activity_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97bus.html><IMG
SRC=images/business_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97cal.html><IMG
SRC=images/calendar_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97child.html><IMG
SRC=images/child_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=pg.html><IMG
SRC=images/courses_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=search.html><IMG
SRC=images/search_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=main.html><IMG
SRC=images/home_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97house.html><IMG
SRC=images/house_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=http://itsmtgs.com/ala-ats><IMG
SRC=images/regist_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=sessions.html><IMG
SRC=images/session_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=special.html><IMG
SRC=images/special_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97tours.html><IMG
SRC=images/tour_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97travel.html><IMG
SRC=images/travel_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
</P></CENTER>
<HR SIZE="4" WIDTH="80%">
<CENTER><FONT SIZE="+2"><B><I>American Thoracic Society</I></B></FONT><BR>
1740 Broadway<BR> New York, NY 10019<BR> VOICE:  212-315-8700<BR> Copyright &copy;
1996 American Lung Association.<BR> The American Thoracic  Society is the
medical section <BR>of the American Lung Association.<BR> 
</CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-74</DOCNO>
<DOCOLDNO>IA013-000139-B027-14</DOCOLDNO>
<DOCHDR>
http://www.thoracic.org:80/ic97/a52.html 206.138.195.144 19970217071620 text/html 5660
HTTP/1.0 200 OK
Date: Monday, 17-Feb-97 07:11:36 GMT
Server: NCSA/1.3
MIME-version: 1.0
Content-type: text/html
Last-modified: Friday, 24-Jan-97 16:14:58 GMT
Content-length: 5480
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//SQ//DTD HTML 2.0 HoTMetaL + extensions//EN">
<HTML>
<HEAD>
<TITLE>CLINICAL TOPICS IN PULMONARY MEDICINE: a52</TITLE></HEAD>
<BODY BGCOLOR="#FFFFFF">
<CENTER><IMG ALIGN="LEFT" SRC="images/banner0.jpg"></CENTER>
<CENTER><BR>
<P>CLINICAL TOPICS IN PULMONARY MEDICINE</P>
<H2>A52: LUNG TRANSPLANTATION: A CRITICAL LOOK AT CLINICAL PROBLEMS AND FUTURE
DIRECTIONS</H2>
<P><BR></P></CENTER>
<HR SIZE="5" NOSHADE="NOSHADE" WIDTH="100%">
<P></P>
<CENTER>
<TABLE BORDER="2">
<TR ALIGN="CENTER" VALIGN="MIDDLE">
<TD ALIGN="CENTER" VALIGN="MIDDLE"><B><SMALL><A HREF="ic97.html">BACK TO
MAIN MENU</A></SMALL></B></TD></TR></TABLE></CENTER>
<P></P>
<HR SIZE="10" WIDTH="85%">
<P></P>
<CENTER>
<P>SUNDAY , MAY 18</P></CENTER>
<BLOCKQUOTE>
<P><B>Assemblies on Clinical Problems/Microbiology, Tuberculosis, and
Pulmonary Infections</B></P>
<P><B>1:30 pm-4:15 pm</B></P></BLOCKQUOTE>
<HR SIZE="4" WIDTH="85%" ALIGN="CENTER" NOSHADE="NOSHADE">
<BLOCKQUOTE>
<P><I><B>Target Audience: </B></I>General pulmonologists, transplant
pulmonologists, cardiothoracic surgeons (general and transplant), transplant
coordinators, critical care physicians.</P>
<P><B>OBJECTIVES</B><BR>At the conclusion of this session, the participant
will be able to:</P>
<UL>
<LI>recognize criteria for referral for lung transplantation in general terms
and for specific diseases;</LI>
<LI>understand the rationale for selection criteria for lung transplantation;</LI>
<LI>understand the critical and medical issues regarding retransplantation;</LI>
<LI>understand the principles governing the evolution and progression of CMV
disease and its optimal treatment in the immunos</LI>
<LI>uppresed patient;</LI>
<LI>understand the significance of fungal airway contamination in both the pre-
and post-transplant period, and the rationale for suggested management
algorithms;</LI>
<LI>understand the choices in current immunosuppression protocols, and the data
supporting the relative benefits and disadvantages of these immunosuppresives;</LI>
<LI>understand the areas of lung transplantation which need to be critically
examined in the future and how these areas will impact on both lung function,
survival, and the role of lung transplantation in therapy.</LI></UL>
<P>With the change in health care policies, and transplantation funding, lung
transplanation is rapidly following the path of other organ transplants - that
is toward outcome analysis, standardization of selection criteria, a withdrawal
from anecdotal approaches, demand or multicenter treatment and protocol review,
an development of scientific rationales for such treatment and decisions. The
results of a multicenter consensus questionnaire and conference will be
showcased in this symposium and the areas greatly impacting on current patterns
of practice - infection management, and recipient selection as well as the
controversial status of retransplantation will be reviewed. The future
directions for scientific exploration and the rationale for pursuing these will
be explored.</P>
<P><I><B>Chairing: </B></I>A.E. Frost, M.D., Houston, TXE.P. Trulock, M.D.,
St. Louis, MOI. Paradis, M.D., Oklahoma City, OK</P>
<P><I>1:30</I> <B>Selection Criteria for Lung Transplant Candidates</B>/E.P.
Trulock, M.D., St. Louis, MO/I. Paradis, M.D., Oklahoma City, OK</P>
<P><I>2:20</I> <B>Pro: Re-Transplantation</B>/A.E. Frost, M.D., Houston, TX</P>
<P><I>2:20</I> <B>Con: Re-Transplantation</B>/J.R. Maurer, M.D., Cleveland,
OH</P>
<P><I>2:55</I> <B>Immunosuppression for Lung Transplantation: Which Drug and
How Much?</B>/J.H. Dauber, M.D., Pittsburgh, PA</P>
<P><I>3:15</I> <B>The Future of Lung Transplantation: What Do We Need to
Study?</B>/L. Schulman, M.D., New York, NY</P>
<P><I>3:35</I> <B>Prevention and Treatment of CMV after Lung Transplantation</B>/J.A.
Fishman, M.D., Charlestown, MA</P>
<P><I>3:55</I> <B>Fungal Prophylaxis After Lung Transplantation</B>/R.
Keenan, M.D., Pittsburgh, PA</P></BLOCKQUOTE>
<P></P>
<HR SIZE="4" WIDTH="80%">
<CENTER>
<P><A HREF=97ala.html><IMG
SRC=images/activity_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97bus.html><IMG
SRC=images/business_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97cal.html><IMG
SRC=images/calendar_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97child.html><IMG
SRC=images/child_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=pg.html><IMG
SRC=images/courses_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=search.html><IMG
SRC=images/search_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=main.html><IMG
SRC=images/home_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97house.html><IMG
SRC=images/house_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=http://itsmtgs.com/ala-ats><IMG
SRC=images/regist_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=sessions.html><IMG
SRC=images/session_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=special.html><IMG
SRC=images/special_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97tours.html><IMG
SRC=images/tour_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97travel.html><IMG
SRC=images/travel_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
</P></CENTER>
<HR SIZE="4" WIDTH="80%">
<CENTER><FONT SIZE="+2"><B><I>American Thoracic Society</I></B></FONT><BR>
1740 Broadway<BR> New York, NY 10019<BR> VOICE:  212-315-8700<BR> Copyright &copy;
1996 American Lung Association.<BR> The American Thoracic  Society is the
medical section <BR>of the American Lung Association.<BR> 
</CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-75</DOCNO>
<DOCOLDNO>IA013-000139-B027-45</DOCOLDNO>
<DOCHDR>
http://www.thoracic.org:80/ic97/b1.html 206.138.195.144 19970217071629 text/html 3807
HTTP/1.0 200 OK
Date: Monday, 17-Feb-97 07:11:45 GMT
Server: NCSA/1.3
MIME-version: 1.0
Content-type: text/html
Last-modified: Friday, 24-Jan-97 16:15:09 GMT
Content-length: 3627
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//SQ//DTD HTML 2.0 HoTMetaL + extensions//EN">
<HTML>
<HEAD>
<TITLE>CLINICAL TOPICS IN PULMONARY MEDICINE: b1</TITLE></HEAD>
<BODY BGCOLOR="#FFFFFF">
<CENTER><IMG ALIGN="LEFT" SRC="images/banner0.jpg"></CENTER>
<CENTER><BR>
<P>CLINICAL TOPICS IN PULMONARY MEDICINE</P><BR>
<H2>B1: CLINICAL YEAR IN REVIEW 2</H2></CENTER>
<HR SIZE="5" NOSHADE="NOSHADE" WIDTH="100%">
<P></P>
<CENTER>
<TABLE BORDER="2">
<TR ALIGN="CENTER" VALIGN="MIDDLE">
<TD ALIGN="CENTER" VALIGN="MIDDLE"><B><SMALL><A HREF="ic97.html">BACK TO
MAIN MENU</A></SMALL></B></TD></TR></TABLE></CENTER>
<P></P>
<HR SIZE="10" WIDTH="85%">
<P></P>
<BLOCKQUOTE>
<CENTER>
<P>MONDAY , MAY 19</P>
<P><B>Assembly on Clinical Problems</B></P>
<P><B>8:15 am-10:15 am</B></P></CENTER></BLOCKQUOTE>
<HR SIZE="4" WIDTH="85%" ALIGN="CENTER" NOSHADE="NOSHADE">
<BLOCKQUOTE>
<P><I><B>Target Audience: </B></I>Clinicians.</P>
<P><B>OBJECTIVES</B><BR>At the conclusion of this session, the participant
will be able to:</P>
<UL>
<LI>understand the ATS guidelines for approach to nosocomial infections and
other recent advances in this area;</LI>
<LI>recognize how treatments in respiratory care and use other therapies more
appropriately;</LI>
<LI>balance the approaches to treatment of ARDS between many new, but
relatively untested, therapeutic strategies;</LI>
<LI>identify appropriate use of new therapies for cystic fibrosis.</LI></UL>
<P>This session will review the 3-5 major recent clinically relevant papers in
the designated topic areas, putting them in context and indicating how they have
influenced the speaker's clinical practice.</P>
<P><I><B>Chairing: </B></I>R. Maunder, M.D., Portland, ORD.A. White, M.D.,
New York, NYD.H. Ingbar, M.D., Minneapolis, MN</P>
<P><I>8:15</I> <B>Pneumonia</B>/S.J. Skerrett, M.D., Seattle, WA</P>
<P><I>8:45</I> <B>Respiratory Care</B>/D.J. Pierson, M.D., Seattle, WA</P>
<P><I>9:15</I> <B>ARDS and Lung Injury</B>/D.H. Ingbar, M.D., Minneapolis, MN</P>
<P><I>9:45</I> <B>Sleep Disorders</B>/C. Zwillich, M.D., Denver, CO</P>
<P>Discussion after each presentation/5 minutes</P></BLOCKQUOTE>
<P></P>
<HR SIZE="4" WIDTH="80%">
<CENTER>
<P><A HREF=97ala.html><IMG
SRC=images/activity_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97bus.html><IMG
SRC=images/business_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97cal.html><IMG
SRC=images/calendar_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97child.html><IMG
SRC=images/child_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=pg.html><IMG
SRC=images/courses_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=search.html><IMG
SRC=images/search_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=main.html><IMG
SRC=images/home_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97house.html><IMG
SRC=images/house_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=http://itsmtgs.com/ala-ats><IMG
SRC=images/regist_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=sessions.html><IMG
SRC=images/session_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=special.html><IMG
SRC=images/special_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97tours.html><IMG
SRC=images/tour_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97travel.html><IMG
SRC=images/travel_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
</P></CENTER>
<HR SIZE="4" WIDTH="80%">
<CENTER><FONT SIZE="+2"><B><I>American Thoracic Society</I></B></FONT><BR>
1740 Broadway<BR> New York, NY 10019<BR> VOICE:  212-315-8700<BR> Copyright &copy;
1996 American Lung Association.<BR> The American Thoracic  Society is the
medical section <BR>of the American Lung Association.<BR> 
</CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-76</DOCNO>
<DOCOLDNO>IA013-000139-B027-75</DOCOLDNO>
<DOCHDR>
http://www.thoracic.org:80/ic97/b2.html 206.138.195.144 19970217071638 text/html 4942
HTTP/1.0 200 OK
Date: Monday, 17-Feb-97 07:11:55 GMT
Server: NCSA/1.3
MIME-version: 1.0
Content-type: text/html
Last-modified: Friday, 24-Jan-97 16:15:13 GMT
Content-length: 4762
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//SQ//DTD HTML 2.0 HoTMetaL + extensions//EN">
<HTML>
<HEAD>
<TITLE>CLINICAL TOPICS IN PULMONARY MEDICINE: b2</TITLE></HEAD>
<BODY BGCOLOR="#FFFFFF">
<CENTER><IMG ALIGN="LEFT" SRC="images/banner0.jpg"></CENTER>
<CENTER><BR>
<P>CLINICAL TOPICS IN PULMONARY MEDICINE</P><BR>
<H2>B2: LUNG CANCER IN 1996: MORE QUESTIONS THAN ANSWERS</H2></CENTER>
<HR SIZE="5" NOSHADE="NOSHADE" WIDTH="100%">
<P></P>
<CENTER>
<TABLE BORDER="2">
<TR ALIGN="CENTER" VALIGN="MIDDLE">
<TD ALIGN="CENTER" VALIGN="MIDDLE"><B><SMALL><A HREF="ic97.html">BACK TO
MAIN MENU</A></SMALL></B></TD></TR></TABLE></CENTER>
<P></P>
<HR SIZE="10" WIDTH="85%">
<P></P>
<CENTER>
<P>MONDAY , MAY 19</P></CENTER>
<BLOCKQUOTE>
<P><B>Assembly on Clinical Problems</B></P>
<P><B>8:15 am-11:00 am</B></P></BLOCKQUOTE>
<HR SIZE="4" WIDTH="85%" ALIGN="CENTER" NOSHADE="NOSHADE">
<BLOCKQUOTE>
<P><I><B>Target Audience: </B></I>Practicing clinicians.</P>
<P><B>OBJECTIVES</B><BR>At the conclusion of this session, the participant
will be able to:</P>
<UL>
<LI>describe the epidemiology of lung cancer;</LI>
<LI>accurately stage patients with lung cancer;</LI>
<LI>explain the use of neoadjuvant therapy in the treatment of lung cancer;</LI>
<LI>describe the appropriate treatment modality for endobronchial cancer.</LI></UL>
<P>The diagnosis and treatment of lung cancer has become exceedingly complex.
The symposium will begin with a review of the changing epidemiology of lung
cancer. The next several topics will address the pre-treatment evaluation of
patients with lung cancer. The use of radiologic, bronchoscopic,
mediastinoscopic, and thoracoscopic techniques to accurately stage lung cancer
will be discussed. Treatment options will focus on neoadjuvant therapy for lung
cancer. Interventional approaches including ND: Yag laser with stent placement
and brachytherapy will be compared to conventional radiotherapy. Finally, the
application of immunotherapy and gene therapy in lung cancer will be examined.</P>
<P><I><B>Chairing: </B></I>G.A. Silvestri, M.D., Charleston, SCC.M. Dresler,
M.D., Philadelphia, PA</P>
<P><I>8:15</I> <B>The Changing Epidemiology of Lung Cancer</B>/D.C.
Christiani, M.D., Boston, MA</P>
<P><I>8:41</I> <B>The Pre-Treatment Evaluation of Patients with Non-Small
Cell Lung Cancer</B>/G.A. Silvestri, M.D., Charleston, SC</P>
<P><I>9:05</I> <B>Radiologic Differentiation of Benign vs. Malignant
Pulmonary Nodules: Utility of Clinical Indicators, CT Enhancement and PET Scan</B>/T.C.
McLoud, M.D., Boston, MA</P>
<P><I>9:29</I> <B>The Importance of Staging the Mediastinum in Lung Cancer:
CT Scan, Bronchoscopy, Mediastinoscopy and Thoracoscopy</B>/C.M. Dresler, M.D.,
Philadelphia, PA</P>
<P><I>9:53</I> <B>Neoadjuvant Therapy for Lung Cancer: Will It Become
State-of-the-Art or a Passing Fad?</B>/J.R. Jett, M.D., Pittsburgh, PA</P>
<P><I>10:17</I> <B>Interventional Approaches to Endobronchial Tumors: The
Role of ND: Yag Laser with Stent Placement or Brachytherapy with External Beam
Radiation</B>/E.S. Edell, M.D., Rochester, MN</P>
<P><I>10:41</I> <B>What the Future of Cancer Therapy May Look Like in the
Year 2000</B>/S.M. Dubinett, M.D., Los Angeles, CA</P>
<P>Discussion after each presentation/4 minutes</P></BLOCKQUOTE>
<P></P>
<HR SIZE="4" WIDTH="80%">
<CENTER>
<P><A HREF=97ala.html><IMG
SRC=images/activity_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97bus.html><IMG
SRC=images/business_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97cal.html><IMG
SRC=images/calendar_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97child.html><IMG
SRC=images/child_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=pg.html><IMG
SRC=images/courses_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=search.html><IMG
SRC=images/search_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=main.html><IMG
SRC=images/home_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97house.html><IMG
SRC=images/house_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=http://itsmtgs.com/ala-ats><IMG
SRC=images/regist_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=sessions.html><IMG
SRC=images/session_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=special.html><IMG
SRC=images/special_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97tours.html><IMG
SRC=images/tour_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97travel.html><IMG
SRC=images/travel_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
</P></CENTER>
<HR SIZE="4" WIDTH="80%">
<CENTER><FONT SIZE="+2"><B><I>American Thoracic Society</I></B></FONT><BR>
1740 Broadway<BR> New York, NY 10019<BR> VOICE:  212-315-8700<BR> Copyright &copy;
1996 American Lung Association.<BR> The American Thoracic  Society is the
medical section <BR>of the American Lung Association.<BR> 
</CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-77</DOCNO>
<DOCOLDNO>IA013-000139-B027-112</DOCOLDNO>
<DOCHDR>
http://www.thoracic.org:80/ic97/b3.html 206.138.195.144 19970217071650 text/html 4548
HTTP/1.0 200 OK
Date: Monday, 17-Feb-97 07:12:08 GMT
Server: NCSA/1.3
MIME-version: 1.0
Content-type: text/html
Last-modified: Friday, 24-Jan-97 16:15:14 GMT
Content-length: 4368
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//SQ//DTD HTML 2.0 HoTMetaL + extensions//EN">
<HTML>
<HEAD>
<TITLE>CLINICAL TOPICS IN PULMONARY MEDICINE: b3</TITLE></HEAD>
<BODY BGCOLOR="#FFFFFF">
<CENTER><IMG ALIGN="LEFT" SRC="images/banner0.jpg"></CENTER>
<CENTER><BR>
<P>CLINICAL TOPICS IN PULMONARY MEDICINE</P><BR>
<H2>B3: EVIDENCE BASED MEDICINE AND OUTCOMES ASSESSMENT IN PULMONARY DISEASE
MANAGEMENT</H2></CENTER>
<HR SIZE="5" NOSHADE="NOSHADE" WIDTH="100%">
<P></P>
<CENTER>
<TABLE BORDER="2">
<TR ALIGN="CENTER" VALIGN="MIDDLE">
<TD ALIGN="CENTER" VALIGN="MIDDLE"><B><SMALL><A HREF="ic97.html">BACK TO
MAIN MENU</A></SMALL></B></TD></TR></TABLE></CENTER>
<P></P>
<HR SIZE="10" WIDTH="85%">
<P></P>
<CENTER>
<P>MONDAY , MAY 19</P></CENTER>
<BLOCKQUOTE>
<P><B>Assemblies on Clinical Problems/Behavioral Science</B></P>
<P><B>8:15 am-11:00 am</B></P></BLOCKQUOTE>
<HR SIZE="4" WIDTH="85%" ALIGN="CENTER" NOSHADE="NOSHADE">
<BLOCKQUOTE>
<P><I><B>Target Audience: </B></I>General pulmonary clinicians.</P>
<P><B>OBJECTIVES</B><BR>At the conclusion of this session, the participant
will be able to:</P>
<UL>
<LI>understand the steps toward the application of evidence based medical
practice in clinical pulmonary disease;</LI>
<LI>review the application of evidence based medicine and outcomes assessment
in selected pulmonary management problems.</LI></UL>
<P>Pulmonary clinicians are faced with increased economic pressure to employ
cost efficient strategies for patient management. Clinical pathways, guidelines,
and protocols are being developed as a &quot;best care&quot; approach using
available medical evidence. This session will outline the mechanics of evidence
based medicine and the appropriate outcome measures to employ when developing
and assessing new strategies for patients with pulmonary disease. Selected
difficult patient management issues have been selected for review.</P>
<P><I><B>Chairing: </B></I>M.P. Donahoe, M.D., Pittsburgh, PAM.R. Waldrum,
M.D., Birmingham, AL</P>
<P><I>8:15</I> <B>Introduction</B>/M.P. Donahoe, M.D., Pittsburgh, PA</P>
<P><I>8:20</I> <B>Evidence Based Medicine: Application to Pulmonary Disease
Management</B>/G. Cox, M.D., Hamilton, ON, Canada</P>
<P><I>8:45</I> <B>Outcomes Assessment for Efficient COPD Care</B>/A.L. Ries,
M.D., San Diego, CA</P>
<P><I>9:10</I> <B>Application of Outcomes Assessment to ICU Clinical Problems</B>/M.R.
Waldrum, M.D., Birmingham, AL</P>
<P><I>9:30</I> <I>Break</I></P>
<P><I>9:40</I> <B>Management Decisions in Thromboembolic Disease</B>/V.F.
Tapson, M.D., Durham, NC</P>
<P><I>10:05</I> <B>Management of Chronic Respiratory Failure: Do We Have the
Evidence?</B>/M.P. Donahoe, M.D., Pittsburgh, PA</P>
<P><I>10:25</I> <B>The Pulmonary Academic Physician After Realigning and
Downsizing</B>/M.J. Belman, M.D., Los Angeles, CA</P>
<P><I>10:50</I> <I>Discussion</I></P></BLOCKQUOTE>
<P></P>
<HR SIZE="4" WIDTH="80%">
<CENTER>
<P><A HREF=97ala.html><IMG
SRC=images/activity_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97bus.html><IMG
SRC=images/business_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97cal.html><IMG
SRC=images/calendar_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97child.html><IMG
SRC=images/child_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=pg.html><IMG
SRC=images/courses_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=search.html><IMG
SRC=images/search_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=main.html><IMG
SRC=images/home_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97house.html><IMG
SRC=images/house_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=http://itsmtgs.com/ala-ats><IMG
SRC=images/regist_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=sessions.html><IMG
SRC=images/session_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=special.html><IMG
SRC=images/special_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97tours.html><IMG
SRC=images/tour_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97travel.html><IMG
SRC=images/travel_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
</P></CENTER>
<HR SIZE="4" WIDTH="80%">
<CENTER><FONT SIZE="+2"><B><I>American Thoracic Society</I></B></FONT><BR>
1740 Broadway<BR> New York, NY 10019<BR> VOICE:  212-315-8700<BR> Copyright &copy;
1996 American Lung Association.<BR> The American Thoracic  Society is the
medical section <BR>of the American Lung Association.<BR> 
</CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-78</DOCNO>
<DOCOLDNO>IA013-000139-B027-146</DOCOLDNO>
<DOCHDR>
http://www.thoracic.org:80/ic97/b51.html 206.138.195.144 19970217071704 text/html 4810
HTTP/1.0 200 OK
Date: Monday, 17-Feb-97 07:12:18 GMT
Server: NCSA/1.3
MIME-version: 1.0
Content-type: text/html
Last-modified: Friday, 24-Jan-97 16:15:15 GMT
Content-length: 4630
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//SQ//DTD HTML 2.0 HoTMetaL + extensions//EN">
<HTML>
<HEAD>
<TITLE>CLINICAL TOPICS IN PULMONARY MEDICINE: b51</TITLE></HEAD>
<BODY BGCOLOR="#FFFFFF">
<CENTER><IMG ALIGN="LEFT" SRC="images/banner0.jpg"></CENTER>
<CENTER><BR>
<P>CLINICAL TOPICS IN PULMONARY MEDICINE</P><BR>
<H2>B51: MALIGNANT PLEURAL MESOTHELIOMA</H2></CENTER>
<HR SIZE="5" NOSHADE="NOSHADE" WIDTH="100%">
<P></P>
<CENTER>
<TABLE BORDER="2">
<TR ALIGN="CENTER" VALIGN="MIDDLE">
<TD ALIGN="CENTER" VALIGN="MIDDLE"><B><SMALL><A HREF="ic97.html">BACK TO
MAIN MENU</A></SMALL></B></TD></TR></TABLE></CENTER>
<P></P>
<HR SIZE="10" WIDTH="85%">
<P></P>
<BLOCKQUOTE>
<CENTER>
<P>MONDAY , MAY 19</P>
<P><B>Assemblies on Clinical Problems/<BR>Environmental and Occupational
Health</B></P>
<P><B>1:30 pm-4:15 pm</B></P></CENTER></BLOCKQUOTE>
<HR SIZE="4" WIDTH="85%" ALIGN="CENTER" NOSHADE="NOSHADE">
<BLOCKQUOTE>
<P><I><B>Target Audience: </B></I>Clinicians, pulmonologists, and thoracic
surgeons.</P>
<P><B>OBJECTIVES</B><BR>At the conclusion of this session, the participant
will be able to:</P>
<UL>
<LI>describe the predominant clinical and histopathologic features most
suggestive of malignant mesothelioma of the pleural;</LI>
<LI>describe how the controversial issues surrounding risk factors, asbestos
exposure, and fiber burden are handled &quot;in court&quot;, as well as in the
laboratory;</LI>
<LI>recognize the potential benefits and shortcomings of current medical
oncologic and thoracic surgical therapies;</LI>
<LI>understand the use of laboratory models and recognize their role in
developing new therapeutic strategies.</LI></UL>
<P>Because annual deaths from malignant mesothelioma will peak during the next
5 years, physicians and surgeons will continue to see patients with this disease
in their practices. Each facet of mesothelioma diagnosis and management,
however, is debatable. Although some treatments appear promising others provide
no benefit. Laboratory models may occupy an important role in the study of tumor
growth patterns and new therapeutic modalities. This session will provide an
overview of the controversial issues surrounding the diagnosis and therapy of
malignant pleural mesothelioma, as well as provide a basic understanding of
laboratory models and need for further research.</P>
<P><I><B>Chairing: </B></I>H.G. Colt, M.D., San Diego, CA</P>
<P><I>1:30</I> <B>Clinical Diagnosis and Management</B>/H.G. Colt, M.D., San
Diego, CA</P>
<P><I>1:55</I> <B>Pathology and Differential Diagnosis</B>/T.V. Colby, M.D.,
Scottsdale, AZ</P>
<P><I>2:20</I> <B>Fiber Burden Studies and Legal Ramifications of the
Diagnosis</B>/A.M. Churg, M.D., Ph.D., Vancouver, BC, Canada</P>
<P><I>2:45</I> <B>Prognosis, Staging, and Results of Thoracic Surgical
Treatment</B>/V.W. Rusch, M.D., New York, NY</P>
<P><I>3:10</I> <B>Prognosis, Staging, and Results of Chemotherapy and
Radiation</B>/J.R. Jett, M.D., Pittsburgh, PA</P>
<P><I>3:35</I> <B>Laboratory Models, Gene Therapy, and Future Developments</B>/S.M.
Albelda, M.D., Philadelphia, PA</P>
<P><I>4:00</I> <B>Panel Discussion</B></P></BLOCKQUOTE>
<P></P>
<HR SIZE="4" WIDTH="80%">
<CENTER>
<P><A HREF=97ala.html><IMG
SRC=images/activity_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97bus.html><IMG
SRC=images/business_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97cal.html><IMG
SRC=images/calendar_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97child.html><IMG
SRC=images/child_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=pg.html><IMG
SRC=images/courses_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=search.html><IMG
SRC=images/search_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=main.html><IMG
SRC=images/home_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97house.html><IMG
SRC=images/house_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=http://itsmtgs.com/ala-ats><IMG
SRC=images/regist_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=sessions.html><IMG
SRC=images/session_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=special.html><IMG
SRC=images/special_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97tours.html><IMG
SRC=images/tour_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97travel.html><IMG
SRC=images/travel_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
</P></CENTER>
<HR SIZE="4" WIDTH="80%">
<CENTER><FONT SIZE="+2"><B><I>American Thoracic Society</I></B></FONT><BR>
1740 Broadway<BR> New York, NY 10019<BR> VOICE:  212-315-8700<BR> Copyright &copy;
1996 American Lung Association.<BR> The American Thoracic  Society is the
medical section <BR>of the American Lung Association.<BR> 
</CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-79</DOCNO>
<DOCOLDNO>IA013-000139-B027-183</DOCOLDNO>
<DOCHDR>
http://www.thoracic.org:80/ic97/b52.html 206.138.195.144 19970217071716 text/html 4500
HTTP/1.0 200 OK
Date: Monday, 17-Feb-97 07:12:34 GMT
Server: NCSA/1.3
MIME-version: 1.0
Content-type: text/html
Last-modified: Friday, 24-Jan-97 16:15:16 GMT
Content-length: 4320
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//SQ//DTD HTML 2.0 HoTMetaL + extensions//EN">
<HTML>
<HEAD>
<TITLE>CLINICAL TOPICS IN PULMONARY MEDICINE: b52</TITLE></HEAD>
<BODY BGCOLOR="#FFFFFF">
<CENTER><IMG ALIGN="LEFT" SRC="images/banner0.jpg"></CENTER>
<CENTER><BR>
<P>CLINICAL TOPICS IN PULMONARY MEDICINE</P><BR>
<H2>B52: CLINICAL DECISION MAKING: AN INTERNATIONAL APPROACH</H2></CENTER>
<HR SIZE="5" NOSHADE="NOSHADE" WIDTH="100%">
<P></P>
<CENTER>
<TABLE BORDER="2">
<TR ALIGN="CENTER" VALIGN="MIDDLE">
<TD ALIGN="CENTER" VALIGN="MIDDLE"><B><SMALL><A HREF="ic97.html">BACK TO
MAIN MENU</A></SMALL></B></TD></TR></TABLE></CENTER>
<P></P>
<HR SIZE="10" WIDTH="85%">
<P></P>
<BLOCKQUOTE>
<CENTER>
<P>MONDAY , MAY 19</P>
<P><B>Assembly on Clinical Problems</B></P>
<P><B>1:30 pm-4:15 pm</B></P></CENTER></BLOCKQUOTE>
<HR SIZE="4" WIDTH="85%" ALIGN="CENTER" NOSHADE="NOSHADE">
<BLOCKQUOTE>
<P><I><B>Target Audience: </B></I>Pulmonary trainees and staff physicians
from all countries.</P>
<P><B>OBJECTIVES</B><BR>At the conclusion of this session, the participant
will be able to:</P>
<UL>
<LI>identify differences in the approach to diagnosis and management of
tuberculosis in industrialized countries and third world countries;</LI>
<LI>evaluate the European and American approach to diagnosis and treatment of
interstitial lung disease;</LI>
<LI>describe differences in treatment of sleep related disorders in North
America and the United Kingdom.</LI></UL>
<P>This international symposium will pair speakers from North America and
Europe to review the difference in the evaluation and treatment of diseases in
various countries. These diseases include tuberculosis, interstitial lung
disease and sleep related disorders. The approach to tuberculosis in third world
countries will be reviewed by the scientific director of the IUATLD and
contrasted with the current approach to this disease in the United States. This
symposium will offer attendees the opportunity to learn different perspectives
about specific issues related to these diseases.</P>
<P><I><B>Chairing: </B></I>U. Specks, M.D., Rochester, MNA.A. Woodcock, M.D.,
Manchester, England</P>
<P><I>1:30</I> <B>Management of Tuberculosis</B>/M.D. Iseman, M.D., Denver,
CO</P>
<P><I>1:55</I> <B>Management of Tuberculosis</B>/D.A. Enarson, M.D., Paris,
France</P>
<P><I>2:25</I> <B>Interstitial Lung Disease: Diagnosis and Treatment</B>/U.
Specks, M.D., Rochester, MN</P>
<P><I>2:50</I> <B>Interstitial Lung Disease: Diagnosis and Treatment</B>/J.
Egan, M.D., Manchester, England</P>
<P><I>3:20</I> <B>Issues with Sleep Related Disorders</B>/N.J. Douglas, M.D.,
Edinburgh, Scotland</P>
<P><I>3:45</I> <B>Issues with Sleep Related Disorders</B>/J.A. Fleetham,
M.D., Vancouver, BC, Canada</P>
<P>Discussion after each presentation/5 minutes</P></BLOCKQUOTE>
<P></P>
<HR SIZE="4" WIDTH="80%">
<CENTER>
<P><A HREF=97ala.html><IMG
SRC=images/activity_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97bus.html><IMG
SRC=images/business_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97cal.html><IMG
SRC=images/calendar_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97child.html><IMG
SRC=images/child_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=pg.html><IMG
SRC=images/courses_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=search.html><IMG
SRC=images/search_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=main.html><IMG
SRC=images/home_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97house.html><IMG
SRC=images/house_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=http://itsmtgs.com/ala-ats><IMG
SRC=images/regist_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=sessions.html><IMG
SRC=images/session_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=special.html><IMG
SRC=images/special_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97tours.html><IMG
SRC=images/tour_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97travel.html><IMG
SRC=images/travel_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
</P></CENTER>
<HR SIZE="4" WIDTH="80%">
<CENTER><FONT SIZE="+2"><B><I>American Thoracic Society</I></B></FONT><BR>
1740 Broadway<BR> New York, NY 10019<BR> VOICE:  212-315-8700<BR> Copyright &copy;
1996 American Lung Association.<BR> The American Thoracic  Society is the
medical section <BR>of the American Lung Association.<BR> 
</CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-80</DOCNO>
<DOCOLDNO>IA013-000139-B027-206</DOCOLDNO>
<DOCHDR>
http://www.thoracic.org:80/ic97/c1.html 206.138.195.144 19970217071724 text/html 3941
HTTP/1.0 200 OK
Date: Monday, 17-Feb-97 07:12:42 GMT
Server: NCSA/1.3
MIME-version: 1.0
Content-type: text/html
Last-modified: Friday, 24-Jan-97 16:15:25 GMT
Content-length: 3761
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//SQ//DTD HTML 2.0 HoTMetaL + extensions//EN">
<HTML>
<HEAD>
<TITLE>CLINICAL TOPICS IN PULMONARY MEDICINE: c1</TITLE></HEAD>
<BODY BGCOLOR="#FFFFFF">
<CENTER><IMG ALIGN="LEFT" SRC="images/banner0.jpg"></CENTER>
<CENTER><BR>
<P>CLINICAL TOPICS IN PULMONARY MEDICINE</P><BR>
<H2>C1: CLINICAL YEAR IN REVIEW 3</H2></CENTER>
<HR SIZE="5" NOSHADE="NOSHADE" WIDTH="100%">
<P></P>
<CENTER>
<TABLE BORDER="2">
<TR ALIGN="CENTER" VALIGN="MIDDLE">
<TD ALIGN="CENTER" VALIGN="MIDDLE"><B><SMALL><A HREF="ic97.html">BACK TO
MAIN MENU</A></SMALL></B></TD></TR></TABLE></CENTER>
<P></P>
<HR SIZE="10" WIDTH="85%">
<P></P>
<BLOCKQUOTE>
<CENTER>
<P>TUESDAY , MAY 20</P>
<P><B>Assembly on Clinical Problems</B></P>
<P><B>8:15 am-10:15 am</B></P></CENTER></BLOCKQUOTE>
<HR SIZE="4" WIDTH="85%" ALIGN="CENTER" NOSHADE="NOSHADE">
<BLOCKQUOTE>
<P><I><B>Target Audience: </B></I>Clinicians.</P>
<P><B>OBJECTIVES</B><BR>At the conclusion of this session, the participant
will be able to:</P>
<UL>
<LI>identify advances in treatment of COPD, including possible indications for
lung reduction surgery;</LI>
<LI>recognize new environmental and occupational conditions affecting the lungs
and/or new therapies;</LI>
<LI>discuss natural history and complications of sepsis and multi-system organ
dysfunction;</LI>
<LI> use new respiratory monitoring modalities properly.</LI></UL>
<P>This session will review the 3-5 major recent clinically relevant papers in
the designated topic areas:  putting them in context and indicating how they
have influenced the speaker's clinical practice.</P>
<P><I><B>Chairing: </B></I>D.A. White, M.D., New York, NYD.H. Ingbar, M.D.,
Minneapolis, MNR.J. Maunder, M.D., Portland, OR</P>
<P><I>8:15</I> <B>Sepsis and Multi-system Organ Dysfunction</B>/G.R. Bernard,
M.D., Nashville, TN</P>
<P><I>8:45</I> <B>Occupational and Environmental Disorders</B>/S. Barnhart,
M.D., Seattle, WA</P>
<P><I>9:15</I> <B>COPD</B>/A. Anzueto, M.D., San Antonio, TX</P>
<P><I>9:45</I> <B>Respiratory Monitoring</B>/M.J. Tobin, M.D., Hines, IL</P>
<P>Discussion after each presentation/5 minutes</P>
<CENTER>
<P>This session is supported by an educational grant from <BR><I><B>Glaxo
Wellcome, Inc.</B></I></P></CENTER></BLOCKQUOTE>
<P></P>
<HR SIZE="4" WIDTH="80%">
<CENTER>
<P><A HREF=97ala.html><IMG
SRC=images/activity_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97bus.html><IMG
SRC=images/business_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97cal.html><IMG
SRC=images/calendar_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97child.html><IMG
SRC=images/child_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=pg.html><IMG
SRC=images/courses_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=search.html><IMG
SRC=images/search_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=main.html><IMG
SRC=images/home_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97house.html><IMG
SRC=images/house_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=http://itsmtgs.com/ala-ats><IMG
SRC=images/regist_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=sessions.html><IMG
SRC=images/session_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=special.html><IMG
SRC=images/special_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97tours.html><IMG
SRC=images/tour_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97travel.html><IMG
SRC=images/travel_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
</P></CENTER>
<HR SIZE="4" WIDTH="80%">
<CENTER><FONT SIZE="+2"><B><I>American Thoracic Society</I></B></FONT><BR>
1740 Broadway<BR> New York, NY 10019<BR> VOICE:  212-315-8700<BR> Copyright &copy;
1996 American Lung Association.<BR> The American Thoracic  Society is the
medical section <BR>of the American Lung Association.<BR> 
</CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-81</DOCNO>
<DOCOLDNO>IA013-000139-B027-241</DOCOLDNO>
<DOCHDR>
http://www.thoracic.org:80/ic97/c2.html 206.138.195.144 19970217071735 text/html 4829
HTTP/1.0 200 OK
Date: Monday, 17-Feb-97 07:12:50 GMT
Server: NCSA/1.3
MIME-version: 1.0
Content-type: text/html
Last-modified: Friday, 24-Jan-97 16:15:29 GMT
Content-length: 4649
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//SQ//DTD HTML 2.0 HoTMetaL + extensions//EN">
<HTML>
<HEAD>
<TITLE>CLINICAL TOPICS IN PULMONARY MEDICINE: c2</TITLE></HEAD>
<BODY BGCOLOR="#FFFFFF">
<CENTER><IMG ALIGN="LEFT" SRC="images/banner0.jpg"></CENTER>
<CENTER><BR>
<P>CLINICAL TOPICS IN PULMONARY MEDICINE</P><BR>
<H2>C2: BRONCHOSCOPY FOR THE 21ST CENTURY</H2></CENTER>
<HR SIZE="5" NOSHADE="NOSHADE" WIDTH="100%">
<P></P>
<CENTER>
<TABLE BORDER="2">
<TR ALIGN="CENTER" VALIGN="MIDDLE">
<TD ALIGN="CENTER" VALIGN="MIDDLE"><B><SMALL><A HREF="ic97.html">BACK TO
MAIN MENU</A></SMALL></B></TD></TR></TABLE></CENTER>
<P></P>
<HR SIZE="10" WIDTH="85%">
<P></P>
<BLOCKQUOTE>
<CENTER>
<P>TUESDAY , MAY 20</P>
<P><B>Assembly on Clinical Problems</B></P>
<P><B>8:15 am-11:00 am</B></P></CENTER></BLOCKQUOTE>
<HR SIZE="4" WIDTH="85%" ALIGN="CENTER" NOSHADE="NOSHADE">
<BLOCKQUOTE>
<P><I><B>Target Audience: </B></I>Practicing pulmonologists and pulmonary and
critical care medicine trainees.</P>
<P><B>OBJECTIVES</B><BR>At the conclusion of this session, the participant
will be able to:</P>
<UL>
<LI>instruct and supervise bronchoscopy technicians and nurses in the
appropriate care and decontamination/sterilization of bronchoscopic equipment;</LI>
<LI>understand the technologic development of the fiberoptic bronchoscope and
accessory instrumentation used to sample the lower respiratory tract;</LI>
<LI>understand the utility of fiberoptic bronchoscopy and controversy
surrounding its use in three commonly encountered pulmonary disease processes:
infection, malignancy and interstitial lung disease;</LI>
<LI>describe the potential benefits and pitfalls of interventional bronchoscopy
(lasers, stents and brachytherapy) in the &quot;non-tertiary referral&quot;
setting.</LI></UL>
<P>Bronchoscopy is the most widely used diagnostic technique in respiratory
medicine. Expertise is acquired during training, by participating in
postgraduate courses, and through repeated performance of procedures. This
symposium is designed to review the currently accepted role for flexible
bronchoscopy in patient care, address areas of controversy, and point to future
directions for instrumentation and procedures.</P>
<P><I><B>Chairing: </B></I>H.G. Colt, M.D., San Diego, CAK.G. Torrington,
M.D., Washington, DC</P>
<P><I>8:15</I> <B>Care and Maintenance in Infection Control in the
Bronchoscopy Lab</B>/A.C. Mehta, M.B.B.S., Cleveland, OH</P>
<P><I>8:40</I> <B>What Can and Can't We Do with the Bronchoscope? Has
Anything Changed in Twenty-Five Years?</B>/J. Rodriguez, M.D., Mineola, NY</P>
<P><I>9:05</I> <B>Bronchoscopy for Pneumonia: Early, Late, and Never</B>/A.M.
Fein, M.D., Mineola, NY</P>
<P><I>9:30</I> <B>Bronchoscopy for Suspected Lung Cancer: If and When</B>/K.G.
Torrington, M.D., Washington, DC</P>
<P><I>9:55</I> <B>Bronchoscopy for Diffuse Lung Disease: Yes or No?</B>/J.P.
Lynch, III, M.D., Ann Arbor, MI</P>
<P><I>10:20</I> <B>Interventional Bronchoscopy: Can You Use It in Your Own
Hospital?</B>/H.G. Colt, M.D., San Diego, CA</P>
<P><I>10:45</I> <B>Panel Discussion</B></P>
<P>Discussion after each presentation/5 minutes</P></BLOCKQUOTE>
<P></P>
<HR SIZE="4" WIDTH="80%">
<CENTER>
<P><A HREF=97ala.html><IMG
SRC=images/activity_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97bus.html><IMG
SRC=images/business_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97cal.html><IMG
SRC=images/calendar_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97child.html><IMG
SRC=images/child_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=pg.html><IMG
SRC=images/courses_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=search.html><IMG
SRC=images/search_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=main.html><IMG
SRC=images/home_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97house.html><IMG
SRC=images/house_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=http://itsmtgs.com/ala-ats><IMG
SRC=images/regist_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=sessions.html><IMG
SRC=images/session_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=special.html><IMG
SRC=images/special_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97tours.html><IMG
SRC=images/tour_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97travel.html><IMG
SRC=images/travel_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
</P></CENTER>
<HR SIZE="4" WIDTH="80%">
<CENTER><FONT SIZE="+2"><B><I>American Thoracic Society</I></B></FONT><BR>
1740 Broadway<BR> New York, NY 10019<BR> VOICE:  212-315-8700<BR> Copyright &copy;
1996 American Lung Association.<BR> The American Thoracic  Society is the
medical section <BR>of the American Lung Association.<BR> 
</CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-82</DOCNO>
<DOCOLDNO>IA013-000139-B027-269</DOCOLDNO>
<DOCHDR>
http://www.thoracic.org:80/ic97/c3.html 206.138.195.144 19970217071802 text/html 5201
HTTP/1.0 200 OK
Date: Monday, 17-Feb-97 07:13:01 GMT
Server: NCSA/1.3
MIME-version: 1.0
Content-type: text/html
Last-modified: Friday, 24-Jan-97 16:15:29 GMT
Content-length: 5021
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//SQ//DTD HTML 2.0 HoTMetaL + extensions//EN">
<HTML>
<HEAD>
<TITLE>CLINICAL TOPICS IN PULMONARY MEDICINE: c3</TITLE></HEAD>
<BODY BGCOLOR="#FFFFFF">
<CENTER><IMG ALIGN="LEFT" SRC="images/banner0.jpg"></CENTER>
<CENTER><BR>
<P>CLINICAL TOPICS IN PULMONARY MEDICINE</P><BR>
<H2>C3: INTERSTITIAL LUNG DISEASE: PATHOLOGY UPDATE WITH CLINICAL AND
RADIOLOGICAL CORRELATIONS</H2></CENTER>
<HR SIZE="5" NOSHADE="NOSHADE" WIDTH="100%">
<P></P>
<CENTER>
<TABLE BORDER="2">
<TR ALIGN="CENTER" VALIGN="MIDDLE">
<TD ALIGN="CENTER" VALIGN="MIDDLE"><B><SMALL><A HREF="ic97.html">BACK TO
MAIN MENU</A></SMALL></B></TD></TR></TABLE></CENTER>
<P></P>
<HR SIZE="10" WIDTH="85%">
<P></P>
<BLOCKQUOTE>
<CENTER>
<P>TUESDAY , MAY 20</P>
<P><B>Assembly on Clinical Problems</B></P>
<P><B>8:15 am-11:00 am</B></P></CENTER></BLOCKQUOTE>
<HR SIZE="4" WIDTH="85%" ALIGN="CENTER" NOSHADE="NOSHADE">
<BLOCKQUOTE>
<P><I><B>Target Audience: </B></I>Pulmonologists, radiologists, pathologists,
residents, and research scientists.</P>
<P><B>OBJECTIVES</B><BR>At the conclusion of this session, the participant
will be able to:</P>
<UL>
<LI>describe the current pathologic classification of interstitial lung
disease;</LI>
<LI>understand the importance of correlation between clinical, pathologic and
radiologic data to achieve the best diagnosis;</LI>
<LI>realize the clinical and therapeutic signifance of separating the various
clinicopathologic entities;</LI>
<LI>appreciate the difficulties in classification of some interstitial lung
disorders.</LI></UL>
<P>In the past decade, pathologic concepts in interstitial lung disease have
evolved considerably. This evolution has had a substantial impact on the
approach to the diagnosis and clinical management of patients with interstitial
lung disorders. Some of the changes have led to considerable confusion,
especially with entities such as nonspecific interstitial pneumonia. A firm
grasp of the pathologic basis for separating these disorders is essential for
any physician involved with the care of these patients.</P>
<P>The purpose of this symposium is to review the current state-of-the-art in
pathologic classification of interstitial lung diseases. Clinical and radiologic
correlation of this pathologic classification will be made. Presentations will
be by leading experts in this field. The importance of integrating clinical,
radiologic and pathologic information to achieve an accurate diagnosis will be
emphasized.</P>
<P><I><B>Chairing: </B></I>W.D. Travis, M.D., Washington, DCT.V. Colby, M.D.,
Scottsdale, AZ</P>
<P><I>8:15</I> <B>Introduction</B>/W.D. Travis, M.D., Washington, DC</P>
<P><B><FONT SIZE="+1">Idiopathic Interstitial Pneumonias</FONT></B></P>
<P><I>8:20</I> <B>Pathology</B>/W.D. Travis, M.D., Washington, DC</P>
<P><I>8:35</I> <B>Clinical/</B>G. Raghu, M.D., Seattle, WA</P>
<P><B><FONT SIZE="+1">Nonspecific Interstitial Pneumonia</FONT></B></P>
<P><I>8:50</I> <B>Pathology</B>/J.L. Myers, M.D., Rochester, MN</P>
<P><I>9:05</I> <B>Clinical</B>/J.Hoon Ryu, M.D., Rochester, MN</P>
<P><B><FONT SIZE="+1">BOOP, Bronchiolitis and Other Interstitial Lung
Diseases</FONT></B></P>
<P><I>9:30</I> <B>Pathology</B>/T.V. Colby, M.D., Scottsdale, AZ</P>
<P><I>9:45</I> <B>Clinical</B>/T.E. King, Jr., M.D., Denver, CO</P>
<P><I>10:00</I> <B>New Developments in High Resolution CT Scan Evaluation of
Interstitial Lung Disease</B>/N.L. Muller, M.D., Vancouver, BC, Canada</P>
<P><I>10:30</I> <B>Panel Discussion</B></P></BLOCKQUOTE>
<P></P>
<HR SIZE="4" WIDTH="80%">
<CENTER>
<P><A HREF=97ala.html><IMG
SRC=images/activity_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97bus.html><IMG
SRC=images/business_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97cal.html><IMG
SRC=images/calendar_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97child.html><IMG
SRC=images/child_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=pg.html><IMG
SRC=images/courses_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=search.html><IMG
SRC=images/search_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=main.html><IMG
SRC=images/home_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97house.html><IMG
SRC=images/house_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=http://itsmtgs.com/ala-ats><IMG
SRC=images/regist_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=sessions.html><IMG
SRC=images/session_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=special.html><IMG
SRC=images/special_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97tours.html><IMG
SRC=images/tour_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97travel.html><IMG
SRC=images/travel_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
</P></CENTER>
<HR SIZE="4" WIDTH="80%">
<CENTER><FONT SIZE="+2"><B><I>American Thoracic Society</I></B></FONT><BR>
1740 Broadway<BR> New York, NY 10019<BR> VOICE:  212-315-8700<BR> Copyright &copy;
1996 American Lung Association.<BR> The American Thoracic  Society is the
medical section <BR>of the American Lung Association.<BR> 
</CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-83</DOCNO>
<DOCOLDNO>IA013-000139-B027-302</DOCOLDNO>
<DOCHDR>
http://www.thoracic.org:80/ic97/c51.html 206.138.195.144 19970217071813 text/html 5358
HTTP/1.0 200 OK
Date: Monday, 17-Feb-97 07:13:28 GMT
Server: NCSA/1.3
MIME-version: 1.0
Content-type: text/html
Last-modified: Friday, 24-Jan-97 16:15:31 GMT
Content-length: 5178
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//SQ//DTD HTML 2.0 HoTMetaL + extensions//EN">
<HTML>
<HEAD>
<TITLE>CLINICAL TOPICS IN PULMONARY MEDICINE: c51</TITLE></HEAD>
<BODY BGCOLOR="#FFFFFF">
<CENTER><IMG ALIGN="LEFT" SRC="images/banner0.jpg"></CENTER>
<CENTER><BR>
<P>CLINICAL TOPICS IN PULMONARY MEDICINE</P><BR>
<H2>C51: LYMPHANGIOLEIOMYOMATOSIS (LAM): NEW INSIGHTS INTO BIOLOGY AND
MANAGEMENT</H2></CENTER>
<HR SIZE="5" NOSHADE="NOSHADE" WIDTH="100%">
<P></P>
<CENTER>
<TABLE BORDER="2">
<TR ALIGN="CENTER" VALIGN="MIDDLE">
<TD ALIGN="CENTER" VALIGN="MIDDLE"><B><SMALL><A HREF="ic97.html">BACK TO
MAIN MENU</A></SMALL></B></TD></TR></TABLE></CENTER>
<P></P>
<HR SIZE="10" WIDTH="85%">
<P></P>
<BLOCKQUOTE>
<CENTER>
<P>TUESDAY , MAY 20</P>
<P><B>Assembly on Clinical Problems</B></P>
<P><B>3:15 PM&#151;6:00 PM</B></P></CENTER></BLOCKQUOTE>
<HR SIZE="4" WIDTH="85%" ALIGN="CENTER" NOSHADE="NOSHADE">
<BLOCKQUOTE>
<P><I><B>Target Audience: </B></I>Basic scientists and clinicians.</P>
<P><B>OBJECTIVES</B><BR>At the conclusion of this session, the participant
will be able to:</P>
<UL>
<LI>describe new insights into the basic biology of LAM cells, including
features they share with angiomyolipoma and malignant melanoma cells;</LI>
<LI>explain genetic similarities between tuberous sclerosis and LAM, and
discuss new diagnostic approaches to LAM, including HMB-45 monoclonal antibody
staining of LAM tissue;</LI>
<LI>understand the effectiveness of therapeutic approaches to LAM, including
hormonal manipulation and lung transplantation, and review the occurrence of two
cases of LAM arising in transplanted donor lung tissue;</LI>
<LI>identify the LAM Foundation as the key patient advocacy and support group
for patients with LAM, be familiar with the results of the recent NIH Working
Group on LAM and establishment of a LAM clinical registry, tissue bank, and
basic research strategies.</LI></UL>
<P>This symposium will present new insights into the biology and management of
LAM. A NIH Working Group met in 1995 to establish recommendations for pursuing
greater understanding into the basic biology, pathophysiology, and management of
patients with LAM. A national registry and tissue bank have been created and
LAM-related research has been solicited. Much has been learned about the basic
biology of LAM cells in the past two years. Shared characteristics between LAM,
angiomyolipoma, and malignant melanoma cells will be presented. Genetic
similarities between tuberous sclerosis and LAM cells will be reviewed. The
symposium will address new diagnostic approaches to LAM, including HMB-45
monoclonal antibody staining of tissue. The occurence of LAM in transplanted
donor lung tissue will be described and possible mechanisms will be addressed.
Finally, newer approaches to therapy will be discussed.</P>
<P><I><B>Chairing: </B></I>T.A. Raffin, M.D., Stanford, CAJ. Moss, M.D.,
Ph.D., Bethesda, MDM.K. Glassberg, M.D., Miami, FL</P>
<P><I>3:15</I> <B>Introduction</B>/T.A. Raffin, M.D., Stanford, CA</P>
<P><I>3:20</I> <B>Natural History and Differential Diagnosis</B>/J.H. Ryu,
M.D., Rochester, MN</P>
<P><I>3:50</I> <B>Pathologic and Ultrastructural Similarities Between LAM,
Angiomyolipoma and Malignant Melanoma</B>/T.V. Colby, M.D., Scottsdale, AZ</P>
<P><I>4:20</I> <B>Molecular Characterization of LAM</B>/S.C. Chu, M.D.,
Bethesda, MD</P>
<P><I>4:50</I> <B>Molecular Genetics of Tuberous Sclerosis and LAM</B>/F.X.
McCormack, Jr., M.D., Cincinnati, OH</P>
<P><I>5:20</I> <B>New Therapeutic Approaches to LAM</B>/K.G. Kalassian, M.D.,
Stanford, CA</P>
<P><I>5:50</I> <I>Discussion</I></P>
<P>Discussion after each presentation/5 minutes</P></BLOCKQUOTE>
<P></P>
<HR SIZE="4" WIDTH="80%">
<CENTER>
<P><A HREF=97ala.html><IMG
SRC=images/activity_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97bus.html><IMG
SRC=images/business_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97cal.html><IMG
SRC=images/calendar_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97child.html><IMG
SRC=images/child_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=pg.html><IMG
SRC=images/courses_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=search.html><IMG
SRC=images/search_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=main.html><IMG
SRC=images/home_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97house.html><IMG
SRC=images/house_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=http://itsmtgs.com/ala-ats><IMG
SRC=images/regist_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=sessions.html><IMG
SRC=images/session_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=special.html><IMG
SRC=images/special_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97tours.html><IMG
SRC=images/tour_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97travel.html><IMG
SRC=images/travel_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
</P></CENTER>
<HR SIZE="4" WIDTH="80%">
<CENTER><FONT SIZE="+2"><B><I>American Thoracic Society</I></B></FONT><BR>
1740 Broadway<BR> New York, NY 10019<BR> VOICE:  212-315-8700<BR> Copyright &copy;
1996 American Lung Association.<BR> The American Thoracic  Society is the
medical section <BR>of the American Lung Association.<BR> 
</CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-84</DOCNO>
<DOCOLDNO>IA013-000139-B027-328</DOCOLDNO>
<DOCHDR>
http://www.thoracic.org:80/ic97/c52.html 206.138.195.144 19970217071821 text/html 4654
HTTP/1.0 200 OK
Date: Monday, 17-Feb-97 07:13:39 GMT
Server: NCSA/1.3
MIME-version: 1.0
Content-type: text/html
Last-modified: Friday, 24-Jan-97 16:15:31 GMT
Content-length: 4474
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//SQ//DTD HTML 2.0 HoTMetaL + extensions//EN">
<HTML>
<HEAD>
<TITLE>CLINICAL TOPICS IN PULMONARY MEDICINE: c52</TITLE></HEAD>
<BODY BGCOLOR="#FFFFFF">
<CENTER><IMG ALIGN="LEFT" SRC="images/banner0.jpg"></CENTER>
<CENTER><BR>
<P>CLINICAL TOPICS IN PULMONARY MEDICINE</P><BR>
<H2>C52: UPDATE ON HEMOPTYSIS</H2></CENTER>
<HR SIZE="5" NOSHADE="NOSHADE" WIDTH="100%">
<P></P>
<CENTER>
<TABLE BORDER="2">
<TR ALIGN="CENTER" VALIGN="MIDDLE">
<TD ALIGN="CENTER" VALIGN="MIDDLE"><B><SMALL><A HREF="ic97.html">BACK TO
MAIN MENU</A></SMALL></B></TD></TR></TABLE></CENTER>
<P></P>
<HR SIZE="10" WIDTH="85%">
<P></P>
<BLOCKQUOTE>
<CENTER>
<P>TUESDAY , MAY 20</P>
<P><B>Assembly on Clinical Problems</B></P>
<P><B>3:15 PM&#151;6:00 PM</B></P></CENTER></BLOCKQUOTE>
<HR SIZE="4" WIDTH="85%" ALIGN="CENTER" NOSHADE="NOSHADE">
<BLOCKQUOTE>
<P><I><B>Target Audience: </B></I>Pulmonary and critical care physicians,
fellows, respiratory therapists, and nurses.</P>
<P><B>OBJECTIVES</B><BR>At the conclusion of this session, the participant
will be able to:</P>
<UL>
<LI>describe the causes of hemoptysis as it is encountered in outpatient and
critical care settings, its diverse clinical presentations, and unresolved
controversies;</LI>
<LI>describe current approaches to diagnosis of hemoptysis, with particular
emphasis upon the role of newer imaging techniques and use of bronchoscopy;</LI>
<LI>define optimum integrated roles of interventional bronchoscopy, radiology,
surgery, and other modalities in the management of patients with hemoptysis;</LI>
<LI>identify areas where further clinical investigation is needed.</LI></UL>
<P>Hemoptysis is a classic symptom and sign of major respiratory disease, but
its epidemiology and clinical presentations continue to evolve. Technologic
progress in imaging and bronchoscopy has led to new algorithms in the diagnosis
and management ofsuch patients, but major controvesies remain. This
multidisciplinary symposium will address current clinical aspects of hemoptysis,
the approaches associated with better patient outcomes, and the uncertainties
which require further clinical investigation.</P>
<P><I><B>Chairing: </B></I>E.F. Haponik, M.D., Winston-Salem, NC</P>
<P><I>3:15</I> <B>Hemoptysis: Clinical Presentations and Controversies</B>/E.F.
Haponik, M.D., Winston-Salem, NC</P>
<P><I>3:40</I> <B>Hemoptysis: The Radiologist's Perspective</B>/D. Naidich,
M.D., New York, NY</P>
<P><I>4:05</I> <B>Hemoptysis: Diagnostic and Therapeutic Bronchoscopy</B>/D.
Shure, M.D., St. Louis, MO</P>
<P><I>4:30</I> <B>Capillaritis and Alveolar Hemorrhage Syndromes</B>/M.I.
Schwarz, M.D., Denver, CO</P>
<P><I>4:55</I> <B>Hemoptysis: The Thoracic Surgeon's View</B>/M.S. Allen,
M.D., Rochester, MN</P>
<P><I>5:20</I> <B>Management of Patients with Hemoptysis</B>/D.H. Ingbar,
M.D., Minneapolis, MN</P>
<P><I>5:45</I> <B>Panel Discussion</B></P>
<P>Discussion after each presentation/5 minutes</P></BLOCKQUOTE>
<P></P>
<HR SIZE="4" WIDTH="80%">
<CENTER>
<P><A HREF=97ala.html><IMG
SRC=images/activity_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97bus.html><IMG
SRC=images/business_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97cal.html><IMG
SRC=images/calendar_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97child.html><IMG
SRC=images/child_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=pg.html><IMG
SRC=images/courses_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=search.html><IMG
SRC=images/search_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=main.html><IMG
SRC=images/home_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97house.html><IMG
SRC=images/house_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=http://itsmtgs.com/ala-ats><IMG
SRC=images/regist_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=sessions.html><IMG
SRC=images/session_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=special.html><IMG
SRC=images/special_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97tours.html><IMG
SRC=images/tour_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97travel.html><IMG
SRC=images/travel_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
</P></CENTER>
<HR SIZE="4" WIDTH="80%">
<CENTER><FONT SIZE="+2"><B><I>American Thoracic Society</I></B></FONT><BR>
1740 Broadway<BR> New York, NY 10019<BR> VOICE:  212-315-8700<BR> Copyright &copy;
1996 American Lung Association.<BR> The American Thoracic  Society is the
medical section <BR>of the American Lung Association.<BR> 
</CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-85</DOCNO>
<DOCOLDNO>IA013-000139-B027-365</DOCOLDNO>
<DOCHDR>
http://www.thoracic.org:80/ic97/d1.html 206.138.195.144 19970217071833 text/html 3733
HTTP/1.0 200 OK
Date: Monday, 17-Feb-97 07:13:48 GMT
Server: NCSA/1.3
MIME-version: 1.0
Content-type: text/html
Last-modified: Friday, 24-Jan-97 16:15:41 GMT
Content-length: 3553
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//SQ//DTD HTML 2.0 HoTMetaL + extensions//EN">
<HTML>
<HEAD>
<TITLE>CLINICAL TOPICS IN PULMONARY MEDICINE: d1</TITLE></HEAD>
<BODY BGCOLOR="#FFFFFF">
<CENTER><IMG ALIGN="LEFT" SRC="images/banner0.jpg"></CENTER>
<CENTER><BR>
<P>CLINICAL TOPICS IN PULMONARY MEDICINE</P><BR>
<H2>D1: CLINICAL YEAR IN REVIEW 4</H2></CENTER>
<HR SIZE="5" NOSHADE="NOSHADE" WIDTH="100%">
<P></P>
<CENTER>
<TABLE BORDER="2">
<TR ALIGN="CENTER" VALIGN="MIDDLE">
<TD ALIGN="CENTER" VALIGN="MIDDLE"><B><SMALL><A HREF="ic97.html">BACK TO
MAIN MENU</A></SMALL></B></TD></TR></TABLE></CENTER>
<P></P>
<HR SIZE="10" WIDTH="85%">
<P></P>
<BLOCKQUOTE>
<CENTER>
<P>WEDNESDAY , MAY 21</P>
<P><B>Assembly on Clinical Problems</B></P>
<P><B>8:15 am-10:15 am</B></P></CENTER></BLOCKQUOTE>
<HR SIZE="4" WIDTH="85%" ALIGN="CENTER" NOSHADE="NOSHADE">
<BLOCKQUOTE>
<P><I><B>Target Audience: </B></I>Clinicians.</P>
<P><B>OBJECTIVES</B><BR>At the conclusion of this session, the participant
will be able to:</P>
<UL>
<LI> improve general ICU management;</LI>
<LI>identify new developments in interstitial lung diseases;</LI>
<LI>discuss new aspects of pulmonary complications of AIDS and HIV;</LI>
<LI>be aware of new diagnostic and therapeutic modalities for sleep disorders
of breathing.</LI></UL>
<P>This session will review the 3-5 major recent clinically relevant papers in
the designated topic areas: putting them in context and indicating how they have
influenced the speaker's clinical practice.</P>
<P><I><B>Chairing: </B></I>D.H. Ingbar, M.D., Minneapolis, MNR.J. Maunder,
M.D., Portland, ORD.A. White, M.D., New York, NY</P>
<P><I>8:15</I> <B>General Critical Care Management</B>/D.P. Schuster, M.D.,
St. Louis, MO</P>
<P><I>8:45</I> <B>Interstitial Lung Disease</B>/T.E. King, Jr., M.D., Denver,
CO</P>
<P><I>9:15</I> <B>HIV and AIDS Prognosis and Treatment</B>/D.E. Stover, M.D.,
New York, NY</P>
<P><I>9:45</I> <B>Cystic Fibrosis</B>/<I>Speaker to be announced.</I></P>
<P>Discussion after each presentation/5 minutes</P></BLOCKQUOTE>
<P></P>
<HR SIZE="4" WIDTH="80%">
<CENTER>
<P><A HREF=97ala.html><IMG
SRC=images/activity_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97bus.html><IMG
SRC=images/business_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97cal.html><IMG
SRC=images/calendar_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97child.html><IMG
SRC=images/child_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=pg.html><IMG
SRC=images/courses_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=search.html><IMG
SRC=images/search_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=main.html><IMG
SRC=images/home_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97house.html><IMG
SRC=images/house_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=http://itsmtgs.com/ala-ats><IMG
SRC=images/regist_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=sessions.html><IMG
SRC=images/session_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=special.html><IMG
SRC=images/special_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97tours.html><IMG
SRC=images/tour_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97travel.html><IMG
SRC=images/travel_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
</P></CENTER>
<HR SIZE="4" WIDTH="80%">
<CENTER><FONT SIZE="+2"><B><I>American Thoracic Society</I></B></FONT><BR>
1740 Broadway<BR> New York, NY 10019<BR> VOICE:  212-315-8700<BR> Copyright &copy;
1996 American Lung Association.<BR> The American Thoracic  Society is the
medical section <BR>of the American Lung Association.<BR> 
</CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-86</DOCNO>
<DOCOLDNO>IA013-000139-B028-3</DOCOLDNO>
<DOCHDR>
http://www.thoracic.org:80/ic97/d2.html 206.138.195.144 19970217071842 text/html 4359
HTTP/1.0 200 OK
Date: Monday, 17-Feb-97 07:13:58 GMT
Server: NCSA/1.3
MIME-version: 1.0
Content-type: text/html
Last-modified: Friday, 24-Jan-97 16:15:42 GMT
Content-length: 4179
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//SQ//DTD HTML 2.0 HoTMetaL + extensions//EN">
<HTML>
<HEAD>
<TITLE>CLINICAL TOPICS IN PULMONARY MEDICINE: d2</TITLE></HEAD>
<BODY BGCOLOR="#FFFFFF">
<CENTER><IMG ALIGN="LEFT" SRC="images/banner0.jpg"></CENTER>
<CENTER><BR>
<P>CLINICAL TOPICS IN PULMONARY MEDICINE</P><BR>
<H2>D2: CLINICAL PEDIATRIC CHEST ROUNDS</H2></CENTER>
<HR SIZE="5" NOSHADE="NOSHADE" WIDTH="100%">
<P></P>
<CENTER>
<TABLE BORDER="2">
<TR ALIGN="CENTER" VALIGN="MIDDLE">
<TD ALIGN="CENTER" VALIGN="MIDDLE"><B><SMALL><A HREF="ic97.html">BACK TO
MAIN MENU</A></SMALL></B></TD></TR></TABLE></CENTER>
<P></P>
<HR SIZE="10" WIDTH="85%">
<P></P>
<BLOCKQUOTE>
<CENTER>
<P>WEDNESDAY , MAY 21</P>
<P><B>Assemblies on Clinical Problems/Pediatrics</B></P>
<P><B>8:15 am-11:00 am</B></P></CENTER></BLOCKQUOTE>
<HR SIZE="4" WIDTH="85%" ALIGN="CENTER" NOSHADE="NOSHADE">
<BLOCKQUOTE>
<P><I><B>Target Audience: </B></I>Health care professionals who care for
children and young adults with a variety of lung diseases.</P>
<P><B>OBJECTIVES</B><BR>At the conclusion of this session, the participant
will be able to:</P>
<UL>
<LI>differentiate the causes of cyanosis in an HIV positive young man;</LI>
<LI>recognize the potential causes of fatal pneumonia in an adolescent;</LI>
<LI>understand the different pulmonary-renal syndromes that may effect a child;</LI>
<LI>discuss the management of an infant with fixed airway obstruction.</LI></UL>
<P>Four unusual and particularly educational cases will be presented as
unknowns for the purpose of discussion by a clinically recognized expert. The
cases will focus on a difficult diagnosis, an infection, a pathologic diagnosis,
and a management problem. Discussion from the audience will be encouraged.</P>
<P><I><B>Chairing: </B></I>P.C. Stillwell, M.D., Cleveland, OH</P>
<P><I>8:15</I> <B>Case 1: Presentation Cyanosis in a 17 Year Old HIV-Positive
Boy</B>/M.A. Brown, M.D., Tucson, AZ</P>
<P><I>8:30</I> <B>Case 1: Discussion</B>/M.R. Bye, M.D., New York, NY</P>
<P><I>9:00</I> <B>Case 2: Presentation Fatal Pneumonia in a Diabetic</B>/S.E.
Chesrown, M.D., Ph.D., Gainesville, FL</P>
<P><I>9:10</I> <B>Case 2: Discussion</B>/J.R. Starke, M.D., Houston, TX</P>
<P><I>9:40</I> <B>Case 3: Presentation Pulmonary Infiltrates and Renal
Insufficiency</B>/P.C. Stillwell, M.D., Cleveland, OH</P>
<P><I>9:50</I> <B>Case 3: Discussion</B>/U. Specks, M.D., Rochester, MN</P>
<P><I>10:20</I> <B>Case 4: Presentation Severe Fixed Airway Obstruction in an
Infant</B>/B.M. Schnapf, M.D., Tampa, FL</P>
<P><I>10:30</I> <B>Case 4: Discussion</B>/P. McKeown, M.D., Tampa, FL</P>
<P>Discussion after each presentation/5 minutes</P></BLOCKQUOTE>
<P></P>
<HR SIZE="4" WIDTH="80%">
<CENTER>
<P><A HREF=97ala.html><IMG
SRC=images/activity_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97bus.html><IMG
SRC=images/business_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97cal.html><IMG
SRC=images/calendar_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97child.html><IMG
SRC=images/child_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=pg.html><IMG
SRC=images/courses_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=search.html><IMG
SRC=images/search_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=main.html><IMG
SRC=images/home_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97house.html><IMG
SRC=images/house_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=http://itsmtgs.com/ala-ats><IMG
SRC=images/regist_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=sessions.html><IMG
SRC=images/session_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=special.html><IMG
SRC=images/special_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97tours.html><IMG
SRC=images/tour_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97travel.html><IMG
SRC=images/travel_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
</P></CENTER>
<HR SIZE="4" WIDTH="80%">
<CENTER><FONT SIZE="+2"><B><I>American Thoracic Society</I></B></FONT><BR>
1740 Broadway<BR> New York, NY 10019<BR> VOICE:  212-315-8700<BR> Copyright &copy;
1996 American Lung Association.<BR> The American Thoracic  Society is the
medical section <BR>of the American Lung Association.<BR> 
</CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-87</DOCNO>
<DOCOLDNO>IA013-000139-B028-26</DOCOLDNO>
<DOCHDR>
http://www.thoracic.org:80/ic97/d3.html 206.138.195.144 19970217071850 text/html 3434
HTTP/1.0 200 OK
Date: Monday, 17-Feb-97 07:14:07 GMT
Server: NCSA/1.3
MIME-version: 1.0
Content-type: text/html
Last-modified: Friday, 24-Jan-97 16:15:42 GMT
Content-length: 3254
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//SQ//DTD HTML 2.0 HoTMetaL + extensions//EN">
<HTML>
<HEAD>
<TITLE>CLINICAL TOPICS IN PULMONARY MEDICINE: d3</TITLE></HEAD>
<BODY BGCOLOR="#FFFFFF">
<CENTER><IMG ALIGN="LEFT" SRC="images/banner0.jpg"></CENTER>
<CENTER><BR>
<P>CLINICAL TOPICS IN PULMONARY MEDICINE</P><BR>
<H2>D3: RADIOLOGY AND CLINICAL CORRELATION FOR THE CHEST PHYSICIAN </H2></CENTER>
<HR SIZE="5" NOSHADE="NOSHADE" WIDTH="100%">
<P></P>
<CENTER>
<TABLE BORDER="2">
<TR ALIGN="CENTER" VALIGN="MIDDLE">
<TD ALIGN="CENTER" VALIGN="MIDDLE"><B><SMALL><A HREF="ic97.html">BACK TO
MAIN MENU</A></SMALL></B></TD></TR></TABLE></CENTER>
<P></P>
<HR SIZE="10" WIDTH="85%">
<P></P>
<BLOCKQUOTE>
<CENTER>
<P>WEDNESDAY , MAY 21</P>
<P><B>Council of Chapter Representatives</B></P>
<P><B>8:15 am-11:00 am</B></P></CENTER></BLOCKQUOTE>
<HR SIZE="4" WIDTH="85%" ALIGN="CENTER" NOSHADE="NOSHADE">
<BLOCKQUOTE>
<P><I><B>Target Audience: </B></I>Practicing pediatric and adult
pulmonologists.</P>
<P><B>OBJECTIVES</B><BR>At the conclusion of this session, the participant
will be able to:</P>
<UL>
<LI> examine the differential diagnosis of an unknown abnormal chest
roetgenogram and chest CT.</LI></UL>
<P>Clinical, pathological, radiological correlation of interesting
pulmonary-critical care cases. Cases will be presented as unknowns and discussed
by radiology, pulmonary and pathology specialists.</P>
<P><I><B>Chairing: </B></I>M.R. Crain, M.D., Birmingham, ALR.C. Beckerman,
M.D., New Orleans, LA</P>
<P><B>Pulmonology</B>K. Young, Jr., M.D., Birmingham, AL/W.R. Summer, M.D.,
New Orleans, LA/C.F. Veal, M.D., Seattle, WA</P>
<P><B>Radiology</B>C. Sanders, M.D., Birmingham, AL</P>
<P><B>Pathology</B>J.V. Myers, M.D., Rochester, MN</P></BLOCKQUOTE>
<P></P>
<HR SIZE="4" WIDTH="80%">
<CENTER>
<P><A HREF=97ala.html><IMG
SRC=images/activity_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97bus.html><IMG
SRC=images/business_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97cal.html><IMG
SRC=images/calendar_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97child.html><IMG
SRC=images/child_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=pg.html><IMG
SRC=images/courses_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=search.html><IMG
SRC=images/search_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=main.html><IMG
SRC=images/home_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97house.html><IMG
SRC=images/house_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=http://itsmtgs.com/ala-ats><IMG
SRC=images/regist_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=sessions.html><IMG
SRC=images/session_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=special.html><IMG
SRC=images/special_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97tours.html><IMG
SRC=images/tour_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97travel.html><IMG
SRC=images/travel_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
</P></CENTER>
<HR SIZE="4" WIDTH="80%">
<CENTER><FONT SIZE="+2"><B><I>American Thoracic Society</I></B></FONT><BR>
1740 Broadway<BR> New York, NY 10019<BR> VOICE:  212-315-8700<BR> Copyright &copy;
1996 American Lung Association.<BR> The American Thoracic  Society is the
medical section <BR>of the American Lung Association.<BR> 
</CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-88</DOCNO>
<DOCOLDNO>IA013-000139-B028-59</DOCOLDNO>
<DOCHDR>
http://www.thoracic.org:80/ic97/d51.html 206.138.195.144 19970217071904 text/html 4351
HTTP/1.0 200 OK
Date: Monday, 17-Feb-97 07:14:15 GMT
Server: NCSA/1.3
MIME-version: 1.0
Content-type: text/html
Last-modified: Friday, 24-Jan-97 16:15:44 GMT
Content-length: 4171
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//SQ//DTD HTML 2.0 HoTMetaL + extensions//EN">
<HTML>
<HEAD>
<TITLE>CLINICAL TOPICS IN PULMONARY MEDICINE: d51</TITLE></HEAD>
<BODY BGCOLOR="#FFFFFF">
<CENTER><IMG ALIGN="LEFT" SRC="images/banner0.jpg"></CENTER>
<CENTER><BR>
<P>CLINICAL TOPICS IN PULMONARY MEDICINE</P><BR>
<H2>D51: COMMUNITY-ACQUIRED PNEUMONIA: THE OUT-PATIENT INTERFACE</H2></CENTER>
<HR SIZE="5" NOSHADE="NOSHADE" WIDTH="100%">
<P></P>
<CENTER>
<TABLE BORDER="2">
<TR ALIGN="CENTER" VALIGN="MIDDLE">
<TD ALIGN="CENTER" VALIGN="MIDDLE"><B><SMALL><A HREF="ic97.html">BACK TO
MAIN MENU</A></SMALL></B></TD></TR></TABLE></CENTER>
<P></P>
<HR SIZE="10" WIDTH="85%">
<P></P>
<BLOCKQUOTE>
<CENTER>
<P>WEDNESDAY , MAY 21</P>
<P><B>Assemblies on Clinical Problems/<BR>Microbiology, Tuberculosis and
Pulmonary Infections</B></P>
<P><B>1:30 pm-4:15 pm</B></P></CENTER></BLOCKQUOTE>
<HR SIZE="4" WIDTH="85%" ALIGN="CENTER" NOSHADE="NOSHADE">
<BLOCKQUOTE>
<P><I><B>Target Audience: </B></I>Pulmonary primary care physicians,
residents, and fellows in training.</P>
<P><B>OBJECTIVES</B><BR>At the conclusion of this session, the participant
will be able to:</P>
<UL>
<LI>understand epidemiology of mild pneumonia;</LI>
<LI>recognize patients who may be safely treated in out-patient setting;</LI>
<LI>become familiar with antibiotics available for treatment of out-patient
pneumonia;</LI>
<LI>understand practice and procedures to prevent pneumonia.</LI></UL>
<P>The purpose of this symposium is to offer clinicians an in-depth view of the
state of information available on the epidemiology, diagnosis, treatment, and
prevention of pneumonia in the outpatient setting. The assembled group of
speakers will provide clinicians with a road map to guide them as they seek to
move respiratory care from the confines of the hospital to the home in a safe,
cost effective, yet humane fashion.</P>
<P><I><B>Chairing: </B></I>A.M. Fein, M.D., Mineola, NYR.F. Grossman, M.D.,
Toronto, ON, Canada</P>
<P><I>1:30</I> <B>Epidemiology of Mild Pneumonia</B>/T.J. Marrie, M.D.,
Halifax, NS, Canada</P>
<P><I>2:00</I> <B>Management of Pneumonia in the Out-Patient Setting: Is It
Safe and for Whom?</B>/M. Woodhead, M.D., Manchester, England</P>
<P><I>2:30</I> <B>New Antibiotics: Pushing the Out-Patient Envelope</B>/R.F.
Grossman, M.D., Toronto, ON, Canada</P>
<P><I>3:00</I> <B>Switch Therapy: Hospitalization and Follow-Up</B>/A.M.
Fein, M.D., Mineola, NY</P>
<P><I>3:30</I> <B>Preventive Strategies for Community-Acquired Pneumonia</B>/M.S.
Niederman, M.D., Mineola, NY</P>
<P><I>4:00</I> <B>Panel Discussion</B></P>
<P>Discussion after each presentation/5 minutes</P></BLOCKQUOTE>
<P></P>
<HR SIZE="4" WIDTH="80%">
<CENTER>
<P><A HREF=97ala.html><IMG
SRC=images/activity_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97bus.html><IMG
SRC=images/business_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97cal.html><IMG
SRC=images/calendar_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97child.html><IMG
SRC=images/child_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=pg.html><IMG
SRC=images/courses_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=search.html><IMG
SRC=images/search_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=main.html><IMG
SRC=images/home_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97house.html><IMG
SRC=images/house_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=http://itsmtgs.com/ala-ats><IMG
SRC=images/regist_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=sessions.html><IMG
SRC=images/session_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=special.html><IMG
SRC=images/special_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97tours.html><IMG
SRC=images/tour_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97travel.html><IMG
SRC=images/travel_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
</P></CENTER>
<HR SIZE="4" WIDTH="80%">
<CENTER><FONT SIZE="+2"><B><I>American Thoracic Society</I></B></FONT><BR>
1740 Broadway<BR> New York, NY 10019<BR> VOICE:  212-315-8700<BR> Copyright &copy;
1996 American Lung Association.<BR> The American Thoracic  Society is the
medical section <BR>of the American Lung Association.<BR> 
</CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-89</DOCNO>
<DOCOLDNO>IA013-000139-B028-84</DOCOLDNO>
<DOCHDR>
http://www.thoracic.org:80/ic97/d52.html 206.138.195.144 19970217071913 text/html 4530
HTTP/1.0 200 OK
Date: Monday, 17-Feb-97 07:14:30 GMT
Server: NCSA/1.3
MIME-version: 1.0
Content-type: text/html
Last-modified: Friday, 24-Jan-97 16:15:45 GMT
Content-length: 4350
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//SQ//DTD HTML 2.0 HoTMetaL + extensions//EN">
<HTML>
<HEAD>
<TITLE>CLINICAL TOPICS IN PULMONARY MEDICINE: d52</TITLE></HEAD>
<BODY BGCOLOR="#FFFFFF">
<CENTER><IMG ALIGN="LEFT" SRC="images/banner0.jpg"></CENTER>
<CENTER><BR>
<P>CLINICAL TOPICS IN PULMONARY MEDICINE</P><BR>
<H2>D52: PULMONARY INVOLVEMENT IN NON-PULMONARY DISORDERS</H2></CENTER>
<HR SIZE="5" NOSHADE="NOSHADE" WIDTH="100%">
<P></P>
<CENTER>
<TABLE BORDER="2">
<TR ALIGN="CENTER" VALIGN="MIDDLE">
<TD ALIGN="CENTER" VALIGN="MIDDLE"><B><SMALL><A HREF="ic97.html">BACK TO
MAIN MENU</A></SMALL></B></TD></TR></TABLE></CENTER>
<P></P>
<HR SIZE="10" WIDTH="85%">
<P></P>
<BLOCKQUOTE>
<CENTER>
<P>WEDNESDAY , MAY 21</P>
<P><B>Assembly on Clinical Problems</B></P>
<P><B>1:30 pm-4:15 pm</B></P></CENTER></BLOCKQUOTE>
<HR SIZE="4" WIDTH="85%" ALIGN="CENTER" NOSHADE="NOSHADE">
<BLOCKQUOTE>
<P><I><B>Target Audience: </B></I>Practicing pulmonologists, general
internists, respiratory therapists and nurses.</P>
<P><B>OBJECTIVES</B><BR>At the conclusion of this session, the participant
will be able to:</P>
<UL>
<LI> understand the effects of endocrine and neurologic disorders on pulmonary
physiology;</LI>
<LI>describe and understand how inflammatory bowel disease and liver disease
affect the lung and pulmonary functions;</LI>
<LI>understand how pregnancy may result in or affect pulmonary disorders;</LI>
<LI>describe the various types lymphomatous involvement of the lung.</LI></UL>
<P>This session will describe how diabetic and thyroid disorders affect
pulmonary physiology and how these disorders may present with pulmonary
complaints. Concepts of lymphomatous and GI involvement in lung disease are
continuing to evolve and the latest concepts and descriptions of these disorders
will be discussed. Neurologic disorders and their effects on the lung are
difficult management issues for the practicing pulmonologist. How Parkinson and
MS affect the lung and appropriate therapieswill be outlined.</P>
<P><I><B>Chairing: </B></I>R.A. Helmers, M.D., Scottsdale, AZM.J. Krowka,
M.D., Rochester, MN</P>
<P><I>1:30</I> <B>Pulmonary Manifestations of Diabetes Mellitus and Thyroid
Disorders</B>/R.A. Helmers, M.D., Scottsdale, AZ</P>
<P><I>1:50</I> <B>Pulmonary Manifestations of Parkinson's Disease and
Multiple Sclerosis</B>/L.K. Brown, M.D., Phoenix, AZ</P>
<P><I>2:15</I> <B>Pulmonary Manifestations of Inflammatory Bowel Disease</B>/T.V.
Colby, M.D., Scottsdale, AZ</P>
<P><I>2:40</I> <B>The Effects of Pregnancy on the Respiratory System</B>/G.K.
Iwamoto, M.D., Albuquerque, NM</P>
<P><I>3:15</I> <B>Lymphoproliferative Disorders of the Lung</B>/J.L. Myers,
M.D., Rochester, MN</P>
<P><I>3:40</I> <B>Pulmonary Manifestation of Liver Disease</B>/M.J. Krowka,
M.D., Rochester, MN</P>
<P><I>4:05</I> <B>Panel Discussion</B></P></BLOCKQUOTE>
<P></P>
<HR SIZE="4" WIDTH="80%">
<CENTER>
<P><A HREF=97ala.html><IMG
SRC=images/activity_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97bus.html><IMG
SRC=images/business_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97cal.html><IMG
SRC=images/calendar_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97child.html><IMG
SRC=images/child_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=pg.html><IMG
SRC=images/courses_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=search.html><IMG
SRC=images/search_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=main.html><IMG
SRC=images/home_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97house.html><IMG
SRC=images/house_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=http://itsmtgs.com/ala-ats><IMG
SRC=images/regist_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=sessions.html><IMG
SRC=images/session_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=special.html><IMG
SRC=images/special_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97tours.html><IMG
SRC=images/tour_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97travel.html><IMG
SRC=images/travel_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
</P></CENTER>
<HR SIZE="4" WIDTH="80%">
<CENTER><FONT SIZE="+2"><B><I>American Thoracic Society</I></B></FONT><BR>
1740 Broadway<BR> New York, NY 10019<BR> VOICE:  212-315-8700<BR> Copyright &copy;
1996 American Lung Association.<BR> The American Thoracic  Society is the
medical section <BR>of the American Lung Association.<BR> 
</CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-90</DOCNO>
<DOCOLDNO>IA013-000139-B028-112</DOCOLDNO>
<DOCHDR>
http://www.thoracic.org:80/ic97/a4.html 206.138.195.144 19970217071937 text/html 4370
HTTP/1.0 200 OK
Date: Monday, 17-Feb-97 07:14:52 GMT
Server: NCSA/1.3
MIME-version: 1.0
Content-type: text/html
Last-modified: Friday, 24-Jan-97 16:14:57 GMT
Content-length: 4190
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//SQ//DTD HTML 2.0 HoTMetaL + extensions//EN">
<HTML>
<HEAD>
<TITLE>CRITICAL CARE TRACK: a4</TITLE></HEAD>
<BODY BGCOLOR="#FFFFFF">
<CENTER><IMG ALIGN="LEFT" SRC="images/banner0.jpg"></CENTER>
<CENTER><BR>
<P>CRITICAL CARE TRACK</P><BR>
<H2>A4: EFFECTS OF MECHANICAL VENTILATION ON LUNG INJURY AND REPAIR</H2></CENTER>
<HR SIZE="5" NOSHADE="NOSHADE" WIDTH="100%">
<P></P>
<CENTER>
<TABLE BORDER="2">
<TR ALIGN="CENTER" VALIGN="MIDDLE">
<TD ALIGN="CENTER" VALIGN="MIDDLE"><B><SMALL><A HREF="ic97.html">BACK TO
MAIN MENU</A></SMALL></B></TD></TR></TABLE></CENTER>
<P></P>
<HR SIZE="10" WIDTH="85%">
<P></P>
<CENTER>
<P>SUNDAY , MAY 18</P></CENTER>
<BLOCKQUOTE>
<P><B>Assemblies on Clinical Problems/Respiratory Structure and Function</B></P>
<P><B>8:15 am-11:00 am</B></P></BLOCKQUOTE>
<HR SIZE="4" WIDTH="85%" ALIGN="CENTER" NOSHADE="NOSHADE">
<BLOCKQUOTE>
<P><I><B>Target Audience: </B></I>Scientists, physicians, nurses and
respiratory therapists.</P>
<P><B>OBJECTIVES</B><BR>At the conclusion of this session, the participant
will be able to:</P>
<UL>
<LI>describe the causes and clinical manifestations of ventilator induced lung
injury;</LI>
<LI>describe the effects on non-uniform lung injury on regional ventilation;</LI>
<LI>define the consequences of tissue deformation on the pulmonary vasculature,
the surfactant system and on the mechanisms of inflammation.</LI></UL>
<P>There is overwhelming evidence that mechanical ventilation can damage the
lungs. Therefore, the choice of ventilator mode and settings must not be
exclusively based on gas exchange considerations. Rate and amplitude of lung
inflation determine local tissue stress and patterns of lung deformation.
Deformation, in turn may cause damage, initiate or perpetuate an inflammatory
response and effect tissue remodeling.</P>
<P><I><B>Chairing: </B></I>A.S. Slutsky, M.D., Toronto, ON, CanadaR.D.
Hubmayr, M.D., Rochester, MN</P>
<P><I>8:15</I> <B>High Volume Injury: Volu-trauma</B>/D.D. Dreyfuss, M.D.,
Colombes, France</P>
<P><I>8:40</I> <B>Low Volume Injury: Airway Shear Trauma</B>/A.S. Slutsky,
M.D., Toronto, ON, Canada</P>
<P><I>9:05</I> <B>Mechanisms of Ventilator-Induced Edema Formation</B>/J.J.
Marini, M.D., St. Paul, MN</P>
<P><I>9:30</I> <B>Effects of Stress on the Pulmonary Vasculature</B>/J.B.
West, M.D., Ph.D., La Jolla, CA</P>
<P><I>9:55</I> <B>Mechanisms of Impaired Ventilation in Edematous Lungs</B>/R.D.
Hubmayr, M.D., Rochester, MN</P>
<P><I>10:20</I> <B>Why Ventilator Settings Can Alter Pulmonary Surfacant
Kinetics and Function</B>/E.P. Ingenito, M.D., Ph.D., Boston, MA</P>
<P>Discussion after each presentation/5 minutes</P></BLOCKQUOTE>
<P></P>
<HR SIZE="4" WIDTH="80%">
<CENTER>
<P><A HREF=97ala.html><IMG
SRC=images/activity_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97bus.html><IMG
SRC=images/business_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97cal.html><IMG
SRC=images/calendar_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97child.html><IMG
SRC=images/child_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=pg.html><IMG
SRC=images/courses_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=search.html><IMG
SRC=images/search_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=main.html><IMG
SRC=images/home_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97house.html><IMG
SRC=images/house_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=http://itsmtgs.com/ala-ats><IMG
SRC=images/regist_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=sessions.html><IMG
SRC=images/session_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=special.html><IMG
SRC=images/special_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97tours.html><IMG
SRC=images/tour_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97travel.html><IMG
SRC=images/travel_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
</P></CENTER>
<HR SIZE="4" WIDTH="80%">
<CENTER><FONT SIZE="+2"><B><I>American Thoracic Society</I></B></FONT><BR>
1740 Broadway<BR> New York, NY 10019<BR> VOICE:  212-315-8700<BR> Copyright &copy;
1996 American Lung Association.<BR> The American Thoracic  Society is the
medical section <BR>of the American Lung Association.<BR> 
</CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-91</DOCNO>
<DOCOLDNO>IA013-000139-B028-135</DOCOLDNO>
<DOCHDR>
http://www.thoracic.org:80/ic97/a53.html 206.138.195.144 19970217071945 text/html 4406
HTTP/1.0 200 OK
Date: Monday, 17-Feb-97 07:15:03 GMT
Server: NCSA/1.3
MIME-version: 1.0
Content-type: text/html
Last-modified: Friday, 24-Jan-97 16:14:58 GMT
Content-length: 4226
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//SQ//DTD HTML 2.0 HoTMetaL + extensions//EN">
<HTML>
<HEAD>
<TITLE>CRITICAL CARE TRACK: a53</TITLE></HEAD>
<BODY BGCOLOR="#FFFFFF">
<CENTER><IMG ALIGN="LEFT" SRC="images/banner0.jpg"></CENTER>
<CENTER><BR>
<P>CRITICAL CARE TRACK</P>
<H2>A53: CONTROVERSIES IN CRITICAL CARE MEDICINE</H2>
<P><BR></P></CENTER>
<HR SIZE="5" NOSHADE="NOSHADE" WIDTH="100%">
<P></P>
<CENTER>
<TABLE BORDER="2">
<TR ALIGN="CENTER" VALIGN="MIDDLE">
<TD ALIGN="CENTER" VALIGN="MIDDLE"><B><SMALL><A HREF="ic97.html">BACK TO
MAIN MENU</A></SMALL></B></TD></TR></TABLE></CENTER>
<P></P>
<HR SIZE="10" WIDTH="85%">
<P></P>
<CENTER>
<P>SUNDAY , MAY 18</P></CENTER>
<BLOCKQUOTE>
<P><B>Assembly on Critical Care</B></P>
<P><B>1:30 pm-4:15 pm</B></P></BLOCKQUOTE>
<HR SIZE="4" WIDTH="85%" ALIGN="CENTER" NOSHADE="NOSHADE">
<BLOCKQUOTE>
<P><I><B>Target Audience: </B></I>Physicians, nurses, and respiratory
therapists.</P>
<P><B>OBJECTIVES</B><BR>At the conclusion of this session, the participant
will be able to:</P>
<UL>
<LI>describe the benefits and disadvantages of the use of positive
end-expiratory pressure in patients with ARDS;</LI>
<LI>recognize the usefulness of monitoring respiratory work in critically-ill
patients;</LI>
<LI>describe the benefits and limitations of placing patients with acute
respiratory failure in the prone position.</LI></UL>
<P>This symposium consists of pro and con debates on three controversial
topics: the selection of PEEP in patients with ARDS, the usefulness of
monitoring work of breathing, and the value of prone positioning in patients
with acute respiratory failure.</P>
<P><I><B>Chairing: </B></I>M.A. Matthay, M.D., San Francisco, CAG.M.
Matuschak, M.D., St. Louis, MO</P>
<P><I>1:30</I> <B>Pro: PEEP Adjustment in ARDS Should Be Based on the
Inflection Point of the PV Curve</B>/A.S. Slutsky, M.D., Toronto, ON, Canada</P>
<P><I>1:57</I> <B>Con: PEEP Adjustment in ARDS Should Be Based on the
Inflection Point of the PV Curve</B>/R.K. Albert, M.D., Seattle, WA</P>
<P><I>2:25</I> <B>Pro: Proportional Assist Ventilation Represents a
Significant Advance Over Existing Modes of Mechanical Ventilation</B>/M.K.
Younes, M.D., Winnipeg, MB, Canada</P>
<P><I>2:52</I> <B>Con: Proportional Assist Ventilation Represents a
Significant Advance Over Existing Modes of Mechanical Ventilation</B>/A. Rossi,
M.D., Verona, Italy</P>
<P><I>3:20</I> <B>Pro: The Prone Position Is Helpful in the Management of
Acute Respiratory Failure</B>/J.J. Marini, M.D., St. Paul, MN</P>
<P><I>3:47</I> <B>Con: The Prone Position Is Helpful in the Mangement of
Acute Respiratory Failure</B>/R.A. Klocke, M.D., Buffalo, NY</P>
<P>Discussion after each presentation/5 minutes</P></BLOCKQUOTE>
<P></P>
<HR SIZE="4" WIDTH="80%">
<CENTER>
<P><A HREF=97ala.html><IMG
SRC=images/activity_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97bus.html><IMG
SRC=images/business_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97cal.html><IMG
SRC=images/calendar_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97child.html><IMG
SRC=images/child_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=pg.html><IMG
SRC=images/courses_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=search.html><IMG
SRC=images/search_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=main.html><IMG
SRC=images/home_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97house.html><IMG
SRC=images/house_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=http://itsmtgs.com/ala-ats><IMG
SRC=images/regist_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=sessions.html><IMG
SRC=images/session_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=special.html><IMG
SRC=images/special_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97tours.html><IMG
SRC=images/tour_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97travel.html><IMG
SRC=images/travel_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
</P></CENTER>
<HR SIZE="4" WIDTH="80%">
<CENTER><FONT SIZE="+2"><B><I>American Thoracic Society</I></B></FONT><BR>
1740 Broadway<BR> New York, NY 10019<BR> VOICE:  212-315-8700<BR> Copyright &copy;
1996 American Lung Association.<BR> The American Thoracic  Society is the
medical section <BR>of the American Lung Association.<BR> 
</CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-92</DOCNO>
<DOCOLDNO>IA013-000139-B028-167</DOCOLDNO>
<DOCHDR>
http://www.thoracic.org:80/ic97/b4.html 206.138.195.144 19970217071955 text/html 4193
HTTP/1.0 200 OK
Date: Monday, 17-Feb-97 07:15:10 GMT
Server: NCSA/1.3
MIME-version: 1.0
Content-type: text/html
Last-modified: Friday, 24-Jan-97 16:15:15 GMT
Content-length: 4013
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//SQ//DTD HTML 2.0 HoTMetaL + extensions//EN">
<HTML>
<HEAD>
<TITLE>CRITICAL CARE TRACK: b4</TITLE></HEAD>
<BODY BGCOLOR="#FFFFFF">
<CENTER><IMG ALIGN="LEFT" SRC="images/banner0.jpg"></CENTER>
<CENTER><BR>
<P>CRITICAL CARE TRACK</P><BR>
<H2>B4: PATIENT-VENTILATOR INTERACTION</H2></CENTER>
<HR SIZE="5" NOSHADE="NOSHADE" WIDTH="100%">
<P></P>
<CENTER>
<TABLE BORDER="2">
<TR ALIGN="CENTER" VALIGN="MIDDLE">
<TD ALIGN="CENTER" VALIGN="MIDDLE"><B><SMALL><A HREF="ic97.html">BACK TO
MAIN MENU</A></SMALL></B></TD></TR></TABLE></CENTER>
<P></P>
<HR SIZE="10" WIDTH="85%">
<P></P>
<CENTER>
<P>MONDAY , MAY 19</P></CENTER>
<BLOCKQUOTE>
<P><B>Assembly on Critical Care</B></P>
<P><B>8:15 am-11:00 am</B></P></BLOCKQUOTE>
<HR SIZE="4" WIDTH="85%" ALIGN="CENTER" NOSHADE="NOSHADE">
<BLOCKQUOTE>
<P><I><B>Target Audience: </B></I>Physicians, nurses and respiratory
therapists.</P>
<P><B>OBJECTIVE</B><BR>At the conclusion of this session, the participant
will be able to:</P>
<UL>
<LI>describe the pathophysiology of patient-ventilator asynchrony;</LI>
<LI>recognize and identify patient-ventilator asynchrony;</LI>
<LI>optimize patient-ventilator interaction.</LI></UL>
<P>This symposium will focus on the underlying pathophysiology and
identification of patient-ventilator asynchrony, the influence of the various
modes of mechanical ventilation on the interaction, and finally, the mangement
of this commonly encounteredproblem of patients on mechanical ventilation.</P>
<P><I><B>Chairing: </B></I>R.M. Kacmarek, Ph.D., R.T.T., Boston, MAC.S.
Sassoon, M.D., Long Beach, CA</P>
<P><I>8:15</I> <B>Introduction: Why All the Concern About Patient-Ventilator
Synchrony?</B>/R.M. Kacmarek, Ph.D., R.T.T., Boston, MA</P>
<P><I>8:30</I> <B>Pathophysiology of Patient-Ventilator Asynchrony</B>/A.
Rossi, M.D., Verona, Italy</P>
<P><I>8:55</I> <B>Identification of Patient-Ventilator Asynchrony</B>/R.D.
Hubmayr, M.D., Rochester, MN</P>
<P><I>9:20</I> <B>Does Pressure Support Ventilation Promote
Patient-Ventilator Asynchrony?</B>/A. Jubran, M.D., Hines, IL</P>
<P><I>9:45</I> <B>Pressure-Volume Targeted Ventilation: Role in
Patient-Ventilator Synchrony</B>/M.B. P. Amato, M.D., Sao Paulo, SP, Brazil</P>
<P><I>10:10</I> <B>Proportional Assist Ventilation: The Ideal Mode?</B>/V.Marco
Ranieri, M.D., Bari, Italy</P>
<P><I>10:35</I> <B>Optimizing Patient-Ventilator Interaction</B>/J.J. Marini,
M.D., St. Paul, MN</P>
<P>Discussion after each presentation/5 minutes</P></BLOCKQUOTE>
<P></P>
<HR SIZE="4" WIDTH="80%">
<CENTER>
<P><A HREF=97ala.html><IMG
SRC=images/activity_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97bus.html><IMG
SRC=images/business_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97cal.html><IMG
SRC=images/calendar_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97child.html><IMG
SRC=images/child_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=pg.html><IMG
SRC=images/courses_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=search.html><IMG
SRC=images/search_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=main.html><IMG
SRC=images/home_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97house.html><IMG
SRC=images/house_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=http://itsmtgs.com/ala-ats><IMG
SRC=images/regist_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=sessions.html><IMG
SRC=images/session_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=special.html><IMG
SRC=images/special_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97tours.html><IMG
SRC=images/tour_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97travel.html><IMG
SRC=images/travel_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
</P></CENTER>
<HR SIZE="4" WIDTH="80%">
<CENTER><FONT SIZE="+2"><B><I>American Thoracic Society</I></B></FONT><BR>
1740 Broadway<BR> New York, NY 10019<BR> VOICE:  212-315-8700<BR> Copyright &copy;
1996 American Lung Association.<BR> The American Thoracic  Society is the
medical section <BR>of the American Lung Association.<BR> 
</CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-93</DOCNO>
<DOCOLDNO>IA013-000139-B028-192</DOCOLDNO>
<DOCHDR>
http://www.thoracic.org:80/ic97/b53.html 206.138.195.144 19970217072002 text/html 5208
HTTP/1.0 200 OK
Date: Monday, 17-Feb-97 07:15:20 GMT
Server: NCSA/1.3
MIME-version: 1.0
Content-type: text/html
Last-modified: Friday, 24-Jan-97 16:15:16 GMT
Content-length: 5028
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//SQ//DTD HTML 2.0 HoTMetaL + extensions//EN">
<HTML>
<HEAD>
<TITLE>CRITICAL CARE TRACK: b53</TITLE></HEAD>
<BODY BGCOLOR="#FFFFFF">
<CENTER><IMG ALIGN="LEFT" SRC="images/banner0.jpg"></CENTER>
<CENTER><BR>
<P>CRITICAL CARE TRACK</P><BR>
<H2>B53: USING OUTCOMES RESEARCH TO OPTIMIZE THE MANAGEMENT OF CRITICALLY ILL
PATIENTS AND INTENSIVE CARE UNITS</H2></CENTER>
<HR SIZE="5" NOSHADE="NOSHADE" WIDTH="100%">
<P></P>
<CENTER>
<TABLE BORDER="2">
<TR ALIGN="CENTER" VALIGN="MIDDLE">
<TD ALIGN="CENTER" VALIGN="MIDDLE"><B><SMALL><A HREF="ic97.html">BACK TO
MAIN MENU</A></SMALL></B></TD></TR></TABLE></CENTER>
<P></P>
<HR SIZE="10" WIDTH="85%">
<P></P>
<BLOCKQUOTE>
<CENTER>
<P>MONDAY , MAY 19</P>
<P><B>Assembly on Critical Care</B></P>
<P><B>1:30 pm-4:15 pm</B></P></CENTER></BLOCKQUOTE>
<HR SIZE="4" WIDTH="85%" ALIGN="CENTER" NOSHADE="NOSHADE">
<BLOCKQUOTE>
<P><I><B>Target Audience: </B></I>Critical care practitioners (physicians,
nurses, respiratory therapists) and administrators of intensive care units.</P>
<P><B>OBJECTIVES</B><BR>At the conclusion of this session, the participant
will be able to:</P>
<UL>
<LI>describe the role of outcomes research as a tool for rapidly changing the
practice of critical care;</LI>
<LI>describe how change concepts, standardized protocols, and evidence based
medicine can be efficiently evaluated and implemented to improve current ICU
practices;</LI>
<LI>describe the basic premise behind more efficient disease management which
results in lower costs and improved health care outcomes (i.e., eliminating
unintentional variability in the process of medical care).</LI></UL>
<P>In this symposium, the impact of outcomes research on the management of ICU
patients will be addressed. Additionally, the potential influence for outcomes
research to improve the day-to-day running of modern intensive care units will
be discussed. The individual sessions will deal with practical issues related to
diagnostic approaches, individual patient management decisions, resource
utilization, and treatment options. Innovative strategies for improving patient
outcomes and reducing medical care costs will be explored.</P>
<P><I><B>Chairing: </B></I>M.H. Kollef, M.D., St. Louis, MOD.J. Cook, M.D.,
Hamilton, ON, Canada</P>
<P><I>1:30</I> <B>Introduction: An Overview of Recent Developments from
Outcomes Research; &quot;The Example of Respiratory Therapy&quot;</B>/M.H.
Kollef, M.D., St. Louis, MO</P>
<P><I>1:40</I> <B>Using Evidence Based Medicine to Change ICU Medical
Practices</B>/D.J. Cook, M.D., Hamilton, ON, Canada</P>
<P><I>2:00</I> <B>Developing, Implementing, and Gaining Acceptance for ICU
Treatment Protocols</B>/T.P. Clemmer, M.D., Salt Lake City, UT</P>
<P><I>2:20</I> <B>Developing, Evaluating, and Implementing Clinical Practice
Guidelines in the ICU Setting</B>/A.G. Ellrodt, M.D., New York, NY</P>
<P><I>2:40</I> <B>Using Outcomes Research to Improve the Management of
Post-Transplant Patients in the ICU</B>/S. Crawford, M.D., Seattle, WA</P>
<P><I>3:00</I> <B>Weaning Patients from Mechanical Ventilation. Has Outcomes
Research Taught Us Anything?</B>/I.L. Cohen, M.D., Buffalo, NY</P>
<P><I>3:20</I> <B>Strategies for the Cost-Effective Utilization of Ancillary
Services in the ICU</B>/G. Rubenfeld, M.D., Seattle, WA</P>
<P><I>3:40</I> <B>Death and Dying in the ICU. Using Outcomes Research to
Improve Patient Care at the End of Life</B>/P.N. Lanken, M.D., Philadelphia, PA</P>
<P><I>4:00</I> <I>Discussion</I></P></BLOCKQUOTE>
<P></P>
<HR SIZE="4" WIDTH="80%">
<CENTER>
<P><A HREF=97ala.html><IMG
SRC=images/activity_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97bus.html><IMG
SRC=images/business_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97cal.html><IMG
SRC=images/calendar_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97child.html><IMG
SRC=images/child_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=pg.html><IMG
SRC=images/courses_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=search.html><IMG
SRC=images/search_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=main.html><IMG
SRC=images/home_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97house.html><IMG
SRC=images/house_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=http://itsmtgs.com/ala-ats><IMG
SRC=images/regist_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=sessions.html><IMG
SRC=images/session_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=special.html><IMG
SRC=images/special_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97tours.html><IMG
SRC=images/tour_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97travel.html><IMG
SRC=images/travel_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
</P></CENTER>
<HR SIZE="4" WIDTH="80%">
<CENTER><FONT SIZE="+2"><B><I>American Thoracic Society</I></B></FONT><BR>
1740 Broadway<BR> New York, NY 10019<BR> VOICE:  212-315-8700<BR> Copyright &copy;
1996 American Lung Association.<BR> The American Thoracic  Society is the
medical section <BR>of the American Lung Association.<BR> 
</CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-94</DOCNO>
<DOCOLDNO>IA013-000139-B028-223</DOCOLDNO>
<DOCHDR>
http://www.thoracic.org:80/ic97/c4.html 206.138.195.144 19970217072014 text/html 4997
HTTP/1.0 200 OK
Date: Monday, 17-Feb-97 07:15:28 GMT
Server: NCSA/1.3
MIME-version: 1.0
Content-type: text/html
Last-modified: Friday, 24-Jan-97 16:15:30 GMT
Content-length: 4817
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//SQ//DTD HTML 2.0 HoTMetaL + extensions//EN">
<HTML>
<HEAD>
<TITLE>CRITICAL CARE TRACK: c4</TITLE></HEAD>
<BODY BGCOLOR="#FFFFFF">
<CENTER><IMG ALIGN="LEFT" SRC="images/banner0.jpg"></CENTER>
<CENTER><BR>
<P>CRITICAL CARE TRACK</P><BR>
<H2>C4: NUTRITION, THE GUT, AND CRITICAL ILLNESS</H2></CENTER>
<HR SIZE="5" NOSHADE="NOSHADE" WIDTH="100%">
<P></P>
<CENTER>
<TABLE BORDER="2">
<TR ALIGN="CENTER" VALIGN="MIDDLE">
<TD ALIGN="CENTER" VALIGN="MIDDLE"><B><SMALL><A HREF="ic97.html">BACK TO
MAIN MENU</A></SMALL></B></TD></TR></TABLE></CENTER>
<P></P>
<HR SIZE="10" WIDTH="85%">
<P></P>
<BLOCKQUOTE>
<CENTER>
<P>TUESDAY , MAY 20</P>
<P><B>Assembly on Critical Care</B></P>
<P><B>8:15 am-11:00 am</B></P></CENTER></BLOCKQUOTE>
<HR SIZE="4" WIDTH="85%" ALIGN="CENTER" NOSHADE="NOSHADE">
<BLOCKQUOTE>
<P><I><B>Target Audience: </B></I>Physicians interested in intensive care.</P>
<P><B>OBJECTIVES</B><BR>At the conclusion of this session, the participant
will be able to:</P>
<UL>
<LI>identify the benefits and limitations of enteral nutrition regarding GIT
function and risk of infection;</LI>
<LI>describe data indicating gut hypoxia in hypoperfused states occurs, can be
monitored, and should be treated;</LI>
<LI>describe basic clinical information proposing a role for hepatic and GIT
dysfunction in sepsis syndrome;</LI>
<LI>explore the use of gut permeability as a marker for gut dysfunction and
risk factor for MSOF;</LI>
<LI>describe current vasoactive and other drug therapies that could influence
gut perfusion and function in critical illness;</LI>
<LI>delineate pharmacologic influences on GIT that are common in critical
illness.</LI></UL>
<P>Much controversy surrounds even the most fundamental issues concerning
nutrition, gastrointestinal track (GIT) function, and critical illness. This
symposium will explore basic scientific and clinical information concerning
optimal approaches to nutrition in the critically ill, data suggesting GIT
hypoxia exists in critical illness and how it may be detected and treated, the
use of vasoactive drugs to enhance GIT perfusion in hypoperfused states, and the
pharmacologic influences on GIT function in the critically ill patient.</P>
<P><I><B>Chairing: </B></I>S.K. Pingleton, M.D., Kansas City, KST.W. Evans,
M.D., London, England</P>
<P><I>8:15</I> <B>Relationship of Nutrition and GI Prophylactic Therapy to
Pneumonia</B>/D.J. Cook, M.D., Hamilton, ON, Canada</P>
<P><I>8:44</I> <B>GIT Hypoxia in Critical Illness: Does It Exist, Can We
Monitor It, What Are the Consequences?</B>/G. Gutierrez, M.D., Ph.D., Houston,
TX</P>
<P><I>9:12</I> <B>GIT and the Liver in Sepsis: Bench and Clinical Information
Indicating a Role in the Pathophysiology of Sepsis Syndrome and MSOF</B>/G.M.
Matuschak, M.D., St. Louis, MO</P>
<P><I>9:41</I> <B>GIT Permeability in Critical Illness: How Is It Assessed,
Does It Provide Prognosis, and Can We Influence It?</B>/T.W. Evans, M.D.,
London, England</P>
<P><I>10:00</I> <B>Treatment of GIT Hypoxia in Critical Illness: Vasoactive
Drug Use and Other Interventions</B>/R. Hall, M.D., Chicago, IL</P>
<P><I>10:30</I> <B>Pharmacologic Influences on GIT Function in Critical
Illness</B>/M.P. O'Connor, M.D., Chicago, IL</P>
<P>Discussion after each presentation/5 minutes</P></BLOCKQUOTE>
<P></P>
<HR SIZE="4" WIDTH="80%">
<CENTER>
<P><A HREF=97ala.html><IMG
SRC=images/activity_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97bus.html><IMG
SRC=images/business_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97cal.html><IMG
SRC=images/calendar_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97child.html><IMG
SRC=images/child_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=pg.html><IMG
SRC=images/courses_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=search.html><IMG
SRC=images/search_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=main.html><IMG
SRC=images/home_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97house.html><IMG
SRC=images/house_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=http://itsmtgs.com/ala-ats><IMG
SRC=images/regist_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=sessions.html><IMG
SRC=images/session_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=special.html><IMG
SRC=images/special_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97tours.html><IMG
SRC=images/tour_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97travel.html><IMG
SRC=images/travel_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
</P></CENTER>
<HR SIZE="4" WIDTH="80%">
<CENTER><FONT SIZE="+2"><B><I>American Thoracic Society</I></B></FONT><BR>
1740 Broadway<BR> New York, NY 10019<BR> VOICE:  212-315-8700<BR> Copyright &copy;
1996 American Lung Association.<BR> The American Thoracic  Society is the
medical section <BR>of the American Lung Association.<BR> 
</CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-95</DOCNO>
<DOCOLDNO>IA013-000139-B028-253</DOCOLDNO>
<DOCHDR>
http://www.thoracic.org:80/ic97/c53.html 206.138.195.144 19970217072025 text/html 4035
HTTP/1.0 200 OK
Date: Monday, 17-Feb-97 07:15:40 GMT
Server: NCSA/1.3
MIME-version: 1.0
Content-type: text/html
Last-modified: Friday, 24-Jan-97 16:15:32 GMT
Content-length: 3855
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//SQ//DTD HTML 2.0 HoTMetaL + extensions//EN">
<HTML>
<HEAD>
<TITLE>CRITICAL CARE TRACK: c53</TITLE></HEAD>
<BODY BGCOLOR="#FFFFFF">
<CENTER><IMG ALIGN="LEFT" SRC="images/banner0.jpg"></CENTER>
<CENTER><BR>
<P>CRITICAL CARE TRACK</P><BR>
<H2>C53: CLINICAL CASES IN CRITICAL CARE MEDICINE 1</H2></CENTER>
<HR SIZE="5" NOSHADE="NOSHADE" WIDTH="100%">
<P></P>
<CENTER>
<TABLE BORDER="2">
<TR ALIGN="CENTER" VALIGN="MIDDLE">
<TD ALIGN="CENTER" VALIGN="MIDDLE"><B><SMALL><A HREF="ic97.html">BACK TO
MAIN MENU</A></SMALL></B></TD></TR></TABLE></CENTER>
<P></P>
<HR SIZE="10" WIDTH="85%">
<P></P>
<BLOCKQUOTE>
<CENTER>
<P>TUESDAY , MAY 20</P>
<P><B>Assembly on Critical Care</B></P>
<P><B>3:15 PM&#151;6:00 PM</B></P></CENTER></BLOCKQUOTE>
<HR SIZE="4" WIDTH="85%" ALIGN="CENTER" NOSHADE="NOSHADE">
<BLOCKQUOTE>
<P><I><B>Target Audience: </B></I>Physicians, nurses, and respiratory
therapists.</P>
<P><B>OBJECTIVES</B><BR>At the conclusion of this session, the participant
will be able to:</P>
<UL>
<LI>describe the advantages and limitations of non-invasive ventilation;</LI>
<LI>understand unique problems that arise in patients with severe asthma who
require mechanical ventilation, and identify methods of minimizing such
problems;</LI>
<LI>describe the problems that arise in an immuno compromised patient;</LI>
<LI>understand what makes a pneumothorax to be considered under &quot;tension&quot;,
how to identify it, and how to relieve it.</LI></UL>
<P>This session is designed to provide state-of-the-art reviews of diagnosis
and management of patients with various critical illnesses. The session will be
case-oriented with each speaker providing at least one case example to
illustrate sound scientific principles in the management of severely-ill
patients.</P>
<P><I><B>Chairing: </B></I>J.E. Heffner, M.D., Phoenix, AZC. Brun-Buisson,
M.D., Creteil, France</P>
<P><I>3:15</I> <B>Consideration of Tracheostomy in a Ventilator-Supported
Patient</B>/J.E. Heffner, M.D., Phoenix, AZ</P>
<P><I>3:53</I> <B>Non-Invasive Mechanical Ventilation</B>/M.W. Elliott, M.D.,
Leeds, England</P>
<P><I>4:31</I> <I>Break</I></P>
<P><I>4:41</I> <B>The Febrile Patient on a Ventilator</B>/C. Brun-Buisson,
M.D., Creteil, France</P>
<P><I>5:19</I> <B>Tension Pneumothorax</B>/R.W. Light, M.D., Long Beach, CA</P></BLOCKQUOTE>
<P></P>
<HR SIZE="4" WIDTH="80%">
<CENTER>
<P><A HREF=97ala.html><IMG
SRC=images/activity_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97bus.html><IMG
SRC=images/business_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97cal.html><IMG
SRC=images/calendar_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97child.html><IMG
SRC=images/child_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=pg.html><IMG
SRC=images/courses_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=search.html><IMG
SRC=images/search_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=main.html><IMG
SRC=images/home_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97house.html><IMG
SRC=images/house_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=http://itsmtgs.com/ala-ats><IMG
SRC=images/regist_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=sessions.html><IMG
SRC=images/session_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=special.html><IMG
SRC=images/special_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97tours.html><IMG
SRC=images/tour_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97travel.html><IMG
SRC=images/travel_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
</P></CENTER>
<HR SIZE="4" WIDTH="80%">
<CENTER><FONT SIZE="+2"><B><I>American Thoracic Society</I></B></FONT><BR>
1740 Broadway<BR> New York, NY 10019<BR> VOICE:  212-315-8700<BR> Copyright &copy;
1996 American Lung Association.<BR> The American Thoracic  Society is the
medical section <BR>of the American Lung Association.<BR> 
</CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-96</DOCNO>
<DOCOLDNO>IA013-000139-B028-284</DOCOLDNO>
<DOCHDR>
http://www.thoracic.org:80/ic97/d4.html 206.138.195.144 19970217072036 text/html 3981
HTTP/1.0 200 OK
Date: Monday, 17-Feb-97 07:15:54 GMT
Server: NCSA/1.3
MIME-version: 1.0
Content-type: text/html
Last-modified: Friday, 24-Jan-97 16:15:44 GMT
Content-length: 3801
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//SQ//DTD HTML 2.0 HoTMetaL + extensions//EN">
<HTML>
<HEAD>
<TITLE>CRITICAL CARE TRACK: d4</TITLE></HEAD>
<BODY BGCOLOR="#FFFFFF">
<CENTER><IMG ALIGN="LEFT" SRC="images/banner0.jpg"></CENTER>
<CENTER><BR>
<P>CRITICAL CARE TRACK</P><BR>
<H2>D4: INHALED THERAPY IN RESPIRATORY FAILURE</H2></CENTER>
<HR SIZE="5" NOSHADE="NOSHADE" WIDTH="100%">
<P></P>
<CENTER>
<TABLE BORDER="2">
<TR ALIGN="CENTER" VALIGN="MIDDLE">
<TD ALIGN="CENTER" VALIGN="MIDDLE"><B><SMALL><A HREF="ic97.html">BACK TO
MAIN MENU</A></SMALL></B></TD></TR></TABLE></CENTER>
<P></P>
<HR SIZE="10" WIDTH="85%">
<P></P>
<BLOCKQUOTE>
<CENTER>
<P>WEDNESDAY , MAY 21</P>
<P><B>Assembly on Critical Care</B></P>
<P><B>8:15 am-11:00 am</B></P></CENTER></BLOCKQUOTE>
<HR SIZE="4" WIDTH="85%" ALIGN="CENTER" NOSHADE="NOSHADE">
<BLOCKQUOTE>
<P><I><B>Target Audience: </B></I>Physicians, nurses and respiratory
therapists.</P>
<P><B>OBJECTIVES</B><BR>At the conclusion of this session, the participant
will be able to:</P>
<UL>
<LI>describe the options in inhalational therapy;</LI>
<LI>review data indicating the possible role of inhalational therapies in
respiratory failure;</LI>
<LI>identify the benefits and limitations of inhalational therapies in
respiratory failure.</LI></UL>
<P>Until recently, treatment of respiratory failure has been systemic with the
exception of aerosol administration. Considerable recent progress has been made
in the field of inhalational therapies, especially nitric oxide inhalation. The
latest area of intense interest and investigation is liquid ventilation. The
move from gas to liquid ventilation leads us to a fundamental re-evaluation of
respiratory physiology.</P>
<P><I><B>Chairing: </B></I>J.G. C. Vincent, M.D., Brussels, BelgiumT.W.
Evans, M.D., Ph.D., London, England</P>
<P><I>8:15</I> <B>Inhaled Surfactant</B>/A.H. Jobe, M.D., Torrance, CA</P>
<P><I>8:48</I> <B>Inhaled NO Therapy</B>/D. Payen, M.D., Ph.D., Paris, France</P>
<P><I>9:21</I> <B>Inhaled Prostaglandins</B>/W. Seeger, M.D., Giessen,
Germany</P>
<P><I>9:54</I> <B>Inhaled Bronchodilators</B>/R. Dhand, M.D., Hines, IL</P>
<P><I>10:27</I> <B>Liquid Ventilation</B>/B. Lachmann, M.D., Ph.D.,
Rotterdam, The Netherlands</P>
<P>Discussion after each presentation/5 minutes</P></BLOCKQUOTE>
<P></P>
<HR SIZE="4" WIDTH="80%">
<CENTER>
<P><A HREF=97ala.html><IMG
SRC=images/activity_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97bus.html><IMG
SRC=images/business_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97cal.html><IMG
SRC=images/calendar_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97child.html><IMG
SRC=images/child_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=pg.html><IMG
SRC=images/courses_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=search.html><IMG
SRC=images/search_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=main.html><IMG
SRC=images/home_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97house.html><IMG
SRC=images/house_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=http://itsmtgs.com/ala-ats><IMG
SRC=images/regist_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=sessions.html><IMG
SRC=images/session_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=special.html><IMG
SRC=images/special_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97tours.html><IMG
SRC=images/tour_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97travel.html><IMG
SRC=images/travel_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
</P></CENTER>
<HR SIZE="4" WIDTH="80%">
<CENTER><FONT SIZE="+2"><B><I>American Thoracic Society</I></B></FONT><BR>
1740 Broadway<BR> New York, NY 10019<BR> VOICE:  212-315-8700<BR> Copyright &copy;
1996 American Lung Association.<BR> The American Thoracic  Society is the
medical section <BR>of the American Lung Association.<BR> 
</CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-97</DOCNO>
<DOCOLDNO>IA013-000139-B028-315</DOCOLDNO>
<DOCHDR>
http://www.thoracic.org:80/ic97/d53.html 206.138.195.144 19970217072117 text/html 4206
HTTP/1.0 200 OK
Date: Monday, 17-Feb-97 07:16:35 GMT
Server: NCSA/1.3
MIME-version: 1.0
Content-type: text/html
Last-modified: Friday, 24-Jan-97 16:15:46 GMT
Content-length: 4026
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//SQ//DTD HTML 2.0 HoTMetaL + extensions//EN">
<HTML>
<HEAD>
<TITLE>CRITICAL CARE TRACK: d53</TITLE></HEAD>
<BODY BGCOLOR="#FFFFFF">
<CENTER><IMG ALIGN="LEFT" SRC="images/banner0.jpg"></CENTER>
<CENTER><BR>
<P>CRITICAL CARE TRACK</P><BR>
<H2>D53: INVESTIGATING THE INJURED LUNG</H2></CENTER>
<HR SIZE="5" NOSHADE="NOSHADE" WIDTH="100%">
<P></P>
<CENTER>
<TABLE BORDER="2">
<TR ALIGN="CENTER" VALIGN="MIDDLE">
<TD ALIGN="CENTER" VALIGN="MIDDLE"><B><SMALL><A HREF="ic97.html">BACK TO
MAIN MENU</A></SMALL></B></TD></TR></TABLE></CENTER>
<P></P>
<HR SIZE="10" WIDTH="85%">
<P></P>
<BLOCKQUOTE>
<CENTER>
<P>WEDNESDAY , MAY 21</P>
<P><B>Assembly on Clinical Problems</B></P>
<P><B>1:30 pm-4:15 pm</B></P></CENTER></BLOCKQUOTE>
<HR SIZE="4" WIDTH="85%" ALIGN="CENTER" NOSHADE="NOSHADE">
<BLOCKQUOTE>
<P><I><B>Target Audience: </B></I>Physicians, nurses and respiratory
therapists.</P>
<P><B>OBJECTIVES</B><BR>At the conclusion of this session, the participant
will be able to:</P>
<UL>
<LI>describe the new information resulting from research using CT scanning;</LI>
<LI>describe the pathophysiological alterations in pulmonary gas-exchange and
mechanics;</LI>
<LI>describe mechanisms that control alveolar fluid balance;</LI>
<LI>describe the usefulness of disease-severity scoring systems.</LI></UL>
<P>Defining the nature and extent of lung injury in patients with acute
respiratory distress syndrome is important in understanding the pathophysiology
of this order, in planning appropriate therapy, and in development of new
treatment strategies. This symposium will cover recent advances in new methods
of assessment, ranging from molecular mechanisms to gross anatomical changes
detected by imaging modalities.</P>
<P><I><B>Chairing: </B></I>S.K. Epstein, M.D., Boston, MAD.P. Schuster, M.D.,
St. Louis, MO</P>
<P><I>1:30</I> <B>CT and Other Imaging Modalities</B>/L. Gattinoni, M.D.,
Milano, Italy</P>
<P><I>1:57</I> <B>Evaluating Normal Mechanisms of Clearance of Alveolar Edema
Fluid</B>/I.J. Sznajder, M.D., Chicago, IL</P>
<P><I>2:25</I> <B>Bronchoalveolar Lavage and Peripheral Blood Markers in
Patients with ALI/ARDS</B>/M.A. Matthay, M.D., San Francisco, CA</P>
<P><I>2:53</I> <B>Respiratory Mechanics</B>/C.S. Sassoon, M.D., Long Beach,
CA</P>
<P><I>3:21</I> <B>Pulmonary Gas Exchange</B>/R. Rodriguez-Roisin, M.D.,
F.R.C.P., Barcelona, Spain</P>
<P><I>3:49</I> <B>Scoring Systems in ALI/ARDS: Accuracy and Relevance</B>/G.R.
Bernard, M.D., Nashville, TN</P></BLOCKQUOTE>
<P></P>
<HR SIZE="4" WIDTH="80%">
<CENTER>
<P><A HREF=97ala.html><IMG
SRC=images/activity_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97bus.html><IMG
SRC=images/business_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97cal.html><IMG
SRC=images/calendar_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97child.html><IMG
SRC=images/child_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=pg.html><IMG
SRC=images/courses_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=search.html><IMG
SRC=images/search_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=main.html><IMG
SRC=images/home_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97house.html><IMG
SRC=images/house_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=http://itsmtgs.com/ala-ats><IMG
SRC=images/regist_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=sessions.html><IMG
SRC=images/session_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=special.html><IMG
SRC=images/special_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97tours.html><IMG
SRC=images/tour_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97travel.html><IMG
SRC=images/travel_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
</P></CENTER>
<HR SIZE="4" WIDTH="80%">
<CENTER><FONT SIZE="+2"><B><I>American Thoracic Society</I></B></FONT><BR>
1740 Broadway<BR> New York, NY 10019<BR> VOICE:  212-315-8700<BR> Copyright &copy;
1996 American Lung Association.<BR> The American Thoracic  Society is the
medical section <BR>of the American Lung Association.<BR> 
</CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-98</DOCNO>
<DOCOLDNO>IA013-000139-B028-332</DOCOLDNO>
<DOCHDR>
http://www.thoracic.org:80/ic97/profs1.html 206.138.195.144 19970217072125 text/html 5165
HTTP/1.0 200 OK
Date: Monday, 17-Feb-97 07:16:43 GMT
Server: NCSA/1.3
MIME-version: 1.0
Content-type: text/html
Last-modified: Friday, 24-Jan-97 16:16:22 GMT
Content-length: 4985
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//SQ//DTD HTML 2.0 HoTMetaL + extensions//EN">
<HTML>
<HEAD>
<TITLE>MEET THE PROFESSOR SEMINARS</TITLE></HEAD>
<BODY BGCOLOR="#FFFFFF">
<CENTER><IMG ALIGN="LEFT" SRC="images/master.jpg"></CENTER>
<CENTER><BR> 
<H2>MEET THE PROFESSOR SEMINARS</H2>
<P><BR></P></CENTER>
<HR SIZE="5" NOSHADE="NOSHADE" WIDTH="100%">
<P></P>
<CENTER>
<TABLE BORDER="2">
<TR ALIGN="CENTER" VALIGN="MIDDLE">
<TD ALIGN="CENTER" VALIGN="MIDDLE"><B><SMALL><A HREF="ic97.html">BACK TO
MAIN MENU</A></SMALL></B></TD></TR></TABLE></CENTER>
<P></P>
<HR SIZE="10" WIDTH="85%">
<P></P>
<CENTER>
<P>SUNDAY , MAY 18</P></CENTER>
<BLOCKQUOTE>
<P><B>Registration Fee: $20.00 (includes box lunch)</B>. <I>Attendance is
limited. Advance registration is required and on a first come, first served
basis.</I></P>
<P><B>12:00 noon-1:00 pm</B></P></BLOCKQUOTE>
<HR SIZE="4" WIDTH="85%" ALIGN="CENTER" NOSHADE="NOSHADE">
<BLOCKQUOTE>
<P><I> MP401. </I> <B>GENE THERAPY FOR MALIGNANCIES </B><I>Convener/</I>S.M.
Albelda, M.D., Philadelphia, PA</P>
<P><I> MP402. </I> <B>RATING RESPIRATORY IMPAIRMENT AND DISABILITY:
SCIENTIFIC BASIS AND PRACTICAL APPROACH </B><I>Convener</I>/S. Barnhart, M.D.,
Seattle, WA</P>
<P><I> MP403. </I> <B>ACUTE LUNG INJURY </B><I>Convener</I>/D.H. Ingbar,
M.D., Minneapolis, MN</P>
<P><I> MP404.</I> <B>TODAY'S VIEWS ON IMMUNOTHERAPY FOR THE PULMONOLOGIST
</B><I>Convener</I>/J. Bousquet, M.D., Ph.D., Montpellier, France</P>
<P><I> MP405.</I> <B>HYPERSENSITIVITY PNEUMONITIS </B><I>Convener</I>/S.M.
Brooks, M.D., Tampa, FL</P>
<P><I> MP406.</I> <B>PULMONARY REHABILITATION </B><I>Convener</I>/B.R.
Celli, M.D., Boston, MA</P>
<P><I> MP407.</I> <B>PULMONARY COMPLICATIONS OF ILLICITDRUG USE </B><I>Convener</I>/A.E.
O'Donnell, M.D., Washington, DC</P>
<P><I> MP408.</I> <B>CHILDHOOD RESPIRATORY VIRUSES: ADULT MANIFESTATIONS </B><I>Convener</I>/B.
Rubin, M.D., St. Louis, MI</P>
<P><I> MP409.</I> <B>DIAGNOSIS AND MANAGEMENT OF PULMONARY VASCULITIS </B><I>Convener</I>/J.F.
Cordier, M.D., Lyon, France</P>
<P><I> MP410.</I> <B>DYSPNEA </B><I>Convener</I>/F.J. Curley, M.D.,
Worcester, MA</P>
<P><I> MP411.</I> <B>NEW DEVELOPMENTS IN NEONATAL RESPIRATORY FAILURE </B><I>Convener</I>/J.M.
Davis, M.D., Mineola, NY</P>
<P><I> MP412.</I> <B>TUBERCULOSIS: AN INTERNATIONAL PERSPECTIVE </B><I>Convener</I>/D.A.
Enarson, M.D., Paris, France</P>
<P><I> MP413.</I> <B>PRACTICAL APPROACH TO NONPULMONARY PROBLEMS IN THE COPD
PATIENT </B><I>Convener</I>/S.B. Fiel, M.D., Philadelphia, PA</P>
<P><I> MP414.</I> <B>MANAGEMENT OF SEVERE PULMONARY SARCOIDOSIS </B><I>Convener</I>/M.X.
FitzGerald, M.D., Dublin, Ireland</P>
<P><I> MP415.</I> <B>MANAGING MANAGED CARE: HOW TO ORGANIZE OUR PRACTICE FOR
MANAGED CARE </B><I>Convener</I>/J. Hansen-Flaschen, M.D., Philadelphia, PA</P>
<P><I> MP416.</I> <B>HOW TO INCREASE YOUR YIELD FROM TRANSBRONCHIAL NEEDLE
ASPIRATION </B><I>Convener</I>/E.F. Haponik, M.D., Winston-Salem, NC</P>
<P><I> MP417.</I> <B>THE ROLE OF NITRIC OXIDE IN THE MANAGEMENT OF ADULT LUNG
DISEASE </B><I>Convener</I>/C.M. Hart, M.D., Indianapolis, IN</P>
<P><I> MP418.</I> <B>DVT/PE</B><I>Convener</I>/R. Hull, M.D., Calgary, AB,
Canada</P>
<P><I> MP419.</I> <B>LUNG VOLUME REDUCTION SURGERY: WHAT DOES THE FUTURE
HOLD? </B><I>Convener</I>/B.J. Make, M.D., Denver, </P>
<P><I> MP420.</I> <B>WHICH PATIENTS SHOULD RECEIVE LUNG TRANSPLANTS AND WHEN
SHOULD THEY BE PLACED ON THE LIST? </B><I>Convener</I>/J.R. Maurer, M.D.,
Cleveland, OH</P></BLOCKQUOTE>
<P></P>
<HR SIZE="4" WIDTH="80%">
<CENTER>
<P><A HREF=97ala.html><IMG
SRC=images/activity_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97bus.html><IMG
SRC=images/business_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97cal.html><IMG
SRC=images/calendar_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97child.html><IMG
SRC=images/child_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=pg.html><IMG
SRC=images/courses_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=search.html><IMG
SRC=images/search_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=main.html><IMG
SRC=images/home_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97house.html><IMG
SRC=images/house_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=http://itsmtgs.com/ala-ats><IMG
SRC=images/regist_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=sessions.html><IMG
SRC=images/session_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=special.html><IMG
SRC=images/special_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97tours.html><IMG
SRC=images/tour_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97travel.html><IMG
SRC=images/travel_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
</P></CENTER>
<HR SIZE="4" WIDTH="80%">
<CENTER><FONT SIZE="+2"><B><I>American Thoracic Society</I></B></FONT><BR>
1740 Broadway<BR> New York, NY 10019<BR> VOICE:  212-315-8700<BR> Copyright &copy;
1996 American Lung Association.<BR> The American Thoracic  Society is the
medical section <BR>of the American Lung Association.<BR> 
</CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-99</DOCNO>
<DOCOLDNO>IA013-000139-B029-6</DOCOLDNO>
<DOCHDR>
http://www.thoracic.org:80/ic97/profs2.html 206.138.195.144 19970217072132 text/html 4981
HTTP/1.0 200 OK
Date: Monday, 17-Feb-97 07:16:50 GMT
Server: NCSA/1.3
MIME-version: 1.0
Content-type: text/html
Last-modified: Friday, 24-Jan-97 16:16:22 GMT
Content-length: 4801
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//SQ//DTD HTML 2.0 HoTMetaL + extensions//EN">
<HTML>
<HEAD>
<TITLE>MEET THE PROFESSOR SEMINARS</TITLE></HEAD>
<BODY BGCOLOR="#FFFFFF">
<CENTER><IMG ALIGN="LEFT" SRC="images/banner0.jpg"></CENTER>
<CENTER></CENTER>
<CENTER><BR> 
<H2>MEET THE PROFESSOR SEMINARS</H2>
<P><BR></P></CENTER>
<HR SIZE="5" NOSHADE="NOSHADE" WIDTH="100%">
<P></P>
<CENTER>
<TABLE BORDER="2">
<TR ALIGN="CENTER" VALIGN="MIDDLE">
<TD ALIGN="CENTER" VALIGN="MIDDLE"><B><SMALL><A HREF="ic97.html">BACK TO
MAIN MENU</A></SMALL></B></TD></TR></TABLE></CENTER>
<P></P>
<HR SIZE="10" WIDTH="85%">
<P></P>
<CENTER>
<P>MONDAY MAY 19</P></CENTER>
<BLOCKQUOTE>
<P><B>Registration Fee: $20.00 (includes box lunch).</B> <I>Attendance is
limited. Advance registration is required and on a first come, first served
basis.</I></P>
<P><B>12:00 noon-1:00 pm</B></P></BLOCKQUOTE>
<HR SIZE="4" WIDTH="85%" ALIGN="CENTER" NOSHADE="NOSHADE">
<BLOCKQUOTE>
<P><I>MP501.</I> <B>PULMONARY ANGIOSCOPY </B><I>Convener</I>/W.R. Auger,
M.D., San Diego, CA</P>
<P><I>MP502.</I> <B>BRONCHIECTASIS</B><I>Convener</I>/P.J. Cole, B.S.C.,
M.B., London, England</P>
<P><I>MP503.</I> <B>MANAGEMENT OF THE PATIENT POSTLUNG TRANSPLANTATION </B><I>Convener</I>/J.H.
Dauber, M.D., Pittsburgh, PA</P>
<P><I>MP504.</I> <B>DIAGNOSIS AND MANAGEMENT OF EMPYEMA </B><I>Convener</I>/J.E.
Heffner, M.D., Phoenix, AZ</P>
<P><I>MP505.</I> <B>ARDS: AN UPDATE </B><I>Convener/</I>L.D. Hudson, M.D.,
Seattle, WA</P>
<P><I>MP506.</I> <B>DIFFUSE PANBRONCHIOLITIS: FROM JAPANESE DISEASE TO
WORLDWIDE </B><I>Convener/</I>T. Izumi, M.D., Kyoto, Japan</P>
<P><I>MP507.</I> <B>NUANCES IN THE MANAGEMENT OF MALIGNANT PLEURAL EFFUSIONS
</B><I>Convener/</I>V.B. Antony, M.D., Indianapolis, IN</P>
<P><I>MP508.</I> <B>STANDARDS FOR THE PREVENTION OF NOSOCOMIAL PNEUMONIA IN
1997</B> <I>Convener/</I>M.H. Kollef, M.D., St. Louis, MO</P>
<P><I>MP509.</I> <B>GENE THERAPY FOR ACQUIRED LUNG DISEASE</B><I>Convener</I>/J.K.
Kolls, M.D., New Orleans, LA </P>
<P><I>MP510.</I> <B>RESPIRATORY MUSCLE DISORDERS </B><I>Convener</I>/W.S.
Krell, M.D., Detroit, MI</P>
<P><I>MP511.</I> <B>LUNG REDUCTION SURGERY </B><I>Convener</I>/J. LoCicero,
III, M.D., Boston, MA</P>
<P><I>MP512.</I> <B>NOCTURNAL ASTHMA: NEW INSIGHTS </B><I>Convener</I>/R.J.
Martin, M.D., Denver, CO</P>
<P><I>MP513.</I> <B>LOCALLY ADVANCED LUNG CANCER: DIFFERENT APPROACHES</B>
<I>Convener</I>/R.A. Matthay, M.D., New Haven, CT</P>
<P><I>MP514.</I> <B>STATE-OF-THE-ART: NEW WAYS OF THINKING ABOUT AND
MEASURING DIAPHRAGMATIC FUNCTION </B><I>Convener</I>/F. McCool, M.D., Bristol,
RI</P>
<P><I>MP515.</I> <B>SOLITARY PULMONARY NODULE: EVALUATION IN THE 90'S </B>
<I>Convener</I>/D.E. Midthun, M.D., Rochester, MN</P>
<P><I>MP516.</I> <B>CLINICAL PFT'S </B><I>Convener</I>/A. Miller, M.D.,
Jamaica, NY</P>
<P><I>MP517.</I> <B>ALTERNATIVE TREATMENTS FOR SARCODOSIS </B><I>Convener</I>/R.
Young, M.D., Birmingham, AL</P>
<P><I>MP518.</I> <B>SLEEP APNEA</B> <I>Convener</I>/B.A. Phillips, M.D.,
Lexington, KY</P>
<P><I>MP519.</I> <B>PULMONARY HEMORRHAGE IN THE PEDIATRIC PATIENT: DIAGNOSIS
AND THERAPY</B> <I>Convener</I><B> </B>/J.M. Sherman, M.D., Gainesville, FL</P>
<P><I>MP520.</I> <B>WEANING FROM MECHANICAL VENTILATION</B> <I>Convener/</I>M.J.
Tobin, M.D., Hines, IL</P></BLOCKQUOTE>
<P></P>
<HR SIZE="4" WIDTH="80%">
<CENTER>
<P><A HREF=97ala.html><IMG
SRC=images/activity_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97bus.html><IMG
SRC=images/business_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97cal.html><IMG
SRC=images/calendar_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97child.html><IMG
SRC=images/child_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=pg.html><IMG
SRC=images/courses_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=search.html><IMG
SRC=images/search_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=main.html><IMG
SRC=images/home_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97house.html><IMG
SRC=images/house_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=http://itsmtgs.com/ala-ats><IMG
SRC=images/regist_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=sessions.html><IMG
SRC=images/session_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=special.html><IMG
SRC=images/special_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97tours.html><IMG
SRC=images/tour_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97travel.html><IMG
SRC=images/travel_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
</P></CENTER>
<HR SIZE="4" WIDTH="80%">
<CENTER><FONT SIZE="+2"><B><I>American Thoracic Society</I></B></FONT><BR>
1740 Broadway<BR> New York, NY 10019<BR> VOICE:  212-315-8700<BR> Copyright &copy;
1996 American Lung Association.<BR> The American Thoracic  Society is the
medical section <BR>of the American Lung Association.<BR> 
</CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-100</DOCNO>
<DOCOLDNO>IA013-000139-B029-36</DOCOLDNO>
<DOCHDR>
http://www.thoracic.org:80/ic97/profs3.html 206.138.195.144 19970217072141 text/html 4954
HTTP/1.0 200 OK
Date: Monday, 17-Feb-97 07:16:58 GMT
Server: NCSA/1.3
MIME-version: 1.0
Content-type: text/html
Last-modified: Friday, 24-Jan-97 16:16:23 GMT
Content-length: 4774
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//SQ//DTD HTML 2.0 HoTMetaL + extensions//EN">
<HTML>
<HEAD>
<TITLE>MEET THE PROFESSOR SEMINARS</TITLE></HEAD>
<BODY BGCOLOR="#FFFFFF">
<CENTER><IMG ALIGN="LEFT" SRC="images/master.jpg"></CENTER>
<CENTER><BR> 
<H2>MEET THE PROFESSOR SEMINARS</H2>
<P><BR></P></CENTER>
<HR SIZE="5" NOSHADE="NOSHADE" WIDTH="100%">
<P></P>
<CENTER>
<TABLE BORDER="2">
<TR ALIGN="CENTER" VALIGN="MIDDLE">
<TD ALIGN="CENTER" VALIGN="MIDDLE"><B><SMALL><A HREF="ic97.html">BACK TO
MAIN MENU</A></SMALL></B></TD></TR></TABLE></CENTER>
<P></P>
<HR SIZE="10" WIDTH="85%">
<P></P>
<CENTER>
<P>TUESDAY , MAY 20</P></CENTER>
<BLOCKQUOTE>
<P><B>Registration Fee: $20.00 (includes box lunch)</B>. <I>Attendance is
limited. Advance registration is required and on a first come, first served
basis.</I></P>
<P><B>12:00 noon-1:00 pm</B></P></BLOCKQUOTE>
<HR SIZE="4" WIDTH="85%" ALIGN="CENTER" NOSHADE="NOSHADE">
<BLOCKQUOTE>
<P><I>MP601.</I> <B>ROLE OF RHINOVIRUS IN CHILDHOOD ASTHMA </B><I>Convener/</I>S.T.
Holgate, M.D., Hampshire, England</P>
<P><I>MP602.</I> <B>NEW DEVELOPMENTS IN MECHANICAL VENTILATION </B><I>Convener</I>/R.D.
Hubmayr, M.D., Rochester, MN</P>
<P><I>MP603.</I> <B>DIAGNOSIS OF EARLY LUNG CANCER </B><I>Convener</I>/T.L.
Petty, M.D., Denver, CO/J.J. Bechtel, M.D., Grand Junction, CO</P>
<P><I>MP604.</I> <B>THE ETHICAL BASIS OF CRITICAL CARE </B><I>Convener</I>/M.L.
Osborne, M.D., Ph.D., Portland, OR</P>
<P><I>MP605.</I> <B>PULMONARY ALVEOLAR PROTEINOSIS </B><I>Convener</I>/C.A.
Piantadosi, M.D., Durham, NC</P>
<P><I>MP606.</I> <B>DIAGNOSTIC APPROACH TO PULMONARY HYPERTENSION </B><I>Convener</I>/S.I.
Rounds, M.D., Providence, RI</P>
<P><I>MP607.</I> <B>TREATMENT STRATEGIES FOR SLEEP-RELATED DISORDERS </B><I>Convener</I>/M.H.
Sanders, M.D., Pittsburgh, PA</P>
<P><I>MP608.</I> <B>NONINVASIVE POSITIVE PRESSURE </B><I>Convener</I>/U.
Shivaram, M.B.B.S., Brooklyn, NY</P>
<P><I>MP609.</I> <B>EXERCISE TESTING </B><I>Convener</I>/K.E. Sietsema,
M.D., Torrance, CA</P>
<P><I>MP610.</I> <B>PROTOCOL-GUIDED RESPIRATORY THERAPY </B><I>Convener</I>/J.K.
Stoller, M.D., Cleveland, OH</P>
<P><I>MP611.</I> <B>PNEUMOTHORAX </B><I>Convener</I>/C. Strange, M.D.,
Charleston, SC</P>
<P><I>MP612.</I> <B>OUTCOME </B><I>Convener</I>/M.G. Titler, Ph.D., Iowa
City, IA</P>
<P><I>MP613.</I> <B>PULMONARY INVOLVEMENT IN COLLAGEN VASCULAR DISORDERS </B><I>Convener</I>/L.T.
Tanoue, M.D., New Haven, CT</P>
<P><I>MP614.</I> <B>PULMONARY DEFENSE MECHANISMS</B> <I>Convener/</I>G.B.
Toews, M.D., Ann Arbor, MI</P>
<P><I>MP615.</I> <B>THERAPEUTIC BRONCHOSCOPY</B><I>Convener</I>/M. Unger,
M.D., Philadelphia, PA</P>
<P><I>MP616.</I> <B>SEPSIS </B><I>Convener</I>/J.G.C. Vincent, M.D.,
Brussels, Belgium</P>
<P><I>MP617.</I> <B>SCREENING FOR OCCUPATIONAL LUNG DISEASE </B><I>Convener</I>/G.R.
Wagner, M.D., Morgantown, WV</P>
<P><I>MP618.</I> <B>PULMONARY COMPLICATIONS OF HIV DISEASE </B><I>Convener</I>/J.M.
Wallace, M.D., Sylmar, CA</P>
<P><I>MP619.</I> <B>CURRENT DIAGNOSTIC APPROACH IN THE IMMUNOCOMPROMISED
HOST: WHEN TO DO BRONCHOSCOPY AND OPEN BIOPSY </B><I>Convener</I>/D.A. White,
M.D., New York, NY</P>
<P><I>MP620.</I> <B>NUTRITION IN COPD PATIENTS </B><I>Convener</I>/E.F.
Wouters, M.D., Ph.D., AZ Maastricht, The Netherlands</P></BLOCKQUOTE>
<P></P>
<HR SIZE="4" WIDTH="80%">
<CENTER>
<P><A HREF=97ala.html><IMG
SRC=images/activity_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97bus.html><IMG
SRC=images/business_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97cal.html><IMG
SRC=images/calendar_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97child.html><IMG
SRC=images/child_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=pg.html><IMG
SRC=images/courses_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=search.html><IMG
SRC=images/search_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=main.html><IMG
SRC=images/home_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97house.html><IMG
SRC=images/house_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=http://itsmtgs.com/ala-ats><IMG
SRC=images/regist_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=sessions.html><IMG
SRC=images/session_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=special.html><IMG
SRC=images/special_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97tours.html><IMG
SRC=images/tour_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97travel.html><IMG
SRC=images/travel_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
</P></CENTER>
<HR SIZE="4" WIDTH="80%">
<CENTER><FONT SIZE="+2"><B><I>American Thoracic Society</I></B></FONT><BR>
1740 Broadway<BR> New York, NY 10019<BR> VOICE:  212-315-8700<BR> Copyright &copy;
1996 American Lung Association.<BR> The American Thoracic  Society is the
medical section <BR>of the American Lung Association.<BR> 
</CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-101</DOCNO>
<DOCOLDNO>IA013-000139-B029-68</DOCOLDNO>
<DOCHDR>
http://www.thoracic.org:80/ic97/ws1.html 206.138.195.144 19970217072148 text/html 3578
HTTP/1.0 200 OK
Date: Monday, 17-Feb-97 07:17:07 GMT
Server: NCSA/1.3
MIME-version: 1.0
Content-type: text/html
Last-modified: Friday, 24-Jan-97 16:16:36 GMT
Content-length: 3398
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//SQ//DTD HTML 2.0 HoTMetaL + extensions//EN">
<HTML>
<HEAD>
<TITLE>CLINICAL WORKSHOP: ws1</TITLE></HEAD>
<BODY BGCOLOR="#FFFFFF">
<CENTER><IMG ALIGN="LEFT" SRC="images/master.jpg"></CENTER>
<CENTER><BR>
<P>CLINICAL WORKSHOP</P><BR>
<H2>WS1: MASTER CLINICIANS 1</H2></CENTER>
<HR SIZE="5" NOSHADE="NOSHADE" WIDTH="100%">
<P></P>
<CENTER>
<TABLE BORDER="2">
<TR ALIGN="CENTER" VALIGN="MIDDLE">
<TD ALIGN="CENTER" VALIGN="MIDDLE"><B><SMALL><A HREF="masters.html">BACK TO
MAIN MENU</A></SMALL></B></TD></TR></TABLE></CENTER>
<P></P>
<HR SIZE="10" WIDTH="85%">
<P></P>
<CENTER>
<P>SUNDAY , MAY 18</P></CENTER>
<BLOCKQUOTE>
<P><B>Registration Fee: $20.00 (includes box lunch)</B>. <I>Attendance is
limited. Advance registration is required and on a first come, first served
basis.</I></P>
<P><B>Assembly on Clinical Problems</B></P>
<P><B>12:00 noon-1:30 pm</B></P></BLOCKQUOTE>
<HR SIZE="4" WIDTH="85%" ALIGN="CENTER" NOSHADE="NOSHADE">
<BLOCKQUOTE>
<P><I><B>Target Audience: </B></I>Pulmonary fellows and pulmonary physicians.</P>
<P><B>OBJECTIVES</B><BR>At the conclusion of this workshop, the participant
will be able to:</P>
<UL>
<LI>describe differential diagnosis of pulmonary symptoms and signs;</LI>
<LI>observe how established experts approach an unknown clinical case;</LI>
<LI>describe unusual manifestations of common problems and presenting signs and
symptoms of uncommon diseases.</LI></UL>
<P>During this workshop, unknown cases will be presented for the first time to
the audience and the Master Clinicians. The Master Clinicians will then discuss
the cases in terms of the differential diagnosis evaluation and possible
treatment. Questions from the audience will be welcome.</P>
<P><B>Master Clinicians:</B><BR>S.F. Davies, M.D., Minneapolis, MN<BR>R.A.
Matthay, M.D., New Haven, CT<BR>O.P. Sharma, M.D., Los Angeles, CA</P></BLOCKQUOTE>
<P></P>
<HR SIZE="4" WIDTH="80%">
<CENTER>
<P><A HREF=97ala.html><IMG
SRC=images/activity_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97bus.html><IMG
SRC=images/business_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97cal.html><IMG
SRC=images/calendar_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97child.html><IMG
SRC=images/child_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=pg.html><IMG
SRC=images/courses_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=search.html><IMG
SRC=images/search_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=main.html><IMG
SRC=images/home_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97house.html><IMG
SRC=images/house_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=http://itsmtgs.com/ala-ats><IMG
SRC=images/regist_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=sessions.html><IMG
SRC=images/session_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=special.html><IMG
SRC=images/special_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97tours.html><IMG
SRC=images/tour_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97travel.html><IMG
SRC=images/travel_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
</P></CENTER>
<HR SIZE="4" WIDTH="80%">
<CENTER><FONT SIZE="+2"><B><I>American Thoracic Society</I></B></FONT><BR>
1740 Broadway<BR> New York, NY 10019<BR> VOICE:  212-315-8700<BR> Copyright &copy;
1996 American Lung Association.<BR> The American Thoracic  Society is the
medical section <BR>of the American Lung Association.<BR> 
</CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-102</DOCNO>
<DOCOLDNO>IA013-000139-B029-99</DOCOLDNO>
<DOCHDR>
http://www.thoracic.org:80/ic97/ws2.html 206.138.195.144 19970217072156 text/html 3378
HTTP/1.0 200 OK
Date: Monday, 17-Feb-97 07:17:14 GMT
Server: NCSA/1.3
MIME-version: 1.0
Content-type: text/html
Last-modified: Friday, 24-Jan-97 16:16:37 GMT
Content-length: 3198
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//SQ//DTD HTML 2.0 HoTMetaL + extensions//EN">
<HTML>
<HEAD>
<TITLE>CLINICAL WORKSHOP: ws2</TITLE></HEAD>
<BODY BGCOLOR="#FFFFFF">
<CENTER><IMG ALIGN="LEFT" SRC="images/master.jpg"></CENTER>
<CENTER><BR>
<P>CLINICAL WORKSHOP</P><BR>
<H2>WS2: CPT CODING FOR PULMONARY MEDICINE</H2></CENTER>
<HR SIZE="5" NOSHADE="NOSHADE" WIDTH="100%">
<P></P>
<CENTER>
<TABLE BORDER="2">
<TR ALIGN="CENTER" VALIGN="MIDDLE">
<TD ALIGN="CENTER" VALIGN="MIDDLE"><B><SMALL><A HREF="masters.html">BACK TO
MAIN MENU</A></SMALL></B></TD></TR></TABLE></CENTER>
<P></P>
<HR SIZE="10" WIDTH="85%">
<P></P>
<CENTER>
<P>SUNDAY , MAY 18</P></CENTER>
<BLOCKQUOTE>
<P><B>Registration Fee: $20.00 (includes box lunch)</B>. <I>Attendance is
limited. Advance registration is required and on a first come, first served
basis.</I></P>
<P><B>Council of Chapter Representatives/Assembly on Clinical Problems</B></P>
<P><B>12:00 noon-1:00 pm</B></P></BLOCKQUOTE>
<HR SIZE="4" WIDTH="85%" ALIGN="CENTER" NOSHADE="NOSHADE">
<BLOCKQUOTE>
<P><I><B>Target Audience: </B></I>Clinical practitioners in pulmonary
medicine.</P>
<P><B>OBJECTIVES</B><BR>At the conclusion of this workshop, the participant
will be able to:</P>
<UL>
<LI> understand and apply cpt coding to pulmonary medicine.</LI></UL>
<P>Interesting cases will be presented with the cpt codes utilized. Discussion
and criticism of the codes will follow with corrections and explanations when
appropriate.</P>
<P><I><B>Chairing: </B></I>M.R. Crain, M.D., Birmingham, AL</P>
<P><B>Presentation of Cases</B>/M.S. Braunstein, M.D., Ft. Lauderdale, FL</P>
<P><B>Discussion of Cases</B>/W.J. O'Donohue, Jr., M.D., Omaha, NE </P></BLOCKQUOTE>
<P></P>
<HR SIZE="4" WIDTH="80%">
<CENTER>
<P><A HREF=97ala.html><IMG
SRC=images/activity_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97bus.html><IMG
SRC=images/business_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97cal.html><IMG
SRC=images/calendar_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97child.html><IMG
SRC=images/child_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=pg.html><IMG
SRC=images/courses_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=search.html><IMG
SRC=images/search_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=main.html><IMG
SRC=images/home_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97house.html><IMG
SRC=images/house_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=http://itsmtgs.com/ala-ats><IMG
SRC=images/regist_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=sessions.html><IMG
SRC=images/session_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=special.html><IMG
SRC=images/special_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97tours.html><IMG
SRC=images/tour_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97travel.html><IMG
SRC=images/travel_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
</P></CENTER>
<HR SIZE="4" WIDTH="80%">
<CENTER><FONT SIZE="+2"><B><I>American Thoracic Society</I></B></FONT><BR>
1740 Broadway<BR> New York, NY 10019<BR> VOICE:  212-315-8700<BR> Copyright &copy;
1996 American Lung Association.<BR> The American Thoracic  Society is the
medical section <BR>of the American Lung Association.<BR> 
</CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-103</DOCNO>
<DOCOLDNO>IA013-000139-B029-125</DOCOLDNO>
<DOCHDR>
http://www.thoracic.org:80/ic97/ws3.html 206.138.195.144 19970217072204 text/html 3574
HTTP/1.0 200 OK
Date: Monday, 17-Feb-97 07:17:22 GMT
Server: NCSA/1.3
MIME-version: 1.0
Content-type: text/html
Last-modified: Friday, 24-Jan-97 16:16:37 GMT
Content-length: 3394
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//SQ//DTD HTML 2.0 HoTMetaL + extensions//EN">
<HTML>
<HEAD>
<TITLE>CLINICAL WORKSHOP: ws3</TITLE></HEAD>
<BODY BGCOLOR="#FFFFFF">
<CENTER><IMG ALIGN="LEFT" SRC="images/master.jpg"></CENTER>
<CENTER><BR>
<P>CLINICAL WORKSHOP</P><BR>
<H2>WS3: MASTER CLINICIANS 2 </H2></CENTER>
<HR SIZE="5" NOSHADE="NOSHADE" WIDTH="100%">
<P></P>
<CENTER>
<TABLE BORDER="2">
<TR ALIGN="CENTER" VALIGN="MIDDLE">
<TD ALIGN="CENTER" VALIGN="MIDDLE"><B><SMALL><A HREF="masters.html">BACK TO
MAIN MENU</A></SMALL></B></TD></TR></TABLE></CENTER>
<P></P>
<HR SIZE="10" WIDTH="85%">
<P></P>
<CENTER>
<P>SUNDAY , MAY 18</P></CENTER>
<BLOCKQUOTE>
<P><B>Registration Fee: $20.00 (includes box lunch).</B> <I>Attendance is
limited. Advance registration is required and on a first come, first served
basis.</I></P>
<P><B>Assembly on Clinical Problems</B></P>
<P><B>12:00 noon-1:30 pm</B></P></BLOCKQUOTE>
<HR SIZE="4" WIDTH="85%" ALIGN="CENTER" NOSHADE="NOSHADE">
<BLOCKQUOTE>
<P><I><B>Target Audience: </B></I>Pulmonary fellows and pulmonary physicians.</P>
<P><B>OBJECTIVES</B><BR>At the conclusion of this workshop, the participant
will be able to:</P>
<UL>
<LI>describe differential diagnosis of pulmonary symptoms and signs;</LI>
<LI>observe how established experts approach an unknown clinical case;</LI>
<LI>describe unusual manifestations of common problems and presenting signs and
symptoms of uncommon diseases.</LI></UL>
<P>During this workshop, unknown cases will be presented for the first time to
the audience and the Master Clinicians. The Master Clinicians will then discuss
the cases in terms of the differential diagnosis evaluation and possible
treatment. Questions from the audience will be welcome.</P>
<P><B>Master Clinicians:</B><BR>J.R. Maurer, M.D., Cleveland, OH<BR>M.J.
Rosen, M.D., New York, NY<BR>W.R. Summer, M.D., New Orleans, LA</P></BLOCKQUOTE>
<P></P>
<HR SIZE="4" WIDTH="80%">
<CENTER>
<P><A HREF=97ala.html><IMG
SRC=images/activity_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97bus.html><IMG
SRC=images/business_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97cal.html><IMG
SRC=images/calendar_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97child.html><IMG
SRC=images/child_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=pg.html><IMG
SRC=images/courses_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=search.html><IMG
SRC=images/search_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=main.html><IMG
SRC=images/home_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97house.html><IMG
SRC=images/house_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=http://itsmtgs.com/ala-ats><IMG
SRC=images/regist_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=sessions.html><IMG
SRC=images/session_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=special.html><IMG
SRC=images/special_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97tours.html><IMG
SRC=images/tour_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97travel.html><IMG
SRC=images/travel_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
</P></CENTER>
<HR SIZE="4" WIDTH="80%">
<CENTER><FONT SIZE="+2"><B><I>American Thoracic Society</I></B></FONT><BR>
1740 Broadway<BR> New York, NY 10019<BR> VOICE:  212-315-8700<BR> Copyright &copy;
1996 American Lung Association.<BR> The American Thoracic  Society is the
medical section <BR>of the American Lung Association.<BR> 
</CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-104</DOCNO>
<DOCOLDNO>IA013-000139-B029-151</DOCOLDNO>
<DOCHDR>
http://www.thoracic.org:80/ic97/ws4.html 206.138.195.144 19970217072210 text/html 3391
HTTP/1.0 200 OK
Date: Monday, 17-Feb-97 07:17:29 GMT
Server: NCSA/1.3
MIME-version: 1.0
Content-type: text/html
Last-modified: Friday, 24-Jan-97 16:16:37 GMT
Content-length: 3211
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//SQ//DTD HTML 2.0 HoTMetaL + extensions//EN">
<HTML>
<HEAD>
<TITLE>CLINICAL WORKSHOP: ws4</TITLE></HEAD>
<BODY BGCOLOR="#FFFFFF">
<CENTER><IMG ALIGN="LEFT" SRC="images/master.jpg"></CENTER>
<CENTER><BR>
<P>CLINICAL WORKSHOP</P><BR>
<H2>WS4: CPT CODING FOR CRITICAL CARE MEDICINE </H2></CENTER>
<HR SIZE="5" NOSHADE="NOSHADE" WIDTH="100%">
<P></P>
<CENTER>
<TABLE BORDER="2">
<TR ALIGN="CENTER" VALIGN="MIDDLE">
<TD ALIGN="CENTER" VALIGN="MIDDLE"><B><SMALL><A HREF="masters.html">BACK TO
MAIN MENU</A></SMALL></B></TD></TR></TABLE></CENTER>
<P></P>
<HR SIZE="10" WIDTH="85%">
<P></P>
<CENTER>
<P>SUNDAY , MAY 18</P></CENTER>
<BLOCKQUOTE>
<P><B>Registration Fee: $20.00 (includes box lunch).</B> <I>Attendance is
limited. Advance registration is required and on a first come, first served
basis.</I></P>
<P><B>Council of Chapter Representatives/Assembly on Clinical Problems</B></P>
<P><B>12:00 noon-1:00 pm</B></P></BLOCKQUOTE>
<HR SIZE="4" WIDTH="85%" ALIGN="CENTER" NOSHADE="NOSHADE">
<BLOCKQUOTE>
<P><I><B>Target Audience: </B></I>Clinical practitioners in critical care
medicine.</P>
<P><B>OBJECTIVES</B><BR>At the conclusion of this workshop, the participant
will be able to:</P>
<UL>
<LI>understand and apply cpt coding to critical care medicine.</LI></UL>
<P>Interesting cases will be presented with the cpt codes utilized. Discussion
and criticism of the codes will follow with corrections and explanations when
appropriate.</P>
<P><I><B>Chairing: </B></I>M.R. Crain, M.D., Birmingham, AL</P>
<P><B>Presentations of Cases</B>/M.S. Braunstein, M.D., Ft. Lauderdale, FL
</P>
<P><B>Discussion of Cases</B>/W.J. O'Donohue, Jr., M.D., Omaha, NE</P></BLOCKQUOTE>
<P></P>
<HR SIZE="4" WIDTH="80%">
<CENTER>
<P><A HREF=97ala.html><IMG
SRC=images/activity_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97bus.html><IMG
SRC=images/business_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97cal.html><IMG
SRC=images/calendar_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97child.html><IMG
SRC=images/child_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=pg.html><IMG
SRC=images/courses_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=search.html><IMG
SRC=images/search_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=main.html><IMG
SRC=images/home_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97house.html><IMG
SRC=images/house_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=http://itsmtgs.com/ala-ats><IMG
SRC=images/regist_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=sessions.html><IMG
SRC=images/session_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=special.html><IMG
SRC=images/special_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97tours.html><IMG
SRC=images/tour_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97travel.html><IMG
SRC=images/travel_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
</P></CENTER>
<HR SIZE="4" WIDTH="80%">
<CENTER><FONT SIZE="+2"><B><I>American Thoracic Society</I></B></FONT><BR>
1740 Broadway<BR> New York, NY 10019<BR> VOICE:  212-315-8700<BR> Copyright &copy;
1996 American Lung Association.<BR> The American Thoracic  Society is the
medical section <BR>of the American Lung Association.<BR> 
</CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-105</DOCNO>
<DOCOLDNO>IA013-000139-B029-173</DOCOLDNO>
<DOCHDR>
http://www.thoracic.org:80/ic97/ws5.html 206.138.195.144 19970217072219 text/html 3578
HTTP/1.0 200 OK
Date: Monday, 17-Feb-97 07:17:38 GMT
Server: NCSA/1.3
MIME-version: 1.0
Content-type: text/html
Last-modified: Friday, 24-Jan-97 16:16:38 GMT
Content-length: 3398
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//SQ//DTD HTML 2.0 HoTMetaL + extensions//EN">
<HTML>
<HEAD>
<TITLE>CLINICAL WORKSHOP: ws5</TITLE></HEAD>
<BODY BGCOLOR="#FFFFFF">
<CENTER><IMG ALIGN="LEFT" SRC="images/master.jpg"></CENTER>
<CENTER><BR>
<P>CLINICAL WORKSHOP</P><BR>
<H2>WS5: MASTER CLINICIANS 3</H2></CENTER>
<HR SIZE="5" NOSHADE="NOSHADE" WIDTH="100%">
<P></P>
<CENTER>
<TABLE BORDER="2">
<TR ALIGN="CENTER" VALIGN="MIDDLE">
<TD ALIGN="CENTER" VALIGN="MIDDLE"><B><SMALL><A HREF="masters.html">BACK TO
MAIN MENU</A></SMALL></B></TD></TR></TABLE></CENTER>
<P></P>
<HR SIZE="10" WIDTH="85%">
<P></P>
<CENTER>
<P>TUESDAY, MAY 20</P></CENTER>
<BLOCKQUOTE>
<P><B>Registration Fee: $20.00 (includes box lunch).</B> <I>Attendance is
limited. Advance registration is required and on a first come, first served
basis.</I></P>
<P><B>Assembly on Clinical Problems</B></P>
<P><B>12:00 noon-1:30 pm</B></P></BLOCKQUOTE>
<HR SIZE="4" WIDTH="85%" ALIGN="CENTER" NOSHADE="NOSHADE">
<BLOCKQUOTE>
<P><I><B>Target Audience: </B></I>Pulmonary fellows and pulmonary physicians.</P>
<P><B>OBJECTIVES</B><BR>At the conclusion of this workshop, the participant
will be able to:</P>
<UL>
<LI>describe differential diagnosis of pulmonary symptoms and signs;</LI>
<LI>observe how established experts approach an unknown clinical case;</LI>
<LI>describe unusual manifestations of common problems and presenting signs and
symptoms of uncommon diseases.</LI></UL>
<P>During this workshop, unknown cases will be presented for the first time to
the audience and the Master Clinicians. The Master Clinicians will then discuss
the cases in terms of the differential diagnosis evaluation and possible
treatment. Questions from the audience will be welcome.</P>
<P><B>Master Clinicians:</B><BR>S.F. Davies, M.D., Minneapolis, MN<BR>J.R.
Maurer, M.D., Cleveland, OH<BR>S.R. Warren, M.D., Los Angeles, CA </P></BLOCKQUOTE>
<P></P>
<HR SIZE="4" WIDTH="80%">
<CENTER>
<P><A HREF=97ala.html><IMG
SRC=images/activity_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97bus.html><IMG
SRC=images/business_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97cal.html><IMG
SRC=images/calendar_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97child.html><IMG
SRC=images/child_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=pg.html><IMG
SRC=images/courses_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=search.html><IMG
SRC=images/search_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=main.html><IMG
SRC=images/home_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97house.html><IMG
SRC=images/house_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=http://itsmtgs.com/ala-ats><IMG
SRC=images/regist_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=sessions.html><IMG
SRC=images/session_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=special.html><IMG
SRC=images/special_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97tours.html><IMG
SRC=images/tour_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97travel.html><IMG
SRC=images/travel_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
</P></CENTER>
<HR SIZE="4" WIDTH="80%">
<CENTER><FONT SIZE="+2"><B><I>American Thoracic Society</I></B></FONT><BR>
1740 Broadway<BR> New York, NY 10019<BR> VOICE:  212-315-8700<BR> Copyright &copy;
1996 American Lung Association.<BR> The American Thoracic  Society is the
medical section <BR>of the American Lung Association.<BR> 
</CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-106</DOCNO>
<DOCOLDNO>IA013-000139-B029-198</DOCOLDNO>
<DOCHDR>
http://www.thoracic.org:80/ic97/ws7.html 206.138.195.144 19970217072227 text/html 3584
HTTP/1.0 200 OK
Date: Monday, 17-Feb-97 07:17:45 GMT
Server: NCSA/1.3
MIME-version: 1.0
Content-type: text/html
Last-modified: Friday, 24-Jan-97 16:16:38 GMT
Content-length: 3404
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//SQ//DTD HTML 2.0 HoTMetaL + extensions//EN">
<HTML>
<HEAD>
<TITLE>CLINICAL WORKSHOP: ws7</TITLE></HEAD>
<BODY BGCOLOR="#FFFFFF">
<CENTER><IMG ALIGN="LEFT" SRC="images/master.jpg"></CENTER>
<CENTER><BR>
<P>CLINICAL WORKSHOP</P><BR>
<H2>WS7: MASTER CLINICIANS 4</H2></CENTER>
<HR SIZE="5" NOSHADE="NOSHADE" WIDTH="100%">
<P></P>
<CENTER>
<TABLE BORDER="2">
<TR ALIGN="CENTER" VALIGN="MIDDLE">
<TD ALIGN="CENTER" VALIGN="MIDDLE"><B><SMALL><A HREF="masters.html">BACK TO
MAIN MENU</A></SMALL></B></TD></TR></TABLE></CENTER>
<P></P>
<HR SIZE="10" WIDTH="85%">
<P></P>
<CENTER>
<P>WEDNESDAY  MAY 21</P></CENTER>
<BLOCKQUOTE>
<P><B>Registration Fee: $20.00 (includes box lunch).</B> <I>Attendance is
limited. Advance registration is required and on a first come, first served
basis.</I></P>
<P><B>Assembly on Clinical Problems</B></P>
<P><B>12:00 noon-1:30 pm</B></P></BLOCKQUOTE>
<HR SIZE="4" WIDTH="85%" ALIGN="CENTER" NOSHADE="NOSHADE">
<BLOCKQUOTE>
<P><I><B>Target Audience: </B></I>Pulmonary fellows and pulmonary physicians.</P>
<P><B>OBJECTIVES</B><BR>At the conclusion of this workshop, the participant
will be able to:</P>
<UL>
<LI>describe differential diagnosis of pulmonary symptoms and signs;</LI>
<LI>observe how established experts approach an unknown clinical case;</LI>
<LI>describe unusual manifestations of common problems and presenting signs and
symptoms of uncommon diseases.</LI></UL>
<P>During this workshop, unknown cases will be presented for the first time to
the audience and the Master Clinicians. The Master Clinicians will then discuss
the cases in terms of the differential diagnosis evaluation and possible
treatment. Questions from the audience will be welcome.</P>
<P><B>Master Clinicians:</B><B><BR>M.J. Rosen, M.D., New York, NY<BR>W.R.
Summer, M.D., New Orleans, LA<BR>R.A. Matthay, M.D., New Haven, CT </B></P></BLOCKQUOTE>
<P></P>
<HR SIZE="4" WIDTH="80%">
<CENTER>
<P><A HREF=97ala.html><IMG
SRC=images/activity_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97bus.html><IMG
SRC=images/business_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97cal.html><IMG
SRC=images/calendar_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97child.html><IMG
SRC=images/child_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=pg.html><IMG
SRC=images/courses_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=search.html><IMG
SRC=images/search_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=main.html><IMG
SRC=images/home_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97house.html><IMG
SRC=images/house_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=http://itsmtgs.com/ala-ats><IMG
SRC=images/regist_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=sessions.html><IMG
SRC=images/session_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=special.html><IMG
SRC=images/special_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97tours.html><IMG
SRC=images/tour_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97travel.html><IMG
SRC=images/travel_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
</P></CENTER>
<HR SIZE="4" WIDTH="80%">
<CENTER><FONT SIZE="+2"><B><I>American Thoracic Society</I></B></FONT><BR>
1740 Broadway<BR> New York, NY 10019<BR> VOICE:  212-315-8700<BR> Copyright &copy;
1996 American Lung Association.<BR> The American Thoracic  Society is the
medical section <BR>of the American Lung Association.<BR> 
</CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-107</DOCNO>
<DOCOLDNO>IA013-000139-B029-221</DOCOLDNO>
<DOCHDR>
http://www.thoracic.org:80/ic97/ic97.html 206.138.195.144 19970217072234 text/html 3251
HTTP/1.0 200 OK
Date: Monday, 17-Feb-97 07:17:52 GMT
Server: NCSA/1.3
MIME-version: 1.0
Content-type: text/html
Last-modified: Tuesday, 21-Jan-97 22:00:31 GMT
Content-length: 3070
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//SQ//DTD HTML 2.0 HoTMetaL + extensions//EN">
<HTML>
<HEAD>
<TITLE>American Thoracic Society - International Conference</TITLE></HEAD>
<BODY BACKGROUND="../images/back.jpg">
<CENTER><IMG ALIGN="LEFT" SRC="../images/smlogo.gif">
<H1>1997 ALA/ATS International Conference</H1></CENTER>
<HR SIZE="5" NOSHADE="NOSHADE" WIDTH="100%">
<P><BR></P>
<CENTER><B>INTERNATIONAL CONFERENCE MENU</B>
<BR><BR>
<TABLE BORDER="2">
<TR ALIGN="CENTER" VALIGN="MIDDLE">
<TD><SMALL><A HREF="../ic96.html">1996 ATS/ALA INTERNATIONAL CONFERENCE</A></SMALL></TD></TR>
<TR ALIGN="CENTER" VALIGN="MIDDLE">
<TD><SMALL><A HREF="../ic97.html">1997 ATS/ALA INTERNATIONAL CONFERENCE</A></SMALL></TD></TR>
<TR ALIGN="CENTER" VALIGN="MIDDLE">
<TD><SMALL><A HREF="../futrmeet.html">FUTURE MEETING SITES</A></SMALL></TD></TR></TABLE></CENTER>
<P></P>
<HR SIZE="5" WIDTH="70%">
<P></P>
<CENTER><IMG SRC="../images/ic97.jpg" ALIGN="BOTTOM"></CENTER>
<CENTER>
<H1><FONT COLOR="#FF0000">ONLINE ADVANCED PROGRAM<BR>1/24/97.</FONT></H1></CENTER>
<HR SIZE="4" WIDTH="80%">
<CENTER><A HREF="../about.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="../images/about.gif" ALT="Home Page"></A>
<A HREF="../ssg.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="../images/ss.gif" ALT="Society Structure"></A>
<A HREF="../gpi.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="../images/pi.gif" ALT="Gen Public Info"></A>
<BR>
<A HREF="../ms.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="../images/memserv.gif" ALT="Memb Serv"></A>
<A HREF="../pub.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="../images/pubs.gif" ALT="Publications"></A>
<A HREF="../press.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="../images/press.gif" ALT="Press"></A>
<A HREF="../assemb.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="../images/assemb.gif" ALT="Assemblies"></A>
<A HREF="../research.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="../images/research.gif" ALT="Research"></A>
<BR>
<A HREF="../mep.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="../images/meded.gif" ALT="Med Education"></A>
<A HREF="../wr.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="../images/wr.gif" ALT="Wash Report"></A>
<A HREF="../index.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="../images/home.gif" ALT="Home Page"></A>
<A HREF="../search.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="../images/search.gif" ALT="Search"></A>
<A HREF="../ic.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="../images/ic.gif" ALT="Int
'l Conference"></A>
<A HREF="../store.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="../images/store.gif" ALT="Store"></A>
<!-- <A HREF="sponsors.html"><IMG VSPACE=1 HSPACE=1 BORDER=0
SRC="../images/sponsor.gif" ALT="Sponsors"></A>  -->
</CENTER>
<HR SIZE="4" WIDTH="80%">
<CENTER><FONT SIZE="+2"><B><I>American Thoracic Society</I></B></FONT><BR>
1740 Broadway<BR> New York, NY 10019<BR> VOICE:  212-315-8700<BR> Copyright &amp;copy;
1996 American Lung Association.<BR> The American Thoracic  Society is the
medical section <BR>of the American Lung Association.<BR> 
</CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-108</DOCNO>
<DOCOLDNO>IA013-000139-B029-253</DOCOLDNO>
<DOCHDR>
http://www.thoracic.org:80/ic97/atssun1.html 206.138.195.144 19970217072245 text/html 5200
HTTP/1.0 200 OK
Date: Monday, 17-Feb-97 07:18:01 GMT
Server: NCSA/1.3
MIME-version: 1.0
Content-type: text/html
Last-modified: Friday, 24-Jan-97 16:15:08 GMT
Content-length: 5020
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//SQ//DTD HTML 2.0 HoTMetaL + extensions//EN">
<HTML>
<HEAD>
<TITLE>ATS SUNRISE SEMINARS</TITLE></HEAD>
<BODY BGCOLOR="#FFFFFF">
<CENTER><IMG ALIGN="LEFT" SRC="images/banner0.jpg"></CENTER>
<CENTER></CENTER>
<CENTER><BR> 
<H2>ATS SUNRISE SEMINARS</H2>
<P></P></CENTER>
<HR SIZE="5" NOSHADE="NOSHADE" WIDTH="100%">
<P><BR><BR></P>
<CENTER>
<TABLE BORDER="2">
<TR ALIGN="CENTER" VALIGN="MIDDLE">
<TD ALIGN="CENTER" VALIGN="MIDDLE"><B><SMALL><A HREF="ic97.html">BACK TO
MAIN MENU</A></SMALL></B></TD></TR></TABLE></CENTER>
<P><BR><BR></P>
<HR SIZE="10" WIDTH="85%">
<P></P>
<BLOCKQUOTE>
<CENTER>
<P>MONDAY MAY 19</P></CENTER>
<P><B>Registration Fee: $15.00 (includes continental breakfast). </B><I>Attendance
is limited. Advance registration is required and on a first come, first served
basis.</I></P>
<P><B>7:00 am-8:00 am</B></P></BLOCKQUOTE>
<HR SIZE="4" WIDTH="85%" ALIGN="CENTER" NOSHADE="NOSHADE">
<BLOCKQUOTE>
<P><I>SS101.</I> <B>NEW DEVELOPMENTS IN THE DIAGNOSIS AND MANAGEMENT OF
OCCUPATIONAL ASTHMA </B><I>Convener</I>/C.A. Redlich, M.D., New Haven, CT</P>
<P><I>SS102.</I> <B>DIAGNOSIS AND TREATMENT OF NOSOCOMIAL PNEUMONIA</B> <I>Convener</I>/K.E.
Welty-Wolf, M.D., Durham, NC</P>
<P><I>SS103.</I> <B>DEEP VENOUS THROMBOSIS: DIAGNOSIS AND MANAGEMENT</B> <I>Convener</I>/F.W.
Walsh, M.D., Temple Terrace, FL</P>
<P><I>SS104.</I> <B>SYNCOPE/CHEST PAIN AND SUDDEN CARDIAC DEATH IN CHILDREN
AND YOUNG ADULTS </B><I>Convener</I>/T. Owens, M.D., Torrance, CA</P>
<P><I>SS105.</I> <B>CYTOKINES AND ARDS </B><I>Convener</I>/J.D. Fortenberry,
M.D., Atlanta, GA</P>
<P><I>SS106.</I> <B>NOVEL APPROACHES TO PULMONARY REHABILITATION </B><I>Convener</I>/M.F.
Busk, M.D., M.P.H., Indianapolis, IN</P>
<P><I>SS107.</I> <B>TREATMENT OF MASSIVE PULMONARY EMBOLISM </B><I>Convener</I>/J.R.
Gossage, M.D., Augusta, GA</P>
<P><I>SS108.</I> <B>CLINICAL PROBLEMS IN LUNG TRANSPLANTATION </B><I>Convener</I>/M.B.
King, M.D., Minneapolis, MN</P>
<P><I>SS109.</I> <B>SUBSPECIALTY CONSULTATION FOR THE RURAL PRIMARY CARE
PHYSICIAN: MEETING BOTH THE PATIENTS AND PHYSICIANS NEEDS AND EXPECTATIONS </B><I>Convener</I>/C.A.
Henke, M.D., Minneapolis, MN</P>
<P><I>SS110.</I> <B>BRONCHIOLITIS OBLITERANS </B><I>Convener</I>/D.J.
Romberger, M.D., Omaha, NE</P>
<P><I>SS111.</I> <B>INNER CITY ASTHMA MANAGEMENT </B><I>Convener</I>/P.H.
Mayo, M.D., New Rochelle, NY</P>
<P><I>SS112.</I> <B>INDICATIONS AND TECHNIQUES IN USING DOUBLE-LUMEN
ENDOBRONCHIAL TUBES IN UNILATERAL LUNG DISEASE </B><I>Convener</I>/S. Bowles,
M.D., Pittsburgh, PA</P>
<P><I>SS113.</I> <B>LYMPHOPROLIFERATIVE DISEASES OF THE LUNG </B><I>Convener</I>/A.A.
Lazarus, M.D., Rockville, MD</P>
<P><I>SS114.</I> <B>TREATMENT DELIMAS IN OBSTRUCTIVE SLEEP APNEA </B><I>Convener</I>/C.W.
Atwood, Jr., M.D., Pittsburgh, PA</P>
<P><I>SS115.</I> <B>SARCOIDOSIS: CURRENT ISSUES IN TREATMENT </B><I>Convener</I>/L.S.
Efferen, M.D., Dix Hills, NY</P>
<P><I>SS116.</I> <B>BRONCHOSCOPY IN THE IMMUNOCOMPROMISED HOST </B><I>Convener</I>/P.
White, Jr., M.D., Ellicott City, MD</P>
<P><I>SS117.</I> <B>ALTERNATIVE ANTI-INFLAMMATORY THERAPY IN ASTHMA </B><I>Convener</I>/M.
Castro, M.D., St. Louis, MO</P>
<P><I>SS118.</I> <B>GASTROESOPHAGEAL REFLUX AND LUNG DISEASE </B><I>Convener</I>/S.K.
Field, M.D., Calgary, AB, Canada</P>
<P><I>SS119.</I> <B>VENTILATOR WEANING STRATEGIES </B><I>Convener</I>/K.L.
Yang, M.D., Louisville, KY</P>
<P><I>SS120.</I> <B>CLINICAL EXERCISE TESTING </B><I>Convener</I>/A.B.
Evans, M.D., Boston, MA</P></BLOCKQUOTE>
<P></P>
<HR SIZE="4" WIDTH="80%">
<CENTER>
<P><A HREF=97ala.html><IMG
SRC=images/activity_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97bus.html><IMG
SRC=images/business_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97cal.html><IMG
SRC=images/calendar_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97child.html><IMG
SRC=images/child_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=pg.html><IMG
SRC=images/courses_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=search.html><IMG
SRC=images/search_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=main.html><IMG
SRC=images/home_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97house.html><IMG
SRC=images/house_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=http://itsmtgs.com/ala-ats><IMG
SRC=images/regist_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=sessions.html><IMG
SRC=images/session_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=special.html><IMG
SRC=images/special_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97tours.html><IMG
SRC=images/tour_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97travel.html><IMG
SRC=images/travel_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
</P></CENTER>
<HR SIZE="4" WIDTH="80%">
<CENTER><FONT SIZE="+2"><B><I>American Thoracic Society</I></B></FONT><BR>
1740 Broadway<BR> New York, NY 10019<BR> VOICE:  212-315-8700<BR> Copyright &copy;
1996 American Lung Association.<BR> The American Thoracic  Society is the
medical section <BR>of the American Lung Association.<BR> 
</CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-109</DOCNO>
<DOCOLDNO>IA013-000139-B029-281</DOCOLDNO>
<DOCHDR>
http://www.thoracic.org:80/ic97/atssun2.html 206.138.195.144 19970217072254 text/html 5289
HTTP/1.0 200 OK
Date: Monday, 17-Feb-97 07:18:10 GMT
Server: NCSA/1.3
MIME-version: 1.0
Content-type: text/html
Last-modified: Friday, 24-Jan-97 16:15:08 GMT
Content-length: 5109
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//SQ//DTD HTML 2.0 HoTMetaL + extensions//EN">
<HTML>
<HEAD>
<TITLE>ATS SUNRISE SEMINARS</TITLE></HEAD>
<BODY BGCOLOR="#FFFFFF">
<CENTER><IMG ALIGN="LEFT" SRC="images/banner0.jpg"></CENTER>
<CENTER></CENTER>
<CENTER><BR> 
<H2>ATS SUNRISE SEMINARS</H2>
<P></P></CENTER>
<HR SIZE="5" NOSHADE="NOSHADE" WIDTH="100%">
<P><BR><BR></P>
<CENTER>
<TABLE BORDER="2">
<TR ALIGN="CENTER" VALIGN="MIDDLE">
<TD ALIGN="CENTER" VALIGN="MIDDLE"><B><SMALL><A HREF="ic97.html">BACK TO
MAIN MENU</A></SMALL></B></TD></TR></TABLE></CENTER>
<P><BR><BR></P>
<HR SIZE="10" WIDTH="85%">
<P></P>
<BLOCKQUOTE>
<CENTER>
<P>TUESDAY, MAY 20</P></CENTER>
<P><B>Registration Fee: $15.00 (includes continental breakfast). </B><I>Attendance
is limited. Advance registration is required and on a first come, first served
basis.</I></P>
<P><B>7:00 am-8:00 am</B></P></BLOCKQUOTE>
<HR SIZE="4" WIDTH="85%" ALIGN="CENTER" NOSHADE="NOSHADE">
<BLOCKQUOTE>
<P><I>SS201.</I> <B>PREGNANCY AND CRITICAL CARE </B><I>Convener</I>/A.S.
Multz, M.D., Woodbury, NY</P>
<P><I>SS202.</I> <B>INDOOR POLLUTION: A CHALLENGE FOR THE NEW CENTURY </B><I>Convener</I>/G.B.
Hayes, M.D., Boston, MA</P>
<P><I>SS203.</I> <B>NOVEL APPROACHES TO THERAPY OF DIFFUSE MALIGNANT
MESOTHELIOMA </B><I>Convener/</I>A.M. Boylan, Charleston, SC</P>
<P><I>SS204.</I> <B>THE ROLE OF SPUTUM CYTOLOGY IN THE EARLY DETECTION AND
TREATMENT OF OCCULT LUNG CANCER </B><I>Convener</I>/J.J. Bechtel, M.D., Grand
Junction, CO</P>
<P><I>SS205.</I> <B>LIVING-RELATED DONOR LUNG TRANSPLANTATION </B><I>Convener</I>/R.G.
Barbers, M.D., Los Angeles, CA</P>
<P><I>SS206.</I> <B>PATIENT PERCEPTIONS OF DYSPNEA </B><I>Convener</I>/A.
Harver, Ph.D., Charlotte, NC</P>
<P><I>SS207.</I> <B>ALVEOLAR HEMORRHAGE DUE TO COLLAGEN VASCULAR DISEASES</B>
<I>Convener</I>/I.M. Ndukwu, M.D., Chicago, IL</P>
<P><I>SS208.</I> <B>IMPACT OF COMPOSITION OF ENTERIC FORMULAS ON BACTERIAL
TRANSLOCATION FROM THE GUT AND RISK FOR NOSOCOMIAL PNEUMONIA </B><I>Convener</I>/S.
Schexnayder, M.D., Little Rock, AR</P>
<P><I>SS209.</I> <B>NEW ADVANCES IN THE MANAGEMENT OF PULMONARY HYPERTENSION
</B><I>Convener</I>/M. Cutaia, M.D., Providence, RI</P>
<P><I>SS210.</I> <B>ARDS-OXIDATIVE STRESS </B><I>Convener</I>/S.L. Camhi,
M.D., Tucson, AZ</P>
<P><I>SS211.</I> <B>DELIVERY OF BRONCHODILATORS IN VENTILATED PATIENTS</B>
<I>Convener</I>/R. Dhand, M.D., Oak Park, IL</P>
<P><I>SS212.</I> <B>SUDDEN INFANT DEATH SYNDROME </B><I>Convener</I>/D.
Gozal, M.D., New Orleans, LA</P>
<P><I>SS213.</I> <B>SEDATION VERSUS NEUROMUSCULAR PARALYSIS IN AGITATED
VENTILATED PATIENTS</B><I>Convener</I>/R.R. Riker, M.D., Portland, OR</P>
<P><I>SS214.</I> <B>NEW STRATEGIES IN THE DIAGNOSIS AND TREATMENT OF
PNEUMOCYSTIS PNEUMONIA </B><I>Convener</I>/S.T. Pottratz, M.D., Indianapolis,
IN</P>
<P><I>SS215.</I> <B>TREATMENT OF CYSTIC FIBROSIS: WHEN DOES GENE THERAPY FIT
IN?</B> <I>Convener</I>/J.M. Pilewski, M.D., Pittsburgh, PA</P>
<P><I>SS216.</I> <B>LUNG VOLUME REDUCTION SURGERY: PHYSIOLOGICAL CONSEQUENCES
</B><I>Convener</I>/H. Teschler, M.D., Essen, Germany</P>
<P><I>SS217.</I> <B>LONG-ACTING BETA2 AGONISTS IN CHILDHOOD ASTHMA </B><I>Convener</I>/R.H.
Moore, M.D., Houston, TX</P>
<P><I>SS218.</I> <B>GAS EXCHANGE IN ASTHMA </B><I>Convener</I>/J. Roca,
M.D., Barcelona, Spain</P>
<P><I>SS219.</I> <B>PROSPECTS FOR PRIMARY ALLERGEN AVOIDANCE </B><I>Convener</I>/A.
Custovic, M.D., Manchester, England</P>
<P><I>SS220.</I> <B>THE ROLE OF THE RESPIRATORY THERAPY MEDICAL DIRECTOR IN
TODAY'S COST-CONSCIOUS ENVIRONMENT </B><I>Convener</I>/M.R. Balaan, M.D.,
Morgantown, WV</P></BLOCKQUOTE>
<P></P>
<HR SIZE="4" WIDTH="80%">
<CENTER>
<P><A HREF=97ala.html><IMG
SRC=images/activity_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97bus.html><IMG
SRC=images/business_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97cal.html><IMG
SRC=images/calendar_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97child.html><IMG
SRC=images/child_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=pg.html><IMG
SRC=images/courses_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=search.html><IMG
SRC=images/search_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=main.html><IMG
SRC=images/home_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97house.html><IMG
SRC=images/house_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=http://itsmtgs.com/ala-ats><IMG
SRC=images/regist_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=sessions.html><IMG
SRC=images/session_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=special.html><IMG
SRC=images/special_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97tours.html><IMG
SRC=images/tour_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97travel.html><IMG
SRC=images/travel_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
</P></CENTER>
<HR SIZE="4" WIDTH="80%">
<CENTER><FONT SIZE="+2"><B><I>American Thoracic Society</I></B></FONT><BR>
1740 Broadway<BR> New York, NY 10019<BR> VOICE:  212-315-8700<BR> Copyright &copy;
1996 American Lung Association.<BR> The American Thoracic  Society is the
medical section <BR>of the American Lung Association.<BR> 
</CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-110</DOCNO>
<DOCOLDNO>IA013-000139-B029-312</DOCOLDNO>
<DOCHDR>
http://www.thoracic.org:80/ic97/atssun3.html 206.138.195.144 19970217072302 text/html 5265
HTTP/1.0 200 OK
Date: Monday, 17-Feb-97 07:18:19 GMT
Server: NCSA/1.3
MIME-version: 1.0
Content-type: text/html
Last-modified: Friday, 24-Jan-97 16:15:09 GMT
Content-length: 5085
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//SQ//DTD HTML 2.0 HoTMetaL + extensions//EN">
<HTML>
<HEAD>
<TITLE>ATS SUNRISE SEMINARS</TITLE></HEAD>
<BODY BGCOLOR="#FFFFFF">
<CENTER><IMG ALIGN="LEFT" SRC="images/banner0.jpg"></CENTER>
<CENTER></CENTER>
<CENTER><BR> 
<H2>ATS SUNRISE SEMINARS</H2>
<P></P></CENTER>
<HR SIZE="5" NOSHADE="NOSHADE" WIDTH="100%">
<P><BR><BR></P>
<CENTER>
<TABLE BORDER="2">
<TR ALIGN="CENTER" VALIGN="MIDDLE">
<TD ALIGN="CENTER" VALIGN="MIDDLE"><B><SMALL><A HREF="ic97.html">BACK TO
MAIN MENU</A></SMALL></B></TD></TR></TABLE></CENTER>
<P><BR><BR></P>
<HR SIZE="10" WIDTH="85%">
<P></P>
<BLOCKQUOTE>
<CENTER>
<P>WEDNESDAY, MAY 21</P></CENTER>
<P><B>Registration Fee: $15.00 (includes continental breakfast). </B><I>Attendance
is limited. Advance registration is required and on a first come, first served
basis.</I></P>
<P><B>7:00 am-8:00 am</B></P></BLOCKQUOTE>
<HR SIZE="4" WIDTH="85%" ALIGN="CENTER" NOSHADE="NOSHADE">
<BLOCKQUOTE>
<P><I>SS301.</I> <B>CRITICAL CARE OF THE CARDIAC SURGICAL PATIENT: WHAT THE
PULMONARY CRITICAL CARE SPECIALIST NEEDS TO KNOW </B><I>Convener/</I>H.A
Cassiere, M.D., Mineola, NY</P>
<P><I>SS302.</I> <B>NITRIC OXIDE IN ARDS </B><I>Convener</I>/J.M. Walsh,
M.D., Burr Ridge, IL</P>
<P><I>SS303.</I> <B>MANAGEMENT OF ALLERGIES IN THE ASTHMATIC PATIENT</B> <I>Convener</I>/O.P.
Schaefer, M.D., Worcester, MA</P>
<P><I>SS304.</I> <B>PULMONARY COMPLICATIONS OF PREGNANCY </B><I>Convener</I>/K.L.
Bilello, M.D., Silver Spring, MD</P>
<P><I>SS305.</I> <B>OUTCOME OF PEDIATRIC HIV PATIENTS ADMITTED TO THE
PEDIATRIC ICU </B><I>Convener</I>/E. Conway, Jr., M.D., New York, NY</P>
<P><I>SS306.</I>  <B>DIAGNOSTIC APPROACH TO COMMUNITY-ACQUIRED PNEUMONIA </B><I>Convener</I>/C.M.
Mason, M.D., New Orleans, LA</P>
<P><I>SS307.</I> <B>DRUG-RESISTANT TUBERCULOSIS CLINICAL CONTROVERSIES </B><I>Convener</I>/P.M.
Simone, M.D., Atlanta, GA</P>
<P><I>SS308.</I> <B>TUBERCULOSIS IN THE ICU </B><I>Convener</I>/R.L. Lubman,
M.D., Los Angeles, CA</P>
<P><I>SS309.</I> <B>OUTPATIENT MANAGEMENT OF THE LUNG TRANSPLANT PATIENT </B><I>Convener</I>/G.
O'Brien, M.D., Philidelphia, PA</P>
<P><I>SS310.</I> <B>FATAL ASTHMA IN CHILDREN-RISK FACTORS AND PREVENTATIVE
STRATEGIES </B><I>Convener</I>/M.H. Wagner, M.D., Gainesville, FL</P>
<P><I>SS311.</I> <B>CHILDHOOD OBSTRUCTIVE SLEEP APNEA SYNDROME: DIAGNOSIS AND
MANAGEMENT </B><I>Convener</I>/S.V. Jacob, M.D., Kendall Park, NJ</P>
<P><I>SS312.</I> <B>MEDICAL FUTILITY STATUTES: BRINGING PATIENTS' RIGHTS INTO
BALANCE </B><I>Convener</I>/A.O. Davies, M.D., Houston, TX</P>
<P><I>SS313.</I> <B>OPTIMIZING NASAL CPAP-EXPLORING NONCOMPLIANCE </B><I>Convener</I>/M.K.
Reeves-Hoche, RN, Ph.D., Murrysville, PA</P>
<P><I>SS314.</I> <B>METASTATIC LUNG DISEASE </B><I>Convener</I>/A.C.
Arroliga, M.D., University Heights, OH</P>
<P><I>SS315.</I> <B>EVALUATION OF PLEURAL EFFUSIONS: UPDATE </B><I>Convener</I>/B.J.
Roth, M.D., Roy, WA</P>
<P><I>SS316.</I> <B>INTEGRATING THE CURVE: ACCURACY OF THERMODILUTION CARDIAC
OUTPUT IN CRITICALLY ILL PATIENTS </B><I>Convener/</I>S.W. Stites, M.D., Kansas
City, KS</P>
<P><I>SS317.</I> <B>LUNG CANCER: PATHOGENESIS AND WORK-UP </B><I>Convener</I>/L.
Nici, M.D., Barrington, RI</P>
<P><I>SS318.</I> <B>PGI2: PRIMARY PULMONARY HYPERTENSION </B><I>Convener</I>/W.B.
Williams, M.D., Portland, ME</P>
<P><I>SS319.</I> <B>SETTING UP A PULMONARY REHABILITATION PROGRAM </B><I>Convener</I>/C.A.
Piquette, M.D., Omaha, NE</P>
<P><I>SS320.</I> <B>PULMONARY REHABILITATION WITH ONCOLOGY PATIENTS </B><I>Convener</I>/D.
Wilson, M.S., R.N., R.R.T., New York, NY</P></BLOCKQUOTE>
<P></P>
<HR SIZE="4" WIDTH="80%">
<CENTER>
<P><A HREF=97ala.html><IMG
SRC=images/activity_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97bus.html><IMG
SRC=images/business_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97cal.html><IMG
SRC=images/calendar_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97child.html><IMG
SRC=images/child_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=pg.html><IMG
SRC=images/courses_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=search.html><IMG
SRC=images/search_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=main.html><IMG
SRC=images/home_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97house.html><IMG
SRC=images/house_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=http://itsmtgs.com/ala-ats><IMG
SRC=images/regist_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=sessions.html><IMG
SRC=images/session_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=special.html><IMG
SRC=images/special_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97tours.html><IMG
SRC=images/tour_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97travel.html><IMG
SRC=images/travel_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
</P></CENTER>
<HR SIZE="4" WIDTH="80%">
<CENTER><FONT SIZE="+2"><B><I>American Thoracic Society</I></B></FONT><BR>
1740 Broadway<BR> New York, NY 10019<BR> VOICE:  212-315-8700<BR> Copyright &copy;
1996 American Lung Association.<BR> The American Thoracic  Society is the
medical section <BR>of the American Lung Association.<BR> 
</CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-111</DOCNO>
<DOCOLDNO>IA013-000139-B029-337</DOCOLDNO>
<DOCHDR>
http://www.thoracic.org:80/ic97/atsers.html 206.138.195.144 19970217072309 text/html 2957
HTTP/1.0 200 OK
Date: Monday, 17-Feb-97 07:18:27 GMT
Server: NCSA/1.3
MIME-version: 1.0
Content-type: text/html
Last-modified: Friday, 24-Jan-97 16:15:06 GMT
Content-length: 2777
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//SQ//DTD HTML 2.0 HoTMetaL + extensions//EN">
<HTML>
<HEAD>
<TITLE>ALA/ERS SYMPOSIUM ON COPD</TITLE></HEAD>
<BODY BGCOLOR="#FFFFFF">
<CENTER><IMG ALIGN="LEFT" SRC="images/banner0.jpg"></CENTER>
<CENTER><BR>
<TABLE BORDER="0" ALIGN="CENTER" VALIGN="MIDDLE">
<TR>
<TD ALIGN="CENTER" VALIGN="MIDDLE"><IMG SRC="images/smlogo.gif"><BR>AMERICAN
THORACIC SOCIETY</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE"><IMG SRC="images/litenlog2.gif">
<BR>EUROPEAN RESPIRATORY SOCIETY</TD></TR></TABLE><BR>
<H2>SYMPOSIUM ON TREATMENT OF COPD:<BR>A FUTURISTIC APPROACH </H2></CENTER>
<HR SIZE="5" NOSHADE="NOSHADE" WIDTH="100%">
<P></P>
<CENTER>
<TABLE BORDER="2">
<TR ALIGN="CENTER" VALIGN="MIDDLE">
<TD ALIGN="CENTER" VALIGN="MIDDLE"><B><SMALL><A HREF="main.html">BACK TO
MAIN MENU</A></SMALL></B></TD></TR></TABLE></CENTER>
<P></P>
<HR SIZE="10" WIDTH="85%">
<P></P>
<CENTER>
<P>SUNDAY , MAY 18</P></CENTER>
<BLOCKQUOTE>
<P>The ATS is co-sponsoring a special symposium with the European Respiratory
Society. The symposium on &quot;Treatment of COPD: A Futuristic Approach&quot;
will provide a global look at COPD with emphasis on research and recent
treatment advances. The session will be held on <B>Sunday, May 18, at 1:30 p.m.</B></P></BLOCKQUOTE>
<P></P>
<HR SIZE="4" WIDTH="80%">
<CENTER>
<P><A HREF=97ala.html><IMG
SRC=images/activity_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97bus.html><IMG
SRC=images/business_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97cal.html><IMG
SRC=images/calendar_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97child.html><IMG
SRC=images/child_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=pg.html><IMG
SRC=images/courses_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=search.html><IMG
SRC=images/search_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=main.html><IMG
SRC=images/home_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97house.html><IMG
SRC=images/house_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=http://itsmtgs.com/ala-ats><IMG
SRC=images/regist_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=sessions.html><IMG
SRC=images/session_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=special.html><IMG
SRC=images/special_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97tours.html><IMG
SRC=images/tour_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97travel.html><IMG
SRC=images/travel_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
</P></CENTER>
<HR SIZE="4" WIDTH="80%">
<CENTER><FONT SIZE="+2"><B><I>American Thoracic Society</I></B></FONT><BR>
1740 Broadway<BR> New York, NY 10019<BR> VOICE:  212-315-8700<BR> Copyright &copy;
1996 American Lung Association.<BR> The American Thoracic  Society is the
medical section <BR>of the American Lung Association.<BR> 
</CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-112</DOCNO>
<DOCOLDNO>IA013-000139-B030-19</DOCOLDNO>
<DOCHDR>
http://www.thoracic.org:80/ic97/manpower.html 206.138.195.144 19970217072320 text/html 3497
HTTP/1.0 200 OK
Date: Monday, 17-Feb-97 07:18:35 GMT
Server: NCSA/1.3
MIME-version: 1.0
Content-type: text/html
Last-modified: Friday, 24-Jan-97 16:16:11 GMT
Content-length: 3317
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//SQ//DTD HTML 2.0 HoTMetaL + extensions//EN">
<HTML>
<HEAD>
<TITLE>Committee on Manpower</TITLE></HEAD>
<BODY BGCOLOR="#FFFFFF">
<CENTER><IMG ALIGN="LEFT" SRC="images/banner0.jpg"></CENTER>
<CENTER><BR> 
<H2>COMMITTEE ON MANPOWER FOR PULMONARY AND CRITICAL CARE SOCIETIES: A STUDY TO
ESTIMATE FUTURE WORKFORCE REQUIREMENTS IN PULMONARY AND CRITICAL CARE MEDICINE</H2></CENTER>
<HR SIZE="5" NOSHADE="NOSHADE" WIDTH="100%">
<P></P>
<CENTER>
<TABLE BORDER="2">
<TR ALIGN="CENTER" VALIGN="MIDDLE">
<TD ALIGN="CENTER" VALIGN="MIDDLE"><B><SMALL><A HREF="main.html">BACK TO
MAIN MENU</A></SMALL></B></TD></TR></TABLE></CENTER>
<P></P>
<HR SIZE="10" WIDTH="85%">
<P></P>
<CENTER>
<P>SUNDAY , MAY 18</P></CENTER>
<BLOCKQUOTE>
<P><B>12:00 NOON-1:30 PM</B></P></BLOCKQUOTE>
<HR SIZE="4" WIDTH="85%" ALIGN="CENTER" NOSHADE="NOSHADE">
<BLOCKQUOTE>
<P>The American College of Chest Physicians, the American Thoracic Society, and
the Society of Critical Care Medicine, with participation from the program
directors responsible for training pulmonary and critical care physicians, have
recognized the need to project future requirements for physicians trained in the
specialities of pulmonary and critical care. To achieve this goal, the three
societies formed the Committee on Manpower for Pulmonary and Critical Care
Societies (COMPACCS). This committee has designed a study to capture the current
demand for the care of patients with pulmonary and/or critical illness. This
information will be used to project physician manpower in future scenarios of
health care delivery. This session will describe the concepts, design and
preliminary results of the COMPACCS study.</P>
<P><I><B>Speakers:</B></I> M.A. Kelley, M.D., Philadelphia, PA</P>
<P>Other COMPACCS Members</P></BLOCKQUOTE>
<P></P>
<HR SIZE="4" WIDTH="80%">
<CENTER>
<P><A HREF=97ala.html><IMG
SRC=images/activity_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97bus.html><IMG
SRC=images/business_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97cal.html><IMG
SRC=images/calendar_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97child.html><IMG
SRC=images/child_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=pg.html><IMG
SRC=images/courses_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=search.html><IMG
SRC=images/search_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=main.html><IMG
SRC=images/home_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97house.html><IMG
SRC=images/house_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=http://itsmtgs.com/ala-ats><IMG
SRC=images/regist_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=sessions.html><IMG
SRC=images/session_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=special.html><IMG
SRC=images/special_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97tours.html><IMG
SRC=images/tour_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97travel.html><IMG
SRC=images/travel_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
</P></CENTER>
<HR SIZE="4" WIDTH="80%">
<CENTER><FONT SIZE="+2"><B><I>American Thoracic Society</I></B></FONT><BR>
1740 Broadway<BR> New York, NY 10019<BR> VOICE:  212-315-8700<BR> Copyright &copy;
1996 American Lung Association.<BR> The American Thoracic  Society is the
medical section <BR>of the American Lung Association.<BR> 
</CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-113</DOCNO>
<DOCOLDNO>IA013-000139-B030-58</DOCOLDNO>
<DOCHDR>
http://www.thoracic.org:80/ic97/journals.html 206.138.195.144 19970217072330 text/html 3275
HTTP/1.0 200 OK
Date: Monday, 17-Feb-97 07:18:48 GMT
Server: NCSA/1.3
MIME-version: 1.0
Content-type: text/html
Last-modified: Friday, 24-Jan-97 16:16:03 GMT
Content-length: 3095
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//SQ//DTD HTML 2.0 HoTMetaL + extensions//EN">
<HTML>
<HEAD>
<TITLE>MEET THE EDITORS</TITLE></HEAD>
<BODY BGCOLOR="#FFFFFF">
<CENTER><IMG SRC="images/banner0.jpg" ALIGN="LEFT"></CENTER>
<P></P>
<CENTER>
<TABLE BORDER="0">
<TR>
<TD ALIGN="CENTER" VALIGN="MIDDLE"><IMG SRC="images/smlogo.gif"><BR>
<P>MEET THE EDITORS</P> 
<H2>AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY</H2>
<H2>AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE </H2></TD></TR></TABLE></CENTER>
<HR SIZE="5" NOSHADE="NOSHADE" WIDTH="100%">
<P></P>
<CENTER>
<TABLE BORDER="2">
<TR ALIGN="CENTER" VALIGN="MIDDLE">
<TD ALIGN="CENTER" VALIGN="MIDDLE"><B><SMALL><A HREF="ic97.html">BACK TO
MAIN MENU</A></SMALL></B></TD></TR></TABLE></CENTER>
<P></P>
<HR SIZE="10" WIDTH="85%">
<P></P>
<CENTER>
<P>MONDAY , MAY 19</P></CENTER>
<BLOCKQUOTE>
<P><B>12:00 NOON-1:00 PM</B></P></BLOCKQUOTE>
<HR SIZE="4" WIDTH="85%" ALIGN="CENTER" NOSHADE="NOSHADE">
<BLOCKQUOTE>
<P><I><B>Editors:   </B><BR></I></P>
<UL>
<LI>J.A. McDonald, Ph.D., M.D., Scottsdale, AZ</LI>
<LI>A. Leff, M.D., Chicago, IL</LI></UL>
<P>The Editors will describe the types of manuscripts published in the
journals, the process of peer review used for both publications and criteria
utilized to reach decisions concerning publications. These descriptions will
include statistics of the time required for review of a manuscript as well as
the likelihood of submitted manuscripts being accepted for publication. The
Editors will also be available to answer questions regarding both journals.</P></BLOCKQUOTE>
<P></P>
<HR SIZE="4" WIDTH="80%">
<CENTER>
<P><A HREF=97ala.html><IMG
SRC=images/activity_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97bus.html><IMG
SRC=images/business_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97cal.html><IMG
SRC=images/calendar_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97child.html><IMG
SRC=images/child_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=pg.html><IMG
SRC=images/courses_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=search.html><IMG
SRC=images/search_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=main.html><IMG
SRC=images/home_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97house.html><IMG
SRC=images/house_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=http://itsmtgs.com/ala-ats><IMG
SRC=images/regist_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=sessions.html><IMG
SRC=images/session_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=special.html><IMG
SRC=images/special_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97tours.html><IMG
SRC=images/tour_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97travel.html><IMG
SRC=images/travel_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
</P></CENTER>
<HR SIZE="4" WIDTH="80%">
<CENTER><FONT SIZE="+2"><B><I>American Thoracic Society</I></B></FONT><BR>
1740 Broadway<BR> New York, NY 10019<BR> VOICE:  212-315-8700<BR> Copyright &copy;
1996 American Lung Association.<BR> The American Thoracic Society is the
medical section <BR>of the American Lung Association.<BR> 
</CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-114</DOCNO>
<DOCOLDNO>IA013-000139-B030-90</DOCOLDNO>
<DOCHDR>
http://www.thoracic.org:80/ic97/xfile.html 206.138.195.144 19970217072339 text/html 2203
HTTP/1.0 200 OK
Date: Monday, 17-Feb-97 07:18:55 GMT
Server: NCSA/1.3
MIME-version: 1.0
Content-type: text/html
Last-modified: Friday, 24-Jan-97 14:17:54 GMT
Content-length: 2023
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//SQ//DTD HTML 2.0 HoTMetaL + extensions//EN">
<HTML>
<HEAD>
<TITLE>ATS SESSION</TITLE></HEAD>
<BODY BACKGROUND="images/space1.jpg">
<CENTER><IMG SRC="images/alien.jpg" ALIGN="LEFT"></CENTER>
<CENTER>
<H2><FONT COLOR="#00FFFF">SLEEP PARALYSIS, NOCTURNAL DYSPNEA AND REPORTS OF
<FONT COLOR="#FF0000">EXTRATERRESTRIAL LIFE</FONT></FONT>
</H2></CENTER>
<HR SIZE="10" WIDTH="85%">
<P></P>
<CENTER>
<TABLE BORDER="1" BGCOLOR="#FFFFFF">
<TR>
<TD><FONT SIZE="-1"><B><A HREF="symposia.html"><FONT COLOR="#FF0000">BACK
TO SYMPOSIA</FONT></A></B></FONT></TD></TR></TABLE></CENTER>
<P></P>
<HR SIZE="10" WIDTH="85%">
<P></P>
<BLOCKQUOTE>
<CENTER>
<P><FONT COLOR="#00FFFF">TUESDAY , MAY 20</FONT></P>
<P><B><FONT COLOR="#00FFFF">11:45 AM-1:30 PM</FONT></B></P></CENTER></BLOCKQUOTE>
<HR SIZE="10" WIDTH="85%">
<BLOCKQUOTE>
<P><FONT COLOR="#FF0000">The X-Files come to the ATS. Folk legends of night
creatures including incubi, witches, vampires and extraterrestrial aliens are
probably associated with the phenomenon of sleep paralysis. Sleep paralysis is a
parasomnia characterized by shortness of breath, a sensation of pressure in the
chest and an inability to move body muscles. This will be an informative and
provocative review of the subject.</FONT></P>
<P><I><B><FONT SIZE="+2" COLOR="#FF0000">Speaker: </FONT></B></I><FONT
COLOR="#00FFFF">S.R. Rehm, M.D., St. Louis, MO</FONT></P></BLOCKQUOTE>
<P></P>
<HR SIZE="10" WIDTH="85%">
<P></P>
<CENTER>
<TABLE BORDER="1" BGCOLOR="#FFFFFF">
<TR>
<TD><B><A HREF="main.html"><FONT COLOR="#FF0000" SIZE="+2">BACK TO MAIN MENU</FONT></A></B></TD></TR></TABLE></CENTER>
<P></P>
<HR SIZE="10" WIDTH="85%">
<CENTER><FONT SIZE="+2" COLOR="#FFFFFF"><B><I>American Thoracic Society</I></B></FONT><BR><FONT
COLOR="#FFFFFF">
1740 Broadway<BR> New York, NY 10019<BR> VOICE:  212-315-8700<BR> Copyright &copy;
1996 American Lung Association.<BR> The American Thoracic  Society is the
medical section <BR>of the American Lung Association.<BR> 
</FONT></CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-115</DOCNO>
<DOCOLDNO>IA013-000139-B030-116</DOCOLDNO>
<DOCHDR>
http://www.thoracic.org:80/ic97/l1.html 206.138.195.144 19970217072348 text/html 3847
HTTP/1.0 200 OK
Date: Monday, 17-Feb-97 07:19:06 GMT
Server: NCSA/1.3
MIME-version: 1.0
Content-type: text/html
Last-modified: Friday, 24-Jan-97 16:16:03 GMT
Content-length: 3667
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//SQ//DTD HTML 2.0 HoTMetaL + extensions//EN">
<HTML>
<HEAD>
<TITLE>CENTERS FOR DISEASE CONTROL: L1</TITLE></HEAD>
<BODY BGCOLOR="#FFFFFF">
<CENTER><IMG ALIGN="LEFT" SRC="images/banner0.jpg"></CENTER>
<CENTER><BR>
<P>CENTERS FOR DISEASE CONTROL</P>
<H2>L1: HIGHLIGHTS OF CENTERS FOR DISEASE CONTROL<BR>LUNG DISEASE ACTIVITIES</H2>
<P><BR></P></CENTER>
<HR SIZE="5" NOSHADE="NOSHADE" WIDTH="100%">
<P></P>
<CENTER>
<TABLE BORDER="2">
<TR ALIGN="CENTER" VALIGN="MIDDLE">
<TD ALIGN="CENTER" VALIGN="MIDDLE"><B><SMALL><A HREF="ic97.html">BACK TO
MAIN MENU</A></SMALL></B></TD></TR></TABLE></CENTER>
<P></P>
<HR SIZE="10" WIDTH="85%">
<P></P>
<CENTER>
<P>SUNDAY , MAY 18</P></CENTER>
<BLOCKQUOTE>
<P><B>12:00 noon-1:00 pm</B></P></BLOCKQUOTE>
<HR SIZE="4" WIDTH="85%" ALIGN="CENTER" NOSHADE="NOSHADE">
<BLOCKQUOTE>
<P><I><B>Target Audience: </B></I>ALA volunteers and staff and ATS members.</P>
<P><B>OBJECTIVES</B><BR>At the conclusion of this session, the participant
will be able to:</P>
<UL>
<LI>describe the global pandemic influenza plan and their role(s) in
implementing it;</LI>
<LI>describe the magnitude of pneumonia in the community, the causative agents,
and factors which predispose to pneumonia;</LI>
<LI>discuss the need for nationwide surveillance for, and their role in,
surveillance for acute pulmonary hemorrhage and hemosiderosis.</LI></UL>
<P>This session will feature a presentation of the proposed global pandemic
influenza plan; a description of the incidence, etiology, and risk factors for
pneumonia in an Ohio community; and a proposal for nationwide surveillance of
acute pulmonary hemorrhage and hemosiderosis among infants.</P>
<P><I><B>Chairing: </B></I>D.E. Snider, Jr., M.D., M.P.H., Atlanta, GA</P>
<P><I>12:00</I> <B>Influenza Pandemic: Is the U.S. Prepared?</B>/R. Strikas,
M.D., Atlanta, GA</P>
<P><I>12:20</I> <B>Causes and Risk Factors for Community Acquired Pneumonia</B>/R.
Breiman, M.D., Atlanta, GA</P>
<P><I>12:35</I> <B>Nationwide Surveillance of Pulmonary Hemorrhage and
Hemosiderosis</B>/R.A. Etzel, M.D., Atlanta, GA</P>
<P><I>12:50</I> <B>Panel Discussion</B></P></BLOCKQUOTE>
<P></P>
<HR SIZE="4" WIDTH="80%">
<CENTER>
<P><A HREF=97ala.html><IMG
SRC=images/activity_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97bus.html><IMG
SRC=images/business_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97cal.html><IMG
SRC=images/calendar_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97child.html><IMG
SRC=images/child_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=pg.html><IMG
SRC=images/courses_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=search.html><IMG
SRC=images/search_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=main.html><IMG
SRC=images/home_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97house.html><IMG
SRC=images/house_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=http://itsmtgs.com/ala-ats><IMG
SRC=images/regist_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=sessions.html><IMG
SRC=images/session_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=special.html><IMG
SRC=images/special_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97tours.html><IMG
SRC=images/tour_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97travel.html><IMG
SRC=images/travel_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
</P></CENTER>
<HR SIZE="4" WIDTH="80%">
<CENTER><FONT SIZE="+2"><B><I>American Thoracic Society</I></B></FONT><BR>
1740 Broadway<BR> New York, NY 10019<BR> VOICE:  212-315-8700<BR> Copyright &copy;
1996 American Lung Association.<BR> The American Thoracic  Society is the
medical section <BR>of the American Lung Association.<BR> 
</CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-116</DOCNO>
<DOCOLDNO>IA013-000139-B030-150</DOCOLDNO>
<DOCHDR>
http://www.thoracic.org:80/ic97/l2.html 206.138.195.144 19970217072359 text/html 3763
HTTP/1.0 200 OK
Date: Monday, 17-Feb-97 07:19:14 GMT
Server: NCSA/1.3
MIME-version: 1.0
Content-type: text/html
Last-modified: Friday, 24-Jan-97 16:16:07 GMT
Content-length: 3583
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//SQ//DTD HTML 2.0 HoTMetaL + extensions//EN">
<HTML>
<HEAD>
<TITLE>IUATLD: L2</TITLE></HEAD>
<BODY BGCOLOR="#FFFFFF">
<CENTER><IMG ALIGN="LEFT" SRC="images/banner0.jpg"></CENTER>
<CENTER><BR>
<P>INTERNATIONAL UNION AGAINST<BR>TUBERCULOSIS AND LUNG DISEASE</P>
<H2>L2: THE IUATLD CONTRIBUTION TO WORLD LUNG HEALTH </H2>
<P><BR></P></CENTER>
<HR SIZE="5" NOSHADE="NOSHADE" WIDTH="100%">
<P></P>
<CENTER>
<TABLE BORDER="2">
<TR ALIGN="CENTER" VALIGN="MIDDLE">
<TD ALIGN="CENTER" VALIGN="MIDDLE"><B><SMALL><A HREF="ic97.html">BACK TO
MAIN MENU</A></SMALL></B></TD></TR></TABLE></CENTER>
<P></P>
<HR SIZE="10" WIDTH="85%">
<P></P>
<CENTER>
<P>SUNDAY , MAY 18</P></CENTER>
<BLOCKQUOTE>
<P><B>12:00 noon-1:00 pm</B></P></BLOCKQUOTE>
<HR SIZE="4" WIDTH="85%" ALIGN="CENTER" NOSHADE="NOSHADE">
<BLOCKQUOTE>
<P><I><B>Target Audience: </B></I>Physicians, nurses and other health care
workers interested in health problems in low income nations.</P>
<P><B>OBJECTIVES</B><BR>At the conclusion of this session, the participant
will be able to:</P>
<UL>
<LI>understand which factors of the urban environment contribute to lung
disease;</LI>
<LI> realize the importance of vaccine development and trials for the
eradication of tuberculosis;</LI>
<LI>recognize the challenges faced by health services in providing
cost-effective care for asthma patients.</LI></UL>
<P>From among the numerous health care problems in low income countries, three
topics have been selected to acquaint the participant with possible solutions
and the role of the IUATLD in attaining them: urbanization and the lung; a
vaccine for tuberculosis; asthma management.</P>
<P><I><B>Chairing: </B></I>J.F. Murray, M.D., Paris, France</P>
<P><I>12:00</I> <B>Urbanization and the Lung</B>/M.R. Becklake, M.D.,
Montreal, PQ, Canada</P>
<P><I>12:15</I> <B>A Vaccine for Tuberculosis?</B>/D.A. Enarson, M.D., Paris,
France</P>
<P><I>12:30</I> <B>Asthma Management in Low Income Countries</B>/A.J.
Woolcock, M.D., Sydney, Australia</P>
<P><I>12:45</I> <I>Discussion</I></P></BLOCKQUOTE>
<P></P>
<HR SIZE="4" WIDTH="80%">
<CENTER>
<P><A HREF=97ala.html><IMG
SRC=images/activity_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97bus.html><IMG
SRC=images/business_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97cal.html><IMG
SRC=images/calendar_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97child.html><IMG
SRC=images/child_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=pg.html><IMG
SRC=images/courses_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=search.html><IMG
SRC=images/search_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=main.html><IMG
SRC=images/home_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97house.html><IMG
SRC=images/house_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=http://itsmtgs.com/ala-ats><IMG
SRC=images/regist_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=sessions.html><IMG
SRC=images/session_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=special.html><IMG
SRC=images/special_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97tours.html><IMG
SRC=images/tour_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97travel.html><IMG
SRC=images/travel_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
</P></CENTER>
<HR SIZE="4" WIDTH="80%">
<CENTER><FONT SIZE="+2"><B><I>American Thoracic Society</I></B></FONT><BR>
1740 Broadway<BR> New York, NY 10019<BR> VOICE:  212-315-8700<BR> Copyright &copy;
1996 American Lung Association.<BR> The American Thoracic  Society is the
medical section <BR>of the American Lung Association.<BR> 
</CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-117</DOCNO>
<DOCOLDNO>IA013-000139-B030-181</DOCOLDNO>
<DOCHDR>
http://www.thoracic.org:80/ic97/l3.html 206.138.195.144 19970217072409 text/html 4353
HTTP/1.0 200 OK
Date: Monday, 17-Feb-97 07:19:25 GMT
Server: NCSA/1.3
MIME-version: 1.0
Content-type: text/html
Last-modified: Friday, 24-Jan-97 16:16:07 GMT
Content-length: 4173
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//SQ//DTD HTML 2.0 HoTMetaL + extensions//EN">
<HTML>
<HEAD>
<TITLE>NHLBI: L3</TITLE></HEAD>
<BODY BGCOLOR="#FFFFFF">
<CENTER><IMG ALIGN="LEFT" SRC="images/banner0.jpg"></CENTER>
<CENTER><BR>
<P>DIVISION OF LUNG DISEASES/<BR>NATIONAL HEART, LUNG, AND BLOOD INSTITUTE</P>
<H2>L3: CHILDHOOD ASTHMA MANAGEMENT PROGRAM  </H2>
<P><BR></P></CENTER>
<HR SIZE="5" NOSHADE="NOSHADE" WIDTH="100%">
<P></P>
<CENTER>
<TABLE BORDER="2">
<TR ALIGN="CENTER" VALIGN="MIDDLE">
<TD ALIGN="CENTER" VALIGN="MIDDLE"><B><SMALL><A HREF="ic97.html">BACK TO
MAIN MENU</A></SMALL></B></TD></TR></TABLE></CENTER>
<P></P>
<HR SIZE="10" WIDTH="85%">
<P></P>
<CENTER>
<P>SUNDAY , MAY 18</P></CENTER>
<BLOCKQUOTE>
<P><B>12:00 noon-1:00 pm</B></P></BLOCKQUOTE>
<HR SIZE="4" WIDTH="85%" ALIGN="CENTER" NOSHADE="NOSHADE">
<BLOCKQUOTE>
<P><I><B>Target Audience: </B></I>Physicians and nurses, involved in clinical
practical research.</P>
<P><B>OBJECTIVES</B><BR>At the conclusion of this session, the participant
will be able to:</P>
<UL>
<LI>identify the major environmental exposures that predict airway reactivity
and pulmonary function in children age 5-12 years;</LI>
<LI>describe the relationship between asthma severity and airway
responsiveness;</LI>
<LI>identify strategies to meet the challenges of pulmonary function testing in
children.</LI></UL>
<P>This session will discuss key relationships among environmental exposures,
airway responsiveness and asthma severity as identified in the 1041 children
participating in the Childhood Asthma Management Program. The session will also
discuss the challenges of pulmonary function testing in children age 5-12 years.</P>
<P>The Childhood Asthma Management Program is a study of children with mild to
moderate asthma to determine the long-term (at least 5 years) effects of three
asthma treatments on pulmonary function, asthma morbidity, quality of life and
physical and psychological growth and development.</P>
<P><I><B>Chairing: </B></I>R.M. Cherniack, M.D., Denver, COV.S. Taggart,
M.P.H., Bethesda, MD</P>
<P><I>12:00</I> <B>Introduction and Report of CAMP Progress</B>/R.M.
Cherniack, M.D., Denver, CO</P>
<P><I>12:05</I> <B>Challenges of Pulmonary Function Testing in Children</B>/R.A.
Wise, M.D., Baltimore, MD</P>
<P><I>12:20</I> <B>Relationship Between Environmental Exposures and Pulmonary
Function</B>/S.J. Szefler, M.D., Denver, CO</P>
<P><I>12:35</I> <B>Relationship Between Asthma Severity and Airway
Responsiveness</B>/S. Weiss, M.D., Boston, MA</P>
<P><I>12:50</I> <I>Discussion</I></P>
<P>@TITLE-NO = DIVISION OF LUNG DISEASES/NATIONAL HEART, LUNG, AND BLOOD
INSTITUTE</P></BLOCKQUOTE>
<P></P>
<HR SIZE="4" WIDTH="80%">
<CENTER>
<P><A HREF=97ala.html><IMG
SRC=images/activity_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97bus.html><IMG
SRC=images/business_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97cal.html><IMG
SRC=images/calendar_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97child.html><IMG
SRC=images/child_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=pg.html><IMG
SRC=images/courses_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=search.html><IMG
SRC=images/search_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=main.html><IMG
SRC=images/home_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97house.html><IMG
SRC=images/house_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=http://itsmtgs.com/ala-ats><IMG
SRC=images/regist_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=sessions.html><IMG
SRC=images/session_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=special.html><IMG
SRC=images/special_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97tours.html><IMG
SRC=images/tour_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97travel.html><IMG
SRC=images/travel_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
</P></CENTER>
<HR SIZE="4" WIDTH="80%">
<CENTER><FONT SIZE="+2"><B><I>American Thoracic Society</I></B></FONT><BR>
1740 Broadway<BR> New York, NY 10019<BR> VOICE:  212-315-8700<BR> Copyright &copy;
1996 American Lung Association.<BR> The American Thoracic  Society is the
medical section <BR>of the American Lung Association.<BR> 
</CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-118</DOCNO>
<DOCOLDNO>IA013-000139-B030-208</DOCOLDNO>
<DOCHDR>
http://www.thoracic.org:80/ic97/l4.html 206.138.195.144 19970217072416 text/html 4264
HTTP/1.0 200 OK
Date: Monday, 17-Feb-97 07:19:35 GMT
Server: NCSA/1.3
MIME-version: 1.0
Content-type: text/html
Last-modified: Friday, 24-Jan-97 16:16:08 GMT
Content-length: 4084
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//SQ//DTD HTML 2.0 HoTMetaL + extensions//EN">
<HTML>
<HEAD>
<TITLE>NHLBI: L4</TITLE></HEAD>
<BODY BGCOLOR="#FFFFFF">
<CENTER><IMG ALIGN="LEFT" SRC="images/banner0.jpg"></CENTER>
<CENTER><BR>
<P>DIVISION OF LUNG DISEASES/<BR>NATIONAL HEART, LUNG, AND BLOOD INSTITUTE</P>
<H2>L4: RESULTS OF THE <BR>LUNG HEALTH STUDY </H2>
<P><BR></P></CENTER>
<HR SIZE="5" NOSHADE="NOSHADE" WIDTH="100%">
<P></P>
<CENTER>
<TABLE BORDER="2">
<TR ALIGN="CENTER" VALIGN="MIDDLE">
<TD ALIGN="CENTER" VALIGN="MIDDLE"><B><SMALL><A HREF="ic97.html">BACK TO
MAIN MENU</A></SMALL></B></TD></TR></TABLE></CENTER>
<P></P>
<HR SIZE="10" WIDTH="85%">
<P></P>
<CENTER>
<P>SUNDAY , MAY 18</P></CENTER>
<BLOCKQUOTE>
<P><B>12:00 noon-1:00 pm</B></P></BLOCKQUOTE>
<HR SIZE="4" WIDTH="85%" ALIGN="CENTER" NOSHADE="NOSHADE">
<BLOCKQUOTE>
<P><I><B>Target Audience: </B></I>Clinical research scientists, clinicians,
health educators and behavioral scientists.</P>
<P><B>OBJECTIVES</B><BR>At the conclusion of this session, the participant
will be able to:</P>
<UL>
<LI>describe symptom changes associated with smoking cessation;</LI>
<LI>describe association among measures of quality of life, pulmonary function
and respiratory symptoms;</LI>
<LI>describe association among measures of sleep apnea, pulmonary function and
respiratory symptoms;</LI>
<LI>describe the status of the Euroscop Trial.</LI></UL>
<P>The objective of this session is to present outcome results from Lung Health
Study (LHS) I and Lung Health Study II. The session will present symptom changes
associated with smoking and smoking cessation in LHS-I participants. Initial
results willbe presented on quality of life measures and lung function and sleep
apnea measures and lung function in LHS-II participants.</P>
<P><I><B>Chairing: </B></I>N.R. Anthonisen, M.D., Winnipeg, MB, Canada</P>
<P><I>12:00</I> <B>Introduction</B>/N.R. Anthonisen, M.D., Winnipeg, MB,
Canada</P>
<P><I>12:05</I> <B>Changes in Symptoms in Sustained Quitters, Intermittant
Smokers and Continuing Smokers in Lung Health Study I</B>/R.E. Kanner, M.D.,
Salt Lake City, UT</P>
<P><I>12:20</I> <B>Quality of Life, Lung Function, and Respiratory Symptoms
in Lung Health Study II Participants</B>/C.S. Rand, Ph.D., Baltimore, MD</P>
<P><I>12:35</I> <B>Sleep Apnea, Lung Function, and Respiratory Symptoms in
Lung Health Study II Participants</B>/J.P. Kiley, Ph.D., Bethesda, MD</P>
<P><I>12:45</I> <B>Euroscop: Close to the End</B>/R.A. Pauwels, M.D., Ghent,
Belgium</P>
<P>Discussion after each presentation/5 minutes</P></BLOCKQUOTE>
<P></P>
<HR SIZE="4" WIDTH="80%">
<CENTER>
<P><A HREF=97ala.html><IMG
SRC=images/activity_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97bus.html><IMG
SRC=images/business_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97cal.html><IMG
SRC=images/calendar_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97child.html><IMG
SRC=images/child_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=pg.html><IMG
SRC=images/courses_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=search.html><IMG
SRC=images/search_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=main.html><IMG
SRC=images/home_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97house.html><IMG
SRC=images/house_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=http://itsmtgs.com/ala-ats><IMG
SRC=images/regist_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=sessions.html><IMG
SRC=images/session_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=special.html><IMG
SRC=images/special_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97tours.html><IMG
SRC=images/tour_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97travel.html><IMG
SRC=images/travel_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
</P></CENTER>
<HR SIZE="4" WIDTH="80%">
<CENTER><FONT SIZE="+2"><B><I>American Thoracic Society</I></B></FONT><BR>
1740 Broadway<BR> New York, NY 10019<BR> VOICE:  212-315-8700<BR> Copyright &copy;
1996 American Lung Association.<BR> The American Thoracic  Society is the
medical section <BR>of the American Lung Association.<BR> 
</CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-119</DOCNO>
<DOCOLDNO>IA013-000139-B030-238</DOCOLDNO>
<DOCHDR>
http://www.thoracic.org:80/ic97/l5.html 206.138.195.144 19970217072430 text/html 4311
HTTP/1.0 200 OK
Date: Monday, 17-Feb-97 07:19:46 GMT
Server: NCSA/1.3
MIME-version: 1.0
Content-type: text/html
Last-modified: Friday, 24-Jan-97 16:16:08 GMT
Content-length: 4131
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//SQ//DTD HTML 2.0 HoTMetaL + extensions//EN">
<HTML>
<HEAD>
<TITLE>NIOSH: L5</TITLE></HEAD>
<BODY BGCOLOR="#FFFFFF">
<CENTER><IMG ALIGN="LEFT" SRC="images/banner0.jpg"></CENTER>
<CENTER><BR>
<P>NATIONAL INSTITUTE FOR OCCUPATIONAL SAFETY AND HEALTH
</P>
<H2>L5: COLLABORATIVE PROGRAMS IN OCCUPATIONAL LUNG DISEASE RESEARCH </H2>
<P><BR></P></CENTER>
<HR SIZE="5" NOSHADE="NOSHADE" WIDTH="100%">
<P></P>
<CENTER>
<TABLE BORDER="2">
<TR ALIGN="CENTER" VALIGN="MIDDLE">
<TD ALIGN="CENTER" VALIGN="MIDDLE"><B><SMALL><A HREF="ic97.html">BACK TO
MAIN MENU</A></SMALL></B></TD></TR></TABLE></CENTER>
<P></P>
<HR SIZE="10" WIDTH="85%">
<P></P>
<CENTER>
<P>MONDAY , MAY 19</P></CENTER>
<BLOCKQUOTE>
<P><B>12:00 noon-1:00 pm</B></P></BLOCKQUOTE>
<HR SIZE="4" WIDTH="85%" ALIGN="CENTER" NOSHADE="NOSHADE">
<BLOCKQUOTE>
<P><I><B>Target Audience: </B></I>Pulmonary clinicians and clinical
investigators, epidemiologists, and occupational physicians.</P>
<P><B>OBJECTIVES</B><BR>At the conclusion of this session, the participant
will be able to:</P>
<UL>
<LI>describe selected current occupational lung disease research initiatives in
the agricultural industry;</LI>
<LI>describe selected research and community efforts to reduce tuberculosis
from an occupational perspective;</LI>
<LI>describe state-based surveillance tools being used to enumerate and target
occupational lung diseases, and some of their results;</LI>
<LI>describe grant research results in a selected occupational lung disease
field.</LI></UL>
<P>NIOSH funds many grants and cooperative agreements in the area of
occupational lung disease. This session will present a varied selection of these
activities which are of current interest to NIOSH, as reflected in its National
Occupational ResearchAgenda document. The participant should gain both an
understanding of the types of research and institutions funded by NIOSH, and a
sample of results and implications from this activity.</P>
<P><I><B>Chairing: </B></I>T.K. Hodous, M.D., Morgantown, WV</P>
<P><I>12:00</I> <B>Overview of NIOSH Collaborative Programs in Occupational
Lung Disease Research</B>/T.K. Hodous, M.D., Morgantown, WV</P>
<P><I>12:10</I> <B>Recent Research of Occupational Lung Diseases in
Agriculture</B>/J.A. Merchant, M.D., M.P.H., Iowa City, IA</P>
<P><I>12:25</I> <B>Surveillance for Occupational Asthma</B>/R. Harrison,
M.D., M.P.H., Berkeley, CA</P>
<P><I>12:40</I> <B>Occupational TB Research Issues</B>/K.P. Fennelly, M.D.,
M.P.H., Denver, CO</P>
<P><I>12:55</I> <I>Discussion</I></P>
<P>Discusiion after each presentation/5 minutes</P></BLOCKQUOTE>
<P></P>
<HR SIZE="4" WIDTH="80%">
<CENTER>
<P><A HREF=97ala.html><IMG
SRC=images/activity_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97bus.html><IMG
SRC=images/business_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97cal.html><IMG
SRC=images/calendar_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97child.html><IMG
SRC=images/child_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=pg.html><IMG
SRC=images/courses_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=search.html><IMG
SRC=images/search_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=main.html><IMG
SRC=images/home_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97house.html><IMG
SRC=images/house_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=http://itsmtgs.com/ala-ats><IMG
SRC=images/regist_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=sessions.html><IMG
SRC=images/session_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=special.html><IMG
SRC=images/special_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97tours.html><IMG
SRC=images/tour_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97travel.html><IMG
SRC=images/travel_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
</P></CENTER>
<HR SIZE="4" WIDTH="80%">
<CENTER><FONT SIZE="+2"><B><I>American Thoracic Society</I></B></FONT><BR>
1740 Broadway<BR> New York, NY 10019<BR> VOICE:  212-315-8700<BR> Copyright &copy;
1996 American Lung Association.<BR> The American Thoracic  Society is the
medical section <BR>of the American Lung Association.<BR> 
</CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-120</DOCNO>
<DOCOLDNO>IA013-000139-B030-265</DOCOLDNO>
<DOCHDR>
http://www.thoracic.org:80/ic97/l6.html 206.138.195.144 19970217072448 text/html 3972
HTTP/1.0 200 OK
Date: Monday, 17-Feb-97 07:20:03 GMT
Server: NCSA/1.3
MIME-version: 1.0
Content-type: text/html
Last-modified: Friday, 24-Jan-97 16:16:09 GMT
Content-length: 3792
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//SQ//DTD HTML 2.0 HoTMetaL + extensions//EN">
<HTML>
<HEAD>
<TITLE>NIH: L6</TITLE></HEAD>
<BODY BGCOLOR="#FFFFFF">
<CENTER><IMG ALIGN="LEFT" SRC="images/banner0.jpg"></CENTER>
<CENTER><BR>
<P>NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES/NATIONAL INSTITUTES OF
HEALTH</P>
<H2>L6: FINDINGS OF THE NIAID <BR>INNER-CITY ASTHMA INTERVENTION </H2>
<P><BR></P></CENTER>
<HR SIZE="5" NOSHADE="NOSHADE" WIDTH="100%">
<P></P>
<CENTER>
<TABLE BORDER="2">
<TR ALIGN="CENTER" VALIGN="MIDDLE">
<TD ALIGN="CENTER" VALIGN="MIDDLE"><B><SMALL><A HREF="ic97.html">BACK TO
MAIN MENU</A></SMALL></B></TD></TR></TABLE></CENTER>
<P></P>
<HR SIZE="10" WIDTH="85%">
<P></P>
<CENTER>
<P>MONDAY , MAY 19</P></CENTER>
<BLOCKQUOTE>
<P><B>12:00 noon-1:00 pm</B></P></BLOCKQUOTE>
<HR SIZE="4" WIDTH="85%" ALIGN="CENTER" NOSHADE="NOSHADE">
<BLOCKQUOTE>
<P><I><B>Target Audience: </B></I>Physicians, nurses, health care
professionals and community care providers.</P>
<P><B>OBJECTIVES</B><BR>At the conclusion of this session, the participant
will be able to:</P>
<UL>
<LI>identify important risk factors for asthma among inner-city children;</LI>
<LI>understand the components of a successful asthma intervention for
inner-city children;</LI>
<LI>describe the results and impact of this intervention on inner-city
children;</LI>
<LI>identify those subgroups for whom the asthma intervention is most
effective.</LI></UL>
<P>The National Cooperative Inner City Asthma study (NCICAS) used an asthma
case manager with a social work background to reduce the morbidity of inner-city
children with asthma. Both the NCICAS intervention protocol and techniques
developed to implement the NCICAS protocol will serve as a model for others
wishing to work among inner-city children.</P>
<P><I><B>Chairing: </B></I>P.J. Gergen, M.D., M.P.H., Bethesda, MDE.T.
Smartt, Bethesda, MD</P>
<P><I>12:00</I> <B>Inner City Asthma Study Intervention Protocol</B>/C.M.
Kercsmar, M.D., Cleveland, OH</P>
<P><I>12:20</I> <B>Finding and Outcomes of the Inner City Asthma Intervention</B>/R.
Evans, III, M.D., M.P.H., Chicago, IL</P>
<P><I>12:40</I> <B>For Whom Did the Intervention Work?</B>/H. Mitchell,
Ph.D., Watertown, MA</P>
<P>Discussion after each presentation/5 minutes</P></BLOCKQUOTE>
<P></P>
<HR SIZE="4" WIDTH="80%">
<CENTER>
<P><A HREF=97ala.html><IMG
SRC=images/activity_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97bus.html><IMG
SRC=images/business_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97cal.html><IMG
SRC=images/calendar_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97child.html><IMG
SRC=images/child_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=pg.html><IMG
SRC=images/courses_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=search.html><IMG
SRC=images/search_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=main.html><IMG
SRC=images/home_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97house.html><IMG
SRC=images/house_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=http://itsmtgs.com/ala-ats><IMG
SRC=images/regist_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=sessions.html><IMG
SRC=images/session_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=special.html><IMG
SRC=images/special_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97tours.html><IMG
SRC=images/tour_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97travel.html><IMG
SRC=images/travel_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
</P></CENTER>
<HR SIZE="4" WIDTH="80%">
<CENTER><FONT SIZE="+2"><B><I>American Thoracic Society</I></B></FONT><BR>
1740 Broadway<BR> New York, NY 10019<BR> VOICE:  212-315-8700<BR> Copyright &copy;
1996 American Lung Association.<BR> The American Thoracic  Society is the
medical section <BR>of the American Lung Association.<BR> 
</CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-121</DOCNO>
<DOCOLDNO>IA013-000139-B030-289</DOCOLDNO>
<DOCHDR>
http://www.thoracic.org:80/ic97/l7.html 206.138.195.144 19970217072510 text/html 4429
HTTP/1.0 200 OK
Date: Monday, 17-Feb-97 07:20:16 GMT
Server: NCSA/1.3
MIME-version: 1.0
Content-type: text/html
Last-modified: Friday, 24-Jan-97 16:16:09 GMT
Content-length: 4249
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//SQ//DTD HTML 2.0 HoTMetaL + extensions//EN">
<HTML>
<HEAD>
<TITLE>NHLBI: L7</TITLE></HEAD>
<BODY BGCOLOR="#FFFFFF">
<CENTER><IMG ALIGN="LEFT" SRC="images/banner0.jpg"></CENTER>
<CENTER><BR>
<P>DIVISION OF LUNG DISEASES/<BR>NATIONAL HEART, LUNG, AND BLOOD INSTITUTE</P>
<H2>L7: PATHWAYS TO PULMONARY RESEARCH CAREERS - DIVISION OF LUNG DISEASES
STAFF </H2>
<P><BR></P></CENTER>
<HR SIZE="5" NOSHADE="NOSHADE" WIDTH="100%">
<P></P>
<CENTER>
<TABLE BORDER="2">
<TR ALIGN="CENTER" VALIGN="MIDDLE">
<TD ALIGN="CENTER" VALIGN="MIDDLE"><B><SMALL><A HREF="ic97.html">BACK TO
MAIN MENU</A></SMALL></B></TD></TR></TABLE></CENTER>
<P></P>
<HR SIZE="10" WIDTH="85%">
<P></P>
<CENTER>
<P>MONDAY , MAY 19</P></CENTER>
<BLOCKQUOTE>
<P><B>12:00 noon-1:00 pm</B></P></BLOCKQUOTE>
<HR SIZE="4" WIDTH="85%" ALIGN="CENTER" NOSHADE="NOSHADE">
<BLOCKQUOTE>
<P><I><B>Target Audience: </B></I>Investigators and students interested in
research and training opportunities in pulmonary biology and medicine.</P>
<P><B>OBJECTIVES</B><BR>At the conclusion of this session, the participant
will be able to:</P>
<UL>
<LI>familiarize with the mission and programs of the Division of Lung Diseases,
NHLBI;</LI>
<LI>describe recent major research advances in pulmonary biology and medicine;</LI>
<LI>describe various research grant and training mechanisms available from
NHLBI;</LI>
<LI>establish contacts with DLD program managers for future assistance.</LI></UL>
<P>This session will provide an informal setting to interested investigators to
meet the Director and staff of the Division of Lung Diseases to learn about
NHLBI's pulmonary programs and current research and research training grant
opportunities.</P>
<P><I><B>Chairing: </B></I>S.S. Hurd, Ph.D., Bethesda, MDC. Vreim, Ph.D.,
Bethesda, MD</P>
<P><I>12:00</I> <B>Introduction</B>/S.S. Hurd, Ph.D., Bethesda, MD</P>
<P><B>Lung Cell and Vascular Biology</B>/D.Berlin Gail, Ph.D., Bethesda, MD</P>
<P><B>Lung Development and Pediatric Lung Diseases</B>/M. Berberich, Ph.D.,
Bethesda, MD</P>
<P><B>Pulmonary Immunology and Fibrosis and Also Acute Lung Injury and
Critical Care Medicine</B>/R. Musson, Ph.D., Bethesda, MD</P>
<P><B>AIDS and Tuberculosis</B>/H.H. Peavy, M.D., Bethesda, MD</P>
<P><B>COPD and Environmental Lung Disease</B>/G.G. Weinmann, M.D., Bethesda,
MD</P>
<P><B>Asthma and Cystic Fibrosis</B>/S. Banks-Schlegel, Ph.D., Bethesda, MD</P>
<P><B>Asthma</B>/V. Taggart, M.P.H., Bethesda, MD/M. Hindi-Alexander, Ph.D.,
Bethesda, MD</P>
<P><B>Sleep and Neurobiology</B>/J. Kiley, Ph.D., Betheda, MD/M. Twery, Ph.D.,
Bethesda, MD</P>
<P><B>Training Programs</B>/J.Sri Ram, Ph.D., Bethesda, MD/M. Reilly, MS.,
Bethesda, MD/A. Rothgeb, Bethesda, MD</P></BLOCKQUOTE>
<P></P>
<HR SIZE="4" WIDTH="80%">
<CENTER>
<P><A HREF=97ala.html><IMG
SRC=images/activity_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97bus.html><IMG
SRC=images/business_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97cal.html><IMG
SRC=images/calendar_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97child.html><IMG
SRC=images/child_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=pg.html><IMG
SRC=images/courses_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=search.html><IMG
SRC=images/search_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=main.html><IMG
SRC=images/home_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97house.html><IMG
SRC=images/house_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=http://itsmtgs.com/ala-ats><IMG
SRC=images/regist_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=sessions.html><IMG
SRC=images/session_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=special.html><IMG
SRC=images/special_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97tours.html><IMG
SRC=images/tour_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97travel.html><IMG
SRC=images/travel_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
</P></CENTER>
<HR SIZE="4" WIDTH="80%">
<CENTER><FONT SIZE="+2"><B><I>American Thoracic Society</I></B></FONT><BR>
1740 Broadway<BR> New York, NY 10019<BR> VOICE:  212-315-8700<BR> Copyright &copy;
1996 American Lung Association.<BR> The American Thoracic  Society is the
medical section <BR>of the American Lung Association.<BR> 
</CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-122</DOCNO>
<DOCOLDNO>IA013-000139-B030-322</DOCOLDNO>
<DOCHDR>
http://www.thoracic.org:80/ic97/l8.html 206.138.195.144 19970217072519 text/html 4007
HTTP/1.0 200 OK
Date: Monday, 17-Feb-97 07:20:37 GMT
Server: NCSA/1.3
MIME-version: 1.0
Content-type: text/html
Last-modified: Friday, 24-Jan-97 16:16:10 GMT
Content-length: 3827
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//SQ//DTD HTML 2.0 HoTMetaL + extensions//EN">
<HTML>
<HEAD>
<TITLE>NHLBI: L8</TITLE></HEAD>
<BODY BGCOLOR="#FFFFFF">
<CENTER><IMG ALIGN="LEFT" SRC="images/banner0.jpg"></CENTER>
<CENTER><BR>
<P>DIVISION OF LUNG DISEASES/<BR>NATIONAL HEART, LUNG, AND BLOOD INSTITUTE</P>
<H2>L8: FINDINGS OF THE NAEPP TASK FORCE ON COST EFFECTIVENESS, QUALITY OF
CARE, AND FINANCING OF ASTHMA CARE </H2>
<P><BR></P></CENTER>
<HR SIZE="5" NOSHADE="NOSHADE" WIDTH="100%">
<P></P>
<CENTER>
<TABLE BORDER="2">
<TR ALIGN="CENTER" VALIGN="MIDDLE">
<TD ALIGN="CENTER" VALIGN="MIDDLE"><B><SMALL><A HREF="ic97.html">BACK TO
MAIN MENU</A></SMALL></B></TD></TR></TABLE></CENTER>
<P></P>
<HR SIZE="10" WIDTH="85%">
<P></P>
<CENTER>
<P>MONDAY , MAY 19</P></CENTER>
<BLOCKQUOTE>
<P><B>12:00 noon-1:00 pm</B></P></BLOCKQUOTE>
<HR SIZE="4" WIDTH="85%" ALIGN="CENTER" NOSHADE="NOSHADE">
<BLOCKQUOTE>
<P><I><B>Target Audience: </B></I>Physicians, nurses, health care
professionals and community care providers.</P>
<P><B>OBJECTIVES</B><BR>At the conclusion of this session, the participant
will be able to:</P>
<UL>
<LI>identify important risk factors for asthma among inner-city children;</LI>
<LI>understand the components of a successful asthma intervention for
inner-city children;</LI>
<LI>describe the results and impact of this intervention on inner-city
children;</LI>
<LI>identify those subgroups for whom the asthma intervention is most
effective.</LI></UL>
<P>The National Cooperative Inner City Asthma study (NCICAS) used an asthma
case manager with a social work background to reduce the morbidity of inner-city
children with asthma. Both the NCICAS intervention protocol and techniques
developed to implement the NCICAS protocol will serve as a model for others
wishing to work among inner-city children.</P>
<P><I><B>Chairing: </B></I>P.J. Gergen, M.D., M.P.H., Bethesda, MDE.T.
Smartt, Bethesda, MD</P>
<P><I>12:00</I> <B>Inner City Asthma Study Intervention Protocol</B>/C.M.
Kercsmar, M.D., Cleveland, OH</P>
<P><I>12:20</I> <B>Finding and Outcomes of the Inner City Asthma Intervention</B>/R.
Evans, III, M.D., M.P.H., Chicago, IL</P>
<P><I>12:40</I> <B>For Whom Did the Intervention Work?</B>/H. Mitchell,
Ph.D., Watertown, MA</P>
<P>Discussion after each presentation/5 minutes</P></BLOCKQUOTE>
<P></P>
<HR SIZE="4" WIDTH="80%">
<CENTER>
<P><A HREF=97ala.html><IMG
SRC=images/activity_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97bus.html><IMG
SRC=images/business_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97cal.html><IMG
SRC=images/calendar_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97child.html><IMG
SRC=images/child_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=pg.html><IMG
SRC=images/courses_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=search.html><IMG
SRC=images/search_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=main.html><IMG
SRC=images/home_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97house.html><IMG
SRC=images/house_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=http://itsmtgs.com/ala-ats><IMG
SRC=images/regist_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=sessions.html><IMG
SRC=images/session_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=special.html><IMG
SRC=images/special_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97tours.html><IMG
SRC=images/tour_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97travel.html><IMG
SRC=images/travel_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
</P></CENTER>
<HR SIZE="4" WIDTH="80%">
<CENTER><FONT SIZE="+2"><B><I>American Thoracic Society</I></B></FONT><BR>
1740 Broadway<BR> New York, NY 10019<BR> VOICE:  212-315-8700<BR> Copyright &copy;
1996 American Lung Association.<BR> The American Thoracic  Society is the
medical section <BR>of the American Lung Association.<BR> 
</CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-123</DOCNO>
<DOCOLDNO>IA013-000139-B030-355</DOCOLDNO>
<DOCHDR>
http://www.thoracic.org:80/ic97/l9.html 206.138.195.144 19970217072529 text/html 4045
HTTP/1.0 200 OK
Date: Monday, 17-Feb-97 07:20:46 GMT
Server: NCSA/1.3
MIME-version: 1.0
Content-type: text/html
Last-modified: Friday, 24-Jan-97 16:16:10 GMT
Content-length: 3865
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//SQ//DTD HTML 2.0 HoTMetaL + extensions//EN">
<HTML>
<HEAD>
<TITLE>NHLBI: L9</TITLE></HEAD>
<BODY BGCOLOR="#FFFFFF">
<CENTER><IMG ALIGN="LEFT" SRC="images/banner0.jpg"></CENTER>
<CENTER><BR>
<P>DIVISION OF LUNG DISEASES/<BR>NATIONAL HEART, LUNG, AND BLOOD INSTITUTE</P>
<H2>L9: COLLABORATIVE STUDY ON THE GENETICS OF ASTHMA-UPDATE 1997 </H2>
<P><BR></P></CENTER>
<HR SIZE="5" NOSHADE="NOSHADE" WIDTH="100%">
<P></P>
<CENTER>
<TABLE BORDER="2">
<TR ALIGN="CENTER" VALIGN="MIDDLE">
<TD ALIGN="CENTER" VALIGN="MIDDLE"><B><SMALL><A HREF="ic97.html">BACK TO
MAIN MENU</A></SMALL></B></TD></TR></TABLE></CENTER>
<P></P>
<HR SIZE="10" WIDTH="85%">
<P></P>
<CENTER>
<P>TUESDAY , MAY 20</P></CENTER>
<BLOCKQUOTE>
<P><B>12:00 noon-1:00 pm</B></P></BLOCKQUOTE>
<HR SIZE="4" WIDTH="85%" ALIGN="CENTER" NOSHADE="NOSHADE">
<BLOCKQUOTE>
<P><I><B>Target Audience: </B></I>TBA</P>
<P><B>OBJECTIVES</B><BR>At the conclusion of this session, the participant
will be able to:</P>
<UL>
<LI>understand the CSGA approach to the study of the genetics basis of asthma;</LI>
<LI>understand the latest information regarding the results of the CSGA genome
wide search for asthma and asthma associated phenotype susceptibility genes in
ethnically diverse groups.</LI></UL>
<P>The National Heart, Lung, and Blood Institute Collaborative Study on the
Genetics of Asthma (CSGA) will summarize the results of their multi-center
effort to map asthma and asthma associated phenotype susceptibility genes in the
three ethnic groups (Caucasians, African-Americans, Hispanic Americans) using a
genome screen.</P>
<P><I><B>Chairing: </B></I>M.N. Blumenthal, M.D., Minneapolis, MN</P>
<P><I>12:00</I> <B>Results of the CSGA Genome Wide Search for Asthma
Susceptibility Genes in Ethnically Diverse Populations</B>/M.N. Blumenthal,
M.D., Minneapolis, MN</P>
<P><I>12:15</I> <B>Results of CSGA Genome Wide research for Asthma
Susceptibility Genes in Ethnically Diverse Populations</B>/E.R. Bleecker, M.D.,
Baltimore, MD</P>
<P><I>12:30</I> <B>Results of the CSGA Genome Wide Search for Asthma
Susceptibility Genes for Ethnically Diverse Populations</B>/C. Ober, Ph.D.,
Chicago, IL</P>
<P><I>12:45</I> <B>Results of the CSGA Genome Wide Search for Asthma
Susceptibility Genes in Ethnically Diverse Populations</B>/T. Beaty, Ph.D.,
Baltimore, MD</P></BLOCKQUOTE>
<P></P>
<HR SIZE="4" WIDTH="80%">
<CENTER>
<P><A HREF=97ala.html><IMG
SRC=images/activity_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97bus.html><IMG
SRC=images/business_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97cal.html><IMG
SRC=images/calendar_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97child.html><IMG
SRC=images/child_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=pg.html><IMG
SRC=images/courses_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=search.html><IMG
SRC=images/search_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=main.html><IMG
SRC=images/home_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97house.html><IMG
SRC=images/house_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=http://itsmtgs.com/ala-ats><IMG
SRC=images/regist_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=sessions.html><IMG
SRC=images/session_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=special.html><IMG
SRC=images/special_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97tours.html><IMG
SRC=images/tour_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97travel.html><IMG
SRC=images/travel_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
</P></CENTER>
<HR SIZE="4" WIDTH="80%">
<CENTER><FONT SIZE="+2"><B><I>American Thoracic Society</I></B></FONT><BR>
1740 Broadway<BR> New York, NY 10019<BR> VOICE:  212-315-8700<BR> Copyright &copy;
1996 American Lung Association.<BR> The American Thoracic  Society is the
medical section <BR>of the American Lung Association.<BR> 
</CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-124</DOCNO>
<DOCOLDNO>IA013-000139-B031-5</DOCOLDNO>
<DOCHDR>
http://www.thoracic.org:80/ic97/l10.html 206.138.195.144 19970217072539 text/html 3820
HTTP/1.0 200 OK
Date: Monday, 17-Feb-97 07:20:54 GMT
Server: NCSA/1.3
MIME-version: 1.0
Content-type: text/html
Last-modified: Friday, 24-Jan-97 16:16:04 GMT
Content-length: 3640
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//SQ//DTD HTML 2.0 HoTMetaL + extensions//EN">
<HTML>
<HEAD>
<TITLE>NHLBI: L10</TITLE></HEAD>
<BODY BGCOLOR="#FFFFFF">
<CENTER><IMG ALIGN="LEFT" SRC="images/banner0.jpg"></CENTER>
<CENTER><BR>
<P>DIVISION OF LUNG DISEASES/<BR>NATIONAL HEART, LUNG, AND BLOOD INSTITUTE</P>
<H2>L10: ASTHMA CLINICAL RESEARCH NETWORK </H2>
<P><BR></P></CENTER>
<HR SIZE="5" NOSHADE="NOSHADE" WIDTH="100%">
<P></P>
<CENTER>
<TABLE BORDER="2">
<TR ALIGN="CENTER" VALIGN="MIDDLE">
<TD ALIGN="CENTER" VALIGN="MIDDLE"><B><SMALL><A HREF="ic97.html">BACK TO
MAIN MENU</A></SMALL></B></TD></TR></TABLE></CENTER>
<P></P>
<HR SIZE="10" WIDTH="85%">
<P></P>
<CENTER>
<P>TUESDAY , MAY 20</P></CENTER>
<BLOCKQUOTE>
<P><B>12:00 noon-1:00 pm</B></P></BLOCKQUOTE>
<HR SIZE="4" WIDTH="85%" ALIGN="CENTER" NOSHADE="NOSHADE">
<BLOCKQUOTE>
<P><I><B>Target Audience: </B></I>Clinical scientists interested in
multi-center research on asthma.</P>
<P><B>OBJECTIVES</B>At the conclusion of this session, the participant will be
able to:</P>
<P>BULLET = understand structure and objectives of NHLBI Asthma Clinical
Research Network;</P>
<P>BULLET = understand new research results obtained through network protocols;</P>
<P>BULLET = describe clinical research procedures undertaken in network
studies.</P>
<P>The NHLBI Asthma Clinical Research Network is composed of six clinical
centers and a data coordinating center to conduct clinical investigations in
asthma. The structure of the network and progress in ongoing clinical trials
will be described.</P>
<P><I><B>Chairing: </B></I>J.E. Fish, M.D., Philadelphia, PA</P>
<P><I>12:00</I> <B>Summary of Asthma Clinical Research Network</B>/J.E. Fish,
M.D., Philadelphia, PA</P>
<P><I>12:15</I> <B>Altered Responses to Beta-Agonists in Minority Populations</B>/E.
Israel, M.D., Boston, MA</P>
<P><I>12:30</I> <B>Methacholine Challenge: Safety of Starting FEV1</B>/R.J.
Martin, M.D., Denver, CO</P>
<P><I>12:45</I> <B>Safety and Reproducibility of Sputum Induction in Moderate
Asthma</B>/J.V. Fahy, M.D., San Francisco, CA</P>
<P>Discussion after each presentation/5 minutes</P></BLOCKQUOTE>
<P></P>
<HR SIZE="4" WIDTH="80%">
<CENTER>
<P><A HREF=97ala.html><IMG
SRC=images/activity_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97bus.html><IMG
SRC=images/business_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97cal.html><IMG
SRC=images/calendar_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97child.html><IMG
SRC=images/child_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=pg.html><IMG
SRC=images/courses_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=search.html><IMG
SRC=images/search_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=main.html><IMG
SRC=images/home_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97house.html><IMG
SRC=images/house_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=http://itsmtgs.com/ala-ats><IMG
SRC=images/regist_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=sessions.html><IMG
SRC=images/session_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=special.html><IMG
SRC=images/special_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97tours.html><IMG
SRC=images/tour_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97travel.html><IMG
SRC=images/travel_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
</P></CENTER>
<HR SIZE="4" WIDTH="80%">
<CENTER><FONT SIZE="+2"><B><I>American Thoracic Society</I></B></FONT><BR>
1740 Broadway<BR> New York, NY 10019<BR> VOICE:  212-315-8700<BR> Copyright &copy;
1996 American Lung Association.<BR> The American Thoracic  Society is the
medical section <BR>of the American Lung Association.<BR> 
</CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-125</DOCNO>
<DOCOLDNO>IA013-000139-B031-36</DOCOLDNO>
<DOCHDR>
http://www.thoracic.org:80/ic97/l11.html 206.138.195.144 19970217072549 text/html 4166
HTTP/1.0 200 OK
Date: Monday, 17-Feb-97 07:21:05 GMT
Server: NCSA/1.3
MIME-version: 1.0
Content-type: text/html
Last-modified: Friday, 24-Jan-97 16:16:04 GMT
Content-length: 3986
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//SQ//DTD HTML 2.0 HoTMetaL + extensions//EN">
<HTML>
<HEAD>
<TITLE>NHLBI: L11</TITLE></HEAD>
<BODY BGCOLOR="#FFFFFF">
<CENTER><IMG ALIGN="LEFT" SRC="images/banner0.jpg"></CENTER>
<CENTER><BR>
<P>DIVISION OF LUNG DISEASES/<BR>NATIONAL HEART, LUNG, AND BLOOD INSTITUTE</P>
<H2>L11: RECENT PROGRESS FROM THE NHLBI PROGRAM OF EXCELLENCE IN MOLECULAR
BIOLOGY </H2>
<P><BR></P></CENTER>
<HR SIZE="5" NOSHADE="NOSHADE" WIDTH="100%">
<P></P>
<CENTER>
<TABLE BORDER="2">
<TR ALIGN="CENTER" VALIGN="MIDDLE">
<TD ALIGN="CENTER" VALIGN="MIDDLE"><B><SMALL><A HREF="ic97.html">BACK TO
MAIN MENU</A></SMALL></B></TD></TR></TABLE></CENTER>
<P></P>
<HR SIZE="10" WIDTH="85%">
<P></P>
<CENTER>
<P>TUESDAY , MAY 20</P></CENTER>
<BLOCKQUOTE>
<P><B>12:00 noon-1:00 pm</B></P></BLOCKQUOTE>
<HR SIZE="4" WIDTH="85%" ALIGN="CENTER" NOSHADE="NOSHADE">
<BLOCKQUOTE>
<P><I><B>Target Audience: </B></I>Basic and clinical scientists, trainees,
and students.</P>
<P><B>OBJECTIVES</B><BR>At the conclusion of this session, the participant
will be able to:</P>
<UL>
<LI>describe the NHLBI programs of Excellence in Molecular Biology;</LI>
<LI>highlight recent progress in applying molecular biology to pulmonary
research;</LI>
<LI>demonstrate the utility of transgenic models for the study of lung disease
and development</LI></UL>
<P>This session will describe the goals and accomplishments of the Program of
Excellence in Molecular Biology, Heart and Lung funded by the National
Institutes of Health, NHLBI. Three presentations by present members of the
Program of Excellence will be provided during a one-hour academic session. The
presentations will focus on the application of molecular biology and transgenic
animals to the study of lung biology. Experimental models to understand the role
of specific genes in host defense, lung inflammation and development will be
considered in the presentations.</P>
<P><I><B>Chairing: </B></I>J.A. Whitsett, M.D., Cincinnati, OH</P>
<P><I>12:15</I> <B>Introduction and Description of the Progress of Excellence
in Molecular Biology</B>/J.A. Whitsett, M.D., Cincinnati, OH</P>
<P><I>12:20</I> <B>Lessons from TGF-B Gene Targeting</B>/T. Doetschman,
Ph.D., Cincinnati, OH</P>
<P><I>12:35</I> <B>Modulation of Lung Inflammation and Immune Response by
Adenoviral E3-14 Protein</B>/K. Harrod, Ph.D., Cincinnati, OH</P>
<P><I>12:50</I> <B>Macrophage Scavenger Receptor System</B>/M. Kreiger, M.D.,
Ph.D., Boston, MA</P></BLOCKQUOTE>
<P></P>
<HR SIZE="4" WIDTH="80%">
<CENTER>
<P><A HREF=97ala.html><IMG
SRC=images/activity_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97bus.html><IMG
SRC=images/business_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97cal.html><IMG
SRC=images/calendar_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97child.html><IMG
SRC=images/child_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=pg.html><IMG
SRC=images/courses_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=search.html><IMG
SRC=images/search_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=main.html><IMG
SRC=images/home_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97house.html><IMG
SRC=images/house_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=http://itsmtgs.com/ala-ats><IMG
SRC=images/regist_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=sessions.html><IMG
SRC=images/session_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=special.html><IMG
SRC=images/special_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97tours.html><IMG
SRC=images/tour_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97travel.html><IMG
SRC=images/travel_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
</P></CENTER>
<HR SIZE="4" WIDTH="80%">
<CENTER><FONT SIZE="+2"><B><I>American Thoracic Society</I></B></FONT><BR>
1740 Broadway<BR> New York, NY 10019<BR> VOICE:  212-315-8700<BR> Copyright &copy;
1996 American Lung Association.<BR> The American Thoracic  Society is the
medical section <BR>of the American Lung Association.<BR> 
</CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-126</DOCNO>
<DOCOLDNO>IA013-000139-B031-59</DOCOLDNO>
<DOCHDR>
http://www.thoracic.org:80/ic97/l12.html 206.138.195.144 19970217072556 text/html 4738
HTTP/1.0 200 OK
Date: Monday, 17-Feb-97 07:21:14 GMT
Server: NCSA/1.3
MIME-version: 1.0
Content-type: text/html
Last-modified: Friday, 24-Jan-97 16:16:05 GMT
Content-length: 4558
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//SQ//DTD HTML 2.0 HoTMetaL + extensions//EN">
<HTML>
<HEAD>
<TITLE>NHLBI: L12</TITLE></HEAD>
<BODY BGCOLOR="#FFFFFF">
<CENTER><IMG ALIGN="LEFT" SRC="images/banner0.jpg"></CENTER>
<CENTER><BR>
<P>DIVISION OF LUNG DISEASES/<BR>NATIONAL HEART, LUNG, AND BLOOD INSTITUTE</P>
<H2>L12: SLEEP HEART HEALTH STUDY</H2>
<P><BR></P></CENTER>
<HR SIZE="5" NOSHADE="NOSHADE" WIDTH="100%">
<P></P>
<CENTER>
<TABLE BORDER="2">
<TR ALIGN="CENTER" VALIGN="MIDDLE">
<TD ALIGN="CENTER" VALIGN="MIDDLE"><B><SMALL><A HREF="ic97.html">BACK TO
MAIN MENU</A></SMALL></B></TD></TR></TABLE></CENTER>
<P></P>
<HR SIZE="10" WIDTH="85%">
<P></P>
<CENTER>
<P>TUESDAY , MAY 20</P></CENTER>
<BLOCKQUOTE>
<P><B>12:00 noon-1:00 pm</B></P></BLOCKQUOTE>
<HR SIZE="4" WIDTH="85%" ALIGN="CENTER" NOSHADE="NOSHADE">
<BLOCKQUOTE>
<P><I><B>Target Audience: </B></I>Pulmonary clinicians, sleep researchers,
epidemiologists, cardiovascular scientists, and physiologists.</P>
<P><B>OBJECTIVES</B><BR>At the conclusion of this session, the participant
will be able to:</P>
<UL>
<LI>understand the overview of the SHHS and current recruitment status;</LI>
<LI>understand the quality of the sleep readings obtained in this study;</LI>
<LI>understand the baseline sleep characteristics and preliminary data on the
cohort;</LI>
<LI>understand the definitions of RDI (Respiratory Disturbance Index)
established for SHHS.</LI></UL>
<P>The Sleep Heart Health Study (SHHS) is a multi-center cohort study sponsored
by the National Heart, Lung, and Blood Institute to determine the degree to
which sleep apnea is an independent or contributing risk factor for the
development of cardiovascular and cerebrovascular disease. It is also aimed at
examining possible associations between sleep apnea hypertension and stroke
among different age, gender and ethnic groups. The SHHS will utilize existing
population based cardiovascular cohorts to examine whether sleep disordered
breathing is associated with an increased risk of incident coronary heart
disease events, incident stroke, increase in blood pressure and increased risk
of all cause mortality. This session will provide an overview of the SHHS,
including current status of recruitment; describe the quality of the
polysmnographic readings obtained in the study; provide an overview of the
preliminary baseline sleep characteristics of all subjects screened for the
study; and discuss the important issues considered in defining the RDI
established for the SHHS.</P>
<P><I><B>Chairing: </B></I>J.M. Samet, M.D., Baltimore, MDJ.P. Kiley, Ph.D.,
Bethesda, MD</P>
<P><I>12:00</I> <B>Overview of SHHS and Recruitment</B>/J.M. Samet, M.D.,
Baltimore, MD</P>
<P><I>12:10</I> <B>Quality of Polysomnography in SHHS</B>/C. Iber, M.D.,
Minneapolis, MN</P>
<P><I>12:20</I> <B>Baseline Sleep Characteristics: Preliminary Results</B>/T.B.
Young, Ph.D., Madison, WI</P>
<P><I>12:35</I> <B>Defining Respiratory Disturbance Index (RDI)</B>/D.J.
Gottlieb, M.D., Boston, MA</P>
<P><I>12:50</I> <I>Discussion</I></P></BLOCKQUOTE>
<P></P>
<HR SIZE="4" WIDTH="80%">
<CENTER>
<P><A HREF=97ala.html><IMG
SRC=images/activity_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97bus.html><IMG
SRC=images/business_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97cal.html><IMG
SRC=images/calendar_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97child.html><IMG
SRC=images/child_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=pg.html><IMG
SRC=images/courses_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=search.html><IMG
SRC=images/search_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=main.html><IMG
SRC=images/home_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97house.html><IMG
SRC=images/house_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=http://itsmtgs.com/ala-ats><IMG
SRC=images/regist_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=sessions.html><IMG
SRC=images/session_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=special.html><IMG
SRC=images/special_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97tours.html><IMG
SRC=images/tour_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97travel.html><IMG
SRC=images/travel_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
</P></CENTER>
<HR SIZE="4" WIDTH="80%">
<CENTER><FONT SIZE="+2"><B><I>American Thoracic Society</I></B></FONT><BR>
1740 Broadway<BR> New York, NY 10019<BR> VOICE:  212-315-8700<BR> Copyright &copy;
1996 American Lung Association.<BR> The American Thoracic  Society is the
medical section <BR>of the American Lung Association.<BR> 
</CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-127</DOCNO>
<DOCOLDNO>IA013-000139-B031-84</DOCOLDNO>
<DOCHDR>
http://www.thoracic.org:80/ic97/l13.html 206.138.195.144 19970217072603 text/html 4336
HTTP/1.0 200 OK
Date: Monday, 17-Feb-97 07:21:21 GMT
Server: NCSA/1.3
MIME-version: 1.0
Content-type: text/html
Last-modified: Friday, 24-Jan-97 16:16:05 GMT
Content-length: 4156
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//SQ//DTD HTML 2.0 HoTMetaL + extensions//EN">
<HTML>
<HEAD>
<TITLE>NHLBI: L13</TITLE></HEAD>
<BODY BGCOLOR="#FFFFFF">
<CENTER><IMG ALIGN="LEFT" SRC="images/banner0.jpg"></CENTER>
<CENTER><BR>
<P>DIVISION OF LUNG DISEASES/<BR>NATIONAL HEART, LUNG, AND BLOOD INSTITUTE</P>
<H2>L13: EARLY INTERVENTIONS TO PREVENT ASTHMA: IDENTIFYING STRATEGIES AND
RESEARCH PRIORITIES </H2>
<P><BR></P></CENTER>
<HR SIZE="5" NOSHADE="NOSHADE" WIDTH="100%">
<P></P>
<CENTER>
<TABLE BORDER="2">
<TR ALIGN="CENTER" VALIGN="MIDDLE">
<TD ALIGN="CENTER" VALIGN="MIDDLE"><B><SMALL><A HREF="ic97.html">BACK TO
MAIN MENU</A></SMALL></B></TD></TR></TABLE></CENTER>
<P></P>
<HR SIZE="10" WIDTH="85%">
<P></P>
<CENTER>
<P>WEDNESDAY , MAY 21</P></CENTER>
<BLOCKQUOTE>
<P><B>12:00 noon-1:00 pm</B></P></BLOCKQUOTE>
<HR SIZE="4" WIDTH="85%" ALIGN="CENTER" NOSHADE="NOSHADE">
<BLOCKQUOTE>
<P><I><B>Target Audience: </B></I>Researchers interested in the development
of the immune system and lung as it relates to asthma. Physicians and health
care providers with an interest in the primary prevention of asthma.</P>
<P><B>OBJECTIVES</B><BR>At the conclusion of this session, the participant
will be able to:</P>
<UL>
<LI>describe major risk factors contributing to the increasing prevalence of
asthma in infants and young children;</LI>
<LI>explain potential mechanisms for the development of asthma in infants and
young children;</LI>
<LI>develop priorities for research in interventions for preventing or curbing
the progression of asthma in infants and young children.</LI></UL>
<P>Primary prevention of asthma should be achievable. Recent studies have led
to insights into the mechanisms of asthma and risk factors for the onset of
asthma that suggest exciting and promising avenues for future research. This
session will discuss the recommendations of a May, 1996 NHLBI workshop on asthma
prevention and will elicit comments from the session participants about
intervention strategies and research priorities for preventing asthma in early
childhood.</P>
<P><I><B>Chairing: </B></I>F. Martinez, M.D., Tucson, AZS.T. Holgate, M.D.,
Southampton, EnglandS.T. Weiss, M.D., Boston, MA</P>
<P><I>12:00</I> <B>Trends and Risk Factors for Increasing Prevalence of
Asthma in Early Childhood</B>/F. Martinez, M.D., Tucson, AZ</P>
<P><I>12:10</I> <B>Development of the Immune System and Early Childhood
Asthma</B>/S.T. Holgate, M.D., Southampton, England</P>
<P><I>12:20</I> <B>Targets for Interventions to Prevent Asthma in Early
Childhood: Research Needs</B>/S.T. Weiss, M.D., Boston, MA</P>
<P><I>12:30</I> <B>Panel Discussion</B></P></BLOCKQUOTE>
<P></P>
<HR SIZE="4" WIDTH="80%">
<CENTER>
<P><A HREF=97ala.html><IMG
SRC=images/activity_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97bus.html><IMG
SRC=images/business_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97cal.html><IMG
SRC=images/calendar_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97child.html><IMG
SRC=images/child_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=pg.html><IMG
SRC=images/courses_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=search.html><IMG
SRC=images/search_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=main.html><IMG
SRC=images/home_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97house.html><IMG
SRC=images/house_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=http://itsmtgs.com/ala-ats><IMG
SRC=images/regist_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=sessions.html><IMG
SRC=images/session_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=special.html><IMG
SRC=images/special_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97tours.html><IMG
SRC=images/tour_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97travel.html><IMG
SRC=images/travel_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
</P></CENTER>
<HR SIZE="4" WIDTH="80%">
<CENTER><FONT SIZE="+2"><B><I>American Thoracic Society</I></B></FONT><BR>
1740 Broadway<BR> New York, NY 10019<BR> VOICE:  212-315-8700<BR> Copyright &copy;
1996 American Lung Association.<BR> The American Thoracic  Society is the
medical section <BR>of the American Lung Association.<BR> 
</CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-128</DOCNO>
<DOCOLDNO>IA013-000139-B031-111</DOCOLDNO>
<DOCHDR>
http://www.thoracic.org:80/ic97/l14.html 206.138.195.144 19970217072610 text/html 3950
HTTP/1.0 200 OK
Date: Monday, 17-Feb-97 07:21:28 GMT
Server: NCSA/1.3
MIME-version: 1.0
Content-type: text/html
Last-modified: Friday, 24-Jan-97 16:16:05 GMT
Content-length: 3770
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//SQ//DTD HTML 2.0 HoTMetaL + extensions//EN">
<HTML>
<HEAD>
<TITLE>NHLBI: L14</TITLE></HEAD>
<BODY BGCOLOR="#FFFFFF">
<CENTER><IMG ALIGN="LEFT" SRC="images/banner0.jpg"></CENTER>
<CENTER><BR>
<P>DIVISION OF LUNG DISEASES/<BR>NATIONAL HEART, LUNG, AND BLOOD INSTITUTE</P>
<H2>L14: COLLABORATIVE PROJECT ON ASTHMA AND PREGNANCY </H2>
<P><BR></P></CENTER>
<HR SIZE="5" NOSHADE="NOSHADE" WIDTH="100%">
<P></P>
<CENTER>
<TABLE BORDER="2">
<TR ALIGN="CENTER" VALIGN="MIDDLE">
<TD ALIGN="CENTER" VALIGN="MIDDLE"><B><SMALL><A HREF="ic97.html">BACK TO
MAIN MENU</A></SMALL></B></TD></TR></TABLE></CENTER>
<P></P>
<HR SIZE="10" WIDTH="85%">
<P></P>
<CENTER>
<P>WEDNESDAY , MAY 21</P></CENTER>
<BLOCKQUOTE>
<P><B>12:00 noon-1:00 pm</B></P></BLOCKQUOTE>
<HR SIZE="4" WIDTH="85%" ALIGN="CENTER" NOSHADE="NOSHADE">
<BLOCKQUOTE>
<P><I><B>Target Audience: </B></I>Investigators and health care professionals
interested in clinical problems of asthma during pregnancy.</P>
<P><B>OBJECTIVES</B><BR>At the conclusion of this session, the participant
will be able to:</P>
<UL>
<LI>understand the issues which led to these studies;</LI>
<LI>gain insight into the prevalence of mild, moderate, and severe asthma in
pregnancy;</LI>
<LI>understand the baseline characteristics of women with asthma during
pregnancy.</LI></UL>
<P>The NICHD/NHLBI collaborative program on Asthma and Pregnancy is composed of
two studies designed: 1) to establish, in a controlled, prospective
observational study, the effect of asthma and treatment regimens, on the
prenatal outcome, in pregnant women with mild, moderate or severe asthma and, 2)
to compare the effectiveness of theophylline and beclomethasone in the treatment
of pregnant women with moderate asthma. This seminar will provide details of the
design and conduct of these studies and present preliminary results.</P>
<P><I><B>Chairing: </B></I>M. Dombrowski, M.D., Detroit, MI</P>
<P><I>12:00</I> <B>Background and Literature Review</B>/M. Schatz, M.D., San
Diego, CA</P>
<P><I>12:15</I> <B>Study Design and Demographics</B>/M. Dombrowski, M.D.,
Detroit, MI</P>
<P><I>12:30</I> <B>Preliminary Data/Observations</B>/R.A. Wise, M.D.,
Baltimore, MD</P>
<P><I>12:45</I> <I>Discussion</I></P></BLOCKQUOTE>
<P></P>
<HR SIZE="4" WIDTH="80%">
<CENTER>
<P><A HREF=97ala.html><IMG
SRC=images/activity_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97bus.html><IMG
SRC=images/business_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97cal.html><IMG
SRC=images/calendar_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97child.html><IMG
SRC=images/child_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=pg.html><IMG
SRC=images/courses_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=search.html><IMG
SRC=images/search_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=main.html><IMG
SRC=images/home_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97house.html><IMG
SRC=images/house_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=http://itsmtgs.com/ala-ats><IMG
SRC=images/regist_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=sessions.html><IMG
SRC=images/session_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=special.html><IMG
SRC=images/special_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97tours.html><IMG
SRC=images/tour_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97travel.html><IMG
SRC=images/travel_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
</P></CENTER>
<HR SIZE="4" WIDTH="80%">
<CENTER><FONT SIZE="+2"><B><I>American Thoracic Society</I></B></FONT><BR>
1740 Broadway<BR> New York, NY 10019<BR> VOICE:  212-315-8700<BR> Copyright &copy;
1996 American Lung Association.<BR> The American Thoracic  Society is the
medical section <BR>of the American Lung Association.<BR> 
</CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-129</DOCNO>
<DOCOLDNO>IA013-000139-B031-127</DOCOLDNO>
<DOCHDR>
http://www.thoracic.org:80/ic97/l15.html 206.138.195.144 19970217072617 text/html 3844
HTTP/1.0 200 OK
Date: Monday, 17-Feb-97 07:21:35 GMT
Server: NCSA/1.3
MIME-version: 1.0
Content-type: text/html
Last-modified: Friday, 24-Jan-97 16:16:06 GMT
Content-length: 3664
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//SQ//DTD HTML 2.0 HoTMetaL + extensions//EN">
<HTML>
<HEAD>
<TITLE>NHLBI: L15</TITLE></HEAD>
<BODY BGCOLOR="#FFFFFF">
<CENTER><IMG ALIGN="LEFT" SRC="images/banner0.jpg"></CENTER>
<CENTER><BR>
<P>DIVISION OF LUNG DISEASES/<BR>NATIONAL HEART, LUNG, AND BLOOD INSTITUTE</P>
<H2>L15: ARDS NETWORK: REPORT OF ONGOING AND PROPOSED CLINICAL TRIALS </H2>
<P><BR></P></CENTER>
<HR SIZE="5" NOSHADE="NOSHADE" WIDTH="100%">
<P></P>
<CENTER>
<TABLE BORDER="2">
<TR ALIGN="CENTER" VALIGN="MIDDLE">
<TD ALIGN="CENTER" VALIGN="MIDDLE"><B><SMALL><A HREF="ic97.html">BACK TO
MAIN MENU</A></SMALL></B></TD></TR></TABLE></CENTER>
<P></P>
<HR SIZE="10" WIDTH="85%">
<P></P>
<CENTER>
<P>WEDNESDAY , MAY 21</P></CENTER>
<BLOCKQUOTE>
<P><B>12:00 noon-1:00 pm</B></P></BLOCKQUOTE>
<HR SIZE="4" WIDTH="85%" ALIGN="CENTER" NOSHADE="NOSHADE">
<BLOCKQUOTE>
<P><I><B>Target Audience: </B></I>Physicians, nurses and respiratory
therapists practicing in critical care.</P>
<P><B>OBJECTIVES</B><BR>At the conclusion of this session, the participant
will be able to:</P>
<UL>
<LI>disseminate information regarding the activities of the ARDSnet trials
group;</LI>
<LI>provide an increased understanding of the working hypotheses related to the
various trials of the ARDSnet;</LI>
<LI>provide information regarding the process by which the ARDSnet selects and
conducts clinical investigations.</LI></UL>
<P>The NIH NHLBI ARDSnet is an investigator group composed of 10 clinical
centers and a coordinating center whose purpose is to conduct clinical
investigation in ARDS. The progress of the ongoing trials will be detailed and
proposed projects under active consideration will be discussed.</P>
<P><I><B>Chairing: </B></I>G.R. Bernard, M.D., Nashville, TN</P>
<P><I>12:00</I> <B>Six vs. Twelve ml/kg Tidal Volume Trial</B>/R.G. Brower,
M.D., Baltimore, MD</P>
<P><I>12:10</I> <B>Ketoconazole in ARDS</B>/K.P. Steinberg, M.D., Seattle, WA</P>
<P><I>12:20</I> <B>Late Steroid in ARDS</B>/L.D. Hudson, M.D., Seattle, WA</P>
<P><I>12:30</I> <B>New ARDSnet Strategies</B>/E. Abraham, M.D., Denver, CO</P>
<P><I>12:40</I> <I>Discussion</I></P></BLOCKQUOTE>
<P></P>
<HR SIZE="4" WIDTH="80%">
<CENTER>
<P><A HREF=97ala.html><IMG
SRC=images/activity_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97bus.html><IMG
SRC=images/business_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97cal.html><IMG
SRC=images/calendar_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97child.html><IMG
SRC=images/child_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=pg.html><IMG
SRC=images/courses_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=search.html><IMG
SRC=images/search_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=main.html><IMG
SRC=images/home_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97house.html><IMG
SRC=images/house_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=http://itsmtgs.com/ala-ats><IMG
SRC=images/regist_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=sessions.html><IMG
SRC=images/session_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=special.html><IMG
SRC=images/special_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97tours.html><IMG
SRC=images/tour_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97travel.html><IMG
SRC=images/travel_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
</P></CENTER>
<HR SIZE="4" WIDTH="80%">
<CENTER><FONT SIZE="+2"><B><I>American Thoracic Society</I></B></FONT><BR>
1740 Broadway<BR> New York, NY 10019<BR> VOICE:  212-315-8700<BR> Copyright &copy;
1996 American Lung Association.<BR> The American Thoracic  Society is the
medical section <BR>of the American Lung Association.<BR> 
</CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-130</DOCNO>
<DOCOLDNO>IA013-000139-B031-151</DOCOLDNO>
<DOCHDR>
http://www.thoracic.org:80/ic97/l16.html 206.138.195.144 19970217072624 text/html 3557
HTTP/1.0 200 OK
Date: Monday, 17-Feb-97 07:21:42 GMT
Server: NCSA/1.3
MIME-version: 1.0
Content-type: text/html
Last-modified: Friday, 24-Jan-97 16:16:06 GMT
Content-length: 3377
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//SQ//DTD HTML 2.0 HoTMetaL + extensions//EN">
<HTML>
<HEAD>
<TITLE>NHLBI: L16</TITLE></HEAD>
<BODY BGCOLOR="#FFFFFF">
<CENTER><IMG ALIGN="LEFT" SRC="images/banner0.jpg"></CENTER>
<CENTER><BR>
<P>DIVISION OF LUNG DISEASES/<BR>NATIONAL HEART, LUNG, AND BLOOD INSTITUTE</P>
<H2>L16: NHLBI ACCESS STUDY: A CASE CONTROL ETIOLOGIC STUDY OF SARCOIDOSIS</H2>
<P><BR></P></CENTER>
<HR SIZE="5" NOSHADE="NOSHADE" WIDTH="100%">
<P></P>
<CENTER>
<TABLE BORDER="2">
<TR ALIGN="CENTER" VALIGN="MIDDLE">
<TD ALIGN="CENTER" VALIGN="MIDDLE"><B><SMALL><A HREF="ic97.html">BACK TO
MAIN MENU</A></SMALL></B></TD></TR></TABLE></CENTER>
<P></P>
<HR SIZE="10" WIDTH="85%">
<P></P>
<CENTER>
<P>WEDNESDAY , MAY 21</P></CENTER>
<BLOCKQUOTE>
<P><B>12:00 noon-1:00 pm</B></P></BLOCKQUOTE>
<HR SIZE="4" WIDTH="85%" ALIGN="CENTER" NOSHADE="NOSHADE">
<BLOCKQUOTE>
<P><I><B>Target Audience: </B></I>Pulmonologists, and internists.</P>
<P><B>OBJECTIVES</B><BR>At the conclusion of this session, the participant
will be able to:</P>
<UL>
<LI>understand the general design of the ACCESS study;</LI>
<LI>understand the goals of the ACCESS study.</LI></UL>
<P>The NHLBI ACCESS study, a case control study to determine the etiology of
sarcoidosis, will be described.  A general overview, description of &quot;core&quot;
studies, and description of ancillary studies will be presented.</P>
<P><I><B>Chairing: </B></I>R.M. Cherniack, M.D., Denver, CO</P>
<P><I>12:00</I> <B>Overview of the ACCESS Study: Purpose, Hypotheses, and
General Design</B>/R.M. Cherniack, M.D., Denver, CO</P>
<P><I>12:05</I> <B>Description of ACCESS &quot;Core Studies&quot; and
Clinical Course Study</B>/M.A. Judson, M.D., Charleston, SC</P>
<P><I>12:25</I> <B>Description of ACCESS Ancillary Studies</B>/G. McLennan,
M.D., Iowa City, IA</P>
<P><I>12:45</I> <I>Discussion</I></P></BLOCKQUOTE>
<P></P>
<HR SIZE="4" WIDTH="80%">
<CENTER>
<P><A HREF=97ala.html><IMG
SRC=images/activity_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97bus.html><IMG
SRC=images/business_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97cal.html><IMG
SRC=images/calendar_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97child.html><IMG
SRC=images/child_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=pg.html><IMG
SRC=images/courses_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=search.html><IMG
SRC=images/search_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=main.html><IMG
SRC=images/home_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97house.html><IMG
SRC=images/house_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=http://itsmtgs.com/ala-ats><IMG
SRC=images/regist_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=sessions.html><IMG
SRC=images/session_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=special.html><IMG
SRC=images/special_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97tours.html><IMG
SRC=images/tour_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97travel.html><IMG
SRC=images/travel_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
</P></CENTER>
<HR SIZE="4" WIDTH="80%">
<CENTER><FONT SIZE="+2"><B><I>American Thoracic Society</I></B></FONT><BR>
1740 Broadway<BR> New York, NY 10019<BR> VOICE:  212-315-8700<BR> Copyright &copy;
1996 American Lung Association.<BR> The American Thoracic  Society is the
medical section <BR>of the American Lung Association.<BR> 
</CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-131</DOCNO>
<DOCOLDNO>IA013-000139-B031-180</DOCOLDNO>
<DOCHDR>
http://www.thoracic.org:80/ic97/a13.html 206.138.195.144 19970217072634 text/html 4716
HTTP/1.0 200 OK
Date: Monday, 17-Feb-97 07:21:50 GMT
Server: NCSA/1.3
MIME-version: 1.0
Content-type: text/html
Last-modified: Friday, 24-Jan-97 16:14:54 GMT
Content-length: 4536
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//SQ//DTD HTML 2.0 HoTMetaL + extensions//EN">
<HTML>
<HEAD>
<TITLE>SYMPOSIUM: a13</TITLE></HEAD>
<BODY BGCOLOR="#FFFFFF">
<CENTER><IMG ALIGN="LEFT" SRC="images/banner0.jpg"></CENTER>
<CENTER><BR>
<P>SYMPOSIUM</P><BR>
<H2>A13: MOLECULAR MECHANISMS OF LEUKOCYTE ADHESION AND MIGRATION IN LUNG
INFLAMMATION</H2></CENTER>
<HR SIZE="5" NOSHADE="NOSHADE" WIDTH="100%">
<P></P>
<CENTER>
<TABLE BORDER="2">
<TR ALIGN="CENTER" VALIGN="MIDDLE">
<TD ALIGN="CENTER" VALIGN="MIDDLE"><B><SMALL><A HREF="ic97.html">BACK TO
MAIN MENU</A></SMALL></B></TD></TR></TABLE></CENTER>
<P></P>
<HR SIZE="10" WIDTH="85%">
<P></P>
<CENTER>
<P>SUNDAY , MAY 18</P></CENTER>
<BLOCKQUOTE>
<P><B>Assembly on Allergy, Immunology and Inflammation</B></P>
<P><B>8:15 am-11:00 am</B></P></BLOCKQUOTE>
<HR SIZE="4" WIDTH="85%" ALIGN="CENTER" NOSHADE="NOSHADE">
<BLOCKQUOTE>
<P><I><B>Target Audience: </B></I>Physicians, basic scientists, fellows and
students interested in cellular recruitment and lung inflammatory responses.</P>
<P><B>OBJECTIVES</B><BR>At the conclusion of this session, the participant
will be able to:</P>
<UL>
<LI>describe mechanisms of leukocyte adhesion and the critical receptors
involved;</LI>
<LI>describe modulation of receptor function by receptor-receptor interactions,
and the mechanisms by which these interactions occur;</LI>
<LI>describe modulation of cellular activation by paracrine receptor mediated
events;</LI>
<LI>describe modulation of cellular activation and signaling by receptor
mediated events.</LI></UL>
<P>This symposium will address the mechanisms of leukocyte adhesion, migration
and activation signaling during recruitment to pulmonary inflammatory sites.
Emphasis will be placed on 1) the role of cell surface receptors in this
process, 2) modulation of receptor functions by receptor-receptor interactions,
3) mechanisms of receptor-receptor interactions, 4) autocrine and paracrine
receptor interactions, and 5) receptor mediated cell signaling pathways. The
mechanisms involved in the recruitment of neutrophils, monocytes, and
lymphocytes will be compared and contrasted.</P>
<P><I><B>Chairing: </B></I>M.R. Gyetko, M.D., Ann Arbor, MIG.P. Downey, M.D.,
Toronto, ON, Canada</P>
<P><I>8:15</I> <B>Modulation of T-Cell Traffic</B>/M.J. Holtzman, M.D., St.
Louis, MO</P>
<P><I>8:40</I> <B>Structure/Function Analysis of Leukocyte Integrins</B>/D.J.
Erle, M.D., San Francisco, CA</P>
<P><I>9:05</I> <B>Leukocyte Adhesion and Activation</B>/J.M. Harlan, M.D.,
Seattle, WA</P>
<P><I>9:35</I> <B>Urokinase Receptor/Beta2 Integrin Interactions As
Modulators of Cellular Adhesion and Activation</B>/M.R. Gyetko, M.D., Ann Arbor,
MI</P>
<P><I>10:00</I> <B>Signaling Functions of <I>L-Selectin</I> and
Beta2-Integrins on Neutrophils</B>/G.P. Downey, M.D., Toronto, ON, Canada</P>
<P><I>10:25</I> <I><B>L-Selectin</B></I><B> in Leukocyte-Endothelial
Interactions: Adhesion and Signaling</B>/S.D. Rosen, Ph.D., San Francisco, CA</P>
<P><I>10:50</I> <I>Discussion</I></P></BLOCKQUOTE>
<P></P>
<HR SIZE="4" WIDTH="80%">
<CENTER>
<P><A HREF=97ala.html><IMG
SRC=images/activity_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97bus.html><IMG
SRC=images/business_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97cal.html><IMG
SRC=images/calendar_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97child.html><IMG
SRC=images/child_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=pg.html><IMG
SRC=images/courses_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=search.html><IMG
SRC=images/search_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=main.html><IMG
SRC=images/home_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97house.html><IMG
SRC=images/house_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=http://itsmtgs.com/ala-ats><IMG
SRC=images/regist_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=sessions.html><IMG
SRC=images/session_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=special.html><IMG
SRC=images/special_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97tours.html><IMG
SRC=images/tour_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97travel.html><IMG
SRC=images/travel_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
</P></CENTER>
<HR SIZE="4" WIDTH="80%">
<CENTER><FONT SIZE="+2"><B><I>American Thoracic Society</I></B></FONT><BR>
1740 Broadway<BR> New York, NY 10019<BR> VOICE:  212-315-8700<BR> Copyright &copy;
1996 American Lung Association.<BR> The American Thoracic  Society is the
medical section <BR>of the American Lung Association.<BR> 
</CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-132</DOCNO>
<DOCOLDNO>IA013-000139-B031-205</DOCOLDNO>
<DOCHDR>
http://www.thoracic.org:80/ic97/a15.html 206.138.195.144 19970217072642 text/html 4898
HTTP/1.0 200 OK
Date: Monday, 17-Feb-97 07:22:00 GMT
Server: NCSA/1.3
MIME-version: 1.0
Content-type: text/html
Last-modified: Friday, 24-Jan-97 16:14:55 GMT
Content-length: 4718
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//SQ//DTD HTML 2.0 HoTMetaL + extensions//EN">
<HTML>
<HEAD>
<TITLE>SYMPOSIUM: a15</TITLE></HEAD>
<BODY BGCOLOR="#FFFFFF">
<CENTER><IMG ALIGN="LEFT" SRC="images/banner0.jpg"></CENTER>
<CENTER><BR>
<P>SYMPOSIUM</P><BR>
<H2>A15: HOST RESPONSE MECHANISMS TO MICROBIAL PATHOGENS</H2></CENTER>
<HR SIZE="5" NOSHADE="NOSHADE" WIDTH="100%">
<P></P>
<CENTER>
<TABLE BORDER="2">
<TR ALIGN="CENTER" VALIGN="MIDDLE">
<TD ALIGN="CENTER" VALIGN="MIDDLE"><B><SMALL><A HREF="ic97.html">BACK TO
MAIN MENU</A></SMALL></B></TD></TR></TABLE></CENTER>
<P></P>
<HR SIZE="10" WIDTH="85%">
<P></P>
<CENTER>
<P>SUNDAY , MAY 18</P></CENTER>
<BLOCKQUOTE>
<P><B>Assemblies on Respiratory Cell and Molecular Biology/Allergy, Immunology
and Inflammation/Microbiology, Tuberculosis and Pulmonary Infections</B></P>
<P><B>8:15 am-11:00 am</B></P></BLOCKQUOTE>
<HR SIZE="4" WIDTH="85%" ALIGN="CENTER" NOSHADE="NOSHADE">
<BLOCKQUOTE>
<P><I><B>Target Audience: </B></I>Scientists and clinician-scientists with an
interest in the mechanisms used by inflammatory cells and lung epithelium to
defend against micro-organisms.</P>
<P><B>OBJECTIVES</B><BR>At the conclusion of this session, the participant
will be able to:</P>
<UL>
<LI>describe the basic principles governing the ability of inflammatory cells
to recognize and digest bacteria;</LI>
<LI>describe how the interactions with bacteria initiate a series of programmed
responses by host cells;</LI>
<LI>describe the anti-bacterial function of epithelial products released into
the airway space;</LI>
<LI>describe how the alterations in cell function and the extracellular
microenvironment can hinder host-defense mechanisms.</LI></UL>
<P>The success or failure of bacterial infection is determined, to a large
extent, by the innate response of host cells. The aim of this symposium is to
present emerging evidence of the mechanisms used by inflammatory and lung
epithelial cells to defend against and kill invading microbial pathogens, such
as <I>Mycobacterium tuberculosis</I> and <I>Legionella</I> pneumophilia. The
understanding of these mechanisms should provide a rational basis for
interventions designed to assist host defenses during the course of infection.</P>
<P><I><B>Chairing: </B></I>S.M. Greenberg, M.D., New York, NYC.B. Basbaum,
Ph.D., San Francisco, CA</P>
<P><I>8:15</I> <B>Signal Transduction of Receptor-Mediated Phagocytosis</B>/S.M.
Greenberg, M.D., New York, NY</P>
<P><I>8:40</I> <B>Intracellular Signaling Reactions Induced in Macrophages by
Bacterial Lipopolysaccharide</B>/A.L. DeFranco, Ph.D., San Francisco, CA</P>
<P><I>9:10</I> <B>Contributions of Pulmonary Collectins, SP-A and SP-D, to
Innate Lung Host Defense</B>/E.C. Crouch, M.D., Ph.D., St. Louis, MO</P>
<P><I>9:35</I> <B>Stimulation of Mucin Transcription in Epithelial Cells by
Bacterial Products</B>/C.B. Basbaum, Ph.D., San Francisco, CA</P>
<P><I>10:00</I> <B>Bacterial Gene Products and Epithelial Cytokine Expression</B>/A.S.
Prince, M.D., New York, NY</P>
<P><I>10:30</I> <B>Local Airway Defense Mechanisms and Defective Function in
Cystic Fibrosis</B>/M.J. Welsh, M.D., Iowa City, IA</P>
<P>Discussion after each presentation/5 minutes</P></BLOCKQUOTE>
<P></P>
<HR SIZE="4" WIDTH="80%">
<CENTER>
<P><A HREF=97ala.html><IMG
SRC=images/activity_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97bus.html><IMG
SRC=images/business_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97cal.html><IMG
SRC=images/calendar_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97child.html><IMG
SRC=images/child_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=pg.html><IMG
SRC=images/courses_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=search.html><IMG
SRC=images/search_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=main.html><IMG
SRC=images/home_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97house.html><IMG
SRC=images/house_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=http://itsmtgs.com/ala-ats><IMG
SRC=images/regist_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=sessions.html><IMG
SRC=images/session_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=special.html><IMG
SRC=images/special_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97tours.html><IMG
SRC=images/tour_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97travel.html><IMG
SRC=images/travel_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
</P></CENTER>
<HR SIZE="4" WIDTH="80%">
<CENTER><FONT SIZE="+2"><B><I>American Thoracic Society</I></B></FONT><BR>
1740 Broadway<BR> New York, NY 10019<BR> VOICE:  212-315-8700<BR> Copyright &copy;
1996 American Lung Association.<BR> The American Thoracic  Society is the
medical section <BR>of the American Lung Association.<BR> 
</CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-133</DOCNO>
<DOCOLDNO>IA013-000139-B031-231</DOCOLDNO>
<DOCHDR>
http://www.thoracic.org:80/ic97/a59.html 206.138.195.144 19970217072651 text/html 4746
HTTP/1.0 200 OK
Date: Monday, 17-Feb-97 07:22:09 GMT
Server: NCSA/1.3
MIME-version: 1.0
Content-type: text/html
Last-modified: Friday, 24-Jan-97 16:15:00 GMT
Content-length: 4566
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//SQ//DTD HTML 2.0 HoTMetaL + extensions//EN">
<HTML>
<HEAD>
<TITLE>SYMPOSIUM: a59</TITLE></HEAD>
<BODY BGCOLOR="#FFFFFF">
<CENTER><IMG ALIGN="LEFT" SRC="images/banner0.jpg"></CENTER>
<CENTER><BR>
<P>SYMPOSIUM</P>
<H2>A59: APOPTOSIS AND CELL CYCLE REGULATION</H2>
<P><BR></P></CENTER>
<HR SIZE="5" NOSHADE="NOSHADE" WIDTH="100%">
<P></P>
<CENTER>
<TABLE BORDER="2">
<TR ALIGN="CENTER" VALIGN="MIDDLE">
<TD ALIGN="CENTER" VALIGN="MIDDLE"><B><SMALL><A HREF="ic97.html">BACK TO
MAIN MENU</A></SMALL></B></TD></TR></TABLE></CENTER>
<P></P>
<HR SIZE="10" WIDTH="85%">
<P></P>
<CENTER>
<P>SUNDAY , MAY 18</P></CENTER>
<BLOCKQUOTE>
<P><B>Assembly on Respiratory and Cell Molecular Biology</B></P>
<P><B>1:30 pm-4:30 pm</B></P></BLOCKQUOTE>
<HR SIZE="4" WIDTH="85%" ALIGN="CENTER" NOSHADE="NOSHADE">
<BLOCKQUOTE>
<P><I><B>Target Audience: </B></I>Basic scientists, fellows and junior
faculty interested in basic science.</P>
<P><B>OBJECTIVES</B><BR>At the conclusion of this session, the participant
will be able to:</P>
<UL>
<LI>describe the basic cellular and molecular control mechanisms which are
central to mammalian cell cycle regulation;</LI>
<LI>understand the role of cyclins, cyclin dependent kinases, and cyclin
dependent kinase inhibitors in regulating cell cycle progression;</LI>
<LI>understand disregulated cell cycle control in pulmonary malignancy, lung
fibrosis;</LI>
<LI>describe mechanisms of apoptosis and its relationship to the cell cycle
clock machinery.</LI></UL>
<P>This symposium will focus on the basic molecular mechanisms of eukaryotic
cell cycle control and apoptosis and their roles in lung biology and disease. In
particular, control mechanisms mediated through cyclins, cyclin dependent
kinases, and molecular inhibitors of these enzymes will be highlighted.
Additionally, the interrelationship of molecular mechanisms of apoptosis and
cell cycle regulation will be emphasized. The impact of abnormal cell cycle
control on the pathogenesis of pulmonary malignancy, lung fibrosis, and lung
infections will be defined. Potential therapeutic strategies involving
modulation of cell cycle regulators in the treatment of these disorders will be
discussed.</P>
<P><I><B>Chairing: </B></I>C.A. Henke, M.D., Minneapolis, MNA.H. Limper,
M.D., Rochester, MN</P>
<P><I>1:30</I> <B>Apoptosis and the Cell Cycle</B>/R. Schlegel, Ph.D., East
Walpole, MA</P>
<P><I>2:00</I> <B>Regulation of the Eukaryotic Cell Cycle by TGF-Beta</B>/E.
Leof, Ph.D., Rochester, MN</P>
<P><I>2:30</I> <B>Cyclin Dysregulation in Carcinogenesis</B>/D. Warburton,
M.B.B.S., Los Angeles, CA</P>
<P><I>3:00</I> <B>Interaction of Host and Organism Cell Cycling During Lung
Infection</B>/A.H. Limper, M.D., Rochester, MN</P>
<P><I>3:30</I> <B>ECM-Cell Matrix Receptor Interaction: Role in Fibroblast
Cell Cycle Progression and Apoptosis</B>/C.A. Henke, M.D., Minneapolis, MN</P>
<P><I>4:00</I> <B>Regulation of Epithelial Viability</B>/J.R. Spurzem, M.D.,
Omaha, NE</P>
<P>Discussion after each presentation/5 minutes</P></BLOCKQUOTE>
<P></P>
<HR SIZE="4" WIDTH="80%">
<CENTER>
<P><A HREF=97ala.html><IMG
SRC=images/activity_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97bus.html><IMG
SRC=images/business_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97cal.html><IMG
SRC=images/calendar_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97child.html><IMG
SRC=images/child_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=pg.html><IMG
SRC=images/courses_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=search.html><IMG
SRC=images/search_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=main.html><IMG
SRC=images/home_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97house.html><IMG
SRC=images/house_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=http://itsmtgs.com/ala-ats><IMG
SRC=images/regist_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=sessions.html><IMG
SRC=images/session_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=special.html><IMG
SRC=images/special_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97tours.html><IMG
SRC=images/tour_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97travel.html><IMG
SRC=images/travel_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
</P></CENTER>
<HR SIZE="4" WIDTH="80%">
<CENTER><FONT SIZE="+2"><B><I>American Thoracic Society</I></B></FONT><BR>
1740 Broadway<BR> New York, NY 10019<BR> VOICE:  212-315-8700<BR> Copyright &copy;
1996 American Lung Association.<BR> The American Thoracic  Society is the
medical section <BR>of the American Lung Association.<BR> 
</CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-134</DOCNO>
<DOCOLDNO>IA013-000139-B031-263</DOCOLDNO>
<DOCHDR>
http://www.thoracic.org:80/ic97/a60.html 206.138.195.144 19970217072659 text/html 4742
HTTP/1.0 200 OK
Date: Monday, 17-Feb-97 07:22:17 GMT
Server: NCSA/1.3
MIME-version: 1.0
Content-type: text/html
Last-modified: Friday, 24-Jan-97 16:15:00 GMT
Content-length: 4562
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//SQ//DTD HTML 2.0 HoTMetaL + extensions//EN">
<HTML>
<HEAD>
<TITLE>SYMPOSIUM: a60</TITLE></HEAD>
<BODY BGCOLOR="#FFFFFF">
<CENTER><IMG ALIGN="LEFT" SRC="images/banner0.jpg"></CENTER>
<CENTER><BR>
<P>SYMPOSIUM</P>
<H2>A60: MOLECULAR MECHANISMS UNDERLYING THE EFFECTS OF NITRIC OXIDE AND
REACTIVE OXIDANTS ON AIRWAY AND CHEST WALL MUSCLES</H2>
<P><BR></P></CENTER>
<HR SIZE="5" NOSHADE="NOSHADE" WIDTH="100%">
<P></P>
<CENTER>
<TABLE BORDER="2">
<TR ALIGN="CENTER" VALIGN="MIDDLE">
<TD ALIGN="CENTER" VALIGN="MIDDLE"><B><SMALL><A HREF="ic97.html">BACK TO
MAIN MENU</A></SMALL></B></TD></TR></TABLE></CENTER>
<P></P>
<HR SIZE="10" WIDTH="85%">
<P></P>
<CENTER>
<P>SUNDAY , MAY 18</P></CENTER>
<BLOCKQUOTE>
<P><B>Assembly on Respiratory Structure and Function</B></P>
<P><B>1:30 pm-4:15 pm</B></P></BLOCKQUOTE>
<HR SIZE="4" WIDTH="85%" ALIGN="CENTER" NOSHADE="NOSHADE">
<BLOCKQUOTE>
<P><I><B>Target Audience: </B></I>Basic scientists and clinicians.</P>
<P><B>OBJECTIVES</B><BR>At the conclusion of this session, the participant
will be able to:</P>
<UL>
<LI>identify potential molecular mechanisms underlying the effects of reactive
oxidants on respiratory muscles;</LI>
<LI>describe current state-of-the-art methods employed in studying respiratory
muscle physiology;</LI>
<LI>describe the translation of bench-top research on respiratory muscles to
different disease conditions.</LI></UL>
<P>During the past several years, a considerable amount of new and exciting
information has been presented regarding the effects of nitric oxide (NO) and
other reactive oxidants on respiratory muscles, both skeletal (e.g., diaphragm)
and smooth (e.g., airway). Both reactive oxidants and NO are produced by
respiratory muscles during activation and may be implicated in physiological
regulation as well as disease states including sepsis, ozone exposure, and
ventilatory failure. The major effects ofNO and reactive oxidants on respiratory
muscle contractility may share a common molecular pathway via modification of
critical thiols on contractile proteins or sarcoplasmic reticulum calcium
release channels.</P>
<P><I><B>Chairing: </B></I>G.C. Sieck, Ph.D., Rochester, MNM.B. Reid, Ph.D.,
Houston, TX</P>
<P><I>1:30</I> <B>Measurement of Nitric Oxide and Reactive Oxidants in Muscle</B>/M.B.
Reid, Ph.D., Houston, TX</P>
<P><I>1:55</I> <B>Nitric Oxide and Reactive Oxygen As Modulators of Skeletal
Muscle Function</B>/F.H. Andrade, Ph.D., Houston, TX</P>
<P><I>2:20</I> <B>Molecular Targets of Nitric Oxide in Muscle</B>/W.J.
Perkins, M.D., Rochester, MN</P>
<P><I>2:45</I> <B>Hydrogen Peroxide Effects on Calcium Release and
Contractility</B>/T.M. Nosek, Ph.D., Augusta, GA</P>
<P><I>3:10</I> <B>Nitric Oxide Activates SR Calcium Release Channels via
Regulatory Thiols</B>/G.G. Salama, Ph.D., Pittsburgh, PA</P>
<P><I>3:35</I> <B>Nitric Oxide Effects on Dynamic Calcium Regulation</B>/G.C.
Sieck, Ph.D., Rochester, MN</P>
<P><I>3:55</I> <I>Discussion</I></P>
<P>Discussion after each presentation/5 minutes</P></BLOCKQUOTE>
<P></P>
<HR SIZE="4" WIDTH="80%">
<CENTER>
<P><A HREF=97ala.html><IMG
SRC=images/activity_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97bus.html><IMG
SRC=images/business_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97cal.html><IMG
SRC=images/calendar_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97child.html><IMG
SRC=images/child_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=pg.html><IMG
SRC=images/courses_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=search.html><IMG
SRC=images/search_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=main.html><IMG
SRC=images/home_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97house.html><IMG
SRC=images/house_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=http://itsmtgs.com/ala-ats><IMG
SRC=images/regist_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=sessions.html><IMG
SRC=images/session_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=special.html><IMG
SRC=images/special_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97tours.html><IMG
SRC=images/tour_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97travel.html><IMG
SRC=images/travel_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
</P></CENTER>
<HR SIZE="4" WIDTH="80%">
<CENTER><FONT SIZE="+2"><B><I>American Thoracic Society</I></B></FONT><BR>
1740 Broadway<BR> New York, NY 10019<BR> VOICE:  212-315-8700<BR> Copyright &copy;
1996 American Lung Association.<BR> The American Thoracic  Society is the
medical section <BR>of the American Lung Association.<BR> 
</CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-135</DOCNO>
<DOCOLDNO>IA013-000139-B031-282</DOCOLDNO>
<DOCHDR>
http://www.thoracic.org:80/ic97/a61.html 206.138.195.144 19970217072707 text/html 5029
HTTP/1.0 200 OK
Date: Monday, 17-Feb-97 07:22:25 GMT
Server: NCSA/1.3
MIME-version: 1.0
Content-type: text/html
Last-modified: Friday, 24-Jan-97 16:15:00 GMT
Content-length: 4849
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//SQ//DTD HTML 2.0 HoTMetaL + extensions//EN">
<HTML>
<HEAD>
<TITLE>SYMPOSIUM: a61</TITLE></HEAD>
<BODY BGCOLOR="#FFFFFF">
<CENTER><IMG ALIGN="LEFT" SRC="images/banner0.jpg"></CENTER>
<CENTER><BR>
<P>SYMPOSIUM</P>
<H2>A61: THE INTERSECTION OF LIPID AND POLYPEPTIDE MEDIATORS: FROM STRANGERS TO
BEDFELLOWS</H2>
<P><BR></P></CENTER>
<HR SIZE="5" NOSHADE="NOSHADE" WIDTH="100%">
<P></P>
<CENTER>
<TABLE BORDER="2">
<TR ALIGN="CENTER" VALIGN="MIDDLE">
<TD ALIGN="CENTER" VALIGN="MIDDLE"><B><SMALL><A HREF="ic97.html">BACK TO
MAIN MENU</A></SMALL></B></TD></TR></TABLE></CENTER>
<P></P>
<HR SIZE="10" WIDTH="85%">
<P></P>
<CENTER>
<P>SUNDAY , MAY 18</P></CENTER>
<BLOCKQUOTE>
<P><B>Assembly on Allergy, Immunology and Inflammation</B></P>
<P><B>1:30 pm-4:15 pm</B></P></BLOCKQUOTE>
<HR SIZE="4" WIDTH="85%" ALIGN="CENTER" NOSHADE="NOSHADE">
<BLOCKQUOTE>
<P><I><B>Target Audience: </B></I>Researchers interested in pulmonary
inflammation, generally cytokines or lipid mediators specifically, or
therapeutic potential of anti-cytokine or anti-lipid mediator agents.</P>
<P>Lipids (prostaglandins, leukotrienes, platelet activating factor) and
polypeptides (cytokines, chemokines, growth factors) comprise two major classes
of soluble mediators with both complementary and overlapping roles in immune,
inflammatory,and fibrotic pulmonary processes. Although these two classes of
mediators are typically considered individually, a growing body of evidence
indicates that they actually exert powerful influences on the synthesis and
actions of each other. Recognizing this important intersection of what are
traditionally two very separate scientific universes has important implications
for future advances in understanding lung biology and disease. This symposium
will provide an overview of 1) the basic biology and molecular mechanisms of
action of the major lipid and polypeptide mediators; 2) the modulatory effects
of bioactive lipids on the synthesis and actions of polypeptide mediators; and
3) the modulatory effects of polypeptide mediators on enzymes which regulate
lipid mediator generation.</P>
<P><I><B>Chairing: </B></I>M. Peters-Golden, M.D., Ann Arbor, MIR.M.
Strieter, M.D., Ann Arbor, MI</P>
<P><I>1:30</I> <B>Lipid Mediators: Overview of Synthesis and Actions</B>/M.
Peters-Golden, M.D., Ann Arbor, MI</P>
<P><I>1:40</I> <B>Cytokines and Growth Factors: Overview of Synthesis and
Actions</B>/R.M. Strieter, M.D., Ann Arbor, MI</P>
<P><I>1:50</I> <B>Cytokines and Lipid Mediators As Bidirectional Modulators
of Inflammation</B>/M. Jordana, M.D., Ph.D., Hamilton, ON, Canada</P>
<P><I>2:10</I> <I>Discussion</I></P>
<P><I>2:15</I> <B>Down-Regulation of Cytokine Synthesis and Actions by Lipid
Mediators</B>/D. Riches, Ph.D., Denver, CO</P>
<P><I>2:35</I> <B>Up-Regulation of Cytokine Synthesis and Actions by Lipid
Mediators</B>/M. Rola-Pleszczynski, M.D., Sherbrooke, PQ, Canada</P>
<P><I>2:55</I> <I>Discussion</I></P>
<P><I>3:05</I> <B>Regulation of Phospholipases by Cytokines</B>/J. Arm, M.D.,
Boston, MA</P>
<P><I>3:25</I> <B>Regulation of the 5-Lipoxygenase Pathway by Cytokines</B>/T.
Bigby, M.D., San Diego, CA</P>
<P><I>3:45</I> <B>Regulation of the Cyclooxygenase Pathway by Cytokines</B>/J.R.
Sheller, M.D., Nashville, TN</P>
<P><I>4:05</I> <B>Panel Discussion</B></P></BLOCKQUOTE>
<P></P>
<HR SIZE="4" WIDTH="80%">
<CENTER>
<P><A HREF=97ala.html><IMG
SRC=images/activity_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97bus.html><IMG
SRC=images/business_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97cal.html><IMG
SRC=images/calendar_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97child.html><IMG
SRC=images/child_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=pg.html><IMG
SRC=images/courses_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=search.html><IMG
SRC=images/search_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=main.html><IMG
SRC=images/home_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97house.html><IMG
SRC=images/house_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=http://itsmtgs.com/ala-ats><IMG
SRC=images/regist_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=sessions.html><IMG
SRC=images/session_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=special.html><IMG
SRC=images/special_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97tours.html><IMG
SRC=images/tour_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97travel.html><IMG
SRC=images/travel_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
</P></CENTER>
<HR SIZE="4" WIDTH="80%">
<CENTER><FONT SIZE="+2"><B><I>American Thoracic Society</I></B></FONT><BR>
1740 Broadway<BR> New York, NY 10019<BR> VOICE:  212-315-8700<BR> Copyright &copy;
1996 American Lung Association.<BR> The American Thoracic  Society is the
medical section <BR>of the American Lung Association.<BR> 
</CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-136</DOCNO>
<DOCOLDNO>IA013-000139-B031-314</DOCOLDNO>
<DOCHDR>
http://www.thoracic.org:80/ic97/a62.html 206.138.195.144 19970217072718 text/html 5003
HTTP/1.0 200 OK
Date: Monday, 17-Feb-97 07:22:34 GMT
Server: NCSA/1.3
MIME-version: 1.0
Content-type: text/html
Last-modified: Friday, 24-Jan-97 16:15:01 GMT
Content-length: 4823
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//SQ//DTD HTML 2.0 HoTMetaL + extensions//EN">
<HTML>
<HEAD>
<TITLE>SYMPOSIUM: a62</TITLE></HEAD>
<BODY BGCOLOR="#FFFFFF">
<CENTER><IMG ALIGN="LEFT" SRC="images/banner0.jpg"></CENTER>
<CENTER><BR>
<P>SYMPOSIUM</P>
<H2>A62: BRAINSTEM SEROTONERGIC SYSTEMS: ROLE IN SLEEP AND RESPIRATION</H2>
<P><BR></P></CENTER>
<HR SIZE="5" NOSHADE="NOSHADE" WIDTH="100%">
<P></P>
<CENTER>
<TABLE BORDER="2">
<TR ALIGN="CENTER" VALIGN="MIDDLE">
<TD ALIGN="CENTER" VALIGN="MIDDLE"><B><SMALL><A HREF="ic97.html">BACK TO
MAIN MENU</A></SMALL></B></TD></TR></TABLE></CENTER>
<P></P>
<HR SIZE="10" WIDTH="85%">
<P></P>
<CENTER>
<P>SUNDAY , MAY 18</P></CENTER>
<BLOCKQUOTE>
<P><B>Assembly on Respiratory Neurobiology and Sleep</B></P>
<P><B>1:30 pm-4:15 pm</B></P></BLOCKQUOTE>
<HR SIZE="4" WIDTH="85%" ALIGN="CENTER" NOSHADE="NOSHADE">
<BLOCKQUOTE>
<P><I><B>Target Audience: </B></I>Basic respiratory neurobiologists, clinical
investigators in sleep-disordered respiration, and clinicians actively engaged
in the treatment of sleep apnea and syndromes in adults and children.</P>
<P><B>OBJECTIVES</B><BR>At the conclusion of this session, the participant
will be able to:</P>
<UL>
<LI>understand mechanisms by which serotonin acts on respiratory neurons;</LI>
<LI>define the role of serotonin in the dysfacilitation of respiratory
motoneurons during REM sleep;</LI>
<LI>define the role of serotonin in respiratory control system plasticity;</LI>
<LI>describe how serotonergic modulation of upper airway motor output may
contribute to</LI>
<LI>the pathogenesis of sleep-disordered breathing, and appreciate the
potential for treatment with serotonergic drugs.</LI></UL>
<P>The role of serotonergic systems in brainstem control of both sleep and
respiration have been subjects of intense study during the last few years.
Exciting insights into serotonergic mechanisms have been recently discovered,
including important interactions between sleep-wake state and respiratory
control. New understanding of the role of serotonin in the control of upper
airway muscle activity has led to promising clinical studies of serotonergic
drugs in the treatment of obstructive sleep apnea. This symposium will review
the current concepts of the basic neural mechanisms and relate them to an
evolving therapeutic strategy.</P>
<P><I><B>Chairing: </B></I>R.A. Parisi, M.D., New Brunswick, NJL. Kubin,
Ph.D., Philadelphia, PA</P>
<P><I>1:30</I> <B>Introduction</B>/R.A. Parisi, M.D., New Brunswick, NJ</P>
<P><I>1:35</I> <B>Second Messengers for Serotonin Effects on Respiratory
Neurons</B>/D.W. Richter, Ph.D., Goettingen, Germany</P>
<P><I>2:05</I> <B>Serotonergic Dysfacilitation of Respiratory Motoneurons
During REM Sleep</B>/L. Kubin, Ph.D., Philadelphia, PA</P>
<P><I>2:35</I> <B>Serotonin Effect on Plasticity of the Respiratory Control
System</B>/G. Mitchell, Ph.D., Madison, WI</P>
<P><I>3:05</I> <B>Setotonergic Modulation of Upper Airway Motor Output in an
Animal Model of Sleep-Disordered Breathing</B>/J.C. Hendricks, D.V.M., Ph.D.,
Philadelphia, PA</P>
<P><I>3:35</I> <B>Treatment of Obstructive Sleep Apnea with Serotonergic
Drugs: How Promising?</B>/R.J. Stroble, M.D., New Brunswick, NJ</P>
<P><I>4:05</I> <B>Panel Discussion</B></P>
<P>Discussion after each presentation/5 minutes</P></BLOCKQUOTE>
<P></P>
<HR SIZE="4" WIDTH="80%">
<CENTER>
<P><A HREF=97ala.html><IMG
SRC=images/activity_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97bus.html><IMG
SRC=images/business_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97cal.html><IMG
SRC=images/calendar_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97child.html><IMG
SRC=images/child_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=pg.html><IMG
SRC=images/courses_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=search.html><IMG
SRC=images/search_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=main.html><IMG
SRC=images/home_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97house.html><IMG
SRC=images/house_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=http://itsmtgs.com/ala-ats><IMG
SRC=images/regist_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=sessions.html><IMG
SRC=images/session_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=special.html><IMG
SRC=images/special_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97tours.html><IMG
SRC=images/tour_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97travel.html><IMG
SRC=images/travel_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
</P></CENTER>
<HR SIZE="4" WIDTH="80%">
<CENTER><FONT SIZE="+2"><B><I>American Thoracic Society</I></B></FONT><BR>
1740 Broadway<BR> New York, NY 10019<BR> VOICE:  212-315-8700<BR> Copyright &copy;
1996 American Lung Association.<BR> The American Thoracic  Society is the
medical section <BR>of the American Lung Association.<BR> 
</CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-137</DOCNO>
<DOCOLDNO>IA013-000139-B031-341</DOCOLDNO>
<DOCHDR>
http://www.thoracic.org:80/ic97/b13.html 206.138.195.144 19970217072728 text/html 4607
HTTP/1.0 200 OK
Date: Monday, 17-Feb-97 07:22:45 GMT
Server: NCSA/1.3
MIME-version: 1.0
Content-type: text/html
Last-modified: Friday, 24-Jan-97 16:15:11 GMT
Content-length: 4427
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//SQ//DTD HTML 2.0 HoTMetaL + extensions//EN">
<HTML>
<HEAD>
<TITLE> SYMPOSIUM: b13</TITLE></HEAD>
<BODY BGCOLOR="#FFFFFF">
<CENTER><IMG ALIGN="LEFT" SRC="images/banner0.jpg"></CENTER>
<CENTER><BR>
<P> SYMPOSIUM</P><BR>
<H2>B13: APPETITE SUPPRESSANT - AND TOXIN-INDUCED PULMONARY HYPERTENSION</H2></CENTER>
<HR SIZE="5" NOSHADE="NOSHADE" WIDTH="100%">
<P></P>
<CENTER>
<TABLE BORDER="2">
<TR ALIGN="CENTER" VALIGN="MIDDLE">
<TD ALIGN="CENTER" VALIGN="MIDDLE"><B><SMALL><A HREF="ic97.html">BACK TO
MAIN MENU</A></SMALL></B></TD></TR></TABLE></CENTER>
<P></P>
<HR SIZE="10" WIDTH="85%">
<P></P>
<CENTER>
<P>MONDAY , MAY 19</P></CENTER>
<BLOCKQUOTE>
<P><B>Assemblies on Pulmonary Circulation/Behavioral Science</B></P>
<P><B>8:15 am-10:45 am</B></P></BLOCKQUOTE>
<HR SIZE="4" WIDTH="85%" ALIGN="CENTER" NOSHADE="NOSHADE">
<BLOCKQUOTE>
<P><I><B>Target Audience: </B></I>Clinicians with an interest in pulmonary
hypertension, basic scientists, behaviorists with an interest in weight
reduction.</P>
<P><B>OBJECTIVES</B><BR>At the conclusion of this session, the participant
will be able to:</P>
<UL>
<LI>describe basic mechanisms of toxin or appetite-suppressant induced
pulmonary hypertension;</LI>
<LI>recount the history of the development of pulmonary hypertension following
toxic oil or Aminorex ingestion;</LI>
<LI>review the current epidemiology of pulmonary hypertension associated with
Dexfenflouramine ingestion;</LI>
<LI>discuss the pros and cons of appetite suppressant ingestion.</LI></UL>
<P>This symposium will present basic mechanisms responsible for the development
of pulmonary hypertension arising from toxin ingestion as discovered from animal
models. The history of recent epidemis of pulmonary hypertension induced by
ingested agents will then be reviewed. Current facts on the incidence of
pulmonary hypertension associated with appetite-suppressants will then be
discussed. The session will culminate with a pro-con presentation on the use of
appetite suppressants.</P>
<P><I><B>Chairing: </B></I>H.W. Farber, M.D., Boston, MAT.W. Higenbottam,
M.D., Sheffield, England</P>
<P><I>8:15</I> <B>Pertinent Animal Models of Pulmonary Hypertension</B>/M.S.
Gillespie, Ph.D., Mobile, AL</P>
<P><I>8:40</I> <B>Pulmonary Hypertension Induced by the Toxic Oil Syndrome</B>/<I>Speaker
to be announced</I></P>
<P><I>9:05</I> <B>The Aminorex Pulmonay Hypertension Epidemic: Looking Back
to the Future</B>/J. Miczoch, M.D., Vienna, Austria</P>
<P><I>9:30</I> <B>Appetite-Suppressant Induced Pulmonary Hypertension:
Looking Forward to the Future</B>/T.W. Higenbottam, M.D., Sheffield, England</P>
<P><I>9:55</I> <B>Pro: Dexfenflouramine: Should We or Shouldn't We?</B>/G.
Blackburn, M.D., Boston, MA</P>
<P><I>10:20</I> <B>Con: Dexfenflouramine: Should We or Shouldn't We?</B>/N.F.
Voelkel, M.D., Denver, CO</P>
<P>Discussion after each pro/con issue/5 minutes</P></BLOCKQUOTE>
<P></P>
<HR SIZE="4" WIDTH="80%">
<CENTER>
<P><A HREF=97ala.html><IMG
SRC=images/activity_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97bus.html><IMG
SRC=images/business_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97cal.html><IMG
SRC=images/calendar_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97child.html><IMG
SRC=images/child_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=pg.html><IMG
SRC=images/courses_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=search.html><IMG
SRC=images/search_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=main.html><IMG
SRC=images/home_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97house.html><IMG
SRC=images/house_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=http://itsmtgs.com/ala-ats><IMG
SRC=images/regist_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=sessions.html><IMG
SRC=images/session_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=special.html><IMG
SRC=images/special_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97tours.html><IMG
SRC=images/tour_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97travel.html><IMG
SRC=images/travel_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
</P></CENTER>
<HR SIZE="4" WIDTH="80%">
<CENTER><FONT SIZE="+2"><B><I>American Thoracic Society</I></B></FONT><BR>
1740 Broadway<BR> New York, NY 10019<BR> VOICE:  212-315-8700<BR> Copyright &copy;
1996 American Lung Association.<BR> The American Thoracic  Society is the
medical section <BR>of the American Lung Association.<BR> 
</CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-138</DOCNO>
<DOCOLDNO>IA013-000139-B031-365</DOCOLDNO>
<DOCHDR>
http://www.thoracic.org:80/ic97/b15.html 206.138.195.144 19970217072741 text/html 4589
HTTP/1.0 200 OK
Date: Monday, 17-Feb-97 07:22:56 GMT
Server: NCSA/1.3
MIME-version: 1.0
Content-type: text/html
Last-modified: Friday, 24-Jan-97 16:15:12 GMT
Content-length: 4409
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//SQ//DTD HTML 2.0 HoTMetaL + extensions//EN">
<HTML>
<HEAD>
<TITLE> SYMPOSIUM: b15</TITLE></HEAD>
<BODY BGCOLOR="#FFFFFF">
<CENTER><IMG ALIGN="LEFT" SRC="images/banner0.jpg"></CENTER>
<CENTER><BR>
<P> SYMPOSIUM</P><BR>
<H2>B15: PROTEINASES: BEYOND MATRIX DESTRUCTION</H2></CENTER>
<HR SIZE="5" NOSHADE="NOSHADE" WIDTH="100%">
<P></P>
<CENTER>
<TABLE BORDER="2">
<TR ALIGN="CENTER" VALIGN="MIDDLE">
<TD ALIGN="CENTER" VALIGN="MIDDLE"><B><SMALL><A HREF="ic97.html">BACK TO
MAIN MENU</A></SMALL></B></TD></TR></TABLE></CENTER>
<P></P>
<HR SIZE="10" WIDTH="85%">
<P></P>
<CENTER>
<P>MONDAY , MAY 19</P></CENTER>
<BLOCKQUOTE>
<P><B>Assembly on Respiratory Cell and Molecular Biology</B></P>
<P><B>8:15 am-11:00 am</B></P></BLOCKQUOTE>
<HR SIZE="4" WIDTH="85%" ALIGN="CENTER" NOSHADE="NOSHADE">
<BLOCKQUOTE>
<P><I><B>Target Audience: </B></I>Physicians interested in the pathogenesis
of lung disease and those interested in cell and molecular biology.</P>
<P><B>OBJECTIVES</B><BR>At the conclusion of this session, the participant
will be able to:</P>
<UL>
<LI>gain insight into the variety of proteinases expressed in the lung;</LI>
<LI>appreciate the physiologic functions of proteinases and how, if abnormally
regulated, can lead to lung disease;</LI>
<LI>comprehend the multiple roles that proteinases play in the host response to
inflammation and wound repair;</LI>
<LI>understand how non-host proteinases may cause lung injury.</LI></UL>
<P>Abnormal expression of proteinases cause a variety of destructive lung
diseases. The more difficult question has been: what are the physiologic roles
of proteinases? Recent experimental data have revealed proteolysis represents a
major mode of post-translational regulation of a variety of biologically
important molecules. This symposium will focus on the role of proteinases in
regulating key biological events including apoptosis, cell migration, and
inflammation. The symposium will also focus on the mechanisms whereby excessive
or abnormally regulated host proteinases as well as non-host proteinases may
lead to disease including and beyond matrix destruction.</P>
<P><I><B>Chairing: </B></I>S.D. Shapiro, M.D., St. Louis, MOM.E. Navre,
Ph.D., Santa Clara, CA</P>
<P><I>8:15</I> <B>Metalloelastase-Mediated Inflammatory Cell Recruitment</B>/S.D.
Shapiro, M.D., St. Louis, MO</P>
<P><I>8:50</I> <B>Regulation of Integrin Function by the Urokinase Receptor</B>/H.S.
Chapman, Jr., M.D., Boston, MA</P>
<P><I>9:20</I> <B>Role of Proteinases in Programmed Cell Death</B>/Z. Werb,
Ph.D., San Francisco, CA</P>
<P><I>10:00</I> <B>Host and Non-Host Proteinases in Tissue Destruction</B>/J.
Travis, Ph.D., Athens, GA</P>
<P><I>10:30</I> <B>Role of Metalloproteinases in Epithelial Cell Migration
During Wound Healing</B>/W.C. Parks, Ph.D., St. Louis, MO</P>
<P>Discussion after each presentation/5 minutes</P></BLOCKQUOTE>
<P></P>
<HR SIZE="4" WIDTH="80%">
<CENTER>
<P><A HREF=97ala.html><IMG
SRC=images/activity_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97bus.html><IMG
SRC=images/business_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97cal.html><IMG
SRC=images/calendar_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97child.html><IMG
SRC=images/child_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=pg.html><IMG
SRC=images/courses_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=search.html><IMG
SRC=images/search_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=main.html><IMG
SRC=images/home_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97house.html><IMG
SRC=images/house_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=http://itsmtgs.com/ala-ats><IMG
SRC=images/regist_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=sessions.html><IMG
SRC=images/session_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=special.html><IMG
SRC=images/special_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97tours.html><IMG
SRC=images/tour_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97travel.html><IMG
SRC=images/travel_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
</P></CENTER>
<HR SIZE="4" WIDTH="80%">
<CENTER><FONT SIZE="+2"><B><I>American Thoracic Society</I></B></FONT><BR>
1740 Broadway<BR> New York, NY 10019<BR> VOICE:  212-315-8700<BR> Copyright &copy;
1996 American Lung Association.<BR> The American Thoracic  Society is the
medical section <BR>of the American Lung Association.<BR> 
</CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-139</DOCNO>
<DOCOLDNO>IA013-000139-B032-21</DOCOLDNO>
<DOCHDR>
http://www.thoracic.org:80/ic97/b57.html 206.138.195.144 19970217072801 text/html 4456
HTTP/1.0 200 OK
Date: Monday, 17-Feb-97 07:23:16 GMT
Server: NCSA/1.3
MIME-version: 1.0
Content-type: text/html
Last-modified: Friday, 24-Jan-97 16:15:19 GMT
Content-length: 4276
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//SQ//DTD HTML 2.0 HoTMetaL + extensions//EN">
<HTML>
<HEAD>
<TITLE>SYMPOSIUM: b57</TITLE></HEAD>
<BODY BGCOLOR="#FFFFFF">
<CENTER><IMG ALIGN="LEFT" SRC="images/banner0.jpg"></CENTER>
<CENTER><BR>
<P>SYMPOSIUM</P><BR>
<H2>B57: COMBINED THERAPIES FOR THE TREATMENT OF SEVERE RESPIRATORY FAILURE IN
NEONATES</H2></CENTER>
<HR SIZE="5" NOSHADE="NOSHADE" WIDTH="100%">
<P></P>
<CENTER>
<TABLE BORDER="2">
<TR ALIGN="CENTER" VALIGN="MIDDLE">
<TD ALIGN="CENTER" VALIGN="MIDDLE"><B><SMALL><A HREF="ic97.html">BACK TO
MAIN MENU</A></SMALL></B></TD></TR></TABLE></CENTER>
<P></P>
<HR SIZE="10" WIDTH="85%">
<P></P>
<BLOCKQUOTE>
<CENTER>
<P>MONDAY , MAY 19</P>
<P><B>Assembly on Pediatrics</B></P>
<P><B>1:30 pm-4:15 pm</B></P></CENTER></BLOCKQUOTE>
<HR SIZE="4" WIDTH="85%" ALIGN="CENTER" NOSHADE="NOSHADE">
<BLOCKQUOTE>
<P><I><B>Target Audience: </B></I>Neonatologists, pediatric pulmonologists,
intensivists and respiratory therapists.</P>
<P><B>OBJECTIVES</B><BR>At the conclusion of this session, the participant
will be able to:</P>
<UL>
<LI>understand the role and effects of newer therapeutic agents on neonatal
respiratory failure;</LI>
<LI>explore the ways in which combinations of novel therapy might enhance
outcome;</LI>
<LI>recognize options to maximize therapy with minimal side effects.</LI></UL>
<P>Despite many advances in recent years, respiratory failure is a major cause
of neonatal morbidity and mortality. By combining available therapeutic
strategies, better outcomes have been demonstrated in many cases. Combining
therapies may give new insights on the pathophysiology of severe respiratory
failure. This symposium will discuss possible ways to enhance the beneficial
effects of therapies in neonates.</P>
<P><I><B>Chairing: </B></I>P.A. Dennery, M.D., Palo Alto, CAS.H. Abman, M.D.,
Denver, CO</P>
<P><I>1:30</I> <B>Novel Therapies in Neonatal Respiratory Failure: Matching
Treatment with Physiology</B>/S.H. Abman, M.D., Denver, CO</P>
<P><I>1:40</I> <B>Improving NO Delivery with High Frequency Ventilation</B>/J.
Kinsella, M.D., Denver, CO</P>
<P><I>2:05</I> <B>Use of Phosphodiesterase Inhibitors to Optimize the Effects
of Nitric Oxide</B>/S.W. Clarke, M.D., London, England</P>
<P><I>2:30</I> <B>Liquid Ventilation As a Means of Delivering Therapeutic
Agents to the Alveoli</B>/R. Hirschl, M.D., Ann Arbor, MI</P>
<P><I>2:55</I> <I>Discussion</I></P>
<P><I>3:00</I> <B>Benefits of Surfactant Use Before and on ECMO</B>/B.L.
Short, M.D., Washington, DC</P>
<P><I>3:25</I> <B>Strategy for Use and Optimization of Surfactant</B>/A.H.
Jobe, M.D., Ph.D., Torrance, CA</P>
<P><I>3:50</I> <B>Adjunct Therapies in the Management of Congenital
Diaphragmatic Hernia</B>/K.P. Van Meurs, Palo Alto, CA</P></BLOCKQUOTE>
<P></P>
<HR SIZE="4" WIDTH="80%">
<CENTER>
<P><A HREF=97ala.html><IMG
SRC=images/activity_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97bus.html><IMG
SRC=images/business_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97cal.html><IMG
SRC=images/calendar_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97child.html><IMG
SRC=images/child_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=pg.html><IMG
SRC=images/courses_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=search.html><IMG
SRC=images/search_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=main.html><IMG
SRC=images/home_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97house.html><IMG
SRC=images/house_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=http://itsmtgs.com/ala-ats><IMG
SRC=images/regist_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=sessions.html><IMG
SRC=images/session_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=special.html><IMG
SRC=images/special_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97tours.html><IMG
SRC=images/tour_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97travel.html><IMG
SRC=images/travel_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
</P></CENTER>
<HR SIZE="4" WIDTH="80%">
<CENTER><FONT SIZE="+2"><B><I>American Thoracic Society</I></B></FONT><BR>
1740 Broadway<BR> New York, NY 10019<BR> VOICE:  212-315-8700<BR> Copyright &copy;
1996 American Lung Association.<BR> The American Thoracic  Society is the
medical section <BR>of the American Lung Association.<BR> 
</CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-140</DOCNO>
<DOCOLDNO>IA013-000139-B032-41</DOCOLDNO>
<DOCHDR>
http://www.thoracic.org:80/ic97/b59.html 206.138.195.144 19970217072810 text/html 4804
HTTP/1.0 200 OK
Date: Monday, 17-Feb-97 07:23:28 GMT
Server: NCSA/1.3
MIME-version: 1.0
Content-type: text/html
Last-modified: Friday, 24-Jan-97 16:15:20 GMT
Content-length: 4624
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//SQ//DTD HTML 2.0 HoTMetaL + extensions//EN">
<HTML>
<HEAD>
<TITLE>SYMPOSIUM: b59</TITLE></HEAD>
<BODY BGCOLOR="#FFFFFF">
<CENTER><IMG ALIGN="LEFT" SRC="images/banner0.jpg"></CENTER>
<CENTER><BR>
<P>SYMPOSIUM</P><BR>
<H2>B59: NEW PERSPECTIVES ON THE PATHOGENESIS AND TREATMENT OF SEPSIS</H2></CENTER>
<HR SIZE="5" NOSHADE="NOSHADE" WIDTH="100%">
<P></P>
<CENTER>
<TABLE BORDER="2">
<TR ALIGN="CENTER" VALIGN="MIDDLE">
<TD ALIGN="CENTER" VALIGN="MIDDLE"><B><SMALL><A HREF="ic97.html">BACK TO
MAIN MENU</A></SMALL></B></TD></TR></TABLE></CENTER>
<P></P>
<HR SIZE="10" WIDTH="85%">
<P></P>
<BLOCKQUOTE>
<CENTER>
<P>MONDAY , MAY 19</P>
<P><B>Assembly on Critical Care</B></P>
<P><B>1:30 pm-4:15 pm</B></P></CENTER></BLOCKQUOTE>
<HR SIZE="4" WIDTH="85%" ALIGN="CENTER" NOSHADE="NOSHADE">
<BLOCKQUOTE>
<P><I><B>Target Audience: </B></I>Physicians, nurses, and respiratory
therapists.</P>
<P><B>OBJECTIVES</B><BR>At the conclusion of this session, the participant
will be able to:</P>
<UL>
<LI>define what biologic variables affect the host inflammatory response to
infection and what are the implications for the development of new therapies for
sepsis;</LI>
<LI>describe new therapeutic targets for modulating host responses during
sepsis;</LI>
<LI>describe how inflammatory cell responses to infection is inhibited at the
cell receptor level (i.e., endotoxin) or at the level of intracellular signaling
pathways;</LI>
<LI>review new models of complex biologic systems and their application to the
study of sepsis and multiple organ failure.</LI></UL>
<P>Despite considerable advances made in our understanding of the pathogenesis
of human sepsis, major gaps in knowledge remain. This symposium will present six
research areas that provide new insight into variables that affect host
responses to microbial pathogens and their importance in the development of new
therapies for sepsis. In addition, new methodology for the use of non-linear
models of complex biologic systems will be presented. These variables and models
have implications for the clinical use of immunomodulatory therapies in sepsis.</P>
<P><I><B>Chairing: </B></I>A.F. Suffredini, M.D., Bethesda, MDJ. Pugin, M.D.,
Geneva, Switzerland</P>
<P><I>1:30</I> <B>Rethinking the Anti-Inflammatory Approach to Sepsis: Human
and Animal Trials</B>/P.Q. Eichacker, M.D., Bethesda, MD</P>
<P><I>1:57</I> <B>Critical Role of Anti-Inflammatory Factors in Modulating
Host Responses During Human Sepsis</B>/P. Brandztaeg, M.D., Oslo, Norway</P>
<P><I>2:25</I> <B>Is Nitric Oxide Inhibition Useful in Patients with Sepsis?</B>/T.W.
Evans, M.D., Ph.D., London, England</P>
<P><I>2:52</I> <B>Targeting Intra-Cellular Signaling Pathways in Sepsis</B>/C.
Natanson, M.D., Bethesda, MD</P>
<P><I>3:19</I> <B>Inhibition of Endotoxin-Signaling Pathways: A Viable
Therapeutic Target in Sepsis?</B>/J. Pugin, M.D., Geneva, Switzerland</P>
<P><I>3:47</I> <B>Multiple Organ Failure, Biologic Oscillators, and
Non-Linear Systems</B>/T.G. Buchman, M.D., Ph.D., St. Louis, MO</P>
<P>Discussion after each presentation/5 minutes</P></BLOCKQUOTE>
<P></P>
<HR SIZE="4" WIDTH="80%">
<CENTER>
<P><A HREF=97ala.html><IMG
SRC=images/activity_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97bus.html><IMG
SRC=images/business_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97cal.html><IMG
SRC=images/calendar_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97child.html><IMG
SRC=images/child_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=pg.html><IMG
SRC=images/courses_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=search.html><IMG
SRC=images/search_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=main.html><IMG
SRC=images/home_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97house.html><IMG
SRC=images/house_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=http://itsmtgs.com/ala-ats><IMG
SRC=images/regist_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=sessions.html><IMG
SRC=images/session_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=special.html><IMG
SRC=images/special_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97tours.html><IMG
SRC=images/tour_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97travel.html><IMG
SRC=images/travel_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
</P></CENTER>
<HR SIZE="4" WIDTH="80%">
<CENTER><FONT SIZE="+2"><B><I>American Thoracic Society</I></B></FONT><BR>
1740 Broadway<BR> New York, NY 10019<BR> VOICE:  212-315-8700<BR> Copyright &copy;
1996 American Lung Association.<BR> The American Thoracic  Society is the
medical section <BR>of the American Lung Association.<BR> 
</CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-141</DOCNO>
<DOCOLDNO>IA013-000139-B032-70</DOCOLDNO>
<DOCHDR>
http://www.thoracic.org:80/ic97/b60.html 206.138.195.144 19970217072824 text/html 5388
HTTP/1.0 200 OK
Date: Monday, 17-Feb-97 07:23:40 GMT
Server: NCSA/1.3
MIME-version: 1.0
Content-type: text/html
Last-modified: Friday, 24-Jan-97 16:15:22 GMT
Content-length: 5208
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//SQ//DTD HTML 2.0 HoTMetaL + extensions//EN">
<HTML>
<HEAD>
<TITLE>SYMPOSIUM: b60</TITLE></HEAD>
<BODY BGCOLOR="#FFFFFF">
<CENTER><IMG ALIGN="LEFT" SRC="images/banner0.jpg"></CENTER>
<CENTER><BR>
<P>SYMPOSIUM</P><BR>
<H2>B60: CELLULAR AND MOLECULAR IMPLICATIONS OF MECHANICAL FORCES IN THE LUNG</H2></CENTER>
<HR SIZE="5" NOSHADE="NOSHADE" WIDTH="100%">
<P></P>
<CENTER>
<TABLE BORDER="2">
<TR ALIGN="CENTER" VALIGN="MIDDLE">
<TD ALIGN="CENTER" VALIGN="MIDDLE"><B><SMALL><A HREF="ic97.html">BACK TO
MAIN MENU</A></SMALL></B></TD></TR></TABLE></CENTER>
<P></P>
<HR SIZE="10" WIDTH="85%">
<P></P>
<BLOCKQUOTE>
<CENTER>
<P>MONDAY , MAY 19</P>
<P><B>Assemblies on Allergy, Immunology and Inflammation/<BR>Respiratory
Structure and Function/Critical Care/<BR>Respiratory Cell and Molecular Biology</B></P>
<P><B>1:30 pm-4:15 pm</B></P></CENTER></BLOCKQUOTE>
<HR SIZE="4" WIDTH="85%" ALIGN="CENTER" NOSHADE="NOSHADE">
<BLOCKQUOTE>
<P><I><B>Target Audience: </B></I>Basic scientists, clinicians, and graduate
and post-graduate trainees interested in the inflammatory process within the
lungs.</P>
<P><B>OBJECTIVES</B><BR>At the conclusion of this session, the participant
will be able to:</P>
<UL>
<LI>define and measure the biomechanical forces acting on cells within the
lungs and on the alveolar capillary walls, as well as understand the importance
of alterations in biomechanical properties during inflammation;</LI>
<LI>elucidate the effects of biochemical mediators including cytokines and
adhesion molecules in activation of signaling pathways leading to alterations in
the cytoskeleton and changes in biomechanical properties of neutrophils and
airway smooth muscle cells;</LI>
<LI>understand the effect of mechanical deformations in altering the functions
of neutrophils, bronchial epithelial cells, and type II epithelial cells;</LI>
<LI>describe the effects of mechanical forces exerted by mechanical ventilation
on the enhancement of lung injury by production of pro-inflammatory cytokines.</LI></UL>
<P>Biomechanical forces acting on cells or tissues within the lungs appear to
influence the function of these structures. Biochemical stimuli can alter the
mechanical properties of these cells. This symposium focuses on the mechanisms
and their molecular basis through which mechanical forces exerted on cells
influence their function, as well as the mechanisms where by biochemical stimuli
including cytokines and adhesion molecules alter the biomechanical properties of
cells. The importance of biomechanical events to the inflammatory process is
discussed.</P>
<P><I><B>Chairing: </B></I>C.M. Doerschuk, M.D., Boston, MAG.P. Downey, M.D.,
Toronto, ON, CanadaM.B. Reid, Ph.D., Houston, TX</P>
<P><I>1:30</I> <B>Introduction and Overview</B>/G.P. Downey, M.D., Toronto,
ON, Canada</P>
<P><I>1:45</I> <B>Activation of Intracellular Signalling Pathways by Passive
Deformation in Neutrophils During Passage Through Capillaries</B>/J.C. Hogg,
M.D., Vancouver, BC, Canada</P>
<P><I>2:15</I> <B>Biomechanical Properties of Quiescent and Activated
Neutrophils and Capillaries</B>/C.M. Doerschuk, M.D., Boston, MA</P>
<P><I>2:45</I> <B>Mechanical-Ventilation Induced Production of
Pro-Inflammatory Cytokines by Lung Cells: Implications for Ventilator-Induced
Lung Injury</B>/A.S. Slutsky, M.D., Toronto, ON, Canada</P>
<P><I>3:15</I> <B>Mechanisms of Effects of IL-1 on Responses of Human Airway
Smooth Muscle Cells to Agonists</B>/S.A. Shore, Ph.D., Boston, MA</P>
<P><I>3:45</I> <B>Effect of Mechanical Forces of Surfactant Production in
Health and Disease</B>/B.A. Holm, M.D., Buffalo, NY</P>
<P>Discussion after each presentation/5 minutes</P></BLOCKQUOTE>
<P></P>
<HR SIZE="4" WIDTH="80%">
<CENTER>
<P><A HREF=97ala.html><IMG
SRC=images/activity_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97bus.html><IMG
SRC=images/business_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97cal.html><IMG
SRC=images/calendar_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97child.html><IMG
SRC=images/child_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=pg.html><IMG
SRC=images/courses_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=search.html><IMG
SRC=images/search_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=main.html><IMG
SRC=images/home_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97house.html><IMG
SRC=images/house_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=http://itsmtgs.com/ala-ats><IMG
SRC=images/regist_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=sessions.html><IMG
SRC=images/session_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=special.html><IMG
SRC=images/special_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97tours.html><IMG
SRC=images/tour_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97travel.html><IMG
SRC=images/travel_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
</P></CENTER>
<HR SIZE="4" WIDTH="80%">
<CENTER><FONT SIZE="+2"><B><I>American Thoracic Society</I></B></FONT><BR>
1740 Broadway<BR> New York, NY 10019<BR> VOICE:  212-315-8700<BR> Copyright &copy;
1996 American Lung Association.<BR> The American Thoracic  Society is the
medical section <BR>of the American Lung Association.<BR> 
</CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-142</DOCNO>
<DOCOLDNO>IA013-000139-B032-100</DOCOLDNO>
<DOCHDR>
http://www.thoracic.org:80/ic97/c17.html 206.138.195.144 19970217072838 text/html 5168
HTTP/1.0 200 OK
Date: Monday, 17-Feb-97 07:23:53 GMT
Server: NCSA/1.3
MIME-version: 1.0
Content-type: text/html
Last-modified: Friday, 24-Jan-97 16:15:28 GMT
Content-length: 4988
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//SQ//DTD HTML 2.0 HoTMetaL + extensions//EN">
<HTML>
<HEAD>
<TITLE>SYMPOSIUM: c17</TITLE></HEAD>
<BODY BGCOLOR="#FFFFFF">
<CENTER><IMG ALIGN="LEFT" SRC="images/banner0.jpg"></CENTER>
<CENTER><BR>
<P>SYMPOSIUM</P><BR>
<H2>C17: PARTICULATE POLLUTION AND BIOLOGIC PLAUSIBILITY: CAN STUDIES IN THE
LABORATORY SUBSTANTIATE THE EPIDEMIOLOGY?</H2></CENTER>
<HR SIZE="5" NOSHADE="NOSHADE" WIDTH="100%">
<P></P>
<CENTER>
<TABLE BORDER="2">
<TR ALIGN="CENTER" VALIGN="MIDDLE">
<TD ALIGN="CENTER" VALIGN="MIDDLE"><B><SMALL><A HREF="ic97.html">BACK TO
MAIN MENU</A></SMALL></B></TD></TR></TABLE></CENTER>
<P></P>
<HR SIZE="10" WIDTH="85%">
<P></P>
<BLOCKQUOTE>
<CENTER>
<P>TUESDAY , MAY 20</P>
<P><B>Assembly on Environmental and Occupational Health</B></P>
<P><B>8:15 am-11:00 am</B></P></CENTER></BLOCKQUOTE>
<HR SIZE="4" WIDTH="85%" ALIGN="CENTER" NOSHADE="NOSHADE">
<BLOCKQUOTE>
<P><I><B>Target Audience: </B></I>Researchers interested in environmental
lung injury, and Lung Association volunteers and staff interested in the public
health and regulatory aspects of air pollution.</P>
<P><B>OBJECTIVES</B><BR>At the conclusion of this session, the participant
will be able to:</P>
<UL>
<LI>to critically review in a single venue the most notable hypotheses which
have been offered to explain the recent PM-related epidemiology regarding
mortality and morbidity;</LI>
<LI>provide an overview and critical comparison of the current thinking
regarding the causative nature of the reported PM health adversity.</LI></UL>
<P>Several recent epidemiological studies have demonstrated significant
association between exposure to ambient airborne particles (PM) and excess
mortality and morbidity, especially among apparent susceptible subpopulations,
most notably the elderly and children. The reasons underlying these effects are
unclear, but increasing concern stems from the fact that these effects are
measurable at or below National Ambient Air Quality Standards for PM (50ug/m3
annualized mean). Moreover, the nature of the incriminated particle exposure is
uncertain; neither size nor composition of the particles &quot;inducing&quot;
these effects has discriminated in the epidemiological studies. The minimal
particle exposures apparently inflicting harm in these study scenarios has
directed substantial recent attention in controlled laboratory studies towards
establishing a biologic plausibility for the population study observations.
Several hypotheses have arisen, each with some evidential support. This
symposium will critically review the state-of-the-art of these hypotheses and
how well they provide a reasonable biologic basis for the epidemiology.</P>
<P><I><B>Chairing: </B></I>T. Gordon, Ph.D., Tuxedo, NYD. Costa, Sc.D.,
Research Triangle Park, NC</P>
<P><I>8:15</I> <B>The Nature of the Problem: What Evidence Is There to
Support Your Hypothesis?</B>/T. Gordon, Ph.D., Tuxedo, NY</P>
<P><I>8:30</I> <B>Exposure/Dosimetry</B>/R. Phalen, Ph.D., Irvine, CA</P>
<P><I>8:55</I> <B>Acid Aerosols</B>/L.Chi Chen, Ph.D., Tuxedo, NY</P>
<P><I>9:20</I> <B>Metals</B>/K. Dreher, Research Triangle Park, NC</P>
<P><I>9:45</I> <B>Ultrafine PM</B>/G. Oberdorster, D.V.M., Ph.D., Rochester,
NY</P>
<P><I>10:10</I> <B>Ambient PM</B>/J.J. Godleski, M.D., Boston, MA</P>
<P><I>10:35</I> <B>Conclusions: Does Any of This Make Sense?</B>/D. Costa,
Sc.D., Research Triangle Park, NC</P>
<P>Discussion after each presentation/5 minutes</P></BLOCKQUOTE>
<P></P>
<HR SIZE="4" WIDTH="80%">
<CENTER>
<P><A HREF=97ala.html><IMG
SRC=images/activity_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97bus.html><IMG
SRC=images/business_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97cal.html><IMG
SRC=images/calendar_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97child.html><IMG
SRC=images/child_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=pg.html><IMG
SRC=images/courses_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=search.html><IMG
SRC=images/search_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=main.html><IMG
SRC=images/home_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97house.html><IMG
SRC=images/house_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=http://itsmtgs.com/ala-ats><IMG
SRC=images/regist_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=sessions.html><IMG
SRC=images/session_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=special.html><IMG
SRC=images/special_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97tours.html><IMG
SRC=images/tour_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97travel.html><IMG
SRC=images/travel_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
</P></CENTER>
<HR SIZE="4" WIDTH="80%">
<CENTER><FONT SIZE="+2"><B><I>American Thoracic Society</I></B></FONT><BR>
1740 Broadway<BR> New York, NY 10019<BR> VOICE:  212-315-8700<BR> Copyright &copy;
1996 American Lung Association.<BR> The American Thoracic  Society is the
medical section <BR>of the American Lung Association.<BR> 
</CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-143</DOCNO>
<DOCOLDNO>IA013-000139-B032-120</DOCOLDNO>
<DOCHDR>
http://www.thoracic.org:80/ic97/c55.html 206.138.195.144 19970217072851 text/html 4552
HTTP/1.0 200 OK
Date: Monday, 17-Feb-97 07:24:05 GMT
Server: NCSA/1.3
MIME-version: 1.0
Content-type: text/html
Last-modified: Friday, 24-Jan-97 16:15:33 GMT
Content-length: 4372
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//SQ//DTD HTML 2.0 HoTMetaL + extensions//EN">
<HTML>
<HEAD>
<TITLE>SYMPOSIUM: c55</TITLE></HEAD>
<BODY BGCOLOR="#FFFFFF">
<CENTER><IMG ALIGN="LEFT" SRC="images/banner0.jpg"></CENTER>
<CENTER><BR>
<P>SYMPOSIUM</P><BR>
<H2>C55: RESPIRATORY MECHANICS DURING MECHANICAL VENTILATION: CLINICAL
APPLICATION</H2></CENTER>
<HR SIZE="5" NOSHADE="NOSHADE" WIDTH="100%">
<P></P>
<CENTER>
<TABLE BORDER="2">
<TR ALIGN="CENTER" VALIGN="MIDDLE">
<TD ALIGN="CENTER" VALIGN="MIDDLE"><B><SMALL><A HREF="ic97.html">BACK TO
MAIN MENU</A></SMALL></B></TD></TR></TABLE></CENTER>
<P></P>
<HR SIZE="10" WIDTH="85%">
<P></P>
<BLOCKQUOTE>
<CENTER>
<P>TUESDAY , MAY 20</P>
<P><B>Assembly on Critical Care</B></P>
<P><B>3:15 PM&#151;6:00 PM</B></P></CENTER></BLOCKQUOTE>
<HR SIZE="4" WIDTH="85%" ALIGN="CENTER" NOSHADE="NOSHADE">
<BLOCKQUOTE>
<P><I><B>Target Audience: </B></I>Physicians, nurses, respiratory therapists.</P>
<P><B>OBJECTIVES</B><BR>At the conclusion of this session, the participant
will be able to:</P>
<UL>
<LI>understand the basic principles of respiratory mechanics;</LI>
<LI>describe the technique and limitation in the ICU setting;</LI>
<LI>describe the utility of respiratory mechanics in the management of
ventilatory supported patients.</LI></UL>
<P>Measurements of flow, pressure, and volume which are displayed on most
modern ventilators can provide important information regarding respiratory
mechanics and respiratory muscle function. Although significant technologic and
methodologic advancement in the monitoring of respiratory mechanics in patients
receiving mechanical ventilation have occurred, the clinical application of
these technologies has not yet been defined. This symposium will provide
state-of-the-art assessment of current knowledge regarding the principles behind
these various measurements and their practical applications.</P>
<P><I><B>Chairing: </B></I>A. Jubran, M.D., Hines, ILA. Rossi, M.D., Verona,
Italy</P>
<P><I>3:15</I> <B>Respiratory System Mechanics: Principles and Measurement
Techniques</B>/J. Milic-Emili, M.D., Clinchy, Paris, France</P>
<P><I>3:40</I> <B>Pressure-Volume Curve and Optimal PEEP in the Management of
ARDS</B>/M.B. P. Amato, M.D., Sao Paulo, Brazil</P>
<P><I>4:05</I> <B>Auto-PEEP in Airflow Obstruction: Implication and
Management</B>/D.V. Tuxen, M.B.B.S., Victoria, Australia</P>
<P><I>4:25</I> <B>Bronchodilator Response Testing in Intubated Patients</B>/R.D.
Hubmayr, M.D., Rochester, MN</P>
<P><I>4:45</I> <B>Work of Breathing: Clinical Implications?</B>/L.J.
Brochard, M.D., Creteil, France</P>
<P><I>5:10</I> <B>Respiratory Muscle Function During Weaning</B>/M.J. Tobin,
M.D., Maywood, IL</P>
<P><I>5:35</I> <B>Display of Ventilator Output Waveforms: How Helpful?</B>/D.R.
Hess, Ph.D., Boston, MA</P>
<P>Discussion after each presentation/5 minutes</P></BLOCKQUOTE>
<P></P>
<HR SIZE="4" WIDTH="80%">
<CENTER>
<P><A HREF=97ala.html><IMG
SRC=images/activity_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97bus.html><IMG
SRC=images/business_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97cal.html><IMG
SRC=images/calendar_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97child.html><IMG
SRC=images/child_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=pg.html><IMG
SRC=images/courses_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=search.html><IMG
SRC=images/search_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=main.html><IMG
SRC=images/home_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97house.html><IMG
SRC=images/house_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=http://itsmtgs.com/ala-ats><IMG
SRC=images/regist_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=sessions.html><IMG
SRC=images/session_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=special.html><IMG
SRC=images/special_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97tours.html><IMG
SRC=images/tour_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97travel.html><IMG
SRC=images/travel_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
</P></CENTER>
<HR SIZE="4" WIDTH="80%">
<CENTER><FONT SIZE="+2"><B><I>American Thoracic Society</I></B></FONT><BR>
1740 Broadway<BR> New York, NY 10019<BR> VOICE:  212-315-8700<BR> Copyright &copy;
1996 American Lung Association.<BR> The American Thoracic  Society is the
medical section <BR>of the American Lung Association.<BR> 
</CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-144</DOCNO>
<DOCOLDNO>IA013-000139-B032-151</DOCOLDNO>
<DOCHDR>
http://www.thoracic.org:80/ic97/c56.html 206.138.195.144 19970217072908 text/html 4385
HTTP/1.0 200 OK
Date: Monday, 17-Feb-97 07:24:22 GMT
Server: NCSA/1.3
MIME-version: 1.0
Content-type: text/html
Last-modified: Friday, 24-Jan-97 16:15:33 GMT
Content-length: 4205
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//SQ//DTD HTML 2.0 HoTMetaL + extensions//EN">
<HTML>
<HEAD>
<TITLE>SYMPOSIUM: c56</TITLE></HEAD>
<BODY BGCOLOR="#FFFFFF">
<CENTER><IMG ALIGN="LEFT" SRC="images/banner0.jpg"></CENTER>
<CENTER><BR>
<P>SYMPOSIUM</P><BR>
<H2>C56: NOVEL SIGNALLING PATHWAYS IN PULMONARY VASCULAR BIOLOGY</H2></CENTER>
<HR SIZE="5" NOSHADE="NOSHADE" WIDTH="100%">
<P></P>
<CENTER>
<TABLE BORDER="2">
<TR ALIGN="CENTER" VALIGN="MIDDLE">
<TD ALIGN="CENTER" VALIGN="MIDDLE"><B><SMALL><A HREF="ic97.html">BACK TO
MAIN MENU</A></SMALL></B></TD></TR></TABLE></CENTER>
<P></P>
<HR SIZE="10" WIDTH="85%">
<P></P>
<BLOCKQUOTE>
<CENTER>
<P>TUESDAY , MAY 20</P>
<P><B>Assemblies on Pulmonary Circulation/<BR>Respiratory Cell and Molecular
Biology</B></P>
<P><B>3:15 PM&#151;6:00 PM</B></P></CENTER></BLOCKQUOTE>
<HR SIZE="4" WIDTH="85%" ALIGN="CENTER" NOSHADE="NOSHADE">
<BLOCKQUOTE>
<P><I><B>Target Audience: </B></I>Pulmonary vascular biologists, clinicians
with an interest in the pulmonary circulation.</P>
<P><B>OBJECTIVES</B><BR>At the conclusion of this session, the participant
will be able to:</P>
<UL>
<LI>identify new signalling pathways in pulmonary vascular biology;</LI>
<LI>appreciate how long recognized molecules may serve previously unknown roles
in cell regulation;</LI>
<LI>describe how the pulmonary vasculature uses a variety of signals to respond
to hypoxia.</LI></UL>
<P>The aim of this session is to provide brief, state-of-the-art synopses of
current research into newly discovered or signalling pathways that regulate
pulmonary vascular responses. The session will examine primarily responses to
hypoxia, and will consider how these new insights might lead to new therapeutic
approaches.</P>
<P><I><B>Chairing: </B></I>A.M. K. Choi, M.D., Baltimore, MDN.S. Hill, M.D.,
Providence, RI</P>
<P><I>3:15</I> <B>The Role of Hypoxia-Inducible Factor 1 in Mammalian Oxygen
Homeostasis</B>/G. Semenza, M.D., Ph.D., Baltimore, MD</P>
<P><I>3:40</I> <B>Natriuretic Peptides: Regulators of Pulmonary Vascular
Responses to Hypoxia</B>/J.R. Klinger, M.D., Providence, RI</P>
<P><I>4:05</I> <B>Hypoxic Responses of Vascular Smooth Muscle: Role of Carbon
Monoxide</B>/S. Kourembanas, M.D., Boston, MA</P>
<P><I>4:30</I> <I>Break</I></P>
<P><I>4:45</I> <B>Regulation of HEME Oxygenase-1 Expression in Response to
Hypoxia</B>/A.M. K. Choi, M.D., Baltimore, MD</P>
<P><I>5:10</I> <B>Xanthine Oxidase: Regulation by Endothelium-Derived Nitric
Oxide</B>/P.M. Hassoun, M.D., Boston, MA</P>
<P><I>5:35</I> <B>Gene Transfer of Components of the NO/cGMP Signalling
Pathway</B>/S.P. Janssens, M.D., Ph.D., Leuven, Belgium</P>
<P>Discussion after each presentation/5 minutes</P></BLOCKQUOTE>
<P></P>
<HR SIZE="4" WIDTH="80%">
<CENTER>
<P><A HREF=97ala.html><IMG
SRC=images/activity_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97bus.html><IMG
SRC=images/business_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97cal.html><IMG
SRC=images/calendar_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97child.html><IMG
SRC=images/child_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=pg.html><IMG
SRC=images/courses_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=search.html><IMG
SRC=images/search_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=main.html><IMG
SRC=images/home_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97house.html><IMG
SRC=images/house_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=http://itsmtgs.com/ala-ats><IMG
SRC=images/regist_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=sessions.html><IMG
SRC=images/session_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=special.html><IMG
SRC=images/special_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97tours.html><IMG
SRC=images/tour_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97travel.html><IMG
SRC=images/travel_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
</P></CENTER>
<HR SIZE="4" WIDTH="80%">
<CENTER><FONT SIZE="+2"><B><I>American Thoracic Society</I></B></FONT><BR>
1740 Broadway<BR> New York, NY 10019<BR> VOICE:  212-315-8700<BR> Copyright &copy;
1996 American Lung Association.<BR> The American Thoracic  Society is the
medical section <BR>of the American Lung Association.<BR> 
</CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-145</DOCNO>
<DOCOLDNO>IA013-000139-B032-177</DOCOLDNO>
<DOCHDR>
http://www.thoracic.org:80/ic97/c57.html 206.138.195.144 19970217072918 text/html 4663
HTTP/1.0 200 OK
Date: Monday, 17-Feb-97 07:24:35 GMT
Server: NCSA/1.3
MIME-version: 1.0
Content-type: text/html
Last-modified: Friday, 24-Jan-97 16:15:34 GMT
Content-length: 4483
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//SQ//DTD HTML 2.0 HoTMetaL + extensions//EN">
<HTML>
<HEAD>
<TITLE>SYMPOSIUM: c57</TITLE></HEAD>
<BODY BGCOLOR="#FFFFFF">
<CENTER><IMG ALIGN="LEFT" SRC="images/banner0.jpg"></CENTER>
<CENTER><BR>
<P>SYMPOSIUM</P><BR>
<H2>C57: AIRWAY SMOOTH MUSCLE IN ASTHMA</H2></CENTER>
<HR SIZE="5" NOSHADE="NOSHADE" WIDTH="100%">
<P></P>
<CENTER>
<TABLE BORDER="2">
<TR ALIGN="CENTER" VALIGN="MIDDLE">
<TD ALIGN="CENTER" VALIGN="MIDDLE"><B><SMALL><A HREF="ic97.html">BACK TO
MAIN MENU</A></SMALL></B></TD></TR></TABLE></CENTER>
<P></P>
<HR SIZE="10" WIDTH="85%">
<P></P>
<BLOCKQUOTE>
<CENTER>
<P>TUESDAY , MAY 20</P>
<P><B>Assemblies on Respiratory Structure and Function/<BR>Allergy,
Immunology and Inflammation</B></P>
<P><B>3:15 PM&#151;6:00 PM</B></P></CENTER></BLOCKQUOTE>
<HR SIZE="4" WIDTH="85%" ALIGN="CENTER" NOSHADE="NOSHADE">
<BLOCKQUOTE>
<P><I><B>Target Audience: </B></I>Research scientists, fellows, and
clinicians interested in asthma.</P>
<P><B>OBJECTIVES</B><BR>At the conclusion of this session, the participant
will be able to:</P>
<UL>
<LI>describe the factors contributing to airway smooth muscle proliferation in
asthma;</LI>
<LI>describe the static and dynamic factors that influence airway smooth muscle
shortening;</LI>
<LI>identify differences in airway smooth muscle mechanics and pharmacology in
asthma.</LI></UL>
<P>Airway smooth muscle contraction is a critical component of the
pathophysiology of asthma. How much airway smooth muscle contracts and the
resulting degree of airway lumenal narrowing depends on a number of factors
including the amount of smooth muscle present, the load on the muscle, the
contractile machinery, and the signal transduction process leading from receptor
activation to activation of the contractile apparatus. In addition, lung volume
changes during breathing imposes cyclic stretch on the muscle which can
influence force development and shorthening capacity. Speakers in this symposium
will review each of these factors and address the potential for alterations
induced by inflammation and the evidence for differences between the asthmatic
and the normal airway.</P>
<P><I><B>Chairing: </B></I>S.A. Shore, Ph.D., Boston, MAJ.J. Fredberg, Ph.D.,
Boston, MA</P>
<P><I>3:15</I> <B>Introduction</B>/S.A. Shore, Ph.D., Boston, MA</P>
<P><I>3:20</I> <B>Inflammation-Induced Smooth Muscle Proliferation</B>/M.B.
Hershenson, M.D., Chicago, IL</P>
<P><I>3:45</I> <B>What Is the Load on Airway Smooth Muscle?</B>/P.D. Pare,
Jr., M.D., Vancouver, BC, Canada</P>
<P><I>4:10</I> <B>Effect of Inflammation on Smooth Muscle Mechanics</B>/W.
Gerthoffer, Ph.D., Reno, NV</P>
<P><I>4:35</I> <B>Airway Smooth Muscle Pharmacology in Asthma</B>/J.L. Black,
M.D., Ph.D., New South Wales, Australia</P>
<P><I>5:00</I> <B>Plasticity of Airway Smooth Muscle</B>/L.E. Ford, M.D.,
Indianapolis, IN</P>
<P><I>5:30</I> <B>Disequilibrium of Airway Smooth Muscle</B>/J.J. Fredberg,
Ph.D., Boston, MA</P></BLOCKQUOTE>
<P></P>
<HR SIZE="4" WIDTH="80%">
<CENTER>
<P><A HREF=97ala.html><IMG
SRC=images/activity_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97bus.html><IMG
SRC=images/business_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97cal.html><IMG
SRC=images/calendar_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97child.html><IMG
SRC=images/child_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=pg.html><IMG
SRC=images/courses_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=search.html><IMG
SRC=images/search_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=main.html><IMG
SRC=images/home_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97house.html><IMG
SRC=images/house_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=http://itsmtgs.com/ala-ats><IMG
SRC=images/regist_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=sessions.html><IMG
SRC=images/session_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=special.html><IMG
SRC=images/special_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97tours.html><IMG
SRC=images/tour_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97travel.html><IMG
SRC=images/travel_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
</P></CENTER>
<HR SIZE="4" WIDTH="80%">
<CENTER><FONT SIZE="+2"><B><I>American Thoracic Society</I></B></FONT><BR>
1740 Broadway<BR> New York, NY 10019<BR> VOICE:  212-315-8700<BR> Copyright &copy;
1996 American Lung Association.<BR> The American Thoracic  Society is the
medical section <BR>of the American Lung Association.<BR> 
</CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-146</DOCNO>
<DOCOLDNO>IA013-000139-B032-205</DOCOLDNO>
<DOCHDR>
http://www.thoracic.org:80/ic97/d6.html 206.138.195.144 19970217072928 text/html 4808
HTTP/1.0 200 OK
Date: Monday, 17-Feb-97 07:24:46 GMT
Server: NCSA/1.3
MIME-version: 1.0
Content-type: text/html
Last-modified: Friday, 24-Jan-97 16:15:50 GMT
Content-length: 4628
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//SQ//DTD HTML 2.0 HoTMetaL + extensions//EN">
<HTML>
<HEAD>
<TITLE>SYMPOSIUM: d6</TITLE></HEAD>
<BODY BGCOLOR="#FFFFFF">
<CENTER><IMG ALIGN="LEFT" SRC="images/banner0.jpg"></CENTER>
<CENTER><BR>
<P>SYMPOSIUM</P><BR>
<H2>D6: MATRIX AND CELLULAR INTERACTIONS IN AIRWAY SMOOTH MUSCLE REMODELING</H2></CENTER>
<HR SIZE="5" NOSHADE="NOSHADE" WIDTH="100%">
<P></P>
<CENTER>
<TABLE BORDER="2">
<TR ALIGN="CENTER" VALIGN="MIDDLE">
<TD ALIGN="CENTER" VALIGN="MIDDLE"><B><SMALL><A HREF="ic97.html">BACK TO
MAIN MENU</A></SMALL></B></TD></TR></TABLE></CENTER>
<P></P>
<HR SIZE="10" WIDTH="85%">
<P></P>
<BLOCKQUOTE>
<CENTER>
<P>WEDNESDAY , MAY 21</P>
<P><B>Assemblies on Allergy, Immunology and Inflammation/<BR>Respiratory Cell
and Molecular Biology</B></P>
<P><B>8:15 am-11:00 am</B></P></CENTER></BLOCKQUOTE>
<HR SIZE="4" WIDTH="85%" ALIGN="CENTER" NOSHADE="NOSHADE">
<BLOCKQUOTE>
<P><I><B>Target Audience: </B></I>Clinicians and researchers interested in
the pathogenesis of asthma.</P>
<P><B>OBJECTIVES</B><BR>At the conclusion of this session, the participant
will be able to:</P>
<UL>
<LI>describe the role of airway smooth muscle proliferation in the pathogenesis
of asthma;</LI>
<LI>understand the interactions between inflammatory cells and cellular matrix
which modulate airway smooth muscle growth;</LI>
<LI>understand the relevance of phenotypic variation in airway smooth muscle;</LI>
<LI>gain insight into the cellular and molecular techniques for the
investigation of airway smooth muscle function.</LI></UL>
<P>This symposium will explore the matrix and cellular interactions that may
induce airway smooth muscle remodeling in asthma. The role of airway smooth
muscle in modulating inflammatory cell function and expression of extracellular
matrix will also be described in order to gain insight into new therapeutic
approaches in the treatment of chronic severe asthma.</P>
<P><I><B>Chairing: </B></I>R.A. Panettieri, Jr., M.D., Philadelphia, PAC.H.C.
Twort, M.D., London, England</P>
<P><I>8:15</I> <B>Signaling Pathways that Mediate ASM Cell Growth and
Function in Asthma</B>/R.A. Panettieri, Jr., M.D., Philadelphia, PA</P>
<P><I>8:35</I> <B>G Protein-Coupled Receptor Activation and Downstream
Signaling Events that Modulate ASM Cell Growth</B>/J.A. Posada, Ph.D.,
Burlington, VT</P>
<P><I>8:55</I> <B>Control of ASM Proliferation by T Cells: Role of Adhesion
Molecules</B>/E. Pure, Ph.D., Philadelphia, PA</P>
<P><I>9:15</I> <I>Discussion</I></P>
<P><I>9:25</I> <B>Regulation of Matrix Deposition in the Airways</B>/G.J.
Laurent, Ph.D., London, England</P>
<P><I>9:45</I> <B>The Extracellular Matrix and Control of ASM Proliferation:
Role of ASM Phenotype Plasticity</B>/S.J. Hirst, Ph.D., London, England</P>
<P><I>10:05</I> <B>ASM Phenotype: Relationship to Cell Function</B>/A.J.
Halayko, M.Sc., Winnipeg, MB, Canada</P>
<P><I>10:25</I> <B>Pathophysiologic Consequences of Airway Smooth Muscle
Remodeling in Asthma</B>/J.G. Martin, M.D., Montreal, PQ, Canada</P>
<P><I>10:45</I> <I>Discussion</I></P>
<P>Discussion after each presentation/5 minutes</P></BLOCKQUOTE>
<P></P>
<HR SIZE="4" WIDTH="80%">
<CENTER>
<P><A HREF=97ala.html><IMG
SRC=images/activity_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97bus.html><IMG
SRC=images/business_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97cal.html><IMG
SRC=images/calendar_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97child.html><IMG
SRC=images/child_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=pg.html><IMG
SRC=images/courses_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=search.html><IMG
SRC=images/search_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=main.html><IMG
SRC=images/home_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97house.html><IMG
SRC=images/house_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=http://itsmtgs.com/ala-ats><IMG
SRC=images/regist_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=sessions.html><IMG
SRC=images/session_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=special.html><IMG
SRC=images/special_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97tours.html><IMG
SRC=images/tour_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97travel.html><IMG
SRC=images/travel_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
</P></CENTER>
<HR SIZE="4" WIDTH="80%">
<CENTER><FONT SIZE="+2"><B><I>American Thoracic Society</I></B></FONT><BR>
1740 Broadway<BR> New York, NY 10019<BR> VOICE:  212-315-8700<BR> Copyright &copy;
1996 American Lung Association.<BR> The American Thoracic  Society is the
medical section <BR>of the American Lung Association.<BR> 
</CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-147</DOCNO>
<DOCOLDNO>IA013-000141-B024-190</DOCOLDNO>
<DOCHDR>
http://www.thoracic.org:80/ic97/d8.html 206.138.195.144 19970217073005 text/html 5193
HTTP/1.0 200 OK
Date: Monday, 17-Feb-97 07:25:22 GMT
Server: NCSA/1.3
MIME-version: 1.0
Content-type: text/html
Last-modified: Friday, 24-Jan-97 16:15:51 GMT
Content-length: 5013
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//SQ//DTD HTML 2.0 HoTMetaL + extensions//EN">
<HTML>
<HEAD>
<TITLE>SYMPOSIUM: d8</TITLE></HEAD>
<BODY BGCOLOR="#FFFFFF">
<CENTER><IMG ALIGN="LEFT" SRC="images/banner0.jpg"></CENTER>
<CENTER><BR>
<P>SYMPOSIUM</P><BR>
<H2>D8: UPDATE ON NON-TUBERCULOUS MYCOBACTERIAL (NTM) PULMONARY DISEASES</H2></CENTER>
<HR SIZE="5" NOSHADE="NOSHADE" WIDTH="100%">
<P></P>
<CENTER>
<TABLE BORDER="2">
<TR ALIGN="CENTER" VALIGN="MIDDLE">
<TD ALIGN="CENTER" VALIGN="MIDDLE"><B><SMALL><A HREF="ic97.html">BACK TO
MAIN MENU</A></SMALL></B></TD></TR></TABLE></CENTER>
<P></P>
<HR SIZE="10" WIDTH="85%">
<P></P>
<BLOCKQUOTE>
<CENTER>
<P>WEDNESDAY , MAY 21</P>
<P><B>Assembly on Microbiology, Tuberculosis and Pulmonary Infections</B></P>
<P><B>8:15 am-11:30 am</B></P></CENTER></BLOCKQUOTE>
<HR SIZE="4" WIDTH="85%" ALIGN="CENTER" NOSHADE="NOSHADE">
<BLOCKQUOTE>
<P><I><B>Target Audience: </B></I>Pulmonary and critical care physicians and
other health providers, clinical and basic science investigators with interests
in the epidemiology, clinical manifestations, microbiology and pathogenesis,
diagnostic evaluation, treatment and prophylaxis for non-tuberculous
mycobacterial pulmonary infections.</P>
<P><B>OBJECTIVES</B><BR>At the conclusion of this session, the participant
will be able to:</P>
<UL>
<LI>describe recent advances in the epidemiology and pathogenesis of
non-tuberculous mycobacterial (NTM) infections;</LI>
<LI>identify host susceptibility factors and emerging spectrum of disease for
NTM infections;</LI>
<LI>define the status of new diagnostic tests for NTM infections;</LI>
<LI>describe the antimicrobial agents available for treatment and prophylaxis
in NTM infections.</LI></UL>
<P>Recent advances in our understanding of pulmonary non-Tuberculous
Mycobacterial (NTM) infections will be presented. Discussion will address the
mechanisms of susceptibility and clinical manifestations of NTM disease. Efforts
will be made to review the laboratory characteristics of NTM, provide the
state-of-the-art discussion of current diagnostic approaches, and an update on
agents for the treatment and prophylaxis of NTM disease, including the role for
immunomodulators. Attendees will be able to apply the information acquired in
this session for a rational and comprehensive approach in the evaluation and
management of patients with NTM disease.</P>
<P><I><B>Chairing: </B></I>R.E. Chaisson, M.D., Baltimore, MDH. Koziel, M.D.,
Boston, MAR.J. Wallace, Jr., M.D., Tyler, TX</P>
<P><I>8:15</I> <B>Overview of Recent Advances in NTM Disease: The Colonizer
Turned Pathogen</B>/R.E. Chaisson, M.D., Baltimore, MD</P>
<P><I>8:30</I> <B>Non-Tuberculous Mycobacteria: Laboratory Characteristics
and New Diagnostic Tools</B>/M. Salfinger, M.D., Albany, NY</P>
<P><I>9:00</I> <I><B>Mycobacterium avium</B></I><B> Disease and
Antimicrobial Resistance</B>/C. Inderlied, Ph.D., Los Angeles, CA</P>
<P><I>9:30</I> <B>Host Immune and Genetic Factors in NTM Disease</B>/S.
Holland, M.D., Bethesda, MD</P>
<P><I>10:00</I> <B>Emerging Clinical Aspects of NTM Disease in Non-HIV Hosts</B>/K.N.
Olivier, M.D., M.P.H., Lackland Air Force Base, TX</P>
<P><I>10:30</I> <B>International Perspective on NTM Disease in HIV Infection:
N. American vs. European Experience</B>/J.D. Lundgren, M.D., Hvidovre, Denmark</P>
<P><I>11:00</I> <B>Advances in Treatment and Prophylaxis for NTM Disease</B>/R.J.
Wallace, Jr., M.D., Tyler, TX</P>
<P>Discussion after each presentation/5 minutes</P></BLOCKQUOTE>
<P></P>
<HR SIZE="4" WIDTH="80%">
<CENTER>
<P><A HREF=97ala.html><IMG
SRC=images/activity_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97bus.html><IMG
SRC=images/business_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97cal.html><IMG
SRC=images/calendar_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97child.html><IMG
SRC=images/child_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=pg.html><IMG
SRC=images/courses_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=search.html><IMG
SRC=images/search_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=main.html><IMG
SRC=images/home_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97house.html><IMG
SRC=images/house_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=http://itsmtgs.com/ala-ats><IMG
SRC=images/regist_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=sessions.html><IMG
SRC=images/session_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=special.html><IMG
SRC=images/special_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97tours.html><IMG
SRC=images/tour_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97travel.html><IMG
SRC=images/travel_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
</P></CENTER>
<HR SIZE="4" WIDTH="80%">
<CENTER><FONT SIZE="+2"><B><I>American Thoracic Society</I></B></FONT><BR>
1740 Broadway<BR> New York, NY 10019<BR> VOICE:  212-315-8700<BR> Copyright &copy;
1996 American Lung Association.<BR> The American Thoracic  Society is the
medical section <BR>of the American Lung Association.<BR> 
</CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-148</DOCNO>
<DOCOLDNO>IA013-000141-B024-213</DOCOLDNO>
<DOCHDR>
http://www.thoracic.org:80/ic97/d9.html 206.138.195.144 19970217073013 text/html 4572
HTTP/1.0 200 OK
Date: Monday, 17-Feb-97 07:25:31 GMT
Server: NCSA/1.3
MIME-version: 1.0
Content-type: text/html
Last-modified: Friday, 24-Jan-97 16:15:51 GMT
Content-length: 4392
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//SQ//DTD HTML 2.0 HoTMetaL + extensions//EN">
<HTML>
<HEAD>
<TITLE>SYMPOSIUM: d9</TITLE></HEAD>
<BODY BGCOLOR="#FFFFFF">
<CENTER><IMG ALIGN="LEFT" SRC="images/banner0.jpg"></CENTER>
<CENTER><BR>
<P>SYMPOSIUM</P><BR>
<H2>D9: POTENTIAL THERAPEUTIC TARGETS IN AIRWAY INFLAMMATION</H2></CENTER>
<HR SIZE="5" NOSHADE="NOSHADE" WIDTH="100%">
<P></P>
<CENTER>
<TABLE BORDER="2">
<TR ALIGN="CENTER" VALIGN="MIDDLE">
<TD ALIGN="CENTER" VALIGN="MIDDLE"><B><SMALL><A HREF="ic97.html">BACK TO
MAIN MENU</A></SMALL></B></TD></TR></TABLE></CENTER>
<P></P>
<HR SIZE="10" WIDTH="85%">
<P></P>
<BLOCKQUOTE>
<CENTER>
<P>WEDNESDAY , MAY 21</P>
<P><B>Assemblies on Allergy, Immunology and Inflammation/<BR>Respiratory Cell
and Molecular Biology</B></P>
<P><B>8:15 am-11:00 am</B></P></CENTER></BLOCKQUOTE>
<HR SIZE="4" WIDTH="85%" ALIGN="CENTER" NOSHADE="NOSHADE">
<BLOCKQUOTE>
<P><I><B>Target Audience: </B></I>Clinicians and investigators interested in
understanding the pathophysiology of airway inflammation and potential
strategies for treatment based on the molecular mechanisms of inflammation.</P>
<P><B>OBJECTIVES</B><BR>At the conclusion of this session, the participant
will be able to:</P>
<UL>
<LI>describe the responses of airway cells to inflammation;</LI>
<LI>understand the molecular events involved in airway inflammation;</LI>
<LI>define potential therapeutic strategies for treating airway inflammation,
based on the roles of airway cells in the inflammatory process and the molecular
mechanisms of inflammation.</LI></UL>
<P>The purpose of this symposium is to present state-of-the-art information
regarding the response of the airway to inflammation, focusing on the airway
cells and the molecular events mediating the inflammatory process. At the
conclusion of the symposium, the participant should be able to define potential
therapeutic targets in airway inflammation and understand therapeutic strategies
for treating inflammatory disease.</P>
<P><I><B>Chairing: </B></I>J.H. Shelhamer, M.D., Bethesda, MDJ. Moss, M.D.,
Ph.D., Bethesda, MD</P>
<P><I>8:15</I> <B>Cyclic Nucleotide Phosphodiesterase Isoforms in
Inflammatory Cells</B>/V.C. Manganiello, M.D., Ph.D., Bethesda, MD</P>
<P><I>8:35</I> <B>Lipoxygenases, Lipoxygenase Pathway Products, and Receptors</B>/J.M.
Drazen, M.D., Boston, MA</P>
<P><I>9:00</I> <B>Nitric Oxide-Dependent Signaling Processes in Airway
Inflammation</B>/J.S. Stamler, M.D., Durham, NC</P>
<P><I>9:25</I> <B>Cytokines and Cytokine Receptors</B>/J. Gauldie, Ph.D.,
Hamilton, ON, Canada</P>
<P><I>9:50</I> <B>Protein-Linked Receptors in Airway Inflammation</B>/S.B.
Liggett, M.D., Cincinnati, OH</P>
<P><I>10:15</I> <B>Proteases As Mediators of Airway Inflammation</B>/M.L.
Brantly, M.D., Bethesda, MS</P>
<P><I>10:35</I> <B>Antioxidants in Airway Inflammation</B>/J.D. Crapo, M.D.,
Denver, CO</P></BLOCKQUOTE>
<P></P>
<HR SIZE="4" WIDTH="80%">
<CENTER>
<P><A HREF=97ala.html><IMG
SRC=images/activity_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97bus.html><IMG
SRC=images/business_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97cal.html><IMG
SRC=images/calendar_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97child.html><IMG
SRC=images/child_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=pg.html><IMG
SRC=images/courses_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=search.html><IMG
SRC=images/search_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=main.html><IMG
SRC=images/home_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97house.html><IMG
SRC=images/house_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=http://itsmtgs.com/ala-ats><IMG
SRC=images/regist_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=sessions.html><IMG
SRC=images/session_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=special.html><IMG
SRC=images/special_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97tours.html><IMG
SRC=images/tour_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97travel.html><IMG
SRC=images/travel_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
</P></CENTER>
<HR SIZE="4" WIDTH="80%">
<CENTER><FONT SIZE="+2"><B><I>American Thoracic Society</I></B></FONT><BR>
1740 Broadway<BR> New York, NY 10019<BR> VOICE:  212-315-8700<BR> Copyright &copy;
1996 American Lung Association.<BR> The American Thoracic  Society is the
medical section <BR>of the American Lung Association.<BR> 
</CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-149</DOCNO>
<DOCOLDNO>IA013-000141-B024-243</DOCOLDNO>
<DOCHDR>
http://www.thoracic.org:80/ic97/d54.html 206.138.195.144 19970217073024 text/html 4289
HTTP/1.0 200 OK
Date: Monday, 17-Feb-97 07:25:42 GMT
Server: NCSA/1.3
MIME-version: 1.0
Content-type: text/html
Last-modified: Friday, 24-Jan-97 16:15:47 GMT
Content-length: 4109
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//SQ//DTD HTML 2.0 HoTMetaL + extensions//EN">
<HTML>
<HEAD>
<TITLE>SYMPOSIUM: d54</TITLE></HEAD>
<BODY BGCOLOR="#FFFFFF">
<CENTER><IMG ALIGN="LEFT" SRC="images/banner0.jpg"></CENTER>
<CENTER><BR>
<P>SYMPOSIUM</P><BR>
<H2>D54: GENETIC BASIS OF PULMONARY DISEASE</H2></CENTER>
<HR SIZE="5" NOSHADE="NOSHADE" WIDTH="100%">
<P></P>
<CENTER>
<TABLE BORDER="2">
<TR ALIGN="CENTER" VALIGN="MIDDLE">
<TD ALIGN="CENTER" VALIGN="MIDDLE"><B><SMALL><A HREF="ic97.html">BACK TO
MAIN MENU</A></SMALL></B></TD></TR></TABLE></CENTER>
<P></P>
<HR SIZE="10" WIDTH="85%">
<P></P>
<BLOCKQUOTE>
<CENTER>
<P>WEDNESDAY , MAY 21</P>
<P><B>Assemblies on Pediatrics/<BR>Respiratory Cell and Molecular Biology</B></P>
<P><B>1:30 pm-4:15 pm</B></P></CENTER></BLOCKQUOTE>
<HR SIZE="4" WIDTH="85%" ALIGN="CENTER" NOSHADE="NOSHADE">
<BLOCKQUOTE>
<P><I><B>Target Audience: </B></I>Pediatric pulmonologists, neonatologists,
basic scientists, pulmonologists, and pathologists.</P>
<P><B>OBJECTIVES</B><BR>At the conclusion of this session, the participant
will be able to:</P>
<UL>
<LI>understand the contribution of genetics on the manifestations of
respiratory pathology;</LI>
<LI>explore the effect of genotype on severity and susceptibility to
respiratory disease;</LI>
<LI>promote research in this area and possibly identify other respiratory
illnesses with genetic etiologies.</LI></UL>
<P>With newer technologies, observations with transgenic mice and a better
understanding of the human genome, several respiratory diseases have been
recognized as having a genetic etiology. A discussion of these conditions and
their genetic manifestations could allow for insight into therapeutic and
preventative strategies to enhance present day management.</P>
<P><I><B>Chairing: </B></I>P.A. Dennery, M.D., Palo Alto, CAJ. Floros, Ph.D.,
Hershey, PA</P>
<P><I>1:30</I> <B>Challenges and Approaches to the Study of Complex Traits</B>/J.
Floros, Ph.D., Hershey, PA</P>
<P><I>1:50</I> <B>Genetic Background As a Risk Factor for the Development of
Asthma</B>/S.R. Kleeberger, Ph.D., Baltimore, MD</P>
<P><I>2:20</I> <B>Alveolar Proteinosis: Lesson from Transgenic Mice</B>/W.A.
Jeffrey, M.D., Cincinnatti, OH</P>
<P><I>2:50</I> <B>Surfactant Deficiency Syndromes</B>/L.M. Nogee, Baltimore,
MD</P>
<P><I>3:20</I> <B>Genetic Factors in the Severity of Cystic Fibrosis</B>/<I>Speaker
to be announced</I></P>
<P><I>3:45</I> <B>Genetic Resistance to Pulmonary Infection: Lessons from
Murine Models</B>/M.F. Lipscomb, M.D., Albuquerque, NM</P>
<P>Discussion after each presentation/5 minutes</P></BLOCKQUOTE>
<P></P>
<HR SIZE="4" WIDTH="80%">
<CENTER>
<P><A HREF=97ala.html><IMG
SRC=images/activity_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97bus.html><IMG
SRC=images/business_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97cal.html><IMG
SRC=images/calendar_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97child.html><IMG
SRC=images/child_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=pg.html><IMG
SRC=images/courses_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=search.html><IMG
SRC=images/search_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=main.html><IMG
SRC=images/home_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97house.html><IMG
SRC=images/house_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=http://itsmtgs.com/ala-ats><IMG
SRC=images/regist_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=sessions.html><IMG
SRC=images/session_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=special.html><IMG
SRC=images/special_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97tours.html><IMG
SRC=images/tour_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97travel.html><IMG
SRC=images/travel_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
</P></CENTER>
<HR SIZE="4" WIDTH="80%">
<CENTER><FONT SIZE="+2"><B><I>American Thoracic Society</I></B></FONT><BR>
1740 Broadway<BR> New York, NY 10019<BR> VOICE:  212-315-8700<BR> Copyright &copy;
1996 American Lung Association.<BR> The American Thoracic  Society is the
medical section <BR>of the American Lung Association.<BR> 
</CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-150</DOCNO>
<DOCOLDNO>IA013-000141-B024-283</DOCOLDNO>
<DOCHDR>
http://www.thoracic.org:80/ic97/a12.html 206.138.195.144 19970217073043 text/html 4725
HTTP/1.0 200 OK
Date: Monday, 17-Feb-97 07:25:58 GMT
Server: NCSA/1.3
MIME-version: 1.0
Content-type: text/html
Last-modified: Friday, 24-Jan-97 16:14:54 GMT
Content-length: 4545
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//SQ//DTD HTML 2.0 HoTMetaL + extensions//EN">
<HTML>
<HEAD>
<TITLE>SYMPOSIUM: a12</TITLE></HEAD>
<BODY BGCOLOR="#FFFFFF">
<CENTER><IMG ALIGN="LEFT" SRC="images/banner0.jpg"></CENTER>
<CENTER><BR>
<P>SYMPOSIUM</P><BR>
<H2>A12: THE PRACTICAL POLITICS OF INTERNATIONAL TOBACCO CONTROL: A NUMBER OF
EFFECTIVE STRATEGIES TO CHANGE SMOKING BEHAVIOR AT THE COMMUNITY LEVEL</H2></CENTER>
<HR SIZE="5" NOSHADE="NOSHADE" WIDTH="100%">
<P></P>
<CENTER>
<TABLE BORDER="2">
<TR ALIGN="CENTER" VALIGN="MIDDLE">
<TD ALIGN="CENTER" VALIGN="MIDDLE"><B><SMALL><A HREF="ic97.html">BACK TO
MAIN MENU</A></SMALL></B></TD></TR></TABLE></CENTER>
<P></P>
<HR SIZE="10" WIDTH="85%">
<P></P>
<CENTER>
<P>SUNDAY , MAY 18</P></CENTER>
<BLOCKQUOTE>
<P><B>Assemblies on Behavioral Science/Environmental and Occupational
Health/Clinical Problems/Nursing</B></P>
<P><B>8:15 am-11:00 am</B></P></BLOCKQUOTE>
<HR SIZE="4" WIDTH="85%" ALIGN="CENTER" NOSHADE="NOSHADE">
<BLOCKQUOTE>
<P><I><B>Target Audience: </B></I>Clinicians and researchers interested in
tobacco control policies and Lung Association volunteers and staff.</P>
<P><B>OBJECTIVES</B><BR>At the conclusion of this session, the participant
will be able to:</P>
<UL>
<LI>understand the significant issues in international and national tobacco
control;</LI>
<LI>describe the role of litigation in the battle against tobacco;</LI>
<LI>understand the impact of tobacco marketing on international smoking
prevalence;</LI>
<LI>describe how the U.S. trade policies influence international tobacco
marketing.</LI></UL>
<P>Changing the social environment of smoking through legislation, public
health efforts, and mass media has been shown to effect rates of smoking and
smoking initiation. In addition, public policies which prohibit or restrict
smoking reduces the exposure of non-smokers to environmental tobacco smoke.
Tobacco advertising has been a key focus of many smoking control interventions.
Understanding the international marketing strategies of tobacco companies is key
to preventing the increased prevalence of smoking in developing countries. The
issues, strategies and success of community-level tobacco control will be
discussed from an international perspective.</P>
<P><I><B>Chairing: </B></I>J.M. Samet, M.D., Baltimore, MDC.S. Rand, Ph.D.,
Baltimore, MD</P>
<P><I>8:15</I> <B>Introduction</B>/C.S. Rand, Ph.D., Baltimore, MD/J.M.
Samet, M.D., Baltimore, MD</P>
<P><I>8:20</I> <B>The Global March of the Marlboro Man: Where's He Going,
What's He Doing, and How Do We Stop Him?</B>/R.M. Davis, M.D., Lansing, MI</P>
<P><I>9:00</I> <B>From Sea to Shining Sea: On the Front Lines of America's
Tobacco Wars</B>/F. Stillman, Bethesda, MD</P>
<P><I>9:40</I> <B>The Tobacco Epidemic in 2025</B>/J. Mackay, Ph.D., Sai
Kung, Kowloon, Hong Kong</P>
<P><I>10:20</I> <B>From Steppe to Veldt: The Tobacco War in Europe and Africa</B>/D.
Simpson, London, England</P>
<P><I>10:50</I> <I>Discussion</I></P>
<P>Discussion after each presentation/10 minutes</P></BLOCKQUOTE>
<P></P>
<HR SIZE="4" WIDTH="80%">
<CENTER>
<P><A HREF=97ala.html><IMG
SRC=images/activity_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97bus.html><IMG
SRC=images/business_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97cal.html><IMG
SRC=images/calendar_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97child.html><IMG
SRC=images/child_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=pg.html><IMG
SRC=images/courses_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=search.html><IMG
SRC=images/search_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=main.html><IMG
SRC=images/home_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97house.html><IMG
SRC=images/house_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=http://itsmtgs.com/ala-ats><IMG
SRC=images/regist_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=sessions.html><IMG
SRC=images/session_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=special.html><IMG
SRC=images/special_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97tours.html><IMG
SRC=images/tour_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97travel.html><IMG
SRC=images/travel_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
</P></CENTER>
<HR SIZE="4" WIDTH="80%">
<CENTER><FONT SIZE="+2"><B><I>American Thoracic Society</I></B></FONT><BR>
1740 Broadway<BR> New York, NY 10019<BR> VOICE:  212-315-8700<BR> Copyright &copy;
1996 American Lung Association.<BR> The American Thoracic  Society is the
medical section <BR>of the American Lung Association.<BR> 
</CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-151</DOCNO>
<DOCOLDNO>IA013-000141-B024-321</DOCOLDNO>
<DOCHDR>
http://www.thoracic.org:80/ic97/c13.html 206.138.195.144 19970217073053 text/html 5150
HTTP/1.0 200 OK
Date: Monday, 17-Feb-97 07:26:09 GMT
Server: NCSA/1.3
MIME-version: 1.0
Content-type: text/html
Last-modified: Friday, 24-Jan-97 16:15:27 GMT
Content-length: 4970
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//SQ//DTD HTML 2.0 HoTMetaL + extensions//EN">
<HTML>
<HEAD>
<TITLE>SYMPOSIUM: c13</TITLE></HEAD>
<BODY BGCOLOR="#FFFFFF">
<CENTER><IMG ALIGN="LEFT" SRC="images/banner0.jpg"></CENTER>
<CENTER><BR>
<P>SYMPOSIUM</P><BR>
<H2>C13: HOW CAN CLINICIANS FOSTER SELF-MANAGEMENT IN THEIR PATIENTS?</H2></CENTER>
<HR SIZE="5" NOSHADE="NOSHADE" WIDTH="100%">
<P></P>
<CENTER>
<TABLE BORDER="2">
<TR ALIGN="CENTER" VALIGN="MIDDLE">
<TD ALIGN="CENTER" VALIGN="MIDDLE"><B><SMALL><A HREF="ic97.html">BACK TO
MAIN MENU</A></SMALL></B></TD></TR></TABLE></CENTER>
<P></P>
<HR SIZE="10" WIDTH="85%">
<P></P>
<BLOCKQUOTE>
<CENTER>
<P>TUESDAY , MAY 20</P>
<P><B>Assemblies on Behavioral Science/Pediatrics/<BR>Clinical
Problems/Nursing/American Lung Association</B></P>
<P><B>8:15 am-11:00 am</B></P></CENTER></BLOCKQUOTE>
<HR SIZE="4" WIDTH="85%" ALIGN="CENTER" NOSHADE="NOSHADE">
<BLOCKQUOTE>
<P><I><B>Target Audience: </B></I>Physicians, nurses, and other health care
professionals who treat patients with lung disease, clinical and behavioral
researchers concerned with the quality and outcomes of care, and Lung
Association volunteers and staff.</P>
<P><B>OBJECTIVES</B><BR>At the conclusion of this session, the participant
will be able to:</P>
<UL>
<LI>identify communications skills and educational strategies to use during
clinical encounters to increase the ability of patients and their families to
successfully manage chronic illness;</LI>
<LI>recognize common barriers to clinician-patient communication and how to
overcome these obstacles;</LI>
<LI>resolve to try one or more strategies learned during the session in
clinical practice;</LI>
<LI>consider conducting research to advance our understanding of how clinicians
can help patients improve their self-management skills.</LI></UL>
<P>This session will feature new research on strategies clinicians can use
during regular clinical contacts to improve patient self-management of chronic
illness. These new approaches include studies of communication skills clinicians
can use to build partnerships with patients and of educational strategies to
develop patients' confidence and skill to manage ongoing medical problems.
Presentations will describe interventions to train clinicians to employ these
strategies and reports of the impact of these strategies on patient behavior.</P>
<P><I><B>Chairing: </B></I>R.B. Mellins, M.D., New York, NY</P>
<P><I>8:15</I> <B>The Impact of Community Pediatricians' Use of
Communications Skills and Patient Education on Family Management of Asthma</B>/N.M.
Clark, Ph.D., Ann Arbor, MI</P>
<P><I>8:35</I> <B>Motivating and Assisting Physicians to Provide and Support
Asthma Self-Management Education: Lessons from a Community Demonstration in
Fresno, California</B>/S.R. Wilson, Ph.D., Palo Alto, CA</P>
<P><I>8:55</I> <B>The Impact of Patient Teaching by Physicians on Family
Preventive Behavior and Management of Acute Episodes of Asthma</B>/D. Evans,
Ph.D., New York, NY</P>
<P><I>9:15</I> <B>The Use of Educationally Influential Physicians to Change
Community Practitioner Behavior</B>/J. Stross, M.D., Ann Arbor, MI</P>
<P><I>9:35</I> <B>Doctor-Patient Participation in Developing a Personalized
Asthma Self-Regulation Regimen</B>/B.J. Zimmerman, Ph.D., New York, NY</P>
<P><I>9:55</I> <B>Communications Strategies for Improving Self-Management</B>/R.M.
Frankel, Ph.D., Rochester, NY</P>
<P><I>10:45</I> <I>Discussion</I></P></BLOCKQUOTE>
<P></P>
<HR SIZE="4" WIDTH="80%">
<CENTER>
<P><A HREF=97ala.html><IMG
SRC=images/activity_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97bus.html><IMG
SRC=images/business_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97cal.html><IMG
SRC=images/calendar_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97child.html><IMG
SRC=images/child_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=pg.html><IMG
SRC=images/courses_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=search.html><IMG
SRC=images/search_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=main.html><IMG
SRC=images/home_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97house.html><IMG
SRC=images/house_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=http://itsmtgs.com/ala-ats><IMG
SRC=images/regist_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=sessions.html><IMG
SRC=images/session_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=special.html><IMG
SRC=images/special_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97tours.html><IMG
SRC=images/tour_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97travel.html><IMG
SRC=images/travel_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
</P></CENTER>
<HR SIZE="4" WIDTH="80%">
<CENTER><FONT SIZE="+2"><B><I>American Thoracic Society</I></B></FONT><BR>
1740 Broadway<BR> New York, NY 10019<BR> VOICE:  212-315-8700<BR> Copyright &copy;
1996 American Lung Association.<BR> The American Thoracic  Society is the
medical section <BR>of the American Lung Association.<BR> 
</CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-152</DOCNO>
<DOCOLDNO>IA013-000141-B025-21</DOCOLDNO>
<DOCHDR>
http://www.thoracic.org:80/ic97/c54.html 206.138.195.144 19970217073103 text/html 4707
HTTP/1.0 200 OK
Date: Monday, 17-Feb-97 07:26:18 GMT
Server: NCSA/1.3
MIME-version: 1.0
Content-type: text/html
Last-modified: Friday, 24-Jan-97 16:15:32 GMT
Content-length: 4527
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//SQ//DTD HTML 2.0 HoTMetaL + extensions//EN">
<HTML>
<HEAD>
<TITLE>SYMPOSIUM: c54</TITLE></HEAD>
<BODY BGCOLOR="#FFFFFF">
<CENTER><IMG ALIGN="LEFT" SRC="images/banner0.jpg"></CENTER>
<CENTER><BR>
<P>SYMPOSIUM</P><BR>
<H2>C54: NATIONAL ASTHMA EDUCATION AND PREVENTION PROGRAM: EXPERT PANEL
GUIDELINES UPDATE REPORT</H2></CENTER>
<HR SIZE="5" NOSHADE="NOSHADE" WIDTH="100%">
<P></P>
<CENTER>
<TABLE BORDER="2">
<TR ALIGN="CENTER" VALIGN="MIDDLE">
<TD ALIGN="CENTER" VALIGN="MIDDLE"><B><SMALL><A HREF="ic97.html">BACK TO
MAIN MENU</A></SMALL></B></TD></TR></TABLE></CENTER>
<P></P>
<HR SIZE="10" WIDTH="85%">
<P></P>
<BLOCKQUOTE>
<CENTER>
<P>TUESDAY , MAY 20</P>
<P><B>Division of Lung Diseases/<BR>National Heart, Lung, and Blood Institute</B></P>
<P><B>3:15 PM&#151;6:00 PM</B></P></CENTER></BLOCKQUOTE>
<HR SIZE="4" WIDTH="85%" ALIGN="CENTER" NOSHADE="NOSHADE">
<BLOCKQUOTE>
<P><I><B>Target Audience: </B></I>Clinicians, health educators and research
scientists interested in asthma management.</P>
<P><B>OBJECTIVES</B><BR>At the conclusion of this session, the participant
will be able to:</P>
<UL>
<LI>describe the objectives of the NAEPP Expert Panel Report on Asthma
Management and the process used to develop this document;</LI>
<LI>describe recommendations for measures of assessment and factors
contributing to asthma severity;</LI>
<LI>describe recommendations for chronic and acute management of asthma;</LI>
<LI>describe recommendations for education of patients through building a
partnership for asthma;</LI>
<LI>describe differences in this updated document from the 1991 Expert Panel
Report.</LI></UL>
<P>The National Asthma Education and Prevention Program (NAEPP) has updated the
Expert Panel Report: Guidelines for the Diagnosis and Management of Asthma,
published in 1991, to reflect recent scientific findings, availability of new
medications, and experience implementing the recommendations of the original
report. This session will discuss the major recommendations of the Expert Panel
Report II and the processes used to develop them.</P>
<P><I><B>Chairing: </B></I>C. Lenfant, M.D., Bethesda, MDS.A. Murphy, M.D.,
Albuquerque, NM</P>
<P><I>3:15</I> <B>Introduction: NAEPP Expert Panel Guidelines Update</B>/C.
Lenfant, M.D., Bethesda, MD</P>
<P><I>3:25</I> <B>Expert Panel Update: Summary Recommendations</B>/S.A.
Murphy, M.D., Albuquerque, NM</P>
<P><I>3:35</I> <B>Measures of Assessment: Diagnosis and Monitoring</B>/A.
Buist, M.D., Portland, OR</P>
<P><I>4:00</I> <B>Education for a Partnership in Asthma Care</B>/S. Janson,
Ph.D., San Francisco, CA</P>
<P><I>4:20</I> <B>Factors Contributing to Asthma Severity</B>/H.S. Nelson,
M.D., Denver, CO</P>
<P><I>4:40</I> <B>Pharmacotherapy: Long-Term Management of Asthma</B>/W.W.
Busse, M.D., Madison, WI</P>
<P><I>5:20</I> <B>Managing Acute Exacerbations of Asthma</B>/H.A. Boushey,
M.D., San Francisco, CA</P>
<P><I>5:40</I> <B>Summary and Discussion</B>/S.A. Murphy, M.D., Albuquerque,
NM</P></BLOCKQUOTE>
<P></P>
<HR SIZE="4" WIDTH="80%">
<CENTER>
<P><A HREF=97ala.html><IMG
SRC=images/activity_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97bus.html><IMG
SRC=images/business_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97cal.html><IMG
SRC=images/calendar_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97child.html><IMG
SRC=images/child_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=pg.html><IMG
SRC=images/courses_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=search.html><IMG
SRC=images/search_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=main.html><IMG
SRC=images/home_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97house.html><IMG
SRC=images/house_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=http://itsmtgs.com/ala-ats><IMG
SRC=images/regist_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=sessions.html><IMG
SRC=images/session_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=special.html><IMG
SRC=images/special_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97tours.html><IMG
SRC=images/tour_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97travel.html><IMG
SRC=images/travel_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
</P></CENTER>
<HR SIZE="4" WIDTH="80%">
<CENTER><FONT SIZE="+2"><B><I>American Thoracic Society</I></B></FONT><BR>
1740 Broadway<BR> New York, NY 10019<BR> VOICE:  212-315-8700<BR> Copyright &copy;
1996 American Lung Association.<BR> The American Thoracic  Society is the
medical section <BR>of the American Lung Association.<BR> 
</CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-153</DOCNO>
<DOCOLDNO>IA013-000141-B025-63</DOCOLDNO>
<DOCHDR>
http://www.thoracic.org:80/ic97/d7.html 206.138.195.144 19970217073115 text/html 4831
HTTP/1.0 200 OK
Date: Monday, 17-Feb-97 07:26:31 GMT
Server: NCSA/1.3
MIME-version: 1.0
Content-type: text/html
Last-modified: Friday, 24-Jan-97 16:15:50 GMT
Content-length: 4651
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//SQ//DTD HTML 2.0 HoTMetaL + extensions//EN">
<HTML>
<HEAD>
<TITLE>SYMPOSIUM: d7</TITLE></HEAD>
<BODY BGCOLOR="#FFFFFF">
<CENTER><IMG ALIGN="LEFT" SRC="images/banner0.jpg"></CENTER>
<CENTER><BR>
<P>SYMPOSIUM</P><BR>
<H2>D7: STRESS AND ASTHMA: EMERGING LINE OF EVIDENCE</H2></CENTER>
<HR SIZE="5" NOSHADE="NOSHADE" WIDTH="100%">
<P></P>
<CENTER>
<TABLE BORDER="2">
<TR ALIGN="CENTER" VALIGN="MIDDLE">
<TD ALIGN="CENTER" VALIGN="MIDDLE"><B><SMALL><A HREF="ic97.html">BACK TO
MAIN MENU</A></SMALL></B></TD></TR></TABLE></CENTER>
<P></P>
<HR SIZE="10" WIDTH="85%">
<P></P>
<BLOCKQUOTE>
<CENTER>
<P>WEDNESDAY , MAY 21</P>
<P><B>Assemblies on Behavioral Science/<BR>Allergy, Inflammation and
Immunology/<BR>Clinical Problems/Environmental and Occupational Health/<BR>Nursing/American
Lung Association</B></P>
<P><B>8:15 am-11:00 am</B></P></CENTER></BLOCKQUOTE>
<HR SIZE="4" WIDTH="85%" ALIGN="CENTER" NOSHADE="NOSHADE">
<BLOCKQUOTE>
<P><I><B>Target Audience: </B></I>Physicians, other health care providers,
clinical, biomedical and behavioral researchers.</P>
<P><B>OBJECTIVES</B><BR>At the conclusion of this session, the participant
will be able to:</P>
<UL>
<LI>identify stressors which are related to markers of inflammation;</LI>
<LI>identify family factors which predict the onset of respiratory symptoms and
asthma in children;</LI>
<LI>identify stressors associated with asthma prevalence in adults;</LI>
<LI>describe how biofeedback can be used to treat asthmatic patients.</LI></UL>
<P>Evidence for a causal link between stress and asthma has been intriguing but
incomplete. It is only recently that a body of rigorous clinical, behavioral and
epidemiolgic research is converging to illuminate the multiple psychological,
social and physiologic mechanisms through which stress affects asthma. This
symposium will bring together investigators from the fields of allergy,
immunology, psychology, epidemiology and pediatrics conducting state-of-the-art
research on the role of stressors and emotions to asthma incidence, severity and
health care utilization among children and adults.</P>
<P><I><B>Chairing: </B></I>B.G. Bender, Ph.D., Denver, COD. McLean, Ph.D.,
New York, NY</P>
<P><I>8:15</I> <B>Potential Relationship Between Stress and Allergic
Inflammation</B>/W.W. Busse, M.D., Madison, WI</P>
<P><I>8:35</I> <B>Stressors, Depression and Physiologic Response Among Adults
with Asthma in a Minority Community</B>/D. McLean, Ph.D., New York, NY</P>
<P><I>8:55</I> <B>Family Stress and Asthma in a Birth Cohort of Young
Children</B>/M. Klinnert, Ph.D., Denver, CO</P>
<P><I>9:30</I> <B>Stress and Its Influence on Wheezing and Asthma Incidence
in a Cohort of Children of Atopic Parents</B>/D.R. Gold, M.D., M.P.H., Boston,
MA/R.J. Wright, M.D., Boston, MA</P>
<P><I>9:50</I> <B>Stress Management and Biofeedback Methods in Treating
Asthma</B>/P. Lehrer, Ph.D., Piscataway, NJ</P>
<P><I>10:10</I> <B>Stress and Asthma: Where Do We Go from Here?</B>/L.
Underwood-Gordon, Ph.D., Kalamazoo, MI</P>
<P><I>10:30</I> <I>Discussion</I></P>
<P>Discussion after each presentation/5 minutes</P></BLOCKQUOTE>
<P></P>
<HR SIZE="4" WIDTH="80%">
<CENTER>
<P><A HREF=97ala.html><IMG
SRC=images/activity_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97bus.html><IMG
SRC=images/business_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97cal.html><IMG
SRC=images/calendar_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97child.html><IMG
SRC=images/child_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=pg.html><IMG
SRC=images/courses_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=search.html><IMG
SRC=images/search_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=main.html><IMG
SRC=images/home_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97house.html><IMG
SRC=images/house_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=http://itsmtgs.com/ala-ats><IMG
SRC=images/regist_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=sessions.html><IMG
SRC=images/session_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=special.html><IMG
SRC=images/special_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97tours.html><IMG
SRC=images/tour_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97travel.html><IMG
SRC=images/travel_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
</P></CENTER>
<HR SIZE="4" WIDTH="80%">
<CENTER><FONT SIZE="+2"><B><I>American Thoracic Society</I></B></FONT><BR>
1740 Broadway<BR> New York, NY 10019<BR> VOICE:  212-315-8700<BR> Copyright &copy;
1996 American Lung Association.<BR> The American Thoracic  Society is the
medical section <BR>of the American Lung Association.<BR> 
</CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-154</DOCNO>
<DOCOLDNO>IA013-000141-B025-99</DOCOLDNO>
<DOCHDR>
http://www.thoracic.org:80/ic97/a14.html 206.138.195.144 19970217073137 text/html 4560
HTTP/1.0 200 OK
Date: Monday, 17-Feb-97 07:26:53 GMT
Server: NCSA/1.3
MIME-version: 1.0
Content-type: text/html
Last-modified: Friday, 24-Jan-97 16:14:54 GMT
Content-length: 4380
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//SQ//DTD HTML 2.0 HoTMetaL + extensions//EN">
<HTML>
<HEAD>
<TITLE>SYMPOSIUM: a14</TITLE></HEAD>
<BODY BGCOLOR="#FFFFFF">
<CENTER><IMG ALIGN="LEFT" SRC="images/banner0.jpg"></CENTER>
<CENTER><BR>
<P>SYMPOSIUM</P><BR>
<H2>A14: IMPLEMENTATION AND UTILIZATION OF CLINICAL PRACTICE GUIDELINES FOR
LUNG DISEASE</H2></CENTER>
<HR SIZE="5" NOSHADE="NOSHADE" WIDTH="100%">
<P></P>
<CENTER>
<TABLE BORDER="2">
<TR ALIGN="CENTER" VALIGN="MIDDLE">
<TD ALIGN="CENTER" VALIGN="MIDDLE"><B><SMALL><A HREF="ic97.html">BACK TO
MAIN MENU</A></SMALL></B></TD></TR></TABLE></CENTER>
<P></P>
<HR SIZE="10" WIDTH="85%">
<P></P>
<CENTER>
<P>SUNDAY , MAY 18</P></CENTER>
<BLOCKQUOTE>
<P><B>Assemblies on Nursing/Clinical Problems/Critical Care</B></P>
<P><B>8:15 am-11:00 am</B></P></BLOCKQUOTE>
<HR SIZE="4" WIDTH="85%" ALIGN="CENTER" NOSHADE="NOSHADE">
<BLOCKQUOTE>
<P><I><B>Target Audience: </B></I>Nurses, physicians, respiratory therapists,
health care administrators, and others who are interested in implementation and
utilization of Clinical Practice Guidelines.</P>
<P><B>OBJECTIVES</B><BR>At the conclusion of this session, the participant
will be able to:</P>
<UL>
<LI>describe the scientific basis of Clinical Practice Guidelines (CPG's) for
lung disease;</LI>
<LI>describe implementation and utilization of CPG's;</LI>
<LI>debate clinical and cost benefits of CPG's for asthma, COPD, pneumonia, and
mechanical ventilation.</LI></UL>
<P>CPG's are being developed and implemented in clinical practice settings with
increasing frequency. They are particularly attractive to managed care
organizations that strive to improve outcomes and patient satisfaction while
controlling costs. However, few studies have documented reduced cost and
improved quality of care by using CPG's. The objectives of this symposium are to
describe the scientific basis of CPG's and to discuss their implementation,
utilization, and effectiveness.</P>
<P><I><B>Chairing: </B></I>J.R. Turner, M.S., R.N., San Francisco, CAJ.M.
Luce, M.D., San Francisco, CA</P>
<P><I>8:15</I> <B>Scientific Basis of CPG's</B>/A.H. Morris, M.D., Salt Lake
City, UT</P>
<P><I>8:40</I> <B>Strategies for Implementation and Utilization of CPG's</B>/M.G.
Titler, R.N., Ph.D., Iowa City, IA</P>
<P><I>9:05</I> <B>CPG's for Care of the Patient with Asthma</B>/A.A. Large,
R.N., M.S.N., Pittsburgh, PA</P>
<P><I>9:30</I> <B>CPG's for Care of the Patient with COPD</B>/G.L. Narsavage,
R.N.C.S., Ph.D., Scranton, PA</P>
<P><I>9:55</I> <B>CPG's for Treatment of Pneumonia</B>/N.C. Dean, M.D., Salt
Lake City, UT</P>
<P><I>10:20</I> <B>CPG's for Sedation, Paralysis for ARDS</B>/T.P. Clemmer,
M.D., Salt Lake City, UT</P>
<P><I>10:45</I> <B>Do CPG's Reduce Cost and Improve Quality of Care?</B>/J.M.
Luce, M.D., San Francisco, CA</P>
<P>Discussion after each presentation/5 minutes</P></BLOCKQUOTE>
<P></P>
<HR SIZE="4" WIDTH="80%">
<CENTER>
<P><A HREF=97ala.html><IMG
SRC=images/activity_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97bus.html><IMG
SRC=images/business_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97cal.html><IMG
SRC=images/calendar_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97child.html><IMG
SRC=images/child_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=pg.html><IMG
SRC=images/courses_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=search.html><IMG
SRC=images/search_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=main.html><IMG
SRC=images/home_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97house.html><IMG
SRC=images/house_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=http://itsmtgs.com/ala-ats><IMG
SRC=images/regist_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=sessions.html><IMG
SRC=images/session_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=special.html><IMG
SRC=images/special_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97tours.html><IMG
SRC=images/tour_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97travel.html><IMG
SRC=images/travel_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
</P></CENTER>
<HR SIZE="4" WIDTH="80%">
<CENTER><FONT SIZE="+2"><B><I>American Thoracic Society</I></B></FONT><BR>
1740 Broadway<BR> New York, NY 10019<BR> VOICE:  212-315-8700<BR> Copyright &copy;
1996 American Lung Association.<BR> The American Thoracic  Society is the
medical section <BR>of the American Lung Association.<BR> 
</CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-155</DOCNO>
<DOCOLDNO>IA013-000141-B025-138</DOCOLDNO>
<DOCHDR>
http://www.thoracic.org:80/ic97/a63.html 206.138.195.144 19970217073155 text/html 4343
HTTP/1.0 200 OK
Date: Monday, 17-Feb-97 07:27:11 GMT
Server: NCSA/1.3
MIME-version: 1.0
Content-type: text/html
Last-modified: Friday, 24-Jan-97 16:15:01 GMT
Content-length: 4163
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//SQ//DTD HTML 2.0 HoTMetaL + extensions//EN">
<HTML>
<HEAD>
<TITLE>ALA/ERS: a63</TITLE></HEAD>
<BODY BGCOLOR="#FFFFFF">
<CENTER><IMG ALIGN="LEFT" SRC="images/banner0.jpg"></CENTER>
<CENTER><BR>
<TABLE BORDER="0" ALIGN="CENTER" VALIGN="MIDDLE">
<TR>
<TD ALIGN="CENTER" VALIGN="MIDDLE"><IMG SRC="images/smlogo.gif"><BR>AMERICAN
THORACIC SOCIETY</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE"><IMG SRC="images/litenlog2.gif">
<BR>EUROPEAN RESPIRATORY SOCIETY</TD></TR></TABLE><BR>
<H2>A63: TREATMENT OF COPD: A FUTURISTIC APPROACH</H2></CENTER>
<HR SIZE="5" NOSHADE="NOSHADE" WIDTH="100%">
<P></P>
<CENTER>
<TABLE BORDER="2">
<TR ALIGN="CENTER" VALIGN="MIDDLE">
<TD ALIGN="CENTER" VALIGN="MIDDLE"><B><SMALL><A HREF="ic97.html">BACK TO
MAIN MENU</A></SMALL></B></TD></TR></TABLE></CENTER>
<P></P>
<HR SIZE="10" WIDTH="85%">
<P></P>
<CENTER>
<P>SUNDAY , MAY 18</P></CENTER>
<BLOCKQUOTE>
<P><B>1:30 pm-4:15 pm</B></P></BLOCKQUOTE>
<HR SIZE="4" WIDTH="85%" ALIGN="CENTER" NOSHADE="NOSHADE">
<BLOCKQUOTE>
<P><I><B>Target Audience: </B></I>Clinicians.</P>
<P><B>OBJECTIVES</B><BR>At the conclusion of this session, the participant
will be able to:</P>
<UL>
<LI>define the use of pulmonary rehabiliation in the treatment of COPD;</LI>
<LI>describe the effects of bronchodilators in COPD;</LI>
<LI>describe the side effects of corticosteroids in COPD;</LI>
<LI>understand the potential for modulation of the pulmonary vascular response;</LI>
<LI>understand the usefulness of lung volume reduction surgery.</LI></UL>
<P>This symposium is directed to the clinician managing patients with
sympthomatic COPD. The topics selected are timely and subject of interest
research and recent advances. It is proposed with a transatlantic view and to be
presented by experts.</P>
<P><I><B>Chairing: </B></I>B.R. Celli, M.D., Wellesley, MAP.M. Calverley,
M.D., Liverpool, England</P>
<P><I>1:30</I> <B>Introduction</B>/B.R. Celli, M.D., Wellesley, MA</P>
<P><I>1:40</I> <B>Rehabilitation: A Consensus Statement</B>/A.L. Ries, M.D.,
M.P.H., San Diego, CA</P>
<P><I>2:00</I> <B>Bronchodilators in COPD: Which, Why and How</B>/P.J. Rees,
M.D., London, England</P>
<P><I>2:25</I> <I>Break</I></P>
<P><I>2:35</I> <B>Corticosteroids: May Be Good for the Airways, but Perhaps
Bad for the Pump</B>/M. Decramer, M.D., Ph.D., Leuven, Belgium</P>
<P><I>3:00</I> <B>Modulating the Pulmonary Vascular Response: Is It Possible?</B>/R.
Rodriguez-Roisin, M.D., Ph.D., Barcelona, Spain</P>
<P><I>3:25</I> <B>Lung Volume Reduction: A Pulmonologist Perspective</B>/F.
Martinez, M.D., Ann Arbor, MI</P>
<P>Discussion after each presentation/5 minutes</P></BLOCKQUOTE>
<P></P>
<HR SIZE="4" WIDTH="80%">
<CENTER>
<P><A HREF=97ala.html><IMG
SRC=images/activity_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97bus.html><IMG
SRC=images/business_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97cal.html><IMG
SRC=images/calendar_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97child.html><IMG
SRC=images/child_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=pg.html><IMG
SRC=images/courses_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=search.html><IMG
SRC=images/search_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=main.html><IMG
SRC=images/home_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97house.html><IMG
SRC=images/house_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=http://itsmtgs.com/ala-ats><IMG
SRC=images/regist_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=sessions.html><IMG
SRC=images/session_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=special.html><IMG
SRC=images/special_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97tours.html><IMG
SRC=images/tour_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97travel.html><IMG
SRC=images/travel_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
</P></CENTER>
<HR SIZE="4" WIDTH="80%">
<CENTER><FONT SIZE="+2"><B><I>American Thoracic Society</I></B></FONT><BR>
1740 Broadway<BR> New York, NY 10019<BR> VOICE:  212-315-8700<BR> Copyright &copy;
1996 American Lung Association.<BR> The American Thoracic  Society is the
medical section <BR>of the American Lung Association.<BR> 
</CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-156</DOCNO>
<DOCOLDNO>IA013-000141-B025-164</DOCOLDNO>
<DOCHDR>
http://www.thoracic.org:80/ic97/b14.html 206.138.195.144 19970217073204 text/html 4367
HTTP/1.0 200 OK
Date: Monday, 17-Feb-97 07:27:22 GMT
Server: NCSA/1.3
MIME-version: 1.0
Content-type: text/html
Last-modified: Friday, 24-Jan-97 16:15:12 GMT
Content-length: 4187
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//SQ//DTD HTML 2.0 HoTMetaL + extensions//EN">
<HTML>
<HEAD>
<TITLE> SYMPOSIUM: b14</TITLE></HEAD>
<BODY BGCOLOR="#FFFFFF">
<CENTER><IMG ALIGN="LEFT" SRC="images/banner0.jpg"></CENTER>
<CENTER><BR>
<P> SYMPOSIUM</P><BR>
<H2>B14: CURRENT ISSUES IN PULMONARY REHABILITATION</H2></CENTER>
<HR SIZE="5" NOSHADE="NOSHADE" WIDTH="100%">
<P></P>
<CENTER>
<TABLE BORDER="2">
<TR ALIGN="CENTER" VALIGN="MIDDLE">
<TD ALIGN="CENTER" VALIGN="MIDDLE"><B><SMALL><A HREF="ic97.html">BACK TO
MAIN MENU</A></SMALL></B></TD></TR></TABLE></CENTER>
<P></P>
<HR SIZE="10" WIDTH="85%">
<P></P>
<CENTER>
<P>MONDAY , MAY 19</P></CENTER>
<BLOCKQUOTE>
<P><B>Assemblies on Nursing/Clinical Problems/Behavioral Science</B></P>
<P><B>8:15 am-11:00 am</B></P></BLOCKQUOTE>
<HR SIZE="4" WIDTH="85%" ALIGN="CENTER" NOSHADE="NOSHADE">
<BLOCKQUOTE>
<P><I><B>Target Audience: </B></I>Pulmonary rehabilitation staff, nurses,
respiratory and pulmonary therapists, physicians.</P>
<P><B>OBJECTIVES</B><BR>At the conclusion of this session, the participant
will be able to:</P>
<UL>
<LI>describe strategies that can be utilized to expand services beyond your
current rehabilitation program;</LI>
<LI>define issues and interventions in promoting patient adherence and
motivation for lifestyle changes;</LI>
<LI>discuss ethical implications surrounding rehabilitation for patients with
advanced or endstage lung disease.</LI></UL>
<P>Pulmonary rehabilitation is an integral component of comprehensive COPD
management. In the current era of managed care, pulmonary rehabilitation
professionals must be cognizant of state-of-the-art strategies to maintain
existing programs and expand pulmonary rehabilitation services. Furthermore,
pulmonary rehabilitation professionals must respond to tough issues such as
promoting patient adherence to ongoing lifestyle modifications, what type of
patients we rehabilitate and how we stream line services, as well as ethical
considerations for dealing with end of life issues.</P>
<P><I><B>Chairing: </B></I>D. Sanders, M.S.N., R.N., Danville, PAB.J. Make,
M.D., Denver, CO</P>
<P><I>8:15</I> <B>Introduction: Opening Remarks</B>/B.J. Make, M.D., Denver,
CO</P>
<P><I>8:30</I> <B>Program Survival in Managed Care</B>/J.E. Hodgkin, M.D.,
Deer Park, CA</P>
<P><I>9:00</I> <B>Innovative Strategies in Expanding Your Rehabilitation
Program</B>/D. Sassi, B.S.N., R.N., San Diego, CA</P>
<P><I>9:25</I> <I>Break</I></P>
<P><I>9:35</I> <B>Issues in Adherence/Motivation</B>/R. Dishman</P>
<P><I>10:00</I> <B>Ethical Considerations in Advanced Lung Disease</B>/J.E.
Heffner, M.D., Phoenix, AZ</P>
<P><I>10:25</I> <B>Panel Discussion</B></P></BLOCKQUOTE>
<P></P>
<HR SIZE="4" WIDTH="80%">
<CENTER>
<P><A HREF=97ala.html><IMG
SRC=images/activity_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97bus.html><IMG
SRC=images/business_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97cal.html><IMG
SRC=images/calendar_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97child.html><IMG
SRC=images/child_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=pg.html><IMG
SRC=images/courses_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=search.html><IMG
SRC=images/search_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=main.html><IMG
SRC=images/home_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97house.html><IMG
SRC=images/house_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=http://itsmtgs.com/ala-ats><IMG
SRC=images/regist_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=sessions.html><IMG
SRC=images/session_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=special.html><IMG
SRC=images/special_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97tours.html><IMG
SRC=images/tour_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97travel.html><IMG
SRC=images/travel_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
</P></CENTER>
<HR SIZE="4" WIDTH="80%">
<CENTER><FONT SIZE="+2"><B><I>American Thoracic Society</I></B></FONT><BR>
1740 Broadway<BR> New York, NY 10019<BR> VOICE:  212-315-8700<BR> Copyright &copy;
1996 American Lung Association.<BR> The American Thoracic  Society is the
medical section <BR>of the American Lung Association.<BR> 
</CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-157</DOCNO>
<DOCOLDNO>IA013-000141-B025-201</DOCOLDNO>
<DOCHDR>
http://www.thoracic.org:80/ic97/b16.html 206.138.195.144 19970217073218 text/html 4736
HTTP/1.0 200 OK
Date: Monday, 17-Feb-97 07:27:33 GMT
Server: NCSA/1.3
MIME-version: 1.0
Content-type: text/html
Last-modified: Friday, 24-Jan-97 16:15:13 GMT
Content-length: 4556
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//SQ//DTD HTML 2.0 HoTMetaL + extensions//EN">
<HTML>
<HEAD>
<TITLE> SYMPOSIUM: b16</TITLE></HEAD>
<BODY BGCOLOR="#FFFFFF">
<CENTER><IMG ALIGN="LEFT" SRC="images/banner0.jpg"></CENTER>
<CENTER><BR>
<P> SYMPOSIUM</P><BR>
<H2>B16: TRANSCRIPTION FACTORS IN INFLAMMATORY LUNG DISEASE</H2></CENTER>
<HR SIZE="5" NOSHADE="NOSHADE" WIDTH="100%">
<P></P>
<CENTER>
<TABLE BORDER="2">
<TR ALIGN="CENTER" VALIGN="MIDDLE">
<TD ALIGN="CENTER" VALIGN="MIDDLE"><B><SMALL><A HREF="ic97.html">BACK TO
MAIN MENU</A></SMALL></B></TD></TR></TABLE></CENTER>
<P></P>
<HR SIZE="10" WIDTH="85%">
<P></P>
<CENTER>
<P>MONDAY , MAY 19</P></CENTER>
<BLOCKQUOTE>
<P><B>Assemblies on Allergy, Immunology and Inflammation/Respiratory Cell and
Molecular Biology</B></P>
<P><B>8:15 am-10:45 am</B></P></BLOCKQUOTE>
<HR SIZE="4" WIDTH="85%" ALIGN="CENTER" NOSHADE="NOSHADE">
<BLOCKQUOTE>
<P><I><B>Target Audience: </B></I>Researchers, academic clinicians, and
allergists.</P>
<P><B>OBJECTIVES</B><BR>At the conclusion of this session, the participant
will be able to:</P>
<UL>
<LI>define the role of transcription factors involved in chronic lung
inflammation (AP-1, NF-KappaB, CREB etc.);</LI>
<LI>understand the molecular mechanism of action of steroids and other
antinflammatory drugs which inhibit transcription factors;</LI>
<LI>understand the role of transcription factors in asthma and allergy;</LI>
<LI>describe new approaches to therapy of inflammatory lung diseases based on
inhibition of transcription factors.</LI></UL>
<P>Transcription factors (DNA-binding proteins) play a key role in the
expression of inflammatory genes in lung cells and may be of critical importance
in inflammatory lung diseases, such as asthma and interstitial fibrosis.
Transcription factors may be activated by extracellular signals (cytokines,
viruses, oxidants) and thus translate environmental stimuli into altered gene
expression. Transcription factors can amplify and perpetuate the inflammation of
chronic lung disease and are therefore a target for therapeutic intervention.
Glucocorticoids control inflammation by inhibiting transcription factors, such
as NF-KappaB. This symposium will bring together experts from a variety of
fields to discuss this very important topic that is of enormous importance to
pulmonology.</P>
<P><I><B>Chairing: </B></I>L. Rosenwasser, M.D., Denver, COP.J. Barnes, M.D.,
D.M., D.Sc., F.R.C.P., London, England</P>
<P><I>8:15</I> <B>Regulation of Gene Transcription and the Role of
Transcription Factors</B>/M. Karin, M.D., La Jolla, CA</P>
<P><I>8:40</I> <B>Regulation Cytokine Gene Expression</B>/A. Ray, M.D., New
Haven, CT</P>
<P><I>9:05</I> <B>Transcription Factors in Allergic Disease</B>/L.
Rosenwasser, M.D., Denver, CO</P>
<P><I>9:30</I> <B>Transcription Factors in Asthma</B>/P.J. Barnes, M.D.,
D.M., D.Sc., F.R.C.P., London, England</P>
<P><I>9:55</I> <B>New Therapeutic Approaches Based on Transcription Factors</B>/A.
Lewis, M.D., San Diego, CA</P>
<P><I>10:20</I> <B>Panel Discussion</B></P></BLOCKQUOTE>
<P></P>
<HR SIZE="4" WIDTH="80%">
<CENTER>
<P><A HREF=97ala.html><IMG
SRC=images/activity_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97bus.html><IMG
SRC=images/business_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97cal.html><IMG
SRC=images/calendar_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97child.html><IMG
SRC=images/child_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=pg.html><IMG
SRC=images/courses_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=search.html><IMG
SRC=images/search_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=main.html><IMG
SRC=images/home_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97house.html><IMG
SRC=images/house_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=http://itsmtgs.com/ala-ats><IMG
SRC=images/regist_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=sessions.html><IMG
SRC=images/session_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=special.html><IMG
SRC=images/special_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97tours.html><IMG
SRC=images/tour_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97travel.html><IMG
SRC=images/travel_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
</P></CENTER>
<HR SIZE="4" WIDTH="80%">
<CENTER><FONT SIZE="+2"><B><I>American Thoracic Society</I></B></FONT><BR>
1740 Broadway<BR> New York, NY 10019<BR> VOICE:  212-315-8700<BR> Copyright &copy;
1996 American Lung Association.<BR> The American Thoracic  Society is the
medical section <BR>of the American Lung Association.<BR> 
</CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-158</DOCNO>
<DOCOLDNO>IA013-000141-B025-237</DOCOLDNO>
<DOCHDR>
http://www.thoracic.org:80/ic97/b17.html 206.138.195.144 19970217073301 text/html 5271
HTTP/1.0 200 OK
Date: Monday, 17-Feb-97 07:28:17 GMT
Server: NCSA/1.3
MIME-version: 1.0
Content-type: text/html
Last-modified: Friday, 24-Jan-97 16:15:13 GMT
Content-length: 5091
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//SQ//DTD HTML 2.0 HoTMetaL + extensions//EN">
<HTML>
<HEAD>
<TITLE>SYMPOSIUM: b17</TITLE></HEAD>
<BODY BGCOLOR="#FFFFFF">
<CENTER><IMG ALIGN="LEFT" SRC="images/banner0.jpg"></CENTER>
<CENTER><BR>
<P> SYMPOSIUM</P><BR>
<H2>B17: THE CHANGING SPECTRUM OF HIV-RELATED PULMONARY DISEASE</H2></CENTER>
<HR SIZE="5" NOSHADE="NOSHADE" WIDTH="100%">
<P></P>
<CENTER>
<TABLE BORDER="2">
<TR ALIGN="CENTER" VALIGN="MIDDLE">
<TD ALIGN="CENTER" VALIGN="MIDDLE"><B><SMALL><A HREF="ic97.html">BACK TO
MAIN MENU</A></SMALL></B></TD></TR></TABLE></CENTER>
<P></P>
<HR SIZE="10" WIDTH="85%">
<P></P>
<CENTER>
<P>MONDAY , MAY 19</P></CENTER>
<BLOCKQUOTE>
<P><B>Assembly on Microbiology, Tuberculosis and Pulmonary Infections</B></P>
<P><B>8:15 am-11:00 am</B></P></BLOCKQUOTE>
<HR SIZE="4" WIDTH="85%" ALIGN="CENTER" NOSHADE="NOSHADE">
<BLOCKQUOTE>
<P><I><B>Target Audience: </B></I>Clinicians, health care providers, and
researchers interested in clinical management and diagnostic work-up of
HIV-infected patients with pulmonary disease.</P>
<P><B>OBJECTIVES</B><BR>At the conclusion of this session, the participant
will be able to:</P>
<UL>
<LI>understand the therapeutic impact that improved understanding of the HIV
pathogenesis and new antiretroviral drugs have had in recent years;</LI>
<LI>describe the changing spectrum of the most prominent pulmonary etiologies,
and possible reasons for these changes;</LI>
<LI>understand the development and application of the tools utilizing molecular
biological techniques for the diagnosis of pulmonary opportunistic infections;</LI>
<LI>apply non-invasive diagnostic techniques in the diagnostic work-up of
HIV-infected patients with pulmonary symptoms.</LI></UL>
<P>The epidemiology and clinical presentation of HIV-related pulmonary disease
have changed considerably since the start of the AIDS epidemic. This symposium
will review how the combination of enhanced understanding of the pathogenesis of
the HIV-infection and new antiretroviral drug modalities have changed the
natural course of the HIV-infection. For all of the three major pulmonary
pathogens, considerable changes in epidemiology have occured. There are multiple
explanations for this shift, and these will be discussed, together with a status
of the improved understanding of the pathophysiology and molecular epidemiology
of these pathogens. Introduction of molecular diagnosis has been studied
extensively in this decade. A status on this expanding and so-to-come clinical
relevant technique in routine diagnostic work-ups will be reviewed. Finally, a
presentation of the advances in ability to use non-invasive diagnostic
approaches will be featured. In the end of the session, a panel discussion of
illustrative case stories and future perspectives will take place.</P>
<P><I><B>Chairing: </B></I>J.D. Lundgren, M.D., Hvidovre, DenmarkJ.M. Beck,
M.D., Ann Arbor, MI</P>
<P><I>8:15</I> <B>Treatment of HIV</B>/P. Volberding, M.D., San Francisco, CA</P>
<P><I>8:40</I> <B>Bacterial Infections</B>/M.J. Rosen, M.D., New York, NY</P>
<P><I>9:05</I> <B>Mycobacterial Infections</B>/R.E. Chaisson, M.D.,
Baltimore, MD</P>
<P><I>9:30</I> <I><B>Pneumocystis carinii </B></I><B>Infections</B>/H.
Masur, M.D., Bethesda, MD</P>
<P><I>9:55</I> <B>Molecular Diagnosis of Pulmonary Opportunistic Infections</B>/L.
Drew, M.D., San Francisco, CA</P>
<P><I>10:20</I> <B>Non-Invasive Diagnostic Approaches</B>/L. Huang, M.D., San
Francisco, CA</P>
<P><I>10:45</I> <B>Panel Discussion</B></P>
<P>Discussion after each presentation/5 minutes</P></BLOCKQUOTE>
<P></P>
<HR SIZE="4" WIDTH="80%">
<CENTER>
<P><A HREF=97ala.html><IMG
SRC=images/activity_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97bus.html><IMG
SRC=images/business_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97cal.html><IMG
SRC=images/calendar_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97child.html><IMG
SRC=images/child_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=pg.html><IMG
SRC=images/courses_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=search.html><IMG
SRC=images/search_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=main.html><IMG
SRC=images/home_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97house.html><IMG
SRC=images/house_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=http://itsmtgs.com/ala-ats><IMG
SRC=images/regist_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=sessions.html><IMG
SRC=images/session_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=special.html><IMG
SRC=images/special_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97tours.html><IMG
SRC=images/tour_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97travel.html><IMG
SRC=images/travel_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
</P></CENTER>
<HR SIZE="4" WIDTH="80%">
<CENTER><FONT SIZE="+2"><B><I>American Thoracic Society</I></B></FONT><BR>
1740 Broadway<BR> New York, NY 10019<BR> VOICE:  212-315-8700<BR> Copyright &copy;
1996 American Lung Association.<BR> The American Thoracic  Society is the
medical section <BR>of the American Lung Association.<BR> 
</CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-159</DOCNO>
<DOCOLDNO>IA013-000141-B025-273</DOCOLDNO>
<DOCHDR>
http://www.thoracic.org:80/ic97/b58.html 206.138.195.144 19970217073312 text/html 4942
HTTP/1.0 200 OK
Date: Monday, 17-Feb-97 07:28:27 GMT
Server: NCSA/1.3
MIME-version: 1.0
Content-type: text/html
Last-modified: Friday, 24-Jan-97 16:15:20 GMT
Content-length: 4762
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//SQ//DTD HTML 2.0 HoTMetaL + extensions//EN">
<HTML>
<HEAD>
<TITLE>SYMPOSIUM: b58</TITLE></HEAD>
<BODY BGCOLOR="#FFFFFF">
<CENTER><IMG ALIGN="LEFT" SRC="images/banner0.jpg"></CENTER>
<CENTER><BR>
<P>SYMPOSIUM</P><BR>
<H2>B58: OCCUPATIONAL AND ENVIRONMENTAL ASTHMA: THE LATEST IN DIAGNOSIS AND
MANAGEMENT</H2></CENTER>
<HR SIZE="5" NOSHADE="NOSHADE" WIDTH="100%">
<P></P>
<CENTER>
<TABLE BORDER="2">
<TR ALIGN="CENTER" VALIGN="MIDDLE">
<TD ALIGN="CENTER" VALIGN="MIDDLE"><B><SMALL><A HREF="ic97.html">BACK TO
MAIN MENU</A></SMALL></B></TD></TR></TABLE></CENTER>
<P></P>
<HR SIZE="10" WIDTH="85%">
<P></P>
<BLOCKQUOTE>
<CENTER>
<P>MONDAY , MAY 19</P>
<P><B>Assemblies on Environmental and Occupational Health/<BR>Allergy,
Immunology and Inflammation/Clinical Problems/<BR>American Lung
Association/European Respiratory Society/<BR>American Academy of Allergy,
Asthma and Immunology/<BR>European Academy of Allergy and Clinical Immunology</B></P>
<P><B>1:30 pm-4:15 pm</B></P></CENTER></BLOCKQUOTE>
<HR SIZE="4" WIDTH="85%" ALIGN="CENTER" NOSHADE="NOSHADE">
<BLOCKQUOTE>
<P><I><B>Target Audience: </B></I>Pulmonary physicians, allergists,
occupational medicine physicians, Lung Association volunteers and staff.</P>
<P><B>OBJECTIVES</B><BR>At the conclusion of this session, the participant
will be able to:</P>
<UL>
<LI>identify the major occupational and environmental exposures which can cause
and exacerbate asthma;</LI>
<LI>diagnose occupational and/or environmental asthma, and know the advantages
and disadvantages of the different diagnostic strategies;</LI>
<LI>describe the optimal treatment strategies, including management of the
patient, his/her work and/or home environment, and disability and compensation
issues;</LI>
<LI>know how to identify, diagnose and manage reactive airways dysfunction
syndrome (RADS).</LI></UL>
<P>This symposium will present an up-to-date review of occupational and
environmental asthma and RADS for the allergist, pulmonologist, occupational
medicine physician and other practitioners. The speakers will emphasize
important clinical aspects including: the etiology and natural history of
occupational and environmental asthma, how best to diagnose the disease,
management of the patient and his/her home and work environment, and issues of
disability and compensation.</P>
<P><I><B>Chairing: </B></I>C.A. Redlich, M.D., New Haven, CTW.S. Beckett,
M.D., Rochester, MN</P>
<P><I>1:30</I> <B>The Major Causes and Natural History of Occupational Asthma</B>/M.
Chan-Yeung, M.D., Vancouver, BC, Canada</P>
<P><I>1:55</I> <B>Use of PEFRs in the Diagnosis of Asthma</B>/S. Burge, M.D.,
Birmingham, England</P>
<P><I>2:20</I> <B>The Use of Bronchoprovocation Tests and Specific Challenges
in the Diagnosis of Occupational Asthma</B>/A. Cartier, M.D., Montreal, PQ,
Canada</P>
<P><I>2:45</I> <I>Break</I></P>
<P><I>3:00</I> <B>Impairment and Disability</B>/S. Barnhart, M.D., Seattle,
WA</P>
<P><I>3:25</I> <B>The Diagnosis and Management of RADS</B>/H.M. Kipen, M.D.,
Piscataway, NJ</P>
<P><I>3:50</I> <B>The Assessment and Management of the Home Environment</B>/T.A.
Platts-Mills, M.D., Ph.D., Charlottesville, VA</P>
<P>Discussion after each presentation/5 minutes</P></BLOCKQUOTE>
<P></P>
<HR SIZE="4" WIDTH="80%">
<CENTER>
<P><A HREF=97ala.html><IMG
SRC=images/activity_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97bus.html><IMG
SRC=images/business_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97cal.html><IMG
SRC=images/calendar_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97child.html><IMG
SRC=images/child_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=pg.html><IMG
SRC=images/courses_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=search.html><IMG
SRC=images/search_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=main.html><IMG
SRC=images/home_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97house.html><IMG
SRC=images/house_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=http://itsmtgs.com/ala-ats><IMG
SRC=images/regist_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=sessions.html><IMG
SRC=images/session_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=special.html><IMG
SRC=images/special_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97tours.html><IMG
SRC=images/tour_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97travel.html><IMG
SRC=images/travel_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
</P></CENTER>
<HR SIZE="4" WIDTH="80%">
<CENTER><FONT SIZE="+2"><B><I>American Thoracic Society</I></B></FONT><BR>
1740 Broadway<BR> New York, NY 10019<BR> VOICE:  212-315-8700<BR> Copyright &copy;
1996 American Lung Association.<BR> The American Thoracic  Society is the
medical section <BR>of the American Lung Association.<BR> 
</CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-160</DOCNO>
<DOCOLDNO>IA013-000141-B025-306</DOCOLDNO>
<DOCHDR>
http://www.thoracic.org:80/ic97/b61.html 206.138.195.144 19970217073325 text/html 3565
HTTP/1.0 200 OK
Date: Monday, 17-Feb-97 07:28:40 GMT
Server: NCSA/1.3
MIME-version: 1.0
Content-type: text/html
Last-modified: Friday, 24-Jan-97 16:15:23 GMT
Content-length: 3385
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//SQ//DTD HTML 2.0 HoTMetaL + extensions//EN">
<HTML>
<HEAD>
<TITLE>SYMPOSIUM: b61</TITLE></HEAD>
<BODY BGCOLOR="#FFFFFF">
<CENTER><IMG ALIGN="LEFT" SRC="images/banner0.jpg"></CENTER>
<CENTER><BR>
<P>SYMPOSIUM</P><BR>
<H2>B61: PULMONARY PHYSICIANS AS PRIMARY CARE PROVIDER</H2></CENTER>
<HR SIZE="5" NOSHADE="NOSHADE" WIDTH="100%">
<P></P>
<CENTER>
<TABLE BORDER="2">
<TR ALIGN="CENTER" VALIGN="MIDDLE">
<TD ALIGN="CENTER" VALIGN="MIDDLE"><B><SMALL><A HREF="ic97.html">BACK TO
MAIN MENU</A></SMALL></B></TD></TR></TABLE></CENTER>
<P></P>
<HR SIZE="10" WIDTH="85%">
<P></P>
<BLOCKQUOTE>
<CENTER>
<P>MONDAY , MAY 19</P>
<P><B>This session is also offered on Tuesday afternoon, session
<A HREF="c58.html">C58</A>, beginning at 3:15 p.m.</B></P>
<P><B>1:30 pm-4:15 pm</B></P></CENTER></BLOCKQUOTE>
<HR SIZE="4" WIDTH="85%" ALIGN="CENTER" NOSHADE="NOSHADE">
<BLOCKQUOTE>
<P>This is a &quot;back to the basics&quot; symposia series covering commonly
encountered clinical problems in Internal Medicine. The symposia is designed to
help the pulmonary physician meet the primary care needs of patients with
chronic lung disease. The speakers will provide specific information on current
approaches to diagnosis and management of common disorders including
hypertension, diabetes, angina, diarrhea, peptic ulcer disease, skin disorders,
arthritis and back pain, nonpulmonary infections, common endocrine disorders,
etc. The speakers will use a case presentation format and will provide handouts
summarizing up-to-date diagnostic approaches and specific therapies e.g. dosing
schedules of commonly used drugs. This &quot;refresher course&quot; in internal
medicine will be useful for pulmonary physicians who wish to be &quot;principal
care providers&quot; as managed care systems evolve.</P>
<P>Program and faculty to be announced.</P></BLOCKQUOTE>
<P></P>
<HR SIZE="4" WIDTH="80%">
<CENTER>
<P><A HREF=97ala.html><IMG
SRC=images/activity_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97bus.html><IMG
SRC=images/business_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97cal.html><IMG
SRC=images/calendar_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97child.html><IMG
SRC=images/child_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=pg.html><IMG
SRC=images/courses_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=search.html><IMG
SRC=images/search_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=main.html><IMG
SRC=images/home_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97house.html><IMG
SRC=images/house_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=http://itsmtgs.com/ala-ats><IMG
SRC=images/regist_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=sessions.html><IMG
SRC=images/session_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=special.html><IMG
SRC=images/special_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97tours.html><IMG
SRC=images/tour_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97travel.html><IMG
SRC=images/travel_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
</P></CENTER>
<HR SIZE="4" WIDTH="80%">
<CENTER><FONT SIZE="+2"><B><I>American Thoracic Society</I></B></FONT><BR>
1740 Broadway<BR> New York, NY 10019<BR> VOICE:  212-315-8700<BR> Copyright &copy;
1996 American Lung Association.<BR> The American Thoracic  Society is the
medical section <BR>of the American Lung Association.<BR> 
</CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-161</DOCNO>
<DOCOLDNO>IA013-000141-B025-332</DOCOLDNO>
<DOCHDR>
http://www.thoracic.org:80/ic97/c14.html 206.138.195.144 19970217073334 text/html 4413
HTTP/1.0 200 OK
Date: Monday, 17-Feb-97 07:28:51 GMT
Server: NCSA/1.3
MIME-version: 1.0
Content-type: text/html
Last-modified: Friday, 24-Jan-97 16:15:27 GMT
Content-length: 4233
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//SQ//DTD HTML 2.0 HoTMetaL + extensions//EN">
<HTML>
<HEAD>
<TITLE>SYMPOSIUM: c14</TITLE></HEAD>
<BODY BGCOLOR="#FFFFFF">
<CENTER><IMG ALIGN="LEFT" SRC="images/banner0.jpg"></CENTER>
<CENTER><BR>
<P>SYMPOSIUM</P><BR>
<H2>C14: TUBERCULOSIS: THE YEAR IN REVIEW</H2></CENTER>
<HR SIZE="5" NOSHADE="NOSHADE" WIDTH="100%">
<P></P>
<CENTER>
<TABLE BORDER="2">
<TR ALIGN="CENTER" VALIGN="MIDDLE">
<TD ALIGN="CENTER" VALIGN="MIDDLE"><B><SMALL><A HREF="ic97.html">BACK TO
MAIN MENU</A></SMALL></B></TD></TR></TABLE></CENTER>
<P></P>
<HR SIZE="10" WIDTH="85%">
<P></P>
<BLOCKQUOTE>
<CENTER>
<P>TUESDAY , MAY 20</P>
<P><B>Assembly on Microbiology, Tuberculosis and Pulmonary Infections</B></P>
<P><B>8:15 am-11:00 am</B></P></CENTER></BLOCKQUOTE>
<HR SIZE="4" WIDTH="85%" ALIGN="CENTER" NOSHADE="NOSHADE">
<BLOCKQUOTE>
<P><I><B>Target Audience: </B></I>Clinical providers and researchers in
tuberculosis and public health professionals.</P>
<P><B>OBJECTIVES</B><BR>At the conclusion of this session, the participant
will be able to:</P>
<UL>
<LI>understand advances in the immunology of tuberculosis which are likely to
lead to novel therapeutics;</LI>
<LI>understand progress towards new TB drug targets and the mechanisms of
current antituberculous drugs;</LI>
<LI>appreciate new trends in the epidemiology and management of tuberculosis;</LI>
<LI>understand and appreciate changes in TB control in the new managed care
environment.</LI></UL>
<P>Tuberculosis remains a significant pulmonary problem in the United States
and is a control crisis overseas. In this session, leaders in basic science
research on tuberculosis will review immunological and biochemical advances
which are likely to lead to new therapeutic and diagnostic tools for
tuberculosis. In addition, new trends in the epidemiology, cost control, and
management of tuberculosis will be discussed by national authorities in these
arenas.</P>
<P><I><B>Chairing: </B></I>B. Miller, M.D., M.Sc., Atlanta, GAW. Bishai,
M.D., Ph.D., Baltimore, MD</P>
<P><I>8:15</I> <B>Mycobacterial Cell Wall and Drug Targets</B>/P.J. Brennan,
Ph.D., Ft. Collins, CO</P>
<P><I>8:38</I> <B>Tuberculosis and HIV Coinfection</B>/J.J. Ellner, M.D.,
Cleveland, OH</P>
<P><I>9:01</I> <B>Cytokine Therapy for Tuberculosis</B>/G. Kaplan, Ph.D., New
York, NY</P>
<P><I>9:24</I> <B>Nitric Oxide and the Control of Tuberculosis in Macrophages</B>/L.W.
Riley, M.D., Berkeley, CA</P>
<P><I>9:47</I> <B>Impact of Managed Care on Tuberculosis Control</B>/S.
Rosenbaum, M.D., Washington, DC</P>
<P><I>10:10</I> <B>Hospitalizations for Tuberculosis: Causes and Costs</B>/Z.
Taylor, M.D., M.S., Atlanta, GA</P>
<P><I>10:56</I> <B>Panel Discussion</B></P></BLOCKQUOTE>
<P></P>
<HR SIZE="4" WIDTH="80%">
<CENTER>
<P><A HREF=97ala.html><IMG
SRC=images/activity_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97bus.html><IMG
SRC=images/business_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97cal.html><IMG
SRC=images/calendar_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97child.html><IMG
SRC=images/child_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=pg.html><IMG
SRC=images/courses_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=search.html><IMG
SRC=images/search_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=main.html><IMG
SRC=images/home_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97house.html><IMG
SRC=images/house_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=http://itsmtgs.com/ala-ats><IMG
SRC=images/regist_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=sessions.html><IMG
SRC=images/session_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=special.html><IMG
SRC=images/special_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97tours.html><IMG
SRC=images/tour_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97travel.html><IMG
SRC=images/travel_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
</P></CENTER>
<HR SIZE="4" WIDTH="80%">
<CENTER><FONT SIZE="+2"><B><I>American Thoracic Society</I></B></FONT><BR>
1740 Broadway<BR> New York, NY 10019<BR> VOICE:  212-315-8700<BR> Copyright &copy;
1996 American Lung Association.<BR> The American Thoracic  Society is the
medical section <BR>of the American Lung Association.<BR> 
</CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-162</DOCNO>
<DOCOLDNO>IA013-000141-B025-361</DOCOLDNO>
<DOCHDR>
http://www.thoracic.org:80/ic97/c15.html 206.138.195.144 19970217073342 text/html 4639
HTTP/1.0 200 OK
Date: Monday, 17-Feb-97 07:29:00 GMT
Server: NCSA/1.3
MIME-version: 1.0
Content-type: text/html
Last-modified: Friday, 24-Jan-97 16:15:27 GMT
Content-length: 4459
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//SQ//DTD HTML 2.0 HoTMetaL + extensions//EN">
<HTML>
<HEAD>
<TITLE>SYMPOSIUM: c15</TITLE></HEAD>
<BODY BGCOLOR="#FFFFFF">
<CENTER><IMG ALIGN="LEFT" SRC="images/banner0.jpg"></CENTER>
<CENTER><BR>
<P>SYMPOSIUM</P><BR>
<H2>C15: CLINICAL OUTCOME MEASURES IN SLEEP APNEA</H2></CENTER>
<HR SIZE="5" NOSHADE="NOSHADE" WIDTH="100%">
<P></P>
<CENTER>
<TABLE BORDER="2">
<TR ALIGN="CENTER" VALIGN="MIDDLE">
<TD ALIGN="CENTER" VALIGN="MIDDLE"><B><SMALL><A HREF="ic97.html">BACK TO
MAIN MENU</A></SMALL></B></TD></TR></TABLE></CENTER>
<P></P>
<HR SIZE="10" WIDTH="85%">
<P></P>
<BLOCKQUOTE>
<CENTER>
<P>TUESDAY , MAY 20</P>
<P><B>Assemblies on Respiratory Neurobiology and Sleep/Nursing</B></P>
<P><B>8:15 am-11:00 am</B></P></CENTER></BLOCKQUOTE>
<HR SIZE="4" WIDTH="85%" ALIGN="CENTER" NOSHADE="NOSHADE">
<BLOCKQUOTE>
<P><I><B>Target Audience: </B></I>This program will be of interest to
clinicians as well as clinical and basic researchers interested in sleep apnea
syndromes.</P>
<P><B>OBJECTIVES</B><BR>At the conclusion of this session, the participant
will be able to:</P>
<UL>
<LI>understand general health status, quality of life and functional status
assessment in sleep apnea patients;</LI>
<LI>understand the results of neurobehavioral testing in sleep apnea patients;</LI>
<LI>determine how to use clinical outcome measurements to document improvements
that sleep apnea patients experience with therapy.</LI></UL>
<P>Sleep apnea occurs primarily as a result of the narrowing and collapse of
the upper airway during sleep that often results in sleep deprivation, daytime
somnolence, mood disorders and cognitive dysfunction. Diagnosis and treatment
result in substantial improvements; however may be expensive. Decisions
regarding diagnosis and treatment should be based on cost effective strategies
that result in objective improvements as documented on results of measuring (1)
neurocognitive parameters of sleep apnea patients, and (2) utilization and costs
associated with an integrated home and sleep lab based diagnostic pathway.</P>
<P><I><B>Chairing: </B></I>N.J. Douglas, M.D., Edinburgh, ScotlandW.Ward
Flemons, M.D., Calgary, AB, Canada</P>
<P><I>8:15</I> <B>Introduction and Overview</B>/N.J. Douglas, M.D.,
Edinburgh, Scotland</P>
<P><I>8:20</I> <B>Utilization and Cost of Evaluating OSA</B>/J.B. DeMaine,
M.D., Redmond, WA</P>
<P><I>8:45</I> <B>Functional Status Outcomes Associated with OSA</B>/T.E.
Weaver, Ph.D., Philadelphia, PA</P>
<P><I>9:10</I> <B>General Health Status (SF-36)</B>/T.B. Young, Ph.D.,
Madison, WI</P>
<P><I>9:35</I> <B>The Calgary Sleep Apnea Quality of Life Index</B>/W.Ward
Flemons, M.D., Calgary, AB, Canada</P>
<P><I>9:50</I> <B>Neuropsychological Testing</B>/H. Engleman, Ph.D.,
Edinburgh, Scotland</P>
<P><I>10:30</I> <B>Measuring Driving Performance Using Simulators</B>/C.F. P.
George, M.D., London, ON, Canada</P>
<P><I>10:55</I> <I>Discussion</I></P></BLOCKQUOTE>
<P></P>
<HR SIZE="4" WIDTH="80%">
<CENTER>
<P><A HREF=97ala.html><IMG
SRC=images/activity_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97bus.html><IMG
SRC=images/business_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97cal.html><IMG
SRC=images/calendar_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97child.html><IMG
SRC=images/child_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=pg.html><IMG
SRC=images/courses_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=search.html><IMG
SRC=images/search_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=main.html><IMG
SRC=images/home_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97house.html><IMG
SRC=images/house_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=http://itsmtgs.com/ala-ats><IMG
SRC=images/regist_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=sessions.html><IMG
SRC=images/session_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=special.html><IMG
SRC=images/special_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97tours.html><IMG
SRC=images/tour_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97travel.html><IMG
SRC=images/travel_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
</P></CENTER>
<HR SIZE="4" WIDTH="80%">
<CENTER><FONT SIZE="+2"><B><I>American Thoracic Society</I></B></FONT><BR>
1740 Broadway<BR> New York, NY 10019<BR> VOICE:  212-315-8700<BR> Copyright &copy;
1996 American Lung Association.<BR> The American Thoracic  Society is the
medical section <BR>of the American Lung Association.<BR> 
</CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-163</DOCNO>
<DOCOLDNO>IA013-000141-B025-410</DOCOLDNO>
<DOCHDR>
http://www.thoracic.org:80/ic97/c16.html 206.138.195.144 19970217073417 text/html 4713
HTTP/1.0 200 OK
Date: Monday, 17-Feb-97 07:29:30 GMT
Server: NCSA/1.3
MIME-version: 1.0
Content-type: text/html
Last-modified: Friday, 24-Jan-97 16:15:28 GMT
Content-length: 4533
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//SQ//DTD HTML 2.0 HoTMetaL + extensions//EN">
<HTML>
<HEAD>
<TITLE>SYMPOSIUM: c16</TITLE></HEAD>
<BODY BGCOLOR="#FFFFFF">
<CENTER><IMG ALIGN="LEFT" SRC="images/banner0.jpg"></CENTER>
<CENTER><BR>
<P>SYMPOSIUM</P><BR>
<H2>C16: NORMAL AND ABNORMAL CONTROL OF VENTILATION IN INFANCY AND CHILDHOOD</H2></CENTER>
<HR SIZE="5" NOSHADE="NOSHADE" WIDTH="100%">
<P></P>
<CENTER>
<TABLE BORDER="2">
<TR ALIGN="CENTER" VALIGN="MIDDLE">
<TD ALIGN="CENTER" VALIGN="MIDDLE"><B><SMALL><A HREF="ic97.html">BACK TO
MAIN MENU</A></SMALL></B></TD></TR></TABLE></CENTER>
<P></P>
<HR SIZE="10" WIDTH="85%">
<P></P>
<BLOCKQUOTE>
<CENTER>
<P>TUESDAY , MAY 20</P>
<P><B>Assemblies on Pediatrics/Respiratory Neurobiology and Sleep</B></P>
<P><B>8:15 am-11:00 am</B></P></CENTER></BLOCKQUOTE>
<HR SIZE="4" WIDTH="85%" ALIGN="CENTER" NOSHADE="NOSHADE">
<BLOCKQUOTE>
<P><I><B>Target Audience: </B></I>Pediatric pulmonologists and others
interested in control of ventilation and sudden infant death syndrome.</P>
<P><B>OBJECTIVES</B><BR>At the conclusion of this session, the participant
will be able to:</P>
<UL>
<LI>describe the normal process of maturation of respiratory control;</LI>
<LI>outline the modifiable risk factors for sudden infant death syndrome;</LI>
<LI>describe potential mechanisms of death in sudden infant death syndrome;</LI>
<LI>understand the presentation, pathophysiology and treatment of disorders of
respiratory control in infants and children.</LI></UL>
<P>Control of ventilation is a dynamic process in infants and children,
affected by developmental, behavioral state, and environmental factors. Despite
the presence of protective mechanisms, apparently normal infants succumb to
sudden infant death syndrome, perhaps due to a failure of normal ventilatory
control. Other children have better defined abnormalities of ventilatory control
that are amenable to treatment. An appreciation of the normal features of
respiratory control and the situations and disease states that compromise this
system is the focus of this symposium.</P>
<P><I><B>Chairing: </B></I>S.L. Davidson Ward, M.D., Los Angeles, CAD.E.
Weese-Mayer, M.D., Chicago, IL</P>
<P><I>8:15</I> <B>Introduction</B>/S.L. Davidson Ward, M.D., Los Angeles, CA</P>
<P><I>8:20</I> <B>Surviving Infancy: Postnatal Development of Respiratory
Control</B>/J.L. Carroll, M.D., Baltimore, MD</P>
<P><I>8:45</I> <B>SIDS, Modifiable Risk Factors and the Window of
Vulnerability</B>/P. Fleming, M.B., Ph.D., Bristol, England</P>
<P><I>9:20</I> <B>Proposed Mechanisms of SIDS Deaths and the Failure of
Protective Responses</B>/J.S. Kemp, M.D., St. Louis, MO</P>
<P><I>9:45</I> <B>Clinical Spectrum and Physiologic Investigations of Central
Hypoventilation Syndromes</B>/T.G. Keens, M.D., Los Angeles, CA</P>
<P><I>10:10</I> <B>Therapeutic Options for Disorders of Respiratory Control</B>/D.E.
Weese-Mayer, M.D., Chicago, IL</P>
<P><I>10:30</I> <B>Panel Discussion</B></P>
<P>Discussion after each presentation/5 minutes</P></BLOCKQUOTE>
<P></P>
<HR SIZE="4" WIDTH="80%">
<CENTER>
<P><A HREF=97ala.html><IMG
SRC=images/activity_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97bus.html><IMG
SRC=images/business_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97cal.html><IMG
SRC=images/calendar_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97child.html><IMG
SRC=images/child_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=pg.html><IMG
SRC=images/courses_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=search.html><IMG
SRC=images/search_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=main.html><IMG
SRC=images/home_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97house.html><IMG
SRC=images/house_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=http://itsmtgs.com/ala-ats><IMG
SRC=images/regist_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=sessions.html><IMG
SRC=images/session_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=special.html><IMG
SRC=images/special_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97tours.html><IMG
SRC=images/tour_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97travel.html><IMG
SRC=images/travel_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
</P></CENTER>
<HR SIZE="4" WIDTH="80%">
<CENTER><FONT SIZE="+2"><B><I>American Thoracic Society</I></B></FONT><BR>
1740 Broadway<BR> New York, NY 10019<BR> VOICE:  212-315-8700<BR> Copyright &copy;
1996 American Lung Association.<BR> The American Thoracic  Society is the
medical section <BR>of the American Lung Association.<BR> 
</CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-164</DOCNO>
<DOCOLDNO>IA013-000141-B026-7</DOCOLDNO>
<DOCHDR>
http://www.thoracic.org:80/ic97/c58.html 206.138.195.144 19970217073426 text/html 3569
HTTP/1.0 200 OK
Date: Monday, 17-Feb-97 07:29:43 GMT
Server: NCSA/1.3
MIME-version: 1.0
Content-type: text/html
Last-modified: Friday, 24-Jan-97 16:15:34 GMT
Content-length: 3389
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//SQ//DTD HTML 2.0 HoTMetaL + extensions//EN">
<HTML>
<HEAD>
<TITLE>SYMPOSIUM: c58</TITLE></HEAD>
<BODY BGCOLOR="#FFFFFF">
<CENTER><IMG ALIGN="LEFT" SRC="images/banner0.jpg"></CENTER>
<CENTER><BR>
<P>SYMPOSIUM</P><BR>
<H2>C58: PULMONARY PHYSICIANS AS PRIMARY CARE PROVIDER</H2></CENTER>
<HR SIZE="5" NOSHADE="NOSHADE" WIDTH="100%">
<P></P>
<CENTER>
<TABLE BORDER="2">
<TR ALIGN="CENTER" VALIGN="MIDDLE">
<TD ALIGN="CENTER" VALIGN="MIDDLE"><B><SMALL><A HREF="ic97.html">BACK TO
MAIN MENU</A></SMALL></B></TD></TR></TABLE></CENTER>
<P></P>
<HR SIZE="10" WIDTH="85%">
<P></P>
<BLOCKQUOTE>
<CENTER>
<P>TUESDAY , MAY 20</P>
<P><B>This session is also offered on Monday afternoon, session
<A HREF="b61.html">B61</A>, beginning at 1:30 p.m.</B></P>
<P><B>3:15 PM&#151;6:00 PM</B></P></CENTER></BLOCKQUOTE>
<HR SIZE="4" WIDTH="85%" ALIGN="CENTER" NOSHADE="NOSHADE">
<BLOCKQUOTE>
<P>This is a &quot;back to the basics&quot; symposia series covering commonly
encountered clinical problems in Internal Medicine. The symposia is designed to
help the pulmonary physician meet the primary care needs of patients with
chronic lung disease. The speakers will provide specific information on current
approaches to diagnosis and management of common disorders including
hypertension, diabetes, angina, diarrhea, peptic ulcer disease, skin disorders,
arthritis and back pain, nonpulmonary infections,common endocrine disorders,
etc. The speakers will use a case presentation format and will provide handouts
summarizing up-to-date diagnostic approaches and specific therapies e.g. dosing
schedules of commonly used drugs. This &quot;refresher course&quot; in internal
medicine will be useful for pulmonary physicians who wish to be &quot;principal
care providers&quot; as managed care systems evolve.</P>
<P>Program and faculty to be announced.</P></BLOCKQUOTE>
<P></P>
<HR SIZE="4" WIDTH="80%">
<CENTER>
<P><A HREF=97ala.html><IMG
SRC=images/activity_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97bus.html><IMG
SRC=images/business_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97cal.html><IMG
SRC=images/calendar_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97child.html><IMG
SRC=images/child_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=pg.html><IMG
SRC=images/courses_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=search.html><IMG
SRC=images/search_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=main.html><IMG
SRC=images/home_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97house.html><IMG
SRC=images/house_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=http://itsmtgs.com/ala-ats><IMG
SRC=images/regist_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=sessions.html><IMG
SRC=images/session_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=special.html><IMG
SRC=images/special_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97tours.html><IMG
SRC=images/tour_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97travel.html><IMG
SRC=images/travel_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
</P></CENTER>
<HR SIZE="4" WIDTH="80%">
<CENTER><FONT SIZE="+2"><B><I>American Thoracic Society</I></B></FONT><BR>
1740 Broadway<BR> New York, NY 10019<BR> VOICE:  212-315-8700<BR> Copyright &copy;
1996 American Lung Association.<BR> The American Thoracic  Society is the
medical section <BR>of the American Lung Association.<BR> 
</CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-165</DOCNO>
<DOCOLDNO>IA013-000141-B026-29</DOCOLDNO>
<DOCHDR>
http://www.thoracic.org:80/ic97/d5.html 206.138.195.144 19970217073435 text/html 4663
HTTP/1.0 200 OK
Date: Monday, 17-Feb-97 07:29:52 GMT
Server: NCSA/1.3
MIME-version: 1.0
Content-type: text/html
Last-modified: Friday, 24-Jan-97 16:15:44 GMT
Content-length: 4483
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//SQ//DTD HTML 2.0 HoTMetaL + extensions//EN">
<HTML>
<HEAD>
<TITLE>SYMPOSIUM: d5</TITLE></HEAD>
<BODY BGCOLOR="#FFFFFF">
<CENTER><IMG ALIGN="LEFT" SRC="images/banner0.jpg"></CENTER>
<CENTER><BR>
<P>SYMPOSIUM</P><BR>
<H2>D5: CLASSICS IN PHYSIOLOGY: THE PHYSIOLOGY OF RESPIRATORY MUSCLES</H2></CENTER>
<HR SIZE="5" NOSHADE="NOSHADE" WIDTH="100%">
<P></P>
<CENTER>
<TABLE BORDER="2">
<TR ALIGN="CENTER" VALIGN="MIDDLE">
<TD ALIGN="CENTER" VALIGN="MIDDLE"><B><SMALL><A HREF="ic97.html">BACK TO
MAIN MENU</A></SMALL></B></TD></TR></TABLE></CENTER>
<P></P>
<HR SIZE="10" WIDTH="85%">
<P></P>
<BLOCKQUOTE>
<CENTER>
<P>WEDNESDAY , MAY 21</P>
<P><B>8:15 am-10:45 am</B></P></CENTER></BLOCKQUOTE>
<HR SIZE="4" WIDTH="85%" ALIGN="CENTER" NOSHADE="NOSHADE">
<BLOCKQUOTE>
<P><I><B>Target Audience: </B></I>Pulmonologists, respiratory physiologists,
pulmonary fellows, and other critical care physicians, nurses, and technicians.</P>
<P><B>OBJECTIVES</B><BR>At the conclusion of this session, the participant
will be able to:</P>
<UL>
<LI>clarify the basic structure and function of respiratory muscles;</LI>
<LI>understand the effects of disease on respiratory muscles;</LI>
<LI>define the issues surrounding respiratory muscles and weaning patients from
mechanical ventilation;</LI>
<LI> identify the current approaches to evaluating and treating respiratory
muscle dysfunction.</LI></UL>
<P>Our understanding of the clinical role of respiratory muscle dysfunction in
disease is increasing rapidly. Advances have been made in understanding
respiratory muscle structure and function and the role of respiratory muscles in
diseases. These, in turn, have lead to a better understanding of how respiratory
muscle function can be clinically evaluated and how respiratory muscle failure
can be treated. This symposium brings together five world renowned experts in
respiratory muscle physiologyto address topics ranging from basic physiology to
practical applications in clinical medicine. Each will discuss the subject to
which he has made major contributions during his career. The presentations will
include a critical review of basic science, clinical applications and future
directions.</P>
<P><I><B>Chairing: </B></I>P.D. Wagner, M.D., La Jolla, CAC.G. Gallagher,
M.B., F.R.C.P.(C), Dublin, IrelandR.O. Crapo, M.D., Salt Lake City, UT</P>
<P><I>8:15</I> <B>Structure and Function of the Respiratory Muscles</B>/G.C.
Sieck, Ph.D., Rochester, MN</P>
<P><I>8:45</I> <B>Respiratory Muscle Fatigue</B>/A.E. Grassino, M.D.,
Montreal, PQ, Canada</P>
<P><I>9:15</I> <B>Effects of Cardiopulmonary Diseases on Respiratory Muscle
Function</B>/P.T. Macklem, M.D., Montreal, PQ, Canada</P>
<P><I>9:45</I> <B>Respiratory Muscles, Mechanical Ventilation and Weaning</B>/M.
Younes, M.D., Ph.D., F.R.C.P.(C), Winnipeg, MB, Canada</P>
<P><I>10:15</I> <B>Evaluation and Treatment of Respiratory Muscle Dysfunction</B>/J.R.
Rodarte, M.D., Houston, TX</P></BLOCKQUOTE>
<P></P>
<HR SIZE="4" WIDTH="80%">
<CENTER>
<P><A HREF=97ala.html><IMG
SRC=images/activity_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97bus.html><IMG
SRC=images/business_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97cal.html><IMG
SRC=images/calendar_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97child.html><IMG
SRC=images/child_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=pg.html><IMG
SRC=images/courses_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=search.html><IMG
SRC=images/search_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=main.html><IMG
SRC=images/home_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97house.html><IMG
SRC=images/house_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=http://itsmtgs.com/ala-ats><IMG
SRC=images/regist_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=sessions.html><IMG
SRC=images/session_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=special.html><IMG
SRC=images/special_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97tours.html><IMG
SRC=images/tour_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97travel.html><IMG
SRC=images/travel_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
</P></CENTER>
<HR SIZE="4" WIDTH="80%">
<CENTER><FONT SIZE="+2"><B><I>American Thoracic Society</I></B></FONT><BR>
1740 Broadway<BR> New York, NY 10019<BR> VOICE:  212-315-8700<BR> Copyright &copy;
1996 American Lung Association.<BR> The American Thoracic  Society is the
medical section <BR>of the American Lung Association.<BR> 
</CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-166</DOCNO>
<DOCOLDNO>IA013-000141-B026-58</DOCOLDNO>
<DOCHDR>
http://www.thoracic.org:80/ic97/d55.html 206.138.195.144 19970217073448 text/html 4957
HTTP/1.0 200 OK
Date: Monday, 17-Feb-97 07:30:03 GMT
Server: NCSA/1.3
MIME-version: 1.0
Content-type: text/html
Last-modified: Friday, 24-Jan-97 16:15:47 GMT
Content-length: 4777
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//SQ//DTD HTML 2.0 HoTMetaL + extensions//EN">
<HTML>
<HEAD>
<TITLE>SYMPOSIUM: d55</TITLE></HEAD>
<BODY BGCOLOR="#FFFFFF">
<CENTER><IMG ALIGN="LEFT" SRC="images/banner0.jpg"></CENTER>
<CENTER><BR>
<P>SYMPOSIUM</P><BR>
<H2>D55: ASTHMA DISEASE STATE MANAGEMENT IN THE MANAGED CARE ENVIRONMENT</H2></CENTER>
<HR SIZE="5" NOSHADE="NOSHADE" WIDTH="100%">
<P></P>
<CENTER>
<TABLE BORDER="2">
<TR ALIGN="CENTER" VALIGN="MIDDLE">
<TD ALIGN="CENTER" VALIGN="MIDDLE"><B><SMALL><A HREF="ic97.html">BACK TO
MAIN MENU</A></SMALL></B></TD></TR></TABLE></CENTER>
<P></P>
<HR SIZE="10" WIDTH="85%">
<P></P>
<BLOCKQUOTE>
<CENTER>
<P>WEDNESDAY , MAY 21</P>
<P><B>Assemblies on Nursing/Behavioral Science/<BR>American Lung Association</B></P>
<P><B>1:30 pm-4:15 pm</B></P></CENTER></BLOCKQUOTE>
<HR SIZE="4" WIDTH="85%" ALIGN="CENTER" NOSHADE="NOSHADE">
<BLOCKQUOTE>
<P><I><B>Target Audience: </B></I>Clinicians, researchers and health care
professionals interested in state-of-the-art asthma disease management in a
changing health care environment.</P>
<P><B>OBJECTIVES</B><BR>At the conclusion of this session, the participant
will be able to:</P>
<UL>
<LI>describe the role of the managed care organization in asthma disease state
management;</LI>
<LI>describe a program template that improves clinical outcome measures in a
large Medicaid managed care organization;</LI>
<LI>characterize the value of asthma critical pathways;</LI>
<LI>define the interaction of a referral center with primary care in health
maintenance organizations;</LI>
<LI>characterize the advantages and disadvantages of objective measures of
airflow in disease state management.</LI></UL>
<P>In the U.S., asthma prevalence, morbidity and mortality rates are
increasing. New approaches in the management of asthma are therefore necessary
to reverse these dramatic and costly trends. The appropriate allocation of
health care resources has become a primary concern in the managed care
environment, particularly for diseases such as asthma, where patterns of high
health care utilization have emerged.</P>
<P>In this session, the panel will describe innovative asthma disease state
management programs that identify new roles for the provider in the changing
health care environment and explore impediments to case management including
access to health care and patient adherence.</P>
<P><I><B>Chairing: </B></I>R.A. Panettieri, Jr., M.D., Philadelphia, PA</P>
<P><I>1:30</I> <B>Introductory Remarks</B>/R.A. Panettieri, Jr., M.D.,
Philadelphia, PA</P>
<P><I>1:40</I> <B>The Role of Managed Care Organization</B>/M.L. Osborne,
M.D., Ph.D., Portland, OR</P>
<P><I>2:05</I> <B>Defining the Template</B>/R.A. Panettieri, Jr., M.D.,
Philadelphia, PA</P>
<P><I>2:30</I> <B>The Role of the Specialist</B>/H.A. Boushey, Jr., M.D., San
Francisco, CA</P>
<P><I>2:55</I> <B>The Nurse's Role in Identifying and Removing Obstacles to
Care</B>/M.R. George, M.S.N., R.N., Philadelphia, PA</P>
<P><I>3:20</I> <B>Peak Flow Measures and Disease State Management</B>/S.
Janson, D.N.Sc., R.N., San Francisco, CA</P>
<P><I>3:45</I> <B>Improving Adherence with Patient Education</B>/C.S. Ciampa,
M.S.N., R.N., Indianapolis, IN</P>
<P>Discussion after each presentation/5 minutes</P></BLOCKQUOTE>
<P></P>
<HR SIZE="4" WIDTH="80%">
<CENTER>
<P><A HREF=97ala.html><IMG
SRC=images/activity_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97bus.html><IMG
SRC=images/business_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97cal.html><IMG
SRC=images/calendar_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97child.html><IMG
SRC=images/child_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=pg.html><IMG
SRC=images/courses_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=search.html><IMG
SRC=images/search_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=main.html><IMG
SRC=images/home_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97house.html><IMG
SRC=images/house_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=http://itsmtgs.com/ala-ats><IMG
SRC=images/regist_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=sessions.html><IMG
SRC=images/session_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=special.html><IMG
SRC=images/special_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97tours.html><IMG
SRC=images/tour_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97travel.html><IMG
SRC=images/travel_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
</P></CENTER>
<HR SIZE="4" WIDTH="80%">
<CENTER><FONT SIZE="+2"><B><I>American Thoracic Society</I></B></FONT><BR>
1740 Broadway<BR> New York, NY 10019<BR> VOICE:  212-315-8700<BR> Copyright &copy;
1996 American Lung Association.<BR> The American Thoracic  Society is the
medical section <BR>of the American Lung Association.<BR> 
</CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-167</DOCNO>
<DOCOLDNO>IA013-000141-B026-117</DOCOLDNO>
<DOCHDR>
http://www.thoracic.org:80/ic97/d57.html 206.138.195.144 19970217073514 text/html 4567
HTTP/1.0 200 OK
Date: Monday, 17-Feb-97 07:30:29 GMT
Server: NCSA/1.3
MIME-version: 1.0
Content-type: text/html
Last-modified: Friday, 24-Jan-97 16:15:49 GMT
Content-length: 4387
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//SQ//DTD HTML 2.0 HoTMetaL + extensions//EN">
<HTML>
<HEAD>
<TITLE>SYMPOSIUM: d57</TITLE></HEAD>
<BODY BGCOLOR="#FFFFFF">
<CENTER><IMG ALIGN="LEFT" SRC="images/banner0.jpg"></CENTER>
<CENTER><BR>
<P>SYMPOSIUM</P><BR>
<H2>D57: INFECTIOUS AND ECONOMICAL ISSUES ARISING FROM VENTILATOR CIRCUITS</H2></CENTER>
<HR SIZE="5" NOSHADE="NOSHADE" WIDTH="100%">
<P></P>
<CENTER>
<TABLE BORDER="2">
<TR ALIGN="CENTER" VALIGN="MIDDLE">
<TD ALIGN="CENTER" VALIGN="MIDDLE"><B><SMALL><A HREF="ic97.html">BACK TO
MAIN MENU</A></SMALL></B></TD></TR></TABLE></CENTER>
<P></P>
<HR SIZE="10" WIDTH="85%">
<P></P>
<BLOCKQUOTE>
<CENTER>
<P>WEDNESDAY , MAY 21</P>
<P><B>Assembly on Critical Care</B></P>
<P><B>1:30 pm-4:15 pm</B></P></CENTER></BLOCKQUOTE>
<HR SIZE="4" WIDTH="85%" ALIGN="CENTER" NOSHADE="NOSHADE">
<BLOCKQUOTE>
<P><I><B>Target Audience: </B></I>Critical care physicians, and respiratory
therapists, critical care nurses.</P>
<P><B>OBJECTIVES</B><BR>At the conclusion of this session, the participant
will be able to:</P>
<UL>
<LI>describe the relationship between patient and circuit contamination and the
development of pneumonia;</LI>
<LI>describe the respective merits, risks and indications of airway humidifying
devices during mechanical ventilation;</LI>
<LI>describe the cost-effectiveness issues related to mechanical ventilation.</LI></UL>
<P>This symposium will clarify the interaction between the patient and the
ventilator in the pathogenesis of ventilator-associated pneumonia and to assess
the infectious risks and the cost-effectiveness of different approaches to
patient-ventilator management.</P>
<P><I><B>Chairing: </B></I>D.D. Dreyfuss, M.D., Columbes, FranceR.M.
Kacmarek, Ph.D., R.R.T., Boston, MA</P>
<P><I>1:30</I> <B>From Oropharyngeal and Lower Airway Colonization to
Ventilator-Associated Pneumonia</B>/M.S. Niederman, M.D., Mineola, NY</P>
<P><I>1:53</I> <B>Patient Positioning During Mechanical Ventilation: A Simple
Measure to Prevent Ventilator-Associated Pneumonia?</B>/A. Torres, M.D.,
Barcelona, Spain</P>
<P><I>2:16</I> <B>Infectious Risks Associated with Endotracheal and
Tracheostomy Tubes</B>/J.E. Heffner, M.D., Phoenix, AZ</P>
<P><I>2:39</I> <B>Circuit Contamination During Mechanical Ventilation:
Natural History and Infectious Risks</B>/M.H. Kollef, M.D., St. Louis, MO</P>
<P><I>3:02</I> <B>Frequency of Circuit Changes During Mechanical Ventilation:
Can We Reduce Cost of Mechanical Ventilation Without Increasing Infectious Risk?</B>/R.M.
Kacmarek, Ph.D., R.R.T., Boston, MA</P>
<P><I>3:25</I> <B>Heat and Moisture Exchangers Humidifying Performance: Is It
Enough?</B>/A.R. Webb, M.D., Oxford, England</P>
<P><I>3:48</I> <B>Infectious and Economical Issues During Mechanical
Ventilation with Heated Humidifiers and Heat and Moisture Exchangers</B>/D.D.
Dreyfuss, M.D., Columbes, France</P></BLOCKQUOTE>
<P></P>
<HR SIZE="4" WIDTH="80%">
<CENTER>
<P><A HREF=97ala.html><IMG
SRC=images/activity_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97bus.html><IMG
SRC=images/business_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97cal.html><IMG
SRC=images/calendar_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97child.html><IMG
SRC=images/child_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=pg.html><IMG
SRC=images/courses_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=search.html><IMG
SRC=images/search_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=main.html><IMG
SRC=images/home_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97house.html><IMG
SRC=images/house_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=http://itsmtgs.com/ala-ats><IMG
SRC=images/regist_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
<A HREF=sessions.html><IMG
SRC=images/session_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=special.html><IMG
SRC=images/special_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97tours.html><IMG
SRC=images/tour_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A>
<A HREF=97travel.html><IMG
SRC=images/travel_but.jpg BORDER=0 WIDTH=84 HEIGHT=35></A><BR>
</P></CENTER>
<HR SIZE="4" WIDTH="80%">
<CENTER><FONT SIZE="+2"><B><I>American Thoracic Society</I></B></FONT><BR>
1740 Broadway<BR> New York, NY 10019<BR> VOICE:  212-315-8700<BR> Copyright &copy;
1996 American Lung Association.<BR> The American Thoracic  Society is the
medical section <BR>of the American Lung Association.<BR> 
</CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-168</DOCNO>
<DOCOLDNO>IA013-000141-B026-168</DOCOLDNO>
<DOCHDR>
http://www.thoracic.org:80/barc0996.html 206.138.195.144 19970217073535 text/html 81996
HTTP/1.0 200 OK
Date: Monday, 17-Feb-97 07:30:42 GMT
Server: NCSA/1.3
MIME-version: 1.0
Content-type: text/html
Last-modified: Friday, 20-Dec-96 20:23:48 GMT
Content-length: 81815
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//SQ//DTD HTML 2.0 HoTMetaL + extensions//EN">
<HTML>
<HEAD>
<TITLE>American Thoracic Society - ABSTRACTS; September 1996: Volume 154,
Number 3</TITLE></HEAD>
<BODY BACKGROUND="images/back.jpg">
<CENTER><IMG ALIGN="LEFT" SRC="images/smlogo.gif"><BR>
<H1>AJRCCM ABSTRACTS</H1></CENTER>
<HR SIZE="5" NOSHADE="NOSHADE" WIDTH="100%">
<P></P>
<HR>
<CENTER>
<TABLE BORDER="2">
<TR>
<TD ALIGN="CENTER" VALIGN="MIDDLE"><SMALL><B><A HREF="bluearch.html">BACK TO
ARCHIVES MAIN PAGE</A></B></SMALL></TD></TR></TABLE></CENTER>
<HR>
<CENTER>
<H2> September 1996: Volume 154, Number 3</H2>
<P><B><A NAME="top">AJRCCM ABSTRACT MENU</A></B></P></CENTER>
<CENTER>
<TABLE BORDER="1">
<TR ALIGN="CENTER" VALIGN="MIDDLE">
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#ats1">The Association
Between Occupation and Tuberculosis: A Population-based Survey</A></B></SMALL></TD></TR>
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#ats2">Interactions
Between Neutrophils and Cytokines in Blood and Alveolar Spaces During ARDS</A></B></SMALL></TD></TR>
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#ats3">Inflammatory
Cytokines in Patients with Persistence of the Acute Respiratory Distress
Syndrome</A></B></SMALL></TD></TR>
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#ats4">Efficacy of
Tracheal Gas Insufflation in Acute Respiratory Distress Syndrome with Permissive
Hypercapnia</A></B></SMALL></TD></TR>
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#ats5">Bacteremia &amp;
Severe Sepsis in Adults: A Multicenter Prospective Survey in ICUs and Wards of
24 Hospitals</A></B></SMALL></TD></TR>
<TR>
<TD><SMALL><B><A HREF="#ats6">Alveolar and Tissue Surfactant Pool Sizes in
Humans</A></B></SMALL></TD></TR>
<TR>
<TD><SMALL><B><A HREF="#ats7">Nonadrenergic Noncholinergic Relaxation of
Human Pulm. Arteries is Partially Mediated by Nitric Oxide</A></B></SMALL></TD></TR>
<TR>
<TD><SMALL><B><A HREF="#ats8">Daily Asthma Severity in Relation to Personal
Ozone Exposure and Outdoor Fungal Spores</A></B></SMALL></TD></TR>
<TR>
<TD><SMALL><B><A HREF="#ats9">Shape and Position of the Complete
Dose-Response Curve for Inhaled Methacholine in Normal Subjects</A></B></SMALL></TD></TR>
<TR>
<TD><SMALL><B><A HREF="#ats10">Inhaled Tryptase Causes Bronchoconstriction
in Sheep Via Histamine Release</A></B></SMALL></TD></TR>
<TR>
<TD><SMALL><B><A HREF="#ats11">The Relationship Between Upper Resp. 
Infections &amp; Hospital Admissions for Asthma</A></B></SMALL></TD></TR>
<TR>
<TD><SMALL><B><A HREF="#ats12">Lower Airway Responses to Influenza A Virus
in Healthy Allergic and Nonallergic Subjects</A></B></SMALL></TD></TR>
<TR>
<TD><SMALL><B><A HREF="#ats36">Comparison of Resp.  Inductance
Plethysmography w/ Thoracoabdominal Compression in Bronchial Challenges in
Infants and Young Children</A></B></SMALL></TD></TR>
<TR>
<TD><SMALL><B><A HREF="#ats13">Passive Respiratory Mechanics in Healthy
Infants: Effects of Growth, Gender, and Smoking</A></B></SMALL></TD></TR>
<TR>
<TD><SMALL><B><A HREF="#ats14">Risk Factors for Childhood Asthma and
Wheezing: Importance of Maternal and Household Smoking</A></B></SMALL></TD></TR>
<TR>
<TD><SMALL><B><A HREF="#ats15">Pulmonary Function During the First Year of
Life Following Acute Viral Bronchiolitis</A></B></SMALL></TD></TR>
<TR>
<TD><SMALL><B><A HREF="#ats16">Lung Function in Children and Adolescents
with Occasional Exposure to Environmental Tobacco Smoke</A></B></SMALL></TD></TR>
<TR>
<TD><SMALL><B><A HREF="#ats17">Exposure to Biomass Smoke and Chronic Airway
Disease in Mexican Women: A Case-Control Study</A></B></SMALL></TD></TR>
<TR>
<TD><SMALL><B><A HREF="#ats18">Prognostic Value of Ia+ T Lymphocytes in
Bronchoalveolar Lavage Fluid in Pulmonary Sarcoidosis</A></B></SMALL></TD></TR>
<TR>
<TD><SMALL><B><A HREF="#ats19">Anti-inflammatory Cytokine Release by
Alveolar Macrophages in Pulmonary Sarcoidosis</A></B></SMALL></TD></TR>
<TR>
<TD><SMALL><B><A HREF="#ats20">Elastin-derived Peptides and Neutrophil
Elastase in Bronchoalveolar Lavage Fluid</A></B></SMALL></TD></TR>
<TR>
<TD><SMALL><B><A HREF="#ats21">Cykokeratins as Serum Markers in Lung Cancer:
A Comparison of CYFRA 21-1 and TPS</A></B></SMALL></TD></TR>
<TR>
<TD><SMALL><B><A HREF="#ats22">Automated Continuous Positive Airway Pressure
Titration for Obstructive Sleep Apnea Syndrome</A></B></SMALL></TD></TR>
<TR>
<TD><SMALL><B><A HREF="#ats23">Radiographic and Pathologic Correlation of
Coal Workers' Pneumoconiosis</A> </B></SMALL></TD></TR>
<TR>
<TD><SMALL><B><A HREF="#ats24">Airway Muscle Stereology: Implications for
Increased Shortening in Asthma</A></B></SMALL></TD></TR>
<TR>
<TD><SMALL><B><A HREF="#ats25">Number and Proliferation of Neuroendocrine
Cells in Normal Human Airway Epithelium</A></B></SMALL></TD></TR>
<TR>
<TD><SMALL><B><A HREF="#ats26">Exogenous Surfactant Improves Ventilation
Efficiency &amp; Alveolar Expansion in Rats w/ Meconium Aspiration</A></B></SMALL></TD></TR>
<TR>
<TD><SMALL><B><A HREF="#ats27">Glucocorticoid Receptor Localization in
Normal and Asthmatic Lung</A></B> </SMALL></TD></TR>
<TR>
<TD><SMALL><B><A HREF="#ats28">Tyloxapol Inhibits NF-[kappa]B &amp; Cytokine
Release, Scavenges HOCI, &amp; Reduces Viscosity of Cystic Fibrosis Sputum</A></B></SMALL></TD></TR>
<TR>
<TD><SMALL><B><A HREF="#ats29">Causes of Pulmonary Impairment in
Asbestos-Exposed Individuals with Diffuse Pleural Thickening</A></B></SMALL></TD></TR>
<TR>
<TD><SMALL><B><A HREF="#ats30">Interstitial Lung Disease in Primary Sj&ouml;gren's
Syndrome: Clinical-Pathological Evaluation &amp; Response to Treatment</A></B></SMALL></TD></TR>
<TR>
<TD><SMALL><B><A HREF="#ats31">Rib Cage Dimensions in Hyperinflated Patients
with Severe Chronic Obstructive Pulmonary Disease</A></B></SMALL></TD></TR>
<TR>
<TD><SMALL><B><A HREF="#ats32">Mechanical Properties of the Velopharynx in
Obese Patients with Obstructive Sleep Apnea</A></B></SMALL></TD></TR>
<TR>
<TD><SMALL><B><A HREF="#ats33">Increased Exhalation of Hydrogen Peroxide in
Patients with Stable and Unstable Chronic Obstructive Pulmonary Disease</A></B></SMALL></TD></TR>
<TR>
<TD><SMALL><B><A HREF="#ats34">Bronchoalveolar Lavage Fluid Composition in
Alveolar Proteinosis: Early Changes After Therapeutic Lavage </A></B></SMALL></TD></TR>
<TR>
<TD><SMALL><B><A HREF="#ats35">Ethical Considerations of Ensuring an
Informed &amp; Autonomous Consent in Research Involving Critically Ill Patients</A></B></SMALL></TD></TR></TABLE></CENTER>
<P></P>
<HR>
<P><B><A NAME="ats1">The Association Between Occupation and Tuberculosis: A
Population-based Survey 154:587-593</A></B></P>
<P>There has been increasing interest in the potential association between
occupation and the risk of tuberculosis. Therefore, we analyzed occupational
information collected on all patients with clinically active tuberculosis in 29
states from 1984 to 1985. Census data were used to estimate the number of
persons in each of the occupations. Information on employment and occupation was
ascertained for 9,534 (99%) of the working age (16 through 64 yr) tuberculosis
patients. The overall case rate of tuberculosis in this age group in the study
areas was 8.4 per 100,000 persons, which was slightly lower than the national
rate of 9.3 per 100,000 persons. As a group, health care workers had rates of
tuberculosis similar to the general population (standardized morbidity ratio
[SMR]: 1.0; 95% CI: 0.9 to 1.1). However, elevated rates were observed for
inhalation therapists (SMR: 2.9; 95% CI: 1.2 to 6.0), and lower-paid health care
workers (SMR: 1.3; 95% CI: 1.1 to 1.5). Elevated rates were also noted for
funeral directors (SMR: 6.1; 95% CI: 2.2 to 3.9) and farm workers (SMR: 4.1; 95%
CI: 3.4 to 3.7). These data suggest that even in communities with relatively low
rates of tuberculosis certain occupations may be associated with an elevated
risk. <B>McKenna MT, Hutton M, Cauthen G, Onorato IM. AM J RESPIR CRIT CARE MED
1996.</B></P>
<TABLE BORDER="1">
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#top">BACK TO MENU</A></B></SMALL></TD></TR></TABLE>
<P></P>
<HR>
<P><B><A NAME="ats2">Interactions Between Neutrophils and Cytokines in Blood
and Alveolar Spaces During ARDS 154:594-601</A></B></P>
<P>Although the pathogenesis of the acute respiratory distress syndrome (ARDS)
is complex and poorly understood, several observations point to an important
role of interactions between polymorphonuclear neutrophils (PMN) and cytokines
in this process. We therefore studied certain parameters involved in PMN
transendothelial migration (adhesion molecule expression and cytoskeletal
organization) in patients with ARDS (n = 14) in comparison with other ventilated
patients (n = 15). We found that in the basal state, both whole-blood PMN and
alveolar PMN obtained by bronchoalveolar lavage (BAL) were activated, as shown
by decreased L-selectin CD62L and increased &szlig;2 integrin CD11b expression,
as well as decreased F-actin content. The degree of PMN activation increased
with the degree of lung injury and with the levels of tumor necrosis factor-a
(TNF-a), interleukin-6 (IL-6), and interleukin-8 (IL-8). Moreover, the capacity
of <I>ex vivo</I> stimulation of alveolar PMN by a bacterial peptide was low in
ARDS and could partly account for the high susceptibility of these patients to
lung infection. Therefore, ARDS-associated lung injury could be caused, at least
in part, by inappropriate adhesion and transendothelial migration of
proinflammatory cytokine-primed PMN. <B>Chollet-Martin S, Jourdain B, Gibert C,
Elbim C, Chastre J, Gougerot-Pocidalo MA. AM J RESPIR CRIT CARE MED 1996.</B></P>
<TABLE BORDER="1">
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#top">BACK TO MENU</A></B></SMALL></TD></TR></TABLE>
<P></P>
<HR>
<P><B><A NAME="ats3">Inflammatory Cytokines in Patients with Persistence of
the Acute Respiratory Distress Syndrome 154:602-611</A></B></P>
<P>To determine the relationship between airspace cytokines and cellular
inflammatory responses in patients with the acute respiratory distress syndrome
(ARDS), we performed bronchoalveolar lavage (BAL) in 82 prospectively
identified, mechanically ventilated patients on Days 3, 7, 14, and/or 21 after
the onset of ARDS. We studied the relationships between bronchoalveolar lavage
fluid (BALF) cell populations and the concentrations of two potent neutrophil
(PMN) chemoattractants, interleukin-8 (IL-8) and epithelial cell-derived
neutrophil activator-78 (ENA-78); two potent monocyte chemoattractants, monocyte
chemotactic peptide-1 (MCP-1) and macrophage inflammatory peptide-1a (MIP-1a);
and the early response cytokine interleukin-1&szlig; (IL-1&szlig;) and its
naturally occurring antagonist, IL-1 receptor antagonist protein (IRAP). We
found that all of these cytokines were significantly increased regardless of the
duration of ARDS. IL-8 and ENA-78 were the cytokines most strongly and
consistently correlated with PMN concentrations in the lung fluids of patients
with ARDS, and the correlations were independent of the other cytokines or
coexisting lung infection. None of the cytokines tested correlated with
macrophage concentrations. MCP-1 was directly correlated with lung injury score
on Days 7, 14, and 21. Although neither IL-8 nor ENA-78 was associated with
outcome, levels of IL-1&szlig; measured on Day 7 were associated with an
increased risk of death (odds ratio [OR] = 2.8; 95% confidence interval [CI] =
1.1 to 7.4). These data demonstrate potential molecular mechanisms of the
persistent inflammatory process in the lungs of patients with ARDS. <B>Goodman
RB, Strieter RM, Martin DP, Steinberg KP, Milberg JA, Maunder RJ, Kunkel SL,
Walz A, Hudson LD, Martin TR. AM J RESPIR CRIT CARE MED 1996.</B></P>
<TABLE BORDER="1">
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#top">BACK TO MENU</A></B></SMALL></TD></TR></TABLE>
<P></P>
<HR>
<P><B><A NAME="ats4">Efficacy of Tracheal Gas Insufflation in Acute
Respiratory Distress Syndrome with Permissive Hypercapnia 154:612-616</A></B></P>
<P>This study was conducted to assess the CO2-elimination efficiency of
tracheal gas insufflation (TGI) in 20 patients with acute respiratory distress
syndrome and to compare its efficacy during volume-controlled (VCV) and
pressure-controlled ventilation (PCV). TGI was initially applied as an adjunct
to VCV, with continuous flows (Vcath) of 4 and 6 L/min delivered through a
catheter positioned 2 cm above the carina. Total effective tidal volume (VTeff)
was held constant. The percent reductions in PaCO2 (%[DELTA]PaCO2) were 13.3 &#177;
2.1 and 16.7 &#177; 2.7% at Vcath 4 and 6 L/min, respectively, which correlated
well with the percent reduction in the end-tidal PCO2 from baseline
(%[DELTA]PETCO2) (r = 0.75, p &lt; 0.001). An inverse relationship (r = -0.65, p
&lt; 0.001 and r = -0.59, p &lt; 0.01 at Vcath 4 and 6 L/min, respectively) was
found between the %[DELTA]PaCO2 and the baseline ratio of artery to PETCO2
difference to PaCO2, which was determined as the fraction of alveolar dead space
(Vdalv) relative to total alveolar ventilation. Twelve patients were
subsequently switched to PCV combined with Vcath 6 L/min, which provided a
%[DELTA]PaCO2 of 16.1 &#177; 3.0% (p = NS versus 17.1 &#177; 2.6% during VCV).
These data suggest that in patients with ARDS the change in PETCO2 may be
helpful in predicting the decrement in PaCO2 during TGI, and the existence of a
high Vdalv tends to limit its effectiveness. Further, the efficacy of TGI with
VCV is equivalent to that with PCV. <B>Kuo P-H, Wu H-D, Yu C-J, Yang S-C, Lai
Y-L, Yang PC. AM J RESPIR CRIT CARE MED 1996.</B></P>
<TABLE BORDER="1">
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#top">BACK TO MENU</A></B></SMALL></TD></TR></TABLE>
<P></P>
<HR>
<P><B><A NAME="ats5">Bacteremia and Severe Sepsis in Adults: A Multicenter
Prospective Survey in ICUs and Wards of 24 Hospitals 154:617-624</A></B></P>
<P>To examine the relationships between bacteremia and severe sepsis and assess
the influence of characteristics of infection on the risk of severe sepsis and
outcome of bacteremia, we analyzed all clinically significant episodes of
bacteremia occurring during a 2-mo prospective survey of 85,750 admissions to
adult wards and intensive care units (ICUs) of 24 hospitals in France. Incidence
rates of bacteremia and of bacteremic severe sepsis were 9.8 (95% CI: 9.2 to
10.5) and 2.6 (95% CI: 2.2 to 2.9), respectively, per 1,000 adult admissions;
these rates were eight and 32 times higher in ICUs than in wards, respectively.
Independent risk factors for severe sepsis during bacteremia included age (p &lt;
0.001) and an intraabdominal (p &lt; 0.001), pulmonary (p &lt; 0.001),
neuromeningeal (p = 0.004), or multiple (p &lt; 0.001) source of bacteremia, but
not categories of organisms involved. The probability of death at 28 d after
bacteremia was 25% (95% CI: 23% to 29%), and was 54% (95% CI: 48% to 61%) in
patients with bacteremic severe sepsis. The risk of death after bacteremia
increased with age (p &lt; 0.001), a rapidly or ultimately fatal underlying
disease (p &lt; 0.001), and the presence of severe sepsis (p &lt; 0.001), shock
(p = 0.03), and infection caused by gram-positive organisms other than
coagulase-negative staphylococci, relative to other organisms (p &lt; 0.001). A
primary urinary tract source of infection was associated with a better prognosis
(p = 0.03). We conclude that whereas sources of infection influence both the
risk of severe sepsis and the outcome of bacteremia, the microbiologic
characteristics of infection influence only the outcome, with gram-negative
organisms and coagulase-negative staphylococci posing a lesser risk than other
organisms. <B>Brun-Buisson C, Doyon F, Carlet J, and the French
Bacteremia-Sepsis Study Group. AM J RESPIR CRIT CARE MED 1996.</B></P>
<TABLE BORDER="1">
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#top">BACK TO MENU</A></B></SMALL></TD></TR></TABLE>
<P></P>
<HR>
<P><B><A NAME="ats6">Alveolar and Tissue Surfactant Pool Sizes in Humans
154:625-628</A></B></P>
<P>The amounts of surfactant in human lung tissue and in the alveolar pool have
not been extensively reported. We used 24 human lungs from persons over the age
range of 13 mo to 80 yr to investigate whether the amount of saturated
phosphatidylcholine (Sat-PC) in the human lung changed with age. Lung lavages
also were obtained from 10 lungs at autopsy for measurements of the alveolar
Sat-PC and surfactant protein-A (SP-A) concentrations. We found that (mean &#177;
SEM) lung Sat-PC/body weight (28.4 &#177; 2.2 mmol/kg), Sat-PC/lung protein
(0.060 &#177; 0.005 mmol/mg), and Sat-PC/lung deoxyribonucleic acid (DNA) (0.23 &#177;
0.01 mmol/mg) did not vary significantly with age. The amounts of alveolar
Sat-PC (1.9 &#177; 0.2 mmol/kg) and SP-A (105 &#177; 15 mg/kg) were lower than
previous estimates in other species. The relatively small surfactant pools in
the human may make the lung more susceptible to injuries that interfere with
surfactant function. <B>Rebello CM, Jobe AH, Eisele JW, Ikegami M. AM J RESPIR
CRIT CARE MED 1996.</B></P>
<TABLE BORDER="1">
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#top">BACK TO MENU</A></B></SMALL></TD></TR></TABLE>
<P></P>
<HR>
<P><B><A NAME="ats7">Nonadrenergic Noncholinergic Relaxation of Human
Pulmonary Arteries is Partially Mediated by Nitric Oxide 154:629-632</A></B></P>
<P>Nonadrenergic noncholinergic (NANC) vasodilator mechanisms may contribute to
the maintenance of low vascular resistance characteristic of the pulmonary
circulation. Previous studies have demonstrated that nitric oxide (NO) is the
principal NANC neurotransmitter in guinea pig pulmonary arteries. We examined
whether NANC relaxation could be demonstrated in human pulmonary arteries, and
the role of NO in this phenomenon. Fresh human pulmonary artery rings, with and
without an intact endothelium, were mounted in organ baths containing Krebs'
solution and precontracted with U44069 (0.3 mM). Adrenergic and cholinergic
neurostransmitter pathways were blocked with guanethidine and atropine,
respectively (10 mM each). In both endothelium-intact and -denuded vessels,
electrical field stimulation (EFS, 1 to 10 Hz, 100 V) resulted in a
frequency-dependent relaxation (maximal relaxation of 25 &#177; 4% and 15 &#177;
2% in endothelium-intact and -denuded vessels, respectively). Tetrodotoxin (0.3
mM) abolished the EFS-induced relaxation. l-NG-nitro-arginine methyl ester
(l-NAME, 10 mM), was used to block enzymatic synthesis of NO. In both
endothelium-intact and -denuded vessels, l-NAME reduced NANC relaxation to
approximately 50% of control values. This reduction was reversible with the
application of l-arginine (100 mM). We conclude that NANC relaxation exists in
human pulmonary arteries and that it is partly mediated through NO. <B>Scott
JA, Craig I, McCormack DG. AM J RESPIR CRIT CARE MED 1996.</B></P>
<TABLE BORDER="1">
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#top">BACK TO MENU</A></B></SMALL></TD></TR></TABLE>
<P></P>
<HR>
<P><B><A NAME="ats8">Daily Asthma Severity in Relation to Personal Ozone
Exposure and Outdoor Fungal Spores 154:633-641</A></B></P>
<P>Epidemiologic investigations of ambient ozone (O3) effects on daily asthma
status have not used personal O3 exposures and have often lacked
well-characterized allergen exposures. To address this, we studied 12 asthmatic
subjects aged 9 to 16 yr, who recorded daily asthma symptoms (functional levels
0 to 5) and as-needed inhaler use during September and October 1993 in San
Diego, California. Outdoor aeroallergens, O3, and fine particle concentrations
were measured at a central outdoor site, and personal 12-h daytime exposures to
O3 were measured daily. Personal O3 differed greatly between subjects and was
27% of mean outdoor O3. In random-effects autoregression models controlling for
weekend days and fungal spores, personal O3 was associated with asthma severity:
for a 90th percentile increase in O3 (25 ppb), symptom scores increased by 25%
(95% Cl: 0 to 49%) and inhaler use increased by 26% (95% Cl: 3 to 48%) over
their averages. Outdoor 12-h O3, but not 1-h maximum O3, was associated with
inhaler use (p &lt; 0.03). Fungal spores were significantly associated with
symptoms (scores increased by 0.1 to 0.3/1,000 spores/m3) and inhaler use (0.1
to 0.4 puffs/1,000 spores/ m3) across speciated groups. Pollen and fine
particles (low levels) were not associated with any outcomes. These findings
illustrate that the epidemiologic importance of O3 and allergenic cofactors can
be underestimated by failure to account for personal O3 and fungal exposures.
<B>Delfino RJ, Coate BD, Zeiger RS, Seltzer JM, Street DH, Koutrakis P. AM J
RESPIR CRIT CARE MED 1996.</B></P>
<TABLE BORDER="1">
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#top">BACK TO MENU</A></B></SMALL></TD></TR></TABLE>
<P></P>
<HR>
<P><B><A NAME="ats9">Shape and Position of the Complete Dose-Response Curve
for Inhaled Methacholine in Normal Subjects 154:642-648</A></B></P>
<P>Plateaus on the inhalation concentration-response curve have been described
in normal subjects and patients with mild asthma. To determine the prevalence of
plateaus on inhalation concentration-response curves, and the position of the
curves in normal subjects, we measured complete dose-response curves for
methacholine (1 mg/ml to 256 mg/ml) in 73 nonatopic, nonsmoking, nonasthmatic
normal subjects between the ages of 20 and 76 yr. Measurements included FEV1,
maximal expiratory flow at 50% and 30% of vital capacity on partial and complete
forced expiratory flow-volume curves (Vmax50p, Vmax50c, Vmax30p, Vmax30c) and
pulmonary resistance (Rl). Plateau responses, EC50 values and slopes were
measured. Plateaus were present in 25, 27, 24, 34, 35, and 16 subjects for FEV1,
Vmax50c, Vmax30c, Vmax50p, Vmax30p, and Rl, respectively. In those who achieved
a plateau, the mean maximal decrease in FEV1 (&#177; SD) was 21 &#177; 8%, in
Vmax50c it was 46 &#177; 16%, in Vmax50p it was 67 &#177; 12%, in Vmax30c it was
58 &#177; 21%, and in Vmax30p it was 75 &#177; 15%, and the increase in Rl was
213 &#177; 89%. In summary, the results of this study showed that easily
identifiable plateaus develop on the inhalation concentration-response curves of
approximately 40% of normal subjects after only moderate decreases in maximum
flow and increases in Rl. Maximal response at the plateau was greater on partial
flow-volume curves and at lower lung volumes (30% versus 50% of VC). Comparison
of these data with data from patients at risk for airway hyperresponsiveness
will allow definition of the mechanisms leading to airway hyperresponsiveness.
<B>Moore B, Hilliam C, Verburgt L, Wiggs B, Vedal S, Par&eacute; P. AM J RESPIR
CRIT CARE MED 1996.</B></P>
<TABLE BORDER="1">
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#top">BACK TO MENU</A></B></SMALL></TD></TR></TABLE>
<P></P>
<HR>
<P><B><A NAME="ats10">Inhaled Tryptase Causes Bronchoconstriction in Sheep
Via Histamine Release 154:649-653</A></B></P>
<P>Allergen-induced bronchoconstriction involves mast cell activation. Tryptase
is a mast cell serine protease that is released during this process, but little
is known about the action of tryptase in the airway. The purpose of this study
was to determine: (<I>1</I>) if aerosolized tryptase causes
bronchoconstriction, and (<I>2</I>) the mechanism by which this occurs. We
measured mean pulmonary flow resistance (Rl) in five allergic sheep before and
after consecutive inhalations of 100 and 500 ng tryptase (in 2 ml total volume).
Inhaled tryptase at 100 and 500 ng increased Rl (mean &#177; SE) by 33 &#177; 12
and 122 &#177; 8% (p &lt; 0.05) over baseline. The response was reproducible
upon repeat challenges. These studies were repeated in the same animals after
pretreatment with aerosolized APC 366 (9 mg/3 ml), a specific tryptase
inhibitor. In APC-366-treated sheep, tryptase increased Rl by 10 &#177; 3 and 6 &#177;
2% (p &lt; 0.05 versus control values) at 100 and 500 ng, respectively. The
response to tryptase was also blocked by pretreating the sheep intravenously
with the histamine H1-antagonist chlorpheniramine (2 mg/kg), in which RL
increased only 5 &#177; 4 and 7 &#177; 6% after 100 and 500 ng tryptase. APC
366, however, did not block histamine-induced bronchoconstriction. Consistent
with these findings was the observation that segmental bronchial challenge with
tryptase (1 mg) resulted in a significant increase in histamine levels in
bronchoalveolar lavage. Inhaled tryptase (500 ng) also caused airway
hyperresponsiveness to aerosolized carbachol 2 h after tryptase challenge. This
tryptase-induced airway hyperresponsiveness could be blocked either by
pretreating the sheep with APC 366 (30 min before challenge) or by treating the
sheep 30 min after challenge. These results indicate that inhaled tryptase
causes bronchoconstriction and airway hyperresponsiveness in allergic sheep by
an event that may involve mast cell activation. <B>Molinari JF, Scuri M, Moore
WR, Clark J, Tanaka R, Abraham WM. AM J RESPIR CRIT CARE MED 1996.</B></P>
<TABLE BORDER="1">
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#top">BACK TO MENU</A></B></SMALL></TD></TR></TABLE>
<P></P>
<HR>
<P><B><A NAME="ats11">The Relationship Between Upper Respiratory Infections
and Hospital Admissions for Asthma: A Time-trend Analysis 154:654-660</A></B></P>
<P>We have shown that viruses are associated with 80 to 85% of asthma
exacerbations in school-age children in the community. We hypothesize that viral
infections are also associated with severe attacks of asthma precipitating
hospital admissions. To investigate this, we conducted a time-trend analysis,
comparing the seasonal patterns of respiratory infections and hospital
admissions for asthma in adults and children. During a 1-yr study in the
Southampton area of the United Kingdom, 108 school-age children monitored upper
and lower respiratory symptoms and took peak expiratory flow rate (PEFR)
recordings. From children reporting a symptomatic episode or a decrease in PEFR,
samples were taken for detection of viruses and atypical bacteria. A total of
232 respiratory viruses and four atypical bacteria were detected. The
half-monthly rates of upper respiratory infection were compared with the
half-monthly rates for hospital admissions for asthma (International
Classification of Diseases [ICD] code 493) for the same time period for the
hospitals serving the areas from which the cohort of schoolchildren was drawn.
The relationships of upper respiratory infections and hospital admissions for
asthma with school attendance were studied. Strong correlations were found
between the seasonal patterns of upper respiratory infections and hospital
admissions for asthma (r = 0.72; p &lt; 0.0001). This relationship was stronger
for pediatric (r = 0.68; p &lt; 0.0001) than for adult admissions (r = 0.53; p &lt;
0.01). Upper respiratory infections and admissions for asthma were more frequent
during periods of school attendance (87% of pediatric and 84% of total
admissions), than during school holiday periods (p &lt; 0.001). These
relationships remained significant when allowance was made for linear trend and
seasonal variation using multiple regression analysis (p &lt; 0.01). Not
surprisingly, school attendance, because it is a major factor in respiratory
virus transmission, was found to be a major confounding variable in children.
This study demonstrates that upper respiratory viral infections are strongly
associated in time with hospital admissions for asthma in children and adults.
Rhinoviruses were the major pathogen implicated, and the majority of viral
infections and asthma admissions occurred during school attendance. <B>Johnston
SL, Pattemore PK, Sanderson G, Smith S, Campbell MJ, Josephs LK, Cunningham A,
Robinson BS, Myint SH, Ward ME, Tyrrell DAJ, Holgate ST. AM J RESPIR CRIT CARE
MED 1996.</B></P>
<TABLE BORDER="1">
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#top">BACK TO MENU</A></B></SMALL></TD></TR></TABLE>
<P></P>
<HR>
<P><B><A NAME="ats12">Lower Airway Responses to Influenza A Virus in Healthy
Allergic and Nonallergic Subjects 154:661-664</A></B></P>
<P>Acute asthma is considered a complication of respiratory viral infections.
This investigation assessed the effects of influenza A virus infection on both
the patency and responsiveness of the lower airways. Subjects with allergic
rhinitis (AR; n = 21) and without AR (non-AR; n = 25) were intranasally
inoculated with influenza A virus and monitored for 8 d in a cloistered
environment for changes in symptoms, signs, and airway physiology (pulmonary
function, bronchial methacholine provocation). All subjects were infected after
inoculation. Significant increases in nasal symptoms and secretion weights were
observed, with peak effects on Days 3 and 4. Cough was a relatively minor
symptom, and none of the subjects developed wheezing. Likewise, there were no
significant changes in the measured functions of the lower airways. No effects
on allergy status were observed. Under these experimental conditions, influenza
A virus infection did not produce detectable alterations in lower airway
function in healthy AR and non-AR subjects. <B>Skoner DP, Doyle WJ, Seroky J,
Fireman P. AM J RESPIR CRIT CARE MED 1996.</B></P>
<TABLE BORDER="1">
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#top">BACK TO MENU</A></B></SMALL></TD></TR></TABLE>
<P></P>
<HR>
<P><B><A NAME="ats36">Comparison of Respiratory Inductance Plethysmography
with Thoracoabdominal Compression in Bronchial Challenges in Infants and Young
Children 154:665-669</A></B></P>
<P>Respiratory inductance plethysmography measuring thoracoabdominal asynchrony
(TAA) has been claimed to be a useful tool for measuring changes in airway
resistance in infants. In this study we evaluated the response to methacholine
by thoracoabdominal compression and respiratory inductance plethysmography.
Seventeen infants (mean age, 13.1 &#177; 4.7 mo) with recurrent episodes of
cough or wheeze underwent bronchial challenge with inhaled methacholine. Lung
function was evaluated by measuring maximal expiratory flow at resting lung
volume (VmaxFRC), and the degree of TAA was measured by phase angle ([theta]).
Methacholine was inhaled for 1 min during tidal breathing using increasing
doubling concentrations until a fall of at least 40% in VmaxFRC was achieved
(final concentration). All infants responded to the final concentration of
methacholine by a significant fall in VmaxFRC (from 31 &#177; 10 to 12 &#177; 5
ml/s/kg, p &lt; 0.001). All but one infant responded to methacholine at the
final concentration with a significant increase in phase angle (median [theta]
increased from 11.7 to 31.7 degrees, p &lt; 0.001). In two other infants there
was an early response in [theta] compared with the response in VmaxFRC. Phase
angle increase after methacholine was expressed as Z-scores (the difference
between postmethacholine [theta ] and postbuffer [theta] divided by the standard
deviation of postbuffer [theta]). An increase of at least 2.0 Z-scores in
[theta] was observed at the same concentration of methacholine when VmaxFRC fell
by at least 40% in 15 of the 17 infants (88%). We conclude that respiratory
inductance plethysmography is a sensitive method to measure bronchial reactivity
to methacholine in most of the infants studied (14 of 17, 82%). A concentration
of methacholine causing an increase in [theta] of at least 2.0 standard
deviations above baseline is equivalent to the concentration causing a 40% fall
in VmaxFRC. <B>Springer C, Godfrey S, Vilozni D, Bar-Yishay E, Noviski N,
Avital A. AM J RESPIR CRIT CARE MED 1996.</B></P>
<TABLE BORDER="1">
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#top">BACK TO MENU</A></B></SMALL></TD></TR></TABLE>
<P></P>
<HR>
<P><B><A NAME="ats13">Passive Respiratory Mechanics in Healthy Infants:
Effects of Growth, Gender, and Smoking 154:670-680</A></B></P>
<P>This investigation characterizes the normal growth, variability, and effects
of gender and smoking on passive respiratory mechanics in healthy infants.
Passive respiratory mechanics were assessed at 193 test sessions on 127 infants
(55 boys, 72 girls) between 2 wk and 18 mo of age using the single-occlusion
passive flow-volume technique. Respiratory compliance (Crs) increased
significantly with increasing infant length, whereas respiratory resistance
(Rrs) declined. No significant gender differences were apparent for Crs,
although there was a tendency for this measure to be both lower at birth and
increase at a slower rate in girls than in boys. Rrs was significantly higher at
birth in infant boys than in infant girls, but the rate of the normal decline in
Rrs during the first 18 mo also occurred at a significantly greater rate in
boys. The passive respiratory time constant (Trs) overall showed little change
over this age range, but it was both lower near birth and increased at a
significantly greater rate versus infant length in girls than in boys. Maternal
smoking during pregnancy was associated with lower levels of Rrs at birth, as
well as with significantly slower growth of Crs and natural decline of Rrs in
the first 18 mo of life. These data suggest that infant girls may have more
mature respiratory mechanics at birth, but that postnatal growth/maturation may
be faster in boys. <B>Hanrahan JP, Brown RW, Carey VJ, Castile RG, Speizer FE,
Tager IB. AM J RESPIR CRIT CARE MED 1996.</B></P>
<TABLE BORDER="1">
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#top">BACK TO MENU</A></B></SMALL></TD></TR></TABLE>
<P></P>
<HR>
<P><B><A NAME="ats14">Risk Factors for Childhood Asthma and Wheezing:
Importance of Maternal and Household Smoking 154:681-688</A></B></P>
<P>To identify modifiable risk factors for wheezing illness in childhood, the
associations between current asthma or wheezing and factors such as household
smoking, damp and dietary salt preference were measured in a questionnaire-based
prevalence study of schoolchildren 7 to 9 yr of age in Cape Town. In a random
sample of 15 schools, questionnaires were completed by parents of 1,955
children, from which 368 cases and 294 controls were selected on the basis of
reported asthma diagnosis or symptoms. Urinary cotinine concentrations were
measured, and the parents were interviewed. An exposure-response relationship
between the urinary cotinine creatinine ratio and asthma/wheeze was observed. In
multivariate analysis, predictors of asthma/wheeze were hay fever (odds ratio
[OR] = 5.30; 95% confidence interval [CI] = 3.16 to 8.89), eczema (OR = 2.19;
95% CI = 1.33-3.62), parental asthma (OR = 1.77; 95% CI = 1.11 to 2.84), absence
of paternal contribution to income (OR = 1.72; 95% CI = 1.17 to 2.54), maternal
smoking in pregnancy (OR = 1.87; 95% CI = 1.25 to 2.81), and each additional
household smoker (OR = 1.15; 95% CI = 1.01 to 1.30). Findings were similar, with
higher odds ratios for most variables, except number of household smokers, when
the group was restricted to children with parent-reported asthma. The findings
confirm that household smoking is an important modifiable risk factor in
asthma/wheeze among young schoolchildren, and they suggest that maternal smoking
in pregnancy and current household exposure are independent contributors to this
effect. <B>Ehrlich RI, Du Toit D, Jordaan E, Zwarenstein M, Potter P, Volmink
JA, Weinberg E. AM J RESPIR CRIT CARE MED 1996.</B></P>
<TABLE BORDER="1">
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#top">BACK TO MENU</A></B></SMALL></TD></TR></TABLE>
<P></P>
<HR>
<P><B><A NAME="ats15">Pulmonary Function During the First Year of Life
Following Acute Viral Bronchiolitis 154:689-694</A></B></P>
<P>It has been suggested that acute viral bronchiolitis in infants may result
in functional changes that predispose toward chronic pulmonary disease later in
life. We assessed pulmonary function (PF) during the acute phase of viral
bronchiolitis in infants and up to 12 mo later from static respiratory system
compliance (Crs), using weighted spirometry, the distribution of ventilation by
the mixing index (MI), and the functional residual capacity (FRC) measured by
closed-circuit helium dilution (FRCHe). The study was performed in 24 infants
(13 males and 11 females; median [25 to 75% range] age: 11 [9.6 to 13.3] wk;
weight: 4.8 [4.3 to 5.0] kg; crown-to-heel length: 57.7 [55.5 to 59.0] cm) at
admission and at 2 wk. In 17 infants, measurements were repeated 3 mo and 12 mo
later. Predicted values and individual 95% prediction intervals for Crs, MI, and
FRCHe were derived from 69 healthy infants (33 boys and 36 girls; median age [25
to 75% range]: 4.7 [2.0 to 21.4] wk; weight: 3.6 [3.0 to 6.9] kg; crown-to-heel
length: 51.5 [48 to 61] cm). Data at admission and after discharge were compared
by analysis of variance (ANOVA) with those in the healthy controls matched for
crown-to-heel length. At admission all three variables gave lower average
results than predicted means. Values for each index had attained a normal level
2 wk after admission; normal levels were maintained at 3 and 12 mo. The
prevalence of recurrent wheezing (five of the 17 infants) was comparable with
that reported in population studies. These findings suggest that in this
population acute viral bronchiolitis did not lead to permanent changes in PF.
<B>Merth IT, de Winter JP, Zonderland HM, Brand R, Quanjer PH. AM J RESPIR CRIT
CARE MED 1996.</B></P>
<TABLE BORDER="1">
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#top">BACK TO MENU</A></B></SMALL></TD></TR></TABLE>
<P></P>
<HR>
<P><B><A NAME="ats16">Lung Function in Children and Adolescents with
Occasional Exposure to Environmental Tobacco Smoke 154:695-700</A></B></P>
<P>We investigated the effects of occasional exposure to environmental tobacco
smoke (ETS) on lung function in children. A total of 317 healthy 12- to
15-yr-old nonsmoking children and adolescents, living in households in which
none of the adults were active smokers, were selected for the present analysis.
The urinary cotinine:creatinine ratio (CCR) was taken as the biologic indicator
of exposure, and children were classified according to CCR quartiles. The ratio
between FEV1 and FVC (FEV1/FVC) and both early (peak expiratory flow [PEF]) and
midexpiratory flow rates (FEF25-75) were lower in children with higher CCR
values. In percent terms, the decrease in adjusted lung function for children
belonging to the second, third, and fourth quartiles in comparison with those in
the first quartile was -1.37, -2.12, and -1.94 for FEV1/FVC (p for trend =
0.012); 0.98, -3.31, and -4.54 for PEF (p for trend = 0.024); and -0.05, -4.85,
and -6.13 for FEF25-75 (p for trend = 0.022), respectively. The effects remained
significant when possible confounding by father's education and urinary
creatinine level had been taken into account, and when children whose parents'
smoking status may have been misclassified were excluded. This study suggests an
adverse effect on lung function from even low-level exposure to ETS among
nonsmoking children living with reportedly nonsmoking parents. <B>Corbo GM,
Agabiti N, Forastiere F, Dell'Orco V, Pistelli R, Kriebel D, Pacifici R, Zuccaro
P, Ciappi G, Perucci CA. AM J RESPIR CRIT CARE MED 1996.</B></P>
<TABLE BORDER="1">
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#top">BACK TO MENU</A></B></SMALL></TD></TR></TABLE>
<P></P>
<HR>
<P><B><A NAME="ats17">Exposure to Biomass Smoke and Chronic Airway Disease in
Mexican Women: A Case-Control Study 154:701-706</A></B></P>
<P>A case-control study was performed in women older than 40 yr of age to
evaluate the risk of cooking with traditional wood stoves for chronic bronchitis
and chronic airway obstruction (CAO). The subjects were recruited from patients
attending a referral chest hospital in Mexico City. We selected 127 patients
with chronic bronchitis or CAO, of which 63 had chronic bronchitis alone, 23 had
CAO alone (FEV1 less than 75% of predicted), and 41 had both chronic bronchitis
and CAO (cases). Four control groups were selected: 83 patients with pulmonary
tuberculosis, 100 patients with interstitial lung diseases, 97 patients with
ear, nose and throat ailments, and 95 healthy visitors to the hospital
(controls). Exposure to wood smoke, assessed as any or none, and as hour-years
(years of exposure multiplied by average hours of exposure per day) was
significantly higher in cases than in controls. Crude odds ratios for wood smoke
exposure were 3.9 (95% CI, 2.0 to 7.6) for chronic bronchitis only, 9.7 (95% CI,
3.7 to 27) for CAO plus chronic bronchitis, and 1.8 (95% CI, 0.7 to 4.7) for CAO
only. Differences in exposure to wood smoke persisted after adjusting by
stratification and logistic regression for age, income, education, smoking,
place of residence, and place of birth. Risk of chronic bronchitis alone and
chronic bronchitis with CAO increased linearly with hour-years of cooking with a
wood stove; odds ratios for exposure to more than 200 hour-years compared with
nonexposed were 15.0 (95% CI, 5.6 to 40) for chronic bronchitis only and 75 (95%
CI, 18 to 306) for chronic bronchitis with CAO. The findings support a causal
role of domestic wood smoke exposure in chronic bronchitis and chronic airflow
obstruction. <B>P&eacute;rez-Padilla R, Regalado J, Vedal S, Par&eacute; P,
Chapela R, Sansores R, Selman M. AM J RESPIR CRIT CARE MED 1996.</B></P>
<TABLE BORDER="1">
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#top">BACK TO MENU</A></B></SMALL></TD></TR></TABLE>
<P></P>
<HR>
<P><B><A NAME="ats18">Prognostic Value of Ia+ T Lymphocytes in
Bronchoalveolar Lavage Fluid in Pulmonary Sarcoidosis 154:707-712</A></B></P>
<P>We investigated the value of the Ia+ T-lymphocyte (CD3+ HLA-DR+) ratio in
bronchoalveolar lavage fluid (BALF) for predicting the outcome of pulmonary
sarcoidosis. Analysis of the BALF Ia+ T% in 166 patients with pulmonary
sarcoidosis by dual-color flow cytometry revealed a wide range of values, of
from 0.5 to 85.3%. Although the majority of patients had less than 40% Ia+ T
cells in their BALF, a minor peak was observed at 50 to 60%. The BALF Ia+ T%
value was not influenced by smoking, sex, or age, thus differing from other BALF
activation markers. Fifty patients could be followed up precisely for 3 yr after
their initial bronchoalveolar lavage (BAL) to evaluate outcome with respect to
chest X-ray findings, clinical symptoms, serum angiotensin converting enzyme
(ACE) activity, and extrapulmonary involvement. The 50 patients were divided
into two groups, with a BALF Ia+ T% &lt; 40% (n = 34) and &#179; 40% (n = 16),
respectively. Serum ACE activity returned to normal within 1 yr in the &lt; 40%
T group, but remained high for the entire follow-up period in the &#179; 40%
group. The significant difference was observed in the persistence of pulmonary
involvement between the two groups except for four patients who showed Stage 0
disease (p &lt; 0.02). Thirteen of 31 patients in the &lt; 40% group showed
normalization of chest X-ray findings after three years, whereas only one out of
15 patients in the &#179; 40% group showed resolution of pulmonary involvement.
Our results suggest that the BALF Ia+ T% may be a novel marker for predicting
the long-term prognosis in pulmonary sarcoidosis. <B>Suzuki K, Tamura N, Iwase
A, Dambara T, Kira S. AM J RESPIR CRIT CARE MED 1996.</B></P>
<TABLE BORDER="1">
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#top">BACK TO MENU</A></B></SMALL></TD></TR></TABLE>
<P></P>
<HR>
<P><B><A NAME="ats19">Anti-inflammatory Cytokine Release by Alveolar
Macrophages in Pulmonary Sarcoidosis 154:713-719</A></B></P>
<P>Sarcoidosis is a systemic, granulomatous disorder with a high rate of
spontaneous remission indicating the presence of antiinflammatory mechanisms.
Antiinflammatory mediators such as interleukin-10 (IL-10) and transforming
growth factor-&szlig; (TGF-&szlig;) should be able to induce spontaneous
remission of sarcoidosis. By measuring the release of both mediators in culture
supernatants of bronchoalveolar lavage (BAL) cells, we investigated their
relevance in the spontaneous remission of sarcoidosis. No spontaneous IL-10
release was observed by BAL cells of sarcoid patients. In supernatants of BAL
cells of seven patients found retrospectively to be free of any interstitial
lung disease, we found 612 &#177; 261.2 pg/ml (mean &#177; SEM) TGF-&szlig;.
TGF-&szlig; release was recorded in 20 of 39 patients with active disease.
Patients with active disease without TGF-&szlig; release in BAL cell culture
either required therapy (n = 21; 677 &#177; 159 pg/ml) or showed evidence of
persisting disease (n = 6; 762 &#177; 419 pg/ml). Patients with active disease
without indications for therapy and with significantly increased TGF-&szlig;
release (n = 12; 1,422 &#177; 215 pg/ml; p &lt; 0.004 in all comparisons) had a
spontaneous remission within 6 mo. Increased TGF-&szlig; release (1,560 &#177;
353 pg/ml) was observed in five of five patients receiving therapy. We conclude
that TGF-&szlig; is a regulator of the inflammatory process in sarcoidosis. <B>Zissel
G, Homolka J, Schlaak J, Schlaak M, M&uuml;ller-Quernheim J. AM J RESPIR CRIT
CARE MED 1996.</B></P>
<TABLE BORDER="1">
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#top">BACK TO MENU</A></B></SMALL></TD></TR></TABLE>
<P></P>
<HR>
<P><B><A NAME="ats20">Elastin-derived Peptides and Neutrophil Elastase in
Bronchoalveolar Lavage Fluid 154:720-724</A></B></P>
<P>To evaluate effects of current smoking on the breakdown of lung elastin, we
measured levels of elastin-derived peptides (EDP) in unconcentrated
bronchoalveolar lavage (BAL) fluid from 42 community-based older asymptomatic
volunteers (60 &#177; 11 yr [mean &#177; SD]) and examined the relationships of
the concentrations of EDP with immunologically detected neutrophil elastase (NE)
bound with a1-proteinase inhibitor and with esterolytic activity against the
NE-sensitive synthetic substrate, methoxysuccinyl-alanyl-alanyl-prolyl-valyl
paranitroanilide (MEOSAAPVNA). The measurement of EDP levels was carried out by
an indirect, competitive ELISA, using a sheep IgG fraction generated against
insoluble human lung elastin as a primary antibody. EDP concentrations were
significantly elevated in current smokers (n = 24) compared with age-matched
noncurrent smokers (n = 18) (29.9 &#177; 3.5 [mean &#177; SE] versus 17.0 &#177;
1.8 ng/mg BAL fluid albumin, p &lt; 0.01). We found weak but significant
correlations of EDP levels with NE-a1-proteinase inhibitor complex (r = 0.38, p
&lt; 0.05) and with the esterolytic activity against the NE-sensitive synthetic
substrate in BAL fluid (r = 0.65, p &lt; 0.001). In addition, EDP levels in BAL
fluid had a significant positive relationship with plasma cotinine
concentrations (r = 0.53, p &lt; 0.001), though not with pack-years of smoking
(r = 0.1, NS). These data provide further evidence that the concentrations of
EDP increase in BAL fluid from current smokers compared with noncurrent smokers
and that enhanced breakdown of the lung elastin is associated with the increased
load of NE in the lung. <B>Betsuyaku T, Nishimura M, Yoshioka A, Takeyabu K,
Miyamoto K, Kawakami Y. AM J RESPIR CRIT CARE MED 1996.</B></P>
<TABLE BORDER="1">
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#top">BACK TO MENU</A></B></SMALL></TD></TR></TABLE>
<P></P>
<HR>
<P><B><A NAME="ats21">Cykokeratins as Serum Markers in Lung Cancer: A
Comparison of CYFRA 21-1 and TPS 154:725-733</A></B></P>
<P>We examined two recently described cytokeratin markers, CYFRA 21-1
(cytokeratin fragment recognized by KS 19-1 and BM 19-21 antibodies) and TPS
(specific M3 epitope of the tissue polypeptide antigen), in 405 lung cancer
patients (91 small-cell and 314 non-small-cell lung cancers) and 59 patients
presenting with nonmalignant pulmonary disease. Sensitivity-specificity
relationship, as analyzed by receiver operating characteristic curves,
demonstrated a higher accuracy of CYFRA 21-1 in comparison with TPS in both
small-cell and non-small-cell lung cancers. Thresholds of 3.6 ng/ml and 140 U/L
for CYFRA 21-1 and TPS respectively gave a 90% to 95% specificity. Sensitivity
of CYFRA 21-1 was the highest in squamous-cell carcinomas (0.61) and the lowest
in small-cell lung cancers (0.36), whereas sensitivity of TPS did not vary
significantly according to histology (overall sensitivity, 0.40). In
non-small-cell lung cancers, both serum CYFRA 21-1 and serum TPS distributions
varied significantly according to Mountain's stage of the disease, nodal status,
tumor status, and performance status, inasmuch as the worse each above-mentioned
variable became, the higher the median and interquartile serum marker level was.
Neither CYFRA 21-1 nor TPS was able to accurately discriminate between stage
IIIa (marginally resectable) and stage IIIb (unresectable) non-small-cell lung
cancers, however. In both small-cell and non-small-cell lung cancers, univariate
survival analyses demonstrated that either a CYFRA 21-1 level over 3.6 ng/ml or
a TPS level over 140 U/L significantly indicated a poor survival rate. In the
whole population, taking into account other significant variables, Cox's model
analysis demonstrated that a poor performance index, an advanced stage of the
disease, the presence of metastases, elevated serum lactate dehydrogenase, and
high serum CYFRA 21-1 (odds ratio, 1.74; 95% confidence interval, [1.33-2.27])
were independent prognostic variables. We concluded that CYFRA 21-1 is a
significant determinant of survival. Other applications of cytokeratin markers
in lung cancer are still limited. <B>Pujol J-L, Grenier J, Parrat E, Lehmann M,
Lafontaine T, Quantin X, Michel F-B. AM J RESPIR CRIT CARE MED 1996.</B></P>
<TABLE BORDER="1">
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#top">BACK TO MENU</A></B></SMALL></TD></TR></TABLE>
<P></P>
<HR>
<P><B><A NAME="ats22">Automated Continuous Positive Airway Pressure Titration
for Obstructive Sleep Apnea Syndrome 154:734-740</A></B></P>
<P>This study tested the effectiveness of the AutoSettm self-titrating nasal
continuous positive airway pressure (nCPAP) system in treating obstructive sleep
apnea (OSA), and choosing a suitable pressure for subsequent conventional
fixed-pressure nCPAP therapy. Twenty-one adult men with untreated OSA were
studied with full polysomnography on each of four nights: diagnostic, manual and
AutoSet nCPAP titration (in random order), and conventional fixed-pressure nCPAP
at the pressure recommended by the AutoSet titration. Titration was
satisfactorily performed in 20 of 21 subjects. Severe mask leak prevented
automated titration in one subject and caused transient unnecessary increases in
pressure in three subjects. In the 20 subjects, respiratory disturbance index
(RDI) was 60.3 &#177; 5.7 events/h (mean &#177; SEM) on the diagnostic night.
RDI was lower with manual titration (10.1 &#177; 3.0, p &lt; 0.001), and lower
still with AutoSet (2.8 &#177; 0.9, p &lt; 0.01) and fixed pressure (2.5 &#177;
0.7, p = ns versus AutoSet) nCPAP. There were similar changes in the arousal
index, which was 52.7 &#177; 4.6 events/h on the diagnostic night, 14.2 &#177;
2.4 with manual titration and 8.9 &#177; 0.9 with AutoSet titration, and 9.5 &#177;
1.0 on the night of conventional fixed-pressure cPAP (p &lt; 0.001 versus
diagnostic). We conclude that the AutoSet system is suitable for automated nCPAP
pressure titration. <B>Teschler H, Berthon-Jones M, Thompson AB, Henkel A,
Henry J, Konietzko N. AM J RESPIR CRIT CARE MED 1996.</B></P>
<TABLE BORDER="1">
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#top">BACK TO MENU</A></B></SMALL></TD></TR></TABLE>
<P></P>
<HR>
<P><B><A NAME="ats23">Radiographic and Pathologic Correlation of Coal
Workers' Pneumoconiosis 154:741-748</A></B></P>
<P>The relationships between chest radiographs (CXR) and corresponding
pathology were investigated in 430 autopsied coal miners from West Virginia.
Whole-lung sections were reviewed and graded on four-point severity scales for
the following lesions of coal workers' pneumoconiosis (CWP): macules, micro- and
macronodules (small and large fibrotic nodules), and progressive massive
fibrosis (PMF). Antemortem CXR were classified by three B readers using the 1971
International Labor Office (ILO) U/C classification (6). On pathologic
examination, 96% of miners had macules, 70% micronodules, 45% macronodules, 15%
silicosis, and 28% PMF. By CXR, 69% of the miners had small, rounded opacity
profusions of category &#179; 0/1. Data analysis revealed increasing odds that
small opacities of category &#179; 0/1 would be detected with increasing grade
of nodules. Profusion category 0/0 was often reported for cases with macules of
mild to moderate grade and mild levels of micronodules. Overall, q-type
opacities were associated with macules and micronodules, whereas the large
r-type opacities were associated with macronodules. By CXR, larger opacities
showed good correlation with pathologic PMF. However, about one-third of cases
identified as having large opacities by CXR were not substantiated as PMF by
pathology. One-fourth of these cases could be explained by lung lesions such as
Caplan's nodules, tuberculosis scars, and tumors. Similarly, 22% of cases
classified as PMF on pathology had no large opacities by CXR. In half of these
cases, the radiologists had noted other abnormalities (cancer, tuberculosis) by
CXR as large opacities. Overall, the study showed good agreement (Somer's d =
0.64) between the predicted probabilities and observed responses of a profusion
category &#179; 0/1 for pathologic CWP lesions. However, the study also showed
that CXR were insensitive for detecting minimal CWP lesions, and were unreliable
indicators in the presence of concomitant pulmonary pathology. <B>Vallyathan V,
Brower PS, Green FHY, Attfield MD. AM J RESPIR CRIT CARE MED 1996.</B></P>
<TABLE BORDER="1">
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#top">BACK TO MENU</A></B></SMALL></TD></TR></TABLE>
<P></P>
<HR>
<P><B><A NAME="ats24">Airway Muscle Stereology: Implications for Increased
Shortening in Asthma 154:749-757</A></B></P>
<P>Increased airway smooth muscle, resulting from either hyperplasia or
hypertrophy, has been implicated as a cause of excessive bronchoconstriction in
asthma despite the many methodologic limitations of studies to date. Our recent
failure to demonstrate increased muscle volume in an asthmatic airway
preparation having 3-fold greater shortening than nonasthmatic controls prompted
us to reassess the quantity of muscle in asthmatic versus nonasthmatic airways.
Smooth muscle was quantified in axially sectioned, 2nd- to 4th-generation
bronchi, using standardized stereologic methods on high-magnification images of
cross-sectional airway smooth muscle profiles in tissues from five asthmatic
subjects and five nonasthmatic smokers. When data were normalized by total
cross-sectional tissue area, no differences between the two groups (asthmatic
versus nonasthmatic) were detected for the proportion of smooth muscle (3.45 &#177;
0.81% versus 2.74 &#177; 0.76%), extracellular matrix between muscle cells (1.65
&#177; 0.46% versus 1.06 &#177; 0.25%), or connective tissue within smooth
muscle bundles (1.65 &#177; 0.34% versus 1.53 &#177; 0.59%). These methodologies
for evaluating cross-sectional airway muscle in axial airway sections at high
resolution provide no evidence of increased airway smooth muscle in asthmatic
large airways, and suggest that differences in mechanical responses of asthmatic
airways cannot be explained solely by the amount of smooth muscle. <B>Thomson
RJ, Bramley AM, Schellenberg RR. AM J RESPIR CRIT CARE MED 1996.</B></P>
<TABLE BORDER="1">
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#top">BACK TO MENU</A></B></SMALL></TD></TR></TABLE>
<P></P>
<HR>
<P><B><A NAME="ats25">Number and Proliferation of Neuroendocrine Cells in
Normal Human Airway Epithelium 154:758-763</A></B></P>
<P>Pulmonary neuroendocrine cells (PNECs) are ubiquitous in human adult airway
epithelium, and are implicated in pulmonary disease as PNEC hyperplasia has been
described in a great number of different pulmonary lesions. The purpose of this
study was to determine the baseline quantity and proliferative fraction of adult
PNECs in the conducting airway epithelium of normal lungs. Autopsy was performed
within 6 h of death on 250 subjects. In 9 of 250 cases without pulmonary
disease, seven sequential samples were taken from trachea down to respiratory
bronchioles, fixed in formalin, and embedded in paraffin. After microwave
pretreatment in citrate buffer, sequential immunohistochemical staining was
carried out, using MIB-1 (antibody directed against recombinant parts of the
Ki-67 antigen) as marker for the proliferation fraction and chromogranin-A (CgA)
for the identification of PNECs. Quantification of all epithelial cells of the
conducting airways, MIB-1, and CgA immunoreactive cells, and length of basement
membrane was interactively performed using image analysis. The results show that
microwave treatment significantly enhances the sensitivity of CgA without loss
of specificity. In total, 326,500 epithelial cells and 105 cm of basement
membrane (BM) length were counted (3,101 cells/cm BM). The proliferation
fraction of all epithelial cells was 0.76 &#177; 0.53% (mean &#177; SD). No
mitosis was seen. The mean quantity of PNECs was 0.41 &#177; 0.17% of all
epithelial cells (12.5 cells/cm BM). Many dendritic PNEC processes parallel to
the basement membrane could be appreciated between adjacent epithelial cells. No
difference in the number of PNECs was found between large and small conducting
airways. PNECs were not observed in the alveoli. Only 13 PNECs were
immunoreactive for MIB-1; the proliferative fraction of PNECs was 1 to 2%. In
histologically normal adult human conducting airway epithelium, the average
overall proliferation fraction is 0.76%. The proliferation fraction of PNECs is
equal to the overall proliferative fraction. The fraction of PNECs is 0.41%,
using anti-CgA antiserum after microwave pretreatment of slides, 12 times more
than previously reported. Many dendritic neuroendocrine cell processes were seen
between non-neuroendocrine epithelial cells adjacent to the basement membrane.
The widely held belief that neuroendocrine cells are of little importance in the
adult lung is contradicted by the relative high density of PNECs and its
cytoplasmic processers. <B>Boers JE, Den Brok JLM, Koudstaal J, Arends JW,
Thunnissen FBJM. AM J RESPIR CRIT CARE MED 1996.</B></P>
<TABLE BORDER="1">
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#top">BACK TO MENU</A></B></SMALL></TD></TR></TABLE>
<P></P>
<HR>
<P><B><A NAME="ats26">Exogenous Surfactant Improves Ventilation Efficiency
and Alveolar Expansion in Rats with Meconium Aspiration 154:764-770</A></B></P>
<P>The pathogenesis of neonatal meconium aspiration syndrome (MAS) may involve
inactivation of endogenous surfactant, and data from clinical pilot studies
indicate that treatment with exogenous surfactant may alleviate respiratory
failure in babies with MAS. We studied ventilation efficiency after treatment
with a modified porcine surfactant in experimental meconium aspiration. Adult
rats were anesthetized and tracheotomized, and received via a tracheal cannula
from 4 to 6 ml/kg body weight of a saline suspension of human meconium (25 mg
[dry weight]/ml). After 30 min of ventilation with 100% oxygen, the animals were
in respiratory failure, with dynamic lung-thorax compliance &lt; 0.5 ml/cm
H2O/kg and PaO2 &lt; 8 kPa (60 mm Hg). Animals were then allocated to: (<I>1</I>)
immediate treatment with surfactant (200 mg/kg); (<I>2</I>) treatment with
surfactant (200 mg/kg) 3 h later; or (<I>3</I>) a control group not receiving
surfactant. All animals were ventilated for 6 h with variable FiO2 and peak
inspiratory/positive end-expiratory pressure (PIP/PEEP). In the control group,
six of 12 animals died of respiratory failure with hypoxemia and acidosis
despite ventilation with 100% oxygen and high mean airway pressure (&gt;20 cm
H2O). The lungs of all animals in this group showed severe atelectasis, influx
of neutrophils, edema, and hyaline membranes. In contrast, animals allocated to
immediate or late surfactant treatment had lower mortality (one of seven and two
of eight, respectively), a reduction of oxygen supply by 30%, and a decrease in
mean airway pressure of 3 to 4 cm H2O. This was associated with a &gt;50%
increase in static lung volume at 40 cm H2O inflation and 10 cm H2O deflation
pressure and improved alveolar expansion in histologic sections. Hyaline
membranes tended to be less prominent in surfactant-treated animals than in
controls. We conclude that both early and late treatment with surfactant is
effective in this animal model of MAS. <B>Sun B, Curstedt T, Robertson B. *BAM
J RESPIR CRIT CARE MED 1996.</B></P>
<TABLE BORDER="1">
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#top">BACK TO MENU</A></B></SMALL></TD></TR></TABLE>
<P></P>
<HR>
<P><B><A NAME="ats27">Glucocorticoid Receptor Localization in Normal and
Asthmatic Lung 154:771-782</A></B></P>
<P>The localization and distribution of the human glucocorticoid receptor (GR)
mRNA and protein was investigated in human lung obtained from transplant donors
and recipients by <I>in situ</I> hybridization, RNA blot analysis,
immunolocalization, and Western analysis. Subjects were either nonasthmatic or
had mild asthma requiring only &szlig;2-agonists. No difference in amount of GR
mRNA was found in total RNA isolated from nonasthmatic or asthmatic donor lung.
<I>In situ</I> hybridization showed the highest concentration of GR mRNA in the
alveolar walls and vascular endothelium and smooth muscle, with lesser amounts
in the airway epithelium and smooth muscle. There was no change in the level or
sites of expression of GR mRNA between normal and asthmatic subjects.
Immunolocalization of GR confirmed the <I>in situ</I> hybridization data. There
was no change in the level or sites of expression of GR, in either the lung or
airway, between normal and asthmatic subjects. Immunolocalization of GR in
bronchial biopsies from two normal and asthmatic subjects confirmed the
localization and distribution of GR. Western analysis and mobility shift assays
confirmed no differences in GR levels between the two subject groups. The
localization of GR mRNA and protein to specific cell types within lung and
airway will make it possible to study the cellular targets of glucocorticoid
therapy in inflammatory lung diseases such as asthma. <B>Adcock IM, Gilbey T,
Gelder CM, Chung KF, Barnes PJ. AM J RESPIR CRIT CARE MED 1996.</B></P>
<TABLE BORDER="1">
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#top">BACK TO MENU</A></B></SMALL></TD></TR></TABLE>
<P></P>
<HR>
<P><B><A NAME="ats28">Tyloxapol Inhibits NF-[kappa]B and Cytokine Release,
Scavenges HOCI, and Reduces Viscosity of Cystic Fibrosis Sputum 154:783-788</A></B></P>
<P>Cystic fibrosis (CF) patients develop progressive cytokine-mediated
inflammatory lung disease, with abundant production of thick, tenacious,
protease- and oxidant-rich purulent airway secretions that are difficult to
clear even with physiotherapy. In the search for a potential treatment, we have
tested tyloxapol, an alkylaryl polyether alcohol polymer detergent previously
used as a mucolytic agent in adult chronic bronchitis. Tyloxapol inhibits
activation of the transcription factor nuclear factor-kappa B (NK-[kappa]B),
reduces resting secretion of the cytokine interleukin-8 (IL-8) in cultured human
monocytes, and inhibits lipopolysaccharide (LPS)-stimulated release of tumor
necrosis factor-a (TNF-a), IL-1&szlig;, IL-6, IL-8, granulocyte-macrophage
colony-stimulating factor (GM-CSF), and the eiconsanoids thromboxane A2 and
leukotriene B<I>4</I> (LTB4). We have previously shown that tyloxapol is a
potent antioxidant for hydroxyl radicals (.OH). Tyloxapol (0.05 to 0.1% wt/vol)
effectively scavenges the oxidant hypochlorous acid (HOCl; 1 to 7.5 mM) <I>in
vitro</I>, and protects from HOCl-mediated lung injury in rats. Tyloxapol also
reduces the viscosity of CF sputum (from 463 &#177; 133 to 128 &#177; 52
centipoise). We conclude that tyloxapol is potentially useful as a new
antiinflammatory therapy for CF lung disease, and could possibly promote
clearance of secretions in the CF airway. <B>Ghio AJ, Marshall BC, Diaz JL,
Hasegawa T, Samuelson W, Povia D, Kennedy TP, Piantadosi CA. AM J RESPIR CRIT
CARE MED 1996.</B></P>
<TABLE BORDER="1">
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#top">BACK TO MENU</A></B></SMALL></TD></TR></TABLE>
<P></P>
<HR>
<P><B><A NAME="ats29">Causes of Pulmonary Impairment in Asbestos-Exposed
Individuals with Diffuse Pleural Thickening 154:789-793</A></B></P>
<P>To examine whether diffuse pleural thickening (DPT) causes impairment of
pulmonary function independent of other manifestations of asbestos-related
disease, we studied individuals selected from 1,150 men with occupational
asbestos exposure who had undergone pulmonary function testing and computed
tomographic (CT) scanning. The CT scans revealed 84 subjects with DPT as defined
for CT. Of these 84 subjects, 53 eligible study cases were matched by age with a
referent group without DPT from the same exposed group. No difference was
demonstrated between cases and referents in smoking history, length of exposure,
latency, or the proportion with either interstitial fibrosis or pleural plaques.
Individuals with DPT demonstrated significantly reduced forced vital capacity
(FVC) (p = 0.002) and diffusing capacity for carbon monoxide (DLCO) (p = 0.002)
as compared with the referents. No difference was found in the two groups' FEV1
to FVC ratio (FEV1/FVC). Individuals with DPT and either interstitial fibrosis
or pleural plaques showed a significantly lower FVC than did those with fibrosis
or pleural plaques alone. Individuals with DPT and rounded atelectasis had
similar pulmonary function to those with DPT and no rounded atelectasis.
Subjects with DPT had a more frequent history of coronary bypass surgery than
referents (19% versus 2%; p = 0.008). We conclude that subjects with DPT have
restrictive pulmonary function and reduced diffusing capacity independent of
other manifestations of asbestos-related disease. <B>Kee ST, Gamsu G, Blanc P.
AM J RESPIR CRIT CARE MED 1996.</B></P>
<TABLE BORDER="1">
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#top">BACK TO MENU</A></B></SMALL></TD></TR></TABLE>
<P></P>
<HR>
<P><B><A NAME="ats30">Interstitial Lung Disease in Primary Sj&ouml;gren's
Syndrome: Clinical-Pathological Evaluation and Response to Treatment 154:794-799</A></B></P>
<P>Interstitial disease is a recognized form of lung involvement in primary Sj&ouml;gren's
syndrome in which frequency and severity have not yet been established. We
studied 20 patients 61.2 &#177; 36.4 mo after the first symptoms of the syndrome
that fulfilled criteria for both xerostomia and xerophtalmia. Eighteen patients
exhibited pulmonary symptoms; nine presented a restrictive functional pattern.
The chest roentgenogram disclosed interstitial involvement in nine patients.
Gallium-67 lung scan presented hypercaptation in 15 of 19 patients studied.
Thirteen patients who submitted to bronchoalveolar lavage presented higher cell
counts with increases of lymphocytes and/or polymorphonuclear cells. All
patients had abnormal results in at least one of the above. Lung biopsy,
undertaken in 12 patients, showed a whole spectrum of interstitial disease, from
a follicular bronchiolitis to a lymphoid interstitial pneumonia and finally
fibrosis with honeycombing. One patient presented with associated sarcoid
granulomas. We treated 11 patients with an azathioprine-based regimen and found
a significant improvement in the forced vital capacity (p &lt; 0.05) after at
least 6 mo when compared with nontreated patients. We conclude that the
frequency of interstitial lung disease is high in Sj&ouml;gren's syndrome and
that an azathioprine-based treatment can favorably change the outcome in this
population. <B>Deheinzelin D, Capelozzi VL, Kairalla RA, Filho JVB, Saldiva
PHN, de Carvalho CRR. AM J RESPIR CRIT CARE MED 1996.</B></P>
<TABLE BORDER="1">
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#top">BACK TO MENU</A></B></SMALL></TD></TR></TABLE>
<P></P>
<HR>
<P><B><A NAME="ats31">Rib Cage Dimensions in Hyperinflated Patients with
Severe Chronic Obstructive Pulmonary Disease 154:800-805</A></B></P>
<P>Using computed tomography we assessed rib cage dimensions at the levels of
Th4, Th6, Th8, and Th10 in seven supine patients with COPD who were severely
obstructed (FEV1, 25 &#177; 7% of predicted) and hyperinflated (FRC, 234 &#177;
34% of predicted) and seven matched normal control subjects. The midsagittal
anteroposterior (AP) diameter, the maximal AP diameter of the right and left
hemithorax, and the maximal transverse (T) diameter were measured on scans
obtained at relaxed TLC, FRC, and RV. At each volume, AP diameters were
invariably 2 to 3 cm greater in patients with COPD than in normal subjects, but
no significant differences in T diameters were found. When compared at a given
absolute lung volume, T diameters at all thoracic levels and AP diameters at
Th4-6 were smaller in patients with COPD than in normal subjects; in contrast,
at Th8-10, AP diameters were similar in the two groups. We conclude that the
marked hyperinflation of patients with severe COPD produces complex changes in
rib cage dimensions: (<I>1</I>) there is an increase in AP but not in T
diameters such that the rib cage adopts a more circular shape; (<I>2</I>) at a
given absolute lung volume, AP diameters are smaller in patients with COPD than
in normal subjects in the upper but not in the lower portion of the rib cage.
These differences in rib cage dimensions may have implications regarding
respiratory muscle length and function in patients with COPD. <B>Cassart M,
Gevenois PA, Estenne M. AM J RESPIR CRIT CARE MED 1996.</B></P>
<TABLE BORDER="1">
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#top">BACK TO MENU</A></B></SMALL></TD></TR></TABLE>
<P></P>
<HR>
<P><B><A NAME="ats32">Mechanical Properties of the Velopharynx in Obese
Patients with Obstructive Sleep Apnea 154:806-812</A></B></P>
<P>Epidemiologic data indicate that the relationship between obesity and
obstructive sleep apnea (OSA) is largely explained by variation in neck size.
Fat deposits in the neck may predispose to upper airway (UA) occlusion during
sleep by altering the mechanical properties of the UA, particularly at the level
of the velopharynx (VP). To determine whether effective compliance (CEFF) of the
VP is related to obesity in the neck, we have performed anthropometrics,
polysomnography, and dynamic UA videoendoscopy in 18 patients with OSA and eight
nonapneic control subjects. Following topical anesthesia (cocaine 4%) to one
nasal passage, subjects were examined with a thin fiberscope (outer diameter
[OD] 3.8 mm) while awake, supine, breathing exclusively through the nose, during
a maximal vital capacity (VC) maneuver against an unoccluded airway. UA
cross-sectional area (CSA), anteroposterior (AP) and lateral (L) diameters were
measured from stored images. CEFF was expressed as the ratio of CSAVP in
expiration (E) to inspiration (I) during the maximal VC maneuver (expiratory
CSAMAX/inspiratory CSAMIN), and airway shape as AP/L diameter. The OSA patients
were divided into two groups based on median neck circumference (NC). CEFF of
the VP was greater in OSA patients compared with control subjects (CEFF 2.0 &#177;
0.8 versus 1.1 &#177; 0.5; p &lt; 0.001). CEFF was greater in the large NC group
compared with both the small NC group (p &lt; 0.05) and control subjects (p &lt;
0.01), but the difference between the small NC group and control subjects was
not significant. CEFF was related to NC (r = 0.63; p = 0.001; n = 26), body mass
index (r = 0.54; p &lt; 0.01, n = 26), and apnea-hypopnea index (r = 0.43; p &lt;
0.05; n = 23). The change in CSAVP during the maximal VC maneuver was mainly due
to inspiratory narrowing. Obese patients with large necks have a more
collapsible velopharynx during wakefulness, which may predispose to upper airway
obstruction during sleep. <B>Ryan CF, Love LL. AM J RESPIR CRIT CARE MED 1996.</B></P>
<TABLE BORDER="1">
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#top">BACK TO MENU</A></B></SMALL></TD></TR></TABLE>
<P></P>
<HR>
<P><B><A NAME="ats33">Increased Exhalation of Hydrogen Peroxide in Patients
with Stable and Unstable Chronic Obstructive Pulmonary Disease 154:813-816</A></B></P>
<P>An imbalance between oxidative stress and antioxidative capacity is thought
to play an important role in the development and progression of chronic
obstructive pulmonary disease (COPD). To assess the lung oxidative status in
patients with COPD, we studied whether exhaled hydrogen peroxide (H2O2) is
increased in breath condensate of patients with stable COPD (n = 12, mean FEV1
51% pred) and in patients with exacerbated COPD (n = 19, actual FEV1 36% pred)
compared with a healthy control group (n = 10, FEV1 108% pred). Expired breath
condensate during 15 min of tidal breathing was collected by cooling. The
concentration of H2O2 was measured spectrophotometrically by means of horse
radish peroxidase-catalyzed oxidation of tetramethylbenzidine. Concentrations of
H2O2 (mean &#177; SEM) were significantly elevated at 0.205 &#177; 0.054 mM in
patients with stable COPD compared with 0.029 &#177; 0.012 mM in the control
group (p &lt; 0.05) and were further increased to 0.600 &#177; 0.075 mM in
patients with acutely exacerbated COPD (p &lt; 0.001 compared with patients with
stable COPD). Patients with pulmonary infiltrates on chest radiograph showed
similar values compared with patients without obvious infiltrates. These
findings demonstrate that patients with stable COPD exhibit increased oxidant
production in the airways and that oxidant production increases further during
exacerbations. <B>Dekhuijzen PNR, Aben KKH, Dekker I, Aarts LPHJ, Wielders
PLML, Van Herwaarden CLA, Bast A. AM J RESPIR CRIT CARE MED 1996.</B></P>
<TABLE BORDER="1">
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#top">BACK TO MENU</A></B></SMALL></TD></TR></TABLE>
<P></P>
<HR>
<P><B><A NAME="ats34">Bronchoalveolar Lavage Fluid Composition in Alveolar
Proteinosis: Early Changes After Therapeutic Lavage 154:817-820</A></B></P>
<P>In patients with idiopathic alveolar proteinosis, the alveoli are filled
with materials rich in surfactant components, especially surfactant protein A
(SP-A). The anomaly could be caused by either increased secretion, decreased
clearance, or both. To clarify this point, we studied five patients who
underwent therapeutic lavage and then were ventilated mechanically for 24 h.
During the first 8 h of mechanical ventilation, a surfactant-depleted lung was
lavaged at selected intervals, and the bronchoalveolar lavage fluid was
analyzed. We observed that, after lavage, various surfactant components
accumulated in the airways with different time courses. We also observed that
SP-A increased until the second hour and then dropped rapidly, suggesting the
existence of an efficient mechanism of removal. These findings suggest that
idiopathic alveolar proteinosis might be caused by a primary defect in a slow
mechanism of removal or by the presence of factor(s) that interfere with the
clearance of surfactant and that can be removed by lavage. It seems clear,
however, that an increased secretion rate is unlikely to be the major cause of
idiopathic alveolar proteinosis. <B>Alberti A, Luisetti M, Braschi A, Rodi G,
Iotti G, Sella D, Poletti V, Benori V, Baritussio A. AM J RESPIR CRIT CARE MED
1996.</B></P>
<TABLE BORDER="1">
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#top">BACK TO MENU</A></B></SMALL></TD></TR></TABLE>
<P></P>
<HR>
<P><B><A NAME="ats35">Ethical Considerations of Ensuring an Informed and
Autonomous Consent in Research Involving Critically Ill Patients 154:582-586</A></B></P>
<P>The informed consent process in clinical research is a mechanism through
which two values are promoted: respect for subject autonomy and promotion of
subject welfare as perceived by subjects themselves. The Nuremberg Code of 1947
(1), issued in response to the unwilling participation of subjects in Nazi
experiments, emphasized the essentialness of an informed and voluntary consent
from human subjects. Despite this and subsequent codes of research ethics (1),
informed and voluntary subject participation in research studies was
inconsistently achieved in the U.S. during the 1950s and 1960s. Examples of
research abuses included the purposeful infection with hepatitis of residents at
the Willowbrook State School for the Retarded; the injection of cancer cells in
elderly and unconsenting patients in a New York hospital; and the Tuskegee
study, where treatment for syphilis was deliberately withheld from a group of
black patients in an attempt to study the long-term effects of syphilis (2).
These instances of lapses in research ethics made clear the need for regulation
to prevent harm to research subjects, as reliance on professional judgment to
ensure high ethical standards was inadequate. Consequently, governmental
agencies issued guidelines controlling clinical research (3). For example, in
1966 the FDA described comprehensive rules regarding informed consent in
clinical drug trials and the Public Health Service required any research it
funded to undergo a prospective ethics review of the potential benefits and
harms, a requirement that led to the formation of institutional review boards
(IRBs). Despite these regulations, several authors still question the quality of
the informed consent process (4-6), as only the information-giving aspect of &quot;informed&quot;
consent is stressed by the research community. For example, IRBs examine only
the language in the informed consent form and not the informed consent process
itself (7). However, informed consent means more than the mere telling of
information. Indeed, writings from moral philosophy (8, 9) emphasize a more
robust concept of informed consent that stresses two additional requirements to
ensure that a consent is not only informed, but autonomous as well: subject
competence and voluntariness of the consent. This broadened concept of informed
consent entails that, in addition to disclosure, investigators are obligated to
promote and assess subject competence and ameliorate any coercive influences
that might be playing a role in subjects' decisions. Because behavior is
influenced partly by the concepts espoused, this report aims to stimulate a
reappraisal of the informed consent process by discussing issues involved with
disclosure, competence, and voluntariness. In doing so, substantive issues
related to obtaining an informed and autonomous consent from critically ill
patients will be discussed. I will conclude by making several suggestions to
enhance the current practice of obtaining informed consent. <B>Silverman HJ. AM
J RESPIR CRIT CARE MED 1996.</B></P>
<TABLE BORDER="1">
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#top">BACK TO MENU</A></B></SMALL></TD></TR></TABLE>
<P></P>
<HR SIZE="4" WIDTH="80%">
<CENTER><A HREF="about.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/about.gif" ALT="About Society"></A>
<A HREF="ssg.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/ss.gif" ALT="Society Structure"></A>
<A HREF="calendar.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/calendar.gif" ALT="ATS Calendar"></A>
<A HREF="gpi.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/pi.gif" ALT="Gen Public Info"></A>
<A HREF="ms.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/memserv.gif" ALT="Memb Serv"></A>
<BR>
<A HREF="pub.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/pubs.gif" ALT="Publications"></A>
<A HREF="press.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/press.gif" ALT="Press"></A>
<A HREF="index.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/home.gif" ALT="Home Page"></A>
<A HREF="search.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/search.gif" ALT="Search"></A>
<A HREF="assemb.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/assemb.gif" ALT="Assemblies"></A>
<A HREF="research.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/research.gif" ALT="Research"></A>
<BR>
<A HREF="mep.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/meded.gif" ALT="Med Education"></A>
<A HREF="wr.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/wr.gif" ALT="Wash Report"></A>
<A HREF="ic.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/ic.gif" ALT="Int'l Conference"></A>
<A HREF="source.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/link.gif" ALT="Web Links"></A>
<A HREF="store.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/store.gif" ALT="Store"></A> 
<A HREF="sig.html"><IMG SRC="images/special.gif" ALT="Special" HSPACE=1 VSPACE=1 BORDER=0 HEIGHT=35 WIDTH=84></A>
</CENTER>
<HR SIZE="4" WIDTH="80%">
<CENTER><FONT SIZE="+2"><B><I>American Thoracic Society</I></B></FONT><BR>
1740 Broadway<BR> New York, NY 10019<BR> VOICE:  212-315-8700<BR> Copyright &copy;
1996 American Lung Association.<BR> The American Thoracic  Society is the
medical section <BR>of the American Lung Association.<BR> 
</CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-169</DOCNO>
<DOCOLDNO>IA013-000141-B026-233</DOCOLDNO>
<DOCHDR>
http://www.thoracic.org:80/barc1096.html 206.138.195.144 19970217073558 text/html 102638
HTTP/1.0 200 OK
Date: Monday, 17-Feb-97 07:31:02 GMT
Server: NCSA/1.3
MIME-version: 1.0
Content-type: text/html
Last-modified: Friday, 20-Dec-96 20:23:49 GMT
Content-length: 102456
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//SQ//DTD HTML 2.0 HoTMetaL + extensions//EN">
<HTML>
<HEAD>
<TITLE>American Thoracic Society - ABSTRACTS; October 1996: Volume 154, Number
4</TITLE></HEAD>
<BODY BACKGROUND="images/back.jpg">
<CENTER><IMG ALIGN="LEFT" SRC="images/smlogo.gif"><BR>
<H1>AJRCCM ABSTRACTS</H1></CENTER>
<HR SIZE="5" NOSHADE="NOSHADE" WIDTH="100%">
<P></P>
<HR>
<CENTER>
<TABLE BORDER="2">
<TR>
<TD ALIGN="CENTER" VALIGN="MIDDLE"><SMALL><B><A HREF="bluearch.html">BACK TO
ARCHIVES MAIN PAGE</A></B></SMALL></TD></TR></TABLE></CENTER>
<HR>
<CENTER>
<H2> October 1996: Volume 154, Number 4</H2>
<P><B><A NAME="top">AJRCCM ABSTRACT MENU</A></B></P></CENTER>
<CENTER>
<TABLE BORDER="1">
<TR ALIGN="CENTER" VALIGN="MIDDLE">
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#ats1">Lipid Mediators
in Oxygen&#150;induced Airway Remodeling and Hyperresponsiveness in Newborn Rats
154:837*&#150;842</A></B></SMALL></TD></TR>
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#ats2">Heterogeneity of
Allergic Airway Responses in Sheep: Differences in Signal Transduction? 154:843&#150;849</A></B></SMALL></TD></TR>
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#ats3">Persistent Airway
Eosinophilia After Leukotriene (LT) D4 Administration in the Guinea Pig:
Modulation by the LTD4 Receptor Antagonist, Pranlukast, or an Interleukin&#150;5
Monoclonal Antibody 154:850&#150;857</A></B></SMALL></TD></TR>
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#ats4">Toluene
Diisocyanate&#150;Induced <I>in vitro</I> Tracheal Hyperreactivity in the Mouse
154:858&#150;865</A></B></SMALL></TD></TR>
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#ats5">Spontaneous and
Induced Sputum to Measure Indices of Airway Inflammation in Asthma 154:866&#150;869</A></B></SMALL></TD></TR>
<TR>
<TD><SMALL><B><A HREF="#ats6">On Adjusting Measurements of Airway
Responsiveness for Lung Size and Airway Caliber 154:870&#150;875</A></B></SMALL></TD></TR>
<TR>
<TD><SMALL><B><A HREF="#ats7">Prolonged Effect of Tiotropium Bromide on
Methacholine&#150;induced Bronchoconstriction in Asthma 154:876&#150;880</A></B></SMALL></TD></TR>
<TR>
<TD><SMALL><B><A HREF="#ats8">Seasonal Variations in House Dust Mite
Influence the Circadian Peak Expiratory Flow Amplitude 154:881&#150;884</A></B></SMALL></TD></TR>
<TR>
<TD><SMALL><B><A HREF="#ats9">Intravenous Lidocaine and Oral Mexiletine
Block Reflex Bronchoconstriction in Asthmatic Subjects 154:885&#150;888</A></B></SMALL></TD></TR>
<TR>
<TD><SMALL><B><A HREF="#ats10">Changes in Peak Flow, Symptom Score, and the
Use of Medications During Acute Exacerbations of Asthma 154:889&#150;893</A></B></SMALL></TD></TR>
<TR>
<TD><SMALL><B><A HREF="#ats11">Asthma among Puerto Rican Hispanics: A Multi&#150;ethnic
Comparison Study of Risk Factors 154:894&#150;899</A></B></SMALL></TD></TR>
<TR>
<TD><SMALL><B><A HREF="#ats12">Protective Effect of B464, a Lipid A Analog,
on Endotoxin&#150;induced Cellular Responses and Acute Lung Injury 154:900&#150;906</A></B></SMALL></TD></TR>
<TR>
<TD><SMALL><B><A HREF="#ats36">Estimation of Occlusion Pressure During
Assisted Ventilation in Patients with Intrinsic PEEP 154:907&#150;912</A></B></SMALL></TD></TR>
<TR>
<TD><SMALL><B><A HREF="#ats13">The Accuracy of Pneumotachograph Measurements
During Mechanical Ventilation 154:913&#150;917</A></B></SMALL></TD></TR>
<TR>
<TD><SMALL><B><A HREF="#ats14">Changes in Lung Volume and Static Expiratory
Pressure&#150;Volume Diagram after Surfactant Rescue Treatment of Neonates with
Established Respiratory Distress Syndrome 154:918&#150;923</A></B></SMALL></TD></TR>
<TR>
<TD><SMALL><B><A HREF="#ats15">Respiratory Sensation Related to Resistive
Loads in Lung Transplant Recipients 154:924&#150;930</A></B></SMALL></TD></TR>
<TR>
<TD><SMALL><B><A HREF="#ats16">Microcirculatory Changes in Rat Skeletal
Muscle in Sepsis 154:931&#150;937</A></B></SMALL></TD></TR>
<TR>
<TD><SMALL><B><A HREF="#ats17">Comparison of Static and Dynamic Intrinsic
Positive End&#150;Expiratory Pressure Using the Campbell Diagram 154:938&#150;944</A></B></SMALL></TD></TR>
<TR>
<TD><SMALL><B><A HREF="#ats18">Mechanism of Short&#150;term Improvement in
Lung Function after Emphysema Resection 154:945&#150;951</A></B></SMALL></TD></TR>
<TR>
<TD><SMALL><B><A HREF="#ats19">Altered Composition of Urinary Heparan
Sulfate in Patients with COPD 154:952&#150;958</A></B></SMALL></TD></TR>
<TR>
<TD><SMALL><B><A HREF="#ats20">Outcomes Following Acute Exacerbation of
Severe Chronic Obstructive Lung Disease 154:959&#150;967</A></B></SMALL></TD></TR>
<TR>
<TD><SMALL><B><A HREF="#ats21">Western Red Cedar Dust Exposure and Lung
Function: A Dose&#150;Response Relationship 154:968&#150;973</A></B></SMALL></TD></TR>
<TR>
<TD><SMALL><B><A HREF="#ats22">A Regression Approach to the Analysis of
Serial Peak Flow among Fuel Oil Ash Exposed Workers 154:974&#150;980</A></B></SMALL></TD></TR>
<TR>
<TD><SMALL><B><A HREF="#ats23">Effect of Ambient Ozone Exposure on Lung
Function in Farm Workers 154:981&#150;987</A> </B></SMALL></TD></TR>
<TR>
<TD><SMALL><B><A HREF="#ats24">Mechanism of Apnea Lengthening Across the
Night in Obstructive Sleep Apnea 154:988&#150;993</A></B></SMALL></TD></TR>
<TR>
<TD><SMALL><B><A HREF="#ats25">Role of Hypoxemia and Pulmonary Mechanics in
Exercise Limitation in Interstitial Lung Disease 154:994&#150;1001</A></B></SMALL></TD></TR>
<TR>
<TD><SMALL><B><A HREF="#ats26">Increased Surface Tension of the Lung and
Surfactant in Bleomycin&#150;induced Pulmonary Fibrosis in Rats 154:1002&#150;1005</A></B></SMALL></TD></TR>
<TR>
<TD><SMALL><B><A HREF="#ats27">Tuberculosis Infection among Health Care
Workers in Montreal 154:1006&#150;1012</A></B> </SMALL></TD></TR>
<TR>
<TD><SMALL><B><A HREF="#ats28">Cost&#150;Effectiveness of Directly Observed
Versus Self&#150;Administered Therapy for Tuberculosis 154:1013&#150;1019</A></B></SMALL></TD></TR>
<TR>
<TD><SMALL><B><A HREF="#ats29">The Accuracy of Elevated Concentrations of
Endotoxin in Bronchoalveolar Lavage Fluid for the Rapid Diagnosis of Gram&#150;negative
Pneumonia 154:1020&#150;1028</A></B></SMALL></TD></TR>
<TR>
<TD><SMALL><B><A HREF="#ats30">Lack of Association of Induration Size with
HIV Infection among Drug Users Reacting to Tuberculin 154:1029&#150;1033</A></B></SMALL></TD></TR>
<TR>
<TD><SMALL><B><A HREF="#ats31">Six&#150;Month Supervised Intermittent
Tuberculosis Therapy in Haitian Patients With and Without HIV Infection 154:1034&#150;1038</A></B></SMALL></TD></TR>
<TR>
<TD><SMALL><B><A HREF="#ats32">Fluticasone Propionate in Children with
Moderate Asthma 154:1039&#150;1044</A></B></SMALL></TD></TR>
<TR>
<TD><SMALL><B><A HREF="#ats33">Chest Wall Compliance in Infants and Children
with Neuromuscular Disease 154:1045&#150;1048</A></B></SMALL></TD></TR>
<TR>
<TD><SMALL><B><A HREF="#ats34">Patient&#150;triggered Ventilation in
Neonates: Comparison of a Flow&#150;and an Impedance&#150;triggered System
154:1049&#150;1054</A></B></SMALL></TD></TR>
<TR>
<TD><SMALL><B><A HREF="#ats35">Systemic Oxidative Stress in Asthma, COPD,
and Smokers 154:1055&#150;1060</A></B></SMALL></TD></TR>
<TR>
<TD><FONT SIZE="-1"><B><A HREF="#ats37">Expression of Interleukin&#150;1
Beta (IL&#150;1&szlig;) and Interleukin&#150;1 Receptor Antagonist (IL&#150;1ra)
on Asthmatic Bronchial Epithelium 154:1061&#150;1066</A></B></FONT></TD></TR>
<TR>
<TD><FONT SIZE="-1"><B><A HREF="#ats38">Increased Expression of Gelatinases
and Collagenase in Rat Lungs Exposed to 100% Oxygen 154:1067&#150;1075</A></B></FONT></TD></TR>
<TR>
<TD><FONT SIZE="-1"><B><A HREF="#ats39">Transforming Growth Factor&#150;&szlig;
(TGF&#150;&szlig;) in Silicosis 154:1076&#150;1081</A></B></FONT></TD></TR>
<TR>
<TD><FONT SIZE="-1"><B><A HREF="#ats40">Reduction in Pulmonary Fibrosis <I>In
Vivo</I> by Halofuginone 154:1082&#150;1086</A></B></FONT></TD></TR>
<TR>
<TD><FONT SIZE="-1"><B><A HREF="#ats41">Angiotensin Converting Enzyme
Expression in Primary Pulmonary Hypertension 154:1087&#150;1091</A></B></FONT></TD></TR>
<TR>
<TD><FONT SIZE="-1"><B><A HREF="#ats42">Elafin/elastase&#150;specific
Inhibitor in Bronchoalveolar Lavage of Normal Subjects and Farmer's Lung
154:1092&#150;1098</A></B></FONT></TD></TR>
<TR>
<TD><FONT SIZE="-1"><B><A HREF="#ats43">Bilateral Magnetic Stimulation of
the Phrenic Nerves from an Anterolateral Approach 154:1099&#150;1105</A></B></FONT></TD></TR>
<TR>
<TD><FONT SIZE="-1"><B><A HREF="#ats44">Upper Airway and Soft Tissue
Structural Changes Induced by CPAP in Normal Subjects 154:1106&#150;1116</A></B></FONT></TD></TR>
<TR>
<TD><FONT SIZE="-1"><B><A HREF="#ats45">Detection of p53 Gene Mutations in
Cytopathology and Biopsy Specimens from Patients with Lung Cancer 154:1117&#150;1123</A></B></FONT></TD></TR>
<TR>
<TD><FONT SIZE="-1"><B><A HREF="#ats46">Age&#150;related 4,977 bp Deletion
in Human Lung Mitochondrial DNA 154:1141&#150;1145</A></B></FONT></TD></TR>
<TR>
<TD><FONT SIZE="-1"><B><A HREF="#ats47">Inspiratory Pressure Support Reduces
Slowing of Inspiratory Muscle Relaxation Rate During Exhaustive Treadmill
Walking in Severe COPD 154:1146&#150;1150</A></B></FONT></TD></TR></TABLE></CENTER>
<P></P>
<HR>
<P><B><A NAME="ats1">Lipid Mediators in Oxygen&#150;induced Airway Remodeling
and Hyperresponsiveness in Newborn Rats 154:837*&#150;842</A></B></P>
<P>We examined whether lipid mediators have a causal role in neonatal hyperoxia&#150;induced
lung damage, specifically, airway remodeling and hyperresponsiveness. Newborn
rat pups were exposed to hyperoxia (&gt; 95% O2 from Days 4 to 14 and 65% from
Days 14 to 32) or normoxia. The 5&#150;lipoxygenase inhibitor, LTD4 receptor
antagonist, and inhibitor of platelet&#150;activating factor synthesis, Wy&#150;50,295
(30 mg/kg), or vehicle was administered daily from Days 3 to 32. Oxygen exposure
significantly increased (p &lt; 0.05) the production of one potential lipid
mediator group, peptido&#150;LTs, from explanted lung slices and large airways
from 2&#150;wk&#150;old rat pups. At 4 wk, only the large airway tissue output
showed significant elevation because of oxygen exposure. At both ages, Wy&#150;50,295
significantly decreased (p &lt; 0.05) the production of peptido&#150;LTs in the
lung and large airways of oxygen&#150;exposed pups. Pulmonary function and
airway wall morphometry were studied in 5&#150;wk&#150;old rat pups 2 to 3 d
after oxygen exposure and drug administration ceased. The resistance change in
response to methacholine (0 to 20 mg/kg body weight given intravenously) was
greater (p &lt; 0.02) in oxygen&#150;exposed animals. Oxygen exposure caused
significant (60% increase) smooth muscle thickening (p &lt; 0.05). Wy&#150;50,295
prevented the oxygen&#150;induced airway hyperresponsiveness and smooth muscle
thickening. We conclude that chronic hyperoxic exposure causes an increase in
pulmonary production of at least one lipid mediator, peptido&#150;LTs, from
newborn rats and that this is associated with airway smooth muscle layer
thickening and, consequently, airway hyperresponsiveness. <B>Burghardt JS,
Boros V, Biggs DF, Olson DM. </B>AM J RESPIR CRIT CARE MED 1996.</P>
<TABLE BORDER="1">
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#top">BACK TO MENU</A></B></SMALL></TD></TR></TABLE>
<P></P>
<HR>
<P><B><A NAME="ats2">Heterogeneity of Allergic Airway Responses in Sheep:
Differences in Signal Transduction? 154:843&#150;849</A></B></P>
<P>In preliminary studies we have observed that inhaled heparin blocks antigen&#150;induced
airway responses in sheep that develop only acute responses to inhaled antigen
(acute responders) but not in sheep that develop both acute and later responses
(dual responders). Because heparin is an antagonist of inositol triphosphate
(IP3) (one of the pathways involved in stimulus&#150;secretion&#150;coupling in
mast cells), the differential effect of inhaled heparin in acute responders and
dual responders might indicate the involvement of different signaling pathways
during IgE&#150;mediated mast cell reactions. Therefore, in this study we
compared the effects of heparin on antigen&#150;induced bronchconstriction,
allergic cutaneous reaction, and histamine release into bronchoalveolar lavage
fluid (BAL) in sheep that develop only acute responses or dual responses to
inhaled <I>Ascaris suum</I> antigen. Specific lung resistance (SRl) was
measured in 21 sheep (eight acute responders; 13 dual responders) before and
after inhalation challenge with antigen, without and after pretreatment with
inhaled heparin (1,000 units/kg). Histamine in BAL was measured by RIA before
and after segmental antigen challenge, without and after pretreatment with
inhaled heparin (eight acute responders; eight dual responders). In acute
responders, mean &#177; SE SRl increased by 197 &#177; 21% with antigen; this
was prevented by inhaled heparin ([DELTA]SRl = 15 &#177; 7%; p &lt; 0.05). In
dual responders, inhaled heparin had no effect on antigen&#150;induced early
([DELTA]SRl = 328 &#177; 51% versus 305 &#177; 76%) or late ([DELTA]SRl = 201 &#177;
33% versus 163 &#177; 15%) responses. After segmental antigen challenge, BAL
mean &#177; SE histamine increased from 2.09 &#177; 0.8 nM to 75.4 &#177; 21.1
nM in acute responders and 1.58 &#177; 0.7 nM to 66.8 &#177; 27.3 nM in dual
responders (p &lt; 0.01). Inhaled heparin inhibited the increase in BAL
histamine by 81% in acute responders (p &lt; 0.05) and by only 19% in dual
responders (p = NS). As was seen in the airways, heparin attenuated the allergic
cutaneous reaction in acute responders by 46% (p &lt; 0.05), but it was
ineffective in dual responders. In contrast, H&#150;7, a nonspecific protein
kinase C inhibitor, attenuated the cutaneous reaction in dual responders by 28%
(p &lt; 0.05), but it was ineffective in acute responders. These data suggest
that heterogeneity of allergic airway response is related to difference in mast
cell signal transduction; IP3 is the predominant second messenger in acute
responders, whereas non&#150;IP3 pathways may be involved in dual responders.
<B>Ahmed T, D'Brot J, Abraham WM, Lucio J, Mendelssohn R, Robinson MJ, Shakir
S, Sanpedro B. </B>AM J RESPIR CRIT CARE MED 1996.</P>
<TABLE BORDER="1">
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#top">BACK TO MENU</A></B></SMALL></TD></TR></TABLE>
<P></P>
<HR>
<P><B><A NAME="ats3">Persistent Airway Eosinophilia After Leukotriene (LT) D4
Administration in the Guinea Pig: Modulation by the LTD4 Receptor Antagonist,
Pranlukast, or an Interleukin&#150;5 Monoclonal Antibody 154:850&#150;857</A></B></P>
<P>Aerosolized cysteinyl leukotrienes (CysLTs) elicit migration of eosinophils
into guinea pig lungs and the airways of patients with asthma. The present
studies were designed to analyze the concentration&#150;response relationship,
time course, and pharmacologic and histologic characteristics of leukotriene D4
(LTD4)&#150;induced eosinophil influx into the airways of conscious guinea pigs.
Animals were exposed to aerosols of 0.3 to 30 mg/ml LTD4 for 1 min, during which
specific airway conductance (sGaw) was monitored. Bronchoalveolar lavages (BALs)
of guinea pig airways were conducted at selected times from 4 h to 4 wk after
LTD4 challenge. LTD4 produced maximal decreases in sGaw (70 to 90% reduction) at
all concentrations tested and concentration&#150;related increases in eosinophil
levels in BALs, assessed 24 h after challenge. Increased numbers of eosinophils
in the bronchial epithelium and subepithelium were confirmed histologically.
Significant eosinophilia was maintained for up to 4 wk postchallenge.
Pretreatment with the LTD4 receptor antagonist, pranlukast (ONO&#150;1078, SB
205312) (20 mg/kg, intragastrically), significantly inhibited both the
bronchoconstriction and the eosinophilia at 24 h, whereas the cyclooxygenase
inhibitor, meclofenamic acid (5 mg/kg, intragastrically), had no effect on
either parameter. Histologic observations were consistent with BAL results.
Pretreatment with the rat anti&#150;mouse antibody to interleukin&#150;5 (IL&#150;5),
TRFK&#150;5 (10&#150;300 mg, intraperitoneally), produced dose&#150;related
inhibition of LTD4&#150;induced eosinophilia, measured in 24 h or 3 wk BAL, but
did not affect the acute bronchoconstriction. These results indicate that LTD4
elicits airway eosinophil influx in guinea pigs which persists as long as 4 wk
after a single exposure, and provide the first evidence that IL&#150;5 may have
a role in LTD4&#150;induced airways inflammation. This and other previously
reported proinflammatory effects of LTD4 may contribute significantly to its
overall influential role in the pathophysiology of asthma, and may underlie the
therapeutic benefit of CysLT receptor antagonists, such as pranlukast, in this
disorder. <B>Underwood DC, Osborn RR, Newsholme SJ, Torphy TJ, Hay DWP.</B> AM
J RESPIR CRIT CARE MED 1996.</P>
<TABLE BORDER="1">
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#top">BACK TO MENU</A></B></SMALL></TD></TR></TABLE>
<P></P>
<HR>
<P><B><A NAME="ats4">Toluene Diisocyanate&#150;Induced <I>in vitro</I>
Tracheal Hyperreactivity in the Mouse 154:858&#150;865</A></B></P>
<P>Toluene diisocyantate (TDI) is a low&#150;molecular&#150;weight compound
that is known to cause occupational asthma in 5% to 10% of exposed workers.
These patients exhibit marked airway hyperresponsiveness and granulocyte
accumulation in the airways, and 10% to 20% were also determined to have TDI&#150;specific
IgE in their serum. In this study, we developed a murine model for TDI&#150;induced
asthma. After several sensitization and challenge regimens were tested, it was
decided that optimal sensitization was observed after mice (BALB/c) were skin
sensitized with TDI (1%) two times on two consecutive days and challenged
intranasally 8 d later with TDI (1%). Sensitized mice exhibited tracheal
hyperreactivity to carbachol 24 h after challenge (69% increase in maximal
contractile response). In contrast, no differences between the control and TDI&#150;treated
groups was observed 2 and 48 h after challenge with 1% TDI. There appeared to be
no elevation in TDI&#150;specific IgE antibodies in the serum at all time points
measured. In addition, no influx of leukocytes could be detected histologically
in the trachea and lung tissue or airway lumen 2, 24, and 48 h after the
challenge. Surprisingly, the tracheal hyperreactivity was associated with a
marked increase in myeloperoxidase but not eosinophil peroxidase activity in the
lung tissue and in the cells of the bronchoalveolar lavage fluid at 24 h after
the challenge. To investigate the role of lymphocytes in the induction of
tracheal hyperreactivity, mice were passively sensitized by intravenous
injection of lymphoid cells from TDI&#150;sensitized donor mice. Similar to
active sensitization, adoptive transfer of lymphocytes from sensitized donors
resulted in tracheal hyperreactivity 24 h after challenge of the recipients. In
conclusion, these data show that TDI is capable of inducing lymphocyte&#150;dependent
but IgE&#150;independent tracheal hyperreactivity in the mouse that is not
associated with cellular infiltratration in the airways. This model can be used
to further investigate the possible mechanisms involved in the development of
occupational asthma induced by TDI. <B>Scheerens H, Buckley TL, Davidse EM,
Garssen J, Nijkamp FP, Van Loveren H. </B>AM J RESPIR CRIT CARE MED 1996.</P>
<TABLE BORDER="1">
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#top">BACK TO MENU</A></B></SMALL></TD></TR></TABLE>
<P></P>
<HR>
<P><B><A NAME="ats5">Spontaneous and Induced Sputum to Measure Indices of
Airway Inflammation in Asthma 154:866&#150;869</A></B></P>
<P>Inhalation of hypertonic saline to induce sputum may alter cells and fluid&#150;phase
markers in sputum. We have compared indices of inflammation in sputum produced
spontaneously with sputum induced by an aerosol of hypertonic saline. Twenty&#150;three
asthmatics produced spontaneous followed by induced sputum on the same day. The
sputum specimen was separated from saliva within 2 h, dispersed with
dithiothreitol (DTT) and processed to obtain cytospins and supernatant. The
statistical power to detect a 20% difference in sputum parameters was &gt; 90%.
Results are expressed as median and interquartile range [IQR]. Induced sputum
had a higher proportion of viable cells (77.0 [19.0] versus 47.0 [38.0]%, p &lt;
0.001), less squamous cell contamination (1.0 [1.2] versus 1.8 [34.0]%, p &lt;
0.001) and better quality cytospins (score of 8.0 [4.0] versus 4.0 [2.0], p &lt;
0.001). It also had lower fluid&#150;phase levels of eosinophil cationic protein
(ECP) (1,358 [1,102] versus 1,574 [2,479] mg/L) and fibrinogen (1,560.0
[3,130.0] versus 4,350.0 [5,970.0] ng/ml) but only the latter was significantly
different (p = 0.02). Induced sputum was similar to spontaneous sputum in weight
(200.0 [219.0] versus 270.0 [227.0] mg), total cell count (3.3 [4.1] versus 3.5
[4.5] x 106/ml), proportion of nonsquamous cells, and levels of tryptase. The
agreement between induced and spontaneous measurements was good, but fluid&#150;phase
levels were affected by the low viability of some spontaneous samples. We
conclude that for the indices measured in asthmatic subjects, induced sputum
separated from saliva is similar to lower respiratory secretions expectorated
spontaneously and has the advantage of better cell viability. <B>Pizzichini
MMM, Popov TA, Efthimiadis A, Hussack P, Evans S, Pizzichini E, Dolovich J,
Hargreave FE. AM J RESPIR CRIT CARE MED 1996.</B></P>
<TABLE BORDER="1">
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#top">BACK TO MENU</A></B></SMALL></TD></TR></TABLE>
<P></P>
<HR>
<P><B><A NAME="ats6">On Adjusting Measurements of Airway Responsiveness for
Lung Size and Airway Caliber 154:870&#150;875</A></B></P>
<P>It has been suggested that during bronchial challenge with a pharmacologic
agent, subjects with small lungs receive a proportionally greater dose of
agonist than do those with larger lungs. This infers that measurements of airway
hyperresponsiveness (AHR) between different age and gender groups may not be
comparable.To examine this, we analyzed data from population samples of 1,613
children 7 to 12 yr of age and 1,484 adults 25 to 50 yr of age in whom we
measured airway responsiveness by histamine inhalation test. We used FVC as a
surrogate measurement for lung size and FEV1/FVC as a surrogate measurement for
airway caliber. When AHR was adjusted for FVC, FEV1/FVC, and gender, the
differences in prevalence between age groups was reduced. The prevalence of AHR
in those between 7 and 9 yr of age decreased from 20.2% (95% CI, 17.7 to 22.7)
to 15.7% (95% CI, 13.4 to 18.0), but the prevalence of AHR in those 35 to 44 yr
of age remained the same at 7.6% (95% CI, 5.9 to 9.3). We conclude that FVC and
FEV1/FVC have a small but significant effect on the measurement of airway
responsiveness and that more precise measurements of the prevalence of AHR can
be obtained by standardization for these parameters. <B>Peat JK, Salome CM,
Xuan W. </B><B>AM J RESPIR CRIT CARE MED 1996.</B></P>
<TABLE BORDER="1">
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#top">BACK TO MENU</A></B></SMALL></TD></TR></TABLE>
<P></P>
<HR>
<P><B><A NAME="ats7">Prolonged Effect of Tiotropium Bromide on Methacholine&#150;induced
Bronchoconstriction in Asthma 154:876&#150;880</A></B></P>
<P>Inhaled anticholinergic drugs are effective in the treatment of chronic
obstructive pulmonary diseases (COPD), of acute asthma, and of some patients
with nocturnal asthma. Tiotropium bromide (tiotropium) is a novel
anticholinergic agent with a long duration of action and kinetic selectivity for
M1&#150; and M3&#150;subtypes of muscarinic receptors. We investigated the
duration of protection of a single dose of inhaled tiotropium against
methacholine&#150;induced bronchoconstriction in 12 male atopic asthmatic
volunteers in a double&#150;blind, placebo&#150;controlled study. On four
separate occasions 8 to 24 d apart, methacholine PC20 was measured serially for
up to 48 h after placebo and after three doses of tiotropium (10, 40, and 80
mg). Each dose of tiotropium produced mild bronchodilatation as measured by an
increase in FEV1 of between 5.5 and 11.1% from baseline, that was sustained for
24 h. There was significant dose&#150;dependent protection against methacholine
challenge at 2 h of 5.0 &#177; 1.1, 7.1 &#177; 0.5, and 7.9 &#177; 0.7 (mean &#177;
SEM) doubling doses after 10, 40, and 80 mg respectively, and this persisted for
48 h. There were no adverse effects reported at any dose. The prolonged
bronchodilator response and protection against methacholine challenge suggest
that tiotropium may be useful in the treatment of COPD and nocturnal asthma and
that once&#150;daily dosing may be sufficient. <B>O'Connor BJ, Towse LJ, Barnes
PJ. </B>AM J RESPIR CRIT CARE MED 1996.</P>
<TABLE BORDER="1">
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#top">BACK TO MENU</A></B></SMALL></TD></TR></TABLE>
<P></P>
<HR>
<P><B><A NAME="ats8">Seasonal Variations in House Dust Mite Influence the
Circadian Peak Expiratory Flow Amplitude 154:881&#150;884</A></B></P>
<P>The aim of the study was to investigate whether seasonal differences in
house dust mite (HDM) allergen exposure influence the circadian peak expiratory
flow (PEF) amplitude in asthmatic children. Asthmatic children (n = 25) with a
solitary allergy to HDM were studied in spring and in autumn. All used inhaled
corticosteroids (ICS) regularly. Six days after withdrawal of ICS, PEF amplitude
(every 4 h during 24 h, highest &#190; lowest / percentage of mean value) was
assessed. HDM allergen (HDMA) in living rooms, bedrooms, and mattresses was
collected. HDMA levels were not always highest in autumn. PEF amplitudes in
spring and autumn did not correlate with HDMA levels in the same season.
However, the seasonal difference in PEF amplitude (autumn value &#190; spring
value) correlated positively and significantly with the seasonal difference in
HDMA exposure levels from the mattresses (rho = 0.34, p &lt; 0.05). Multivariate
analysis showed that the seasonal difference in HDMA exposure in the mattress
was the single parameter explaining seasonal difference in PEF amplitudes by
21.0% (p = 0.02). Our cross&#150;sectional study showed a higher PEF amplitude
not to be significantly associated with higher HDMA exposure in mattresses in a
group of HDM&#150;allergic asthmatic children. However, the change in HDMA
exposure over seasons contributed significantly to the change in PEF amplitude
after withdrawal of ICS in HDM&#150;allergic asthmatic children. <B>Meijer GG,
Postma DS, van der Heide S, de Reus DM, Ko&euml;ter GH, Roorda RJ, van Aalderen
WMC. </B>AM J RESPIR CRIT CARE MED 1996.groeben</P>
<TABLE BORDER="1">
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#top">BACK TO MENU</A></B></SMALL></TD></TR></TABLE>
<P></P>
<HR>
<P><B><A NAME="ats9">Intravenous Lidocaine and Oral Mexiletine Block Reflex
Bronchoconstriction in Asthmatic Subjects 154:885&#150;888</A></B></P>
<P>Stimulation of the airways of asthmatic individuals causes severe
bronchoconstriction, which is in part neurally mediated via the vagus nerve.
Local anesthetics are commonly administered to prevent this reflex&#150;induced
bronchoconstriction. Therefore, in a double&#150;blind, placebo&#150;controlled
prospective study, we tested the effectiveness of oral mexiletine and
intravenous lidocaine at blocking histamine&#150;induced reflex
bronchoconstriction. Fifteen subjects with mild asthma were selected (for whom
the provocative concentration of histamine aerosol causing a 20% decrease in
FEV1 (PC20) was less than 18 mg/ml). Subsequently, the subjects were pretreated
with oral mexiletine, intravenous lidocaine, or placebo, and the histamine
challenges were repeated. The baseline PC20 for histamine was 8.8 &#177; 1.8
mg/ml. Mexiletine and lidocaine at therapeutic serum concentrations blocked
reflex bronchoconstriction. Oral mexiletine increased the PC20 to 21.1 &#177;
5.0 mg/ml (serum concentration: 0.7 &#177; 0.05 mg/ml). Likewise, intravenous
lidocaine increased the PC20 to 24.5 &#177; 4.9 mg/ml (serum concentration: 2.6 &#177;
0.15 mg/ml). Oral mexiletine and intravenous lidocaine block reflex&#150;induced
bronchoconstriction. Furthermore, mexiletine may have additional airway benefits
when selected for the treatment of dysrhythmias or chronic pain in patients with
coexisting lung diseases. <B>Groeben H, Foster WM, Brown RH.</B> AM J RESPIR
CRIT CARE MED 1996.chan</P>
<TABLE BORDER="1">
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#top">BACK TO MENU</A></B></SMALL></TD></TR></TABLE>
<P></P>
<HR>
<P><B><A NAME="ats10">Changes in Peak Flow, Symptom Score, and the Use of
Medications During Acute Exacerbations of Asthma 154:889&#150;893</A></B></P>
<P>Changes in symptom score and peak expiratory flow (PEF) and the use of
medications during the first acute exacerbation of asthma were studied in 41
patients and matched controls who took part in a panel study. An acute
exacerbation was defined as the presence of at least one of the following: any
unscheduled physician visit, visit to an emergency room, or hospitalization for
treatment of asthma; a decrease in PEF by 30% from the patient's best reading;
an increase in asthma symptoms during the day and night for over 48 h and not
responding to usual medications; and the commencement or doubling of the dose of
oral or inhaled steroids for any of the foregoing reasons. Data from &#190;9 to &#190;7
d before the onset of an acute exacerbation were taken as the baseline data,
with which the values of the subsequent 14 d were compared. Significant
increases in symptoms occurred before a significant reduction in PEF. None of
the patients had a decrease of more than 30% in PEF before the onset of
symptoms. Daily variation in PEF was not significantly increased from the
baseline. Our results suggest that PEF monitoring is not as sensitive as a
symptom diary for revealing acute exacerbations of asthma, and that a 30%
decrease in PEF is too stringent a criterion for defining an acute exacerbation.
<B>Chan&#150;Yeung M, Chang JH, Manfreda J, Ferguson A, Becker A. </B>AM J
RESPIR CRIT CARE MED 1996.beckett</P>
<TABLE BORDER="1">
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#top">BACK TO MENU</A></B></SMALL></TD></TR></TABLE>
<P></P>
<HR>
<P><B><A NAME="ats11">Asthma among Puerto Rican Hispanics: A Multi&#150;ethnic
Comparison Study of Risk Factors 154:894&#150;899</A></B></P>
<P>For a study of childhood asthma we interviewed 9,276 mothers during 1993&#150;1994,
ascertaining whether they had asthmatic children younger than 18 yr of age and
asking about genetic and environmental risk factors for asthma. Independent risk
factors for asthma in 7,776 children were: Hispanic and African American
ethnicity, maternal history of asthma, lower socioeconomic status (SES) of the
mother, and the presence of a cigarette smoker in the household. Hispanic
ethnicity was also a strong risk factor for asthma in the mother. The prevalence
of asthma among children of Hispanic (mainly Puerto Rican) mothers with one or
more children older than 9 mo of age was 18.4%, for blacks it was 11.3%, and for
non&#150;Hispanic whites it was 7.4%. The marked increased risk for asthma in
children of Hispanic mothers was not explained by SES or maternal age. In
addition, increased risk for asthma in these children was not associated with
higher reporting of environmental tobacco smoke (ETS) exposure. In this study of
asthma in primarily Puerto Rican Hispanics, the risk of physician&#150;diagnosed
asthma as reported by mothers was significantly associated with Hispanic
ethnicity, and it was not confounded by SES or active smoking in the home. <B>Beckett
WS, Belanger K, Gent JF, Holford TR, Leaderer BP.</B> AM J RESPIR CRIT CARE MED
1996.</P>
<TABLE BORDER="1">
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#top">BACK TO MENU</A></B></SMALL></TD></TR></TABLE>
<P></P>
<HR>
<P><B><A NAME="ats12">Protective Effect of B464, a Lipid A Analog, on
Endotoxin&#150;induced Cellular Responses and Acute Lung Injury 154:900&#150;906</A></B></P>
<P>B464 is a novel synthetic analog of lipid A, a toxic component of endotoxin
(LPS; lipopolysaccharide). We investigated the effects of B464 on both LPS&#150;induced
cellular responses <I>in vitro</I> and acute lung injury <I>in vivo.</I> In
the <I>in vitro</I> study, B464 inhibited tumor necrosis factor&#150;a (TNF&#150;a)
production from human monocytes, priming and stiffening of neutrophils, and
expression of adhesion molecules on endothelial cells induced by LPS. We then
studied the effects of B464 pretreatment on acute lung injury elicited by
intravenous LPS administration <I>in vivo.</I> Guinea pigs were divided into
saline control, B464 alone, LPS alone, and LPS + B464 groups. Animals were
observed for 4 h after LPS administration, and lung injury was evaluated by
extravascular lung water, 125I&#150;albumin leakage in lung tissue, and lung
neutrophil accumulation. In the LPS alone group, rapid and sustained peripheral
neutropenia (p &lt; 0.001 versus saline at 15 min and at 1, 2, and 4 h), an
increased plasma TNF&#150;a concentration (p &lt; 0.005 at 1 h), and increases
in lung injury parameters (p &lt; 0.05) were observed. In the LPS + B464 group,
no changes were observed in either plasma TNF&#150;a or lung injury parameters.
Transient peripheral neutropenia and subsequent rapid recovery (p &gt; 0.05, p &lt;
0.001, p &lt; 0.01, and p &gt; 0.05 at 15 min and 1, 2, and 4 h, respectively)
were observed in the LPS + B464 group. These <I>in vivo</I> data, together with
<I>in vitro</I> evidence of suppressed cellular responses, suggest that B464 (<I>1</I>)
inhibits neutrophil accumulation in lung tissue, and (<I>2</I>) attenuates the
development of acute lung injury by blocking the activation of neutrophils and
mononuclear cells as well as the interaction between neutrophils and endothelial
cells. <B>Soejima K, Ishizaka A, Urano T, Sayama K, Sakamaki F, Nakamura H,
Terashima T, Waki Y, Tasaka S, Fujishima S, Kawata T, Christ WJ, Kanazawa M.
</B>AM J RESPIR CRIT CARE MED 1996.</P>
<TABLE BORDER="1">
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#top">BACK TO MENU</A></B></SMALL></TD></TR></TABLE>
<P></P>
<HR>
<P><B><A NAME="ats36">Estimation of Occlusion Pressure During Assisted
Ventilation in Patients with Intrinsic PEEP 154:907&#150;912</A></B></P>
<P>We conducted a study to assess the validity of the occlusion pressure (P0.1)
measured during activation of the trigger mechanism (P0.1awtrig) in patients
showing variable levels of PEEPi during pressure&#150;support ventilation. We
first compared P0.1awtrig and P0.1 measured with the conventional method (i.e.,
the airway pressure drop after the first 100 ms of an occluded inspiration) in
16 patients with chronic obstructive pulmonary disease (COPD). We observed good
agreement and a highly significant correlation (r = 0.99; bias = 0.3 &#177; 0.5
cm H2O) between the two methods. In a second part of the study, we compared, in
17 patients, P0.1awtrig with (P0.1es), measured as the depression generated on
the esophageal pressure tracing in the first 100 ms of the inspiratory negative
swing, and with P0.1 measured on the Pes tracing simultaneously with Pawtrig
(P0.1es&#150;synchro). Our results showed a good correlation and good agreement
between Pawtrig and P0.1es (r = 0.92; bias = 0.3 &#177; 0.5 cm H2O); Pawtrig and
P0.1es&#150;synchro (r = 0.97; bias = 0.1 &#177; 0.2 cm H2O); and P0.1es and
P0.1es&#150;synchro (r = 0.95, bias = 0.2 &#177; 0.4 cm H2O), respectively. This
study suggests that reliable measurements of inspiratory drive can be obtained
easily, on a breath&#150;by&#150;breath basis, from airway pressure tracings
during pressure&#150;support ventilation in patients with variable levels of
PEEPi. <B>Conti G, Cinnella G, Barboni E, Lemaire F, Harf A, Brochard L. </B>AM
J RESPIR CRIT CARE MED 1996.</P>
<TABLE BORDER="1">
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#top">BACK TO MENU</A></B></SMALL></TD></TR></TABLE>
<P></P>
<HR>
<P><B><A NAME="ats13">The Accuracy of Pneumotachograph Measurements During
Mechanical Ventilation 154:913&#150;917</A></B></P>
<P>We hypothesized that differences between the conditions under which a
pneumotachograph (PT) is calibrated and those during data collection might lead
to large errors in measured flow and volume during mechanical ventilation. A
Fleisch No. 1 and Fleisch No. 2 and a screen PT were connected to &quot;ideal&quot;
tubing configurations that optimized flow characteristics, and to ventilator
tubing with and without a Y&#150;connector and endotracheal (ET) tube. Each PT
was also evaluated after water had accumulated in its resistive element. Air was
passed through each PT configuration, using both a continuous and a pulsatile
flow pattern, and collected in a water&#150;seal spirometer. &quot;Measured&quot;
and &quot;true&quot; flow and volume were determined from the PT and the
spirometer, respectively. Measured flow and volume were falsely low when the PT
was adapted to ventilator tubing. Addition of a Y&#150;connector and ET tube
caused measured flow and volume to increase, and, in some cases the relationship
between measured and true flow became nonlinear. Water accumulation in the PT
did not lead to measurement errors. We conclude that when a PT is used during
mechanical ventilation, tubing geometry must be identical during calibration and
data collection, and that calibration should be performed over the entire range
of relevant flows. <B>Kreit JW, Sciurba FC. </B>AM J RESPIR CRIT CARE MED 1996.</P>
<TABLE BORDER="1">
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#top">BACK TO MENU</A></B></SMALL></TD></TR></TABLE>
<P></P>
<HR>
<P><B><A NAME="ats14">Changes in Lung Volume and Static Expiratory Pressure&#150;Volume
Diagram after Surfactant Rescue Treatment of Neonates with Established
Respiratory Distress Syndrome 154:918&#150;923</A></B></P>
<P>The effect of natural surfactant on respiratory system mechanics in infants
with respiratory distress syndrome (RDS) is incompletely understood, possibly
because the analysis has usually been confined to the tidal breath. We studied
11 paralyzed neonates weighing 540 to 1,850 g before and approximately 30 min
after surfactant, which was instilled at 4 to 41 h of age. Diagrams relating
airway pressure to expired volume were obtained by having the infant exhale
passively through a flowmeter, starting at 30 and ending at 0 cm H2O of
pressure. An interrupter intermittently stopped the flow so that pressure could
be recorded under static conditions. FRC was measured by sulfur hexafluoride
washout, and TLC was calculated from FRC and the pressure&#150;volume (P&#150;V)
curve. Ventilation homogeneity was assessed from the washout curve as pulmonary
clearance delay (PCD). TLC increased by 10% or more in five infants, but it
remained unchanged in the others. Median TLC was 19 ml/kg before and 21.5 ml/kg
after surfactant (p = 0.39). The P&#150;V curve became markedly steeper at low
pressures after surfactant in most infants, the slope of the steepest segment,
i.e., maximal compliance, increasing from 0.65 to 1.22 ml/cm H2O/kg (medians, p
= 0.008). Dynamic compliance (Cdyn) was unchanged at 0.28 ml/cm H2O/kg, whereas
specific dynamic compliance (Cdyn/FRC) decreased (p = 0.04). There was no
significant immediate change in PCD. The findings imply that during the first 30
min surfactant acted mainly by stabilizing already ventilated air spaces. <B>Bj&ouml;rklund
LJ, Vilstrup CT, Larsson A, Svenningsen NW, Werner O. </B>AM J RESPIR CRIT CARE
MED 1996.peiffer</P>
<TABLE BORDER="1">
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#top">BACK TO MENU</A></B></SMALL></TD></TR></TABLE>
<P></P>
<HR>
<P><B><A NAME="ats15">Respiratory Sensation Related to Resistive Loads in
Lung  Transplant Recipients 154:924&#150;930</A></B></P>
<P>In order to assess the contribution of pulmonary afferent nerves to the
processing of respiratory sensation, we compared sensation related to
inspiratory resistive loaded breathing in 14 lung transplant recipients with
normal lung function with that in 14 matched healthy control subjects.
Respiratory sensation was characterized for each subject by the correlation
coefficient and slope of the linear relationship between the intensity of
sensation (expressed as Borg scores [BSc]) and peak inspiratory mouth pressure
(peak Pm), which was considered the main physical stimulus of the sensation.
Individual correlation coefficients were very high and did not differ between
lung transplant recipients and controls. In contrast, individual slopes of BSc
as a function of peak Pm (BSc/peak Pm slopes) were significantly lower in lung
transplant recipients than in controls (0.63 versus 1.26; p &lt; 0.01).
Furthermore, ventilatory responses to external loads differed significantly
between lung transplant recipients and controls in terms of higher values and
ranges of generated peak Pm and peak inspiratory flow in lung transplant
recipients than in controls (all p &lt; 0.05). These results suggest that
pulmonary afferent nerves may contribute to ventilatory and sensory responses to
external loads. However, as suggested by the inverse relation between BSc/peak
Pm slopes and peak Pm ranges, higher stimulus ranges in lung transplant
recipients may also have contributed to intergroup differences in respiratory
sensation related to loaded breathing. <B>Peiffer C, Silbert D, Cerrina J,
Ladurie FLR, Dartevelle P, Chapelier A, Herv&eacute; P. </B>AM J RESPIR CRIT
CARE MED 1996.piper</P>
<TABLE BORDER="1">
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#top">BACK TO MENU</A></B></SMALL></TD></TR></TABLE>
<P></P>
<HR>
<P><B><A NAME="ats16">Microcirculatory Changes in Rat Skeletal Muscle in
Sepsis 154:931&#150;937</A></B></P>
<P>The aim of this study was to confirm that microvascular perfusion was
abnormal during the early phases of normotensive sepsis and to determine whether
these changes were due to the development of tissue edema. Skeletal muscle red
blood cell (RBC) flow was studied in rats made septic by cecal ligation and
perforation (CLP). After anesthesia with halothane, arterial and venous cannulae
were inserted and, in the treatment group, a CLP performed. At 6, 24, and 48 h
after entry into the study, the incidence of microcirculatory absence of flow in
the extensor digitorum longus muscle (EDL) was examined with intravital
microscopy. The number of capillaries containing RBCs were counted over a 60&#150;s
interval, and the flow status of each capillary was recorded. A significant
increase in the number of stopped&#150;flow capillaries was observed in the CLP
group (p &lt; 0.01) as compared with time&#150;matched controls. In both groups
the number of capillaries with stopped flow was greater than in naive animals.
The severity of absence of flow was negatively correlated with the systemic
hemoglobin concentration. These changes were not associated with an increase in
tissue wet/dry weight ratio or albumin flux. This study shows that sepsis was
associated with increased RBC flow heterogeneity. These changes, which occur
within 24 h of the septic insult, are a persistent feature of the evolving
septic process in the absence of tissue edema. These observations support the
view that extrinsic compression of the microcirculation by tissue edema is not
the primary cause of alterations in microcirculatory flow in sepsis. <B>Piper
RD, Pitt&#150;Hyde M, Li F, Sibbald WJ, Potter RF. </B>AM J RESPIR CRIT CARE MED
1996.</P>
<TABLE BORDER="1">
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#top">BACK TO MENU</A></B></SMALL></TD></TR></TABLE>
<P></P>
<HR>
<P><B><A NAME="ats17">Comparison of Static and Dynamic Intrinsic Positive End&#150;Expiratory
Pressure Using the Campbell Diagram 154:938&#150;944</A></B></P>
<P>Intrinsic positive end&#150;expiratory pressure (PEEPi) due to dynamic
hyperinflation has been measured as a plateau airway opening pressure during
airway occlusion (PEEPi,stat). PEEPi has also been dynamically determined as a
fall in esophageal pressure (Pes) before the inspiratory flow starts
(PEEPi,dyn). The aims of the current study were to systematically compare
PEEPi,stat and PEEPi,dyn and to explain the underlying mechanisms of their
difference. The study was performed in healthy subjects with dynamic
hyperinflation induced by expiration through a Starling resistor. The Campbell
diagram was constructed for each subject by determining the static pressure&#150;volume
curves of the lung (Pst,[l]) and chest wall (Pst,[w]). For a given end&#150;expiratory
volume, PEEPi,stat was measured on the Campbell diagram as the pressure
difference between Pst(w) and &#190;Pst(l). PEEPi,dyn was measured as mentioned
above. The effects of respiratory muscle recruitment on PEEPi,dyn were estimated
by the Pes values when Pes started to fall relative to Pst(w). We found that: (<I>1</I>)
there was a great variability of the PEEPi,dyn/PEEPi,stat ratio among and within
subjects; (<I>2</I>) expiratory muscle recruitment was evident on most
occasions; (<I>3</I>) persistent inspiratory muscle activity during expiration
was present in some subjects; (<I>4</I>) the Pes values at the start of
inspiratory flow were frequently on the left of &#190;Pst(l), which contributed
to the difference between PEEPi,stat and PEEPi,dyn and implied a greater dynamic
than static elastance presumably due to viscoelastic properties; (<I>5</I>)
chest wall distortions characterized by inflation of the abdomen with deflation
of the rib cage during the initial inspiratory efforts were observed in three
subjects. In conclusion, interpretation of PEEPi,dyn needs to be cautious
because both expiratory and tonic inspiratory muscle activities that lead to
significant over&#150;or underestimation of PEEPi by PEEPi,dyn, respectively,
are associated with acute dynamic hyperinflation. In addition, the effects of
viscoelastic properties and chest wall distortions on PEEPi,dyn need to be
further investigated. <B>Yan S, Kayser B, Tobiasz M, Sliwinski P. </B>AM J
RESPIR CRIT CARE MED 1996.</P>
<TABLE BORDER="1">
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#top">BACK TO MENU</A></B></SMALL></TD></TR></TABLE>
<P></P>
<HR>
<P><B><A NAME="ats18">Mechanism of Short&#150;term Improvement in Lung
Function after Emphysema Resection 154:945&#150;951 </A></B></P>
<P>We prospectively investigated the mechanism of airflow limitation before and
after targeted emphysematous resection in 12 consecutively studied adult
patients 68 &#177; 4 yr of age (mean &#177; SD) with very severe COPD undergoing
bilateral thoracoscopic stapling techniques. Lung function, static lung elastic
recoil, and airway conductance was measured 2 wk before and 5 to 6 mo after
surgery. After surgery, there was a significant (p &lt; 0.01) reduction in TLC
(9.3 &#177; 0.3 [mean &#177; SEM] to 7.7 &#177; 0.4 L), functional residual
capacity, and residual volume. Airway conductance, FVC, and FEV1 (0.7 &#177; 0.1
to 1.2 &#177; 0.2 L) all improved significantly (p &lt; 0.01). Lung elastic
recoil increased markedly at TLC (from 10.3 &#177; 0.5 to 14.6 &#177; 1.0 cm
H2O; p &lt; 0.001) as did maximal expiratory airflow in every patient. Analysis
of maximal expiratory flow&#150;static elastic recoil pressure curve indicated
that conductance of the S segment (Gs) increased from 0.20 &#177; 0.03 (mean &#177;
SEM) to 0.27 &#177; 0.03 L/s/cm H2O (p &lt; 0.01), and the critical transmural
pressure (Ptm') decreased from 3.1 &#177; 0.2 to 2.4 &#177; 0.2 cm H2O (p &lt;
0.02). Mean airway conductance increased from 0.14 to 0.22 L/s/cm H2O (p &lt;
0.01). The improvement in maximal expiratory airflow can be primarily attributed
to increased lung elastic recoil and its secondary effect on enlarging airway
diameter causing increased airway conductance, increased Gs, and decreased Ptm'.
<B>Gelb AF, Zamel N, McKenna RJ, Jr., Brenner M.</B> AM J RESPIR CRIT CARE MED
1996.</P>
<TABLE BORDER="1">
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#top">BACK TO MENU</A></B></SMALL></TD></TR></TABLE>
<P></P>
<HR>
<P><B><A NAME="ats19">Altered Composition of Urinary Heparan Sulfate in
Patients with COPD 154:952&#150;958</A></B></P>
<P>In patients with emphysema the integrity of the extracellular matrix
(connective tissue skeleton) is compromised. In this study we analyzed
glycosaminoglycans, which are main constituents of this matrix, in urines from
patients with chronic obstructive pulmonary disease (COPD)/emphysema.
Glycosaminoglycans (GAGs) were purified by anion exchange chromatography and
quantified using the 1,9&#150;dimethylmethylene blue assay. Heparan sulfate (HS)
was assayed using three different chemical methods: digestion with heparitinase
or with nitrous acid and by use of an adapted 1,9&#150;dimethylmethylene blue
assay. A specific epitope on the HS molecule, defined by the monoclonal antibody
JM403, was determined using an inhibition enzyme immunoassay. In patients with
COPD total urinary glycosaminoglycan and HS content were not altered. The JM403
epitope of HS, however, was greatly decreased in patients (0.6 versus 4.1
units/mg creatinine for control subjects, p &lt; 0.0001). A similar pattern was
observed when patients with bronchial carcinoma with and without emphysema were
compared (0.4 versus 2.4 units/mg creatinine respectively, p &lt; 0.0005).
Patients with sarcoidosis did not show a decreased epitope content. These
results indicate a structural change or an altered processing of the HS molecule
in patients with emphysema. Taking into consideration the importance of HS for
the stability of the alveolar extracellular matrix, this change may be
associated with the pathogenesis of emphysema. <B>van de Lest CH, Versteeg EM,
Veerkamp JH, Berden JH, van den Born J, Heunks L, Lammers J&#150;WJ, van
Herwaarden CL, Dekhuijzen PNR, van Kuppevelt TH.</B> AM J RESPIR CRIT CARE MED
1996.</P>
<TABLE BORDER="1">
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#top">BACK TO MENU</A></B></SMALL></TD></TR></TABLE>
<P></P>
<HR>
<P><B><A NAME="ats20">Outcomes Following Acute Exacerbation of Severe Chronic
Obstructive Lung Disease 154:959&#150;967</A></B></P>
<P>In order to describe the outcomes of patients hospitalized with an acute
exacerbation of severe chronic obstructive pulmonary disease (COPD) and
determine the relationship between patient characteristics and length of
survival, we studied a prospective cohort of 1,016 adult patients from five
hospitals who were admitted with an exacerbation of COPD and a PaCO2 of 50 mm Hg
or more. Patient characteristics and acute physiology were determined. Outcomes
were evaluated over a 6 mo period. Although only 11% of the patients died during
the index hospital stay, the 60&#150;d, 180&#150;d, 1&#150;yr, and 2&#150;yr
mortality was high (20%, 33%, 43%, and 49%, respectively). The median cost of
the index hospital stay was 7,100 (4,100 to 16,000; interquartile range). The
median length of the index hospital stay was 9 d (5 to 15 d). After discharge,
446 patients were readmitted 754 times in the next 6 mo. At 6 mo, only 26% of
the cohort were both alive and able to report a good, very good, or excellent
quality of life. Survival time was independently related to severity of illness,
body mass index (BMI), age, prior functional status, PaO2/FIO2, congestive heart
failure, serum albumin, and the presence of cor pulmonale. Patients and
caregivers should be aware of the likelihood of poor outcomes following
hospitalization for exacerbation of COPD associated with hypercarbia. <B>Connors
AF, Dawson NV, Thomas C, Harrell FE Jr, Desbiens N, Fulkerson WJ, Kussin P,
Bellamy P, Goldman L, Knaus WA. </B>AM J RESPIR CRIT CARE MED 1996.</P>
<TABLE BORDER="1">
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#top">BACK TO MENU</A></B></SMALL></TD></TR></TABLE>
<P></P>
<HR>
<P><B><A NAME="ats21">Western Red Cedar Dust Exposure and Lung Function: A
Dose&#150;Response Relationship 154:968&#150;973</A></B></P>
<P>The relationship between levels of cumulative red cedar dust exposure and
decline in lung function was explored in an 11&#150;yr follow&#150;up study of
243 sawmill workers who participated in at least two occasions. We also studied
140 office workers in a similar manner as control subjects. Workers with asthma
were excluded from the analysis. During the period of the study, 916 personal
and 216 area samples of dust were collected from the sawmill. Cumulative wood
dust exposure was calculated for each sawmill worker according to the duration
and exposure in each job, based on the geometric mean of all dust measurements
for that job. Average daily dust exposure was calculated by dividing the total
cumulative exposure by the number of days of work. Workers were divided into low&#150;,
medium&#150;, and high&#150;exposure groups with mean daily level of exposure of
&lt; 0.2, 0.2 to 0.4, and &gt; 0.4 mg/m3, respectively. Sawmill workers had
significantly greater declines in FEV1 and FVC compared with office workers
adjusted for age, smoking, and initial lung function. A dose&#150;response
relationship was observed between the level of exposure and the annual decline
in FVC. We conclude that exposure to Western red cedar dust is associated with a
greater decline in lung function which may lead to development of chronic
airflow limitation. <B>Noertjojo HK, Dimich&#150;Ward H, Peelen S, Dittrick M,
Kennedy SM, Chan&#150;Yeung M.</B> AM J RESPIR CRIT CARE MED 1996.</P>
<TABLE BORDER="1">
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#top">BACK TO MENU</A></B></SMALL></TD></TR></TABLE>
<P></P>
<HR>
<P><B><A NAME="ats22">A Regression Approach to the Analysis of Serial Peak
Flow among Fuel Oil Ash Exposed Workers 154:974&#150;980</A></B></P>
<P>We investigated the association between exposure to fuel oil ash and acute
airway obstruction in 31 boilermakers and 31 utility workers during the overhaul
of a large oil&#150;fired boiler. Air flow was assessed with self&#150;recorded
serial peak expiratory flow rate measurements (PEFR) using a mini&#150;Wright
meter. Exposure to thoracic particulates with an aerodynamic diameter of 10 mm
or smaller (PM10) was assessed using personal sampling devices and detailed work
diaries. All subjects were male, with an average age of 43 yr, and an average of
18 yr at their current trade. Average PM1t0 exposure on work days was 2.75 mg/m3
for boilermakers and 0.57 mg/m3 for utility workers. Three daily PEFR
measurements (start&#150;of&#150;shift, end&#150;of&#150;shift, and bed&#150;time)
were analyzed simultaneously, using Huber linear regression. After adjustment
for job title, welder status, age, height, smoking, and weld&#150;years, for
each mg/m3 increase in PM10, the estimated decline in PEFR was 13.2 L/min (p =
0.008) for end&#150;of&#150;shift, 9.9 L/min (p = 0.045) for bed&#150;time, and
6.6 L/min (p = 0.26) for start&#150;of&#150;shift of the following day. This
decline of the exposure effect over the 24&#150;h period that follows was
statistically significant (p = 0.004). No other factors were found to
significantly modify the effect of exposure. Our results suggest that
occupational exposure to fuel oil ash is associated with significant acute
decrements in peak flow. <B>Hauser R, Daskalakis C, Christiani DC.</B> AM J
RESPIR CRIT CARE MED 1996.</P>
<TABLE BORDER="1">
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#top">BACK TO MENU</A></B></SMALL></TD></TR></TABLE>
<P></P>
<HR>
<P><B><A NAME="ats23">Effect of Ambient Ozone Exposure on Lung Function in
Farm Workers 154:981&#150;987</A></B></P>
<P>Effects of ozone exposure on outdoor farm workers in the Fraser Valley of
British Columbia, Canada, were investigated. Fifty&#150;eight workers underwent
spirometry daily before and after each 8&#150; to 14&#150;h workday from June 23
to August 26, 1993. The mean daily maximum (1 h) ambient ozone concentration was
40 ppb (range: 13 to 84 ppb). Concentrations of acid aerosols and fine
particulates, potential confounders of ozone effects, were very low. In
individual regressions of evening FEV1 and FVC on maximum daily ozone
concentration, 47 of 53 workers with valid data (46 of 53 for FVC) had negative
slopes. The average slopes (weighted by the inverse SE of the regression
coefficients) were &#190;3.3 and &#190;4.7 ml for FEV1 and FVC, respectively,
for each ppb increase in ozone (p &lt; 0.001). Following correction for an
individual's mean lung function level, date, and temperature, regression of
either the afternoon or the daily change (afternoon &#190; morning) corrected
for the morning measurement of FEV1 and FVC on ozone showed similar magnitudes
of effect. These associations were still apparent on the following morning,
suggesting a persistent ozone effect. These results indicate that exposure of a
population of outdoor workers to ambient ozone concentrations below 85 ppb is
associated with decreased lung function over the day, which persists to the
following day. <B>Brauer M, Blair J, Vedal S.</B> AM J RESPIR CRIT CARE MED
1996.</P>
<TABLE BORDER="1">
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#top">BACK TO MENU</A></B></SMALL></TD></TR></TABLE>
<P></P>
<HR>
<P><B><A NAME="ats24">Mechanism of Apnea Lengthening Across the Night in
Obstructive  Sleep Apnea 154:988&#150;993</A></B></P>
<P>We have previously shown in patients with obstructive sleep apnea (OSA) that
the length of apneas increases from the beginning to the end of the night (<I>Chest</I>
1994;106:1695&#150;1701). To investigate this, in light of recent evidence that
neural feedback related to inspiratory effort during apneas plays an important
role in apnea termination (<I>Am. J. Respir. Crit. Care Med.</I> 1994; 149:707&#150;714),
we measured transdiaphragmatic pressure (Pdi) and the diaphragm tension&#150;time
index (TTdi = Pdi/Pdimax x Ti/Ttot) during overnight polysomnography in seven
male subjects with severe OSA (mean apnea&#150;hypopnea index [AHI] = 64.1 &#177;
8.8 [SD] events/h). We assessed apnea duration, SaO2, and inspiratory effort
during apneas at the start and end of the night in Stage 2 sleep. Mean apnea
duration increased from 26.6 &#177; 2.0 s (SEM) to 32.6 &#177; 2.5 s (p &lt;
0.05). The rate of fall in SaO2 during apneas decreased, and end&#150;apneic
SaO2 remained unchanged across the night, suggesting a possible role for
metabolic factors in mediating the increase in apnea duration. Both Pdi and TTdi
at end&#150;apnea just prior to arousal increased significantly from the
beginning to the end of the night (e.g., Pdi from 41.0 &#177; 4.9 to 49.9 &#177;
7.9 cm H2O; p &lt; 0.05). These findings, together with those in previous
studies, suggest that there is a blunting over the night of the arousal response
to neural stimuli produced during obstructed inspiratory effort, which plays a
major role in mediating apnea lengthening across the night in OSA. <B>Montserrat
JM, Kosmas EN, Cosio MG, Kimoff RJ. </B>AM J RESPIR CRIT CARE MED 1996.</P>
<TABLE BORDER="1">
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#top">BACK TO MENU</A></B></SMALL></TD></TR></TABLE>
<P></P>
<HR>
<P><B><A NAME="ats25">Role of Hypoxemia and Pulmonary Mechanics in Exercise
Limitation in Interstitial Lung Disease 154:994&#150;1001</A></B></P>
<P>We have previously shown that respiratory factors (arterial hypoxemia and/or
pulmonary mechanics) contribute to limit maximal incremental exercise in
interstitial lung disease (ILD). In this study, we tested the hypothesis that
arterial hypoxemia, not pulmonary mechanics, primarily limits maximal exercise
in subjects with ILD. Seven subjects with ILD underwent two incremental exercise
tests in random order. Test 1: breathing room air (RA); Test 2: breathing 60% O2
with added external dead space (O2vR). Added vR was used to prevent the fall in
minute ventilation (VoI) while breathing O2. All subjects demonstrated impaired
exercise performance (maximal oxygen uptake [VO2], 56 &#177; 13% predicted)
while breathing RA. There was a significant increase in peak VI (RA, 64.9 &#177;
22.3 L/min versus O2VD, 71.0 &#177; 20.6; p &lt; 0.05), maximal work rate (RA,
99 &#177; 12 watts versus O2VD, 109 &#177; 15 watts; p &lt; 0.01), exercise
duration (RA, 383 &#177; 67 s versus O2VD; 426 &#177; 72 s; p &lt; 0.0005) and
maximal VO2 (RA, 1.25 &#177; 0.21 L/min versus O2VD, 1.39 &#177; 0.26; p &lt;
0.05) during the O2VD exercise test. There was a significant correlation between
the percent increase in exercise duration during the O2VD test and the DLCO (r =
&#190;0.813, p &lt; 0.05). At matched levels of ventilation, subjects
demonstrated a significantly deeper and slower pattern of breathing during the
O2VD test. Because subjects with ILD were able to further improve their exercise
and further increase their VI during the O2VD exercise study, we conclude that
arterial hypoxemia, and not respiratory mechanics, predominantly limits maximal
incremental exercise in subjects with ILD. <B>Harris&#150;Eze AO, Sridhar G,
Clemens RE, Zintel TA, Gallagher CG, Marciniuk DD.</B> AM J RESPIR CRIT CARE MED
1996.</P>
<TABLE BORDER="1">
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#top">BACK TO MENU</A></B></SMALL></TD></TR></TABLE>
<P></P>
<HR>
<P><B><A NAME="ats26">Increased Surface Tension of the Lung and Surfactant in
Bleomycin&#150;induced Pulmonary Fibrosis in Rats 154:1002&#150;1005</A></B></P>
<P>The increased elastic recoil of the lung in bleomycin&#150;induced pulmonary
fibrosis in the rat is due in part to increased surface forces. This study was
designed to determine the role of surface tension <I>in situ</I> and <I>in
vitro</I> 21 d after instillation of bleomycin. Using sequentially measured
pressure&#150;volume curves generated with air, saline, air after lavage with
Tween 20, and saline, surface tension was significantly higher in bleomycin&#150;treated
lungs than in untreated lungs (4.7 &#177; 1.1 versus 1.8 &#177; 0.2 dyne/cm, p &lt;
0.01). Surface tension was determined <I>in vitro</I> with a Wilhelmy balance
using bronchoalveolar lavage fluid, surfactant, and organic solvent lipid
extracts of surfactant. Bleomycin treatment resulted in elevated minimal surface
tensions: BALF (20.7 &#177; 0.6 versus 13.6 &#177; 3.8 dyne/cm, p &lt; 0.02),
isolated surfactant (12.0 &#177; 1.3 versus 3.0 &#177; 0.5 dyne/cm, p &lt;
0.02), and the organic solvent lipid extracted surfactant (11.0 versus 3.2
dyne/cm). These results indicate that the physical properties of surfactant in
lungs of rats treated with bleomycin are abnormal and contribute to the
increased elastic recoil in this model of pulmonary fibrosis. <B>Horiuchi T,
Ikegami M, Cherniack RM, Mason RJ. </B>AM J RESPIR CRIT CARE MED 1996.</P>
<TABLE BORDER="1">
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#top">BACK TO MENU</A></B></SMALL></TD></TR></TABLE>
<P></P>
<HR>
<P><B><A NAME="ats27">Tuberculosis Infection among Health Care Workers in
Montreal 154:1006&#150;1012</A></B></P>
<P>We conducted a cross&#150;sectional survey to estimate the prevalence of
tuberculosis infection among health care workers at two downtown Montreal
hospitals. Participants completed questionnaires, then underwent two&#150;step
tuberculin testing. Records of previous tuberculin tests and BCG vaccinations
were reviewed. Charts of all tuberculosis patients admitted in 1992&#150;93 were
also reviewed. Air changes and direction of air flow in patient care areas were
measured using tracer gas techniques and smoke tubes. Of 619 eligible workers,
522 participated (84%). 196 (38%) were tuberculin reactors; 23 (4%) had
documented conversions. Inadequate ventilation and delays in diagnosis were
identified at both hospitals. Comparing clinical with nonclinical personnel, the
adjusted odds of a significant initial tuberculin reaction were 2.6 (95%
confidence interval 1.3, 5.2), of a documented conversion 13.6 (1.4, 132), and
of a booster reaction 0.9 (0.2, 3.6). Initial tuberculin reactivity was
associated with male gender (p = 0.008), BCG vaccination (p = 0.0001), foreign
birth (p = 0.007), age (p &lt; 0.0001), and occupation (p = 0.02); conversion
with male gender (p = 0.001) and occupation (p = 0.01); and boosting with older
age (p = 0.02) and BCG vaccination (p = 0.001). Among clinical personnel at two
hospitals, the prevalence of significant tuberculin reactions and of documented
conversions was unexpectedly high. <B>Schwartzman K, Loo V, Pasztor J, Menzies
D. </B>AM J RESPIR CRIT CARE MED 1996.</P>
<TABLE BORDER="1">
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#top">BACK TO MENU</A></B></SMALL></TD></TR></TABLE>
<P></P>
<HR>
<P><B><A NAME="ats28">Cost&#150;Effectiveness of Directly Observed Versus
Self&#150;Administered Therapy for Tuberculosis 154:1013&#150;1019</A></B></P>
<P>Decision analysis was used to compare three alternative strategies for a 6&#150;mo
course of treatment for tuberculosis: directly observed drug therapy (DOT), self&#150;administered
fixed&#150;dose combination drug therapy, and self&#150;administered
conventional individual drug therapy. Estimates of effectiveness were obtained
from the published literature. Estimates of costs were obtained from the
literature and the Baltimore City Health Department. Both DOT and fixed&#150;dose
combination therapy were less costly and more effective than conventional
therapy, although DOT was most cost&#150;effective. In total, the average cost
per patient treated was 13,925 for DOT, 13,959 for fixed&#150;dose combination
therapy, and 15,003 for conventional therapy. Per 1,000 patients treated, 31
relapses and three deaths could be expected for DOT, 96 relapses and eight
deaths for fixed&#150;dose combination therapy, and 133 relapses and 13 deaths
for conventional therapy. The marginal cost&#150;effectiveness of DOT relative
to fixed&#150;dose combination therapy was most sensitive to variability in the
direct cost of DOT and less sensitive to relapse rates for DOT and fixed&#150;dose
combination therapy. The inferior cost&#150;effectiveness of conventional
therapy was not sensitive to plausible variability in cost or effectiveness.
Both DOT and fixed&#150;dose combination therapy were cost&#150;effective
relative to conventional therapy, although DOT is probably most cost&#150;effective.
<B>Moore RD, Chaulk CP, Griffiths R, Cavalcante S, Chaisson RE. </B>AM J RESPIR
CRIT CARE MED 1996.</P>
<TABLE BORDER="1">
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#top">BACK TO MENU</A></B></SMALL></TD></TR></TABLE>
<P></P>
<HR>
<P><B><A NAME="ats29">The Accuracy of Elevated Concentrations of Endotoxin in
Bronchoalveolar Lavage Fluid for the Rapid Diagnosis of Gram&#150;negative
Pneumonia 154:1020&#150;1028</A></B></P>
<P>The purpose of this study was to determine the accuracy of elevated
concentrations of endotoxin in bronchoalveolar lavage (BAL) fluid for the
diagnosis of gram&#150;negative pneumonia. Sixty&#150;three hospitalized adults
underwent 71 evaluations with BAL using quantitative cultures for suspected lung
infection. A cutoff value of &gt; 5 EU/ml for the concentration of endotoxin in
BAL fluid yielded the best operating characteristics for the diagnosis of gram&#150;negative
pneumonia (sensitivity, 100%; specificity, 75.0%; area under receiver operating
characteristic [ROC] curve, 0.88). Good diagnostic agreement was found between
elevated concentrations of endotoxin in BAL fluid and microbiologically
confirmed gram&#150;negative pneumonia (kappa statistic, 0.64; concordance
83.1%). Gram stain examination of BAL fluid for the presence of gram&#150;negative
bacteria yielded inferior operating characteristics (sensitivity, 63.2%;
specificity, 75.0%; area under ROC curve, 0.69). Poor diagnostic agreement was
observed between BAL fluid Gram stain results and microbiologically confirmed
gram&#150;negative pneumonia (kappa statistic, 0.35; concordance, 71.8%). These
findings suggest that a concentration of endotoxin in BAL fluid &gt; 5 EU/ml is
superior to Gram stain examination for the rapid identification of patients with
gram&#150;negative pneumonia. <B>Kollef MH, Eisenberg PR, Ohlendorf MF, Wick
MR. </B>AM J RESPIR CRIT CARE MED 1996.</P>
<TABLE BORDER="1">
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#top">BACK TO MENU</A></B></SMALL></TD></TR></TABLE>
<P></P>
<HR>
<P><B><A NAME="ats30">Lack of Association of Induration Size with HIV
Infection among Drug Users Reacting to Tuberculin 154:1029&#150;1033</A></B></P>
<P>Smaller tuberculin test induration sizes suggest eligibility for
tuberculosis chemoprophylaxis in HIV&#150;seropositive than in HIV&#150;seronegative
persons. To determine whether human immunodeficiency virus (HIV) infection is
associated with induration size among tuberculin reactors, a cross&#150;sectional
study of HIV&#150;seropositive and &#150;seronegative drug users was performed.
Twenty&#150;four of 160 (15%) HIV&#150;seropositive and 68 of 284 (24%) HIV&#150;seronegative
patients had reactions to purified protein derivative (PPD) of &#179; 2 mm (OR =
0.56, 95% CI 0.32 to 0.96). However, the prevalence of tuberculin reactivity was
equal among nonanergic subjects with and without HIV infection. Median
induration size was similar among HIV&#150;seropositive (20.5 mm) and &#150;seronegative
(17.5 mm) reactors. Thus, although HIV&#150;seropositive patients were less
likely, due to cutaneous anergy, to be PPD reactors, induration size was not
associated with HIV infection among reactors. Although using a reduced cutpoint
to determine suitability of chemoprophylaxis in HIV&#150;seropositive persons
may be prudent, the logical assumption that the loss of specificity this entails
is accompanied by an increase in sensitivity for detecting <I>Mycobacterium
tuberculosis</I> infection remains to be proved. <B>Gourevitch MN, Hartel D,
Schoenbaum EE, Klein RS. </B>AM J RESPIR CRIT CARE MED 1996.</P>
<TABLE BORDER="1">
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#top">BACK TO MENU</A></B></SMALL></TD></TR></TABLE>
<P></P>
<HR>
<P><B><A NAME="ats31">Six&#150;Month Supervised Intermittent Tuberculosis
Therapy in Haitian Patients With and Without HIV Infection 154:1034&#150;1038</A></B></P>
<P>We enrolled 427 consecutive patients with tuberculosis diagnosed in Cit&eacute;
Soleil, Haiti in a trial of short&#150;course intermittent therapy. All patients
received supervised therapy with isoniazid, rifampin, pyrazinamide, and
ethambutol thrice weekly for 8 wk, followed by isoniazid and rifampin thrice
weekly for 18 wk. At entry, the 177 human immunodeficiency virus (HIV)&#150;infected
patients (42%) were found significantly more likely to have extrapulmonary
tuberculosis and negative tuberculin skin tests (p &lt; 0.05). Treatment was
well tolerated by both groups of patients, and adherence to the treatment
regimen was over 90%. Among patients with pulmonary or intrathoracic
tuberculosis, 9% of HIV&#150;seropositive and 1% of HIV&#150;seronegative
patients died during therapy (p &lt; 0.001), whereas 81% and 87%, respectively,
of those in the two groups were cured. Relapses occurred in 5.4% of HIV&#150;seropositive
and 2.8% of HIV&#150;seronegative patients who completed treatment (p = 0.36).
Survival after tuberculosis was poorer in HIV&#150;seropositive patients, whose
probability of dying was 33% at 18 mo after diagnosis as compared with 3% for
HIV&#150;seronegative patients (p &lt; 0.001). HIV&#150;seropositive patients
who died had significantly lower median CD4 lymphocyte counts than did HIV&#150;seropositive
patients who survived (p &lt; 0.001). Treatment of tuberculosis with short&#150;course,
thrice&#150;weekly, supervised therapy in the setting of a developing country is
highly efficacious in both HIV&#150;seropositive and &#150;seronegative
patients. <B>Chaisson RE, Clermont HC, Holt EA, Cantave M, Johnson MP, Atkinson
J, Davis H, Boulos R, Quinn TC, Halsey NA, and the JHU&#150;CDS Research Team.
</B>AM J RESPIR CRIT CARE MED 1996.</P>
<TABLE BORDER="1">
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#top">BACK TO MENU</A></B></SMALL></TD></TR></TABLE>
<P></P>
<HR>
<P><B><A NAME="ats32">Fluticasone Propionate in Children with Moderate Asthma
154:1039&#150;1044</A></B></P>
<P>Inhaled corticosteroids are considered to be effective and safe to treat
children with asthma. These drugs, often used as maintenance treatment, can,
however, influence the HPA&#150;axis, which might be reflected by the serum and
urine cortisol concentration. The aim of the present study was to investigate
the efficacy and safety of fluticasone propionate (FP) 100 mg administered twice
a day via a Diskhaler+ for 3 mo. FP was tested in a double&#150;blind randomized
placebo&#150;controlled parallel trial in a group of 35 children with moderate
asthma who did not use inhaled steroids for at least 4 wk prior to the study. At
home, symptoms and peak flow recordings (PEFR) were noted in a diary. At each
visit lung function was measured, and serum and urinary cortisol were
determined. During treatment, wheezing decreased and PEFR values increased in
the FP group. FEV1 and PC20&#150;histamine increased and the reversibility
decreased in the FP group. All changes were significant, with the exception of
the change in nocturnal PEFR. Four weeks after cessation of FP all parameters
returned to pretreatment values. Serum cortisol did not change significantly in
either treatment group. The decrease in urinary cortisol in the FP group was
significant only if it was compared with the increase in urinary cortisol in the
placebo group. We conclude that FP 100 mg given twice a day is effective in
children with moderate stable asthma. Suppression of the HPA&#150;axis by FP 100
mg given twice daily, although not likely, cannot be ruled out by this study
since the absence of a significant decrease in urinary cortisol in the FP group
could be due to an insufficient number of patients. Additional studies are
required to solve this problem. <B>Hoekstra MO, Grol MH, Bouman K, Stijnen T,
Ko&euml;ter GH, Kauffman HF, Gerritsen J. </B>AM J RESPIR CRIT CARE MED 1996.</P>
<TABLE BORDER="1">
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#top">BACK TO MENU</A></B></SMALL></TD></TR></TABLE>
<P></P>
<HR>
<P><B><A NAME="ats33">Chest Wall Compliance in Infants and Children with
Neuromuscular Disease 154:1045&#150;1048</A></B></P>
<P>Respiratory muscle weakness is the primary cause of respiratory dysfunction
in neuromuscular disease (NMD), but structural abnormalities of the chest wall
also play a role. In adults with NMD, restrictive lung disease is in part caused
by reduced chest wall compliance (CW), believed to reflect stiffening of
connective tissue resulting from chronically reduced chest wall motion in the
presence of respiratory muscle weakness. We hypothesized that chronic limitation
of chest wall motion in young children with NMD leads to structural
underdevelopment of the chest wall, and results in increased, rather than
decreased, CW. In 18 subjects with NMD, ranging from 3 mo to 3.8 yr of age, we
compared CW with values obtained in children without NMD. A modification of the
Mead&#150;Whittenberger technique was used, with respiratory muscle relaxation
provided by brief manual ventilation. Respiratory system compliance (Crs) and
lung compliance (CL) were calculated from airway opening pressure,
transpulmonary pressure, and tidal volume. CW was calculated as 1/CW = 1/Crs &#190;
1/CL during manual ventilation. CW/kg was higher in subjects with NMD than in
controls, at 5.2 &#177; 2.8 (mean &#177; SD) versus 2.4 &#177; 0.8 ml/cm H2O (p &lt;
0.001). In subjects who had normal lung compliance values during spontaneous
breathing (CLspont), CW/CLspont was significantly greater in subjects with NMD
(5.5 &#177; 3.2) than in controls (1.9 &#177; 1.0) (p &lt; 0.001). By
predisposing to rib cage deformation and reduced end&#150;expiratory lung
volume, abnormally high CW in infants and young children with NMD may contribute
to respiratory dysfunction. <B>Papastamelos C, Panitch HB, Allen JL. </B>AM J
RESPIR CRIT CARE MED 1996.</P>
<TABLE BORDER="1">
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#top">BACK TO MENU</A></B></SMALL></TD></TR></TABLE>
<P></P>
<HR>
<P><B><A NAME="ats34">Patient&#150;triggered Ventilation in Neonates:
Comparison of a Flow&#150;and an Impedance&#150;triggered System 154:1049&#150;1054</A></B></P>
<P>We conducted a study with the objective of comparing the performance of two
different systems for patient&#150;triggered ventilation in neonates (impedance
versus flow/volume&#150;triggered) by measuring response time, autotrigger and
trigger failure rates, ventilation, and gas exchange. The two ventilator systems
were applied in random order in 10 preterm neonates (median gestational age:
30.5 wk; range: 27 to 34 wk; body weight: 1,266 g; range: 840 to 2,240 g) using
identical ventilator settings. The median (range) response time was 169 (98 to
305) ms for the impedance system and 115 (79 to 184) ms for the flow/volume
system (p &lt; 0.01). The longer and more variable response time of the
impedance system was secondary to a phase lag of the impedance signal caused by
chest wall distortion. Although 13.1 (0.2 to 29.4)% of mechanical breaths were
autotriggered with the impedance system, there were no autotriggered breaths
using the flow/volume system (p &lt; 0.01). The rate of trigger failures was not
significantly different with the two systems, at 1.2 (0 to 4.4)% (impedance)
versus 3.1 (0 to 6.4)% (flow/volume). Minute ventilation was smaller with the
impedance system (p &lt; 0.001), because of the larger number of breaths
triggered late in inspiration or during expiration. We conclude that the
flow/volume&#150;triggered system is less prone to autotriggering and has a
shorter and more consistent response time than the impedance&#150;triggered
system. The impedance&#150;triggered system is more susceptible to artifacts and
chest wall distortion. <B>Hummler HD, Gerhardt T, Gonzalez A, Bolivar J, Claure
N, Everett R, Bancalari E. </B>AM J RESPIR CRIT CARE MED 1996.</P>
<P></P>
<TABLE BORDER="1">
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#top">BACK TO MENU</A></B></SMALL></TD></TR></TABLE>
<P></P>
<HR>
<P><B><A NAME="ats35">Systemic Oxidative Stress in Asthma, COPD, and Smokers
154:1055&#150;1060</A></B></P>
<P>An imbalance between oxidants and antioxidants is proposed in smokers and in
patients with airways diseases. We tested this hypothesis by measuring the
Trolox equivalent antioxidant capacity (TEAC) of plasma and the levels of
products of lipid peroxidation as indices of overall oxidative stress. The
plasma TEAC was markedly reduced (0.66 &#177; 0.07 mmol/L; mean &#177; SEM; n =
11), with increased levels of lipid peroxidation products, in healthy chronic
smokers as compared with healthy nonsmokers (1.31 &#177; 0.10 mmol/L, n = 14, p &lt;
0.001), an effect that was exaggerated in those who had smoked 1 h before the
study. Plasma TEAC was also low in patients presenting with acute exacerbations
of chronic obstructive pulmonary disease (COPD) (0.46 &#177; 0.10 mmol/L, n =
20, p &lt; 0.001) or asthma (0.61 &#177; 0.05 mmol/L, n = 9, p &lt; 0.01) with
increases in plasma lipid peroxidation products. There was a negative
correlation between superoxide anion release by stimulated neutrophils and
plasma antioxidant capacity (r = &#190;0.73, p &lt; 0.001) in patients with
acute exacerbations of COPD. The profound decrease in TEAC was associated with a
decreased plasma protein sulfhydryl concentrations in acute exacerbations of
COPD but not in smokers or in asthmatic subjects. Therefore smoking, acute
exacerbations of COPD, and asthma are associated with a marked
oxidant/antioxidant imbalance in the blood, associated with evidence of
increased oxidative stress. The decreased antioxidant capacity in plasma may
result from different mechanisms in these conditions. <B>Rahman I, Morrison D,
Donaldson K, MacNee W. </B>AM J RESPIR CRIT CARE MED 1996.</P>
<P></P>
<TABLE BORDER="1">
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#top">BACK TO MENU</A></B></SMALL></TD></TR></TABLE>
<P></P>
<HR>
<P><B><A NAME="ats37">Expression of Interleukin&#150;1 Beta (IL&#150;1&szlig;)
and Interleukin&#150;1 Receptor Antagonist (IL&#150;1ra) on Asthmatic Bronchial
Epithelium 154:1061&#150;1066</A></B></P>
<P>Accumulating evidence suggests that the cytokine network is central to the
immunopathology of bronchial asthma and recent findings have suggested that
naturally occurring cytokine antagonists may also be involved. In this study we
looked at the expression of interleukin&#150;1 beta (IL&#150;1&szlig;) and its
naturally occurring receptor antagonist, IL&#150;1ra, in the normal and
asthmatic bronchial wall. Frozen bronchial biopsies from 12 normal and 18
asthmatic individuals were double stained with EBM11 (a CD68 macrophage marker)
and either a rabbit anti&#150;IL&#150;1&szlig; or a rabbit anti&#150;IL&#150;1ra.
Hue&#150;saturation&#150;intensity color image analysis (HSI) was used to
quantify the brown immunoperoxidase reaction product present on the bronchial
epithelium. There was an increased expression of both IL&#150;1&szlig; and IL&#150;1ra
in the asthmatic bronchial epithelium, p &lt; 0.0002 and p &lt; 0.0001,
respectively. Additionally, the numbers of macrophages, of IL&#150;1&szlig;
producing cells, and the percentage of macrophages producing IL&#150;1&szlig;
were significantly increased in the asthmatic submucosa (p &lt; 0.004, p &lt;
0.002, and p &lt; 0.008, respectively). <B>Sousa AR, Lane SJ, Nakhosteen JA,
Lee TH, Poston RN. </B>AM J RESPIR CRIT CARE MED 1996.</P>
<P></P>
<TABLE BORDER="1">
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#top">BACK TO MENU</A></B></SMALL></TD></TR></TABLE>
<P></P>
<HR>
<P><B><A NAME="ats38">Increased Expression of Gelatinases and Collagenase in
Rat Lungs Exposed to 100% Oxygen 154:1067&#150;1075</A></B></P>
<P>Exposure of adult rats to 100% O2 produces a lethal injury by 72 h. We
reasoned that matrix metalloproteinases participate in the pathogenesis of
hyperoxic lung injury. To that end we studied the expression and activity of
gelatinases A and B and interstitial collagenase in lung tissues and
bronchoalveolar lavage fluids (BALF) of rats exposed to 100% oxygen for 60 h.
Gelatin zymography of BALF samples revealed a ~72 kDa molecular species both in
controls and oxygen&#150;exposed animals. In addition, BALF from hyperoxic rats
exhibited a 95&#150;kDa gelatinase. Likewise, BALF total gelatinolytic and
collagenolytic activities were significantly increased in oxygen&#150;exposed
rats. <I>In situ</I> hybridization revealed an increase in type IV collagenases
as well as interstitial collagenase mRNAs in the oxygen&#150;exposed lungs. The
three enzymes were expressed by alveolar macrophages, and in variable degrees by
interstitial and alveolar epithelial cells. Immunoreactive gelatinase B and
collagenase paralleled the cell localization of the mRNAs but were also detected
in the alveolar walls and interstitium. <I>In situ</I> zymography showed
gelatinolytic activity in frozen sections of oxygen&#150;exposed lungs but not
in normal lungs. The upregulation of these metalloproteinases during acute
exposure to 100% O2 suggests that they might contribute to hyperoxic lung damage
through the degradation of extracellular matrix components. <B>Pardo A, Selman
M, Ridge K, Barrios R, Sznajder JI. </B>AM J RESPIR CRIT CARE MED 1996.</P>
<P></P>
<TABLE BORDER="1">
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#top">BACK TO MENU</A></B></SMALL></TD></TR></TABLE>
<P></P>
<HR>
<P><B><A NAME="ats39">Transforming Growth Factor&#150;&szlig; (TGF&#150;&szlig;)
in Silicosis 154:1076&#150;1081</A></B></P>
<P>Silicosis is characterized by fibrosing nodular lesions that may eventually
develop into progressive massive fibrosis (PMF). Cytokines (interleukin&#150;1&szlig;
[IL&#150;1&szlig;], tumor necrosis factor&#150;a [TNF&#150;a] and growth factors
insulin&#150;like growth factor&#150;1 [IGF&#150;1] platelet&#150;derived growth
factor [PDGF]) have been implicated in the formation of these lesions. TGF&#150;&szlig;
promotes extracellular matrix accumulation by upregulating collagen and
fibronectin gene expression, and inhibits matrix degradation by decreasing
secretion of proteases and increasing secretion of protease inhibitors. We
hypothesized that TGF&#150;&szlig; is associated with matrix deposition and
fibrosis in silicosis. To test this hypothesis we studied early and late nodular
lesions and PMF (11 cases and two controls) with immunohistochemistry, using
rabbit polyclonal antibody to the purified whole molecule of TGF&#150;&szlig; in
Bouin's fixed lung tissue. This antibody is reactive with both intra&#150; and
extracellular forms of TGF&#150;&szlig;. In the control lungs, small amounts of
TGF&#150;&szlig; were present in the bronchial epithelium, macrophages,
bronchial and vascular smooth muscle, and bronchial glands. There was minimal to
moderate staining in the early silicotic peribronchiolar lesions. In the nodular
lesions of silicosis, central hyalinized areas contained the maximum staining
for TGF&#150;&szlig;. Fibroblasts in the periphery of the nodular lesions were
also positive. In acute silicosis, there was marked staining of hyperplastic
alveolar epithelium. Macrophages were markedly positive. In the PMF lesions,
large areas of scar tissue contained TGF&#150;&szlig;. These data suggest a
major role for TGF&#150;&szlig; in silicosis, particularly in the formation of
silicotic nodules and the development of PMF. <B>Jagirdar J, Beg&iacute;n R,
Dufresne A, Goswami S, Lee TC, Rom WN. </B>AM J RESPIR CRIT CARE MED 1996.</P>
<P></P>
<TABLE BORDER="1">
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#top">BACK TO MENU</A></B></SMALL></TD></TR></TABLE>
<P></P>
<HR>
<P><B><A NAME="ats40">Reduction in Pulmonary Fibrosis <I>In Vivo</I> by
Halofuginone 154:1082&#150;1086</A></B></P>
<P>Pulmonary fibrosis is a disorder causing a high mortality rate for which
therapeutic options are limited. Therefore, the effect of halofuginone, a novel
inhibitor of collagen type I synthesis, on bleomycin&#150;induced pulmonary
fibrosis was studied in rats. Pulmonary fibrosis was induced by intraperitoneal
injections of bleomycin for seven consecutive days, and halofuginone was
administered intraperitoneally every second day during the entire experimental
period of 42 d. Collagen determination in the lungs and the examination of
histologic sections showed that halofuginone significantly reduced fibrosis
relative to the untreated control rats. We conclude that halofuginone is a
potent <I>in vivo</I> inhibitor of bleomycin&#150;induced pulmonary fibrosis,
and that it may potentially be used as a novel therapeutic agent for the
treatment of this dysfunction. <B>Nagler A, Firman N, Feferman R, Cotev S,
Pines M, Shoshan S. </B>AM J RESPIR CRIT CARE MED 1996.</P>
<P></P>
<TABLE BORDER="1">
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#top">BACK TO MENU</A></B></SMALL></TD></TR></TABLE>
<P></P>
<HR>
<P><B><A NAME="ats41">Angiotensin Converting Enzyme Expression in Primary
Pulmonary Hypertension 154:1087&#150;1091</A></B></P>
<P>We compared immunoreactivity for angiotensin converting enzyme (ACE) in
pulmonary artery and lung parenchymal tissues (obtained at the time of resection
for lung transplantation) from eight patients with Stage IV primary pulmonary
hypertension (PPH) with the reactivity in similar tissues from eight normal
donors. ACE immunoreactivity was markedly and consistently increased in the
endothelium and subendothelial neointimal regions of elastic pulmonary arteries
from patients with PPH as compared with normal pulmonary arteries.
Immunoreactivity in normal muscular pulmonary arteries was usually less than in
surrounding capillary endothelial cells, whereas it was usually of comparable
intensity with that in surrounding alveolar capillaries in muscular pulmonary
arteries of patients with PPH. These observations suggest that ACE may be
involved in the pathogenesis of vascular remodeling associated with neointimal
formation in pulmonary arteries. <B>Schuster DP, Crouch EC, Parks WC, Johnson
T, Botney MD. </B>AM J RESPIR CRIT CARE MED 1996.</P>
<P></P>
<TABLE BORDER="1">
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#top">BACK TO MENU</A></B></SMALL></TD></TR></TABLE>
<P></P>
<HR>
<P><B><A NAME="ats42">Elafin/elastase&#150;specific Inhibitor in
Bronchoalveolar Lavage of Normal Subjects and Farmer's Lung 154:1092&#150;1098</A></B></P>
<P>Secretory leukocyte proteinase inhibitor (SLPI) and a1&#150;proteinase
inhibitor (a1PI) cannot fully explain the total neutrophil elastase (NE)
inhibitory capacity detected in bronchoalveolar lavage (BAL) fluid, suggesting
the existence of other NE inhibitor(s). In the present study, we measured the
concentrations of elafin, a newly described, low&#150;molecular&#150;weight
serine proteinase inhibitor, SLPI, and a1PI in BAL fluids from eight healthy
subjects, 13 asymptomatic farmers, seven farmers with active farmer's lung (FL),
and seven farmers with previous (Ex) FL. In addition to SLPI and a1PI, elafin
was present in BAL fluids from control subjects and asymptomatic farmers, 13 (7&#150;31)
and 12 (7&#150;67) mmol/mol of albumin (median and range) respectively. Elafin
concentration increased significantly to 105 (38&#150;207) mmol/mol of albumin
in farmers with active FL and was also elevated in farmers with Ex FL. Elafin
levels were highly correlated with lung inflammatory cell numbers, especially
lymphocytes, and the decrease in single&#150;breath diffusion capacity (Dlco).
Elafin and SLPI were linked to yet uncharacterized proteins in BAL fluids. In
conclusion, elafin is a constituent of BAL fluid from normal subjects and is
found in enhanced concentrations in FL and in farmers with lymphocytic
alveolitis. This suggests that elafin may play a role in lung homeostasis and
inflammation. <B>Tremblay GM, Sallenave J&#150;M, Isra&euml;l&#150;Assayag E,
Cormier Y, Gauldie J. </B>AM J RESPIR CRIT CARE MED 1996.</P>
<P></P>
<TABLE BORDER="1">
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#top">BACK TO MENU</A></B></SMALL></TD></TR></TABLE>
<P></P>
<HR>
<P><B><A NAME="ats43">Bilateral Magnetic Stimulation of the Phrenic Nerves
from an Anterolateral Approach 154:1099&#150;1105</A></B></P>
<P>We investigated whether bilateral magnetic stimulation of the phrenic nerves
from an anterolateral approach (BAMPS) could combine the reproducibility and
ease of use of cervical magnetic stimulation (CMS) with the specificity of
bilateral electrical stimulation (BES) and whether it could be used in supine
subjects. We placed two double 43&#150;mm coils over the phrenic nerves in the
neck. BAMPS produced supramaximal phrenic stimulation by electromyogram (EMG)
assessment in six of seven subjects. There was no significant difference in the
twitch gastric pressure/twitch esophageal pressure ratio (twitch Pgas/Pes)
between BAMPS (1.2) and BES (1.3). Both differed from CMS (0.9, p &lt; 0.001).
The effect of a change in posture on twitch transdiaphragmatic pressure (TwPdi)
and Pgas/Pes ratio was the same for BAMPS and BES. In normal subjects and
patients BAMPS correlated significantly with BES (r = 0.97), maximal sniffs (r =
0.85), and CMS (r = 0.92). The mean difference between BAMPS and BES was 0.3 cm
H2O (SD = 2.3). Two&#150;minute maximal isocapnic ventilation produced a 19%
fall in TwPdi elicited by BAMPS. BAMPS is easy, well tolerated and can be used
in the supine subject. TwPdi and partitioning of Pes and Pgas were very close
for BAMPS and BES, suggesting similar specificity for the diaphragm. <B>Mills
GH, Kyroussis D, Hamnegard CH, Polkey MI, Green M, Moxham J. </B>AM J RESPIR
CRIT CARE MED 1996.</P>
<P></P>
<TABLE BORDER="1">
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#top">BACK TO MENU</A></B></SMALL></TD></TR></TABLE>
<P></P>
<HR>
<P><B><A NAME="ats44">Upper Airway and Soft Tissue Structural Changes Induced
by CPAP in Normal Subjects 154:1106&#150;1116</A></B></P>
<P>Nasal continuous positive airway pressure (CPAP) is the treatment of choice
for adults with obstructive sleep apnea. CPAP is known to increase upper airway
size; however, the direct effects of CPAP on soft tissue structures surrounding
the upper airway are less well understood. Magnetic resonance imaging was used
to study the effect of incremental levels (0, 5, 10, and 15 cm H2O) of CPAP on
the upper airway and surrounding soft tissue structures in 10 normal subjects.
Progressive increases in CPAP resulted in the following major findings: (<I>1</I>)
airway volume and airway area (measured at several different locations
[midregion, minimal, maximal]) within the retropalatal and retroglossal regions
increased; (<I>2</I>) lateral airway dimensional changes were greater than
anterior&#150;posterior changes; (<I>3</I>) lateral upper airway soft tissue
structural changes were significantly greater than anterior&#150;posterior
changes; (<I>4</I>) lateral pharyngeal wall thickness decreased and the
distance between the lateral parapharyngeal fat pads increased. An inverse
relationship was demonstrated between CPAP level and pharyngeal wall thickness;
(<I>5</I>) minimal changes were noted in the soft palate and tongue. These data
suggest that the lateral pharyngeal walls are more &quot;compliant&quot; than
the soft palate and tongue. This investigation provides further evidence that
the lateral pharyngeal walls play an important role in mediating upper airway
caliber. <B>Schwab RJ, Pack AI, Gupta KB, Metzger LJ, Oh E, Getsy JE, Hoffman
EA, Gefter WB. </B>AM J RESPIR CRIT CARE MED 1996.</P>
<P></P>
<TABLE BORDER="1">
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#top">BACK TO MENU</A></B></SMALL></TD></TR></TABLE>
<P></P>
<HR>
<P><B><A NAME="ats45">Detection of p53 Gene Mutations in Cytopathology and
Biopsy Specimens from Patients with Lung Cancer 154:1117&#150;1123</A></B></P>
<P>In order to ascertain the feasibility of detecting p53 gene mutations in
patients with lung cancer in a nonsurgical diagnostic setting before starting
treatment, we screened for p53 gene mutations in tumor specimens obtained using
diagnostic methods such as fiberoptic bronchoscopy, thoracentesis, and
percutaneous needle aspiration. We examined 206 specimens from 66 patients
diagnosed with primary lung cancer at Hiroshima University Hospital between
October 1991 and July 1993 using the polymerase chain reaction/denaturing
gradient gel electrophoresis technique. p53 gene mutations were found in 64 of
159 (40%) cytologically positive specimens, but in none of 47 cytologically
negative specimens. The PCR&#150;based assay did not increase the sensitivity of
the cytopathologic examination in detecting malignant cells. The type and
location of the p53 gene mutation was the same in cytologically positive
specimens obtained by different methods, but from the same patient. Of the 66
patients, p53 gene mutations were found in 27 (41%) at the time of the first
nonsurgical diagnostic examination: 7 of 12 (58%) with small cell carcinoma, 9
of 20 (45%) with squamous cell carcinoma, and 11 of 34 (32%) with adenocarcinoma
of the lung. The incidence of p53 gene mutation for each histologic subtype was
comparable to previously published data examining surgically and/or autopsy&#150;obtained
specimens. These results indicate that detection of p53 gene mutations in a
nonsurgical, diagnostic setting is feasible. This technique will make it
possible to assess the significance of p53 gene mutations in relation to
survival and response to therapy before starting treatment, in future
prospective studies. <B>Murakami I, Fujiwara Y, Yamaoka N, Hiyama K, Ishioka S,
Yamakido M. </B>AM J RESPIR CRIT CARE MED 1996.</P>
<P></P>
<TABLE BORDER="1">
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#top">BACK TO MENU</A></B></SMALL></TD></TR></TABLE>
<P></P>
<HR>
<P><B><A NAME="ats46">Age&#150;related 4,977 bp Deletion in Human Lung
Mitochondrial DNA 154:1141&#150;1145</A></B></P>
<P>The accumulation of mitochondrial DNA (mtDNA) mutations has been suggested
to be an important contributor to human aging and degenerative diseases. The
lung is exposed to ambient air and makes direct contact with the external
environment. Numerous potentially noxious agents may damage lung tissues
directly or indirectly through free&#150;radical&#150;mediated reactions. In
previous studies, we demonstrated an age&#150;dependent increase of mtDNA
mutations in various human tissues. We hypothesize that the accumulation of the
4,977 bp (base pairs) deleted mtDNA in human lung tissues is also age&#150;dependent.
Using the polymerase chain reaction technique, we determined the incidence of
the 4,977 bp&#150;deleted mtDNA in 127 human lung specimens from 34&#150;wk
gestation to 79 yr of age. The results showed that 77 lung biopsies (60.6%)
contained the 4,977 bp&#150;deleted mtDNA, which started to appear in lung
tissues after the fourth decade of life. The incidence apparently increased from
14.3% (one of seven) of the subjects in the 30&#150; to 39&#150;yr age group to
77.8% (two of 27) of the subjects in the 70&#150; to 79&#150;yr age group (p &lt;
0.0001). The mean (&#177; SEM) proportion of the 4,977 bp&#150;deleted mtDNA in
lung tissues significantly increased from 0.007 &#177; 0.007% of the subjects in
the 30&#150; to 39&#150;yr age group to 0.833 &#177; 0.330% of those in the 70&#150;
to 79&#150;yr age group (p &lt; 0.005). Other factors such as sex, pulmonary
function indices, and smoking status did not have statistically significant
impact on the amount of the deleted mtDNA. These findings suggest that the
accumulation of the 4,977 bp&#150;deleted mtDNA is associated with aging human
lung. <B>Fahn H&#150;J, Wang L&#150;S, Hsieh R&#150;H, Chang S&#150;C, Kao S&#150;H,
Huang MH, Wei Y&#150;H. </B>AM J RESPIR CRIT CARE MED 1996.</P>
<P></P>
<TABLE BORDER="1">
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#top">BACK TO MENU</A></B></SMALL></TD></TR></TABLE>
<P></P>
<HR>
<P><B><A NAME="ats47">Inspiratory Pressure Support Reduces Slowing of
Inspiratory Muscle Relaxation Rate During Exhaustive Treadmill Walking in Severe
COPD 154:1146&#150;1150</A></B></P>
<P>When patients with COPD walk to a state of intolerable dyspnea, there is
excessive inspiratory muscle loading, as evidenced by slowing of the maximum
relaxation rate of the inspiratory muscles, measured from esophageal pressure
during a sniff (Sn Pes MRR). In this setting, inspiratory pressure support (IPS)
delivered via an orofacial mask increases walking distance and reduces dyspnea,
but the mechanism by which this benefit is achieved remains unclear. In this
study we compared Sn Pes MRR after equidistant treadmill walking in six men with
severe COPD (mean FEV1: 0.6 L, 22% predicted). After the free walk there was a
mean slowing of Sn Pes MRR of 41% (p &lt; 0.03). After the IPS&#150;assisted
walks, the slowing of Sn Pes MRR was 20% of baseline; this was significantly
less than after the free walk (p &lt; 0.05). Four subjects performed shorter
walks; after free walks of one third and two thirds of maximum distance, the
mean slowing of Sn Pes MRR was 23% and 28%, respectively. We conclude that when
patients with COPD walk to exhaustion, IPS reduces slowing of inspiratory muscle
MRR, and that this represents a considerable unloading of the inspiratory
muscles. The magnitude of the reduction is approximately the same as reducing
the distance walked by two thirds. <B>Polkey MI, Kyroussis D, Mills GH,
Hamnegard C&#150;H, Keilty SEJ, Green M, Moxham J. </B>AM J RESPIR CRIT CARE MED
1996.</P>
<P></P>
<TABLE BORDER="1">
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#top">BACK TO MENU</A></B></SMALL></TD></TR></TABLE>
<P></P>
<HR>
<HR SIZE="4" WIDTH="80%">
<CENTER><A HREF="about.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/about.gif" ALT="About Society"></A>
<A HREF="ssg.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/ss.gif" ALT="Society Structure"></A>
<A HREF="calendar.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/calendar.gif" ALT="ATS Calendar"></A>
<A HREF="gpi.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/pi.gif" ALT="Gen Public Info"></A>
<A HREF="ms.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/memserv.gif" ALT="Memb Serv"></A>
<BR>
<A HREF="pub.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/pubs.gif" ALT="Publications"></A>
<A HREF="press.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/press.gif" ALT="Press"></A>
<A HREF="index.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/home.gif" ALT="Home Page"></A>
<A HREF="search.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/search.gif" ALT="Search"></A>
<A HREF="assemb.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/assemb.gif" ALT="Assemblies"></A>
<A HREF="research.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/research.gif" ALT="Research"></A>
<BR>
<A HREF="mep.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/meded.gif" ALT="Med Education"></A>
<A HREF="wr.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/wr.gif" ALT="Wash Report"></A>
<A HREF="ic.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/ic.gif" ALT="Int'l Conference"></A>
<A HREF="source.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/link.gif" ALT="Web Links"></A>
<A HREF="store.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/store.gif" ALT="Store"></A> 
<A HREF="sig.html"><IMG SRC="images/special.gif" ALT="Special" HSPACE=1 VSPACE=1 BORDER=0 HEIGHT=35 WIDTH=84></A>
</CENTER>
<HR SIZE="4" WIDTH="80%">
<CENTER><FONT SIZE="+2"><B><I>American Thoracic Society</I></B></FONT><BR>
1740 Broadway<BR> New York, NY 10019<BR> VOICE:  212-315-8700<BR> Copyright &copy;
1996 American Lung Association.<BR> The American Thoracic  Society is the
medical section <BR>of the American Lung Association.<BR> 
</CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-170</DOCNO>
<DOCOLDNO>IA013-000141-B026-285</DOCOLDNO>
<DOCHDR>
http://www.thoracic.org:80/barc1196.html 206.138.195.144 19970217073611 text/html 114707
HTTP/1.0 200 OK
Date: Monday, 17-Feb-97 07:31:24 GMT
Server: NCSA/1.3
MIME-version: 1.0
Content-type: text/html
Last-modified: Friday, 20-Dec-96 20:23:50 GMT
Content-length: 114525
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//SQ//DTD HTML 2.0 HoTMetaL + extensions//EN">
<HTML>
<HEAD>
<TITLE>American Thoracic Society - ABSTRACTS; November 1996 Volume 154 Number 5</TITLE></HEAD>
<BODY BACKGROUND="images/back.jpg">
<CENTER><IMG ALIGN="LEFT" SRC="images/smlogo.gif"><BR>
<H1>AJRCCM ABSTRACTS</H1></CENTER>
<HR SIZE="5" NOSHADE="NOSHADE" WIDTH="100%">
<P></P>
<HR>
<CENTER>
<TABLE BORDER="2">
<TR>
<TD ALIGN="CENTER" VALIGN="MIDDLE"><SMALL><B><A HREF="bluearch.html">BACK TO
ARCHIVES MAIN PAGE</A></B></SMALL></TD></TR></TABLE></CENTER>
<HR>
<CENTER>
<H2> November 1996 Volume 154 Number 5</H2>
<P><B><A NAME="top">AJRCCM ABSTRACT MENU</A></B></P></CENTER>
<CENTER>
<TABLE BORDER="1">
<TR ALIGN="CENTER" VALIGN="MIDDLE">
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#ats1">Interleukin-12
Prevents Antigen-induced Eosinophil Recruitment into Mouse Airways 154:1257&#150;1260</A></B></SMALL></TD></TR>
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#ats2">Exposure to
Bacteria in Swine-House Dust and Acute Inflammatory Reactions in Humans 154:1261&#150;1266</A></B></SMALL></TD></TR>
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#ats3">Effects of
Inhaled Budesonide on Allergen-induced Airway Responses and Airway Inflammation
154:1267&#150;1271</A></B></SMALL></TD></TR>
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#ats4">Incubation with
IgE Increases Cholinergic Neurotransmission in Human Airways <I>In Vitro</I>
154:1272&#150;1276</A></B></SMALL></TD></TR>
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#ats5"><I>In Vivo</I>
Quantification of Human Pulmonary &szlig;-Adrenoceptors: Effect of &szlig;-Agonist
Therapy 154:1277&#150;1283</A></B></SMALL></TD></TR>
<TR>
<TD><SMALL><B><A HREF="#ats6">Respiratory Muscle and Cardiopulmonary
Function During Exercise in Very Severe COPD 154:000&#150;000</A></B></SMALL></TD></TR>
<TR>
<TD><SMALL><B><A HREF="#ats7">Urinary Desmosine Excretion in Smokers With
and Without Rapid Decline of Lung Function: The Normative Aging Study 154:1290&#150;1295</A></B></SMALL></TD></TR>
<TR>
<TD><SMALL><B><A HREF="#ats8">Integrin Upregulation on Sputum Neutrophils in
Smokers with Chronic Airway Obstruction 154:1296&#150;1300</A></B></SMALL></TD></TR>
<TR>
<TD><SMALL><B><A HREF="#ats9">Partitioning of Inspiratory Muscle Workload
and Pressure Assistance in Ventilator-dependent COPD Patients 154:1301&#150;1309</A></B></SMALL></TD></TR>
<TR>
<TD><SMALL><B><A HREF="#ats10">Diaphragm Strength in Chronic Obstructive
Pulmonary Disease 154:1310&#150;1317</A></B></SMALL></TD></TR>
<TR>
<TD><SMALL><B><A HREF="#ats11">Effects of Bronchomotor Tone and Gas Density
on Time Dependence of Forced Expiratory Vital Capacity Maneuver 154:1318&#150;1322</A></B></SMALL></TD></TR>
<TR>
<TD><SMALL><B><A HREF="#ats12">Efficacy of Cardiopulmonary Resuscitation
Using Intratracheal Insufflation 154:1323&#150;1329</A></B></SMALL></TD></TR>
<TR>
<TD><SMALL><B><A HREF="#ats36">Proportional Assist Ventilation in Acute
Respiratory Failure: Effects on Breathing Pattern and Inspiratory Effort
154:1330&#150;1338</A></B></SMALL></TD></TR>
<TR>
<TD><SMALL><B><A HREF="#ats13">Risk Factors for Pneumonia, and Colonization
of Respiratory Tract and Stomach in Mechanically Ventilated ICU Patients
154:1339&#150;1346</A></B></SMALL></TD></TR>
<TR>
<TD><SMALL><B><A HREF="#ats14">Effects of Chronic Dexfenfluramine Treatment
on Pulmonary Hemodynamics in Dogs 154:1347&#150;1350</A></B></SMALL></TD></TR>
<TR>
<TD><SMALL><B><A HREF="#ats15">The Effect of Atrial Natriuretic Peptide on
Pulmonary Acid Injury in a Pig Model 154:1351&#150;1356</A></B></SMALL></TD></TR>
<TR>
<TD><SMALL><B><A HREF="#ats16">Descriptors of Breathlessness in
Cardiorespiratory Diseases 154:1357&#150;1363</A></B></SMALL></TD></TR>
<TR>
<TD><SMALL><B><A HREF="#ats17">Lung Injury after Hepatoenteric
Ischemia-Reperfusion: Role of Xanthine Oxidase 154:000&#150;000</A></B></SMALL></TD></TR>
<TR>
<TD><SMALL><B><A HREF="#ats18">Production of Nitric Oxide (NO) in
Intrathoracic Airways of Normal Humans 154:1370&#150;1374</A></B></SMALL></TD></TR>
<TR>
<TD><SMALL><B><A HREF="#ats19">Effects of Nitric Oxide Inhalation on
Pulmonary Serial Vascular Resistances in ARDS 154:1375&#150;1381</A></B></SMALL></TD></TR>
<TR>
<TD><SMALL><B><A HREF="#ats20">Tracheal Microvascular Responses to
Inhibition of Nitric Oxide Synthesis in Anesthetized Rats 154:1382&#150;1386</A></B></SMALL></TD></TR>
<TR>
<TD><SMALL><B><A HREF="#ats21">Value of Perfusion Lung Scan in the Diagnosis
of Pulmonary Embolism: Results of the Prospective Investigative Study of Acute
Pulmonary Embolism Diagnosis (PISA-PED) 154:1387&#150;1393</A></B></SMALL></TD></TR>
<TR>
<TD><SMALL><B><A HREF="#ats22">An Epidemiologic Investigation of Asthma in
Welders 54:1394&#150;1400</A></B></SMALL></TD></TR>
<TR>
<TD><SMALL><B><A HREF="#ats23">Does Dietary Intake of Vitamins C and E
Influence Lung Function in Older People? 154:1401&#150;1404</A> </B></SMALL></TD></TR>
<TR>
<TD><SMALL><B><A HREF="#ats24">Refractory Ceramic Fiber Exposure and Pleural
Plaques 154:1405&#150;1410</A></B></SMALL></TD></TR>
<TR>
<TD><SMALL><B><A HREF="#ats25">Delayed Maturation of Hering-Breuer Inflation
Reflex Activity in Preterm Infants 154:1411&#150;1417</A></B></SMALL></TD></TR>
<TR>
<TD><SMALL><B><A HREF="#ats26">Ventilatory Mechanics at Rest and During
Exercise in Patients with Cystic Fibrosis 154:1418&#150;1425</A></B></SMALL></TD></TR>
<TR>
<TD><SMALL><B><A HREF="#ats27">Increased DNA Levels in Bronchoalveolar
Lavage Fluid Obtained From Infants with Cystic Fibrosis 154:1426&#150;1429</A></B>
</SMALL></TD></TR>
<TR>
<TD><SMALL><B><A HREF="#ats28">Biomarkers of Lung Inflammation in
Recreational Joggers Exposed to Ozone 154:1430&#150;1435</A></B></SMALL></TD></TR>
<TR>
<TD><SMALL><B><A HREF="#ats29">Characterization of Carotenoid, Vitamin A,
and a-Tocopheral Levels in Human Lung Tissue and Pulmonary Macrophages 154:1436&#150;1443</A></B></SMALL></TD></TR>
<TR>
<TD><SMALL><B><A HREF="#ats30">Morphologic Determinants of Airway
Responsiveness in Chronic Smokers 154:1444&#150;1449</A></B></SMALL></TD></TR>
<TR>
<TD><SMALL><B><A HREF="#ats31">Community-acquired Pneumonia in the Elderly:
A Multivariate Analysis of Risk and Prognostic Factors 154:1450&#150;1455</A></B></SMALL></TD></TR>
<TR>
<TD><SMALL><B><A HREF="#ats32">Community-acquired Pneumonia in Chronic
Obstructive Pulmonary Disease: A Spanish Multicenter Study 154:1456&#150;1461</A></B></SMALL></TD></TR>
<TR>
<TD><SMALL><B><A HREF="#ats33">Efficacy and Safety of Rifabutin in the
Treatment of Patients with Newly Diagnosed Pulmonary Tuberculosis 154:1462&#150;1467</A></B></SMALL></TD></TR>
<TR>
<TD><SMALL><B><A HREF="#ats34">Clinical Predictors of Tuberculosis as a
Guide for a Respiratory Isolation Policy 154:1468&#150;1472</A></B></SMALL></TD></TR>
<TR>
<TD><SMALL><B><A HREF="#ats35">Rifampin Preventive Therapy for Tuberculosis
in Boston's Homeless 154:1473&#150;1477</A></B></SMALL></TD></TR>
<TR>
<TD><FONT SIZE="-1"><B><A HREF="#ats37">The Impact of Human Immunodeficiency
Virus Infection on Drug-resistant Tuberculosis 154:1478&#150;1483</A></B></FONT></TD></TR>
<TR>
<TD><FONT SIZE="-1"><B><A HREF="#ats38">Mechanisms for Diaghragmatic Fatigue
Following High-intensity Leg Exercise 154:000&#150;000</A></B></FONT></TD></TR>
<TR>
<TD><FONT SIZE="-1"><B><A HREF="#ats39">Depressed Baroreflex Sensitivity in
Patients with Obstructive Sleep Apnea 154:1490&#150;1496</A></B></FONT></TD></TR>
<TR>
<TD><FONT SIZE="-1"><B><A HREF="#ats40">IL-4 and IL-5 mRNA and Protein in
Bronchial Biopsies from Patients with Atopic and Nonatopic Asthma: Evidence
Against &quot;Intrinsic&quot; Asthma Being a Distinct Immunopathologic Entity
154:1497&#150;1504</A></B></FONT></TD></TR>
<TR>
<TD><FONT SIZE="-1"><B><A HREF="#ats41">Alveolar Tissue Inflammation in
Asthma 154:1505&#150;1510</A></B></FONT></TD></TR>
<TR>
<TD><FONT SIZE="-1"><B><A HREF="#ats42">Pulmonary Fibrogenesis after Three
Consecutive Inhalation Exposures to Chrysotile Asbestos 154:1511&#150;1519</A></B></FONT></TD></TR>
<TR>
<TD><FONT SIZE="-1"><B><A HREF="#ats43">Nicotine Enhances Expression of the
Neutrophil Elastase Gene and Protein in a Human Myeloblast/Promyelocyte Cell
Line 154:1520&#150;1524</A></B></FONT></TD></TR>
<TR>
<TD><FONT SIZE="-1"><B><A HREF="#ats44">Tissue Localization of Transforming
Growth Factor-&szlig;1 in Pulmonary Eosinophilic Granuloma 154:1525&#150;1530</A></B></FONT></TD></TR>
<TR>
<TD><FONT SIZE="-1"><B><A HREF="#ats45">Bronchiolar Disease in Rheumatoid
Arthritis 154:1531&#150;1536</A></B></FONT></TD></TR>
<TR>
<TD><FONT SIZE="-1"><B><A HREF="#ats46">Use of a Magnified Cardiac Airflow
Oscillation to Classify Neonatal Apnea 154:1537&#150;1542</A></B></FONT></TD></TR>
<TR>
<TD><FONT SIZE="-1"><B><A HREF="#ats47">Chest X-ray Changes in Air Space
Disease Are Associated with Parameters of Mechanical Ventilation in ICU Patients
154:1543&#150;1550</A></B></FONT></TD></TR>
<TR>
<TD><FONT SIZE="-1"><B><A HREF="#ats48">Roles of Calcitonin Gene&#150;related
Peptide (CGRP) in Hyperpnea-induced Constriction in Guinea Pigs 154:1551&#150;1556</A></B></FONT></TD></TR>
<TR>
<TD><FONT SIZE="-1"><B><A HREF="#ats49">Human Airway Narrowing Measured
Using High Resolution Computed Tomography 154:1557&#150;1562</A></B></FONT></TD></TR>
<TR>
<TD><FONT SIZE="-1"><B><A HREF="#ats50">Effect of Hyperventilation on Airway
Mucosal Blood Flow in Normal Subjects 154:1563&#150;1566</A></B></FONT></TD></TR>
<TR>
<TD><FONT SIZE="-1"><B><A HREF="#ats51">Improved Arterial Oxygenation After
Oleic Acid Lung Injury in the Pig Using a Computer-Controlled Mechanical
Ventilator 154:1567&#150;1572</A></B></FONT></TD></TR></TABLE></CENTER>
<P></P>
<HR>
<P><B><A NAME="ats1">Interleukin-12 Prevents Antigen-induced Eosinophil
Recruitment into Mouse Airways 154:1257&#150;1260</A></B></P>
<P>Interleukin-12 (IL-12) is a key cytokine that promotes Th1-type
cell-mediated immunity and inhibits Th2-type responses. We have previously shown
that antigen-induced eosinophil recruitment into the airways of sensitized mice
is mediated by Th2-type CD4+ T cells that produce IL-5. Therefore, to determine
whether IL-12 regulates antigen-induced eosinophil recruitment into the airways,
we studied the effect of recombinant murine IL-12 on antigen-induced eosinophil
infiltration into the tracheas of sensitized mice, and also the effect of IL-12
on IL-5 and interferon-&amp;g (IFN-&amp;g) levels in bronchoalveolar lavage
fluid (BALF) from the mice. The intraperitoneal administration of recombinant
IL-12 (rIL-12) inhibited antigen-induced eosinophil infiltration into the mouse
trachea in a dose-dependent manner. The administration of rIL-12 suppressed IL-5
levels but enhanced IFN-&amp;g levels in the BALF of the mice after antigen
inhalation. The administration of rIL-12 also decreased <I>in vitro</I>
antigen-induced IL-4 and IL-5 production, but not IFN-&amp;g production, in
spleen cells of the mice. Furthermore, pretreatment with anti-IFN-&amp;g
monoclonal antibody prevented the IL-12 inhibition of antigen-induced eosinophil
infiltration into the tracheas of the mice. These results indicate that IL-12
downregulates antigen-induced eosinophil recruitment into the airways by
inhibiting IL-5 production in sensitized animals. <B>Iwamoto I, Kumano K, Kasai
M, Kurasawa K, Nakao A. </B>AM J RESPIR CRIT CARE MED 1996.</P>
<TABLE BORDER="1">
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#top">BACK TO MENU</A></B></SMALL></TD></TR></TABLE>
<P></P>
<HR>
<P><B><A NAME="ats2">Exposure to Bacteria in Swine-House Dust and Acute
Inflammatory Reactions in Humans 154:1261&#150;1266</A></B></P>
<P>Inhalation of swine-house dust may cause an acute airway inflammatory
condition (organic dust toxic syndrome). Thirty-eight healthy subjects were
exposed to swine dust while weighing swine for 3 h. We studied the correlation
between acute health effects and the inhaled bacterial exposure markers
peptidoglycan (the main constituent of the cell walls of gram-positive bacteria,
but also present in lesser amounts in gram-negative bacteria) and
lipopolysaccharides (LPS; present only in gram-negative bacteria). LPS activity
in airborne dust was measured with the <I>Limulus</I> amebocyte lysate assay
(LPSlal), and the total LPS was estimated from 3-hydroxy fatty acids, which were
measured with gas chromatography-mass spectrometry (GC-MS) (LPSgc-ms).
Peptidoglycan was estimated from muramic acid measured with GC-MS. The median
(25th to 75th percentile) concentration of inhalable dust was 21 (16 to 25)
mg/m3. LPSlal was 1.2 (0.9 to 1.4) mg/m3; LPSgc-ms was 3.9 (2.5 to 4.9) mg/m3;
and the peptidoglycan concentration in airborne dust was 6.5 (2.7 to 13) mg/m3.
All exposure markers correlated significantly with an increase in serum
interleukin-6. LPSlal showed the highest correlation (r2 = 0.29) and total
inhaled dust the lowest (r2 = 0.09). LPSlal also correlated with symptoms and
with an increase in bronchial responsiveness and decrease in vital capacity
(VC). Peptidoglycan, but not LPSlal, correlated with an increase in the blood
granulocyte concentration and in body temperature. The results suggest that
several microbial agents in inhaled swine-house dust may contribute to acute
systemic health effects. <B>Zhiping W, Malmberg P, Larsson B-M, Larsson K,
Larsson L, Saraf A. </B>AM J RESPIR CRIT CARE MED 1996.</P>
<TABLE BORDER="1">
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#top">BACK TO MENU</A></B></SMALL></TD></TR></TABLE>
<P></P>
<HR>
<P><B><A NAME="ats3">Effects of Inhaled Budesonide on Allergen-induced Airway
Responses and Airway Inflammation 154:1267&#150;1271</A></B></P>
<P>Allergen inhalation by sensitized subjects results in acute
bronchoconstriction, which can be followed by a later bronchoconstrictor
response, allergen-induced airway hyperresponsiveness, and increases in airway
inflammatory cells. Treatment with inhaled glucocorticosteroids attenuates
allergen-induced asthmatic airway responses. The purpose of this study was to
determine whether a 1-wk pretreatment with inhaled budesonide influences
allergen-induced changes in inflammatory cells in blood and induced sputum.
Seven subjects with mild atopic asthma were treated in a double-blind,
placebo-controlled, randomized, crossover fashion with either inhaled budesonide
400 mg/d, or placebo for 7 d. Allergen challenges were carried out the morning
after treatment was discontinued and sputum samples were obtained 7 h after
allergen inhalation. Methacholine airway responsiveness was measured, and blood
and sputum samples were obtained 24 h post-allergen. Budesonide treatment
attenuated the ??magnitude of both the early and the late asthmatic response,
reduced allergen-induced methacholine airway hyperresponsiveness, and attenuated
allergen-induced increases in total eosinophils and activated eosinophils. These
results suggest that the effects of inhaled glucocorticosteroids on
allergen-induced airway responses may be mediated through their inhibition of
allergen-induced eosinophil migration and activation. <B>Gauvreau GM, Doctor J,
Watson RM, Jordana M, O'Byrne PM. </B>AM J RESPIR CRIT CARE MED 1996.</P>
<TABLE BORDER="1">
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#top">BACK TO MENU</A></B></SMALL></TD></TR></TABLE>
<P></P>
<HR>
<P><B><A NAME="ats4">Incubation with IgE Increases Cholinergic
Neurotransmission in Human Airways <I>In Vitro</I> 154:1272&#150;1276</A></B></P>
<P>Airway cholinergic hyperresponsiveness is frequently observed in asthmatic
patients. Recent reports suggest the possible involvement of IgE in
hyperresponsiveness, although the exact mechanism is still uncertain. In this
study, we examined whether incubation with IgE could facilitate the cholinergic
function in human airways. Bronchi were obtained from 20 patients undergoing
lung resection. Cholinergic contractile responses were induced by electrical
field stimulation (EFS) or exogenous acetylcholine (ACh), and they were assessed
by isometric tension measurement. EFS-induced ACh release from cholinergic
nerves was also measured by high performance liquid chromatography. Incubation
with IgE significantly enhanced EFS-induced bronchial contraction and ACh
release as compared with the values of the bronchi incubated with heat
inactivated IgE (control) (p &lt; 0.05, respectively), but it did not alter the
contractile responses induced by exogenous ACh. Pretreatment with the muscarinic
M2-receptor agonist pilocarpine reduced the EFS-induced ACh release in the
control tissues (p &lt; 0.05), but not in the tissues incubated with IgE. The
M2-receptor antagonist methoctramine significantly enhanced the EFS-induced
contraction in control bronchi (p &lt; 0.05), but this augmentation was not
observed in the tissues incubated with IgE. These results suggest that IgE
itself can enhance cholinergic bronchial contraction via facilitation of ACh
release from cholinergic nerves and that this augmentation is related to
autoreceptor M2 dysfunction at nerve endings. <B>Ichinose M, Miura M, Tomaki M,
Oyake T, Kageyama N, Ikarashi Y, Maruyama Y, Shirato K. </B>AM J RESPIR CRIT
CARE MED 1996.</P>
<TABLE BORDER="1">
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#top">BACK TO MENU</A></B></SMALL></TD></TR></TABLE>
<P></P>
<HR>
<P><B><A NAME="ats5"><I>In Vivo</I> Quantification of Human Pulmonary &szlig;-Adrenoceptors:
Effect of &szlig;-Agonist Therapy 154:1277&#150;1283</A></B></P>
<P>In human subjects, chronic &szlig;2-agonist dosing reduces mononuclear
leukocyte (MNL) &szlig;-adrenoceptor numbers. The aim of this study was to
investigate whether this downregulation also occurs in the lung. Seven healthy
male subjects were treated for 2 wk with oral (up to 16 mg/d) and inhaled (up to
1.6 mg/d) albuterol (salbutamol in Europe). Pulmonary maximal &szlig;-adrenoceptor
binding capacity (Bmax) was determined <I>in vivo</I> using positron emission
tomography (PET) and the &szlig;-receptor antagonist ligand, 11C-labeled
CGP-12177, before and after the 2-wk chronic dosing. MNL Bmax was also measured,
using a radioligand binding assay and 3H-labeled CGP-12177. Bronchodilator
responses to the &szlig;2-agonist were determined after each PET scan by
measuring the change in specific airway conductance (SGaw) after increasing
doses of inhaled albuterol. Pulmonary and MNL Bmax fell by 22% &#177; 14% (p &lt;
0.05) and 42% &#177; 19% (p &lt; 0.05) respectively. The changes in pulmonary
and MNL Bmax were correlated (r = 0.9, p &lt; 0.05). There was also a reduction
in the bronchodilator response to inhaled albuterol. In a further six subjects,
pulmonary and MNL Bmax did not change during an acute infusion of albuterol (2
to 4 mg/kg/h). The reduction in pulmonary &szlig;-adrenoceptor numbers after
chronic albuterol dosing may be predictable from the changes observed in
circulating MNL cells. Hayes MJ, Qing F, Rhodes CG, Rahman SU, Ind PW,
Sriskandan S, Jones T, Hughes JMB. AM J RESPIR CRIT CARE MED 1996.</P>
<TABLE BORDER="1">
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#top">BACK TO MENU</A></B></SMALL></TD></TR></TABLE>
<P></P>
<HR>
<P><B><A NAME="ats6">Respiratory Muscle and Cardiopulmonary Function During
Exercise in Very Severe COPD 154:000&#150;000</A></B></P>
<P>Chronic obstructive pulmonary disease (COPD) is thought to limit exercise
capacity through a decreased ventilatory reserve, with cardiovascular factors
playing a minimal role. We assessed respiratory muscle (RM) and cardiopulmonary
function during exercise in very severe COPD (FEV1 0.79 &#177; 0.17 L). We
determined minute ventilation (VE), oxygen consumption (VO2), carbon dioxide
production (VCO2), heart rate (HR), respiratory rate (RR), and O2 pulse with a
metabolic cart. RM function was assessed from esophageal and gastric pressures.
Dyspnea was assessed with a visual analog scale (VAS). Exercise capacity (peak
VO2 = 36 &#177; 31%), ventilatory reserve (VE/maximum voluntary ventilation
[MVV] = 89 &#177; 31%), HR = 76 &#177; 15%, and O2 pulse (O2Pmax = 45 &#177;
15%) were abnormal. Peak VO2 correlated with O2P max(r = 0.82), the change in
end-inspiratory pleural pressure (&amp;DPpli) (r = &#190;0.74), maximal
transdiaphragmatic pressure (Pdimax) (r = 0.68), and VEmax (r = 0.58). There
were similar correlations with exercise endurance time. Multiple regression
analysis revealed OPmax to be the best predictor of peak VO2. Thereafter, only
VEmax and &amp;DPpli remained significant (r2 = 0.87). O2Pmax correlated with
inspiratory muscle function (Pplimax, r = &#190;0.58; Pdimax, r = 0.53; &amp;DPpli,
r = &#190;0.47; and PImax, r = &#190;.47). By multiple regression analysis, the
predictors of O2Pmax were Pplimax and &amp;DPpli (r2 = 0.47). In very severe
COPD, the impressive swings in intrathoracic pressure resulting from deranged
ventilatory mechanics are the most likely cause of exercise limitation and
reduced O2 pulse. The contributions of factors such as deconditioning,
hypoxemia, and concurrent heart disease remain unknown. <B>Montes de Oca M,
Rassulo J, Celli BR. </B>AM J RESPIR CRIT CARE MED 1996.</P>
<TABLE BORDER="1">
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#top">BACK TO MENU</A></B></SMALL></TD></TR></TABLE>
<P></P>
<HR>
<P><B><A NAME="ats7">Urinary Desmosine Excretion in Smokers With and Without
Rapid Decline of Lung Function: The Normative Aging Study 154:1290&#150;1295</A></B></P>
<P>It is hypothesized that smoking-related chronic obstructive pulmonary
disease (COPD) results in part from excess lung elastin degradation. Taking
advantage of spirometry performed over a 12-yr period at the Normative Aging
Study, we conducted a nested case-control study of elastin and collagen
degradation rates in current smokers with (n = 10) and without (n = 8) rapid
decline of lung function, using a biochemical assay for urinary desmosine (DES),
a specific marker for mature elastin degradation, and hydroxylysylpyridinoline
(HP), a specific marker for mature fibrillar collagen degradation. Mean urinary
excretion of DES in rapid decliners was 36% greater than in slow decliners (9.8
&#177; 0.7 [mean &#177; SE] versus 7.2 &#177; 0.4 mg/g creatinine, p &lt; 0.01);
after adjustment for age and lean body mass (LBM), DES excretion in rapid
decliners was 30% greater than in slow decliners (9.6 &#177; 0.6 versus 7.4 &#177;
0.7 mg/g creatinine, p = 0.06). Among rapid decliners, there was no difference
in DES excretion between those with and those without computed tomogaphic
evidence of emphysema. There was no significant difference between rapid and
slow decliners in mean urinary excretion of HP (24.7 &#177; 1.4 versus 21.6 &#177;
1.8 nmol/mmol creatinine, p = 0.18). Among all subjects, rate of decline of FEV1
was significantly correlated with DES excretion (r = 0.61, p &lt; 0.01). In a
linear regression model adjusting for age and LBM, an increase in DES excretion
of 1 mg/g creatinine was associated with an excess decline of FEV1 of 10.6 ml/yr
(p = 0.04). This study provides further evidence in support of the
elastase-antielastase hypothesis of the pathogenesis of COPD, and it suggests a
role for elastin degradation in both emphysema and small airways disease.
Moreover, it suggests that urinary DES excretion may be a useful biochemical
marker for the study of interventions designed to prevent the development or
progression of COPD. <B>Gottlieb DJ, Stone PJ, Sparrow D, Gale ME, Weiss ST,
Snider GL, O'Connor GT.</B> AM J RESPIR CRIT CARE MED 1996.</P>
<TABLE BORDER="1">
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#top">BACK TO MENU</A></B></SMALL></TD></TR></TABLE>
<P></P>
<HR>
<P><B><A NAME="ats8">Integrin Upregulation on Sputum Neutrophils in Smokers
with Chronic Airway Obstruction 154:1296&#150;1300</A></B></P>
<P>To determine the relationship between the expression of leukocyte-specific
integrins in the airways and the airway obstruction in smokers, we analyzed
hypertonic saline-induced sputum in 33 male subjects, age 64.7 &#177; 0.5 yr
(mean &#177; SEM), with a smoking history of 12 to 94 pack-years, at the end of
a 15-yr follow-up study. Average FEV1/VC ratio was 69 &#177; 1% at the beginning
of the study and 66 &#177; 2% at the end of the follow-up period, and annual
decline of FEV1 was 20 &#177; 3 ml/yr. Fourteen individuals exhibited airway
obstruction as assessed by a FEV1/VC ratio lower than 63.3%. Differential
leukocyte count was performed on cytospin preparations and the expression of
integrin a (CD11a, CD11b, CD11c) and &szlig; (CD18) chains was assessed on
granulocytes and mononuclear cells by immunocytology. The numbers of neutrophils
expressing CD11b and CD18, but not CD11c or CD11a, were increased in the
subjects with airway obstruction compared with those without airway obstruction.
CD11b- and CD18-positive neutrophils were negatively correlated with FEV1VC
ratio (p &lt; 0.01). No significant correlations were found between CD11a-,
CD11b-, CD11c-, CD18-positive mononuclear cells and lung function measurements.
In conclusion, our results suggest that leukocyte-specific integrin CD11b/CD18
expressed on sputum polymorphonuclear leukocytes represents a marker for the
smokers who develop chronic airway obstruction. <B>Maestrelli P, Calcagni PG,
Saetta M, Bertin T, Mapp CE, Sanna A, Veriter C, Fabbri LM, Stanescu D. </B>AM J
RESPIR CRIT CARE MED 1996.</P>
<TABLE BORDER="1">
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#top">BACK TO MENU</A></B></SMALL></TD></TR></TABLE>
<P></P>
<HR>
<P><B><A NAME="ats9">Partitioning of Inspiratory Muscle Workload and Pressure
Assistance in Ventilator-dependent COPD Patients 154:1301&#150;1309</A></B></P>
<P>To investigate the mechanisms underlying ventilator-dependence in patients
with chronic obstructive pulmonary disease (COPD), and to assess the effects of
the combination of positive end-expiratory pressure (PEEP) and pressure-support
ventilation (PSV) on inspiratory muscle effort, we investigated respiratory
mechanics in eight ventilator-dependent COPD patients. The patients' breathing
pattern, lung mechanics, diaphragmatic effort (PTPdi), diaphragmatic tension&#150;time
index (TTdi), and arterial blood gases were measured during both spontaneous
breathing (SB) and ventilatory assistance consisting of PSV alone (15, 20, and
25 cm H2O) and PSV combined with a PEEP of 5 cm H2O (reducing PSV to 10, 15, and
20 cm H2O, respectively, to maintain equivalent inspiratory pressure). The
different levels of ventilatory support were delivered in a randomized sequence.
Maximal inspiratory (MIP), esophageal (Pplmax) and transdiaphragmatic (Pdimax)
pressures and respiratory drive (P0.1) were measured at the beginning of the
procedure during SB. We found a high P0.1 (6.1 &#177; 1.7 cm H2O), which seemed
to rule out an impairment of respiratory-center output. Apparently, inspiratory
muscle strength was compatible with successful weaning (38.5 &#177; 8.8, 50.9 &#177;
9.7, and 51.8 &#177; 9.5 cm H2O for MIP, PPlmax and Pdimax, respectively).
However, abnormal respiratory mechanics (particularly an intrinsic positive
end-expiratory pressure (PEEPi) of 8.3 &#177; 1.9 cm H2O and pulmonary
resistance 24.7 &#177; 9.5 cm H2O/L/s imposed an excessive load on the
inspiratory muscles, as indicated by a high PTPdi (499 &#177; 122 cm H2O . s).
Increasing levels of PSV progressively and significantly unloaded the patients'
inspiratory muscles, although at pressures above 20 cm H2O uncoupling occurred
between patient and ventilator respiratory frequency. Application of PEEP during
PSV improved ventilatory assistance by further reducing the inspiratory effort
(by 17% on average) and by ameliorating patient&#150;ventilator interaction. We
conclude that the excessive mechanical load, and in particular the high PEEPi,
is the major determinant of ventilator-dependence in COPD patients. Application
of PEEP improves the efficiency of PSV in unloading these patients' inspiratory
muscles, and can sometimes improve patient-ventilator interaction. <B>Appendini
L, Purro A, Patessio A, Zanaboni S, Carone, M, Spada E, Donner CF, Rossi A. </B>AM
J RESPIR CRIT CARE MED 1996.</P>
<TABLE BORDER="1">
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#top">BACK TO MENU</A></B></SMALL></TD></TR></TABLE>
<P></P>
<HR>
<P><B><A NAME="ats10">Diaphragm Strength in Chronic Obstructive Pulmonary
Disease 154:1310&#150;1317</A></B></P>
<P>The diaphragm is normally the main inspiratory muscle and diaphragm strength
in chronic obstructive pulmonary disease (COPD) is therefore of interest. We
assessed diaphragm strength in 20 patients with severe stable COPD (mean FEV1
0.61, mean thoracic gas volume [Vtg] 5.31) and seven normal control subjects,
measuring both maximal sniff transdiaphragmatic pressure (sniff Pdimax) and
twitch transdiaphragmatic pressure (Tw Pdi) elicited by cervical magnetic
stimulation (CMS) of the phrenic nerve roots at FRC. Acute-on-chronic
hyperinflation was examined in four patients. Mean Tw Pdi in patients and
control subjects was 18.5 cm H2O and 25.4 cm H2O, respectively (p &lt; 0.01),
and mean sniff Pdi was 81.9 cm H2O and 118 cm H2O, respectively (p &lt; 0.001).
Reduction in mean intrathoracic pressures was more marked; twitch esophageal
pressure (Tw Pes) was &#190;7.3 cm H2O and &#190;16.3 cm H2O, respectively (p &lt;
0.001) and sniff Pes was &#190;67 cm H2O and &#190;97.8 cm H2O (p &lt; 0.001).
During acute-on-chronic hyperinflation there was a linear negative correlation
of Tw Pdi with increasing lung volume of 3.5 cm H2O/L. The ability of the
diaphragm to generate transdiaphragmatic, and particularly a negative
intrathoracic, pressure is reduced in COPD and these changes are exaggerated
with acute-on-chronic hyperinflation. <B>Polkey MI, Kyroussis D, Hamnegard C-H,
Mills GH, Green M, Moxham J. </B>AM J RESPIR CRIT CARE MED 1996.</P>
<TABLE BORDER="1">
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#top">BACK TO MENU</A></B></SMALL></TD></TR></TABLE>
<P></P>
<HR>
<P><B><A NAME="ats11">Effects of Bronchomotor Tone and Gas Density on Time
Dependence of Forced Expiratory Vital Capacity Maneuver 154:1318&#150;1322</A></B></P>
<P>It has been shown that in normal subjects and chronic obstructive pulmonary
disease (COPD) patients the maximal expiratory flows and FEV1 are significantly
higher if the FVC maneuver is preceded by a rapid inspiration without an
end-inspiratory pause (maneuver 1) compared with a slow inspiration with an
end-inspiratory pause of approximately 5 s (maneuver 2). This time dependency of
FVC was attributed primarily to loss of lung recoil (stress relaxation) during
breath-holding at TLC, in association with time constant inequality within the
lungs, and changes in bronchomotor tone. To examine the role of bronchomotor
tone on time dependency of FVC, 11 COPD and 10 asthmatic patients performed FVC
maneuvers 1 and 2 before and after administration of a bronchodilator drug
(salbutamol). In addition, using the same approach, the effects of changing
airway resistance per se were assessed in another group of 10 COPD patients and
10 normal subjects, while breathing air and after equilibration with 80% helium
in oxygen. Main findings were: peak expiratory flow (PEF), FEV1, and maximal
midexpiratory flow rate (MMF) were significantly larger with maneuver 1 than 2;
after salbutamol administration and during helium&#150;oxygen breathing, all
indices increased significantly with both maneuvers but the relative differences
between maneuvers 1 and 2 were unchanged. We conclude that time dependency of
maximal expiratory flow&#150;volume (MEFV) curves, as indexed by PEF, FEV1, and
MMF, is largely independent of bronchomotor tone and gas density, and probably
reflects mainly stress relaxation of the respiratory tissues. The relevance of
time dependency of FVC maneuver in the assessment of bronchodilator response and
density dependence is discussed. <B>D'Angelo E, Milic-Emili J, Marazzini L.
</B>AM J RESPIR CRIT CARE MED 1996.</P>
<TABLE BORDER="1">
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#top">BACK TO MENU</A></B></SMALL></TD></TR></TABLE>
<P></P>
<HR>
<P><B><A NAME="ats12">Efficacy of Cardiopulmonary Resuscitation Using
Intratracheal Insufflation 154:1323&#150;1329</A></B></P>
<P>The effects of constant-flow insufflation (CFI) of air in the trachea at the
distal end of a modified endotracheal tube as the sole mode of ventilation
during cardiopulmonary resuscitation (CPR) were studied in pigs. The ventilatory
effect of CFI (15 &#177; 2 L/min) generating a positive pressure of about 10 cm
H2O with concomitant chest compression was studied first. In nine sedated,
paralyzed animals disconnected from the ventilator, CFI alone did not
significantly alter the decrease in PaO2 and the rise in PaCO2 observed during
apnea. By contrast, the combination of precordial compression and CFI (CFI-CPR)
maintained arterial blood gases over a 4-min period at the level obtained during
mechanical ventilation. In the second part of the study, ventricular
fibrillation was induced and CFI-CPR was compared with standard CPR using
conventional mechanical ventilation during two successive 4-min periods, in
random order. Ventilatory parameters were identical in the two situations,
whereas hemodynamic parameters were similar or better with CFI-CPR than with
standard CPR. Significant differences were observed between standard CPR and
CFI-CPR for systolic aortic pressure (72 &#177; 22 versus 82 &#177; 27 mm Hg,
respectively; p &lt; 0.02) and for systolic (322 &#177; 216 versus 431 &#177;
237 ml/s; p &lt; 0.01) and mean (116 &#177; 106 versus 143 &#177; 108 ml/s; p &lt;
0.01) common carotid blood flows. The ease of use of CFI together with its
beneficial hemodynamic effects suggests that CFI deserves to be investigated
further as a mode of ventilation during CPR. <B>Brochard L, Boussignac G, Adnot
S, Bertrand C, Isabey D, Harf A. AM J RESPIR CRIT CARE MED 1996.</B></P>
<TABLE BORDER="1">
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#top">BACK TO MENU</A></B></SMALL></TD></TR></TABLE>
<P></P>
<HR>
<P><B><A NAME="ats36">Proportional Assist Ventilation in Acute Respiratory
Failure: Effects on Breathing Pattern and Inspiratory Effort 154:1330&#150;1338</A></B></P>
<P>Proportional assist ventilation (PAV) is a new mode of assisted ventilation
which, by applying pressure in proportion to volume (volume assist, VA) and flow
(flow assist, FA), should specifically reduce the inspiratory effort needed to
overcome respiratory system elastance (Ers) and resistance (Rrs), respectively.
The aims of this study were to determine (<I>1</I>) the effects of varying the
level of VA on breathing pattern, inspiratory effort, and work of breathing, and
(<I>2</I>) the interaction between VA and FA. In eight intubated patients with
acute respiratory failure, four levels of VA (20 to 80% Ers) with and without a
fixed amount of FA (~50% Rrs) were evaluated. Compared with spontaneous
breathing, VA increased tidal volume (Vt) while respiratory rate (RR) was
unchanged or fell slightly. The increase in minute ventilation (VE) was small
and not significant. The addition of FA further increased Vt while RR was
significantly reduced so that VE remained unchanged. Increasing VA produced a
graded reduction in inspiratory effort, reflected by decreases in the
pressure-time integral of the diaphragm and the inspiratory muscles. These were
further reduced when FA was added. VA decreased the elastic work of breathing
(Wel) whereas resistive work (Wres) tended to increase so that the fall in total
work (Wtot) was less than expected. At each VA setting, the addition of FA
significantly reduced Wres and, as a result, Wtot. These results demonstrate
that PAV can improve breathing pattern while reducing inspiratory effort by
specifically decreasing Wel and Wres, and that VA and FA should be used together
to optimize reductions in Wtot and the efficacy of assistance provided. <B>Navalesi
P, Hernandez P, Wongsa A, Laporta D, Goldberg P, Gottfried SB. </B>AM J RESPIR
CRIT CARE MED 1996.</P>
<TABLE BORDER="1">
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#top">BACK TO MENU</A></B></SMALL></TD></TR></TABLE>
<P></P>
<HR>
<P><B><A NAME="ats13">Risk Factors for Pneumonia, and Colonization of
Respiratory Tract and Stomach in Mechanically Ventilated ICU Patients 154:1339&#150;1346</A></B></P>
<P>Risk factors for the development of ventilator-associated pneumonia (VAP)
and colonization of the respiratory tract and stomach with enteric gram-negative
bacteria (EGB) and Pseudomonadaceae were determined in 141 ventilated patients
using univariate analysis and the Cox proportional hazards model. VAP was caused
by EGB in 14 patients (10%), and by Pseudomonadaceae in 19 patients (13%). The
duration of ventilation was a significant risk factor for VAP caused by EGB and
Pseudomonadaceae, and for acquired colonization in oropharynx, stomach, and
trachea with these species. Of 20 other variables, oropharyngeal colonization
with EGB on admission (hazard ratio [HR] = 4.5) and an infection on admission
(HR = 2.7) were selected as risk factors for VAP caused by EGB. Acquired
colonization with Pseudomonadaceae in oropharynx (HR = 5.0) was the most
important risk factor for VAP caused by these species. Gastric colonization with
EGB or Pseudomonadaceae were no risk factors for VAP. For acquired oropharyngeal
colonization with EGB only the duration of ventilation was a risk factor,
whereas preceding colonization of the trachea with Pseudomonodaceae and duration
of ventilation were risk factors for acquired oropharyngeal colonization with
these species. In the Cox model, only the duration of ventilation was
significantly related to acquired gastric colonization with EGB. Preceding
colonization of the orophayrnx and of the trachea with Pseudomonadaceae were
risk factors for acquired colonization with these species in the stomach. Twelve
patients with VAP (46%) and 38 without VAP (33%) died (p = 0.21). In conclusion,
duration of ventilation and colonization of the upper respiratory tract are the
most important risk factors for VAP caused by EGB or Pseudomonadaceae. <B>Bonten
MJM, Bergmans DCJJ, Ambergen AW, de Leeuw PW, van der Geest S, Stobberingh EE,
Gaillard CA.</B> AM J RESPIR CRIT CARE MED 1996.</P>
<TABLE BORDER="1">
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#top">BACK TO MENU</A></B></SMALL></TD></TR></TABLE>
<P></P>
<HR>
<P><B><A NAME="ats14">Effects of Chronic Dexfenfluramine Treatment on
Pulmonary Hemodynamics in Dogs 154:1347&#150;1350</A></B></P>
<P>An epidemic of primary pulmonary hypertension occurred in Europe in the
1960s, after the introduction of the appetite suppressant aminorex. Recently, a
cluster of cases of pulmonary hypertension was observed in France in relation to
the intake of the appetite suppressant dexfenfluramine. We previously reported
that intravenous dexfenfluramine enhances hypoxic pulmonary vasoconstriction in
dogs. We therefore investigated the pulmonary hemodynamic effects of chronic
oral intake of this drug. Twenty-four dogs with a strong (n = 12) and a weak
hypoxic pulmonary vasoconstriction (n = 12) respectively were randomly allocated
in a double blind manner to a twice daily oral intake of either a placebo or
dexfenfluramine 1.5 mg/kg for 20 d. A strong hypoxic vasoconstriction was
defined as a hypoxia-induced increase in pulmonary artery pressure by more than
3 mm Hg at a standardized cardiac output of 3 L/min/m2. Pulmonary hemodynamics
were studied in hyperoxia (fraction of inspired O2 [FIO2] 0.4) and in hypoxia
(FIO2 0.1) before and after treatment. Venous return was manipulated at
post-treatment evaluation for isoflow comparisons of pulmonary vascular
pressures. Dexfenfluramine had no effect on systemic hemodynamics or blood
gases, but increased pulmonary vascular resistance from 155 &#177; 17 to 192 &#177;
14 dyne . s . cm&#190;5 in hyperoxia (mean &#177; SE, p &lt; 0.05) and from 237 &#177;
27 to 293 &#177; 47 dyne . s . cm&#190;5 in hypoxia (p &lt; 0.01).
Dexfenfluramine, and not placebo, increased the isoflow pulmonary vascular
pressure gradient in hyperoxia and in hypoxia. This effect was unrelated to the
magnitude of pretreatment hypoxic vasoconstriction. We conclude that the chronic
intake of dexfenfluramine in dogs is associated with a moderate increase in
pulmonary vascular resistance which is unrelated to pulmonary vasoreactivity to
hypoxia. <B>Naeije R, Maggiorini M, Delcroix M, Leeman M, M&eacute;lot C. </B>AM
J RESPIR CRIT CARE MED 1996.</P>
<TABLE BORDER="1">
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#top">BACK TO MENU</A></B></SMALL></TD></TR></TABLE>
<P></P>
<HR>
<P><B><A NAME="ats15">The Effect of Atrial Natriuretic Peptide on Pulmonary
Acid Injury in a Pig Model 154:1351&#150;1356</A></B></P>
<P>The effect of exogenous atrial natriuretic peptide (ANP) on pulmonary injury
induced by aspiration of hydrochloric acid (0.1 N HCl, 2.0 ml/kg) was examined
in anesthetized pigs ventilated with 100% oxygen. Group-specific diuretic
treatment was used 60 min after asspiration and followed for a further 120 min.
No diuretics were used for Group 1, 0.1 mg/kg/min of ANP was infused
intravenously for 60 min in Group 2, and 0.05 mg/kg of furosemide was injected
(intravenous bolus IV) in Group 3. Total urine volume after diuretic treatment
did not differ significantly between Groups 2 and 3. However, the increase in
PaO2 (to 386.3 &#177; 67.5 mm Hg) after infusion of ANP was significantly higher
than the increase in PaO2 (to 275.9 &#177; 63.3 mm Hg) after furosemide
treatment, and in the no treatment control (to 171.1 &#177; 31.5 mm Hg).
Pulmonary hypertension induced by acid aspiration was significantly reduced (p &lt;
0.01 versus Groups 1 and 3) during ANP infusion. ANP has a beneficial effect on
acute lung injury, possibly through its diuretic and/or pulmonary vasodilating
action. Tanabe M, Ueda M, Endo M, Kitajima M. AM J RESPIR CRIT CARE MED 1996.</P>
<TABLE BORDER="1">
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#top">BACK TO MENU</A></B></SMALL></TD></TR></TABLE>
<P></P>
<HR>
<P><B><A NAME="ats16">Descriptors of Breathlessness in Cardiorespiratory
Diseases 154:1357&#150;1363</A></B></P>
<P>The purposes of this study were: to examine the decriptors of breathlessness
chosen by a large sample of patients with cardiorespiratory disease; to
determine test-retest reliability of a patient's selection of the descriptors;
and to assess whether a patient's recall of the experience of breathlessness is
the same as that provoked by physical activity. Questionnaire data were
collected at an initial visit for patients who complained of breathlessness and
at a second visit in a subgroup of patients. A total of 218 patients who sought
medical care for difficulty breathing due to one of seven different conditions
were recruited from an outpatient pulmonary disease clinic at a university
medical center. Patients selected statements that described qualities of
breathlessness from a 15-item questionnaire and completed pulmonary function
tests. At a subsequent visit (4 to 15 d later) a subgroup of 16 patients with
chronic obstructive pulmonary disease (COPD) repeated the questionnaire at rest
(to assess reliability) and after walking in a hallway to provoke a moderate
intensity of breathlessness (to compare recall with direct experiences). The
relationship among descriptors was evaluated by cluster analysis. The &quot;work/effort&quot;
cluster was common for all diagnoses. Each condition was characterized by more
than one cluster except COPD. Each diagnosis was associated with a unique set of
clusters (e.g., asthma with &quot;work/effort&quot; and &quot;tight,&quot;
interstitial lung disease with &quot;work/effort&quot; and &quot;rapid&quot;
breathing). Percent agreement for all descriptors selected at Visits 1 and 2
(recall) was 79% (r = 0.82; p = 0.001). Percent agreement at Visit 2 between
descriptors for recall and for breathlessness provoked by walking was 68% (r =
0.69; p = 0.004). We conclude that patients with different cardiorespiratory
conditions experience distinct qualities of breathlessness. Patients' recall of
their sensations of breathlessness is reliable and comparable to dyspnea with
walking. Employing a questionnaire containing descriptors of breathlessness may
help to establish a specific diagnosis and to identify mechanisms whereby a
specific intervention relieves dyspnea. <B>Mahler DA, Harver A, Lentine T,
Scott JA, Beck K, Schwartzstein RM. </B>AM J RESPIR CRIT CARE MED 1996.</P>
<TABLE BORDER="1">
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#top">BACK TO MENU</A></B></SMALL></TD></TR></TABLE>
<P></P>
<HR>
<P><B><A NAME="ats17">Lung Injury after Hepatoenteric Ischemia-Reperfusion:
Role of Xanthine Oxidase 154:000&#150;000</A></B></P>
<P>Oxidant stress plays a major role in the pathophysiologic processes
associated with ischemia-reperfusion injury. Xanthine oxidase (XO) is often
implicated as a significant source of oxidants and increases in the circulation
after hepatoenteric ischemia-reperfusion. We hypothesized that pulmonary injury
is associated with hepatic ischemia-reperfusion resulting from descending
thoracic aorta occlusion-reperfusion (AoOR). We also proposed that this remote
pulmonary injury is attenuated through inactivation of circulating and tissue XO
by tungstate, implicating an XO-dependent mechanism. Aortic occlusion was
established in rabbits (standard or tungstate diet) for 40 min by 2 h
reperfusion. Sham operated rabbits (standard or tungstate diet) served as
controls. Hepatic reperfusion injury, as manifested by release of the
hepatocellular enzyme alanine aminotransferase (ALT), was markedly increased
after AoOR. Suprarenal-infrahepatic occlusion failed to increase ALT release.
Tungstate pretreatment significantly (p &lt; 0.05) reduced XO activity and
ameliorated liver and intestinal injury (p &lt; 0.05). Lung injury, manifested
by increased bronchoalveolar lavage (BAL) protein concentration, BAL lactate
dehydrogenase (LDH) activity and increased lung edema was significantly
associated with liver injury (p &lt; 0.05) and circulating XO activity (p &lt;
0.001). XO inactivation significantly decreased BAL protein concentration, BAL
LDH activity, and lung edema (p &lt; 0.05). We conclude that remote pulmonary
injury is significantly influenced by the extent of liver injury and circulating
XO activity. Nielsen VG, Tan S, Weinbroum A, McCammon AT, Samuelson PN, Gelman
S, Parks DA. AM J RESPIR CRIT CARE MED 1996.</P>
<TABLE BORDER="1">
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#top">BACK TO MENU</A></B></SMALL></TD></TR></TABLE>
<P></P>
<HR>
<P><B><A NAME="ats18">Production of Nitric Oxide (NO) in Intrathoracic
Airways of Normal Humans 154:1370&#150;1374</A></B></P>
<P>To gain insight into the source of exhaled NO in normal humans, we examined
the effects of respiratory pattern on the concentration of NO in exhaled air
while subjects were wearing a noseclip and then under endotracheal intubation,
using a specially designed gas sampling system to separate exhaled air into two
fractions: the initially exhaled 200 ml (Fraction 1; F1), and the remainder
(Fraction 2; F2). We also examined the effect of hypoxic gas inhalation (FIO2 =
0.1, 3 min) on the concentration of exhaled NO. The concentration of exhaled NO
measured with a chemiluminescence NO analyzer was significantly lower with
intubation, by 59.2 &#177; 10.6% (mean &#177; SD) (F1) and 54.4 &#177; 8.0%
(F2), than without intubation. The concentration of NO in F1 was consistently
higher than that in F2 with or without intubation. With breath holding, the
concentration of NO increased markedly only in F1. In contrast, prolongation of
the expiratory phase slightly but significantly increased the concentration of
NO only in F2. Inhalation of hypoxic gas did not cause any significant change in
NO concentration in either fraction. These data indicate that in normal humans
wearing a noseclip, about 40 to 45% of NO in exhaled air originates from the
lungs, particularly from intrathoracic airways. The concentration of exhaled NO
collected from subjects wearing a noseclip is not affected by hypoxic gas
inhalation. <B>Tsujino I, Miyamoto K, Nishimura M, Shinano H, Makita H, Saito
S, Nakano T, Kawakami Y. </B>AM J RESPIR CRIT CARE MED 1996.</P>
<TABLE BORDER="1">
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#top">BACK TO MENU</A></B></SMALL></TD></TR></TABLE>
<P></P>
<HR>
<P><B><A NAME="ats19">Effects of Nitric Oxide Inhalation on Pulmonary Serial
Vascular Resistances in ARDS 154:1375&#150;1381</A></B></P>
<P>The pulmonary vasculature site of action of nitric oxide (NO) in patients
with acute respiratory distress syndrome (ARDS) is still unknown. Seven patients
were studied during the early stage of ARDS. The bedside pulmonary artery
single-occlusion technique, which allows estimation of the pulmonary capillary
pressure (Pcap) and segmental pulmonary vascular resistance, was used without NO
or with increasing inhaled NO concentrations (15 and 25 parts per million
[ppm]). Systemic circulatory parameters remained unaltered during 15 ppm NO
inhalation, whereas 25 ppm NO inhalation slightly decreased mean systemic
arterial pressure from 76.7 &#177; 5.1 (mean &#177; SEM) to 69 &#177; 5.2 mm Hg
(p &lt; 0.01). Mean pulmonary arterial pressure (Ppam) and mean pulmonary
capillary pressure (Pcapm) fell during 25 ppm NO inhalation from 27.4 &#177; 3.5
to 21 &#177; 2.2 mm Hg (p &lt; 0.001) and from 14.8 &#177; 1.5 to 10.7 &#177;
1.4 mm Hg (p &lt; 0.001) respectively, the total pulmonary resistance decreased
by 28% (p &lt; 0.01). The resistance of the capillary-venous compartment fell
during 25 ppm NO inhalation from 100 &#177; 16 to 47 &#177; 16 dyn.s.m.2.cm&#190;5
(p &lt; 0.01), whereas the pulmonary arterial resistance was unchanged. In these
patients NO inhalation during the early stage of ARDS reduces selectively Ppam
and Pcapm by decreasing the pulmonary capillary-venous resistance. This latter
effect may reduce the filtration through the capillary bed and hence alveolar
edema during ARDS. <B>Rosetti M, Gu&eacute;nard H, Gabinski C. </B>AM J RESPIR
CRIT CARE MED 1996.</P>
<TABLE BORDER="1">
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#top">BACK TO MENU</A></B></SMALL></TD></TR></TABLE>
<P></P>
<HR>
<P><B><A NAME="ats20">Tracheal Microvascular Responses to Inhibition of
Nitric Oxide Synthesis in Anesthetized Rats 154:1382&#150;1386</A></B></P>
<P>We previously demonstrated that rat tracheal arterioles and large venules
constrict in response to a-adrenergic agonists and dilate in response to &szlig;-adrenergic
agonists. To further investigate the vasodilatory mechanisms in these vessels,
we hypothesized that the vascular tone in the tracheal microcirculation is
regulated in part by endogenously released nictric oxide (NO). To test this
hypothesis, rat tracheal microvessels were visualized <I>in vivo</I> with a
video microscope. The change in diameter af adventitial arteriolar (14.5 to 42.0
mm initial diameter, n = 41) and large venular (50.0 to 100.0 mm initial
diameter, n = 41) microvessels following the suffusion of vasoactive drugs was
measured with video calipers. Significant constriction was observed in
arterioles (to 70.0% of initial diameter) and large venules (to 76.6% of initial
diameter) after 20 min of suffusion with L-NAME, an inhibitor of NO synthesis.
This constriction was in large part reversed by L-arginine, a biochemical
precursor of NO, in arterioles (to 93.2% of initial diameter) and in venules (to
90.8% of initial diameter). The combination of prazosin, a selective
a1-adrenergic antagonist, and yohimbine, a selective a2-adrenergic antagonist,
also reduced L-NAME-induced constriction in arterioles (to 87.9% of initial
diameter) and in venules (to 85.2% of initial diameter). L-arginine or the
combination of prazosin and yohimbine alone did not affect the diameter of
tracheal microvessels. These data suggest that NO exerts an important influence
on tracheal microvascular tone in rats, and may attenuate a-adrenergic
constriction in these vessels. <B>Corboz MR, Ballard ST, Inglis SK, Taylor AE.
</B>AM J RESPIR CRIT CARE MED 1996.</P>
<TABLE BORDER="1">
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#top">BACK TO MENU</A></B></SMALL></TD></TR></TABLE>
<P></P>
<HR>
<P><B><A NAME="ats21">Value of Perfusion Lung Scan in the Diagnosis of
Pulmonary Embolism: Results of the Prospective Investigative Study of Acute
Pulmonary Embolism Diagnosis (PISA-PED) 154:1387&#150;1393</A></B></P>
<P>To assess the value of perfusion lung scan in the diagnosis of pulmonary
embolism, we prospectively evaluated 890 consecutive patients with suspected
pulmonary embolism. Prior to lung scanning, each patient was assigned a clinical
probability of pulmonary embolism (very likely, possible, unlikely). Perfusion
scans were independently classified as follows: (<I>1</I>) normal, (<I>2</I>)
near-normal, (<I>3</I>) abnormal compatible with pulmonary embolism (PE=:
single or multiple wedge-shaped perfusion defects), or (<I>4</I>) abnormal not
compatible with pulmonary embolism (PE&#190;: perfusion defects other than
wedge-shaped). The study design required pulmonary angiography and clinical and
scintigraphic follow-up in all patients with abnormal scans. Of 890 scans, 220
were classified as normal/or near-normal and 670 as abnormal. A definitive
diagnosis was established in 563 (84%) patients with abnormal scans. The overall
prevalence of pulmonary embolism was 39%. Most patients with angiographically
proven pulmonary embolism had PE= scans (sensitivity: 92%). Conversely, most
patients without emboli on angiography had PE&#190; scans (specificity: 87%). A
PE= scan associated with a very likely or possible clinical presentation of
pulmonary embolism had positive predictive values of 99 and 92%, respectively. A
PE&#190; scan paired with an unlikely clinical presentation had a negative
predictive value of 97%. Clinical assessment combined with perfusion-scan
evaluation established or excluded pulmonary embolism in the majority of
patients with abnormal scans. Our data indicate that accurate diagnosis of
pulmonary embolism is possible by perfusion scanning alone, without ventilation
imaging. Combining perfusion scanning with clinical assessment helps to restrict
the need for angiography to a minority of patients with suspected pulmonary
embolism. <B>Miniati M, Pistolesi M, Marini C, DiRicco G, Formichi B,
Prediletto R, Allescia G, Tonelli L, Sostman HD, Giuntini C (The PISA-PED
Investigators). </B>AM J RESPIR CRIT CARE MED 1996.</P>
<TABLE BORDER="1">
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#top">BACK TO MENU</A></B></SMALL></TD></TR></TABLE>
<P></P>
<HR>
<P><B><A NAME="ats22">An Epidemiologic Investigation of Asthma in Welders
54:1394&#150;1400</A></B></P>
<P>To clarify whether asthma may be caused by fume from welding mild steel and
to evaluate the possible strength of such an effect, we quantified airway
responsiveness among young shipyard workers with different levels of fume
exposure. Clinical investigation comprised a cross-sectional survey of 19- to
27-yr-old workers who were completing 3 to 9 yr of employment in various trades,
and a control group of 15- to 17-yr-old school leavers who were applying for
apprenticeships within the same trades. Both groups were subdivided into
negligible-, ambient-, or high-exposure subgroups according to expected levels
of fume exposure. Actual exposures were assessed in a parallel environmental
survey. Participants were investigated by questionnaire, skin prick tests,
spirometry, and methacholine tests. Complete data sets were obtained from 1,024
of the 1,070 eligible subjects (96%). Among the workers but not the school
leaver controls, there was an increasing prevalence of positive methacholine
tests across the exposure subgroups--negligible 37%, ambient 44%, high 49% (p &lt;
0.05). Regression analyses showed that in males after allowing for the effects
of atopy, current smoking, and age, the estimated geometric mean level of airway
responsiveness of regular welders was twice that of workers with negligible
exposure after 5 yr of work. This implies that fume exposure may have been
critical in causing asthma in about 1% of the welders. A lesser effect (though
not significantly so) was noted among the workers with ambient exposure. <B>Beach
JR, Dennis JH, Avery AJ, Bromly CL, Ward RJ, Walters EH, Stenton SC, Hendrick
DJ. </B>AM J RESPIR CRIT CARE MED 1996.</P>
<TABLE BORDER="1">
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#top">BACK TO MENU</A></B></SMALL></TD></TR></TABLE>
<P></P>
<HR>
<P><B><A NAME="ats23">Does Dietary Intake of Vitamins C and E Influence Lung
Function in Older People? 154:1401&#150;1404</A></B></P>
<P>Antioxidants in the lung have a protective role against oxidative damage. We
have investigated whether dietary antioxidant intake in elderly people is
related to lung function. Dietary intakes of ascorbic acid (vitamin C) and
alpha-tocopherol (vitamin E) and lung function were assessed in 178 men and
women aged 70 to 96 yr selected on the basis of reported respiratory symptoms.
After adjustment for age, gender, height, smoking habits, total energy intake,
and vitamin C intake by multiple linear regression, vitamin E intake was
significantly associated with FEV1 p = 0.012 and FVC p = 0.003. There was no
evidence of any interaction between vitamin E intake and current tobacco smoking
as determinants of lung function. For every extra milligram increase in vitamin
E in the daily diet, FEV1 increased by an estimated 42 ml and FVC by an
estimated 54 ml. These results suggest that dietary intake of vitamin E may
influence lung function in the elderly, but food frequency questionnaires in
this study were not of sufficient sensitivity to explore this hypothesis
further. <B>Dow L, Tracey M, Villar A, Coggon D, Margetts BM, Campbell MJ,
Holgate ST.</B> AM J RESPIR CRIT CARE MED 1996.</P>
<TABLE BORDER="1">
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#top">BACK TO MENU</A></B></SMALL></TD></TR></TABLE>
<P></P>
<HR>
<P><B><A NAME="ats24">Refractory Ceramic Fiber Exposure and Pleural Plaques
154:1405&#150;1410</A></B></P>
<P>Refractory ceramic fibers (RCF) are manmade vitreous fibers (MMVF)
manufactured for high-temperature applications. Between 1987 and 1992, a
retrospective cohort and nested case-control study evaluated chest radiographs
from 652 workers involved in the manufacture of these fibers for plausibility of
a causal relationship between exposure to RCF and chest-radiographic changes.
The exposure&#150;response relationship was modeled with three variables: years
since first fiber production job, years in fiber production, and cumulative
fiber exposure to date of study X-ray. The case-control study used a
comprehensive characterization of possible asbestos exposure to investigate
asbestos as the potential causative agent of chest-radiographic changes. Chest
radiographs of 20 workers (3.1%) demonstrated 19 pleural plaques and one diffuse
pleural thickening. Nine of 72 workers (12.5%) with more than 20 yr since their
first fiber-production job had plaques (odds ratio [OR] = 9.5; 95% confidence
interval [CI] = 1.9 to 48.2). Five of 19 workers with more than 20 yr in
fiber-production work (26.3%) had plaques (OR = 22.3; 95% CI = 3.6 to 137.0).
Similarly, adjusted ORs demonstrated a progressive relationship between
cumulative fiber-months per milliliter (fiber-mo/ml) exposure and plaques. The
case-control study confirmed that asbestos exposure did not account for the
observed association between fiber exposure and plaques. A validity review of
historical films demonstrated biologic plausibility for the association, since
sufficient latency existed from the time of first RCF exposure to the
development of plaques. There was no significant increase in parenchymal changes
consistent with interstitial fibrosis. <B>Lockey J, Lemasters G, Rice C, Hansen
K, Levin L, Shipley R, Spitz H, Wiot J.</B> AM J RESPIR CRIT CARE MED 1996.</P>
<TABLE BORDER="1">
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#top">BACK TO MENU</A></B></SMALL></TD></TR></TABLE>
<P></P>
<HR>
<P><B><A NAME="ats25">Delayed Maturation of Hering-Breuer Inflation Reflex
Activity in Preterm Infants 154:1411&#150;1417</A></B></P>
<P>We have previously shown that the strength of the Hering-Breuer inflation
reflex (HBIR) diminishes between 2 and 12 mo of age in full-term babies. The
purpose of this study was to determine whether the onset of this decline had
commenced by 3 to 4 mo of age in healthy full-term infants and whether preterm
delivery influences the pattern of maturation. Serial measurements of HBIR
activity using the end-inspiratory occlusion technique were made in 25 preterm
and 27 full-term infants at matched postnatal and postconceptional ages during
the first 6 mo of life. Although similar levels of reflex activity were observed
at birth (mean &#177; SD of 101.2% &#177; 42.4% in preterm, and 101.0% &#177;
33.9% in full-term infants), by 40 wk postconceptional age (PCA) (i.e., term
equivalent) HBIR activity (mean &#177; SD) had increased to 121.7% &#177; 51.2%
in preterm infants, which was significantly greater than that in full-term
infants of similar PCA (95% CI of difference: 0.2; 41.2%). By 15 wk postnatal
age (PNA), HBIR activity had decreased to 68.8% &#177; 26.6% in full-term
infants, but remained significantly higher in those delivered prematurely (87.8%
&#177; 32.7%). However, when measurements were repeated at approximately 4 mo
after the expected rather than actual date of delivery, these differences were
no longer evident (95% CI difference preterm--full-term: &#190;21.2; 3.8%). This
study suggests that important transitions in respiratory control mechanisms
occur between 8 and 15 wk PNA in full-term infants and that these changes are
delayed in preterm infants. <B>Stocks J, Dezateux C, Hoo A-F, Rabbette PS,
Costeloe K, Wade A. </B>AM J RESPIR CRIT CARE MED 1996.</P>
<TABLE BORDER="1">
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#top">BACK TO MENU</A></B></SMALL></TD></TR></TABLE>
<P></P>
<HR>
<P><B><A NAME="ats26">Ventilatory Mechanics at Rest and During Exercise in
Patients with Cystic Fibrosis 154:1418&#150;1425</A></B></P>
<P>Ventilatory mechanics were measured at rest and during steady-state (25%,
50%, 75%) and maximal exercise (W-Max) on a cycle-ergometer in eight adult
patients (FEV1 22 to 114% of predicted) with cystic fibrosis (CF). Tidal flow&#150;volume
loops were measured at rest and during exercise and placed within the maximal
pre- and postexercise flow&#150;volume loops, based on measured end-expiratory
lung volume (EELV). The degree of flow limitation was expressed as the
percentage of the tidal flow&#150;volume loop that met the expiratory boundary
of the maximal loop (TFVL%). Pressure&#150;volume relationships were assessed by
measurement of transpulmonary pressure (PTP ). Peak inspiratory PTP  was
compared with maximal inspiratory pressures at rest and during exercise (Pcapi)
at the equivalent lung volume. The maximal effective expiratory pressure (Pmaxe)
was determined using the orifice technique. Three patients with milder disease
(FEV1 114, 98, 89% of predicted) did not show any flow limitation at rest or 50%
W-Max but two did show some flow limitation at W-Max (0, 3, 23 TFVL%) with a
decrease in EELV (&#190;400, &#190;200, &#190;300 ml). There was considerable
reserve for inspiratory and expiratory pressure generation at W-Max. Flow
limitation was noted at rest in three patients and at 50% W-Max in the five
patients with more severe airways obstruction. The increased flow was achieved
by an increase in EELV in all five patients (=400, =430, =330, =150, =700 ml at
W-Max). Pcapi was reached in two patients (&#190;28, &#190;36 cm H2O), while
Pmaxe was exceeded by four patients suggesting inefficient pressure generation.
Expiratory flow limitation, hyperinflation, and pressure swings approaching
capacity severely compromised the capacity to generate ventilation in some
patients with CF. <B>Regnis JA, Donnelly PM, Robinson M, Alison JA, Bye PTP.
</B>AM J RESPIR CRIT CARE MED 1996.</P>
<TABLE BORDER="1">
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#top">BACK TO MENU</A></B></SMALL></TD></TR></TABLE>
<P></P>
<HR>
<P><B><A NAME="ats27">Increased DNA Levels in Bronchoalveolar Lavage Fluid
Obtained From Infants with Cystic Fibrosis 154:1426&#150;1429</A></B></P>
<P>Airway inflammation in children younger than 5 yr of age is difficult to
assess, particularly in patients with cystic fibrosis (CF). Furthermore,
determining responses to therapies is often subjective in infants, especially
those with CF. To determine whether airway DNA levels could be used as an index
of airway inflammation, we measured DNA levels in bronchoalveolar lavage fluid
(BALF), using a Hoechst dye-binding assay. BALF DNA levels and neutrophils from
16 infants with CF were compared with levels obtained from seven older CF
patients and nine control children who underwent bronchoalveolar lavage for
evaluation of other pulmonary diseases. BALF DNA was increased in both infants
(3.2 &#177; 0.7 mg/ml) and older patients with CF (5.4 &#177; 0.9 mg/ml)
compared with the controls (0.7 &#177; 0.2 mg/ml) (mean &#177; SEM). BALF DNA
levels were not significantly different between infants and older patients with
CF. BALF neutrophil counts in CF patients were significantly higher than in
controls. Furthermore, BALF DNA levels and total neutrophil counts in infants
with CF correlated positively with one another. We conclude that: (<I>1</I>)
DNA levels were easily quantifiable in BALF of young children; (<I>2</I>) DNA
levels in BALF from CF patients were greater than in a group of children with
other pulmonary diseases, and that in some infants with CF, BALF DNA levels were
equivalent to those of much older patients with CF; (<I>3</I>) DNA levels in
BALF correlate with BALF neutrophil number, an index of inflammation; and (<I>4</I>)
some infants with CF have increased levels of DNA in BALF, which may justify a
clinical trial of aerosolized rhDNase in this population. <B>Kirchner KK,
Wagener JS, Khan TZ, Copenhaver SC, Accurso FJ.</B> AM J RESPIR CRIT CARE MED
1996.</P>
<TABLE BORDER="1">
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#top">BACK TO MENU</A></B></SMALL></TD></TR></TABLE>
<P></P>
<HR>
<P><B><A NAME="ats28">Biomarkers of Lung Inflammation in Recreational Joggers
Exposed to Ozone 154:1430&#150;1435</A></B></P>
<P>Humans exhibit an acute inflammatory response in the lungs after controlled
laboratory exposure to ozone. The present study was designed to test whether
biomarkers of inflammation are detectable in humans exposed to ozone and
associated copollutants under natural conditions outdoors. Bronchoscopy with
bronchoalveolar lavage (BAL) was carried out on 19 normal volunteer joggers from
Governors Island, NY, who exercised in the afternoon during the 1992 summer (S1)
season. Fifteen subjects were retested during the following, low ozone, winter
season (W). The BAL protocol involved an initial instillation of 20 ml saline
followed by four sequential 50-ml saline washes carried out in both the right
middle lobe and the lingula. The eight 50-ml samples were pooled as the &quot;alveolar&quot;
sample. Analyses performed on the alveolar lavage samples included cell
differentials, release of IL-8, TNF-a, and reactive oxygen species (ROS) by
pooled cells, and levels of IL-8, protein, LDH, fibronectin, a1-antitrypsin
(a1-AT), complement fragment 3a (C3a), and prostaglandin E2 (PGE2) in lavage
fluids. Release of ROS by stimulated BAL cells was lower in S1 than in W (p =
0.03). In contrast, LDH levels in BAL fluids were 2-fold higher in S1 than in W
(p = 0.02), as were IL-8 (p = 0.12) and PGE2 (p = 0.06). These results suggest a
possible ongoing inflammatory response in the lungs of recreational joggers
exposed to ozone and associated copollutants during the summer months. <B>Kinney
PL, Nilsen DM, Lippmann M, Brescia M, Gordon T, McGovern T, El Fawal H, Devlin
RB, Rom WN. </B>AM J RESPIR CRIT CARE MED 1996.</P>
<TABLE BORDER="1">
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#top">BACK TO MENU</A></B></SMALL></TD></TR></TABLE>
<P></P>
<HR>
<P><B><A NAME="ats29">Characterization of Carotenoid, Vitamin A, and
a-Tocopheral Levels in Human Lung Tissue and Pulmonary Macrophages 154:1436&#150;1443</A></B></P>
<P>Increasing evidence suggests that &szlig;-carotene, retinol (vitamin A), and
a-tocopheral (vitamin E) may have important protective effects in the lung.
However, surprisingly little is known about their storage and metabolism in
human lung. Levels of &szlig;-carotene, retinol, and a-tocopherol in human lung
tissues and bronchoalveolar lavage (BAL) cells were determined with
reverse-phase high-pressure liquid chromatography (HPLC). Fresh lung tissue,
serum, and dietary questionnaires were obtained from 21 patients undergoing open
lung surgery, and BAL cells from 12 of these patients. Dietary and serum levels
of carotenoids, &szlig;-carotene, retinol, and a-tocopherol were consistent with
previously reported values. Lung tissue levels of total carotenoids, &szlig;-carotene,
retinol, and a-tocopherol were respectively 0.34 &#177; 0.36 mg/g, 0.13 &#177;
0.27 mg/g, 0.15 &#177; 0.06 mg/g, and 9.60 &#177; 4.86 mg/g tissue. Levels of
these nutrients were also measured in BAL cells to establish potential markers
for their lung tissue levels. Correlations between serum, BAL-cell, tissue, and
dietary levels of the nutrients were determined. Lung tissue levels of total
carotenoids, &szlig;-carotene, and a-tocopherol, but not retinol, correlated
well with their serum levels. Lung tissue levels of retinol and a-tocopherol
correlated with their BAL-cell levels. These studies demonstrate quantifiable
levels of retinol, a-tocopherol, and total carotenoids or &szlig;-carotene in
human lung tissue and BAL cells, and show that serum and/or BAL-cell levels of
these nutrients can potentially be used to predict their lung tissue levels.
<B>Redlich CA, Grauer JN, Van Bennekum AM, Clever SL, Ponn RB, Blaner WS. </B>AM
J RESPIR CRIT CARE MED 1996.</P>
<TABLE BORDER="1">
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#top">BACK TO MENU</A></B></SMALL></TD></TR></TABLE>
<P></P>
<HR>
<P><B><A NAME="ats30">Morphologic Determinants of Airway Responsiveness in
Chronic Smokers 154:1444&#150;1449</A></B></P>
<P>Nonspecific bronchial hyperresponsiveness (NSBH) occurs in asthmatics and in
smokers who have airway obstruction. NSBH may be caused by different mechanisms
in these conditions. We hypothesized that NSBH in smokers was a consequence of
the structural changes that occur in chronic obstructive pulmonary disease
(COPD) and lead to airway obstruction. We measured nonspecific bronchial
responsiveness, assessed by PC20, in 77 smokers who had mild to moderate airflow
obstruction prior to lung resection for a pulmonary nodule. We related airway
responsiveness to baseline airway function (FEV1 % predicted), to functional
(Plmax, PL90, and P-V curve shape) and morphometric (alveolar attachments)
markers of lung elasticity as well as to thickening in small airways. Airway
wall thickness, internal and external to the outer border of smooth muscle was
quantified by plotting the square root of airway wall area (WA) versus a marker
of airway size, airway internal perimeter (Pi). PC20 was significantly related
to FEV1% predicted and Plmax and when these functional parameters were
controlled for, PC20 was also inversely related to airway wall thickness. There
was also a trend for the most responsive patients to have fewer alveolar
attachments per millimeter on the external perimeter of the airway walls. These
data suggest that exaggerated nonspecific airway narrowing in COPD is secondary
to structural changes caused by the disease. <B>Riess A, Wiggs B, Verburgt L,
Wright JL, Hogg JC, Par&eacute; PD. </B>AM J RESPIR CRIT CARE MED 1996.</P>
<TABLE BORDER="1">
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#top">BACK TO MENU</A></B></SMALL></TD></TR></TABLE>
<P></P>
<HR>
<P><B><A NAME="ats31">Community-acquired Pneumonia in the Elderly: A
Multivariate Analysis of Risk and Prognostic Factors 154:1450&#150;1455</A></B></P>
<P>To assess the risk and prognostic factors of community-acquired pneumonia
occurring in the elderly (over age 65 yr) requiring hospitalization, two
studies, case-control and cohort, were performed over an 8-mo period in a
1,000-bed university teaching hospital. We studied 101 patients with pneumonia
(cases), age 78.5 &#177; 7.9 yr (mean &#177; SD). Each case was matched for sex,
age (&#177; 5 yr), and date of admission (&#177; 2 d) with a control subject,
without pneumonia during the preceding 3 yr, arriving at the emergency room.
Etiologic diagnosis was obtained in 43 of 101 (42%) cases. The main microbial
agents causing pneumonia were: <I>Streptococcus pneumoniae</I> (19 of 43, 44%),
and <I>Chlamydia pneumoniae</I> (9 of 43, 21%). Gram-negative bacilli were
uncommon (2 of 43, 5%). The multivariate analysis demonstrated that large-volume
aspiration, and low serum albumin (&lt; 30 mg/dl) were independent risk factors
associated with the development of pneumonia. Crude mortality rate was 26% (26
of 101), while pneumonia-related mortality was 20% (20 of 101). The attributable
mortality was 23% (odds ratio [OR]: 11.3; 95% confidence interval [CI]: 3.25 to
60.23; p &lt; 0.0001). The multivariate analysis showed that patients had a
worse prognosis if they were previously bedridden, had prior swallowing
disorders, body temperature on admission was less than 37&#183;C, respiratory
frequency was greater than 30/min or had three or more affected lobes on chest
radiograph. Age by itself was not a significant factor related to prognosis.
Among the significant risk factors, only nutritional status is probably amenable
to medical intervention. The prognostic factors found in this study may help to
identify, upon admission, those subjects at higher risk and who may require
special observation. <B>Riquelme R, Torres A, El-Ebiary M, de la Bellacasa JP,
Estruch R, Mensa J, Fern&aacute;ndez-Sol&aacute; J, Hern&aacute;ndez C,
Rodriguez-Roisin R. </B>AM J RESPIR CRIT CARE MED 1996.</P>
<TABLE BORDER="1">
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#top">BACK TO MENU</A></B></SMALL></TD></TR></TABLE>
<P></P>
<HR>
<P><B><A NAME="ats32">Community-acquired Pneumonia in Chronic Obstructive
Pulmonary Disease: A Spanish Multicenter Study 154:1456&#150;1461</A></B></P>
<P>Community-acquired pneumonia (CAP) is an infectious illness that frequently
motivates hospital admission when comorbid conditions are present. However, the
epidemiology of CAP in relation to the underlying disease of the patients is not
well known. We performed a prospective multicenter study with the aim of
assessing the clinical characteristics, etiology, and outcome of chronic
obstructive pulmonary disease (COPD) patients with CAP. Between October 1992 and
December 1994 we studied 124 COPD patients (mean FEV1 40 &#177; 11% of
predicted, mean FVC/FEV1 49 &#177; 10) admitted because of CAP to one of the
participating centers. An attempt to obtain an etiologic diagnosis was performed
by means of blood cultures (n = 123), sputum cultures (n = 97), pleural fluid
cultures (n = 17), protected specimen brush samples (n = 41), percutaneous
transthoracic needle aspiration (n = 41), and serology (n = 106). Etiologic
diagnosis was achieved in 80 (64%) of cases, however, diagnosis based upon valid
techniques was only possible in 73 (59%) cases. The main causal microorganisms
were the following: <I>Streptococcus pneumoniae</I> in 32 (43%), <I>Chlamydia
pneumoniae</I> in 9 (12%), <I>Hemophilus influenzae</I> in 7 (9%), <I>Legionella
pneumophila</I> in 7 (9%), <I>Streptococcus viridans</I> in 3 (4%), <I>Coxiella
burnetii</I> in 3 (4%), <I>Mycoplasma pneumoniae</I> in 2 (3%), <I>Nocardia
asteroides</I> 2, <I>Aspergillus</I> ssp. 1, and others 10. In three of these
cases the etiology was polymicrobial. Bacteremia was present in 19 (15%) cases;
<I>S. pneumoniae</I> was the most frequent isolate (13 cases). Antibiotic
treatment was modified in 22 cases due to etiologic findings, and in 9 due to
therapeutic failure. Ten patients died (8%), and 22 needed mechanical
ventilation, the mortality rate in the latter population being 23%. Total or
partial resistance of <I>S. pneumoniae</I> to penicillin was observed in 10 of
32 (31%) isolations, and to erythromycin in 2 (6%). The results of this study
are important for the standardization of empiric antibiotic strategies in COPD
patients with pneumonia. <B>Torres A, Dorca J, Zalacan R, Bello S, El-Ebiary M,
Molinos L, Ar&eacute;valo M, Blanquer J, Celis R, Iriberri M, Prats E, Fern&aacute;ndez
R, Irigaray R, Serra J. </B>AM J RESPIR CRIT CARE MED 1996.</P>
<TABLE BORDER="1">
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#top">BACK TO MENU</A></B></SMALL></TD></TR></TABLE>
<P></P>
<HR>
<P><B><A NAME="ats33">Efficacy and Safety of Rifabutin in the Treatment of
Patients with Newly Diagnosed Pulmonary Tuberculosis 154:1462&#150;1467</A></B></P>
<P>The efficacy and safety of rifabutin (RBT) and rifampicin (RMP) were
compared in 298 patients with newly diagnosed pulmonary tuberculosis. In the
initial 8-wk phase, all patients received isoniazid 400 mg/d, ethambutol 1200
mg/d, and pyrazinamide 2 g/d and were randomly allocated to receive either RMP
600 mg/d or RBT 300 mg/d. In the 16-wk continuation phase, patients received
intermittent treatment (twice weekly) with isoniazid 600 mg/d, ethambutol 2400
mg/d and either RMP 600 mg/d or RBT 300 mg/d. Two hundred twenty-five (RMP =
118; RBT = 107) patients completed the 24-wk treatment period (evaluable patient
population). Bacteriologic conversion rates in the RMP and RBT groups were 87.7
versus 92.0% at Week 8, 99.1 versus 99.0% at Week 12, 93.5 versus 93.8% at Week
24, and 89.8 versus 95.3% at the last valid observation. The mean time to first
bacteriologic conversion was 14.1 wk in the RMP group and 14.3 wk in the RBT
group. None of these differences was significant. Adverse events were reported
by four patients (five events) in the RMP group and six patients (six events) in
the RBT group. Those events thought to be associated with RMP were increased
SGOT and leucopenia and, with RBT, increased SGOT and thrombocytopenia. Two
hundred four patients entered the follow-up phase, and, of these, 95 (RMP = 49;
RBT = 46) completed the scheduled 24-mo period. The overall rate of relapse was
3.8% (4/106) for the RMP group and 5.1% (5/98) for the RBT group. These
differences were not significant. All relapsed patients, except for two who
could not be traced, were successfully retreated. We conclude that the efficacy
and tolerability of RBT is equivalent to that of RMP in the treatment of newly
diagnosed uncomplicated tuberculosis, and that RBT can be effectively
administered in a part-daily, part-intermittent dosage schedule. <B>McGregor
MM, Olliaro P, Wolmarans L, Mabuza B, Bredell M, Felten MK, Fourie PB. </B>AM J
RESPIR CRIT CARE MED 1996.</P>
<TABLE BORDER="1">
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#top">BACK TO MENU</A></B></SMALL></TD></TR></TABLE>
<P></P>
<HR>
<P><B><A NAME="ats34">Clinical Predictors of Tuberculosis as a Guide for a
Respiratory Isolation Policy 154:1468&#150;1472</A></B></P>
<P>An expanded respiratory isolation policy was implemented in a public
hospital that cares for about 200 patients with active tuberculous each year.
This led to proper isolation of &#179;95% of patients with tuberculosis on
admission but involved an 8-fold overuse of isolation rooms. We developed a
model policy to decrease overisolation of nontuberculosus patients. Clinical
findings in 295 patients admitted to respiratory isolation during a 3-mo period
were evaluated for their usefulness in determining which patients had
tuberculosis. Multivariate analysis identified five predictive variables: chest
radiograph with upper lobe infiltrate (odds ratio, 5.00; CI, 2.38 to 10.51; p =
0.001) or cavity (odds ratio, 3.93; CI, 1.06 to 14.62; p = 0.041), history of
having known someone with tuberculosis (odds ratio, 2.42; CI, 1.10 to 5.32, p =
0.027), self-reported positive tuberculin skin test (odds ratio, 5.67; CI, 1.57
to 22.01; p = 0.009), self-reported isoniazid preventive therapy (odds ratio,
0.18; CI, 0.04 to 0.82; p = 0.027). Using these variables to determine which
patients required isolation would have decreased the number of isolated
nontuberculous patients from 253 to 95, but it would have missed eight of 42
patients with tuberculosis. Further work is needed to identify clinical
predictors that would decrease overuse of isolation beds while maintaining
satisfactory sensitivity for patients with tuberculosis. <B>Bock NN, McGowan
JE, Jr., Ahn J, Tapia J, Blumberg HM.</B> AM J RESPIR CRIT CARE MED 1996.</P>
<TABLE BORDER="1">
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#top">BACK TO MENU</A></B></SMALL></TD></TR></TABLE>
<P></P>
<HR>
<P><B><A NAME="ats35">Rifampin Preventive Therapy for Tuberculosis in
Boston's Homeless 154:1473&#150;1477</A></B></P>
<P>An epidemic of isoniazid (INH)- and streptomycin (SM)-resistant tuberculosis
began among Boston's homeless population in 1984. Individuals with skin test
conversions who agreed to preventive therapy received either INH, rifampin, or a
combination of INH and rifampin. A total of 204 individuals with documented
tuberculin skin test conversions who did not have active tuberculosis at the
time of the clinical evaluation for their positive skin test were eligible for
preventive therapy. Data on type and length of preventive therapy were obtained
from the Tuberculosis Clinic and the Boston Tuberculosis Registry records at
Boston City Hospital. The individuals were followed for development of active
tuberculosis. Six of 71 (8.6%) individuals who received no therapy, 3 of 38
(7.9%) in the INH group, and none in the rifampin or rifampin plus INH groups
(49 and 37 persons, respectively) developed active tuberculosis. Patients in the
rifampin group were significantly less likely to develop tuberculosis than
patients in the no therapy group (p = 0.04; odds ratio [OR] = 0.00, 95%
confidence interval [CI] = 0.00&#150;0.91). Treatment with any
rifampin-containing preventive therapy (rifampin or rifampin plus INH) was
effective (p &lt; 0.01) in preventing development of active disease. The three
INH failures were with organisms that were resistant to INH. <B>Polesky A,
Farber HW, Gottlieb DJ, Park H, Levinson S, O'Connell JJ, McInnis B, Nieves RL,
Bernardo J. </B>AM J RESPIR CRIT CARE MED 1996.</P>
<TABLE BORDER="1">
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#top">BACK TO MENU</A></B></SMALL></TD></TR></TABLE>
<P></P>
<HR>
<P><B><A NAME="ats37">The Impact of Human Immunodeficiency Virus Infection on
Drug-resistant Tuberculosis 154:1478&#150;1483</A></B></P>
<P>Infection with human immunodeficiency virus (HIV) has been associated with
increased rates of single- and multidrug-resistant (MDR) tuberculosis in the New
York City area. In order to examine the relationship of HIV infection to
drug-resistant tuberculosis in other selected regions of the United States, we
established a registry of cases of culture-proven tuberculosis. Data were
collected from sites participating in an NIH-funded, community-based HIV
clinical trials group. All cases of tuberculosis, regardless of HIV status,
which occurred between January 1992 and June 1994 were recorded. Overall, 1,373
cases of tuberculosis were evaluated, including 425 from the New York City area,
and 948 from seven other metropolitan areas. The overall prevalence of
resistance to one or more drugs was 20.4%, and 5.6% of isolates were resistant
to both isoniazid and rifampin (MDR). In the New York City area, HIV-infected
patients were significantly more likely than persons not known to be
HIV-infected, to have resistance to at least one drug (37% versus 19%) and MDR
(19% versus 6%). In other geographic areas, overall drug resistance was 16%, and
only 2.2% of isolates were MDR. In multiple logistic regression analyses, HIV
infection was shown to be a risk factor for drug-resistant tuberculosis,
independent of geographic location, history of prior therapy, age, and race. We
concluded that HIV infection is associated with increased rates of resistance to
antituberculosis drugs in both the New York City area and other geographic
areas. MDR tuberculosis is occurring predominantly in the New York City area and
is highly correlated with HIV infection. <B>Gordin FM, Nelson ET, Matts JP,
Cohn DL, Ernst J, Benator D, Besch CL, Crane LR, Sampson JH, Bragg PS, El-Sadr
W, and the Terry Beirn Community Programs for Clinical Research on AIDS. </B>AM
J RESPIR CRIT CARE MED 1996.</P>
<TABLE BORDER="1">
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#top">BACK TO MENU</A></B></SMALL></TD></TR></TABLE>
<P></P>
<HR>
<P><B><A NAME="ats38">Mechanisms for Diaghragmatic Fatigue Following
High-intensity Leg Exercise 154:000&#150;000</A></B></P>
<P>Diaphragmatic fatigue can occur following high-intensity leg exercise to
exhaustion. Exercise-induced diaphragmatic fatigue may be due to changes in the
milieu to which the diaphragm is exposed (i.e., acidosis, etc.) and/or to
increases in diaphragmatic activity during exercise. The purpose of this study
was to determine whether changes in milieu are responsible for exercise-induced
diaphragmatic fatigue. Fourteen subjects exercised at 70 to 75% of their maximal
work capacity until volitional exhaustion. Transdiaphragmatic twitch pressure
(Pdi) was measured during bilateral transcutaneous supramaximal phrenic nerve
stimulation and adductor pollicis twitch force was measured during
transcutaneous supramaximal ulnar nerve stimulation before and 10 to 15, 30, and
60 min after exercise. On a separate day, arterialized venous blood samples were
obtained for lactate measurements at baseline and 5, 15, 30, and 60 min
postexercise. Nine subjects demonstrated a &#179;10% decrease in twitch Pdi
postexercise, which was considered indicative of diaphragmatic fatigue (fatigue
group). In these subjects, twitch Pdi fell from 24.3 &#177; 1.6 at baseline to
19.7 &#177; 1.6 cm H2O at 10 min postexercise (p &lt; 0.0001, ANOVA). Adductor
pollicis twitch force was not significantly different from baseline at any time
postexercise in either the fatiguers or nonfatiguers. In both groups, a
significant lactic acidosis developed during exercise and the magnitude of this
acidosis was similar for the two groups. The adductor pollicis muscle (a
nonexercising muscle during cycle exercise) is exposed to the same milieu as the
diaphragm. Because adductor pollicis twitch force was unchanged postexercise
while twitch Pdi fell, changes in milieu cannot be solely responsible for
exercise-induced diaphragmatic fatigue. <B>Mador MJ, Dahuja M. </B>AM J RESPIR
CRIT CARE MED 1996.</P>
<TABLE BORDER="1">
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#top">BACK TO MENU</A></B></SMALL></TD></TR></TABLE>
<P></P>
<HR>
<P><B><A NAME="ats39">Depressed Baroreflex Sensitivity in Patients with
Obstructive Sleep Apnea 154:1490&#150;1496</A></B></P>
<P>Muscle nerve sympathetic activity (MSA), the interval between two R-waves in
the ECG, or the interbeat interval (RR-interval), and blood pressure (BP) were
recorded in 10 awake patients with obstructive sleep apnea (OSA) and in nine
sex- and age-matched controls. Changes in RR-interval and MSA, evoked by sodium
nitroprusside-induced reduction of BP, were used to quantitate baroreflex
sensitivity. Both the cardiac (expressed as the RR-interval versus mean arterial
BP slope) and the muscle sympathetic (mean MSA area versus diastolic BP slope)
baroreflex sensitivity were depressed in patients as compared with controls.
Cardiac baroreflex slope sensitivity (expressed as a regression coefficient) was
5.5 &#177; 1.2 (mean &#177; SEM) in patients and 9.6 &#177; 0.96 in controls (p &lt;
0.05). The corresponding figures for the sympathetic slope sensitivity were &#190;4.9
&#177; 0.9 and &#190;13.1 &#177; 2.3, respectively (p &lt; 0.05). Differences
remained after stepwise correction for age, body mass index (BMI), and to some
extent BP. Resting MSA correlated with cardiac (r = 0.67, p &lt; 0.003) and
sympathetic (r = 0.56, p &lt; 0.025) baroreflex sensitivity in the entire study
group. We conclude that OSA patients exhibit an impaired baroreflex sensitivity
to a hypotensive stimulus, which may represent an adaptive response to changes
in BP or hypoxemia occurring in association with nocturnal apneas. Baroreflex
adaptation may also contribute to the augmentation of resting MSA observed in
OSA patients in this as well as in a previous study. <B>Carlson JT, Hedner JA,
Sellgren J, Elam M, Wallin BG. AM J RESPIR CRIT CARE MED 1996.</B></P>
<TABLE BORDER="1">
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#top">BACK TO MENU</A></B></SMALL></TD></TR></TABLE>
<P></P>
<HR>
<P><B><A NAME="ats40">IL-4 and IL-5 mRNA and Protein in Bronchial Biopsies
from Patients with Atopic and Nonatopic Asthma: Evidence Against &quot;Intrinsic&quot;
Asthma Being a Distinct Immunopathologic Entity 154:1497&#150;1504</A></B></P>
<P>Intrinsic (nonatopic) asthma is considered to be a distinct pathogenetic
variant of asthma since, unlike extrinsic (atopic) asthma, patients with the
disease are skin test-negative to common aeroallergens, and have total serum IgE
concentrations within the normal range. Nevertheless, the recent demonstration
of increased numbers of cells expressing the high-affinity IgE receptor in
bronchial biopsies from atopic and nonatopic asthmatic subjects, together with
epidemiologic evidence indicating that serum IgE concentrations relate closely
to asthma prevalence regardless of atopic status, suggests that IgE-mediated
mechanisms may participate in the pathogenesis of both atopic and nonatopic
asthma. Furthermore both variants of the disease are associated with bronchial
mucosal eosinophilic inflammation. Interleukin-4 (IL-4) is an essential cofactor
for IgE synthesis, and there is strong evidence that IL-5 plays a major role in
eosinophil accumulation in asthmatic inflammation. For these reasons we compared
the expression of IL-4 and IL-5 mRNA and protein product using a
semiquantitative reverse transcriptase-polymerase chain reaction (RT-PCR)
amplification, <I>in situ</I> hybridization, and immunohistochemistry in
bronchial biopsies from symptomatic atopic and nonatopic asthmatic subjects and
atopic and nonatopic controls. The results showed that as compared with
controls, biopsies from both groups of asthmatic subjects had increased numbers
of IL-4 and IL-5 mRNA copies relative to &szlig;-actin mRNA as detected by
RT-PCR. Similarly, <I>in situ</I> hybridization and immunohistochemistry
demonstrated increased numbers of cells expressing IL-4 and IL-5 mRNA and
protein in asthmatic subjects, irrespective of their atopic status. We conclude
that individuals with either atopic or nonatopic asthma show infiltration of the
bronchial mucosa with cells expressing Th2-type cytokines, providing further
evidence for similarities in the immunopathogenesis of these clinically distinct
forms of asthma. <B>Humbert M, Durham SR, Ying S, Kimmitt P, Barkans J, Assoufi
B, Pfister R, Menz G, Robinson DS, Kay AB, Corrigan CJ. </B>AM J RESPIR CRIT
CARE MED 1996.</P>
<TABLE BORDER="1">
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#top">BACK TO MENU</A></B></SMALL></TD></TR></TABLE>
<P></P>
<HR>
<P><B><A NAME="ats41">Alveolar Tissue Inflammation in Asthma 154:1505&#150;1510</A></B></P>
<P>As physiologic and autopsy evidence suggests that peripheral airways and
parenchyma are involved in asthma, we hypothesized that significant alveolar
tissue inflammation is present in patients with stable, chronic asthma. Eleven
patients with nocturnal asthma (NA) and 10 patients with non-nocturnal asthma
(NNA) were studied. Each subject underwent two bronchoscopies with proximal
airway endobronchial and distal alveolar tissue transbronchial biopsy in a
random order at 4:00 p.m. and 4:00 a.m. Morphometric analysis was used to
determine the number per volume (Nv) of inflammatory cells. Between-group
comparisons showed that the Nv of eosinophils was greater in the NA alveolar
tissue 4:00 a.m. compared with the subjects with NNA (40.2 x 103 [26.4&#150;57.1
x 103, IQ] versus 15.7 x 103 [2.1&#150;35.2 x 103, IQ], p = 0.05). In regard to
the airway biopsies, no difference in the inflammatory and epithelial cells
between the two groups was seen at either time. The NA group exhibited greater
eosinophils and macrophages in the alveolar tissue at 4:00 a.m. compared with
4:00 p.m. (40.2 x 103 [26.4&#150;57.1 x 103, IQ] versus 10.3 x 103 [2.7&#150;16.8
x 103, IQ], p = 0.016 for eosinophils and 215.1 x 103 [129.9&#150;356.1 x 103,
IQ] versus 166.3 x 103 [150.7&#150;212.6 x 103, IQ], p = 0.031 for macrophages).
Only alveolar tissue eosinophils, not proximal airway tissue eosinophils,
correlated with the nocturnal decrement in lung function (r = &#190;0.54, p =
0.03). These findings suggest that eosinophils and macrophages accumulate to a
greater extent in the alveolar tissue and these changes contribute more to the
variation in lung function compared with inflammation in the more proximal
tissue. <B>Kraft M, Djukanovic R, Wilson S, Holgate ST, Martin RJ. </B>AM J
RESPIR CRIT CARE MED 1996.</P>
<TABLE BORDER="1">
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#top">BACK TO MENU</A></B></SMALL></TD></TR></TABLE>
<P></P>
<HR>
<P><B><A NAME="ats42">Pulmonary Fibrogenesis after Three Consecutive
Inhalation Exposures to Chrysotile Asbestos 154:1511&#150;1519</A></B></P>
<P>Previously, this laboratory developed a model of asbestos-induced pulmonary
fibrogenesis in rats and mice after a brief (1 to 3-h) inhalation exposure.
However, typical human environmental exposures would be repeated, although at
lower concentrations than those used in our animal model. Here we have extended
this model to encompass repeated exposures and consequent long-term effects.
Groups of rats were exposed to chrysotile aerosol (10 mg/m3) for 3- to 5-h
periods over 3 consecutive days. Lung fiber burden and pathologic features were
studied for as long as 6 mo after exposure. We found that many of the longest (&#179;8
mm) fibers were retained in the lung for at least 6 mo, whereas shorter fibers
were cleared more rapidly. The three exposures to chrysotile caused a large
increase in DNA synthesis in the epithelium of terminal bronchioles and more
proximal airways. When compared with a single exposure, the triple exposure
caused an enhanced inflammatory response as well as a prolonged period of
increased DNA synthesis in the proximal alveolar region. Hyperplastic, fibrotic
lesions subsequently developed in the same region and persisted for at least 6
mo after exposure. These findings will be valuable in directing future studies
of the mechanisms of pulmonary fibrosis in this model. <B>Coin PG,
Osornio-Vargas AR, Roggli VL, Brody AR. </B>AM J RESPIR CRIT CARE MED 1996.</P>
<TABLE BORDER="1">
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#top">BACK TO MENU</A></B></SMALL></TD></TR></TABLE>
<P></P>
<HR>
<P><B><A NAME="ats43">Nicotine Enhances Expression of the Neutrophil Elastase
Gene and Protein in a Human Myeloblast/Promyelocyte Cell Line 154:1520&#150;1524</A></B></P>
<P>The pathogenesis of emphysema is considered to be an imbalance of protease
and antiprotease activity in the lower respiratory tract leading to uninhibited
degradation of lung interstitium by elastolytic enzymes. An increased amount of
the serine protease neutrophil elastase (NE) is though to play a major role in
this degradation. Because the expression of NE is limited to neutrophil
precursors in the bone marrow, we hypothesized that nicotine, which is readily
absorbed from lung and distributed to tissue, including bone marrow, would
increase expression of the NE gene and protein. HL-60 cells, a
myeloblast/promyelocyte cell line, were cultured in the presence or absence of
0.06 and 0.8 mM nicotine for 5 d. Both concentrations of nicotine caused a 2.4-
to 3.3-fold increase, respectively, in NE gene expression over unstimulated
cells, and NE protein increased 4.8- to 3.4-fold over unstimulated cells,
respectively, similar to our positive control DMSO. Nicotine did not induce
upregulation of the NE gene by initiating cell differentiation. Both low and
high nicotine concentrations upregulate the NE gene in HL-60 cells leading to
increased NE protein concentration per cell suggesting a pathophysiologic
mechanism for emphysema. <B>Armstrong LW, Rom WN, Martiniuk FT, Hart D,
Jagirdar J, Galdston M. </B>AM J RESPIR CRIT CARE MED 1996.</P>
<TABLE BORDER="1">
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#top">BACK TO MENU</A></B></SMALL></TD></TR></TABLE>
<P></P>
<HR>
<P><B><A NAME="ats44">Tissue Localization of Transforming Growth Factor-&szlig;1
in Pulmonary Eosinophilic Granuloma 154:1525&#150;1530</A></B></P>
<P>Pulmonary eosinophilic granuloma is characterized by infiltration of the
lungs with fibronodular lesions containing specialized Langerhans' cells. In
some patients, progressive pulmonary fibrosis leads to significant respiratory
impairment. Transforming growth factor-&szlig;1 (TGF-&szlig;1) promotes fibrosis
by enhancing the synthesis of extracellular matrix components. The role of TGF-&szlig;1
in promoting fibrosis in the setting of pulmonary eosinophilic granuloma is
currently unknown. We used immunohistochemistry to evaluate the extent and
distribution of TGF-&szlig;1 and the extracellular matrix components type I
collagen and decorin, a TGF-&szlig;1-binding proteoglycan. Lung biopsies from 11
patients with pulmonary eosinophilic granuloma were evaluated. In biopsies with
active inflammatory lesions containing Langerhans' cells, hyperplastic type 2
pneumocytes and alveolar macrophages within and surrounding the fibronodular
lesions contained abundant TGF-&szlig;1. Langerhans' cells were consistently
devoid of immunoreactive TGF-&szlig;1. Active inflammatory lesions also
exhibited staining for decorin, in a loosely organized distribution. Advanced
fibrotic lesions of eosinophilic granuloma, containing minimal inflammatory
cells and few or no Langerhans' cells, exhibited weak or absent staining for
TGF-&szlig;1 within either hyperplastic type 2 pneumocytes or alveolar
macrophages. The fibroconnective tissues of these advanced fibrotic lesions
consistently revealed dense staining for decorin. Through their actions on
extracellular matrix protein accumulation, TGF-&szlig;1 and the TGF-&szlig;1-binding
proteoglycan decorin may modulate fibrotic repair accompanying pulmonary
eosinophilic granuloma. <B>Asakura S, Colby TV, Limper AH.  </B>AM J RESPIR
CRIT CARE MED 1996.</P>
<TABLE BORDER="1">
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#top">BACK TO MENU</A></B></SMALL></TD></TR></TABLE>
<P></P>
<HR>
<P><B><A NAME="ats45">Bronchiolar Disease in Rheumatoid Arthritis 154:1531&#150;1536</A></B></P>
<P>The pulmonary manifestations of rheumatoid arthritis (RA) include
bronchiolar diseases such as follicular bronchiolitis (FB) and bronchiolitis
obliterans (BO). In this study, we investigated the clinical and pathologic
features of FB and BO, as well as the effect of erythromycin (EM) on these
diseases. The subjects included 15 RA patients with biopsy-proven bronchiolar
disease (eight with FB, seven with BO). None of the patients had Sj&ouml;gren's
syndrome. Eleven patients (73%) had chronic sinusitis, and 14 (93%) had a
chronic cough with sputum. Bacterial culture of sputum was positive in 50% and
71% of the FB and BO patients, respectively. High-resolution computed tomography
(HRCT) revealed small nodular shadows in the centrilobular regions (FB and BO),
patchy areas of low attenuation (BO), and peribronchial thickening (FB and BO).
Eleven patients who received EM therapy showed a significant improvement of
symptoms. In addition, none of the 15 patients died of the bronchiolar disease
during follow-up. In conclusion, RA patients with FB or BO basically have a
chronic clinical course with main complaint of productive cough, and EM may be
useful for the management of these diseases. <B>Hayakawa H, Sato A, Imokawa S,
Toyoshima M, Chida K, Iwata M. </B>AM J RESPIR CRIT CARE MED 1996.</P>
<TABLE BORDER="1">
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#top">BACK TO MENU</A></B></SMALL></TD></TR></TABLE>
<P></P>
<HR>
<P><B><A NAME="ats46">Use of a Magnified Cardiac Airflow Oscillation to
Classify Neonatal Apnea 154:1537&#150;1542</A></B></P>
<P>Currently the classification of neonatal apnea relies upon an inference of
airway closure based upon the presence of breathing efforts against such an
obstruction. In this study we evaluate a new method of classification which
utilizes the presence or absence of cardiac airflow oscillation to detect airway
closure. Specifically, this evaluation consisted of an examination of the
transmission characteristics of an artificially produced airflow oscillation
through discrete airway narrowing in a model system; a confirmation that
voluntary upper airway occlusion in adult volunteers uniformly induces complete
loss of the oscillation; and a comparison of the cardiac oscillation method with
the traditional method of apnea classification in a cohort of 4,309 apneas in 32
infants. We determined that the amplitude of the oscillation is negatively
correlated with resistance (r = 0.97) and positively with the radius (r = 0.98)
of narrowing in a model system, and that voluntary airway obstruction in adult
subjects uniformly results in loss of transmitted cardiac oscillations.
Moreover, although there was similarity in the frequency distribution of
central, obstructive, and mixed apneas in our infants, there were statistically
significantly greater obstructive events detected by the cardiac oscillation
method. In addition, the cardiac oscillation method had the additional advantage
of providing information regarding the timing of airway obstruction during
apnea. <B>Lemke RP, Al-Saedi SA, Alvaro RE, Wiseman NE, Cates DB, Kwiatkowski
K, Rigatto H. </B>AM J RESPIR CRIT CARE MED 1996.</P>
<TABLE BORDER="1">
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#top">BACK TO MENU</A></B></SMALL></TD></TR></TABLE>
<P></P>
<HR>
<P><B><A NAME="ats47">Chest X-ray Changes in Air Space Disease Are Associated
with Parameters of Mechanical Ventilation in ICU Patients 154:1543&#150;1550</A></B></P>
<P>To assess relationships between parameters of mechanical ventilation (MV)
and portable chest X-ray (CXR) measurements of lung length (LL) and severity of
air space disease, a prospective, randomized, blinded comparison of 102 adults
in a university hospital was performed. Each patient received two portable,
supine CXRs on different MV breaths within 5 min of one another. Ventilator
parameters were recorded. All 204 CXRs were randomly assorted and read
independently by three radiologists. Air space disease was considered more
severe with pressure support ventilation (PSV) breaths than with intermittent
mandatory ventilation (IMV) breaths (p = 0.0003), and its extent correlated
inversely with static compliance (p = 0.0001, r = &#190;0.40). Among patients
having CXRs on both IMV and PSV breaths, 15 of 67 (22%) had their overall degree
of air space disease read differently by one category (mild, moderate, or
severe). Increases in LL between the two CXRs were associated with increasing
peak (p = 0.0038) or mean (p = 0.0065) airway pressure, tidal volume (Vt) (p =
0.022), and Vt per kilogram (p = 0.006). We conclude that lung volume changes
during MV, typically not noted nor controlled for during portable chest
radiography, may substantially alter the interpretation of air space disease and
LL. Physicians monitoring intensive care unit (ICU) patients with daily CXRs
should be aware of the variables influencing interpretation of portable CXRs of
ICU patients. <B>Ely EW, Johnson MM, Chiles C, Rushing JT, Bowton DL, Freimanis
RI, Choplin RH, Haponik EF. </B>AM J RESPIR CRIT CARE MED 1996.</P>
<TABLE BORDER="1">
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#top">BACK TO MENU</A></B></SMALL></TD></TR></TABLE>
<P></P>
<HR>
<P><B><A NAME="ats48">Roles of Calcitonin Gene&#150;related Peptide (CGRP) in
Hyperpnea-induced Constriction in Guinea Pigs 154:1551&#150;1556</A></B></P>
<P>It has been reported that hyperpnea-induced bronchoconstriction in guinea
pigs is a potential model for exercise-induced asthma in humans. We hypothesized
that calcitonin gene&#150;related peptide (CGRP) could modulate leukotriene D4
(LTD4)-induced responses and be involved in the pathophysiology in this asthma
model. We measured tracheal (Ptr) and alveolar pressure (Pa) using alveolar
capsules in open-chested, mechanically ventilated (f = 1 Hz, Vt = 9 ml/kg, PEEP
= 4 cm H2O) guinea pigs. Animals were intravenously pretreated with saline
(SAL), CGRP(8&#150;37) (CGRP receptor antagonist), CGRP, MK-571 (LTD4 receptor
antagonist), MK-886 (5-lipoxygenase inhibitor), or CGRP(8&#150;37) = MK-571, and
then underwent dry gas hyperpnea challenge (HC, 95% O2&#150;5% CO2, 150
breaths/min, 7 min). We calculated resistance of lung (Rl), tissue (Rti), and
airway (Raw). HC increased Rl, Rti, and Raw in SAL controls (322 &#177; 27, 430 &#177;
59, 299 &#177; 23% baseline, respectively). MK-571, MK-886, and CGRP
significantly reduced the responses to HC, while CGRP(8&#150;37) enhanced
HC-induced responses. Pretreatment with CGRP(8&#150;37) and MK-571 in
combination attenuated HC-induced constriction. In addition, pretreatment with
CGRP reduced responses induced by intravenous administration of LTD4. These
observations suggest that CGRP might be involved in the pathophysiology of
hyperpnea-induced constriction in guinea pigs via modulation of LTD4-elicited
responses. <B>Nagase T, Ohga E, Katayama H, Sudo E, Aoki T, Matsuse T, Ouchi Y,
Fukuchi Y. </B>AM J RESPIR CRIT CARE MED 1996.</P>
<TABLE BORDER="1">
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#top">BACK TO MENU</A></B></SMALL></TD></TR></TABLE>
<P></P>
<HR>
<P><B><A NAME="ats49">Human Airway Narrowing Measured Using High Resolution
Computed Tomography 154:1557&#150;1562</A></B></P>
<P>Exaggerated airway narrowing in response to bronchoconstricting stimuli is a
characteristic feature of asthmatic subjects. It is unknown whether the site of
airway narrowing differs in asthmatic subjects from that observed in normal
subjects. Increased airway wall thickness has been suggested as a contributing
cause for airway hyperresponsiveness in asthma, based on histologic
measurements. We measured airway wall thickness and the site and magnitude of
airway narrowing in response to inhaled methacholine in normal subjects and in
patients with mild to moderate asthma using high resolution computed tomography
(HRCT). After a comparable decrease in FEV1, there were no differences in the
site or magnitude of airway narrowing for any category of airway size in
asthmatic subjects and normals. However, the results show that the smaller
airways of the asthmatic subjects are significantly thickened and that the
airway wall area does not change after bronchoconstriction whereas it decreases
in normal subjects. We conclude that airway wall thickening and the lack of a
change in airway wall dimensions following bronchoconstricting stimuli could
contribute to exaggerated airway narrowing in asthma. <B>Okazawa M, M&uuml;ller
N, McNamara AE, Child S, Verburgt L, Par&eacute; PD. </B>AM J RESPIR CRIT CARE
MED 1996.</P>
<TABLE BORDER="1">
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#top">BACK TO MENU</A></B></SMALL></TD></TR></TABLE>
<P></P>
<HR>
<P><B><A NAME="ats50">Effect of Hyperventilation on Airway Mucosal Blood Flow
in Normal Subjects 154:1563&#150;1566</A></B></P>
<P>The purpose of this study was to determine the effect of hyperventilation
(40 L/min) with room air (25&#183; C; 70% relative humidity) and frigid air (&#190;10&#183;
C; 0% relative humidity) on airway mucosal blood flow (Qaw) in normal subjects
(n = 7; 26 to 54 yr of age). Qaw was measured with the dimethyl ether uptake
technique, which reflects blood flow in the mucosa of large airways
corresponding to a 50-ml anatomic dead space segment extending distally from the
trachea. Mean (&#177; SE) baseline Qaw during quiet (room air) breathing was 6.6
&#177; 0.6 ml/min (range, 3.9 to 10.9). Qaw failed to change significantly
during and after eucapnic hyperventilation with room air (thermal stress, 224
cal/min). In contrast, eucapnic hyperventilation with frigid air (thermal
stress, 720 cal/min) increased Qaw in every subject, with the peak value
occurring either during or over a 30-min period after hyperventilation; by 60
min, Qaw had returned toward baseline. The mean maximal Qaw was 310 &#177; 49%
of baseline (p &lt; 0.05). Neither type of hyperventilation had an effect on
airway resistance. We conclude that in normal subjects, Qaw increases during
and/or after eucapnic hyperventilation with frigid air, and that this response
is related to the magnitude of the thermal stress rather than to the level of
ventilation. <B>Kim HH, LeMerre C, Demirozu CM, Chediak AD, Wanner A. </B>AM J
RESPIR CRIT CARE MED 1996.</P>
<TABLE BORDER="1">
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#top">BACK TO MENU</A></B></SMALL></TD></TR></TABLE>
<P></P>
<HR>
<P><B><A NAME="ats51">Improved Arterial Oxygenation After Oleic Acid Lung
Injury in the Pig Using a Computer-Controlled Mechanical Ventilator 154:1567&#150;1572</A></B></P>
<P>We compared computer-controlled mechanical ventilation programmed for
biologic variability of respiratory rate (RR) and tidal volume (Vt) with
conventional intermittent positive-pressure ventilation (IPPV) in an oleic acid
(OA) lung injury model. Seventeen pigs were ventilated with an Ohio 7000
anesthesia ventilator. Minute ventilation (Ve) was adjusted to maintain Paco2 at
30 to 35 mm Hg at baseline and was not altered further. OA was infused at 0.2
ml/kg/h until PaO2 decreased to &lt; 125 mm Hg (FI = 0.5). Animals were randomly
assigned to continue with conventional IPPV (control group; n = 8) or had IPPV
computer-controlled (computer group; n = 9). Hemodynamic, respiratory gas,
airway pressure, and volume data were obtained at baseline (before OA infusion),
at Time 30 (after infusion), and at 30-min intervals for 240 min after OA. At
experiment completion, the lungs were removed to determine the wet:dry weight
ratios. The control group had RR fixed at 20 breaths/min. The computer group had
a RR of 20 &#177; 2.3 breaths/min (range, 15 to 27 breaths/min), comprising 369
different RR values with reciprocal changes in Vt over 1,089 s before the
program looped to repeat itself. There was no difference between groups in the
volume of OA infused. By 120 min after lung injury, animals in the computer
group had significantly greater PaO2, associated with a lower Qs/Qt. Mean airway
pressures and mean peak airway pressures were not different in the two groups.
By 180 min, respiratory system compliance (Crs) was significantly lower in the
control group. The wet:dry lung weight ratios were greater in the control group.
Thus, in a porcine model of OA lung injury, computer-controlled mechanical
ventilation, which is programmed for biologic variability, resulted in improved
blood oxygenation without increasing mean airway pressures when compared with
conventional IPPV. <B>Lefevre GR, Kowalski SE, Girling LG, Thiessen DB, Mutch
WAC. </B>AM J RESPIR CRIT CARE MED 1996.</P>
<TABLE BORDER="1">
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#top">BACK TO MENU</A></B></SMALL></TD></TR></TABLE>
<P></P>
<HR SIZE="4" WIDTH="80%">
<CENTER><A HREF="about.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/about.gif" ALT="About Society"></A>
<A HREF="ssg.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/ss.gif" ALT="Society Structure"></A>
<A HREF="calendar.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/calendar.gif" ALT="ATS Calendar"></A>
<A HREF="gpi.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/pi.gif" ALT="Gen Public Info"></A>
<A HREF="ms.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/memserv.gif" ALT="Memb Serv"></A>
<BR>
<A HREF="pub.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/pubs.gif" ALT="Publications"></A>
<A HREF="press.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/press.gif" ALT="Press"></A>
<A HREF="index.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/home.gif" ALT="Home Page"></A>
<A HREF="search.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/search.gif" ALT="Search"></A>
<A HREF="assemb.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/assemb.gif" ALT="Assemblies"></A>
<A HREF="research.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/research.gif" ALT="Research"></A>
<BR>
<A HREF="mep.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/meded.gif" ALT="Med Education"></A>
<A HREF="wr.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/wr.gif" ALT="Wash Report"></A>
<A HREF="ic.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/ic.gif" ALT="Int'l Conference"></A>
<A HREF="source.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/link.gif" ALT="Web Links"></A>
<A HREF="store.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/store.gif" ALT="Store"></A> 
<A HREF="sig.html"><IMG SRC="images/special.gif" ALT="Special" HSPACE=1 VSPACE=1 BORDER=0 HEIGHT=35 WIDTH=84></A>
</CENTER>
<HR SIZE="4" WIDTH="80%">
<CENTER><FONT SIZE="+2"><B><I>American Thoracic Society</I></B></FONT><BR>
1740 Broadway<BR> New York, NY 10019<BR> VOICE:  212-315-8700<BR> Copyright &copy;
1996 American Lung Association.<BR> The American Thoracic  Society is the
medical section <BR>of the American Lung Association.<BR> 
</CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-171</DOCNO>
<DOCOLDNO>IA013-000141-B026-328</DOCOLDNO>
<DOCHDR>
http://www.thoracic.org:80/rarc0996.html 206.138.195.144 19970217073625 text/html 43533
HTTP/1.0 200 OK
Date: Monday, 17-Feb-97 07:31:39 GMT
Server: NCSA/1.3
MIME-version: 1.0
Content-type: text/html
Last-modified: Friday, 20-Dec-96 20:24:27 GMT
Content-length: 43352
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//SQ//DTD HTML 2.0 HoTMetaL + extensions//EN">
<HTML>
<HEAD>
<TITLE>American Thoracic Society -  AJRCMB ABSTRACTS: September 1996 Volume 15
Number 3</TITLE></HEAD>
<BODY BACKGROUND="images/back.jpg">
<CENTER><IMG ALIGN="LEFT" SRC="images/smlogo.gif"><BR>
<H1>AJRCMB ABSTRACTS</H1></CENTER>
<HR SIZE="5" NOSHADE="NOSHADE" WIDTH="100%">
<P></P>
<HR>
<CENTER>
<TABLE BORDER="2">
<TR>
<TD ALIGN="CENTER" VALIGN="MIDDLE"><SMALL><B><A HREF="redarch.html">BACK TO
ARCHIVES MAIN PAGE</A></B></SMALL></TD></TR></TABLE></CENTER>
<HR>
<CENTER>
<H2> September 1996: Volume 15, Number 3</H2>
<P><B><A NAME="top">AJRCCM ABSTRACT MENU</A></B></P></CENTER>
<CENTER>
<TABLE BORDER="1">
<TR ALIGN="CENTER" VALIGN="MIDDLE">
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#ats1">Expansion of
bronchial epithelial cell populations by <I>in vitro</I> culture of explants
from dysplastic and histologically normal sites. </A></B></SMALL></TD></TR>
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#ats2">Allergen-induced
increase in bone marrow progenitors in airway hyperresponsive dogs: regulation
by a serum hemopoietic factor. </A></B></SMALL></TD></TR>
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#ats3">Morphologic and
functional properties of bronchial cells isolated from normal and asthmatic
subjects.</A></B></SMALL></TD></TR>
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#ats4">Modulation of
ICAM-1 expression by extracellular glutathione in hyperoxia-exposed human
pulmonary artery endothelial cells.</A></B></SMALL></TD></TR>
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#ats5">Keratinocyte
growth factor and embryonic rat lung morphogenesis. </A></B></SMALL></TD></TR>
<TR>
<TD><SMALL><B><A HREF="#ats6">Extensive apoptosis of lung T-lymphocytes
maintained <I>in vitro</I>. </A></B></SMALL></TD></TR>
<TR>
<TD><SMALL><B><A HREF="#ats7">erbB-2 knockout employing an intracellular
single-chain antibody (sFv) accomplishes specific toxicity in erbB-2-expressing
lung cancer cells.</A></B></SMALL></TD></TR>
<TR>
<TD><SMALL><B><A HREF="#ats8">Specific inhibition of &szlig;-tryptase
expression in a human mast cell line by granulocyte-macrophage
colony-stimulating factor produced by airways structural cells.</A></B></SMALL></TD></TR>
<TR>
<TD><SMALL><B><A HREF="#ats9">Monkey Clara cell 10 kDa protein (CC10): a
characterization of the amino acid sequence with an evolutional comparison with
humans, rabbits, rats, and mice.</A></B></SMALL></TD></TR>
<TR>
<TD><SMALL><B><A HREF="#ats10">Cytokine expression in the presence or
absence of late airway responses after antigen challenge of sensitized rats.</A></B></SMALL></TD></TR>
<TR>
<TD><SMALL><B><A HREF="#ats11">Expression of dopamine D2-receptor mRNA
isoforms at the peripheral chemoreflex afferent pathway in developing rabbits.</A></B></SMALL></TD></TR>
<TR>
<TD><SMALL><B><A HREF="#ats12">Interleukin 13 inhibits macrophage
inflammatory protein-1a production from human alveolar macrophages and
monocytes.</A></B></SMALL></TD></TR>
<TR>
<TD><SMALL><B><A HREF="#ats13">Site-specific responses to
monocrotaline-induced vascular injury: evidence for two distinct mechanisms of
remodeling.</A></B></SMALL></TD></TR>
<TR>
<TD><SMALL><B><A HREF="#ats14">Isolation and characterization of nucleolin
gene as one of the vitamin A-responsive genes in airway epithelium by a
palindromic primer-based mRNA differential display method.</A></B></SMALL></TD></TR>
<TR>
<TD><SMALL><B><A HREF="#ats15">Transforming growth factor &szlig;1 (TGF&szlig;1)
gene expression by eosinophils in asthmatic airway inflammation.</A></B></SMALL></TD></TR>
<TR>
<TD><SMALL><B><A HREF="#ats16">Nitric oxide-induced inhibition of lung
endothelial cell nitric oxide synthase via interaction with allosteric thiols:
role of thioredoxin in regulation of catalytic activity.</A></B></SMALL></TD></TR>
<TR>
<TD><SMALL><B><A HREF="#ats17">T cells are the predominant source of
interleukin-5 but not interleukin-4 mRNA expression in the lungs of
antigen-challenged allergic mice.</A></B></SMALL></TD></TR></TABLE></CENTER>
<P></P>
<HR>
<P><B><A NAME="ats1">Expansion of bronchial epithelial cell populations by
<I>in vitro</I> culture of explants from dysplastic and histologically normal
sites. </A></B></P>
<P>The genetic and phenotypic properties of cells which ultimately give rise to
carcinoma of the lung are not well defined in part because of unavailability of
preneoplastic cells from well-characterized dysplastic sites. In order to expand
bronchial epithelial cell populations from patients at high risk for lung
cancer, endobronchial biopsy specimens were explanted onto collagen- and
fibronectin-coated dishes and cultured in serum-free, chemically defined media.
One hundred forty-nine biopsy pairs were obtained from smokers and from healthy
volunteers for culture and histologic evaluation. The histologic appearances of
mucosa adjacent to the site of the cultured biopsies ranged from normal through
varying degrees of noninvasive squamous dysplasia to invasive carcinoma.
Confluent monolayers of pure epithelial cells were obtained from 68% of the
cultured explants. Sites exhibiting high-grade dysplasia were 51% more likely to
yield successful cultures than sites exhibiting normal histology (13 of 14
cultures successful versus 52 of 83 cultures successful, <I>P</I> &lt; 0.02).
Cultures had a maximum proliferative life span of 81 days and none of the
cultures spontaneously became immortalized. Immunolabeling studies revealed that
all cultured epithelial cells, regardless of the <I>in situ</I> histologic
appearances of the mucosa at the biopsy site, strongly expressed keratin and
epidermal growth factor receptor, weakly expressed transferrin receptor and
human folate receptor, and were negative for neural cell adhesion molecule and
human leukocyte antigen DR (HLADR). Ploidy and karyotypic analyses were
performed in a limited number of explants from normal and dysplastic sites and
all were found to be diploid without karyotypic abnormality. We conclude that
pure bronchial epithelial cell populations can be routinely expanded from
histologically normal and dysplastic sites by tissue culture of biopsy explants
and that the expanded cell populations may represent a library of normal and
preneoplastic cells which are suitable for immunophenotypic, ploidy, genetic, or
functional analyses. <B>Franklin, W. A., J. M. Folkvord, M. Varella-Garcia, T.
Kennedy, S. Proudfoot, R. Cook, E. C. Dempsey, K. Helm, P. A. Bunn, and Y. E.
Miller. 1996. Am. J. Respir. Cell Mol. Biol. 15:297-304.</B></P>
<TABLE BORDER="1">
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#top">BACK TO MENU</A></B></SMALL></TD></TR></TABLE>
<P></P>
<HR>
<P><B><A NAME="ats2">Allergen-induced increase in bone marrow progenitors in
airway hyperresponsive dogs: regulation by a serum hemopoietic factor. </A></B></P>
<P>We have previously reported that bone marrow progenitors in dogs,
specifically granulocyte-macrophage colony-forming units (GM-CFU), increase
developing airway hyperresponsiveness after inhalation of the allergen <I>Ascaris
suum</I>. In the present study, we evaluated whether this increased marrow
hemopoietic activity can be stimulated by a factor in serum after allergen
challenge. Serum samples taken from dogs prior to and 20 min, 2 h, and 24 h
after <I>Ascaris</I> or diluent challenge were added to bone marrow cells
aspirated prior to challenge, and GM-CFU measured. A second bone marrow aspirate
was performed 24 h after challenge. Nonadherent mononuclear bone marrow cells
were incubated for 8 days in the presence of the serum and recombinant canine
hemopoietic cytokines (stem cell factor, granulocyte colony-stimulating factor,
GM colony-stimulating factor). Eight dogs that developed (airway responders) and
eight dogs that did not develop (airway nonresponders) allergen-induced airway
hyperresponsiveness were studied. Allergen inhalation increased bone marrow
GM-CFU in response to all three growth media <I>in vitro</I> for the airway
responder (<I>P</I> &lt; 0.05) but not airway nonresponder dogs. The 24-h
serum, taken from the airway responder but not the airway nonresponder dogs,
produced a similar increase in granulocyte progenitors when added to the bone
marrow taken before allergen inhalation (<I>P</I> &lt; 0.05). These findings
demonstrate that bone marrow-derived granulocyte progenitors are upregulated by
a factor that can be shown to be present in serum 24 h after allergen challenge
in dogs that develop allergen-induced airway hyperresponsiveness. Whether <I>in
vivo</I> stimulation of bone marrow inflammatory cell production is necessary
for the development of allergen-induced airway hyperresponsiveness remains to be
proven. <B>Inman, M. D., J. A. Denburg, R. Ellis, M. Dahlbck, and P. M.
O'Byrne. 1996. Am. J. Respir. Cell Mol. Biol. 15:305-11.</B></P>
<TABLE BORDER="1">
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#top">BACK TO MENU</A></B></SMALL></TD></TR></TABLE>
<P></P>
<HR>
<P><B><A NAME="ats3">Morphologic and functional properties of bronchial cells
isolated from normal and asthmatic subjects.</A></B></P>
<P>Recent advances in biomedical sciences have led to the development of
various methods for the evaluation of the physiopathology of respiratory
diseases. This study reports morphologic and functional features of cells
isolated by a new method from bronchial biopsies of normal and asthmatic
subjects. Both epithelial and fibroblastic cells were isolated from the same
biopsies using collagenase. The cells were cultured for several passages and
stored frozen. Two selective culture media were used in order to obtain pure
epithelial and fibroblastic cell populations. Immunofluorescence analysis of
intermediate filaments, keratins, and vimentin confirmed the type of the
isolated cells. The proportions of a-actin-expressing cells varied among the
fibroblastic cell populations isolated from normal and asthmatic subjects.
Interestingly, the population containing high numbers of a-actin-expressing
cells and presenting the fastest collagen contraction kinetic was isolated from
bronchial biopsies of an asthmatic subject. Moreover, the fibroblastic cells
that showed the best contractile properties 24 h after their seeding in floating
collagen gels were isolated from bronchial biopsies of asthmatic patients having
PC20 values below 1 mg/ml. On the basis of these data, we propose a new approach
to isolate, culture and characterize human bronchial cells <I>in vitro</I>.
<B>Goulet, F., L.-P. Boulet, J. Chakir, N. Tremblay, J. Dub&eacute;, M.
Laviolette, M. Boutet, W. Xu, L. Germain, and F. A. Auger. 1996. Am. J. Respir.
Cell Mol. Biol. 15:312-18.</B></P>
<TABLE BORDER="1">
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#top">BACK TO MENU</A></B></SMALL></TD></TR></TABLE>
<P></P>
<HR>
<P><B><A NAME="ats4">Modulation of ICAM-1 expression by extracellular
glutathione in hyperoxia-exposed human pulmonary artery endothelial cells.</A></B></P>
<P>To investigate the mechanisms regulating hyperoxia-induced intercellular
adhesion molecule-1 (ICAM-1) expression, we studied the effects of antioxidants
on ICAM-1 expression, and the relationship between ICAM-1 expression and
extracellular glutathione levels in human pulmonary artery endothelial cells
(HPAEC) and human umbilical vein endothelial cells (HUVEC). Cells were cultured
to confluence and exposed to hyperoxia (90% O2) for 48 h with or without various
antioxidants, including superoxide dismutase (SOD), catalase, <I>N</I>-acetylcysteine
(NAC), and glutathione. The levels of ICAM-1 expression in the endothelial cells
and the concentrations of reduced (GSH) and oxidized glutathione (GSSG) in the
media were examined by flow cytometry and spectrophotometry, respectively. After
exposure to hyperoxia, ICAM-1 expression was increased, and the supernatant
total glutathione was decreased as compared with those at normoxia. SOD did not
change ICAM-1 expression. The hyperoxia-induced increase in ICAM-1 expression
was even greater with the addition of catalase. The ICAM-1 expression was
decreased and the GSH concentration was increased with the addition of NAC.
There were negative relationships between the level of ICAM-1 expression and the
supernatant total glutathione concentration in catalase-treated HPAEC (R =
0.822, <I>P</I> &lt; 0.0005) and HUVEC (R = 0.567, <I>P</I> &lt; 0.01).
Negative relationships were also demonstrated between the level of ICAM-1
expression and the total extracellular glutathione concentrations in NAC-treated
HPAEC (R = 0.877, <I>P</I> &lt; 0.0005) and HUVEC (R = 0.727, <I>P</I> &lt;
0.0005). Exogenous GSH decreased ICAM-1 expression in both hyperoxia-exposed
HPAEC and HUVEC, while exogenous GSSG did not. These results suggest that
extracellular GSH plays a role in regulating hyperoxia-induced ICAM-1 expression
in HPAEC and HUVEC. <B>Aoki, T., Y. Suzuki, K. Suzuki, A. Miyata, Y. Oyamada,
T. Takasugi, M. Mori, H. Fujita, and K. Yamaguchi. 1996.  Am. J. Respir. Cell
Mol. Biol. 15:319-27.</B></P>
<TABLE BORDER="1">
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#top">BACK TO MENU</A></B></SMALL></TD></TR></TABLE>
<P></P>
<HR>
<P><B><A NAME="ats5">Bacteremia and Severe Sepsis in Adults: A Multicenter
Prospective Survey in ICUs and Wards of 24 Hospitals 154:617-624</A></B></P>
<P>We examined possible roles of keratinocyte growth factor (KGF) and
hepatocyte growth factor (HGF) in lung morphogenesis. By polymerase chain
reaction, transcripts for both KGF and its receptor were detected early (rat
gestational days 16 and 14, respectively) and their abundance increased during
lung morphogenesis. To evaluate possible role of KGF in lung morphogenesis, day
14 lung explants were cul tured in Dulbecco's modified Eagle medium + 10% fetal
calf serum for 1 to 4 days in the presence (5-50 ng/ml) or absence of KGF
(control). KGF (at 25 and 50 ng/ml) induced a marked reduction in the number of
terminal branches and distension of the distal epithelium into cyst-like
structures. These effects of exogenous KGF were progressively diminished by
increasing concentrations of anti-KGF (2-16 mg/ml). Electron microscopic
examination revealed that the epithelial cells of the cystic structures
contained lamellar bodies, and were therefore type II cells and/or their
progenitors. Northern blot analysis showed higher expression of surfactant
protein C (SP-C) mRNA (a marker for alveolar epithelial type II cells) in
KGF-treated fetal lungs. <I>In situ</I> hybridization of the KGF-treated lungs
revealed that the SP-C mRNA-expressing cells were arranged distally in the form
of linear arrays, a pattern distinctly different from that in control lungs.
Acidic fibroblast growth factor, which also binds KGF receptors, in the presence
of heparin mimicked the effect of KGF on branching. Transforming growth factor-&szlig;1
(TGF-&szlig;1) inhibited branching of fetal lungs in culture, and this effect
dominated over that induced by KGF. Blocking of endogenous HGF with antibodies
or addition of HGF to cultures of fetal lung explants had no significant effect
on branching or growth. In conclusion, KGF markedly influences branching, and
epithelial growth, differentiation, and patterning during lung morphogenesis.
<B>Shiratori, M., E. Oshika, L. P. Ung, G. Singh, H. Shinozuka, D. Warburton,
G. Michalopoulos, and S. L. Katyal. 1996. Am. J. Respir. Cell Mol. Biol.
15:328-38.</B></P>
<TABLE BORDER="1">
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#top">BACK TO MENU</A></B></SMALL></TD></TR></TABLE>
<P></P>
<HR>
<P><B><A NAME="ats6">Extensive apoptosis of lung T-lymphocytes maintained
<I>in vitro</I>. </A></B></P>
<P>The phenotypic and functional properties of T cells recovered from the lung
indicate that many of these cells have been recently activated. Because such
recently activated cells are often more susceptible to death through apoptotic
mechanisms, the viability of lung T cells recovered from bronchoalveolar lavage
and those isolated from peripheral blood was compared. The progressive loss of
viable cells following <I>in vitro</I> culture was considerably greater for
lavage T cells than blood T cells, and was observed for cells from both patients
with sarcoidosis and control subjects. Following 4 days of culture, 76 &#177;
14% of blood cells, but only 31 &#177; 13% of lavage cells from sarcoid patients
were viable. The evaluation of morphologic fea tures and flow cytometric
profiles, as well as the demonstration of typical oligonucleosomal fragmentation
of DNA extracted from these cells indicated that lavage T cells were dying by
apoptotic mechanisms. CD4+ T cells appeared to be particularly sensitive to
apoptosis. Most lavage T cells from controls and sarcoid patients expressed Fas
(CD95) antigen. Although some lavage T cells were sensitive to Fas-induced
apoptosis, the viability of lavage T cells was not improved by incubation in the
presence of a monoclonal antibody that inhibits Fas-induced apoptosis. Culture
in the presence of interleukin 2 did prevent, at least in part, the progressive
death of lavage T cells, suggesting that the viability of T cells in the lung
may depend on the presence of locally delivered trophic signals. These studies
emphasize that T cells on the alveolar surface are in a different state of
activation and differentiation compared with that of circulating T cells, and
offer a possible explanation for the impaired functional capacities observed for
lavage T cells in some <I>in vitro</I> studies. <B>Herry, I., M. Bonay, F.
Bouchonnet, M.-P. Schuller, D. Lecossier, A. Tazi, D. H. Lynch, and A. J. Hance.
1996. Am. J. Respir. Cell Mol. Biol. 15:339-47.</B></P>
<TABLE BORDER="1">
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#top">BACK TO MENU</A></B></SMALL></TD></TR></TABLE>
<P></P>
<HR>
<P><B><A NAME="ats7">erbB-2 knockout employing an intracellular single-chain
antibody (sFv) accomplishes specific toxicity in erbB-2-expressing lung cancer
cells.</A></B></P>
<P>erbB-2 is known to be overexpressed in several human malignancies including
lung cancer. Because of its role in neoplastic transformation as well as its
association with poor prognosis, this oncogene has been targeted through various
anti-cancer methodologies. In this regard, we have recently demonstrated that
erbB-2-overexpressing ovarian tumor cell lines transfected with an endoplasmic
reticulum form of an anti-erbB-2 single-chain antibody undergo a specific
cytotoxicity through the induction of apoptosis. Since certain forms of lung
cancer are also associated with overexpression of erbB-2, we evaluated the use
of this novel therapeutic in this context. For these studies, several human lung
adenocarcinoma cell lines were stably and transiently transfected with the
anti-erbB-2 sFv gene. We demonstrate here that the anti-erbB-2 sFv can cause
specific cytotoxicity in lung cancer cells. As a first step toward clinical
translation of this strategy, we constructed a replication-deficient recombinant
adenoviral vector expressing the anti-erbB-2 sFv construct. We further
demonstrate that our anti-erbB-2 sFv-encoding adenoviral vector can accomplish
high levels of cytotoxicity in lung cancer cells. Based on these results, it is
proposed that this strategy of oncoprotein ablation may have use in the
treatment of some forms of human lung cancer. <B>Grim, J., J. Deshane, M. Feng,
A. Lieber, M. Kay, and D. T. Curiel. 1996.  Am. J. Respir. Cell Mol. Biol.
15:348-54.</B></P>
<TABLE BORDER="1">
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#top">BACK TO MENU</A></B></SMALL></TD></TR></TABLE>
<P></P>
<HR>
<P><B><A NAME="ats8">Specific inhibition of &szlig;-tryptase expression in a
human mast cell line by granulocyte-macrophage colony-stimulating factor
produced by airways structural cells.</A></B></P>
<P>The growth and differentiation of mast cells are regulated by cytokines
produced in tissue microenvironments. We previously reported that mast cells
isolated from the epithelial compartment of nasal polyp tissue contain
significantly less tryptase when compared with mast cells isolated from the
stroma of the same tissue. In an attempt to explore this finding, we analyzed
the ability of supernatants obtained from cultured nasal polyp epithelial cells
(NP-EpCM) or nasal polyp fibroblasts (NP-FbCM) to regulate the tryptase content
of the immature human mast cell line HMC-1. HMC-1 cells were cultured for 7 days
in Iscove's modified Dulbecco's medium (IMDM) with 30% of either NP-FbCM or
NP-EpCM or 20% MoCM (supernatant of a leukemic T cell line). As assessed by
radioimmunoassay and test for enzymatic activity, all three conditioned media
were shown to significantly decrease tryptase protein expression in HMC-1, when
compared with cultures performed with IMDM alone (NP-EpCM <I>P</I> &lt; 0.001;
NP-FbCM <I>P</I> &lt; 0.04; MoCM <I>P</I> &lt; 0.004). In addition, Northern
blot analysis demonstrated lower tryptase mRNA levels upon exposure to all three
conditioned media tested, suggesting that tryptase downregulation occurs at the
transcriptional level. In further studies we found that preincubation of MoCM
with anti-granulocyte-macrophage colony-stimulating factor (GM-CSF) completely
blocked the observed downregulation of tryptase expression mediated by this
conditioned medium. The findings suggest that GM-CSF has a suppressive effect on
expression of protease in mast cells, and may thus play a modulatory role in
determining the extent of tissue inflammation in allergic airways disease. <B>Finotto,
S., J. S. Marshall, J. H. Butterfield, and J. A. Denburg. 1996.  Am. J. Respir.
Cell Mol. Biol. 15:355-60.</B></P>
<TABLE BORDER="1">
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#top">BACK TO MENU</A></B></SMALL></TD></TR></TABLE>
<P></P>
<HR>
<P><B><A NAME="ats9">Monkey Clara cell 10 kDa protein (CC10): a
characterization of the amino acid sequence with an evolutional comparison with
humans, rabbits, rats, and mice.</A></B></P>
<P>Monkey Clara cell 10 kDa protein (CC10) was purified from monkey lung
lavage. This protein showed an apparent molecular weight of about 10 kDa and 5
kDa under non-reducing and reducing conditions, respectively, as determined by
sodium dodecyl sulfate-polyacrylamide gel electrophoresis. From the amino acid
sequence data, monkey CC10 protein consisted of two identical 70-amino-acid
polypeptide chains joined by two cystine residues, and possessed sequence
identities of 78.6%, 52.9%, 52.9%, and 44.3% with human CC10, rat CC10 (PCB
binding protein), rabbit uteroglobin, and mouse CC10, respectively. When monkey
CC10 was compared with rabbit uteroglobin (progesterone binding protein), two
polar residues of Tyr-21 and Thr-60, important for progesterone binding
specificity, were substituted for Phe-21 and Met-60, and thus monkey CC10 may
not have a binding capacity with progesterone. Monkey CC10 also possessed a
surface homology with lipocortin I (anti-inflammatory peptide), thus suggesting
that monkey CC10 plays a role in the anti-inflammatory process at the air-liquid
interface over the bronchio-bronchiolar epithelium. <B>Hashimoto, S., K.
Nakagawa, and K. Sueishi. 1996. Am. J. Respir. Cell Mol. Biol. 15:361-66.</B></P>
<TABLE BORDER="1">
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#top">BACK TO MENU</A></B></SMALL></TD></TR></TABLE>
<P></P>
<HR>
<P><B><A NAME="ats10">Cytokine expression in the presence or absence of late
airway responses after antigen challenge of sensitized rats.</A></B></P>
<P>To assess whether Th-2 cytokines are involved in the late airway response
(LR) after antigen challenge, we evaluated cytokine mRNA expression in the lungs
of two strains of rats before and 8 h after saline or antigen challenge: Brown
Norway (BN) rats, high IgE producers that develop LR after antigen challenge and
Sprague-Dawley (SD) rats, low IgE producers that develop little LR and no
increased airway responsiveness after antigen challenge. Rats were sensitized
with ovalbumin (OA) and 14 days later, lungs were obtained before or after OA
challenge and measurement of lung physiology for 8 h. Lung tissue was either
fixed for <I>in situ</I> hybridization or frozen for evaluation of mRNA
expression by reverse transcription-polymerase chain reaction (RT-PCR). We
examined mRNA expression for interleukin-4 (IL-4), and IL-5 (Th-2 cytokines) and
IL-2 and interferon gamma (IFN-gamma, Th-1 cytokines). <I>In situ</I>
hybridization showed that cells expressing IL-4 and -5 mRNA were increased in
the airways of the lungs of BN rats after OA challenge (<I>P</I> &lt; 0.05) and
that cells expressing mRNA for IFN-gamma and IL-2 were higher in SD than in BN
rats after antigen challenge (<I>P</I> &lt; 0.05). Results from PCR showed that
prior to antigen challenge, BN rats expressed in their lungs mRNA for IL-4 and
-5 and SD rats expressed very little mRNA for IL-5 only. After antigen challenge
most BN and SD rats expressed mRNA for IL-4 and -5 but expression of mRNA for
IL-2 and IFN-gamma was only found in SD rats. In conclusion, rats that develop a
LR after antigen challenge preferentially increase Th-2 cytokine expression in
their lungs whereas those without LRs preferentially express Th-1 cytokines. Our
results support the role of Th-2 cytokines in the LR and asthma. <B>Renzi, P.
M., A. S. Al Assaad, J. Yang, Z. Yasruel, and Q. Hamid. 1996. Am. J. Respir.
Cell Mol. Biol. 15:367-73.</B></P>
<TABLE BORDER="1">
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#top">BACK TO MENU</A></B></SMALL></TD></TR></TABLE>
<P></P>
<HR>
<P><B><A NAME="ats11">Expression of dopamine D2-receptor mRNA isoforms at the
peripheral chemoreflex afferent pathway in developing rabbits.</A></B></P>
<P>The two isoforms of dopamine D2 receptor, D2 short (D2S) and D2 long, are
generated by alternative splicing of premessenger RNA and differ in the length
of their third cytoplasmic loop. Expression of these two isoforms has not yet
been studied at the level of the peripheral arterial chemoreflex pathway. Using
reverse transcriptase-polymerase chain reaction, we evaluated the relative
abundance of dopamine D2 receptor mRNA by amplifying a common segment between
both D2 receptor mRNA isoforms which reflects the total D2-receptor mRNA and the
two isoforms in the carotid bodies, the petrosal ganglia, and the superior
cervical ganglia of 1-, 10-, and 25-day-old and adult rabbits. GH4C1 cell line,
which does not express D2 receptors, was used as negative control, whereas GH4C1
19 cell line, which expresses only the D2S mRNA and the striatum of each age,
were used as positive controls. Both D2-receptor mRNA isoforms were found to be
expressed in all organs studied of newborn and adult rabbits. The expression of
total D2 receptor mRNA in 10- and 25-day-old and adult rabbits was found to be
3-, 5-, and 1.5-fold more, respectively, compared with 1-day-old rabbits for all
organs studied. Our data suggest that the expression of D2-receptor mRNA is
modulated with age at the level of the peripheral arterial chemoreflex pathway.
<B>Bairam, A., C. Dauphin, F. Rousseau, and E. W. Khandjian. 1996. Am. J.
Respir. Cell Mol. Biol. 15:374-81.</B></P>
<TABLE BORDER="1">
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#top">BACK TO MENU</A></B></SMALL></TD></TR></TABLE>
<P></P>
<HR>
<P><B><A NAME="ats12">Interleukin 13 inhibits macrophage inflammatory
protein-1a production from human alveolar macrophages and monocytes.</A></B></P>
<P>Interleukin 13 (IL-13) is a recently described protein secreted by activated
T cells and is a potent <I>in vitro</I> modulator of human monocyte and B-cell
functions. IL-13 shares some biologic properties as well as structural
similarities with IL-4. Macrophage-inflammatory protein 1a (MIP-1a) is a product
of activated monocytes and macrophages and an important activator of T cells,
monocytes, and macrophages. We determined the effect of human recombinant IL-13
on lipopolysaccharide (LPS)- and IL-1&szlig;-induced MIP-1a mRNA and protein
expression from peripheral blood monocytes (PBM) and alveolar macrophages (AM).
In PBM, basal MIP-1a protein was 20 &#177; 7 pM and increased following LPS and
IL-1&szlig; to 1,520 &#177; 193 (<I>P</I> &lt; 0.001) and 233 &#177; 50 (<I>P</I>
&lt; 0.003) pM. IL-13 (25 ng/ml) reduced these values by 55 &#177; 10% [not
significant (NS)], 43 &#177; 9% (<I>P</I> &lt; 0.03), and 44 &#177; 15% (NS),
respectively. LPS- and IL-1&szlig;-induced MIP-1a mRNA expression was reduced by
43 &#177; 5% (<I>P</I> &lt; 0.01) and 41 &#177; 4% (NS). In AM, IL-13 reduced
LPS-induced MIP-1a protein release of 2,030 &#177; 242 pM by 32 &#177; 8% (<I>P</I>
&lt; 0.05) and MIP-1a mRNA by 27 &#177; 1% (NS). For both PBM and AM, the
inhibitory effect of IL-13 on MIP-1a protein was maximal at 24 h, was dose
dependent with a maximal effect at 100 ng/ml, and was similar to, although
slightly less potent than, that seen with IL-4. In PBM, the inhibitory effect of
IL-13 required <I>de novo</I> protein synthesis and was not due to enhanced
mRNA decay. Thus, IL-13 has inhibitory effects on the transcription of MIP-1a
from monocytes and macrophages, and as is the case with IL-4 and IL-10, may be
an important mediator for suppressing inflammatory responses. <B>Berkman, N.,
M. John, G. Roesems, P. Jose, P. J. Barnes, and K. F. Chung. 1996. Am. J.
Respir. Cell Mol. Biol. 15:382-89.</B></P>
<TABLE BORDER="1">
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#top">BACK TO MENU</A></B></SMALL></TD></TR></TABLE>
<P></P>
<HR>
<P><B><A NAME="ats13">Site-specific responses to monocrotaline-induced
vascular injury: evidence for two distinct mechanisms of remodeling.</A></B></P>
<P>Monocrotaline (MCT)-induced pulmonary vascular injury was used to begin
studying the mechanism(s) of vascular remodeling in Fischer 344 rats, using
extracellular matrix (ECM) gene expression to define areas of remodeling. By day
28 after injection, pulmonary artery pressures were increased and right
ventricular hypertrophy had developed compared with normal controls.
Tropoelastin, fibronectin, and a1(I) procollagen mRNA levels increased at least
2-fold by day 28. <I>In situ</I> hybridization demonstrated tropoelastin gene
expression by cells adjacent to the lumen and procollagen gene expression at the
medial-adventitial border in both small muscular and large elastic pulmonary
arteries. This pattern of gene expression was observed as early as 1 wk after
MCT injury. These observations indicated two distinct areas of remodeling, one
along the vascular lumen at the site of monocrotaline-induced injury and the
other at a second distinct site.<BR>To determine whether other differences may
be involved at these two sites, the presence of transforming growth factor-&szlig;
(TGF-&szlig;) was studied. Total TGF-&szlig; protein was 4-fold higher in
remodeling lungs compared with normal lungs. Gene expression for all three
isoforms of TGF-&szlig; colocalized with tropoelastin gene expression along the
vascular lumen but not with a1(I) procollagen gene expression. These results
suggest a complex site-specific response to injury mediated by two distinct
pathways in this model of pulmonary vascular remodeling. <B>Tanaka, Y., M. L.
Bernstein, R. P. Mecham, G. A. Patterson, J. D. Cooper, and M. D. Botney. 1996. 
Am. J. Respir. Cell Mol. Biol. 15:390-97.</B></P>
<TABLE BORDER="1">
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#top">BACK TO MENU</A></B></SMALL></TD></TR></TABLE>
<P></P>
<HR>
<P><B><A NAME="ats14">Isolation and characterization of nucleolin gene as one
of the vitamin A-responsive genes in airway epithelium by a palindromic
primer-based mRNA differential display method.</A></B></P>
<P>A palindromic primer-based mRNA differential display method has been used to
isolate various vitamin A-responsive genes from primary cultures of monkey
tracheobronchial epithelial cells. This method, as compared with the original
mRNA differential display (mDD) method described by Liang and Pardee, used only
one arbitrarily designed primer instead of two in the polymerase chain reaction.
The single-primer mDD method has several advantages over the two-primer mDD
system, especially in the reamplification and the selection of 5'-end cDNA
clone. To verify the usefulness of this approach, one of these differential
display bands, M34, was initially chosen for further amplification and cloning.
The clone derived from the M34 band has a DNA sequence with &gt;90% homology to
the human nucleolin gene. Furthermore, DNA sequencing confirms that both 5' and
3' ends of the insert of M34 contain the invertly repetitive nucleotide sequence
that was used to direct this cloning. Nucleolin is a multifunctional
phosphoprotein that plays an important role in ribosome biogenesis and mRNA
stability. Northern blot analysis demonstrated that in addition to the elevation
by vitamin A, the level of nucleolin message is significantly higher in fetal
than in adult tracheobronchial epithelial cultures. Furthermore, <I>in situ</I>
hybridization demonstrated that the amount of nucleolin message is significantly
higher in both basal and ciliated cell types than in mucous and intermediary
cell types. These results support the feasibility that the single-primer mDD
technique can be used to isolate vitamin A-responsive genes with a palindromic
nature. <B>Sekhar Reddy, P. M., G. An, Y.-P. Di, Y. H. Zhao, and R. Wu. 1996.
Am. J. Respir. Cell Mol. Biol. 15:398-403.</B></P>
<TABLE BORDER="1">
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#top">BACK TO MENU</A></B></SMALL></TD></TR></TABLE>
<P></P>
<HR>
<P><B><A NAME="ats15">Transforming growth factor &szlig;1 (TGF&szlig;1) gene
expression by eosinophils in asthmatic airway inflammation.</A></B></P>
<P>The increase in thickness of bronchial walls by such structural changes as
subepithelial fibrosis contributes to the severity and chronicity of asthma by
amplifying airway narrowing. However, the pathogenesis of this structural
alteration is not known. Transforming growth factor &szlig;1 (TGF&szlig;1) is
known to have biologic activities relevant to the cellular and molecular events
in subepithelial fibrosis, such as the deposition of collagen I and III and the
increase of myofibroblasts beneath the epithelial basement membrane. Therefore,
we examined TGF&szlig;1 gene expression in bronchial biopsy tissues from five
severe asthmatics, five mild asthmatics, and five normal subjects using <I>in
situ</I> hybridization combined with histochemical staining. Cells expressing
TGF&szlig;1 mRNA were detected in tissues from four normal subjects, one mild
asthmatic, and five severe asthmatics. The density of positive cells in severe
asthmatic tissues (52.1 &#177; 22.7, mean &#177; SD/mm2) was significantly
greater than that in mild asthmatic tissues (1.0 &#177; 1.9/mm2, <I>P</I> &lt;
0.01) or normal tissues (10.5 &#177; 10.6/mm2, <I>P</I> &lt; 0.02). The density
in mild asthmatic tissues was not significantly different from that in normal
tissues. The vast majority of positive cells in severe (99.1 &#177; 1.7%) and
mild (100%) asthmatic tissues were identified as eosinophils. In contrast,
eosinophils constituted a small portion of positive cells (20.8 &#177; 21.6%) in
normal tissues. These results indicated that TGF&szlig;1 mRNA was overexpressed
in severe asthmatics and that the main source of the mRNA was eosinophils,
suggesting that eosinophils play an important role in the pathogenesis not only
of inflammation but also of structural changes, such as subepithelial fibrosis,
in asthmatic airways. <B>Ohno, I., Y. Nitta, K. Yamauchi, H. Hoshi, M. Honma,
K. Woolley, P. O'Byrne, G. Tamura, M. Jordana, and K. Shirato. 1996. Am. J.
Respir. Cell Mol. Biol. 15:404-9.</B></P>
<TABLE BORDER="1">
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#top">BACK TO MENU</A></B></SMALL></TD></TR></TABLE>
<P></P>
<HR>
<P><B><A NAME="ats16">Nitric oxide-induced inhibition of lung endothelial
cell nitric oxide synthase via interaction with allosteric thiols: role of
thioredoxin in regulation of catalytic activity.</A></B></P>
<P>Nitric oxide (NO) synthase is a hemoprotein containing several cysteinyl
residues including thiolate as its proximal heme ligand. Exposure to NO is known
to induce S-nitrosylation of protein thiols and modulation of enzyme activities,
including the catalytic activity of NO synthase. Because S-nitrosylation of
vicinal thiols promotes disulfide formation, we determined whether exposure to
NO results in modulation of the catalytic activity of NO synthase and whether
disulfide reduction catalyzed by thioredoxin/thioredoxin reductase (T/TR) and/or
by glutaredoxin restores the catalytic activity of NO synthase in pulmonary
artery endothelial cells (PAEC). Exposure of intact PAEC, isolated total
membranes, plasma membranes, or purified NO synthase to NO significantly reduced
NO synthase catalytic activity. Similarly, exposure of isolated total membranes
or purified NO synthase to potassium ferricyanide (FeCN) also reduced catalytic
activity of NO synthase in a concentration-dependent fashion. Although the
catalytic activity of NO synthase was significantly reduced following exposure
of intact cells to NO, the expression of NO synthase mRNA was unchanged. NO
synthase activity in intact cells or isolated membranes exposed to nitrate,
nitrite, or 10 ppm nitrogen dioxide gas was comparable to controls. Incubation
in the presence of oxyhemoglobin prevented but did not reverse NO-induced
inhibition of NO synthase. Incubation in the presence of T/TR but not
glutaredoxin reversed NO-induced reduction of NO synthase activity in the
membranes of intact NO-exposed cells as well as in isolated total membranes,
plasma membranes, and a purified enzyme preparation exposed directly to NO.
Similarly, FeCN-induced reduction of NO synthase activity was also reversed in
the presence of T/TR but not by glutaredoxin. These results demonstrate that the
interaction of NO with the regulatory domain of NO synthase protein is
responsible for post-translational reduction of its catalytic activity.
Thioredoxin-regulated reversal of NO-induced modulation of NO synthase protein
suggests that an oxidative conformational change in vicinal thiols, resulting in
the formation of intramolecular or intermolecular disulfides or both, is
involved. <B>Patel, J. M., J. Zhang, and E. R. Block. 1996. Am. J. Respir. Cell
Mol. Biol. 15:410-19.</B></P>
<TABLE BORDER="1">
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#top">BACK TO MENU</A></B></SMALL></TD></TR></TABLE>
<P></P>
<HR>
<P><B><A NAME="ats17">T cells are the predominant source of interleukin-5 but
not interleukin-4 mRNA expression in the lungs of antigen-challenged allergic
mice.</A></B></P>
<P>Pulmonary inflammation is characterized by the accumulation of eosinophils
and other leukocytes in the lungs of individuals challenged with antigen.
Cytokines released by the Th2 lymphocyte subset, especially interleukin-4 (IL-4)
and interleukin-5 (IL-5), are also present and thought to play an important role
in this process. Previously, we used a model of aerosolized antigen challenge of
sensitized mice to show that T cells were necessary for the accumulation of
eosinophils and the production of cytokines in the airways. In this study, we
elucidate the contribution of T cells to the production of cytokine steady-state
messenger ribonucleic acid (mRNA). T cells were isolated from lung tissue at a
time (4 h) when high levels of IL-4 and IL-5 mRNAs had accumulated, and from
bronchoalveolar lavage fluid (BALF) and lung tissue at a later time (24 h), when
inflammation could be detected by lavage. Lung-derived lymphocytes from
sensitized challenged mice consisted of approximately 40% Thy1+ T cells (20%
CD4+, 13% CD8+, and 6% CD4+/CD8+) and 30% B220+ B cells. Both BALF- and
lung-derived T lymphocytes exhibited a similar activated/memory phenotype (CD44+
CD45RBlo), although lung tissue also contained less differentiated cells (CD44+
CD45RBhi). Thy1+ BALF cells isolated by magnetic bead-mediated separation
accounted for approximately 88% of the IL-5 mRNA, 21% of the interferon-gamma
(IFN-gamma) mRNA, and &lt; 2% of the IL-4 mRNA detected in unseparated samples
by reverse transcriptase-polymerase chain reaction (RT-PCR). Thy1+ T cells from
lung tissue accounted for approximately 98% and 89% of IL-5 mRNA, 56% and 80% of
IFN-gamma mRNA, and 23% and 40% of IL-4 mRNA at 4 h and 24 h after challenge,
respectively. These experiments demonstrate that isolated T cells from BALF and
lung are responsible for most of the IL-5 mRNA, but not all of the IFN-gamma or
IL-4 mRNAs, detected in this model. These results are consistent with human
studies indicating T cells as the major source of IL-5 mRNA in the lungs of
asthmatic patients. <B>Garlisi, C. G., A. Falcone, M. M. Billah, R. W. Egan,
and S. P. Umland. 1996. Am. J. Respir. Cell Mol. Biol. 15:420-28.</B></P>
<TABLE BORDER="1">
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#top">BACK TO MENU</A></B></SMALL></TD></TR></TABLE>
<P></P>
<HR SIZE="4" WIDTH="80%">
<CENTER><A HREF="about.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/about.gif" ALT="About Society"></A>
<A HREF="ssg.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/ss.gif" ALT="Society Structure"></A>
<A HREF="calendar.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/calendar.gif" ALT="ATS Calendar"></A>
<A HREF="gpi.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/pi.gif" ALT="Gen Public Info"></A>
<A HREF="ms.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/memserv.gif" ALT="Memb Serv"></A>
<BR>
<A HREF="pub.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/pubs.gif" ALT="Publications"></A>
<A HREF="press.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/press.gif" ALT="Press"></A>
<A HREF="index.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/home.gif" ALT="Home Page"></A>
<A HREF="search.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/search.gif" ALT="Search"></A>
<A HREF="assemb.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/assemb.gif" ALT="Assemblies"></A>
<A HREF="research.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/research.gif" ALT="Research"></A>
<BR>
<A HREF="mep.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/meded.gif" ALT="Med Education"></A>
<A HREF="wr.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/wr.gif" ALT="Wash Report"></A>
<A HREF="ic.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/ic.gif" ALT="Int'l Conference"></A>
<A HREF="source.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/link.gif" ALT="Web Links"></A>
<A HREF="store.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/store.gif" ALT="Store"></A> 
<A HREF="sig.html"><IMG SRC="images/special.gif" ALT="Special" HSPACE=1 VSPACE=1 BORDER=0 HEIGHT=35 WIDTH=84></A>
</CENTER>
<HR SIZE="4" WIDTH="80%">
<CENTER><FONT SIZE="+2"><B><I>American Thoracic Society</I></B></FONT><BR>
1740 Broadway<BR> New York, NY 10019<BR> VOICE:  212-315-8700<BR> Copyright &copy;
1996 American Lung Association.<BR> The American Thoracic  Society is the
medical section <BR>of the American Lung Association.<BR> 
</CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-172</DOCNO>
<DOCOLDNO>IA013-000141-B026-363</DOCOLDNO>
<DOCHDR>
http://www.thoracic.org:80/rarc1096.html 206.138.195.144 19970217073639 text/html 36754
HTTP/1.0 200 OK
Date: Monday, 17-Feb-97 07:31:55 GMT
Server: NCSA/1.3
MIME-version: 1.0
Content-type: text/html
Last-modified: Friday, 20-Dec-96 20:24:28 GMT
Content-length: 36573
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//SQ//DTD HTML 2.0 HoTMetaL + extensions//EN">
<HTML>
<HEAD>
<TITLE>American Thoracic Society -  AJRCMB ABSTRACTS: October 1996: Volume 15,
Number 4</TITLE></HEAD>
<BODY BACKGROUND="images/back.jpg">
<CENTER><IMG ALIGN="LEFT" SRC="images/smlogo.gif"><BR>
<H1>AJRCMB ABSTRACTS</H1></CENTER>
<HR SIZE="5" NOSHADE="NOSHADE" WIDTH="100%">
<P></P>
<HR>
<CENTER>
<TABLE BORDER="2">
<TR>
<TD ALIGN="CENTER" VALIGN="MIDDLE"><SMALL><B><A HREF="redarch.html">BACK TO
ARCHIVES MAIN PAGE</A></B></SMALL></TD></TR></TABLE></CENTER>
<HR>
<CENTER>
<H2> October 1996: Volume 15, Number 4</H2>
<P><B><A NAME="top">AJRCCM ABSTRACT MENU</A></B></P></CENTER>
<CENTER>
<TABLE BORDER="1">
<TR ALIGN="CENTER" VALIGN="MIDDLE">
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#ats1">Keratinocyte
Growth Factor Reduces Lung Damage Due to Acid Instillation in Rats</A></B></SMALL></TD></TR>
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#ats2">Eosinophil
Infiltration in Nonallergic Chronic Hyperplastic Sinusitis with Nasal Polyposis
(CHS/NP) Is Associated with Endothelial VCAM-1 Upregulation and Expression of
TNF-a</A></B></SMALL></TD></TR>
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#ats3">Quantitation of
the Alveolar Distribution of Surfactant Mixtures in Normal and Injured Lungs</A></B></SMALL></TD></TR>
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#ats4">Human Lung
Fibroblasts Inhibit Tumor Necrosis Factor-a Production by LPS-Activated
Monocytes</A></B></SMALL></TD></TR>
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#ats5">Early Regulatory
Changes in Rat Pulmonary Artery of Renin-Dependent Systemic Hypertension Models</A></B></SMALL></TD></TR>
<TR>
<TD><SMALL><B><A HREF="#ats6">Human Lung Mast Cell Activation Leads to IL-13
mRNA Expression and Protein Release</A></B></SMALL></TD></TR>
<TR>
<TD><SMALL><B><A HREF="#ats7">Expression of Laminins in the Airways in
Various Types of Asthmatic Patients: A Morphometric Study</A></B></SMALL></TD></TR>
<TR>
<TD><SMALL><B><A HREF="#ats8">Human SP-A Locus: Allele Frequencies and
Linkage Disequilibrium between the Two Surfactant Protein A Genes</A></B></SMALL></TD></TR>
<TR>
<TD><SMALL><B><A HREF="#ats9">Reversal of Lung Lesions in Transgenic
Transforming Growth Factor a Mice by Expression of Mutant Epidermal Growth
Factor Receptor</A></B></SMALL></TD></TR>
<TR>
<TD><SMALL><B><A HREF="#ats10">Surfactant Proteins A and D Increase in
Response to Intratracheal Lipopolysaccharide</A></B></SMALL></TD></TR>
<TR>
<TD><SMALL><B><A HREF="#ats11">A Transformed Human Tracheal Gland Cell Line,
MM-39, that Retains Serous Secretory Functions</A></B></SMALL></TD></TR>
<TR>
<TD><SMALL><B><A HREF="#ats12">Microanatomy of Secretory Granule Release
from Guinea Pig Tracheal Goblet Cells</A></B></SMALL></TD></TR>
<TR>
<TD><SMALL><B><A HREF="#ats13">Contrasting Response of Lung Parenchymal
Cells to Instilled TNFa and IFN&amp;g: The Inducibility of Specific Cell ICAM-1
<I>In Vivo</I></A></B></SMALL></TD></TR>
<TR>
<TD><SMALL><B><A HREF="#ats14">Different Roles for PDGF-a and -&szlig;
Receptors in Embryonic Lung Development</A></B></SMALL></TD></TR></TABLE></CENTER>
<P></P>
<HR>
<P><B><A NAME="ats1">Keratinocyte Growth Factor Reduces Lung Damage Due to
Acid Instillation in Rats</A></B></P>
<P>Acid aspiration is a serious complication of anesthesia and other forms of
unconsciousness that can result in the adult respiratory distress syndrome
(ARDS), which continues to have a very high mortality despite our current
therapeutic interventions. This type of injury damages the alveolar epithelium,
principally alveolar type I cells, and requires proliferation of alveolar type
II cells to restore gas exchange units. Since keratinocyte growth factor (KGF)
has been shown to be a potent mitogen for alveolar type II cells, we evaluated
whether intrabronchial administration of KGF would minimize lung injury due to
the unilateral instillation of 0.1 N hydrochloric acid (HCl). Rats were
pretreated or post-treated by intrabronchial instillation of KGF (5 mg/kg) into
the left lung before HCl instillation. All rats receiving KGF at 48 or 72 h
before HCl instillation survived for the 7-day observation period, whereas the
mortality rate for those receiving HCl alone or saline followed by HCl was 31%
and 33%, respectively. Pretreatment with KGF at 72 h but not at 24 or 48 h
considerably ameliorated morphologic damage produced by HCl. Inflammatory cells
in bronchoalveolar lavage were markedly decreased 3 and 7 days after HCl
instillation by the 72-h KGF pretreatment. Pretreatment with KGF at 72 h also
attenuated the reduction of total lung capacity, decreased the a1(I) procollagen
mRNA levels, and diminished hydroxyproline accumulation due to HCl instillation.
Saline pretreatment at 72 h had no significant effect on the HCl injury and
subsequent physiologic abnormalities. Our attempts to improve outcome with
post-treatment instillation of KGF were unsuccessful. We conclude that KGF
pretreatment reduces lung injury due to acid instillation and can prevent
subsequent pulmonary fibrosis. <B>Yano, T., R. R. Deterding, W. S. Simonet, J.
M. Shannon, and R. J. Mason. 1996. Keratinocyte growth factor reduces lung
damage due to acid instillation in rats. Am. J. Respir. Cell Mol. Biol. 15:433&#150;442.</B></P>
<TABLE BORDER="1">
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#top">BACK TO MENU</A></B></SMALL></TD></TR></TABLE>
<P></P>
<HR>
<P><B><A NAME="ats2">Eosinophil Infiltration in Nonallergic Chronic
Hyperplastic Sinusitis with Nasal Polyposis (CHS/NP) Is Associated with
Endothelial VCAM-1 Upregulation and Expression of TNF-a</A></B></P>
<P>We studied potential mechanisms of eosinophil accumulation in nonallergic
chronic hyperplastic sinusitis with nasal polyposis (CHS/NP). We measured
expression of endothelial vascular cell adhesion molecule-1 (VCAM-1), which
mediates selective eosinophil transendothelial migration, the cytokines
interleukin (IL)-1&szlig;, TNF-a and IL-13 which upregulate VCAM-1 expression,
and the chemokine RANTES which mediates lymphocyte, monocyte, and eosinophil
chemotaxis in chronic hyperplastic sinusitis with nasal polyposis (CHS/NP) nasal
polyps (nonallergic versus allergic) and middle turbinate biopsies from normal
controls. By immunohistochemical staining, the density of EG2+ eosinophils was
increased in both the nonallergic and allergic CHS/NP subgroups compared to
normal controls. VCAM-1 expression was significantly increased in CHS/NP
subjects compared to normal controls (<I>P</I> = 0.0005), with the highest
intensity seen in nonallergic CHS/NP. By <I>in situ</I> hybridization, the
densities of IL-1&szlig;, TNF-a, IL-13, and RANTES mRNA+ cells were all
increased in nonallergic CHS/NP compared to normal controls (<I>P</I> = 0.009,
0.0005, 0.0005, and 0.001, respectively). In comparison to allergic CHS/NP,
nonallergic CHS/NP had a significantly higher tissue density of TNF-a (<I>P</I>
= 0.04) and a lower density of IL-13 (<I>P</I> = 0.005) mRNA+ cells. In
general, VCAM-1 expression correlated strongly in CHS/NP with the density of
TNF-a (R = .91, <I>P</I> = 0.0005) but not the density of IL-1&szlig;, IL-13,
or RANTES mRNA+ cells. We conclude that upregulation of VCAM-1 and elaboration
of RANTES may contribute to the marked accumulation of eosinophils in
nonallergic CHS/NP. TNF-a may play a critical role in VCAM-1 upregulation in
this nonallergic eosinophilic disorder. <B>Hamilos, D. L., D. Y. M. Leung, R.
Wood, D. K. Bean, Y. L. Song, E. Schotman, and Q. Hamid. 1996. Eosinophil
infiltration in nonallergic chronic hyperplastic sinusitis with nasal polyposis
(CHS/NP) is associated with endothelial VCAM-1 upregulation and expression of
TNF-a. Am. J. Respir. Cell Mol. Biol. 15:443&#150;450.</B></P>
<TABLE BORDER="1">
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#top">BACK TO MENU</A></B></SMALL></TD></TR></TABLE>
<P></P>
<HR>
<P><B><A NAME="ats3">Quantitation of the Alveolar Distribution of Surfactant
Mixtures in Normal and Injured Lungs</A></B></P>
<P>The uptake and distribution of two surfactant mixtures, Exosurf and
Infasurf, instilled into the lungs of normal and hyperoxia-exposed (100% O2, 60
h) rabbits, were quantified at the alveolar level using flow cytometry and
fluorescence microscopy. The surfactants were labeled with the fluorescent
phospholipid analog NBD-C12-PC
(1-palmitoyl-2-[12-[(7-nitro-2-1,3-benzoxadiazol-4-yl)amino]dodecanoyl]-sn-gly
cero-3-phosphocholine) in 100:1 molar ratio. Rabbits were killed 2 h after the
instillation of either surfactant (80 mg phospholipid [PL]/kg), and alveolar
macrophages (AM) and alveolar type II (ATII) cells were isolated and examined
for the presence of NBD fluorescence. The fractions of cells, with NBD
fluorescence values higher than autofluorescence, isolated from the lungs of
air-breathing rabbits instilled with either Infasurf or Exosurf, were 84% and
63% for AM, and 55% and 45% for ATII cells. Exposure of rabbits to hyperoxia
decreased the fraction of NBD-positive AM following Infasurf instillation, and
the mean increase in NBD-associated fluorescence in ATII cells following Exosurf
instillation. Our results suggest that sublethal hyperoxia decreases the
short-term uptake but not the distribution of intratracheally instilled Exosurf.
<B>Pataki, G., L. Czopf, B. A. Holm, and S. Matalon. 1996. Quantitation of the
alveolar distribution of surfactant mixtures in normal and injured lungs. Am. J.
Respir. Cell Mol. Biol. 15:451&#150;459.</B></P>
<TABLE BORDER="1">
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#top">BACK TO MENU</A></B></SMALL></TD></TR></TABLE>
<P></P>
<HR>
<P><B><A NAME="ats4">Human Lung Fibroblasts Inhibit Tumor Necrosis Factor-a
Production by LPS-Activated Monocytes</A></B></P>
<P>Mononuclear phagocytes are important regulators of normal immune,
inflammatory, and fibrotic responses. These functions are mediated through the
production of several cytokines, including tumor necrosis factor-a (TNF-a),
which regulate the activity of inflammatory and tissue structural cells such as
fibroblasts. It is increasingly evident that fibroblasts are also capable of
releasing a number of cytokines and soluble factors that can, in turn, interact
with monocytes and thereby modulate the inflammatory process. In this study we
provide evidence that human lung fibroblasts, through the release of soluble
factors such as prostaglandin E2 (PGE2), inhibit both TNF messenger ribonucleic
acid (mRNA) accumulation and TNF-a protein release by lipopolysaccharide
(LPS)-activated human peripheral blood monocytes (PBM). Reverse transcriptase&#150;polymerase
chain reaction (RT&#150;PCR) results showed that fibroblast-conditioned medium
(FCM) caused a 50% reduction of the TNF-a transcript accumulation in
LPS-stimulated monocytes. Furthermore, FCM induced a significant decrease in the
release of TNF-a by LPS-activated PBM. This effect was dependent on the
concentration of the FCM and the number of fibroblasts producing it. The maximal
effect was seen with monocytes cultured in 100% FCM produced by 2 x 106
fibroblasts. This indicated that one or possibly more soluble factors released
by fibroblasts were responsible for the effect. Considering that exogenous PGE2
can inhibit TNF-a production by PBM, and that fibroblasts are a good source of
PGE2, we determined the content of PGE2 in the FCM used in our experiments. We
found a good correlation (r = 0.949) between the amount of PGE2 produced by
fibroblasts and the degree of TNF-a inhibition exerted. In addition, the
inhibitory effect of FCM was mimicked by the addition to PBM cultures of
exogenous PGE2 in amounts similar to those spontaneously released by fibroblasts
in FCM. All of these data suggest a molecular and cellular interaction between
PBM and fibroblasts that could contribute to those modulatory mechanisms
involved in the self-limitation of the fibrotic process. <B>Vancheri, C., N.
Crimi, E. Conte, M. P. Pistorio, C. Mastruzzo, M. Lamicela, A. Messina, and A.
Mistretta. 1996. Human lung fibroblasts inhibit tumor necrosis factor-a
production by LPS-activated monocytes. Am. J. Respir. Cell Mol. Biol. 15:460&#150;466.</B></P>
<TABLE BORDER="1">
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#top">BACK TO MENU</A></B></SMALL></TD></TR></TABLE>
<P></P>
<HR>
<P><B><A NAME="ats5">Early Regulatory Changes in Rat Pulmonary Artery of
Renin-Dependent Systemic Hypertension Models</A></B></P>
<P>Patients with systemic hypertension of various etiologies maintain their
pulmonary artery pressures within normal limits. We have reported in isolated
perfused rat lungs that low basal tone appears to be regulated by nitric oxide
(NO)-dependent and -independent mechanisms of soluble guanylate cyclase
activation, and similar results are seen in isolated small pulmonary arteries
(PA) from these animals. The abdominal aorta of rats was ligated above the left
and below the right renal artery (aortic coarctation, AC). The mean arterial
pressure (MAP) and pulmonary artery pressure (PAP) of 24-h post-AC rats (MAP 123
&#177; 7.1 mm Hg and PAP 4.2 &#177; 0.9 mm Hg) showed no significant change when
compared with those of sham control rats (MAP 116 &#177; 7.0 mm Hg and PAP 5.0 &#177;
0.04 mm Hg). Hypoxic contractions in isolated small rat PA (160 to 260 mm
diameter) were significantly increased from 56.7 &#177; 12.0 mg in the control
group to 139 &#177; 31 mg in the 24-h post-AC rats (<I>P</I> &lt; 0.05). PA
contractions in the presence of 100 mM nitro-l-arginine (NLA) increased from 102
&#177; 34 mg among the sham control group to 261 &#177; 30 mg among the 24-h
post-AC rats (<I>P</I> &lt; 0.05). After NLA, the hypoxic contractions
decreased to 15 &#177; 2.9 mg in the control rats and 45 &#177; 16 mg in the
24-h post-AC rats when compared with pre-NLA values (<I>P</I> &lt; 0.05).
Western and Northern blotting of protein and messenger ribonucleic acid (mRNA)
extracted from the whole rat lung showed a significant rise in endothelial cell
nitric oxide synthase (EcNOS; 207 &#177; 34%) and EcNOS mRNA (2-fold) when
comparing controls with 24-h post-AC rats. These data indicate that there is
increased EcNOS activity and synthesis that maintain low PA tone in these rat
models as early as 24 h after AC; in addition, this effect is independent of the
systemic blood pressure. <B>Itani, M. M., M. G. Talerico, P. A. Pino, and T.
Burke-Wolin. 1996. Early regulatory changes in rat pulmonary artery of
renin-dependent systemic hypertension models. Am. J. Respir. Cell Mol. Biol.
15:467&#150;472.</B></P>
<TABLE BORDER="1">
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#top">BACK TO MENU</A></B></SMALL></TD></TR></TABLE>
<P></P>
<HR>
<P><B><A NAME="ats6">Human Lung Mast Cell Activation Leads to IL-13 mRNA
Expression and Protein Release</A></B></P>
<P>Using reverse transcriptase&#150;polymerase chain reaction (RT-PCR) and
enzyme-linked immunosorbent assay (ELISA), we studied the generation of the
recently described Th2 cytokine interleukin-13 (IL-13) by anti-IgE-activated
lung fragments (LF), lung mast cells (LMC), and the mast cell line HMC-1. We
found that IL-13 messenger ribonucleic acid (mRNA) was constitutively expressed
in LF and rapidly increased after anti-IgE challenge, persisting throughout a
16-h period. Quantitative-competitive PCR (QCPCR) demonstrated an increase from
1.2 fg to 120 fg of IL-13 mRNA/mg LF total cellular RNA. Time-course experiments
showed that IL-13 protein was not increased in supernatants at 2 h after
activation, but was upregulated by 8 h. Anti-IgE-activated LF supernatants
contained 592.1 &#177; 314.8 pg IL-13/g wet weight of tissue at 24 h (mean &#177;
SE; <I>n</I> = 11). LMC demonstrated upregulation of IL-13 mRNA expression
following treatment with A23187 (<I>n</I> = 4), with maximal upregulation by 3
h; anti-IgE or phorbol myristate acetate (PMA) also led to increased IL-13 mRNA
expression. QCPCR analysis of LMC IL-13 mRNA expression at 4 h after activation
showed a 7-, 13.8-, and 13.2-fold increase after A23187, anti-IgE, and PMA,
respectively. Quantities of IL-13 released from optimally activated LMC and
peripheral blood T cells were comparable. HMC-1 also showed enhanced IL-13 mRNA
beginning 30 min after A23187 activation, with peak expression from 1 to 10 h,
followed by waning over the subsequent 24 h. A23187 stimulation of HMC-1 led to
100-fold upregulation of IL-13 mRNA within 4 h and detectable IL-13 in 24-h
supernatants. These results demonstrate that activation of LF and LMC through
multiple signal-transduction pathways results in increased IL-13 mRNA and
protein expression temporally consistent with a potential role in chronic
allergic inflammation. <B>Jaffe, J. S., D. G. Raible, T. J. Post, Y. Wang, M.
C. Glaum, J. H. Butterfield, and E. S. Schulman. 1996. Human lung mast cell
activation leads to IL-13 mRNA expression and protein release. Am. J. Respir.
Cell Mol. Biol. 15:473&#150;481.</B></P>
<TABLE BORDER="1">
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#top">BACK TO MENU</A></B></SMALL></TD></TR></TABLE>
<P></P>
<HR>
<P><B><A NAME="ats7">Expression of Laminins in the Airways in Various Types
of Asthmatic Patients: A Morphometric Study</A></B></P>
<P>Laminins (Ln) are crucial in airway morphogenesis. Because they are able to
interact with inflammatory cells, they are likely to participate in inflammation
accompanied by airway structural remodeling in asthma. Taking biopsies and using
immunohistochemistry and quantitative image analysis, we characterized the
distribution of Ln chains a1, a2, and &szlig;2 in the bronchial mucosa of
patients with seasonal (<I>n</I> = 17), early occupational (<I>n</I> = 8), and
chronic asthma (<I>n</I> = 16) for comparison with that of normal controls (<I>n</I>
= 8). In all asthmatic patients, both Ln chains a1 and &szlig;2 were confined to
the superficial margin of the basement membrane (BM), blood vessels, and smooth
muscle. The thickness of Ln &szlig;2 expression in BM was significantly greater
in patients with chronic (1.9 &#177; 0.1mm; <I>P</I> &lt; 0.001) and
occupational asthma (1.7 &#177; 0.1 mm; <I>P</I> &lt; 0.05) than in controls
(0.4 &#177; 0.3 mm). Only in patients with occupational asthma was the thickness
of the Ln a1 layer (2.3 &#177; 0.2 mm; mean &#177; SEM) significantly different
from that in controls (1.4 &#177; 0.5 mm; <I>P</I> &lt; 0.05). There was no
immunoreactivity for the Ln a2 chain in controls or patients with mild asthma,
but in clinically severe chronic asthma we found a discontinuous staining along
the epithelial margin of the BM. Since Ln chains a2 and &szlig;2 appear to
function only during morphogenesis, increased expression of these Ln chains in
adult asthma patients suggests accelerated tissue turnover in the airways,
possibly as a result of airway inflammation in asthma. <B>Altraja, A., A.
Laitinen, I. Virtanen, M. K&auml;mpe, B. G. Simonsson, S.-E. Karlsson, L.
Hakansson, P. Venge, H. Sillastu, and L. A. Laitinen. 1996. Expression of
laminins in the airways in various types of asthmatic patients: a morphometric
study. Am. J. Respir. Cell Mol. Biol. 15:482&#150;488.</B></P>
<TABLE BORDER="1">
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#top">BACK TO MENU</A></B></SMALL></TD></TR></TABLE>
<P></P>
<HR>
<P><B><A NAME="ats8">Human SP-A Locus: Allele Frequencies and Linkage
Disequilibrium between the Two Surfactant Protein A Genes</A></B></P>
<P>Two surfactant protein A (SP-A) genes and several alleles for each SP-A
locus have been previously described. In this report we investigate the
potential usefulness of the SP-A loci as markers for genetic studies. We
establish conditions that allow the identification of alleles with very similar
sequences; We also determine the degree of polymorphism for each SP-A locus: The
heterozygosity and polymorphism information content (PIC) values for the SP-A1
locus are 0.63 and 0.55, respectively, and for the SP-A2 locus are 0.50 and
0.56. In the course of these studies, we identify one new SP-A2 allele and show
that the SP-A1 and SP-A2 loci are in linkage disequilibrium (<I>P</I> &lt;
0.000001). We also identify 19 of the 20 possible haplotypes in a population of
<I>n</I> = 239. Nine of the observed haplotypes reach statistical significance
(<I>P</I> &lt; 0.01) in this population, and the segregation of two haplotypes
(6A2/1A0 and 6A4/1A) without recombination is verified in a family pedigree.
These data together indicate that both SP-A loci are sufficiently polymorphic to
be good markers for use in genetic studies. Furthermore, the finding of one
novel allele suggests that additional unknown SP-A alleles are yet to be found.
<B>Floros, J., S. DiAngelo, M. Koptides, A. M. Karinch, P. K. Rogan, H.
Nielsen, R. G. Spragg, K. Watterberg, and G. Deiter. 1996. Human SP-A Locus:
allele frequencies and Linkage disequilibrium between the two surfactant protein
A genes. Am. J. Respir. Cell Mol. Biol. 15:489&#150;498.</B></P>
<TABLE BORDER="1">
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#top">BACK TO MENU</A></B></SMALL></TD></TR></TABLE>
<P></P>
<HR>
<P><B><A NAME="ats9">Reversal of Lung Lesions in Transgenic Transforming
Growth Factor a Mice by Expression of Mutant Epidermal Growth Factor Receptor</A></B></P>
<P>Transgenic mice expressing transforming growth factor a (TGF-a) in type II
cells under control of the lung-specific surfactant protein-C (SP-C) promoter
develop pulmonary fibrosis and marked airspace hypoplasia. To identify cellular
signaling mechanisms involved in lesion formation, we generated transgenic mice
expressing a mutant epidermal growth factor receptor lacking a portion of the
intracytoplasmic domain (EGF-R-M) under control of the human SP-C promoter.
Transcripts of the SP-C-EGF-R-M transgene were detected in distal bronchiolar
and type II cells by in situ hybridization. The morphology of lungs from the
SP-C-EGF-R-M transgenic mice was normal. Lung fibrosis was not detectable and
airspace hypoplasia was significantly corrected in bitransgenic mice derived by
breeding SP-C-TGF-a and SP-C-EGF-R-M mice. Correction of lung pathology in the
bitransgenic mice occurred without altering the level of hTGF-a mRNA. To further
demonstrate that reversal of TGF-a lesions required signaling through the EGF-R,
SP-C-TGF-a transgenic mice were bred to mice homozygous for the <I>wa</I>-2
mutation which encodes a mutated EGF-R. TGF-a&#150;induced lesions were reversed
in homozygous <I>wa</I>-2 mice. Amelioration of TGF-a&#150;dependent pulmonary
lesions in SP-C-EGF-R-M mice or <I>wa</I>-2/wa-2 mice supports the concept that
autocrine and paracrine signaling mediate fibrosis and airspace remodeling
caused by TGF-a. <B>Hardie, W. D., C. B. Kerlakian, M. D. Bruno, K. M.
Huelsman, S. E. Wert, S. W. Glasser, J. A. Whitsett, and T. R. Korfhagen. 1996.
Reversal of lung lesions in transgenic transforming growth factor a mice by
expression of mutant epidermal growth factor receptor. Am. J. Respir. Cell Mol.
Biol. 15:499&#150;508.</B></P>
<TABLE BORDER="1">
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#top">BACK TO MENU</A></B></SMALL></TD></TR></TABLE>
<P></P>
<HR>
<P><B><A NAME="ats10">Surfactant Proteins A and D Increase in Response to
Intratracheal Lipopolysaccharide</A></B></P>
<P>Surfactant proteins A (SP-A) and D (SP-D) are &quot;collectins&quot;:
proteins with collagen-like region and lectin domain that bind carbohydrates in
a calcium-dependent manner. Mannose-binding protein, a serum collectin, is an
acute-phase protein. We hypothesized that SP-A and SP-D would respond to an
acute stress, such as lung inflammation, in the same manner as does
mannose-binding protein, with increased messenger ribonucleic acid (mRNA) and
protein production. Rats received intratracheal lipopolysaccharide (LPS; 0.5
mg/kg) or vehicle and were killed 1, 6, 24, and 72 h later. Their lungs were
lavaged and the lung tissue homogenized and analyzed for SP-A, SP-D, and
phospholipids. Tissue levels of SP-A were increased by 6 h, peaked at 24 h, and
were still elevated at 72 h in LPS-treated animals as compared with those given
vehicle. SP-A and SP-D levels in lavage fluid were significantly elevated at 72
h. Message levels for SP-A and SP-D, but not SP-B, were significantly increased
at 24 h. Lavage phospholipid levels first increased, then decreased in both the
control and LPS-treated animals, and significantly less phospholipid was
recovered in the lavage fluid of the LPS-treated animals than in that of
controls at 72 h. Although other mechanisms, including altered surfactant
metabolism, may be involved, these data are consistent with our hypothesis that
SP-A and SP-D are upregulated by an acute inflammatory stress in a manner
analogous to that of the structurally and functionally related serum acute-phase
reactant, mannose-binding protein. We speculate that this upregulation may be a
protective response for the lungs. <B>McIntosh, J. C., A. H. Swyers, J. H.
Fisher, and J. R. Wright. 1996. Surfactant proteins A and D increase in response
to intratracheal lipopolysaccharide. Am. J. Respir. Cell Mol. Biol. 15:509&#150;519.</B></P>
<TABLE BORDER="1">
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#top">BACK TO MENU</A></B></SMALL></TD></TR></TABLE>
<P></P>
<HR>
<P><B><A NAME="ats11">A Transformed Human Tracheal Gland Cell Line, MM-39,
that Retains Serous Secretory Functions</A></B></P>
<P>Infection with the wild type SV40 virus was used to transform primary
cultures of human tracheal gland serous (HTGS) cells. Over 80 different cell
lines were obtained, but the majority had lost some of their epithelial and
secretory features. However, one of these cell lines, MM-39, was shown to have
conserved the physiologic characteristics of the genuine HTGS cells--i.e., the
presence of cytokeratin, expression of cystic fibrosis transmembrane conductance
regulator mRNA, a level of secretory leukocyte proteinase inhibitor secretion
comparable to that of the native cells (25 &#177; 3 ng/106 cells/h), and the
responsiveness to pharmacological agonists: carbachol (+260 &#177; 40%),
isoproterenol (+260 &#177; 40%), and adenosine 5'-triphosphate (+280 &#177;
30%). These characteristics describe a transformed cell line of human tracheal
gland cells which has retained the features of the native serous cells. As a
result, this cell line appears to be a useful tool for large-scale physiologic
and pharmacologic studies of bronchial secretion at the cellular level. <B>Merten,
M. D., W. Kammouni, W. Renaud, F. Birg, M. G. Matt&eacute;i, and C. Figarella.
1996. A transformed human tracheal gland cell line, MM-39, that retains serous
secretory functions. Am. J. Respir. Cell Mol. Biol. 15:520&#150;528.</B></P>
<TABLE BORDER="1">
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#top">BACK TO MENU</A></B></SMALL></TD></TR></TABLE>
<P></P>
<HR>
<P><B><A NAME="ats12">Microanatomy of Secretory Granule Release from Guinea
Pig Tracheal Goblet Cells</A></B></P>
<P>The microanatomy of mucin granule release from epithelial goblet cells has
been investigated in guinea pig tracheae. Using a tannic acid arrest procedure,
granule release under basal conditions and after high K+ or acetylcholine (ACh)
application was arrested and a variety of granule fusion sites were identified
in ultrathin sections and freeze-fracture replicas. Rather than there being
subclasses of secretory cells containing either electron-lucent granules
(indicative of mucin) or smaller electron-dense (serous) granules, the majority
of secretory cells in both control and treated groups contained granules with an
electron-dense core surrounded by an electron-lucent region. Granule release
sites were of three principal types: (<I>1</I>) simple exocytosis, where the
membranes of single granules fused directly with the plasma membrane to give an
&quot;omega&quot; profile; (<I>2</I>) compound exocytosis, where granule
membranes, fused together intracellularly, were found in continuity with the
plasma membrane; and (<I>3</I>) apocrine-like secretion, which involved the
loss of the central apical mass of granules together with elements of the cell
cytoplasm. In treated preparations, there was an increase in the number of cells
exhibiting fusion sites; the percentage showing simple fusions fell from 82% to
59% (with ACh) and 57% (with KCl), whereas the percentage of cells exhibiting
compound and apocrine-like secretion increased. Dense cores were frequently
retained at the sites of fusion and, despite the expansive decondensation of
mucin known to occur, there was also evidence of some retention of the
electron-lucent material. <B>Newman, T. M., A. Robichaud, and D. F. Rogers.
1996. Microanatomy of secretory granule release from guinea pig tracheal goblet
cells. Am. J. Respir. Cell Mol. Biol. 15:529&#150;539.</B></P>
<TABLE BORDER="1">
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#top">BACK TO MENU</A></B></SMALL></TD></TR></TABLE>
<P></P>
<HR>
<P><B><A NAME="ats13">Contrasting Response of Lung Parenchymal Cells to
Instilled TNFa and IFN&amp;g: The Inducibility of Specific Cell ICAM-1 <I>In
Vivo</I></A></B></P>
<P>Induction of intercellular adhesion molecule-1 (ICAM-1) by proinflammatory
cytokines during inflammation plays an important role in regulating
polymorphonuclear neutrophil (PMN) migration and localization. In this report,
we examined the effects of tumor necrosis factor-a (TNFa) and interferon-&amp;g
(IFN&amp;g) on specific lung cell expression of ICAM-1 <I>in vivo</I> and the
accompanying morphological changes. Balb-c mice were treated with
phosphate-buffered saline (PBS) alone or with PBS containing 5 mg TNFa or IFN&amp;g
through intranasal instillation. Twenty-four hours after treatment, their lungs
were processed for immunoblot analysis and electron microscope
immunocytochemistry. In the normal lung, the ICAM-1 level is high on type I
alveolar epithelial cells, medium on arterial and venous endothelial cells, low
on type II epithelial cells and capillary endothelium, and not detectable on
bronchial epithelium. Topical treatment of the lung with either TNFa or IFN&amp;g
induced a 50&#150;60% increase in total lung and alveolar ICAM-1. A dramatic
increase of alveolar type II cell surface ICAM-1 was observed (&gt; 20-fold).
Both cytokines caused 2&#150;3-fold higher ICAM-1 expression on capillary
endothelial cells and a 40% increase of ICAM-1 on alveolar type I cells that was
not uniform. However, due to the large total surface area of type I epithelium,
type I cells contribute 70&#150;86% of total alveolar septal ICAM-1 and &gt; 90%
of alveolar surface ICAM-1 in either treated or normal mouse lungs. Increased
ICAM-1 expression was also observed on nonparenchymal endothelial and epithelial
cells. Margination and sequestration of PMN in cytokine-treated lungs were
observed by histologic examination, measurements of total lung myloperoxidase
activity, and number of neutrophils recovered in bronchoalveolar lavage fluid.
These results showed that TNFa and IFN&amp;g induce ICAM-1 expression and
infiltration of neutrophils in the lung. The response of specific lung cells in
terms of induction of ICAM-1 in response to cytokine stimulation varied
significantly, particularly between type I and type II epithelial cells. <B>Kang,
B.-H., B. D. Manderschied, Y.-C. T. Huang, J. D. Crapo, and L.-Y. Chang. 1996.
Contrasting response of lung parenchymal cells to instilled TNFa and IFN&amp;g:
the inducibility of specific cell ICAM-1 in vivo. Am. J. Respir. Cell Mol. Biol.
15:540&#150;550.</B></P>
<TABLE BORDER="1">
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#top">BACK TO MENU</A></B></SMALL></TD></TR></TABLE>
<P></P>
<HR>
<P><B><A NAME="ats14">Different Roles for PDGF-a and -&szlig; Receptors in
Embryonic Lung Development</A></B></P>
<P>Platelet-derived growth factor (PDGF) is implicated in the process of normal
lung development. We have previously shown the presence of PDGF-AA and BB
homodimers in embryonic rat lung. Also, we reported that PDGF-AA is involved in
embryonic lung branching, whereas PDGF-BB influences embryonic lung growth. PDGF
isoforms bind with different affinities to two related receptors, denoted the
PDGF a- and &szlig;-receptors, respectively. The a-receptor binds both PDGF
isoforms, whereas the &szlig;-receptor binds only PDGF-BB. In the present study,
we investigated the role of both receptors in early embryonic rat lung
development. Reverse-transcriptase&#150;polymerase chain reaction (RT&#150;PCR)
analysis revealed that both PDGF a- and &szlig;-receptor mRNAs are mainly
expressed in the mesenchyme. Phosphorothioate antisense receptor
oligonucleotides decreased PDGF receptor mRNA expression in early lung explants.
PDGF-induced receptor tyrosine phosphorylation was also reduced by the antisense
oligonucleotides. Incubation of embryonic lung explants with antisense &szlig;-receptor
oligonucleotides inhibited lung growth but not early lung branching. Neither
growth nor branching were affected by sense &szlig;-receptor oligonucleotides.
The inhibitory effect of antisense &szlig;-receptor oligonucleotides on
embryonic lung growth was reversed by the addition of PDGF-BB or PDGF-AA,
suggesting that the a-receptor can transduce similar mitogenic signals as the &szlig;-receptor
in early lung development. Antisense a-receptor oligonucleotides reduced both
embryonic lung growth and branching. Sense a-receptor treatment had no effect on
lung growth and branching. PDGF-BB but not PDGF-AA partially attenuated the
inhibitory effect of antisense a-receptor oligonucleotides on lung growth. In
contrast, PDGF-BB did not overcome the inhibitory effect on early lung
branching, indicating that the &szlig;-receptor cannot replace this biologic
role of the a-receptor in early lung development. These data suggest that
PDGF-BB stimulation of both receptors leads to lung growth, whereas PDGF-AA
stimulation of the a-receptor induces transduction pathways that lead lung
branching. <B>Souza, P., A. K. Tanswell, and M. Post. Different roles for
PDGF-a and -&szlig; receptors in embryonic lung development. Am. J. Respir. Cell
Mol. Biol. 15:551&#150;562.</B></P>
<TABLE BORDER="1">
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#top">BACK TO MENU</A></B></SMALL></TD></TR></TABLE>
<P></P>
<HR SIZE="4" WIDTH="80%">
<CENTER><A HREF="about.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/about.gif" ALT="About Society"></A>
<A HREF="ssg.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/ss.gif" ALT="Society Structure"></A>
<A HREF="calendar.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/calendar.gif" ALT="ATS Calendar"></A>
<A HREF="gpi.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/pi.gif" ALT="Gen Public Info"></A>
<A HREF="ms.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/memserv.gif" ALT="Memb Serv"></A>
<BR>
<A HREF="pub.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/pubs.gif" ALT="Publications"></A>
<A HREF="press.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/press.gif" ALT="Press"></A>
<A HREF="index.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/home.gif" ALT="Home Page"></A>
<A HREF="search.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/search.gif" ALT="Search"></A>
<A HREF="assemb.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/assemb.gif" ALT="Assemblies"></A>
<A HREF="research.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/research.gif" ALT="Research"></A>
<BR>
<A HREF="mep.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/meded.gif" ALT="Med Education"></A>
<A HREF="wr.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/wr.gif" ALT="Wash Report"></A>
<A HREF="ic.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/ic.gif" ALT="Int'l Conference"></A>
<A HREF="source.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/link.gif" ALT="Web Links"></A>
<A HREF="store.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/store.gif" ALT="Store"></A> 
<A HREF="sig.html"><IMG SRC="images/special.gif" ALT="Special" HSPACE=1 VSPACE=1 BORDER=0 HEIGHT=35 WIDTH=84></A>
</CENTER>
<HR SIZE="4" WIDTH="80%">
<CENTER><FONT SIZE="+2"><B><I>American Thoracic Society</I></B></FONT><BR>
1740 Broadway<BR> New York, NY 10019<BR> VOICE:  212-315-8700<BR> Copyright &copy;
1996 American Lung Association.<BR> The American Thoracic  Society is the
medical section <BR>of the American Lung Association.<BR> 
</CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-173</DOCNO>
<DOCOLDNO>IA013-000141-B027-23</DOCOLDNO>
<DOCHDR>
http://www.thoracic.org:80/rarc1196.html 206.138.195.144 19970217073648 text/html 38172
HTTP/1.0 200 OK
Date: Monday, 17-Feb-97 07:32:06 GMT
Server: NCSA/1.3
MIME-version: 1.0
Content-type: text/html
Last-modified: Friday, 20-Dec-96 20:24:28 GMT
Content-length: 37991
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//SQ//DTD HTML 2.0 HoTMetaL + extensions//EN">
<HTML>
<HEAD>
<TITLE>American Thoracic Society -  AJRCMB ABSTRACTS: November 1996: Volume 15,
Number 5</TITLE></HEAD>
<BODY BACKGROUND="images/back.jpg">
<CENTER><IMG ALIGN="LEFT" SRC="images/smlogo.gif"><BR>
<H1>AJRCMB ABSTRACTS</H1></CENTER>
<HR SIZE="5" NOSHADE="NOSHADE" WIDTH="100%">
<P></P>
<HR>
<CENTER>
<TABLE BORDER="2">
<TR>
<TD ALIGN="CENTER" VALIGN="MIDDLE"><SMALL><B><A HREF="redarch.html">BACK TO
ARCHIVE MAIN PAGE</A></B></SMALL></TD></TR></TABLE></CENTER>
<HR>
<CENTER>
<H2> November 1996: Volume 15, Number 5</H2>
<P><B><A NAME="top">AJRCCM ABSTRACT MENU</A></B></P></CENTER>
<CENTER>
<TABLE BORDER="1">
<TR ALIGN="CENTER" VALIGN="MIDDLE">
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#ats1">Lung Cancer Cell
Lines Inhibit Leukotriene B4 Production by Human Polymorphonuclear Leukocytes at
the Level of Phospholipase A2</A></B></SMALL></TD></TR>
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#ats2">Intratracheal
Administration of Hepatocyte Growth Factor/Scatter Factor Stimulates Rat
Alveolar Type II Cell Proliferation ITIn Vivo</A></B></SMALL></TD></TR>
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#ats3">Evidence for
Major Basic Protein Immunoreactivity and Interleukin 5 Gene Activation during
the Late Phase Response in Explanted Airways</A></B></SMALL></TD></TR>
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#ats4">Enhanced Growth
Response of Airway Smooth Muscle in Inbred Rats with Airway Hyperresponsiveness</A></B></SMALL></TD></TR>
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#ats5">Differential
Expression of aE&szlig;7 Integrins on Bronchoalveolar Lavage T Lymphocyte
Subsets: Regulation by a4&szlig;1-integrin Crosslinking and TGF-&szlig;</A></B></SMALL></TD></TR>
<TR>
<TD><SMALL><B><A HREF="#ats6">Postpneumonectomy Lung Growth: A Model of
Reinitiation of Tropoelastin and Type I Collagen Production in a Normal Pattern
in Adult Rat Lung</A></B></SMALL></TD></TR>
<TR>
<TD><SMALL><B><A HREF="#ats7">Epithelial Barrier Integrity During ITIn Vitro
Wound Repair of the Airway Epithelium</A></B></SMALL></TD></TR>
<TR>
<TD><SMALL><B><A HREF="#ats8">Pulmonary Artery NADPH-oxidase Is Activated in
Hypoxic Pulmonary Vasoconstriction</A></B></SMALL></TD></TR>
<TR>
<TD><SMALL><B><A HREF="#ats9">Increased Levels of CD34+ Hemopoietic
Progenitor Cells in Atopic Subjects</A></B></SMALL></TD></TR>
<TR>
<TD><SMALL><B><A HREF="#ats10">Intra-alveolar Macrophage-inflammatory
Peptide 2 Induces Rapid Neutrophil Localization in the Lung</A></B></SMALL></TD></TR>
<TR>
<TD><SMALL><B><A HREF="#ats11">Differential Regulation of Airway Epithelial
Integrins by Growth Factors</A></B></SMALL></TD></TR>
<TR>
<TD><SMALL><B><A HREF="#ats12">Sharp Increase in Rat Lung Water Channel
Expression in the Perinatal Period </A></B></SMALL></TD></TR>
<TR>
<TD><SMALL><B><A HREF="#ats13">Upregulatory Effects of Interleukin-4 and
Interleukin-13 but not Interleukin-10 on Granulocyte/macrophage
Colony-stimulating Factor Production by Human Bronchial Epithelial Cells</A></B></SMALL></TD></TR></TABLE></CENTER>
<P></P>
<HR>
<P><B><A NAME="ats1">Lung Cancer Cell Lines Inhibit Leukotriene B4 Production
by Human Polymorphonuclear Leukocytes at the Level of Phospholipase A2</A></B></P>
<P>We studied cellular interactions between human polymorphonuclear leukocytes
(PMN) and lung cancer cell lines by investigating the influence of cancer cells
on the production of leukotriene B4 (LTB4) and superoxide anion (O2&#190;) by
stimulated PMN. Of the nine cancer cell lines established from human lung
cancers that we examined, H23 cells showed the highest LTA4 hydrolase activity.
When PMN were stimulated by the calcium ionophore A23187 in the presence of H23
cells, the production of LTB4, 5(S)-hydroxyeicosatetraenoic acid (5-HETE), and
12(S)-hydroxyeicosatetraenoic acid (12-HETE) decreased in a dose-dependent
manner. On the contrary, H23 did not inhibit O2&#190; production by PMN. Two
other cell lines (N417 and Q9) caused similar inhibition of LTB4 production by
PMN. These three cancer cell lines alone did not generate any metabolites of the
arachidonic acid (AA) lipoxygenase pathway or any O2&#190; upon stimulation with
A23187 alone. The addition of AA dose-dependently reversed the H23-induced
inhibition of LTB4, 5-HETE, and 12-HETE production by PMN, suggesting inhibition
at the phospholipase A2 (PLA2) level. Furthermore, addition of the cancer cell
line Q9 inhibited 14C release from [14C]AA prelabeled PMN in a cell
number-dependent manner in the buffer, with and without albumin. The supernatant
of H23 cells also inhibited the production of LTB4 by PMN stimulated by A23187,
as did the addition of H23 lysate or its 104 x <I>g</I> centrifugation
supernatant. While neither the 105 x <I>g</I> supernatant (cytosol) nor the
pellet (microsome) exhibited inhibitory activity, the combination of the
separated cytosol and microsomal fractions restored the inhibitory activity.
Furthermore, addition of the 104 x <I>g</I> supernatant of Q9 lysate to
partially purified human cytosolic PLA2 inhibited PLA2 activity in a
dose-dependent manner. Our results indicate that the lung cancer cell lines used
in our study inhibit LTB4 production by human PMN through inhibition of
phospholipase A2 activity, which may contribute to a predisposition to pulmonary
infections in patients with lung cancer. <B>Abe, M., H. Matsuki, M. Domae, H.
Kuwata, I. Kudo, Y. Nakanishi, N. Hara, T. Mitsuyama, and T. Furukawa. Lung
cancer cell lines inhibit leukotriene B4 production by human polymorphonuclear
leukocytes at the level of phospholipase A2. Am. J. Respir. Cell Mol. Biol.
15:565&#150;73.</B></P>
<TABLE BORDER="1">
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#top">BACK TO MENU</A></B></SMALL></TD></TR></TABLE>
<P></P>
<HR>
<P><B><A NAME="ats2">Intratracheal Administration of Hepatocyte Growth
Factor/Scatter Factor Stimulates Rat Alveolar Type II Cell Proliferation </A></B></P>
<P>Alveolar epithelial injury occurs universally in common respiratory
illnesses associated with diffuse lung damage. After alveolar injury, type II
cells proliferate and reestablish epithelial integrity, thereby restoring normal
lung structure and function. However, the regulation of type II cell
proliferation and alveolar epithelial repair is poorly understood. Hepatocyte
growth factor/scatter factor (HGF/SF) is a heparin-binding growth factor that
has been shown to be mitogenic for cultured alveolar type II cells. In this
study, we determined the effect of intratracheal instillation of rhHGF/SF on
type II cell proliferation <I>in vivo.</I> To quantify the alveolar type II
cell proliferative response, we developed a double-label immunohistochemical
technique to detect replicating alveolar type II cells in formalin-fixed lung
sections that utilized the identification of proliferating cells by
bromodeoxyuridine (BrdUrd) incorporation into DNA and alveolar type II cells by
3F9 immunoreactivity. BrdUrd detection was optimized by enzymatic antigen
recovery and silver intensification of the horseradish peroxidase reaction
product. Intratracheal instillation of rhHGF/SF induced a time- and
dose-dependent increase in type II cell proliferation. The type II cell labeling
index increased to 12.3 &#177; 6.0% 48 h after 1.0 mg/kg rhHGF/SF
administration, compared with 2.6 &#177; 0.9% after PBS instillation. To compare
the normal type II cell reparative response with the level of proliferation
after exogenous rhHGF/SF administration, we measured the specific alveolar type
II cell labeling index in rat lung sections obtained from animals exposed to
hyperoxia for 50 h and then allowed to recover in room air. After 1 day of
recovery, the alveolar type II cell labeling index was 0.45 &#177; 0.2%. The
specific labeling index increased to 5.4 &#177; 1.3% at 2 days and then declined
to 0.31 &#177; 0.16% 5 days after hyperoxia exposure. In animals not exposed to
hyperoxia, the alveolar type II cell labeling index was 0.6 &#177; 0.14%. These
studies demonstrated that intratracheal instillation of rhHGF/SF promoted
alveolar type II cell proliferation <I>in vivo.</I> The maximal level of type
II cell proliferation after rhHGF/SF administration was more than twice that
reached during recovery from hyperoxia exposure. Thus, intratracheal
instillation of HGF/SF may provide a potential strategy to promote type II cell
proliferation and augment alveolar epithelial repair after lung injury. <B>Panos,
R. J., R. Patel, and P. M. Bak. 1996. Intratracheal administration of hepatocyte
growth factor/scatter factor stimulates rat alveolar type II cell proliferation
in vivo. Am. J. Respir. Cell Mol. Biol. 15:574&#150;81.</B></P>
<TABLE BORDER="1">
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#top">BACK TO MENU</A></B></SMALL></TD></TR></TABLE>
<P></P>
<HR>
<P><B><A NAME="ats3">Evidence for Major Basic Protein Immunoreactivity and
Interleukin 5 Gene Activation during the Late Phase Response in Explanted
Airways</A></B></P>
<P>Current evidence suggests that the events subsequent to antigen challenge in
allergic asthmatics involve eosinophil activation and the synthesis of
proinflammatory cytokines, in particular interleukin 5 (IL-5). However, little
is known about how local inflammatory cell infiltration and activation are
related to the changes in lung function following allergen exposure. We have
developed a novel technique to investigate the local inflammatory events during
late-onset allergic bronchoconstriction in lung explants from sensitized
Brown-Norway (BN) rats. In this study we tested the hypothesis that the <I>in
vitro</I> late airway response involves IL-5 gene activation and recruitment and
activation of eosinophils. Explants were prepared from excised lungs of BN rats
(<I>n</I> = 9) sensitized 2 wk previously to ovalbumin (OVA). Lungs were
inflated with liquid agarose solution (2% wt/vol, 48 ml/kg) following perfusion
with cold Ca2+/Mg2+-free Hanks' solution, and refrigerated briefly to gel the
agarose, and 0.5- to 1.0-mm slices were prepared and cultured overnight at 37&#183;C.
Airways were identified and challenged by direct application of OVA (20 mg).
Cryostat sections of explants were immunostained for major basic protein (MBP)
and IL-5 mRNA was detected by a 35S-uridine triphosphate-labeled probe and <I>in
situ</I> hybridization. Explants harvested immediately prior to challenge showed
little evidence of MBP and IL-5 mRNA expression. Explants harvested at 6 h which
exhibited evidence of bronchoconstriction showed strong cell-associated
immunostaining for MBP and high expression of IL-5 mRNA in the bronchial mucosa.
Colocalization studies performed in lung explants demonstrating late-onset
airway responses suggested that the majority of IL-5 mRNA expression was not
found in MBP-positive cells. When compared with explants from sham-sensitized
rats (<I>n</I> = 4), there was a significant increase in MBP-positive and IL-5
mRNA-positive cells per millimeter of basement membrane of the airway. The
presence of MBP immunoreactivity and IL-5 gene expression was not observed in
explants taken from sensitized BN rats which did not undergo late-onset airway
responses, indicating an association between inflammatory cell activation and
airway constriction. The increase in MBP-positive cells several hours after OVA
suggests activation, local recruitment, and/or differentiation of eosinophils.
This study provides direct evidence for a temporal association between IL-5
expression, eosinophil infiltration, and the late response in individual
cultured airways. <B>Eidelman, D. H., E. Minshall, R. J. Dandurand, E.
Schotman, Y. L. Song, Z. Yasruel, R. Moqbel, and Q. Hamid. 1996. Evidence for
major basic protein immunoreactivity and interleukin 5 gene activation during
the late phase response in explanted airways. Am. J. Respir. Cell Mol. Biol.
15:582&#150;89.</B></P>
<TABLE BORDER="1">
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#top">BACK TO MENU</A></B></SMALL></TD></TR></TABLE>
<P></P>
<HR>
<P><B><A NAME="ats4">Enhanced Growth Response of Airway Smooth Muscle in
Inbred Rats with Airway Hyperresponsiveness</A></B></P>
<P>The highly inbred Fisher rat strain demonstrates both hyperresponsiveness of
the airways to bronchoconstrictors and increased amounts of airway smooth muscle
when compared with Lewis rats. We postulated that the excess airway smooth
muscle in Fisher was attributable to a greater sensitivity to endogenous
mitogenic stimuli with signaling mechanisms common to contractile stimuli. To
test this possibility we investigated differences in the growth response of
cultured airway smooth muscle cells (SMC) from these two strains. The Fisher SMC
demonstrated an enhanced growth response to fetal bovine serum (FBS), as
measured both by cell counting and [3H]thymidine incorporation. The difference
in growth response was attributable to a more rapid transition in Fisher than
Lewis SMC from the G0/G1 phase to the S phase of the cell cycle. When SMC growth
was stimulated by either serotonin, endothelin 1, insulin, platelet-derived
growth factor (PDGF), or combinations of the above factors, significant
interstrain growth response differences were found only with either human PDGF
(AB) or a combination of porcine PDGF (BB) and insulin. A polyclonal antibody to
PDGF was less inhibitory to Fisher than Lewis SMC following stimulation with
FBS. Thus, interstrain growth differences may reflect different responses to
PDGF present in FBS, or to other factors which exert an influence during the G0
or G1 phase of the cell cycle. <B>Zacour, M. E., and J. G. Martin. 1996.
Enhanced growth response of airway smooth muscle in inbred rats with airway
hyperresponsiveness. Am. J. Respir. Cell Mol. Biol. 15:590&#150;99.</B></P>
<TABLE BORDER="1">
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#top">BACK TO MENU</A></B></SMALL></TD></TR></TABLE>
<P></P>
<HR>
<P><B><A NAME="ats5">Differential Expression of aE&szlig;7 Integrins on
Bronchoalveolar Lavage T Lymphocyte Subsets: Regulation by a4&szlig;1-integrin
Crosslinking and TGF-&szlig;</A></B></P>
<P>T lymphocytes expressing the aE&szlig;7 integrin are localized and
selectively retained in mucosal tissues. To investigate a potential relationship
between aE&szlig;7 expression and pulmonary inflammation, the distribution of aE&szlig;7-bearing
CD4+ and CD8+ T cells in peripheral blood and bronchoalveolar lavage (BAL)
fluids obtained from patients with allergic asthma, sarcoidosis,
hypersensitivity pneumonitis, and idiopathic pulmonary fibrosis (IPF) was
determined. In contrast to the distribution in peripheral blood, BAL fluid from
these patients contained high number of cells expressing aE&szlig;7 with
markedly different expression patterns on CD4 or CD8 cells as well as among the
various diseases. Despite similar numbers of activated CD4 cells, aE&szlig;7CD4+
T cells ranged from 15% in asthmatics to 70% in IPF. In contrast, even in normal
individuals, 60% to 90% of BAL fluid CD8+ T cells express aE&szlig;7, suggesting
differential induction mechanisms on CD4 and CD8 cells. <I>In vitro</I>
experiments revealed that a substantial proportion of peripheral blood CD8+ T
cells express aE&szlig;7 after stimulation with anti-CD3 antibodies, and up to
80% positive cells were found after the addition of TGF-&szlig;. In contrast,
less than 10% of CD4 cells express this particular integrin after <I>in vitro</I>
stimulation, and the presence of TGF-&szlig; only increased the number to 30%.
Supernatants from <I>in vitro</I>-activated BAL cells as well as concentrated
BAL fluid from patients with high aE&szlig;7 expression had no further enhancing
effect. However, crosslinking of a4&szlig;1-, but not &szlig;2-integrins,
significantly increased the number of aE&szlig;7 expressing CD4+ and CD8+ T
cells, even in the absence of TGF-&szlig;. These data indicate that in addition
to TGF-&szlig;, the interaction of particular T-cell subsets with specific
endothelial cell and extracellular matrix proteins may upregulate aE&szlig;7
integrin expression and thereby contribute to the selective accumulation of
these cells in inflammatory lung diseases. <B>Rihs, S., C. Walker, J.-C.
Virchow, Jr., C. Boer, C. Kroegel, S. N. Giri, and R. K. Braun. 1996.
Differential expression of aE&szlig;7 integrins on bronchoalveolar lavage T
lymphocyte subsets: regulation by a4&szlig;1-integrin crosslinking and TGF-&szlig;.
Am. J. Respir. Cell Mol. Biol. 15:600&#150;10.</B></P>
<TABLE BORDER="1">
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#top">BACK TO MENU</A></B></SMALL></TD></TR></TABLE>
<P></P>
<HR>
<P><B><A NAME="ats6">Postpneumonectomy Lung Growth: A Model of Reinitiation
of Tropoelastin and Type I Collagen Production in a Normal Pattern in Adult Rat
Lung</A></B></P>
<P>Elastic and collagen fibers confer recoil and tensile strength on the
pulmonary vasculature, airways, alveolar walls, and pleura. These durable
extracellular matrix components are primarily synthesized during lung
development and growth, and are expressed at very low levels in healthy adult
lung. However, reinitiation of elastin and collagen synthesis in diseases of
adult lung, such as idiopathic pulmonary fibrosis, often leads to excessive or
aberrant deposition of elastin and collagen which contribute to the
pathophysiology of these diseases. We used an experimental model of
postpneumonectomy lung growth to determine whether normal patterns of synthesis
and deposition of these critical structural components can occur in the adult
lung. Male Sprague-Dawley rats (250&#150;300 grams) were subjected to left
pneumonectomy and right lobectomy. The remaining lung tissue was harvested for
analysis after 3, 7, or 14 days. Compensatory growth of the remaining right lung
progressed throughout the time course. Total desmosine and hydroxyproline
content increased in the postpneumonectomy lung, reflecting increased elastin
and collagen accumulation, but both were normal in content per weight of lung
tissue. Northern analysis demonstrated induction of tropoelastin and type I
procollagen mRNA expression in lungs of pneumonectomy rats. <I>In situ</I>
hybridization localized tropoelastin and type I procollagen mRNA expression to
anatomical sites similar to those seen during lung development. These data
indicate that the adult lung can reinitiate elastin and collagen production and
deposit these extracellular matrix components in a normal pattern. <B>Koh, D.
W., J. D. Roby, B. Starcher, R. M. Senior, and R. A. Pierce. Postpneumonectomy
lung growth: a model of reinitiation of tropoelastin and type I collagen
production in a normal pattern in adult rat lung. Am. J. Respir. Cell Mol. Biol.
15:611&#150;23.</B></P>
<TABLE BORDER="1">
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#top">BACK TO MENU</A></B></SMALL></TD></TR></TABLE>
<P></P>
<HR>
<P><B><A NAME="ats7">Epithelial Barrier Integrity During ITIn Vitro Wound
Repair of the Airway Epithelium</A></B></P>
<P>The surface epithelium of the airway mucosa forms a continuous barrier to a
wide number of noxious substances present in the lumen. The restoration of the
barrier integrity after injury represents a key issue in the defense capacity of
the airway epithelium. Using an <I>in vitro</I> wound repair model of the
airway epithelium, we investigated the dynamic of the restoration of the
epithelial barrier integrity during the wound repair process. Airway epithelial
cells in culture were chemically wounded by sodium hydroxide. The
immunolocalization of zonula occludens 1 (ZO-1), a cytoplasmic protein
associated with the tight junctions, was examined during the wound repair
process. Junctional integrity was examined by analyzing the transepithelial
resistance (TER) and the permeability to [3H]mannitol and by visualizing the
permeability to lanthanum nitrate during 5 days after injury. Immediately after
injury, we simultaneously observed a 36.7% decrease in the TER and a 74.9% rise
in the permeability to [3H]mannitol. In addition, lanthanum nitrate penetrated
in the intercellular spaces in the repairing area, which was also characterized
by the absence of ZO-1 staining, as opposed to nonrepairing cells. TER and
[3H]mannitol flux values as well as lanthanum nitrate and ZO-1 localizations
were found to be similar to those observed in confluent cultures only 1 to 2
days after complete wound closure. This study demonstrates that using our
culture model, confluent airway epithelial cells form a continuous and efficient
barrier with tight junctions. Epithelial integrity is affected immediately after
injury and is completely restored within 1 to 2 days after wound closure. During
such a period of time, the airway epithelium may remain exposed to the noxious
effect of environment <I>in vivo</I>, which can prevent the epithelial barrier
restoration by modifying tight junction formation. <B>Herard, A.-L., J.-M.
Zahm, D. Pierrot, J. Hinnrasky, C. Fuchey, and E. Puchelle. 1996. Epithelial
barrier integrity during <I>in vitro</I> wound repair of the airway epithelium.
Am. J. Respir. Cell Mol. Biol. 15:624&#150;32.</B></P>
<TABLE BORDER="1">
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#top">BACK TO MENU</A></B></SMALL></TD></TR></TABLE>
<P></P>
<HR>
<P><B><A NAME="ats8">Pulmonary Artery NADPH-oxidase Is Activated in Hypoxic
Pulmonary Vasoconstriction</A></B></P>
<P>An NADPH-oxidase complex containing at least two protein components (gp91-<I>phox</I>
and p22-<I>phox</I>) and a unique low redox potential (&#190;245mV) cytochrome
b&#190;245 is the source of superoxide generated for bacterial killing in
neutrophils and has been suggested as the oxygen sensor in the carotid body. In
pure cultures of smooth muscle cells from calf small pulmonary arteries (300 mm
diameter) the presence of the 91 kD protein specific to this cytochrome was
demonstrated by Western blot analysis with monoclonal antibody 48.
Low-temperature-difference spectrophotometry of homogenates of these cells
demonstrated the characteristic cytochrome b&#190;245 spectrum when titrated
between redox potentials of &#190;152 and &#190;345 mV, consistent with the low
redox potential form. When these same cells were exposed to hypoxia (~ 40 mmHg),
superoxide production increased significantly from 1.4 &#177; 0.2 to 73 &#177;
12 nmoles.min&#190;1 mg&#190;1 protein. Hypoxic generation of superoxide was
inhibited by the NADPH-oxidase inhibitor diphenyleneiodonium (DPI: 10 mM) but
not by the mitochondrial inhibitor myxathiazole (10 mM). The hypoxic superoxide
increase was significantly greater than that observed from smooth muscle cells
from large pulmonary arteries or from large or small systemic arteries.
Fluorescence immunocytochemistry revealed the presence of the NADPH-oxidase
protein in the walls of pulmonary arteries in rat lung slices, and confocal
microscopy showed the complex to be widely distributed in the vicinity of the
arterial smooth muscle walls. In hypoxia or norepinephrine (NP)-induced
vasoconstriction of pulmonary artery rings from cats, the sensitivity to
inhibition by DPI was observed to be significantly greater for hypoxia (ED50 =
0.8 mM) than for NP-induced (ED50 = 13.4 mM) constriction. Together these
observations demonstrate that the unique cytochrome b&#190;245 containing
NADPH-oxidase is present in pulmonary artery smooth muscle and that an
NADPH-oxidase or NADH-oxidoreductase complex is activated to release superoxide
by hypoxic conditions. It is concluded that a trans-membrane NADPH-oxidase is
the most likely and that activation of this system may be involved in the
initiation of hypoxic pulmonary vasoconstriction. <B>Marshall, C., A. J.
Mamary, A. J. Verhoeven, and B. E. Marshall. 1996. Pulmonary artery
NADPH-oxidase is activated in hypoxic pulmonary vasoconstriction. Am. J. Resp.
Cell Mol. Biol. 15:633&#150;44.</B></P>
<TABLE BORDER="1">
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#top">BACK TO MENU</A></B></SMALL></TD></TR></TABLE>
<P></P>
<HR>
<P><B><A NAME="ats9">Increased Levels of CD34+ Hemopoietic Progenitor Cells
in Atopic Subjects</A></B></P>
<P>We investigated the contribution of hemopoietic progenitors to the
accumulation of inflammatory cells in allergic airways disease. Using a
multiparameter flow-cytometric method, the detection of peripheral blood (PB)
and bone marrow (BM) cells expressing CD34, a progenitor cell marker, was
explored. True CD34+ blast cells were detected as a discrete cluster exhibiting
low intensity CD45 expression, low granularity, and low to intermediate cell
size. A significantly greater number of CD34+ cells was detected in the PB of
atopic individuals (1,438 &#177; 347/106 nonadherent mononuclear cells [NAMNC],
<I>n</I> = 19) compared with nonatopics (236 &#177; 77/106 NAMNC, <I>n</I> =
13; <I>P</I> = 0.006). Similarly, in BM samples, a significantly greater number
of CD34+ cells was detected in atopic (17,537 &#177; 4,986/106 NAMNC, <I>n</I>
= 7) compared with nonatopic subjects (6,422 &#177; 1,853/106 NAMNC, <I>n</I> =
13, <I>P</I> = 0.02). Greater numbers of total colony-forming units (CFU)
(granulocyte/macrophage [GM] and Eo/Baso) were present in cultures of PB NAMNC
from atopics (24 &#177; 5 CFU/106 NAMNC) cultured with recombinant human
interleukin 5 (rhIL-5) (1 ng/ml) compared with nonatopics (5 &#177; 2 CFU/106
NAMNC; <I>P</I> = 0.003). Analyses of colony subtypes showed significantly
greater numbers of IL-5&#150;responsive Eo/Baso-CFU in cultures from atopics (15
&#177; 2 CFU/106 NAMNC) compared with nonatopics (5 &#177; 2 CFU/106 NAMNC; <I>P</I>
= 0.011). In contrast, no significant differences in colony counts were found
between the two subject groups in cultures with rhIL-3 (1 ng/ml) or rhGM-CSF (10
ng/ml). A positive correlation was observed between PB CD34+ cell numbers and
total CFU in cultures with rhIL-5 (<I>r</I> = 0.43, <I>n</I> = 32, <I>P</I> =
0.01) and rhGM-CSF (<I>r</I> = 0.45, <I>n = 32, </I><I>P</I> = 0.009).
Purging BM NAMNC with an anti-CD34 monoclonal antibody completely abrogated <I>in
vitro</I> colony growth, supporting the view that a subset of CD34+ cells
represents the relevant population of progenitors growing in culture. These data
indicate that flow cytometric estimation of CD34+ cells is predictive of the
colony-forming capacity of the sample and may be a useful alternative tool to
clonogenic assays for enumerating progenitors. In addition, raised levels of
CD34+ cells and IL-5&#150;responsive Eo/Baso-CFU in atopics, including patients
with atopic asthma, indicate a role for progenitors in allergic airways disease.
<B>Sehmi, R., K. Howie, D. R. Sutherland, W. Schragge, P. M. O'Byrne, and J. A.
Denburg. 1996. Increased levels of CD34+ hemopoietic progenitor cells in atopic
subjects. Am. J. Respir. Cell Mol. Biol. 15:645&#150;55.</B></P>
<TABLE BORDER="1">
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#top">BACK TO MENU</A></B></SMALL></TD></TR></TABLE>
<P></P>
<HR>
<P><B><A NAME="ats10">Intra-alveolar Macrophage-inflammatory Peptide 2
Induces Rapid Neutrophil Localization in the Lung</A></B></P>
<P>Endotoxin-induced lung injury is characterized by neutrophil infiltration of
the lungs. The various mechanisms which mediate movement of neutrophils from
vascular space to lung interstitium and alveoli remain unclear.
Macrophage-inflammatory protein 2 (MIP-2) is a potent chemoattractant for
neutrophils and may play a significant role in recruiting neutrophils in acute
lung injury in rats. Experiments were performed in male Sprague Dawley rats to:
(<I>1</I>) evaluate the kinetics of neutrophil influx in the lung following
intraperitoneal administration of <I>Salmonella enteritidis</I>
lipopolysaccharide (LPS); (<I>2</I>) determine the expression of transcripts
for chemokines and adhesion molecules in the lung following intraperitoneal LPS;
and (<I>3</I>) elucidate the effects of intra-alveolar instillation of
recombinant rat MIP-2 on neutrophil influx into the lung. Intraperitoneal LPS
resulted in an increase in neutrophil sequestration in the lung capillaries of
rats as early as 45 min following administration, and there was a parallel
increase in lung myeloperoxidase activity. There were also major increases in
mRNA in whole-lung homogenates of LPS-treated rats for chemokines MIP-2 and KC
(cytokine-induced neutrophil chemoattractant) and adhesion molecules P- and
E-selectin at 1 and 2 h following LPS. When recombinant rat MIP-2 was instilled
into the alveolar space of rats through a catheter wedged into a bronchus, there
was profound neutrophil localization both in the vascular and alveolar space
which significantly differed (<I>P</I> &lt; 0.05) from the contralateral lungs
of the same animals, and lungs of control animals instilled with control buffer.
These observations reveal that MIP-2 is a potent chemoattractant in rat lungs,
and suggest that chemoattractants locally released in alveoli can recruit
neutrophils to those alveoli. This suggests that alveolar macrophages may play
an important role in neutrophil sequestration in sepsis and other inflammatory
lung diseases which produce a neutrophilic alveolitis. <B>Gupta, S., L. Feng,
T. Yoshimura, J. Redick, S. M. Fu, and C. E. Rose, Jr. 1996. Intra-alveolar
macrophage-inflammatory peptide 2 induces rapid neutrophil localization in the
lung. Am. J. Respir. Cell Mol. Biol. 15:656&#150;63.</B></P>
<TABLE BORDER="1">
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#top">BACK TO MENU</A></B></SMALL></TD></TR></TABLE>
<P></P>
<HR>
<P><B><A NAME="ats11">Differential Regulation of Airway Epithelial Integrins
by Growth Factors</A></B></P>
<P>The pattern of integrin expression on human airway epithelium changes
significantly in injury or inflammation. In particular, two integrins, the
fibronectin receptor, a5&szlig;1 and the fibronectin/tenascin receptor av&szlig;6,
are expressed at low or undetectable levels in normal airways <I>in vivo</I>
but are induced in response to airway epithelial injury. We investigated the
effects of various growth factors known to be present in the airways on the
expression of constitutively expressed and inducible airway epithelial integrins
using flow cytometry. In primary cultures of human airway epithelial cells,
transforming growth factor-&szlig;1 (TGF&szlig;1) dramatically increased
expression of av&szlig;6 and essentially did not affect the expression of any
other integrin, including a5&szlig;1. In contrast, epidermal growth factor (EGF)
upregulated surface levels of both av&szlig;6 and a5&szlig;1 as well as a2&szlig;1.
Together, TGF&szlig;1 and EGF had an additive effect on av&szlig;6 and a5&szlig;1
expression while increasing levels of a2&szlig; and decreasing expression of a3&szlig;1-
and a6-containing integrins. In contrast, the transformed airway epithelial cell
line, BEAS-2B, expressed a markedly different repertoire of integrins. Integrin
expression on BEAS-2B cells was not affected by any of the growth factors tested
in this study. These results demonstrate that, in primary cultures of human
airway epithelial cells, the pattern of integrin expression can be dramatically
altered by growth factors. The inducible integrins, av&szlig;6, and a5&szlig;1
are most subject to regulation by growth factors and expression of each of these
can be differentially regulated. The differential regulation of the two
principal fibronectin receptors on airway epithelial cells suggests that they
may mediate different cellular responses to fibronectin. <B>Wang, A., Y.
Yokosaki, R. Ferrando, J. Balmes, and D. Sheppard. 1996. Differential regulation
of airway epithelial integrins by growth factors. Am. J. Respir. Cell Mol. Biol.
15:664&#150;72.</B></P>
<TABLE BORDER="1">
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#top">BACK TO MENU</A></B></SMALL></TD></TR></TABLE>
<P></P>
<HR>
<P><B><A NAME="ats12">Sharp Increase in Rat Lung Water Channel Expression in
the Perinatal Period </A></B></P>
<P>Three members of the water channel (aquaporin) family are expressed in adult
rat lung: CHIP28 (AQP-1), MIWC (AQP-4), and AQP-5. Because water channels may be
important in the clearance of fluid from the newborn lung, the expression of
water channels just before and after birth was investigated using the
ribonuclease (RNAse) protection assay. RNA was isolated from lungs, brain, and
heart of prenatal rats (fetal days F19, F20, and F21) and postnatal rats (days
+1, +2, +5, +7, +21, and adult). Transcript expression was measured relative to
a &szlig;-actin control by quantitative densitometry. Whereas &szlig;-actin mRNA
expression was nearly constant over time, distinct expression patterns were
observed for the three water channels. CHIP28 mRNA expression rose slowly from
days F19 to +1, then strongly at day +2, and remained elevated over the first
week. MIWC mRNA was weakly expressed prenatally, but strongly increased just
after birth. AQP-5 mRNA increased slowly and monotonically between days F20 and
+7. These patterns contrasted sharply with the developmental expression of
CHIP28 in heart, which decreased over time, and MIWC in brain.
Immunocytochemistry showed CHIP28 protein expression in capillary endothelia and
MIWC in airway epithelia by day +1; quantitative immunoblot analysis showed
increased CHIP28 protein expression over time. These findings are consistent
with a role of lung water channels in perinatal fluid clearance; however, proof
of physiologic significance will require functional measurements of air space&#150;capillary
water permeability. <B>Umenishi, F., E. P. Carter, B. Yang, B. Oliver, M. A.
Matthay, and A. S. Verkman. 1996. Sharp increase in rat lung water channel
expression in the perinatal period. Am. J. Respir. Cell Mol. Biol. 15:673&#150;79.</B></P>
<TABLE BORDER="1">
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#top">BACK TO MENU</A></B></SMALL></TD></TR></TABLE>
<P></P>
<HR>
<P><B><A NAME="ats13">Upregulatory Effects of Interleukin-4 and
Interleukin-13 but not Interleukin-10 on Granulocyte/macrophage
Colony-stimulating Factor Production by Human Bronchial Epithelial Cells</A></B></P>
<P>Airway epithelial cells are known to produce a granulocyte/macrophage
colony-stimulating factor (GM-CSF), which induces eosinophilic inflammation in
bronchial asthma. Interleukin-4 (IL-4), IL-10, and IL-13 produced by Th2 cells
are involved in the pathogenesis of bronchial asthma. To assess their
contributions to airway inflammation, we examined their effects on GM-CSF
production by bronchial epithelial cells. Human bronchial epithelial cells were
obtained under bronchoscopy from 21 patients with various respiratory diseases
and incubated with or without IL-4, IL-10, or IL-13. Then the GM-CSF
concentrations in the cell-free supernatants were measured by enzyme-linked
immunosorbent assay. Results showed that IL-4 and IL-13 stimulated GM-CSF
production by the epithelial cells dose-dependently, whereas IL-10 did not. The
eosinophil survival-stimulating activity in the culture supernatants was closely
correlated with GM-CSF concentration and was neutralized by anti-GM-CSF
antibody. Thus, IL-4 and IL-13 may contribute to airway inflammation by
upregulating GM-CSF production by bronchial epithelial cells. <B>Nakamura, Y.,
M. Azuma, Y. Okano, T. Sano, T. Takahashi, Y. Ohmoto, and S. Sone. 1996.
Upregulatory effects of interleukin-4 and interleukin-13 but not interleukin-10
on granulocyte/macrophage colony-stimulating factor production by human
bronchial epithelial cells. Am. J. Respir. Cell Mol. Biol. 15:680&#150;87.</B></P>
<TABLE BORDER="1">
<TR>
<TD ALIGN="LEFT" VALIGN="MIDDLE"><SMALL><B><A HREF="#top">BACK TO MENU</A></B></SMALL></TD></TR></TABLE>
<P></P>
<HR SIZE="4" WIDTH="80%">
<CENTER><A HREF="about.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/about.gif" ALT="About Society"></A>
<A HREF="ssg.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/ss.gif" ALT="Society Structure"></A>
<A HREF="calendar.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/calendar.gif" ALT="ATS Calendar"></A>
<A HREF="gpi.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/pi.gif" ALT="Gen Public Info"></A>
<A HREF="ms.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/memserv.gif" ALT="Memb Serv"></A>
<BR>
<A HREF="pub.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/pubs.gif" ALT="Publications"></A>
<A HREF="press.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/press.gif" ALT="Press"></A>
<A HREF="index.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/home.gif" ALT="Home Page"></A>
<A HREF="search.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/search.gif" ALT="Search"></A>
<A HREF="assemb.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/assemb.gif" ALT="Assemblies"></A>
<A HREF="research.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/research.gif" ALT="Research"></A>
<BR>
<A HREF="mep.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/meded.gif" ALT="Med Education"></A>
<A HREF="wr.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/wr.gif" ALT="Wash Report"></A>
<A HREF="ic.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/ic.gif" ALT="Int'l Conference"></A>
<A HREF="source.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/link.gif" ALT="Web Links"></A>
<A HREF="store.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/store.gif" ALT="Store"></A> 
<A HREF="sig.html"><IMG SRC="images/special.gif" ALT="Special" HSPACE=1 VSPACE=1 BORDER=0 HEIGHT=35 WIDTH=84></A>
</CENTER>
<HR SIZE="4" WIDTH="80%">
<CENTER><FONT SIZE="+2"><B><I>American Thoracic Society</I></B></FONT><BR>
1740 Broadway<BR> New York, NY 10019<BR> VOICE:  212-315-8700<BR> Copyright &copy;
1996 American Lung Association.<BR> The American Thoracic  Society is the
medical section <BR>of the American Lung Association.<BR> 
</CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-174</DOCNO>
<DOCOLDNO>IA013-000141-B027-56</DOCOLDNO>
<DOCHDR>
http://www.thoracic.org:80/art.html 206.138.195.144 19970217073658 text/html 5268
HTTP/1.0 200 OK
Date: Monday, 17-Feb-97 07:32:15 GMT
Server: NCSA/1.3
MIME-version: 1.0
Content-type: text/html
Last-modified: Friday, 20-Dec-96 20:23:44 GMT
Content-length: 5088
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//SQ//DTD HTML 2.0 HoTMetaL + extensions//EN">
<HTML>
<HEAD><TITLE>American Thoracic Society - Submitting the Best Quality Artwork</TITLE></HEAD>
<BODY BACKGROUND="images/back.jpg">
<CENTER><IMG ALIGN="LEFT" SRC="images/smlogo.gif"><BR><H1>Submitting the
Best Quality Artwork</H1></CENTER>
<HR SIZE="5" NOSHADE="NOSHADE" WIDTH="100%">
<P><BR><BR></P>
<CENTER><TABLE BORDER="2"><TR ALIGN="CENTER" VALIGN="MIDDLE"><TD COLSTART="1"><SMALL><A
HREF="redinfo.html">RETURN TO AJRCMB CONTACT PAGE</A></SMALL></TD></TR><TR
ALIGN="CENTER" VALIGN="MIDDLE"><TD COLSTART="1"><SMALL><A
HREF="blueinfo.html">RETURN TO AJRCCM CONTACT PAGE</A></SMALL></TD></TR></TABLE></CENTER>
<P></P>
<HR SIZE="5" WIDTH="70%">
<P><BR><BR>
</P>
<H2>Halftones</H2>
<P>These are generally black-and-white photographs such as light and electron
micrographs. The best quality photographs include a continuous gradient of tone
from black to pale gray. If several pictures are to be printed as one group,
reproduction will be best if all of the photographs have about the same level of
gray-black density.</P>
<P>Please consider the size and orientation of your figures as they will appear
on the printed page. If you have not trimmed the figures to fit the single- or
double-column width of the journal, you must provide an overlay on the figure
with the important areas circled so that the printer can trim it appropriately.</P>
<H2>Color Figures</H2>
<P>Color illustrations may be submitted as either a print or a transparency,
although a color print is preferred. The best reproduction will be obtained from
an original print rather than from copies made of it. Figures consisting of
multiple pieces will yield the best reproduction if they are separated into
groupings of similar colors. The cost of publishing color prints will be borne
by the author.</P>
<H2>Line Drawings and Graphs</H2>
<P>Unmounted glossy prints are preferred. Computer graphics are discouraged
because they may not have sharp lines and distinct letters when reproduced
photographically. All symbols and letters should be sized proportionately to the
figure so that they are readable when the figure is reproduced. Broken lines and
poorly reproduced symbols cannot be corrected by the printer.</P>
<H2>Tables</H2>
<P>Tables should be submitted typed as the rest of the manuscript. They should
be formatted so that they will fit vertically in a single- or double-column page
width.</P>
<P>Remember, it is very expensive to re-shoot illustrations at the time you
receive the proofs of your article. It is in your best interest to submit the
best quality artwork.</P>
<P><B>For Assistance Please Contact:</B><BR>American Thoracic Society,
Editorial Division<BR>1740 Broadway, New York, NY 10019-4374.  Phone
(212)315-6440; FAX (212)315-6455. E-Mail:
<A HREF="mailto:cshepherd@lungusa.org">cshepherd@lungusa.org</A></P>
<P><BR><BR> 
</P>
<HR SIZE="4" WIDTH="80%"> 
<CENTER>
<A HREF="about.html"><IMG VSPACE="1" HSPACE="1" BORDER="0" 
SRC="images/about.gif" ALT="About Society"></A>
<A HREF="ssg.html"><IMG VSPACE="1" HSPACE="1" BORDER="0" 
SRC="images/ss.gif" ALT="Society Structure"></A>
<A HREF="calendar.html"><IMG VSPACE="1" HSPACE="1" BORDER="0" 
SRC="images/calendar.gif" ALT="ATS Calendar"></A>
<A HREF="gpi.html"><IMG VSPACE="1" HSPACE="1" BORDER="0" 
SRC="images/pi.gif" ALT="Gen Public Info"></A>
<A HREF="ms.html"><IMG VSPACE="1" HSPACE="1" BORDER="0" 
SRC="images/memserv.gif" ALT="Memb Serv"></A>
<BR>
<A HREF="pub.html"><IMG VSPACE="1" HSPACE="1" BORDER="0" 
SRC="images/pubs.gif" ALT="Publications"></A>
<A HREF="press.html"><IMG VSPACE="1" HSPACE="1" BORDER="0" 
SRC="images/press.gif" ALT="Press"></A>
<A HREF="index.html"><IMG VSPACE="1" HSPACE="1" BORDER="0" 
SRC="images/home.gif" ALT="Home Page"></A>
<A HREF="search.html"><IMG VSPACE="1" HSPACE="1" BORDER="0" 
SRC="images/search.gif" ALT="Search"></A>
<A HREF="assemb.html"><IMG VSPACE="1" HSPACE="1" BORDER="0" 
SRC="images/assemb.gif" ALT="Assemblies"></A>
<A HREF="research.html"><IMG VSPACE="1" HSPACE="1" BORDER="0" 
SRC="images/research.gif" ALT="Research"></A>
<BR>
<A HREF="mep.html"><IMG VSPACE="1" HSPACE="1" BORDER="0" 
SRC="images/meded.gif" ALT="Med Education"></A>
<A HREF="wr.html"><IMG VSPACE="1" HSPACE="1" BORDER="0" 
SRC="images/wr.gif" ALT="Wash Report"></A>
<A HREF="ic.html"><IMG VSPACE="1" HSPACE="1" BORDER="0" 
SRC="images/ic.gif" ALT="Int'l Conference"></A>
<A HREF="source.html"><IMG VSPACE="1" HSPACE="1" BORDER="0" 
SRC="images/link.gif" ALT="Web Links"></A>
<A HREF="store.html"><IMG VSPACE="1" HSPACE="1" BORDER="0" 
SRC="images/store.gif" ALT="Store"></A> 
<A HREF="sig.html"><IMG SRC="images/special.gif" ALT="Special" HSPACE=1 VSPACE=1 BORDER=0 HEIGHT=35 WIDTH=84></A>
</CENTER>
<HR SIZE="4" WIDTH="80%"> 
<CENTER><FONT SIZE="+2"><B><I>American Thoracic Society</I></B></FONT><BR>
1740 Broadway<BR> New York, NY 10019<BR> VOICE:  212-315-8700<BR> Copyright &#169;
1996 American Lung Association.<BR> The American Thoracic  Society is the
medical section <BR>of the American Lung Association.<BR> 
</CENTER>
</BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-175</DOCNO>
<DOCOLDNO>IA013-000141-B027-103</DOCOLDNO>
<DOCHDR>
http://www.thoracic.org:80/stmttime.html 206.138.195.144 19970217073710 text/html 6681
HTTP/1.0 200 OK
Date: Monday, 17-Feb-97 07:32:25 GMT
Server: NCSA/1.3
MIME-version: 1.0
Content-type: text/html
Last-modified: Friday, 27-Sep-96 21:20:53 GMT
Content-length: 6501
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//SQ//DTD HTML 2.0 HoTMetaL + extensions//EN">
<HTML>
<HEAD><TITLE>American Thoracic Society - Timetable for Development of
Statements and Position Papers</TITLE></HEAD>
<BODY BGCOLOR="#FFFFFF" BACKGROUND="images/back.jpg">
<CENTER><IMG ALIGN="LEFT" SRC="images/smlogo.gif"><BR><H1>Timetable for
Development of Statements and Position Papers</H1></CENTER>
<CENTER><IMG SRC="images/ybar.jpg" ALIGN="MIDDLE"></CENTER>
<P></P>
<CENTER><TABLE BORDER="2"><TR><TD COLSTART="1"><B><A
HREF="ncycle2.html#ats1"><SMALL>BACK TO PROJECT FORM</SMALL></A></B></TD></TR></TABLE><P></P></CENTER>
<CENTER><IMG SRC="images/ybar.jpg" ALIGN="MIDDLE"></CENTER>
<P></P>
<CENTER><TABLE BORDER="4"><TR ALIGN="CENTER" VALIGN="MIDDLE"><TD COLSTART="1"><B>Time
Period Prior to Board Meeting</B></TD><TD COLSTART="2"><B># of weeks need to
complete task</B></TD><TD COLSTART="3"><B>Steps</B></TD></TR><TR><TD
COLSTART="1" ALIGN="CENTER">1 Year or more</TD><TD COLSTART="2" ALIGN="CENTER">1
Month or less</TD><TD COLSTART="3">Develop a comprehensive strategy for the
development of the draft statement/position paper. This includes determining the
number and date of all future meetings and outlining the nature of
responsibilities required of each committee member. This can be done in a
one-day planning meeting.</TD></TR><TR><TD COLSTART="1" ALIGN="CENTER">
1 Year or more</TD><TD COLSTART="2" ALIGN="CENTER">6 Months or less</TD><TD
COLSTART="3">Develop a draft document. This is usually accomplished using the
following strategies: Meetings, Conference Calls, fax, mail.</TD></TR><TR><TD
COLSTART="1" ALIGN="CENTER">20 Weeks</TD><TD COLSTART="2" ALIGN="CENTER">4
Weeks</TD><TD COLSTART="3">Circulate the final draft document to all members of
the writing committee; poll members to ensure that they are comfortable with the
content. Work out any last minute issues.</TD></TR><TR><TD
COLSTART="1" ALIGN="CENTER">16 Weeks</TD><TD COLSTART="2" ALIGN="CENTER">1
Week</TD><TD COLSTART="3">The Assembly Chairman will be asked to appoint 2 or
more expert reviewers to review the document.</TD></TR><TR><TD
COLSTART="1" ALIGN="CENTER">15 Weeks</TD><TD COLSTART="2" ALIGN="CENTER">5
Weeks or more</TD><TD COLSTART="3">Potential reviewers will be invited to serve
as official reviewers.
<BR><BR>Draft document and &quot;reviewer instructions&quot; are sent to all
confirmed reviewers.<BR><BR>Reviewers will complete their reviews. Reviewers
are encouraged to contact members of the writing committee as the need arises to
discuss the document.<BR><BR>Reviewers will forward their original set of
comments to the ATS Office.</TD></TR><TR><TD COLSTART="1" ALIGN="CENTER">10
Weeks</TD><TD COLSTART="2" ALIGN="CENTER">6 Weeks</TD><TD COLSTART="3">Reviewer's
comments will be forwarded to the chairman of the writing committee, who will
then;<BR>A) formulate a response to the reviews and<BR>B) modify the document
accordingly. The typical response documents whether or not the reviewers'
comments were accepted or rejected and how the Statement or Position Paper was
modified re: Reviewer's comments.<BR><BR>It may be decided to re-circulate the
document to members of the writing committee for final approval if the new
document differs significantly from the one that was approved previously.</TD></TR><TR
><TD COLSTART="1" COLSPAN="2" ALIGN="CENTER">4 Weeks</TD><TD COLSTART="3">At
this time, the document should be in the final stages of preparation. You must
forward the final document to the ATS Office at least 3 weeks prior to the Board
meeting.</TD></TR><TR><TD COLSTART="1" COLSPAN="2" ALIGN="CENTER">At the Board
of Directors Meeting</TD><TD COLSTART="3">The Chairman of the writing committee
will attend the Board meeting to &quot;defend&quot; the document if deemed
necessary.
</TD></TR><TR><TD COLSTART="1" COLSPAN="2" ALIGN="CENTER">After the Board
Meeting</TD><TD COLSTART="3">If the document is approves as is, we will prepare
and submit if for publication in the AJRCCM.<BR><BR>If the document was
approved with modifications, the chairman of the writing committee is
responsible for making all changes and submitting the new document to the ATS
Office. The ATS Office will then prepare and submit it for publication in the
AJRCCM.<BR><BR>If the document is rejected, it needs to go back to the
committee for major modifications. The chairman will bring it back to the Board
at a later date.</TD></TR></TABLE></CENTER>
<P><BR><BR> 
</P>
<HR SIZE="4" WIDTH="80%"> 
<CENTER>
<A HREF="about.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/about.gif" ALT="About Society"></A>
<A HREF="ssg.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/ss.gif" ALT="Society Structure"></A>
<A HREF="calendar.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/calendar.gif" ALT="ATS Calendar"></A>
<A HREF="gpi.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/pi.gif" ALT="Gen Public Info"></A>
<A HREF="ms.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/memserv.gif" ALT="Memb Serv"></A>
<BR>
<A HREF="pub.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/pubs.gif" ALT="Publications"></A>
<A HREF="press.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/press.gif" ALT="Press"></A>
<A HREF="index.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/home.gif" ALT="Home Page"></A>
<A HREF="search.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/search.gif" ALT="Search"></A>
<A HREF="assemb.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/assemb.gif" ALT="Assemblies"></A>
<A HREF="research.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/research.gif" ALT="Research"></A>
<BR>
<A HREF="mep.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/meded.gif" ALT="Med Education"></A>
<A HREF="wr.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/wr.gif" ALT="Wash Report"></A>
<A HREF="ic.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/ic.gif" ALT="Int'l Conference"></A>
<A HREF="source.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/link.gif" ALT="Web Links"></A>
<A HREF="store.html"><IMG
VSPACE="1" HSPACE="1" BORDER="0" SRC="images/store.gif" ALT="Store"></A> 
</CENTER>
<HR SIZE="4" WIDTH="80%"> 
<CENTER><FONT SIZE="+2"><B><I>American Thoracic Society</I></B></FONT><BR>
1740 Broadway<BR> New York, NY 10019<BR> VOICE:  212-315-8700<BR> Copyright &#169;
1996 American Lung Association.<BR> The American Thoracic  Society is the
medical section <BR>of the American Lung Association.<BR> 
</CENTER>
</BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-176</DOCNO>
<DOCOLDNO>IA013-000140-B014-91</DOCOLDNO>
<DOCHDR>
http://www.thoracic.org:80/ 206.138.195.144 19970217061533 text/html 8854
HTTP/1.0 200 OK
Date: Monday, 17-Feb-97 06:10:49 GMT
Server: NCSA/1.3
MIME-version: 1.0
Content-type: text/html
Last-modified: Friday, 14-Feb-97 20:57:15 GMT
Content-length: 8674
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 3.2//EN">
<HTML>
<HEAD>
<TITLE>American Thoracic Society</TITLE>
<META NAME="GENERATOR" CONTENT="Mozilla/3.0Gold (Win16; U) [Netscape]"></HEAD>
<BODY BGCOLOR="#FFFFFF" BACKGROUND="images/back1.jpg">
<CENTER>
<TABLE>
<TR>
<TD><IMG SRC="images/atsnew2.gif" HEIGHT="152" WIDTH="379" ALIGN="ABSBOTTOM">
</TD>
<TD><IMG SRC="images/globe2.gif" HEIGHT="90" WIDTH="90">
</TD></TR></TABLE>
<TABLE BORDER="0">
<TR ALIGN="CENTER" VALIGN="MIDDLE">
<TD><BR>
<B>The Medical Section of the:<BR>
<A HREF="http://www.lungusa.org/index.html"><IMG
SRC="images/lunglog2.gif" BORDER="0" HEIGHT="79" WIDTH="494" ALIGN="CENTER"></A></B></TD></TR></TABLE></CENTER>
<CENTER>
<P><A HREF="ic97/main.html"><IMG
SRC="images/confban.jpg" BORDER="0" HEIGHT="80" WIDTH="320"></A>
</P></CENTER>
<CENTER>
<P><A HREF="newinfo.html"><IMG
SRC="images/newanim2.gif" BORDER="0" WIDTH="60" HEIGHT="25"></A></P>
<TABLE BORDER="4" WIDTH="100%">
<TR ALIGN="CENTER" VALIGN="MIDDLE">
<TD COLSPAN="2"><B>SUBJECT</B></TD>
<TD COLSPAN="3"><B>CONTENTS</B></TD></TR>
<TR ALIGN="CENTER" VALIGN="MIDDLE">
<TD COLSPAN="2" ALIGN="LEFT"><IMG
SRC="images/shdbull.gif" HEIGHT="27" WIDTH="23" ALIGN="ABSCENTER"><B><A
HREF="about.html">About the Society:</A></B><BR>
</TD>
<TD COLSPAN="3" ALIGN="CENTER">
<TABLE>
<TR>
<TD><B><FONT SIZE="-1"><A HREF="mission.html">[ATS Mission Statement]</A></FONT></B></TD>
<TD><B><FONT SIZE="-1"><A HREF="by.html">[By-Laws]</A></FONT></B></TD>
<TD><B><FONT SIZE="-1"><A HREF="sum.html">[Society Update]</A></FONT></B></TD></TR></TABLE></TD></TR>
<TR ALIGN="CENTER" VALIGN="MIDDLE">
<TD COLSPAN="2" ALIGN="LEFT"><IMG
SRC="images/shdbull.gif" HEIGHT="27" WIDTH="23" ALIGN="ABSCENTER"><B><A
HREF="ssg.html">Structure &amp; Governance:</A></B><BR>
</TD>
<TD COLSPAN="3" ALIGN="CENTER">
<TABLE>
<TR ALIGN="CENTER" VALIGN="TOP">
<TD ALIGN="CENTER"><B><FONT SIZE="-1"><A HREF="leader.html">[ATS Leadership]</A></FONT></B></TD>
<TD><B><FONT SIZE="-1"><A HREF="committ.html">[Committees]</A></FONT></B></TD>
<TD><B><FONT SIZE="-1"><A HREF="bod.html">[Board of Directors]</A></FONT></B></TD></TR>
<TR ALIGN="CENTER" VALIGN="TOP">
<TD ALIGN="CENTER"><B><FONT SIZE="-1"><A HREF="chapters.html">[ATS Chapters]</A></FONT></B></TD>
<TD><B><FONT SIZE="-1"><A HREF="state.html">[State Thoracic Societies]</A></FONT></B></TD>
<TD><B><FONT SIZE="-1"><A HREF="national.html">[ATS Staff]</A></FONT></B></TD></TR></TABLE></TD></TR>
<TR ALIGN="LEFT" VALIGN="MIDDLE">
<TD COLSPAN="2" ALIGN="LEFT" VALIGN="MIDDLE"><IMG
SRC="images/shdbull.gif" HEIGHT="27" WIDTH="23" ALIGN="ABSCENTER">
<B><A HREF="calendar.html">Calendar of Events</A></B></TD>
<TD COLSPAN="3" ALIGN="CENTER" VALIGN="MIDDLE"><IMG
SRC="images/shdbull.gif" HEIGHT="27" WIDTH="23" ALIGN="ABSCENTER">
<B><A HREF="ms.html">Membership Services</A></B></TD></TR>
<TR ALIGN="CENTER" VALIGN="MIDDLE">
<TD ALIGN="CENTER" COLSPAN="5"><IMG
SRC="images/shdbull.gif" HEIGHT="27" WIDTH="23" ALIGN="ABSCENTER">
<B><A HREF="http://www.lungusa.org/index.html">General Public Information</A></B>
<B>(Link to the American Lung Association)</B></TD></TR>
<TR ALIGN="CENTER">
<TD COLSPAN="2" ALIGN="LEFT" VALIGN="MIDDLE"><IMG
SRC="images/shdbull.gif" HEIGHT="27" WIDTH="23" ALIGN="ABSCENTER"><B><A
HREF="pub.html">ATS Publications:</A></B><BR>
</TD>
<TD COLSPAN="3" ALIGN="LEFT">
<TABLE>
<TR>
<TD COLSPAN="2"><B><FONT SIZE="-1"><A HREF="bluemain.html">[American Journal
of Respiratory and Critical Care Medicine]</A></FONT></B></TD></TR>
<TR>
<TD COLSPAN="2"><B><FONT SIZE="-1"><A HREF="redmain.html">[American Journal
of Respiratory Cell and Molecular Biology]</A></FONT></B></TD></TR>
<TR ALIGN="CENTER" VALIGN="MIDDLE">
<TD><B><FONT SIZE="-1"><A HREF="news.html">[ATS News]</A></FONT></B></TD>
<TD><B><FONT SIZE="-1"><A HREF="statemnt.html">[Statements and Position
Papers]</A></FONT></B></TD></TR></TABLE></TD></TR>
<TR ALIGN="LEFT" VALIGN="MIDDLE">
<TD COLSPAN="5"><IMG
SRC="images/shdbull.gif" HEIGHT="27" WIDTH="23" ALIGN="ABSCENTER"><B><A
HREF="press.html">Press Releases:</A></B></TD></TR>
<TR ALIGN="CENTER" VALIGN="MIDDLE">
<TD COLSPAN="2" ALIGN="LEFT"><IMG
SRC="images/shdbull.gif" HEIGHT="27" WIDTH="23" ALIGN="ABSCENTER"><B><A
HREF="assemb.html">Assemblies:</A></B><BR>
</TD>
<TD COLSPAN="3" ALIGN="CENTER">
<TABLE>
<TR>
<TD><B><FONT SIZE="-1"><A HREF="assmb_ls.html">[Assembly Index]</A></FONT></B></TD>
<TD><B><FONT SIZE="-1"><A HREF="assmb_pr.html">[Assembly Projects]</A></FONT></B></TD></TR></TABLE></TD></TR>
<TR ALIGN="CENTER" VALIGN="MIDDLE">
<TD ALIGN="CENTER" COLSPAN="5"><IMG
SRC="images/shdbull.gif" HEIGHT="27" WIDTH="23" ALIGN="ABSCENTER"><B><A
HREF="http://www.lungusa.org/discover/research.html">Research</A> (Link to the
American Lung Association)</B></TD></TR>
<TR ALIGN="CENTER" VALIGN="MIDDLE">
<TD COLSPAN="2" ALIGN="LEFT"><IMG
SRC="images/shdbull.gif" HEIGHT="27" WIDTH="23" ALIGN="ABSCENTER"><B><A
HREF="mep.html">Medical Education:</A></B><BR>
</TD>
<TD COLSPAN="3" ALIGN="CENTER">
<TABLE>
<TR>
<TD><B><FONT SIZE="-1"><A HREF="atsed.html">[Education Programs]</A></FONT></B></TD>
<TD><B><FONT SIZE="-1"><A HREF="train.html">[Training Programs]</A></FONT></B></TD>
<TD><B><FONT SIZE="-1"><A HREF="cdpubs.html">[CD-ROM Programs]</A></FONT></B></TD></TR></TABLE></TD></TR>
<TR ALIGN="CENTER" VALIGN="MIDDLE">
<TD COLSPAN="2" ALIGN="LEFT"><IMG
SRC="images/shdbull.gif" HEIGHT="27" WIDTH="23" ALIGN="ABSCENTER"><B><A
HREF="wr.html">Washington Reports:</A></B><BR>
</TD>
<TD COLSPAN="3" ALIGN="CENTER">
<TABLE>
<TR ALIGN="CENTER" VALIGN="TOP">
<TD><B><FONT SIZE="-1"><A HREF="legupd.html">[Legislative Update]</A></FONT></B></TD>
<TD><B><FONT SIZE="-1"><A HREF="wrarch.html">[12 Month Legislative Archives]</A></FONT></B></TD></TR></TABLE></TD></TR>
<TR ALIGN="CENTER" VALIGN="MIDDLE">
<TD COLSPAN="2" ALIGN="LEFT"><IMG
SRC="images/shdbull.gif" HEIGHT="27" WIDTH="23" ALIGN="ABSCENTER"><B><A
HREF="ic.html">International Conference:</A></B><BR>
</TD>
<TD COLSPAN="3" ALIGN="CENTER">
<TABLE>
<TR>
<TD ALIGN="CENTER" VALIGN="CENTER" COLSPAN="2"><B><FONT SIZE="-1"><A
HREF="ic96.html">[Highlights of the 1996 International Conference]</A></FONT></B></TD></TR>
<TR>
<TD><B><FONT SIZE="-1"><A HREF="ic97/main.html">[1997 International
Conference]</A></FONT></B></TD>
<TD><B><FONT SIZE="-1"><A HREF="futrmeet.html">[Future Meeting Sites]</A></FONT></B></TD></TR></TABLE></TD></TR>
<TR ALIGN="CENTER" VALIGN="MIDDLE">
<TD COLSPAN="2" ALIGN="LEFT"><IMG
SRC="images/shdbull.gif" HEIGHT="27" WIDTH="23" ALIGN="ABSCENTER"><B><A
HREF="sig.html">Special Interest Groups:</A></B><BR>
</TD>
<TD COLSPAN="3" ALIGN="CENTER">
<TABLE>
<TR>
<TD><B><FONT SIZE="-1">[Quality of Life Information Center]</FONT></B></TD></TR></TABLE></TD></TR>
<TR ALIGN="LEFT" VALIGN="MIDDLE">
<TD COLSPAN="2" ALIGN="LEFT" VALIGN="MIDDLE"><IMG
SRC="images/shdbull.gif" HEIGHT="27" WIDTH="23" ALIGN="CENTER">
<B><A HREF="store.html">ATS Store</A></B></TD>
<TD COLSPAN="3" ALIGN="CENTER" VALIGN="MIDDLE"><IMG
SRC="images/shdbull.gif" HEIGHT="27" WIDTH="23" ALIGN="ABSCENTER">
<B><A HREF="source.html">Resource Links</A></B></TD></TR></TABLE>
<H2 ALIGN="CENTER"><A HREF="mailto:aprescott@lungusa.org"><IMG
SRC="images/2mailk.jpg" BORDER="0" HEIGHT="62" WIDTH="64"></A><BR>
<B><FONT SIZE="-1">COMMENTS/SUGGESTIONS?</FONT></B></H2></CENTER>
<CENTER>
<P></P></CENTER>
<HR SIZE="4" WIDTH="60%">
<H3 ALIGN="CENTER">Search the <I>American Thoracic Society Web Site</I><BR>
<A HREF="search.html"><IMG
SRC="images/searchbtn.gif" BORDER="0" HEIGHT="92" WIDTH="242" ALIGN="BOTTOM"></A></H3>
<P></P>
<HR SIZE="4" WIDTH="80%">
<H2 ALIGN="CENTER"><FONT COLOR="#408080">This SITE is best viewed when using<BR>
NETSCAPE NAVIGATOR 2.0 or better!</FONT></H2>
<P></P>
<HR SIZE="4" WIDTH="80%">
<CENTER>
<TABLE BORDER="5">
<TR>
<TD><A HREF="awards.html"><IMG
SRC="images/award.gif" BORDER="0" HEIGHT="150" WIDTH="120"></A></TD></TR></TABLE></CENTER>
<CENTER>
<P><BR>
<B><FONT SIZE="+1">TROPHY ROOM</FONT></B> </P></CENTER>
<CENTER>
<P></P></CENTER>
<HR SIZE="4" WIDTH="80%">
<CENTER>
<P><B><I><FONT SIZE="+2">American Thoracic Society<BR>
</FONT></I></B>1740 Broadway<BR> New York, NY 10019<BR> VOICE: 212-315-8700<BR>
ATS Webmaster, <A HREF="mailto:aprescott@lungusa.org">Andrew Prescott<BR>
</A>Copyright &copy; 1996 American Lung Association.<BR> The American Thoracic
Society is the medical section <BR> of the American Lung Association.<BR>
<BR>
<B>Creation By:<BR>
<BR>
<A HREF="http://www.vpe.com"><IMG
SRC="images/wsvpelog.gif" BORDER="0" HEIGHT="65" WIDTH="78"></A></B>
<BR>
<BR>
<B>Driven By:<BR>
<BR>
<A HREF="http://home.mcom.com/comprod/mirror/index.html"><IMG
SRC="images/ns.gif" HEIGHT="46" WIDTH="147"></A></B>
</P>
<P><BR>
</P></CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-177</DOCNO>
<DOCOLDNO>IA013-000140-B022-158</DOCOLDNO>
<DOCHDR>
http://www.thoracic.org:80/cgi-bin/imagemap/maps/usmap.map 206.138.195.144 19970217062909 text/html 269
HTTP/1.0 200 OK
Date: Monday, 17-Feb-97 06:24:26 GMT
Server: NCSA/1.3
MIME-version: 1.0
Content-type: text/html
</DOCHDR>
<title>Mapping Server Error</title><h1>Mapping Server Error</h1>This server encountered an error:<p>Wrong number of arguments, client may not support ISMAP.
</DOC>
<DOC>
<DOCNO>WT23-B18-178</DOCNO>
<DOCOLDNO>IA012-000124-B047-53</DOCOLDNO>
<DOCHDR>
http://www.independentliving.org:80/index.html 193.13.228.238 19970216213343 text/html 5071
HTTP/1.0 200 OK
Last-Modified: Sun, 16 Feb 1997 13:24:10 +0000
Date: Sun, 16 Feb 1997 21:33:31 +0000
Expires: Sun, 16 Feb 1997 21:31:51 +0000
Content-type: text/html
Server: RoxenEnterprise/1.0
Content-length: 4846
</DOCHDR>
<HTML>
<HEAD>
    <TITLE>Institute_on_Independent_Living</TITLE>
</HEAD>
<BODY TEXT="#090235" BGCOLOR="#ffffff" LINK="#0000ff">
<FORM ACTION="http://www.netcreations.com/cgi/pinpoint/pinpoint.pl" 
METHOD=
"POST" ENCTYPE="x-www-form-encoded">
<INPUT TYPE="hidden" NAME="id" VALUE="YOUR CHOSEN ID">
<INPUT TYPE="hidden" NAME="id" VALUE="ratzka">
<INPUT TYPE="hidden" NAME="id" VALUE="ratzka">
<INPUT TYPE="hidden" NAME="id" VALUE="ratzka">
<INPUT TYPE="hidden" NAME="id" VALUE="ratzka">
<INPUT TYPE="hidden" NAME="id" VALUE="52120">
<INPUT TYPE="hidden" NAME="id" VALUE="52120">
<INPUT TYPE="hidden" NAME="id" VALUE="191427"><HTML><HEAD> <META 
NAME="description" 

CONTENT="Individuals and organizations of persons with disabilities can 
publish, free of charge,  articles, reports, training manuals, 
announcements, etc. on Independent Living, personal assistance,
advocacy, 

peer support, accessibility, legislation and related subjects. "><META 
NAME="keywords" CONTENT="Independent Living, personal assistance, 
advocacy, peer support, direct payments, anti-discrimination
legislation, 

accessibility, disability, disability rights"></HEAD><BODY TEXT="#090235" 
BGCOLOR="#ffffff" LINK="#0000ff"><BR>
<BR>
<IMG SRC="InstLogoBig.gif" WIDTH="380" HEIGHT="108" ALIGN="BOTTOM" 
NATURALSIZEFLAG=
"3"> 
<BLOCKQUOTE>
<BLOCKQUOTE><IMG SRC="Pixel1x1.gif" WIDTH="1" HEIGHT="1" ALIGN="BOTTOM"
NATURALSIZEFLAG="3"><BR>
<FONT SIZE="5">I</FONT>ndependent Living is a philosophy and a movement
of people with disabilities who work for equal opportunities, 
self-respect
and self determination.<BR>
<BR>
<BR>
Independent Living does not mean that we do not need anybody, that we 
want
to do everything by ourselves, that we want to live in isolation. 
Independent
Living means that we demand the same life opportunities and the same 
control
over our every-day lives that our non-disabled brothers and sisters, 
neighbors
and friends take for granted. We want to grow up in our families, go to
the neighborhood school, use the same bus, work in jobs that are in line
with our education and abilities. Most importantly, just like everybody
else, we need to be in charge of our own lives, think and speak for 
ourselves.
<BR>
<BR>
To this end we need to support and learn from each other, organize 
ourselves
and work for political changes that lead to legal protection of our human

and civil rights.<BR>
<IMG SRC="Pixel1x1.gif" WIDTH="1" HEIGHT="1" ALIGN="BOTTOM" 
NATURALSIZEFLAG=
"3"><IMG SRC="Pixel1x1.gif" WIDTH="1" HEIGHT="1" ALIGN="BOTTOM" 
NATURALSIZEFLAG=
"3"><BR>
<FONT SIZE="5">T</FONT>he Institute's webserver invites individuals and
organizations to share their texts with our readers. We publish, free of
charge, your materials on Independent Living, personal assistance, 
accessibility,
legislation, peer support, etc. in the form of letters, articles, 
training
manuals, monographs, project proposals, announcements of upcoming events,

conference proceedings, and other documents. <BR>
<BR>
If you are interested in having your material placed on this website, <A 
HREF="mailto:ratzka@independentliving.org">contact
us.</A> 
<BLOCKQUOTE>
<P><CENTER><BR>
<A HREF="Homepage1b.html">Swedish</A></CENTER>
</BLOCKQUOTE>
</BLOCKQUOTE>
</BLOCKQUOTE>
<BLOCKQUOTE>
<BLOCKQUOTE>
<H2><A HREF="Contents.html">Contents</A><BR>
<A HREF="guestbook.html">Bulletin board</A><BR>
<A HREF="help_wanted.html">Help wanted<BR>
</A>Search our site for: <INPUT TYPE="text" NAME="searchstring" 
SIZE="40">
<INPUT SRC="http://www.netcreations.com/pinpoint/gfx/pinsearch.gif" TYPE=

"image" NAME="submit" VALUE="PinPoint Search!" BORDER="0" ALIGN="TOP" 
WIDTH=
"102" HEIGHT="28" NATURALSIZEFLAG="0"> </H2>
</BLOCKQUOTE>
<P><CENTER><IMG SRC="blend_top.gif" WIDTH="591" HEIGHT="5" 
NATURALSIZEFLAG=
"0" ALIGN="BOTTOM"></CENTER>
<P>2370<FONT SIZE="-1"><IMG SRC="Pixel1x1.gif" WIDTH="1" HEIGHT="1"

ALIGN="BOTTOM" NATURALSIZEFLAG="3"><IMG SRC="Pixel1x1.gif" WIDTH="1" 
HEIGHT=
"1" ALIGN="BOTTOM" NATURALSIZEFLAG="3"><IMG SRC="Pixel1x1.gif" WIDTH="1"
HEIGHT="1" ALIGN="BOTTOM" NATURALSIZEFLAG="3"><IMG SRC="Pixel1x1.gif" 
WIDTH=
"1" HEIGHT="1" ALIGN="BOTTOM" NATURALSIZEFLAG="3"><IMG SRC="Pixel1x1.gif"

WIDTH="1" HEIGHT="1" ALIGN="BOTTOM" NATURALSIZEFLAG="3"><IMG 
SRC="Pixel1x1.gif"
WIDTH="1" HEIGHT="1" ALIGN="BOTTOM" NATURALSIZEFLAG="3"><IMG 
SRC="Pixel1x1.gif"
WIDTH="1" HEIGHT="1" ALIGN="BOTTOM" NATURALSIZEFLAG="3">visitors since 
August
5, 1996</FONT> <BR>
<FONT SIZE="-1">Last updated February 16, 1997</FONT><BR>
<FONT SIZE="-1">&copy;<IMG SRC="Pixel1x1.gif" WIDTH="1" HEIGHT="1" ALIGN=

"BOTTOM" NATURALSIZEFLAG="3"><IMG SRC="Pixel1x1.gif" WIDTH="1" HEIGHT="1"

ALIGN="BOTTOM" NATURALSIZEFLAG="3">Institute on Independent 
Living</FONT><BR>
<FONT SIZE="-1"><A 
HREF="mailto:ratzka@independentliving.org">Webmaster</A></FONT>
</BLOCKQUOTE>
</FORM>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-179</DOCNO>
<DOCOLDNO>IA012-000124-B046-120</DOCOLDNO>
<DOCHDR>
http://www.independentliving.org:80/Homepage1b.html 193.13.228.238 19970216213133 text/html 2714
HTTP/1.0 200 OK
Last-Modified: Tue, 06 Aug 1996 19:59:05 +0000
Date: Sun, 16 Feb 1997 21:31:16 +0000
Expires: Sun, 16 Feb 1997 21:29:36 +0000
Content-type: text/html
Server: RoxenEnterprise/1.0
Content-length: 2489
</DOCHDR>
<HTML>
<HEAD>
    <TITLE>Institute_on_Independent_Living</TITLE>
</HEAD>
<BODY LINK="#00003d" BGCOLOR="#ffffff" TEXT="#000038">
<META NAME="description" 
CONTENT="Individuals and organizations of persons with disabilities can 
publish, free of charge,  articles, reports, training manuals, 
announcements, etc. on Independent Living, personal assistance, advocacy, 

peer support, accessibility, legislation and related subjects. "><META 
NAME="keywords" CONTENT="Independent Living, personal assistance, 
advocacy, peer support, direct payments, anti-discrimination legislation, 

accessibility, disability, disability rights">
<H4><BR>
<P><CENTER>V&auml;lkommen till hemsidan f&ouml;r </CENTER>
<P></H4>
<H1><CENTER><IMG SRC="image1.gif" WIDTH="482" HEIGHT="4" NATURALSIZEFLAG=

"0" ALIGN="BOTTOM"><BR>
Institutet f&ouml;r Independent Living<BR>
<IMG SRC="image1.gif" WIDTH="482" HEIGHT="4" NATURALSIZEFLAG="0" ALIGN=
"BOTTOM"></CENTER>
</H1>
<H2><CENTER>resurscentret f&ouml;r den svenska <BR>
Independent Living-r&ouml;relsen</CENTER>
</H2>
<P><CENTER><A HREF="index.html">in english</A></CENTER>
<BLOCKQUOTE>
<BLOCKQUOTE>Under de n&auml;rmaste m&aring;naderna kommer vi att bygga 
h&auml;r
websidor om Independent Living. Sidorna &auml;r t&auml;nkta att 
underl&auml;tta
utbytet av resurser mellan personer med funktionshinder och deras 
organisationer.
<BR>
<BR>
Materialet best&aring;r av artiklar, tr&auml;ning manualer, rapporter, 
projektbeskrivningar,
annonser av kommande evenemang, konferens rapporter och andra 
dokument.</BLOCKQUOTE>
Idag finns det l&auml;nkar h&auml;r till </BLOCKQUOTE>
<UL>
  <DL>
    <DD><A HREF="STIL/STIL.html">STIL, Stockholmskooperativet f&ouml;r 
Independent
Living</A> 
    <DD><A HREF="STIL/STILStandardRegler1.html">FN:s Standard Regler</A>
<BR>
<A HREF="ENIL/ENILhomepage.html">ENIL, Euopean Network on Independent 
Living</A>
(p&aring; engelska)<BR>
<A HREF="other_links.html">Andra intressanta l&auml;nka</A> 
  </DL>
</UL>
<P><CENTER><IMG SRC="image1.gif" WIDTH="482" HEIGHT="4" NATURALSIZEFLAG=
"0" ALIGN="BOTTOM"></CENTER>
<BLOCKQUOTE><BR>
<A HREF="Homepage2b.html">L&auml;s mer om Institutet f&ouml;r Independent

Living </A><BR>
<BR>
Verksamhetsledare fil dr Adolf Ratzka <BR>
Adress 
<BLOCKQUOTE>Peters&eacute;ns V&auml;g 2 <BR>
1278 41 Sk&auml;rholmen <BR>
Tel 08-740 4200 <BR>
Fax 08-740 4500 <BR>
e-mail <A 
HREF="mailto:ratzka@independentliving.org">ratzka@independentliving.org</
A></BLOCKQUOTE>
</BLOCKQUOTE>
<BR>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-180</DOCNO>
<DOCOLDNO>IA012-000124-B046-158</DOCOLDNO>
<DOCHDR>
http://www.independentliving.org:80/Contents.html 193.13.228.238 19970216213202 text/html 6997
HTTP/1.0 200 OK
Last-Modified: Sun, 06 Oct 1996 19:26:47 +0000
Date: Sun, 16 Feb 1997 21:32:04 +0000
Expires: Sun, 16 Feb 1997 21:30:24 +0000
Content-type: text/html
Server: RoxenEnterprise/1.0
Content-length: 6772
</DOCHDR>
<HTML>
<HEAD>
    <TITLE>Institute_on_Independent_Living</TITLE>
</HEAD>
<BODY TEXT="#020a3f" BGCOLOR="#ffffff" LINK="#000042">
<META  name="description"
content="Individuals and organizations of persons with disabilities can 
publish, free of charge,  articles, reports, training manuals, 
announcements, etc. on Independent Living, personal assistance, advocacy, 
peer support, accessibility, legislation and related subjects. "><META  
name="keywords" content="Independent Living, personal assistance, 
advocacy, peer support, direct payments, anti-discrimination legislation, 
accessibility, disability, disability rights"
<BR><IMG SRC="InstLogoSmall.gif" WIDTH="198" HEIGHT="57" ALIGN="BOTTOM"
NATURALSIZEFLAG="3"> 
<H3>Contents</H3>
<BLOCKQUOTE>
<H4>Access</H4>
</BLOCKQUOTE>
<BLOCKQUOTE>
<UL>
  <LI><A HREF="CIB/CIBhomepage.html">CIB W84 &quot;Building 
Non-Handicapping
Environments&quot; Reports up to 1994 </A>
  <LI><A HREF="CIB/CIBRio94Access.html">A brief survey of studies on 
costs
and benefits of non-handicapping environments </A>
  <LI><A HREF="ToolsforPower/Tools35.html">Toward a barrier-free home 
</A>
  <LI><A HREF="UCapeTown95.html">Opening universities to students with 
disabilities:
University of Cape Town, South Africa </A>
  <LI><A HREF="ToolsforPower/Tools36.html">Resources </A>
  <LI>United Nations Standard Rules:<A HREF="ToolsforPower/Tools36.html">

</A><A HREF="StandardRules2.html#anchor1370198">Accessibility</A> 
</UL>
</BLOCKQUOTE>
<BLOCKQUOTE>
<H4>Independent Living, general</H4>
</BLOCKQUOTE>
<BLOCKQUOTE>
<UL>
  <LI><A HREF="ToolsforPower/Tools7.html">Independent Living: a European
definition</A> 
  <LI><A HREF="ToolsforPower/Tools8.html">An American definition of 
Independent
Living</A> 
  <LI><A HREF="ToolsforPower/Tools9.html">Resources</A> <A 
HREF="ToolsforPower/Tools2.html">History
of the Independent Living Movement: declaring independence in 
Berkeley</A>
  <LI><A HREF="ToolsforPower/Tools1.html">Tools for Power: Independent 
Living
Resources</A> 
  <LI><A HREF="ENIL/ENILStockholmSem1.html">Report of the Third ENIL 
Seminar,
Stockholm 1991.</A> 
  <LI><A HREF="ToolsforPower/Tools3c.html">The challenge of middle age 
for
the Independent Living Movement </A>
  <LI><A HREF="ToolsforPower/Tools3b.html">Divisions in the disability 
community
</A>
  <LI><A HREF="ToolsforPower/Tools4.html">Resources</A> 
</UL>
</BLOCKQUOTE>
<BLOCKQUOTE>
<H4>Family, love and sexuality</H4>
</BLOCKQUOTE>
<BLOCKQUOTE>
<UL>
  <LI><A HREF="SexualityComment.html">Comment on sexuality</A> 
  <LI><A HREF="ToolsforPower/Tools25.html">Disability, women and love</A>

  <LI><A HREF="FamilyCRSweden.html">Independent Living and the family: 
The
context of Costa Rica and Sweden</A> 
</UL>
</BLOCKQUOTE>
<BLOCKQUOTE>
<H4>Personal Assistance</H4>
</BLOCKQUOTE>
<BLOCKQUOTE>
<UL>
  <LI><A HREF="ToolsforPower/Tools15.html">What is personal assistance?
</A>
  <LI><A HREF="PersonalAssistance%26Pride.html">Personal Assistance and
Disability Pride</A> 
  <LI><A HREF="IntroDirectPayments.html">Introduction to direct payments
for personal assistance</A> 
  <LI><A HREF="WRFmono/WRFmono1.html">Independent Living and Attendant 
Care
in Sweden: A Consumer Perspective</A> 
  <LI><A HREF="ToolsforPower/Tools18.html">Developing assistants 
management
skills</A> 
  <LI><A HREF="Aufstand_der_Betreuten.html">Aufstand der Betreuten</A> 
(German)
  <LI><A HREF="PersAssistenzinSchweden.html">Pers&ouml;nliche Assistenz
in Schweden (German)</A> 
  <LI><A HREF="PersAssistanceResearch.html">Research briefs </A>
</UL>
</BLOCKQUOTE>
<BLOCKQUOTE>
<H4>Employmen/Self-employment </H4>
</BLOCKQUOTE>
<BLOCKQUOTE>
<UL>
  <LI><A HREF="ToolsforPower/Tools31.html">Self Help Association of 
Paraplegics,
SHAP, Republic of South Africa </A>
  <LI><A HREF="ToolsforPower/Tools32.html">Manufacturing assistive 
devices
in developing countries </A>
  <LI><A HREF="ToolsforPower/Tools33.html">Turning a service into an 
income
generating project</A> 
  <LI><A HREF="ToolsforPower/Tools34.html">Resources </A>
</UL>
</BLOCKQUOTE>
<BLOCKQUOTE>
<H4>Organizations</H4>
</BLOCKQUOTE>
<BLOCKQUOTE>
<UL>
  <LI><A HREF="ENIL/ENILhomepage.html">ENIL, European Network on 
Independent
Living</A> 
  <LI><A HREF="http://www.stil.se/">STIL, Stockholm Cooperative for 
Independent
Living </A>
  <LI><A HREF="ResCILs.html">Research on Independent Living Centers</A>
</UL>
</BLOCKQUOTE>
<BLOCKQUOTE>
<H4>United Nations Documents</H4>
</BLOCKQUOTE>
<BLOCKQUOTE>
<UL>
  <LI><A HREF="StandardRules1.html">The United Nations Standard Rules on
the Equalization of Opportunities of Disabled Persons</A> 
  <LI><A HREF="IntroductionStandardRules.html">Preface to the Standard 
Rules
by Bengt Lindqvist, MP, Special United Nations Rapporteur</A>
  <LI><A HREF="TallinnGuidelines.html">The Tallinn Guidelines</A>
</UL>
<B>Euthanasia</B></BLOCKQUOTE>
<BLOCKQUOTE>
<UL>
  <LI><A HREF="DenounceKevorkian.html">Denounce Kevorkian by Paul K. 
Longmore
</A>
</UL>
</BLOCKQUOTE>
<BLOCKQUOTE>
<H4>Country Profiles</H4>
</BLOCKQUOTE>
<BLOCKQUOTE>
<UL>
  <LI><A HREF="BehinderunginSchweden.html">Schweden (in German): 
Behinderung
oder Selbstbestimmung - zur Lage von Menschen mit Behinderungen in 
Schweden</A>
von Adolf Ratzka 
  <LI><A HREF="ENIL/ENILDirectPayment.html">Direct Payments Campaign in
the U.K. by John Evans and Frances Hasler</A> 
</UL>
</BLOCKQUOTE>
<BLOCKQUOTE>
<H4>Funding proposals</H4>
</BLOCKQUOTE>
<BLOCKQUOTE>
<UL>
  <LI><A HREF="ProposlPASouthAfrica.html">Personal Assistance for 
Independent
Living Programme, Republic of South Africa</A> 
</UL>
</BLOCKQUOTE>
<BLOCKQUOTE>
<H4>Events</H4>
</BLOCKQUOTE>
<BLOCKQUOTE>
<UL>
  <LI><A HREF="WomensConference.html">Overview of the Conference 
&quot;Self-determined
Living for Disabled Women in Europe&quot;, Munich, Germany, August 15-18,

1996</A> 
</UL>
<A HREF="Homepage2a.html"><BR>
</A><A HREF="guestbook.html">Guestbook<BR>
</A><A HREF="Homepage2a.html">About the Institute</A> <BR>
<A HREF="other_links.html">Interesting links</A> <BR>
<A HREF="help_wanted.html">Help wanted<BR>
<BR>
<BR>
<BR>
</A><FONT SIZE="5">T</FONT>he Institute invites individuals and 
organizations
to share their texts with our readers. We publish on our webpages, free
of charge, your materials on Independent Living, personal assistance, 
accessibility,
legislation, peer support, etc. in the form of letters, articles, 
training
manuals, monographs, project proposals, announcements of upcoming events,

conference proceedings, and other documents. <BR>
<BR>
<BR>
If you are interested in having your material placed on this website, <A 
HREF="mailto:ratzka@independentliving.org">contact
us.</A> </BLOCKQUOTE>
<HR><BR>
<P><CENTER><FONT SIZE="2">[ <A HREF="index.html">Institute on Independent

Living ]</A></FONT></CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-181</DOCNO>
<DOCOLDNO>IA012-000124-B046-262</DOCOLDNO>
<DOCHDR>
http://www.independentliving.org:80/guestbook.html 193.13.228.238 19970216213248 text/html 69780
HTTP/1.0 200 OK
Last-Modified: Sun, 16 Feb 1997 13:31:29 +0000
Date: Sun, 16 Feb 1997 21:32:44 +0000
Expires: Sun, 16 Feb 1997 21:31:04 +0000
Content-type: text/html
Server: RoxenEnterprise/1.0
Content-length: 69554
</DOCHDR>
<HTML>
<HEAD>
    <TITLE>Institute_on_Independent_Living</TITLE>
</HEAD>
<BODY>
<HTML><BODY><HEAD></HEAD><BODY TEXT="#000237" BGCOLOR="#ffffff" 
LINK="#0000ff"><IMG SRC=
"InstLogoSmall.gif" WIDTH="198" HEIGHT="57" ALIGN="BOTTOM" 
NATURALSIZEFLAG=
"3"> 
<H2><CENTER>Bulletin Board</CENTER>
</H2>
<BR>
<BR>
<BR>
Thank you for visiting our pages!<BR>
<BR>
Would you like to leave a <A HREF="addguestbook.html">message</A> in our
bulletin board?  A steadily growing number of visitors will read your 
text
and might respond.<BR>
<P><CENTER><HR></CENTER>
<P>My 22 year old son suffered a Traumatic Head Injury at the age of 18.
He is presently in a home (The Rowan Community) in Denver, Colorado. He
is wanting to acquire some skills to obtain a job and be independent. He
is funded only by Social Security/SSI/Medicaid. At the present time I am
looking for a place for him in the Orlando, Florida area where he can 
continue
to make progress and reach his goals. He has had many behavioral problems

in the past. The verbal report I recently received from The Rowan 
Community
is that<BR>
he has made a lot of improvement. He is also wanting to be near some of
his family, most of us are here in Florida, no one is in Colorado. He was

in &quot;the system&quot; here in Florida about a year and a half ago, 
living
with me and involved in some outatient rehab programs. However, now I 
feel
that it was all a little premature for his level of awareness, ability to

cope, ability to control behaviors, etc. He is mobile with severe 
left-side
neglect (reduced mostly to vision, now) and is unable to use his left 
arm/hand.
He<BR>
is able to walk safely with a quad cane and is working on not using that,

but still relies on a half leg brace. Please send me a response at this
internet address or you may mail information to:<BR>
Valerie Steuart<BR>
1697 S. Kirkman Rd. #104<BR>
Orlando, FL 32811<BR>
<BR>
Thank-you and Happy Holidays<BR>
Valerie Steuart &lt;RSteuart@AOL.Com&gt;<BR>
Orlando, USA - Thursday, November 28, 1996 at 05:06:12 (MET)<BR>
-------------------------------------------------------------------------
---<BR>
Hi there,<BR>
<BR>
I have been involved with a charitable foundation in Thailand providing
computer courses for disabled young people which has transformed many 
disabled
people's lives here. I have been living in Russia for the past 6 months
and together with a Swedish person there we are interested in trying to
establish a similar school there (in Cheboksari 700 kms east of Moscow).
We would be interested in hearing from anybody who knows of organizations

which deal in disposing of used PCs in Western Europe, as we want to 
try<BR>
to obtain such computers for the disabled in Russia. I can be contacted
through my email address:<BR>
derekp@ibm.net<BR>
Thank you<BR>
Derek Proctor &lt;derekp@ibm.net&gt;<BR>
Bangkok, Thailand - Tuesday, November 26, 1996 at 17:55:31 (MET)<BR>
-------------------------------------------------------------------------
---<BR>
Hi, guys!<BR>
First of all, let me introduce my self: my name is Renzo Romagnoli and I
am attending the last year at the Therapist School in Ferrara; I would 
like
to dissert my thesis on &quot;Peer- Counseling&quot;, as this regards me
closely, because I am a paraplegic person. Well, I am looking for some 
literature
abaut this subject; at first American Indipendent Living Movement, 
outlining
in particular the way this moment spread throughout Europe. I would be 
therefore
interesting to get some information about the current the current 
situation
in Europe: the way this movement is developping, the prospects of work-
integration of the paraplegic therapist into the current rehabilitation
system. Furthermore, I would like to outline the importance and 
effectiveness
of a traning work done by a &quot;peer- counselor&quot;, compared to a 
'normal'
therapist. I've not yet decided how to do this; I think, it would be 
interesting
to prepare interviews, i.e. how the interviewed has been trained, who 
taught
him/her the strategies necessary to get his/her indipendence, how he/she
got a better lifestyle and if he/she feels more at ease by dealing with
people having his/her same problem. These are some of the topics I would
like to develop, but I would really appreciate any suggestion or advise.
If possible, please, let me have the E-mail addresses of other people 
interested
in this subject, of those people who think could help me do this work. 
In particular, do you know whether similar reaseaches have already been
made? If so, can you help me get in touch with the people who did them 
and
have some more literature? Thank you.  I look forward to receipt of your
reply.<BR>
<BR>
Renzo Romagnoli<BR>
<BR>
Renzo Romagnoli c/o Informahandicap 
&lt;salute.comfe@fe.nettuno.it&gt;<BR>
Ferrara, Italy - Monday, November 25, 1996 at 17:30:08 (MET)<BR>
-------------------------------------------------------------------------
---<BR>
Hello<BR>
I'm looking for applications for Apple computers for handicapped users.
any ideas? Thanks everybody<BR>
<BR>
Charles R. Schwab &lt;cschwab@mus.ch&gt;<BR>
Bern, Switzerland - Monday, November 25, 1996 at 10:13:06 (MET)<BR>
-------------------------------------------------------------------------
---<BR>
Hello I am disabled and a survivor of childhood abuse. I have a website
dedicated to healing issues for abled bodied and disabled alike, with a
webpage geared towards disabled issues only. I am always looking for 
documents,
links, and other websites that I can put on this page. Just by casual 
contact,
I have come to the conclusion there are many disabled on the 'net who 
have
been abused in horrific ways, but are hiding, or there are not resources
there for them. Many sexual assault centres, etc are not accessible for
the disabled, and many therapists do not understand the complexities of
being disabled and being abused. If you have any resources that I could
add to my pages, please email me.  The website address is<BR>
http://www.geocities.com/HotSprings/2891/abusedis.html<BR>
<BR>
kayjay &lt;kayjay@ns.asarian.org&gt;<BR>
Edmonton, Canada - Wednesday, November 20, 1996 at 21:43:43 (MET)<BR>
-------------------------------------------------------------------------
---<BR>
I've found your site.<BR>
Love Dyfan<BR>
Dr Dyfan Lewis &lt;dyfan@lewis.se&gt;<BR>
Stockholm, Sweden - Sunday, November 17, 1996 at 21:41:09 (MET)<BR>
-------------------------------------------------------------------------
---<BR>
The Lt. Joseph P. Kennedy Institute was founded in 1959, with a generous
donation from Mr. Joseph P. Kennedy, Sr., as a school for children with
mental retardation. Like all other children, these too became adults. 
Today
the Institute supports our alumni and other community members with 
disabilities.
Through the COMMUNITY LIVING PARTNERSHIP (CLP) we help families and 
individuals
with disabilities design an independent living plan that meets their 
needs
and supports their goals in life. We ask each family to make a $150.00 
one
time contribution to join the CLP. This contribution can be paid in 
installments
as small as $1.00 a month. The important thing is to bring people with 
disabilities,
their families and invested members of the community together. We develop

relationships that facilitate supported employment, independent living,
a roommate matching program, social services, and inclusion in community
activities. Our hope is to help at least 30 persons during the first 
year,
to design independent living models for themselves and to execute them.
Most of our program participants are unable to afford the high cost of 
self-pay
independent living in the USA. For this reason we depend on grants and 
donations
from the private sector. We avoid government grants as much as possible.
Many of these grants come<BR>
with conditions that limit the choices our program participants can make.

Some of the funding programs offered through the government require that
our friends with disabilities adapt their homes to meet institutional 
safety
standards or that they submit to the supervision of a case manager. We 
believe
that none of us would allow another to tell us at what temperature we 
should
set our water heaters or that we must put up sprinkler systems in every
room in our home. This is not the way the average American lives. Our 
friends
have the right to arrange their homes in any way that meets their 
comfort,
health, safety, and aesthetic needs. We also help our friends hire 
support
providers that can adapt to the individual's needs and that are properly
trained. We also train. Our biggest problem is money. WE WOULD APPRECIATE

ANY ASSISTANCE ANYONE CAN GIVE US BY WAY OF GUIDANCE TO RAISE FUNDS TO 
SUBSIDIZE
OUR FRIENDS. At present we are in desperate need of $200,000.00  to 
purchase
a home that has an elevator and is wheelchair accessible. This home can
house up to four persons and one service provider. Currently, about 2% of

every American living on the streets has a developmental disability. This

does not include those that have mental illnesses. We want to bring those

people in from the streets and help them design their own destiny. Won't
you help us? The Kennedy Institute is not connected in any way with the
Kennedy Foundation nor the Kennedy family. You can contact me: Jay J. 
Rivera,
Director of Community Living. Kennedy  Institute, 801 Buchanan St, N.E.,
Washington, DC 20017. Tel (202) 529-7600<BR>
Ext. 272. Fax (202) 529-2028. I look forward to hearing from all of you
out<BR>
there. Thank You and God Bless You<BR>
Jay J. Rivera &lt;riverraj@mail.erols&gt;<BR>
Washington,DC, USA - Thursday, November 14, 1996 at 06:07:57 (MET)<BR>
-------------------------------------------------------------------------
---<BR>
I am hoping to come in contact with organizations for persons with 
amputations
world wide. Some of the guests in this guest book use abbriv. In Norway
I am a member of LFA-NHF - what did that tell you?! I lost my right arm
10 years ago, but most members have<BR>
lost legs. Send me an e-mail, if you have some interesting information on

the subject!<BR>
Sigbjorn Ronning &lt;sigbjorn@trondernett.no&gt;<BR>
Trondheim, Norway - Sunday, November 10, 1996 at 18:46:25 (MET)<BR>
-------------------------------------------------------------------------
---<BR>
Great site !!! Could jump around for ever. Keep up the good work and 
check
out our site Http://www.islandnet.com/~rcil/homepage.htm<BR>
Cheryl Robertson &lt;rcil@islandnet.com&gt;<BR>
Victoria, Canada - Monday, November 04, 1996 at 01:13:32 (MET)<BR>
-------------------------------------------------------------------------
---<BR>
I am a teacher working in the disability field. I mainly teach adults who

would like to find work in disability services. I found this page while
researching some of my teaching subjects. If anybody has any good info 
sites
on the net I would appreciate you letting me know. My main interest area
is intellectual disability but any related area would be of interest.<BR>

Thank you<BR>
Michelle Watters &lt;mwatters@ozemail.com.au&gt;<BR>
Caringbah, Australia - Saturday, November 02, 1996 at 14:14:29 (MET)<BR>
-------------------------------------------------------------------------
---<BR>
Greetings. Our business is in the manufacturing of the VENTRAC. Our 
vision
is dedicated to enhancing the lives of disable, abled and elderly to 
experience
and achieve their highest level of independence and personal fulfillment.

We have designed a unit to allow for the mobility of people with 
disabilities.
We would like to share this information with anyone that has an interest.

Please contact us here at Venture Products Inc. PO Box 148<BR>
Orrville, Ohio 44667 or by e-mail venture@bright.net.<BR>
Ray Miller &lt;venture@bright.net&gt;<BR>
Orrville, USA - Thursday, October 24, 1996 at 16:02:18 (MET DST)<BR>
-------------------------------------------------------------------------
---<BR>
Hello everyone. I am excited to know that this chat board is available.
I am interesed if Anyone knows of any t.v. programs that focus on persons

with disabilities. I'm speaking of shows that may provide information or
inspiration. I know about the occasional movies they have. If anyone has
any knowledge about this I would certainly appreciate your help.<BR>
Thank you in advance<BR>
Maria<BR>
Maria &lt;harriam@pop.erols.com&gt;<BR>
Alexandria, U.S. - Tuesday, October 15, 1996 at 18:12:09 (MET DST)<BR>
-------------------------------------------------------------------------
---<BR>
I am the General Secretary of a national organisation of people with 
Neuromuscular
Impairments, called Muscle Power. We run a major disability information
and news service called Disability Net. Please add a link to Disability
Net which can be found at<BR>
http://www.globalnet.co.uk/~pmatthews/DisabilityNet/<BR>
<BR>
Thank you,<BR>
<BR>
Paul Matthews<BR>
Paul Matthews &lt;pmatthews@cix.co.uk&gt;<BR>
Derby, United Kingdom - Saturday, October 12, 1996 at 19:39:58 (MET 
DST)<BR>
-------------------------------------------------------------------------
---<BR>
I am looking for information on the funding that was awarded to the 
International
Center on the disabled by the J.M. Foundation. Thanks for your help in 
this
matter. Please contact me at: envis@nicoh.net Thank You!!!<BR>
Jeananne Whitmer &lt;envis@nicoh.net&gt;<BR>
Pocatello, USA - Tuesday, October 08, 1996 at 05:52:35 (MET DST)<BR>
-------------------------------------------------------------------------
---<BR>
The State of Missouri has recieved appropriations to fund 9 new CIL's by
January 1, 1996, bringing our State to a total of 20 CIL's at that time.
It is a fast and furious pace right now. I hope to review materials here
to see what, if any, kind of ideas are available to new CIL's that are 
early
in the development stages.<BR>
Steve Wooderson &lt;swooders@services.dese.state.mo.us&gt;<BR>
Jefferson City, MO, USA - Monday, October 07, 1996 at 16:48:29 (MET 
DST)<BR>
-------------------------------------------------------------------------
---<BR>
I am in the process of setting up a non-profit to provide housing for 
people
with Multiple Chemical Sensitivies, Environmental Illness and Chronic 
Fatigue
Syndrome in New Mexico. This type of housing will be for people who have
low income and cannot live in conventional housing because of their 
allergies
or reactions to materials in conventional housing. Any input would be 
appreciated.
Thank you Ken Hess<BR>
Ken Hess &lt;74742.2244@compuserve.com&gt;<BR>
Albuquerque, USA - Monday, October 07, 1996 at 05:59:27 (MET DST)<BR>
-------------------------------------------------------------------------
---<BR>
Your web site must be very helpful to many people. I have a friend with
multiple sclerosis who has a full-time job, but she still doesn't have 
much
money. I would appreciate any information on how she could obtain a 
motor-vehicle
with hand controls. Thanks. Please send to my e-mail or  through 
snail-mail
to J. Renner, 1221 S. Grand Blvd., St. Louis, Mo. 63104<BR>
// Phone (314) 577-8727.<BR>
J. Renner &lt;rennerj@wpogate.slu.edu&gt;<BR>
St. Louis, USA - Thursday, October 03, 1996 at 23:04:34 (MET DST)<BR>
-------------------------------------------------------------------------
---<BR>
This is a valuable resource and as it grows I'm ssure will benefit many
people in like situations. I am willing to share IL info in S. A. with 
anyone
as we are at a wonderful stage of our history in that we have a brand new

constitution that recognises the rights of disabled people. It will be 
worth
watching to see how we implement services for disabled people in a 
consumer
driven manner. Good luck with you web site.<BR>
Fadila Lagadien &lt;laggies@iafrica.com&gt;<BR>
Cape Town, South Africa - Thursday, September 19, 1996 at 13:01:36 (MET
DST)<BR>
-------------------------------------------------------------------------
---<BR>
Our local center for independent living receives 140,000 dollars over an
eleven month period. The fixed costs plus salaries accounts for 80% of 
the
budget. Travel expenses are 6200 dollars. These costs seem quite high. 
Comparatively
little is left fot training and all the other tasks required to help the
disabled. Are these cost out ou line?<BR>
Tom Fehnel &lt;tfehnel@cswnet.com&gt;<BR>
Mt. Ida, USA - Wednesday, September 18, 1996 at 22:40:06 (MET DST)<BR>
-------------------------------------------------------------------------
---<BR>
Independent Living Center of Kern County<BR>
1927 Eye Street<BR>
Bakersfield, CA 93309<BR>
<BR>
Please send information on how to publish articles to the above 
address.<BR>
<BR>
Thank you,<BR>
Mona Twocats<BR>
Independent Living Advisor<BR>
Mona Twocats<BR>
Bakersfield, CA, usa - Thursday, September 12, 1996 at 06:27:58 (MET 
DST)<BR>
-------------------------------------------------------------------------
---<BR>
Hej Alla/Hello All<BR>
<BR>
H&auml;lsningar fr&aring;n en som jobbar som vice arbetsledare inom 
STIL<BR>
Greetings from one who is working as &quot;resourse person&quot; in 
STIL<BR>
Peter<BR>
Peter Moberg &lt;retep@bahnhof.se&gt;<BR>
Stockholm, Sverige - Monday, September 09, 1996 at 23:12:08 (MET DST)<BR>

-------------------------------------------------------------------------
---<BR>
I'm hoping to find some useful information through your resources. I do
research and budget work for the Kansas Legislature and concentrate in 
the
areas of developmental disabilities and mental illness. Thanks for the 
information.<BR>
Susan Wiegers &lt;susanw@lr01.wpo.state.ks.us&gt;<BR>
Topeka, USA - Thursday, August 29, 1996 at 23:06:53 (MET DST)<BR>
-------------------------------------------------------------------------
---<BR>
Hello from the Gardem State in the USA!! I am Chairperson of the NJ 
Personal
Assistant Services Cooperative, Inc. I am eager  to share information 
about
PAS and independent living. Please feel free to contact me anytime. <BR>
Mary Lynn Noonan<BR>
Mary Lynn Noonan &lt;HandiMom@ix.netcom.com&gt;<BR>
East Hanover, NJ, USA - Tuesday, August 27, 1996 at 02:06:47 (MET 
DST)<BR>
-------------------------------------------------------------------------
---<BR>
<!--begin-->
<b>test</b><br>
a &lt;<a href="mailto:b">b</a>&gt;<br>
 - Sunday, February 16, 1997 at 14:31:29 (MET)<hr>

<b>Assistive Devices of Texas, designer and manufacturer of the Hayden-Preston System (HPS), <br>
would like to announce an innovative upper extremity terminal system.  <br>
<br>
The system was designed by a below the elbow amputee to serve the upper limb amputee with <br>
a quick disconnect terminal device, hand tools and implements. The HPS is not designed to<br>
permanently replace the conventional terminal device hook.  It is designed to assist the <br>
amputee in performing special tasks with ease in the course of normal daily living <br>
activities at home and work.  <br>
<br>
Utilizing this specialized terminal device, with its unique tool adaptation, <br>
provides versatility and flexibility with a safety index unattainable in <br>
current terminal devices.  An amputee may now use hand tools and implements to<br>
perform a task with reduced risk of the tool slipping (as in comparison to common<br>
occurrences when utilizing a hook). <br>
<br>
The system is easy as 1,2,3 and requires no tools, nuts and bolts for attachment. <br>
To use the system the amputee must simply...<br>
<br>
(1)  remove the hook from the body-powered prosthesis wrist unit<br>
(2)  insert the specialized Preston Terminal Device into the prosthesis <br>
(3)  select and insert the adapted Hayden Tool into the Preston Terminal<br>
      Device. <br>
<br>
A brochure detailing the availability of the device and tool adaptations will be forwarded to<br>
you providing you send your mailing address. <br>
<br>
Please contact us with any concerns you may have.<br>
<br>
Assistive Devices of Texas<br>
Ron Farquharson (409)798-8809<br>
Glenn Betts     (409)297-5447<br>
Web Site        http://www.tgn.net/~pbetts/<br>
e-mail		pbetts@tgn.net<br>
</b><br>
Glenn Betts &lt;<a href="mailto:pbetts@tgn.net">pbetts@tgn.net</a>&gt;<br>
Lake Jackson, Tx, USA - Saturday, February 15, 1997 at 03:15:08 (MET)<hr>

<b>Assistive Devices of Texas, designer and manufacturer of the<br>
Hayden-Preston System (HPS), would like to announce an <br>
innovative upper extremity terminal system.  <br>
<br>
The system was designed by a below the elbow amputee to <br>
serve the upper limb amputee with a quick disconnect <br>
terminal device, hand tools and implements. The HPS is not <br>
designed to permanently replace the conventional terminal <br>
device hook.  It is designed to assist the amputee in <br>
performing special tasks with ease in the course of normal <br>
daily living activities at home and work.  <br>
<br>
Utilizing this specialized terminal device, with its unique <br>
tool adaptation, provides versatility and flexibility with a<br>
safety index unattainable in current terminal devices.  An <br>
amputee may now use hand tools and implements to perform a <br>
task with reduced risk of the tool slipping (as in comparison<br>
to common occurrences when utilizing a hook). <br>
<br>
The system is easy as 1,2,3 and requires no tools, nuts and<br>
bolts for attachment.  To use the system the amputee must <br>
simply...<br>
<br>
(1)  remove the hook from the body-powered prosthesis wrist unit<br>
(2)  insert the specialized Preston Terminal Device into the prosthesis <br>
(3)  select and insert the adapted Hayden Tool into the Preston Terminal<br>
      Device. <br>
<br>
A brochure detailing the availability of the device and tool<br>
adaptations will be forwarded to you providing you send your<br>
mailing address. <br>
<br>
Please contact us with any concerns you may have.<br>
<br>
Assistive Devices of Texas<br>
Ron Farquharson (409)798-8809<br>
Glenn Betts     (409)297-5447<br>
Web Site        http://www.tgn.net/~pbetts/<br>
e-mail		pbetts@tgn.net<br>
</b><br>
Glenn Betts &lt;<a href="mailto:pbetts@tgn.net">pbetts@tgn.net</a>&gt;<br>
Lake Jackson, Tx, USA - Saturday, February 15, 1997 at 03:06:01 (MET)<hr>

<b>I'm a C5-6 quad living in NY with my parents and I'm in search for group or residential housing that concentrates on spinal cord injured individuals. If anyone can help me out with my search it would be greatly appreciated.  Please email me at HANDICHAP@AOL<br>
Thanks,<br>
Glenn</b><br>
Glenn &lt;<a href="mailto:HANDICHAP">HANDICHAP</a>&gt;<br>
NY, USA - Tuesday, February 04, 1997 at 03:58:40 (MET)<hr>

<b>Hello,<br>
<br>
From now you can write "independent living flanders" by e-mail. The adress is indliv.vlaand@unicall.be. I hope to read something from you!<br>
<br>
<br>
</b><br>
Damien Kinds &lt;<a href="mailto:indliv.vlaand@unicall.be">indliv.vlaand@unicall.be</a>&gt;<br>
Brugge, Belgium - Monday, January 27, 1997 at 21:41:29 (MET)<hr>

<b>Hello,<br>
<br>
From now you can write "independent living flanders" by e-mail. The adress is indliv.vlaand@unicall.be. I hope to read something from you!<br>
<br>
<br>
</b><br>
Damien Kinds &lt;<a href="mailto:indliv.vlaand@unicall.be">indliv.vlaand@unicall.be</a>&gt;<br>
Brugge, Belgium - Monday, January 27, 1997 at 21:41:26 (MET)<hr>

<b>Hello,<br>
<br>
From now you can write "independent living flanders" by e-mail. The adress is indliv.vlaand@unicall.be. I hope to read something from you!<br>
<br>
<br>
</b><br>
Damien Kinds &lt;<a href="mailto:indliv.vlaand@unicall.be">indliv.vlaand@unicall.be</a>&gt;<br>
Bruge, Belgium - Monday, January 27, 1997 at 21:37:19 (MET)<hr>

<b>We are helping our 81 year old friend Dr. Estelle Witzling-Moskowitz who was forced to retire from her practice as a Clinical Psycologist due to the hardships endured during her 17 years of confinement to her bed because of MS.<br>
She publishes the only newsletter to home bound elders with the use of a computer which she uses as a word processor. It is time for us to get her into the internet because she has so much to offer. Our problem is that she has bad eyesight among her other ailments and can not clearly see the cursor on the word processor. We are wondering<br>
if anyone in the community working with disabled persons has come across a program to keep the arrow visible when in a word processor.<br>
She is using a Macintosh quadra #605 and we have shown her how to use easy access program as well as installing a fat mouse to make it easier for her to enjoy the screen.<br>
We appreciate any and all thoughts and help with this matter.<br>
Please respond to our E mail address<br>
Thank you for allowing us to post in this page,it is a wonderful opportunity.</b><br>
Harvey Lisker/Dorie Lurie &lt;<a href="mailto:dorrie@icanect.net">dorrie@icanect.net</a>&gt;<br>
Surfside Florida, USA - Saturday, January 25, 1997 at 20:30:49 (MET)<hr>

<b>My name is Barry Peebles I am a C-4 Qaud.  I am trying to find<br>
a way to raise money to purchase a wheelchair accessible van. <br>
I just built a web page at: http://members.aol.com/BEP4U/index.html<br>
if you have any ideas or comments please go there and tell me know.</b><br>
Barry Peebles &lt;<a href="mailto:BEP4U@aol.com">BEP4U@aol.com</a>&gt;<br>
Norfolk, U.S.A. - Friday, January 24, 1997 at 19:44:16 (MET)<hr>

<b>If you are about to take a big step into independent living you might want to check this out. We have a 3Bd/2Ba Mobile home that is adapted to anyone confined to a wheelchair.  It comes with over 100 sq.ft of counter space, front and rear deck and ramp entrances, and a screened in jacuzzi room.  It is designed with open walls for access to the bathroom and bedrooms with an overhead hoist for transfers.  We are located in Central Florida, connected to the Chain-of-Lakes via canal.  We are less than 30 minutes from Orlando and all of the Disney Attractions. Nestled in an oak grove we enjoy excellent fishing just 50 feet from our door.  Less than 1 mile from conveniences, with virtually no crime rate you can enjoy sunshine and warm weather 335+ days a year!  Attendent care and help with household duties can be available at very reasonable rates right here in this friendly little park.  $26,000.00 Firm (this is under what the appraisal is).</b><br>
Kami &lt;<a href="mailto:kami.fla@worldnet.att.net">kami.fla@worldnet.att.net</a>&gt;<br>
Clermont, USA - Friday, January 24, 1997 at 01:28:11 (MET)<hr>

<b>Hello,<br>
<br>
I'm looking for information on privately initiated group living situations for mentally retarded adults in the United States. My parents, now 59 and 60, are beginnning the process of moving my disabled brother (he is 31 years old, brain damaged and suffers from Lennox-Gastaud epilepsy) from their home into another living situation. They are interested in contacted other family memebers or organizations with experience on this matter. Is there anyone out there who has either established their own group living situation or who might have information about them? Any help would be appreciated. Thanks.</b><br>
Michael Krass &lt;<a href="mailto:mbk@xs4all.nl">mbk@xs4all.nl</a>&gt;<br>
Amsterdam, Netherlands - Friday, January 17, 1997 at 10:32:49 (MET)<hr>

<b>We are searching for partners in all Eu countries, who like to cooperate with us for a HORIZON project of the European Union. This partners should work on the following issue: training and advanced training on working with computers.Our goal is to get younger people with severe physical disabilities to attend courses for working with and on computers. Courses not especially designed for this people, but designed for everyone who likes to go there, disabled or not. Our activities should be concentrated on the topic: wich conditions are necessary, that this people can attend this normal courses.Who likes to come along with us and work on that topic? You are just invited. snailmail: MOSAIK  z.H.Rudi Rux, Kalvarienguertel 62,A-8020 Graze-mail: woolf@magnet.at</b><br>
mosaik &lt;<a href="mailto:woolf@magnet.at">woolf@magnet.at</a>&gt;<br>
graz, austria - Friday, January 10, 1997 at 09:25:54 (MET)<hr>

<b>I nice domain, i used it to gain info about independent<br>
living in the US. I am studying Heilerzieher a german job <br>
specialized for work with mentaly retardet.<br>
CU</b><br>
Klaus Bolte &lt;<a href="mailto:kbolte@metronet.de">kbolte@metronet.de</a>&gt;<br>
Freyersen, FRG - Wednesday, January 08, 1997 at 01:24:27 (MET)<hr>

<b>Kate, I finally found you on the Internet.  Drop me a line some time and tell me how you are doing.  Missed you.  I'm at home right now.  The e-mail address above is my office e-mail.  My home e-mail is GerbenDJ@AOL.com.  Our office has a home page but I cannot remember the location on the Internet.  Do you get our office newsletter?  If not, let me know and I'll be sure to send you a copy.  I hope this message gets to you.  My best.  Gerben</b><br>
Gerben DeJong &lt;<a href="mailto:gxd3@mhg.edu">gxd3@mhg.edu</a>&gt;<br>
Washington, DC, USA - Monday, January 06, 1997 at 01:24:08 (MET)<hr>

<b>NOTICE OF POSITION VACANCY<br>
EXECUTIVE DIRECTOR<br>
San Antonio Independent Living Services<br>
See the SAILS web site at:<br>
http://www.txdirect.net/users/sdyer/sails.htm <br>
<br>
Salary: <br>
Commensurate with education and experience<br>
<br>
Job Description:<br>
Responsible for the management and direction of the organization. <br>
Executive Director sets direction, raises funds, ensures quality control for delivery of direct and indirect services to consumers with disabilities and administers government/grant funding.<br>
<br>
Candidates must have proven skills in the following areas:<br>
Implementing board policies<br>
Financial management<br>
Personnel management<br>
Program development<br>
Public relations and marketing<br>
Facility management<br>
<br>
Educational Requirements:<br>
Master's Degree in Social Work, Rehabilitation, Psychology, or a related human services field - or - Bachelor's Degree in the above stated fields and five (5) years management experience in a board-governed non-profit organization.<br>
<br>
To apply, respond by January 25, 1997 @ 4:30p.m.:<br>
Mail a letter of application and resume to:<br>
<br>
Judith Panozzo, Search Committee Chair<br>
San Antonio Independent Living Services<br>
P.O. Box 701065<br>
San Antonio, TX 78210-1065<br>
Or:<br>
E-mail a letter of application and resume in Microsoft Word .doc<br>
format to:<br>
sdyer@txdirect.net<br>
<br>
Qualified applicants will receive notification by mail<br>
</b><br>
Jim Hungerford &lt;<a href="mailto:sdyer@txdirect.net">sdyer@txdirect.net</a>&gt;<br>
San Antonio, TX, USA - Thursday, January 02, 1997 at 02:45:31 (MET)<hr>

<b>Like most of you, I have trouble fully grasping International Autism Day<br>
1997 http://spidernet.nl/~martijn_dekker/otsp/a-day-status.html, what<br>
it's about, who it's for, why it should be done at all  .... all these<br>
questions and many more keep fading into and out of focus.<br>
<br>
Well, in reading the recently posted poetry of a fellow autistic, David<br>
Miedzianik,<br>
http://spidernet.nl/~martijn_dekker/otsp/miedzianik.html#ghosts I came<br>
away with a far clearer picture as I know you will in thoughtfully<br>
reading the poems.  May we never get lost in the mere mechanics of<br>
International Autism Day 1997.<br>
<br>
It is appropriate to ask this Christmas eve for whom the International<br>
Autism Day 1997 bell tolls ... who is it for?  Well is it for the<br>
thousands of Davids, Marlas, Glenns, Justins, Ruperts, Andrews, Mary<br>
Margarets, Fionas, Larissas, Maritjns, Temples, Deans, Donnas, Ilzes,<br>
Pauls, Dicks, Jerrys, Marys, James, Alexes, Tonys, Johns, Michaels,<br>
Mathews, Edwards, Glennas, Anns, Susans, Bills, Freds, Dans, Peters,<br>
Tors, Lias, Janes, Amnons, Janes, Anthonys, Chrises. Phils, Martins,<br>
Marcias, Dovs, Perttis, Lauras, J.Js, Jeffreys,  Leslies, Dorines,<br>
Steves, Jennifers, Lynns, Idas,  Arturos,  Pierres, Franks, Georges,<br>
Toms, Jeans, Genes  ... and oh, so many more .... may they all find room<br>
in the inn, peace, and hope this night.    Regards, Gavin</b><br>
Gavin Simpson &lt;<a href="mailto:a203@amug.org">a203@amug.org</a>&gt;<br>
Tempe, AZ USA - Wednesday, December 25, 1996 at 16:04:00 (MET)<hr>

<b>Like most of you, I have trouble fully grasping International Autism Day<br>
1997 <http://spidernet.nl/~martijn_dekker/otsp/a-day-status.html>, what<br>
it's about, who it's for, why it should be done at all  .... all these<br>
questions and many more keep fading into and out of focus.<br>
<br>
Well, in reading the recently posted poetry of a fellow autistic, David<br>
Miedzianik,<br>
<http://spidernet.nl/~martijn_dekker/otsp/miedzianik.html#ghosts> I came<br>
away with a far clearer picture as I know you will in thoughtfully<br>
reading the poems.  May we never get lost in the mere mechanics of<br>
International Autism Day 1997.<br>
<br>
It is appropriate to ask this Christmas eve for whom the International<br>
Autism Day 1997 bell tolls ... who is it for?  Well is it for the<br>
thousands of Davids, Marlas, Glenns, Justins, Ruperts, Andrews, Mary<br>
Margarets, Fionas, Larissas, Maritjns, Temples, Deans, Donnas, Ilzes,<br>
Pauls, Dicks, Jerrys, Marys, James, Alexes, Tonys, Johns, Michaels,<br>
Mathews, Edwards, Glennas, Anns, Susans, Bills, Freds, Dans, Peters,<br>
Tors, Lias, Janes, Amnons, Janes, Anthonys, Chrises. Phils, Martins,<br>
Marcias, Dovs, Perttis, Lauras, J.Js, Jeffreys,  Leslies, Dorines,<br>
Steves, Jennifers, Lynns, Idas,  Arturos,  Pierres, Franks, Georges,<br>
Toms, Jeans, Genes  ... and oh, so many more .... may they all find room<br>
in the inn, peace, and hope this night.    Regards, Gavin</b><br>
Gavin Simpson &lt;<a href="mailto:a203@amug.org">a203@amug.org</a>&gt;<br>
Tempe, AZ USA - Wednesday, December 25, 1996 at 16:03:07 (MET)<hr>

<b>Our company, IBM, has a very cool speech recognition software package available on the web called, "IBM VoiceType Connection NS Edition".  This is a speech recognition software package that runs on Windows 95 <br>
with 32-bit Netscape Navigator 3.0/3.01.  We are currently in beta, and the beta is a FREE download available at: http://www.software.ibm.com/is/voicetype/vtconn/vtconn.html.  Check us out and tell your friends!<br>
<br>
We are currently on the IBM home page (http://www.ibm.com) and will soon be featured on other websites.  However, we feel that our software can help those with medical conditions/disabilities that makes it painful <br>
to use a keyboard.  Our software allows them to navigate the internet using their voice, and with additional software packages such as Simply Speaking or VoiceType 3.0, they can also dictate e-mail and navigate <br>
other applications on their computer by voice.  More information on these two products can be found on the VoiceType page at<br>
http://www.ibm.com/voicetype.</b><br>
IBM - VoiceType Connection NS Edition Software &lt;<a href="mailto:vtconn@vnet.ibm.com">vtconn@vnet.ibm.com</a>&gt;<br>
West Palm Beach, USA - Monday, December 23, 1996 at 22:21:51 (MET)<hr>

People with Disabilities Magazine in New Jersey. I am very interested in
consumer-directed services, but the approach is very new here. I am 
looking
for interviews via email on this subject. Feel free to contact me if you
want, Address mail to Personal_Assistance@njdhs.uu.holonet.net to say 
hello
to the consumer board that runs the program here. I am a sysop on our 
statewide
BBS and this address goes directly to their space on our virtual 
mall.<BR>
Marc Mercer &amp;lt;<A 
HREF="mailto:words@voicenet.com">words@voicenet.com</A>&amp;gt;
Lambertville, NJ, USA - Wednesday, August 21, 1996 at 04:43:13 (MET DST)
<P><CENTER><HR> <FONT SIZE=2>[<A HREF="Contents.html">Institute on 
Independent
Living contents</A>]</FONT> </CENTER>
<P>
</BODY>
<!--begin-->
<b>test</b><br>
a &lt;<a href="mailto:b">b</a>&gt;<br>
 - Sunday, February 16, 1997 at 14:31:29 (MET)<hr>

<b>Assistive Devices of Texas, designer and manufacturer of the Hayden-Preston System (HPS), <br>
would like to announce an innovative upper extremity terminal system.  <br>
<br>
The system was designed by a below the elbow amputee to serve the upper limb amputee with <br>
a quick disconnect terminal device, hand tools and implements. The HPS is not designed to<br>
permanently replace the conventional terminal device hook.  It is designed to assist the <br>
amputee in performing special tasks with ease in the course of normal daily living <br>
activities at home and work.  <br>
<br>
Utilizing this specialized terminal device, with its unique tool adaptation, <br>
provides versatility and flexibility with a safety index unattainable in <br>
current terminal devices.  An amputee may now use hand tools and implements to<br>
perform a task with reduced risk of the tool slipping (as in comparison to common<br>
occurrences when utilizing a hook). <br>
<br>
The system is easy as 1,2,3 and requires no tools, nuts and bolts for attachment. <br>
To use the system the amputee must simply...<br>
<br>
(1)  remove the hook from the body-powered prosthesis wrist unit<br>
(2)  insert the specialized Preston Terminal Device into the prosthesis <br>
(3)  select and insert the adapted Hayden Tool into the Preston Terminal<br>
      Device. <br>
<br>
A brochure detailing the availability of the device and tool adaptations will be forwarded to<br>
you providing you send your mailing address. <br>
<br>
Please contact us with any concerns you may have.<br>
<br>
Assistive Devices of Texas<br>
Ron Farquharson (409)798-8809<br>
Glenn Betts     (409)297-5447<br>
Web Site        http://www.tgn.net/~pbetts/<br>
e-mail		pbetts@tgn.net<br>
</b><br>
Glenn Betts &lt;<a href="mailto:pbetts@tgn.net">pbetts@tgn.net</a>&gt;<br>
Lake Jackson, Tx, USA - Saturday, February 15, 1997 at 03:15:08 (MET)<hr>

<b>Assistive Devices of Texas, designer and manufacturer of the<br>
Hayden-Preston System (HPS), would like to announce an <br>
innovative upper extremity terminal system.  <br>
<br>
The system was designed by a below the elbow amputee to <br>
serve the upper limb amputee with a quick disconnect <br>
terminal device, hand tools and implements. The HPS is not <br>
designed to permanently replace the conventional terminal <br>
device hook.  It is designed to assist the amputee in <br>
performing special tasks with ease in the course of normal <br>
daily living activities at home and work.  <br>
<br>
Utilizing this specialized terminal device, with its unique <br>
tool adaptation, provides versatility and flexibility with a<br>
safety index unattainable in current terminal devices.  An <br>
amputee may now use hand tools and implements to perform a <br>
task with reduced risk of the tool slipping (as in comparison<br>
to common occurrences when utilizing a hook). <br>
<br>
The system is easy as 1,2,3 and requires no tools, nuts and<br>
bolts for attachment.  To use the system the amputee must <br>
simply...<br>
<br>
(1)  remove the hook from the body-powered prosthesis wrist unit<br>
(2)  insert the specialized Preston Terminal Device into the prosthesis <br>
(3)  select and insert the adapted Hayden Tool into the Preston Terminal<br>
      Device. <br>
<br>
A brochure detailing the availability of the device and tool<br>
adaptations will be forwarded to you providing you send your<br>
mailing address. <br>
<br>
Please contact us with any concerns you may have.<br>
<br>
Assistive Devices of Texas<br>
Ron Farquharson (409)798-8809<br>
Glenn Betts     (409)297-5447<br>
Web Site        http://www.tgn.net/~pbetts/<br>
e-mail		pbetts@tgn.net<br>
</b><br>
Glenn Betts &lt;<a href="mailto:pbetts@tgn.net">pbetts@tgn.net</a>&gt;<br>
Lake Jackson, Tx, USA - Saturday, February 15, 1997 at 03:06:01 (MET)<hr>

<b>I'm a C5-6 quad living in NY with my parents and I'm in search for group or residential housing that concentrates on spinal cord injured individuals. If anyone can help me out with my search it would be greatly appreciated.  Please email me at HANDICHAP@AOL<br>
Thanks,<br>
Glenn</b><br>
Glenn &lt;<a href="mailto:HANDICHAP">HANDICHAP</a>&gt;<br>
NY, USA - Tuesday, February 04, 1997 at 03:58:40 (MET)<hr>

<b>Hello,<br>
<br>
From now you can write "independent living flanders" by e-mail. The adress is indliv.vlaand@unicall.be. I hope to read something from you!<br>
<br>
<br>
</b><br>
Damien Kinds &lt;<a href="mailto:indliv.vlaand@unicall.be">indliv.vlaand@unicall.be</a>&gt;<br>
Brugge, Belgium - Monday, January 27, 1997 at 21:41:29 (MET)<hr>

<b>Hello,<br>
<br>
From now you can write "independent living flanders" by e-mail. The adress is indliv.vlaand@unicall.be. I hope to read something from you!<br>
<br>
<br>
</b><br>
Damien Kinds &lt;<a href="mailto:indliv.vlaand@unicall.be">indliv.vlaand@unicall.be</a>&gt;<br>
Brugge, Belgium - Monday, January 27, 1997 at 21:41:26 (MET)<hr>

<b>Hello,<br>
<br>
From now you can write "independent living flanders" by e-mail. The adress is indliv.vlaand@unicall.be. I hope to read something from you!<br>
<br>
<br>
</b><br>
Damien Kinds &lt;<a href="mailto:indliv.vlaand@unicall.be">indliv.vlaand@unicall.be</a>&gt;<br>
Bruge, Belgium - Monday, January 27, 1997 at 21:37:19 (MET)<hr>

<b>We are helping our 81 year old friend Dr. Estelle Witzling-Moskowitz who was forced to retire from her practice as a Clinical Psycologist due to the hardships endured during her 17 years of confinement to her bed because of MS.<br>
She publishes the only newsletter to home bound elders with the use of a computer which she uses as a word processor. It is time for us to get her into the internet because she has so much to offer. Our problem is that she has bad eyesight among her other ailments and can not clearly see the cursor on the word processor. We are wondering<br>
if anyone in the community working with disabled persons has come across a program to keep the arrow visible when in a word processor.<br>
She is using a Macintosh quadra #605 and we have shown her how to use easy access program as well as installing a fat mouse to make it easier for her to enjoy the screen.<br>
We appreciate any and all thoughts and help with this matter.<br>
Please respond to our E mail address<br>
Thank you for allowing us to post in this page,it is a wonderful opportunity.</b><br>
Harvey Lisker/Dorie Lurie &lt;<a href="mailto:dorrie@icanect.net">dorrie@icanect.net</a>&gt;<br>
Surfside Florida, USA - Saturday, January 25, 1997 at 20:30:49 (MET)<hr>

<b>My name is Barry Peebles I am a C-4 Qaud.  I am trying to find<br>
a way to raise money to purchase a wheelchair accessible van. <br>
I just built a web page at: http://members.aol.com/BEP4U/index.html<br>
if you have any ideas or comments please go there and tell me know.</b><br>
Barry Peebles &lt;<a href="mailto:BEP4U@aol.com">BEP4U@aol.com</a>&gt;<br>
Norfolk, U.S.A. - Friday, January 24, 1997 at 19:44:16 (MET)<hr>

<b>If you are about to take a big step into independent living you might want to check this out. We have a 3Bd/2Ba Mobile home that is adapted to anyone confined to a wheelchair.  It comes with over 100 sq.ft of counter space, front and rear deck and ramp entrances, and a screened in jacuzzi room.  It is designed with open walls for access to the bathroom and bedrooms with an overhead hoist for transfers.  We are located in Central Florida, connected to the Chain-of-Lakes via canal.  We are less than 30 minutes from Orlando and all of the Disney Attractions. Nestled in an oak grove we enjoy excellent fishing just 50 feet from our door.  Less than 1 mile from conveniences, with virtually no crime rate you can enjoy sunshine and warm weather 335+ days a year!  Attendent care and help with household duties can be available at very reasonable rates right here in this friendly little park.  $26,000.00 Firm (this is under what the appraisal is).</b><br>
Kami &lt;<a href="mailto:kami.fla@worldnet.att.net">kami.fla@worldnet.att.net</a>&gt;<br>
Clermont, USA - Friday, January 24, 1997 at 01:28:11 (MET)<hr>

<b>Hello,<br>
<br>
I'm looking for information on privately initiated group living situations for mentally retarded adults in the United States. My parents, now 59 and 60, are beginnning the process of moving my disabled brother (he is 31 years old, brain damaged and suffers from Lennox-Gastaud epilepsy) from their home into another living situation. They are interested in contacted other family memebers or organizations with experience on this matter. Is there anyone out there who has either established their own group living situation or who might have information about them? Any help would be appreciated. Thanks.</b><br>
Michael Krass &lt;<a href="mailto:mbk@xs4all.nl">mbk@xs4all.nl</a>&gt;<br>
Amsterdam, Netherlands - Friday, January 17, 1997 at 10:32:49 (MET)<hr>

<b>We are searching for partners in all Eu countries, who like to cooperate with us for a HORIZON project of the European Union. This partners should work on the following issue: training and advanced training on working with computers.Our goal is to get younger people with severe physical disabilities to attend courses for working with and on computers. Courses not especially designed for this people, but designed for everyone who likes to go there, disabled or not. Our activities should be concentrated on the topic: wich conditions are necessary, that this people can attend this normal courses.Who likes to come along with us and work on that topic? You are just invited. snailmail: MOSAIK  z.H.Rudi Rux, Kalvarienguertel 62,A-8020 Graze-mail: woolf@magnet.at</b><br>
mosaik &lt;<a href="mailto:woolf@magnet.at">woolf@magnet.at</a>&gt;<br>
graz, austria - Friday, January 10, 1997 at 09:25:54 (MET)<hr>

<b>I nice domain, i used it to gain info about independent<br>
living in the US. I am studying Heilerzieher a german job <br>
specialized for work with mentaly retardet.<br>
CU</b><br>
Klaus Bolte &lt;<a href="mailto:kbolte@metronet.de">kbolte@metronet.de</a>&gt;<br>
Freyersen, FRG - Wednesday, January 08, 1997 at 01:24:27 (MET)<hr>

<b>Kate, I finally found you on the Internet.  Drop me a line some time and tell me how you are doing.  Missed you.  I'm at home right now.  The e-mail address above is my office e-mail.  My home e-mail is GerbenDJ@AOL.com.  Our office has a home page but I cannot remember the location on the Internet.  Do you get our office newsletter?  If not, let me know and I'll be sure to send you a copy.  I hope this message gets to you.  My best.  Gerben</b><br>
Gerben DeJong &lt;<a href="mailto:gxd3@mhg.edu">gxd3@mhg.edu</a>&gt;<br>
Washington, DC, USA - Monday, January 06, 1997 at 01:24:08 (MET)<hr>

<b>NOTICE OF POSITION VACANCY<br>
EXECUTIVE DIRECTOR<br>
San Antonio Independent Living Services<br>
See the SAILS web site at:<br>
http://www.txdirect.net/users/sdyer/sails.htm <br>
<br>
Salary: <br>
Commensurate with education and experience<br>
<br>
Job Description:<br>
Responsible for the management and direction of the organization. <br>
Executive Director sets direction, raises funds, ensures quality control for delivery of direct and indirect services to consumers with disabilities and administers government/grant funding.<br>
<br>
Candidates must have proven skills in the following areas:<br>
Implementing board policies<br>
Financial management<br>
Personnel management<br>
Program development<br>
Public relations and marketing<br>
Facility management<br>
<br>
Educational Requirements:<br>
Master's Degree in Social Work, Rehabilitation, Psychology, or a related human services field - or - Bachelor's Degree in the above stated fields and five (5) years management experience in a board-governed non-profit organization.<br>
<br>
To apply, respond by January 25, 1997 @ 4:30p.m.:<br>
Mail a letter of application and resume to:<br>
<br>
Judith Panozzo, Search Committee Chair<br>
San Antonio Independent Living Services<br>
P.O. Box 701065<br>
San Antonio, TX 78210-1065<br>
Or:<br>
E-mail a letter of application and resume in Microsoft Word .doc<br>
format to:<br>
sdyer@txdirect.net<br>
<br>
Qualified applicants will receive notification by mail<br>
</b><br>
Jim Hungerford &lt;<a href="mailto:sdyer@txdirect.net">sdyer@txdirect.net</a>&gt;<br>
San Antonio, TX, USA - Thursday, January 02, 1997 at 02:45:31 (MET)<hr>

<b>Like most of you, I have trouble fully grasping International Autism Day<br>
1997 http://spidernet.nl/~martijn_dekker/otsp/a-day-status.html, what<br>
it's about, who it's for, why it should be done at all  .... all these<br>
questions and many more keep fading into and out of focus.<br>
<br>
Well, in reading the recently posted poetry of a fellow autistic, David<br>
Miedzianik,<br>
http://spidernet.nl/~martijn_dekker/otsp/miedzianik.html#ghosts I came<br>
away with a far clearer picture as I know you will in thoughtfully<br>
reading the poems.  May we never get lost in the mere mechanics of<br>
International Autism Day 1997.<br>
<br>
It is appropriate to ask this Christmas eve for whom the International<br>
Autism Day 1997 bell tolls ... who is it for?  Well is it for the<br>
thousands of Davids, Marlas, Glenns, Justins, Ruperts, Andrews, Mary<br>
Margarets, Fionas, Larissas, Maritjns, Temples, Deans, Donnas, Ilzes,<br>
Pauls, Dicks, Jerrys, Marys, James, Alexes, Tonys, Johns, Michaels,<br>
Mathews, Edwards, Glennas, Anns, Susans, Bills, Freds, Dans, Peters,<br>
Tors, Lias, Janes, Amnons, Janes, Anthonys, Chrises. Phils, Martins,<br>
Marcias, Dovs, Perttis, Lauras, J.Js, Jeffreys,  Leslies, Dorines,<br>
Steves, Jennifers, Lynns, Idas,  Arturos,  Pierres, Franks, Georges,<br>
Toms, Jeans, Genes  ... and oh, so many more .... may they all find room<br>
in the inn, peace, and hope this night.    Regards, Gavin</b><br>
Gavin Simpson &lt;<a href="mailto:a203@amug.org">a203@amug.org</a>&gt;<br>
Tempe, AZ USA - Wednesday, December 25, 1996 at 16:04:00 (MET)<hr>

<b>Like most of you, I have trouble fully grasping International Autism Day<br>
1997 <http://spidernet.nl/~martijn_dekker/otsp/a-day-status.html>, what<br>
it's about, who it's for, why it should be done at all  .... all these<br>
questions and many more keep fading into and out of focus.<br>
<br>
Well, in reading the recently posted poetry of a fellow autistic, David<br>
Miedzianik,<br>
<http://spidernet.nl/~martijn_dekker/otsp/miedzianik.html#ghosts> I came<br>
away with a far clearer picture as I know you will in thoughtfully<br>
reading the poems.  May we never get lost in the mere mechanics of<br>
International Autism Day 1997.<br>
<br>
It is appropriate to ask this Christmas eve for whom the International<br>
Autism Day 1997 bell tolls ... who is it for?  Well is it for the<br>
thousands of Davids, Marlas, Glenns, Justins, Ruperts, Andrews, Mary<br>
Margarets, Fionas, Larissas, Maritjns, Temples, Deans, Donnas, Ilzes,<br>
Pauls, Dicks, Jerrys, Marys, James, Alexes, Tonys, Johns, Michaels,<br>
Mathews, Edwards, Glennas, Anns, Susans, Bills, Freds, Dans, Peters,<br>
Tors, Lias, Janes, Amnons, Janes, Anthonys, Chrises. Phils, Martins,<br>
Marcias, Dovs, Perttis, Lauras, J.Js, Jeffreys,  Leslies, Dorines,<br>
Steves, Jennifers, Lynns, Idas,  Arturos,  Pierres, Franks, Georges,<br>
Toms, Jeans, Genes  ... and oh, so many more .... may they all find room<br>
in the inn, peace, and hope this night.    Regards, Gavin</b><br>
Gavin Simpson &lt;<a href="mailto:a203@amug.org">a203@amug.org</a>&gt;<br>
Tempe, AZ USA - Wednesday, December 25, 1996 at 16:03:07 (MET)<hr>

<b>Our company, IBM, has a very cool speech recognition software package available on the web called, "IBM VoiceType Connection NS Edition".  This is a speech recognition software package that runs on Windows 95 <br>
with 32-bit Netscape Navigator 3.0/3.01.  We are currently in beta, and the beta is a FREE download available at: http://www.software.ibm.com/is/voicetype/vtconn/vtconn.html.  Check us out and tell your friends!<br>
<br>
We are currently on the IBM home page (http://www.ibm.com) and will soon be featured on other websites.  However, we feel that our software can help those with medical conditions/disabilities that makes it painful <br>
to use a keyboard.  Our software allows them to navigate the internet using their voice, and with additional software packages such as Simply Speaking or VoiceType 3.0, they can also dictate e-mail and navigate <br>
other applications on their computer by voice.  More information on these two products can be found on the VoiceType page at<br>
http://www.ibm.com/voicetype.</b><br>
IBM - VoiceType Connection NS Edition Software &lt;<a href="mailto:vtconn@vnet.ibm.com">vtconn@vnet.ibm.com</a>&gt;<br>
West Palm Beach, USA - Monday, December 23, 1996 at 22:21:51 (MET)<hr>

<!--begin-->
<b>test</b><br>
a &lt;<a href="mailto:b">b</a>&gt;<br>
 - Sunday, February 16, 1997 at 14:31:29 (MET)<hr>

<b>Assistive Devices of Texas, designer and manufacturer of the Hayden-Preston System (HPS), <br>
would like to announce an innovative upper extremity terminal system.  <br>
<br>
The system was designed by a below the elbow amputee to serve the upper limb amputee with <br>
a quick disconnect terminal device, hand tools and implements. The HPS is not designed to<br>
permanently replace the conventional terminal device hook.  It is designed to assist the <br>
amputee in performing special tasks with ease in the course of normal daily living <br>
activities at home and work.  <br>
<br>
Utilizing this specialized terminal device, with its unique tool adaptation, <br>
provides versatility and flexibility with a safety index unattainable in <br>
current terminal devices.  An amputee may now use hand tools and implements to<br>
perform a task with reduced risk of the tool slipping (as in comparison to common<br>
occurrences when utilizing a hook). <br>
<br>
The system is easy as 1,2,3 and requires no tools, nuts and bolts for attachment. <br>
To use the system the amputee must simply...<br>
<br>
(1)  remove the hook from the body-powered prosthesis wrist unit<br>
(2)  insert the specialized Preston Terminal Device into the prosthesis <br>
(3)  select and insert the adapted Hayden Tool into the Preston Terminal<br>
      Device. <br>
<br>
A brochure detailing the availability of the device and tool adaptations will be forwarded to<br>
you providing you send your mailing address. <br>
<br>
Please contact us with any concerns you may have.<br>
<br>
Assistive Devices of Texas<br>
Ron Farquharson (409)798-8809<br>
Glenn Betts     (409)297-5447<br>
Web Site        http://www.tgn.net/~pbetts/<br>
e-mail		pbetts@tgn.net<br>
</b><br>
Glenn Betts &lt;<a href="mailto:pbetts@tgn.net">pbetts@tgn.net</a>&gt;<br>
Lake Jackson, Tx, USA - Saturday, February 15, 1997 at 03:15:08 (MET)<hr>

<b>Assistive Devices of Texas, designer and manufacturer of the<br>
Hayden-Preston System (HPS), would like to announce an <br>
innovative upper extremity terminal system.  <br>
<br>
The system was designed by a below the elbow amputee to <br>
serve the upper limb amputee with a quick disconnect <br>
terminal device, hand tools and implements. The HPS is not <br>
designed to permanently replace the conventional terminal <br>
device hook.  It is designed to assist the amputee in <br>
performing special tasks with ease in the course of normal <br>
daily living activities at home and work.  <br>
<br>
Utilizing this specialized terminal device, with its unique <br>
tool adaptation, provides versatility and flexibility with a<br>
safety index unattainable in current terminal devices.  An <br>
amputee may now use hand tools and implements to perform a <br>
task with reduced risk of the tool slipping (as in comparison<br>
to common occurrences when utilizing a hook). <br>
<br>
The system is easy as 1,2,3 and requires no tools, nuts and<br>
bolts for attachment.  To use the system the amputee must <br>
simply...<br>
<br>
(1)  remove the hook from the body-powered prosthesis wrist unit<br>
(2)  insert the specialized Preston Terminal Device into the prosthesis <br>
(3)  select and insert the adapted Hayden Tool into the Preston Terminal<br>
      Device. <br>
<br>
A brochure detailing the availability of the device and tool<br>
adaptations will be forwarded to you providing you send your<br>
mailing address. <br>
<br>
Please contact us with any concerns you may have.<br>
<br>
Assistive Devices of Texas<br>
Ron Farquharson (409)798-8809<br>
Glenn Betts     (409)297-5447<br>
Web Site        http://www.tgn.net/~pbetts/<br>
e-mail		pbetts@tgn.net<br>
</b><br>
Glenn Betts &lt;<a href="mailto:pbetts@tgn.net">pbetts@tgn.net</a>&gt;<br>
Lake Jackson, Tx, USA - Saturday, February 15, 1997 at 03:06:01 (MET)<hr>

<b>I'm a C5-6 quad living in NY with my parents and I'm in search for group or residential housing that concentrates on spinal cord injured individuals. If anyone can help me out with my search it would be greatly appreciated.  Please email me at HANDICHAP@AOL<br>
Thanks,<br>
Glenn</b><br>
Glenn &lt;<a href="mailto:HANDICHAP">HANDICHAP</a>&gt;<br>
NY, USA - Tuesday, February 04, 1997 at 03:58:40 (MET)<hr>

<b>Hello,<br>
<br>
From now you can write "independent living flanders" by e-mail. The adress is indliv.vlaand@unicall.be. I hope to read something from you!<br>
<br>
<br>
</b><br>
Damien Kinds &lt;<a href="mailto:indliv.vlaand@unicall.be">indliv.vlaand@unicall.be</a>&gt;<br>
Brugge, Belgium - Monday, January 27, 1997 at 21:41:29 (MET)<hr>

<b>Hello,<br>
<br>
From now you can write "independent living flanders" by e-mail. The adress is indliv.vlaand@unicall.be. I hope to read something from you!<br>
<br>
<br>
</b><br>
Damien Kinds &lt;<a href="mailto:indliv.vlaand@unicall.be">indliv.vlaand@unicall.be</a>&gt;<br>
Brugge, Belgium - Monday, January 27, 1997 at 21:41:26 (MET)<hr>

<b>Hello,<br>
<br>
From now you can write "independent living flanders" by e-mail. The adress is indliv.vlaand@unicall.be. I hope to read something from you!<br>
<br>
<br>
</b><br>
Damien Kinds &lt;<a href="mailto:indliv.vlaand@unicall.be">indliv.vlaand@unicall.be</a>&gt;<br>
Bruge, Belgium - Monday, January 27, 1997 at 21:37:19 (MET)<hr>

<b>We are helping our 81 year old friend Dr. Estelle Witzling-Moskowitz who was forced to retire from her practice as a Clinical Psycologist due to the hardships endured during her 17 years of confinement to her bed because of MS.<br>
She publishes the only newsletter to home bound elders with the use of a computer which she uses as a word processor. It is time for us to get her into the internet because she has so much to offer. Our problem is that she has bad eyesight among her other ailments and can not clearly see the cursor on the word processor. We are wondering<br>
if anyone in the community working with disabled persons has come across a program to keep the arrow visible when in a word processor.<br>
She is using a Macintosh quadra #605 and we have shown her how to use easy access program as well as installing a fat mouse to make it easier for her to enjoy the screen.<br>
We appreciate any and all thoughts and help with this matter.<br>
Please respond to our E mail address<br>
Thank you for allowing us to post in this page,it is a wonderful opportunity.</b><br>
Harvey Lisker/Dorie Lurie &lt;<a href="mailto:dorrie@icanect.net">dorrie@icanect.net</a>&gt;<br>
Surfside Florida, USA - Saturday, January 25, 1997 at 20:30:49 (MET)<hr>

<b>My name is Barry Peebles I am a C-4 Qaud.  I am trying to find<br>
a way to raise money to purchase a wheelchair accessible van. <br>
I just built a web page at: http://members.aol.com/BEP4U/index.html<br>
if you have any ideas or comments please go there and tell me know.</b><br>
Barry Peebles &lt;<a href="mailto:BEP4U@aol.com">BEP4U@aol.com</a>&gt;<br>
Norfolk, U.S.A. - Friday, January 24, 1997 at 19:44:16 (MET)<hr>

<b>If you are about to take a big step into independent living you might want to check this out. We have a 3Bd/2Ba Mobile home that is adapted to anyone confined to a wheelchair.  It comes with over 100 sq.ft of counter space, front and rear deck and ramp entrances, and a screened in jacuzzi room.  It is designed with open walls for access to the bathroom and bedrooms with an overhead hoist for transfers.  We are located in Central Florida, connected to the Chain-of-Lakes via canal.  We are less than 30 minutes from Orlando and all of the Disney Attractions. Nestled in an oak grove we enjoy excellent fishing just 50 feet from our door.  Less than 1 mile from conveniences, with virtually no crime rate you can enjoy sunshine and warm weather 335+ days a year!  Attendent care and help with household duties can be available at very reasonable rates right here in this friendly little park.  $26,000.00 Firm (this is under what the appraisal is).</b><br>
Kami &lt;<a href="mailto:kami.fla@worldnet.att.net">kami.fla@worldnet.att.net</a>&gt;<br>
Clermont, USA - Friday, January 24, 1997 at 01:28:11 (MET)<hr>

<b>Hello,<br>
<br>
I'm looking for information on privately initiated group living situations for mentally retarded adults in the United States. My parents, now 59 and 60, are beginnning the process of moving my disabled brother (he is 31 years old, brain damaged and suffers from Lennox-Gastaud epilepsy) from their home into another living situation. They are interested in contacted other family memebers or organizations with experience on this matter. Is there anyone out there who has either established their own group living situation or who might have information about them? Any help would be appreciated. Thanks.</b><br>
Michael Krass &lt;<a href="mailto:mbk@xs4all.nl">mbk@xs4all.nl</a>&gt;<br>
Amsterdam, Netherlands - Friday, January 17, 1997 at 10:32:49 (MET)<hr>

<b>We are searching for partners in all Eu countries, who like to cooperate with us for a HORIZON project of the European Union. This partners should work on the following issue: training and advanced training on working with computers.Our goal is to get younger people with severe physical disabilities to attend courses for working with and on computers. Courses not especially designed for this people, but designed for everyone who likes to go there, disabled or not. Our activities should be concentrated on the topic: wich conditions are necessary, that this people can attend this normal courses.Who likes to come along with us and work on that topic? You are just invited. snailmail: MOSAIK  z.H.Rudi Rux, Kalvarienguertel 62,A-8020 Graze-mail: woolf@magnet.at</b><br>
mosaik &lt;<a href="mailto:woolf@magnet.at">woolf@magnet.at</a>&gt;<br>
graz, austria - Friday, January 10, 1997 at 09:25:54 (MET)<hr>

<b>I nice domain, i used it to gain info about independent<br>
living in the US. I am studying Heilerzieher a german job <br>
specialized for work with mentaly retardet.<br>
CU</b><br>
Klaus Bolte &lt;<a href="mailto:kbolte@metronet.de">kbolte@metronet.de</a>&gt;<br>
Freyersen, FRG - Wednesday, January 08, 1997 at 01:24:27 (MET)<hr>

<b>Kate, I finally found you on the Internet.  Drop me a line some time and tell me how you are doing.  Missed you.  I'm at home right now.  The e-mail address above is my office e-mail.  My home e-mail is GerbenDJ@AOL.com.  Our office has a home page but I cannot remember the location on the Internet.  Do you get our office newsletter?  If not, let me know and I'll be sure to send you a copy.  I hope this message gets to you.  My best.  Gerben</b><br>
Gerben DeJong &lt;<a href="mailto:gxd3@mhg.edu">gxd3@mhg.edu</a>&gt;<br>
Washington, DC, USA - Monday, January 06, 1997 at 01:24:08 (MET)<hr>

<b>NOTICE OF POSITION VACANCY<br>
EXECUTIVE DIRECTOR<br>
San Antonio Independent Living Services<br>
See the SAILS web site at:<br>
http://www.txdirect.net/users/sdyer/sails.htm <br>
<br>
Salary: <br>
Commensurate with education and experience<br>
<br>
Job Description:<br>
Responsible for the management and direction of the organization. <br>
Executive Director sets direction, raises funds, ensures quality control for delivery of direct and indirect services to consumers with disabilities and administers government/grant funding.<br>
<br>
Candidates must have proven skills in the following areas:<br>
Implementing board policies<br>
Financial management<br>
Personnel management<br>
Program development<br>
Public relations and marketing<br>
Facility management<br>
<br>
Educational Requirements:<br>
Master's Degree in Social Work, Rehabilitation, Psychology, or a related human services field - or - Bachelor's Degree in the above stated fields and five (5) years management experience in a board-governed non-profit organization.<br>
<br>
To apply, respond by January 25, 1997 @ 4:30p.m.:<br>
Mail a letter of application and resume to:<br>
<br>
Judith Panozzo, Search Committee Chair<br>
San Antonio Independent Living Services<br>
P.O. Box 701065<br>
San Antonio, TX 78210-1065<br>
Or:<br>
E-mail a letter of application and resume in Microsoft Word .doc<br>
format to:<br>
sdyer@txdirect.net<br>
<br>
Qualified applicants will receive notification by mail<br>
</b><br>
Jim Hungerford &lt;<a href="mailto:sdyer@txdirect.net">sdyer@txdirect.net</a>&gt;<br>
San Antonio, TX, USA - Thursday, January 02, 1997 at 02:45:31 (MET)<hr>

<b>Like most of you, I have trouble fully grasping International Autism Day<br>
1997 http://spidernet.nl/~martijn_dekker/otsp/a-day-status.html, what<br>
it's about, who it's for, why it should be done at all  .... all these<br>
questions and many more keep fading into and out of focus.<br>
<br>
Well, in reading the recently posted poetry of a fellow autistic, David<br>
Miedzianik,<br>
http://spidernet.nl/~martijn_dekker/otsp/miedzianik.html#ghosts I came<br>
away with a far clearer picture as I know you will in thoughtfully<br>
reading the poems.  May we never get lost in the mere mechanics of<br>
International Autism Day 1997.<br>
<br>
It is appropriate to ask this Christmas eve for whom the International<br>
Autism Day 1997 bell tolls ... who is it for?  Well is it for the<br>
thousands of Davids, Marlas, Glenns, Justins, Ruperts, Andrews, Mary<br>
Margarets, Fionas, Larissas, Maritjns, Temples, Deans, Donnas, Ilzes,<br>
Pauls, Dicks, Jerrys, Marys, James, Alexes, Tonys, Johns, Michaels,<br>
Mathews, Edwards, Glennas, Anns, Susans, Bills, Freds, Dans, Peters,<br>
Tors, Lias, Janes, Amnons, Janes, Anthonys, Chrises. Phils, Martins,<br>
Marcias, Dovs, Perttis, Lauras, J.Js, Jeffreys,  Leslies, Dorines,<br>
Steves, Jennifers, Lynns, Idas,  Arturos,  Pierres, Franks, Georges,<br>
Toms, Jeans, Genes  ... and oh, so many more .... may they all find room<br>
in the inn, peace, and hope this night.    Regards, Gavin</b><br>
Gavin Simpson &lt;<a href="mailto:a203@amug.org">a203@amug.org</a>&gt;<br>
Tempe, AZ USA - Wednesday, December 25, 1996 at 16:04:00 (MET)<hr>

<b>Like most of you, I have trouble fully grasping International Autism Day<br>
1997 <http://spidernet.nl/~martijn_dekker/otsp/a-day-status.html>, what<br>
it's about, who it's for, why it should be done at all  .... all these<br>
questions and many more keep fading into and out of focus.<br>
<br>
Well, in reading the recently posted poetry of a fellow autistic, David<br>
Miedzianik,<br>
<http://spidernet.nl/~martijn_dekker/otsp/miedzianik.html#ghosts> I came<br>
away with a far clearer picture as I know you will in thoughtfully<br>
reading the poems.  May we never get lost in the mere mechanics of<br>
International Autism Day 1997.<br>
<br>
It is appropriate to ask this Christmas eve for whom the International<br>
Autism Day 1997 bell tolls ... who is it for?  Well is it for the<br>
thousands of Davids, Marlas, Glenns, Justins, Ruperts, Andrews, Mary<br>
Margarets, Fionas, Larissas, Maritjns, Temples, Deans, Donnas, Ilzes,<br>
Pauls, Dicks, Jerrys, Marys, James, Alexes, Tonys, Johns, Michaels,<br>
Mathews, Edwards, Glennas, Anns, Susans, Bills, Freds, Dans, Peters,<br>
Tors, Lias, Janes, Amnons, Janes, Anthonys, Chrises. Phils, Martins,<br>
Marcias, Dovs, Perttis, Lauras, J.Js, Jeffreys,  Leslies, Dorines,<br>
Steves, Jennifers, Lynns, Idas,  Arturos,  Pierres, Franks, Georges,<br>
Toms, Jeans, Genes  ... and oh, so many more .... may they all find room<br>
in the inn, peace, and hope this night.    Regards, Gavin</b><br>
Gavin Simpson &lt;<a href="mailto:a203@amug.org">a203@amug.org</a>&gt;<br>
Tempe, AZ USA - Wednesday, December 25, 1996 at 16:03:07 (MET)<hr>

<b>Our company, IBM, has a very cool speech recognition software package available on the web called, "IBM VoiceType Connection NS Edition".  This is a speech recognition software package that runs on Windows 95 <br>
with 32-bit Netscape Navigator 3.0/3.01.  We are currently in beta, and the beta is a FREE download available at: http://www.software.ibm.com/is/voicetype/vtconn/vtconn.html.  Check us out and tell your friends!<br>
<br>
We are currently on the IBM home page (http://www.ibm.com) and will soon be featured on other websites.  However, we feel that our software can help those with medical conditions/disabilities that makes it painful <br>
to use a keyboard.  Our software allows them to navigate the internet using their voice, and with additional software packages such as Simply Speaking or VoiceType 3.0, they can also dictate e-mail and navigate <br>
other applications on their computer by voice.  More information on these two products can be found on the VoiceType page at<br>
http://www.ibm.com/voicetype.</b><br>
IBM - VoiceType Connection NS Edition Software &lt;<a href="mailto:vtconn@vnet.ibm.com">vtconn@vnet.ibm.com</a>&gt;<br>
West Palm Beach, USA - Monday, December 23, 1996 at 22:21:51 (MET)<hr>

</HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-182</DOCNO>
<DOCOLDNO>IA012-000124-B046-288</DOCOLDNO>
<DOCHDR>
http://www.independentliving.org:80/help_wanted.html 193.13.228.238 19970216213259 text/html 1712
HTTP/1.0 200 OK
Last-Modified: Sun, 06 Oct 1996 19:26:04 +0000
Date: Sun, 16 Feb 1997 21:33:17 +0000
Expires: Sun, 16 Feb 1997 21:31:37 +0000
Content-type: text/html
Server: RoxenEnterprise/1.0
Content-length: 1487
</DOCHDR>
<HTML>
<HEAD>
    <TITLE>help_wanted.html</TITLE>
</HEAD>
<BODY BGCOLOR="#f6ffff" LINK="#00003d" TEXT="#000038">
<META NAME="description" 
CONTENT="Individuals and organizations of persons with disabilities can 
publish, free of charge,  articles, reports, training manuals, 
announcements, etc. on Independent Living, personal assistance, advocacy, 

peer support, accessibility, legislation and related subjects. "><META 
NAME="keywords" CONTENT="Independent Living, personal assistance, 
advocacy, peer support, direct payments, anti-discrimination legislation, 

accessibility, disability, disability rights"><IMG 
SRC="InstLogoSmall.gif"
WIDTH="198" HEIGHT="57" ALIGN="BOTTOM" NATURALSIZEFLAG="3"> 
<BLOCKQUOTE><IMG SRC="Pixel1x1.gif" WIDTH="1" HEIGHT="1" ALIGN="BOTTOM"
NATURALSIZEFLAG="3"><IMG SRC="Pixel1x1.gif" WIDTH="1" HEIGHT="1" ALIGN=
"BOTTOM" NATURALSIZEFLAG="3"></BLOCKQUOTE>
<BLOCKQUOTE>
<H2><BR>
Help wanted</H2>
We need help with </BLOCKQUOTE>
<BLOCKQUOTE>
<UL>
  <LI>scanning and proof-reading (mainly English)
  <LI>web page construction
  <LI>cgi programming
</UL>
You can be based anywhere in the world as long as we can communicate by
snail mail, fax and e-mail. <BR>
<BR>
Wage to be negotiated.<BR>
<BR>
Sounds interesting? <A HREF="mailto:ratzka@independentliving.org">Contact

us !<BR>
</A></BLOCKQUOTE>
<P><CENTER><HR><FONT SIZE=2><A HREF="Contents.html">[Institute on 
Independent
Living contents</A><A HREF="index.html">]</A></FONT></CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-183</DOCNO>
<DOCOLDNO>IA012-000124-B047-115</DOCOLDNO>
<DOCHDR>
http://www.independentliving.org:80/STIL/STIL.html 193.13.228.238 19970216213415 text/html 4324
HTTP/1.0 200 OK
Last-Modified: Mon, 15 Jul 1996 16:11:58 +0000
Date: Sun, 16 Feb 1997 21:34:27 +0000
Expires: Sun, 16 Feb 1997 21:32:47 +0000
Content-type: text/html
Server: RoxenEnterprise/1.0
Content-length: 4099
</DOCHDR>
<HTML>
<HEAD>
    <TITLE>STIL.html</TITLE>
</HEAD>
<BODY LINK="#00003d" VLINK="#412605" BGCOLOR="#ffffff">
<H4><IMG SRC="STILtopbar.gif" WIDTH="480" HEIGHT="21" ALIGN="BOTTOM" 
NATURALSIZEFLAG="3"></H4>
<H1><CENTER><BR>
Stockholmskooperativet f&ouml;r <BR>
Independent Living</CENTER>
</H1>
<P><CENTER>STIL och 5 andra svenska brukarkooperativ f&ouml;r personlig
assistans &auml;r del av den internationella 
medborgarr&auml;ttsr&ouml;relsen
av m&auml;nniskor med funktionshinder - Independent Living-r&ouml;relsen.

Dess sammanslutning i Europa &auml;r <A 
HREF="../ENIL/ENILhomepage.html">ENIL</A>,
det europeiska n&auml;tverket f&ouml;r Independent Living.<BR>
<BR>
<A HREF="STILEnglish.html">About STIL in English</A><BR>
<BR>
<TABLE WIDTH="500" BORDER="1" CELLPADDING="2" CELLSPACING="3"> <TR><TD>
<BR>
<A HREF="STILinfo.html">Vad &auml;r STIL ?</A><IMG 
SRC="../Pixel1x1clear.gif" WIDTH="1" HEIGHT="1" ALIGN="BOTTOM" 
NATURALSIZEFLAG="3"><BR>
Historik, ideologi och hur man blir medlem<BR>
Viktiga <A HREF="STILartiklar1.html">debattartiklar</A> om STILs ideologi

och arbetss&auml;tt<BR>
</TD><TH><BR>
<A HREF="STILDemo60222.html"><IMG SRC="STILDemo60222Thumb.gif" 
WIDTH="107" HEIGHT="69" ALIGN="BOTTOM" NATURALSIZEFLAG="3"></A><BR>
</TH><TD> <BR>
STIL i aktion vid minus 15 grader framf&ouml;r finansdepartementet<BR>
</TD></TR><TR> <TD> <BR>
<A HREF="STILvadhander.html">R&ouml;r inte assistansreformen !</A><BR>
Dagsl&auml;get av STILs kampanj mot <BR>
f&ouml;rs&auml;mringar i LASS<BR>
</TD><TH><BR>
<A HREF="STILEvaLarge.html"><IMG SRC="STILEvaThumb.gif" WIDTH="85" 
HEIGHT="70" ALIGN="BOTTOM" NATURALSIZEFLAG="3"><BR>
</A></TH><TD> Kontakta STIL !<BR>
Kansliet: <BR>
<A 
HREF="mailto:bjorn.jideus@mailbox.swipnet.se">bjorn.jideus@mailbox.swipne
t.se.
<BR>
<BR>
</A>Webmaster: <A 
HREF="mailto:indliv@canit.se">ratzka@independentliving.org</A><BR>
</TD></TR><TR><TD> <BR>
<A HREF="STILstadgar.html">STILs stadgar<BR>
</A>&Auml;ndam&aring;lsparagrafen m m<BR>
</TD><TD> <BR>
<A HREF="STILStandardRegler1.html">FNs Standard Regler<BR>
</A>Vad Sverige skrev under<BR>
<BR>
<A HREF="STILochEUrapport1.html">Rapport: EU och STIL</A><BR>
</TD><TD> <BR>
<A HREF="../other_links.html">Andra l&auml;nkar<BR>
</A>H&auml;nvisningar till intressanta websidor.<BR>
</TD></TR><TR><TD> <BR>
Konferensrapporter<BR>
<A HREF="STILhearing1.html">&quot;Hemtj&auml;nst i omdaning&quot;</A> 
samt
<BR>
STILs och Handikappombudsmannens <BR>
konferens <A HREF="STILforaldraskap1.html">R&auml;tten till 
f&ouml;r&auml;ldraskap</A><BR>
</TD><TD> <BR>
<IMG SRC="STILHelenaChildrenThumb.gif" WIDTH="60" HEIGHT="71" 
ALIGN="BOTTOM" NATURALSIZEFLAG="3"><IMG SRC="../Pixel1x1clear.gif" 
WIDTH="1" HEIGHT="1" ALIGN="BOTTOM" NATURALSIZEFLAG="3"><IMG 
SRC="../Pixel1x1clear.gif" WIDTH="1" HEIGHT="1" ALIGN="BOTTOM" 
NATURALSIZEFLAG="3"><IMG SRC="../Pixel1x1clear.gif" WIDTH="1" HEIGHT="1" 
ALIGN="BOTTOM" NATURALSIZEFLAG="3"><IMG SRC="STILETTENcover.gif" 
WIDTH="50" HEIGHT="71" ALIGN="BOTTOM" NATURALSIZEFLAG="3"><BR>
</TD><TD> <BR>
<A HREF="STILSchledermann.html">Fru Schledermann !<BR>
</A>Videofilm om STIL<BR>
<BR>
STILETTEN,<BR>
STIL:s vassa tidskrift<BR>
</TD></TR> </TABLE><BR>
L&auml;mna g&auml;rna synpunkter m m till nedanst&aring;ende e-mail 
adress.
</CENTER>
<P>STIL<BR>
Bondegatan 39<BR>
113 66 Stockholm<BR>
Tel 08-640 8110, Fax 08-641 67 10<BR>
e-mail: <A 
HREF="mailto:bjorn.jideus@mailbox.swipnet.se">bjorn.jideus@mailbox.swipne
t.se
</A><BR>
<BR>
<HR><FONT SIZE="-1">sist uppdaterat 1996 05 24</FONT><BR>
<FONT SIZE="-1">&copy;<IMG SRC="../Pixel1x1clear.gif" WIDTH="1" 
HEIGHT="1" ALIGN="BOTTOM" NATURALSIZEFLAG="3">STIL<IMG 
SRC="../Pixel1x1clear.gif" WIDTH="1" HEIGHT="1" ALIGN="BOTTOM" 
NATURALSIZEFLAG="3">1996</FONT><BR>
<FONT SIZE="-1">Webmaster <A 
HREF="mailto:ratzka@independentliving.org">ratzka@independentliving.org</
A></FONT>
<BR>
<P><CENTER><FONT SIZE="-1">[I<A HREF="../Homepage1b.html">nstitutet 
f&ouml;r
Independent Living ]</A></FONT> <FONT SIZE="-1">[ <A 
HREF="../other_links.html">intressanta
l&auml;nkar </A><A HREF="../Homepage1b.html">]</A></FONT> </CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-184</DOCNO>
<DOCOLDNO>IA012-000124-B047-171</DOCOLDNO>
<DOCHDR>
http://www.independentliving.org:80/STIL/STILStandardRegler1.html 193.13.228.238 19970216213441 text/html 29108
HTTP/1.0 200 OK
Last-Modified: Mon, 15 Jul 1996 16:19:41 +0000
Date: Sun, 16 Feb 1997 21:34:42 +0000
Expires: Sun, 16 Feb 1997 21:33:02 +0000
Content-type: text/html
Server: RoxenEnterprise/1.0
Content-length: 28882
</DOCHDR>
<HTML>
<HEAD>
    <TITLE>StandardRegler1.html</TITLE>
</HEAD>
<BODY BGCOLOR="#ffffff" LINK="#000047" BACKGROUND="../redborder.gif" 
TEXT="#00003d">
<BLOCKQUOTE>
<BLOCKQUOTE><IMG SRC="STILunlogo1.gif" WIDTH="80" HEIGHT="69" 
ALIGN="BOTTOM" NATURALSIZEFLAG="3"><IMG SRC="../Pixel1x1clear.gif" 
WIDTH="1" HEIGHT="1" ALIGN="BOTTOM" NATURALSIZEFLAG="3"><IMG 
SRC="../Pixel1x1clear.gif" WIDTH="1" HEIGHT="1" ALIGN="BOTTOM" 
NATURALSIZEFLAG="3"><IMG SRC="../Pixel1x1clear.gif" WIDTH="1" HEIGHT="1" 
ALIGN="BOTTOM" NATURALSIZEFLAG="3"><IMG SRC="../Pixel1x1clear.gif" 
WIDTH="1" HEIGHT="1" ALIGN="BOTTOM" NATURALSIZEFLAG="3"><IMG 
SRC="../Pixel1x1clear.gif" WIDTH="1" HEIGHT="1" ALIGN="BOTTOM" 
NATURALSIZEFLAG="3"><IMG SRC="../Pixel1x1clear.gif" WIDTH="1" HEIGHT="1" 
ALIGN="BOTTOM" NATURALSIZEFLAG="3"><IMG SRC="../Pixel1x1clear.gif" 
WIDTH="1" HEIGHT="1" ALIGN="BOTTOM" NATURALSIZEFLAG="3"><IMG 
SRC="../Pixel1x1clear.gif" WIDTH="1" HEIGHT="1" ALIGN="BOTTOM" 
NATURALSIZEFLAG="3"><IMG SRC="../Pixel1x1clear.gif" WIDTH="1" HEIGHT="1" 
ALIGN="BOTTOM" NATURALSIZEFLAG="3"><IMG SRC="../Pixel1x1clear.gif" 
WIDTH="1" HEIGHT="1" ALIGN="BOTTOM" NATURALSIZEFLAG="3"><IMG 
SRC="../Pixel1x1clear.gif" WIDTH="1" HEIGHT="1" ALIGN="BOTTOM" 
NATURALSIZEFLAG="3"><IMG SRC="../Pixel1x1clear.gif" WIDTH="1" HEIGHT="1" 
ALIGN="BOTTOM" NATURALSIZEFLAG="3"><IMG SRC="../Pixel1x1clear.gif" 
WIDTH="1" HEIGHT="1" ALIGN="BOTTOM" NATURALSIZEFLAG="3"><IMG 
SRC="../Pixel1x1clear.gif" WIDTH="1" HEIGHT="1" ALIGN="BOTTOM" 
NATURALSIZEFLAG="3"><IMG SRC="../Pixel1x1clear.gif" WIDTH="1" HEIGHT="1" 
ALIGN="BOTTOM" NATURALSIZEFLAG="3"><IMG SRC="../Pixel1x1clear.gif" 
WIDTH="1" HEIGHT="1" ALIGN="BOTTOM" NATURALSIZEFLAG="3"><IMG 
SRC="../Pixel1x1clear.gif" WIDTH="1" HEIGHT="1" ALIGN="BOTTOM" 
NATURALSIZEFLAG="3"><IMG SRC="../Pixel1x1clear.gif" WIDTH="1" HEIGHT="1" 
ALIGN="BOTTOM" NATURALSIZEFLAG="3"><IMG SRC="../Pixel1x1clear.gif" 
WIDTH="1" HEIGHT="1" ALIGN="BOTTOM" NATURALSIZEFLAG="3"><IMG 
SRC="../Pixel1x1clear.gif" WIDTH="1" HEIGHT="1" ALIGN="BOTTOM" 
NATURALSIZEFLAG="3"><IMG SRC="../Pixel1x1clear.gif" WIDTH="1" HEIGHT="1" 
ALIGN="BOTTOM" NATURALSIZEFLAG="3"><IMG SRC="../Pixel1x1clear.gif" 
WIDTH="1" HEIGHT="1" ALIGN="BOTTOM" NATURALSIZEFLAG="3"><IMG 
SRC="../Pixel1x1clear.gif" WIDTH="1" HEIGHT="1" ALIGN="BOTTOM" 
NATURALSIZEFLAG="3"><IMG SRC="../Pixel1x1clear.gif" WIDTH="1" HEIGHT="1" 
ALIGN="BOTTOM" NATURALSIZEFLAG="3"><IMG SRC="../Pixel1x1clear.gif" 
WIDTH="1" HEIGHT="1" ALIGN="BOTTOM" NATURALSIZEFLAG="3"><IMG 
SRC="../Pixel1x1clear.gif" WIDTH="1" HEIGHT="1" ALIGN="BOTTOM" 
NATURALSIZEFLAG="3"><IMG SRC="../Pixel1x1clear.gif" WIDTH="1" HEIGHT="1" 
ALIGN="BOTTOM" NATURALSIZEFLAG="3"><IMG SRC="../Pixel1x1clear.gif" 
WIDTH="1" HEIGHT="1" ALIGN="BOTTOM" NATURALSIZEFLAG="3">for English 
original</BLOCKQUOTE>
</BLOCKQUOTE>
<BLOCKQUOTE>
<BLOCKQUOTE>
<H1><BR>
<BR>
<BR>
Standardregler</H1>
</BLOCKQUOTE>
</BLOCKQUOTE>
<BLOCKQUOTE>
<BLOCKQUOTE>
<H2>f&ouml;r att tillf&ouml;rs&auml;kra <BR>
m&auml;nniskor med<BR>
funktionsneds&auml;ttning <BR>
delaktighet och j&auml;mlikhet</H2>
</BLOCKQUOTE>
<BR>
<BR>
<BR>
</BLOCKQUOTE>
			
<BLOCKQUOTE><BR>
 
<BLOCKQUOTE>United Nations<IMG SRC="../Pixel1x1clear.gif" WIDTH="1" 
HEIGHT="1" ALIGN="BOTTOM" NATURALSIZEFLAG="3"><IMG 
SRC="../Pixel1x1clear.gif" WIDTH="1" HEIGHT="1" ALIGN="BOTTOM" 
NATURALSIZEFLAG="3"><IMG SRC="../Pixel1x1clear.gif" WIDTH="1" HEIGHT="1" 
ALIGN="BOTTOM" NATURALSIZEFLAG="3">Utrikesdepartementet<IMG 
SRC="../Pixel1x1clear.gif" WIDTH="1" HEIGHT="1" ALIGN="BOTTOM" 
NATURALSIZEFLAG="3"><IMG SRC="../Pixel1x1clear.gif" WIDTH="1" HEIGHT="1" 
ALIGN="BOTTOM" NATURALSIZEFLAG="3"><IMG SRC="../Pixel1x1clear.gif" 
WIDTH="1" HEIGHT="1" ALIGN="BOTTOM" 
NATURALSIZEFLAG="3">Socialdepartementet</BLOCKQUOTE>
<HR></BLOCKQUOTE>
<BLOCKQUOTE>
<H3><BR>
<BR>
F&Ouml;RORD</H3>
<BR>
<BR>
I december 1993 antog FN:s generalf&ouml;rsamling enh&auml;lligt ett 
f&ouml;rslag
om internationella regler f&ouml;r personer med funktionshinder. 
Tillsammans
med FN:s v&auml;rldsaktionsprogram f&ouml;r handikappade &auml;r dessa 
Standardregler
f&ouml;r att tillf&ouml;rs&auml;kra m&auml;nniskor med 
funktionsneds&auml;ttning
delaktighet och j&auml;mlikhet av grundl&auml;ggande betydelse f&ouml;r
handikappolitiken i FN:s alla medlemsl&auml;nder. Reglerna uttrycker 
tydliga
principiellla st&aring;ndpunkter n&auml;r det g&auml;ller 
r&auml;ttigheter,
m&ouml;jligheter och ansvar och ger konkreta f&ouml;rslag om hur ett land

kan undanr&ouml;ja hinder f&ouml;r funktionshindrade personer och skapa
ett tillg&auml;ngligt samh&auml;lle.<BR>
<BR>
Det finns en klar &ouml;verensst&auml;mmelse mellan inneh&aring;llet i 
reglerna
och m&aring;let f&ouml;r den svenska handikappolitiken. F&ouml;r Sveriges

del &auml;r det naturligt att ha FN:s standardregler som 
utg&aring;ngspunkt
i det p&aring;g&aring;ende handikappolitiska arbetet och vi kommer att 
aktivt
verka f&ouml;r att oms&auml;tta reglerna i praktisk handling.<BR>
<BR>
Standardreglerna presenteras h&auml;rmed p&aring; svenska. De ber&ouml;r
praktiskt taget alla samh&auml;llsomr&aring;den. Alla i samh&auml;llet,
regeringen, offentliga organ p&aring; alla niv&aring;er, f&ouml;retag, 
organisationer
m.fl., har ett ansvar f&ouml;r att reglerna blir k&auml;nda och 
respekterade
och att den vision om ett samh&auml;lle f&ouml;r alla, som reglerna 
uttrycker,
ocks&aring; blir verklighet.<BR>
<BR>
<BR>
<BR>
Stockholm i mars 1995<BR>
<BR>
<BR>
Ingela Thal&eacute;n<BR>
Lena Hjelm-Wall&eacute;n</BLOCKQUOTE>
<BLOCKQUOTE>
<H3><A NAME="anchor57460"></A><HR>Standardregler f&ouml;r att 
tillf&ouml;rs&auml;kra
m&auml;nniskor med funktionsneds&auml;ttning delaktighet och 
j&auml;mlikhet</H3>
<BR>
<BR>
<A HREF="#anchor5303015">INTRODUKTION</A><BR>
Bakgrund och nul&auml;ge<BR>
<A HREF="#anchor5340499">Tidigare internationella 
&aring;tg&auml;rder</A><BR>
<A HREF="#anchor5351215">V&auml;gen mot standardregler</A><BR>
<A HREF="#anchor5356685">Standardreglernas syfte och 
inneh&aring;ll</A><BR>
<A HREF="#anchor13772">Gundl&auml;ggande begrepp i 
handikappolitiken</A><BR>
<A HREF="#anchor17529">Funktionsneds&auml;ttning och handikapp<BR>
</A><A HREF="#anchor18482">F&ouml;rebyggande &aring;tg&auml;rder<BR>
</A><A HREF="#anchor18745">Rehabilitering</A><BR>
<A HREF="#anchor19114">Delaktighet och j&auml;mlikhet<BR>
</A><BR>
<BR>
<A HREF="STILStandardRegler2.html">INLEDNING</A><BR>
I. F&Ouml;RUTS&Auml;TTNINGAR F&Ouml;R DELAKTIGHET P&Aring; LIKA 
VILLKOR<BR>
Regel 1. <A HREF="STILStandardRegler2.html#anchor21055">&Ouml;kad 
medvetenhet</A><BR>
Regel 2. <A HREF="STILStandardRegler2.html#anchor21954">Medicinsk 
v&aring;rd
och behandling</A><BR>
Regel 3. <A 
HREF="STILStandardRegler2.html#anchor22357">Rehabilitering</A><BR>
Regel 4. <A HREF="STILStandardRegler2.html#anchor22780">St&ouml;d och 
service</A><BR>
<BR>
<BR>
II. HUVUDOMR&Aring;DEN F&Ouml;R DELAKTIGHET P&Aring; LIKA VILLKOR<BR>
Regel 5. <A 
HREF="STILStandardRegler2.html#anchor23263">Tillg&auml;nglighet</A><BR>
Regel 6. <A 
HREF="STILStandardRegler2.html#anchor24776">Utbildning</A><BR>
Regel 7. <A HREF="STILStandardRegler2.html#anchor25393">Arbete</A><BR>
Regel 8. <A HREF="STILStandardRegler2.html#anchor25986">Ekonomisk och 
social
trygghet</A><BR>
Regel 9. <A HREF="STILStandardRegler2.html#anchor26515">Familjeliv och 
personlig
integritet</A><BR>
Regel 10. <A HREF="STILStandardRegler2.html#anchor27307">Kultur</A><BR>
Regel 11. <A HREF="STILStandardRegler2.html#anchor27965">Rekreation och
idrott</A><BR>
Regel 12. <A HREF="STILStandardRegler2.html#anchor28472">Religion</A><BR>

<BR>
<BR>
III. GENOMF&Ouml;RANDE<BR>
Regel 13. <A HREF="STILStandardRegler3.html">Kunskap och 
forskning</A><BR>
Regel 14. <A HREF="STILStandardRegler3.html">Policy och planering</A><BR>

Regel 15. <A HREF="STILStandardRegler3.html">Lagstiftning</A><BR>
Regel 16. <A HREF="STILStandardRegler3.html">Ekonomisk politik</A><BR>
Regel 17. <A HREF="STILStandardRegler3.html">Samordning</A><BR>
Regel 18. <A 
HREF="STILStandardRegler3.html">Handikapporganisationer</A><BR>
Regel 19. <A HREF="STILStandardRegler3.html">Personalutbildning</A><BR>
Regel 20. <A HREF="STILStandardRegler3.html">Nationell granskning och 
utv&auml;rdering
av handikapprogram i</A> <A HREF="STILStandardRegler3.html">samband med
Standardreglernas genomf&ouml;rande</A><BR>
Regel 21. <A HREF="STILStandardRegler3.html">Tekniskt och ekonomiskt 
samarbete</A><BR>
Regel 22. <A HREF="STILStandardRegler3.html">Internationellt 
samarbete</A><BR>
<BR>
<BR>
IV. <A HREF="STILStandardRegler3.html">UPPF&Ouml;LJNING OCH 
UTV&Auml;RDERING</A><BR>
<A NAME="anchor5303015"></A></BLOCKQUOTE>
<HR>
<BLOCKQUOTE><IMG SRC="STILunlogo1.gif" WIDTH="80" HEIGHT="69" 
ALIGN="BOTTOM" NATURALSIZEFLAG="3"><BR>
<BR>
<BR>
INTRODUKTION<BR>
<BR>
<BR>
<BR>
<BR>
Bakgrund och nul&auml;ge<BR>
<BR>
1. I alla delar av v&auml;rlden, i varje land och p&aring; alla 
samh&auml;llsniv&aring;er
finns m&auml;nniskor med funktionsneds&auml;ttningar. Deras antal i 
v&auml;rlden
&auml;r stort och det &ouml;kar.<BR>
<BR>
2. Funktionsneds&auml;ttningens orsaker och konsekvenser &auml;r olika i
olika delar av v&auml;rlden. Skillnaderna beror p&aring; olika sociala 
och
ekonomiska f&ouml;rh&aring;llanden och p&aring; vilka &aring;tg&auml;rder

staterna vidtar f&ouml;r sina medborgares v&auml;lf&auml;rd.<BR>
<BR>
3. Nuvarande handikappolitik &auml;r resultatet av en utveckling under de

senaste 200 &aring;ren. P&aring; m&aring;nga s&auml;tt &aring;terspeglar
utvecklingen de allm&auml;nna levnadsvillkoren och den sociala och 
ekonomiska
politiken under olika epoker. P&aring; handikappomr&aring;det finns det
emellertid m&aring;nga faktorer som har p&aring;verkat 
levnadsf&ouml;rh&aring;llandena
f&ouml;r m&auml;nniskor med funktionsneds&auml;ttning. Okunnighet, 
likgiltighet,
vidskepelse och r&auml;dsla &auml;r sociala faktorer som under historiens

g&aring;ng har isolerat m&auml;nniskor med funktionsneds&auml;ttningar 
och
f&ouml;rdr&ouml;jt deras utvecklingsm&ouml;jligheter.<BR>
<BR>
4. Handikappolitik har under &aring;ren utvecklats fr&aring;n att 
tillhandah&aring;lla
v&aring;rd p&aring; institutioner till att ge utbildning f&ouml;r barn 
med
funktionsneds&auml;ttningar och rehabilitering av m&auml;nniskor som 
f&aring;tt
en funktionsneds&auml;ttning i vuxen &aring;lder. Genom utbildning och 
rehabilitering
har de sj&auml;lva mer aktivt kunnat driva utvecklingen av 
handikappolitiken
vidare. De, deras familjer och deras f&ouml;retr&auml;dare bildade 
organisationer
som k&auml;mpade f&ouml;r b&auml;ttre m&ouml;jligheter f&ouml;r 
m&auml;nniskor
med funktionsneds&auml;ttningar. Efter andra v&auml;rldskriget 
inf&ouml;rdes
begreppen integrering och normalisering, vilket var ett uttryck f&ouml;r
den &ouml;kade medvetenheten om dessa m&auml;nniskors f&ouml;rm&aring;ga
och m&ouml;jligheter.<BR>
<A NAME="anchor5340499"></A><BR>
5. Mot slutet av 1960-talet b&ouml;rjade handikapporganisationerna i 
n&aring;gra
l&auml;nder att formulera ett nytt handikappbegrepp. Detta nya begrepp 
antydde
det n&auml;ra sambandet mellan den begr&auml;nsning som m&auml;nniskor 
med
funktionshinder upplevde i milj&ouml;ns utformning och beskaffenhet och
den attityd som fanns hos allm&auml;nheten. Samtidigt kom 
handikappfr&aring;gorna
i utvecklingsl&auml;nderna att lyftas fram mer och mer. I n&aring;gra av
dessa l&auml;nder ber&auml;knades antalet m&auml;nniskor med 
funktionsneds&auml;ttning
i befolkningen vara mycket h&ouml;gt och de flesta av dessa var ytterst
fattiga.<BR>
<BR>
<BR>
Tidigare internationella &aring;tg&auml;rder<BR>
<BR>
6. F&ouml;renta nationerna och andra internationella organisationer har
under l&aring;ng tid &auml;gnat stor uppm&auml;rksamhet &aring;t 
r&auml;ttigheter
f&ouml;r m&auml;nniskor med funktionsneds&auml;ttning. Det viktigaste 
resultatet
av Internationella handikapp&aring;ret, 1981, var 
&quot;v&auml;rldsaktionsprogrammet
f&ouml;r personer med funktionshinder som antogs av 
Generalf&ouml;rsamlingen
i resolution 37/52. Internationella handikapp&aring;ret och 
v&auml;rldsaktionsprogrammet
bidrog starkt till att &aring;stadkomma framsteg p&aring; omr&aring;det.
B&aring;da lade tonvikten vid att m&auml;nniskor med 
funktionsneds&auml;ttning
har r&auml;tt att f&aring; samma m&ouml;jligheter som andra medborgare 
och
att f&aring; lika del i de f&ouml;rb&auml;ttringar av levnadsvillkor som
&auml;r resultatet av ekonomisk och social utveckling. H&auml;r 
definierades
ocks&aring; f&ouml;r f&ouml;rsta g&aring;ngen handikapp som ett 
f&ouml;rh&aring;llande
mellan m&auml;nniskor med funktionsneds&auml;ttning och deras 
omgivning.<BR>
<BR>
7. FN:s expertm&ouml;te om handikappfr&aring;gor h&ouml;lls i Stockholm
&aring;r 1987. D&auml;r f&ouml;reslogs att det skulle utvecklas ett 
syns&auml;tt
till v&auml;gledning f&ouml;r vad som skulle prioriteras under de 
kommande
&aring;ren. Grunden skulle vara att erk&auml;nna att m&auml;nniskor med
funktionsneds&auml;ttning har samma r&auml;ttigheter som andra.<BR>
<BR>
8. M&ouml;tet rekommenderade d&auml;rf&ouml;r att 
Generalf&ouml;rsamlingen
skulle sammankalla en s&auml;rskild konferens med uppgift att g&ouml;ra
ett utkast till en internationell konvention. M&aring;let skulle vara att

avskaffa all diskriminering mot m&auml;nniskor med 
funktionsneds&auml;ttningar
och konventionen skulle vid handikapp&aring;rtiondets slut ratificeras av

alla stater.<BR>
<A NAME="anchor5351215"></A><BR>
9. Ett utkast till konventionstext f&ouml;rbereddes av Italien och lades
fram f&ouml;r Generalf&ouml;rsamlingen under dess fyrtioandra session. 
Ytterligare
f&ouml;rslag om en konvention lades fram av Sverige under 
Generalf&ouml;rsamlingens
fyrtiofj&auml;rde session. Det gick emellertid inte att uppn&aring; 
enighet
om behovet av en s&aring;dan konvention vid n&aring;got av dessa 
tillf&auml;llen.
M&aring;nga representanter ans&aring;g att existerande dokument om 
m&auml;nskliga
r&auml;ttigheter redan garanterar m&auml;nniskor med 
funktionsneds&auml;ttning
samma r&auml;ttigheter som andra m&auml;nniskor.<BR>
<BR>
<BR>
V&auml;gen mot standardregler<BR>
<BR>
10. V&auml;gledd av &ouml;verl&auml;ggningarna i Generalf&ouml;rsamlingen

kom man under Ekonomiska och sociala r&aring;dets f&ouml;rsta ordinarie
session 1990 &ouml;verens om att koncentrera sig p&aring; att utveckla 
ett
internationellt instrument av ett annat slag. I resolution 1990/26 den 24

maj 1990 gav r&aring;det FN:s sociala utvecklingskommission i uppdrag att

under sin trettiotredje session &ouml;vervaga att tills&auml;tta en 
s&auml;rskild
arbetsgrupp med uppgift att utarbeta standardregler f&ouml;r delaktighet
och j&auml;mlikhet f&ouml;r barn, ungdomar och vuxna med 
funktionsneds&auml;ttning.
Arbetsgruppen skulle best&aring; av regeringsexperter vars medverkan 
skulle
finansieras genom frivilliga bidrag. Arbetet skulle g&ouml;ras i 
n&auml;ra
samarbete med ber&ouml;rda fackorgan, mellanstatliga organisationer och
frivilligorganisationer, speciellt med handikapporganisationerna. 
R&aring;det
bad ocks&aring; kommissionen att slutf&ouml;ra texten till reglerna 
s&aring;
att den kunde behandlas &aring;r 1993 och f&ouml;rel&auml;ggas 
Generalf&ouml;rsamlingen
vid dess fyrtio&aring;ttonde session samma &aring;r.<BR>
<BR>
11. De efterf&ouml;ljande diskussionerna i Generalf&ouml;rsamlingens 
tredje
utskott under den fyrtiofemte sessionen visade att det fanns brett 
st&ouml;d
f&ouml;r initiativet att utarbeta standardregler f&ouml;r att 
tillf&ouml;rs&auml;kra
m&auml;nniskor med funktionsneds&auml;ttningar delaktighet och 
j&auml;mlikhet.<BR>
<A NAME="anchor5356685"></A><BR>
12. N&auml;r den sociala utvecklingskommissionen h&ouml;ll sin 
trettiotredje
session fick initiativet till standardregler st&ouml;d av ett stort antal

representanter och diskussionerna ledde till att resolution 32/2 antogs
den 20 februari 1991, i vilken besl&ouml;ts att en s&auml;rskild 
arbetsgrupp
skulle tills&auml;ttas i enlighet med Ekonomiska och sociala r&aring;dets

resolution 1990/26.<BR>
<BR>
<BR>
<HR><A HREF="#anchor57460">till inneh&aring;llsf&ouml;rteckningen</A><BR>

<HR>Standardreglernas syfte och inneh&aring;ll<BR>
<BR>
13. Standardreglerna har utvecklats utifr&aring;n erfarenheter som gjorts

under F&ouml;renta nationernas handikapp&aring;rtionde (1983-1992) . Den
politiska och moraliska grunden f&ouml;r dessa regler utg&ouml;r de 
internationella
reglerna om m&auml;nskliga r&auml;ttigheter. Dessa best&aring;r av den 
allm&auml;nna
f&ouml;rklaringen om de m&auml;nskliga r&auml;ttigheterna , den 
internationella
konventionen om ekonomiska, sociala och kulturella r&auml;ttigheter, den
internationella konventionen om medborgerliga och politiska 
r&auml;ttigheter
, konventionen om barnets r&auml;ttigheter och konventionen om 
avskaffande
av all slags diskriminering av kvinnor liksom 
v&auml;rldsaktionsprogrammet
f&ouml;r handikappade.<BR>
<BR>
14. &Auml;ven om standardreglerna inte ar juridiskt bindande, kan de bli
internationell praxis n&auml;r de anv&auml;nds av ett stort antal stater
som en folkr&auml;ttslig regel. Standardreglerna inneb&auml;r ett 
moraliskt
och politiskt &aring;tagande fr&aring;n staternas sida att anpassa 
samh&auml;llet
till m&auml;nniskor med funktionsneds&auml;ttning. D&auml;r finns viktiga

principer om ansvar, agerande och samarbete. Omr&aring;den pekas ut som
&auml;r av avg&ouml;rande betydelse f&ouml;r livskvaliteten och f&ouml;r
m&ouml;jligheter att n&aring; full delaktighet och j&auml;mlikhet. 
Standardreglerna
erbjuder ett instrument som kan anv&auml;ndas vid utformningen av 
handikappolitiken
och anger l&auml;mpliga &aring;tg&auml;rder till gagn f&ouml;r 
m&auml;nniskor
med funktionsneds&auml;ttning och deras organisationer. De utg&ouml;r 
ocks&aring;
en grund f&ouml;r tekniskt och ekonomiskt samarbete mellan 
medlemsl&auml;nderna,
F&ouml;renta nationerna och andra internationella organisationer.<BR>
<BR>
15. Syftet med reglerna &auml;r att s&auml;kerst&auml;lla att flickor, 
pojkar,
m&auml;n och kvinnor med funktionsneds&auml;ttning som medborgare har 
samma
r&auml;ttigheter och skyldigheter som andra medborgare i samh&auml;llet.
I alla samh&auml;llen i v&auml;rlden finns fortfarande hinder som 
g&ouml;r
det om&ouml;jligt f&ouml;r m&auml;nniskor med funktionsneds&auml;ttning
att ut&ouml;va sina r&auml;ttigheter och friheter och 
f&ouml;rsv&aring;rar
f&ouml;r dem att delta fullt ut i samh&auml;llets aktiviteter. Ansvaret
att undanr&ouml;ja s&aring;dana hinder vilar p&aring; 
medlemsl&auml;nderna.
M&auml;nniskor med funktionsneds&auml;ttning och deras organisationer 
b&ouml;r
spela en aktiv roll i den processen. Att anpassa samh&auml;llet till 
dessa
m&auml;nniskor &auml;r ett viktigt bidrag till den allm&auml;nna och 
v&auml;rldsomfattande
str&auml;van att mobilisera m&auml;nskliga resurser. S&auml;rskild 
uppm&auml;rksamhet
b&ouml;r riktas mot kvinnor, barn, &aring;ldringar, fattiga, migrerande
arbetare, m&auml;nniskor med flera och komplicerade 
funktionsneds&auml;ttningar,
ursprungsbefolkningar och etniska minoriteter. Dessutom finns det ett 
stort
antal flyktingar med funktionsneds&auml;ttning som har speciella behov 
som
beh&ouml;ver uppm&auml;rksammas.<BR>
<A NAME="anchor13772"></A><BR>
<BR>
Grundl&auml;ggande begrepp i handikappolitiken<BR>
<BR>
16. De begrepp som f&ouml;ljer nedan anv&auml;nds genomg&aring;ende i 
reglerna.
De bygger i huvudsak p&aring; begrepp anv&auml;nda i 
v&auml;rldsaktionsprogrammet
f&ouml;r handikappade. I vissa fall avspeglar de den utveckling som 
&auml;gt
rum under F&ouml;renta nationernas handikapp&aring;rtionde.<BR>
<A NAME="anchor17529"></A><BR>
<BR>
Funktionsneds&auml;ttning och handikapp<BR>
<BR>
17. Begreppet &quot;funktionsneds&auml;ttning&quot; innefattar ett stort
antal olika funktionshinder i olika befolkningsgrupper &ouml;verallt i 
v&auml;rlden.
M&auml;nniskor kan ha funktionsneds&auml;ttningar p&aring; grund av 
fysiska
eller intellektuella skador eller sjukdomar, syn- eller h&ouml;rselskador

eller -sjukdomar, medicinska tillst&aring;nd eller mentalsjukdomar. 
S&aring;dana
skador, tillst&aring;nd eller sjukdomar kan vara av best&aring;ende eller

&ouml;verg&aring;ende natur.<BR>
<BR>
18. &quot;Handikapp&quot; avser f&ouml;rlust eller begr&auml;nsning av 
m&ouml;jligheterna
att delta i samh&auml;llslivet p&aring; samma s&auml;tt som andra. 
&quot;Handikapp&quot;
beskriver m&ouml;tet mellan m&auml;nniskor med funktionsneds&auml;ttning
och omgivningen. Syftet &auml;r att f&auml;sta uppm&auml;rksamheten 
p&aring;
brister i milj&ouml;n och inom olika samh&auml;llsomr&aring;den, 
exempelvis
brister i information, kommunikation och utbildning som hindrar 
m&auml;nniskor
med funktionsneds&auml;ttning fr&aring;n att delta p&aring; lika 
villkor.<BR>
<BR>
19. Anv&auml;ndningen av de tv&aring; begreppen 
&quot;funktionsneds&auml;ttning&quot;
och &quot;handikapp&quot;, som de definieras i paragraferna 17 och 18, 
b&ouml;r
ses i ljuset av den moderna handikapphistorien. Under 1970-talet fanns en

stark reaktion mot den tidens spr&aring;kbruk bland representanterna 
f&ouml;r
handikapporganisationerna och de yrkes-verksamma inom 
handikappomr&aring;det.
Begreppen &quot;funktionsnedsttning&quot; och &quot;handikapp&quot; 
anv&auml;ndes
ofta p&aring; ett oklart och f&ouml;rvirrande s&auml;tt, vilket gav 
d&aring;lig
v&auml;gledning f&ouml;r politiska strategier och &aring;tg&auml;rder. 
Spr&aring;kbruket
speglade en medicinsk och diagnostisk inst&auml;llning som inte tog 
h&auml;nsyn
till bristerna i det omgivande samh&auml;llet.<BR>
<BR>
20. &Aring;r 1980 antog V&auml;rldsh&auml;lsoorganisationen (WHO) en 
internationell
klassificering av skada, sjukdom, funktionsneds&auml;ttning och handikapp

som angav en mer precis men samtidigt flexibel inst&auml;llning. Den 
internationella
klassificeringen avs kada, sjukdom, funktionsneds&auml;ttning och 
handikapp
g&ouml;r en klar skillnad mellan &quot;skada eller sjukdom&quot;, 
&quot;funktionsneds&auml;ttning&quot;
och &quot;handikapp&quot;. Den har anv&auml;nts i stor utstr&auml;ckning
inom omr&aring;dena rehabilitering, utbildning, statistik, politik, 
lagstiftning,
demografi, sociologi, ekonomi och antropologi. En del anv&auml;ndare av
klassificeringen har uttryckt farh&aring;gor f&ouml;r att definitionen av

begreppet &quot;handikapp&quot; fortfarande kan anses vara alltf&ouml;r
medicinsk och alltf&ouml;r starkt inriktat p&aring; individen och att den

inte tillr&auml;ckligt belyser samspelet mellan f&ouml;rh&aring;llanden
eller f&ouml;rv&auml;ntningar i samh&auml;llet och den enskilda 
m&auml;nniskans
f&ouml;rm&aring;ga. Dessa farh&aring;gor, och andra som uttryckts under
de tolv &aring;ren sedan publiceringen av klassificeringen, kommer att 
tas
upp n&auml;r klassificeringen revideras.<BR>
<BR>
21. &Ouml;kade kunskaper om och st&ouml;rre f&ouml;rst&aring;else 
f&ouml;r
handikappfr&aring;gor och den terminologi som anv&auml;nds har utvecklats

efter hand. Detta beror p&aring; erfarenheter samband med 
genomf&ouml;randet
av v&auml;rldsaktionsprogrammet och den allm&auml;nna diskussion som 
&auml;gde
rum under F&ouml;renta nationernas handikapp&aring;rtionde. Den 
terminologi
som anv&auml;nds i dag bekr&auml;ftar att det &auml;r 
n&ouml;dv&auml;ndigt
att ta h&auml;nsyn till b&aring;de individens behov (t.ex. rehabilitering

och tekniska hj&auml;lpmedel) och samh&auml;llets brister.<BR>
<A NAME="anchor18482"></A><BR>
<BR>
F&ouml;rebyggande &aring;tg&auml;rder<BR>
<BR>
22. F&ouml;rebyggande &aring;tg&auml;rder &auml;r &aring;tg&auml;rder som

syftar till att hindra uppkomsten av fysiska, intellektuella, psykiska 
skador
eller sjukdomar eller syn- och h&ouml;rselskador (prim&auml;rt 
f&ouml;rebyggande).
F&ouml;rebyggande &aring;tg&auml;rder &auml;r ocks&aring; 
&aring;tg&auml;rder
som skall hindra att skador orsakar best&aring;ende 
funktionsbegr&auml;nsning
eller funktionsneds&auml;ttning (sekund&auml;rt f&ouml;rebyggande). 
F&ouml;rebyggande
&aring;tg&auml;rder kan vara av m&aring;nga olika slag. Det kan vara 
prim&auml;rh&auml;lsov&aring;rd,
m&ouml;dra- och sp&auml;dbarnsv&aring;rd, n&auml;ringsl&auml;ra, 
vaccinering
mot smittsamma sjukdomar och &aring;tg&auml;rder f&ouml;r att h&aring;lla

endemiska sjukdomar under kontroll. Det kan vara 
s&auml;kerhets&aring;tg&auml;rder
och handlingsprogram f&ouml;r att i olika milj&ouml;er f&ouml;rebygga 
olycksfall;
h&auml;r inbegrips anpassning av arbetsplatser s&aring; att 
arbetshandikapp
och sjukdomar f&ouml;rebyggs. Det kan vara f&ouml;rebyggande 
&aring;tg&auml;rder
mot funktionsneds&auml;ttningar p&aring; grund av 
milj&ouml;f&ouml;roreningar
och v&auml;pnade konflikter.<BR>
<A NAME="anchor18745"></A><BR>
<BR>
Rehabilitering<BR>
<BR>
23. Begreppet &quot;rehabilitering&quot; avser en process som syftar till

att m&auml;nniskor med funktionsneds&auml;ttningar skall uppn&aring; och
beh&aring;lla b&auml;sta m&ouml;jliga fysiska, intellektuella, psykiska
eller sociala funktionsf&ouml;rm&aring;ga och att ge dem m&ouml;jligheter

att f&ouml;r&auml;ndra sina liv och uppn&aring; ett st&ouml;rre 
oberoende.
Rehabilitering kan innefatta &aring;g&auml;rder av skilda slag, som att
&aring;terst&auml;lla en funktion, kompensera f&ouml;rlusten eller 
avsaknaden
av en funktion eller kompensera en funktionsbegr&auml;nsning. 
Rehabiliteringsprocessen
innefattar inte prim&auml;r h&auml;lso- och sjukv&aring;rd. D&auml;remot
innefattar den ett stort antal &aring;tg&auml;rder och aktiviteter, 
fr&aring;n
mer grundl&auml;ggande och allm&auml;n rehabilitering till 
m&aring;lorienterade
aktiviteter, som till exempel yrkesrehabilitering.<BR>
<A NAME="anchor19114"></A><BR>
<BR>
Delaktighet och j&auml;mlikhet<BR>
<BR>
24. Begreppet innefattar en process som leder till att b&aring;de olika
samh&auml;llsomr&aring;den och omgivningen blir tillg&auml;ngliga 
f&ouml;r
alla, s&auml;rskilt f&ouml;r m&auml;nniskor med 
funktionsneds&auml;ttning.
Det g&auml;ller service, aktiviteter, information och dokumentation.<BR>
<BR>
25. Principen om lika r&auml;ttigheter inneb&auml;r att varje individ har

lika v&auml;rde. Det betyder ocks&aring; att individens behov m&aring;ste

ligga till grund f&ouml;r samh&auml;llsplanering och att alla resurser 
m&aring;ste
anv&auml;ndas p&aring; ett s&aring;dant s&auml;tt att varje individ ges
lika m&ouml;jlighet att delta i samh&auml;llet.<BR>
<BR>
26. M&auml;nniskor med funktionsneds&auml;ttningar &auml;r 
samh&auml;llsmedborgare
och har r&auml;tt att f&aring; stanna kvar d&auml;r de bor. De b&ouml;r
f&aring; det st&ouml;d de beh&ouml;ver inom de regulj&auml;ra systemen 
f&ouml;r
utbildning, h&auml;lso- och sjukv&aring;rd, arbetsmarknad och social 
service.<BR>
<BR>
27. I takt med att m&auml;nniskor med funktionsneds&auml;ttning f&aring;r

samma r&auml;ttigheter som andra b&ouml;r de ocks&aring; f&aring; samma
skyldigheter som andra. Efterhand kan ocks&aring; samh&auml;llet &ouml;ka

sina f&ouml;rv&auml;ntningar p&aring; dem. Som en del av denna utveckling

b&ouml;r &aring;tg&auml;rder vidtas f&ouml;r att m&auml;nniskor med 
funktionsneds&auml;ttning
skall fullt ut kunna ta ansvar som samh&auml;llsmedborgare.<BR>
<BR>
<BR>
Slut p&aring; dokumentet<BR>
<BR>
<HR></BLOCKQUOTE>
<BLOCKQUOTE>
<H3><BR>
<BR>
<BR>
<BR>
Kommentar till den svenska &ouml;vers&auml;ttningen</H3>
<BR>
av <A HREF="../Homepage1b.html">Adolf Ratzka</A><BR>
<BR>
Den officiella svenska &ouml;vers&auml;ttningen &ouml;vers&auml;tter 
begreppet
&quot;organizations of disabled persons&quot; med 
&quot;handikapporganisationer&quot;,
det brukliga uttrycket i Sverige. Problemet med &ouml;vers&auml;ttningen
&auml;r dock att den inte till&aring;ter en &aring;tskiljning mellan 
organisationer
f&ouml;r m&auml;nniskor med funktionshinder och organisationer av 
personer
med funktionshinder. Den h&auml;r distinktionen g&ouml;rs s&auml;llan i
Sverige. D&auml;rmed finns det risken dels att personer med egna 
funktionshinder
inte har en ledande roll i de s k  handikapporganisationerna och dels att

de f&aring; organisationer som &auml;r organisationer av personer med 
funktionshinder
inte f&aring;r den betydelse som de borde ha enligt FN:s Standard Regler.

L&auml;s sj&auml;lv den <A 
HREF="gopher://gopher.undp.org:70/00/undocs/gad/RES/48/96">engelska
versionen</A> f&ouml;r att uppleva skillnaden!<BR>
<BR>
L&auml;s om betydelsen av sj&auml;lvbest&auml;mmandet &auml;ven i <A 
HREF="STILinfo.html#anchor2344167">v&aring;ra
organisationer.</A><BR>
<BR>
<HR><BR>
<P><CENTER><FONT SIZE="-1">[ <A 
HREF="STIL.html">Inneh&aring;llsf&ouml;rteckning
</A><A HREF="../Homepage1b.html">]</A></FONT> <BR>
<FONT SIZE="-1">[ <A HREF="STIL.html">STILs hemsida</A><A 
HREF="../other_links.html">
</A><A HREF="../Homepage1b.html">]</A></FONT> <FONT SIZE="-1">[I<A 
HREF="../Homepage1b.html">nstitutet
f&ouml;r Independent Living ]</A></FONT> <FONT SIZE="-1">[ <A 
HREF="../other_links.html">intressanta
l&auml;nkar </A><A HREF="../Homepage1b.html">]</A></FONT> </CENTER>
</BLOCKQUOTE>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-185</DOCNO>
<DOCOLDNO>IA012-000124-B047-212</DOCOLDNO>
<DOCHDR>
http://www.independentliving.org:80/ENIL/ENILhomepage.html 193.13.228.238 19970216213506 text/html 3107
HTTP/1.0 200 OK
Last-Modified: Sat, 28 Sep 1996 10:21:51 +0000
Date: Sun, 16 Feb 1997 21:35:17 +0000
Expires: Sun, 16 Feb 1997 21:33:37 +0000
Content-type: text/html
Server: RoxenEnterprise/1.0
Content-length: 2882
</DOCHDR>
<HTML>
<HEAD>
    <TITLE>ENIL,_the_European Network_on_Independent_Living</TITLE>
</HEAD>
<BODY TEXT="#020136" BGCOLOR="#ffffff" LINK="#00007f">
<P><CENTER><IMG SRC="ENILlogoblueL.gif" WIDTH="408" HEIGHT="110" ALIGN=
"BOTTOM" NATURALSIZEFLAG="3"></CENTER>
<P><FONT SIZE="4">E</FONT>NIL is the umbrella of individuals and 
organizations
dedicated to<BR>
promoting Independent Living among persons with disabilities and the 
general
public in Europe.<BR>
<BR>
<BR>
<FONT SIZE="4">I</FONT>ndependent Living is a philosophy and a movement
of people with disabilities who work for equal opportunities, 
self-respect
and self-determination.<BR>
<BR>
<FONT SIZE="4">I</FONT>ndependent Living does not mean that we do not 
need
anybody, that we want to live in isolation. &quot;Independent 
Living&quot;
means that we want the same control and the same choices in every-day 
life
that our non-disabled brothers and sisters, neighbors and friends take 
for
granted. We want to grow up in our families, go to the neighborhood 
school,
use the same bus, work in jobs that are in line with our education and 
abilities.
Most importantly, just like everybody else, we need to be in charge of 
our
own lives, think and speak for ourselves. <BR>
<BR>
<FONT SIZE="4">T</FONT>o this end we need to support and learn from each
other, organize ourselves and work for political changes that lead to 
legal
protection of our human and civil rights. 
<H3><A HREF="ENILContents.html">Contents</A></H3>
<BR>
<HR>219<FONT SIZE="2"><IMG SRC="../Pixel1x1.gif" WIDTH="1" HEIGHT=

"1" ALIGN="BOTTOM" NATURALSIZEFLAG="3"><IMG SRC="../Pixel1x1.gif" WIDTH=
"1" HEIGHT="1" ALIGN="BOTTOM" NATURALSIZEFLAG="3"><IMG 
SRC="../Pixel1x1.gif"
WIDTH="1" HEIGHT="1" ALIGN="BOTTOM" NATURALSIZEFLAG="3"><IMG 
SRC="../Pixel1x1.gif"
WIDTH="1" HEIGHT="1" ALIGN="BOTTOM" NATURALSIZEFLAG="3"><IMG 
SRC="../Pixel1x1.gif"
WIDTH="1" HEIGHT="1" ALIGN="BOTTOM" NATURALSIZEFLAG="3"><IMG 
SRC="../Pixel1x1.gif"
WIDTH="1" HEIGHT="1" ALIGN="BOTTOM" NATURALSIZEFLAG="3"><IMG 
SRC="../Pixel1x1.gif"
WIDTH="1" HEIGHT="1" ALIGN="BOTTOM" NATURALSIZEFLAG="3">visitors since 
August
5, 1996</FONT> <BR>
<FONT SIZE="2">This website is maintained by the<IMG 
SRC="../Pixel1x1.gif"
WIDTH="1" HEIGHT="1" ALIGN="BOTTOM" NATURALSIZEFLAG="3"><IMG 
SRC="../Pixel1x1.gif"
WIDTH="1" HEIGHT="1" ALIGN="BOTTOM" NATURALSIZEFLAG="3"><A 
HREF="../index.html">
Institute on Independent Living</A></FONT><BR>
<FONT SIZE="2">Last updated September 23, 1996</FONT> <BR>
<FONT SIZE="2">&copy;<IMG SRC="../Pixel1x1.gif" WIDTH="1" HEIGHT="1" 
ALIGN=
"BOTTOM" NATURALSIZEFLAG="3"><IMG SRC="../Pixel1x1.gif" WIDTH="1" HEIGHT=

"1" ALIGN="BOTTOM" NATURALSIZEFLAG="3"><IMG SRC="../Pixel1x1.gif" WIDTH=
"1" HEIGHT="1" ALIGN="BOTTOM" NATURALSIZEFLAG="3">ENIL</FONT> <BR>
<FONT SIZE="2"><A 
HREF="mailto:ratzka@independentliving.org">Webmaster</A></FONT>
<BR>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-186</DOCNO>
<DOCOLDNO>IA012-000124-B047-250</DOCOLDNO>
<DOCHDR>
http://www.independentliving.org:80/other_links.html 193.13.228.238 19970216213529 text/html 2940
HTTP/1.0 200 OK
Last-Modified: Sun, 06 Oct 1996 19:25:50 +0000
Date: Sun, 16 Feb 1997 21:35:38 +0000
Expires: Sun, 16 Feb 1997 21:33:58 +0000
Content-type: text/html
Server: RoxenEnterprise/1.0
Content-length: 2715
</DOCHDR>
<HTML>
<!--This file created 96-07-15 18.05 by Claris Home Page version 1.0b1-->

<HEAD>
    <TITLE>Institute_on_Independent_Living</TITLE>
</HEAD>
<BODY TEXT="#060236" BGCOLOR="#ffffff" LINK="#040539">
<META  name="description"
content="Individuals and organizations of persons with disabilities can 
publish, free of charge,  articles, reports, training manuals, 
announcements, etc. on Independent Living, personal assistance, advocacy, 
peer support, accessibility, legislation and related subjects. "><META  
name="keywords" content="Independent Living, personal assistance, 
advocacy, peer support, direct payments, anti-discrimination legislation, 
accessibility, disability, disability rights"><X-SAS-WINDOW TOP=66 
BOTTOM=624 LEFT=8 RIGHT=538>
<META NAME="GENERATOR" CONTENT="User-Agent: Mozilla/3.0b4Gold (Macintosh; 
I; PPC)"></HEAD><BODY TEXT="#000042" BGCOLOR="#FFFFFF" 
LINK="#000042"><IMG SRC=
"InstLogoSmall.gif" WIDTH="198" HEIGHT="57" ALIGN="BOTTOM" 
NATURALSIZEFLAG=
"3"> 
<H2><CENTER><BR>
<BR>
<BR>
<IMG SRC="linksaroundworld.gif" WIDTH="231" HEIGHT="53" ALIGN="BOTTOM" 
NATURALSIZEFLAG="3"> </CENTER>
</H2>
<H4>English:</H4>
<UL>
  <LI><A HREF="http://www.dpi.org/">DPI,</A> Disabled Peoples 
International
  <LI><A HREF="http://www.poptel.org.uk/nptonpeople1st/">Northamptonshire

People First,</A> 
  <LI>possibily the first organisation run and controlled by people with
learning difficulties to join the Internet Community. 
  <LI>Other sites on <A 
HREF="http://query.webcrawler.com/cgi-bin/WebQuery?text=Independent_Livin
g">Independent
Living</A> 
  <LI>Sites on <A 
HREF="http://query.webcrawler.com/cgi-bin/WebQuery?text=disability_law">d
isability
and law</A> 
</UL>
<H4>Swedish:</H4>
<UL>
  <LI><A HREF="http://www.stil.se/">STIL,</A> the Stockholm Cooperative
for Independent Living 
  <LI><A HREF="http://www.sposit.se/index.html">Svensk psykologi &amp; 
social
informations tj&auml;nst</A> 
</UL>
<H4>German</H4>
<UL>
  <LI><A HREF="http://www.wien.at/behinderte/">bizeps</A> 
</UL>
<H4>French</H4>
<UL>
  <LI><A HREF="http://www.etatne.ch/hapi/hapi.htm">Handicap - 
Internet</A>
</UL>
<H4>Italian</H4>
<UL>
  <LI><A HREF="http://www.agora.stm.it/enil4/">Italian E.N.I.L. 
Committee</A>
</UL>
<H4>Portuguese</H4>
<UL>
  <LI><A HREF="http://www.ibase.org.br/~cvirj/index.html">Center for 
Independent
Living Rio de Janeiro</A> <BR>
<BR>
<BR>
</UL>
<H3><A HREF="guestbook.html">Visit our Guestbook</A></H3>
<P><CENTER><HR><FONT SIZE=2>[<A HREF="Contents.html">Contents</A><A 
HREF="ENIL/ENILhomepage.html">]</A></FONT><FONT SIZE=2>[<A 
HREF="index.html">Institute
on Independent Living Homepage</A> <A 
HREF="ENIL/ENILhomepage.html">]</A></FONT>
<BR>
<BR>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-187</DOCNO>
<DOCOLDNO>IA012-000124-B047-303</DOCOLDNO>
<DOCHDR>
http://www.independentliving.org:80/Homepage2b.html 193.13.228.238 19970216213604 text/html 6149
HTTP/1.0 200 OK
Last-Modified: Tue, 06 Aug 1996 19:59:10 +0000
Date: Sun, 16 Feb 1997 21:36:03 +0000
Expires: Sun, 16 Feb 1997 21:34:23 +0000
Content-type: text/html
Server: RoxenEnterprise/1.0
Content-length: 5924
</DOCHDR>
<HTML>
<HEAD>
    <TITLE>Institute_on_Independent_Living</TITLE>
</HEAD>
<BODY BGCOLOR="#ffffff" LINK="#000042" TEXT="#00003d">
<FORM ACTION="default.cgi" ENCTYPE="x-www-form-encoded" 
METHOD="POST"><META NAME="description" 
CONTENT="Individuals and organizations of persons with disabilities can 
publish, free of charge,  articles, reports, training manuals, 
announcements, etc. on Independent Living, personal assistance, advocacy, 

peer support, accessibility, legislation and related subjects. "><META 
NAME="keywords" CONTENT="Independent Living, personal assistance, 
advocacy, peer support, direct payments, anti-discrimination legislation, 

accessibility, disability, disability rights">
<H2><BR>
<P><CENTER><IMG SRC="image1.gif" WIDTH="482" HEIGHT="4" NATURALSIZEFLAG=
"0" ALIGN="BOTTOM"><BR>
<BR>
Institutet f&ouml;r Independent Living</CENTER>
<P></H2>
<H4><CENTER><IMG SRC="image1.gif" WIDTH="482" HEIGHT="4" NATURALSIZEFLAG=

"0" ALIGN="BOTTOM"></CENTER>
</H4>
<H4><BR>
<BR>
Syfte</H4>
<FONT SIZE="+3">S</FONT>tiftelsens &auml;ndam&aring;l &auml;r att 
fr&auml;mja
m&ouml;jligheterna f&ouml;r m&auml;nniskor med funktionshinder till mer
personlig och politisk makt, sj&auml;lvbest&auml;mmande, full delaktighet

och j&auml;mlikhet i Sverige och internationellt genom att bedriva 
utbildningsprojekt.
D&auml;rtill h&ouml;r att framst&auml;lla och sprida utbildningsmaterial
och information, planera och organisera kurser och seminarier samt ordna
studiebes&ouml;k.<BR>
<BR>
Stiftelsen ska ha n&auml;ra samarbete med andra organisationer som 
st&ouml;der
dessa m&aring;l p&aring; det lokala, nationella och internationella 
planet,
&auml;ven i u-l&auml;nder. Stiftelsen ska samarbeta och samordna sin 
verksamhet
med liknande forsknings-, tr&auml;nings- och informationscenter som 
fr&auml;mjar
sj&auml;lvbest&auml;mmande f&ouml;r m&auml;nniskor med funktionshinder.
<H4>Backgrund</H4>
<FONT SIZE="+3">A</FONT>pril 1989 m&ouml;ttes &ouml;ver 80 personer med
omfattande funktionshinder vid Europa Parlamentet i Strasbourg f&ouml;r
en 3-dagars konferens om personlig assistans. Vid detta evenemang 
grundades
<A HREF="ENIL/ENILhomepage.html">ENIL, det europeiska n&auml;tverket 
f&ouml;r
Independent Living</A>.<BR>
<BR>
Tv&aring; av de Independent Living gr&auml;srotsorganisationer som var 
representerade
i Strasbourg, STIL, Stockholmskooperativet f&ouml;r Independent Living,
och GIL, G&ouml;teborgs Independent Living, stiftade 1993 tillsammans 
Institutet
f&ouml;r att fr&auml;mja utvecklingen av Independent Living-r&ouml;relsen

inom och utanf&ouml;r Sverige genom utbildnings- och 
informationsinsatser.
<H4>Organisation </H4>
<FONT SIZE="+3">I</FONT>nstitutet &auml;r en registrerad stiftelse enligt

svensk lag. Styrelsen best&aring;r av 
<BLOCKQUOTE>Rolf Bergfors, GIL, Sweden, e-mail: <A 
HREF="mailto:rbergfors@nn.apc.org">rbergfors@nn.apc.org</A>
<BR>
Phillip Mason, United Kingdom<BR>
Adolf Ratzka, STIL, Sweden, ordf&ouml;rande e-mail:<A 
HREF="mailto:ratzka@independentliving.org">ratzka@independentliving.org</
A><BR>
Bente Skansg&aring;rd, Norway, e-mail: <A 
HREF="mailto:Hecter@msn.com">Hecter@msn.com</A></BLOCKQUOTE>
<H4>Konsultuppdrag med websidor</H4>
<FONT SIZE="+3">V</FONT>i p&aring; Institutet har l&auml;rt oss en del om

hur man bygger sina websidor. Vi erbjuder oss att h&auml;lpa andra 
organisationer
med sina websidor. <BR>
Institutet f&ouml;r Independent Living<BR>
fil dr <A HREF="Ratzka.html">Adolf D.Ratzka, verksamhetsledare</A><BR>
Address: 
<BLOCKQUOTE>Institutet f&ouml;r Independent Living <BR>
Petersens V&auml;g 2 <BR>
127 41 Stockholm-Sk&auml;rholmen<BR>
Tel 08 740 42 00 <BR>
Fax 08 740 45 00 <BR>
e-mail<A HREF="mailto:indliv@canit.se"> </A><A 
HREF="mailto:ratzka@independentliving.org">ratzka@independentliving.org</
A></BLOCKQUOTE>
<P><CENTER><IMG SRC="image1.gif" WIDTH="600" HEIGHT="4" NATURALSIZEFLAG=
"0" ALIGN="BOTTOM"></CENTER>
<BLOCKQUOTE>
<H1><CENTER><BR>
<BR>
Institutets g&auml;stbok</CENTER>
</H1>
</BLOCKQUOTE>
<HR>
<BLOCKQUOTE>V g ta en minut f&ouml;r att fylla in den h&auml;r 
blanketten:
</BLOCKQUOTE>
<BR>
<HR>
<BLOCKQUOTE>f&ouml;rnamn <INPUT NAME="first_name" TYPE="text" 
SIZE="20">efternamn<INPUT
="================"LAST" NAME="last_name" TYPE="text" SIZE="20" 
TYPE="text"
SIZE="20" NAME="name" TYPE="text" SIZE="20" NAME="name" TYPE="text" SIZE=

"20" NAME="name" TYPE="text" SIZE="20" NAME="name" TYPE="text" SIZE="20"
NAME="name"><BR>
Organisation <INPUT ="================"ORGANIZATION=organization" 
TYPE="text" SIZE="50" NAME="name&quot;&quot;" TYPE="&quot;text&quot;" 
SIZE="&quot;20&quot;" NAME="&quot;name"
TYPE="text" SIZE="20" NAME="name" TYPE="text" SIZE="20" NAME="name" TYPE=

"text" SIZE="20" NAME="name" TYPE="text" SIZE="20" NAME="name" 
TYPE="text"
SIZE="20" NAME="name"><BR>
Adress <INPUT ="================"ADDRESS=Address" TYPE="text" SIZE="41" 
NAME="name&quot;&quot;" TYPE="&quot;text&quot;" SIZE="&quot;20&quot;" 
NAME="&quot;name"
TYPE="text" SIZE="20" NAME="name" TYPE="text" SIZE="20" NAME="name" TYPE=

"text" SIZE="20" NAME="name" TYPE="text" SIZE="20" NAME="name" 
TYPE="text"
SIZE="20" NAME="name"><BR>
Postnummer<INPUT ="================"POSTAL" 
="==============="CODE=postal_code"
TYPE="text" SIZE="20" NAME="name"> Ort<INPUT 
="================"CITY=City" TYPE="text" SIZE="24" 
NAME="name&quot;&quot;" TYPE="&quot;text&quot;" SIZE="&quot;20&quot;" 
NAME="&quot;name"
TYPE="text" SIZE="20" NAME="name" TYPE="text" SIZE="20" NAME="name" TYPE=

"text" SIZE="20" NAME="name" TYPE="text" SIZE="20" NAME="name" 
TYPE="text"
SIZE="20" NAME="name"><BR>
e-mail adress<INPUT ="================"EMAIL" 
="==============="ADDRESS=email_address"
TYPE="text" SIZE="22" NAME="name"></BLOCKQUOTE>
<HR>
<BLOCKQUOTE><INPUT TYPE="submit" VALUE="Submit answers"><BR>
<INPUT TYPE="reset" VALUE="Start over"></BLOCKQUOTE>
<A HREF="Homepage1b.html">back to the Institute&#180;s homepage</A><BR>
<BR>
</FORM>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-188</DOCNO>
<DOCOLDNO>IA012-000124-B047-360</DOCOLDNO>
<DOCHDR>
http://www.independentliving.org:80/CIB/CIBhomepage.html 193.13.228.238 19970216213629 text/html 5508
HTTP/1.0 200 OK
Last-Modified: Tue, 06 Aug 1996 20:05:47 +0000
Date: Sun, 16 Feb 1997 21:36:32 +0000
Expires: Sun, 16 Feb 1997 21:34:52 +0000
Content-type: text/html
Server: RoxenEnterprise/1.0
Content-length: 5283
</DOCHDR>
<HTML>
<HEAD>
    <TITLE>The_Institute_on_Independent_Living</TITLE>
    <META NAME="GENERATOR" CONTENT="User-Agent: Mozilla/3.0b5Gold 
(Macintosh; I; PPC)">
</HEAD>
<BODY BGCOLOR="#ffffff" BACKGROUND="greenborder.gif">
<META NAME="description" 
CONTENT="Individuals and organizations of persons with disabilities can 
publish, free of charge,  articles, reports, training manuals, 
announcements, etc. on Independent Living, personal assistance, advocacy, 

peer support, accessibility, legislation and related subjects. "><META 
NAME="keywords" CONTENT="Independent Living, personal assistance, 
advocacy, peer support, direct payments, anti-discrimination legislation, 

<BLOCKQUOTE>accessibility, disability, disability rights"><!--This file 
created 96-07-13 15.36 by Claris Home Page version 1.0b1--><X-SAS-WINDOW 
TOP="66" BOTTOM="618" LEFT="8" RIGHT="617">
<BLOCKQUOTE>&nbsp;<BR>
<BR>
<TABLE CELLSPACING="0" CELLPADDING="0"> <TR ALIGN="BASELINE"> <TD> <BR>
<BR>
<IMG SRC="CIBlogo.gif" HEIGHT="74" WIDTH="82" NATURALSIZEFLAG="0" ALIGN=
"BOTTOM"><BR>
<BR>
</TD> <TD> <BR>
<BR>
<B><FONT SIZE="+2">&nbsp;&nbsp;</FONT><FONT SIZE="+1">&nbsp;</FONT><FONT 
SIZE="+2">&nbsp;International
Building Research </FONT></B><BR>
<BR>
<B><FONT SIZE="+2">&nbsp;&nbsp;&nbsp;&nbsp;and Documentation 
Council</FONT></B><BR>
<BR>
</TD> </TR> <TR> <TD></TD> <TD></TD> </TR> </TABLE> <BR>
<BR>
<BR>
<BR>
<FONT SIZE="+2">T</FONT>his website contains the documents of the CIB 
Working
Commission W84 &quot;Building Non-Handicapping Environments&quot; 
published
up to 1994. For more recent publications and the present acticvities of
CIB W84 see<BR>
<BR>
<FONT SIZE="+2">C</FONT>IB is the abbreviation of the French title of the

International Council for Building Research, Studies and Documentation.
CIB's purpose is to facilitate and develop international cooperation in
building, housing and planning research, studies and documentation, 
covering
not only the technical but also the economic and social aspects of 
building
and the related environment. CIB with its over 100 Working Commissions 
works
through Congresses, Symposia and Colloquia. Working Commission W84 
&quot;Building
Non-Handicapping Environments&quot; was founded in 1984 with founding 
coordinator
Professor Sven Thiberg, Department of Building Function Analysis, 
Department
of Architecture, Royal Institute of Technology, Stockholm.<BR>
<BR>
<FONT SIZE="+2">T</FONT>he Department of Building Function Analysis, 
Department
of Architecture, Royal Institute of Technology, Stockholm studies the 
relationship
between man, built environment and society. The original focus has 
shifted
from the definition of spatial and other basic functional user 
requirements
to more complex aspects of the use of buildings and urban environments 
including
decision processes in planning, building and management as well as 
housing
in developing countries. The aim is to provide data and arguments to 
enable
environmental designers and users to advocate users' interests in the 
planning
process and to widen the public debate in cultural, economic and 
political
terms.<A NAME="anchor4768296"></A><BR>
<BR>
<BR>
<B><FONT SIZE="+1">Contents<BR>
<BR>
</FONT></B>Stockholm Seminar<B>: </B>Building Concept for the 
Handicapped.
Report of the International Expert Seminar in Stockholm, April 10-12, 
1984
. Stockholm: The Royal Institute of Technology, Dept. of Building 
Function
Analysis, 1987. Ratzka, Adolf Dieter, Editor.<BR>
<BR>
Prague Seminar: Renewal of Inner Cities and Accessibility for Old and 
Disabled
Citizens. Proceedings of the Second CIB W84 Expert Seminar 'Building 
Non-Handicapping
Environments', Prague 1987. Stockholm: The Royal Institute of Technology,

Dept. of Building Function Analysis, 1988. Ratzka, Adolf Dieter, 
Editor.<BR>
<BR>
Tokyo Seminar: Accessibility in Developing Countries. Proceedings of the
Third CIB W84 Expert Seminar 'Building Non-Handicapping Environments', 
Tokyo,
1988. Stockholm: The Royal Institute of Technology, Dept. of Building 
Function
Analysis, 1989. Ratzka, Adolf Dieter, Editor.<BR>
<BR>
Budapest Seminar: Access Legislation and Design Solutions. Proceedings of

the Fourth CIB W84 Expert Seminar 'Building Non-Handicapping 
Environments',
Budapest 1991. Stockholm: The Royal Institute of Technology, Dept. of 
Building
Function Analysis, 1992. Ratzka, Adolf Dieter, Editor.<BR>
<BR>
<A HREF="http://www.canit.se/~indliv/CIB/CIBHarare1.html">Harare Seminar:

</A>Access Legislation and Design Solutions. Proceedings of the Fifth CIB

W84 Expert Seminar 'Building Non-Handicapping Environments', Harare, 
January
1991. Stockholm: The Royal Institute of Technology, Dept. of Building 
Function
Analysis, 1992. Ratzka, Adolf Dieter, Editor.<BR>
<BR>
Montevideo Seminar: Legislaci&oacute;n sobre accesibilidad - soluciones
de dise&ntilde;o. CIB W84 Seminario-Taller Montevideo, Uruguay, Mayo de
1992. Stockholm: The Royal Institute of Technology, Dept. of Building 
Function
Analysis, 1993. El&eacute;na Sir&eacute;, Editor.<BR>
<P><CENTER><HR><FONT SIZE="-1">[<A 
HREF="http://www.canit.se/~indliv/index.html">Institute
on Independent Living Homepage</A><A 
HREF="http://www.canit.se/~indliv/ENIL/ENILhomepage.html">]</A>
</FONT></CENTER>
</BLOCKQUOTE>
</BLOCKQUOTE>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-189</DOCNO>
<DOCOLDNO>IA012-000124-B048-68</DOCOLDNO>
<DOCHDR>
http://www.independentliving.org:80/CIB/CIBRio94Access.html 193.13.228.238 19970216213709 text/html 32401
HTTP/1.0 200 OK
Last-Modified: Mon, 19 Aug 1996 21:26:14 +0000
Date: Sun, 16 Feb 1997 21:36:56 +0000
Expires: Sun, 16 Feb 1997 21:35:16 +0000
Content-type: text/html
Server: RoxenEnterprise/1.0
Content-length: 32175
</DOCHDR>
<HTML>
<!--This file created 96-08-19 21.54 by Claris Home Page version 1.0b1-->

<HEAD>
    <TITLE>Institute_on_Independent_Living</TITLE>
</HEAD>
<BODY>
<X-SAS-WINDOW TOP=42 BOTTOM=621 LEFT=4 RIGHT=534> </HEAD><BODY><BR>
<BR>
</HEAD><BODY><META NAME="description"
CONTENT="Individuals and organizations of persons with disabilities can
publish, free of charge, articles, reports, training manuals,
announcements, etc. on Independent Living, personal assistance, advocacy,

peer support, accessibility, legislation and related subjects. "><META
NAME="keywords" CONTENT="Independent Living, personal assistance,
advocacy, peer support, direct payments, anti-discrimination legislation,

accessibility, disability, disability rights"></HEAD><BODY TEXT="#020B3B" 
BGCOLOR="#FFFFFF" LINK="#000042" BACKGROUND="greenborder.gif"><BR>
<BLOCKQUOTE>
<H2><IMG SRC="ciblogosmall.gif" WIDTH="62" HEIGHT="55" ALIGN="MIDDLE" 
NATURALSIZEFLAG=
"3"></H2>
</BLOCKQUOTE>
<BLOCKQUOTE>
<H2><CENTER>A brief survey of studies on costs and benefits<BR>
of non-handicapping environments</CENTER>
</H2>
<P><CENTER>Presentation at the International Congress on 
Accessibility<BR>
in Rio de Janeiro, Brazil, June 1994<BR>
<BR>
by Dr. Adolf Ratzka<BR>
Associate Coordinator of CIB/84 &quot;Building Non-Handicapping 
Environments&quot;<BR>
Department of Building Function Analysis<BR>
School of Architecture and Planning<BR>
Royal Institute of Technology, Stockholm, Sweden</CENTER>
</BLOCKQUOTE>
<BLOCKQUOTE>
<H4>Introduction</H4>
At the Royal Institute of Technology in Stockholm Professor Thiberg and
I coordinate the Working Commission &quot;Building Non-Handicapping 
Environments&quot;
which is part of the CIB network. CIB is the abbreviation of the French
title of the International Council for Building Research, Studies and 
Documentation.
CIB's purpose is to facilitate and develop international cooperation in
building, housing and planning research, studies and documentation, 
covering
not only the technical but also the economic and social aspects of 
building
and the related environment. CIB, with its over 100 Working Commissions,
works through congresses, symposia and colloquia.<BR>
<BR>
Working Commission W84 &quot;Building Non-Handicapping Environments&quot;

was founded in 1984. In the 10 years of our work we have had a number of
international seminars in several world regions. At these events 
altogether
some 500 persons participated and over 200 papers were given on various
aspects of accessibility in the built environment. The proceedings of the

meetings have been published by the Royal Institute of Technology in 
Stockholm.
The documents present a wealth of information, studies and reports 
representing
the state-of-the-art in access research in 40 countries.<BR>
<BR>
Among the many issues taken up in the proceedings of our working 
commission
one recurring topic is the cost of barrier free construction compared to
the costs of building inaccessible environments. In the first part of my
paper I will briefly summarize the results of a number of papers 
presented
or referred to at our W84 events by researchers and practitioners from 
different
countries. In the second part of my presentation I discuss some studies
which put the additional costs of accessible construction in relation to
the benefits that can be expected from barrier-free environments. I will
conclude my paper with a few observations on the topic of costs, expected

benefits and the politics of accessibility.<BR>
</BLOCKQUOTE>
<BLOCKQUOTE>
<H4>Definitions</H4>
Accessibility standards<BR>
<BR>
In discussing barrier-free design we first have to agree on the level of
accessibility on which we base our comparisons. Shall we consider a 
building
to be accessible where a wheelchair user with strong arms and hands can
move around in a manual chair all by himself or herself? Are we looking
at the level of accessibility needed by persons using power chairs like
myself? Shall we assume that the access needs of persons using crutches
or canes are also covered by design which is geared to wheelchair users?
Do we include the access needs of persons with sight and hearing 
impairments?
Shall we also consider the needs of persons with intellectual 
disabilities
who might have difficulties in finding their way in a larger building? 
And,
finally, what about the growing number of people who are allergic to 
various
substances?<BR>
<BR>
Which activities shall a barrier-free design support? Is it enough to 
enter
and move about in a structure or do we include in our definition also the

use of a building's facilities such as toilets, water fountains, 
telephones,
vending machines, etc.? In residential structures, do we consider 
&quot;visitability&quot;
as the standard or &quot;liveability&quot;?<BR>
<BR>
These are only a few questions that come to mind in discussing 
accessibility
in the built environment for persons with disabilities. The present paper

is based on a survey of other studies which all are based on different 
access
standards. For these reasons it is not possible to make exact comparisons

between them nor is it possible to directly apply their results to other
situations.<BR>
<BR>
Macro vs. micro design<BR>
<BR>
The concept of macro and micro planning, to my knowledge was first 
introduced
by Selwyn Goldsmith (1981). Historically, people with disabilities have
been isolated and shut off from society in the form of micro solutions,
i.e. solutions specifically and exclusively geared to this group. 
Examples
are special kindergartens, special schools, sheltered workshops, special
and segregated housing, that is institutions. Our present cities are full

of micro solutions: one accessible housing complex or shopping street in
a whole city. one accessible phone booth in a row of inaccessible ones,
one accessible public toilet within several city blocks. Macro planning,
on the other hand, takes into account the needs of all citizens. As a 
consequence,
the built environment will enable disabled people to participate in every

aspect of society.<BR>
<BR>
In the present paper I am discussing macro solutions, i. e. accessible 
structures
and other environments that are not special purpose built for disabled 
persons.<BR>
</BLOCKQUOTE>
<BLOCKQUOTE>
<H4>Costs of barrier-free design</H4>
Organizations of disabled persons all over the world are demanding with
growing indignation that their needs have to be taken into consideration
in building our societies. They claim that accessibility is a human and
civil right. They also maintain that an accessible built environment is
a better and safer environment for all. A common answer to these 
arguments
is that while accessible transportation, accessible public buildings, 
accessible
housing, streets and parks, etc. would surely be good to have, we simply
cannot afford it. In the struggle for barrier-free construction we have
to meet this wide-spread attitude with solid facts and figures. Is 
universal
design more expensive than &quot;conventional&quot; design and, if so, by

how much?<BR>
<BR>
Cost comparisons can be done in two way. One, an existing inaccessible 
building
is to be brought up to a certain accessibility standard through 
renovation.
What does this renovation cost compared to the original construction 
costs?
Two, given an inaccessible building, what would have been the costs, if
it had been constructed with universal access right from the beginning?
Below I provide a brief survey over available studies that are referred
to in the proceedings of our CIB W84 expert seminars. Most often, the 
studies
only take up one type of comparison.<BR>
<BR>
Public buildings<BR>
<BR>
In a US study (Schroeder and Steinfeld, 1979) different types of existing

structures were subjected to the two comparisons. The results are 
summarized
in Table 1.<BR>
<BR>
Table 1. Cost increases due to accessibility in public buildings. 
Renovation
and original barrier-free design compared to conventional (inaccessible)
structures.<BR>
<BR>
<TABLE BORDER=1 CELLPADDING=1 WIDTH="80%" HEIGHT=166> <TR> <TD> <BR>
<BR>
<BR>
<BR>
&nbsp; </TD><TD> <BR>
<BR>
Col 1 <BR>
<BR>
Cost increase due to accessible renovation </TD><TD VALIGN=top> <BR>
<BR>
Col 2 <BR>
<BR>
original barrier-free design </TD><TD VALIGN=top> <BR>
<BR>
Col 1/Col 2 </TD></TR> <TR> <TD> <BR>
<BR>
Convention hall </TD><TD> <BR>
<BR>
0.12% </TD><TD> <BR>
<BR>
0.02 % </TD><TD> <BR>
<BR>
6 </TD></TR> <TR> <TD> <BR>
<BR>
Town Hall </TD><TD> <BR>
<BR>
0.2%, </TD><TD> <BR>
<BR>
0.05% </TD><TD> <BR>
<BR>
4 </TD></TR> <TR> <TD> <BR>
<BR>
College Classroom </TD><TD> <BR>
<BR>
0.51% </TD><TD> <BR>
<BR>
0.13% </TD><TD> <BR>
<BR>
4 </TD></TR> <TR> <TD> <BR>
<BR>
Shopping center </TD><TD> <BR>
<BR>
0.22% </TD><TD> <BR>
<BR>
0.006% </TD><TD> <BR>
<BR>
35 </TD></TR> </TABLE><BR>
<BR>
<BR>
<BR>
Source: Schroeder and Steinfeld (1979) The estimated cost of accessible
buildings. US Department of Housing and Urban Development.<BR>
<BR>
Regarding the first type of comparison, what is the cost of accessible 
retrofitting
compared with original construction costs, the estimates range from 0.12
per cent to 0.5 per cent. The other comparisons, how much more it would
have cost, if the structures had been designed without barriers right 
from
the beginning, range from 0.006% in the case of the shopping center to 
0.13%
in the case of the college classroom.<BR>
<BR>
A 1980 study by the Singapore Urban Redevelopment Authority referred to
by Harrison (CIB W84 Report 1993) used a type two cost comparison for a
large center consisting of commercial offices, multi-storey car park, 
food
center and market). A controlled costing exercise was carried out to 
compare
the cost of the building with and without facilities of access for 
disabled
persons, and the conclusion was that these could be provided for an 
additional
0.11 per cent of the total cost.<BR>
<BR>
Residential construction<BR>
<BR>
Housing involves more functions than office buildings, classrooms or 
supermarkets.
Also, housing structures tend to be smaller and access features will make

up a larger portion of total construction.<BR>
<BR>
Regarding multi-family housing, a French study referred to by Armani (CIB

W84 Report 1993) estimated the additional costs for bringing up 
multi-family
housing to accessibility standard, on an average, to between 0.5 and 1.0
per cent of total construction costs in new construction. The same 
estimates
for multi-family housing have been made by the Swedish Building Research
Council for Sweden. Almost identical results are reported by Wrightson 
and
Pope (1989) regarding Australia where the Australian Uniform Building 
Regulations
Coordinating Council had undertaken comparative cost studies. Wrightson
and Pope comment that for new projects the exercise to identify extra 
costs
of access features might be more expensive than the design time required
to include them.<BR>
<BR>
Phillipen (CIB W84 Report 1993) reports from German studies on 
multi-family
housing that the difference in cost between traditional (read 
inaccessible)
construction and the new type of barrier-free building construction is 
negligible.
The studies resulted in additional investments of between 3.01 to 3.2 per

cent of total cost which, according to Philipen, can be neglected since
rearranging of financing and logistics in a building project, can very 
well
compensate for this minor increase.<BR>
<BR>
Research on single-family units has been carried out in Canada. In 
Ottawa,
9 specially designed units in a project of 54 townhouses cost 8 - 10 per
cent more than the others but added only 0.5 per cent to the overall 
project
cost. The effect on rental scales is therefore negligible. (This cost 
comparison
does not involve universal access, since the other 45 townhouses 
apparently
were not accessible.) A report by the Canadian Mortgage Housing Company
of 17 case studies indicated that, in most cases, the accessibility 
features
added 0.39 - 0.53 per cent to the building cost. (Champagne CIB W84 
Report
1988) Dunn (CIB W84 Report 1993) reports that in an actual project, 
Project
Open House, an average of only $1,500 was spent in 1986 to adapt existing

homes of consumers to make them accessible. He also refers to a US study
by Bartelle Memorial Institute which found that if accessibility is 
incorporated
into a design prior to construction, the cost of making 10 per cent of 
the
units accessible is less than 1 per cent of the total constructions 
costs.
(Again, a comparison not based on universal access design.)<BR>
<BR>
Various studies by U.S. HUD have estimated the costs of 
&quot;adaptable&quot;
housing, that is housing with basic access features that easily can be 
complemented
by individuals as needed. The findings were about one-half of one per 
cent
of new construction costs. A recent H.U.D. study for guidelines for the
Fair Housing Amendments Act of 1988 showed an average cost increase of 
0.5
per cent in typical single-family homes in four suburban projects. (Park
CIB W84 Report 1993)<BR>
<BR>
The US study conducted by Schroeder and Steinfeld (1979) already referred

to above also contains housing examples shown in the following table.<BR>

<BR>
Table 2. Cost increases due to accessibility in residential buildings. 
Renovation
and original barrier-free design compared to conventional (inaccessible)
structures.<BR>
<BR>
<TABLE BORDER=1 CELLPADDING=1 WIDTH="80%"> <TR> <TD> <BR>
<BR>
<BR>
</TD><TD> <BR>
<BR>
Col 1 Cost increase due<BR>
to accessible renovation </TD><TD VALIGN=top> <BR>
<BR>
Col 2 original<BR>
barrier-free design </TD><TD VALIGN=top> <BR>
<BR>
Col 1/Col 2 </TD></TR> <TR> <TD> <BR>
<BR>
High rise tower multi-family structure. </TD><TD> <BR>
<BR>
1.0% </TD><TD> <BR>
<BR>
0.25% </TD><TD> <BR>
<BR>
4 </TD></TR> <TR> <TD> <BR>
<BR>
Single family homes, one floor </TD><TD> <BR>
<BR>
21% </TD><TD> <BR>
<BR>
3.0% </TD><TD> <BR>
<BR>
7 </TD></TR> <TR> <TD> <BR>
<BR>
College dormitory </TD><TD> <BR>
<BR>
0.40% </TD><TD> <BR>
<BR>
0.10% </TD><TD> <BR>
<BR>
4 </TD></TR> </TABLE><BR>
<BR>
<BR>
Source: Schroeder and Steinfeld (1979) The estimated cost of accessible
buildings. US Department of Housing and Urban Development.<BR>
<BR>
The results of this study indicate that accessible renovation amounted up

to 21 per cent of the total construction in single-family units and to a
maximum of 1 per cent in high rise multi-family apartments. Designing the

structures from the very beginning barrier free would have cost only 3 
per
cent in their single-family example and 0.25 per cent more in the 
high-rise
complex they studied.<BR>
<BR>
In analyzing the studies presented so far we can derive several 
conclusions.
For one, whether making an existing building accessible or designing it
from scratch without barriers, the smaller the unit of comparison, the 
larger
the additional costs due to access features. This explains why it will 
cost
more to make housing accessible than public buildings, and single-family
housing more expensive than multi-family housing.<BR>
<BR>
The most consistent result is that renovating existing buildings is much
more expensive than building the same structure with barrier free design
from the beginning. The latter is between 4 and 35 times cheaper (see Col

1/Col 2) in the tables.<BR>
<BR>
Single-family home builders often point out that even in the case of new
construction the additional costs due to access features will be far too
high for the market, implying that nobody would buy their accessible 
houses.
When analyzing their cost estimates Park (CIB W84 Report 1993) has found
that often builders have not changed their thinking and see access as a
matter of adding on extra features rather than incorporating access 
already
in the basic design. &quot;Stretching old plans to meet particular 
elements
of new design requirements makes them more expensive than re-designing 
anew.
A relatively small investment in architectural costs will result in lower

construction costs for access. Inevitably there are some transitional 
costs
associated with any change in codes and regulations. With public 
accommodations
we have seen these smooth out once suppliers begin to provide standard 
products
and materials that meet access requirements.&quot; (Park CIB W84 Report
1993) This requires major rethinking on the part of all actors. If 
building
laws and regulations at all levels incorporate disabled people's needs in

the every-day design practice and on-site construction work, the whole 
industry
including planners, architects, suppliers of fittings and materials will
be forced to change. Standards for materials, such as doors, for example,

and new routines will change to meet the new specifications. Thereafter
the difference in costs of products between the old and new standard will

be negligible. A 80 cm wide door blade does not cost that much more than
a 60 cm wide one. A wider door means fewer bricks for the wall, and the
differences in cost disappear.<BR>
<BR>
We can conclude from the studies presented so far that access legislation

would raise new construction costs in public buildings by less than 0.1
per cent, on an average, in multi-family housing by up to 3 per cent and
in single-family homes (single floor) also up to 3 per cent. It is 
probably
safe to assume that once architects', builders' and suppliers' experience

with universal access design has become deeper and more wide-spread, 
costs
will come down considerably.<BR>
</BLOCKQUOTE>
<BLOCKQUOTE>
<H4>Benefits of barrier-free design</H4>
The built environment represents one of the largest investments in any 
country.
There is no other industry that is more capital intensive than the real
estate industry. As with all investments the amounts to be invested have
to be seen in relation to the expected gains. Thus, the additional costs
of making structures accessible, have to be compared to the expected 
benefits.<BR>
<BR>
What then are the expected benefits from barrier free design? There are
basically two groups: tangible ones, that is those that can be expressed
in dollars and cents and so-called intangible benefits which are more 
difficult,
if not impossible, to quantify.<BR>
<BR>
Among tangible benefits will be reduction in accidents, their related 
costs
in terms of health services and loss of production. The reasoning is that

accessible environments are also safe environments (see Wrightson and 
Pope).
Examples are ramps rather than steps, elevators instead of staircases. 
According
to the World Health Organization &quot;accidents cause more deaths than
any single illness except cancer and cardiovascular disease&quot; (quoted

in Ratzka 1984). The number of accidents due to stairs and the associated

costs to society can be and has been estimated (see for example Ratzka 
1984).<BR>
Another tangible benefit is the increase in housing quality which most 
access
features entail. Elevators are a convenience, the wider doors and 
hallways,
kitchens and bathrooms are also quality increasing features which the 
housing
market values in the form of higher rents or property prices.<BR>
<BR>
Among other tangible benefits is the decreased demand for institutional
residential living on the part of many older persons who often are forced

to leave their own inaccessible dwelling and move to nursing homes or old

age homes. Given an accessible environment in their old home, however, 
many
of them would be able to manage longer by themselves and stay out of 
institutions.
Dunn (1993), for example, refers to a study which found that 50 per cent
of the applicants to a residential center for the aged in Boston were 
capable
of functioning in the community with appropriate supports and accessible
housing.<BR>
<BR>
In some countries old and disabled persons are eligible to use public 
home
help or personal assistance services. Again, an accessible environment 
will
reduce the need for such services with savings to the public as a result.

In places where such services are provided not by the state but by the 
family,
a barrier free environment results in less work for the relatives - often

the daughters or wives - who will have better opportunities on the labor
market outside the home which results in higher production and gains to
the national economy.<BR>
<BR>
Other benefits are more difficult to quantify such as the improvement in
disabled persons' freedom of movement and social mobility. Given barrier
free environments more persons with disabilities can educate themselves
and enter the labor market. I am aware that inaccessible transportation
systems, schools and workplaces are not the sole reason for the sky-high
rate of unemployment among persons with disabilities. From my own 
personal
experience, however, I would not underestimate the daily expenditures of
physical and mental energy and monetary costs that are needed to pursue
gainful employment in handicapping environments.<BR>
</BLOCKQUOTE>
<BLOCKQUOTE>
<H4>Cost-benefit analysis</H4>
Cost -benefit analysis is a tool to compare the magnitudes of the costs
of a given investment to its expected benefits over time in order to 
assess
the desirability of projects. Given the scarcity of resources, those 
projects
would then be given priority where the ratio of expected benefits over 
costs
is higher than in other projects.<BR>
<BR>
There are only a few studies which have tried to apply cost-benefit 
analysis
to investments in accessibility. The first of its kind, as far as I know,

is the study commissioned by the US Department of Housing and Urban 
Development
and carried out by Chollet (1979). It focuses on accessibility of a 
specified
level, the American National Standards Institute (ANSI) standard A117.1
of 1978. Cost comparisons between institutional and community living for
older persons and people with disabilities are used to estimate the 
benefits
of renovating existing buildings and removing architectural barriers. The

analysis contains case studies of three types of residential structures:
high rise apartments, garden apartments, and single-family homes. Only 
easily
measurable economic costs and benefits accruing to disabled individuals
are included. Cost estimates refer to bringing up the structures to the
ANSI standard. The estimated benefits are the market value of personal 
assistance
services that disabled persons are now able to provide for themselves due

to the absence of architectural barriers. The findings are that in the 
instances
studied, renovating housing without barriers yields benefits which amount

to 13 to 22 times the level of the renovation costs. These overwhelmingly

positive results, however, are due mainly to a decisive limitation of the

study: the assumption was made that the renovated units would be rented
to disabled tenants only. In that way the study avoids the difficult 
methodological
issue of assessing the rate of utilization by disabled tenants but loses
much of its value as an argument for universal access design. It assumes
100 per cent utilization, that is ghettos. Universal access design on the

other hand, implies that a structure is made accessible regardless of who

will move in and when. Universal means just that: all housing is to be 
built
accessible as a principle.<BR>
<BR>
The only study, that I am aware of, which incorporates a universal design

philosophy is Ratzka 1984. In that study a large actual housing area in
the city of Stockholm consisting of three-story walk-up apartments built
in the 1940's and 1950's was analyzed. In the 1980's the units had to 
undergo
major modernization and the question was raised whether the opportunity
should be used to equip all these buildings with elevators. By that time
Sweden had developed a technology of retrofitting this type of apartment
structure with elevators. Each elevator would serve only nine apartments
in the study area. The costs of the installation was known. The question
asked was, what does it cost not to install elevators. The costs of not
installing elevators are the lost benefits in the form of reduced number
of accidents, reduced demand for residential institutions by the present
tenants, reduced demand for municipal home help services and the market
valuation of elevators as an amenity. The benefits were estimated using
the calculated probability that a given apartment would be occupied by a
household with an old and disabled member. In other words, it was not 
assumed
that all apartments would be occupied all the time by disabled persons,
as the H.U.D. study did. Despite these very hard assumptions, however, 
the
results of the study allow the conclusion that society would gain from 
elevator
installation. Applied to new construction of apartment housing, the 
results
of the study suggest tremendous gains to society by making all new 
housing
construction barrier free.<BR>
</BLOCKQUOTE>
<BLOCKQUOTE>
<H4>&quot;Intangible&quot; costs of handicapping environments</H4>
Studies of this type seem always unsatisfactory, since they have to leave

out many factors that are impossible to quantify but are decisive 
nevertheless.
Some of the most important costs of handicapping environments fall in 
this
category. In the following I would like to briefly summarize some of the
social costs of inaccessible environments.<BR>
<BR>
Inaccessible environments not only discriminate against us in very 
concrete
ways, they also affect us in more subtle ways. An example: Assume that 
you
as the employer are interviewing a job applicant for a staff position. 
Your
office can be reached via a flight of steps only. The job applicant is a
wheelchair user and has to be carried upstairs. In this situation, is it
not likely that the applicant's helplessness in climbing stairs might 
also
affect your assessment of his or her mental abilities? And is it not 
possible
that a person who all his life is made dependent on other people at every

step will begin to see himself dependent on other people also in other 
respects?
For the people around us and even for ourselves it is not always clear 
that
the problem is not within us, is not because we are incompetent and 
passive,
but because architects, planners and politicians deny us our equal 
rights.<BR>
<BR>
Micro solutions, that is isolated examples of barrier free design that 
are
limited to one particular building or area, will not do. In a micro 
society
disabled people will be reminded at literally every step of the limits 
that
somebody else has imposed on them. Micro solutions represent accessible
islands in an otherwise inaccessible ocean. Outside these islands people
with disabilities appear helpless and are made to feel helpless. In a 
micro
world people with disabilities are made dependent on the choices that 
architects
and planners consider sufficient for them.<BR>
<BR>
The physical and mental energy spent on coping with our inaccessible 
cities,
the imposed restrictions in life style, occupational and social 
opportunities
are costs borne not only by disabled people, their families and friends
but by all citizens. The economist will call these costs 
&quot;intangible&quot;,
but to the actual people involved they are as tangible as a flight of 
stairs.<BR>
</BLOCKQUOTE>
<BLOCKQUOTE>
<H4>Conclusions</H4>
I am afraid that studies of the type I have summarized here will not 
convince
property owners to make their structures accessible. The costs of the 
modifications
are borne by the individual owner, most of the gains, on the other hand,
benefit somebody else. What matters to the individual owner is the 
cash-flow
that he sees in his bank account, not the gains that accrue to such a 
diffuse
entity as &quot;society&quot;.<BR>
<BR>
The policy implications of this brief survey on the relative costs of 
accessibility
seem to be that in the case of renovating existing structures the state,
that is the entity that includes all those who benefit from investments
in universal access design, must provide economic incentives in some form

of other. When it comes to new construction, the additional costs of 
universal
access design, if any, are so negligible that they can be borne by the 
owner
who, in turn, may pass them on to the users. Thus, as economist, I have
no scruples to suggest comprehensive and effective legislation that 
guarantees
all new construction, both public buildings and residences, to be barrier

free.<BR>
<BR>
I want to close with a personal observation. Although I am an economist
by training, I have difficulties in using economic arguments when it 
comes
to such basic human rights as freedom of movement and the right to 
participate
in society on equal terms. Human and civil rights cannot be expressed in
dollars and cents. If our countries can afford to invest billions in the
most sophisticated weapons to kill and disable other human beings, then
our governments surely have enough money to invest in a barrier free 
society,
a more democratic and human society for all.<BR>
</BLOCKQUOTE>
<BLOCKQUOTE>
<H4></H4>
<BLOCKQUOTE>More recent cost-benefit studies are available from <BR>
Prof.  Edward Steinfeld<BR>
Adaptive Environment. Lab. <BR>
SUNY/Buffalo<BR>
112 Hayes  Hall, 3435 Main St.<BR>
Buffalo,  NY 14214<BR>
United&nbsp;States<BR>
<BR>
</BLOCKQUOTE>
</BLOCKQUOTE>
<BLOCKQUOTE>
<H4>Bibliography</H4>
Deborah J. Chollet (1979) A cost-benefit Analysis of accessibility. U.S.
Department of Housing and Urban Development, Washington.<BR>
<BR>
Steven Schroeder and Edward Steinfeld (1979) The estimated cost of 
accessible
buildings. U.S. Department of Housing and Urban Development, 
Washington.<BR>
<BR>
Selwyn Goldsmith (1981) The built environment - who does it handicap? 
Proceedings
of the research colloquium: The built environment and the handicapped. 
Department
of Housing Design Chalmers Technical University, Gothenburg.<BR>
<BR>
Adolf Ratzka (1984) The cost of disabling environments. Swedish Council
for Building Research D9:1984, Stockholm.<BR>
<BR>
William Wrightson and Campbell Pope (1989) From Barrier free to save 
environments:
The New Zealand experience, World Rehabilitation Fund Monograph #44, 
World
Rehabilitation Fund, New York.<BR>
<BR>
Report of the International Expert Seminar 'Building Concept for the 
Handicapped'
in Stockholm, April 10-12, 1984 . Stockholm: The Royal Institute of 
Technology,
Dept. of Building Function Analysis, 1987.<BR>
<BR>
Renewal of Inner Cities and Accessibility for Old and Disabled Citizens:
Proceedings of the Second CIB W84 Expert Seminar 'Building 
Non-Handicapping
Environments', Prague, October 15-17, 1987. Stockholm: The Royal 
Institute
of Technology, Dept. of Building Function Analysis, 1988.<BR>
<BR>
Accessibility in Developing Countries: Proceedings of the Third CIB W84
Expert Seminar 'Building Non-Handicapping Environments', Tokyo, September

8, 1988 . Stockholm: The Royal Institute of Technology, Dept. of Building

Function Analysis, 1989.<BR>
<BR>
Access Design Solutions and Legislation: Proceedings of the Fourth CIB 
W84
Expert Seminar 'Building Non-Handicapping Environments', Budapest, 
September
3-5, 1991. Stockholm: The Royal Institute of Technology, Dept. of 
Building
Function Analysis, 1993.<BR>
<BR>
Access Design Solutions and Legislation: Proceedings of the Fifth CIB W84

Expert Seminar 'Building Non-Handicapping Environments', Harare, January
7-9, 1992. Stockholm: The Royal Institute of Technology, Dept. of 
Building
Function Analysis, 1993.<BR>
<BR>
Legislaci&oacute;n sobre accesibilidad - Soluciones de dise&ntilde;o, 
Documentaci&oacute;n
del CIB W84 &quot;Building Non-Handicapping Environments&quot; 
Seminario-Taller
, Montevideo, Uruguay, Mayo de 1992, Royal Institute of Technology, 
Department
of Building Function Analysis, Estoccolmo, 1993.<BR>
<P><CENTER><HR><FONT SIZE=1><A HREF="CIBhomepage.html#anchor4768296">CIB
Contents]</A></FONT><FONT SIZE=1><A HREF="../Homepage1b.html">, 
[</A></FONT><FONT SIZE=1><A HREF="../Contents.html">Institute
on Independent Living Contents</A></FONT><FONT SIZE=1><A 
HREF="CIBHarare1.html#anchor52685">]</A></FONT>
</CENTER>
</BLOCKQUOTE>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-190</DOCNO>
<DOCOLDNO>IA012-000124-B048-181</DOCOLDNO>
<DOCHDR>
http://www.independentliving.org:80/ToolsforPower/Tools35.html 193.13.228.238 19970216213755 text/html 10283
HTTP/1.0 200 OK
Last-Modified: Tue, 06 Aug 1996 20:03:39 +0000
Date: Sun, 16 Feb 1997 21:37:46 +0000
Expires: Sun, 16 Feb 1997 21:36:06 +0000
Content-type: text/html
Server: RoxenEnterprise/1.0
Content-length: 10057
</DOCHDR>
<HTML>
<HEAD>
    <TITLE>Institute_on_Independent_Living</TITLE>
</HEAD>
<BODY BGCOLOR="#ffffff">
<META NAME="description" 
CONTENT="Individuals and organizations of persons with disabilities can 
publish, free of charge,  articles, reports, training manuals, 
announcements, etc. on Independent Living, personal assistance, advocacy, 

peer support, accessibility, legislation and related subjects. "><META 
NAME="keywords" CONTENT="Independent Living, personal assistance, 
advocacy, peer support, direct payments, anti-discrimination legislation, 

accessibility, disability, disability rights">
<H4>Housing adaptation<BR>
</H4>
<H2><CENTER>Toward a barrier-free home</CENTER>
</H2>
<BR>
<FONT SIZE="+3">A</FONT>n environment that is barrier free is a vital 
aspect
to independence; it can substantially increase the options for 
establishing
your own routine of daily living and working activity. There are many 
ways
to change a seemingly inaccessible environment into a barrier-free living

situation. The changes that you decide to make will depend on the 
following:
<UL>
  <LI>Personal financial resources 
  <LI>Applicable building codes 
  <LI>Availability of a qualified, experienced carpenter 
  <LI>Approval from your landlord if you rent or lease 
  <LI>Your own ideas and creativity 
</UL>
While a dream house with all the features of accessibility may not at 
present
be affordable, there are a number of changes that can be made for 
reasonable
costs. A professional carpenter can make structural modifications that 
you
need. However, a large number of modifications can be made by persons who

are skillful with their hands. Whether you use a professional or a 
weekend
carpenter, it is important that you make sure that the person knows 
exactly
what modifications are to be done before beginning the work.<BR>
<BR>
Another preliminary task involves checking to see if adding a room, 
moving
a wall, or making other structural changes at your location requires a 
building
permit.<BR>
<BR>
If you are renting or leasing, you are required to get written permission

from your landlord to make structural changes. Your landlord may be 
willing
to share or pay for the cost of modifications. 
<H3>Features of accessibility</H3>
<H4>Doorways</H4>
<FONT SIZE="+3">A</FONT> width of 30 inches is required for manual and 
power
wheelchairs. In the United States doors come in standard widths of 28, 
30,
32, 34, and 36 inches. Doors with odd widths or larger than 36 inches are

considered custom doors and have to be specially ordered. A 28-inch door
can be made accessible by installing wrap-around hinges since they allow
the door to open past the frame. These hinges are available at hardware
supply stores.<BR>
<BR>
Door handles with lever action can be installed in place of 
doorknobs.<BR>
Sliding doors save space but are considerably more expensive than 
standard
doors.<BR>
Folding doors save swing space but take up valuable space in the doorway
when folded. 
<H4>Electricity</H4>
<FONT SIZE="+3">R</FONT>elocating light switches and plug sockets will 
run
approximately $30-45 each. Improperly installed electrical wiring can be
dangerous, so a qualified electrician should be used to install or 
reroute
the electrical wiring. The electrician should be given the exact 
locations
for switches, plugs, and appliances. 
<H4>Ramps</H4>
<FONT SIZE="+3">R</FONT>amps should be 36 to 38 inches wide with a slope
of no more than 15 degrees or one foot of length for every inch in 
height.
Wooden ramps exposed to weather should be constructed with treated lumber

and marine-grade plywood. Rails at a height of 30 to 32 inches are 
recommended.
A non-skid texturizer should be added to exterior paint on the ramp 
surface.
The supports or legs for the ramp should be cemented 12 to 18 inches into

the ground if the ramp exceeds a length of 10 feet. A deck or porch of 
4-1/2
x 4-1/2 feet is recommended for exterior entry ways to allow for a 
360-degree
turning radius for a wheelchair. Similar platforms are needed at the end
of a ramp and for ramps that change directions. The same dimensions apply

for concrete ramps as for wooden ramps. Reinforcement steel rods are 
recommended
for ramps that are longer than 8 feet. 
<H4>Bathrooms</H4>
<FONT SIZE="+3">R</FONT>oll-in showers generally require 16 to 20 square
feet (4x4 feet or 4x5 feet) floor space. A sloped entrance and proper 
drainage
are critical to prevent seepage into the floor or foundation. The 
installation
and relocation of shower controls and drain can be done by a plumber. 
Lever
action controls fro faucets are available at hardware stores. Also, 
curtains
are easier to operate than doors on showers. Vanity cabinets can be 
removed
from underneath the sink to allow for more mobility inside the 
bathroom.<BR>
<BR>
Hot water pipes should be insulated to prevent burns or other 
injuries.<BR>
Lever action faucets for the sink are available.<BR>
Mirrors should be installed so that they can be used both by people 
standing
and by people seated in wheelchairs. Adjustable mirrors may also be 
installed.<BR>
The seat of the commode needs to be 17 to 19 inches from the floor. There

are brackets available to raise the seat or a plumber can raise the 
entire
commode to the desired height.<BR>
Grab-bars for steadying can be installed on sturdy walls next to the 
toilet
and in the shower approximately 33 to 36 inches from the floor and of 
sufficient
length to meet your needs. 
<H4>Bedrooms</H4>
<FONT SIZE="+3">C</FONT>loset doors which are 32 inches wide with a 
maximum
threshold height of 1/2 inch are recommended.<BR>
<BR>
Clothing rods may be lowered and adjustable shelves may be installed to
make the contents of closets more accessible.<BR>
<BR>
The room should have a 5-foot diameter turning space.<BR>
<BR>
Location of temperature control switches is important. Switches for air
conditioning units, fans, heaters, and thermostats all need to be 33 to
36 inches from the floor. Windows that open with ease by using a lever or

a weighted pulley system located at a comfortable height for the user can

be installed and modifications can be made to accommodate the user. 
<H4>Kitchens</H4>
<FONT SIZE="+3">A</FONT> width of 5 feet is required between counters for

turning space. <BR>
Stoves that are level with the counter make the transfer of pots and pans

easier. It is safer to have temperature controls on the front of the 
stove
and staggered burner plates. Ovens that open to the side can be 
approached
more closely for the removal of hot items. Also, ovens that are placed 
either
below or above the counter should have controls and racks within 
reach.<BR>
An open area underneath the sink can be made by removing the cabinet. The

area at minimum should be a height of 27 inches, a width of 30 inches, 
and
depth of 19 inches.<BR>
Switches for lights and garbage disposal can be placed on the front of 
the
counter or cabinets.<BR>
Cabinet doors can be replaced with curtains. Cabinets and shelves need a
toe space of 9 inches high and 4 to 5 inches deep. Carousel shelves and
shelves on smooth rollers can be useful for reaching objects stored on 
the
back part of the shelf. Small carousel shelves are also handy to use 
inside
the refrigerator for storing small items. 
<H4>Communications</H4>
<FONT SIZE="+3">S</FONT>pecific information about telephones such as 
speaker
phones, pushbutton dials, self-dialing phones for frequently used 
numbers,
and volume-control receivers is available from your telephone company. 
Teletypewriters
(TTYs, TDDs) are available for people who are hearing impaired.<BR>
Citizen-band radios are useful back-up systems for communication in cases

when the power goes off.<BR>
Flashing lights can be installed to indicate to a hearing impaired person

that someone is at the door or that the phone is ringing. 
<H4>Mobility</H4>
<FONT SIZE="+3">H</FONT>ard surfaces are best for wheelchairs since 
surfaces
such as loose gravel and shag carpets, to say nothing of loose earth, 
make
travel difficult. For people who are visually impaired, rope trails with
spaces for cross traffic can be helpful in bad weather or when crossing
large open spaces, such as fields. Different textures of soil, grass, 
gravel,
and corner-marking stones can also be used to mark paths without rails 
for
people who are visually impaired.<BR>
<BR>
Steep grades and uneven ground can be leveled in frequently traveled 
areas.
Proper drainage is necessary to prevent mud and erosion. Conversions and
modifications can be made on trucks, tractors, and other farm machinery
to allow for greater use of the vehicles. For more information on 
adapting
farm machinery, contact Bill Field, Breaking New Ground Project, Purdue
University, Lafayette, IN 47907. Other types of travel machines can be 
modified
too, including snowmobiles, 3-wheel motor bikes, bicycles, etc. 
<H4>In conclusion</H4>
<FONT SIZE="+3">W</FONT>hen considering ways to make your home more 
accessible,
the best of all tools and designs is a well coordinated amount of common
sense and a generous use of your creativity.<BR>
<BR>
<BR>
For more information about modifications, contact:<BR>
<BR>
Accessibility Guidelines for Multi-family Housing, Regional 
Rehabilitation
Continuing Education Program<BR>
P.O. Box 1358<BR>
Hot Springs, AR 71901<BR>
Breaking New Ground Project<BR>
Purdue University<BR>
Lafayette, IN 47907, United States<BR>
<BR>
National Clearinghouse for Rehabilitation Training Materials<BR>
115 Old USDA Building<BR>
Oklahoma State University<BR>
Stillwater, OK 74074, United States<BR>
<BR>
Barrier-Free Environments, Inc.<BR>
Ron Mace<BR>
P.O. Box 30634<BR>
Raleigh, NC 276722, United States<BR>
<BR>
<BR>
Source:<BR>
ILRU at Texas Institute for Rehabilitation, 2323 S. Shepherd, Suite 1000,

Houston, TX 77019, United States.<BR>
<P><CENTER><HR><FONT SIZE=2>[<A HREF="Tools1.html">Tools for Power 
contents]</A></FONT><FONT SIZE=2>[<A HREF="../Contents.html">Institute
on Independent Living contents</A>]</FONT></CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-191</DOCNO>
<DOCOLDNO>IA012-000124-B048-234</DOCOLDNO>
<DOCHDR>
http://www.independentliving.org:80/UCapeTown95.html 193.13.228.238 19970216213834 text/html 25932
HTTP/1.0 200 OK
Last-Modified: Tue, 06 Aug 1996 19:59:59 +0000
Date: Sun, 16 Feb 1997 21:38:39 +0000
Expires: Sun, 16 Feb 1997 21:36:59 +0000
Content-type: text/html
Server: RoxenEnterprise/1.0
Content-length: 25706
</DOCHDR>
<HTML>
<HEAD>
    <TITLE>Institute_on_Independent_Living</TITLE>
</HEAD>
<BODY TEXT="#020a3f" BGCOLOR="#ffffff" LINK="#000042">
<META NAME="description" 
CONTENT="Individuals and organizations of persons with disabilities can 
publish, free of charge,  articles, reports, training manuals, 
announcements, etc. on Independent Living, personal assistance, advocacy, 

peer support, accessibility, legislation and related subjects. "><META 
NAME="keywords" CONTENT="Independent Living, personal assistance, 
advocacy, peer support, direct payments, anti-discrimination legislation, 

accessibility, disability, disability rights">
<IMG SRC="InstLogoSmall.gif" WIDTH="198" HEIGHT="57" ALIGN="BOTTOM" 
NATURALSIZEFLAG=
"3"> <BR>
<H2>Opening universities to students with disabilities: <BR>
University of Cape Town, South Africa</H2>
<BR>
PROGRESS REPORT 1994-1995 <BR>
<H4>INTRODUCTION</H4>
<BR>
The Disability Unit at the University of Cape Town aims to `mainstream'
rather than follow the `welfare model' and to dismantle the many barriers

that inhibit students and staff who have disabilities or chronic 
illnesses,
from participating equally and fully in all aspects of the 
University.<BR>
<BR>
Our work in the DU is complex and wide ranging. And, as many of the basic

facts have been explored in previous Reports, this Progress Report will
place a special emphasis on the way our philosophy influences our 
direction,
and the way in which it links us to other types of socio-political 
developments.
It also identifies the way our methods of working diverge from some of 
the
historical presumptions that have developed and which dominate work with
disabled people. We will report on specific areas that we have worked in,

primarily where they illuminate the role we play. 
<H4>PRINCIPLES AND PHILOSOPHY OF ACCESS</H4>
The general principle of making institutions `accessible to, and 
conducive
for all people to participate equally and fully' in terms of gender and
race is now part of the fabric of our society. However, there has not yet

been a firm commitment in South Africa to creating equality in our 
society
for people with disabilities. Moreover, the process of how a society 
addresses
the backlog of numerous barriers that prevent such participation is still

in its infancy.<BR>
<BR>
The rate at which the process of dismantling discrimination can occur, 
depends
on the intransigence and synergistic reactions of many components. They
range from historical circumstances and historically patronizing social
attitudes, through to existing structures. Very often, barriers are so 
subtlety
hidden from society and to the institution itself, that only when they 
are
challenged by a person's desire to confront them do they receive 
attention.<BR>
<BR>
As in other parallel discriminatory acts, it is not enough for the 
institution
simply to state the desire to be non-discriminatory and inclusive; 
neither
does it create long-term and meaningful change simply to use quota 
systems
as attempts to `fulfill' the objectives of `equal rights and 
participation'.
As in other fields of anti-discrimanatory activity, the achievement of 
`equal
participation' necessitates meaningful changes to internal structures, 
and
not simply a provision of separate services supposedly designed to `make
the life of a disabled person' (the person discriminated against) more 
tolerable.<BR>
<BR>
Most legislation informs of a RIGHT TO ACCESS and a right `not to be 
discriminated
against'. In the case of disability, if any legislation is to be at all
meaningful, this `right' has to include a process whereby the achievement

of non-discrimination can be both understood as well as obtainable far 
beyond
access for the individual.<BR>
<BR>
The DU believes that if meaningful participation is to be achieved, then
development and structural change of the institution as a whole must 
occur.<BR>
<BR>
Because of its complex and integrative nature, this process requires the
support of the Executive if it is to succeed. It must not be 
marginalised.
<H4>THE PROCESS</H4>
Acting as the interface between students and staff with disabilities, and

the University, the DU facilitates changes in attitude, the built 
environment,
communication skills, translating material, and most importantly, the 
creation
of knowledge and skills for staff and student needs that are required 
within
the University mainstream. While this sometimes may not be achievable 
without
the provision of specific services, it is most certainly our stated 
intention
and goal to achieve the necessary institutional change. If we were only
to provide special services, we would persist in perpetuating the 
situation
where people with disabilities continue to be treated as `welfare 
recipients'.<BR>
<BR>
Aiming to create equal opportunity, our method is to decentralize so that

the existing structures cater equally for people with disabilities and 
chronic
illnesses within the mainstream. This is, of course, not possible in all
situations; particularly at the start of any new area of work.<BR>
<BR>
As we believe that the existence of someone's particular disability or 
chronic
illness does not, in itself, mean that they will, or necessarily, 
experience
discrimination, neither do we expect people to disclose their condition.
Accordingly, we have no screening process whereby we collect such data (a

lesson the world has had to learn from those who are HIV positive, or who

have AIDS). Thus, in our attempt to take the focus OFF the individual 
with
a disability, (who in the past has always been seen `as the problem'), we

insist on adherence to a policy that no staff or student HAS TO `belong'
to the DU. We work instead on referral or on individual choice. My 
experience
has been that any request of people with disabilities to categorize 
themselves
as `disabled' leads to discomfort, `hiding' and, consequently, to 
inaccurate
information. Any records we keep concerning students or staff are purely
for contact and communication purposes.<BR>
<BR>
While in the short term we might overlook some people on their entrance
into the University, within the broad framework of ENABLING PEOPLE TO 
PARTICIPATE
EQUALLY, we feel that our policy: 
<UL>
  <LI>serves to take the focus off the individual, and aims it at the 
institution,
where it belongs; 
  <LI>means that our education at the student/staff interface (Faculties,

Departments and numerous mainstream services) has to be THE focus; 
  <LI>allows each individual the right to privacy and to &quot;get on 
with
their life&quot; if they are well integrated. 
</UL>
<H4>OUR ROLE WITHIN THE UNIVERSITY</H4>
In practice the DU works with different sections of the University, 
feeding
into existing structures which ordinarily provide services for any part
of the University Community. These range from faculty registration and 
administration,
academic teaching and supervision, communication, venue allocation, 
buildings
and structural services, technological services, financial aid, student
housing, health and counselling services, extra time in examinations, 
parking,
and any other facet that presents as a long- or short-term barrier to 
full
and equal participation of people with disabilities.<BR>
<BR>
Our role is to help University structures to understand how to provide 
those
same services that they ordinarily provide, rather than to provide equal
and/or parallel services, separate from the mainstream for those 
University
staff and students with disabilities. The DU might, in some cases, 
temporarily,
provide part, or all, of a service until we understand enough of how this

is achieved. Our policy then, is to pass on this knowledge or 
responsibility
to the specific part of the University, or in some cases directly to the
disabled person. In other situations we may continue to provide one 
aspect
of a service, for example, Special Parking or Extra-time in examinations.

Here, we interview the disabled person and assess the professional 
documentation
concerning their disability. We then make recommendations to the 
appropriate
section of the University.<BR>
<BR>
In the case of specialised services, we will not, for instance, consider
setting up a computer laboratory that is specialized for students who are

partially sighted or blind, or who have another disability. Rather we aim

at all times, to integrate such students with a disability into regular
computer laboratories, taught by those tutors who would ordinarily teach
in the mainstream. We do, however, see an occasional need for our staff
to undertake specialized tutoring, but such tutoring would be focused on
the mainstream tutors per se, rather than on individual disabled 
student/s.
Likewise we will not allow ourselves to be forced to set up special wings

in Residences for wheelchair users for this is simply perpetuating the 
commonly
held misconception that people with disabilities need to be catered for
separately. Thus, our aim is to create as much accessible accommodation
in as many Residences as possible.<BR>
<BR>
Such beliefs and practices can have adverse funding implications, 
particularly
as some Donors want to present money `for a specific and highly visible
project'. This is very unfortunate for, in effect, it coerces Units like
ours to advocate &quot;separate facilities&quot; instead of going the 
long
road of making the mainstream facilities accessible. In this regard, it
is important that Donors and Universities alike see the dangerous 
parallels
between providing `separate facilities' for people with disabilities, 
within
an institution, and our dreadful recent history of Apartheid.<BR>
<BR>
Institutional change is, by nature, extremely complex and therefore is a
slow process. As such, progress is not easily measurable by the 
individual's
experience at a particular time, rather it has to be measured 
collectively,
over time. 
<H4>CONSTITUENCY</H4>
We are often asked to `define disability', or are asked `what numbers of
disabled people' we work with. I strongly refute such questions as they
imply a reality of the many `fixed' definitions of disability as well as
perpetuating the notion that there are `fixed' percentages of people with

disabilities present in the population. Rather, I agree with Irving K 
Zola's
statement (1993, 18), that the reality of disability revolves around the
fact that the question &quot;... is not whether but when, not so much 
which
one but how many and in what combination&quot;, disability occurs, and 
that:<BR>
&quot;Disability is thus not a fixed status but a continuously changing
and evolving set of characteristics&quot; (1993, 24).<BR>
<BR>
Zola goes on to say: 
<BLOCKQUOTE>&quot;Any use of a specific and fixed figure for any 
planning,
whether it be in the allocation of resources, benefits, funding, or 
affirmative
action, is almost certainly inaccurate as well as underestimated.&quot;
(1993, 19).</BLOCKQUOTE>
The oft quoted `findings' that some 12.5% of the population have a 
disability
is as dangerous as it is erroneous, and to base some argument about the
experience of disability on such figures is utterly spurious. One is only

able to obtain answers to those questions that one actually asks. Thus,
if one asks flawed, simplistic questions, one will inevitably receive 
flawed,
simplistic answers. (As is often said in computer jargon, `garbage in, 
garbage
out'!).<BR>
<BR>
Zola's statements about disability statistics and definitions, then, 
might
in part provide an understanding as to why I will not participate in the
`numbers game' in order to justify our services. Our belief is that while

inequality exists for some of our students and staff, who happen to have
a disability, or who live with a chronic illness within the University 
and
the community, the work of the DU needs to continue apace.<BR>
We deal with numerous students and staff with longterm and/or temporary
disabilities, including wheelchair users, people with walking 
disabilities,
people with pain and fatigue disabilities, people with sensory 
disabilities
or epilepsy, people with chronic illnesses (eg. cancer, AIDS, ME, Mycenia

Gravis, etc) and this year we have started to work with students who are
head injured. 
<H4>STRATEGY</H4>
In working with individual people with disabilities, our role is to 
listen
carefully to their experience of different barriers, and then to initiate

ways of changing the effects of these barriers in our University 
community.
This, in part, involves serving on various committees and communicating
with a wide variety of individuals and sections of the University about
what we do. Understanding the structures of the institution enables us to

act decisively and continuously in order to counteract disadvantage when
and where it occurs. I firmly believe that every conversation which I, or

my staff, have with another member of our University community, has to 
play
this educative role, at least in part.<BR>
<BR>
There are enormous variations between University departments. For 
instance,
because of a combination of social attitudes and specific academic or 
professional
requirements, one department might be perfectly comfortable with the 
presence
of a person with a particular disability, while another, because of these

same elements, might find it very difficult to see its way to making 
accommodation
for a particular student.<BR>
<BR>
Our role in the DU has not necessarily been to insist outright that all
Departments simply take disabled students, but rather, it has been to 
undertake
appropriate research (which might be global in scope) in order to try and

find examples and experiences of people with similar disabilities in 
similar
professional fields. Having done this, we try to initiate international
communication, and examine the way in which other Universities or 
Colleges
have overcome the specific barriers that our department has `identified'.

In such cases, we either link our department directly with the 
appropriate
international community, or we liaise between the two. In this way we 
make
use of experienced people in different cities or countries as a resource
for our own University, whilst simultaneously enlarging the DU's own data

base.<BR>
<BR>
This process can take many years, depending on how complicated the 
barriers
are, but at all times our role is to work through this process with the
individual student/staff (and possibly their family) as well as with the
UCT department and faculty. In this way, we involve as many people as 
possible
in the process of learning, including the Equal Opportunities Officer at
UCT. Once a second student, with the same disability, applies to the same

department, the learning curve is much lower and the time-consuming, 
intense
and complicated process of research and translation of experience and 
knowledge
can more easily be put into effect.<BR>
<BR>
While people with certain types of disability might not realistically be
able to enter certain disciplines, historically limits have frequently 
been
too rigidly defined. We believe there is a real need to support and 
research
the possibilities of disabled students choosing disciplines which 
previously
had been barred them.<BR>
<BR>
A few examples include deaf students in Occupational Therapy and 
Physiotherapy,
a blind student applying for Clinical Masters in Psychology (involving 
Neuropsychology),
and a quadriplegic wheelchair-user doing Drama. Another area under 
investigation
has been the feasibility of head-injured and spinal-injured students 
returning
before their &quot;normal&quot; expected rehabilitation has been 
completed.<BR>
<BR>
It is always the first generation of students with particular 
disabilities
in specific departments that need to undergo the most rigorous 
investigation,
and who have to meet certain criteria before they are accepted and can 
get
on with their studies in the mainstream. However, I have no doubt from my

twenty years of experience in Universities that every student who is a 
trailblazer
in one particular department, or field of study, creates a much easier 
path
for the next generation. 
<H4>BARRIER FREE ACCESS</H4>
Our Barrier Free Design work has two components:<BR>
<BR>
1. New buildings:<BR>
<BR>
This generally involves work with outside architects, and is a chance to
educate architects more broadly, over and above the design of a 
particular
UCT building. Our intention is that they will ultimately take both the 
general
awareness and the knowledge gained into their work outside the 
University.<BR>
<BR>
However, although it is nearly ten years since the Barrier Free Design 
legislation
was first passed, it is my experience, that because it is such a complex
and detailed field, and one that is out of the ordinary experience of 
most
architects, without a consultant many architects still do not interpret
the specified details correctly, wasting both time and money and causing
frustration and hardship.<BR>
<BR>
2. Existing buildings:<BR>
<BR>
Together with the Planning Unit we are involved in investigating all 
existing
University buildings and their environs in order to make them accessible
to people with different disabilities. This is a complex, time-consuming
and very intensive task, and each building and its environ has to be 
investigated
in its own right. It is undertaken on three fronts: 
<UL>
  <LI>whenever renovations are undertaken in a building and environ; 
  <LI>in response to a student or staff member requiring access to 
particular
area; 
  <LI>high profile/used, public areas. 
</UL>
<H4>SPECIAL PARKING</H4>
We continue to undertake the assessments and recommendations for all 
staff
and students with temporary and permanent disabilities. 
<H4>EXAMINATIONS </H4>
In 1994 I was involved in a committee of the University that undertook to

develop a Policy for Extra Time in Examinations and Practicals. One of 
the
aims of this Policy was to enable the University to provide facilities 
for
students with a very wide range of disabilities. The policy has now been
operating successfully for the whole of 1995.<BR>
<BR>
Our involvement encompasses those students whose disabilities necessitate

either alternate methods of undertaking examinations and/or extra time.
This process can involve us in extensive assessments of individual 
students,
in conjunction with departmental requirements for the examination. We 
closely
liaise with the Student Health Service in order that they, or we, can 
make
recommendations to the University Administration as to the appropriate 
means
of examination. 
<H4>FINANCIAL AID</H4>
We continue to be involved with student applications for bursaries from
the Department of Labour. We also advise both the Department and the 
University
on specialized academic expenses which students with disabilities incur.
<H4>HOUSING</H4>
We have developed a good working relationship with the Residence 
Administration
and Maintenance Department, working towards accessible housing for 
disabled
students. Our residences are old and far from main campus, and this can
be a difficult issue. 
<H4>ACCESSIBLE TRANSPORT</H4>
We continue to research ways in which we can provide access transport to
physically disabled students. 
<H4>HEALTH ISSUES</H4>
We find that we are sharing basic primary-health and stress-reduction 
information
with more and more temporary and permanently disabled students. We 
coordinate
our activities with those of the Student Health Service. 
<H4>COUNSELLING</H4>
The counselling that I am involved with is often very focussed. Because
of my position as Vice-Chancellor's Nominee on Sexual Harassment, I find
that I am also involved in counselling additional problems relating to 
sexual
harassment and physical abuse.<BR>
<BR>
One of my fundamental beliefs in counselling at the level at which people

like myself serve, is that an enormous amount is done within the context
of trying to empower the individual to continue functioning with more 
strength
in the community. In this context, I find that I am also very often 
involved
in counselling the support groups of affected individuals, be they 
families
or networks of close friends or colleagues. I feel that this aspect is 
important
as it, again, not only takes the emphasis and pressure off the 
individual,
but serves to share skills with a wider group of people who very often 
would
not have identified themselves as being in a `counselling' role. 
<H4>HIV/AIDS</H4>
I continue to work in HIV/AIDS education. We are gradually building up 
the
AIDS Education Work Group's Resource Center which is coordinated by the
DU. 
<H4>SEXUAL HARASSMENT</H4>
Having become more active in the field of Sexual Harassment on UCT 
campus,
in 1994 I attended a course on counselling. In 1995 I was appointed one
of the Vice Chancellor's two nominees on Sexual Harassment. In this 
capacity
I have been involved in the `Informal Executive' of the Sexual Harassment

Prevention and Support Service (SHARPSS). SHARPSS is involved with a 
broad
range of activities, such as counselling, education and advocacy. I have
also been involved in the development of University Policy on Sexual 
Assault
and Rape, and have recently completed an Introductory Course on 
Mediation.
<H4>SENSORY DISABILITIES</H4>
Deaf Students<BR>
<BR>
At present the DU is not in the position to be able to fund interpreters
for deaf students. However, during the last two years we have been able
to accept, into various departments, deaf and partially deaf students who

communicate orally.<BR>
<BR>
In reference to earlier discussion, (page 7), deaf students have 
necessitated
particularly intensive research in regard to their choice of professional

training.<BR>
<BR>
Blind Student Reading Programme (BSRP)<BR>
<BR>
We continue to run a service which translates the printed word (for 
academic
purposes) primarily onto audio cassettes, but also sometimes into 
Braille.<BR>
<BR>
Technology<BR>
<BR>
We continue to keep up to date with the most recent `blind-access' 
technology,
and explore ways of introducing it into the mainstream of the University.

This is a vast, swiftly moving field, that requires great commitment in
order to keep abreast of it, so as to be able to keep the University 
informed.
<H4>HEAD INJURIES</H4>
In the 1990's we are witnessing high levels of social violence, abuse of
alcohol and motor vehicle accidents. This, together with medical 
technology's
ability to keep people who would otherwise have died alive, has meant 
that
we are seeing students who have had head injuries (HI) wishing to return
to tertiary education. As many traumatic brain injuries affect the very
aspects of a person that tertiary education is reliant on, the issues of
when, or if, a student is able to return to University are extremely 
complex.<BR>
<BR>
This year the DU has been involved in a great deal of research, 
communication
and dissemination of information about head-injured students. We have 
worked
closely with individuals, families and friends as well as faculties, 
departments
and the service structures affected by a number of returning HI students.

In some instances, we have had to set up trial models of support and 
investigation,
in order to assess the complex relationship between a HI student and the
University. 
<H4>ACADEMIC</H4>
Teaching<BR>
<BR>
Due to overload of work this year I brought in disabled colleagues from
the community to undertake some of my teaching. This has proved to be an
important means of giving a new generation the chance to broaden their 
expertise.<BR>
<BR>
Library<BR>
<BR>
We run an extensive library on issues of disability and chronic illness.
This resource is used by a variety of staff and students in both our own
and other universities, as well as people from the community. Running 
this
resource involves an enormous amount of work. While we are able to keep
up with some of the demands in less busy times, we have to impose many 
unfortunate
limits on potential developments and networking.<BR>
<BR>
Supervision/Advising<BR>
<BR>
As well as the academic work which I formally supervise, we advise many
students undertaking work on disability and AIDS-related issues. It has
been particularly interesting to be involved with students undertaking 
new
areas of research. For example, the integration of disabled people in the

environment. 
<H4>MY THANKS </H4>
I would like to take this opportunity formally to thank my staff, without

whom I could not undertake such work. The positive and productive 
interplay
of personalities that has built up in the team in the last three months,
and the enormous individual and communal committment each staff member 
has,
has been an absolute delight and pleasure to work with. My warm thanks to

everybody as individuals and for making an effort to work so hard and 
take
so much responsibility as a team in the DU.<BR>
<BR>
DR KATHRYN JAGOE <BR>
DIRECTOR: DISABILITY UNIT<BR>
VICE CHANCELLOR'S NOMINEE ON SEXUAL HARASSMENT 
<BLOCKQUOTE>&quot;At all times our aim is to enable staff and students 
with
disabilities and chronic illnesses to participate equally in the 
mainstream
of the University, and not to provide special and separate facilities for

them&quot;. <BR>
Kathryn Jagoe Ph D (hc)</BLOCKQUOTE>
<BR>
REFERENCE <BR>
<BR>
Zola, I K (1993) Disability Statistics, What We Count and What It Tells
Us. A Personal and Political Analysis. Journal of Disability Policy 
Studies,
Vol. 4 (2), 12-39: Department of Sociology, Brandeis University, U.S.A.
<BR>
<P><CENTER><HR><FONT SIZE=2>[<A HREF="Contents.html">Institute on 
Independent
Living contents</A>]</FONT></CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-192</DOCNO>
<DOCOLDNO>IA012-000125-B018-435</DOCOLDNO>
<DOCHDR>
http://www.independentliving.org:80/ToolsforPower/Tools36.html 193.13.228.238 19970216213859 text/html 12327
HTTP/1.0 200 OK
Last-Modified: Tue, 06 Aug 1996 20:03:36 +0000
Date: Sun, 16 Feb 1997 21:39:03 +0000
Expires: Sun, 16 Feb 1997 21:37:23 +0000
Content-type: text/html
Server: RoxenEnterprise/1.0
Content-length: 12101
</DOCHDR>
<HTML>
<HEAD>
    <TITLE>Institute_on_Independent_Living</TITLE>
</HEAD>
<BODY BGCOLOR="#ffffff">
<META NAME="description" 
CONTENT="Individuals and organizations of persons with disabilities can 
publish, free of charge,  articles, reports, training manuals, 
announcements, etc. on Independent Living, personal assistance, advocacy, 

peer support, accessibility, legislation and related subjects. "><META 
NAME="keywords" CONTENT="Independent Living, personal assistance, 
advocacy, peer support, direct payments, anti-discrimination legislation, 

accessibility, disability, disability rights">
<H4>Housing adaptation<BR>
</H4>
<H2><CENTER>Resources</CENTER>
</H2>
<BR>
The following organizations may provide architectural accessibility 
information
and printed materials related to architectural design standards and 
specifications.
<BR>
<BR>
Abledata, Newington Children's Hospital, 181 East Cedar Street, 
Newington,
CT. 06111, United States.<BR>
<BR>
American National Standards Institute (ANSI), 1430 Broadway, New York, 
NY.
10018, United States.<BR>
<BR>
Architectural and Transportation Barriers Compliance Board, 1111 18th 
St.,
N.W., Washington, DC. 20202, United States.<BR>
<BR>
Center for Accessible Housing, Research and Training Center, Box 8613, 
North
Carolina State University, Raleigh, NC. 27695.8613, United States.<BR>
<BR>
National Organization on Disability, 2100 Pennsylvania Avenue, NW, Suite
234, Washington, DC. 20037, United States.<BR>
<BR>
National Rehabilitation Information Center (NARIC), 8455 Colesville Road,

Suite 935, Silver Spring, MD. 20910-3319, United States.<BR>
<BR>
Paralyzed Veterans of America, 801 18th Street, NW, Washington, DC. 
20006,
United States.<BR>
<BR>
Rehabilitation Engineering Center on Modifications to Worksites &amp; 
Educational
Settings, CP Research Foundation of Kansas, Inc., 2021 North Old Manor,
Box 8217, Wichita, KS. 67208, United States.<BR>
<BR>
Rehabilitation Training Center on Community Living, University of 
Minnesota,
101 Pattee Hall, 150 Pillsbury Drive, SE., Minneapolis, MN. 55455, United

States.<BR>
<BR>
CIB W84 &quot;Building Non-Handicapping Environments&quot; is an 
international
NGO committed to universal barrier-free design. CIB W84 works for better
awareness of the environmental needs of old and disabled persons, 
technical
expertise on design solutions and access legislation. The following 
publications
are available:<BR>
<BR>
CIB Building Non-Handicapping Environments Newsletter<BR>
<BR>
Urban Renewal and Accessibility for Old and Disabled Persons, Proceedings

of the CIB W84 Expert Seminar in Prague 1987.<BR>
<BR>
Accessibility Issues in Developing Countries, Proceedings of the CIB W84
Expert Seminar in Tokyo 1988.<BR>
<BR>
Address: CIB W84 Secretariat, Department of Building Function Analysis,
Royal Institute of Technology, 100 44 Stockholm, Sweden.<BR>
<BR>
&quot;A Barrier-Free House: Accommodating a Wheelchair Calls for Careful
Planning Inside and Out&quot;, in Fine Homebuilding Magazine, No. 53, 
April/May
1989, pp. 67-71.<BR>
<BR>
Both exterior and interior design are covered in this 5 page document 
which
includes a copy of the floor plan and several photographs of selected 
features.
<BR>
<BR>
Adaptable Housing: Marketable Accessible Housing for Everyone. 1987. <BR>

<BR>
This book advocates well designed housing that is usable by all 
populations
and does not look any different than any other house. <BR>
<BR>
Available from HUD USER, PO Box 6091, Rockville, Maryland 20850, United
States.<BR>
<BR>
American National Standard for Building Facilities: Providing 
Accessibility
and Usability for Physically Handicapped People. Revised 1986. <BR>
<BR>
These are the ANSI specifications for making buildings and facilities 
accessible
to and usable by persons with disabilities. These are intended for use in

new buildings, and renovations to older buildings except 
&quot;historic&quot;
structures. Reference for this publication is under A117.1-1986 of the 
ANSI
publications listing. Contact the American National Standards Institute
at the address above.<BR>
<BR>
Creation of the Barrier-Free Interior. 1988. Written by Patricia M. 
Johnson
<BR>
<BR>
This is an excellent publication which focuses on all areas of home 
accessibility.
It also gives tips on accessible interior design. 148 page publication,
well illustrated.<BR>
<BR>
Available from A Positive Approach, Inc., 1600 Malone Street, Municipal
Airport, Millville, NJ. 08332, United States.<BR>
<BR>
&quot;Designing a Barrier-Free Environment for Deaf and Hard of Hearing
Persons&quot; in Rehabilitation Digest, Vol.&nbsp;20, No.1, Spring 1989,
pp. 12-14.<BR>
<BR>
This is a short narrative discussion of the need for and means of 
designing
buildings and homes for sensory-impaired persons. This article has a 
Canadian
perspective that gives design solutions for various problems. <BR>
<BR>
Source: Request Program, Rehabilitation Engineering Center, National 
Rehabilitation
Hospital, 102 Irving Street, NW., Washington, DC. 20010-2949, United 
States.<BR>
<BR>
Daviels, T., Beasley, K. &quot;Accessible Housing&quot;, in Paraplegia 
News:
Vol. 43, No. 5, May 1989.<BR>
<BR>
Narrative discussion of the status of accessible housing, building 
products
and related regulations for aging and disabled citizens in the U.S. 
Developers
are encouraged to offer basic plans with sufficient flexibility, allowing

units to be modified at the time of purchase to meet the buyer's specific

needs or allowing the owner to make future modifications, at reasonable
cost, should the need rise. Other topics include: multifamily housing and

assisted living; changes in residential construction and home products;
and, accessible housing in the context of the community. Figures and a 
summary
of the Fair Housing Amendments Act of 1988 included.<BR>
<BR>
Sharp,David, Laurel Richards, Laurie Gerken, and Kathleen Hampton. 
Constructing
a Barrier-free Home. ILRU Field Work No. 3. Houston: ILRU Program, 
1985.<BR>
<BR>
This is the third of a set of three brochures developed for ILRU&#180;s
National Technical Assistance Project for Rural Independent Living. In 
this
concise format, authors provide information on modifying one&#180;s home
to make it more accessible. It includes basic accessibility requirements
for key features such as doorways, kitchens, bathrooms, cabinets, and 
ramps.<BR>
<BR>
Address: ILRU at Texas Institute for Rehabilitation, 2323 S. Shepherd, 
Suite
1000, Houston, TX 77019, United States.<BR>
<BR>
Design with Care: A Guide to Adaptation of the Built Environment for 
Disabled
Persons in Developing Regions, United Nations Center, Vienna 1981.<BR>
<BR>
The aim of the guide is to facilitate the work of planners, architects,
and designers, as well as others who are engaged in public and private 
building
projects in developing regions. The guide refers primarily to public 
buildings
at urban or village level. The guide also attempts to present simple 
solutions
to frequently occurring practical problems, in order to make public 
buildings
and the entire urban environment usable for various groups of disabled 
persons.
<BR>
<BR>
Available from: United Nations Center, CSDHA/United Nations, P.O.Box 500,

1400 Vienna, Austria<BR>
<BR>
Housing and Home Services for the Disabled: Guidelines and Experiences in

Independent Living, Laurie, Gini, editor. Harper and Row, 1977. <BR>
<BR>
A world-wide assortment of housing experiments is presented. The aim is
to enable government agencies, voluntary organizations, organizations of
disabled persons and individuals to find either specific solutions to 
these
problems or pertinent examples to use as models. Reference to legislative

and housing projects designed for the elderly, developmentally disabled,
and physically disabled are included.<BR>
<BR>
Available from: Harper and Row Publishers, Inc., 2350 Virginia Avenue, 
Hagerstown,
MD 21740, United States.<BR>
<BR>
Lifchez, Raymond and Winslow, Barbara, Design for Independent Living: The

Environment and Physically Disabled People, University of California 
Press,
Berkeley and Los Angeles, 1979.<BR>
<BR>
This book is as much on accessible architecture as it is on the community

of disabled people living in Berkeley, California. It gives useful 
examples
and hints on how to make your house or apartment more accessible. At the
same time, it provides the reader with portraits and role models of 
disabled
individuals by way of beautiful and very personal photos. Unlike most 
books
on such subjects, Design for Independent Living depicts us as unique 
individuals.<BR>
<BR>
Lifchez, Raymond, &quot;Designing Supportive Physical Environments&quot;,

in Crewe, Nancy M. &amp; Zola, Irving Kenneth, Independent Living for 
Physically
Disabled People, Jossey-Bass Publishers, San Francisco, 1983.<BR>
<BR>
Lifchez, Raymond, &quot;The Environment as a Support System for 
Independent
Living.&quot; Archives of Physical Medicine and Rehabilitation. Vol. 60,
No. 10, October 1979. American Academy of Physical Medicine and 
Rehabilitation,
30 N. Michigan Avenue, Chicago, Illinois 60602, United States.<BR>
<BR>
This study evaluates the environment of physically disabled young adults
living independently in Berkeley, California and its ability to 
accommodate
their needs. <BR>
<BR>
Harkness, Sarah P. and James N. Groom, Jr. Building without Barriers for
the Disabled. New York: The Whitney Library of Design, 1976.<BR>
<BR>
Resource Guide to Literature on Barrier-Free Environments. Washington, 
D.C.:
Architectural and Transportation Compliance Board, January 1977. <BR>
<BR>
Steinfeld, Ed (ed.) Access to the Built Environment: A Review of 
Literature,
US Department of Housing and Urban Development, Washington, D.C., 
1979.<BR>
<BR>
Address: Prof. Ed Steinfeld, Adaptive Environments Laboratory, 
SUNY/Buffalo,
112 Hayes Hall, 3435 Main St., Buffalo, NY 14214, United States.<BR>
<BR>
The following resources are published by the Research and Training Center

on Independent Living, University of Kansas:<BR>
<BR>
Mace, R L, Young, L C, &amp; Telles, C (1980). Planner's guide to barrier

free meetings. Raleigh, NC: Barrier Free Environment &amp; Harold Russell

Association, Waltham, MA. <BR>
<BR>
Offers practical advice on how to include disabled people in general 
meeting-planning
activities. Covers preplanning concerns, such as site&nbsp;selection, 
services,
publicity; accessibility of meeting rooms and overnight rooms; locating
resources for services and equipment.<BR>
<BR>
Scott, B (1986). Book of renovations. Lawrence: RTC/IL, University of 
Kansas.<BR>
<BR>
Beautiful illustrations depict most common problems and solutions to 
renovating
existing buildings and facilities to make them accessible to and usable
by people with physical disabilities.<BR>
<BR>
Lifchez, R (1981). Architects and the movement for barrier-free design.
Lawrence: RTC/IL, University of Kansas. Presentation for Conference on 
Independence,
University of Kansas.<BR>
<BR>
Discusses architect's noncommitment to barrier-free design. Accessibility

laws examined as well as possibility of uniform accessible building 
codes.<BR>
<BR>
Nelson, C F, Jones, M L, &amp; Salkind, N J (1986). &quot;Promoting 
wheelchair
accessibility of private settings.&quot; Environmental and Behavior, 18
(1).<BR>
<BR>
Documents barriers to access by wheelchair in a sample of 2,000 privately

owned, public use settings in one midwestern city. Six intervention 
strategies
evaluated to encourage getting managers to call or write for free 
technical
assistance in making their setting more accessible.<BR>
<BR>
Address: RTC/IL, 4089 Dole Bldg./LSI,University of Kansas, Lawrence, KS
66045, United States.<BR>
<BR>
Penton, John, A Handbook on Housing for the Disabled, Center for 
Accessible
Environments, London. Address: CAE, 35 Great Smith Street, London SW1P 
3BJ,
United Kingdom.<BR>
<P><CENTER><HR><FONT SIZE=2>[<A HREF="Tools1.html">Tools for Power 
contents]</A></FONT><FONT SIZE=2>[<A HREF="../Contents.html">Institute
on Independent Living contents</A>]</FONT></CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-193</DOCNO>
<DOCOLDNO>IA012-000125-B019-25</DOCOLDNO>
<DOCHDR>
http://www.independentliving.org:80/StandardRules2.html 193.13.228.238 19970216213921 text/html 45883
HTTP/1.0 200 OK
Last-Modified: Sun, 06 Oct 1996 19:26:01 +0000
Date: Sun, 16 Feb 1997 21:39:29 +0000
Expires: Sun, 16 Feb 1997 21:37:49 +0000
Content-type: text/html
Server: RoxenEnterprise/1.0
Content-length: 45657
</DOCHDR>
<HTML>
<HEAD>
    <TITLE>Institute_on_Independent_Living</TITLE>
</HEAD>
<BODY BGCOLOR="#ffffff" LINK="#000047" BACKGROUND="redborder.gif" TEXT=
"#00003d">
<META  name="description"
<BLOCKQUOTE>
<BLOCKQUOTE>content="Individuals and organizations of persons with 
disabilities can publish, free of charge, articles, reports, training 
manuals, announcements, etc. on Independent Living, personal assistance, 
advocacy, peer support, accessibility, legislation and related subjects. 
"> <META  name="keywords" content="Independent Living, personal 
assistance, advocacy, peer support, direct payments, anti-discrimination 
legislation, accessibility, disability, disability rights"><IMG SRC=
"STIL/STILunlogo1.gif" WIDTH="80" HEIGHT="69" ALIGN="BOTTOM" 
NATURALSIZEFLAG=
"3"><IMG SRC="Pixel1x1.gif" WIDTH="1" HEIGHT="1" ALIGN="BOTTOM" 
NATURALSIZEFLAG=
"3"><IMG SRC="Pixel1x1.gif" WIDTH="1" HEIGHT="1" ALIGN="BOTTOM" 
NATURALSIZEFLAG=
"3"><IMG SRC="Pixel1x1.gif" WIDTH="1" HEIGHT="1" ALIGN="BOTTOM" 
NATURALSIZEFLAG=
"3"><IMG SRC="Pixel1x1.gif" WIDTH="1" HEIGHT="1" ALIGN="BOTTOM" 
NATURALSIZEFLAG=
"3"><IMG SRC="Pixel1x1.gif" WIDTH="1" HEIGHT="1" ALIGN="BOTTOM" 
NATURALSIZEFLAG=
"3"><IMG SRC="Pixel1x1.gif" WIDTH="1" HEIGHT="1" ALIGN="BOTTOM" 
NATURALSIZEFLAG=
"3"><BR>
Continuation<IMG SRC="Pixel1x1.gif" WIDTH="1" HEIGHT="1" ALIGN="BOTTOM"
NATURALSIZEFLAG="3"><IMG SRC="Pixel1x1.gif" WIDTH="1" HEIGHT="1" ALIGN=
"BOTTOM" NATURALSIZEFLAG="3"><BR>
<A HREF="StandardRules1.html">Standard Rules Contents</A><IMG 
SRC="Pixel1x1.gif"
WIDTH="1" HEIGHT="1" ALIGN="BOTTOM" NATURALSIZEFLAG="3"><IMG 
SRC="Pixel1x1.gif"
WIDTH="1" HEIGHT="1" ALIGN="BOTTOM" NATURALSIZEFLAG="3"><IMG 
SRC="Pixel1x1.gif"
WIDTH="1" HEIGHT="1" ALIGN="BOTTOM" NATURALSIZEFLAG="3"><IMG 
SRC="Pixel1x1.gif"
WIDTH="1" HEIGHT="1" ALIGN="BOTTOM" NATURALSIZEFLAG="3"><IMG 
SRC="Pixel1x1.gif"
WIDTH="1" HEIGHT="1" ALIGN="BOTTOM" NATURALSIZEFLAG="3"><IMG 
SRC="Pixel1x1.gif"
WIDTH="1" HEIGHT="1" ALIGN="BOTTOM" NATURALSIZEFLAG="3"><IMG 
SRC="Pixel1x1.gif"
WIDTH="1" HEIGHT="1" ALIGN="BOTTOM" NATURALSIZEFLAG="3"><IMG 
SRC="Pixel1x1.gif"
WIDTH="1" HEIGHT="1" ALIGN="BOTTOM" NATURALSIZEFLAG="3"><IMG 
SRC="Pixel1x1.gif"
WIDTH="1" HEIGHT="1" ALIGN="BOTTOM" NATURALSIZEFLAG="3"><IMG 
SRC="Pixel1x1.gif"
WIDTH="1" HEIGHT="1" ALIGN="BOTTOM" NATURALSIZEFLAG="3"><IMG 
SRC="Pixel1x1.gif"
WIDTH="1" HEIGHT="1" ALIGN="BOTTOM" NATURALSIZEFLAG="3"><IMG 
SRC="Pixel1x1.gif"
WIDTH="1" HEIGHT="1" ALIGN="BOTTOM" NATURALSIZEFLAG="3"><IMG 
SRC="Pixel1x1.gif"
WIDTH="1" HEIGHT="1" ALIGN="BOTTOM" NATURALSIZEFLAG="3"><IMG 
SRC="Pixel1x1.gif"
WIDTH="1" HEIGHT="1" ALIGN="BOTTOM" NATURALSIZEFLAG="3"><IMG 
SRC="Pixel1x1.gif"
WIDTH="1" HEIGHT="1" ALIGN="BOTTOM" NATURALSIZEFLAG="3"><IMG 
SRC="Pixel1x1.gif"
WIDTH="1" HEIGHT="1" ALIGN="BOTTOM" NATURALSIZEFLAG="3"><IMG 
SRC="Pixel1x1.gif"
WIDTH="1" HEIGHT="1" ALIGN="BOTTOM" NATURALSIZEFLAG="3"><IMG 
SRC="Pixel1x1.gif"
WIDTH="1" HEIGHT="1" ALIGN="BOTTOM" NATURALSIZEFLAG="3"><IMG 
SRC="Pixel1x1.gif"
WIDTH="1" HEIGHT="1" ALIGN="BOTTOM" NATURALSIZEFLAG="3"><IMG 
SRC="Pixel1x1.gif"
WIDTH="1" HEIGHT="1" ALIGN="BOTTOM" NATURALSIZEFLAG="3"></BLOCKQUOTE>
</BLOCKQUOTE>
<BLOCKQUOTE>
<BLOCKQUOTE>
<BLOCKQUOTE>
<BLOCKQUOTE>
<H2>Standard Rules on the Equalization of Opportunities <BR>
for Persons with Disabilities<A NAME="anchor17238"></A></H2>
</BLOCKQUOTE>
</BLOCKQUOTE>
</BLOCKQUOTE>
</BLOCKQUOTE>
<BLOCKQUOTE>
<H3><CENTER><HR></CENTER>
</H3>
</BLOCKQUOTE>
<BLOCKQUOTE>
<H3><BR>
II. TARGET AREAS FOR EQUAL PARTICIPATION<A NAME="anchor1370198"></A><BR>
<IMG SRC="Pixel1x1.gif" WIDTH="1" HEIGHT="1" ALIGN="BOTTOM" 
NATURALSIZEFLAG=
"3"></H3>
</BLOCKQUOTE>
<BLOCKQUOTE>
<H4>Rule 5. Accessibility</H4>
States should recognize the overall importance of accessibility in the 
process
of the equalization of opportunities in all spheres of society. For 
persons
with disabilities of any kind, States should (a) introduce programmes of
action to make the physical environment accessible; and (b) undertake 
measures
to provide access to information and communication.<BR>
<BR>
(a) Access to the physical environment<BR>
<BR>
1. States should initiate measures to remove the obstacles to 
participation
in the physical environment. Such measures should be to develop standards

and guidelines and to consider enacting legislation to ensure 
accessibility
to various areas in society, such as housing, buildings, public transport

services and other means of transportation, streets and other outdoor 
environments.<BR>
<BR>
2. States should ensure that architects, construction engineers and 
others
who are professionally involved in the design and construction of the 
physical
environment have access to adequate information on disability policy and
measures to achieve accessibility.<BR>
<BR>
3. Accessibility requirements should be included in the design and 
construction
of the physical environment from the beginning of the designing 
process.<BR>
<BR>
4. Organizations of persons with disabilities should be consulted when 
standards
and norms for accessibility are being developed. They should also be 
involved
locally from the initial planning stage when public construction projects

are being designed, thus ensuring maximum accessibility.<BR>
<BR>
(b) Access to information and communication<BR>
<BR>
5. Persons with disabilities and, where appropriate, their families and
advocates should have access to full information on diagnosis, rights and

available services and programmes, at all stages. Such information should

be presented in forms accessible to persons with disabilities.<BR>
<BR>
6. States should develop strategies to make information services and 
documentation
accessible for different groups of persons with disabilities. Braille, 
tape
services, large print and other appropriate technologies should be used
to provide access to written information and documentation for persons 
with
visual impairments. Similarly, appropriate technologies should be used to

provide access to spoken information for persons with auditory 
impairments
or comprehension difficulties.<BR>
<BR>
7. Consideration should be given to the use of sign language in the 
education
of deaf children, in their families and communities. Sign language 
interpretation
services should also be provided to facilitate the communication between
deaf persons and others.<BR>
<BR>
8. Consideration should also be given to the needs of people with other
communication disabilities.<BR>
<BR>
9. States should encourage the media, especially television, radio and 
newspapers,
to make their services accessible.<BR>
<BR>
10. States should ensure that new computerized information and service 
systems
offered to the general public are either made initially accessible or are

adapted to be made accessible to persons with disabilities.<BR>
<BR>
11. Organizations of persons with disabilities should be consulted when
measures to make information services accessible are being developed.<A
NAME="anchor1373939"></A><BR>
<IMG SRC="Pixel1x1.gif" WIDTH="1" HEIGHT="1" ALIGN="BOTTOM" 
NATURALSIZEFLAG=
"3"></BLOCKQUOTE>
<BLOCKQUOTE>
<H4>Rule 6. Education</H4>
States should recognize the principle of equal primary, secondary and 
tertiary
educational opportunities for children, youth and adults with 
disabilities,
in integrated settings. They should ensure that the education of persons
with disabilities is an integral part of the educational system.<BR>
<BR>
1. General educational authorities are responsible for the education of
persons with disabilities in integrated settings. Education for persons
with disabilities should form an integral part of national educational 
planning,
curriculum development and school organization.<BR>
<BR>
2. Education in mainstream schools presupposes the provision of 
interpreter
and other appropriate support services. Adequate accessibility and 
support
services, designed to meet the needs of persons with different 
disabilities,
should be provided.<BR>
<BR>
3. Parent groups and organizations of persons with disabilities should be

involved in the education process at all levels.<BR>
<BR>
4. In States where education is compulsory it should be provided to girls

and boys with all kinds and all levels of disabilities, including the 
most
severe.<BR>
<BR>
5. Special attention should be given in the following areas:<BR>
<BR>
(a) Very young children with disabilities;<BR>
<BR>
(b) Pre-school children with disabilities;<BR>
<BR>
(c) Adults with disabilities, particularly women.<BR>
<BR>
6. To accommodate educational provisions for persons with disabilities in

the mainstream, States should:<BR>
<BR>
(a) Have a clearly stated policy, understood and accepted at the school
level and by the wider community;<BR>
<BR>
(b) Allow for curriculum flexibility, addition and adaptation;<BR>
<BR>
(c) Provide for quality materials, ongoing teacher training and support
teachers.<BR>
<BR>
7. Integrated education and community-based programmes should be seen as
complementary approaches in providing cost-effective education and 
training
for persons with disabilities. National community-based programmes should

encourage communities to use and develop their resources to provide local

education to persons with disabilities.<BR>
<BR>
8. In situations where the general school system does not yet adequately
meet the needs of all persons with disabilities, special education may be

considered. It should be aimed at preparing students for education in the

general school system. The quality of such education should reflect the
same standards and ambitions as general education and should be closely
linked to it. At a minimum, students with disabilities should be afforded

the same portion of educational resources as students without 
disabilities.
States should aim for the gradual integration of special education 
services
into mainstream education. It is acknowledged that in some instances 
special
education may currently be considered to be the most appropriate form of
education for some students with disabilities.<BR>
<BR>
9. Owing to the particular communication needs of deaf and deaf/blind 
persons,
their education may be more suitably provided in schools for such persons

or special classes and units in mainstream schools. At the initial stage,

in particular, special attention needs to be focused on culturally 
sensitive
instruction that will result in effective communication skills and 
maximum
independence for people who are deaf or deaf/blind.<A 
NAME="anchor1376299"></A><BR>
<IMG SRC="Pixel1x1.gif" WIDTH="1" HEIGHT="1" ALIGN="BOTTOM" 
NATURALSIZEFLAG=
"3"></BLOCKQUOTE>
<BLOCKQUOTE>
<H4>Rule 7. Employment</H4>
States should recognize the principle that persons with disabilities must

be empowered to exercise their human rights, particularly in the field of

employment. In both rural and urban areas they must have equal 
opportunities
for productive and gainful employment in the labour market.<BR>
<BR>
1. Laws and regulations in the employment field must not discriminate 
against
persons with disabilities and must not raise obstacles to their 
employment.<BR>
<BR>
2. States should actively support the integration of persons with 
disabilities
into open employment. This active support could occur through a variety
of measures, such as vocational training, incentive-oriented quota 
schemes,
reserved or designated employment, loans or grants for small business, 
exclusive
contracts or priority production rights, tax concessions, contract 
compliance
or other technical or financial assistance to enterprises employing 
workers
with disabilities. States should also encourage employers to make 
reasonable
adjustments to accommodate persons with disabilities.<BR>
<BR>
3. States' action programmes should include:<BR>
<BR>
(a) Measures to design and adapt workplaces and work premises in such a
way that they become accessible to persons with different 
disabilities;<BR>
<BR>
(b) Support for the use of new technologies and the development and 
production
of assistive devices, tools and equipment and measures to facilitate 
access
to such devices and equipment for persons with disabilities to enable 
them
to gain and maintain employment;<BR>
<BR>
(c) Provision of appropriate training and placement and ongoing support
such as personal assistance and interpreter services.<BR>
<BR>
4. States should initiate and support public awareness-raising campaigns
designed to overcome negative attitudes and prejudices concerning workers

with disabilities.<BR>
<BR>
5. In their capacity as employers, States should create favourable 
conditions
for the employment of persons with disabilities in the public sector.<BR>

<BR>
6. States, workers' organizations and employers should cooperate to 
ensure
equitable recruitment and promotion policies, employment conditions, 
rates
of pay, measures to improve the work environment in order to prevent 
injuries
and impairments and measures for the rehabilitation of employees who have

sustained employment-related injuries.<BR>
<BR>
7. The aim should always be for persons with disabilities to obtain 
employment
in the open labour market. For persons with disabilities whose needs 
cannot
be met in open employment, small units of sheltered or supported 
employment
may be an alternative. It is important that the quality of such 
programmes
be assessed in terms of their relevance and sufficiency in providing 
opportunities
for persons with disabilities to gain employment in the labour 
market.<BR>
<BR>
8. Measures should be taken to include persons with disabilities in 
training
and employment programmes in the private and informal sectors.<BR>
<BR>
9. States, workers' organizations and employers should cooperate with 
organizations
of persons with disabilities concerning all measures to create training
and employment opportunities, including flexible hours, part-time work,
job-sharing, self-employment and attendant care for persons with 
disabilities.<A
NAME="anchor1390193"></A><IMG SRC="Pixel1x1.gif" WIDTH="1" HEIGHT="1" 
ALIGN=
"BOTTOM" NATURALSIZEFLAG="3"><BR>
<IMG SRC="Pixel1x1.gif" WIDTH="1" HEIGHT="1" ALIGN="BOTTOM" 
NATURALSIZEFLAG=
"3"></BLOCKQUOTE>
<BLOCKQUOTE>
<H4>Rule 8. Income maintenance and social security</H4>
States are responsible for the provision of social security and income 
maintenance
for persons with disabilities.<BR>
<BR>
1. States should ensure the provision of adequate income support to 
persons
with disabilities who, owing to disability or disability-related factors,

have temporarily lost or received a reduction in their income or have 
been
denied employment opportunities. States should ensure that the provision
of support takes into account the costs frequently incurred by persons 
with
disabilities and their families as a result of the disability.<BR>
<BR>
2. In countries where social security, social insurance or other social
welfare schemes exist or are being developed for the general population,
States should ensure that such systems do not exclude or discriminate 
against
persons with disabilities.<BR>
<BR>
3. States should also ensure the provision of income support and social
security protection to individuals who undertake the care of a person 
with
a disability.<BR>
<BR>
4. Social security systems should include incentives to restore the 
income-earning
capacity of persons with disabilities. Such systems should provide or 
contribute
to the organization, development and financing of vocational training. 
They
should also assist with placement services.<BR>
<BR>
5. Social security programmes should also provide incentives for persons
with disabilities to seek employment in order to establish or 
re-establish
their income-earning capacity.<BR>
<BR>
6. Income support should be maintained as long as the disabling 
conditions
remain in a manner that does not discourage persons with disabilities 
from
seeking employment. It should only be reduced or terminated when persons
with disabilities achieve adequate and secure income.<BR>
<BR>
7. States, in countries where social security is to a large extent 
provided
by the private sector, should encourage local communities, welfare 
organizations
and families to develop self-help measures and incentives for employment
or employment-related activities for persons with disabilities.<A NAME=
"anchor1394587"></A><BR>
<IMG SRC="Pixel1x1.gif" WIDTH="1" HEIGHT="1" ALIGN="BOTTOM" 
NATURALSIZEFLAG=
"3"></BLOCKQUOTE>
<BLOCKQUOTE>
<H4>Rule 9. Family life and personal integrity</H4>
States should promote the full participation of persons with disabilities

in family life. They should promote their right to personal integrity and

ensure that laws do not discriminate against persons with disabilities 
with
respect to sexual relationships, marriage and parenthood.<BR>
<BR>
1. Persons with disabilities should be enabled to live with their 
families.
States should encourage the inclusion in family counselling of 
appropriate
modules regarding disability and its effects on family life. Respite-care

and attendant-care services should be made available to families which 
include
a person with disabilities. States should remove all unnecessary 
obstacles
to persons who want to foster or adopt a child or adult with 
disabilities.<BR>
<BR>
2. Persons with disabilities must not be denied the opportunity to 
experience
their sexuality, have sexual relationships and experience parenthood. 
Taking
into account that persons with disabilities may experience difficulties
in getting married and setting up a family, States should encourage the
availability of appropriate counselling. Persons with disabilities must
have the same access as others to family-planning methods, as well as to
information in accessible form on the sexual functioning of their 
bodies.<BR>
<BR>
3. States should promote measures to change negative attitudes towards 
marriage,
sexuality and parenthood of persons with disabilities, especially of 
girls
and women with disabilities, which still prevail in society. The media 
should
be encouraged to play an important role in removing such negative 
attitudes.<BR>
<BR>
4. Persons with disabilities and their families need to be fully informed

about taking precautions against sexual and other forms of abuse. Persons

with disabilities are particularly vulnerable to abuse in the family, 
community
or institutions and need to be educated on how to avoid the occurrence of

abuse, recognize when abuse has occurred and report on such acts.<A NAME=

"anchor1397689"></A><BR>
<IMG SRC="Pixel1x1.gif" WIDTH="1" HEIGHT="1" ALIGN="BOTTOM" 
NATURALSIZEFLAG=
"3"></BLOCKQUOTE>
<BLOCKQUOTE>
<H4>Rule 10. Culture</H4>
States will ensure that persons with disabilities are integrated into and

can participate in cultural activities on an equal basis.<BR>
<BR>
1. States should ensure that persons with disabilities have the 
opportunity
to utilize their creative, artistic and intellectual potential, not only
for their own benefit, but also for the enrichment of their community, be

they in urban or rural areas. Examples of such activities are dance, 
music,
literature, theatre, plastic arts, painting and sculpture. Particularly
in developing countries, emphasis should be placed on traditional and 
contemporary
art forms, such as puppetry, recitation and story-telling.<BR>
<BR>
2. States should promote the accessibility to and availability of places
for cultural performances and services, such as theatres, museums, 
cinemas
and libraries, to persons with disabilities.<BR>
<BR>
3. States should initiate the development and use of special technical 
arrangements
to make literature, films and theatre accessible to persons with 
disabilities.<A
NAME="anchor1400448"></A><BR>
<IMG SRC="Pixel1x1.gif" WIDTH="1" HEIGHT="1" ALIGN="BOTTOM" 
NATURALSIZEFLAG=
"3"></BLOCKQUOTE>
<BLOCKQUOTE>
<H4>Rule 11. Recreation and sports</H4>
States will take measures to ensure that persons with disabilities have
equal opportunities for recreation and sports.<BR>
<BR>
1. States should initiate measures to make places for recreation and 
sports,
hotels, beaches, sports arenas, gym halls, etc., accessible to persons 
with
disabilities. Such measures should encompass support for staff in 
recreation
and sports programmes, including projects to develop methods of 
accessibility,
and participation, information and training programmes.<BR>
<BR>
2. Tourist authorities, travel agencies, hotels, voluntary organizations
and others involved in organizing recreational activities or travel 
opportunities
should offer their services to all, taking into account the special needs

of persons with disabilities. Suitable training should be provided to 
assist
that process.<BR>
<BR>
3. Sports organizations should be encouraged to develop opportunities for

participation by persons with disabilities in sports activities. In some
cases, accessibility measures could be enough to open up opportunities 
for
participation. In other cases, special arrangements or special games 
would
be needed. States should support the participation of persons with 
disabilities
in national and international events.<BR>
<BR>
4. Persons with disabilities participating in sports activities should 
have
access to instruction and training of the same quality as other 
participants.<BR>
<BR>
5. Organizers of sports and recreation should consult with organizations
of persons with disabilities when developing their services for persons
with disabilities.<A NAME="anchor1404112"></A><BR>
<IMG SRC="Pixel1x1.gif" WIDTH="1" HEIGHT="1" ALIGN="BOTTOM" 
NATURALSIZEFLAG=
"3"></BLOCKQUOTE>
<BLOCKQUOTE>
<H4>Rule 12. Religion</H4>
States will encourage measures for equal participation by persons with 
disabilities
in the religious life of their communities.<BR>
<BR>
1. States should encourage, in consultation with religious authorities,
measures to eliminate discrimination and make religious activities 
accessible
to persons with disabilities.<BR>
<BR>
2. States should encourage the distribution of information on disability
matters to religious institutions and organizations. States should also
encourage religious authorities to include information on disability 
policies
in the training for religious professions, as well as in religious 
education
programmes.<BR>
<BR>
3. They should also encourage the accessibility of religious literature
to persons with sensory impairments.<BR>
<BR>
4. States and/or religious organizations should consult with 
organizations
of persons with disabilities when developing measures for equal 
participation
in religious activities.<A NAME="anchor1406628"></A><BR>
<P><CENTER><HR></CENTER>
</BLOCKQUOTE>
<BLOCKQUOTE>
<H3>III. IMPLEMENTATION MEASURES<A NAME="anchor1411195"></A><BR>
<IMG SRC="Pixel1x1.gif" WIDTH="1" HEIGHT="1" ALIGN="BOTTOM" 
NATURALSIZEFLAG=
"3"></H3>
</BLOCKQUOTE>
<BLOCKQUOTE>
<H4>Rule 13. Information and research</H4>
States assume the ultimate responsibility for the collection and 
dissemination
of information on the living conditions of persons with disabilities and
promote comprehensive research on all aspects, including obstacles that
affect the lives of persons with disabilities.<BR>
<BR>
1. States should, at regular intervals, collect gender-specific 
statistics
and other information concerning the living conditions of persons with 
disabilities.
Such data collection could be conducted in conjunction with national 
censuses
and household surveys and could be undertaken in close collaboration, 
inter
alia, with universities, research institutes and organizations of persons

with disabilities. The data collection should include questions on 
programmes
and services and their use.<BR>
<BR>
2. States should consider establishing a data bank on disability, which
would include statistics on available services and programmes as well as
on the different groups of persons with disabilities. They should bear in

mind the need to protect individual privacy and personal integrity.<BR>
<BR>
3. States should initiate and support programmes of research on social,
economic and participation issues that affect the lives of persons with
disabilities and their families. Such research should include studies on
the causes, types and frequencies of disabilities, the availability and
efficacy of existing programmes and the need for development and 
evaluation
of services and support measures.<BR>
<BR>
4. States should develop and adopt terminology and criteria for the 
conduct
of national surveys, in cooperation with organizations of persons with 
disabilities.<BR>
<BR>
5. States should facilitate the participation of persons with 
disabilities
in data collection and research. To undertake such research States should

particularly encourage the recruitment of qualified persons with 
disabilities.<BR>
<BR>
6. States should support the exchange of research findings and 
experiences.<BR>
<BR>
7. States should take measures to disseminate information and knowledge
on disability to all political and administration levels within national,

regional and local spheres.<A NAME="anchor1417671"></A><BR>
<IMG SRC="Pixel1x1.gif" WIDTH="1" HEIGHT="1" ALIGN="BOTTOM" 
NATURALSIZEFLAG=
"3"></BLOCKQUOTE>
<BLOCKQUOTE>
<H4>Rule 14. Policy-making and planning</H4>
States will ensure that disability aspects are included in all relevant
policy-making and national planning.<BR>
<BR>
1. States should initiate and plan adequate policies for persons with 
disabilities
at the national level, and stimulate and support action at regional and
local levels.<BR>
<BR>
2. States should involve organizations of persons with disabilities in 
all
decision-making relating to plans and programmes concerning persons with
disabilities or affecting their economic and social status.<BR>
<BR>
3. The needs and concerns of persons with disabilities should be 
incorporated
into general development plans and not be treated separately.<BR>
<BR>
4. The ultimate responsibility of States for the situation of persons 
with
disabilities does not relieve others of their responsibility. Anyone in
charge of services, activities or the provision of information in society

should be encouraged to accept responsibility for making such programmes
available to persons with disabilities.<BR>
<BR>
5. States should facilitate the development by local communities of 
programmes
and measures for persons with disabilities. One way of doing this could
be to develop manuals or check-lists and provide training programmes for
local staff.<A NAME="anchor1414288"></A><BR>
<IMG SRC="Pixel1x1.gif" WIDTH="1" HEIGHT="1" ALIGN="BOTTOM" 
NATURALSIZEFLAG=
"3"></BLOCKQUOTE>
<BLOCKQUOTE>
<H4>Rule 15. Legislation</H4>
States have a responsibility to create the legal bases for measures to 
achieve
the objectives of full participation and equality for persons with 
disabilities.<BR>
<BR>
1. National legislation, embodying the rights and obligations of 
citizens,
should include the rights and obligations of persons with disabilities.
States are under an obligation to enable persons with disabilities to 
exercise
their rights, including their human, civil and political rights, on an 
equal
basis with other citizens. States must ensure that organizations of 
persons
with disabilities are involved in the development of national legislation

concerning the rights of persons with disabilities, as well as in the 
ongoing
evaluation of that legislation.<BR>
<BR>
2. Legislative action may be needed to remove conditions that may 
adversely
affect the lives of persons with disabilities, including harassment and
victimization. Any discriminatory provisions against persons with 
disabilities
must be eliminated. National legislation should provide for appropriate
sanctions in case of violations of the principles of 
non-discrimination.<BR>
<BR>
3. National legislation concerning persons with disabilities may appear
in two different forms. The rights and obligations may be incorporated in

general legislation or contained in special legislation. Special 
legislation
for persons with disabilities may be established in several ways:<BR>
<BR>
(a) By enacting separate legislation, dealing exclusively with disability

matters;<BR>
<BR>
(b) By including disability matters within legislation on particular 
topics;<BR>
<BR>
(c) By mentioning persons with disabilities specifically in the texts 
that
serve to interpret existing legislation.<BR>
<BR>
A combination of those different approaches might be desirable. 
Affirmative
action provisions may also be considered.<BR>
<BR>
4. States may consider establishing formal statutory complaints 
mechanisms
in order to protect the interests of persons with disabilities.<A NAME=
"anchor1421127"></A><BR>
<IMG SRC="Pixel1x1.gif" WIDTH="1" HEIGHT="1" ALIGN="BOTTOM" 
NATURALSIZEFLAG=
"3"></BLOCKQUOTE>
<BLOCKQUOTE>
<H4>Rule 16. Economic policies</H4>
States have the financial responsibility for national programmes and 
measures
to create equal opportunities for persons with disabilities.<BR>
<BR>
1. States should include disability matters in the regular budgets of all

national, regional and local government bodies.<BR>
<BR>
2. States, non-governmental organizations and other interested bodies 
should
interact to determine the most effective ways of supporting projects and
measures relevant to persons with disabilities.<BR>
<BR>
3. States should consider the use of economic measures (loans, tax 
exemptions,
earmarked grants, special funds, and so on) to stimulate and support 
equal
participation by persons with disabilities in society.<BR>
<BR>
4. In many States it may be advisable to establish a disability 
development
fund, which could support various pilot projects and self-help programmes

at the grass-roots level.<A NAME="anchor1424780"></A><BR>
<IMG SRC="Pixel1x1.gif" WIDTH="1" HEIGHT="1" ALIGN="BOTTOM" 
NATURALSIZEFLAG=
"3"></BLOCKQUOTE>
<BLOCKQUOTE>
<H4>Rule 17. Coordination of work</H4>
States are responsible for the establishment and strengthening of 
national
coordinating committees, or similar bodies, to serve as a national focal
point on disability matters.<BR>
<BR>
1. The national coordinating committee or similar bodies should be 
permanent
and based on legal as well as appropriate administrative regulation.<BR>
<BR>
2. A combination of representatives of private and public organizations
is most likely to achieve an intersectoral and multidisciplinary 
composition.
Representatives could be drawn from concerned government ministries, 
organizations
of persons with disabilities and non-governmental organizations.<BR>
<BR>
3. Organizations of persons with disabilities should have considerable 
influence
in the national coordinating committee in order to ensure proper feedback

of their concerns.<BR>
<BR>
4. The national coordinating committee should be provided with sufficient

autonomy and resources to fulfil its responsibilities in relation to its
decision-making capacities. It should report to the highest governmental
level.<A NAME="anchor1427588"></A><BR>
<IMG SRC="Pixel1x1.gif" WIDTH="1" HEIGHT="1" ALIGN="BOTTOM" 
NATURALSIZEFLAG=
"3"></BLOCKQUOTE>
<BLOCKQUOTE>
<H4>Rule 18. Organizations of persons with disabilities</H4>
States should recognize the right of the organizations of persons with 
disabilities
to represent persons with disabilities at national, regional and local 
levels.
States should also recognize the advisory role of organizations of 
persons
with disabilities in decision-making on disability matters.<BR>
<BR>
1. States should encourage and support economically and in other ways the

formation and strengthening of organizations of persons with 
disabilities,
family members and/or advocates. States should recognize that those 
organizations
have a role to play in the development of disability policy.<BR>
<BR>
2. States should establish ongoing communication with organizations of 
persons
with disabilities and ensure their participation in the development of 
government
policies.<BR>
<BR>
3. The role of organizations of persons with disabilities could be to 
identify
needs and priorities, to participate in the planning, implementation and
evaluation of services and measures concerning the lives of persons with
disabilities, and to contribute to public awareness and to advocate 
change.<BR>
<BR>
4. As instruments of self-help, organizations of persons with 
disabilities
provide and promote opportunities for the development of skills in 
various
fields, mutual support among members and information sharing.<BR>
<BR>
5. Organizations of persons with disabilities could perform their 
advisory
role in many different ways such as having permanent representation on 
boards
of government-funded agencies, serving on public commissions and 
providing
expert knowledge on different projects.<BR>
<BR>
6. The advisory role of organizations of persons with disabilities should

be ongoing in order to develop and deepen the exchange of views and 
information
between the State and the organizations.<BR>
<BR>
7. Organizations should be permanently represented on the national 
coordinating
committee or similar bodies.<BR>
<BR>
8. The role of local organizations of persons with disabilities should be

developed and strengthened to ensure that they influence matters at the
community level.<A NAME="anchor1431717"></A><BR>
<IMG SRC="Pixel1x1.gif" WIDTH="1" HEIGHT="1" ALIGN="BOTTOM" 
NATURALSIZEFLAG=
"3"></BLOCKQUOTE>
<BLOCKQUOTE>
<H4>Rule 19. Personnel training</H4>
States are responsible for ensuring the adequate training of personnel,
at all levels, involved in the planning and provision of programmes and
services concerning persons with disabilities.<BR>
<BR>
1. States should ensure that all authorities providing services in the 
disability
field give adequate training to their personnel.<BR>
<BR>
2. In the training of professionals in the disability field, as well as
in the provision of information on disability in general training 
programmes,
the principle of full participation and equality should be appropriately
reflected.<BR>
<BR>
3. States should develop training programmes in consultation with 
organizations
of persons with disabilities, and persons with disabilities should be 
involved
as teachers, instructors or advisers in staff training programmes.<BR>
<BR>
4. The training of community workers is of great strategic importance, 
particularly
in developing countries. It should involve persons with disabilities and
include the development of appropriate values, competence and 
technologies
as well as skills which can be practised by persons with disabilities, 
their
parents, families and members of the community.<A 
NAME="anchor1435772"></A><BR>
<IMG SRC="Pixel1x1.gif" WIDTH="1" HEIGHT="1" ALIGN="BOTTOM" 
NATURALSIZEFLAG=
"3"></BLOCKQUOTE>
<BLOCKQUOTE>
<H4>Rule 20. National monitoring and evaluation of disability programmes
in the implementation of the Rules</H4>
States are responsible for the continuous monitoring and evaluation of 
the
implementation of national programmes and services concerning the 
equalization
of opportunities for persons with disabilities.<BR>
<BR>
1. States should periodically and systematically evaluate national 
disability
programmes and disseminate both the bases and the results of the 
evaluations.<BR>
<BR>
2. States should develop and adopt terminology and criteria for the 
evaluation
of disability-related programmes and services.<BR>
<BR>
3. Such criteria and terminology should be developed in close cooperation

with organizations of persons with disabilities from the earliest 
conceptual
and planning stages.<BR>
<BR>
4. States should participate in international cooperation in order to 
develop
common standards for national evaluation in the disability field. States
should encourage national coordinating committees to participate 
also.<BR>
<BR>
5. The evaluation of various programmes in the disability field should be

built in at the planning stage, so that the overall efficacy in 
fulfilling
their policy objectives can be evaluated.<A NAME="anchor1444339"></A><BR>

<IMG SRC="Pixel1x1.gif" WIDTH="1" HEIGHT="1" ALIGN="BOTTOM" 
NATURALSIZEFLAG=
"3"></BLOCKQUOTE>
<BLOCKQUOTE>
<H4>Rule 21. Technical and economic cooperation</H4>
States, both industrialized and developing, have the responsibility to 
cooperate
in and take measures for the improvement of the living conditions of 
persons
with disabilities in developing countries.<BR>
<BR>
1. Measures to achieve the equalization of opportunities of persons with
disabilities, including refugees with disabilities, should be integrated
into general development programmes.<BR>
<BR>
2. Such measures must be integrated into all forms of technical and 
economic
cooperation, bilateral and multilateral, governmental and 
non-governmental.
States should bring up disability issues in discussions on such 
cooperation
with their counterparts.<BR>
<BR>
3. When planning and reviewing programmes of technical and economic 
cooperation,
special attention should be given to the effects of such programmes on 
the
situation of persons with disabilities. It is of the utmost importance 
that
persons with disabilities and their organizations are consulted on any 
development
projects designed for persons with disabilities. They should be directly
involved in the development, implementation and evaluation of such 
projects.<BR>
<BR>
4. Priority areas for technical and economic cooperation should 
include:<BR>
<BR>
(a) The development of human resources through the development of skills,

abilities and potentials of persons with disabilities and the initiation
of employment-generating activities for and of persons with 
disabilities;<BR>
<BR>
(b) The development and dissemination of appropriate disability-related
technologies and know-how.<BR>
<BR>
5. States are also encouraged to support the formation and strengthening
of organizations of persons with disabilities.<BR>
<BR>
6. States should take measures to improve the knowledge of disability 
issues
among staff involved at all levels in the administration of technical and

economic cooperation programmes.<A NAME="anchor1448034"></A><BR>
<IMG SRC="Pixel1x1.gif" WIDTH="1" HEIGHT="1" ALIGN="BOTTOM" 
NATURALSIZEFLAG=
"3"></BLOCKQUOTE>
<BLOCKQUOTE>
<H4>Rule 22. International cooperation</H4>
States will participate actively in international cooperation concerning
policies for the equalization of opportunities for persons with 
disabilities.<BR>
<BR>
1. Within the United Nations, the specialized agencies and other 
concerned
intergovernmental organizations, States should participate in the 
development
of disability policy.<BR>
<BR>
2. Whenever appropriate, States should introduce disability aspects in 
general
negotiations concerning standards, information exchange, development 
programmes,
etc.<BR>
<BR>
3. States should encourage and support the exchange of knowledge and 
experience
among:<BR>
<BR>
(a) Non-governmental organizations concerned with disability issues;<BR>
<BR>
(b) Research institutions and individual researchers involved in 
disability
issues;<BR>
<BR>
(c) Representatives of field programmes and of professional groups in the

disability field;<BR>
<BR>
(d) Organizations of persons with disabilities;<BR>
<BR>
(e) National coordinating committees.<BR>
<BR>
4. States should ensure that the United Nations and the specialized 
agencies,
as well as all intergovernmental and interparliamentary bodies, at global

and regional levels, include in their work the global and regional 
organizations
of persons with disabilities.<A NAME="anchor1451084"></A><BR>
<P><CENTER><HR></CENTER>
</BLOCKQUOTE>
<BLOCKQUOTE>
<H3>IV. MONITORING MECHANISM</H3>
<BR>
1. The purpose of a monitoring mechanism is to further the effective 
implementation
of the Rules. It will assist each State in assessing its level of 
implementation
of the Rules and in measuring its progress. The monitoring should 
identify
obstacles and suggest suitable measures that would contribute to the 
successful
implementation of the Rules. The monitoring mechanism will recognize the
economic, social and cultural features existing in individual States. An
important element should also be the provision of advisory services and
the exchange of experience and information between States.<BR>
<BR>
2. The Rules shall be monitored within the framework of the sessions of
the Commission for Social Development. A Special Rapporteur with relevant

and extensive experience in disability issues and international 
organizations
shall be appointed, if necessary, funded by extrabudgetary resources, for

three years to monitor the implementation of the Rules.<BR>
<BR>
3. International organizations of persons with disabilities having 
consultative
status with the Economic and Social Council and organizations 
representing
persons with disabilities who have not yet formed their own organizations

should be invited to create among themselves a panel of experts, on which

organizations of persons with disabilities shall have a majority, taking
into account the different kinds of disabilities and necessary equitable
geographical distribution, to be consulted by the Special Rapporteur and,

when appropriate, by the Secretariat.<BR>
<BR>
4. The panel of experts will be encouraged by the Special Rapporteur to
review, advise and provide feedback and suggestions on the promotion, 
implementation
and monitoring of the Rules.<BR>
<BR>
5. The Special Rapporteur shall send a set of questions to States, 
entities
within the United Nations system, and intergovernmental and 
non-governmental
organizations, including organizations of persons with disabilities. The
set of questions should address implementation plans for the Rules in 
States.
The questions should be selective in nature and cover a number of 
specific
rules for in-depth evaluation. In preparing the questions the Special 
Rapporteur
should consult with the panel of experts and the Secretariat.<BR>
<BR>
6. The Special Rapporteur shall seek to establish a direct dialogue not
only with States but also with local non-governmental organizations, 
seeking
their views and comments on any information intended to be included in 
the
reports. The Special Rapporteur shall provide advisory services on the 
implementation
and monitoring of the Rules and assistance in the preparation of replies
to the sets of questions.<BR>
<BR>
7. The Department for Policy Coordination and Sustainable Development of
the Secretariat, as the United Nations focal point on disability issues,
the United Nations Development Programme and other entities and 
mechanisms
within the United Nations system, such as the regional commissions and 
specialized
agencies and inter-agency meetings, shall cooperate with the Special 
Rapporteur
in the implementation and monitoring of the Rules at the national 
level.<BR>
<BR>
8. The Special Rapporteur, assisted by the Secretariat, shall prepare 
reports
for submission to the Commission for Social Development at its 
thirty-fourth
and thirty-fifth sessions. In preparing such reports, the Rapporteur 
should
consult with the panel of experts.<BR>
<BR>
9. States should encourage national coordinating committees or similar 
bodies
to participate in implementation and monitoring. As the focal points on
disability matters at the national level, they should be encouraged to 
establish
procedures to coordinate the monitoring of the Rules. Organizations of 
persons
with disabilities should be encouraged to be actively involved in the 
monitoring
of the process at all levels.<BR>
<BR>
10. Should extrabudgetary resources be identified, one or more positions
of interregional adviser on the Rules should be created to provide direct

services to States, including:<BR>
<BR>
(a) The organization of national and regional training seminars on the 
content
of the Rules;<BR>
<BR>
(b) The development of guidelines to assist in strategies for 
implementation
of the Rules;<BR>
<BR>
(c) Dissemination of information about best practices concerning 
implementation
of the Rules.<BR>
<BR>
11. At its thirty-fourth session, the Commission for Social Development
should establish an open-ended working group to examine the Special 
Rapporteur's
report and make recommendations on how to improve the application of the
Rules. In examining the Special Rapporteur's report, the Commission, 
through
its open-ended working group, shall consult international organizations
of persons with disabilities and specialized agencies, in accordance with

rules 71 and 76 of the rules of procedure of the functional commissions
of the Economic and Social Council.<BR>
<BR>
12. At its session following the end of the Special Rapporteur's mandate,

the Commission should examine the possibility of either renewing that 
mandate,
appointing a new Special Rapporteur or considering another monitoring 
mechanism,
and should make appropriate recommendations to the Economic and Social 
Council.<BR>
<BR>
13. States should be encouraged to contribute to the United Nations 
Voluntary
Fund on Disability in order to further the implementation of the 
Rules.<BR>
<P><CENTER><HR></CENTER>
</BLOCKQUOTE>
<P><CENTER><FONT SIZE="-1">[<A HREF="StandardRules1.html">Standard Rules
Contents</A><A HREF="ENIL/ENILhomepage.html">]</A></FONT> <FONT 
SIZE="-1">[<A HREF="ENIL/ENILhomepage.html">ENIL
homepage]</A></FONT> <FONT SIZE="-1">[<A 
HREF="ENIL/ENILContents.html">ENIL
Website Contents</A><A HREF="ENIL/ENILhomepage.html">]</A></FONT><FONT 
SIZE="-1">[<A HREF="index.html">Institute
on Independent Living Homepage</A> <A 
HREF="ENIL/ENILhomepage.html">]</A></FONT>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-194</DOCNO>
<DOCOLDNO>IA012-000125-B019-54</DOCOLDNO>
<DOCHDR>
http://www.independentliving.org:80/ToolsforPower/Tools7.html 193.13.228.238 19970216213934 text/html 7912
HTTP/1.0 200 OK
Last-Modified: Tue, 06 Aug 1996 20:02:57 +0000
Date: Sun, 16 Feb 1997 21:39:47 +0000
Expires: Sun, 16 Feb 1997 21:38:07 +0000
Content-type: text/html
Server: RoxenEnterprise/1.0
Content-length: 7687
</DOCHDR>
<HTML>
<HEAD>
    <TITLE>Institute_on_Independent_Living</TITLE>
</HEAD>
<BODY BGCOLOR="#ffffff" TEXT="#030235" LINK="#00007f">
<META NAME="description" 
CONTENT="Individuals and organizations of persons with disabilities can 
publish, free of charge,  articles, reports, training manuals, 
announcements, etc. on Independent Living, personal assistance, advocacy, 

peer support, accessibility, legislation and related subjects. "><META 
NAME="keywords" CONTENT="Independent Living, personal assistance, 
advocacy, peer support, direct payments, anti-discrimination legislation, 

accessibility, disability, disability rights">
<H4><IMG SRC="../InstLogoSmall.gif" WIDTH="198" HEIGHT="57" 
ALIGN="BOTTOM"
NATURALSIZEFLAG="3"><BR>
<BR>
<BR>
</H4>
<H2><CENTER>Independent Living: a European definition</CENTER>
</H2>
<FONT SIZE="+3">I</FONT>ndependent Living is the international civil 
rights
movement of people with disabilities that works against discrimination 
and
for more personal and political power for people with disabilities. The
movement consists of people of all ages and all types of disabilities. 
With
origins dating back to the 1960's it has derived much of its philosophy
from the American civil rights movements of blacks and women and is now
represented in a growing number of countries. The movement consists of an

informal network of local organizations which work as political pressure
groups for equal opportunities and provide such services as advocacy, 
counseling,
peer support, personal assistance referral and housing referral. In some
countries national coalitions of Independent Living initiatives exist 
that
have gained wide political recognition.<BR>
<BR>
The philosophy of the Independent Living Movement or Disability Rights 
Movement,
as it is also referred to, is based on the principles of 
self-determination,
self-help and consumer control. 
<H4>Anti-discrimination</H4>
<FONT SIZE="+3">S</FONT>tatistics show that in all countries disabled 
people
as a group are worse off than the rest of the population in terms of 
education,
jobs, income, housing, social and political opportunities. For this 
reason
the Independent Living Movement is working for anti-discrimination 
legislation
and for services which guarantee us equal opportunities. 
<H4>The medical model</H4>
<FONT SIZE="+3">O</FONT>ne of the reasons for the discrimination disabled

people are exposed to is that deviants are often declared sick. This 
medical
model of disability assigns us the helpless and passive patient role in
which we are considered dependent upon the care of others, unable to 
work,
exempt from normal duties, leading worthless lives, as evidenced by the
still common term &quot;invalid&quot; (Latin for 
&quot;worthless&quot;).<BR>
<BR>
In the traditional rehabilitation process the problem is seen within the
individual who is to be normalized and integrated by experts. Who defines

&quot;normal&quot;? Integration at whose terms? Instead, the Independent
Living Movement demands self-determination.<BR>
<BR>
Disability is not a medical problem but a problem of unequal power. We 
are
an underprivileged political minority whose second class citizenship 
standing
can only be improved through political power and far-reaching systemic 
changes.
<H4>De-institutionalization</H4>
<FONT SIZE="+3">W</FONT>ith the justification that we are sick and unable

to care for ourselves many of us are confined in institutions, deprived
of the most basic decisions and opportunities which other people take for

granted. They suffer loss of social skills, self-confidence and stunted
human growth. The Independent Living Movement has amply demonstrated that

nobody, regardless of type and extent of disability, needs to waste his
life in an institution, if provided with the appropriate services in the
community. <BR>
<BR>
Institutions need not consist of brick and mortar. The Independent Living

Movement has shown that many of the services presently provided in the 
community
carry institutional vestiges in that they deprive us of the freedom of 
choice,
prevent us from taking responsibility and keep us in paternalistic 
dependency.
<H4>Control over our services</H4>
<FONT SIZE="+3">T</FONT>oday many services such as housing, 
transportation
and personal assistance are designed for the needs of the service 
provider
and not the needs of disabled people. As a result, we are forced to use
uniform, general solutions which cannot meet our individual, differing 
needs.
Such services deny our uniqueness as human beings and deprive us of 
choices.
<BR>
<BR>
The Independent Living Movement demands the same range of options and the

same degree of control over our lives that our non-disabled peers enjoy.
To this end people with disabilities need to take as much initiative as
possible in designing services that maximize choice and control by the 
individual
consumer. Choice is the key to Independent Living. Nobody else can make
that choice for us. We are the experts on our lives. 
<H4>Control over our organizations</H4>
<FONT SIZE="+3">T</FONT>raditional disability organizations are organized

along diagnostic lines, for each medical condition a separate 
organization,
thereby emphasizing the sick role and focusing on what divides us instead

of concentrating on our common agenda. Seeing disability as a medical 
problem
instead of a political problem traditional disability organizations are
often run by non-disabled experts both in elected and staff 
positions.<BR>
<BR>
The Independent Living Movement claims that our organizations can work 
more
effectively towards the goal of full participation and equality when 
disabled
people themselves are in control, since we are the best experts on our 
needs.
We need to demonstrate to the public and to ourselves that we are fully
capable of taking our cause in our own hands. Given the high unemployment

among disabled people we need the work and training opportunities in our
organizations ourselves. 
<H4>Peer support</H4>
<FONT SIZE="+3">S</FONT>ince people with disabilities are part of their
respective communities, many of us have internalized society's prejudices

against disability. The Independent Living Movement recognizes that our
political emancipation must go hand in hand with liberating ourselves 
from
internalized oppression, self-contempt, and low self-confidence. For this

purpose the movement has developed its own pedagogy, peer counseling. 
<BR>
<BR>
Peer counseling means to share the fruits of one's experience. In peer 
counseling
courses and support sessions individuals with disabilities learn from 
each
other the practical and social skills needed for a self-directed life in
the community. The living example of a person in the same situation with
which one can identify oneself is a more powerful intervention than the
advice of the best rehabilitation expert. <BR>
<BR>
Peer counseling provides appropriate role models, helps to increase 
self-reliance
and encourages to take charge of one's life. No longer are we helpless 
victims
dependent upon other people's charitable attitude. Regardless of type and

extent of disability, we all can learn to take more responsibility for 
ourselves.
The Independent Living Movement seeks to empower the individual with the
tools to bring about these changes in one's life. <BR>
<BR>
<BR>
<BR>
Source: <BR>
Stockholm Cooperative for Independent Living (STIL), <BR>
Bondegatan 39, 113 66 Stockholm, Sweden <BR>
<P><CENTER><HR><FONT SIZE=2>[<A HREF="Tools1.html">Tools for Power 
contents]</A></FONT><FONT SIZE=2>[<A HREF="../Contents.html">Institute
on Independent Living contents</A>]</FONT></CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-195</DOCNO>
<DOCOLDNO>IA012-000125-B019-80</DOCOLDNO>
<DOCHDR>
http://www.independentliving.org:80/ToolsforPower/Tools8.html 193.13.228.238 19970216213946 text/html 6678
HTTP/1.0 200 OK
Last-Modified: Tue, 06 Aug 1996 20:02:55 +0000
Date: Sun, 16 Feb 1997 21:40:01 +0000
Expires: Sun, 16 Feb 1997 21:38:21 +0000
Content-type: text/html
Server: RoxenEnterprise/1.0
Content-length: 6453
</DOCHDR>
<HTML>
<HEAD>
    <TITLE>Institute_on_Independent_Living</TITLE>
</HEAD>
<BODY BGCOLOR="#ffffff" TEXT="#020136" LINK="#00007f">
<META NAME="description" 
CONTENT="Individuals and organizations of persons with disabilities can 
publish, free of charge,  articles, reports, training manuals, 
announcements, etc. on Independent Living, personal assistance, advocacy, 

peer support, accessibility, legislation and related subjects. "><META 
NAME="keywords" CONTENT="Independent Living, personal assistance, 
advocacy, peer support, direct payments, anti-discrimination legislation, 

accessibility, disability, disability rights">
<H4><IMG SRC="../InstLogoSmall.gif" WIDTH="198" HEIGHT="57" 
ALIGN="BOTTOM"
NATURALSIZEFLAG="3"><BR>
</H4>
<H2><CENTER>An American definition of Independent Living</CENTER>
</H2>
<H4>What is Independent Living? </H4>
<FONT SIZE="+3">E</FONT>ssentially, it is living just like everyone else
- having opportunities to make decisions that affect one's life, able to
pursue activities of one's own choosing - limited only in the same ways
that one's nondisabled neighbors are limited.<BR>
<BR>
Independent living should not be defined in terms of living on one's own,

being employed in a job fitting one's capabilities and interests, or 
having
an active social life. These are aspects of living independently. 
Independent
living has to do with self-determination. It is having the right and the
opportunity to pursue a course of action. And, it is having the freedom
to fail - and to learn from one's failures, just as nondisabled people 
do.<BR>
<BR>
There are, of course, individuals who have certain mental impairments 
which
may affect their abilities to make complicated decisions or pursue 
complex
activities. For these individuals, Independent Living means having every
opportunity to be as self-sufficient as possible. <BR>
<BR>
Independent living. It isn't easy, and it can be risky. But millions of
people with disabilities rate it higher than a life of dependency and 
narrow
opportunities and unfulfilled expectations. 
<H4>Independent Living centers</H4>
<FONT SIZE="+3">F</FONT>ortunately, people with disabilities don't have
to do it all on their own. The purpose of this brochure is to describe a
kind of service organization which is designed specifically to assist 
people
with disabilities who themselves have been successful in establishing 
independent
lives. These people have both training and the personal experience to 
know
exactly what is needed to live independently. And, they have deep 
commitment
to assisting other disabled people in becoming more independent.<BR>
Services of Independent Living centers<BR>
<BR>
Centers offer a wide variety of services. Four are essential to efforts
of people with disabilities to live independently, including: 
<UL>
  <LI>Information and referral: Centers maintain comprehensive 
information
files on availability in their communities of accessible housing; 
transportation;
employment opportunities; rosters of persons available to serve as 
personal
assistants, interpreters for hearing impaired people, or readers for 
visually
impaired people; and many other services.<BR>
<BR>
  <LI>Independent living skills training: Centers provide training 
courses
to help people with disabilities gain skills that would enable them to 
live
more independently; courses may include using various public 
transportation
systems, managing a personal budget, dealing with intensive and 
discriminatory
behavior by members of the general public, and many other subjects.<BR>
<BR>
  <LI>Peer counseling: Centers offer a service in which a person with a
disability can work with other persons who have disabilities and who are
living independently in the community. The objective is to explore 
options
and to solve problems that sometimes occur for people with disabilities,
for example, making adjustments to a newly acquired disability, 
experiencing
changes in living arrangements, or learning to use community services 
more
effectively.<BR>
<BR>
  <LI>Advocacy: Centers provide two kinds of advocacy: 1) consumer 
advocacy,
which involves center staff working with persons with disabilities to 
obtain
necessary support services from other agencies in the community and 2) 
community
advocacy, which involves center staff, board members, and volunteers 
initiating
activities to make changes in the community that make it easier for all
persons with disabilities to live more independently.<BR>
<BR>
  <LI>Other services: Centers also offer a number of other services, 
generally
depending on specific needs of their consumers and lack of availability
elsewhere in the community. Among the most frequently provided services
are community education and other public education services, equipment 
repair,
recreational activities, and home modifications. 
</UL>
<H4>How Independent Living centers differ from other service 
organizations</H4>
<FONT SIZE="+3">T</FONT>here are many different types of organizations 
which
serve people with disabilities - state vocational rehabilitation 
agencies,
group homes, rehabilitation hospitals, sheltered workshops, nursing 
homes,
senior centers, home health care agencies and so forth. These 
organizations
provide valuable services and are important links in the network of 
services
that help people with disabilities maintain independent lifestyles.<BR>
<BR>
What makes Independent Living centers very different from these other 
organizations
is that centers have substantial involvement of people with disabilities
making policy decisions and delivering services. Why this emphasis on 
control
by people with disabilities? The basic idea behind Independent Living is
that the ones who know best what services people with disabilities need
in order to live independently are disabled people themselves. 
<H4>A final word on Independent Living</H4>
<FONT SIZE="+3">C</FONT>hanges that make life more satisfying don't occur

overnight. But, for people who are willing to work toward greater 
independence,
Independent Living centers can help put the pieces together.<BR>
<BR>
<BR>
Source: <BR>
ILRU at Texas Institute for Rehabilitation, <BR>
2323 S. Shepherd, Suite 1000, Houston, TX 77019, United States. <BR>
<P><CENTER><HR><FONT SIZE=2>[<A HREF="Tools1.html">Tools for Power 
contents]</A></FONT><FONT SIZE=2>[<A HREF="../Contents.html">Institute
on Independent Living contents</A>]</FONT></CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-196</DOCNO>
<DOCOLDNO>IA012-000125-B019-146</DOCOLDNO>
<DOCHDR>
http://www.independentliving.org:80/ToolsforPower/Tools9.html 193.13.228.238 19970216214035 text/html 3285
HTTP/1.0 200 OK
Last-Modified: Tue, 06 Aug 1996 20:02:52 +0000
Date: Sun, 16 Feb 1997 21:40:18 +0000
Expires: Sun, 16 Feb 1997 21:38:38 +0000
Content-type: text/html
Server: RoxenEnterprise/1.0
Content-length: 3060
</DOCHDR>
<HTML>
<HEAD>
    <TITLE>Institute_on_Independent_Living</TITLE>
</HEAD>
<BODY BGCOLOR="#ffffff">
<META NAME="description" 
CONTENT="Individuals and organizations of persons with disabilities can 
publish, free of charge,  articles, reports, training manuals, 
announcements, etc. on Independent Living, personal assistance, advocacy, 

peer support, accessibility, legislation and related subjects. "><META 
NAME="keywords" CONTENT="Independent Living, personal assistance, 
advocacy, peer support, direct payments, anti-discrimination legislation, 

accessibility, disability, disability rights">
<H4>Independent Living: <BR>
Ideology &amp; definitions <BR>
</H4>
<H2><CENTER>Resources</CENTER>
</H2>
<BR>
By the time this kit is ready for distribution, the BBC Education Service

will have produced a series of 5 one-hour television programs on 
disability
under the catchy title &quot;Labelled Disabled&quot;. One of these 
programs
will be on Independent Living featuring many of the persons, projects and

locations that you find here. The BBC will also produce a publication 
accompanying
the television programs. For details write to BBC Education Service, 
Villiers
House The Broadway, Ealing W5 2PA, United Kingdom.<BR>
<BR>
Berrol S, &quot;Independent Living Programs: The Role of the Able-Bodied
Professional&quot;, Arch Phys Med Rehabil, 60:456-457, 1979.<BR>
<BR>
The Independent Living Program movement was created by the disabled 
community.
It has established a broad coalition of diverse disabilities functioning
to provide services on a broader scale than has been traditionally 
offered
by the rehabilitation community. The effectiveness and the strength of 
the
movement lies in consumer control. The non-disabled professional can 
provide
expertise, balance and a vital link with established rehabilitation 
programs.
The integrity of the Independent Living program movement can only be 
maintained
and developed if these basic concepts are respected.<BR>
<BR>
Nosek, Peg, Yayoi Narita, Yoshiko Dart. A Philosophical Foundation for 
the
Independent Living &amp; Disability Rights Movement. Occasional Paper No.

1. Houston: ILRU Program, 1982.<BR>
<BR>
This monograph presents a personal reflection on the nature of 
Independent
Living. It includes a blend of philosophical concepts form many cultures
and critical lessons from personal experiences. The views are also shaped

by discussions the authors held with leaders of the Independent Living 
Movement.<BR>
<BR>
Address: ILRU at Texas Institute for Rehabilitation, 2323 S. Shepherd, 
Suite
1000, Houston, TX 77019, United States.<BR>
<BR>
DeJong, Gerben, &quot;Defining and Implementing the Independent Living 
Concept&quot;,
in Crewe, Nancy M. &amp; Zola, Irving Kenneth, Independent Living for 
Physically
Disabled People, Jossey-Bass Publishers, San Francisco, 1983. <BR>
<P><CENTER><HR><FONT SIZE=2>[<A HREF="Tools1.html">Tools for Power 
contents]</A></FONT><FONT SIZE=2>[<A HREF="../Contents.html">Institute
on Independent Living contents</A>]</FONT></CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-197</DOCNO>
<DOCOLDNO>IA012-000125-B019-247</DOCOLDNO>
<DOCHDR>
http://www.independentliving.org:80/ToolsforPower/Tools2.html 193.13.228.238 19970216214124 text/html 33994
HTTP/1.0 200 OK
Last-Modified: Tue, 06 Aug 1996 20:04:30 +0000
Date: Sun, 16 Feb 1997 21:41:16 +0000
Expires: Sun, 16 Feb 1997 21:39:36 +0000
Content-type: text/html
Server: RoxenEnterprise/1.0
Content-length: 33768
</DOCHDR>
<HTML>
<HEAD>
    <TITLE>Institute_on_Independent_Living</TITLE>
</HEAD>
<BODY BGCOLOR="#ffffff" TEXT="#030634" LINK="#00007f">
<META NAME="description" 
CONTENT="Individuals and organizations of persons with disabilities can 
publish, free of charge,  articles, reports, training manuals, 
announcements, etc. on Independent Living, personal assistance, advocacy, 

peer support, accessibility, legislation and related subjects. "><META 
NAME="keywords" CONTENT="Independent Living, personal assistance, 
advocacy, peer support, direct payments, anti-discrimination legislation, 

accessibility, disability, disability rights"><IMG 
SRC="../InstLogoSmall.gif"
WIDTH="198" HEIGHT="57" ALIGN="BOTTOM" NATURALSIZEFLAG="3"><BR>
<BR>
<BR>
Here a reprint of an old article in &quot;Psychology today&quot; for a 
flavor
of the original CIL,<BR>
Center for Independent Living.
<H2><CENTER>Declaring independence in Berkeley</CENTER>
</H2>
<H4><CENTER>by Sonny Kleinfield<BR>
</CENTER>
</H4>
<FONT SIZE="+3">A</FONT>t the Center for Independent Living in Berkeley,
California, one encounters the revolution in microcosm. From a crowded 
storefront,
disabled people of all kinds agitate in the community for better jobs and

housing. They also apply their talents to finding ways to help one 
another.<BR>
<BR>
They make revolutions in Berkeley. This is where the Free Speech Movement

and the People's Park struggles found their momentum. The hotbed of 
liberal
fervor. In more recent years, something new and positive has been 
happening
here. People with disabilities were clanking into town and living 
independent
lives. The reason for all the action, I was told almost reverently, was
the Center for Independent Living. <BR>
<BR>
The center crouched low on Telegraph Avenue. It had the look of a 
lawn-furniture
store from the outside, an unlovely affair with walls splashed with white

paint, wedged between Pancho Villa Mexican restaurant and a small parking

lot. With a staff of 120 people, half of them disabled, the center now 
serves
about 5,000 clients on an irregular basis. Every conceivable degree of 
disability
is handled, from the elderly who have mild mobility problems and need to
be bused, to the totally paralyzed.<BR>
<BR>
I walked inside. There was an imploded look to the place. Some 
individuals
in wheelchairs jostled along the hallways. Several people at the 
reception
desk were hugging phones and talking animatedly. The white hallway walls
were scuffed from wheelchairs whacking against them. They resembled 
retaining
walls at auto racetracks, dirtied from cars slewing out of control. From
an open office I heard a young woman, progressively going blind, 
tearfully
unloading her problems to a counselor. I checked out some of the many 
notes
thumbtacked to cork bulletin boards in the corridor. One read: 
&quot;Disabled
man seeks companion for headtripping, studying together, Scrabbles, etc.
Ray&quot;. Another: &quot;For sale, one chrome wheelchair. Used for three

months. $100. Call Peter.&quot; Another: &quot;For sale. 1977 Dodge van.
Built to drive from a wheelchair. Low mileage. Like new. Price: $10,000.
Call Mike.&quot; Another: &quot;Self-defense course. Become familiar with

your own areas of strengths and weaknesses and how to apply these to 
self-defense
techniques. The course will concentrate on using canes, crutches, and 
wheelchairs
as tools in self-protection. Starting March 6.&quot; If you were disabled

and needed help, this seemed to be the place to come. <BR>
<BR>
The mover and shaker behind the center was an outspoken and vigilant man
named Ed Roberts. In 1962, Roberts, a postpolio quadriplegic, became one
of the first severely disabled students to attend the University of 
California
at Berkeley. Not only was Roberts using a wheelchair, but he also needed
to spend most of his time inside an iron lung. He was put up at the 
Cowell
Hospital on campus. Within a couple of years Cowell became a haven for a
dozen seriously disabled students in what had turned into a formal 
program,
the Cowell Residence Program. The patients, however, found the hospital
custodial in nature. They rarely ventured off campus into the community,
the main reason being that the community was architecturally inaccessible

to them. A unity developed, with a dim sense of purpose. They began to 
entertain
the selfish, ambitious hope that they could get out of the hospital and
live like non-disabled folks. <BR>
<BR>
They decided to whip up some alternative to the Cowell arrangement. With
funds from the federal Office of Education, they created a Physically 
Disabled
Students' Program in 1970. lt was a sharp departure from past practice in

medical and rehabilitation fields. The notion was to assume a hostile 
approach
to society's limitations and to set up services directed at getting 
people
with disabilities to live independent lives. The philosophy of the nine
founding members was: these who best know the needs of persons with 
disabilities
are the disabled themselves; comprehensive programs are urgently needed
to meet those needs; disabled people must get out and get into the 
community.
<BR>
<BR>
As the founders began to sculpt and implement programs, they found the 
disabled
student population steadily swelling at Berkeley; more and more of these
students began to move from Cowell into the community. Requests for help
rose at an astonishing rate. Rarely were pleas turned away, even when 
they
came from nonstudents. By the spring of 1971, the amount of time devoted
to community people began to impinge seriously on the program's ability
to meet the needs of students. Thus was hatched the idea of a separate 
Center
for Independent Living to serve everybody. <BR>
<BR>
The particulars were hammered out for more than a year. The group was 
officially
formed in April of 1972. A roach-infested two-bedroom apartment was found

with haste on, appropriately enough, Haste Street. The organization had
one nagging problem: no money. Dollars were dug out of personal pockets,
some benefit poker games were arranged, but not until July of 1972 was 
the
financial squeeze settled. The Rehabilitation Services Administration 
produced
a grant for $50,000, enough to tide them over while other funds were 
secured.
<BR>
<BR>
Jerry Wolf, who use a walker to hobble about because of the effects of 
multiple
sclerosis, coordinates the housing department. He was my first stop. The
purpose of Wolf's department is to act as a listing agency of accessible
housing for persons with disabilities and an advocacy group to prod 
landlords
into making their housing accessible. The formidable hurdles it faces 
were
in black and white on a tattered map of Berkeley tacked to the wall 
behind
Wolf's desk. Shaded-in portions represented accessible housing. That 
meant
six or fewer steps to get in. Most of the town's perhaps 90 percent was
unshaded. One reason was that a ramp to surmount just six steps could 
cost
as much as $1,000. <BR>
<BR>
&quot;The general vacancy rate in Berkeley is just 1 percent,&quot; Wolf
said to me. &quot;Finding wheelchair-accessible places cuts the supply 
down
quite a lot. Anyway, rents are usually too high. They've gone up a good
deal lately, so that a two-bedroom is $200 or up. Finding a studio under
150 bucks is a feat of magic. We keep lists of people looking and try to
arrange roommates. That's the only way some of these people can afford to

put a roof over their heads.&quot; Wolf pointed out that although persons

with disabilities can apply for housing subsidies, they're tough to get
and insufficient as yet to keep pace with demand. <BR>
<BR>
Around 100 requests a month were streaming into the department, far too
many to fill. &quot;One of the problems we have is that Berkeley is being

advertised as a Utopia for disabled people,&quot; Wolf said. &quot;But 
not
enough housing is a available. People are literally flocking here from 
all
over the country. They are landing at the airport and calling us up. 
About
once a month someone pulls up outside in a taxi with all his belongings
and says, 'Here I am.' One person showed up with an assistant and we had
to put him in a hotel. His assistant left and he started asking bellhops
to empty his leg bag. The hotel kicked him out. We finally found him a 
place
with another assistant. People commonly show up with no money. One guy 
hitchhiked
here with his wheelchair.&quot;<BR>
<BR>
Wolf shook his head. &quot;The truth is, we're placing about eight to 10
people a month, though sometimes I'm surprised that we place anyone at 
all.&quot;
I wondered how successful Wolf had been in convincing landlords to make
the modifications that would render more dwellings accessible to persons
who have a disability. &quot;Mixed success,&quot; he said. &quot;A lot of

landlords are reluctant to do anything because they think ramps look 
ugly.
Then again, every so often we get a call from a landlord who wants to 
rent
to disabled people. He likes them because the turnover tends to be low.
One of the big problems is that no one provides money for modifications.
We try charitable organizations and private benefactors. We do get money
sometimes, but not much. lt's a case of twisting arms.&quot; New housing,

under law, is required to set aside a certain number of apartments 
accessible
to persons with disabilities. However, the law is useless if no housing
is going up. Berkeley hasn't seen any since 1972. Land is expensive; 
nobody
is buying. <BR>
<BR>
I walked outside and meandered through the parking lot to a cluster of 
garages.
This was where the van modification and wheelchair-repair departments 
were
housed. At the far end of the garages was a shop where wheelchairs were
fixed. &quot;We can fix 'most anything the same day,&quot; one of the men

in the shop said. &quot;You go to many places and they'll take weeks. 
Here,
if we take any length of time, we have chairs to loan out so these people

don't lose their mobility.&quot; Eight repairmen work in the shop, three
of whom ride chairs themselves. The shop does about $10,000 worth of 
repair
work a month. Wheelchair frames break constantly. &quot;We do a whole lot

of welding work,&quot; one of the men said. &quot;A regular user may be
in almost every week for repairs. These chairs are made terribly.&quot;
<BR>
<BR>
In a small room off the chair shop toiled Vance Grippi, design engineer.
Since late in 1975, he has been working to build the perfect wheelchair,
a superchair. If he has his way, extant wheelchair manufacturers can go
into the lawnmower business. His chair will be the best. Taped on the 
wall
was a gigantic artist's rendition of it. &quot;You know, nobody has given

a thought to the mobility of disabled people ,&quot; Grippi said, playing

with a pencil. &quot;Nobody cares about building a better chair. Well, I
care. We talked to a lot of disabled people and most of them were unhappy

with what they were riding. The speed, the range, the reliability, the 
flexibility.
They really had no voice in what they needed. 'Here's a wheelchair,' they

were told; 'take it or leave it.' Wheelchairs, understand, are their 
legs.
We started with a clean sheet of paper.&quot; <BR>
<BR>
He pointed out some of the features of the superchair. lt will have a 
cast
frame that will be much sturdier. State-of-the-art technology will be 
incorporated.
Grippi has designed an electric system that he claims will be much more
reliable than conventional system. &quot;Most chairs will go four or five

miles an hour and 10 or 12 miles before the battery needs charging,&quot;

he said. &quot;Ours will go six miles an hour and 30 miles without 
charging.
We've got a totally solid-state system, rather than a relay system.&quot;

<BR>
<BR>
The chair will be adjustable to handle any size person. With a 
traditional
chair, you have to pull the armrests out of the sockets and toss them on
the floor to transfer out of the seat. In Grippi's chair, the rests will
pivot downward electronically. The wheels are sturdier. And the chair is
being constructed out of standard equipment that you can get anywhere. 
For
instance, it uses Schwinn bicycle tires and an ordinary automobile 
battery.
Everest and Jennings has its own tires and batteries. The model is 
expected
to be out sometime in late 1980. <BR>
<BR>
That night I ate dinner with Phil Draper and Judy Heumann - executive 
director
and associate director, respectively, of the center. Both are 
quadriplegics.
The Chinese restaurant was a tiny, dimly lit place. A half-dozen young 
people
were crammed into the small room, their leathery faces and rumpled 
clothes
blending with the dun-colored walls. Because of its proximity to the 
center,
the restaurant often was patronized by disabled people, and so fellow 
diners
paid us no particular mind. Draper used a fork that was strapped to his
wrist with an Ace bandage. But he could shovel food down pretty fast. The

wheelchair doesn't disguise Draper's owlish, rabinical bent. He speaks,
not with soapbox intensity, but softly, with an almost mournful tone.<BR>

<BR>
I asked Draper and Heumann how they spent their time. &quot;The 
administration
of CIL devotes most of its time to looking for money,&quot; Draper said
unhappily. &quot;It's a hard sell. It shouldn't have to be that way. 
We're
not eating the money. This is a damned good cause. You find me a better
one.&quot; The center was operating on a yearly budget of approximately
$1.2 million, money extracted from about 25 different sources. &quot;We
have tapped every conceivable source,&quot; Draper said. &quot;One of the

biggest problems is that we have no permanent source for funding. So it's

soft money. Most places fund for a year and that's it. Social-service 
programs
have a high mortality rate.&quot;<BR>
<BR>
I asked them how the movement was going. &quot;One thing that's very 
important,&quot;
Draper said, &quot;is the collectiveness, people working together. That's

how they got their strength. Activism is found in only a few places in 
this
country. We need more involvement. Too many disabled people are still 
sitting
in their attics and reading old comic books. They've got to start 
shouting.&quot;
Heumann is a petite woman with a positive, earnest manner. She is 30. She

was once arrested on an airplane for refusing to get off after she and 
her
wheelchair had been cleared to fly. She went to court and won.<BR>
<BR>
&quot;I think the movement lies in the hands of disabled 
individuals,&quot;
she said. &quot;I am concerned that not enough people understand the 
Independent
Living program. One of the reasons I think CIL is so successful is 
because
it's run by disabled people. Our clients have hope when they see other 
disabled
people managing their own lives. I don't know that the government is 
pleased
that disabled people run these programs. Disabled people need to be much
more militant about this. I think the next few years are going to be 
critical
in the development of the movement. In a sense, the movement is just 
beginning.&quot;<BR>
<BR>
Are more demonstrations needed? &quot;More involvement,&quot; Draper 
said.
&quot;Just more involvement.&quot; Heumann was crisp and downright. 
&quot;We
need more demonstrations. We still have many scores to settle.&quot; The
center's Law Resource Center is housed in a shopworn building across the
street from the main building, and the next morning, I went there to talk

to the program's director. Mismatched desks and chairs and bookshelves 
were
spaced around the room. The floor was much scuffed up; track marks from
wheelchairs were plainly visible. Old Congressional Records and Federal
Registers were piled high on the floor. Coffee was percolating in a 
percolator.
A spider plant was hanging in the window.<BR>
<BR>
The director of the law center, Bob Funk, is a lawyer, one of two in the
department. We sat and talked in a small airless room. &quot;Our goal 
here
is to be a backup to a lot of community groups,&quot; Funk said. 
&quot;We're
agitating to get disabled folks to be more assertive. To have them know
they can raise hell.&quot;<BR>
<BR>
A good deal of what the office does is to explain the laws and rights of
disabled people. It will also file suits and negotiate settlements. Funk
said three suits were in court at the moment, and six were about to be 
filed.
Three previous suits had already run their course, all successful for the

center. He said he was trying to help about 160 clients at the moment, 
the
vast majority of them complaining about discrimination of one form of 
another.
Funk rattled off some recent cases. Three local restaurants wouldn't 
serve
customers riding wheelchairs. A waiter at one of them flatly said, 
&quot;We
don't serve wheelchairs.&quot; The second restaurant said it would serve
the person if he sat in an isolated walkway that joined the place to a 
coffee
shop. The third place refused service because it said the person was too
disturbing a presence. He was in a wheelchair folding out like a bed. 
&quot;He
would be disturbing,&quot; Funk said. &quot;But that's tough. That's the
law.&quot;<BR>
<BR>
Complaints were reaching the center about auto-insurance firms charging
disabled people 30 to 50 percent higher rates than non-disabled people,
though documentation makes clear they aren't greater risks. Funk said a
class-action suit was being readied against one immense insurance firm.
&quot;We are clearly in the right in almost every case we get,&quot; Funk

said. &quot;They're blatant cases of discrimination. Not even subtle 
discrimination.
They haven't a chance in court. Discrimination is such a traditional 
thing
in this country that these people don't even realize they're 
discriminating.
We can't possibly lose most of these cases. In fact, we're forced into 
court
a lot more often than we should be.&quot;<BR>
<BR>
Funk laughed at the thought of how ridiculously simple most of the cases
were. &quot;What's likely to happen is that, at first, all of the cases
will be blatant. Then, they'll get subtler and subtler. People will get
more sophisticated in their discrimination. Restaurants will refuse to 
serve
a disabled person, but say the reason is that he's rowdy or doesn't have
a tie on. The disability won't even be mentioned. This happened with the
civil rights movement, and took 20 years to run its course. The same will

happen with disabled people.&quot;<BR>
<BR>
Anna Steiner is a beautiful woman with raised eyebrows and poignant 
circles
of pure white skin around her eyes. Her only disability is a bad case of
arthritis. She's in her 30s and has an infirmity most people don't get 
until
their 60s. She heads the center's job-development program, which faces 
the
awesome task of trying to get jobs for disabled people. &quot;Basically,
we're a placement service,&quot; Steiner said to me. &quot;Somebody has
to come in here with some education, skills, abilities that could be 
translated
into jobs. We've had lawyers. We've had a person who was a missionary. 
We've
had a talented artist. We're mostly working with physically disabled 
persons,
but we're expanding into the mentally disabled .&quot;<BR>
<BR>
The program has a caseload of 125 clients, Steiner said. Since the 
program
began in the fall of 1975, the placement rate has hovered around 40 
percent,
she said, though it had of late nudged up to 60 percent. She spoke of 
some
unusual cases. A blind janitor had been placed in a nearby town. 
&quot;This
was one of the cases where I said, no way, there's just no way for this
one.&quot; The man told Steiner that he had experience scrubbing his 
father's
laundromat. He was totally blind in one eye and legally blind in the 
other.
How would he clean a room? He said he would scout out the premises in 
advance
until he knew the area by memory. How would he tell what was dirty and 
what
was clean? He said he would assume everything was dirty and clean it all.

Steiner said that a man with muscular dystrophy got a job doing drafting
for the Navy. The only necessary concession was a lower drafting 
table.<BR>
<BR>
&quot;We work a lot with employers, too,&quot; Steiner said. 
&quot;Basically,
we try to advocate for disabled people in general. We don't go in and 
say,
&quot;Hey, you're really stupid to have the kind of attitude you have.'
We're subtler than that. We generally work with personnel people, who are

sympathetic, because they don't have to work with disabled people. We'll
do whatever is needed to help the employers. We'll check out the work 
environment
to see what modifications are necessary. We'll help draft 
affirmative-action
plans. We're getting a lot more interest from employers worried about the

law.&quot;<BR>
<BR>
Tanya Temporal, a counselor in the research and demonstration project, 
sat
on top of a desk on the first floor, beneath the blind-services 
department.
She was finishing a staff meeting. Temporal counsels severely disabled 
people.
The project she is a part of hopes to prove that peer counseling works 
better
than any other kind. Her short frame and lean, cheerful face belongs in
California; her hair, wild and electric, looks fine in Berkeley. She's in

her early 20s, and prematurely gray. Her conversation is a stream of 
information,
a Niagara of words that, even so, somehow seems laconic. She smiles 
quickly
and steadily.<BR>
<BR>
&quot;One of the main things we do is emotional counseling,&quot; she 
told
me. &quot;Getting people to deal with their disability and to accept it.
We have five part-time counselors, and each one handles about 10 clients.

We have a caseload, altogether, of about 80 clients.&quot; She talked 
about
her most difficult case at the moment: a 23-year-old girl with severe 
cerebral
palsy who was living in an institution. Her speech is extremely difficult

to understand.<BR>
<BR>
&quot;I'm dealing with her on an emotional level,&quot; Tanya said. 
&quot;I'm
not telling her. I'm allowing her to discover. A lot of time we 
role-play.
'Okay, here we are in your apartment. I know you like to bowl. Let's go
over how you'll set up a bowling appointment. Who are you going to call?'

I've got to get her to demand to go out and do things, not wait around 
for
others to ask. She hasn't really accepted her disability. She views it as

a burden that God has placed on her. She believes that by God's magic 
power
she'll recover some day. She's very religious. I try not to discourage 
that
belief altogether. I try to tell her, okay, for today you're not going to

get better. What can we do today?&quot;<BR>
<BR>
Tanya studied human development in college. For 13 years, she has had 
rheumatoid
arthritis. She has no idea why she got it. She has no pain, but has 
trouble
walking and holding things. She occasionally resorts to a wheelchair. 
&quot;I
have accepted my disability,&quot; she said. &quot;I can't say I don't 
get
angry when I drop something on the floor and can't pick it up. But I 
don't
let anger overtake me. I'm not going to paint the picture of the Super 
Crip.
Some people make it out that they're the Super Crip and it's wonderful to

be disabled. But you can still be a whole person, still be a happy 
person.&quot;<BR>
<BR>
I went next to another hive to chat with Lon Kuntze. He, too, is in his
early 20s, a big, broad-shouldered man with frizzy hair and a beard. Deaf

since birth, he runs the deaf-services program. He nodded hello when I 
came
by. Lynette Taylor, the center's staff interpreter, was to assist in our
interview, though she was preoccupied with some phone calls. Kuntze 
suggested
we begin by writing questions and answers on a legal pad.<BR>
<BR>
&quot;The biggest problem for deaf people,&quot; he wrote, &quot;is, of
course, communications. Deaf people are the only disabled group that 
can't
regularly use the phone.&quot; The only way deaf people can talk, Kuntze
explained, is by use of what are known as TTYs. Basically old 
teletypewriters
that, by use of a jack, can be hooked to a phone line, they clack out in
written form what conversation is to be exchanged. They aren't cheap and
they aren't readily available, so even if a deaf person could get hold of

one, he couldn't call very many people. Some federal offices have 
installed
them, as has the phone company at a few of its service centers. One of 
the
troubles is that it's an agonizingly slow way to talk, yet anyone talking

over a TTY pays standard phone rates. A popular deaf person can run up 
staggering
bills. <BR>
<BR>
Lynette finished with her calls, and came over to interpret. Her mother
was deaf, so she picked up sign language early on. Kuntze was relieved;
he was getting a writing cramp. &quot;Deafness is a disability on the 
communications
level, whereas other disabilities are on a physical level,&quot; Kuntze
said. &quot;Deaf persons can't deal with people who don't know sign 
language.
The best remedy for the communications problem is interpreters. The 
biggest
trouble is there aren't enough interpreters, and there's no money for 
interpreters.
They cost up to $10 an hour. Most of them get $7.50. Court work costs 
$15.
The money, from their standpoint, is terribly low. It should be equal to
foreign-language interpreters, who get $15 to $35 an hour. That's why 
more
interpreters haven't been attracted to the field. Deaf interpreters 
simply
don't get a decent wage.&quot;<BR>
<BR>
My last visit was with the community affairs department. Its aim is to 
address
community issues and to inspire demonstrations when it senses the need.
I spoke with Kitty Cone, who has muscular dystrophy, and with Hale Zukas,

whose cerebral palsy is so severe that he has but limited use of his 
hands
and can barely utter intelligible speech. When he gets bogged down, he 
spells
out his thoughts with a brisk tapping of the pointer. The back of his 
wheelchair
sports a button reading: &quot;ACCESS AMERICA.&quot;<BR>
<BR>
Of late, the department had been working at mobility and architectural 
issues.
Thumbtacked on the wall were two immense maps, one of Berkeley and one of

Oakland. Black dots were inked in where ramps or curb cuts had been made.

Berkeley looked pretty good, but Oakland had a long way to go before it
could be called an accessible city. &quot;We are working quite a bit on
transportation issues,&quot; Kitty said. Hale began to struggle, wanting
to say something. I couldn't understand his grunting. Saliva drooled down

his beard and onto his clothes. Kitty had to interpret. &quot;Hale says,
'Boy, do we work on transportation. We're suing everybody in the 
world.'&quot;<BR>
<BR>
Paramount to all severely disabled people is the issue of getting around.

For long distances, matters have improved since the Federal Aviation 
Administration
ruled in May of 1977 that airlines can't deny seats to disabled 
individuals.
It had ben common practice for the airlines to boot disabled people off
planes, contending that they might hamper evacuation procedures should 
there
be an emergency. Now, all airline personnel are required to be properly
schooled in ways of assisting disabled people. Several cruise ships have
started to take wheelchair travelers. The first ocean liner so designed,
the Queen Elizabeth II, boasts nine staterooms that were made for 
disabled
passengers. Thirteen elevators are on the ship. Some of Amtrak's trains
can accommodate wheelchair riders in certain bedrooms, and these trains
offer accessible bathrooms. Stations are being built barrier-free. Hertz
and Avis have hand-control cars at some of their locations, and the newer

highway rest areas accommodate disabled people. For lodging, Holiday Inns

is making one in every 100 rooms accessible to the disabled 
population.<BR>
<BR>
Local travel, though, is something else again. Wheelchair users can't 
very
well hop into taxis. Subways, with the exception of the San Francisco, 
Washington,
and Atlanta lines, aren't available to the severely disabled. And no 
available
evidence suggests they ever will be. Elevators would be needed, and the
cost is prohibitive. Public busses aren't much better, since their floors

are around 35 inches above street level. A protracted battle, involving
a spate of suits by disabled groups, resulted in an order in May of 1977,

from Transportation Secretary Brock Adams, requiring that busses with 
22-inch
floors-called Transbusses-be produced by 1979. Twenty-two inches is about

as low as busses can be made without having them scrape the ground when
climbing hills or going over bumps. The busses would also have to include

ramps that would shoot out from underneath to allow wheel-chair riders 
and
mobility-hampered individuals to come aboard.<BR>
<BR>
Disabled people, however, aren't exactly ablaze with enthusiasm over the
Transbusses. For one thing, the low-floor busses won't start rolling down

city streets until 1981 or 1982, and a complete transition will take a 
good
deal longer. The old busses must first wear out. What's more, how are 
disabled
people going to get from their homes and offices to the nearest bus 
stops?<BR>
<BR>
The center was in the midst of a suit against AC Transit, the biggest bus

line in the Berkeley area, for failing to order accessible busses, as 
required
by a California law, as well as by the federal order. AC owns a fleet of
about 800 busses. As I talked with Kitty and Hale, a big AC bus rumbled
past. &quot;Let us ride your bus,&quot; Kitty shouted out the window. 
Hale
laughed loudly and nodded his head in agreement.<BR>
<BR>
Another transportation issue had to do with BART (Bay Area Rapid 
Transit).
One of the three accessible subway systems in the country, BART was 
planning
to automate a lot of its stations by withdrawing agents and monitoring 
stations
through closed-circuit TV. The disabled people were aghast at the 
prospect.
They sometimes needed help to pay their fares, and if someone has an 
epileptic
seizure or a blind person falls on the tracks, no agent would be 
available
to assist. The main issue is safety, though, since disabled people fear
that muggings and rapes would climb at an alarming rate. So Kitty and 
Hale
were orchestrating protests to pressure BART into abandoning the idea. 
Pickets
and rallies were being planned. &quot;We don't want to badmouth BART, 
because
they are accessible to us,&quot; Kitty said. &quot;But this just isn't 
going
to happen. No automation. Automation is for the birds.&quot; <BR>
<BR>
Kitty then related a horrifying story that illustrated the inequities in
the benefits system for people with disabilities. A 27-year-old woman 
named
Lynn Tompson who had muscular dystrophy lived with an assistant in Los 
Angeles.
Most of her medical expenses were being picked up by Supplemental 
Security
Income Payments. In general, Social Security laws define a disabled 
person
as someone who can't engage in &quot;substantial gainful activity.&quot;
Such activity, according to these laws, is any enterprise generating an
average income of $200 a month over a nine-month stretch. That means, in
effect, that someone who can't budge a muscle below his chin, but who 
holds
a job paying a mere $200 a month, isn't disabled in the eyes of the law,
and thus isn't eligible for the SSI program or for Medicaid and other 
benefits.
It's a rotten system, disabled people agree.<BR>
<BR>
Without paying staggering premiums, severely disabled people can't get 
conventional
medical coverage. The architects of the welfare laws plainly never 
imagined
that severely disabled people might earn a salary. Under current laws, 
they
would have to either make a pretty scant income and get benefits to help
out, or else earn a fairly hefty salary.<BR>
<BR>
Lynn Tompson wasn't happy sitting in her apartment and rotting away. So
she started working as a dispatcher. Eventually, she worked her way up to

an income of $500 a month, hardly enough to meet all her bills by itself,

but she was gaining some freedom. Social security people stopped in one
day to check up on her and discovered her extra income. She hadn't 
reported
it to them. Her payments were immediately cut off. What's more, she was
notified that she owed $10,000 in back payments that had been made to 
her.
The only way she could live would be to go to a nursing home. Instead, in

February of 1977, she committed suicide. She left a note saying that her
death could be blamed on Social Security.<BR>
<BR>
One of the cruel ironies of the case was the fact that, unbeknownst to 
Lynn,
California had recently passed a measure allowing disabled people to draw

medical coverage, as well as funds to pay for personal assistance, while
they're working. The law established a graduated scale so that, beyond a
certain income, a person chips in part of his expenses and the state 
furnishes
the rest. Disability groups are trying to persuade other states to follow

that precedent. &quot;The tragedy of this story,&quot; Kitty said, 
&quot;is
that Lynn Tompsons can be found all over the country. California has done

something to rectify the benefits problem, but what are other states 
doing?
Disabled people must scream at their legislators to start moving, because

the laws are sending us to psychological deaths.&quot;<BR>
<BR>
Early the next morning, I caught a plane out of San Francisco, leaving 
the
center behind. Beyond doubt, I had returned to the &quot;real&quot; 
world.
I checked carefully the passengers aboard my crowded United Airlines 
flight.
Not o one was disabled.<BR>
<BR>
Source: Psychology today <BR>
<P><CENTER><HR><FONT SIZE=2>[<A HREF="Tools1.html">Tools for Power 
contents]</A></FONT><FONT SIZE=2>[<A HREF="../Contents.html">Institute
on Independent Living contents</A>]</FONT></CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-198</DOCNO>
<DOCOLDNO>IA012-000125-B019-315</DOCOLDNO>
<DOCHDR>
http://www.independentliving.org:80/ToolsforPower/Tools1.html 193.13.228.238 19970216214152 text/html 8484
HTTP/1.0 200 OK
Last-Modified: Tue, 06 Aug 1996 20:05:10 +0000
Date: Sun, 16 Feb 1997 21:41:50 +0000
Expires: Sun, 16 Feb 1997 21:40:10 +0000
Content-type: text/html
Server: RoxenEnterprise/1.0
Content-length: 8259
</DOCHDR>
<HTML>
<HEAD>
    <TITLE>Institute_on_Independent_Living</TITLE>
</HEAD>
<BODY BGCOLOR="#ffffff" LINK="#00006b">
<META NAME="description" 
CONTENT="Individuals and organizations of persons with disabilities can 
publish, free of charge,  articles, reports, training manuals, 
announcements, etc. on Independent Living, personal assistance, advocacy, 

peer support, accessibility, legislation and related subjects. "><META 
NAME="keywords" CONTENT="Independent Living, personal assistance, 
advocacy, peer support, direct payments, anti-discrimination legislation, 

accessibility, disability, disability rights">
<H2><IMG SRC="../InstLogoSmall.gif" WIDTH="198" HEIGHT="57" 
ALIGN="BOTTOM"
NATURALSIZEFLAG="3"></H2>
<H2><CENTER>Resource Kit for Independent Living</CENTER>
</H2>
<H1><CENTER>TOOLS FOR POWER</CENTER>
</H1>
<H3><CENTER><FONT SIZE="+3">D</FONT>isabled <FONT 
SIZE="+3">P</FONT>eoples'
<FONT SIZE="+3">I</FONT>nternational<BR>
<FONT SIZE="+3">I</FONT>ndependent <FONT SIZE="+3">L</FONT>iving <FONT 
SIZE="+3">C</FONT>ommittee<BR>
April 1992</CENTER>
</H3>
<H3><HR><FONT SIZE="+3">T</FONT>able of <FONT 
SIZE="+3">C</FONT>ontents</H3>
History of the Independent Living Movement 
<DL>
  <DD><A HREF="Tools2.html">Declaring independence in Berkeley by Sonny
Kleinfield</A> 
  <DD><A HREF="Tools3a.html">Power to the people by April D'Aubin</A> 
  <DD><A HREF="Tools3b.html">Divisions in the disability community by 
David
Pfeiffer</A> 
  <DD><A HREF="Tools3c.html">The challenge of middle age for the 
Independent
Living Movement by Gerben DeJong</A> 
  <DD><A HREF="Tools4.html">Resources</A> 
</DL>
Independent Living: Ideology &amp; definitions 
<DL>
  <DD><A HREF="Tools5.html">Possibilities of Independent Living of 
persons
with disabilities in Africa by Felix Silwimba</A> 
  <DD><A HREF="Tools6.html#anchor427066">The Disability Rights Movement
- its development in South Africa by Kathy Jagoe</A> 
  <DD><A HREF="Tools7.html">Independent Living: a European definition</A>

  <DD><A HREF="Tools8.html">An American definition of Independent 
Living</A>
  <DD><A HREF="Tools9.html">Resources</A> 
</DL>
Personal accounts 
<DL>
  <DD><A HREF="Tools11.html">What is your personal definition of 
Independent
Living?</A><BR>
<A HREF="Tools11.html#anchor147530">Is your current lifestyle an example
of Independent Living?</A> 
  <DD><A HREF="Tools11.html#anchor7520592">What obstacles did you have to

surmount in order to achieve your current lifestyle?</A> 
  <DD><A HREF="Tools11.html#anchor7524831">What governmental and 
community
changes do you believe are required to facilitate Independent Living 
efforts?</A>
  <DD><A HREF="Tools11.html#anchor7529602">What recommendations do you 
have
for other disabled citizens?<BR>
</A><A HREF="Tools11.html#anchor7535356">Interview with Mr. Javed Hassan,

Pakistan, with commentary by Mr. Phil Mason, UK<BR>
</A><A HREF="Tools12.html">Resources</A> 
</DL>
Advocacy 
<DL>
  <DD><A HREF="Tools13a.html">Disability issues: organizing community 
support
</A>
  <DD><A HREF="Tools13b.html">Preserving disability civil rights: a 
step-by-step
guide to taking action</A> 
  <DD><A HREF="Tools14.html">Resources</A> <A NAME="anchor826091"></A>
</DL>
Personal assistance 
<DL>
  <DD><A HREF="Tools15.html">What is personal assistance? </A>
  <DD><A HREF="Tools16.html">Employing your own personal assistant </A>
  <DD><A HREF="../ENIL/ENILStrasbourgResolutions.html">&quot;The 
Strasbourg
Resolutions&quot; on how to design systems for independence </A>
  <DD><A HREF="Tools18.html">Developing assistants management skills </A>

  <DD><A HREF="Tools19.html">Concepts for Independence, Inc. - a unique
approach to personal assistance </A>
  <DD><A HREF="Tools20.html">A comparison of some of the characteristics
of two models of personal assistance services </A>
  <DD><A HREF="Tools21.html">Resources </A>
</DL>
Peer support 
<DL>
  <DD><A HREF="Tools22.html">Peer counseling: an overview </A>
  <DD><A HREF="Tools23.html">Peer counseling programs: observations from
the field </A>
  <DD><A HREF="Tools24.html">Resources </A>
</DL>
Women, sexuality, old persons, people with various disabilities 
<DL>
  <DD><A HREF="Tools25.html">Disability, women and love by Junka Asaka 
</A>
  <DD><A HREF="Tools26.html">Independent Living for various disability 
categories
</A>
  <DD><A HREF="Tools27.html">A brief history of brokerage by Craig V. 
Shields
</A>
  <DD><A HREF="Tools28.html">Independent Living Movement: organizing for
an active, disabled old age by Judith E. Heumann </A>
  <DD><A HREF="Tools29.html">The changing role of the People First 
advisor
by Charles Curtis </A>
  <DD><A HREF="Tools30.html">Resources </A>
</DL>
Employmen/Self-employment 
<DL>
  <DD><A HREF="Tools31.html">Self Help Association of Paraplegics, SHAP,
Republic of South Africa </A>
  <DD><A HREF="Tools32.html">Manufacturing assistive devices in 
developing
countries </A>
  <DD><A HREF="Tools33.html">Turning a service into an income generating
project</A> 
  <DD><A HREF="Tools34.html">Resources </A>
</DL>
Housing adaptation 
<DL>
  <DD><A HREF="Tools35.html">Toward a barrier-free home </A>
  <DD><A HREF="Tools36.html">Resources </A>
</DL>
Research &amp; evaluation 
<DL>
  <DD><A HREF="Tools37.html">ILRU Research &amp; Training Center on 
Independent
Living at TIRR </A>
  <DD><A HREF="Tools38.html">Independent Living as a state of mind by 
Gerben
DeJong <BR>
</A><A HREF="Tools39.html">The World Institute on Disability </A>
  <DD><A HREF="Tools40.html">Resources </A>
</DL>
<P><CENTER><HR></CENTER>
<H3>Editor's preface</H3>
<BR>
<BR>
<FONT SIZE="+3">T</FONT>he &quot;Resource Kit for Independent Living 
1992&quot;
is a first attempt. Its purpose is to illustrate some of the 
possibilities
such a kit can offer and to show the direction in which it can 
develop.<BR>
<BR>
The resources presented here represent a very limited and biased sample
of all the materials that exist. Limited, because we had very little time

and money in the production; biased, because we are not aware of all 
groups/organizations,
and finally, only a small percentage of those asked to respond supplied
us with information. <BR>
<BR>
The Independent Living Movement and its ideology exist in many more 
countries
than are represented here. For this issue we received hardly any material

from outside North America and the United Kingdom. In the future, we hope

to have resources to be able to translate and edit texts from and into 
other
languages.<BR>
<BR>
The aim of the &quot;Resource Kit&quot; is threefold: 
<UL>
  <LI>to empower disabled individuals and organizations of disabled 
persons
by providing them with easily accessible information on Independent 
Living
philosophy and approach, model projects, and sources of technical 
assistance
in organizing grass-root initiatives, 
  <LI>to serve as a handbook for professionals working in such areas as
community planning, social policy and services, rehabilitation, and 
vocational
training, 
  <LI>to aid NGO's in their disability work and to inform potential 
sponsors
about the innovative approach that Independent Living entails for the 
equalization
of opportunities for persons with disabilities. 
</UL>
Present plans are to update and publish a new issue of the &quot;Resource

Kit for Independent Living&quot; every third year. We hope that there 
will
be more and more people with disabilities from a growing number of 
countries
joining the Independent Living network, that we will start new projects,
expand into new areas, produce more documents and find new and better 
tools
to empower ourselves.<BR>
<BR>
In this sense we hope that any edition of the &quot;Resource Kit on 
Independent
Living&quot; will be outdated as soon it is printed.<BR>
<BR>
April 1992<BR>
<BR>
for the Independent Living Committee of Disabled Peoples' 
International<BR>
<BR>
Adolf D. Ratzka, Ph.D<BR>
Institute on Independent Living, <BR>
Petersens V&auml;g 2<BR>
127 41 Stockholm-Sk&auml;rholmen<BR>
Sweden, Fax 46 8 740 4500<BR>
e-mail <A 
HREF="mailto:ratzka@independentliving.org">ratzka@independentliving.org</
A><BR>
<P><CENTER><HR><FONT SIZE=2><A HREF="../Contents.html">[Institute on 
Independent
Living contents</A><A HREF="../index.html">]</FONT></A></CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-199</DOCNO>
<DOCOLDNO>IA012-000125-B019-376</DOCOLDNO>
<DOCHDR>
http://www.independentliving.org:80/ENIL/ENILStockholmSem1.html 193.13.228.238 19970216214217 text/html 22672
HTTP/1.0 200 OK
Last-Modified: Wed, 31 Jul 1996 19:11:10 +0000
Date: Sun, 16 Feb 1997 21:42:23 +0000
Expires: Sun, 16 Feb 1997 21:40:43 +0000
Content-type: text/html
Server: RoxenEnterprise/1.0
Content-length: 22446
</DOCHDR>
<HTML>
<HEAD>
    <TITLE>ENILStockholmSem1.html</TITLE>
</HEAD>
<BODY BGCOLOR="#ffffff" LINK="#00003d" TEXT="#000038">
<H3><IMG SRC="ENILlogoblues.gif" WIDTH="311" HEIGHT="61" ALIGN="BOTTOM" 
NATURALSIZEFLAG="3"><BR>
<BR>
</H3>
<H2><CENTER>Third ENIL Seminar<BR>
Stockholm, Sweden <BR>
June 1991</CENTER>
</H2>
<H4><CENTER>Organizer: ENIL, European Network on Independent Living<BR>
Host: <A HREF="../STIL/STILEnglish.html">STIL</A>, Stockholm Cooperative 
for Independent
Living<BR>
<BR>
<HR></CENTER>
</H4>
<H2>Table of Contents</H2>
<DL>
  <DD><A HREF="#anchor2862569">Preface</A> 
  <DD><A HREF="#anchor2863159">Background to the Seminar</A> 
  <DD><A HREF="#anchor2882503">Aims</A> 
  <DD><A HREF="#anchor2882698">Approach</A> 
  <DD><A HREF="#anchor2883036">Topics</A> 
  <DD><A HREF="#anchor2865062">Opening address by Kalle 
K&ouml;nkk&ouml;l&auml;</A>
  <DD><A HREF="#anchor2865789">Principles of Independent Living by Adolf
Ratzka</A> 
  <DD><A HREF="ENILStockholmSem2.html">Disability in Bulgaria: crisis due

to the transition to a market economy by Gallina Atanassova</A> 
  <DD><A HREF="ENILStockholmSem2.html#anchor2902199">Berliner Zentrum 
f&uuml;r
Selbstbestimmtes Leben behinderter Menschen e.V.</A> 
  <DD><A HREF="ENILStockholmSem2.html#anchor2903034">Club Contacts, 
Moscow
by Ekaterina Kim</A> 
  <DD><A HREF="ENILStockholmSem3.html">Alternative forms of fundraising
by Ulf Andersson</A> 
  <DD><A HREF="ENILStockholmSem3.html#anchor2952551">Alternative forms of

fundraising continued by J&ouml;rn Hammarstrand</A> 
  <DD><A HREF="ENILStockholmSem4.html">Conslusions from the ENIL 
Seminar</A>
  <DD><A HREF="ENILStockholmSem4.html#anchor2964607">Presentation of the
host organizer</A> 
  <DD><A HREF="ENILStockholmSem4.html#anchor2969718">List of 
participants</A><A NAME="anchor2862569"></A> 
</DL>
<H2><CENTER><HR></CENTER>
</H2>
<H2>Preface</H2>
<BR>
<FONT SIZE="+3">T</FONT>he third ENIL Seminar held in June 1991 was 
organized
on a shoestring budget. Our guests were put up at STIL members' homes and

shared food and transportation with them. At times conditions were 
somewhat
crowded. There are definite advantages to learning about Independent 
Living
from each other while waiting in line to get to your own toilet! <BR>
<BR>
We first had other plans for the documentation of the Seminar. In the end

it had to be done by volunteers who typically take their time.<BR>
<BR>
The participants from Central and Eastern Europe did not seem to mind the

tight budget and the makeshift organization of the whole. They seem to be

quite used to improvization. I think, here is something very important 
for
all of us in the richer countries to learn: rely on group dynamics, trust

in people's ability to learn from each other, do not get uptight about 
timetables
and programs. Keep events small and inexpensive, see a virtue and a 
necessity
in spontaneity and improvisation.<BR>
<BR>
The theme of the Seminar was to be &quot;Alternative forms of 
fundraising&quot;.
It soon turned out that we had severe language difficulties. I am not 
only
referring here to the need for interpreting every sentence first to 
English
and then back to Italian, Russian, Swedish, Czech, Bulgarian and German.
Here went my first preconceived notion: I had expected everybody from 
Central
and Eastern Europe to speak Russian. <BR>
<BR>
How to explain the Independent Living philosophy to people who need just
about everything that I am taking for granted in my part of the world, 
such
as food, housing, health care ? Our critique of our system of service 
delivery
for assistive devices or personal assistance does not carry much weight
in the eyes of someone who has to wait two years or more to get a 
wheelchair
in a society where everybody takes it for granted that the family 
&quot;takes
care of&quot; you until the bitter end. It is easy for us Westerners to
claim that Independent Living is a mind set, not a shopping list of 
material
goodies. <BR>
<BR>
The biggest language barrier, however, was that even when we thought we
understood the words somebody used we still did not grasp the concept 
that
was to be conveyed. Take the idea that organizations of people with 
disabilities
should start businesses in order to create employment for members and 
hopefully
create some profits which can be used to organize the disability 
community.
Try to explain to somebody from Russia that profits are not the automatic

result of all economic activity. Our friends from Moscow assumed that as
long as you have a company and produce anything, you are bound to make 
plentiful
profits. When you try to show them that one first has to have a good 
product,
an efficient form of production and distribution, competitive quality and

a better price than the guy next door, they probably think that you are
a hopeless leftist who wants to talk them out of embracing the market 
economy.<BR>
<BR>
The Seminar did not spend much time on alternative forms of fundraising.
We found other, more immediate needs to talk about. Unfortunately, we 
could
not record our very interesting discussions with the amazing and often 
enlightening
misunderstandings we created for each other. We did learn a lot from each

other though and I am looking forward to the next event of this kind.<BR>

<BR>
Adolf Ratzka,<BR>
Editor <BR>
<P><CENTER><A NAME="anchor2863159"></A><HR></CENTER>
<H3><CENTER>Planning Seminar with representatives of disability 
organizations
<BR>
from Eastern and Central Europe in Stockholm, June 17-19, 1991</CENTER>
</H3>
<H4>Background</H4>
<FONT SIZE="+3">I</FONT>n countries with severe economic problems and 
where
disability issues have been neglected, organizations of disabled persons
have great difficulties in raising the necessary funds for their 
activities.<BR>
<BR>
Traditional fundraising methods consist of approaching charitable 
organizations,
corporate sponsors, governments and international governmental bodies. 
These
sources carry high costs in the form of influence by the donor on the 
organization's
politics. Funds that can be used at the sole discretion of the respective

disability organization are difficult to find. <BR>
<BR>
Historically, many organizations of disabled persons started out as 
self-help
groups geared towards creating income generating projects in order to 
provide
both employment opportunities for their members and resources for their
political work. Today, emerging disability organizations could benefit 
from
a similar approach. Yet most people with disabilities are not encouraged
to develop entrepreneurial skills. Another bottleneck to economic 
self-help
schemes is shortage of venture capital. <A NAME="anchor2882503"></A>
<H4>Aims</H4>
Participants will start a planning process which will eventually result
in a larger conference in 1992. After the planning seminar in June 1991
we will hopefully have 
<UL>
  <LI>a planning group 
  <LI>the aims of the proposed conference relevant to the participants'
needs and priorities 
  <LI>the target groups for the planned conference 
  <LI>a list of themes for the planned conference 
  <LI>discussion of suitable locations and dates for the planned 
conference
  <LI>a rough preliminary budget <A NAME="anchor2882698"></A>
</UL>
<H4>Approach</H4>
<BR>
One of the major topics for the planned larger meeting in 1992 is 
suggested
to be alternative financing methods. The Independent Living Movement 
places
great value in developing projects that provide members with job and 
training
opportunities and generate income for economic independence of our 
organizations.
One of the major bottlenecks is usually lack of starting capital. This is

also true for the conference planned for 1992.<BR>
<BR>
Participants will discuss different fundraising methods. In a dialogue 
with
potential sponsors from the Swedish technical aids industry and Swedish
popular movements (such as a large consumer cooperative and a labor 
union)
we will train ourselves in the use of alternative fundraising methods 
which
participants can try to use in their home countries. <A 
NAME="anchor2883036"></A>
<H4>Topics</H4>
<UL>
  <LI>Presentation and analysis of some emerging disability organizations

in Central and Eastern Europe, 
  <LI>discussion of aims, scope, organizational structure, underlying 
philosophy,
  <LI>presentation of the Independent Living Movement, its philosophy, 
aims
and approach in Europe, 
  <LI>presentation of schemes for creating venture capital which are 
being
used by other socially disadvantaged or alternative groups<BR>
<BR>
  <LI><A HREF="ENILStockholmSem3.html#anchor39383">Women&#180;s World 
Bank</A>
  <LI><A HREF="ENILStockholmSem3.html#anchor45645">The Briar Patch &amp;
Honest Business </A>
  <LI><A HREF="ENILStockholmSem3.html#anchor51499">Mondragon, Spain</A>
  <LI><A HREF="ENILStockholmSem3.html#anchor57507">Memo, Netwerk 
Vlaanderen,
Belgium</A> 
  <LI><A HREF="ENILStockholmSem3.html#anchor63285">Netzwerk, Germany</A>
  <LI><A HREF="ENILStockholmSem3.html#anchor54481">Grameen Bank</A><BR>
<BR>
<A NAME="anchor2865062"></A>
</UL>
<P><CENTER><HR></CENTER>
<H3>Opening address</H3>
<BR>
Kalle K&ouml;nkk&ouml;l&auml;, Threshold, Helsinki, Finland<BR>
Chair, DPI Europe<BR>
<BR>
<BR>
<FONT SIZE="+3">D</FONT>PI is now in a strong developing phase. DPI 
officers
made a decision in London last May to allocate resources for Europe for
two years. This means that we have new possibilities to work and develop
the European region under the next couple years.<BR>
<BR>
In practice, this means we will have, from the beginning of August 1991
a half day development officer for Europe situated in Helsinki. We will
have later this year a normal secretariat in Lisbon, Portugal.<BR>
<BR>
The most important part of the developmental work in Europe is to attract

new members in the central and eastern parts of the continent. Secondly,
we are trying to get the organization functioning in this region. 
Thirdly,
we have adopted different kinds of practical programmes.<BR>
<BR>
One special area of these programmes i Independent Living. This means in
practice that DPI/E will work in close cooperation with ENIL. ENIL can 
give
important substance to DPI/E. We must, of course, remember that ENIL is
part of the DPI Independent Living Network.<BR>
<BR>
DPI is a worldwide movement with approximately 90 members around the 
globe.
Europe is still a weak link in the chain but we have great possibilities
in front of us. Political and economic changes in our region 
simultaneously
create new challenges and new threats. Breaking physical walls is a 
reality
but invisible economic walls is something we have to fight against.<BR>
<BR>
We know from experience around the world that disabled people have to 
fight
for themselves. Nobody else is liberating and emancipating ourselves but
us. We have to support each other; we have to work together, locally, 
regionally
and globally. That is the only way to create a better world for 
ourselves.
And this is our duty for our sisters and brothers.<BR>
<BR>
DPI has decided to create a new structure for Independent Living. This 
decision
was made last year in Finland. It means network approach and it gives 
possibility
to every individual group and organization to join the family. This is an

important principle so that we can link all of us together in the 
future.<BR>
<BR>
With these few words, I wish you all the best and don't hesitate to 
contact
me as the chair of DPI/E and DPI's Independent Living Committee.<A 
NAME="anchor2865789"></A><BR>
<P><CENTER><HR></CENTER>
<H3>Principles of the Independent Living philosophy</H3>
<BR>
Adolf Ratzka, STIL<BR>
Chair, ENIL 
<H4>Introduction</H4>
<FONT SIZE="+3">S</FONT>ocial policy is typically not made by the people
who are most affected by it. Up to now, we, the users of social policies,

have had to accept the decisions handed down to us by other people. Since

we are often considered helpless and incapable of taking charge of our 
own
lives, the public and often we ourselves have taken for granted that it
is best for us, if others, the professionals make these decisions for us.

The time has come that we, the users of services, empower ourselves and
take the initiative in shaping such key services as personal assistance.
<BR>
<BR>
From our own experience we know that the way these services are organized

can make a tremendous difference in our lives: in some services we give
other people the permission to treat us like mindless vegetables who have

no will of their own, no life of their own, endless patience and nothing
to do. The goal is, of course, to design services which enable us to 
become
citizen with full participation and equality. Equality is our right, but
rights are not handed out, they have to be taken. The Independent Living
Movement shows us how to go about this.<BR>
<BR>
What is the philosophy of the Independent Living Movement and what are 
its
aims? 
<H4>Anti-discrimination</H4>
The Movement works against the discrimination of people with disabilities

and for more personal and political power. Everywhere people with 
disabilities
as a group are disadvantaged in education, work, income, housing, 
transportation,
in family life, in the social, political and economic lives of our 
communities.
Some of us do not even get a chance to live, because they are killed 
before
they are born. The more assistance we need, the worse is the 
discrimination
we are exposed to, the more limited is our life through attitudinal and
physical barriers. One of our goals is to introduce legislation in all 
countries,
that makes it illegal to discriminate against anybody on the basis of 
disability.
Such legislation has to include the provision of services such as 
personal
assistance for those of us who need these services for equal 
opportunities.
<H4>De-medicalization</H4>
One of the reasons why we are discriminated against is that we deviate 
from
what people think is &quot;normal&quot;. Society has a tendency to label
people who are different as &quot;sick&quot;. Sick people do not have to
work, are exempted from the normal duties of life, and are marginalized.
As long as we are considered sick by the general public, there will be 
little
understanding, for example, why we want to use regular public 
transportation
and are not satisfied to go by ambulance or para-transit. <BR>
<BR>
Whether or not we think of ourselves as sick, has a great impact on 
personal
assistance services. If we let other people treat us as if we were sick
persons, we should not be surprised, if they will make up lots of rules
to protect us, rules that limit our lives and give them control over us.
<BR>
<BR>
One of our main goals is to make clear to our communities and to 
ourselves
the difference between being sick and being healthy, normal citizens with

disabilities who have the same rights to the good life as everybody else.

<H4>De-institutionalization</H4>
Since we are often considered sick, many of us are shut away in hospitals

and hospital-like institutions. There, it is claimed, we can be better 
&quot;cared
for&quot;. With this argument we are put into special kindergartens, 
special
schools, special workshops, special housing and special transportation.
The only places that are still not segregated are the cemeteries! We have

to shut down these special, dehumanizing and degrading Apartheid 
solutions
and force our way into the mainstream of society. <BR>
<BR>
But institutions do not have to consist of brick and mortar. There are 
community-based
services that can turn your very own private home into an institution. I
am talking about the situation when you are made dependent on people who
tell you what to do, people you have not hired yourself. I am talking 
about
the situation when you are forced to adjust your needs to the needs of 
other
users, when you are reminded that you have to be reasonable in your 
demands
on life, be considerate and exercise solidarity with other users of the
services. <BR>
<BR>
Let's take a hard look at our housing situation and the services which we

need such as personal assistance or transportation. Who has come up with
these solutions to our needs? Do these services enable us to live a life
with the same opportunities that the general public enjoys or do these 
services
limit us, make us appear different and give other people power over us?
<H4>De-professionalization</H4>
Many people think of us as sick people who have to be &quot;cured&quot;
or at least &quot;rehabilitated&quot;. Many believe that we need special,

tender loving care by lots of people in white coats. The more disabled we

are, the sicker we are in the eyes of our surroundings and the more 
professional
training the people need who are charged with the task of taking care of
us. In this way, society has handed over to the professionals control 
over
our lives. Many of us have been raised in the belief that a medical 
doctor
or a social worker is best qualified to make decisions regarding our 
lives.
The more power we attribute to the person in the white coat, the less we
believe in our own strength. <BR>
<BR>
It is time that we come to a realistic assessment of what other people 
can
do for us and what we can do for ourselves. It is time that we take back
the power we have handed over to the professionals. 
<H4>Control over our organizations</H4>
Do we have organizations for disabled people or of disabled people? Are
non-disabled professionals in control who look upon disabled people as 
cases
or clients? Or are people in charge who themselves know what it is like
to be part of an oppressed minority, people who are fighting for their 
own
rights as well? At the present unemployment rate among our people we need

the work and training opportunities that our organizations provide for 
ourselves.
Society looks upon us as helpless people who cannot speak for themselves.

If we allow non-disabled people in our own organizations to speak on 
behalf
of us, we are confirming these prejudices. What would the public think 
about
a women's liberation group with mainly men in the office? We want 
self-determination!<BR>
<BR>
In Canada like in the US an Independent Living Center has to have at 
least
51 per cent of people with disabilities on the board. Why is it only 51
per cent? Why not 75, 90 or 100 per cent? Aren't we the best experts on
our needs? And how about staff? Is there any minimum percentage 
stipulated
in your bylaws? <BR>
<BR>
We need the coalition with non-disabled friends in our fight for equal 
rights.
But if our friends really understand our cause, they will step down from
important positions within our organizations. <BR>
Self-management of our services<BR>
<BR>
One reason why we need to have staff who have first-hand experience with
disability is that we are the best experts on our needs. Services, such
as transportation or assistance are typically designed, controlled and 
run
by non-disabled professionals. These people, however well-intentioned 
they
may be, simply cannot have the insight in our needs, life-styles and 
aspirations
which we have. As a result we see paratransit systems that run Monday 
through
Friday, as if we had no need to leave our homes on weekends. We see 
personal
assistance schemes that provide services only within one building complex

or within the political boundaries of our communities, as if we never had

the need to leave our homes or cross city limits. If we leave design and
control over such services to other people, we should not be surprised,
if they come up with solutions which fit the needs of their existing 
bureaucracies
instead of our needs, services which fit their preconceived notion of 
&quot;what
disabled people are like&quot; instead of services which can be vehicles
of our emancipation. <BR>
<BR>
We have a choice: we can go on feeling as powerless victims, as victims
of other people's insensitivity, lack of understanding, conspiracy or 
whatever.
Or we can choose to feel in control of our life and take charge of it. If

we don't want to play the role of the victim, we have to take the 
initiative
in the political and practical work of creating our own services. 
<H4>Peer support</H4>
Independent Living is really basic applied psychology. The most important

change we have to make is the change within ourselves. We do not need to
wait until other people get around to changing their attitudes towards 
us.
When we look at ourselves differently, other people too will see us in a
different light. When we respect ourselves as citizens with equal rights,

it will be easier for us to convince others that we indeed have equal 
rights.
<BR>
<BR>
To change one's perception of oneself is difficult. There are times when
we need to talk with people we can identify with because they are or have

been in a similar situation. The example of such a person is a much more
powerful help than the best advice of a non-disabled expert. The 
Independent
Living Movement utilizes this principle in a systematic fashion. We call
it peer support. Peer support means to share the fruits of one's 
experience.
It is our foremost educational tool to empower each other by exchanging
practical information, personal experiences and insights and by raising
our consciousness about our role in society and what it takes to liberate

ourselves.<BR>
<BR>
Our organizations will be most effective, if they make the best use of 
the
peer counselling principle. For this reason too we need to have as many
disabled people on the staff as possible. 
<H4>Networking</H4>
In providing examples for each other and in sharing our experiences we 
need
each other. We all are in the same situation, we all face oppression in
our society. Once we realize this, it is only a small step to see that we

have to support each other, that we must band together to fight the 
system
and together make this a better world for all.<BR>
<P><CENTER><HR></CENTER>
<P><A HREF="ENILStockholmSem2.html">Next article</A><A 
HREF="ENILStockholmSem1.html"><BR>
Table of Contents<BR>
</A>
<P><CENTER><FONT SIZE="-1">[<A HREF="ENILhomepage.html">ENIL 
homepage]</A></FONT>
<FONT SIZE="-1">[<A HREF="ENILContents.html">ENIL Website Contents</A><A 
HREF="ENILhomepage.html">]</A></FONT><FONT SIZE="-1">[<A 
HREF="../index.html">Institute
on Independent Living Homepage</A> <A 
HREF="ENILhomepage.html">]</A></FONT></CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-200</DOCNO>
<DOCOLDNO>IA012-000125-B020-46</DOCOLDNO>
<DOCHDR>
http://www.independentliving.org:80/ToolsforPower/Tools3c.html 193.13.228.238 19970216214254 text/html 11854
HTTP/1.0 200 OK
Last-Modified: Tue, 06 Aug 1996 20:03:17 +0000
Date: Sun, 16 Feb 1997 21:43:06 +0000
Expires: Sun, 16 Feb 1997 21:41:26 +0000
Content-type: text/html
Server: RoxenEnterprise/1.0
Content-length: 11628
</DOCHDR>
<HTML>
<HEAD>
    <TITLE>Institute_on_Independent_Living</TITLE>
</HEAD>
<BODY BGCOLOR="#ffffff" TEXT="#010436" LINK="#00007f">
<META NAME="description" 
CONTENT="Individuals and organizations of persons with disabilities can 
publish, free of charge,  articles, reports, training manuals, 
announcements, etc. on Independent Living, personal assistance, advocacy, 

peer support, accessibility, legislation and related subjects. "><META 
NAME="keywords" CONTENT="Independent Living, personal assistance, 
advocacy, peer support, direct payments, anti-discrimination legislation, 

accessibility, disability, disability rights">
<H4><IMG SRC="../InstLogoSmall.gif" WIDTH="198" HEIGHT="57" 
ALIGN="BOTTOM"
NATURALSIZEFLAG="3"><BR>
</H4>
<H2><CENTER>The challenge of middle age for the <BR>
Independent Living Movement</CENTER>
</H2>
<H4><CENTER>by Gerben DeJong</CENTER>
</H4>
<FONT SIZE="+3">T</FONT>en years ago, the U.S. Congress passed the 1978
amendments to the Rehabilitation Act. These Amendments included Title 
VII,
a new grant program for Independent Living centers. Title VII was hailed
as a victory for the Independent Living Movement. Today, there are 
approximately
200 Independent Living centers, many of which had their beginnings in the

Title VII program. But with the passage of the 1978 Amendments, the 
Independent
Living (IL) movement crossed a threshold and entered a new stage in its
life cycle as a social movement.<BR>
<BR>
Social movements, like the rest of us, go through life cycles. Knowing 
where
we are in our life cycle can significantly enhance our understanding of
who we are, where we have come from, and where we might be going. In an
analogous way, the IL movement has gone through various developmental 
stages.
The 10th anniversary of the 1978 Amendments offers a propitious occasion
on which to reflect on Independent Living as a social movement.<BR>
<BR>
In the early stages of our own development, we seek to establish our 
identity
as individuals with distinct interests, commitments, and needs. We seek
to communicate to the rest of the world who we are. We tend to be 
self-absorbed
with our own identity. Later, as we become more secure about ourselves,
we also have an enhanced capacity to reach out to others and help meet 
their
needs through friendships, marital relationships, business relationships,

and through participation in the larger life of the community. More 
secure
in the knowledge of ourselves, we make selected accommodations with the
larger society and its institutions. We do not necessarily &quot;sell 
out,&quot;
but we tend to have a deeper understanding of the tensions between our 
individual
values and the values of the institutions in which we are involved.<BR>
<BR>
I would like to suggest that this scenario is not unlike some of the 
developmental
issues faced by the IL movement. At present there are two major 
developmental
issues for the IL movement that can be better understood in the context
of &quot;life cycle theory.&quot;<BR>
<BR>
The first issue is the tension between the movement&#180;s &quot;grass 
rootsy&quot;
origins and the movement&#180;s willingness to take on providers status.
It is the old advocacy versus provider status issue. The 1978 Amendments,

in a sense, conferred official legitimacy on the movement by offering 
provider
status for IL centers - the main service delivery vehicle of the IL 
movement.
The real significance of the 1978 Amendments is that they signified a 
shift
in movement history away from the in-the-streets advocacy to the 
nurturing
of institutional structures committed to movement goals.<BR>
<BR>
The second issue is the movement&#180;s ability to broaden its base to 
incorporate
persons with disabilities whose disabilities are different from those of
the movement&#180;s original adherents. The early leadership of the 
movement
was largely drawn from the ranks of those with disabilities such as 
spinal
cord injury, post-polio, cerebral palsy, and a few others. This problem
has been particularly acute in regard to the ability of the movement to
assimilate persons who have a diminished capacity for self-direction such

as persons who have mental retardation or brain injury. 
<H4>The issue of provider status</H4>
<FONT SIZE="+3">A</FONT> social movement cannot sustain itself by being
in the streets indefinitely. Eventually, the ideals and values of the 
movement
are assimilated by others and achieve sufficient social legitimacy to by
incorporated in legislation and in various societal institutions. At that

stage, the identity and legitimacy of the movement is no longer the focal

issue. Instead, attention can be turned to how the movement can sustain
itself financially and institutionally.<BR>
<BR>
The 1978 Amendments offered IL Centers a funding source that allowed IL
Centers to become more financially viable despite the very limited 
availability
of Title VII funds. IL centers, like other provider groups, have 
organized
themselves into a national organization known as the National Council on
Independent Living (NCIL) which has also become the IL movement&#180;s 
focal
organization. Instead of marching and wheeling in the streets, 
NCIL&#180;s
membership ply the halls of Congress and various governmental 
organizations.
Instead of demonstrating at the gates of the White House, members are 
giving
cocktail parties on Capitol Hill. The IL movement has come of age. 
&#168;<BR>
<BR>
However, the basic conflict between advocacy and provider status has not
been resolved. Nowhere is this issue more apparent than in the hotly 
contested
issue of whether IL centers should be accredited by an external 
accrediting
body such as the Commission on Accreditation of Rehabilitation 
Facilities,
an accrediting body developed within the framework of the movement, or in

some other group. The fundamental issue, I believe, is not whether IL 
centers
should be accredited but rather the extent to which movement 
organizations
are willing to take on the additional trappings of provider status in the

hopes of achieving greater organizational legitimacy while coping with 
all
the baggage that comes with being a service provider.<BR>
<BR>
There are enormous economic advantages in acquiring provider status. 
External
accreditation legitimizes IL centers as service delivery organizations in

the eyes of funding sources. Procvider-based financing also pays the 
salaries
of movement leaders and offers resources for travel that enable movement
leaders to participate in movement activities.<BR>
<BR>
The down side is also apparent. Being beholden to certain funding sources

does tend to blunt the sharpness of one, advocacy. The old adage still 
applies:
It is difficult to bite the hand that feeds you. However, movement ideas
and ideals must be operationalized institutionally if they are to survive

the convictions of the movement&#180;s original leaders and adherents. 
Institutions
offer a framework in which human energy can be harnessed (and 
compensated)
in the pursuit of specific movement goals. I am not advocating 
accreditation,
but if social movements are to be mainstreamed into American life, they
cannot just be viewed as fringe elements. They must become part of the 
system
- on their own terms, of course.<BR>
<BR>
Persons with disabilities want to be included in the mainstream of 
American
life. However, at the risk of some generalization, I am not sure that 
leaders
within the IL movement are prepared to see movement organizations such as

IL centers fully mainstreamed into the fabric of America&#180;s health 
and
human services system for fear that the movement&#180;s cutting edge will

be blunted. Thus, at midlife, the movement remains torn as to the nature
of its accommodation within various social institutions. 
<H4>The issue of incorporating new groups</H4>
<FONT SIZE="+3">T</FONT>he other issue for the IL movement is its ability

to fully assimilate persons whose disabilities have compromised their 
capacity
for self-direction. Some observers speak of the movement&#180;s original
spinal cord injury bias or the movement&#180;s bias toward disabled 
persons
who are young and fit.<BR>
<BR>
At the outset of the movement in the early 1970s, persons with physical
disabilities wanted to be viewed as competent, self-directed, and capable

of managing their own lives. The participation of persons, whose capacity

for self-direction had been compromised, threatened that image of 
competence.<BR>
<BR>
Many IL programs deserve credit for reaching out to groups who earlier 
had
been overlooked as partners in the IL movement. However, the broadening
of the IL movement in recent years comes as much from overlooked groups
seeking the help of IL programs. Nowhere is this more evident than among
persons with brain injury and their advocates who have looked to IL 
programs
for support. The brain injury community has become increasingly organized

and has challenged many of the assumptions of the IL movement such as the

IL movement&#180;s traditional aversion to transitional living 
programs.<BR>
<BR>
As the movement becomes more secure about its own identity, it will 
assimilate
disability groups from outside its original group of adherents. The 
people
with persons who are less self-directed is that their participation in IL

programs is often attended by the not-too-distant and heavy hand of 
professional
paternalism or by anxious parents who have continued/resumed their 
parenting
role in the lives of their adult children. Such participation is viewed
as an affront to the very principles on which the IL movement was 
founded.
<H4>Mid-life crisis?</H4>
<FONT SIZE="+3">T</FONT>he IL movement is now about 17 years old 
depending
on how one chooses to date the movement. As far as social movements are
concerned, the IL movement is well into middle age. Some might argue the
IL movement is in late adolescence or young adulthood, depending on the
issue at hand. In any case, issues that remain unresolved in the early 
stages
of a movement&#180;s life cycle are sure to resurface as the movement 
ages
and matures. The assumption of provider status and the broadening of its
constituency challenge the very assumptions and identity of the IL 
movement
and its place in American social and political life.<BR>
<BR>
The stage theory of life-cycle approach to understanding the IL movement
- and its closely related movement, the disability rights movement - can
also be misleading. The theory assumes that the IL movement has affected
all disability groups uniformly. A more accurate assessment is that 
specific
disability groups are at various stages of development in terms of their
own identity and role in American life. We have only to witness the 
recent
uprisings of students with hearing impairments at Gallaudet University in

Washington, D.C. to remind us that all disability groups have not 
benefited
equally in the quest for full equality and full participation in American

life. <BR>
<BR>
I am not prepared to describe the IL movement as having a mid-life crisis

but I do believe that a life-cycle understanding of social movements can
give us a better understanding of the issues and tensions within the IL
movement.<BR>
<BR>
<BR>
Source: Disability Studies Quarterly, Summer 1988. Editor Kenneth I. 
Zola,
Dept of Sociology, Brandeis University, Waltham,MA 02254, United States.
<BR>
<P><CENTER><HR><FONT SIZE=2>[<A HREF="Tools1.html">Tools for Power 
contents]</A></FONT><FONT SIZE=2>[<A HREF="../Contents.html">Institute
on Independent Living contents</A>]</FONT></CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-201</DOCNO>
<DOCOLDNO>IA012-000125-B020-88</DOCOLDNO>
<DOCHDR>
http://www.independentliving.org:80/ToolsforPower/Tools3b.html 193.13.228.238 19970216214313 text/html 7066
HTTP/1.0 200 OK
Last-Modified: Tue, 06 Aug 1996 20:03:20 +0000
Date: Sun, 16 Feb 1997 21:43:26 +0000
Expires: Sun, 16 Feb 1997 21:41:46 +0000
Content-type: text/html
Server: RoxenEnterprise/1.0
Content-length: 6841
</DOCHDR>
<HTML>
<HEAD>
    <TITLE>Institute_on_Independent_Living</TITLE>
</HEAD>
<BODY BGCOLOR="#ffffff" TEXT="#010236" LINK="#00007f">
<META NAME="description" 
CONTENT="Individuals and organizations of persons with disabilities can 
publish, free of charge,  articles, reports, training manuals, 
announcements, etc. on Independent Living, personal assistance, advocacy, 

peer support, accessibility, legislation and related subjects. "><META 
NAME="keywords" CONTENT="Independent Living, personal assistance, 
advocacy, peer support, direct payments, anti-discrimination legislation, 

accessibility, disability, disability rights">
<H4><IMG SRC="../InstLogoSmall.gif" WIDTH="198" HEIGHT="57" 
ALIGN="BOTTOM"
NATURALSIZEFLAG="3"><BR>
</H4>
<H2><CENTER>Divisions in the disability community</CENTER>
</H2>
<H4><CENTER>by David Pfeiffer</CENTER>
</H4>
<FONT SIZE="+3">W</FONT>ithin the community of disabled persons in this
country there is a division between those concerned with civil rights and

those concerned with service delivery. On the one hand, there is the 
Independent
Living Movement which is a necessary fact of life for disabled persons in

this country today, whether or not they require the services of an 
Independent
Living center. There is also the Disability Rights Movement which is a 
necessary
for disabled persons in this country today, whether or not they face 
civil
rights violations. Although there is an overlapping membership, persons
who identify with the Independent Living Movement are concerned with the
provision of services to disabled individuals in order to make them truly

independent. They say that without transportation, income, housing, and
other necessities, disabled persons cannot be in a position to work for
civil rights. Persons who identify with the Disability Rights Movement 
say
that services will never be consistently and adequately provided until 
the
civil rights battle is fought and won. The differences can be illustrated

by an example. If a disabled person has a job, but no transportation to
that job, a person in the Independent Living Movement would assist 
him/her
to obtain some means of transportation to work. A person in the 
Disability
Rights Movement would assist him/her to undertake political and legal 
action
to make local transportation accessible and available because the 
disabled
person, as a matter of law, has the right to use it as other persons in
the community can use it. The Independent Living Movement people would 
talk
about reduced fares, paratransit, and negotiation. The Disability Rights
Movement people would talk about lobbying, demonstrations, and law suits.

The recent disputes between ADAPT and some local Independent Living 
centers
reflect this divergent perspective on the problem of transportation.<BR>
<BR>
It is an interesting side note that many claim that California was the 
origin
of both the demand for services and the fight for civil rights. They lump

both together under the name of the Independent Living Movement. Others
claim that Massachusetts was the origin of both the demand for services
and the fight for civil rights. They lump both together under the name of

the Disability Rights Movement. Persons in Illinois, Florida, Texas and
almost every other state make a similar claim. Opponents to the various
claims say that Californians were concerned about civil rights only as an

afterthought, while in Massachusetts services were viewed only as a means

to obtain activists. Illinois is criticized for not being controlled by
disabled persons. Florida is criticized for being concerned only with 
physical
disability, thereby leaving out half of the disability community. Texas
is shrugged off as a newcomer. This writer was born in Texas and lived 
there
until 1964. I can state unequivocally that by 1948, as a teenager, I was
working for both services and civil rights. However, I was a voice crying

in the wilderness and did not encounter any organized activity until 
moving
to Boston in 1970. Nevertheless, the final resolution of this question on

the origin of the Movement(s) I will leave to some historian. My point is

that the divisions are not recent and are not inconsequential.<BR>
<BR>
This split is also seen in the Association on Handicapped Student Service

Programs in Post-Secondary Education (AHSSPPE). Many members of AHSSPPE
come from a student personnel orientation and express the position that
the association and its journal (Journal of Post-Secondary Education and
Disability) should focus on the delivery of services to disabled 
post-secondary
students. The field, as they understand it, encompasses concerns such as
the administration of an office for the delivery of these services, 
attitudes
of faculty and administrators toward disabled students, technical details

of how persons with various disabilities can be accommodated in different

courses, questions of admission and retention, data about specific 
disabilities
with implications within the post-secondary context, and related matters.

On the other hand, AHSSPPE was one of the earliest professional 
associations
that welcomed papers which went beyond this range of topics at its 
national
meetings. In part, it was because many (including members coming from a
student personnel orientation) perceived their job in terms of the civil
rights of disabled post-secondary students. It was also because a large
number of AHSSPPE members taught on a regular basis. Many of them guest
lectured in courses, many taught as adjuncts, and many (including this 
writer
and the editor of the DSQ) had regular faculty appointments. 
Nevertheless,
the division between providers and advocates can be seen in the topics 
listed
in the annual AHSSPPE meeting programs, but it is diminishing.<BR>
<BR>
This FOCUS began with a discussion of division as a split. However, there

is another meaning of division which is very important. Division can also

mean a part of something. The &quot;divisions&quot; of which I write can
be seen as parts of the overall whole. There is no necessary conflict 
between
those mostly concerned with civil rights. Both activities must occur at
the same time: individual and systemic advocacy for services and civil 
rights
and there will not be people to fight for civil rights without the 
provided
services. We must work cooperatively to achieve the goal of an open 
society
composed of truly independent and interdependent people.<BR>
<BR>
Source: Disability Studies Quarterly, Summer 1988. Editor Kenneth I. 
Zola,
Dept of Sociology, Brandeis University, Waltham, MA 02254, United 
States.<BR>
<P><CENTER><HR><FONT SIZE=2>[<A HREF="Tools1.html">Tools for Power 
contents]</A></FONT><FONT SIZE=2>[<A HREF="../Contents.html">Institute
on Independent Living contents</A>]</FONT></CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-202</DOCNO>
<DOCOLDNO>IA012-000125-B020-117</DOCOLDNO>
<DOCHDR>
http://www.independentliving.org:80/ToolsforPower/Tools4.html 193.13.228.238 19970216214327 text/html 2844
HTTP/1.0 200 OK
Last-Modified: Tue, 06 Aug 1996 20:03:13 +0000
Date: Sun, 16 Feb 1997 21:43:43 +0000
Expires: Sun, 16 Feb 1997 21:42:03 +0000
Content-type: text/html
Server: RoxenEnterprise/1.0
Content-length: 2619
</DOCHDR>
<HTML>
<HEAD>
    <TITLE>Institute_on_Independent_Living</TITLE>
</HEAD>
<BODY BGCOLOR="#ffffff">
<META NAME="description" 
CONTENT="Individuals and organizations of persons with disabilities can 
publish, free of charge,  articles, reports, training manuals, 
announcements, etc. on Independent Living, personal assistance, advocacy, 

peer support, accessibility, legislation and related subjects. "><META 
NAME="keywords" CONTENT="Independent Living, personal assistance, 
advocacy, peer support, direct payments, anti-discrimination legislation, 

accessibility, disability, disability rights">
<H4>History of the <BR>
Independent Living Movement<BR>
<BR>
</H4>
<H2><CENTER>Resources</CENTER>
</H2>
<BR>
The following resources are published by the Independent Living Ressearch

Utilization Program, Houston:<BR>
<BR>
Tate, Denise and Linda Chadderdon, eds. International Perspectives about
Independent Living. 1983. University Center for International 
Rehabilitation
Publications. Available from ILRU.<BR>
<BR>
Summarizes presentations and discussions at a one-day conference held to
view Independent Living issues in the U.S., discusses related programs 
and
practices abroad, and makes recommendations for future directions in the
U.S.<BR>
<BR>
Tate, Denise and Linda Chadderdon, eds. Independent Living: An Overview
of Efforts in Five Countries. 1982. University Center for International
Rehabilitation Publications. Available from ILRU.<BR>
<BR>
Rehabilitation and special education professionals from five 
countries--Costa
Rica, Denmark, the Federal Republic of Germany, Japan, and 
Yugoslavia--describe
their services for people with disabilities, including the development of

Independent Living programs The volume concludes with summaries and 
comparisons
of the basic aspects of each country.<BR>
<BR>
Address: ILRU at Texas Institute for Rehabilitation, 2323 S. Shepherd, 
Suite
1000, Houston, TX 77019, United States.<BR>
<BR>
Crewe, Nancy M. &amp; Harkins, Arthur,&quot;The Future of Independent 
Living&quot;,
in Crewe, Nancy M. &amp; Zola, Irving Kenneth, Independent Living for 
Physically
Disabled People, Jossey-Bass Publishers, San Francisco, 1983.<BR>
<BR>
Zola, Irving Kenneth,&quot;Toward Independent Living: Goals and 
Dilemmas&quot;,
in Crewe, Nancy M. &amp; Zola, Irving Kenneth, Independent Living for 
Physically
Disabled People, Jossey-Bass Publishers, San Francisco, 1983<BR>
<P><CENTER><HR><FONT SIZE=2>[<A HREF="Tools1.html">Tools for Power 
contents]</A></FONT><FONT SIZE=2>[<A HREF="../Contents.html">Institute
on Independent Living contents</A>]</FONT></CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-203</DOCNO>
<DOCOLDNO>IA012-000125-B020-166</DOCOLDNO>
<DOCHDR>
http://www.independentliving.org:80/SexualityComment.html 193.13.228.238 19970216214346 text/html 7540
HTTP/1.0 200 OK
Last-Modified: Tue, 06 Aug 1996 19:59:35 +0000
Date: Sun, 16 Feb 1997 21:43:54 +0000
Expires: Sun, 16 Feb 1997 21:42:14 +0000
Content-type: text/html
Server: RoxenEnterprise/1.0
Content-length: 7315
</DOCHDR>
<HTML>
<!--This file created 96-07-24 20.23 by Claris Home Page version 1.0b1-->

<HEAD>
    <TITLE>Institute_on_Independent_Living</TITLE>
</HEAD>
<BODY TEXT="#060137" BGCOLOR="#ffffff" LINK="#00007f">
<META NAME="description" 
CONTENT="Individuals and organizations of persons with disabilities can 
publish, free of charge,  articles, reports, training manuals, 
announcements, etc. on Independent Living, personal assistance, advocacy, 

peer support, accessibility, legislation and related subjects. "><META 
NAME="keywords" CONTENT="Independent Living, personal assistance, 
advocacy, peer support, direct payments, anti-discrimination legislation, 

accessibility, disability, disability rights">
<H3><BR>
<BR>
<IMG SRC="InstLogoSmall.gif" WIDTH="198" HEIGHT="57" ALIGN="BOTTOM" 
NATURALSIZEFLAG=
"3"><BR>
<BR>
<BR>
<BR>
Comment</H3> 
<H2>Sexuality and people with disabilities:<BR>
What experts are often not aware of</H2>
<BR>
<FONT SIZE=5>F</FONT>or most people sexuality is a very intimate area of
their personal life which they do not wish to share with other people 
with
the exception, perhaps, of a few very close persons. On the other hand,
other peoples' sex life is of great interest to a large part of the 
population
as evidenced by the huge market for sex-oriented films, magazines and 
similar
products. Often, this interest in other peoples' sex life has to do with
one's own deep personal problems in this area. I do not want to 
oversimplify
the issue but I have the impression that experts on disabled peoples' 
sexuality
who are mainly concerned with topics such as erective and ejaculatory 
capability,
positions or sexual technical aids may have little knowledge of our 
every-day
lives. How else can one explain why they overlook the most blatant 
obstacles
that prevent many of us disabled people from fully enjoying our 
sexuality?
In this short comment I would like to draw attention to a few obvious but

nevertheless often forgotten difficulties that many of us face who have
more significant disabilities.<BR>
<BR>
Sexuality is a form of communication, of expressing one's own personality

to another person. The way I present myself will largely depend on how I
see myself. How can I feel attractive, how can I love somebody, if I do
not love myself! Society constantly bombards us with outright and 
indirect
messages that our lives are worthless, that we are helpless, hopeless 
cripples.
Often I have received the dubious compliment: &quot;You must be strong,
because in your place I would have killed myself long ago.&quot; The most

important task we face is to build up our own value system independent of

our surroundings. Only then can we reach the point where we appreciate 
our
personal resources and our uniqueness as human beings. To reach this 
position
is nearly impossible, if each of us had to do it by himself or herself.
In this task we need the support of other disabled persons. By sharing 
our
experiences and insights we understand that we are not alone. By learning

to appreciate each other as the capable, interesting and caring people we

are we can immunize ourselves against negative attitudes.<BR>
<BR>
Let's face it, society does not think of us first and foremost as sexual
beings. Most of us are considered objects of care, somebody one has to be

nice to. Disabled people are often seen as sick. Sick persons are not 
expected
to have a regular life with social responsibilities such as work. Sick 
people
are definitely not expected to start a family. In many countries disabled

people are begging in the street. Elsewhere well-intentioned politicians
try to mobilize taxpayers' money for disability programs by depicting us
as the weakest members of society. In both instances our unproductive 
image
does not help our self-esteem, it does not contribute to our sex appeal.
Who wants to fall in love with a sick person, who would want to spend the

honeymoon with a beggar?<BR>
<BR>
Disabled people often receive inferior schooling, if any, and face 
enormous
problems in getting employment. No wonder that so many of us have a poor
self-confidence. Without self-confidence it will be difficult to see 
oneself
as an attractive sexual being.<BR>
<BR>
Those of us who need assistance in their daily lives with such tasks as
getting dressed, washed, going to the toilet, etc. are exposed most to 
the
paternalistic and protective attitudes of our surroundings. Our physical
dependence on others is automatically equated with intellectual and 
emotional
dependence. If we ourselves feel dependent and if other people believe 
that
too, it will be difficult to be sexy in your own and somebody else's 
eyes.
A person who feels inferior will not be able to establish a sound 
relationship
with another person that is based on equality.<BR>
<BR>
In countries without personal assistance services many of us have to 
spend
their lives with their parents. How can one develop a mature sexuality,
if one has to live in forced dependency and childhood?<BR>
<BR>
Those who do not have any relatives who can assist them often are locked
up in institutions where they share their room with several other 
persons,
where the inmates are separated into a male wing and a female wing, where

they cannot come and go as they please, where they have to eat and 
defecate
according to specific schedules. I myself spent 5 years of my youth in 
one
of these institutions; it felt like prison. Who can develop a gratifying
sexuality in a prison?<BR>
<BR>
For many disabled people who need personal assistance the only liberation

from the institution or the parental home is marriage with a non-disabled

partner. Without tax-funded personal assistance services partnership and
marriage - not to speak of childrearing - under these circumstances 
involve
an enormous amount of responsibility on the part of the non-disabled 
partner.
Often this means forgoing a career and a life of one's own. Providing the

practical assistance is then seen as a sign of love. When the 
non-disabled
partner becomes overpowered by the tremendous mutual dependence and the
sheer amount of work, guilt feelings will result on both parts. Some 
relationships
are kept together by guilt feelings which are often mistaken for love. I
am a personal assistance user myself married to a non-disabled woman. I
am in the privileged position that the government provides me with money
to employ my personal assistants. I am not dependent on my wife in that
respect. Those times when I am negligent in arranging personal assistants

for myself and have to ask my wife to help me, I feel and function 
differently.
Dependency does influence a relationship negatively.<BR>
<BR>
Sexuality is the result of the whole person's life situation. Without the

prerequisites for self-esteem and personal independence there can be no
sound sexuality. What I hope to have shown in this brief comment is that
for many of us who have significant disabilities our sexual liberation 
does
not so much depend on sex counselling or mechanical sex aids but on the
availability of tax-funded personal assistance services which empower us
to take control over our own lives.<BR>
<BR>
Adolf D. Ratzka, Ph.D<BR>
<P><CENTER><HR><FONT SIZE=2>[<A 
HREF="Contents.html">Contents</A>]</FONT></CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-204</DOCNO>
<DOCOLDNO>IA012-000125-B020-211</DOCOLDNO>
<DOCHDR>
http://www.independentliving.org:80/ToolsforPower/Tools25.html 193.13.228.238 19970216214404 text/html 10671
HTTP/1.0 200 OK
Last-Modified: Tue, 06 Aug 1996 20:04:08 +0000
Date: Sun, 16 Feb 1997 21:44:12 +0000
Expires: Sun, 16 Feb 1997 21:42:32 +0000
Content-type: text/html
Server: RoxenEnterprise/1.0
Content-length: 10445
</DOCHDR>
<HTML>
<HEAD>
    <TITLE>Institute_on_Independent_Living</TITLE>
</HEAD>
<BODY BGCOLOR="#ffffff" TEXT="#050334" LINK="#00007f">
<META NAME="description" 
CONTENT="Individuals and organizations of persons with disabilities can 
publish, free of charge,  articles, reports, training manuals, 
announcements, etc. on Independent Living, personal assistance, advocacy, 

peer support, accessibility, legislation and related subjects. "><META 
NAME="keywords" CONTENT="Independent Living, personal assistance, 
advocacy, peer support, direct payments, anti-discrimination legislation, 

accessibility, disability, disability rights">
<H4><IMG SRC="../InstLogoSmall.gif" WIDTH="198" HEIGHT="57" 
ALIGN="BOTTOM"
NATURALSIZEFLAG="3"><BR>
</H4>
<H2><CENTER>Disability, women and love</CENTER>
</H2>
<BR>
<FONT SIZE="+3">I</FONT>t is the most natural thing in the world for a 
human
being to love someone. It springs from the most basic human instinct of
all - preservation of the species. However, for me being physically 
disabled,
loving someone was always fraught with great fear and pain. Nevertheless,

I couldn't deny my natural emotions and have loved many men since I was
young. It took me a long time to learn to express my own feelings and 
live
naturally without fear and also to have confidence in being loved myself.

Now I have been in love with my boyfriend for nearly three years and 
realize,
if you don't love yourself you can't love anybody else.<BR>
<BR>
When I think about my past life, I realize I was treated negatively from
the moment I was born; &quot;What a pity!&quot;, &quot;How can she be 
happy
with that body?&quot;, &quot;You should never have been born.&quot;. As
I grew up I completely lost my self-confidence and couldn't love myself
at all. When I was twenty years old I became involved with a group of 
disabled
people who were trying to live independent lives. The ten years following

I struggled to work through the deep sexual problems I had accumulated 
through
the lack of recognition of myself as a sexual being while growing up. 
Almost
all people with disabilities are confronted with this problem. Many of us

develop personality scars because of never having been acknowledged as a
true man or woman. We therefore build up great illusions in our minds 
about
marriage and male and female roles. 
<H4>My disability</H4>
<FONT SIZE="+3">I</FONT> was born with a bone malfunction which was 
characterized
by stunted growth and bone fragility. It is a very rare condition and so
far, neither cure nor treatment has been discovered. I have had more than

twenty bone fractures and subsequent operations. I spent one fifth of my
life in bed wearing a plaster cast up to my chest, during my primary 
school
period. I find it difficult to describe the harshness, both in words and
actions, of the doctors who treated me during this time. These awful 
experiences
have left their mark on me.<BR>
<BR>
I'm now involved in &quot;co-counselling&quot;, a form of peer counseling

and therapy which attempts to clear blocked emotions through reliving 
stress
situations and releasing the blocked energy. I am an ardent believer in
this method and active in disseminating it throughout Japan. After such
a session, problems come into clearer focus. When I relive past 
experiences
in these sessions, I am astonished by how much I must have suffered when
I was young. I have never felt comfortable about my body. On the 
contrary,
it was always the cause of pain and suffering and because of it I was 
pitied,
denied and despised most of the time. I never received compliments. 
Despite
all the complexes I had to cope with, on reaching puberty and entering 
adolescence
I discovered my own potential for sexual relationships. I then entered 
into
relationships not because I loved but because of my need to be accepted.
During this time I never felt any satisfaction in love, but I accepted 
that
this was the only path open to me. 
<H4>Relationship with my first boyfriend</H4>
<FONT SIZE="+3">T</FONT>he relationship with my first boyfriend (if I can

call him that) started on shaky ground, neither of us daring to 
communicate
verbally with the other. It was not so important for me to attract him 
mentally,
but I always felt great anxiety about my tiny misshapen body being 
physically
attractive to him. It was so important for me to feel accepted by him. We

therefore spent a lot of time together exploring eroticism. It was a 
typical
male/female relationship, the woman as sexual object, the man judging her

by her appearances. The time I spent with this boyfriend reflected such
habits and was very painful to me. I was afraid to ask him to use 
contraception
and of telling him I didn't feel any satisfaction from our relations. The

need for my body to be accepted was so intense, it distorted this 
impulsive
young act imagining it to be love.<BR>
<BR>
Recently I read a report about prostitution. It detailed how many girls
involved in prostitution had no financial need for doing so, but that 
they
had been sexually abused as children. I think there is a lot of truth in
this. Harsh experience paves the way for a woman to allow herself to be
treated as a soulless sexual object. When I reflect on my first 
relationship
it saddens me how I was treated merely as an object and that I couldn't
assert myself as the woman I am. Out of my many painful memories, there
is one story of abuse by medical personnel that I would like to share 
now.
<H4>Behind closed doors</H4>
<FONT SIZE="+3">B</FONT>efore starting primary school, I had to have an
X-ray examination. A radiologist asked my mother to wait for me outside
the room. That was unusual. He then told me to lie down on the cold X-ray

machine. He took my underwear off with such authority that I didn't dare
protest. That was also unusual. I felt great fear and anxiety. Then he 
abused
me sexually using a metal stick, all the while whistling and looking as
if he were enjoying himself. I could neither scream nor tell mother 
afterwards
about the dreadful violence. This affair left me deeply scarred.<BR>
<BR>
This is one great danger we disabled women have to face. On one hand we
are denied and insulted as women but on the other hand we can easily be
raped. I really wish to point out to people with disabilities that we 
must
not allow ourselves to be discouraged by such hard situations. There is
no limitation on our ability to love. We can even perhaps achieve a 
better,
deeper and more honest kind of communication through our disabiliyt and
learn to live our lives to the fullest. But in the meantime we are very
dependent on the sensitivity and humaneness of medical personnel. To 
enable
us to develop more positively we really need medical personnel who are 
self-confident
and mature. I sincerely hope for more of this type in the future. 
<H4>About my marriage</H4>
<FONT SIZE="+3">A</FONT>fter I split up with my young lover, I lived 
together
with a disabled man for nearly six years. This relationship was the first

step in learning to love myself. However I didn't ever consider marrying
him, because I didn't believe that marriage would improve the low status
we had in society. But on the other hand I believed in my own mind that
if, I married an able-bodied man, this would be my passport into normal
society and would lessen the discrimination against me.<BR>
<BR>
In 1983, after I finished my six month course of study in the United 
States,
I told myself, &quot;This life I only live once, so I should live it how
I want to.&quot; At that time I had a strong desire for marriage and soon

after started to live with an able-bodied man. My life with the disabled
man finished with his kind words, &quot;You must live as you think 
best.&quot;
Later I realized how different living together and marriage really are,
and his parting message came to mind.<BR>
<BR>
The proposed marriage with the able-bodied man was opposed violently by
his parents and our relationship ended after eight months or so. Now I'm
glad that they opposed the marriage. However at that time I was so 
surprised,
disgusted, angry and sad. I began to realize how distorted the current 
marriage
system was with its discrimination and lack of humaneness. Traditionally
in Japan, being a good wife required obedience to the husband's family.
The love and hope of the couple came second. The capacity to bear 
children
was the woman's greatest asset. I didn't fulfill any of these 
expectations
so I was completely rejected by my fianc&eacute;'s family. If the 
marriage
system depends on the notion that a man and a woman have to have fixed 
roles
in society, it is extremely difficult for us disabled people to be part
of that system.<BR>
<BR>
Even if we had been able to be married without opposition, we would soon
have realized that we couldn't have a balanced relationship because of 
the
social inequality of the sexes. For eight months I took on the role of 
proper
housewife and was treated as his wife by all people except for his 
family.
Before we decided to marry, he looked after his guests by himself and I
was able to keep up my old habits. However, after deciding to marry, I 
felt
that I was responsible for the care of his guests and should therefore 
change
my lifestyle. Even being called by his name seemed to me to be destroying

the sense of my own identity.<BR>
<BR>
Through all these experiences I realize that I am discriminated not only
for my disability but also for my being of the female sex. In Japan, we
believe that marriage is a passport to join society. However, my desire
for marriage has completely disappeared since I became aware of how much
our society is based on sex discrimination. Of course, I wouldn't 
question
anyone's attempt to create a balanced relationship for themselves through

living together, but as a means of recovering from my pains, it is very
comfortable for me to meet my boyfriend just three or four times a week.
It took me a long time to come to the realization that only we two can 
decide
how to love each other. Now we are trying with love and trust to live 
what
we have learned.<BR>
<BR>
<BR>
<BR>
Ms. Junko Asaka<BR>
Address: Kita 2-4-13 Kunitachi, 186 Tokyo, Japan.<BR>
<P><CENTER><HR><FONT SIZE=2>[<A HREF="Tools1.html">Tools for Power 
contents]</A></FONT><FONT SIZE=2>[<A HREF="../Contents.html">Institute
on Independent Living contents</A>]</FONT></CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-205</DOCNO>
<DOCOLDNO>IA012-000125-B020-267</DOCOLDNO>
<DOCHDR>
http://www.independentliving.org:80/FamilyCRSweden.html 193.13.228.238 19970216214430 text/html 16031
HTTP/1.0 200 OK
Last-Modified: Thu, 22 Aug 1996 17:40:35 +0000
Date: Sun, 16 Feb 1997 21:44:33 +0000
Expires: Sun, 16 Feb 1997 21:42:53 +0000
Content-type: text/html
Server: RoxenEnterprise/1.0
Content-length: 15805
</DOCHDR>
<HTML>
<HEAD>
    <TITLE>Institute_on_Independent_Living</TITLE>
</HEAD>
<BODY TEXT="#020a3f" BGCOLOR="#ffffff" LINK="#000042">
<META NAME="description" 
CONTENT="Individuals and organizations of persons with disabilities can 
publish, free of charge,  articles, reports, training manuals, 
announcements, etc. on Independent Living, personal assistance, advocacy, 

peer support, accessibility, legislation and related subjects. "><META 
NAME="keywords" CONTENT="Independent Living, personal assistance, 
advocacy, peer support, direct payments, anti-discrimination legislation, 

accessibility, disability, disability rights">
<BR>
<IMG SRC="InstLogoSmall.gif" WIDTH="198" HEIGHT="57" ALIGN="BOTTOM" 
NATURALSIZEFLAG=
"3"><BR>
<BR>
<BR>
<BR>
<H2><CENTER>Independent Living and the family:<BR>
the context of Costa Rica and Sweden</CENTER>
</H2>
<P><CENTER><BR>
Paper presented at the First National Congress on Family and Disability,
<BR>
San Jos&eacute;, Costa Rica, December 8-10, 1994<BR>
<BR>
by Dr. Adolf Ratzka, <BR>
University of Costa Rica and Royal Institute of Technology, Sweden<BR>
</CENTER>
<P>Independent Living is a philosophy and a movement of people with 
disabilities
that works for equal opportunities, self-respect and self-determination.
&quot;Independent Living&quot; does not mean that we do not need anybody,

that we want to live in isolation. &quot;Independent Living&quot; means
that we want the same control and the same choices in every-day life that

our non-disabled brothers and sisters, neighbors and friends take for 
granted.
We want to grow up in our families, go to the neighborhood school, use 
the
same bus, work in jobs that are in line with our education and abilities.

Most importantly, just like everybody else, we need to be in charge of 
our
own lives, think and speak for ourselves. <BR>
<BR>
In my contribution to this congress I will address three topics that are
intimately linked to the concept of Independent Living: society's present

view of disability and sexuality; the tendency to place persons with 
disabilities
in institutions; and, thirdly, ways to support disabled people to live in

the community rather than in institutions.<BR>
<H4>Society's view of disability and sexuality</H4>
In the context of the family, the concept of Independent Living implies
that we need to take our rightful place in the family and the community
with the same duties and rights that non-disabled persons take for 
granted.
This also includes participation in one of the most important areas of 
human
life, that is loving relationships, sexuality and parenthood.<BR>
<BR>
Children with disabilities - as all children - need to be raised in the
conviction that they will grow up to be capable and attractive human 
beings
who will fall in love, get married, have children and support their 
families.
Unfortunately, this is a topic that most parents of disabled children and

professionals working in this field have great difficulties with. There
are many persons with disabilities, in Costa Rica and other countries, 
who
are married, who are fathers or mothers and who successfully raise their
children. Yet despite this evidence, the topic of sexuality, childbearing

and raising families still seems to be taboo. Parents of disabled 
children
and also professionals working in this field often do not picture us as
sexual beings who are capable of gratifying loving relationships.<BR>
<BR>
This conference about family and disability is no exception. Anybody 
looking
at the topics of this event will get the impression that disabled people
need to be taken care of like children and never grow up to be real 
adults
with jobs and families of their own. We are seen as objects, not as 
subjects,
as a burden to our families and not as contributors.<BR>
<H4>Institutionalization</H4>
As one of the results of this view of persons with disabilities, there is

a growing tendency in this country to commit us to institutions. In light

of the recent publicity around sexual abuse of residents in institutions
in Costa Rica one might well wonder whether this is really the best way
of growing up for children, whether institutions are really the best 
places
for old persons to spend their last years. Is there not enough evidence
in the form of scientific studies and statements from persons who were 
forced
to live in institutions that the best way to grow up, to live and to grow

old for all people - whether they have physical or intellectual 
disabilities
or no disabilities at all - is in one's family and the community?<BR>
<BR>
Why, then, do some families send their children or old parents away and
isolate them from normal community life? For some disabled persons one of

the biggest obstacles to staying with their families is that they need 
personal
assistance in their daily lives, for example, with getting up in the 
morning,
getting dressed, going to the toilet, with eating or getting around town.

Often, a paid worker who comes to the house of the family to provide 
these
services for a number of hours each day would be all that is needed in 
order
to keep the disabled family member out of an institution.<BR>
<BR>
Personal assistance costs money, but so does running an institution. 
Often
the institution owns its land and buildings which together represent a 
significant
capital. The country's largest institution for disabled persons, for 
example,
the Hogar de Rehabilitaci&oacute;n de Santa Ana, owns land and buildings
worth an estimated 450 millions Colones. If that capital was invested at,

say, 10% in real terms, the annual return would amount to some 45 
millions
Colones. Add to that the institution's annual budget of presently 18 
million
Colones (for the residents) and divide the result among the institution's

20 disabled residents and you get an annual amount of over 3 million 
Colones
per resident, on the average. This annual amount would surely be more 
than
sufficient to enable a family to buy assistive devices such as 
wheelchairs,
to make adaptations to the house such as adding ramps or another room, to

provide transportation to the school, pay for other services such as 
physical
therapy and, most importantly, to cover the salaries of one or two 
domestic
workers who would provide the personal assistance.<BR>
<H4>Supporting disabled people in the community</H4>
The task then seems to be to design services which support persons with
disabilities of all ages to stay and live in the community. Yet in most
countries the importance of the family as a form of social insurance is
declining. As the extended family gradually disappears with 
industrialization
and the labor market's demand on geographical mobility, as divorce rates
go up and single parents become increasingly common, the ability of the
family to provide mutual aid in everyday life is diminishing. One of the
results is that families have fewer resources left for members with 
special
needs such as disabled children or old parents. If there is no place for
these groups in the family, where can they turn to?<BR>
<BR>
In industrialized countries there has been a long history of putting 
persons
with disabilities, old and young, into institutions. The view that 
disabled
people belong in institutions is intimately linked to the notion that 
disability
is some form of disease whose carriers are to be subjected to medical 
treatment
and to isolation from the rest of humanity. Where institutions exist, 
disabled
people are seen as patients to be cared for rather than citizens who have

a right to participate in society on equal terms. Institutionalization is

increasingly questioned by organizations of persons with disabilities and

researchers. Their contention is that institutions are wasteful both in
terms of human and financial capital. They severely limit personal growth

and life opportunities and tend to be costly relative to the low level of

quality of life they provide. Rather than using public funds to maintain
institutions, it is argued, resources should be made available to support

families with disabled children or old parents.<BR>
<BR>
As developing countries, such as Costa Rica, approach the demographic 
situation
of industrialized countries, it is not always easy to avoid the mistakes
of the so-called developed countries. In the following I will attempt to
outline how families can be supported in order to avoid the 
institutionalization
of family members with disabilities. As an example, Swedish social policy

in this area will be described. <BR>
<BR>
Let me begin by stating that Sweden is not a paradise - neither for 
disabled
nor for non-disabled citizens. As in other countries, people with 
disabilities
are still second class citizens there. As a group, they are less 
educated,
have lower incomes, are less likely to work or to get married, as recent
government statistics show. But the contention is made here that some 
Swedish
social policy measures are effective in improving the living conditions
and the status of persons with extensive disabilities.<BR>
<BR>
In the metropolitan areas of Sweden, almost half of all children grow up
with only one parent. With a female labor market participation of nearly
80% child care is a common problem - not only for single parents -  for
which common solutions have been developed. By law, it is the local 
governments'
responsibility to offer child care for children from the age of a few 
months
up to 14 years during the times of the day when they are not in school 
and
the parent(s) not at home. In some communities, child care centers take
children even during night hours when the parent(s) work night shift. The

lion's share of the costs of these services is born by the local 
governments
through taxes; parents contribute with a modest fee per child. Child care

centers are open also to children with disabilities. For children with 
intellectual
disabilities or deafness, for example, it is recognized that additional
resources in the form of trained staff are needed. At least one child 
care
center in each community will have such special resources. All municipal
child care centers are integrated and accessible: children with and 
without
disabilities are welcome. The situation for public schools is similar. 
Children
with disabilities commute to child care centers or school by cabs paid 
for
by the municipality.<BR>
<BR>
All parents get a child allowance from the National Social Insurance. 
Social
Insurance also pays salaries during an employee's sick leave. Parents can

take such paid sick leave also for days when their children are sick. 
Social
Insurance  - which incidentally also covers health care including the 
provision
of assistive devices such as wheelchairs -   is funded by taxes and all
payments are made regardless of the recipients' income. For children with

disabilities who need more than 20 hours of care over and above what 
non-disabled
children of the same age might need Social Insurance pays a monthly sum
that covers the costs of a paid worker for the amount of hours needed for

which the child has been assessed by the Social Insurance's social 
worker.
For example, if it has been determined that a child needs, say, 45 hours
a week of assistance on account of its disability, Social Insurance will
pay the parents a monthly amount which corresponds to the market wage for

these hours including all social insurances and other payments that law
and labor union contracts oblige the employer to pay. The parents can 
hire
anybody they find fit for that purpose including themselves. In many 
families
one parent chooses to give up work outside the home and assist the child
instead. Other parents rather continue with their career and employ 
outside
persons for this purpose. There is also the possibility to combine these
solutions and stay with the child part of the time and employ somebody 
else
take for the remaining hours. The aim of the policy is to give parents a
choice.<BR>
<BR>
Social Insurance provides the payments for personal assistance also to 
adults
with extensive disabilities up to the age of 65. These funds allow 
persons
with extensive disabilities to hire personal assistants who will enable
them to live on their own - with or without their family. The choice is
theirs. Many persons with extensive disabilities have educated themselves

in a profession, obtained employment and started families of their own.
In most cases, these achievements would have been impossible without 
personal
assistance.<BR>
<BR>
Individuals working as personal assistants in Sweden, typically, do not
have special training in this field, since their jobs entail non-medical
tasks, such as helping the user to get dressed, to bathe, go to the 
toilet,
go to bed, cook, clean and do other household work, assist with 
transportation
and help him or her at work or accompany him around town. For 
sight-impaired
persons assistants will function as readers. For persons with 
intellectual
disabilities, assistants will provide cognitive guidance and structure.
Often, assistants are students who need part-time work, mothers of small
children who do not want to work full-time or retired persons who have 
some
spare time. Usually the user of such services will have several persons
employed in order to be flexible enough for workers' need of free time,
vacations, sick leaves and other emergencies. Having more than one 
personal
assistant will also help to decrease dependence on the person providing
these important services.<BR>
<BR>
More than half of all households in the metropolitan areas of Sweden 
consist
of single persons - mainly older people. Often, their relatives live 
elsewhere
or are unable to visit them regularly. If these old persons acquire a 
disability
which makes it difficult or impossible for them to manage their daily 
lives
by themselves, their only recourse would be an old-age home  - unless 
there
exist community based services. In Sweden, the provision of assistance 
services
to older persons is the legal responsibility of local governments. These
services are designed to assist older disabled persons - mainly single 
individuals
-  in their daily lives in their homes so that they do not need to move
to institutions. Assistants are employed by the local government's social

services office and will typically assist with meal preparation, other 
household
chores and personal hygiene, if needed. There are also paramedics 
employed
by this office who will make periodic house calls to assist older persons

with taking medication, shots and similar tasks.<BR>
<BR>
The argument can be made that policy instruments, such as those available

in Sweden, lessen the impact of a disability on the family and the 
community.
To acquire a disability need not automatically be a catastrophe for the
individual and the family, if there exists adequate support  -  
especially
in material terms. I do not claim that the family is always the best 
place
for all persons - with or without disabilities. Obviously, that will 
depend
on the family's resources in terms of the family members' motivation, 
emotional
maturity and material standard. Yet personal assistance services for 
persons
with disabilities of all ages, as described above, can support the family

and prevent its breakdown. In many instances, such services not only help

persons with disabilities to stay out of institutions but also enable 
them
to become contributing members of their families and their community, to
get employment, to get married and to have children - in short, to enable

them to do all that which this congress should have been about!<BR>
<BR>
<HR>
<P><CENTER><FONT SIZE=2>[<A 
HREF="Contents.html">Contents</A>]</FONT></CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-206</DOCNO>
<DOCOLDNO>IA012-000125-B021-42</DOCOLDNO>
<DOCHDR>
http://www.independentliving.org:80/ToolsforPower/Tools15.html 193.13.228.238 19970216214446 text/html 11929
HTTP/1.0 200 OK
Last-Modified: Tue, 06 Aug 1996 20:04:41 +0000
Date: Sun, 16 Feb 1997 21:45:01 +0000
Expires: Sun, 16 Feb 1997 21:43:21 +0000
Content-type: text/html
Server: RoxenEnterprise/1.0
Content-length: 11703
</DOCHDR>
<HTML>
<HEAD>
    <TITLE>Institute_on_Independent_Living</TITLE>
</HEAD>
<BODY BGCOLOR="#ffffff" TEXT="#020436" LINK="#000042">
<META NAME="description" 
CONTENT="Individuals and organizations of persons with disabilities can 
publish, free of charge,  articles, reports, training manuals, 
announcements, etc. on Independent Living, personal assistance, advocacy, 

peer support, accessibility, legislation and related subjects. "><META 
NAME="keywords" CONTENT="Independent Living, personal assistance, 
advocacy, peer support, direct payments, anti-discrimination legislation, 

accessibility, disability, disability rights">
<H4><IMG SRC="../InstLogoSmall.gif" WIDTH="198" HEIGHT="57" 
ALIGN="BOTTOM"
NATURALSIZEFLAG="3"></H4>
<H2>What is personal assistance ? </H2>
<BR>
<FONT SIZE="+3">E</FONT>verybody uses assistance. Nowadays, we all are 
dependent
on each other. Nobody can perform all the tasks necessary to sustain his
life-style. So, people instead of fixing their own car take it to a 
mechanic.
Most people do not know enough about cars or do not have the time. By 
utilizing
somebody else's knowledge and resources we can compensate our lack of 
ability
or lack of time. People like to specialize in doing what they are good 
at.
Most other things they delegate to somebody else. In this way one can be
more efficient in the sense that one gets more done. <BR>
&quot;Personal assistance&quot; then means that we compensate our 
disabilities
by delegating tasks to other persons. These tasks involve activities 
which
we cannot carry out ourselves or which we are not good at. We delegate in

order to have the time and energy to specialize in those activities which

we can perform well. &quot;Personal&quot; connotes that the assistance 
has
to be customized to my individual needs. &quot;Personal&quot; also means
that the user decides what activities are to be delegated, to whom and 
when
and how the tasks are to be carried out. I think in a world of personal
computers and personal telephones the term &quot;personal 
assistance&quot;
is quite descriptive.<BR>
<BR>
What are the alternatives to &quot;personal assistance&quot;? In English,

the terms &quot;attendants&quot;, &quot;personal care attendants&quot;,
&quot;carer&quot;, &quot;home help&quot;, etc are used. Most of these 
words
contain the word &quot;care&quot;. To me this word carries the 
connotation
of taking care of somebody who cannot take care of himself or herself. 
The
relationship between &quot;carer&quot; and &quot;caree&quot; implied by
this term is not one of voluntary association for mutual gain, it does 
not
clearly state that the &quot;caree&quot; is the one who decides what has
to be done. The term &quot;home helper&quot; indicates that 
&quot;help&quot;
is to support activities only in one's home as opposed to a lot of other
places such as at work, on the bus, at a friends' house, on trips, etc.
I am sure that in most languages we will find similar expressions which
imply that we are helpless, somewhat stupid persons who, like small 
children,
cannot look after themselves and need supervision.<BR>
<BR>
If we want to design services which get us closer to the goal of equal 
opportunities,
we have to find expressions for such services which portray us as 
responsible
and capable citizens who are in command of their lives and not as passive

objects. Language both influences and reveals attitudes including our own

attitudes towards ourselves. <BR>
<BR>
In what forms has assistance been available so far? 
<H4>Family as assistance provider</H4>
<FONT SIZE="+3">I</FONT>n most countries the most common form is the 
family.
Reliance on the family may work for some time but the limitations - even
under the best of circumstances - are given. Family members get older, 
they
are risking their health in assisting us. Children often have to take too

much responsibility too early in their lives. Adults cannot pursue their
career and feel locked in. The results are relationships of mutual 
dependence,
sacrifice and guilt. Where guilt is often mistaken for love.<BR>
<BR>
Facing the alternative which in many countries is institutional placement

of the disabled family member most families hold out as long as they can
- often without any outside assistance - burdened by immense physical, 
financial
and emotional strain. 
<H4>Volunteers</H4>
<FONT SIZE="+3">I</FONT>n some places families get help from volunteers.
The virtues of volunteerism are most often praised by conservative 
politicians
whose motives are to cut taxes for the benefit of their voters. 
Obviously,
users of assistance from volunteers cannot demand the same competent, 
punctual,
and courteous work from volunteers as they might from assistants who are
paid competitive wages. But in most instances users who utilize 
volunteers
do not have that choice. 
<H4>Stationary institutions</H4>
<FONT SIZE="+3">T</FONT>he alternative that most of us in Europe have is
to live in some sort of institution. Institutions are administrative 
entities
and as such are governed by the necessities of administering buildings,
workers and inmates within the boundaries given by budget, labor unions,
and state regulatory agencies. These constraints are expressed in a 
multitude
of rules which cannot be adapted to the needs of each individual. 
Otherwise
there would be chaos. As a result, a certain order has to be maintained
to guarantee the smooth functioning of the whole. The individual's 
challenge,
then, is to adapt himself or herself to the existing order both 
physically
and psychologically without losing one's integrity as a human being. That

is very difficult. One of the survival strategies is to develop a 
pleasing
personality with which you can achieve privileges at the expense of other

inmates who are not as adaptable. <BR>
<BR>
The general results of institutional living are known as 
&quot;hospitalism&quot;,
that is loss of social skills, foregone life opportunities, and stunted
human growth. The problem we are facing in helping people who have been
staying in institutions is that they often have lost their 
self-confidence
and are frightened by the prospect of leaving their secure confinement.
<H4>A definition of an institution</H4>
<FONT SIZE="+3">P</FONT>erhaps it is appropriate at this point to attempt

a definition of an institution. I suggest that we face an institution if
<UL>
  <LI>there is no other alternative, 
  <LI>we cannot choose who is to assist us, 
  <LI>the user has to adapt his needs to the needs of the whole scheme,
  <LI>there are written and unwritten rules regulating the assistance, 
rules
over which the user has no control, 
  <LI>the assistance is limited to certain hours, activities, locations
(for example, you have to live in certain houses as opposed to living 
anywhere),
  <LI>the staff providing assistance is shared by several persons, 
  <LI>there is a hierarchy with the user at the bottom of the pyramid. 
</UL>
If we accept this list of institutional characteristics, then most forms
of assistance fall under this category. 
<H4>Mobile, ambulatory institutions</H4>
<FONT SIZE="+3">T</FONT>ake community-based public services. In most of
these schemes a caseworker at the municipal social service department or
at some charity organization assesses your needs and sends workers into
your home. Tasks and hours are well defined. Hiring, training and 
scheduling
of the workers is done by the supervisor. These services constitute a 
tremendous
advantage over institutional placement. But you as the user are not in 
control,
you share assistants whom you cannot choose or train yourself. As a 
result,
you are made dependent on other persons' judgement and have to limit your

life. You might even limit the use of this type of service to the 
absolute
minimum, because the quality is so low.<BR>
<BR>
Sometimes community-based services are run by organizations of disabled
people. If they use the same organizational solutions, the quality of 
their
services will not be much better. 
<H4>False independence</H4>
<FONT SIZE="+3">T</FONT>hose of us who need assistance are used to 
restricted
lives. For one, most of us have been exposed to the present 
rehabilitation
philosophy which wants us to do as much for ourselves as we possibly can
and even more. &quot;Push your limits, try harder. Exercise, exercise. 
Don't
get lazy, use your manual wheelchair, not your power chair! &quot;<BR>
<BR>
Our first goal, according to rehabilitation professionals, is to be 
independent
and manage with a minimum of technical aids. Personal assistance should
only be used as a very last resort, since it is considered a recognition
of failure on the part of the professionals and ourselves. Or have any of

us been taught by a rehabilitation specialist how to delegate tasks to 
other
people? Many of us have accepted these professional priorities. Their 
purpose
in life seems to get out of bed by themselves, get washed and dressed by
themselves, to cook and clean. Never mind that it takes the whole 
morning.
Never mind that they get so worn out that they have to rest the other 
half
of the day to recover enough strength for going to bed. They may not have

a job, they may not be able to do much outside the home, they may not 
have
time and energy to get involved in disability politics and fight for 
equal
rights. But they are proud of being independent. <BR>
<BR>
This narrow definition of independence is reinforced by society around 
us.
&quot;Good boy, look how hard he is trying!&quot; Politicians and 
administrators
like to see us try hard, since they save money on us this way. Personal
assistance is expensive. But what a narrow definition of costs this is!
What about the time and energy we could use for other achievements, if we

allowed ourselves to use personal assistance! <BR>
<BR>
Medical evidence in recent years shows that many of us overexert their 
remaining
muscles, nerve cells and ligaments. As a result they wear themselves out
before their time. Too much exercise may cause irreparable damage. The 
harder
we try, the faster we waste ourselves.<BR>
<BR>
The brainwashing that many of us receive in rehabilitation distracts us
often effectively from painful comparisons with other people, our 
non-disabled
friends, relatives and neighbors. How often do we allow ourselves to 
compare
our lives with theirs? It can be painful to admit to oneself that we too
would like to have a good job, a nice home and a family. But for many of
us these things will be out of reach forever, if we do not have the 
possibility
of delegating practical tasks to personal assistants. Ultimately, it is
a question of self-respect. If we respect ourselves as persons of equal
value, then we expect and demand the same lifestyle that others take for
granted. Then, we will also want to use personal assistance as one of the

tools to achieve these goals.<BR>
<BR>
I would like to use an analogy. An entrepreneur or administrator will 
realize
that he or she alone can get done only so much. By employing other 
persons
the entrepreneur can delegate work and in this way increase the total 
output.
Would it be wise for a factory owner to try to do everything all by 
himself?
Most likely such a person would either die of exhaustion or be out of 
business
pretty fast. If entrepreneurs and administrators are not ashamed to 
utilize
manpower to achieve their goals why should we hesitate to do the same? 
<BR>
<BR>
Adolf Ratzka <BR>
<P><CENTER><HR><FONT SIZE=2>[<A HREF="Tools1.html">Tools for Power 
contents]</A></FONT><FONT SIZE=2>[<A HREF="../Contents.html">Institute
on Independent Living contents</A>]</FONT></CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-207</DOCNO>
<DOCOLDNO>IA012-000125-B021-67</DOCOLDNO>
<DOCHDR>
http://www.independentliving.org:80/PersonalAssistance%26Pride.html 193.13.228.238 19970216214507 text/html 4694
HTTP/1.0 200 OK
Last-Modified: Thu, 22 Aug 1996 17:40:37 +0000
Date: Sun, 16 Feb 1997 21:45:23 +0000
Expires: Sun, 16 Feb 1997 21:43:43 +0000
Content-type: text/html
Server: RoxenEnterprise/1.0
Content-length: 4469
</DOCHDR>
<HTML>
<!--This file created 96-07-13 17.44 by Claris Home Page version 1.0b1-->

<HEAD>
    <TITLE>Institute_on_Independent_Living</TITLE>
</HEAD>
<BODY TEXT="#010b3b" BGCOLOR="#ffffff">
<META  name="description"
content="Individuals and organizations of persons with disabilities can 
publish, free of charge,  articles, reports, training manuals, 
announcements, etc. on Independent Living, personal assistance, advocacy, 
peer support, accessibility, legislation and related subjects. "><META  
name="keywords" content="Independent Living, personal assistance, 
advocacy, peer support, direct payments, anti-discrimination legislation, 
accessibility, disability, disability rights"><X-SAS-WINDOW TOP="66" 
BOTTOM="624" LEFT="8" RIGHT="538">
</HEAD><BODY TEXT="#00003D" BGCOLOR="#FFFFFF" LINK="#000038"><BR>
<IMG SRC="InstLogoSmall.gif" WIDTH="198" HEIGHT="57" ALIGN="BOTTOM" 
NATURALSIZEFLAG=
"3"><BR>
<BR>
<BR>
<BR>
Presented at the Disability Pride Parade in Dublin November 1993  by 
Adolf
Ratzka<BR>
<BR>
<BR>
<BR>
<H2><CENTER>Personal Assistance and Disability Pride</CENTER>
</H2>
<BR>
Today we celebrate Disabilty Pride and Dignity. In order to be proud, 
though,
many of us need personal assistance services.<BR>
<BR>
I was forced to spend 5 years of my youth in an institution, because I 
happen
to need personal assistance. A personal assistant is somebody who gets 
paid
for helping me with the things I cannot do by myself like bathing, 
getting
dressed, cooking or cleaning. At that time there existed no such services

in the community. Those 5 years were the most miserable years in my life.

<BR>
<BR>
Today, Irish citizens are still spending their lives in institutions. 
Many
Irish citizens cannot decide when they eat and when they go to bed. <BR>
<BR>
<I>It is hard to be proud, when somebody else decides when you go to the
toilet. <BR>
It is hard to be proud, when you cannot come and go as you 
please.</I><BR>
<BR>
Without personal assistance services people like me are forced into 
institutions.
Without personal assistance services we become a burden on our families.
<BR>
<BR>
It is hard to to be proud when you are seven years old and still need to
ask your mom to pull up your pants.  It is even harder when you are 
40.<BR>
<BR>
Years ago I was living together with a woman. She helped me get up in the

morning, go to the toilet, get dressed. She did the shopping, cooking and

cleaning. She worked 7 days a week, every week of the month, 12 months 
out
of the year. I needed her for everything  -  she knew I was helpless 
without
her. We were chained together. After 1 1/2 years she left.<BR>
 <BR>
<I>On that day it was very difficult to be proud.</I><BR>
<BR>
Today I live in Sweden, I am getting money from the state that covers the

cost of 12 hours of personal assistance a day. With that money I can hire

the people I want to work for me. I am the employer, I decide who will 
work,
when they will work, what is to be done and how it is to be done. I 
decide
when I get up in the morning and when I go to the toilet. My personal 
assistants
help me at my work, they drive me to my meetings, they accompany me on my

travels.<BR>
<BR>
Today I am married. I am not dependent on my wife for personal 
assistance.
I manage by myself - with the help of my assistants. My wife and I share
the household work fifty-fifty. I do my share with the help of my 
assistants.
She does the laundry, I do the cleaning. We share the cooking. I take 
great
pride in the fact that my cooking is at least as good as hers.<BR>
<BR>
We soon expect a child and my assistants will help me to take my part of
the practical work that a baby entails. <BR>
<BR>
Without personal assistance services I would have been hesitant to marry.

<BR>
Without personal assistance services we would not have decided to have a
child.<BR>
<BR>
<I>The day the baby arrives I will be very proud.</I><BR>
<BR>
Thousands of Irish citizens are still dependent on their families or are
living in institutions. For thousands of Irish citizens life is a 
spectator
sport. To work, to travel, to fall in love and raise a family is 
something
they watch other people do on television.<BR>
<BR>
Thousands of Irish people could be proud and productive citizens, if they

had personal assistance services.<BR>
<BR>
<HR><BR>
<P><CENTER><FONT SIZE=2><A HREF="Contents.html">[Institute on Independent

Living contents</A><A HREF="index.html">]</FONT></A></CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-208</DOCNO>
<DOCOLDNO>IA012-000125-B021-104</DOCOLDNO>
<DOCHDR>
http://www.independentliving.org:80/IntroDirectPayments.html 193.13.228.238 19970216214525 text/html 9211
HTTP/1.0 200 OK
Last-Modified: Sun, 29 Sep 1996 08:29:17 +0000
Date: Sun, 16 Feb 1997 21:45:39 +0000
Expires: Sun, 16 Feb 1997 21:43:59 +0000
Content-type: text/html
Server: RoxenEnterprise/1.0
Content-length: 8986
</DOCHDR>
<HTML>
<HEAD>
    <TITLE>Institute_on_Independent_Living</TITLE>
</HEAD>
<BODY TEXT="#020a3f" BGCOLOR="#ffffff" LINK="#000042">
<META NAME="description" 
CONTENT="Individuals and organizations of persons with disabilities can 
publish, free of charge,  articles, reports, training manuals, 
announcements, etc. on Independent Living, personal assistance, advocacy, 

peer support, accessibility, legislation and related subjects. "><META 
NAME="keywords" CONTENT="Independent Living, personal assistance, 
advocacy, peer support, direct payments, anti-discrimination legislation, 

accessibility, disability, disability rights"><BR>
<IMG SRC="InstLogoSmall.gif" WIDTH="198" HEIGHT="57" ALIGN="BOTTOM" 
NATURALSIZEFLAG=
"3"> <BR>
<BR>
<H3>Introduction to direct payments for personal assistance</H3>
<H4>Independent Living</H4>
<BR>
Independent Living is a philosophy and a movement of people with 
disabilities
who work for equal rights and equal opportunities, self-respect and 
self-determination.
&quot;Independent Living&quot; does not mean that persons with 
disabilities
do not need anybody, that they want to do everything by themselves or 
live
in isolation. &quot;Independent Living&quot; means that disabled people
want the same life opportunities and the same choices in every-day life
that their non-disabled brothers and sisters, neighbours and friends take

for granted. That includes growing up in their families, going to the 
neighbourhood
school, using the same bus,  getting employment that is in line with 
their
education and abilities, having equal access to the same services and 
establishments
of social life, culture and leisure. Most importantly, just like everyone

else, persons with disabilities need to be in charge of their own lives,
need to think and speak for themselves without interference from 
others.<BR>
<BR>
To this end persons with disabilities need to learn from and support each

other, organize themselves and work for political changes that lead to 
legal
protection of their human and civil rights. Traditionally, disabled 
persons
have been seen as medical cases and objects of charity and care, pity and

protection. These wide-spread attitudes have been obstacles on their way
to self-determination, self-representation and full citizenship.<BR>
<BR>
In order to reach the same control and the same choices in every-day life

that non-disabled persons take for granted a number of prerequisites are
necessary. For persons with extensive disabilities there are two key 
requirements:
personal assistance and accessibility in the built environment including
accessible housing. Without these two necessities persons with extensive
disabilities can choose only between being a burden on their families or
living in an institution. These extremely limited and limiting options 
are
incompatible with the concept of Independent Living. 
<H4>Personal assistance</H4>
Assistance from paid workers enables the user to carry out such every-day

activities as bathing and dressing, and going to the toilet; household 
chores
such as shopping, preparing meals and cleaning. Assistants help the user
at work, about town and on travel. They assist in communicating or in 
structuring
the day, as the case might be. In brief, assistants help with those 
activities
which the user would have done by himself or herself, had it not been for

a physical, sensory, mental or intellectual disability. <BR>
<BR>
People who are dependent on others for the most basic needs of life face
prejudices. Given their physical dependency the conclusion is close at 
hand
to consider them as dependent on others also emotionally and 
intellectually.
Somebody who cannot pull up his or her pants like a small child, may be
treated as a small child in other respects as well. The result is often
over-protection and custodial care where other people make the 
decisions.<BR>
<BR>
It is no surprise then that the Independent Living philosophy is most 
easily
grasped by people who are dependent on  assistance in their every-day 
lives.
This is also the reason why the Independent Living Movement emphasizes 
the
importance of the quality of assistance for users who want to achieve 
maximum
independence. In order to provide an operational definition for quality,
the Independent Living Movement coined and defined the term 
&quot;personal
assistance&quot;:<BR>
<BR>
&quot;Personal&quot; assistance means that users exercise the maximum 
control
over how services are  organised and custom-design their services 
according
to their individual needs, capabilities, life circumstances and 
aspirations.
In particular, personal assistance requires that the individual user 
decides
<UL>
  <LI>who is to work, 
  <LI>with which tasks, 
  <LI>at which times, 
  <LI>where and 
  <LI>how.
</UL>
Thus, the individual user must be able to recruit, train, schedule, 
supervise,
and, if necessary, fire his or her own assistants. Simply put, 
&quot;personal
assistance&quot;, means that the user is the boss.<BR>
<BR>
It is recognised that users with learning or mental disabilities will 
need
support from third persons with these functions. <BR>
<BR>
Personal assistance enables users to take their rightful place in family,

at work and society with all the rights and duties that the general 
population
takes for granted. With personal assistance persons with extensive 
disabilities
need no longer be a burden on their families. Parents, husbands or wives
do not need to stay at home and sacrifice their careers. Personal 
assistance
users not only manage on their own, they can also take their share of 
household
and child-rearing. With personal assistance we can attend school and 
educate
ourselves, enter the labour market and become tax-payers. When we fall in

love, our partners need not fear that they are about to sign up for a 
life-long
24 hour job.<BR>
<BR>
Most existing services cannot be called &quot;personal&quot; assistance,
since they are not custom-made to the individual&#180;s needs and do not
allow control and acceptable choices. Most often users are not in the 
position
to recruit their own assistants. Instead, they have to accept assistance
from the available staff. This is true for both stationary institutions
or their &quot;ambulatory&quot; counterparts   -  the community-based 
services
of local governments or voluntary organisations. Inherent in these 
solutions
is their hierarchical structure with the user at the bottom. Users are 
forced
to share the common staff which, in itself, reduces choices and freedom
of movement. <BR>
<BR>
Other limitations exist when assistants do not have proper employment 
contracts
and wages. Then, users can neither demand quality work, attention and 
reliability
nor can they feel in charge. 
<H4>Direct Payments</H4>
Today, most assistance services control and limit our lives, make us 
dependent
and helpless. The solution is for us to take a position where we no 
longer
have to adapt our needs to the needs of the service provider but instead
shape our own services according to our needs. Turning &quot;care&quot;
into &quot;personal assistance&quot; requires a fundamental shift in the
distribution of power between user and provider. One precondition for 
this
change is an altered self-perception of the user of the services. Instead

of seeing oneself as the passive object of other people's interventions,
the user needs to be the subject, in charge of his or her own life. The
best help in facilitating the change is peer support. The other 
precondition
is having access to the funds it takes to hire one's assistants. Both 
requirements
go hand in hand. <BR>
<BR>
In order to have access to the necessary money we need to rechannel the
resources which are used in the disability field today. Instead of 
passively
receiving services, the individual user needs to have the money which 
these
services cost. With the same amount users can achieve a better quality of

life. With money in our hands, we can buy services from the provider of
our choice. Or we hire, train and fire our own assistants which is the 
most
direct control over service quality.<BR>
<BR>
Services in kind control us, direct payments empower us. <BR>
<BR>
Resistance to the simple idea of direct payments has been strong given 
the
vested interests of many service providers and the wide-spread prejudices

against disabled people according to which they cannot act in their own
best interest and need to be &quot;taken care of&quot;.<BR>
<BR>
Direct payments are truly the state of the art when it comes to enabling
persons with extensive disabilities to reach self-determination, 
integrity
and full citizenship. <BR>
<BR>
<BR>
Adolf Ratzka<BR>
<BR>
Presentation given at the HELIOS Study Visit on Independent Living and 
Personal
Assistance in Stockholm, June 7-9, 1996. <BR>
<P><CENTER><HR><FONT SIZE=2>[<A HREF="Contents.html">Institute on 
Independent
Living contents</A>]</FONT></CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-209</DOCNO>
<DOCOLDNO>IA012-000125-B021-144</DOCOLDNO>
<DOCHDR>
http://www.independentliving.org:80/WRFmono/WRFmono1.html 193.13.228.238 19970216214553 text/html 25130
HTTP/1.0 200 OK
Last-Modified: Fri, 27 Sep 1996 19:27:48 +0000
Date: Sun, 16 Feb 1997 21:45:59 +0000
Expires: Sun, 16 Feb 1997 21:44:19 +0000
Content-type: text/html
Server: RoxenEnterprise/1.0
Content-length: 24904
</DOCHDR>
<HTML>
<HEAD>
    <TITLE>The_Institute_on_Independent_Living</TITLE>
</HEAD>
<BODY TEXT="#00003d" BGCOLOR="#ffffff" LINK="#000047">
<META NAME="description" 
CONTENT="Individuals and organizations of persons with disabilities can 
publish, free of charge,  articles, reports, training manuals, 
announcements, etc. on Independent Living, personal assistance, advocacy, 

peer support, accessibility, legislation and related subjects. "><META 
NAME="keywords" CONTENT="Independent Living, personal assistance, 
advocacy, peer support, direct payments, anti-discrimination legislation, 
accessibility, disability, disability rights"> <P><CENTER><B>INDEPENDENT
LIVING AND ATTENDANT CARE IN SWEDEN:<BR>
<BR>
A CONSUMER PERSPECTIVE</B><BR>
<BR>
<BR>
by<BR>
Adolf D. Ratzka, Ph.D.<BR>
<BR>
<BR>
Research Economist<BR>
School of Architecture<BR>
Institute of Technology<BR>
Stockholm, Sweden<BR>
<BR>
<BR>
Consultant<BR>
World Institute on Disability<BR>
Berkeley, California<BR>
U.S.A.<BR>
<BR>
<BR>
Spring 1986<BR>
World Rehabilitation Fund, New York<BR>
Monograph No. 34<BR>
<A NAME="anchor3221093"></A><BR>
<HR></CENTER>
<H3>Table of Contents</H3>
<BLOCKQUOTE><A HREF="#anchor4188711">Foreword to the Internet 
edition</A><BR>
<A HREF="#anchor4402202">Acknowledgements</A><BR>
<A HREF="#anchor4405900">About the Author</A><BR>
<A HREF="#anchor3227165">Note to the Reader</A> </BLOCKQUOTE>
<DL>
  <DD><A HREF="#anchor4410164">I. Introduction: Definitions, Scope and 
Purpose
of the Monograph<BR>
</A><BR>
  <DD><A HREF="WRFmono2.html#anchor3235368">II. Swedish Social Welfare 
Policy</A>
  <DD><A HREF="WRFmono2.html">Division of Responsibility</A> 
  <DD><A HREF="WRFmono2.html#anchor4417627">National Insurance Benefits
Available to All</A> 
  <DD><A HREF="WRFmono2.html#anchor4425605">De-Institutionalization 
Efforts
for People with Disabilities and Older Persons</A> 
  <DD><A HREF="WRFmono2.html#anchor4455484">Cash Payments</A> 
  <DD><A HREF="WRFmono2.html#anchor4435405">Assistive Devices</A> 
  <DD><A HREF="WRFmono2.html#anchor4459707">Accessibility in the Built 
Environment</A>
  <DD><A HREF="WRFmono2.html#anchor4465647">Transportation</A> 
  <DD><A HREF="WRFmono2.html#anchor4468178">Personal Assistance at Work
and in School</A> 
  <DD><A HREF="WRFmono2.html#anchor4471978">Swedish Studies on the 
Requirements
of De-Institutionalization</A> 
  <DD><BR>
  <DD><A HREF="WRFmono3.html#anchor3538389">III. In-Home Personal 
Assistance</A>
  <DD><A HREF="WRFmono3.html#anchor3538389">In-Home Personal Assistance
Available to Other Groups</A> 
  <DD><A HREF="WRFmono3.html#anchor4479041">Brief History of Swedish 
In-Home
Personal Assistance Programs</A> 
  <DD><A HREF="WRFmono3.html#anchor3550829">Description and Analysis of
In-Home Personal Assistance Programs</A> 
  <DD><A HREF="WRFmono3.html#anchor3550829">User Statistics</A> 
  <DD><A HREF="WRFmono3.html#anchor4483613">Administration</A> 
  <DD><A HREF="WRFmono3.html#anchor4486862">Needs Assessment</A> 
  <DD><A HREF="WRFmono3.html#anchor4489110">Assistants</A> 
  <DD><A HREF="WRFmono3.html#anchor4491339">Costs</A> 
  <DD><A HREF="WRFmono3.html#anchor4493417">County Home Health 
Services</A>
  <DD><A HREF="WRFmono3.html#anchor4496007">Escort Services</A> 
  <DD><A HREF="WRFmono3.html#anchor4497985">Evening Patrols</A> 
  <DD><A HREF="WRFmono3.html#anchor4500146">Emergency Call Systems</A> 
  <DD><A HREF="WRFmono3.html#anchor4502360">Fokus or Cluster Housing</A>
  <DD><A HREF="WRFmono4.html#anchor3584217">Assessment of Personal 
Assistance
Services</A> 
  <DD><A HREF="WRFmono4.html#anchor3584217">Administrative 
Compartmentalization
of Personal Assistance Services</A> 
  <DD><A HREF="WRFmono4.html#anchor4506652">Economics of and Obstacles to

De-Institutionalization</A> 
  <DD><A HREF="WRFmono4.html#anchor4511829">Professionalization and 
Limited
Consumer Input</A> 
  <DD><A HREF="WRFmono4.html#anchor4516079">Decentralized Financial 
Responsibility
and Regional Inequality</A> 
  <DD><A HREF="WRFmono4.html#anchor4520199">Limited Choices</A> 
  <DD><A HREF="WRFmono5.html#anchor3623507">STIL: Consumer Reaction in 
the
Form of An Incipient Independent Living Movement</A> 
  <DD><BR>
  <DD><A HREF="WRFmono5.html#anchor3631353">IV. Research Issues</A> 
  <DD><A HREF="WRFmono5.html#anchor4524883">Needs Assessment</A> 
  <DD><A HREF="WRFmono5.html#anchor4527175">Re-defining Institutions</A>
  <DD><A HREF="WRFmono5.html#anchor4529969">Degree of Consumer Control 
and
Independent Living Outcomes</A> 
  <DD><A HREF="WRFmono5.html#anchor4533989">Quality Criteria</A> 
  <DD><A HREF="WRFmono5.html#anchor4536679">Designing Programs for A 
Continuum
of Consumer Control and Consumer Needs</A> 
  <DD><BR>
  <DD><A HREF="WRFmono6.html#anchor3667644">V. In Closing</A> 
  <DD><BR>
  <DD><A HREF="WRFmono6.html#anchor3670910">Appendix: Design Criteria for

Personal Assistance Programs</A><BR>
<A HREF="WRFmono6.html#anchor4545218">Overriding Criterion</A> 
  <DD><A HREF="WRFmono6.html#anchor4547826">Language and Attitudes</A> 
  <DD><A HREF="WRFmono6.html#anchor4550559">Consumers As Experts</A> 
  <DD><A HREF="WRFmono6.html#anchor4553214">Services for All Needs</A> 
  <DD><A HREF="WRFmono6.html#anchor4557009">Choice and Changing Needs</A>

  <DD><A HREF="WRFmono6.html#anchor4559691">Programs for Consumer 
Productivity</A>
  <DD><A HREF="WRFmono6.html#anchor4562571">No Volunteer Programs</A> 
  <DD><A HREF="WRFmono6.html#anchor4565472">Funding As Centralized As 
Possible</A>
  <DD><A HREF="WRFmono6.html#anchor4568145">Service Delivery As 
Decentralized
As Possible</A> 
  <DD><A HREF="WRFmono6.html#anchor4571710">Worker Professionalization 
vs.
Consumer Expertise</A> 
  <DD><A HREF="WRFmono6.html#anchor4574600">&quot;Ambulatory 
Institutions&quot;</A>
</DL>
<BLOCKQUOTE><A HREF="WRFmono6.html#anchor3706427">Sources<BR>
<BR>
Commentaries</A></BLOCKQUOTE>
<BLOCKQUOTE>
<DL>
  <DD><A HREF="WRFcomments.html#anchor5699024">Carolyn L. Vash, Ph.D.</A>

  <DD><A HREF="WRFcomments.html#anchor5704426">Hale Zukas</A> 
  <DD><A HREF="WRFcomments.html#anchor5707337">Margaret A. Nosek, 
Ph.D.</A>
  <DD><A HREF="WRFcomments.html#anchor5711231">Gerben DeJong, Ph.D.</A><A

NAME="anchor4188711"></A> 
</DL>
</BLOCKQUOTE>
<P><CENTER><HR></CENTER>
<H3>Foreword to the Internet edition</H3>
<FONT SIZE="+3">A</FONT>s a description of the present Swedish situation
the monograph is getting old and outdated. Much has changed in Swedish 
disability
politics. The government&#180;s austerity programs during the last few 
years
have also affected the disability sector. Living conditions and services
have in many instances worsened. A notable exception is the Personal 
Assistance
Reform (in Swedish known as &quot;Lagen om 
Assistansers&auml;ttningen&quot;
or LASS) which grants eligible persons the legal right to receive funds
directly from the national social insurance scheme to hire one&#180;s own

personal assistants or to purchase such services from the provider of 
one&#180;s
choice.<BR>
<BR>
The reform has come about to a large extent due to the pioneering efforts

of STIL, the Stockholm Cooperative for Independent Living, its 
demonstration
of the viability of consumer-run services, and its political work. <BR>
<BR>
As a background description of the factors leading to the new social 
movement
started by STIL and the PErsonal Assistance Reform the monograph is still

very much relevant. After browsing through the monograph the reader will
better understand the articles found in this database about STIL and its
impact on present day Swedish social policy in this area.<BR>
<BR>
For our Japanese readers: the monograph has been updated and translated
into Japanese and is available from Gendai Shokan Co., Ltd., 2-2-112 
Misakicho
Chiyoda-ku, Tokyo.<BR>
<BR>
Adolf D. Ratzka, PhD<BR>
Founder of STIL<BR>
<BR>
March 1996<BR>
<A NAME="anchor4402202"></A><BR>
<HR>
<H3>Acknowledgements</H3>
<BR>
<FONT SIZE="+3">T</FONT>he present study would not have been possible 
without
the support and kind encouragement of many people. First of all, I would
like to thank the World Rehabilitation Fund, Inc., New York for a grant
which enabled me to spend three months in the spring of 1985 in the 
United
States working as a guest researcher at the World Institute on Disability

in Berkeley, California. The present monograph has its origin in my work
at the Institute and my talks at several conferences during this period,
in particular, the conference on attendant care in Washington, D.C. in 
March
1985 sponsored by the World Rehabilitation Fund and the Third 
International
Polio and Independent Living Conference in St. Louis in May 1985 
sponsored
by the Gazette International Networking Institute, St. Louis. I am 
especially
indebted to Ms. Diane E. Woods, Project Director and Dr. James F. 
Garrett,
Executive Vice President of the World Rehabilitation Fund who arranged 
the
publication of the study.<BR>
<BR>
A number of persons reviewed the manuscript and through their 
encouragement,
critique, suggestions, and questions forced me to clarify and improve the

monograph. Among them I would like to thank my friends and colleagues at
the World Institute on Disability Ms. Judy Heumann, Ms. Joan Leon, Dr. 
Simi
Litvak, and Mr. Hale Zukas; Dr. Gerben DeJong, Drs. Patricia and Joseph
Kauffert, Faculty of Medicine, University of Manitoba, Winnipeg; Dr. 
Margaret
A. Nosek, Independent Living Research Utilization, Texas Institute of 
Rehabilitation
Research, Houston; Ms. Linda Toms Barker, Berkeley Planning Associates,
Berkeley; Dr. Caroline L. Vash, Ms. Karin M&aring;nsson, 
Handikappinstitutet,
Stockholm; Ms. Margareta Nordstr&ouml;m, formerly of the National Board
of Social Welfare (Socialstyrelsen), Stockholm; Mr. Lars-Olof Petersson,
National Association of the Traffic and Polio-Injured (Riksf&ouml;rbund
f&ouml;r Trafik- och Polioskadade), Stockholm; and Dr. Gerdt 
Sundstr&ouml;m,
Department of Gerontology, University of J&ouml;nk&ouml;ping.<BR>
<BR>
I cannot list all of those who have encouraged and supported my interest
and work in the area of consumer-controlled personal assistance. But I do

want to mention my friends in the international Independent Living 
Movement,
Ms. Judy Heumann and Mr. Ed Roberts, World Institute on Disability, 
Berkeley;
Ms. Gini Laurie, Gazette International Networking Institute, St. Louis;
Dr. August R&uuml;ggeberg, Munich, West Germany; Mr. Kalle 
K&ouml;nk&ouml;ll&auml;,
MP, Finland. I also wish to thank Mr. Folke Carlsson, National Board of
Attendants' Service (Styrelsen f&ouml;r v&aring;rdartj&auml;nst), 
Stockholm,
the mentor of the STIL-project; Prof. Sven Thiberg, Institute of 
Technology,
Stockholm; and, most importantly, my friends at STIL (Stockholm 
Independent
Living group) and all the other consumers of personal assistance who let
me share their experiences. <BR>
<BR>
The shortcomings of this monograph are entirely my responsibility and can

in no way be attributed to any of the above listed persons or 
organizations.
<BLOCKQUOTE>Adolf D. Ratzka, Ph.D.<BR>
Royal Institute of Technology<BR>
Stockholm<BR>
February 1986 <BR>
<A NAME="anchor4405900"></A></BLOCKQUOTE>
<HR>
<H3>About the Author</H3>
<BR>
<FONT SIZE="+3">D</FONT>r. Ratzka has been using personal assistants 
since
1961, when he became disabled by polio in his native West Germany. He 
received
his academic training at the University of California at Los Angeles 
(B.A.
in Sociology, M.S. in Business Administration, Ph.D. in Management) and
the University of Stockholm (fil. kand. in Psychology). Since 1973 he has

had his base in Stockholm, Sweden where he works as research economist at

the School of Architecture, Institute of Technology. His current research

interests include cost-revenue studies on accessibility in housing, 
de-institutionalization,
and personal assistance for people with disabilities and older 
persons.<BR>
<BR>
Dr. Ratzka has been a consumer of personal assistance services in West 
Germany,
the United States, and Sweden. Influenced by his frequent contacts with
the Independent Living Movement in the US and other countries he took the

initiative for setting up a pilot project in Stockholm where consumers of

personal assistance organize and administer their own individual 
service.<BR>
<A NAME="anchor3227165"></A>
<H3>Note to the Reader</H3>
<FONT SIZE="+3">T</FONT>he title of this monograph contains the 
expression
&quot;a consumer perspective&quot;. Implied here is the notion that there

is no &quot;value free&quot; treatment of social policy and that there 
are
several viewpoints from which to approach attendant care programs and 
social
services in general. Much of the existing work in this area, be it 
descriptive
or analytic, is commissioned or undertaken by government bodies or 
service
providers. As a natural consequence, such studies tend to focus on 
aspects
such as budgetary requirements or the administrative needs of the agency
and its workers. Seldom is the emphasis on the needs of the consumers of
these services. While, for example, the discussion of costs invariably is

paid a great deal of attention, the quality of the services - the 
variable
that is uppermost in the consumer's mind - is quite often blatantly 
overlooked.
Therefore, analysts and researchers who want to support the demands 
raised
by people with disabilities for services which allow full participation
and equality, have to propagate the notion of consumer-oriented research.

Consumer-oriented research here means work which uses consumer-oriented
criteria and, ideally, is consumer-initiated and controlled. The present
study carried out under the auspices of the World Institute on 
Disability,
a consumer-run policy research and training institute, is an attempt in
this direction.<BR>
<BR>
I find it difficult to give a balanced analysis of Swedish social policy
to a non-Swedish audience. There is a strong temptation to concentrate on

the accomplishments of the Swedish system and to focus on the impressive
array of cash payments and in-kind benefits that make one's material life

as a person with an extensive disability so much easier in Sweden than in

the other countries I have visited and lived in. Speaking abroad to 
disability
advocates and service providers I feel very strongly that I am expected
to provide positive examples of what can be accomplished by a country's
population and politicians who, for the most, believe in equality - not
only at the starting line but also at the finishing line - and who see 
economics
not as an exercise in cutting taxes but as a means to improve the quality

of life for as many as possible. And I do want to provide such examples.
<BR>
<BR>
On the other hand, Sweden is of course no paradise either, neither for 
disabled
nor for non-disabled people. People with disabilities are still second 
class
citizens in material terms as recent government investigations 
demonstrate.
There is yet another problem area that deserves attention. The increasing

professionalization of social services that I observe in several 
countries
has come furthest in Sweden. As one of the negative effects of this 
development
I see a growing dependence among persons with disabilities in many 
aspects
of their lives, dependence on a large cadre of social workers and similar

professions. It is their job to assist us, but many times the services 
they
are providing are not designed in a way which increases our opportunities

for self-direction; instead they often deprive us of possibilitities to
exercise our own initiative, to use and develop our judgement and 
self-confidence.
As a result, many of us do not feel in control of our own lives. In many
countries the lack of material services makes people with disabilities 
openly
dependent on the charitable inclinations of their surroundings and forces

them into a restricted and undignified existence. In Sweden the 
mechanisms
of dependence are much more subtle; many of us experience 
dissatisfaction,
frustration, and despair without knowing where to look for the 
causes.<BR>
<BR>
My critical analysis should in no way be interpreted as an attack against

the existence and extent of these services, the political commitment 
which
brought about the programs, and the underlying intentions of policy 
makers
and service providers. It would be an unfortunate misunderstanding, if 
somebody
would want to use the material presented here as an argument against 
&quot;the
welfare state&quot;. For people with extensive disabilities attendant 
care
services are the very key to a dignified and productive life in the 
community.
In my belief it is the government's responsibility to provide these 
services
as a fundamental civil right.<BR>
<BR>
My aim here is to draw attention to the more intangible and qualitative
aspects of attendant care which impact on consumers' lives as powerfully
as the quantitative extent of service provision. Such issues are power 
and
control, self-determination, self-esteem, and quality of life. Hopefully,

the monograph can contribute to a better appreciation of the difference
between quantity and quality in service delivery, between the amount of
hours provided on the one hand and the way they are delivered on the 
other,
between the level of material means provided by the public and the level
of control exercised by the individual consumer over how these resources
are to be used, between being treated as an object and acting as a 
subject.
<BR>
<BR>
The initiative of STIL (Stockholm's Independent Living group) described
in the text is an example for this distinction: The participants in 
STIL's
pilot project advocate and defend the notion that it is government's 
responsibility
to provide the financial resources for attendant care programs. But what
they insist on is that consumers must be able, if they so choose, to 
organize
their own service systems in order to obtain control over this important
aspect of their lives.<BR>
<BR>
I am well aware that the demand for consumer control may appear as a 
luxury
to people who live in countries with no assistance programs whatsoever,
to people who have to depend entrely on family or volunteers for these 
services,
or to people who have to pay assistants out of their own pockets like my
friend in California who spends a third of her modest annual income on 
such
services. Thus, to many readers the problems addressed here might seem 
far
removed from their every-day reality and too advanced. Yet with the 
continued
rise of the Independent Living Movement people with disabilities the 
world
over will demand personal assistance programs. It will be of paramount 
importance
that we, the consumers, take the initiative in shaping these services 
such
that we gain greater independence and more personal power through 
them.<BR>
<BR>
The Author<BR>
<A NAME="anchor4410164"></A><BR>
<P><CENTER><HR></CENTER>
<H3>Introduction: Definitions, Scope and Purpose of the Monograph</H3>
<BR>
<FONT SIZE="+3">O</FONT>ne of the main aims of the growing Independent 
Living
Movement , the international civil rights movement of people with 
disabilities,
has been to gain control over the services that are necessary for 
participating
in society on equal terms. Of these services attendant care has been 
identified
by the movement as perhaps the most critical prerequisite for a dignified

and productive life for persons with severe disabilities.<BR>
<BR>
Attendant care, briefly, consists of assistance through paid workers with

dressing, bathing, personal hygiene, household chores and all the daily
activities that a person cannot perform by himself or herself. Other 
terms
in use for the same service are home care, in-home support or home help.
Sometimes the distinction is made between household related tasks which
might be called home chore, home helper, domestic or home maker service
and more person and body related work which is commonly referred to as 
personal
care. Most of these terms are unsatisfactory. For one, they create the 
impression
that assistance is needed only in the consumer's home implying that 
people
with disabilities spend their day inactively at home and not in the 
community
pursuing work, travel, social, and cultural activities like everybody 
else.
Assistance at home as well as outside the home is the very key to the 
ability
of persons with extensive disabilities to participate in their community
and any language that suggests the opposite has to be avoided. Also, 
commonly
used terms such as &quot;attendant&quot; and &quot;care&quot; carry 
institutional
connotations and do not project the image of active and self-directed 
consumers
of such services. In the following the use of &quot;personal 
assistance&quot;
is suggested which is hoped to convey a more positive and less 
restrictive
image.<BR>
<BR>
Personal assistance in any country is far from being available to all 
individuals
with disabilities who need it. Where the service does exist it is often
not provided in the extent and the form which would permit consumers to
realize their potential in gaining independence. Thus, in order to be 
able
to influence legislators and policy makers, concerned consumers and 
service
providers are gathering information on those existing personal assistance

programs that contain features which have been shown to support the aims
of consumers. Among the countries that have adopted a national personal
assistance policy the Scandinavian countries are known for their 
extensive
programs in this area. It is for these reasons that Swedish personal 
assistance
schemes for persons with disabilities and older people are presented 
here.<BR>
<BR>
Comparative analysis in the area of social policy encounters many 
obstacles.
Apart from insufficient opportunities for the sharing and exchanging of
experiences across national borders one source of bias and misinformation

consists of the fact that visitors engaged in exchanges of this type are
typically not consumers of the services which they are reviewing. They 
face
the problem of assessing service delivery programs of which neither they
nor their hosts have direct experience. In many instances such 
information
impedes comparative analysis and, ultimately, evaluation of the 
transferability
of programs from one country to another. In the following monograph, the
description of Swedish personal assistance programs is therefore 
supplemented
by some analyses and assessments which are based on the author's 
experience
as a consumer of these services.<BR>
<BR>
Since people with disabilities are an integral part of the general 
population,
social policy in this area cannot be viewed as isolated measures aimed at

this particular segment of society but has to seen in the pertinent 
institutional
framework and in the context of a country's total approach to income 
redistribution,
social welfare, and health planning. Such a holistic view facilitates 
understanding,
evaluation, and assessment of the transferability of individual programs
from one social climate to another.<BR>
<BR>
The presentation will therefore begin with a brief description of Swedish

welfare policy and some of its more important features as they apply to
the population as a whole. Next, an account of the services available to
people with disabilities will be given. The focus of the report is on 
Swedish
personal assistance programs. Such programs are available to a variety of

groups, not just to persons with disabilities. Personal assistance 
services
for people with disabilities are available for a range of situations such

as assistance at work and school. Services for older and disabled 
citizens
in their own homes are perhaps the most important prerequisite for 
keeping
people out of institutions, as a brief survey of recent Swedish studies
on de-institutionalization shows. The main body of the paper consists of
a description and evaluation of such services based on statistical 
material
as far as it is available, information collected through the author's 
contact
with providers and consumers of the services as well as the author's own
experiences. The remainder of the study is taken up by a discussion of 
some
of the research issues raised in the presentation.<BR>
<BR>
As a final introductory note, no specific references are made to the 
mentally
retarded the reason being that all the programs described here are also
available to this group. (The administration of the services might 
differ,
since there is special legislation in this area.) Group homes and similar

institutional or semi-institutional solutions for the mentally retarded,
however, are not covered here.<BR>
<P><CENTER><HR></CENTER>
<P><A HREF="WRFmono2.html">Continue</A><BR>
<A HREF="WRFmono1.html">Contents of monograph</A><BR>
<A HREF="../index.html">Institute on Independent Living homepage</A><BR>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-210</DOCNO>
<DOCOLDNO>IA012-000125-B021-189</DOCOLDNO>
<DOCHDR>
http://www.independentliving.org:80/ToolsforPower/Tools18.html 193.13.228.238 19970216214610 text/html 9889
HTTP/1.0 200 OK
Last-Modified: Tue, 06 Aug 1996 20:04:36 +0000
Date: Sun, 16 Feb 1997 21:46:26 +0000
Expires: Sun, 16 Feb 1997 21:44:46 +0000
Content-type: text/html
Server: RoxenEnterprise/1.0
Content-length: 9664
</DOCHDR>
<HTML>
<HEAD>
    <TITLE>Institute_on_Independent_Living</TITLE>
</HEAD>
<BODY BGCOLOR="#ffffff" TEXT="#030235" LINK="#000042">
<META NAME="description" 
CONTENT="Individuals and organizations of persons with disabilities can 
publish, free of charge,  articles, reports, training manuals, 
announcements, etc. on Independent Living, personal assistance, advocacy, 

peer support, accessibility, legislation and related subjects. "><META 
NAME="keywords" CONTENT="Independent Living, personal assistance, 
advocacy, peer support, direct payments, anti-discrimination legislation, 

accessibility, disability, disability rights">
<H4><IMG SRC="../InstLogoSmall.gif" WIDTH="198" HEIGHT="57" 
ALIGN="BOTTOM"
NATURALSIZEFLAG="3"></H4>
<H2>Developing assistants management skills</H2>
<BR>
<FONT SIZE="+3">W</FONT>ith little or no previous experience the disabled

person seeking to live independently suddenly finds her/himself thrust 
into
the role of employer. Not surprisingly the effective management skills 
essential
to coping with the day-to-day matter of relating to her/his personal 
assistant
are sometimes absent or under-developed.<BR>
<BR>
The relationship between a disabled person and her/his personal 
assistants
has a lot to do with simple human chemistry - but it isn't enough to 
leave
it at that. Disabled people must adopt a responsible approach to the 
working
relationship. It is not good enough to leave things to chance, or 'flying

by the seat of one's pants'. The need for care and the control of care 
lie
at the very heart of a disabled person's existence and we must do what we

can to ensure success in our chosen lifestyle. This means that we need to

be sensitive to the needs of personal assistants, both 'new' and 
long-standing
personal assistants, and be constructive in the way we enable them to 
function.<BR>
Some common complaints among personal assistants are:<BR>
<BR>
The lack of a specific job description - leading to unequal expectations.

Personal assistant understanding that you need one thing and you 
believing
that you are to receive something else. (Adjectives such as 'less' and 
'more'
are often appropriate here.)<BR>
<BR>
The disabled person's inability to provide effective objective feed-back
on performance. Personal assistants want and need something more than 
general
'complaints', 'bad temper', 'euphoric gratitude', or an (apparently) 
'indifferent
silence'. Caring is a job and all humans require ongoing job 
satisfaction,
which only the employer (the disabled person) can provide.<BR>
<BR>
Of course many disabled people have developed their own ways of dealing
with these issues and it is not the purpose of this chapter to imply that

the following is the only acceptable procedure. Rather it is to draw 
attention
to a most important subject and to provide some ideas when considering 
it.
Independent living advocates need to propose procedures that enable a 
disabled
person to train and manage attendants more effectively. For this purpose
we suggest the use of performance check lists. 
<H4>Performance check lists</H4>
<FONT SIZE="+3">T</FONT>hese are compiled by the disabled person and 
outline
specific job descriptions. Each check list details the steps in a given
work routine and can include information how often routines are 
performed,
the materials needed and set-up procedures. <BR>
Drawing up check lists: 
<UL>
  <LI>List the areas where care is essential, such as: bathing, dressing,

bowel and bladder care, meal preparation, housekeeping, passive- 
movements,
transfers, wheelchair maintenance etc. 
  <LI>For each area develop a check list by listing exactly what duties
the personal assistant has to perform. This can be compiled from memory
or have notes taken during the chore, or make a tape recording while the
routine is being performed. It is important that the check list contains
each duty to be performed. 
  <LI>It is very important that each check list reflects YOUR own 
requirements!
You can have check lists for bathing routines, house cleaning tasks, etc.

</UL>
<H4>The check lists provide:</H4>
<FONT SIZE="+3">I</FONT>nstructions to personal assistant, useful in 
interviewing
and training.<BR>
<BR>
Help the disabled person to monitor, evaluate and provide feedback to 
personal
assistant on her/his performance. A prompt for occasions when the 
disabled
person is not present.<BR>
<BR>
After training, the check lists can be used for continued supervision by
providing a means of periodically re-evaluating performance and so 
stimulate
feedback, thereby encouraging consistent performance by the personal 
assistant.
<H4>Using a check list to train a 'new' personal assistant:</H4>
<FONT SIZE="+3">R</FONT>emember, each list gives a 'new' personal 
assistant
a clear idea of what is to be done, when it is done, and in what order.
This is an invaluable training aid.<BR>
<BR>
Make sure the 'new' personal assistant understands each item on the check

list. One way of doing this is for the 'new' personal assistant following

through the list while an 'old' personal assistant does the job 
described.
Or, the disabled person can explain each item as she/he and the 'new' 
personal
assistant go through the list together.<BR>
<BR>
Don't start on-the-job training until 'new' personal assistant 
understands
the routine on the list.<BR>
During training the check list could be clearly displayed enabling a 
ready
prompt for 'new' personal assistant.<BR>
<BR>
Remember: the check list only outlines WHAT is to be done, the disabled
person still needs to supply detailed instructions during training to 
ensure
that the 'new' personal assistant knows HOW things are to be done. 
<H4>Using a check list to provide feedback opportunities:</H4>
<FONT SIZE="+3">I</FONT>mmediately after a care routine is finished the
disabled person and the 'new' personal assistant review the check list 
together,
the disabled person commenting on each item as to the performance of the
personal assistant. Feedback sessions ensure that the 'new' personal 
assistant
receives positive feedback for correct performances and specific 
instructions
to correct areas that need improvement.<BR>
<BR>
Positive feedback: If an item is satisfactorily accomplished then say so
and describe why, thus providing positive feedback. E.g. hair brushing 
&quot;Correct
- you really got to all parts, just as I like it.&quot;<BR>
<BR>
Negative feedback: If an item is unsatisfactorily accomplished and needs
improvement, then say so and explain why, giving specific details on how
to correct the problem. E.g. hair brushing &quot;Not correct - you missed

my hair in front and behind my ears.&quot;<BR>
<BR>
Ongoing feedback: For reasons of job satisfaction it is very important 
that
the personal assistant receives regular, constructive feedback, both 
positive
and corrective, even after the initial training period. Check lists 
should
be used on a continuing basis, even if only intermittently, by way of 
ensuring
ongoing positive feedback and also providing a forum for ironing out 
small
difficulties before they become big problems. 
<H4>To conclude</H4>
<FONT SIZE="+3">Y</FONT>ou may find all these suggestions frighteningly
formal and perhaps contrary to your understanding of a disabled 
person/personal
assistant relationship. You may even think that these suggestions are 
positively
threatening, or damaging to a disabled person/personal assistant 
relationship.
This is not the intention. The purpose is to provide a structure that can

enhance communications between the disabled person and her/his personal
assistant, encourage the very best from each other, and so promote job 
satisfaction
on the part of the personal assistant. It is up to you whether you use 
this
check list system or not, or maybe even devise your own.<BR>
<BR>
The essential human chemistry: your tone, your attitude, respect, the way

you interact, how you 'gel', etc., remain ingredients that only the two
of you, as people, can deal with. If you don't 'get on' with each other,
then a structure may enable you to survive, but it won't resolve the 
basic
'chemistry'. 
<H4>Conclusions</H4>
<UL>
  <LI>Remember you are in an employer/employee situation - a business 
world.
Don't ignore the value of developing management skills that can lead to
positive benefits in the quality of your life. 
  <LI>The traditional medical model of nursing care assumes the training
of the personal assistant. However, in the course of a lifetime a 
disabled
person might employ well over 50 personal assistants. Common sense 
indicates
that it is cheaper to systematically train one person, the disabled 
person,
in her/his specific routine rather than 50 personal assistants. 
  <LI>Not all people will want or have the necessary skills to train 
personal
assistants without any structured input. This is where more focus needs
to be put into training and enabling the development of such skills, 
preferably
through people who have direct experience in Independent Living, or 
through
CILs who sometimes can offer advice and training. 
</UL>
Source: <BR>
Source Book Towards Independent Living, <BR>
Care Support Ideas, HCIL (Hampshire Center for Independent Living)<BR>
<BR>
Address: Philip Mason, <A 
HREF="mailto:100753.1164@compuserve.com">100753.1164@compuserve.com</A>
<BR>
Hampshire Centre for Independent Living, <BR>
4 Plantation Way, Whitehill, Bordon, Hants GU 359 HD, United Kingdom <BR>

<P><CENTER><HR><FONT SIZE=2>[<A HREF="Tools1.html">Tools for Power 
contents]</A></FONT><FONT SIZE=2>[<A HREF="../Contents.html">Institute
on Independent Living contents</A>]</FONT></CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-211</DOCNO>
<DOCOLDNO>IA012-000125-B021-245</DOCOLDNO>
<DOCHDR>
http://www.independentliving.org:80/Aufstand_der_Betreuten.html 193.13.228.238 19970216214632 text/html 43406
HTTP/1.0 200 OK
Last-Modified: Sun, 29 Sep 1996 08:29:00 +0000
Date: Sun, 16 Feb 1997 21:46:37 +0000
Expires: Sun, 16 Feb 1997 21:44:57 +0000
Content-type: text/html
Server: RoxenEnterprise/1.0
Content-length: 43180
</DOCHDR>
<HTML>
<!--This file created 96-07-13 17.44 by Claris Home Page version 1.0b1-->

<HEAD>
    <TITLE>Institute_on_Independent_Living</TITLE>
</HEAD>
<BODY TEXT="#010b3b" BGCOLOR="#ffffff">
<META  name="description"
content="Individuals and organizations of persons with disabilities can 
publish, free of charge,  articles, reports, training manuals, 
announcements, etc. on Independent Living, personal assistance, advocacy, 
peer support, accessibility, legislation and related subjects. "><META  
name="keywords" content="Independent Living, personal assistance, 
advocacy, peer support, direct payments, anti-discrimination legislation, 
accessibility, disability, disability rights"><X-SAS-WINDOW TOP="66" 
BOTTOM="624" LEFT="8" RIGHT="538">
</HEAD><BODY TEXT="#00003D" BGCOLOR="#FFFFFF" LINK="#000038">
<H2><IMG SRC="InstLogoSmall.gif" WIDTH="198" HEIGHT="57" ALIGN="BOTTOM"
NATURALSIZEFLAG="3"><BR>
</H2>
<H2><CENTER>Aufstand der Betreuten</CENTER>
</H2>
<H4>Selbstrespekt als Richtschnur</H4>
<FONT SIZE="5">Z</FONT>iel unserer Behindertenpolitik mu&szlig;sein, dem
Einzelnen mehr pers&ouml;nliche Macht und uns als Gruppe mehr politische
Macht zu verschaffen. Triebfeder und Richtschnur in dieser Arbeit ist 
unser
Selbstrespekt. Unsere Umwelt bombardiert uns st&auml;ndig mit Hinweisen,
da&szlig;unser Leben bemitleidenswert, lebensunwert und unw&uuml;nscht 
ist,
da&szlig;wir B&uuml;rger zweiter Klasse sind. Viele von uns sind mit 
dieser
Haltung aufgewachsen und glauben selbst daran. Wir m&uuml;ssen uns gegen
diese Gehirnw&auml;sche impfen, denn wenn wir nicht selbst davon 
&uuml;berzeugt
sind, da&szlig;unser Leben genauso viel wert ist wie das anderer 
Menschen,
fordern wir auch nicht die gleichen Wahlm&ouml;glichkeiten, die unsere 
nichtbehinderten
Angeh&ouml;rigen, Freunde und Bekannten in allen Bereichen des Lebens 
haben.<BR>
<BR>
Erst wenn wir davon &uuml;berzeugt sind, da&szlig;wir die gleiche 
Lebensqualit&auml;t
verdienen, die andere f&uuml;r selbstverst&auml;ndlich hinnehmen, werden
wir uns nicht mehr in Anstalten und Heime abschieben lassen, sondern 
fordern,
&uuml;berall wohnen zu k&ouml;nnen. Dann werden wir uns nicht l&auml;nger

vom Sonderfahrdienst der Wohlfahrt verfrachten lassen, sondern 
behindertengerechte
Anpassung aller &ouml;ffentlichen Verkehrsmittel und Taxis fordern. Dann
werden wir uns nicht in krankhafte Abh&auml;ngigkeit von unseren 
Angeh&ouml;rigen
zwingen lassen, sondern pers&ouml;nliche Assistenzdienste fordern, die 
uns
freimachen. Dann werden wir nicht mehr dankbar &uuml;ber integrierte 
Teestuben
und Freizeiten Freudentr&auml;nen vergie&szlig;en, sondern gleiche 
B&uuml;rgerrechte
fordern. Dann werden wir uns nicht mehr unserer Behinderung sch&auml;men,

uns verstecken und ein Zuschauerdasein fristen, sondern am Leben als 
freie
und stolze Menschen teilnehmen.<IMG SRC="Pixel1x1.gif" WIDTH="1" HEIGHT=
"1" ALIGN="BOTTOM" NATURALSIZEFLAG="3"> 
<H4>Was ist pers&ouml;nliche Assistenz?</H4>
<FONT SIZE="5">A</FONT>lle Menschen benutzen Assistenz. Manche Leute 
reparieren
z.B. ihre Autos selbst, andere mit weniger Zeit oder einschl&auml;gigen
Kenntnissen ziehen es vor, einen Automechaniker damit zu beauftragen. 
Andere
Beispiele sind Friseur, Klempner und Rechtsanwalt. Man kann nicht alles
selbst machen. Die meisten Menschen wollen sich auf die T&auml;tigkeiten
konzentrieren, die sie gut beherrschen. Auf diese Weise kann man seine 
Zeit
und Energie effektiver einsetzen.<BR>
<BR>
F&uuml;r uns ist Assistenz noch wichtiger, weil wir unsere Behinderung 
kompensieren
m&uuml;ssen, um volle Gleichberechtigung zu erlangen. Assistenz ersetzt
unsere Arme und Beine. Dazu ein Beispiel: Ich kann mir selbst einen 
Pullover
anziehen, wozu ich - je nach Tageskondition - mindestens eine halbe 
Stunde
brauche. Nachher bin ich total ersch&ouml;pft und mu&szlig;mich eine 
Stunde
lang ausruhen. Au&szlig;erdem riskiere ich dabei fr&uuml;hzeitige 
Abnutzung
meines Handgelenks. Da ich meine Zeit und Energie f&uuml;r andere, 
f&uuml;r
mich wichtigere Dinge einsetzen will, beauftrage ich einen Assistenten,
mir beim Anziehen zu helfen. Dazu ben&ouml;tigt mein Assistent eine halbe

Minute. Ich spare also 89 Minuten, die ich f&uuml;r meine Arbeit benutzen

kann.<BR>
<BR>
F&uuml;r die optimale Kompensierung unserer jeweiligen Behinderungen 
m&uuml;ssen
wir technische Hilfsmittel und pers&ouml;nliche Assistenz so einsetzen 
k&ouml;nnen,
wie wir selbst es in der jeweiligen Situation f&uuml;r angebracht halten.

Nur wir selbst k&ouml;nnen diese Abw&auml;gung treffen. Jeder andere, der

dar&uuml;ber entscheiden m&ouml;chte, setzt mein Urteilsverm&ouml;gen in
Frage und bevormundet mich.<BR>
<BR>
Pers&ouml;nliche Assistenz soll ausdr&uuml;cken, da&szlig; ich aus meinen

pers&ouml;nlichen, individuellen Bed&uuml;rfnissen heraus die 
Arbeitsbedingungen
bestimme und entscheide, wen ich als Assistenz einsetze, f&uuml;r welche
Arbeiten, wann und wie die Arbeit zu machen ist.<BR>
<BR>
Die Bezeichnung &quot;pers&ouml;nliche Assistenz&quot; mag f&uuml;r viele

noch ungewohnt klingen, aber was sind die Alternativen? Was dr&uuml;cken
&quot;Pflege&quot; oder &quot;Betreuung&quot; aus? Es gibt gut gemeinte
Ambulante Dienste, in denen nichtbehinderte Sozialarbeiter Menschen mit
Behinderungen integrieren wollen und als 
&quot;Pflegeabh&auml;ngige&quot;,
&quot;Pflegebed&uuml;rftige&quot; oder &quot;zu Betreuende&quot; 
bezeichnen.
Wer braucht eine solche Integrationsbetreuung! Wenn wir uns selbst als 
gesunde,
selbst&auml;ndige und m&uuml;ndige B&uuml;rger sehen und auch von anderen

so gesehen werden wollen, m&uuml;ssen wir organisatorische 
Voraussetzungen
und Bezeichnungen f&uuml;r Assistenzdienste finden, mit denen wir uns 
freimachen,
uns selbst respektieren und von unserer Umwelt geachtet werden 
k&ouml;nnen.
<H4>Einschr&auml;nkung des Lebens durch zuwenig pers&ouml;nliche 
Assistenz</H4>
<FONT SIZE="5">V</FONT>iel zu wenige von uns benutzen pers&ouml;nliche 
Assistenz
in einem Umfang, der ihnen zu den gleichen Lebensbedingungen, die andere
Mitb&uuml;rger haben, verhilft. Ein Grund daf&uuml;r ist die Einstellung
unserer Gesellschaft gegen&uuml;ber Menschen mit Behinderungen. Zwar 
fordert
z.Zt. kein Politiker unsere Liquidierung - allenfalls durch 
Schwangerschaftsunterbrechung
- aber nirgendwo ist unser Recht auf konkrete Voraussetzungen zu gleichen

Lebensbedingungen verb&uuml;rgt. Daher haben wir auch nicht das 
gesetzlich
garantierte Recht auf pers&ouml;nliche Assistenz, die uns 
erm&ouml;glicht,
Ausbildung, Arbeit, Wohnform, Familie, Freizeit, Urlaub - kurz Lebensstil

- im gleichen Ma&szlig;e wie andere so zu w&auml;hlen, wie es unseren 
pers&ouml;nlichen
Neigungen und nicht den Vorstellungen des Sozialamts entspricht.<BR>
<BR>
Schon immer hat man uns - ganz im Gegensatz zur Bundeswehr als 
Zielscheibe
f&uuml;r Sparma&szlig;nahmen gesehen und kaum ein Land der Welt kann es
sich &quot;leisten&quot;, uns ausreichende pers&ouml;nliche Assistenz zur

Verfogung zu stellen. Dagegen schiebt man uns in Anstalten und Heime ab,
wo man uns in Gro&szlig;betrieben rationell nach dem 
Flie&szlig;bandprinzip
verwahrt, um die pro-Kopf Kosten auf ein dem Steuerzahler genehmes 
Minimum
zu reduzieren. Dort wird pers&ouml;nliche Assistenz und damit unsere 
Lebensqualit&auml;t
auf ein Minimum reduziert. Als Rechtfertigung f&uuml;r Pflegeheime wird
angef&uuml;hrt, da&szlig;wir krank und daher in krankenhaus&auml;hnlichen

Institutionen zu &quot;betreuen&quot; seien. Dort bestimmen die 
Bed&uuml;rfnisse
nach reibungslosem Funktionieren der Anstalt. Der Einzelne wird 
systematisch
angepa&szlig;t, unterdr&uuml;ckt, gebrochen, abgestumpft und 
verbl&ouml;det,
bis er zu keiner Eigeninitiative mehr f&auml;hig ist und dem Bild des 
harmlosen,
pflegeleichten Behinderten entspricht, das die &Ouml;ffentlichkeit von 
uns
hat.<BR>
<BR>
In diesem Zusammenhang m&ouml;chte ich auf die gef&auml;hrliche Falle der

Kostenvergleiche hinweisen, in die sich viele von uns man&ouml;vrieren 
lassen.
Sollen wir nur dann f&uuml;r unsere B&uuml;rgerrechte k&auml;mpfen, wenn
damit nachweislich Steuergelder gespart werden k&ouml;nnen und somit mehr

Mittel f&uuml;r R&uuml;stung, umweltfeindliche Produktion und andere 
behinderungsf&ouml;rdernde
Ma&szlig;nahmen &uuml;brigbleiben? Die logische Folgerung des 
Kostenvergleichs
ist, uns kosteng&uuml;nstig zu vergasen. Wenn wir uns also nicht unser 
eigenes
Grab schaufeln wollen, m&uuml;ssen wir Kostenvergleiche als irrelevante
Kriterien ablehnen und statt dessen unsere Menschen- und 
B&uuml;rgerrechte
fordern.
<H4>Selbst ist das Musterkr&uuml;ppelchen</H4>
<FONT SIZE="5">V</FONT>iele von uns beschr&auml;nken freiwillig die 
Anwendung
von pers&ouml;nlicher Assistenz und damit ihr eigenes Leben auf ein 
Minimum,
denn pers&ouml;nliche Assistenz wird in noch viel h&ouml;herem Ma&szlig;e

als technische Hilfsmittel von unserer Umwelt und uns selbst als Merkmal
unseres sozialen Statutes als Menschen zweiter Klasse gesehen.<BR>
<BR>
Die Erkl&auml;rung daf&uuml;r ist in den Wertvorstellungen unserer 
Gesellschaft
zu suchen, die u.a. im Sprichwort &quot;Selbst ist der Mann&quot; zum 
Ausdruck
kommen. Diese Haltung wird uns von Rehafachleuten eingebleut. Die 
medizinischen
Berufe, die Behinderung als eine Art Krankheit sehen, haben den Ehrgeiz,
uns nach bekanntem Vorbild (&quot;Nimm dein Bett und geh&quot;) zu heilen

oder uns zumindest von den Folgen unserer Behinderung zu erl&ouml;sen. 
Behinderung
und damit Bedarf an technischen Hilfsmitteln und vor allem an 
pers&ouml;nlicher
Assistenz kann demnach wegtrainiert werden. Die das nicht schaffen, sind
faul und selber schuld. Pers&ouml;nliche Assistenz soll nur als letzter
Ausweg und nur f&ouml;r das Allern&ouml;tigste verwendet werden.<BR>
<BR>
Das Ideal der St&auml;rke, vom Faschismus vererbt und haupts&auml;chlich
als k&ouml;rperliche St&auml;rke ausgelegt, wirkt auf subtile Weise als
Unterdr&uuml;ckungs- und Selbstverachtungsmechanismus. Diesem Ideal 
zufolge
gelte ich als schwach, hilflos und unterlegen, weil ich mir nicht selbst
die Hosen hochziehen kann. Menschen mit Behinderungen z&auml;hlen wie 
Kinder
zu den Schwachen der Gesellschaft. Wie Kinder brauchen wir daher den 
allgemeinen
Vorstellungen zufolge Bevormundung und Betreuung. K&ouml;rperliche 
Abh&auml;ngigkeit
von praktischen Handreichungen wird gleichgesetzt mit intellektueller und

emotioneller Abh&auml;ngigkeit von anderen. Diese Einstellung dr&uuml;ckt

sich in der Organisation der meisten heutigen Assistenzformen aus, in 
denen
andere &uuml;ber unser Leben bestimmen.<BR>
<BR>
Jeder Marlborough-Mann mit Selbstachtung - M&auml;nner sind f&uuml;r 
dieses
St&auml;rkeideal besonders anf&auml;llig - wird sich daher eher 
buchst&auml;blich
zu Tode rackern, als zu riskieren, vor sich selbst und anderen als 
&quot;Pflegefall&quot;
dazustehen. Wir alle kennen bemitleidenswerte Kollegen, die sich stolz im

manuellen Rollstuhl vorw&auml;rtsqu&auml;len und dabei von anderen im 
Elektrofahrstuhl
flott &uuml;berholt werden. Genauso gibt es Leute unter uns, die es sich
von ihrem schwachen Selbstbewu&szlig;tsein her nicht leisten k&ouml;nnen,

Assistenten einzusetzen.<BR>
<BR>
Unsere Umwelt sieht gerne, da&szlig;wir uns so viel wie m&ouml;glich 
abstrampeln,
um unseren Alltag allein zu bew&auml;ltigen. Auf diese Weise mit uns 
selbst
besch&auml;ftigt, fallen wir dem Sozialhaushalt weniger zur Last, haben
weder Zeit noch Energie, Forderungen nach Chancengleichheit mit 
Ausbildung,
Beruf und sinnvoller Freizeit zu stellen und uns im politischen Kampf 
f&uuml;r
unsere B&uuml;rgerrechte zu engagieren. Kein Wunder also, da&szlig;uns 
das
Musterkr&uuml;ppelchen als Vorbild hingestellt wird, das sich den ganzen
Vormittag mit Waschen, Anziehen und Kochen abm&uuml;ht und sich dann 
&uuml;berm&uuml;det
ausruhen mu&szlig;, um f&uuml;rs Zubettgehen gen&uuml;gend Kraft zu 
sammeln.
<H4>Bevormundung durch station&auml;re und ambulante Pflegeheime </H4>
<FONT SIZE="5">E</FONT>in weiterer Grund f&ouml;r die Stigmafunktion der
pers&ouml;nlichen Assistenz ist die damit verbundene Bevormundung und 
soziale
Kontrolle. In lnstitutionen, wo noch immer viele von uns ihr Leben 
fristen,
sind diejenigen, die am meisten Assistenz brauchen, am st&auml;rksten der

totalit&auml;ren Kontrolle des Apparats unterworfen, der sogar die 
k&ouml;rperliche
Notdurft in der Gewalt hat. Institutionen bestehen aber nicht nur aus 
Gittern
und Mauern. In verschiedenen L&auml;ndern hat man Ambulante Dienste 
(sprich
ambulante Institutionen) aufgebaut, die sich nur wenig von Pflegeheimen
unterscheiden. Wir m&uuml;ssen die Dinge beim rechten Namen nennen. Ich
schlage daher die folgende Definition einer Institution vor. lch stehe 
einer
Institution gegen&uuml;ber, wenn 
<UL>
  <LI>ich keine andere Wahl habe, 
  <LI>ich nicht bestimmen kann, wer als Assistent f&uuml;r mich arbeitet,

mit welchen Arbeiten, wann und wie, 
  <LI>ich es nicht mit einem anderen Menschen zu tun habe, sondern mit 
einer
Angestelltenhierarchie mit geschriebenen und ungeschriebenen Regeln, 
&uuml;ber
die ich keine Kontrolle habe, die nicht meine Bed&uuml;rfnisse, sondern
die der Organisation ber&uuml;cksichtigen, 
  <LI>die Gefahr besteht, da&szlig;sich die Einstellung des Personals mir

gegen&uuml;ber von einer Personalgeneration auf die n&auml;chste vererbt
  <LI>das Personal Anspruch auf Professionalit&auml;t mit Ausbildung und
Bef&ouml;rderungsm&ouml;glichkeiten hat und mich als Objekt und nicht als

Herr im Haus betrachtet. 
</UL>
Dieser Definition nach haben die meisten heute existierenden 
Assistenzl&ouml;sungen
Institutionsz&uuml;ge, die uns beschr&auml;nken und entmachten. Kein 
Wunder
also, da&szlig; viele von uns aus Furcht vor dieser Unterdr&uuml;ckung 
entweder
die Abh&auml;ngigkeit von Angeh&ouml;rigen vorziehen oder versuchen, 
soviel
wie m&ouml;glich ohne Assistenz auszukommen, auch wenn das 
Selbsteinschr&auml;nkung
und Verzicht auf ein normales Leben bedeutet.
<H4>Independent Living f&uuml;r mehr pers&ouml;nliche und politische 
Macht</H4>
<FONT SIZE="5">U</FONT>nsere Aufgabe besteht darin, Organisationsformen
f&ouml;r pers&ouml;nliche Assistenz zu entwickeln, die uns zu mehr 
pers&ouml;nlicher
Macht und den notwendigen Voraussetzungen zu gleichen Lebensbedingungen
verhelfen. Als Beispiel f&uuml;r eine solche Organisationsform 
m&ouml;chte
ich hier das schwedische STIL-Projekt beschreiben. (STIL bedeutet 
&quot;Stockholmer
Kooperativ f&uuml;r Independent Living&quot;.)<BR>
<BR>
In meinen Studienjahren in Kalifornien kam ich Anfang der 70er Jahre mit
der Independent Living Bewegung in Ber&uuml;hrung, die sich seitdem zu 
einem
internationalen Netzwerk und einer B&uuml;rgerrechtsbewegung entwickelt
hat, die gegen Diskriminierung und mehr pers&ouml;nliche und politische
Macht f&uuml;r Menschen mit Behinderungen k&auml;mpft. (Ans&auml;tze zu
Independent Living Gruppen gibt es auch in der BRD, wo man Independent 
Living
teilweise mit dem akademisch-abstrakt klingenden und nicht ganz korrekten

&quot;Autonomes Leben&quot; &uuml;bersetzt. &quot;Selbstbestimmtes Leben'

pa&szlig;t meiner Meinung nach besser.) Die Independent Living Bewegung
fordert, da&szlig;wir die Verantwortung und Kontrolle &uuml;ber unser 
Leben
selbst &uuml;bernehmen, unsere Probleme selbst definieren, L&ouml;sungen
ausarbeiten und nie die Initiative an andere abtreten. Das gilt sowohl 
f&uuml;r
das Leben des Einzelnen als auch f&uuml;r unsere Organisationen.<BR>
<BR>
STIL wurde 1984 von einigen Behinderten mit dem Ziel gegr&uuml;ndet, ein
Projekt mit selbstverwalteter pers&ouml;nlicher Assistenz 
durchzuf&uuml;hren.
Wir w&auml;hlten pers&ouml;nliche Assistenz als Aufgabenbereich, weil in
Schweden trotz der im Vergleich mit anderen L&auml;ndern gut ausgebauten
Ambulanten Dienste unser Leben in hohem Ma&szlig;e vom stark 
professionalisierten
Sozialsektor beherrscht wird. Wie auch anderswo sind wir B&uuml;rger 
zweiter
Klasse, f&uuml;hren ein eingeschr&auml;nktes Leben, werden betreut und 
verwaltet.
<H4>Fokus, Fokus, Hokuspokus</H4>
<FONT SIZE="5">I</FONT>n Schweden ist f&uuml;r viele von uns eine 
Fokuswohnung
die einzige Alternative au&szlig;erhalb von Pflegeheimen - eine Wahl 
zwischen
Pest und Cholera.<BR>
<BR>
Die Fokusl&ouml;sung besteht darin, da&szlig;man in einem 
gew&ouml;hnlichen
Wohnkomplex etwa 10 - 15 Spezialwohnungen einstreut, die durch eine 
Sprechanlage
mit einer rund um die Uhr besetzten Personalzentrale in Verbindung 
stehen.
Fokus wird oft als Patentl&ouml;sung f&uuml;r alle Menschen mit Bedarf an

pers&ouml;nlicher Assistenz hingestellt und erfreut sich z.Zt. in der BRD

und vor allem in den Niederlanden in Ermangelung emanzipierter 
Assistenzl&ouml;sungen
und selbstbewu&szlig;ter Behindertenorganisationen bei Nichtbehinderten
und heimgesch&auml;digten Behinderten gro&szlig;er Beliebtheit.<BR>
<BR>
STIL's Kritik an den Fokuswohnungen, die wir in Anlehnung an die Lage 
unserer
unterdr&uuml;ckten Kollegen in S&uuml;dafrika &quot;home-lands&quot; 
nennen,
zielt auf deren Monopolstellung, die keine Wahlm&ouml;glichkeit von 
Wohnort
und -form zul&auml;&szlig;t und auf deren Institutionscharakter ab. Alle
Punkte der oben aufgestellten Definition einer Institution werden von 
Fokus
zufriedenstellend erf&uuml;llt. Einige der &uuml;berzeugtesten und 
aktivsten
STIL-Mitglieder sind ehemalige Fokusinsassen, denen es gelang, sich mit
Hilfe des STIL-Projekts zu befreien und in ganz gew&ouml;hnliche 
Neubauwohnungen
zu ziehen, die laut Gesetz voll behindertengerecht gebaut werden 
m&uuml;ssen.
<H4>Ein Projekt mit STIL</H4>
<FONT SIZE="5">C</FONT>harakteristisch fbr STIL und das Projekt, das seit

Januar 1987 l&auml;uft, ist die Grundforderung der Independent Living 
Bewegung:
Selbstbestimmung im Leben des Einzelnen und in unserer Organisation.<BR>
<BR>
Dieser Forderung entsprechend haben sich bisher 20 STIL-Mitglieder in 
einer
Genossenschaft zusammengeschlossen, um die maximale Verantwortung 
f&uuml;r
ihre eigene pers&ouml;nliche Assistenz zu &uuml;bernehmen. Keiner wird 
als
Klient behandelt. Jeder ist selbst daf&uuml;r verantwortlich, sich seine
Assistenten durch Zeitungsinserate und andere Wege zu suchen, zu 
interviewen,
anzustellen, auszubilden, anzuleiten, zu bezahlen und - falls notwendig
- zu entlassen. Wir haben also keine Sozialarbeiter im B&uuml;ro, die uns

Leute ins Haus schicken. Das w&auml;re zwar f&uuml;r den Einzelnen 
bequemer,
w&uuml;rde uns aber die Gelegenheit nehmen, endlich selbst diesen 
wichtigen
Teil unseres Lebens in die Hand zu nehmen. Jeder soll die 
gr&ouml;&szlig;tm&ouml;gliche
Freiheit haben, sich sein eigenes System zurechtzuschneidern und nach 
Bedarf
&auml;ndern zu k&ouml;nnen. Jeder soll seine von der Gemeinde genehmigten

Assistenzstunden unter so vielen oder so wenigen Assistenten aufteilen 
und
zu den Zeiten und f&uuml;r die Zwecke verbrauchen, die er selbst f&uuml;r

richtig h&auml;lt. Niemand kennt unsere Bed&uuml;rfnisse besser als 
wir.<BR>
<BR>
Bisher mu&szlig;ten wir unsere Bed&uuml;rfnisse unserer Assistenz 
anpassen.
Im STIL-Projekt passen wir unsere Assistenz unseren Bed&uuml;rfnissen 
an.<BR>
<BR>
Jeder Teilnehmer verf&uuml;gt innerhalb der Genossenschaft &uuml;ber sein

eigenes Konto, um damit seine Assistenten und die mit der Assistenz 
verbundenen
Nebenkosten zu bezahlen. Die Gelder dazu kommen viertelj&auml;hrlich von
der Gemeinde Stockholm und entsprechen den Selbstkosten, die vor dem 
STIL-Projekt
die Ambulanten Dienste oder Fokusunterbringung des jeweiligen 
Projektteilnehmers
f&uuml;r die Gemeinde mit sich f&uuml;hrten. F&uuml;r die Gemeinde 
entstehen
somit keine Mehrkosten durch das Projekt. Die Stadtverwaltung stellt den
Stundenbedarf der einzelnen Projektteilnehmer fest. Bei dieser und 
&auml;hnlichen
Verhandlungen mit der Gemeinde kann sich der Projektteilnehmer auf Wunsch

von anderen Mitgliedern mit mehr Erfahrung begleiten lassen. 
Au&szlig;erdem
&uuml;berwacht STIL den Verlauf dieser Verhandlungen und ist bereit, 
notfalls
unsere Freunde in den verschiedenen &ouml;ffentlichen Verwaltungen, 
politischen
Parteien und der Presse einzuschalten. Wir betreiben eine erfolgreiche 
&Ouml;ffentlichkeitsarbeit.
So wurde das STIL-Projekt vor kurzem in der allj&auml;hrlichen 
allgemeinpolitischen
Debatte der Parteif&uuml;hrer im schwedischen Reichstag ausf&uuml;hrlich
beschrieben und als Vorbild dargestellt.<BR>
<BR>
Die Stundenanzahl wird mit den Durchschnittsselbstkosten der Gemeinde von

z.Zt. 131 kr (ungef&auml;hr DM 35,--) pro Assistenzstunde multipliziert
und auf das STIL-Konto des betreffenden Teilnehmers &uuml;berwiesen. Mit
diesen Geldern bezahlt der einzelne Projektteilnehmer nicht nur seine 
Assistentengeh&auml;lter,
Sozialabgaben und Nebenkosten, wie Mahlzeiten oder Reisekosten der 
Assistenten
(wenn uns z.B. Assistenten auf Reisen begleiten), sondern auch die 
Verwaltungskosten
des Projekts. Dazu geh&ouml;ren B&uuml;romiete und -ausr&uuml;stung, 
Geh&auml;lter
der Projektleitung, &Ouml;ffentlichkeitsarbeit, Kurse f&uuml;r neue 
Mitglieder
und Ausbildung der Projektteilnehmer. Diese Verwaltungskosten werden in
Form von Mitgliedsbeitr&auml;gen an das Kooperativ von den einzelnen 
Projektteilnehmern
bezahlt. Der Mitgliedsbeitrag wird als Prozentsatz des Gesamtbetrages, 
den
die einzelnen Projektteilnehmer von der Stadtverwaltung auf ihr 
jeweiliges
STIL-Konto einbezahlt bekommen, ausgedr&uuml;ckt. Gelder, die dem 
Projektteilnehmer
nach Bezahlung der obigen Posten bei der j&auml;hrlichen Abrechnung 
verbleiben,
gehen an die Gemeinde zur&uuml;ck.
<H4>&quot;Pflegef&auml;lle&quot; als Arbeitgeber</H4>
<FONT SIZE="5">D</FONT>ie Genossenschaft hat die formelle 
Arbeitgeberverantwortung
f&uuml;r unsere Assistenten, denn unser Vertrag mit der schwedischen 
Kommunalarbeitergewerkschaft
l&auml;&szlig;t z.Zt. nur diese Konstruktion zu. Ab Juni 1988 k&ouml;nnen

auch einzelne Projektteilnehmer selbst Arbeitgeber sein. Als Arbeitgeber
haben wir die gr&ouml;&szlig;tm&ouml;gliche Kontrolle &uuml;ber unsere 
Assistenz.
An diesem Punkt erleben wir den st&auml;rksten Widerstand von 
Sozialarbeitern,
nichtbehinderten Behindertenfunktion&auml;ren und angepa&szlig;ten 
Behinderten.<BR>
<BR>
Einmal h&auml;lt man uns nicht dazu in der Lage, diese Rolle zu 
&uuml;bernehmen.
Wie &uuml;blich untersch&auml;tzt man uns, indem man Bedarf an Assistenz
mit Unselbst&auml;ndigkeit, Hilflosigkeit und Unm&uuml;ndigkeit 
gleichsetzt.
Niemand bezeichnet einen Unternehmer als hilflos, nur weil er ohne seine
Arbeitskraft den Betrieb schlie&szlig;en m&uuml;&szlig;te. Der 
Unterschied
liegt darin, da&szlig;wir in den Augen unserer Umgebung Menschen zweiter
Klasse sind. Das Bild vom Arbeitgeber dagegen beinhaltet genau das 
Gegenteil:
dynamisch, hart im Verhandeln, erfolgreich, mit gez&uuml;ckter American
Express Card. Unsere Forderung auf Arbeitgeberstatus kommt demnach einem
Umsturz der ganzen Gesellschaftspyramide gleich.<BR>
<BR>
STIL bekommt auch Widerstand von seiten mancher Sozialarbeiter zu 
sp&uuml;ren,
die sich ausrechnen k&ouml;nnen, da&szlig;das STIL-Projekt, wenn es sich
verbreiten sollte, manche von ihnen um den Arbeitsplatz bringen kann. 
Tiefer
noch sitzt der Schrecken bei einigen vor der Einsicht, da&szlig;Menschen,

die sich bisher dankbar betreuen lie&szlig;en, sich nicht mehr 
automatisch
f&ouml;r die Helferinstinkte anderer hergeben, sondern lieber selbst ihre

Sache in die Hand nehmen.<BR>
<BR>
Viele von unseren eigenen Leuten, die bei diesem Anspruch auf 
Eigenverantwortung
Angst bekommen und die bequeme Bevormundung durch Profis bevorzugen, 
st&ouml;rt
STIL's Sprachgebrauch. Anstatt &quot;Arbeitgeberverantwortung&quot; und
damit &quot;Macht&quot; und &quot;Kontrolle&quot; zu fordern, ziehen sie
&quot;Miteinander-F&uuml;reinander-Hallo-Partner-Dankesch&ouml;n&quot;-Ge
w&auml;sch
vor und wollen allenfalls Mitbestimmung.<BR>
<BR>
Assistenz ersetzt unsere Arme und Beine. Andere Menschen haben direkte 
Kontrolle
&uuml;ber ihre Arme und Beine - nicht Mitbestimmung.<BR>
<BR>
Das Verh&auml;ltnis zu den Assistenten stellen sich viele, die ihr Leben
den W&uuml;nschen und Vorstellungen anderer anpassen mu&szlig;ten und 
sich
vielleicht einsam f&uuml;hlen, lieber als eine Art Freundschaft vor. Eine

Arbeitgeber-Arbeitnehmerbeziehung entspricht somit nicht ihren 
emotionellen
Bed&uuml;rfnissen. In der BRD konnte ich diese Haltung vor allem bei 
Leuten
beobachten, die gleichaltrige Zivildienstleistende besch&auml;ftigen und
sich ihnen gegen&uuml;ber offensichtlich nur schlecht durchsetzen 
k&ouml;nnen.
Der Verdacht dr&auml;ngt sich dabei auf, da&szlig;die Wunschvorstellung
nach einer harmonischen Kumpelbeziehung die Tatsache verstecken soll, 
da&szlig;jemand
aus Schw&auml;che Kompromisse schlie&szlig;t und aus der Not eine Tugend
macht. Das Arbeitgeber-Arbeitnehmerverh&auml;ltnis braucht durchaus nicht

gef&uuml;hlskalt zu sein, dazu ist die Beziehung viel zu nahe. Jemand, 
der
pers&ouml;nliche Assistenz effektiv einsetzen m&ouml;chte, wird jedoch 
Priorit&auml;ten
setzen und von seinen Assistenten in erster Linie P&uuml;nktlichkeit, 
Zuverl&auml;ssigkeit,
Zur&uuml;ckstellung eigener Bed&uuml;rfnisse w&auml;hrend der 
Arbeitszeit,
gute Arbeit und Respekt verlangen. In einem Freundschaftsverh&auml;ltnis
sind diese Qualit&auml;ten zwar durchaus m&ouml;glich, aber nicht als 
Regel
zu erwarten. Dies trifft in besonderem Ma&szlig;auf Assistenten des 
anderen
Geschlechts zu. Pers&ouml;nliche Assistenz ist ein schlechter Ersatz 
f&ouml;r
Freundschafts- oder Partnerbeziehungen. Effektiver Einsatz von 
pers&ouml;nlicher
Assistenz ist jedoch eine notwendige Voraussetzung f&uuml;r 
ebenb&uuml;rtige
Freundschaft und Liebesbeziehungen.<BR>
<BR>
In Schweden gibt es gl&uuml;cklicherweise fast keine 
Zivildienstleistenden.
Dadurch wird uns erspart, Leute als Assistenten zu erdulden, die diese 
Arbeit
nicht aus freien St&uuml;cken und als geringeres &Uuml;bel gew&auml;hlt
haben. Bei Arbeitskr&auml;ften, die so unterbezahlt werden wie 
Zivildienstleistende,
d&uuml;rften auch oft Erwartungen an Belohnungen anderer Art mitspielen,
z.B. ein Anspruch auf Dankbarkeit oder die Vorstellung, sein 
p&auml;dagogisches
Talent beweisen und einen Behinderten auf Vordermann bringen zu 
k&ouml;nnen.
&Auml;hnlich wie bei Freiwilligenhelfern bieten solche Motive keine 
gesunde
Grundlage f&uuml;r gute Arbeit. Es versteht sich von selbst, da&szlig;ich

von jemanden, dem ich einen angemessenen Gehalt bezahle, eher 
Qualit&auml;tsarbeit
und Respekt verlangen kann als von jemanden, dem ich mich zu Dankbarkeit
verpflichtet f&uuml;hlen mu&szlig;. Zivildienstleistende und 
Freiwilligenhelfer
verderben den Arbeitsmarkt f&uuml;r pers&ouml;nliche Assistenten, weil 
ihre
Existenz eine marktgerechte Lohnentwicklung bremst und dadurch zu 
st&auml;ndigen
Unterangebot an pers&ouml;nlichen Assistenten f&uuml;hrt.<BR>
<BR>
Die Arbeitgeberrolle gibt uns die Voraussetzung, nicht mehr Objekt, 
sondern
Subjekt zu sein.
<H4>Selbstbestimmung gibt Durchschlagskraft</H4>
<FONT SIZE="5">Z</FONT>u den Skeptikern des STIL-Projekts geh&ouml;ren 
vor
allem die etablierten Behindertenorganisationen, die auch in Schweden 
noch
stark von engagierten nichtbehinderten Philanthropen im Vorstand und 
Funktion&auml;rskader
kontrolliert werden. Diese Organisationen, die schon seit langem Energie
und Prestige in die Fokusl&ouml;sung investieren, sehen mit Argwohn, wie
STIL mit Vortr&auml;gen, Reportagen in der Tagespresse und seiner 
respektlosen
Monatszeitschrift STILETTEN die Loyalit&auml;t der j&uuml;ngeren 
Mitglieder
unterminiert, die sich in den von ihren nichtbehinderten 
Funktion&auml;ren
abgesegneten Fokuswohnungen zunehmend unwohler f&uuml;hlen - vor allem,
wenn sie den enormen Aufschwung im Leben der STIL-Projektteilnehmer 
beobachten
k&ouml;nnen. Um der Gefahr der Bevormundung durch Nichtbehinderte 
vorzubeugen,
hat STIL laut Statuten nur Menschen mit Bedarf an pers&ouml;nlicher 
Assistenz
als stimmberechtigte Mitglieder und Vorstandsmitglieder. (Nichtbehinderte

sind als St&uuml;tzmitglieder willkommen.) Nur Leute mit Bedarf an 
pers&ouml;nlicher
Assistenz arbeiten im B&uuml;ro. Wozu diese an Rassismus grenzende 
Selbstsegregierung,
kann man sich fragen?<BR>
<BR>
Nur solche Mitglieder sollen Politik und Arbeit des STIL-Projekts 
bestimmen,
die unmittelbar davon betroffen sind. Wir sind die besten Experten. Wir
sind es satt, Zeit und Energie damit zu verlieren, anderen gegen&uuml;ber

immer wieder Erkl&auml;rungen abgeben und unsere Vorstellungen 
verteidigen
zu m&uuml;ssen. Das Gef&uuml;hl der gemeinsamen Bed&uuml;rfnisse und 
Erfahrungen
schafft dagegen Engagement und Zusammenhalt in der Gruppe.<BR>
<BR>
Die Arbeitslosigkeit unter Behinderten und vor allem denen, die 
pers&ouml;nliche
Assistenz brauchen, ist um ein Vielfaches h&ouml;her als die der 
Durchschnittsbev&ouml;lkerung.
Was liegt daher n&auml;her als Arbeitspl&auml;tze in unseren 
Organisationen
f&uuml;r unsere Leute zu reservieren? Wir m&uuml;ssen 
Behindertenorganisationen
ablehnen, in denen nichtbehinderte Vorsitzende Wirtschaft und Staat 
bitten,
Behinderten Arbeitspl&auml;tze zu beschaffen, aber selbst bestenfalls nur

einen Vorzeigekr&uuml;ppel im B&uuml;ro haben.<BR>
<BR>
Eine unserer gr&ouml;&szlig;ten Behinderungen ist unser Image vom 
hilflosen,
harmlosen Kr&uuml;ppelchen. Viele von uns sind dieser Gehirnw&auml;sche
selbst zum Opfer gefallen und haben geringes Selbstvertrauen und 
Erwartungen
an sich. Verst&auml;rken wir nicht diese Vorurteile, wenn wir in unseren
eigenen Organisationen Nichtbehinderte an f&uuml;hrender Stelle f&uuml;r
uns arbeiten und sprechen lassen? Was sollen Jugendliche mit 
Behinderungen
von sich und ihren Zukunftsaussichten halten, wenn sie niemals erwachsene

Behinderte in f&uuml;hrenden Positionen - nicht einmal in unseren eigenen

Organisationen - zu Gesicht bekommen? Wir brauchen positive Vorbilder, 
mit
denen wir uns gegen Jahrhunderte negativer Programmierung impfen 
k&ouml;nnen.<BR>
<BR>
Es gibt viele wohlmeinende und sozial engagierte Menschen - oft 
j&uuml;ngere
Sozialarbeiter, die mit uns f&uuml;r unsere Emanzipation k&auml;mpfen 
wollen.
Wir alle kennen die Situation, wenn sich diese meist gutausgebildeten und

verbalen Leute unserer Sache annehmen und in unseren Gruppen das Wort und

die Initiative ergreifen. Viele von uns dagegen hatten in ihrem Leben 
nicht
viel Gelegenheit dazu, sich die f&uuml;r Vereinsarbeit notwendigen 
F&auml;higkeiten
und das rechte Selbstvertrauen anzueignen. Vor die Wahl gestellt, 
entweder
unerfahrene Behinderte oder geschickte Nichtbehinderte mit einer Aufgabe
zu beauftragen, machen viele Gruppen den Fehler und w&auml;hlen 
Nichtbehinderte
mit der Begr&uuml;ndung, da&szlig;es wohl nicht auf die Behinderung 
ank&auml;me,
sondern ob man sich f&uuml;r eine Arbeit eigne. Auf diese Weise werden 
die
Wortgewandten noch besser und die behinderten Mitglieder noch stummer und

dankbarer daf&uuml;r, da&szlig;ein anderer die Aufgabe &uuml;bernommen 
hat,
z.B. in der Offentlichkeit zu sprechen oder ein Interview zu geben.<BR>
<BR>
Wir m&uuml;ssen endlich einsehen, da&szlig;eigene Erfahrung von 
Behinderung
und das Bewu&szlig;tsein, einer unterdr&uuml;ckten Minderheit 
anzugeh&ouml;ren,
unerl&auml;&szlig;liche Voraussetzungen und Qualifikationen f&uuml;r 
ernsthafte
und erfolgreiche Behindertenpolitik ausmachen.<BR>
<BR>
Ein wichtiger Grund f&ouml;r STIL's bisherigen Erfolg ist, da&szlig;wir
in eigener Sache viel &uuml;berzeugender wirken als die geschicktesten 
nichtbehinderten
Sprecher. Wir w&uuml;rden unsere Glaubw&uuml;rdigkeit in Frage stellen,
wenn wir in der Offentlichkeit und anderen Behinderten gegen&uuml;ber von

unserem Kampf um Selbstbestimmung sprechen und uns dabei von 
Nichtbehinderten
soufflieren oder gar vertreten lie&szlig;en. Selbstbestimmung gibt 
Durchschlagskraft.<BR>
<BR>
Je gr&ouml;&szlig;er der Anteil nichtbehinderter Menschen in 
Mitgliedschaft
und Vorstand, desto weniger haben wir selbst etwas in solchen Vereinen zu

sagen, desto st&auml;rker ist die Organisation auf Betreuung, 
F&uuml;rsorge
und Wohlt&auml;tigkeit ausgerichtet. Eine Frauenorganisation mit 
haupts&auml;chlich
M&auml;nnern im Vorstand w&uuml;rde niemand ernst nehmen. Schwarze 
B&uuml;rgerrechtsorganisationen,
in denen Schwarze selbst ihre Ziele und Arbeitsweise bestimmen wollen, 
werden
auch nicht des Rassismus bezichtigt.<BR>
<BR>
Behinderten, die f&uuml;r nichtbehinderte Vorstandsmitglieder und 
Angestellte
pl&auml;dieren, fehlt politisches Bewu&szlig;tsein und Vertrauen an ihre
eigenen F&auml;higkeiten.
<H4>Weg vom medizinischen Modell der Behinderung</H4>
<FONT SIZE="5">B</FONT>ehinderung ist ein Machtverteilungsproblem, ein 
politisches
Problem. Aber die Vorstellung, da&szlig;wir einer unterdr&uuml;ckten 
politischen
Minderheit angeh&ouml;ren, ist noch recht wenig verbreitet - am 
wenigstens
bei uns selbst. Der Grund daf&uuml;r ist, da&szlig;Behinderung in den 
Augen
der meisten ein medizinisches Problem ist. Wir werden nicht 
diskriminiert,
wir sind ja nur krank. Kranken Leuten kann man doch in einem Sozialstaat
nicht zumuten, z.B. im Berufsleben oder bei der Partnersuche mit Gesunden

zu konkurrieren. Kranke f&uuml;hlen sich am wohlsten im Gr&uuml;nen, 
hinter
hohen Mauern, wo sie abgeschirmt vom Alltag nicht st&auml;ndig vom 
Anblick
der Gesunden daran erinnert werden, da&szlig;sie ein bemitleidenswertes
Leben verbringen m&uuml;ssen. Als Kranke sind wir gew&ouml;hnlichen 
Verpflichtungen
entbunden und k&ouml;nnen immer mit Verst&auml;ndnis der Umwelt rechnen,
wenn wir z.B. mal zu sp&auml;t kommen, ein Versprechen nicht halten oder
keine Lust haben, uns zu engagieren, wenn's am Abend &quot;Dallas&quot;
im Fernsehen gibt. Von Kranken wird auch nicht erwartet, da&szlig;sie die

Initiative &uuml;bernehmen und selbst ihre Lage verbessern. Daf&uuml;r 
gibt
es ja &Auml;rzte, Besch&auml;ftigungstherapeuten, Krankengymnasten, 
Sozialarbeiter
etc., die die geeignete Ausbildung haben und besser wissen, was wir 
brauchen.
Da ist es viel bequemer, anderen Leuten, die daf&uuml;r auch noch bezahlt

werden, die Entscheidungen zu &uuml;berlassen.<BR>
<BR>
Der erste Schritt zu unserer Emanzipation ist, da&szlig;wir uns nicht 
l&auml;nger
selbst als Kranke abschreiben, sondern Forderungen an uns stellen.
<H4>Entprofessionalisierung der Assistenten</H4>
<FONT SIZE="5">N</FONT>ach dem noch allseits verbreiteten medizinischen
Modell der Behinderung m&uuml;ssen wir vorsichtig und behutsam von 
Menschen,
die sich diesem verantwortungsvollen Beruf geweiht haben, 
&quot;gepflegt&quot;
und &quot;betreut&quot; werden. Da wir krank sind, kann man uns nicht 
irgend
jemandem anvertrauen. Die Leute, die uns &quot;versorgen&quot;, 
m&uuml;ssen
besonders f&ouml;r solche schwere F&auml;1le ausgebildet werden. In den
5 Jahren, die ich im Krankenhaus verbrachte, hat mich keiner mal 
&uuml;bers
Wochenende nach Hause eingeladen, weil alle - und vor allem ich selbst -
glaubten, da&szlig;nur ein ausgebildeter Krankenpfleger im wei&szlig;en
Kittel mich ins Bett bringen konnte.<BR>
<BR>
Je kranker der Patient, desto mehr Ausbildung braucht das Pflegepersonal.

Mehr Ausbildung bedeutet im allgemeinen h&ouml;heren professionellen 
Status
und Gehalt. Damit gibt es also ein handfestes wirtschaftliches Motiv, uns

als besonders krank hinzustellen. Mehr Ausbildung bedeutet aber auch mehr

Macht. Je mehr professionellen Status und Macht das Personal hat, desto
weniger Macht hat der Patient.<BR>
<BR>
Viele Ambulante Dienste bilden ihre Assistenten aus. Das Kursangebot 
reicht
je nach Professionalisierungsehrgeiz von Hebe- und Rollstuhltechnik bis
zu Krankheitsprognosen und Psychologie. Manche von uns fordern 
Spezialausbildung
f&uuml;r ihre Assistenten in der Hoffnung, da&szlig;ihnen dann ihre 
W&uuml;nsche
von den Lippen abgelesen werden, ohne da&szlig;sie selbst den Mund zum 
Erkl&auml;ren
und Anleiten aufmachen m&uuml;ssen. Auch wenn wir den Bedarf an 
pers&ouml;nlicher
Assistenz gemeinsam haben, haben wir noch lange nicht die gleichen 
Behinderungen,
Arbeits- und Familienverh&auml;ltnisse, Gewohnheiten, Anspr&uuml;che, 
etc.
Eine allgemeine Ausbildung kann nicht auf unsere individuellen 
Bed&uuml;rfnisse
eingehen und ist daher im besten Fall wertlos. Im schlimmsten Fall werden

wir in diesen Kursen als Kranke hingestellt, die betreut und gepflegt 
werden
sollen - also als passive Objekte, was sich nicht mit der 
Arbeitgeberrolle,
die STIL fordert, vereinbaren l&auml;&szlig;t.<BR>
<BR>
Man fragt sich, welche F&auml;cher eine solche Ausbildung beinhalten 
soll.
Meine Assistenten sind mir beim Aufstehen, Waschen, Toilettengehen, im 
Haushalt,
mit Autofahren, Einkaufen, Reisebegleitung, etc. behilflich. Das sind 
T&auml;tigkeiten,
die die meisten Erwachsenen beherrschen m&uuml;&szlig;ten. Die das nicht
k&ouml;nnen, stelle ich erst gar nicht an. Ich kenne Leute, die von 
Ambulanten
Dienst-Assistenten zu h&ouml;ren bekamen: &quot;Ich wei&szlig;, was du 
brauchst
- ich habe einen 6-st&uuml;ndigen Kurs in Behindertenpsychologie 
gemacht.&quot;
Ausbildung wird hier zum Instrument der Unterdr&uuml;ckung.<BR>
<BR>
Wenn jemand Spezialausbildung f&uuml;r seine Assistenten fordert, soll er

nicht klagen, wenn er in seinen eigenen vier W&auml;nden wie ein Patient
behandelt wird und nichts zu sagen hat.
<H4>&quot;Peer support&quot;, die P&auml;dagogie des Independent Living
</H4>
<FONT SIZE="5">S</FONT>TIL's Anspruch auf Selbsthilfe, Selbstbestimmung
und Eigenverantwortung stellt Forderungen an die einzelnen Mitglieder. 
Nicht
alle, die sich bisher von Gemeindesozialarbeitern betreuen lie&szlig;en,
sind dazu bereit, manchem geht STIL zu schnell vor. Bei vielen 
m&uuml;ssen
zuerst die Sch&auml;den langj&auml;hriger Anpassung an station&auml;re 
und
&quot;ambulante&quot; Pflegeheime, der Selbstbegrenzung und -verachtung
behoben werden, bis sie davon &uuml;berzeugt sind, da&szlig;sie ihr Leben

in die Hand nehmen k&ouml;nnen. Die Verantwortung f&uuml;r die eigene 
pers&ouml;nliche
Assistenz erfordert praktische Kenntnisse, Erfahrung und Geschick im 
Umgang
mit Menschen. Manche f&uuml;hlen sich zun&auml;chst von der Vorstellung
&uuml;berw&auml;ltigt, Zeitungsinserate zu formulieren, monatliche 
Arbeitsschemas
aufzustellen, die Fehler eines Assistenten zu kritisieren oder gar 
jemanden
zu entlassen.<BR>
<BR>
Pflegeheimverwahrung oder &uuml;berbesch&uuml;tzende Eltern geben uns 
selten
die M&ouml;glichkeit zu lernen, wie man andere anweist, ohne dabei weder
die eigenen Bed&uuml;rfnisse zu verleugnen noch zum Tyrannen zu 
werden.<BR>
<BR>
Mitgliedschaft berechtigt die Projektteilnehmer und andere Mitglieder 
u.a.
zu Beratung und Ausbildung in diesen Fragen. Wir sind davon 
&uuml;berzeugt,
da&szlig; nicht unsere Assistenten, sondern wir ausgebildet werden 
m&uuml;ssen.
STIL bietet daher Kurse an, in denen die praktischen Aspekte der 
Arbeitgeberrolle
vermittelt und ge&uuml;bt werden. Daneben steht dem Einzelnen das 
Netzwerk
der anderen Projektteilnehmer zur Verf&uuml;gung. Mitglieder mit 
&auml;hnlichen
Problemen schlie&szlig;en sich zusammen und bilden innerhalb des Projekts

kleine Gruppen, in denen sie ihre Probleme diskutieren und sich 
gegenseitig
Ratschl&auml;ge geben.<BR>
<BR>
Dieses Prinzip der gegenseitigen Information, Beratung und Ermunterung 
wollen
wir in Zukunft systematischer einsetzen. Die Independent Living Bewegung
in den Vereinigten Staaten hat dieses Prinzip zu einer eigenen 
P&auml;dagogik
entwickelt, das sog. peer support (&quot;peer&quot; im Engl. = jemand in
der gleichen Situation, mit dem man sich identifizieren kann). Peer 
support
geht davon aus, da&szlig; wir die besten Experten sind, wenn es um unsere

Bed&uuml;rfnisse und deren L&ouml;sungen geht. Daher k&ouml;nnen wir am
besten voneinander lernen, Erfahrungen und Einsichten austauschen. Das 
wichtigste
Element beim peer support ist das Beispiel eines anderen, mit dem ich 
mich
identifizieren kann. Das Vorbild eines Kollegen gibt einen 
eindrucksvolleren
und nachhaltigeren Effekt als der Einsatz der besten nichtbehinderten 
Experten.<BR>
<BR>
Peer support wird von der Independent Living Bewegung auf drei Ebenen 
eingesetzt:
<UL>
  <LI>als Mittel zum Erwerb von Erfahrungen und F&auml;higkeiten, die wir

zur Bew&auml;ltigung unseres t&auml;glichen Lebens brauchen. Dazu 
geh&ouml;rt
u.a. wie man solche Dienste wie pers&ouml;nliche Assistenz gestaltet und
verwaltet oder sich geben&uuml;ber Beh&ouml;rden sein Recht verschafft.
  <LI>als Gegengewicht gegen die Vorurteile unserer Gesellschaft. Die 
Diskussion
&uuml;ber Euthanasie und Fruchtwasserkontrolle zeigt, da&szlig;unser 
Leben
als wertlos und im h&ouml;chsten Grad unerw&uuml;nscht eingesch&auml;tzt
wird. Da wir Teil unserer Umwelt sind, m&uuml;ssen wir davon ausgehen, 
da&szlig;diese
Wertvorstellungen auch in uns selbst wirken. Peer counselling ist ein 
wirksames
Mittel gegen diese Gehirnw&auml;sche und erh&ouml;ht Selbstvertrauen und
Selbstrespekt. 
  <LI>als Werkzeug in der Behindertenpolitik. Nur wenn wir selbst davon
&uuml;berzeugt sind, da&szlig; wir die gleichen Lebensbedingungen wie 
andere
verdienen, sind wir erfolgreich mit unseren Forderungen nach gleichen 
B&uuml;rgerrechten.
</UL>
In Berkeley, Kalifornien, dem Mekka der internationalen Independent 
Living
Bewegung, hat das World Institute on Disability (WID) eine Ausbildung 
f&ouml;r
ausl&auml;ndische peer counselling-Lehrer entwickelt. Im Mai und 
September
1987 f&uuml;hrte STIL in Zusammenarbeit mit WID in Stockholm die ersten
Kurse durch. Die Ausbildung soll uns helfen, klarer zu sehen, wo wir den
Hebel zur Ver&auml;nderung unserer Lage ansetzen m&uuml;ssen, und wie wir

die Kr&auml;fte in uns freimachen, die wir zu dieser Arbeit brauchen.<BR>

<BR>
Wir haben lange genug geklagt, ohne da&szlig;es uns geholfen h&auml;tte.
Jetzt m&uuml;ssen wir einsehen, da&szlig;nur wir selbst uns helfen 
k&ouml;nnen.
Das STIL-Projekt ist ein Weg, uns mehr pers&ouml;nliche und politische 
Macht
zu verschaffen.<BR>
<BR>
Adolf Ratzka<BR>
<BR>
<BR>
<FONT SIZE="2">Erschienen in A. Mayer, J. R&uuml;tter (Hrsg.), Abschied
vom Heim, Erfahrungsberichte aus Ambulanten Diensten und Zentren f&uuml;r

Selbstbestimmtes Leben. M&uuml;nchen 1988: AG-SPAK-Publ.<BR>
</FONT><IMG SRC="Pixel1x1.gif" WIDTH="1" HEIGHT="1" ALIGN="BOTTOM" 
NATURALSIZEFLAG=
"3"><BR>
<IMG SRC="Pixel1x1.gif" WIDTH="1" HEIGHT="1" ALIGN="BOTTOM" 
NATURALSIZEFLAG=
"3"> 
<H4>Anmerkung</H4>
Ein 45 min VHS Videofilm mit dem gleichen Titel ist vom Verfasser zu 
beziehen.
<H4>Literaturhinweise</H4>
Ratzka, Adolf, &quot;Schweden - Wunderland der Integration?&quot; in: 
Behindernde
Hilfe oder Selbstbestimmung der Behinderten, Kongre&szlig;bericht der 
internationalen
Tagung &quot; Leben, Lernen, Arbeiten in der Gemeinschaft&quot;, 
M&uuml;nchen
1982, Vereinigung Integrationsf&ouml;rderung e.V. M&uuml;nchen 1982, S.
56- 64.<BR>
<BR>
Ratzka, Adolf. <A HREF="WRFmono/WRFmono1.html">Independent Living and 
Attendant
Care in Sweden: A Consumer Perspective</A>, World Rehabilitation Fund 
Monograph
Nr. 34, World Rehabilitation Fund, New York, 1986.<BR>
<BR>
<HR><BR>
<P><CENTER><FONT SIZE=2><A HREF="Contents.html">[Institute on Independent

Living contents</A><A HREF="index.html">]</FONT></A></CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-212</DOCNO>
<DOCOLDNO>IA012-000125-B021-282</DOCOLDNO>
<DOCHDR>
http://www.independentliving.org:80/PersAssistenzinSchweden.html 193.13.228.238 19970216214646 text/html 31547
HTTP/1.0 200 OK
Last-Modified: Sun, 29 Sep 1996 08:29:14 +0000
Date: Sun, 16 Feb 1997 21:46:59 +0000
Expires: Sun, 16 Feb 1997 21:45:19 +0000
Content-type: text/html
Server: RoxenEnterprise/1.0
Content-length: 31321
</DOCHDR>
<HTML>
<HEAD>
    <TITLE>Institute_on_Independent_Living</TITLE>
</HEAD>
<BODY BGCOLOR="#ffffff" TEXT="#020436" LINK="#000042">
<META NAME="description" CONTENT="Individuals and organizations of 
persons with disabilities can 
publish, free of charge,  articles, reports, training manuals, 
announcements, etc. on Independent Living, personal assistance, advocacy, 

peer support, accessibility, legislation and related subjects. "><META 
NAME="keywords" CONTENT="Independent Living, personal assistance, 
advocacy, peer support, direct payments, anti-discrimination legislation, 

accessibility, disability, disability rights"><BR>
<IMG SRC="InstLogoSmall.gif" WIDTH="198" HEIGHT="57" ALIGN="BOTTOM" 
NATURALSIZEFLAG="3"><BR>
<H2><CENTER>Pers&ouml;nliche Assistenz in Schweden</CENTER>
</H2>
<H3><CENTER>Adolf Ratzka</CENTER>
</H3>
<H4>Independent Living</H4>
Independent Living oder Selbsbestimmt Leben ist eine weltweite Bewegung
von Menschen mit Behinderungen, die gegen Aussonderung, Bevormundung und
Diskriminierung arbeiten und f&uuml;r volle B&uuml;rgerrechte, 
Selbstbestimmung
und Selbstrespekt k&auml;mpfen. <BR>
<BR>
Unsere Ziele, einfach ausgedr&uuml;ckt: Wir verlangen das gleiche 
Ma&szlig;
an Macht &uuml;ber unser Leben und Alltag mit den gleichen 
Wahlm&ouml;glichkeiten,
die unsere nicht-behinderten Geschwister, Nachbarn, Freunde und Bekannte
als selbstverst&auml;ndlich hinnehmen. Wir wollen in unseren Familien 
aufwachsen
und nicht in Anstalten, wir wollen die Nachbarschaftsschulen besuchen und

nicht Sonderschulen oder Sonderklassen, wir wollen die &ouml;ffentlichen
Verkehrsmittel benutzen und nicht auf den Sonderfahrdienst des Roten 
Kreuzes
angewiesen sein, wir verlangen &uuml;berall wohnen zun k&ouml;nnen und 
nicht
in Heime, natursch&ouml;ne D&ouml;rfer in der Ein&ouml;de oder andere 
Ghettos
abgeschoben zu werden. Wir verlangen Arbeiten, die unserer Ausbildung und

unseren F&auml;higkeiten entsprechen - keine Besch&auml;ftigungstherapie.

Wir verlangen, als vollwertige B&uuml;rger behandelt zu werden ohne 
bef&uuml;rchten
zu m&uuml;ssen als lebensunwerte Parasiten beschimpft zu werden. Und das
Wichtigste: wie andere auch, wollen wir die Verantwortung &uuml;ber unser

Leben selbst in die Hand nehmen - ohne die Einmischung anderer.<BR>
<BR>
Die Independent Living Bewegung wurde von Menschen mit umfassenden 
Behinderungen
gegr&uuml;ndet. Damit meine ich Leute, die in ihrem t&auml;glichen Leben
von der Assistenz anderer abh&auml;ngig sind. Also nicht nur zum 
gelegentlichen
Putzen, Einkaufen oder Gl&uuml;hbirnen auswechseln sondern Menschen, die
nur mit Hilfe anderer ins Bett oder auf die Toilette kommen oder die sich

nur mit Hilfe anderer verst&auml;ndigen k&ouml;nnen. Assistenzbenutzer 
verstehen
am ehesten, was es hei&szlig;t, die Verantwortung &uuml;ber das eigene 
Leben
besch&uuml;tzenden Angeh&ouml;rigen und den sog. helfenden Berufen 
abringen
zu m&uuml;ssen.
<H4>Pers&ouml;nliche Assistenz</H4>
Eigentlich benutzen alle Menschen Assistenz. Die meisten reparieren z.B.
ihren Fernsehapparat nicht selbst, sondern ziehen es aus Mangel an Zeit
oder einschl&auml;gigen Kenntnissen vor, einen Techniker damit zu 
beauftragen.
<BR>
<BR>
F&uuml;r uns Menschen mit umfassenden Behinderungen ist Assistenz noch 
wichtiger.
Ein Beispiel: lch kann mir selbst einen Pullover anziehen, wozu ich - je
nach Tageskondition - mindestens eine halbe Stunde brauche. Nachher bin
ich total ersch&ouml;pft und mu&szlig; mich mindestens eine weitere halbe

Stunde lang ausruhen. Ich brauche also insgesamt mindestens 60 min. Wenn
ich einen Assistenten damit beauftrage, mir beim Pulloveranziehen zu 
helfen,
spare ich mindestens 59 Minuten, die ich f&uuml;r wichtigere 
T&auml;tigkeiten
verwenden kann. Genauso wie technische Hilfen m&uuml;sen wir auch 
Assistenz
einsetzen und zwar so wie wir selbst es in der jeweiligen Situation 
f&uuml;r
angebracht halten. Damit befinde ich mich in der gleichen Situation wie
jeder andere Arbeitgeber.<BR>
<BR>
Der Ausdruck &quot;pers&ouml;nliche&quot; Assistenz soll klarstellen, 
da&szlig;
ich aus meinen individuellen Bed&uuml;rfnissen heraus die 
Arbeitsbedingungen
bestimme. Ich entscheide, wen ich als Assistent einsetze, f&uuml;r welche

Arbeiten, wann, wo und wie die Arbeit auszuf&uuml;hren ist. 
Pers&ouml;nliche
Assistenz bedeutet: ich bin der Chef.<BR>
<BR>
&quot;Pers&ouml;nliche Assistenz&quot; hat wenig mit anderen 
Dienstleistungen
zu tun, die unter den herk&ouml;mmlichen Bezeichnungen wie 
&quot;Pflege&quot;
oder &quot;Betreuung&quot; bekannt sind. Wieviel hat ein 
&quot;Pflegeabh&auml;ngiger&quot;,
&quot;Pflegebed&uuml;rftiger&quot; oder &quot;zu Betreuender&quot; 
mitzureden?
Diese Ausdr&uuml;cke stellen uns als passive, hilflose Pflegef&auml;lle
dar im Gegensatz zu selbst&auml;ndigen und m&uuml;ndigen B&uuml;rgern. 
Diese
Ausdr&uuml;cke bezeichnen Diensleistungen, die uns als passive Objekte 
behandeln.<BR>
<BR>
Wenige von uns haben Assistenz in einem Umfang, der ihnen zu den 
Lebensbedingungen
verhilft, die andere Mitb&uuml;rger haben. Ein Grund daf&uuml;r ist die
Einstellung unserer Gesellschaft gegen&uuml;ber Menschen mit umfassenden
Behinderungen. F&uuml;r viele sind wir Sozialf&auml;lle, die man aus 
humanit&auml;ren
Gr&uuml;nden mitf&uuml;ttern sollte. Gesetzlich verankerte, einklagbare
Rechte auf Chancengleichheit haben wir keine -- wozu auch, wenn alle 
davon
ausgehen, da&szlig; &quot;Schwerstbehinderte&quot; von hause aus krank 
und
hilflos sind.<BR>
<BR>
Man schiebt uns in Heime und besch&uuml;tzende Wohnungen ab, wo Assistenz

und damit unsere Lebensqualit&auml;t auf ein Minimum reduziert werden. 
Die
Bed&uuml;rfnisse der Anstalt nach reibungslosem Funktionieren bestimmen
unser Leben dort und nicht die Bed&uuml;rfnisse des Einzelnen. Wir werden

angepa&szlig;t, bevormundet und der Eigeninitiative beraubt, bis wir dem
Bild des harmlosen, freundlichen, etwas beschr&auml;nkten Behinderten 
entsprechen,
das die Offentlichkeit von uns hat.<BR>
<BR>
Unsere Umwelt sieht gerne, da&szlig; wir uns so viel wie m&ouml;glich 
abstrampeln,
um unseren Alltag allein zu bew&auml;ltigen. Auf diese Weise mit uns 
selbst
besch&auml;ftigt, fallen wir dem Sozialhaushalt weniger zur Last, haben
weder Zeit noch Energie, Forderungen nach Chancengleichheit mit 
Ausbildung,
Beruf, eigener Familie und sinnvoller Freizeit zu stellen. Kein Wunder 
also,
da&szlig; uns das Musterkr&uuml;ppelchen als Vorbild hingestellt wird, 
das
sich den ganzen Tag mit Aufstehen, Waschen, Anziehen, Kochen, Ausziehen
und zu Bettgehen abm&uuml;ht.<BR>
<BR>
Viele von uns beschr&auml;nken freiwillig die Anwendung von Assistenz und

damit ihr Leben auf ein Minimum, denn Abh&auml;ngigkeit von 
Dienstleistungen
anderer wird in noch viel h&ouml;herem Ma&szlig;e als technische 
Hilfsmittel
von unserer Umwelt und uns selbst als Stigma gesehen.<BR>
<BR>
&quot;Selbst ist der Mann&quot; hei&szlig;t es. Diese Haltung wird von 
Rehafachleuten
verst&auml;rkt - oder gibt es etwa Rehaeinrichtungen, in denen man lernt,

wie man Aufgaben an seine Assistenten delegiert? Stattdessen bekommen wir

vermittelt, da&szlig; man Behinderung wegtrainieren kann. Denjenigen, 
denen
das nicht ganz gelingt, gesteht man die Benutzung von technischen Hilfen
zu. Assistenz wird als letzter Ausweg gesehen, der auf das Notwendigste
beschr&auml;nkt werden sollte.<BR>
<BR>
Das Ideal der St&auml;rke, haupts&auml;chlich als k&ouml;rperliche 
St&auml;rke
ausgelegt, wirkt auf subtile Weise als Unterdr&uuml;ckungs- und 
Selbstverachtungsmechanismus.
Diesem Ideal zufolge gelte ich als schwach, hilflos und unterlegen, weil
ich mir nicht selbst die Hosen hochziehen kann. Menschen mit 
Behinderungen
z&auml;hlen wie Kinder zu den Schwachen der Gesellschaft. 
Abh&auml;ngigkeit
von praktischen Handreichungen wird gleichgesetzt mit intellektueller und

emotioneller Abh&auml;ngigkeit von anderen. Diese Einstellung dr&uuml;ckt

sich in der Organisation der meisten heutigen Assistenzformen aus, in 
denen
andere &uuml;ber unser Leben bestimmen. 
<H4>Die Stockholmer ambulanten Gemeindedienste</H4>
Als Beispiel einer dieser Assistenzformen m&ouml;chte ich das System des
Stockholmer sog Heimdienstes beschreiben, eines der am besten ausgebauten

ambulanten Dienste in Europa mit einer 50-j&auml;hrigen Tradition. Als 
ich
1973 nach Schweden kam, war ich verbl&uuml;fft &uuml;ber die 
Berufsbezeichnung
&quot;Hemsamarit&quot; also w&ouml;rtlich &quot;Heimsamariter&quot;. Das
sind Leute, die von den Gemeinden angestellt sind, um &auml;lteren und 
behinderten
Menschen mit Haushalt und K&ouml;rperpflege zu helfen. Die meisten sind
Frauen, die damit hauptberuflich arbeiten. Es gibt aber auch viele 
Studenten
oder andere, die nebenbei im Heimdienst arbeiten. Laut Gesetz sind die 
Gemeinden
daf&uuml;r verantwortlich, ihren Bewohnern einen &quot;angemessenes 
Lebensstandard&quot;
zu gew&auml;hrleisten, wozu auch die Bereitstellung dieser Dienste 
geh&ouml;rt.
Das Ziel dieser Eins&auml;tze ist, vor allem &auml;lteren Menschen zu 
erm&ouml;glichen,
in ihren Wohnungen zu bleiben und nicht in Sonderwohnformen umziehen zu
m&uuml;ssen.<BR>
<BR>
Ein Sozialarbeiter im Sozialamt stellt fest, in welchen Umfang wann und
wozu Hilfe ben&ouml;tigt wird. Dann schickt der gleiche Sozialarbeiter 
die
&quot;Samariter&quot; ins Feld, die dann nach einem Tagesschema von einem

&quot;Kunden&quot; zu anderen gehen. Die Dienste sind Menschen aller 
Einkommensstufen
offen, jedoch mit einkommensabh&auml;ngiger Kostenbeteiligung.<BR>
<BR>
Die Dienste sind fl&auml;chendeckend. Die Stadt Stockholm ist in 18 
Sozialditrikte
eingeteilt. Jeder Distrikt hat wiederum im Durchschnitt ein Dutzend 
Heimdienstdistrikte.
In jedem dieser Heimdienste gibt es wiederum Gruppenchefs. Unter denen 
rangieren
die Sozialarbeiter, die den Bedarf feststellen und den Einsatz der 
&quot;Samariter&quot;
leiten. In den achtziger Jahren habe ich mir mal die M&uuml;he gemacht,
die Zahl der Stufen in dieser Hierarchie zu z&auml;hlen. Damals gab es 
zwischen
mir, dem Benutzer der Dienste, und dem h&ouml;chsten verantwortlichen 
Chef
in der Stadtverwaltung 15 Chargen.<BR>
<BR>
Die &quot;Samariter&quot; kommen ins Haus nach einem vorherbestimmten 
Schema,
das nur schwer zu &auml;&auml;ndern ist. Braucht man Assistenz 
au&szlig;erhalb
der B&uuml;rozeiten, etwa zum Zu-Bett-Gehen, dann ist daf&uuml;r die 
Abendpatrulle
zust&auml;ndig. Mu&szlig; man nachts gewendet werden,. kommt die 
Nachtpatrulle.
Alles nach Schema. Allerdings mit langem Warten verbunden, denn 
Verz&ouml;gerungen
bei einem Kunden wirken sich auf die nachfolgenden aus. Au&szlig;erdem 
gibt
es st&auml;ndigen Personalwechsel. Man mu&szlig; also jederzeit damit 
rechnen,
einem wildfremden Menschen die ganze Morgenroutine von A-Z erkl&auml;ren
zu m&uuml;ssen. Was normal eine Stunde in Anspruch nimmt, kann dann 2 
Stunden
dauern, womit der eigene Tagesplan platzt. Dienstreisen, 
Wochenendausfl&uuml;ge,
Urlaubsreisen sind unm&ouml;glich. Diese Dienste sind nur in den eigenen
vier W&auml;nden zu haben. Ich spreche daher vom 
&quot;Hausarrestprinzip&quot;.
Die &quot;Samariter&quot; d&uuml;rfen nur bestimmte Haushaltsaufgaben 
&uuml;bernehmen,
z.B. keine Teppiche klopfen, die Fenster nur zu bestimmten Jahreszeiten
putzen, nur einmal in der Woche einkaufen u s w.<BR>
<BR>
Ich m&ouml;chte jetzt nicht unn&ouml;tig gegen ambulante Dienste 
polemisieren.
Es gibt sicher Menschen, die bereit sind, ihre Bed&uuml;rfnisse den 
Begrenzungen
des Apparats anzupassen. Aber jemand der gleiche Bedingungen im Alltag 
anstrebt
mit Beruf, ebenb&uuml;rtiger Partnershaft, Familie und sinnvoller 
Freizeit,
w&uuml;rde daran verzweifeln.<BR>
<BR>
Als Antwort auf die Proteste vor allem j&uuml;ngerer Assistenbenutzer 
wurde
Anfang der 70-er Jahre in Schweden das sogenannte Fokus-Konzept 
geschaffen.
Fokus-wohnungen sollten den Bewohnern rund um die Uhr Personal 
garantieren.
In einem Mietblock werden 10 - 15 Wohnungen durch Haustelefon an ein 
zentrales
Personalzimmer angeschlossen. Der Unterschied zu einem herk&ouml;mmlichen

Sonderwohnheim f&uuml;r Behinderte besteht darin, da&szlig; jeder seine
eigene Wohnung hat und die &uuml;brigen Appartements an Nichtbehinderte
vermietet werden. Meiner Ansicht nach ist dieser Unterschied jedoch 
kosmetischer
Natur. Der Grundcharakter des Heims bleibt erhalten, weil auch bei der 
Fokus-L&ouml;sung
das Personal f&uuml;r alle Insassen gemeinsam ist. Damit ergeben sich 
unvermeidbare
Sachzw&auml;nge. So gilt z.B. die Regel, da&szlig; alle Angestellten 
allen
Insassen helfen m&uuml;ssen. Als Frau kann man keinen Mann abw&auml;hlen,

wenn es um die intime K&ouml;rperpflege geht. Auch in den Fokus-Anlagen
kann man sich also nicht selbst die Assistenten w&auml;hlen, auch hier 
gilt
das Hausarrestprinzip. <BR>
<BR>
So ungef&auml;hr sah die Situation der schwedischen 
Assistenzben&uuml;tzer
in den 80er Jahren aus. Die gro&szlig;en schwedischen 
Behindertenverb&auml;nde
hatten wenig Interesse an dieser Frage, denn viele Vorstandsmitglieder 
und
Funktion&auml;re waren nicht behindert, geschweige denn selbst 
Assistenzben&uuml;tzer.
Nur einer der gro&szlig;en Vereine, der DHR, zeigte Engagemang. Dort sah
man als Hauptursache der Probleme einen Mangel an Ausbildung und 
Professionalit&auml;t
beim Personal. Die Angestellten in den Fokus-Anlagen sollten durch Kurse
f&uuml;r &quot;Pers&ouml;nlichkeitsentwicklung&quot; besser auf ihre 
Aufgaben
vorbereitet werden. Am System selbst hatte man nichts auszusetzen. Unsere

Forderungen und unseren Sprachgebrauch von &quot;Macht&quot; und 
&quot;Geld
in der Tasche&quot; lehnte man entr&uuml;stet ab.
<H4>STIL und der Weg vom Objekt zum Subjekt</H4>
1973 kam ich nach Schweden, um an meiner Doktorarbeit zu arbeiten. Bis 
dahin
hatte ich als Student in den USA meine Assistenten selbst angestellt, was

mir mein Stipendium erm&ouml;glichte. Abrechnung erfolgte mit Quittungen.

Als mir in Schweden mein Forschungsauftrag ausging und ich pl&ouml;tzlich

vom Heimdienst abh&auml;ngig wurde, verschlechterte sich meine 
Lebensqualit&auml;t
radikal. <BR>
<BR>
1983 organisierte ich eine Tagung &uuml;ber Independent Living, zu der 
ich
Freunde aus Kalifornien als Referenten einlud. Zum ersten Mal wurden 
damit
der &Ouml;ffentlichkeit Begriffe vorgestellt wie Selbstbestimmung, 
Selbstrespekt,
Empowerment (also Ergreifung der Macht &uuml;ber sein eigenes Leben) und
Peer Support (etwa gegenseitige Unterst&uuml;tzung unter Betroffenen). 
Als
Folge der Tagung entwickelte sich unter meiner F&uuml;hrung eine 
Arbeitsgruppe
aus Assistenzbenutzern, die dann im Jahre 1984 den Verein STIL, 
Stockholmer
Genossenschaft f&uuml;r Independent Living, gr&uuml;ndete. Bis 1995 war
ich STILs Vorsitzender.<BR>
<BR>
Unser Ziel war einfach: Gelder statt Sachleistungen. Die Kosten unserer
Assistenz durch den Heimdienst oder die Fokus-Anlage wollten wir uns von
der Gemeinde auszahlen lassen, um damit unsere eigenen Dienste nach 
unseren
Vorstellungen aufzubauen. Ein bis dahin unerh&ouml;rtes Ansinnen. Wir 
wurden
stark bek&auml;mpft, von vielen Seiten: <BR>
<BR>
Die Gewerkschaften f&uuml;rchteten, da&szlig; ihre Mitglieder bei uns zu
Leibeigenen reduziert w&uuml;rden. Gewerkschaften sch&auml;tzen nun mal
gro&szlig;e Betriebe, wo sie die Interessen ihrer Mitglieder besser 
sch&uuml;tzen
k&ouml;nnen. <BR>
<BR>
Die gro&szlig;en Behindertenverb&auml;nde, vor allem der DHR, der so viel

Energie und Prestige in die Fokus-L&ouml;sung investiert hatte, 
emp&ouml;rten
sich &uuml;ber uns, weil wir Fokuseinrichtungen als diskriminierende 
Sonderl&ouml;sung
angriffen und sie in Anlehnng an das damalige S&uuml;dafrika als 
&quot;homelands&quot;
bezeichneten. <BR>
<BR>
Die Behindertenverb&auml;nde waren gegen uns, weil viele ihrer Mitglieder

Angst hatten vor unserer Forderung, die Verantwortung &uuml;ber unsere 
Dienste
selbst in die Hand zu nehmen. Die etablierten Verb&auml;nde hatten ihren
Mitgliedern die Schlagworte beigebracht, &quot;die Politiker m&uuml;assen

ihre Verantwortung &uuml;bernehmen&quot;. Oder &quot;deine Vorurteile 
sind
mein gr&ouml;&szlig;tes Hindernis&quot;. Wir dagegen behaupteten, 
da&szlig;
wenn wir nicht selbst die Sache in die Hand nehmen, passiert nur Unsinn.
Da&szlig; jede Ver&auml;nderung eine Ver&auml;nderung unseres eigenen 
Bewu&szlig;tseins
voraussetzt.<BR>
<BR>
Die Funktion&auml;re der Behindertenverb&auml;nde ver&uuml;belten uns 
auch,
da&szlig; wir Selbstbestimmung auch in unseren Organisationen fordern und

alle nichtbehinderten Mitglieder, vor allem im Vorstand, 
hinauskomplimentieren
wollten. In STIL, haben laut Satzung nur Assistenzbenutzer aktives und 
passives
Wahlrecht. Damit wollen wir uns von dem Ballast befreien, st&auml;ndig 
Nicht-Assistenzbenutzern
gegen&uuml;ber unsere Vorstellungen erkl&auml;ren und rechtfertigen und
st&auml;ndig auf der Hut sein zu m&uuml;ssen, da&szlig; sie nicht aus 
Mangel
an eigener Erfahrung und Unkenntnis in der &Ouml;ffentlichkeit Dinge von
sich geben, die nicht unseren Zielen entsprechen. Unser Motto ist: 
Selbstbestimmung
gibt Durchschlagskraft. Wir sind die besten Experten und m&uuml;ssen in
eigener Sache sprechen. <BR>
<BR>
Das hat sich ausgezahlt. Wenn wir mit unseren Elektrofahrst&uuml;hlen zu
Verhandlungen ins Rathaus rollten, wurde deutlich, da&szlig; unsere 
Verhandlungspartner
noch nie diesen Nahkontakt hatten und uns ernsthaft zuh&ouml;rten, 
da&szlig;
sie auf unsere Sachkenntnisse allenfalls mit allgemeinen ideologischen 
Floskeln
argumentieren konnten und dies bald aufgaben.<BR>
<BR>
Politiker der Linken standen uns skeptisch gegen&uuml;ber. Einmal lag es
an unserer Kritik am Sozialstaat. Um es genau auszudr&uuml;cken: wir sind

nicht gegen den Sozialstaat an sich. Wir unterst&uuml;tzen den Gedanken,
da&szlig; die Kosten unserer Assistenz vom Staat bezahlt werden, und zwar

am besten durch das Steueraufkommen auf Landesebene und nicht von der 
Gemeindesteuer.
Wir finden es gut, da&szlig; unser Bedarf an Assistenz vom Staat 
festgestellt
wird, in Zusammenarbeit mit dem Einzelnen. Aber wir wehren uns 
entschieden
gegen die Monopolstellung des &ouml;ffentlichen Sektors in der Produktion

dieser Dienste. Denn da kommt es zu Schreibtischl&ouml;sungen, die 
typisch
f&uuml;r zentralgesteuerte Planwirtschaften sind, und die sich mit ihren
einheitlichen L&ouml;sungen nicht den unterschiedlichen Bed&uuml;rfnisse
Einzelner anpassen k&ouml;nnen. Genauso w&uuml;rden wir uns gegen die 
Monopolstellung
eines fl&auml;chendeckenden privaten Wohlfahrtsvereins wehren. <BR>
<BR>
Wir vermieden, uns auf politische Diskussionen einzulassen, die uns in 
das
eine oder andere Lager festgelegt h&auml;tten. Von der Linken bekamen wir

z.B. immer wieder zu h&ouml;ren, da&szlig; unsere Initiative ein Teil der

Privatisierungswelle sei, die Ende der 80er Jahre auch in Schweden 
anfing,
und da&szlig; wir uns in unserer Beschr&auml;nktheit von den 
Konservativen
ausn&uuml;tzen lie&szlig;en, die den Abbau des Sozialstaats im Sinne 
h&auml;tten.
Meine Antwort darauf war, da&szlig; es in jedem politischen System eine
private Sph&auml;re geben sollte, in der der einzelne B&uuml;rger selbst
&uuml;ber solche grundlegenden Dinge entscheiden k&ouml;nne, wie z.B. wie

oft, wann und wie man aufs Klo geht. <BR>
<BR>
Wir versuchten, die Reizw&ouml;rter der Parteipolitiker zu benutzen, mit
denen wir es jeweils zu tun hatten. Den Linken gegen&uuml;ber sprachen 
wir
von der Aufgabe des solidarischen Sozialstaats, den einzelnen 
Mitb&uuml;rgern
bei der Entfaltung ihres Potentials zu helfen. Bei den Konservativen 
sprachen
wir von Eigenverantwortlichkeit und der Notwendigkeit, dem Markt 
Gelegenheit
zu geben, kundengerechte L&ouml;sungen in freier Konkurrenz zu 
entwickeln.
Den Liberalen dienten wir als Beispiel von Eigeninitiative und 
Wahlfreiheit.
Bei der Zentrumspartei und den Gr&uuml;nen sprachen wir von 
b&uuml;rgernahen
L&ouml;sungen, die Kleinunternehmer beg&uuml;nstigen. Die Liberalen waren

am meisten an uns interessiert. Vom progressiven Fl&uuml;gel der 
Sozialdemokraten
bekamen wir erst Unterst&uuml;tzung, als wir die Absicht bekannt machten,

eine Genossenschaft zu gr&uuml;nden, die als Arbeitgeber f&uuml;r unsere
Assistenten fungieren werde. 
<H4>Das STIL-Projekt</H4>
Wir wollten ein Pilotprojekt starten, um der &Ouml;ffentlichkeit zu 
beweisen,
da&szlig; wir mit den gleichen Geldern ein bedeutend h&ouml;heres 
Ma&szlig;
an Qualit&auml;t in den Assistenzdiensten erzielen k&ouml;nnen. Das 
gr&ouml;&szlig;te
Hindernis auf diesem Weg bestand in den g&auml;ngigen Vorstellungen der
&Ouml;ffentlichkeit von Menschen, die pers&ouml;nliche Assistenz 
brauchen.
Jahrzehntelang hatten Politiker aller Schattierungen Steuerbezahler 
m&uuml;rbe
gemacht mit Hinweisen auf die &quot;Schw&auml;chsten der 
Gesellschaft&quot;.
Diese hilflosen hoffnngslosen Pflegef&auml;lle, diese Personifizierungen
der Schattenseiten des Lebens, jetzt wollten die also nicht l&auml;nger
besch&uuml;tzt, betreut und versorgt werden sondern als Arbeitgeber 
auftreten
und damit die Gesellschaftspyramide von unten nach oben umkrempeln. Das
war den Behindertenverb&auml;nden zuviel, die bestenfalls Mitbestimmung
verlangten aber nicht die Arbeitgeberfunktion. Wir sprachen von der 
Notwendigkeit,
die herrschenden Machtverh&auml;ltnisse zu unseren Gunsten zu 
&auml;ndern,
und behaupteten, da&szlig; Geld in der Tasche uns diese Macht gibt, weil
wir damit unsere eigenen Assistenten anstellen k&ouml;nnen. 
Ausdr&uuml;cke
wie &quot;Macht&quot; und &quot;Geld&quot; verschreckten die Freunde des
Hallo-Partner-Dankesch&ouml;n und Miteinander-F&uuml;reinander. <BR>
<BR>
Ich habe mich so lange bei dem ideologischen &Uuml;berbau aufgehalten, 
weil
unsere Haltung damals die praktische Ausf&uuml;hrung der sp&auml;teren 
schwedischen
Assistenzreform pr&auml;gte. Das wird aus der weiteren Entwicklung 
ersichtlich.<BR>
<BR>
Nach 4-j&auml;hrigem Ringen konnten 1987 22 Assistenznehmer in unserem 
Pilotprojekt
anfangen. Es wurde ein Riesenerforlg. Zwei Jahren sp&auml;ter, nach 
einigen
Stra&szlig;enblockaden, viel Medienarbeit und politischen Kontakten waren

wir dann soweit. Wir erkl&auml;rten unser Pilotprojekt als abgeschlossen
und verlangten, unsere L&ouml;sung allen interessierten Assistenznehmern
anbieten zu k&ouml;nnen. Wir hatten inzwischen soviele Anh&auml;nger 
gewonnen
bei Behinderten, Politikern und in der &Ouml;ffentlichkeit, da&szlig; die

Stadt nicht vermeiden konnte, sich mit uns an den Verhandlungstisch zu 
setzen.
Man bot uns an, die Arbeitgeberverantwortung f&uuml;r unsere Assistenten
zu &uuml;bernehmen um uns diese Arbeit zu ersparen. Wir lehnten sofort 
ab,
weil wir wu&szlig;ten, da&szlig; wir damit in den Augen unserer 
Assistenten
nicht mehr die Chefs sein w&uuml;rden. Man bot uns an, die 
L&ouml;hnekosten
der Assistenten zu bezahlen und dazu umgerechnet 50&nbsp;000 DEM im Jahr
f&uuml;r unsere Verwaltungskosten einschlie&szlig;lich eines kostenlosen
B&uuml;roraums. Wir lehnten ab, denn es war klar, da&szlig; damit die 
Stadt
vollkommene Kontrolle &uuml;ber unsere Arbeit und weitere Entwicklung 
bekommen
w&uuml;rde. Wir bestanden darauf, als Zulieferfirma betrachtet zu werden,

die sich mit der Gemeinde um einen Stundensatz einigt, der alle Kosten 
enth&auml;lt.<BR>
<BR>
Unser Verkaufsslogan war: bessere Qualit&auml;t zum gleichen Preis. Die
Schwierigkeit lag darin, da&szlig; die Gemeindeverwaltung damals nicht im

Stande war, ihre Selbstkosten empirisch zu belegen. Es gab nur vage 
Sch&auml;tzungen,
die nicht aufrecht zu halten waren. Zuletzt kam es dazu, da&szlig; der 
Sozialausschu&szlig;
des Stadtrats unsere Sch&auml;tzung der Selbstkosten der Gemeinde 
akzeptierte.
Das geschah mit einer Stimme Mehrheit. Diesen Betrag bekamen wir dann 
ausbezahlt.<BR>
<BR>
Daraufhin verbreitete sich unsere L&ouml;sung unter dem Namen 
&quot;STIL-Model&quot;
im ganzen Lande. Wir halfen Gruppen von Assistenzbenutzern in anderen 
St&auml;dten
mit praktischer Hilfe, Ausbildung und Darlehen. Heute hat STIL 170 
Mitglieder,
einen Jahresumsatz von 25 Millionen DEM. Es gibt 6 IL Genossenschaften 
mit
insgesamt 500 Mitglieder und ein Dutzend anderer Genossenschaften, die 
unser
Model kopierten.<BR>
<BR>
In meinem Referat habe ich leider nicht die Zeit, eine der wichtigsten 
T&auml;tigkeiten
der Genossenschaft und eine der wichtigsten Voraussetzungen zur 
pers&ouml;nlichen
Assistenz zu ber&uuml;hren. Das ist die Unterst&uuml;tzung des einzelnen
Assistenznehmers bei der Verwandlung vom Objekt zum Subjekt, vom 
&quot;Pflegefall&quot;
zum Arbeitgeber. In den nunmehr 10 Jahren meiner Arbeit mit STIL und 
anderswo
habe ich immer mehr eingesehen, wie wichtig diese Umstellung ist f&uuml;r

die Qualit&auml;t der pers&ouml;nlichen Assistenz. Ein Chef f&auml;llt 
nicht
vom Himmel, schon garnicht wenn er oder sie jahrzehntelang im Elternhaus
oder im Heim gelebt hat. &Uuml;ber dieses Thema m&uuml;&szlig;ten wir 
tagelang
sprechen, heute wollte ich mich auf die ideologischen und politischen 
Aspekte
konzentrieren. 
<H4>Die schwedische Assistenzreform von 1994</H4>
1991 bekam Schweden eine konservative Regierung. Der Parteif&uuml;hrer 
der
Liberalen, Bengt Westerberg, wurde Sozialminsiter. Westerberg hatte sich
schon seit 1987 f&uuml;r uns interessiert und im Parliament von 
&quot;Adolf
und seinen Freunden&quot; erz&auml;hlt, um damit seine Thesen zur Reform
des Sozialstaats zu illustrieren. Unter Westerberg als Minister trat dann

auch die jetzige Assistenzreform im Januar 1994 in Kraft. In der 
Parlamentsdebatte
sprach der Minister lange &uuml;ber die Bedeutung meiner und STIL:s 
Pionierarbeit,
die den Geist und den Inhalt des Gesetzes gepr&auml;gt h&auml;tten. All
die Begriffe, die wir gebrauchten, wie Independent Living, 
pers&ouml;nliche
Assistenz, Macht, Selbstbestimmung, Wahlfreiheit und Eigeninitiative, 
Lebensqualit&auml;t
usw sind im Gesetzestext oder den Vorarbeiten zum Gesetz enthalten. <BR>
<BR>
Die Assistenzreform und ihre Ausf&uuml;hrungsbestimmungen sind zum 
gr&ouml;&szlig;ten
Teil aus der Praxis des STIL-Models &uuml;bernommen, zu dem wir uns in 
Verhandlungen
mit den Gemeinden in den Jahren 1987 bis 1994 durchgek&auml;mpft hatten.
Ich gehe jetzt die wichtigsten Punkte dieses Gesetzes durch.<BR>
<BR>
Die staatliche Sozialversicherung, die durch das Steueraufkommen 
finanziert
wird, zahlt monatliche Betr&auml;ge an Assistenzben&uuml;tzer aus. Die 
Zahlungen
sind steuerfrei und einkommensunababh&auml;ngig.<BR>
<BR>
Das Gesetz garantiert diese Leistung, solange die folgenden Bedingungen
erf&uuml;llt werden: Mindestbedarf von 20 Wochenstunden, Alter bis zu 65
Jahren. Gegen diese Einschr&auml;nkungen konnten wir nichts machen. Das
Gesetz w&auml;re nie zustande gekommen, wenn alle Assistenzbenutzer 
unabh&auml;ngig
von Alter und Bedarfsumfang zu den Leistungen berechtigt gewesen 
w&auml;ren.
Es ist sowieso erstaunlich, da&szlig; es &uuml;berhaupt zu diesem Gesetz
kam, das deutlich gegen den vorherrschenden Trend ging, der 
Dezentralisierung
und &Uuml;berw&auml;lzung von Aufgaben vom Staat auf die Gemeinden, um 
Haushaltsdefizit
und Staatsverschuldung zu bremsen. Man darf nicht vergessen, da&szlig; 
die
jetzige Wirtschaftskrise sich schon damals abzeichnete.<BR>
<BR>
Der Bedarf wird in Wochenstunden ausgedr&uuml;ckt - im Gegensatz zu 
&quot;Eins&auml;tzen&quot;.<BR>
<BR>
Zum Assistenzbedarf m&uuml;ssen grundlegende Bed&uuml;rfnisse 
geh&ouml;ren,
wie z. B. essen, auf die Toilette gehen, aufstehen, sich 
verst&auml;ndigen,
den Tagesablauf strukturieren. Das hei&szlig;t, auch viele Menschen mit
intellektuellen Behinderungen sind zu diesen Leistungen berechtigt.<BR>
<BR>
Die Leistungen sind nur f&uuml;r Menschen, die au&szlig;erhalb von 
Einrichtungen
leben. Damit wird Heiminsassen der Auszug erm&ouml;glicht. Au&szlig;erdem

entsteht dadurch f&uuml;r die Kostentr&auml;ger der Heimunterbringung -
in Schweden den Gemeinden oder Landkreisen - ein finanzieller Anreiz, die

Heiminsassen beim Ausziehen zu unterst&uuml;tzen. Im Gesetz wird der 
Kostenvergleich
zwischen station&auml;rer Unterbringung und dem Leben au&szlig;erhalb von

Einrichtungen nicht diskutiert. Es gibt also nirgendwo die Auflage, 
da&szlig;
die kosteng&uuml;nstigere L&ouml;sung gew&auml;hlt werden mu&szlig;. <BR>

<BR>
Der Stundensatz enth&auml;lt alle gesetzlichen und tariflichen direkten
und indirekten Lohnkosten und Kosten f&uuml;r die Verwaltung. Also keine
staatlich gef&ouml;rderte Schwarzarbeit, sonder voller tariflicher Lohn
mit Urlaubsgeld, Krankenversicherung und Pension. Die Verwaltungskosten
sollen Kosten beim Diensttr&auml;ger, z.B. bei der Genossenschaft, und 
beim
Assistenznehmer decken. Dazu gh&ouml;ren nicht nur Buchhaltung, 
B&uuml;ror&auml;ume,
Beratung, etc. sondern auch die Reisekosten eines mitfolgenden 
Assistenten
und &auml;hnliche Kosten, die dem Arbeitgeber entstehen.<BR>
<BR>
Kostennachweis f&uuml;r die Gelder mu&szlig; geleistet werden. <BR>
<BR>
Assistenznehmer k&ouml;nnen mit den Geldern ihre Dienste bei der Gemeinde

kaufen, von privaten Firmen oder die Arbeitgeberrolle f&uuml;r ihre 
Assistenten
selbst &uuml;bernehmen entweder kollektiv in Form einer Genossenschaft 
oder
als einzelner Arbeitgeber. Alle denkbaren Kombinationen sind denkbar, die

Sozialversicherung hat kein Recht sich dabei einzumischen.<BR>
<BR>
Unverbrauchte Stunden k&ouml;nnen innerhalb eines halben Jahres gespart
werden. Damit k&ouml;nnen wir selbst haushalten und f&uuml;r 
unvorhergesehene
F&auml;lle oder f&uuml;r eine Reise Reserven aufbauen.<BR>
<BR>
Der Stundensatz wird vom Diensttr&auml;ger bestimmt, darf aber den 
h&ouml;chsten
Satz nicht &uuml;bersteigen, den die Regierung jedes Jahr bestimmt. <BR>
<BR>
<BR>
Das Gesetz trat im Januar 1994 in Kraft. Bei den Betroffenen - etwa 7 000

Menschen - und deren Angeh&ouml;rigen hat diese 
verh&auml;ltnism&auml;ssige
billige Reform eine enorme Verbesserung der Lebensqualit&auml;t 
verursacht.
Fokuswohnungen und andere Einrichtungen werden nicht mehr weiter 
ausgebaut
wegen Mangel an Nachfrage. Selbst die gro&szlig;en 
Behindertenverb&auml;nde
- allen voran der DHR, der nun das Urheberrecht der Assistenzreform 
f&uuml;r
sich beansprucht - haben die enormen Vorteile der Geldleistungen 
eingesehen
und haben sich unser Vokabular angeeignet.<BR>
<BR>
Auf l&auml;ngere Sicht wird die Reform zu tiefen Ver&auml;nderungen 
f&uuml;hren.
Mit Hilfe von pers&ouml;nlicher Assistenz haben viele zu studieren und 
arbeiten
angefangen. Pers&ouml;nliche Asssitenz hat manchen den Mut gegeben, eine
Partnerschaftsbeziehungen aufzubauen und Kinder in die Welt zu setzen. 
Allein
im Verein STIL haben wir ein Dutzend Eltern von Kleinkindern, die diesen
Entschlu&szlig; auf das STIL-Model zur&uuml;ckf&uuml;hren. Meine Frau und

ich geh&ouml;ren auch dazu.<BR>
<BR>
Adolf Ratzka<BR>
September 1996<BR>
<BR>
<BR>
<BR>
Mehr &uuml;ber &quot;Heimsamariter&quot;, Fokuswohnungen und die 
schwedische
Situation in<BR>
&quot;<A HREF="Aufstand_der_Betreuten.html">Aufstand der
Betreuten</A>&quot;,<BR>
<A HREF="WRFmono/WRFmono1.html">&quot;Independent Living
and Attendant Care in Sweden&quot;</A> <BR>
<A HREF="BehinderunginSchweden.html">&quot;Behinderung
oder Selbstbestimmung - zur Lage von Menschen mit Behinderungen in 
Schweden&quot;</A><BR>
<P><CENTER><HR><FONT SIZE="2">[<A HREF="Contents.html">Institute
on Independent Living contents</A>]</FONT></CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-213</DOCNO>
<DOCOLDNO>IA012-000125-B022-35</DOCOLDNO>
<DOCHDR>
http://www.independentliving.org:80/PersAssistanceResearch.html 193.13.228.238 19970216214715 text/html 1663
HTTP/1.0 200 OK
Last-Modified: Tue, 06 Aug 1996 19:59:14 +0000
Date: Sun, 16 Feb 1997 21:47:15 +0000
Expires: Sun, 16 Feb 1997 21:45:35 +0000
Content-type: text/html
Server: RoxenEnterprise/1.0
Content-length: 1438
</DOCHDR>
<HTML>
<HEAD>
    <TITLE>Institute_on_Independent_Living</TITLE>
</HEAD>
<BODY TEXT="#020a3f" BGCOLOR="#ffffff" LINK="#000042">
<META NAME="description" 
CONTENT="Individuals and organizations of persons with disabilities can 
publish, free of charge,  articles, reports, training manuals, 
announcements, etc. on Independent Living, personal assistance, advocacy, 

peer support, accessibility, legislation and related subjects. "><META 
NAME="keywords" CONTENT="Independent Living, personal assistance, 
advocacy, peer support, direct payments, anti-discrimination legislation, 

accessibility, disability, disability rights">
<BR><BR>
<IMG SRC="InstLogoSmall.gif" WIDTH="198" HEIGHT="57" ALIGN="BOTTOM" 
NATURALSIZEFLAG=
"3"><BR>
<H3>Research on personal assistance</H3>
<UL>
  <LI><A HREF="ResSatisfaction.html">Life Satisfaction of People with 
Physical
Disabilities: <BR>
Relationship to Personal Assistance, Disability Status, and Handicap</A>
  <LI><A HREF="ResSelfmanagedAss.html">Self-Managed Versus 
Agency-Provided
Personal Assistance Care for Individuals With High Level Tetraplegia </A>

</UL>
<BR>
If you want us to include a reference to your research or other 
people&#180;s
work in this area, include an abstract or publish a whole paper, please,
<A HREF="mailto:ratzka@independentliving.org">contact </A>us. 
<H3><HR></H3>
<P><CENTER><FONT SIZE=2>[<A 
HREF="Contents.html">Contents</A>]</FONT></CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-214</DOCNO>
<DOCOLDNO>IA012-000125-B022-99</DOCOLDNO>
<DOCHDR>
http://www.independentliving.org:80/ToolsforPower/Tools31.html 193.13.228.238 19970216214740 text/html 9231
HTTP/1.0 200 OK
Last-Modified: Tue, 06 Aug 1996 20:03:51 +0000
Date: Sun, 16 Feb 1997 21:47:48 +0000
Expires: Sun, 16 Feb 1997 21:46:08 +0000
Content-type: text/html
Server: RoxenEnterprise/1.0
Content-length: 9006
</DOCHDR>
<HTML>
<HEAD>
    <TITLE>Institute_on_Independent_Living</TITLE>
</HEAD>
<BODY BGCOLOR="#ffffff" TEXT="#020535" LINK="#00007f">
<META NAME="description" 
CONTENT="Individuals and organizations of persons with disabilities can 
publish, free of charge,  articles, reports, training manuals, 
announcements, etc. on Independent Living, personal assistance, advocacy, 

peer support, accessibility, legislation and related subjects. "><META 
NAME="keywords" CONTENT="Independent Living, personal assistance, 
advocacy, peer support, direct payments, anti-discrimination legislation, 

accessibility, disability, disability rights">
<H4><IMG SRC="../InstLogoSmall.gif" WIDTH="198" HEIGHT="57" 
ALIGN="BOTTOM"
NATURALSIZEFLAG="3"></H4>
<BR>
The greatest problem experienced by most disabled people anywhere is 
poverty.
This article shows one example of a possible line of action, the 
employment
scheme of the Self Help Association of Paraplegics, SHAP in Soweto, 
Republic
of South Africa.
<H2><CENTER>Self Help Association of Paraplegics, <BR>
SHAP, Republic of South Africa</CENTER>
</H2>
<H4>The background</H4>
<FONT SIZE="+3">S</FONT>HAP was launched in 1981 by a group of unemployed

Soweto paraplegics who reasoned that a gainfully employed disabled person

would be in a stronger position to help him/herself in all areas of life.

They decided to operate a factory employing only disabled people, doing
work on a subcontract basis for industry.<BR>
<BR>
They found that it you knew where to go, sponsors were relatively 
available
for building, equipment and vehicles (in that order), and to a lessor 
extent,
for cash. The secret of their fund raising success was their self help 
nature,
their self-supporting potential, the imaginative but inexpensive 
presentation
of their case, and their sound administration-the latter allaying fears
of misuse of funds. Their building was completed in 1983. It incorporated

600 sq.m. of potential production space, offices, ablutions and not 
enough
storage. 
<H4>Developing self sufficiency</H4>
<FONT SIZE="+3">D</FONT>uring the months of waiting for the completion of

their building, they had spent their time in assessing, motivating and 
selecting
their initial workforce of 30 paraplegics, and a reserve pool of 30 
workers.
By the time the building was completed, workers were so motivated to 
secure
employment that they worked for six months for only their daily transport

and a simple midday meal-as personal contribution to the project.<BR>
<BR>
With a highly motivated but unskilled workforce only simple packaging and

assembly contracts were sought initially. Later SHAP found that companies

were at times prepared to assist with training, if it meant that 
companies
could 'contract out' an aspect of their production/service which was a 
headache
to their own production process-at a reasonable cost and assured of 
quality.<BR>
<BR>
SHAP has found markets for its products and services in the traditionally

conservative mining industry, in medium sized South African companies, 
small
businessmen as well as from multi-national corporations eager to become
involved with developing Black business.<BR>
<BR>
Whatever the supplying company's original motives for contracting with 
SHAP,
the relationship must remain financially attractive to both parties and
quality of service must obviously be maintained at all times. 
<H4>SHAP today</H4>
<FONT SIZE="+3">T</FONT>he SHAP Factory employs 130 disabled people doing

packaging and assembly work, manufacture of protective clothing and other

sewing products, and repairing sophisticated mechanical and electronic 
devices,
such as cameras and calculators. All administrative and supervisory 
positions
are held by disabled people. Today SHAP only seeks funding from the 
community
for capital projects and in support of its always partially self funded
service programs.<BR>
<BR>
SHAP's success has been widely publicized. SHAP leaders have been 
approached
by disabled people from all over the country for advice on how they too
might organize themselves to undertake a similar self help venture. There

are now approximately 30 such emergent groups around the country seeking
to emulate the SHAP example. 
<H4>The experiences of SHAP are:</H4>
1 . Self help groups, made up of the people experiencing the problems, 
are
in a unique position to identify desirable and effective courses of 
action
to counter the effects of disability.<BR>
2. Self-help groups are attractive to trusts, large companies (including
foreign corporations), foreign embassies/governments, churches.<BR>
3. Self help employment schemes, due to their typically low overhead 
costs
(as a result of donated capital) can compete for a wide range of 
sub-contracted
work from industry.<BR>
4. Self help employment schemes are capable of alleviating the poverty of

disabled people in the townships in a relatively short time and with 
achievable
capital expenditure.<BR>
5. The Self Help Factory differs from traditional concepts such as 
sheltered
workshops, since they are run by disabled people , with all staff, 
including
any able-bodied skilled people, responsible to an executive committee of
disabled people. 
<H4>Principles of Self-Help Factories</H4>
<FONT SIZE="+3">C</FONT>ONTROL/OWNERSHIP<BR>
Control of the project is vested in the management committee which is 
made
up of a majority of disabled people elected by the members of the self 
help
organization, all of whom are themselves disabled people. There are no 
shareholders
and any profits derived from the factory's activity are put back into the

business or used to fund service programmes in the interests of the 
members
e.g. transport, education, health, recreation, etc. The project is 
therefore
owned by the constituted Association rather than the members, although 
the
members typically develop a strong 'sense of ownership'.<BR>
<BR>
<FONT SIZE="+3">S</FONT>STAFFING<BR>
The factory is staffed by disabled people whose continued participation
in the project is determined only by their ability to produce. The 
concept
does not preclude the need for sheltered/protective workshops-the latter
would address the needs of those who cannot compete successfully for work

in either the open labour market or the Self Help Factory. Ideally the 
project
would include all types of disability. Senior management staff will be 
disabled
people, although able-bodied staff with particular skills may be 
employed.
They too will be responsible to the management committee of disabled 
people.<BR>
<BR>
<FONT SIZE="+3">M</FONT>ARKETING<BR>
The Self Help Factory sells its products and services on the open market
dealing with all levels of industry and State contracts. Potential buyers

may be more sympathetic or prejudiced against the project's ability to 
produce.
Sometimes they may also attempt to exploit the project by wishing to pay
less than the market rate. Products and services selected will typically
be labour intensive.<BR>
<BR>
<FONT SIZE="+3">F</FONT>UNDING/VIABILITY<BR>
The Association registers as a Fund Raising Organization. As such it is
able to raise &quot;venture capital&quot; necessary for starting up the
factory. The Self Help Factory aims to be economically independent 
(excluding
the recovery of initial start-up capital and ongoing fund raising for the

purchase of capital items such as equipment, vehicles, and building 
extensions)
and to pay viable wages and salaries. Depending on initial start-up 
funds,
it may only pay viable wages and salaries once its business has developed

to a point where these can be afforded. The disabled workers may be 
prepared
to work for less in order to build up the project in the expectation of
more viable incomes later-in the same way that shareholders in a new 
venture
do not expect to derive significant returns immediately.<BR>
<BR>
In practice, it is unlikely that a Self Help Factory would achieve 100%
comparative levels of productivity to other factories although their 
performance
should not fall below about 75%. Their relative inefficiency may be 
attributed
to inexperience in competitive business standards and methods, and simply

the fact that the disabilities of the employees may limit their overall
production. The net effect of this will be that base-line costs will be
higher than their competitors but this would be offset by lower profit 
expectations
and the fact that capital items would be community sponsored if their 
fund
raising is successful. This relatively lower productivity also provides
the justification for ongoing community support.<BR>
<BR>
<BR>
From an article by <BR>
Mike duToit, DPSA <BR>
in Rehabilitation in S.A., Dec 1989<BR>
<BR>
Address: <BR>
314 Oxford Street<BR>
5201 East London, Rep&nbsp;South&nbsp;Africa<BR>
<P><CENTER><HR><FONT SIZE=2>[<A HREF="Tools1.html">Tools for Power 
contents]</A></FONT><FONT SIZE=2>[<A HREF="../Contents.html">Institute
on Independent Living contents</A>]</FONT></CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-215</DOCNO>
<DOCOLDNO>IA012-000125-B022-137</DOCOLDNO>
<DOCHDR>
http://www.independentliving.org:80/ToolsforPower/Tools32.html 193.13.228.238 19970216214757 text/html 10180
HTTP/1.0 200 OK
Last-Modified: Tue, 06 Aug 1996 20:03:48 +0000
Date: Sun, 16 Feb 1997 21:48:08 +0000
Expires: Sun, 16 Feb 1997 21:46:28 +0000
Content-type: text/html
Server: RoxenEnterprise/1.0
Content-length: 9955
</DOCHDR>
<HTML>
<HEAD>
    <TITLE>Institute_on_Independent_Living</TITLE>
</HEAD>
<BODY BGCOLOR="#ffffff" TEXT="#050037" LINK="#00007f">
<META NAME="description" 
CONTENT="Individuals and organizations of persons with disabilities can 
publish, free of charge,  articles, reports, training manuals, 
announcements, etc. on Independent Living, personal assistance, advocacy, 

peer support, accessibility, legislation and related subjects. "><META 
NAME="keywords" CONTENT="Independent Living, personal assistance, 
advocacy, peer support, direct payments, anti-discrimination legislation, 

accessibility, disability, disability rights">
<H4><IMG SRC="../InstLogoSmall.gif" WIDTH="198" HEIGHT="57" 
ALIGN="BOTTOM"
NATURALSIZEFLAG="3"><BR>
</H4>
<H2><CENTER>Manufacturing assistive devices <BR>
in developing countries</CENTER>
</H2>
<BR>
<FONT SIZE="+3">I</FONT>ndependence through Mobility by Ralf Hotchkiss is

a book about the nuts and bolts of starting a shop and producing the 
Hotchkiss
manual wheelchair with a minimum of equipment, materials, skills and 
capital
in Third World countries. <BR>
<BR>
Disabled people in the Third World are fighting to become actively 
involved
in their communities, more mobile, and economically independent. To 
accomplish
this, they need wheelchairs that are strong enough to withstand the 
stresses
of maneuvering over rugged terrain, yet light and compact enough to be 
agile
and easily portable. These wheelchairs must be affordable and designed to

be repaired locally.<BR>
<BR>
With four year's support from Appropriate Technology International and 
the
assistance of wheelchair builders in over 20 countries, Ralf Hotchkiss 
has
designed a sturdy wheelchair that is ten pounds lighter than similarly 
featured
commercial models. It can be manufactured locally by small groups of 
skilled
mechanics in areas with access to thinwall steel tubing and simple 
welding
equipment. It costs approximately $80 (U.S.) for materials plus the cost,

with overhead, of less than a week's work by a skilled mechanic.<BR>
<BR>
This book contains detailed instructions for making the ATI-Hotchkiss 
Torbellino
wheelchair, plus detailed information on the establishment and operation
of the successful small businesses which have manufactured and sold the
Torbellino wheelchair.<BR>
<BR>
From the table of contents: starting a small business; tools and shop 
facilities;
jigs; designing each chair to fit; taking care of the chair; wheelchair
design challenges. 
<H4>Introduction to Independence through Mobility:</H4>
<FONT SIZE="+3">D</FONT>isabled people throughout the world, together 
with
their families and friends, are beginning to change the ways that they 
live,
work, and participate in their communities. Refusing to be defined by the

attitude that they are a burden on society and no longer willing to 
remain
hidden from others, disabled people are fighting to become actively 
integrated
into schools, regular jobs, places to live, and public life. The know 
from
experience that they can do many things well; they know that being 
successful
does not have to be the exception for disabled people. They intend to 
live
with independence and dignity, and are rapidly overcoming the obstacles
that stand in their way.<BR>
<BR>
Just as a blacksmith needs high quality tools to do a specific job, 
disabled
people need the highest quality equipment to assist them in actively 
pursuing
their goals. People whose mobility needs are not met by crutches or canes

need wheelchairs that will enable them to be as mobile, productive, and
independent as possible.<BR>
<BR>
In the industrial world, the increasing demand from disabled people for
mobility and independence has resulted in a revolution in wheelchair 
design.
Lighter and faster chairs made of space-age materials are being 
introduced
every year. These new wheelchairs designs are allowing U.S. wheelchair 
riders
to compete in events such as the Boston Marathon (where the wheelchair 
racers
make better time than the runners), to get to classes and jobs on time,
and to move more easily, thus saving their energy for other tasks.<BR>
<BR>
Unfortunately, the high cost of lightweight wheelchairs has put them out
of reach of most of the Third World's disabled people. Those who can 
afford
the high price of imported chairs often find that the chairs are not 
built
to withstand the stresses of dirt roads, farm fields, curb climbing, and
pocked pavement. When mechanical failures occur, it is often impossible
to obtain replacement parts.<BR>
<BR>
Poorer disabled people have either gone without a wheelchair or have used

locally manufactured models that are often heavy, confining, and lacking
in many of the necessary features of state of the art chairs.<BR>
<BR>
Third World wheelchair riders need wheelchairs that can fold to fit in 
crowded
living quarters or in the aisle of a bus. Many need wheelchairs with 
folding
footrests that allow the rider to pull in close to beds and tables, and
armrests that do not impede lateral transfer. These wheelchairs should 
have
good traction, stability, and should be light and agile enough for the 
rider
to travel over rough ground. Wheelchairs built for riders in the Third 
World
should be strong enough to withstand rough handling (as they are tossed
on and off the roof of a bus). When parts not least, these wheelchairs 
must
be affordable. Fancy wheelchairs are of no use if no one can afford to 
purchase
them.<BR>
<BR>
Working over the past four years with the support of Appropriate 
Technology
International, and with the assistance of wheelchair builders in over 20
countries, we have designed the ATI-Hotchkiss wheelchair, the Torbellino
(the chair was first named Torbellino, or whirlwind, in Peru). This 
wheelchair
is ten pounds lighter than commercial wheelchairs with similar features,
yet it is strong enough to stand up to heavy use. It can be manufactured
locally and could be sold in many countries for less than one third of 
the
cost of a comparable import.<BR>
<BR>
Most wheelchairs are designed to be mass produced using highly expensive
press forming equipment. Since capital and materials are severely limited

in many Third World countries while resourceful labor is abundant, 
conventional
manufacturing techniques are inappropriate. The Torbellino wheelchair has

been designed to be built by small groups of mechanics using inexpensive
handtools in areas where workers have access to thin wall steel tubing 
and
gas welding. A high level of skill i required to build these chairs 
successfully;
a high level of investment is not.<BR>
<BR>
E. F. Schumacher in his book Small Is Beautiful said: &quot;Any 
third-rate
engineer or researcher can increase complexity; but it takes a certain 
flair
of real insight to make things simple again.&quot; Our wheelchair design
is a collection of such insights gained worldwide from some of the best
wheelchair builders, many of whom are also wheelchair users. We have 
tapped
into a rapidly growing network of small-scale wheelchair makers who are
developing, producing, and selling full featured wheelchairs at highly 
competitive
prices.<BR>
<BR>
This manual has been written to make this technology generally available.

It includes step by step descriptions of how to build the ATI-Hotchkiss
wheelchair, guidelines for starting a small manufacturing business, 
detailed
lists of the tools, parts, and other equipment you will need to begin 
production,
as well as many photographs and diagrams which we hope will communicate
when words fail us.<BR>
<BR>
Even as this book goes to press, new ideas are being developed to improve

the design of the chair and the methods for production. This diagram is
our most recent design. We hope that you will use the ideas in this 
manual,
improve upon them, and send us drawings and explanations of your good 
ideas.
In this way you can join in the efforts of many others throughout the 
world
who, by successfully manufacturing low cost wheelchairs, are enabling 
members
of their communities to live more independent, productive, and dignified
lives.<BR>
<BR>
Ralf Hotchkiss<BR>
<BR>
<BR>
Cooperating organizations: 
<DL>
  <DD>Transcentury Foundation, Washington, D.C. 
  <DD>Combined Disabilities Association, Kingston, Jamaica 
  <DD>* Foundation for Advanced Education (FES) and Program for Small 
Enterprises
(DESAP), Cali, Colombia 
  <DD>* United States Peace Corps, Paraguay 
  <DD>Goodwill International, Washington, D.C. 
  <DD>Asociaci&oacute;n de Rehabilitaci&oacute;n Integral, Costa Rica 
  <DD>Ciudad de los Ni&ntilde;os, Cartago, Costa Rica 
  <DD>Partners of the Americas, Washington, D.C. 
  <DD>Federaci&oacute;n Nacional de Impedidos del Peru, Lima 
  <DD>Appropriate Health Resources and Technologies Action Group, Ltd.,
London, England 
  <DD>* Fundaci&oacute;n Hondere&ntilde;a de Rehabilitaci&oacute;n y 
Integraci&oacute;n
de Limitados Fisicos, Tegucigalpa, Honduras 
  <DD>* Centro de Rehabilitaci&oacute;n Vocacional, Guatemala City, 
Guatemala
  <DD>* Comite Regional de Rehabilitaci&oacute;n, Medellin, Colombia 
  <DD>* RESCU, P.O. Box 66044 KOPJE, Harare, Zimbabwe 
  <DD>* Fundaci&oacute;n Pro-Rehabilitaci&oacute;n del Minusvalido, 
Bogota,
Colombia 
  <DD>* Program for Assisting small Enterprises (PROAPE), Dominican 
Republic
  <DD>* Servicio Evanglico Peruano de Acci&oacute;n Social, Lima, Peru 
  <DD>* Organizacion de Revolucionarios Discapacitados, ORD, Managua, 
Nicaragua
</DL>
* These organizations operate wheelchair shops using ATI-Hotchkiss 
innovations<BR>
<BR>
Source: <BR>
Independence through Mobility: A Guide to the Manufacture of the 
ATI-Hotchkiss
Wheelchair <BR>
by Ralf Hotchkiss, 6505 Farallon, Oakland, CA 94611 United States <BR>
<P><CENTER><HR><FONT SIZE=2>[<A HREF="Tools1.html">Tools for Power 
contents]</A></FONT><FONT SIZE=2>[<A HREF="../Contents.html">Institute
on Independent Living contents</A>]</FONT></CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-216</DOCNO>
<DOCOLDNO>IA012-000125-B022-175</DOCOLDNO>
<DOCHDR>
http://www.independentliving.org:80/ToolsforPower/Tools33.html 193.13.228.238 19970216214815 text/html 8283
HTTP/1.0 200 OK
Last-Modified: Tue, 06 Aug 1996 20:03:45 +0000
Date: Sun, 16 Feb 1997 21:48:26 +0000
Expires: Sun, 16 Feb 1997 21:46:46 +0000
Content-type: text/html
Server: RoxenEnterprise/1.0
Content-length: 8058
</DOCHDR>
<HTML>
<HEAD>
    <TITLE>Institute_on_Independent_Living</TITLE>
</HEAD>
<BODY BGCOLOR="#ffffff" TEXT="#010236" LINK="#00007f">
<META NAME="description" 
CONTENT="Individuals and organizations of persons with disabilities can 
publish, free of charge,  articles, reports, training manuals, 
announcements, etc. on Independent Living, personal assistance, advocacy, 

peer support, accessibility, legislation and related subjects. "><META 
NAME="keywords" CONTENT="Independent Living, personal assistance, 
advocacy, peer support, direct payments, anti-discrimination legislation, 

accessibility, disability, disability rights">
<H4><IMG SRC="../InstLogoSmall.gif" WIDTH="198" HEIGHT="57" 
ALIGN="BOTTOM"
NATURALSIZEFLAG="3"><BR>
</H4>
<H2><CENTER>Turning a service into an income generating project</CENTER>
</H2>
<BR>
<BR>
<FONT SIZE="+3">I</FONT>n some countries the field of disability is 
tightly
controlled by professionals who work in rehabilitation, produce and 
distribute
assistive devices or provide such services as personal assistance and 
paratransit.
Often the services we get are insufficient in quantity and quality, carry

institutional traits and make us more dependent. These services and 
especially
their administration eat up a lot of resources. At the same time many of
us are unemployed and lack training opportunities. What we need to do 
then
is to use our creativity in finding ways to re-channel some of the money
that is spent on behalf of us by other people. Start a business, perhaps
in form of a cooperative, and take over those services when you are 
convinced
that you can do a better job. The advantages are better quality services,

income for our organizations, jobs and training for our own people. All
this at no additional cost to the taxpayer. The following article is 
about
how one Independent Living group has gone about it.<BR>
<BR>
Personal assistance, like no other service, illustrates the key elements
of Independent Living. People who need personal assistance have always 
been
made dependent on others for the most basic needs of life such as eating
or using the toilet. Given this physical dependency the conclusion was 
close
at hand to consider us as dependent on others also emotionally and 
intellectually.
If you cannot pull up your pants like a small child, you may be treated
like a small child in other areas as well. It is no surprise then that 
the
Independent Living philosophy is most easily grasped by people who need
personal assistance. <BR>
<BR>
In the Swedish Independent Living Movement we believe in 
self-representation
and self-determination. We are the experts, nobody speaks for us but us.
In our personal assistance user cooperatives only individuals who use 
personal
assistance are allowed as members and board members. Staff positions are
primarily reserved for people with disabilities, preferably, personal 
assistance
users. In a society where, according to recent government statistics, 70%

of us are unemployed we must reserve the job and training opportunities
in our organizations for ourselves.<BR>
<BR>
In Sweden there are presently 8 personal assistance user cooperatives, 
the
first and largest being <A HREF="http://www.stil.se/">STIL</A>, the 
Stockholm
Cooperative for Independent Living. STIL is the first alternative to the
assistance services which local governments are legally obliged to 
provide
to old and disabled citizens. The cooperative's purpose is to enable its
members to improve the quality of their personal assistance by being 
employers
of their assistants and to train and support members in their employer 
role.
<BR>
<BR>
Each member has his or her personal assistance need assessed by the local

government. The need is expressed in a certain number of hours of 
services
a week. For persons who wish to arrange the services themselves through
membership in STIL the cooperative charges the local government a certain

price per hour of services. Multiplying the number of hours a member has
been granted by the current price per hour determines the size of the 
individual
member's budget from which he or she pays assistants' wages and 
administrative
costs.<BR>
<BR>
The cooperative is the legal employer of our assistants. The presently 
160
members have a total of 800 assistants together. But we do not share 
assistants.
Each coop member is responsible for recruiting, training, scheduling and
supervising his or her own personal assistants. We do not live together
in one house, in the same apartment building or even the same city. Each
of us lives in his own apartment or house with or without family. We are
spread out over the whole county and consider our individual housing 
situation
as completely unrelated to our need of personal assistance. <BR>
<BR>
By establishing personal assistance cooperatives the Swedish Independent
Living movement pursues three goals: 
<UL>
  <LI>to enable service users to take control and responsibility over 
their
own lives, 
  <LI>to create training and employment for persons who have been 
considered
unemployable because they need personal assistance at work, 
  <LI>to use these self-help schemes for income generation for the 
movement.
</UL>
<A HREF="../STIL/STIL.html">STIL</A> is now an established business with
an annual turnover of over $14 million. According to our experience so 
far,
there is definitely a place for this type of venture in the movement. The

potential disadvantages are that running a business takes a lot of energy

and time which the organization otherwise would be able to devote to 
political
work. Also, when a disability organization becomes a service provider, 
the
goal of providing quality services and the goal of generating a surplus
may not always be compatible. The potential goal conflict will depend on
the degree of choice and control exercised by the individual user of the
services. In the case of STIL the high degree of individual 
responsibility
over one's services minimizes the effect of the coop on the quality of 
the
services. Also, dissatisfied members have the option of leaving and 
starting
another coop along their own lines. <BR>
<BR>
Among the many advantages of our scheme are the changes that members have

undergone. There is a strong sense of pride and accomplishment. Instead
of limiting ourselves to complaining about the poor quality of the public

services, we demonstrated for ourselves and the general public that 
disabled
people are capable of taking their affairs in their own hands. The 
demonstration
of the viability of our vision and our capabilities has gained us respect

among politicians and civil servants. We generate good will in the 
community
and contribute to an improved image of disabled people. Representatives
of STIL are now considered experts and are invited to speak on 
cooperatives
and how to improve the quality of public services. In this way we have 
improved
our possibilities of bringing about change.<BR>
<BR>
Running our own business provides members of <A 
HREF="../STIL/STIL.html">STIL</A>
with an exposure to managerial training which many of us would have never

had given the high unemployment among disabled people. This experience is

valuable also for other work in our movement.<BR>
<BR>
Instead of turning to government and private corporations for grants to
finance our movement, we try to generate our own funds by achieving a 
surplus
in our business activities. We use part of our administrative resources
for spreading the Independent Living approach in the country, for 
membership
development, courses and seminars and international work through <A 
HREF="../ENIL/ENILhomepage.html">ENIL,
the European Network on Independent Living</A> and the DPI Independent 
Living
Committee.<BR>
<BR>
<BR>
<A HREF="mailto:ratzka@independentliving.org">Adolf Ratzka</A> <BR>
<P><CENTER><HR><FONT SIZE=2>[<A HREF="Tools1.html">Tools for Power 
contents]</A></FONT><FONT SIZE=2>[<A HREF="../Contents.html">Institute
on Independent Living contents</A>]</FONT></CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-217</DOCNO>
<DOCOLDNO>IA012-000125-B022-213</DOCOLDNO>
<DOCHDR>
http://www.independentliving.org:80/ToolsforPower/Tools34.html 193.13.228.238 19970216214834 text/html 7237
HTTP/1.0 200 OK
Last-Modified: Tue, 06 Aug 1996 20:03:42 +0000
Date: Sun, 16 Feb 1997 21:48:48 +0000
Expires: Sun, 16 Feb 1997 21:47:08 +0000
Content-type: text/html
Server: RoxenEnterprise/1.0
Content-length: 7012
</DOCHDR>
<HTML>
<HEAD>
    <TITLE>Institute_on_Independent_Living</TITLE>
</HEAD>
<BODY BGCOLOR="#ffffff" TEXT="#030136" LINK="#00007f">
<META NAME="description" 
CONTENT="Individuals and organizations of persons with disabilities can 
publish, free of charge,  articles, reports, training manuals, 
announcements, etc. on Independent Living, personal assistance, advocacy, 

peer support, accessibility, legislation and related subjects. "><META 
NAME="keywords" CONTENT="Independent Living, personal assistance, 
advocacy, peer support, direct payments, anti-discrimination legislation, 

accessibility, disability, disability rights">
<H4><IMG SRC="../InstLogoSmall.gif" WIDTH="198" HEIGHT="57" 
ALIGN="BOTTOM"
NATURALSIZEFLAG="3"><BR>
</H4>
<H2><CENTER>Resources</CENTER>
</H2>
<BR>
International Labor Organization, Cooperatives for the Disabled: 
Organization
and Development, ILO, Geneva, 1978.<BR>
<BR>
Harper, Malcolm and Momm, Willi, Self-Employment for Disabled People: 
Experiences
from Africa and Asia, ILO, Geneva, 1989.<BR>
<BR>
The authors of this book - one a small enterprise development specialist
and the other a rehabilitation professional - have come together to see
what disabled people can achieve as entrepreneurs and to examine the 
potential
of self-employment as an option for those who want to and are able to 
earn
their own living. The book is the outcome of a survey of 53 businesses 
run
by disabled people in several Asian and African countries. At its core 
are
16 case studies showing in detail how the disabled entrepreneurs 
succeeded
in self-employment, and highlighting the problems they faced.<BR>
<BR>
Community Based Rehabilitation News, International Newsletter from 
Appropriate
Health Resources &amp; Technologies Action Group Ltd. <BR>
<BR>
Examples of topics from recent issues: Alternative limbmaking, the 
Logmobile
(a self-propelled cart), tricycles from India, How to make cutting-shears

for sheet metal, handgrips made from easily available materials for 
writing
utensils or tools. In the July 1989 issue David Werner, a disabled 
community
organizer and rehabilitation expert, author of Where there is no doctor
and Disabled Village Children among others, describes several innovative
examples of Third World projects run by disabled people themselves 
producing
rehabilitation services and assistive devices as income generating 
projects.
He writes: <BR>
<BR>
&quot;While many exciting and innovative things are happening in programs

for disabled persons in developing countries, my general impression is 
that
there are only a very few programs in which disabled persons themselves
play a leading role. In most of the programs I visited, whether 
government,
religious or private, disabled persons tend to become the objects rather
than subjects. Disabled persons are acted upon and not the actors in the
process. Too often emphasis is on 'normalizing' the disabled persons into

an unfair social order rather than on organizing disabled people in a 
struggle
for a fairer more just society.&quot;<BR>
<BR>
&quot;The Organization of Disabled Revolutionaries, ORD, in Nicaragua, is

a group of mostly spinal cord injured young persons who came together 
over
a common need: wheelchairs. With the increase of disabled persons 
resulting
from the war against the Somoza dictatorship (and more recently against
the Contras), the lack of a wheelchair factory in Nicaragua, and the 
difficulties
of importing wheelchairs due to the United States embargo, the shortage
was severe. Two disabled North Americans, Ralf Hotchkiss and Bruce 
Curtis,
helped ORD set up a small wheelchair factory to design and produce 
low-cost
high-quality, for use on rough terrain, wheelchairs. Now the so-called 
'whirlwind'
steel tube wheelchair is being produced by small collectives of disabled
workers in various countries of Latin America, the Caribbean, and Asia.
ORD has also branched out into different fields and is beginning to 
organize
disabled people throughout Nicaragua.&quot;<BR>
<BR>
&quot;The Center for Rehabilitation of the paralyzed (CRP) in Bangladesh.

In the CRP severely disabled persons, mostly from spinal cord injury and
severe polio, play key roles in leadership, administration, designing, 
teaching,
income generation and other activities of the program. Working from 
wheelchairs
and gurneys, the disabled workers make a wide variety of rehabilitation
aids and hospital equipment.&quot;<BR>
<BR>
&quot;Programs and equipment for disabled persons in developing countries

often suffer from the imposition of Western medical and 
rehabilitation.<BR>
<BR>
Address: AHRTAG, 1 London Bridge Street, London SE1 9SG, United 
Kingdom<BR>
<BR>
The project that David Werner himself helped start is PROJIMO in western
Mexico. PROJIMO can be described as an alternative rural villager run 
rehabilitation
program. Some of its most important functions is income generation and 
training
for persons with disabilities. The PROJIMO team consists of former 
'clients'
who after having received assistive devices and treatment themselves 
stayed
on to learn various marketable skills such as brace and limb making, 
wheelchair
manufacturing and repair, welding, physical therapy and peer counseling.
During the years that PROJIMO has been in existence many of these workers

have left the village to settle in other places of Mexico where they set
up similar projects and activities. Thus, persons who under most other 
circumstances
would have been doomed to a life as beggars have not only become proud 
professionals
who can support themselves and their families through their work; they 
are
also spreading their skills and role models among disabled persons and 
their
families in other communities. <BR>
<BR>
For more information on PROJIMO and David Werner's work see <BR>
<BR>
Project PROJIMO, A villager-run rehabilitation program for disabled 
children
in Western Mexico, The Hesperian Foundation, 1983.<BR>
<BR>
Newsletter From the Sierra Nevada, an occasional newsletter.<BR>
<BR>
Address: The Hesperian Foundation, Box 1692, Palo Alto, California 94302,

USA.<BR>
<BR>
For other appropriate assistive devices and their production in 
developing
countries see <BR>
<BR>
Lagerwall, Tomas, Appropriate Aids and Equipment for Disabled People in
Africa: Ways and Means for Local Production in the Third World, ICTA, 
Stockholm,
1989. <BR>
<BR>
Lagerwall, Tomas, Appropriate Technical Aids for Disabled People: Ways 
and
Means for Local Production in the Third World, ICTA, Stockholm, 1989. 
Address:
Handicap Institute, Box 510, 162 15 V&auml;llingby, Sweden.<BR>
<BR>
Managua Newsletter, editor: Russel Gasser, postal address: Aptdo 5054, 
Managua,
Nicaragua.<BR>
Russel trains disabled Nicas to become wheelchair mechanics and repair 
shop
managers.<BR>
<P><CENTER><HR><FONT SIZE=2>[<A HREF="Tools1.html">Tools for Power 
contents]</A></FONT><FONT SIZE=2>[<A HREF="../Contents.html">Institute
on Independent Living contents</A>]</FONT></CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-218</DOCNO>
<DOCOLDNO>IA012-000125-B022-245</DOCOLDNO>
<DOCHDR>
http://www.independentliving.org:80/ResCILs.html 193.13.228.238 19970216214849 text/html 2071
HTTP/1.0 200 OK
Last-Modified: Tue, 06 Aug 1996 19:59:21 +0000
Date: Sun, 16 Feb 1997 21:49:07 +0000
Expires: Sun, 16 Feb 1997 21:47:27 +0000
Content-type: text/html
Server: RoxenEnterprise/1.0
Content-length: 1846
</DOCHDR>
<HTML>
<HEAD>
    <TITLE>Institute_on_Independent_Living</TITLE>
</HEAD>
<BODY TEXT="#020a3f" BGCOLOR="#ffffff" LINK="#000042">
<META NAME="description" 
CONTENT="Individuals and organizations of persons with disabilities can 
publish, free of charge,  articles, reports, training manuals, 
announcements, etc. on Independent Living, personal assistance, advocacy, 

peer support, accessibility, legislation and related subjects. "><META 
NAME="keywords" CONTENT="Independent Living, personal assistance, 
advocacy, peer support, direct payments, anti-discrimination legislation, 

accessibility, disability, disability rights">
<BR><IMG SRC="InstLogoSmall.gif" WIDTH="198" HEIGHT="57" ALIGN="BOTTOM"
NATURALSIZEFLAG="3"> <BR>
<H2>Research on Centers for Independent Living<BR>
</H2>
<UL>
  <LI><A HREF="ResEvolutionILP.html">The Evolution of Independent Living
Programs: A Longitudinal Study</A> 
  <LI><A HREF="ResRuralILP.html">Assisting Community-Based Rural 
Independent
Living Programs</A> 
  <LI><A HREF="ResRehabilitationILC.html">Collaboration Between Medical
Rehabilitation Programs and Independent Living Centers in Facilitating 
Independent
Living By Persons With Recently Incurred Spinal Cord Injury</A> 
  <LI><A HREF="ResAssTechnologyILP.html">Demonstrating a Model Approach
to Independent Living Center-Based Assistive Technology Services</A> 
  <LI><A HREF="ResAfricanAwD.html">Increasing the Ability of Independent
Living Centers to Serve the Population of African Americans with 
Disabilities</A>
<BR>
</UL>
If you want us to include a reference to your research or other 
people&#180;s
work in this area, include an abstract or publish a whole paper, please,
<A HREF="mailto:ratzka@independentliving.org">contact </A>us. <BR>
<P><CENTER><HR><FONT SIZE=2>[<A 
HREF="Contents.html">Contents</A>]</FONT></CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-219</DOCNO>
<DOCOLDNO>IA012-000125-B022-290</DOCOLDNO>
<DOCHDR>
http://www.independentliving.org:80/StandardRules1.html 193.13.228.238 19970216214907 text/html 46866
HTTP/1.0 200 OK
Last-Modified: Tue, 06 Aug 1996 19:58:57 +0000
Date: Sun, 16 Feb 1997 21:49:16 +0000
Expires: Sun, 16 Feb 1997 21:47:36 +0000
Content-type: text/html
Server: RoxenEnterprise/1.0
Content-length: 46640
</DOCHDR>
<HTML>
<HEAD>
    <TITLE>Institute_on_Independent_Living</TITLE>
</HEAD>
<BODY BGCOLOR="#ffffff" LINK="#000047" BACKGROUND="redborder.gif" TEXT=
"#00003d">
<BLOCKQUOTE><META  name="description" content="Individuals and 
organizations of persons with disabilities can publish, free of charge,  
articles, reports, training manuals, announcements, etc. on Independent 
Living, personal assistance, advocacy, peer support, accessibility, 
legislation and related subjects. "><META  name="keywords" 
content="Independent Living, personal assistance, advocacy, peer support, 
direct payments, anti-discrimination legislation, accessibility, 
disability, disability rights"><IMG SRC=
"STIL/STILunlogo1.gif" WIDTH="80" HEIGHT="69" ALIGN="BOTTOM" 
NATURALSIZEFLAG=
"3"><IMG SRC="Pixel1x1.gif" WIDTH="1" HEIGHT="1" ALIGN="BOTTOM" 
NATURALSIZEFLAG=
"3"><IMG SRC="Pixel1x1.gif" WIDTH="1" HEIGHT="1" ALIGN="BOTTOM" 
NATURALSIZEFLAG=
"3"><IMG SRC="Pixel1x1.gif" WIDTH="1" HEIGHT="1" ALIGN="BOTTOM" 
NATURALSIZEFLAG=
"3"><IMG SRC="Pixel1x1.gif" WIDTH="1" HEIGHT="1" ALIGN="BOTTOM" 
NATURALSIZEFLAG=
"3"><IMG SRC="Pixel1x1.gif" WIDTH="1" HEIGHT="1" ALIGN="BOTTOM" 
NATURALSIZEFLAG=
"3"><IMG SRC="Pixel1x1.gif" WIDTH="1" HEIGHT="1" ALIGN="BOTTOM" 
NATURALSIZEFLAG=
"3"><IMG SRC="Pixel1x1.gif" WIDTH="1" HEIGHT="1" ALIGN="BOTTOM" 
NATURALSIZEFLAG=
"3"><IMG SRC="Pixel1x1.gif" WIDTH="1" HEIGHT="1" ALIGN="BOTTOM" 
NATURALSIZEFLAG=
"3"><IMG SRC="Pixel1x1.gif" WIDTH="1" HEIGHT="1" ALIGN="BOTTOM" 
NATURALSIZEFLAG=
"3"><IMG SRC="Pixel1x1.gif" WIDTH="1" HEIGHT="1" ALIGN="BOTTOM" 
NATURALSIZEFLAG=
"3"><IMG SRC="Pixel1x1.gif" WIDTH="1" HEIGHT="1" ALIGN="BOTTOM" 
NATURALSIZEFLAG=
"3"><IMG SRC="Pixel1x1.gif" WIDTH="1" HEIGHT="1" ALIGN="BOTTOM" 
NATURALSIZEFLAG=
"3"><IMG SRC="Pixel1x1.gif" WIDTH="1" HEIGHT="1" ALIGN="BOTTOM" 
NATURALSIZEFLAG=
"3"><IMG SRC="Pixel1x1.gif" WIDTH="1" HEIGHT="1" ALIGN="BOTTOM" 
NATURALSIZEFLAG=
"3"><IMG SRC="Pixel1x1.gif" WIDTH="1" HEIGHT="1" ALIGN="BOTTOM" 
NATURALSIZEFLAG=
"3"><IMG SRC="Pixel1x1.gif" WIDTH="1" HEIGHT="1" ALIGN="BOTTOM" 
NATURALSIZEFLAG=
"3"><IMG SRC="Pixel1x1.gif" WIDTH="1" HEIGHT="1" ALIGN="BOTTOM" 
NATURALSIZEFLAG=
"3"><IMG SRC="Pixel1x1.gif" WIDTH="1" HEIGHT="1" ALIGN="BOTTOM" 
NATURALSIZEFLAG=
"3"><IMG SRC="Pixel1x1.gif" WIDTH="1" HEIGHT="1" ALIGN="BOTTOM" 
NATURALSIZEFLAG=
"3"><IMG SRC="Pixel1x1.gif" WIDTH="1" HEIGHT="1" ALIGN="BOTTOM" 
NATURALSIZEFLAG=
"3"><IMG SRC="Pixel1x1.gif" WIDTH="1" HEIGHT="1" ALIGN="BOTTOM" 
NATURALSIZEFLAG=
"3"><IMG SRC="Pixel1x1.gif" WIDTH="1" HEIGHT="1" ALIGN="BOTTOM" 
NATURALSIZEFLAG=
"3"><IMG SRC="Pixel1x1.gif" WIDTH="1" HEIGHT="1" ALIGN="BOTTOM" 
NATURALSIZEFLAG=
"3"><IMG SRC="Pixel1x1.gif" WIDTH="1" HEIGHT="1" ALIGN="BOTTOM" 
NATURALSIZEFLAG=
"3"><IMG SRC="Pixel1x1.gif" WIDTH="1" HEIGHT="1" ALIGN="BOTTOM" 
NATURALSIZEFLAG=
"3"><IMG SRC="Pixel1x1.gif" WIDTH="1" HEIGHT="1" ALIGN="BOTTOM" 
NATURALSIZEFLAG=
"3"><IMG SRC="Pixel1x1.gif" WIDTH="1" HEIGHT="1" ALIGN="BOTTOM" 
NATURALSIZEFLAG=
"3"><IMG SRC="Pixel1x1.gif" WIDTH="1" HEIGHT="1" ALIGN="BOTTOM" 
NATURALSIZEFLAG=
"3"> 
<P><CENTER>A/RES/48/96<BR>
85<IMG SRC="Pixel1x1.gif" WIDTH="1" HEIGHT="1" ALIGN="BOTTOM" 
NATURALSIZEFLAG=
"3"><IMG SRC="Pixel1x1.gif" WIDTH="1" HEIGHT="1" ALIGN="BOTTOM" 
NATURALSIZEFLAG=
"3">th plenary meeting<BR>
20 December 1993</CENTER>
</BLOCKQUOTE>
<BLOCKQUOTE>
<H2><CENTER>Standard Rules on the <BR>
Equalization of Opportunities <BR>
for Persons with Disabilities<A NAME="anchor17238"></A><BR>
<BR>
<HR></CENTER>
</H2>
</BLOCKQUOTE>
<BLOCKQUOTE>
<H3>Table of Contents</H3>
INTRODUCTION</BLOCKQUOTE>
<BLOCKQUOTE>
<DL>
  <DD><A HREF="#anchor1043116">Background and current needs</A> 
  <DD><A HREF="#anchor1047662">Previous international action</A> 
  <DD><A HREF="#anchor1050785">Toward standard rules</A> 
  <DD><A HREF="#anchor1053904">Purpose and content of the Standard Rules
on the Equalization of Opportunities for Persons with Disabilities</A> 
  <DD><A HREF="#anchor1059931">Fundamental concepts in disability 
policy</A>
</DL>
<A HREF="#anchor1067914">PREAMBLE</A><BR>
<BR>
I.<IMG SRC="Pixel1x1.gif" WIDTH="1" HEIGHT="1" ALIGN="BOTTOM" 
NATURALSIZEFLAG=
"3"><IMG SRC="Pixel1x1.gif" WIDTH="1" HEIGHT="1" ALIGN="BOTTOM" 
NATURALSIZEFLAG=
"3"><A HREF="#anchor1072137">PRECONDITIONS FOR EQUAL 
PARTICIPATION</A></BLOCKQUOTE>
<BLOCKQUOTE>
<DL>
  <DD>Rule 1.<IMG SRC="Pixel1x1.gif" WIDTH="1" HEIGHT="1" ALIGN="BOTTOM"
NATURALSIZEFLAG="3"><IMG SRC="Pixel1x1.gif" WIDTH="1" HEIGHT="1" ALIGN=
"BOTTOM" NATURALSIZEFLAG="3"><IMG SRC="Pixel1x1.gif" WIDTH="1" HEIGHT="1"

ALIGN="BOTTOM" NATURALSIZEFLAG="3"><A 
HREF="#anchor1076570">Awareness-raising</A>
  <DD>Rule 2.<IMG SRC="Pixel1x1.gif" WIDTH="1" HEIGHT="1" ALIGN="BOTTOM"
NATURALSIZEFLAG="3"><IMG SRC="Pixel1x1.gif" WIDTH="1" HEIGHT="1" ALIGN=
"BOTTOM" NATURALSIZEFLAG="3"><IMG SRC="Pixel1x1.gif" WIDTH="1" HEIGHT="1"

ALIGN="BOTTOM" NATURALSIZEFLAG="3"><A HREF="#anchor1081028">Medical 
care</A>
  <DD>Rule 3.<IMG SRC="Pixel1x1.gif" WIDTH="1" HEIGHT="1" ALIGN="BOTTOM"
NATURALSIZEFLAG="3"><IMG SRC="Pixel1x1.gif" WIDTH="1" HEIGHT="1" ALIGN=
"BOTTOM" NATURALSIZEFLAG="3"><IMG SRC="Pixel1x1.gif" WIDTH="1" HEIGHT="1"

ALIGN="BOTTOM" NATURALSIZEFLAG="3"><A 
HREF="#anchor1085282">Rehabilitation</A>
  <DD>Rule 4.<IMG SRC="Pixel1x1.gif" WIDTH="1" HEIGHT="1" ALIGN="BOTTOM"
NATURALSIZEFLAG="3"><IMG SRC="Pixel1x1.gif" WIDTH="1" HEIGHT="1" ALIGN=
"BOTTOM" NATURALSIZEFLAG="3"><IMG SRC="Pixel1x1.gif" WIDTH="1" HEIGHT="1"

ALIGN="BOTTOM" NATURALSIZEFLAG="3"><A HREF="#anchor1088366">Support 
services</A>
</DL>
II. <A HREF="#anchor1365329">TARGET AREAS FOR EQUAL 
PARTICIPATION</A></BLOCKQUOTE>
<BLOCKQUOTE>
<DL>
  <DD>Rule 5.<IMG SRC="Pixel1x1.gif" WIDTH="1" HEIGHT="1" ALIGN="BOTTOM"
NATURALSIZEFLAG="3"><IMG SRC="Pixel1x1.gif" WIDTH="1" HEIGHT="1" ALIGN=
"BOTTOM" NATURALSIZEFLAG="3"><IMG SRC="Pixel1x1.gif" WIDTH="1" HEIGHT="1"

ALIGN="BOTTOM" NATURALSIZEFLAG="3"><A 
HREF="StandardRules2.html#anchor1370198">Accessibility</A>
  <DD>Rule 6.<IMG SRC="Pixel1x1.gif" WIDTH="1" HEIGHT="1" ALIGN="BOTTOM"
NATURALSIZEFLAG="3"><IMG SRC="Pixel1x1.gif" WIDTH="1" HEIGHT="1" ALIGN=
"BOTTOM" NATURALSIZEFLAG="3"><IMG SRC="Pixel1x1.gif" WIDTH="1" HEIGHT="1"

ALIGN="BOTTOM" NATURALSIZEFLAG="3"><A 
HREF="StandardRules2.html#anchor1373939">Education</A>
  <DD>Rule 7.<IMG SRC="Pixel1x1.gif" WIDTH="1" HEIGHT="1" ALIGN="BOTTOM"
NATURALSIZEFLAG="3"><IMG SRC="Pixel1x1.gif" WIDTH="1" HEIGHT="1" ALIGN=
"BOTTOM" NATURALSIZEFLAG="3"><IMG SRC="Pixel1x1.gif" WIDTH="1" HEIGHT="1"

ALIGN="BOTTOM" NATURALSIZEFLAG="3"><A 
HREF="StandardRules2.html#anchor1376299">Employment</A>
  <DD>Rule 8.<IMG SRC="Pixel1x1.gif" WIDTH="1" HEIGHT="1" ALIGN="BOTTOM"
NATURALSIZEFLAG="3"><IMG SRC="Pixel1x1.gif" WIDTH="1" HEIGHT="1" ALIGN=
"BOTTOM" NATURALSIZEFLAG="3"><IMG SRC="Pixel1x1.gif" WIDTH="1" HEIGHT="1"

ALIGN="BOTTOM" NATURALSIZEFLAG="3"><A 
HREF="StandardRules2.html#anchor1390193">Income
maintenance and social security</A> 
  <DD>Rule 9.<IMG SRC="Pixel1x1.gif" WIDTH="1" HEIGHT="1" ALIGN="BOTTOM"
NATURALSIZEFLAG="3"><IMG SRC="Pixel1x1.gif" WIDTH="1" HEIGHT="1" ALIGN=
"BOTTOM" NATURALSIZEFLAG="3"><IMG SRC="Pixel1x1.gif" WIDTH="1" HEIGHT="1"

ALIGN="BOTTOM" NATURALSIZEFLAG="3"><A 
HREF="StandardRules2.html#anchor1394587">Family
life and personal integrity</A> 
  <DD>Rule 10.<IMG SRC="Pixel1x1.gif" WIDTH="1" HEIGHT="1" ALIGN="BOTTOM"

NATURALSIZEFLAG="3"><IMG SRC="Pixel1x1.gif" WIDTH="1" HEIGHT="1" ALIGN=
"BOTTOM" NATURALSIZEFLAG="3"><A 
HREF="StandardRules2.html#anchor1397689">Culture</A>
  <DD>Rule 11.<IMG SRC="Pixel1x1.gif" WIDTH="1" HEIGHT="1" ALIGN="BOTTOM"

NATURALSIZEFLAG="3"><IMG SRC="Pixel1x1.gif" WIDTH="1" HEIGHT="1" ALIGN=
"BOTTOM" NATURALSIZEFLAG="3"><A 
HREF="StandardRules2.html#anchor1400448">Recreation
and sports</A> 
  <DD>Rule 12.<IMG SRC="Pixel1x1.gif" WIDTH="1" HEIGHT="1" ALIGN="BOTTOM"

NATURALSIZEFLAG="3"><IMG SRC="Pixel1x1.gif" WIDTH="1" HEIGHT="1" ALIGN=
"BOTTOM" NATURALSIZEFLAG="3"><A 
HREF="StandardRules2.html#anchor1404112">Religion</A>
</DL>
III. <A HREF="StandardRules2.html#anchor1406628">IMPLEMENTATION 
MEASURES</A></BLOCKQUOTE>
<BLOCKQUOTE>
<DL>
  <DD>Rule 13.<IMG SRC="Pixel1x1.gif" WIDTH="1" HEIGHT="1" ALIGN="BOTTOM"

NATURALSIZEFLAG="3"><IMG SRC="Pixel1x1.gif" WIDTH="1" HEIGHT="1" ALIGN=
"BOTTOM" NATURALSIZEFLAG="3"><A 
HREF="StandardRules2.html#anchor1411195">Information
and research</A> 
  <DD>Rule 14.<IMG SRC="Pixel1x1.gif" WIDTH="1" HEIGHT="1" ALIGN="BOTTOM"

NATURALSIZEFLAG="3"><IMG SRC="Pixel1x1.gif" WIDTH="1" HEIGHT="1" ALIGN=
"BOTTOM" NATURALSIZEFLAG="3"><A 
HREF="StandardRules2.html#anchor1417671">Policy-making
and planning</A> 
  <DD>Rule 15.<IMG SRC="Pixel1x1.gif" WIDTH="1" HEIGHT="1" ALIGN="BOTTOM"

NATURALSIZEFLAG="3"><IMG SRC="Pixel1x1.gif" WIDTH="1" HEIGHT="1" ALIGN=
"BOTTOM" NATURALSIZEFLAG="3"><A 
HREF="StandardRules2.html#anchor1414288">Legislation</A>
  <DD>Rule 16.<IMG SRC="Pixel1x1.gif" WIDTH="1" HEIGHT="1" ALIGN="BOTTOM"

NATURALSIZEFLAG="3"><IMG SRC="Pixel1x1.gif" WIDTH="1" HEIGHT="1" ALIGN=
"BOTTOM" NATURALSIZEFLAG="3"><A 
HREF="StandardRules2.html#anchor1421127">Economic
policies</A> 
  <DD>Rule 17.<IMG SRC="Pixel1x1.gif" WIDTH="1" HEIGHT="1" ALIGN="BOTTOM"

NATURALSIZEFLAG="3"><IMG SRC="Pixel1x1.gif" WIDTH="1" HEIGHT="1" ALIGN=
"BOTTOM" NATURALSIZEFLAG="3"><A 
HREF="StandardRules2.html#anchor1424780">Coordination
of work</A> 
  <DD>Rule 18.<IMG SRC="Pixel1x1.gif" WIDTH="1" HEIGHT="1" ALIGN="BOTTOM"

NATURALSIZEFLAG="3"><IMG SRC="Pixel1x1.gif" WIDTH="1" HEIGHT="1" ALIGN=
"BOTTOM" NATURALSIZEFLAG="3"><A 
HREF="StandardRules2.html#anchor1427588">Organizations
of persons with disabilities</A> 
  <DD>Rule 19.<IMG SRC="Pixel1x1.gif" WIDTH="1" HEIGHT="1" ALIGN="BOTTOM"

NATURALSIZEFLAG="3"><IMG SRC="Pixel1x1.gif" WIDTH="1" HEIGHT="1" ALIGN=
"BOTTOM" NATURALSIZEFLAG="3"><A 
HREF="StandardRules2.html#anchor1431717">Personnel
training</A> 
  <DD>Rule 20.<IMG SRC="Pixel1x1.gif" WIDTH="1" HEIGHT="1" ALIGN="BOTTOM"

NATURALSIZEFLAG="3"><IMG SRC="Pixel1x1.gif" WIDTH="1" HEIGHT="1" ALIGN=
"BOTTOM" NATURALSIZEFLAG="3"><A 
HREF="StandardRules2.html#anchor1435772">National
monitoring and evaluation of disability programmes in the </A><IMG SRC=
"Pixel1x1.gif" WIDTH="1" HEIGHT="1" ALIGN="BOTTOM" 
NATURALSIZEFLAG="3"><IMG SRC=
"Pixel1x1.gif" WIDTH="1" HEIGHT="1" ALIGN="BOTTOM" 
NATURALSIZEFLAG="3"><IMG SRC=
"Pixel1x1.gif" WIDTH="1" HEIGHT="1" ALIGN="BOTTOM" 
NATURALSIZEFLAG="3"><IMG SRC=
"Pixel1x1.gif" WIDTH="1" HEIGHT="1" ALIGN="BOTTOM" 
NATURALSIZEFLAG="3"><IMG SRC=
"Pixel1x1.gif" WIDTH="1" HEIGHT="1" ALIGN="BOTTOM" 
NATURALSIZEFLAG="3"><IMG SRC=
"Pixel1x1.gif" WIDTH="1" HEIGHT="1" ALIGN="BOTTOM" 
NATURALSIZEFLAG="3"><IMG SRC=
"Pixel1x1.gif" WIDTH="1" HEIGHT="1" ALIGN="BOTTOM" 
NATURALSIZEFLAG="3"><IMG SRC=
"Pixel1x1.gif" WIDTH="1" HEIGHT="1" ALIGN="BOTTOM" 
NATURALSIZEFLAG="3"><IMG SRC=
"Pixel1x1.gif" WIDTH="1" HEIGHT="1" ALIGN="BOTTOM" 
NATURALSIZEFLAG="3"><IMG SRC=
"Pixel1x1.gif" WIDTH="1" HEIGHT="1" ALIGN="BOTTOM" 
NATURALSIZEFLAG="3"><IMG SRC=
"Pixel1x1.gif" WIDTH="1" HEIGHT="1" ALIGN="BOTTOM" 
NATURALSIZEFLAG="3"><IMG SRC=
"Pixel1x1.gif" WIDTH="1" HEIGHT="1" ALIGN="BOTTOM" 
NATURALSIZEFLAG="3"><IMG SRC=
"Pixel1x1.gif" WIDTH="1" HEIGHT="1" ALIGN="BOTTOM" 
NATURALSIZEFLAG="3"><IMG SRC=
"Pixel1x1.gif" WIDTH="1" HEIGHT="1" ALIGN="BOTTOM" 
NATURALSIZEFLAG="3"><IMG SRC=
"Pixel1x1.gif" WIDTH="1" HEIGHT="1" ALIGN="BOTTOM" 
NATURALSIZEFLAG="3"><IMG SRC=
"Pixel1x1.gif" WIDTH="1" HEIGHT="1" ALIGN="BOTTOM" 
NATURALSIZEFLAG="3"><IMG SRC=
"Pixel1x1.gif" WIDTH="1" HEIGHT="1" ALIGN="BOTTOM" 
NATURALSIZEFLAG="3"><IMG SRC=
"Pixel1x1.gif" WIDTH="1" HEIGHT="1" ALIGN="BOTTOM" 
NATURALSIZEFLAG="3"><IMG SRC=
"Pixel1x1.gif" WIDTH="1" HEIGHT="1" ALIGN="BOTTOM" 
NATURALSIZEFLAG="3"><IMG SRC=
"Pixel1x1.gif" WIDTH="1" HEIGHT="1" ALIGN="BOTTOM" 
NATURALSIZEFLAG="3"><IMG SRC=
"Pixel1x1.gif" WIDTH="1" HEIGHT="1" ALIGN="BOTTOM" 
NATURALSIZEFLAG="3"><IMG SRC=
"Pixel1x1.gif" WIDTH="1" HEIGHT="1" ALIGN="BOTTOM" 
NATURALSIZEFLAG="3"><IMG SRC=
"Pixel1x1.gif" WIDTH="1" HEIGHT="1" ALIGN="BOTTOM" NATURALSIZEFLAG="3"><A 
HREF="StandardRules2.html#anchor1435772">implementation
of the Rules</A> 
  <DD>Rule 21.<IMG SRC="Pixel1x1.gif" WIDTH="1" HEIGHT="1" ALIGN="BOTTOM"

NATURALSIZEFLAG="3"><IMG SRC="Pixel1x1.gif" WIDTH="1" HEIGHT="1" ALIGN=
"BOTTOM" NATURALSIZEFLAG="3"><A 
HREF="StandardRules2.html#anchor1444339">Technical
and economic cooperation</A> 
  <DD>Rule 22.<IMG SRC="Pixel1x1.gif" WIDTH="1" HEIGHT="1" ALIGN="BOTTOM"

NATURALSIZEFLAG="3"><IMG SRC="Pixel1x1.gif" WIDTH="1" HEIGHT="1" ALIGN=
"BOTTOM" NATURALSIZEFLAG="3"><A 
HREF="StandardRules2.html#anchor1448034">International
cooperation</A> 
</DL>
IV. <A HREF="StandardRules2.html#anchor1451084">MONITORING 
MECHANISM</A></BLOCKQUOTE>
<BLOCKQUOTE>
<H2><CENTER><HR></CENTER>
</H2>
<BR>
The General Assembly,<BR>
<BR>
Recalling Economic and Social Council resolution 1990/26 of 24 May 1990,
in which the Council authorized the Commission for Social Development to
consider, at its thirty-second session, the establishment of an ad hoc 
open-ended
working group of government experts, funded by voluntary contributions,
to elaborate standard rules on the equalization of opportunities for 
disabled
children, youth and adults, in close collaboration with the specialized
agencies, other intergovernmental bodies and non-governmental 
organizations,
especially organizations of disabled persons, and requested the 
Commission,
should it establish such a working group, to finalize the text of those
rules for consideration by the Council in 1993 and for submission to the
General Assembly at its forty-eighth session,<BR>
<BR>
Also recalling that in its resolution 32/2 of 20 February 1991 the 
Commission
for Social Development decided to establish an ad hoc open-ended working
group of government experts in accordance with Economic and Social 
Council
resolution 1990/26,<BR>
<BR>
Noting with appreciation the participation of many States, specialized 
agencies,
intergovernmental bodies and non-governmental organizations, especially
organizations of disabled persons, in the deliberations of the working 
group,<BR>
<BR>
Also noting with appreciation the generous financial contributions of 
Member
States to the working group,<BR>
<BR>
Welcoming the fact that the working group was able to fulfil its mandate
within three sessions of five working days each,<BR>
<BR>
Acknowledging with appreciation the report of the ad hoc open-ended 
working
group to elaborate standard rules on the equalization of opportunities 
for
persons with disabilities,<BR>
<BR>
Taking note of the discussion in the Commission for Social Development at

its thirty-third session on the draft standard rules contained in the 
report
of the working group,<BR>
<BR>
1. Adopts the Standard Rules on the Equalization of Opportunities for 
Persons
with Disabilities, set forth in the annex to the present resolution;<BR>
<BR>
2. Requests Member States to apply the Rules in developing national 
disability
programmes;<BR>
<BR>
3. Urges Member States to meet the requests of the Special Rapporteur for

information on the implementation of the Rules;<BR>
<BR>
4. Requests the Secretary-General to promote the implementation of the 
Rules
and to report thereon to the General Assembly at its fiftieth 
session;<BR>
<BR>
5. Urges Member States to support, financially and otherwise, the 
implementation
of the Rules.<BR>
<P><CENTER><HR></CENTER>
<P>ANNEX<BR>
<P><CENTER><HR></CENTER>
<P>INTRODUCTION<A NAME="anchor1043116"></A><BR>
<IMG SRC="Pixel1x1.gif" WIDTH="1" HEIGHT="1" ALIGN="BOTTOM" 
NATURALSIZEFLAG=
"3"></BLOCKQUOTE>
<BLOCKQUOTE>
<H3>Background and current needs</H3>
1. There are persons with disabilities in all parts of the world and at
all levels in every society. The number of persons with disabilities in
the world is large and is growing.<BR>
<BR>
2. Both the causes and the consequences of disability vary throughout the

world. Those variations are the result of different socio-economic 
circumstances
and of the different provisions that States make for the well-being of 
their
citizens.<BR>
<BR>
3. Present disability policy is the result of developments over the past
200 years. In many ways it reflects the general living conditions and 
social
and economic policies of different times. In the disability field, 
however,
there are also many specific circumstances that have influenced the 
living
conditions of persons with disabilities. Ignorance, neglect, superstition

and fear are social factors that throughout the history of disability 
have
isolated persons with disabilities and delayed their development.<BR>
<BR>
4. Over the years disability policy developed from elementary care at 
institutions
to education for children with disabilities and rehabilitation for 
persons
who became disabled during adult life. Through education and 
rehabilitation,
persons with disabilities became more active and a driving force in the
further development of disability policy. Organizations of persons with
disabilities, their families and advocates were formed, which advocated
better conditions for persons with disabilities. After the Second World
War the concepts of integration and normalization were introduced, which
reflected a growing awareness of the capabilities of persons with 
disabilities.<BR>
<BR>
5. Towards the end of the 1960s organizations of persons with 
disabilities
in some countries started to formulate a new concept of disability. That
new concept indicated the close connection between the limitation 
experienced
by individuals with disabilities, the design and structure of their 
environments
and the attitude of the general population. At the same time the problems

of disability in developing countries were more and more highlighted. In
some of those countries the percentage of the population with 
disabilities
was estimated to be very high and, for the most part, persons with 
disabilities
were extremely poor.<A NAME="anchor1047662"></A><BR>
<IMG SRC="Pixel1x1.gif" WIDTH="1" HEIGHT="1" ALIGN="BOTTOM" 
NATURALSIZEFLAG=
"3"></BLOCKQUOTE>
<BLOCKQUOTE>
<H4>Previous international action</H4>
6. The rights of persons with disabilities have been the subject of much
attention in the United Nations and other international organizations 
over
a long period of time. The most important outcome of the International 
Year
of Disabled Persons, 1981, was the World Programme of Action concerning
Disabled Persons, adopted by the General Assembly by its resolution 37/52

of 3 December 1982. The Year and the World Programme of Action provided
a strong impetus for progress in the field. They both emphasized the 
right
of persons with disabilities to the same opportunities as other citizens
and to an equal share in the improvements in living conditions resulting
from economic and social development. There also, for the first time, 
handicap
was defined as a function of the relationship between persons with 
disabilities
and their environment.<BR>
<BR>
7. The Global Meeting of Experts to Review the Implementation of the 
World
Programme of Action concerning Disabled Persons at the Mid-Point of the
United Nations Decade of Disabled Persons was held at Stockholm in 1987.
It was suggested at the Meeting that a guiding philosophy should be 
developed
to indicate the priorities for action in the years ahead. The basis of 
that
philosophy should be the recognition of the rights of persons with 
disabilities.<BR>
<BR>
8. Consequently, the Meeting recommended that the General Assembly 
convene
a special conference to draft an international convention on the 
elimination
of all forms of discrimination against persons with disabilities, to be
ratified by States by the end of the Decade.<BR>
<BR>
9. A draft outline of the convention was prepared by Italy and presented
to the General Assembly at its forty-second session. Further 
presentations
concerning a draft convention were made by Sweden at the forty-fourth 
session
of the Assembly. However, on both occasions, no consensus could be 
reached
on the suitability of such a convention. In the opinion of many 
representatives,
existing human rights documents seemed to guarantee persons with 
disabilities
the same rights as other persons.<A NAME="anchor1050785"></A><BR>
<IMG SRC="Pixel1x1.gif" WIDTH="1" HEIGHT="1" ALIGN="BOTTOM" 
NATURALSIZEFLAG=
"3"></BLOCKQUOTE>
<BLOCKQUOTE>
<H4>Towards standard rules</H4>
10. Guided by the deliberations in the General Assembly, the Economic and

Social Council, at its first regular session of 1990, finally agreed to
concentrate on the elaboration of an international instrument of a 
different
kind. By its resolution 1990/26 of 24 May 1990, the Council authorized 
the
Commission for Social Development to consider, at its thirty-second 
session,
the establishment of an ad hoc open-ended working group of government 
experts,
funded by voluntary contributions, to elaborate standard rules on the 
equalization
of opportunities for disabled children, youth and adults, in close 
collaboration
with the specialized agencies, other intergovernmental bodies and 
non-governmental
organizations, especially organizations of disabled persons. The Council
also requested the Commission to finalize the text of those rules for 
consideration
in 1993 and for submission to the General Assembly at its forty-eighth 
session.<BR>
<BR>
11. The subsequent discussions in the Third Committee of the General 
Assembly
at the forty-fifth session showed that there was wide support for the new

initiative to elaborate standard rules on the equalization of 
opportunities
for persons with disabilities.<BR>
<BR>
12. At the thirty-second session of the Commission for Social 
Development,
the initiative for standard rules received the support of a large number
of representatives and discussions led to the adoption of resolution 32/2

of 20 February 1991, in which the Commission decided to establish an ad
hoc open-ended working group in accordance with Economic and Social 
Council
resolution 1990/26.<A NAME="anchor1053904"></A><BR>
<IMG SRC="Pixel1x1.gif" WIDTH="1" HEIGHT="1" ALIGN="BOTTOM" 
NATURALSIZEFLAG=
"3"></BLOCKQUOTE>
<BLOCKQUOTE>
<H4>Purpose and content of the Standard Rules on the Equalization of 
Opportunities
for Persons with Disabilities</H4>
13. The Standard Rules on the Equalization of Opportunities for Persons
with Disabilities have been developed on the basis of the experience 
gained
during the United Nations Decade of Disabled Persons (1983-1992). The 
International
Bill of Human Rights, comprising the Universal Declaration of Human 
Rights,
the International Covenant on Economic, Social and Cultural Rights and 
the
International Covenant on Civil and Political Rights, the Convention on
the Rights of the Child and the Convention on the Elimination of All 
Forms
of Discrimination against Women, as well as the World Programme of Action

concerning Disabled Persons, constitute the political and moral 
foundation
for the Rules.<BR>
<BR>
14. Although the Rules are not compulsory, they can become international
customary rules when they are applied by a great number of States with 
the
intention of respecting a rule in international law. They imply a strong
moral and political commitment on behalf of States to take action for the

equalization of opportunities for persons with disabilities. Important 
principles
for responsibility, action and cooperation are indicated. Areas of 
decisive
importance for the quality of life and for the achievement of full 
participation
and equality are pointed out. The Rules offer an instrument for 
policy-making
and action to persons with disabilities and their organizations. They 
provide
a basis for technical and economic cooperation among States, the United
Nations and other international organizations.<BR>
<BR>
15. The purpose of the Rules is to ensure that girls, boys, women and men

with disabilities, as members of their societies, may exercise the same
rights and obligations as others. In all societies of the world there are

still obstacles preventing persons with disabilities from exercising 
their
rights and freedoms and making it difficult for them to participate fully

in the activities of their societies. It is the responsibility of States
to take appropriate action to remove such obstacles. Persons with 
disabilities
and their organizations should play an active role as partners in this 
process.
The equalization of opportunities for persons with disabilities is an 
essential
contribution in the general and worldwide effort to mobilize human 
resources.
Special attention may need to be directed towards groups such as women,
children, the elderly, the poor, migrant workers, persons with dual or 
multiple
disabilities, indigenous people and ethnic minorities. In addition, there

are a large number of refugees with disabilities who have special needs
requiring attention.<A NAME="anchor1059931"></A><BR>
<IMG SRC="Pixel1x1.gif" WIDTH="1" HEIGHT="1" ALIGN="BOTTOM" 
NATURALSIZEFLAG=
"3"></BLOCKQUOTE>
<BLOCKQUOTE>
<H4>Fundamental concepts in disability policy</H4>
16. The concepts set out below appear throughout the Rules. They are 
essentially
built on the concepts in the World Programme of Action concerning 
Disabled
Persons. In some cases they reflect the development that has taken place
during the United Nations Decade of Disabled Persons.<BR>
<IMG SRC="Pixel1x1.gif" WIDTH="1" HEIGHT="1" ALIGN="BOTTOM" 
NATURALSIZEFLAG=
"3"></BLOCKQUOTE>
<BLOCKQUOTE>
<H4>Disability and handicap</H4>
17. The term &quot;disability&quot; summarizes a great number of 
different
functional limitations occurring in any population in any country of the
world. People may be disabled by physical, intellectual or sensory 
impairment,
medical conditions or mental illness. Such impairments, conditions or 
illnesses
may be permanent or transitory in nature.<BR>
<BR>
18. The term &quot;handicap&quot; means the loss or limitation of 
opportunities
to take part in the life of the community on an equal level with others.
It describes the encounter between the person with a disability and the
environment. The purpose of this term is to emphasize the focus on the 
shortcomings
in the environment and in many organized activities in society, for 
example,
information, communication and education, which prevent persons with 
disabilities
from participating on equal terms.<BR>
<BR>
19. The use of the two terms &quot;disability&quot; and 
&quot;handicap&quot;,
as defined in paragraphs 17 and 18 above, should be seen in the light of
modern disability history. During the 1970s there was a strong reaction
among representatives of organizations of persons with disabilities and
professionals in the field of disability against the terminology of the
time. The terms &quot;disability&quot; and &quot;handicap&quot; were 
often
used in an unclear and confusing way, which gave poor guidance for 
policy-making
and for political action. The terminology reflected a medical and 
diagnostic
approach, which ignored the imperfections and deficiencies of the 
surrounding
society.<BR>
<BR>
20. In 1980, the World Health Organization adopted an international 
classification
of impairments, disabilities and handicaps, which suggested a more 
precise
and at the same time relativistic approach. The International 
Classification
of Impairments, Disabilities, and Handicaps makes a clear distinction 
between
&quot;impairment&quot;, &quot;disability&quot; and &quot;handicap&quot;.
It has been extensively used in areas such as rehabilitation, education,
statistics, policy, legislation, demography, sociology, economics and 
anthropology.
Some users have expressed concern that the Classification, in its 
definition
of the term &quot;handicap&quot;, may still be considered too medical and

too centred on the individual, and may not adequately clarify the 
interaction
between societal conditions or expectations and the abilities of the 
individual.
Those concerns, and others expressed by users during the 12 years since
its publication, will be addressed in forthcoming revisions of the 
Classification.<BR>
<BR>
21. As a result of experience gained in the implementation of the World
Programme of Action and of the general discussion that took place during
the United Nations Decade of Disabled Persons, there was a deepening of
knowledge and extension of understanding concerning disability issues and

the terminology used. Current terminology recognizes the necessity of 
addressing
both the individual needs (such as rehabilitation and technical aids) and

the shortcomings of the society (various obstacles for 
participation).<BR>
<IMG SRC="Pixel1x1.gif" WIDTH="1" HEIGHT="1" ALIGN="BOTTOM" 
NATURALSIZEFLAG=
"3"></BLOCKQUOTE>
<BLOCKQUOTE>
<H4>Prevention</H4>
22. The term &quot;prevention&quot; means action aimed at preventing the
occurrence of physical, intellectual, psychiatric or sensory impairments
(primary prevention) or at preventing impairments from causing a 
permanent
functional limitation or disability (secondary prevention). Prevention 
may
include many different types of action, such as primary health care, 
prenatal
and postnatal care, education in nutrition, immunization campaigns 
against
communicable diseases, measures to control endemic diseases, safety 
regulations,
programmes for the prevention of accidents in different environments, 
including
adaptation of workplaces to prevent occupational disabilities and 
diseases,
and prevention of disability resulting from pollution of the environment
or armed conflict.<BR>
<IMG SRC="Pixel1x1.gif" WIDTH="1" HEIGHT="1" ALIGN="BOTTOM" 
NATURALSIZEFLAG=
"3"></BLOCKQUOTE>
<BLOCKQUOTE>
<H4>Rehabilitation</H4>
23. The term &quot;rehabilitation&quot; refers to a process aimed at 
enabling
persons with disabilities to reach and maintain their optimal physical,
sensory, intellectual, psychiatric and/or social functional levels, thus
providing them with the tools to change their lives towards a higher 
level
of independence. Rehabilitation may include measures to provide and/or 
restore
functions, or compensate for the loss or absence of a function or for a
functional limitation. The rehabilitation process does not involve 
initial
medical care. It includes a wide range of measures and activities from 
more
basic and general rehabilitation to goal-oriented activities, for 
instance
vocational rehabilitation.<BR>
<IMG SRC="Pixel1x1.gif" WIDTH="1" HEIGHT="1" ALIGN="BOTTOM" 
NATURALSIZEFLAG=
"3"></BLOCKQUOTE>
<BLOCKQUOTE>
<H4>Equalization of opportunities</H4>
24. The term &quot;equalization of opportunities&quot; means the process
through which the various systems of society and the environment, such as

services, activities, information and documentation, are made available
to all, particularly to persons with disabilities.<BR>
<BR>
25. The principle of equal rights implies that the needs of each and 
every
individual are of equal importance, that those needs must be made the 
basis
for the planning of societies and that all resources must be employed in
such a way as to ensure that every individual has equal opportunity for
participation.<BR>
<BR>
26. Persons with disabilities are members of society and have the right
to remain within their local communities. They should receive the support

they need within the ordinary structures of education, health, employment

and social services.<BR>
<BR>
27. As persons with disabilities achieve equal rights, they should also
have equal obligations. As those rights are being achieved, societies 
should
raise their expectations of persons with disabilities. As part of the 
process
of equal opportunities, provision should be made to assist persons with
disabilities to assume their full responsibility as members of society.<A

NAME="anchor1067914"></A> <BR>
<P><CENTER><HR></CENTER>
<P>PREAMBLE<BR>
<BR>
States,<BR>
<BR>
Mindful of the pledge made, under the Charter of the United Nations, to
take joint and separate action in cooperation with the Organization to 
promote
higher standards of living, full employment, and conditions of economic
and social progress and development,<BR>
<BR>
Reaffirming the commitment to human rights and fundamental freedoms, 
social
justice and the dignity and worth of the human person proclaimed in the
Charter,<BR>
<BR>
Recalling in particular the international standards on human rights, 
which
have been laid down in the Universal Declaration of Human Rights, the 
International
Covenant on Economic, Social and Cultural Rights and the International 
Covenant
on Civil and Political Rights,<BR>
<BR>
Underlining that those instruments proclaim that the rights recognized 
therein
should be ensured equally to all individuals without discrimination,<BR>
<BR>
Recalling the Convention on the Rights of the Child, which prohibits 
discrimination
on the basis of disability and requires special measures to ensure the 
rights
of children with disabilities, and the International Convention on the 
Protection
of the Rights of All Migrant Workers and Members of Their Families, which

provides for some protective measures against disability,<BR>
<BR>
Recalling also the provisions in the Convention on the Elimination of All

Forms of Discrimination against Women to ensure the rights of girls and
women with disabilities,<BR>
<BR>
Having regard to the Declaration on the Rights of Disabled Persons, the
Declaration on the Rights of Mentally Retarded Persons, the Declaration
on Social Progress and Development, the Principles for the Protection of
Persons with Mental Illness and for the Improvement of Mental Health Care

and other relevant instruments adopted by the General Assembly,<BR>
<BR>
Also having regard to the relevant conventions and recommendations 
adopted
by the International Labour Organisation, with particular reference to 
participation
in employment without discrimination for persons with disabilities,<BR>
<BR>
Mindful of the relevant recommendations and work of the United Nations 
Educational,
Scientific and Cultural Organization, in particular the World Declaration

on Education for All, the World Health Organization, the United Nations
Children's Fund and other concerned organizations,<BR>
<BR>
Having regard to the commitment made by States concerning the protection
of the environment,<BR>
<BR>
Mindful of the devastation caused by armed conflict and deploring the use

of scarce resources in the production of weapons,<BR>
<BR>
Recognizing that the World Programme of Action concerning Disabled 
Persons
and the definition therein of equalization of opportunities represent 
earnest
ambitions on the part of the international community to render those 
various
international instruments and recommendations of practical and concrete
significance,<BR>
<BR>
Acknowledging that the objective of the United Nations Decade of Disabled

Persons (1983-1992) to implement the World Programme of Action is still
valid and requires urgent and continued action,<BR>
<BR>
Recalling that the World Programme of Action is based on concepts that 
are
equally valid in developing and industrialized countries,<BR>
<BR>
Convinced that intensified efforts are needed to achieve the full and 
equal
enjoyment of human rights and participation in society by persons with 
disabilities,<BR>
<BR>
Re-emphasizing that persons with disabilities, and their parents, 
guardians,
advocates and organizations, must be active partners with States in the
planning and implementation of all measures affecting their civil, 
political,
economic, social and cultural rights,<BR>
<BR>
In pursuance of Economic and Social Council resolution 1990/26, and 
basing
themselves on the specific measures required for the attainment by 
persons
with disabilities of equality with others, enumerated in detail in the 
World
Programme of Action,<BR>
<BR>
Have adopted the Standard Rules on the Equalization of Opportunities for
Persons with Disabilities outlined below, in order:<BR>
<BR>
(a) To stress that all action in the field of disability presupposes 
adequate
knowledge and experience of the conditions and special needs of persons
with disabilities;<BR>
<BR>
(b) To emphasize that the process through which every aspect of societal
organization is made accessible to all is a basic objective of 
socio-economic
development;<BR>
<BR>
(c) To outline crucial aspects of social policies in the field of 
disability,
including, as appropriate, the active encouragement of technical and 
economic
cooperation;<BR>
<BR>
(d) To provide models for the political decision-making process required
for the attainment of equal opportunities, bearing in mind the widely 
differing
technical and economic levels, the fact that the process must reflect 
keen
understanding of the cultural context within which it takes place and the

crucial role of persons with disabilities in it;<BR>
<BR>
(e) To propose national mechanisms for close collaboration among States,
the organs of the United Nations system, other intergovernmental bodies
and organizations of persons with disabilities;<BR>
<BR>
(f) To propose an effective machinery for monitoring the process by which

States seek to attain the equalization of opportunities for persons with
disabilities.<BR>
<A NAME="anchor1072137"></A><BR>
<P><CENTER><HR></CENTER>
</BLOCKQUOTE>
<BLOCKQUOTE>
<H3>I. PRECONDITIONS FOR EQUAL PARTICIPATION<A 
NAME="anchor1076570"></A><BR>
<IMG SRC="Pixel1x1.gif" WIDTH="1" HEIGHT="1" ALIGN="BOTTOM" 
NATURALSIZEFLAG=
"3"></H3>
</BLOCKQUOTE>
<BLOCKQUOTE>
<H4>Rule 1. Awareness-raising</H4>
States should take action to raise awareness in society about persons 
with
disabilities, their rights, their needs, their potential and their 
contribution.<BR>
<BR>
1. States should ensure that responsible authorities distribute 
up-to-date
information on available programmes and services to persons with 
disabilities,
their families, professionals in the field and the general public. 
Information
to persons with disabilities should be presented in accessible form.<BR>
<BR>
2. States should initiate and support information campaigns concerning 
persons
with disabilities and disability policies, conveying the message that 
persons
with disabilities are citizens with the same rights and obligations as 
others,
thus justifying measures to remove all obstacles to full 
participation.<BR>
<BR>
3. States should encourage the portrayal of persons with disabilities by
the mass media in a positive way; organizations of persons with 
disabilities
should be consulted on this matter.<BR>
<BR>
4. States should ensure that public education programmes reflect in all
their aspects the principle of full participation and equality.<BR>
<BR>
5. States should invite persons with disabilities and their families and
organizations to participate in public education programmes concerning 
disability
matters.<BR>
<BR>
6. States should encourage enterprises in the private sector to include
disability issues in all aspects of their activity.<BR>
<BR>
7. States should initiate and promote programmes aimed at raising the 
level
of awareness of persons with disabilities concerning their rights and 
potential.
Increased self-reliance and empowerment will assist persons with 
disabilities
to take advantage of the opportunities available to them.<BR>
<BR>
8. Awareness-raising should be an important part of the education of 
children
with disabilities and in rehabilitation programmes. Persons with 
disabilities
could also assist one another in awareness-raising through the activities

of their own organizations.<BR>
<BR>
9. Awareness-raising should be part of the education of all children and
should be a component of teacher-training courses and training of all 
professionals.<A
NAME="anchor1081028"></A><BR>
<IMG SRC="Pixel1x1.gif" WIDTH="1" HEIGHT="1" ALIGN="BOTTOM" 
NATURALSIZEFLAG=
"3"></BLOCKQUOTE>
<BLOCKQUOTE>
<H4>Rule 2. Medical care</H4>
States should ensure the provision of effective medical care to persons
with disabilities.<BR>
<BR>
1. States should work towards the provision of programmes run by 
multidisciplinary
teams of professionals for early detection, assessment and treatment of
impairment. This could prevent, reduce or eliminate disabling effects. 
Such
programmes should ensure the full participation of persons with 
disabilities
and their families at the individual level, and of organizations of 
persons
with disabilities at the planning and evaluation level.<BR>
<BR>
2. Local community workers should be trained to participate in areas such

as early detection of impairments, the provision of primary assistance 
and
referral to appropriate services.<BR>
<BR>
3. States should ensure that persons with disabilities, particularly 
infants
and children, are provided with the same level of medical care within the

same system as other members of society.<BR>
<BR>
4. States should ensure that all medical and paramedical personnel are 
adequately
trained and equipped to give medical care to persons with disabilities 
and
that they have access to relevant treatment methods and technology.<BR>
<BR>
5. States should ensure that medical, paramedical and related personnel
are adequately trained so that they do not give inappropriate advice to
parents, thus restricting options for their children. This training 
should
be an ongoing process and should be based on the latest information 
available.<BR>
<BR>
6. States should ensure that persons with disabilities are provided with
any regular treatment and medicines they may need to preserve or improve
their level of functioning.<A NAME="anchor1085282"></A><BR>
<IMG SRC="Pixel1x1.gif" WIDTH="1" HEIGHT="1" ALIGN="BOTTOM" 
NATURALSIZEFLAG=
"3"></BLOCKQUOTE>
<BLOCKQUOTE>
<H4>Rule 3. Rehabilitation</H4>
States should ensure the provision of rehabilitation services to persons
with disabilities in order for them to reach and sustain their optimum 
level
of independence and functioning.<BR>
<BR>
1. States should develop national rehabilitation programmes for all 
groups
of persons with disabilities. Such programmes should be based on the 
actual
individual needs of persons with disabilities and on the principles of 
full
participation and equality.<BR>
<BR>
2. Such programmes should include a wide range of activities, such as 
basic
skills training to improve or compensate for an affected function, 
counselling
of persons with disabilities and their families, developing 
self-reliance,
and occasional services such as assessment and guidance.<BR>
<BR>
3. All persons with disabilities, including persons with severe and/or 
multiple
disabilities, who require rehabilitation should have access to it.<BR>
<BR>
4. Persons with disabilities and their families should be able to 
participate
in the design and organization of rehabilitation services concerning 
themselves.<BR>
<BR>
5. All rehabilitation services should be available in the local community

where the person with disabilities lives. However, in some instances, in
order to attain a certain training objective, special time-limited 
rehabilitation
courses may be organized, where appropriate, in residential form.<BR>
<BR>
6. Persons with disabilities and their families should be encouraged to
involve themselves in rehabilitation, for instance as trained teachers,
instructors or counsellors.<BR>
<BR>
7. States should draw upon the expertise of organizations of persons with

disabilities when formulating or evaluating rehabilitation programmes.<A
NAME="anchor1088366"></A><BR>
<IMG SRC="Pixel1x1.gif" WIDTH="1" HEIGHT="1" ALIGN="BOTTOM" 
NATURALSIZEFLAG=
"3"></BLOCKQUOTE>
<BLOCKQUOTE>
<H4>Rule 4. Support services</H4>
States should ensure the development and supply of support services, 
including
assistive devices for persons with disabilities, to assist them to 
increase
their level of independence in their daily living and to exercise their
rights.<BR>
<BR>
1. States should ensure the provision of assistive devices and equipment,

personal assistance and interpreter services, according to the needs of
persons with disabilities, as important measures to achieve the 
equalization
of opportunities.<BR>
<BR>
2. States should support the development, production, distribution and 
servicing
of assistive devices and equipment and the dissemination of knowledge 
about
them.<BR>
<BR>
3. To achieve this, generally available technical know-how should be 
utilized.
In States where high-technology industry is available, it should be fully

utilized to improve the standard and effectiveness of assistive devices
and equipment. It is important to stimulate the development and 
production
of simple and inexpensive devices, using local material and local 
production
facilities when possible. Persons with disabilities themselves could be
involved in the production of those devices.<BR>
<BR>
4. States should recognize that all persons with disabilities who need 
assistive
devices should have access to them as appropriate, including financial 
accessibility.
This may mean that assistive devices and equipment should be provided 
free
of charge or at such a low price that persons with disabilities or their
families can afford to buy them.<BR>
<BR>
5. In rehabilitation programmes for the provision of assistive devices 
and
equipment, States should consider the special requirements of girls and
boys with disabilities concerning the design, durability and 
age-appropriateness
of assistive devices and equipment.<BR>
<BR>
6. States should support the development and provision of personal 
assistance
programmes and interpretation services, especially for persons with 
severe
and/or multiple disabilities. Such programmes would increase the level of

participation of persons with disabilities in everyday life at home, at
work, in school and during leisure-time activities.<BR>
<BR>
7. Personal assistance programmes should be designed in such a way that
the persons with disabilities using the programmes have a decisive 
influence
on the way in which the programmes are delivered.<A 
NAME="anchor1365329"></A><BR>
<P><CENTER><HR><FONT SIZE="-1">[<A 
HREF="StandardRules2.html">Continuation</A><A 
HREF="ENIL/ENILhomepage.html">]</A></FONT>
<FONT SIZE="-1">[<A HREF="#anchor17238">Standard Rules Contents</A><A 
HREF="ENIL/ENILhomepage.html">]</A></FONT>
<FONT SIZE="-1">[<A HREF="ENIL/ENILhomepage.html">ENIL 
homepage]</A></FONT>
<FONT SIZE="-1">[<A HREF="ENIL/ENILContents.html">ENIL Website 
Contents</A><A HREF="ENIL/ENILhomepage.html">]</A></FONT><FONT 
SIZE="-1">[<A HREF="index.html">Institute
on Independent Living Homepage</A> <A 
HREF="ENIL/ENILhomepage.html">]</A></FONT>
</CENTER>
</BLOCKQUOTE>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-220</DOCNO>
<DOCOLDNO>IA012-000125-B023-5</DOCOLDNO>
<DOCHDR>
http://www.independentliving.org:80/IntroductionStandardRules.html 193.13.228.238 19970216214933 text/html 20900
HTTP/1.0 200 OK
Last-Modified: Sun, 06 Oct 1996 19:26:43 +0000
Date: Sun, 16 Feb 1997 21:49:34 +0000
Expires: Sun, 16 Feb 1997 21:47:54 +0000
Content-type: text/html
Server: RoxenEnterprise/1.0
Content-length: 20674
</DOCHDR>
<HTML>
<HEAD>
    <TITLE>Institute_on_Independent_Living</TITLE>
</HEAD>
<BODY BGCOLOR="#ffffff" TEXT="#030235" LINK="#00007f">
<META NAME="description" 
CONTENT="Individuals and organizations of persons with disabilities can 
publish, free of charge,  articles, reports, training manuals, 
announcements, etc. on Independent Living, personal assistance, advocacy, 

peer support, accessibility, legislation and related subjects. "><META 
NAME="keywords" CONTENT="Independent Living, personal assistance, 
advocacy, peer support, direct payments, anti-discrimination legislation, 

accessibility, disability, disability rights"><BR>
<IMG SRC="InstLogoSmall.gif" WIDTH="198" HEIGHT="57" ALIGN="BOTTOM" 
NATURALSIZEFLAG=
"3"><BR>
<BR>
<H3><CENTER>Introduction to the United Nations Standard Rules on the <BR>

Equalization of Opportunities for Persons with Disabilities</CENTER>
</H3>
<P><CENTER><BR>
Mr. Bengt Lindqvist, Former M.P. and Cabinet Minister, Sweden<BR>
</CENTER>
<P>1981 was the International Year of Disabled Persons. This was an event

of historical importance. The greatest contribution of this event was, in

my opinion, the theme of the Year: Full Participation and Equality. This
must be considered as a recognition on the highest possible political 
level
of the right of persons with disabilities to full participation and equal

opportunities in the society they belong to. This important achievement
was followed by the adoption of the World Programme of Action concerning
Disabled Persons, which outlined the policies in harmony with the theme
of the Year. <BR>
<BR>
The idea was that these policies should be implemented during the 
subsequent
Decade of Disabled Persons, 1983 - 1992. Some important achievements were

noted during this period, but already in the middle of the decade it was
obvious that too little happened. The international disability community
therefore requested that the United Nations should assume a stronger 
leadership
role in the development of better living conditions for persons with 
disabilities.
The response to this request was the elaboration of the Standard Rules,
which took place between 1990 -1993, when they were adopted. <BR>
<BLOCKQUOTE>&quot;In all societies of the world there are still obstacles

preventing persons with disabilities from exercising their rights and 
freedoms
and making it difficult for them to participate fully in the activities
of their societies. It is the responsibility of States to take 
appropriate
action to remove such obstacles.&quot;</BLOCKQUOTE>
<BR>
These are probably the two most important sentences in the whole Standard

Rules document. You find them in the Introduction, paragraph 15. The 
process
outlined in the Rules is to identify and remove obstacles to full 
participation.
Governments of countries are responsible for taking action to remove such

remaining obstacles. <BR>
<BR>
Well, as you see, we now already know three important things about the 
Standard
Rules. The objective is to achieve full participation and equal 
opportunities.
The method to use is to identify and remove remaining obstacles and 
governments
are responsible for the necessary measures. <BR>
<BR>
The Standard Rules instrument summarizes the message of the World 
Programme
and adds the ideological development during the decade. Above all the 
stronger
emphasis on the human rights perspective, which developed during the 
decade,
has been incorporated. In comparison with the World Programme there are
mainly three features which distinguish the Rules document. The language
of the Rules is far more concentrated and shorter in form. The message of

the Rules is directly addressed to member states, i.e. the governments of

countries. The third characteristic is that the Standard Rules will be 
monitored
through a special monitoring system. <BR>
<BR>
The Standard Rules include an introduction, a preamble, 22 different 
Rules
and a description of the monitoring system. The actual Rules are divided
into three sections: preconditions for participation, target areas for 
equal
participation and implementation measures. <BR>
<BR>
The first section, dealing with the preconditions for participation, 
mainly
presents Rules on different forms of support to the individual, medical
care, rehabilitation and various forms of support services. The purpose
of these  is to reduce the functional limitations and increase the 
independence
of the individual. <BR>
<BR>
The section on target areas deals with sectors and aspects of society, 
which
are of general  importance for the quality of life. There is an initial
Rule on accessibility, which deals with all the various aspects of access

to physical environment and activities and services generally available
to non-disabled persons. The Rules on education, employment and income 
maintenance
and social security are, of course, of great importance. The Rule on 
family
life and personal integrity is new and has no corresponding chapter in 
the
World Programme. It reflects an area, which has attracted considerable 
attention
during the decade. <BR>
<BR>
The third section of the Rules, the implementation measures, presents a
number of rather well-known measures. They are all of importance to 
achieve
results and development in the disability field. I should here like to 
draw
your attention to three of these measures. In the Rule on legislation 
(Rule
15) the message is that states should create a legal base for measures to

achieve full participation and equality for persons with disabilities. 
Legislative
action may also be needed to remove conditions which may adversely affect

the lives of persons with disabilities. <BR>
<BR>
In Rule 18 it is stated that states should recognize the right of the 
organizations
of persons with disabilities to represent their groups at all levels. 
States
should encourage and support the formation and strengthening of such 
organizations.
<BR>
<BR>
The third measure I should like to draw your attention to concerns 
coordination
(Rule 17). Disability involves all spheres of society and therefore it is

necessary to use a comprehensive approach. This also means that there is
a constant need for coordination. It is therefore stated in the Rule that

states are responsible for the establishment and strengthening of 
national
coordinating committees or similar bodies.<BR>
<BR>
The chapter on monitoring among other things contains the following:<BR>
<BLOCKQUOTE>&quot;The purpose of the monitoring mechanism is to further
the effective implementation of the Standard Rules. It will assist each
state to assess its level of implementation of the Standard Rules and to
measure its progress. The monitoring should identify obstacles and 
suggest
suitable measures which would contribute to the successful implementation

of the Rules. <BR>
<BR>
 ...The Rules shall be monitored within the framework of the sessions of
the Commission for Social Development. A Special Rapporteur...shall be 
appointed...
for three years to monitor the implementation of the Rules. International

organizations of persons with disabilities having consultative status 
with
the Economic and Social Council...should be invited to create among 
themselves
a panel of experts, on which organizations of persons with disabilities
shall have a majority...to be consulted by the Special Rapporteur and, 
when
appropriate, the secretariat.&quot; </BLOCKQUOTE>
<BR>
Education and employment should constitute cornerstones in any national
disability policy or plan of action. Rule 6 on education, Rule 7 on 
employment
and Rule 8 on income maintenance and social security present direction 
and
guidelines, particularly for governments, in these important areas. I  
advise
you to  study carefully this text and relate the indicated principles and

measures to your own situation back home. In the following I should like
to make a few comments on the contents of these Rules.<BR>
<BR>
In Rule 6 on education it is stated that Member States should recognize
the principle of equal educational opportunities for persons with 
disabilities,
in integrated settings. States should ensure that the education of 
persons
with disabilities is an integral part of the educational system. Adequate

accessibility and support services, designed to meet the needs of persons

with disabilities should be provided. In States where education is 
compulsory,
it should be provided to girls and boys with all kinds and all levels of
disabilities, including the most severe. Integrated education and 
community
based programs should be seen as complementary approaches in providing 
cost-effective
education and training. In situations where the general school system 
does
not yet adequately meet the needs of all persons with disabilities, 
special
education may be considered. It should be aimed at preparing students for

education in the general school system. The quality of such education 
should
reflect the same standards and ambitions as general education and should
be closely linked to it.<BR>
<BR>
The essence of Rule 7 on employment is that persons with disabilities 
should
be empowered to exercise their right to gainful employment and that it is

the responsibility of states, i.e. governments of countries, to remove 
all
remaining obstacles to employment. As far as possible, and it is possible

to a far greater extent than today, persons with disabilities should have

jobs in the regular labor market. When this, despite all efforts, does 
not
seem to be possible, jobs should be offered in more protected forms.<BR>
<BR>
Let me quote the following paragraphs from the text:<BR>
<BLOCKQUOTE>&quot;Laws and regulations in the employment field must not
discriminate against persons with disabilities and must not raise 
obstacles
to their employment&quot;<BR>
<BR>
&quot;States should actively support the integration of persons with 
disabilities
into open employment&quot;<BR>
<BR>
&quot;States, worker&#165;s organizations and employers should cooperate
with organizations of persons with disabilities concerning all measures
to create training and employment opportunities ....&quot;</BLOCKQUOTE>
<BR>
The text also contains a list of various technical measures, which could
 be taken by governments, in order to obtain these objectives.<BR>
<BR>
In the related area of income maintenance and social security it is, of
course, difficult to establish global guidelines due to the fundamental
differences in economic conditions existing in the world today. Still it
has been possible for the UN General Assembly to agree on some universal
principles, which should be observed by all.  I should here like to quote

the following parts of Rule 8, which outline the basic responsibility of
governments: <BR>
<BLOCKQUOTE>&quot;States are responsible for the provision of social 
security
and income maintenance for persons with disabilities&quot;<BR>
<BR>
&quot;States should ensure the provision of adequate income support to 
persons
with disabilities who, owing to disability or disability related factors,

have temporarily lost or received a reduction in their income or have 
been
denied employment opportunities&quot;<BR>
<BR>
&quot;In countries where social security, social insurance or other 
social
welfare schemes exist or are being developed for the general population,
states should ensure that such systems do not exclude or discriminate 
against
persons with disabilities&quot;<BR>
<BR>
&quot;Social security systems should include incentives to restore the 
income-earning
capacity of persons with disabilities.&quot;</BLOCKQUOTE>
<BR>
In my opinion these principles must be applied in any national effort to
create systems for social security. the principles and guidelines 
outlined
in Rules 6, 7 and 8 have been elaborated in close cooperation with the 
International
Labour Organisation and the UNESCO. It is therefore fair to say that 
these
guidelines represent a valid summary of values, knowledge and experiences

of today.<BR>
<BR>
The Standard Rules document is not an international convention. 
Consequently
it is not legally binding for member states. Formally the Rules are a UN
declaration with some special features, which I pointed out earlier. How
important and committing are the Rules then? Well, the mere fact that 
they
have been unanimously adopted by the UN General Assembly after extensive
preparations and as the consequence of the UN Decade of Disabled Persons,

makes them a strong international document. However, more has been done
to increase the strength of the Rules. At all four major World 
Conferences,
organized by the United Nations from 1993-1995, on human rights in Vienna

1993, on population issues in Cairo 1994, on social development in 
Copenhagen
1995 and on the situation of women in Beijing 1995, Strong statements 
have
been adopted in support of the implementation of the UN Standard Rules.
This remarkable achievement has been made thanks to the untiring efforts
and determination by many representatives of the organized movement of 
persons
with disabilities to make the most of this document and to convince 
governments
to move from words to concrete action to improve the living conditions of

persons with disabilities.<BR>
<BR>
After my presentation of the Rules I often get the following question: Is

it at all possible to adopt a disability policy, which is relevant for 
the
whole world, taking into account the enormous differences in economic and

social conditions between countries? Yes, indeed, it is, as long as you
stick to  general values, and principles. The obvious example of this is
the Universal Declaration of Human Rights. It is, of course, relevant for

all nations in the world. <BR>
<BR>
Even though causes, kinds and numbers of disability vary between regions,

it is an undeniable fact that any national population holds a 
considerable
proportion of citizens with disabilities. Every government sooner or 
later
has to take disability into account. It may then choose to neglect and 
isolate
the phenomenon or it may adopt policies for the mobilization and 
inclusion
of citizens with disabilities in their national efforts. This choice 
should
be fairly simple don't you think? <BR>
<BR>
In this context both  the human rights instruments and the Standard Rules

give clear guidance even to the poorest of all countries. It goes without

saying that  a strong economy and an already existing welfare structure
in a country will make things easier. It sometimes, however,  seems 
easier
for emerging nations and nations in transition to apply the principles 
and
policies of integration and inclusion, expressed in the Standard Rules.
Some industrialized countries seem to have got stuck in structures and 
institutions,
which cost a lot but which do not seem to deliver results in accordance
with the philosophy of full participation and equal opportunities.<BR>
<BR>
Soon the  first two years of monitoring have been completed. It all 
started
when the Secretary-General of the UN during the spring of 1994 appointed
me Special Rapporteur. A Panel of Experts was established in September 
the
same year by the following six international organizations: Disabled 
Peoples
International, Inclusion International, Rehabilitation International, 
World
Blind Union, World Federation of the Deaf and World Federation of 
Psychiatric
Users. There are five men and five women with different disabilities and
from different parts of the world in this panel. I want to take this 
opportunity
to congratulate these six organizations on a remarkable  achievement. 
<BR>
<BR>
In November 1994 I circulated a letter to all governments, asking them 
how
they have received the Rules and how they are going to use them in 
future.
A summary of the 38 replies from governments and four additional replies
from NGOs is available in a report. In April 1995 I presented a first 
report
to the Commission for Social Development, which passed a strong 
resolution
(CSD 34/2) in support of our work. My report to the Commission, together
with the summary of replies, was circulated as a document before the 50th

session of the UN General Assembly. <BR>
<BR>
During February 1995 I met the Panel of Experts for the first time. 
Although
we all realized that the 22 Rules are of great importance, we agreed to
concentrate our efforts, during the remaining two years of this first 
period
of monitoring, mainly on the following six areas: Accessibility, 
education,
employment, legislation, coordination of work and organizations of 
persons
with disabilities. During the remaining time of my appointment I will use

all available opportunities to introduce and explain the philosophy and
contents of the Rules - this most recent and concrete international 
agreement
on policy and standards in the disability field. I have up to now been 
able
to attend all major conferences held by the six organizations in the 
Panel
and a considerable number of other occasions. During August and September

1995 I traveled extensively in Africa and visited the Middle East.<BR>
<BR>
In Africa I participated in a number of regional seminars on disability
policy, in which altogether about 30 African countries participated.  I
hope  we will be able to organize a similar seminar with governments and
organizations in the Middle East. <BR>
<BR>
In the field of education we are cooperating with UNESCO. Among other 
things
we have received material collected in connection with the World 
Conference
on Special needs Education, held in Salamanca in 1994. I think we will be

able to present an interesting and reliable picture of the situation in
special needs education in the 60 countries concerned. <BR>
<BR>
The issues particularly studied are: What does the legal regulation of 
the
right to special education look like? What is the parents role in the 
decision-making
about the placement of children with disabilities? We also study 
financial
aspects, curriculum issues, vocational training  and the issue of 
responsibility
for special education. <BR>
<BR>
Concerning the Rule on employment ILO placed at our disposal the very 
rich
and interesting material collected in the monitoring of the ILO 
convention
 and recommendations. This material will constitute the main source of 
information
in our monitoring of Rule 7 on employment. Most of the issues raised in
Rule 7 will be covered by this data, as the Rule, when it was elaborated,

was based on the ILO Convention 159. Our analysis of this material will
mainly concern the 56 countries, which so far have ratified the 
Convention.
<BR>
<BR>
The remaining four Rule areas - legislation, accessibility, coordination
and the position of organizations - have been included in our own 
questionnaire
to all governments. We have also circulated this questionnaire to all 
national
member organizations of the six internationals belonging to the Panel of
Experts. We have invited them to reply and we have asked them to assist
us in obtaining replies from their governments. <BR>
<BR>
The final day for replies was the 31st of March this year. On 30 May we
had received 70 replies from governments and 150 from organizations. 
However,
we know from experience that many governments are slow in delivering 
information
on request like this. We sincerely hope that we will get many more 
replies
both from governments and NGOs. <BR>
<BR>
During this first monitoring period we have one more year to go. During
the past two years we have seen some really promising initiatives and 
policy
development. Still the situation for the vast majority of persons with 
disabilities is totally unacceptable. Let us now use the remaining time
of this monitoring effort to make real progress  in many more countries
and regions.   We must do it to avoid further suffering and 
discrimination
of persons who happen to be disabled, but we also have to do it to 
protect
general democratic values and the credibility of both the United Nations
and member states.<BR>
<BR>
A society good for disabled people is a better society for all. All of us

gathered here today know that this is true. Let us use our insight to 
convince
others! I wish you progress in your future struggle for a Society for 
All.
I thank you for your attention.<BR>
<BR>
UNITED NATIONS<BR>
Special Rapporteur of the Commission for Social Development on 
Disability<BR>
Box 16363<BR>
103 26 Stockholm<BR>
Sweden<BR>
Tel. 46-8-453 4022  and 453 4021 <BR>
Fax.46-8-248 847  and 453 4050<BR>
<P><CENTER><HR><FONT SIZE=2>[<A HREF="Contents.html">Institute on 
Independent
Living contents</A>]</FONT></CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-221</DOCNO>
<DOCOLDNO>IA012-000125-B023-54</DOCOLDNO>
<DOCHDR>
http://www.independentliving.org:80/TallinnGuidelines.html 193.13.228.238 19970216214955 text/html 31061
HTTP/1.0 200 OK
Last-Modified: Sun, 06 Oct 1996 19:26:54 +0000
Date: Sun, 16 Feb 1997 21:50:01 +0000
Expires: Sun, 16 Feb 1997 21:48:21 +0000
Content-type: text/html
Server: RoxenEnterprise/1.0
Content-length: 30835
</DOCHDR>
<HTML>
<HEAD>
    <TITLE>Institute_on_Independent_Living</TITLE>
</HEAD>
<BODY BGCOLOR="#ffffff" TEXT="#030235" LINK="#00007f">
<META NAME="description" 
CONTENT="Individuals and organizations of persons with disabilities can 
publish, free of charge,  articles, reports, training manuals, 
announcements, etc. on Independent Living, personal assistance, advocacy, 

peer support, accessibility, legislation and related subjects. "><META 
NAME="keywords" CONTENT="Independent Living, personal assistance, 
advocacy, peer support, direct payments, anti-discrimination legislation, 

accessibility, disability, disability rights"><BR>
<IMG SRC="InstLogoSmall.gif" WIDTH="198" HEIGHT="57" ALIGN="BOTTOM" 
NATURALSIZEFLAG=
"3"><BR>
<BR>
<P><CENTER>A/RES/44/70   78th plenary meeting   8 December 1989</CENTER>
<P>
<H3><CENTER>Implementation of the World Programme of Action concerning 
Disabled
 Persons and the United Nations Decade of Disabled Persons</CENTER>
</H3>
<BR>
The General Assembly,<BR>
<BR>
Recalling all its relevant resolutions, including resolution 37/52 of  3
December 1982, by which it adopted the World Programme of Action 
concerning
 Disabled Persons,and resolution 37/53 of 3 December 1982, in which it,
 inter alia, proclaimed the period 1983-1992 the United Nations Decade of

 Disabled Persons,<BR>
<BR>
Recalling also its resolution 43/98 of 8 December 1988, and reaffirming
 all of the relevant provisions contained therein, in particular, the 
list
of  priorities for global activities and programmes during the second 
half
of the  United Nations Decade of Disabled Persons set forth in the annex
to the  resolution,<BR>
<BR>
Taking note of Economic and Social Council resolution 1989/52 of  24 May
1989, in which the Council, inter alia, urged Member States, bodies and
 organizations of the United Nations system and intergovernmental and  
non-governmental
organizations to provide all possible support to the  awareness and 
fund-raising
campaigns to give added momentum to the Decade,<BR>
<BR>
Noting the important work currently being undertaken by the  
Sub-Commission
on Prevention of Discrimination and Protection of Minorities on  human 
rights
and disability, which could serve as a useful basis for the  continued 
efforts
to ensure for disabled persons the enjoyment of human rights  and 
fundamental
freedoms,<BR>
<BR>
Taking into account the concrete measures already carried out by the  
Governments
of Member States, the bodies and organizations of the United  Nations 
system
and non-governmental organizations to implement the objectives  of the 
World
Programme of Action within the framework of the Decade, and  recognizing
that much more should be done at all levels to improve the living  
conditions
of persons with disabilities,<BR>
<BR>
Mindful that Member States bear the ultimate responsibility for the  
implementation
of the World Programme of Action and that national disability  committees

or similar co-ordinating bodies play a crucial role in this regard,<BR>
<BR>
Recognizing the pivotal role of the United Nations in promoting the  
exchange
of information, experience and expertise and closer regional and  
interregional
co-operation towards more effective strategies and policies to  advance
the status and welfare of persons with disabilities,<BR>
<BR>
Stressing that the Centre for Social Development and Humanitarian Affairs

 of the Secretariat is the focal point within the United Nations for the
 implementation and monitoring of the World Programme of Action,<BR>
<BR>
Noting with satisfaction the strengthening of the Disabled Persons Unit
 of the Centre through the generous financial support of some 
Governments,<BR>
<BR>
Concerned that the Voluntary Fund for the United Nations Decade of  
Disabled
Persons continues to suffer from a lack of sufficient contributions  and
that, unless this declining trend is reversed and the resource capacities

 of the Fund are strengthened, many priority requests may not be met and
the  implementation of the World Programme of Action will be seriously 
affected,<BR>
<BR>
Mindful that, since developing countries are experiencing difficulties in

 mobilizing resources, international co-operation should be encouraged to

 assist in national efforts to implement the World Programme of Action 
and
the  objectives of the Decade,<BR>
<BR>
Noting that the International Meeting on Human Resources in the Field of
 Disability was held at Tallinn, Union of Soviet Socialist Republics, 
from
14  to 22 August 1989 and that it adopted a nine-point strategy to 
promote
the  participation, training and employment of disabled persons, 
especially
in  developing countries,<BR>
<BR>
Having considered the report of the Secretary-General,<BR>
<BR>
1.  Reaffirms the validity of the World Programme of Action concerning 
Disabled Persons;<BR>
<BR>
2.  Reiterates that for the second half of the United Nations Decade of
 Disabled Persons, special emphasis should be placed on the equalization
of  opportunities for disabled persons;<BR>
<BR>
3.  Urges Member States, intergovernmental organizations and  
non-governmental
organizations concerned to translate into action at all  levels, as 
appropriate,
the priorities for global activities and programmes  during the second 
half
of the Decade, such as those set forth in the annex to  General Assembly
resolution 43/98;<BR>
<BR>
4.  Renews its invitation to all States to give high priority to  
projects
concerning the prevention of disabilities, rehabilitation and the  
equalization
of opportunities for disabled persons within the framework of  bilateral
assistance, as well as financial support to strengthen organizations  of
disabled persons;<BR>
<BR>
5.  Invites Governments to participate actively in the international  
co-operation
with a view to improving the living conditions of disabled  persons by 
encouraging
professional experts, in particular disabled persons,  in various aspects

of rehabilitation and the equalization of opportunity,  including the 
expertise
of retired persons;<BR>
<BR>
6.  Requests the Secretary-General to assist Member States in  
establishing
and strengthening national committees on disability issues and  similar
co-ordinating bodies and to promote and support the establishment of  
strong
national organizations of disabled persons;<BR>
<BR>
7.  Also requests the Secretary-General to encourage all organs and  
bodies
of the United Nations, including regional commissions, international  
organizations
and specialized agencies, to take into account in their  programmes and
operational activities the specific needs of disabled persons;<BR>
<BR>
8.  Invites the Secretary-General, in connection with the feasibility  
study
on the substantive, financial and administrative implications of  
alternative
ways to mark the end of the Decade in 1992, called for by the  General 
Assembly
in its resolution 43/98, to request Member States, in  consultation with
organizations of disabled persons, to submit their comments  to him by 28

February 1990 for inclusion in the background document to be  discussed
at the meeting of experts to be held at Helsinki in May 1990;<BR>
<BR>
9.  Requests the Secretary-General to strengthen the regional  
commissions
to enable them to promote technical co-operation activities and  the 
sharing
of national resources for personnel training, the exchange of  
information,
policy and programme development and research and the  participation of
disabled persons;<BR>
<BR>
10.  Invites the Secretary-General and Member States to involve disabled
 persons to a greater extent in United Nations programmes and activities,

 including the provision of employment opportunities, and to give 
particular
 attention to improving the situation of special groups as outlined in 
the
 World Programme of Action, emphasizing the need for social justice and
the  participation of these groups in each sector of the society;<BR>
<BR>
11.  Invites the Centre for Social Development and Humanitarian Affairs
 of the Secretariat to expand its close collaboration with 
intergovernmental
 and non-governmental organizations active in the field of disability, in

 particular organizations of disabled persons, and to consult with them
on a  regular and systematic basis on matters relating to the 
implementation
of the  World Programme of Action, with a view to ensuring that the 
results
of the  Decade become meaningful and lasting;<BR>
<BR>
12.  Notes with satisfaction the progress made by the office of the 
Special
Representative for the Promotion of the United Nations Decade of  
Disabled
Persons;<BR>
<BR>
13.  Calls upon Member States, national committees, the United Nations 
system and non-governmental organizations, especially organizations of 
disabled persons, to assist in a global information and fund-raising 
campaign
 to publicize the Decade through all appropriate means;<BR>
<BR>
14.  Recognizes the important role of non-governmental organizations,  
especially
those representing persons with disabilities in the effective  
implementation
of the World Programme of Action, in raising international  awareness of
the concerns of persons with disabilities and in monitoring and  
evaluating
progress achieved during the Decade;<BR>
<BR>
15.  Requests the Secretary-General to ensure that contributions, in cash

 or in kind, related to the Decade are channelled into the Voluntary Fund

for  the United Nations Decade of Disabled Persons, while giving donors
the option  of earmarking contributions for special purposes;<BR>
<BR>
16.  Reaffirms that the resources of the Voluntary Fund should be used to

 support catalytic and innovative activities in order to implement 
further
the  objectives of the World Programme of Action within the framework of
the  Decade, with priority given, as appropriate, to programmes and 
projects
of the  least developed countries;<BR>
<BR>
17.  Invites Governments and non-governmental organizations to continue
 their contributions to the Voluntary Fund, and calls upon Governments 
and
 non-governmental organizations that have not yet done so to consider  
contributing
to the Voluntary Fund so as to enable it to respond effectively  to the
growing demand for assistance;<BR>
<BR>
18.  Requests the Secretary-General to bring the Tallinn Guidelines for
 Action on Human Resources Development in the Field of Disability, the 
text
of  which is annexed to the present resolution, to the attention of 
Member
States,  national co-ordinating mechanisms in the field of disability, 
organizations
of  the United Nations system, other intergovernmental bodies and 
non-governmental
 organizations concerned with disabilities;<BR>
<BR>
19.  Requests the Secretary-General to report to the General Assembly at
 its forty-fifth session on the implementation of the present 
resolution;<BR>
<BR>
20.  Decides to include in the provisional agenda of its forty-fifth  
session
the item entitled &quot;Implementation of the World Programme of Action
 concerning Disabled Persons and the United Nations Decade of Disabled 
Persons&quot;.<BR>
<BR>
<BR>
ANNEX  
<H3></H3>
<H3><CENTER>Tallinn Guidelines for Action on Human Resources  Development

in the Field of Disability  </CENTER>
</H3>
<BR>
INTRODUCTION<BR>
<BR>
1.  The International Meeting on Human Resources in the Field of 
Disability,
 convened at Tallinn, Union of Soviet Socialist Republics, from 14 to  22

August 1989, having considered the situation of human resources 
development
 in the field of disability, particularly in developing countries, firmly

 believes that it is necessary to reinforce existing activities, as well
as to  undertake new and innovative ones, in order to promote the further

development  and continued progress of disabled persons.<BR>
<BR>
2.  Following the adoption of the World Programme of Action concerning 
Disabled Persons by the General Assembly, in its resolution 37/52 of  3
December 1982, there has been a growing need for higher priority to be 
given
 to the development of the human resources of disabled persons, with 
specific
 reference to education and training, employment, and science and 
technology.
 In this connection, the General Assembly, in its resolution 37/53 of  3
December 1982, proclaimed the period 1983-1992 the United Nations Decade
of  Disabled Persons, encouraging Member States to utilize that period as

one of  the means to implement the World Programme of Action.<BR>
<BR>
3.  The main objectives of the World Programme of Action are to promote
 effective measures for the prevention of disability, for rehabilitation
and  for the realization of the goals of full participation and equality
for  persons with disabilities.  To accomplish these goals, due regard 
must
be paid  to education, training and work opportunities.<BR>
<BR>
4.  While it is acknowledged that the living conditions of the general 
population in developing countries urgently need to be improved, the  
objectives
of the World Programme of Action call for the situation of disabled  
persons
to be given special attention during the remainder of the Decade and  
beyond.
 Effective implementation of the World Programme of Action will make  an
important contribution to the process of development of societies through

 the mobilization of more human resources.<BR>
<BR>
5.  While it is also acknowledged that a number of countries have already

 initiated or carried out activities within the framework of the World 
Programme of Action, further concerted efforts should be made to 
integrate
the  human resources development of disabled persons into intersectoral
planning at  the national level.  <BR>
<BR>
<BR>
GUIDING PHILOSOPHY<BR>
<BR>
6.  Human resources development is a process centred on the human person
that  seeks to realize the full potential and capabilities of human 
beings.
 This  process is fundamental to the concept of equalization of 
opportunities,
in  keeping with the goals of the World Programme of Action.<BR>
<BR>
7.  Through human resources development, disabled persons are able  
effectively
to exercise their rights of full citizenship.  As full citizens,  they 
have
the same rights and responsibilities as other members of society,  
including
the right to life, as declared in international human rights  
instruments.
 They also have the same choices as other citizens in the social,  
cultural,
economic and political life of their communities.<BR>
<BR>
8.  Because persons with disabilities are agents of their own destiny 
rather
 than objects of care, Governments and organizations need to reflect this

 perception in their policies and programmes.  This means that disabled
 persons, as individuals and as members of organizations, should be 
involved
in  the decision-making process as equal partners.<BR>
<BR>
9.  The abilities of disabled persons and their families should be  
strengthened
through community-based supplementary services provided by  Governments
and non-governmental organizations.  These services should promote  
self-determination
and enable disabled persons to participate in the  development of 
society.
 Governments should recognize and support the role of  organizations of
disabled persons in enabling those persons to take charge of  their own
lives.<BR>
<BR>
<BR>
STRATEGIES  	<BR>
<BR>
A.  Participation of persons with disabilities<BR>
<BR>
10.  A statutory basis is required to enable disabled persons to 
participate
 as full citizens in decision-making at all levels of the planning,  
implementation,
monitoring and evaluation of policies and programmes.<BR>
<BR>
11.  To facilitate the full participation of disabled persons and to 
enable
 them to exercise their rights as citizens, access to information is  
essential.
 To this end, all information has to be adapted to appropriate  formats.
 These information formats may include Braille script, large print,  
audio-visual
media and sign-language interpretation.  Information channels  should 
include
television, radio, newspapers and postal services.  Governments  should
work with organizations of disabled persons to identify appropriate  
information
formats and channels to reach disabled citizens.<BR>
<BR>
12.  Governments should adopt, enforce and fund legally binding standards

and  regulations to improve access for persons with disabilities, 
ensuring
that  buildings, streets, and road, sea and air transport are 
barrier-free,
 architecturally and in all other ways.  Communication systems and 
security
and  safety measures should be developed and adapted to meet the needs of

disabled  citizens.<BR>
<BR>
13.  To facilitate the recruitment of disabled persons and to assist  
private-sector
industries in hiring them, organizations at the national,  regional and
international levels, including the United Nations, should  identify and
maintain listings of qualified disabled candidates.<BR>
<BR>
<BR>
B.  Strengthening of grass-roots initiatives<BR>
<BR>
14.  Local community initiatives should be especially promoted.  Disabled

 persons and their families should be encouraged to form grass-roots  
organizations,
with governmental recognition of their importance and  governmental 
support
in the form of financing and training.<BR>
<BR>
15.  Governmental and non-governmental organizations concerned with 
disability
 issues should allow disabled persons to participate as equal 
partners.<BR>
<BR>
16.  The efficient functioning of governmental and non-governmental  
organizations
concerned with disability calls for training in organizational  and 
management
skills.<BR>
<BR>
<BR>
C.  Promotion of an integrated approach<BR>
<BR>
17.  Overall national policy frameworks with supporting legislation 
should
be  developed.<BR>
<BR>
18.  The essence of an integrated approach is the inclusion of disability

 issues in all government ministries and at every level of governmental
policy  and planning.  National co-ordination bodies, with linkages at 
the
local,  regional and interregional levels, should be established or 
strengthened.
 The  membership of those bodies should include all government 
ministries,
 legislative committees and non-governmental organizations, particularly
 organizations of disabled persons.  Those bodies should review existing
 policies, plans and programmes, identify existing and projected 
resources
and  monitor and evaluate the implementation of national policies.<BR>
<BR>
19.  National development programmes should include disability 
components.<BR>
<BR>
20.  Disabled women should be included in the existing national and 
regional
 programmes aimed at women.<BR>
<BR>
21.  At the level of service delivery, an integrated approach entails  
co-operation
and referral among professionals working in organizational  settings that

provide educational, vocational, health and social services.<BR>
<BR>
<BR>
D.  Promotion of education and training<BR>
<BR>
22.  The early years are critical in the overall development of a 
disabled
 child and for the fostering of positive attitudes towards the child.  
Specific
 programmes and training materials should be developed to address these
needs  during the formative infant and pre-school years.<BR>
<BR>
23.  Education at the primary, secondary and higher levels should be 
available
 to disabled persons within the regular educational system and in regular

 school settings, as well as in vocational training programmes.  When 
such
 education is provided to deaf students, teachers and/or interpreters who

are  proficient in the indigenous sign language must be provided.<BR>
<BR>
24.  Special education programmes and schools that promote the indigenous

sign  language and the indigenous deaf culture must be available to deaf
people.  Deaf people should be employed in such programmes and 
schools.<BR>
<BR>
25.  Cost-effective alternatives to segregated school facilities should
be  developed and implemented by Governments at the national and local 
levels.
 These alternatives include special education teachers as consultants to
 regular education teachers, resource rooms with specialized personnel 
and
 materials, special classrooms in regular schools and interpreters for 
deaf
 students.<BR>
<BR>
26.  The education of disabled children should involve the co-operation
and  concerted efforts of health and social services, as well as of 
teachers
and  parents.  It should provide support measures, such as technical 
aids,
 especially adapted pedagogical approaches, and incentives for 
teachers.<BR>
<BR>
27.  The content and quality of education and training should ensure the
 acquisition of skills that are economically viable and that provide  
opportunities
for work.  Career education and vocational training programmes  should be

available to ensure the transition of disabled students into the  
economic
mainstream.<BR>
<BR>
28.  In addition to being offered formal skills training and education,
 disabled persons should be offered training in social and self-help 
skills
to  prepare them for independent living.  Special efforts should be made
to  promote education and skills training for disabled girls and women,
in both  urban and rural areas.<BR>
<BR>
29.  General teacher-training curricula should include a course of study
in  skills for teaching disabled children and young persons in regular 
schools.<BR>
<BR>
30.  Each Government should have a national plan for training and 
employing
an  adequate number of health, education and vocational professionals in
 rehabilitation.  Persons with disabilities should be recruited for such
 training and employment.<BR>
<BR>
31.  In fields such as education, labour, health and social services, 
law,
 architecture and technical development, which are often involved in the
 different aspects of rehabilitation, professional training should 
include
 training on the rights and needs of disabled people.  Professionals in
these  fields should also be made aware of the resources available for 
disabled
 persons so that appropriate referrals can be made or services 
provided.<BR>
<BR>
32.  Appropriate technology should be considered essential for the 
utilization
 of available resources.  This may include simple, universally available
 equipment, as well as computer technology.<BR>
<BR>
<BR>
E.  Promotion of employment<BR>
<BR>
33.  Disabled persons have the right to be trained for and to work on 
equal
 terms in the regular labour force.  Community-based rehabilitation 
programmes
 should be encouraged to provide better job opportunities in developing
 countries.  Use should be made of the vocational services, guidance and
 training, placement, employment and related services that already exist
for  workers in general.  On-the-job training may be more effective than
 conventional training.<BR>
<BR>
34.  General development programmes that provide loans, training and 
equipment
 for income-generating activities should include disabled persons.<BR>
<BR>
35.  Employment opportunities can be promoted, primarily, by measures 
relating
 to employment and salary standards that apply to all workers and, 
secondarily,
 by measures offering special support and incentives.  In addition to 
formal
 employment, opportunities should be broadened to include 
self-employment,
 co-operatives and other group income-generating schemes.  Where special
 national employment drives have been launched for youth and unemployed
 persons, disabled persons should be included.  Disabled persons should
be  actively recruited, and when a disabled candidate and a non-disabled
candidate  are equally qualified, the disabled candidate should be 
chosen.<BR>
<BR>
36.  Organizations of employers and of workers should adopt, in 
co-operation
 with organizations of disabled persons, policies that promote the 
training
and  employment of disabled persons, including women, and non-disabled 
persons
on  an equal basis.<BR>
<BR>
37.  Policies for affirmative action should be formulated and implemented

to  increase the employment of disabled women.  Governments and 
non-governmental
 organizations should support the creation of income-generating projects
 involving disabled women.<BR>
<BR>
<BR>
F.  Provisions for funding<BR>
<BR>
38.  In general, funding should be allocated through regular sectoral  
budgeting
systems.  A national rehabilitation fund may be established to  
facilitate
the employment or self-employment of disabled persons.  This fund  could
be used to cover the costs of training, equipment and initial capital  
outlay.<BR>
<BR>
39.  Similarly, funds should be established for loans to small-scale 
pilot
 projects at the grass-roots level; such funds could be administered 
locally
 with the use of simple procedures.<BR>
<BR>
<BR>
G.  Promotion of community awareness<BR>
<BR>
40.  To increase community understanding of the rights, needs and 
potentials
 of disabled persons, collaborative efforts with disabled persons and 
their
 organizations are required to develop and promote a flow of information
using  mass media, especially film, television, radio and print media. 
In  particular, information for disabled persons and their families on 
all
aspects  of living with a disability should be as clear and uncomplicated

as possible.<BR>
<BR>
41.  Community awareness programmes should include specific strategies 
for
the  prevention of disability.  Government efforts aimed at early 
identification,
 intervention and prevention should be strengthened through community 
awareness
 and community involvement in programmes on disability.<BR>
<BR>
42.  Persons with mental disabilities (mental retardation or mental 
illness)
 or multiple disabilities are among the most stigmatized groups of 
citizens.
 They have the right to make choices, take risks, control their own lives

and  live in the community.  Their adult status, abilities and 
aspirations
must be  respected and reinforced by their inclusion in decision-making,
although many  may need individual advocacy to be clearly understood.<BR>

<BR>
43.  It should be acknowledged that people with mental and multiple  
disabilities
benefit from education, skills training and work opportunities.  For many

of these people, opportunities need to be individualized.  Support is  
required
to help them and their families to establish and maintain a positive  
life-style.<BR>
<BR>
44.  The World Programme of Action should be translated into all national

 languages, through governmental action.  Braille, large print and 
simplified
 versions should also be made available by the appropriate media to 
ensure
as  wide a distribution as possible to all citizens, including disabled
persons,  their families, and non-governmental and governmental 
organizations.<BR>
<BR>
<BR>
H.  Improving the methodology for human resources development<BR>
<BR>
45.  Policies and programmes for human resources development concerning
 disabled persons should be based on an assessment of their needs and 
resources
 as well as on the potential of existing development programmes and 
services
to  meet those needs.  The implementation of such policies and programmes

should  be periodically monitored, with adjustments made to ensure 
effective
 implementation.<BR>
<BR>
46.  Evaluation should be built into programmes at the planning stage so
that  their overall efficacy in fulfilling policy objectives can be 
assessed.
 Persons with disabilities should play an active role in developing the
 criteria for monitoring and evaluation.<BR>
<BR>
47.  Increased attention should be given to services for people with 
hearing,
 speech, mental, intellectual or multiple disabilities.<BR>
<BR>
48.  The requirements of particular groups, such as disabled children, 
disabled women, the disabled elderly, disabled migrants and refugees, 
should
 also be recognized and met.<BR>
<BR>
49.  Governmental and non-governmental organizations should utilize 
recent
 developments in education through communications media, also known as 
distance
 education, which has been found to be an appropriate methodology in 
human
 resources development in the field of disability.<BR>
<BR>
50.  The local use of appropriate technologies for producing such items
as  wheel chairs, prosthetic devices and mobility aids, as well as aids
for  hearing and seeing, should take into account the technical, 
socio-economic
and  cultural conditions in the particular society.  Each country should
have a  national system for the delivery of rehabilitation aids.<BR>
<BR>
 <BR>
I.  Regional and international co-operation<BR>
<BR>
51.  Training programmes in human resources development in the field of
 disability should be strengthened by collaborative efforts at the 
regional
 and/or subregional levels.  Such programmes should be co-ordinated 
through
 existing intergovernmental and regional organizations, including those
of  disabled persons.<BR>
<BR>
52.  International development aid projects should include a component 
specifically aimed at supporting organizations of disabled persons and 
training their members.  In addition, employment opportunities should be
made  available to disabled individuals within these projects.<BR>
<BR>
53.  All international development assistance programmes directed at  
macro-level
planning and development, such as those in agriculture or  education, 
should
include a specific component ensuring the participation of  disabled 
persons
in such programmes.<BR>
<BR>
54.  At both the national and interregional levels, Governments should 
strongly support collaboration with non-governmental agencies in specific

 areas of disability, to ensure co-ordination and to prevent duplication
of  services.<BR>
<BR>
55.  Linkages between organizations of disabled persons in developed and
 developing countries should be strengthened.  This can be done through
the  exchange of information, training and meetings to provide forums for

disabled  persons to share experiences on strategic approaches.  
Workshops
and field  studies should be organized to train trainers and the 
management
personnel of  organizations of disabled persons.<BR>
<BR>
56.  Implementation of these Guidelines relies on effective action at the

 national level.  This action should be supplemented by concerted efforts

at  the international level, particularly on the part of the United 
Nations
and  its focal point for the implementation of the World Programme of 
Action
 concerning Disabled Persons, as well as relevant United Nations 
organizations
 and specialized agencies.  National and international non-governmental
 organizations, in particular organizations of disabled persons, should
be  fully involved.
<P><CENTER><HR><FONT SIZE=2>[<A HREF="Contents.html">Institute on 
Independent
Living contents</A>]</FONT></CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-222</DOCNO>
<DOCOLDNO>IA012-000125-B023-93</DOCOLDNO>
<DOCHDR>
http://www.independentliving.org:80/DenounceKevorkian.html 193.13.228.238 19970216215011 text/html 7079
HTTP/1.0 200 OK
Last-Modified: Sun, 06 Oct 1996 19:26:34 +0000
Date: Sun, 16 Feb 1997 21:50:23 +0000
Expires: Sun, 16 Feb 1997 21:48:43 +0000
Content-type: text/html
Server: RoxenEnterprise/1.0
Content-length: 6854
</DOCHDR>
<HTML>
<HEAD>
    <TITLE>Institute_on_Independent_Living</TITLE>
</HEAD>
<BODY TEXT="#020a3f" BGCOLOR="#ffffff" LINK="#000042">
<META NAME="description" CONTENT="Individuals and organizations of 
persons with disabilities can 
publish, free of charge,  articles, reports, training manuals, 
announcements, etc. on Independent Living, personal assistance, advocacy, 

peer support, accessibility, legislation and related subjects. "><META 
NAME="keywords" CONTENT="Independent Living, personal assistance, 
advocacy, peer support, direct payments, anti-discrimination legislation, 

accessibility, disability, disability rights"><BR>
<IMG SRC="InstLogoSmall.gif" WIDTH="198" HEIGHT="57" ALIGN="BOTTOM" 
NATURALSIZEFLAG=
"3"> <BR>
<BR>
<BR>
September 8 1996<BR>
From: PAUL KENNETH LONGMORE<BR>
It is long past time for the disability community to respond to Jack 
Kevorkian's
lethal assaults on our people. Please forward or circulate the statement,

and urge other members of our community to endorse it.<BR>
<P><CENTER><HR></CENTER>
<P>Paul K. Longmore<BR>
<BR>
DISABILITY COMMUNITY LEADERS DENOUNCE JACK KEVORKIAN<BR>
<BR>
Yesterday Jack Kevorkian assisted the suicide of a disabled woman. At 
least
half of the people whose suicides he has abetted have been disabled. As
leaders in the disability community, we are outraged that Michigan 
authorities
allow his killing spree to go on. We are incensed that his repeated 
declarations
of contempt for the lives of our people have been ignored.<BR>
<BR>
Kevorkian has advocated assisted suicide for disabled people all along.
A March 1990 Detroit Free Press Magazine story announced: &quot;Oppressed

by a fatal disease, a severe handicap, a crippling deformity? ....Show 
him
proper, compelling medical evidence that you should die, and Dr. Jack 
Kevorkian
will help you kill yourself, free of charge.&quot; In a February 1992 
medical
journal article, he proposed euthanasia centers, not only for 
terminally-ill
persons, but for those with chronic conditions too.<BR>
<BR>
He also advocates an &quot;auction market for available organs&quot; to
be removed from &quot;subjects&quot; &quot;hopelessly crippled by 
arthritis
or malformations.&quot; The proceeds from sale of euthanized disabled 
persons'
organs could partly go to family members whose financial burdens would be

relieved and &quot;their standard of living enhanced.&quot;<BR>
<BR>
Kevorkian not only views disabled people as having worthless and 
burdensome
lives, he sees us as a drain on society. He told a Michigan Court in 
August
1990: &quot;The voluntary self-elimination of individual and (sic) 
mortally
diseased and crippled lives taken collectively can only enhance the 
preservation
of public health and welfare.&quot;<BR>
<BR>
Though Kevorkian claims to support individual autonomy, he would give 
doctors
power to decide that people with disabilities would be better off dead.
Time Magazine asked him, &quot;How do you decide whom to help? Does the
patient have to suffer from a life-threatening illness?&quot; &quot;No,
of course not,&quot; replied Kevorkian. &quot;And it doesn't have to be
painful, as with quadriplegia. But your life quality has to be nil.&quot;

&quot;And who decides that?&quot; asked Time. &quot;That's up to 
physicians,&quot;
said Kevorkian, &quot;and nobody can gainsay what doctors say. It all 
boils
down to the integrity of the doctors.&quot; Many people with disabilities

have had doctors dismiss their &quot;quality of life&quot; as 
&quot;nil&quot;
and recommend withholding medical treatment to cause their deaths. 
Kevorkian's
plan presents an even more serious threat to disabled people.<BR>
<BR>
Disabled people who opt for suicide often do not to receive appropriate
psychological evaluation or crisis intervention. There is an automatic 
assumption
that they want to die because of their disabilities and that this is a 
rational
choice. Other factors in their situation are ignored.<BR>
<BR>
David Rivlin, quadriplegic from a spinal-cord injury and breathing on a
ventilator, &quot;chose&quot; to die. He attended Oakland University, in
Michigan, aiming to become a psychologist or a college teacher. And he 
struggled
to live in his own apartment. But &quot;independent living&quot; proved
impossible because the state of Michigan granted him less than $300 a 
month
to hire aides. Unable to afford adequate help, he kept getting sick and
having to enter nursing homes. The state paid the nursing homes $230 a 
day.<BR>
<BR>
At first, Rivlin clung to the hope he might escape the nursing home. 
After
three years, he concluded he would never get out and decided he would 
rather
be dead. So he got a court order authorizing a doctor to sedate him and
disconnect his ventilator.<BR>
<BR>
Days before Rivlin died, a reporter asked him what he thought about 
society's
view of disabled people. &quot;It sucks,&quot; said Rivlin. 
&quot;Transportation,
attitudes, financial help, it's all bad.&quot;<BR>
<BR>
Jack Kevorkian visited David Rivlin, later describing him as &quot;having

to be turned and fed and everything done for him. Highly intelligent man,

who had decided that his life now had no meaning and no need to go 
on....After
that case, I knew we had to have a device to help people like Mr. Rivlin,

and that's when I started making it&quot; -- his notorious suicide 
machine.<BR>
<BR>
Jack Kevorkian viewed David Rivlin through the prism of ignorance and 
prejudice.
He disregarded the social factors that cause some people with 
disabilities
to decide that their lives have &quot;no meaning&quot; and are 
unendurable:
public policies that force them into nursing homes, inadequate medical 
and
particularly pain-management treatment, denial of appropriate 
psychological
supports, discrimination in obtaining health insurance, resulting 
financial
distress, the attitude that they burden their families and society, and
the deep prejudice that their lives are worthless.<BR>
<BR>
We urge public attention to the real reasons some people with 
disabilities
choose suicide. We call upon the news media to report Kevorkian's 
bigotted
opinions of disabled people. We demand that Michigan authorities stop him

from abetting the suicides of people with disabilities.<BR>
<BR>
Jack Kevorkian is no folk hero. He is a contemptible enemy of people with

disabilities, and we denounce him. <BR>
<P><CENTER><HR></CENTER>
<P>Dr. Paul Longmore is a professor of history at San Franscisco State 
University,
and he himself has had an extensive physical disability for many years.
Dr. Longmore is authoring a book of historical research about the history

of people with disabilities. <BR>
<BR>
His e-mail address is <A 
HREF="mailto:longmore@sfsu.edu">longmore@sfsu.edu</A>
<BR>
<P><CENTER><HR><FONT SIZE="2">[<A 
HREF="Contents.html">Contents</A>]</FONT></CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-223</DOCNO>
<DOCOLDNO>IA012-000125-B023-142</DOCOLDNO>
<DOCHDR>
http://www.independentliving.org:80/BehinderunginSchweden.html 193.13.228.238 19970216215031 text/html 13994
HTTP/1.0 200 OK
Last-Modified: Sun, 29 Sep 1996 08:29:04 +0000
Date: Sun, 16 Feb 1997 21:50:42 +0000
Expires: Sun, 16 Feb 1997 21:49:02 +0000
Content-type: text/html
Server: RoxenEnterprise/1.0
Content-length: 13768
</DOCHDR>
<HTML>
<HEAD>
    <TITLE>Institute_on_Independent_Living</TITLE>
</HEAD>
<BODY BGCOLOR="#ffffff" TEXT="#020436" LINK="#000042">
<META NAME="description" 
CONTENT="Individuals and organizations of persons with disabilities can 
publish, free of charge,  articles, reports, training manuals, 
announcements, etc. on Independent Living, personal assistance, advocacy, 

peer support, accessibility, legislation and related subjects. "><META 
NAME="keywords" CONTENT="Independent Living, personal assistance, 
advocacy, peer support, direct payments, anti-discrimination legislation, 

accessibility, disability, disability rights"><BR>
<IMG SRC="InstLogoSmall.gif" WIDTH="198" HEIGHT="57" ALIGN="BOTTOM" 
NATURALSIZEFLAG=
"3"><BR>
<BR>
<H3><CENTER>Betreuung oder Selbstbestimmung:<BR>
Zur Lage von Menschen mit Behinderungen in Schweden<BR>
<BR>
Adolf D. Ratzka</CENTER>
</H3>
<BR>
Schweden mit seinen 8,5 Millionen Einwohnern erfreut sich des Rufs eines
fortschrittlichen Sozialstaats, in dem Menschen mit Behinderungen unter
besseren Lebensbedingungen als in den meisten anderen L&auml;ndern leben.

Zu diesem Ruf hat die g&uuml;nstige wirtschaftliche Entwicklung des 
Landes
w&auml;hrend und nach dem Kriege sowie die Reformpolitik der schwedischen

Sozialdemokraten beigetragen, die das Land mit nur kurzen Unterbrechungen

seit den 30-er Jahren regieren. Im Zuge dieser Reformen wurden die 
materiellen
Lebensbedingungen von alten und behinderten Menschen angehoben, so 
da&szlig;
Schweden in der Welt - und vor allem im Lande selbst - als Vorbild auf 
diesem
Gebiet gilt. <BR>
<BR>
So ist z.B. Schweden eines der wenigen L&auml;nder mit 
behindertengerechten
Bauvorschriften. Seit 1966 m&uuml;ssen alle neugebauten 
Arbeitspl&auml;tze
und &ouml;ffentlichen Geb&auml;ude behindertengerecht gebaut werden. Seit

1977 gelten diese Vorschriften auch f&uuml;r den Wohnungsbau. Alle 
neugebauten
Wohnungen in Mehrfamilienh&auml;user mit drei oder mehreren Stockwerken
m&uuml;ssen &uuml;ber Aufz&uuml;ge errecihbar sein und von 
Rollstuhlfahrern
bewohnt werden k&ouml;nnen. Die Kosten f&uuml;r individuelle Anpassungen,

wie automatische T&uuml;r&ouml;ffner, heb- und senkbare 
K&uuml;cheneinrichtungen
werden durch einkommensunabh&auml;ngige Zusch&uuml;sse &uuml;bernommen.
Wegen der geringen Neubaut&auml;tigkeit der letzten Jahre, der mangelnden

Kontrolle und milden Sanktionen sowie den schwachen Bauvorschriften 
f&uuml;r
behindertengerechte Altbausanierung sind jedoch in Stockholm z.B. immer
noch etwa 95 % des Wohnungsbestandes nicht rollstuhlgerecht. <BR>
<BR>
Die Entwicklung von gemeindenahen L&ouml;sungen f&uuml;r alte und 
behinderte
Menschen anstelle von Heimunterbringung und anderen Einrichtungen ist in
Schweden leichter zu vollziehen sein als in vielen anderen L&auml;ndern,
einmal wegen des h&ouml;heren Anteils an behindertengerechten Wohnungen
und zum zweiten wegen des besser ausgebauten Netzes von ambulanten 
Diensten.
In gr&ouml;&szlig;eren Gemeinden bestehen rund um die Uhr-Dienste, die es

vielen &auml;lteren und behinderten Menschen erm&ouml;glichen, in ihrer
eigenen Wohnung anstatt in einem Altenheim oder anderen Einrichtung zu 
leben.
<BR>
<BR>
Der Integrierung von behinderten Sch&uuml;lern wird gro&szlig;es Gewicht
beigemessen und durch Ma&szlig;nahmen wie behindertengrechten Neubau 
aller
Schulen und Kinderg&auml;rten sowie der Bereitstellung von 
pers&ouml;nlichen
Assistenten f&uuml;r behinderte Sch&uuml;ler realisiert. Die meisten 
Sch&uuml;ler
mit Behinderungen gehen in die Regelschule. Der Rest besucht 
Spezialklassen
innerhalb der Regelschule. Bei vielen h&ouml;heren Schulen fehlen jedoch
die Voraussetzungen zur Integration von Sch&uuml;lern mit umfassenden 
Behinderungen.
Es gibt einige Regelgymnasien mit angeschlossenem Internat, wo behinderte

Sch&uuml;ler aus ganz Schweden untergebracht werden.<BR>
<BR>
Ein Gro&szlig;teil der materiellen Verbesserungen geht auf die 
schwedischen
Behindertenverb&auml;nden zur&uuml;ck, die in enger Verbindung mit der 
sozialdemokratischen
Partei ihre Interessen politisch umzusetzen wu&szlig;ten.  Die 
schwedischen
Verb&auml;nde sind auf Grund ihrer relativ guten wirtschaftlichen Lage 
und
langj&auml;hrigen politischen Erfahrungen stark an internationalen Fragen

interessiert, waren z. B. ma&szlig;gebend an der Gr&uuml;ndung von 
Disabled
Peoples International, dem internationalen Dachverband aller 
Behindertenorganisationen,
im internationalen Jahr der Behinderten 1981 beteiligt und verf&uuml;gen
&uuml;ber eine eigene Stiftung, die mit finanzieller Hilfe des 
staatlichen
schwedischen Entwicklungsdienstes den Aufbau von 
Behindertenorganisationen
in der Dritten Welt f&ouml;rdert. <BR>
<BR>
Die neueste Errungenschaft des schwed Wohlfahrtsstaats ist die 
Assistanzreform.
Menschen unter 65 Jahren, deren Abh&auml;ngigkeit von praktischen Hilfen
im Alltag auf 20 Wochenstunden oder mehr eingestuft wurde, erhalten von
der staatlichen Sozialversicherung monatliche Betr&auml;ge, die es ihnen
erm&ouml;glicht, ihre Assistenzdienste von Gemeinde oder privaten Firmen
zu kaufen oder selbst zu organisieren, entweder in einer Genossenschaft
oder als einzelner Arbeitgeber. Die staatliche Sozialversicherung wird 
vom
Steueraufkommen finanziert und ihre Leistungen sind 
einkommensunabh&auml;ngig.
Die Zahlungen decken die vollen Lohn- und Lohnnebenkosten sowie die 
Verwaltungskosten
von Dienstanbieter und Nutzer (etwa die Kosten des begleitenden 
Assistenten
auf Reisen). Verwendung der Mittel mu&szlig; nachgewiesen werden. Das 
Gesetz
wurde stark von der schwedischen Independent Living Bewegung 
gepr&auml;gt.
Bei der Parlamentsdebatte zur Abstimmung &uuml;ber das Gesetz 
erw&auml;hnte
der Socialminister die Pionierrolle von STIL, der Stockholmer 
Genossenschaft
f&uuml;r Independent Living, deren politischer Kampf um selbstbestimmte
pers&ouml;nliche Assistenz ausschlaggebend an der Entstehung der Reform
beteiligt war und deren praktische Arbeit mit selbstverwalteter Assistenz

als Modell f&uuml;r das Gesetz und seinen Auf&uuml;hrungsbestimmungen 
diente.
Da&szlig; die Reform von der Independent Living Bewegung entscheidend 
beeinflu&szlig;t
war, zeigt schon der Name des Gesetzes, &quot;Assistenzreform&quot;. Im
Gegensatz zum herk&ouml;mmlichen Begriff &quot;Pflege&quot;, der uns als
Objekt entm&uuml;digt, pr&auml;gte die schwedische Independent Living 
Bewegung
den Ausdruxk &quot;pers&ouml;nliche Assistenz&quot;, der uns die Rolle 
des
Chefs zuweist.<BR>
<BR>
(Warum die deutsche Selbstbestimmt Leben Bewegung immer noch nicht das 
Wort
&quot;Pflege&quot;, wie in &quot;Pflegeversicherung&quot;, 
&quot;Pflegeabh&auml;ngige&quot;
etc., zur&uuml;ckgewiesen hat, liegt m E an der geringen Selbstbestimmung

der wirklichen Assistenzben&uuml;tzer in der BRD  -  die Mehrzahl der 
nationalen
Vork&auml;mpfer auf diesem Gebiet scheint recht gut ohne t&auml;gliche 
Assistenz
auszukommen. Vielleicht l&auml;&szlig;t sich auch damit der etwas 
schwache
Einflu&szlig; der Selbstbestimmt Leben Bewegung auf die sog 
&quot;Pflegeversicherung&quot;
erkl&auml;ren. Jemand, der ohne fremde Hilfe auf die Toilette oder aus 
dem
Bett kommt, kann zu diesem Thema nur schlecht als Expert in eigener Sache

auftreten. Selbstbestimmung dagegen gibt Durchschlagskraft. In Schweden
verkn&uuml;pft man inzwischen &quot;Independent Living&quot; fast 
ausschlie&szlig;lich
mit pers&ouml;nlicher Assistenz.)<BR>
<BR>
Ich bekomme manchmal Post von Leuten, die nach Schweden auswandern 
wollen.
Bevor jetzt jemand sich etwas &Auml;hnliches &uuml;berlegt, bitte erst 
den
Artikel zu ende lesen!<BR>
<BR>
Nach den expansiven, reformfreundlichen 60er und 70er Jahren haben 
Menschen
mit Behinderungen in Schweden f&uuml;r die n&auml;chste Zukunft keine 
nennenswerten
materiellen Verbesserungen zu erwarten. Im Gegenteil: In einer Zeit 
abnehmendem
Wirtschaftswachstums, der Steuerm&uuml;digkeit, &Uuml;berw&auml;lzung der

Sozialleistungen vom Staat auf die Gemeinden und Abbr&ouml;ckeln des 
Sozialstaats
an allen Ecken und Kanten im Zuge der Anpassungen an die bevorstehende 
Europ&auml;ische
W&auml;hrungsunion schneiden Menschen mit Behinderungen in Schweden in 
Bereichen
wie Ausbildung, Berufschancen, Einkommen, Wohnverh&auml;ltnissen, 
sozialen
Kontakten als Gruppe schlechter als ihre nichtbehinderten Mitb&uuml;rger
ab, wie aus offiziellen schwedischen Statistiken hervorgeht. So war es 
schon
immer. Nur, die Kluft zwischen Menschen mit Behinderungen und der 
&uuml;brigen
Bev&ouml;lkerung ist im Zunehmen.<BR>
Auf dem Arbeitsmarkt werden Menschen mit Behinderungen systematisch 
diskriminiert.
Nur 38% der K&ouml;rperbehinderten im Alter von 16-64 Jahren sind 
erwerbst&auml;tig.
In der gleichen Altersgruppe in der Gesamtbev&ouml;lkerung sind 78% 
besch&auml;ftigt.
J&auml;hrlich werden rund 2&nbsp;000 Jugendliche direkt nach 
Schulabschlu&szlig;
zu Fr&uuml;hrentnern bef&ouml;rdert.  &Ouml;ffentliche Bem&uuml;hungen,
die Arbeitsmarktslage von Menschen mit Behinderungen zu verbessern, 
bestehen
aus Arbeitsplatzbeschaffungsma&szlig;nahmen, Zusch&uuml;ssen zur 
Anpassung
von Arbeitspl&auml;tzen und Bereitstellung von pers&ouml;nlichen 
Assistenten.<BR>
<BR>
Die Einf&uuml;hrung einer Anti-diskriminierungsgesetzgebung ist kein 
ernsthaftes
Thema. Diskutiert wird z.Z. allenfalls ein solches Gesetz f&uuml;r den 
Arbeitsmarkt
in Anlehnung eines Gesetzes zum Schutze von Einwanderern, das es seit 8
Jahren gibt. In den bisher insgesamt 150 behandelten F&auml;llen wurde 
jedoch
noch kein einziger diskriminierender Arbeitgeber verurteilt: Die 
Beweisf&uuml;hrung
w&uuml;rde verlangen, da&szlig; der Arbeitgeber offen zugibt, er habe den

betreffenden Bewerber ausschlie&szlig;lich wegen seiner 
ausl&auml;ndischen
Herkunft nicht eingestellt. Ein &auml;hnliches Schicksal ist f&uuml;r das

Gesetz gegen Diskriminierung am Arbeitsplatz von Menschen mit 
Behinderungen
zu erwarten.<BR>
 <BR>
Dem Grundgesetz nach darf man Menschen mit Behinderungen benachteiligen.
Dort steht n&auml;mlich nichts Gegenteiliges. Laila Freiwald, 
Justizministerin,
wurde in der Presse zitiert, sie habe Verst&auml;ndnis f&uuml;r den 
Restaurantbetreiber,
der einer Gruppe von Menschen mit intellektuellen Behinderungen 
k&uuml;rzlich
den Zutritt verweigerte. Die gro&szlig;en Behindertenverb&auml;nde sind
nur widerstrebend an einer Diskussion &uuml;ber 
Anti-Diskrimireungsgesetze
interessiert. Die Ursache daf&uuml;r liegt wohl z.T. darin, da&szlig; 
viele
Funktion&auml;re nicht selbst behindert sind, da&szlig; gut die 
H&auml;lfte
aller Mitglieder in den gro&szlig;en Verb&auml;nden volles Stimmrecht 
aber
keine Behinderungen haben. Die wichtigste Ursache d&uuml;rfte jedoch 
darin
bestehen, da&szlig; sich so wenige Menschen mit Behinderungen 
benachteiligt
f&uuml;hlen. Laut einer Umfrage f&uuml;hlen sich zwar 35% von 
j&uuml;ngeren
Menschen mit Behinderungen diskriminiert aber nur 17% der &uuml;ber 
50-J&auml;hrigen.
Die meisten Vereinsmitglieder aber sind &uuml;ber 50. <BR>
<BR>
Die skandinavische Tradition h&auml;lt nichts von Sondergesetzen, denn 
deren
Existenz an sich - so argumentiert man h&auml;ufig -  w&uuml;rde 
diskrimierend,
ausgliedernd und stigmatisierend wirken. Aber die krasse Wirklichkeit 
bezeugt,
da&szlig; diese edle Philosophie unsere B&uuml;gerrechte bisher nicht 
garantieren
konnte. Verglichen mit den USA, wo ADA ein solches Sondergesetz 
darstellt,
ist unsere Bewegungsfreiheit bedeutend mehr eingeschr&auml;nkt. Solche 
Vergleiche
sollte man &uuml;brigens in Schweden tunlichst nur im engen Freundeskreis

&auml;u&szlig;ern, denn das sozialdemokratisch gesteuerte Land ist 
empfindlich
stolz auf seine sozialen Errungenschaften. <BR>
<BR>
Behindertenfragen sind nach wie vor humanit&auml;re und soziale Fragen.
Mit Begriffen wie &quot;B&uuml;rgerechte&quot; macht man sich nur als 
politisch
Rechtau&szlig;en verd&auml;chtigt. F&uuml;r B&uuml;rgerrechte arbeitet 
man
im Ausland, in Schweden sollte so etwas nicht n&ouml;tig sein, lautet 
ungef&auml;hr
die Logik. Menschen mit Behinderungen rechnet man zu den schwachen 
Gruppen
in der Gesellschaft, wie Kinder, Alte, Einwanderer oder Alkoholiker, die
der besonderen Obhut des Staates empfohlen werden und den Sonderstatus 
(und
damit auch das soziale Stigma) der F&uuml;rsorgebed&uuml;rftigkeit 
besitzen.
Damit wird der Weg zu ausgliedernden Sonderl&ouml;sungen (wie Fahrdienste

statt behindertengerechten Nahverkehr) und Bevormundung ge&ouml;ffnet. 
<BR>
<BR>
Es ist schwer, ein faires Bild von Schweden zu vermitteln. Zum einem 
exportiert
man hier gerne den Mythos vom Musterl&auml;ndle mit dem 
menschenfreundlichen
Wohlfahrtsstaat. Zum anderen liegt &uuml;berall, in allen L&auml;ndern,
 die Versuchung nahe, auf ein anderes Land zu zeigen und zu behaupten, 
da&szlig;
was dort m&ouml;glich sei auch im eigenen Land eingef&uuml;hrt werden 
m&uuml;sse.
Oft mu&szlig; da Schweden herhalten. Dabei verl&auml;&szlig;t man sich 
nur
allzu gerne auf's H&ouml;rensagen ohne die Informationsquellen genauer zu

kontrollieren. <BR>
<BR>
Also bitte nicht mit der Hoffnung nach Schweden kommen, sich hier mit 
fetten
&ouml;ffentlichen Geldern in den Ruhestand zur&uuml;ckziehen zu 
k&ouml;nnen.
Diese Gelder wird es wohl auch nicht mehr lange geben bei diesem 
internationalem
Wettbewerb um die schnellste Abmagerung der Sozialleistungen. 
Au&szlig;erdem
gibt es hier schon zu viele schwedische Behinderte mit dieser 
Versorgungsmentalit&auml;t.
Was wir hier br&auml;uchten, sind r&uuml;de Raudaubr&uuml;der und 
-schwestern,
die sich nicht versorgen, bevormunden und betreuen lassen, sondern ihre
B&uuml;rgerrechte fordern.<BR>
<BR>
Adolf Ratzka<BR>
September 1996
<P><CENTER><HR><FONT SIZE=2>[<A HREF="Contents.html">Institute on 
Independent
Living contents</A>]</FONT></CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-224</DOCNO>
<DOCOLDNO>IA012-000125-B023-176</DOCOLDNO>
<DOCHDR>
http://www.independentliving.org:80/ENIL/ENILDirectPayment.html 193.13.228.238 19970216215044 text/html 18446
HTTP/1.0 200 OK
Last-Modified: Wed, 31 Jul 1996 21:00:19 +0000
Date: Sun, 16 Feb 1997 21:50:58 +0000
Expires: Sun, 16 Feb 1997 21:49:18 +0000
Content-type: text/html
Server: RoxenEnterprise/1.0
Content-length: 18220
</DOCHDR>
<HTML>
<HEAD>
    <TITLE></TITLE>
</HEAD>
<BODY TEXT="#020136" BGCOLOR="#ffffff" LINK="#00007f">
<IMG SRC="ENILlogoblues.gif" WIDTH="311" HEIGHT="61" ALIGN="BOTTOM" 
NATURALSIZEFLAG="3"><BR>
<BR>
<BR>
<H2>Direct Payments Campaign in the U.K.</H2>
<H4>Presentation for the ENIL Seminar in Stockholm, June 9-11, 1996<BR>
<BR>
<BR>
<BR>
Introduction</H4>
The Direct Payments campaign in the UK was started in 1989 by the BCODP
IL Committee as one of its primary objectives. BCODP (British Council of
Disabled People) the national, democratic, representative organisation of

disabled people in the UK. BCODPs Independent Living committee was formed

as a result of the founding of ENIL (European Network on Independent 
Living)
in Strasbourg in 1989 so that it could advise, develop, monitor, campaign

and co-ordinate IL activities and developments in the UK and also feed 
into
the European scene through ENIL. The Direct Payments campaign was 
initiated
in order to change the legislation to make it easier for local 
authorities
to establish Direct Payment-schemes. 
<H4>Direct Payment Schemes and the Legislation</H4>
The original Independent Living schemes were first set up in the UK in 
the
early 1980s. Throughout the 1980s they developed slowly but they were 
still
few in number and only operated in a limited amount of areas in the 
country.
Most authorities were not keen to take on Independent Living schemes 
because
they either considered them too risky or were wary of handing over all 
the
control to disabled people. Direct Payment schemes represented for the 
first
time a shift of power to disabled people. Most authorities who ran the 
schemes
either did it because it was a new idea and way of providing services, or

had empathy with the Independent Living philosophy in terms of giving 
more
choice and control in a disabled person's life. Other factors which 
restricted
the growth and development of Independent Living schemes was the dubious
and varying interpretation of the appropriate legislation.<BR>
<BR>
After Hampshire had been running Independent Living schemes for three and

a half years, the authorities suddenly reviewed the situation when the 
county
solicitor and treasurer became aware of the uncertainty of the 
legislation
and were poised to stop the schemes. Fortunately, at the same time a 
report
came out from the Audit Commission, which is an independent organisation
that monitors the performance of local authorities. The report 
highlighted
the Independent Living schemes in Hampshire as being innovative and good
community care practice. This proved to be the saving grace, and on 
hearing
this the county solicitor and treasurer then changed their judgement and
the schemes were saved and allowed to continue.<BR>
<BR>
The reason for the confusion and the different interpretation of the 
legislation
was because of a 1948 Social Security Act about Social Services 
provision.
In this act it states that a local authority can only provide services 
and
cannot provide cash payments, hence the stumbling block in the law. Even
though Hampshire changed its mind there are still authorities who will 
not
go ahead with Independent Living schemes which they regard as illegal. 
The
situation was made worse in 1992 when the then current Minister of 
Health,
Virginia Bottomley, sent out a circular to local authorities stating that

Direct Payment schemes were illegal. This exasperated the situation, and
even authorities who had been running schemes up until then withdrew 
them.
This is why the Direct Payments Campaign is so important so it can change

the legislation and clarify everything in black and white. The way local
authorities got around this was by paying the money into a third party 
i.e..
a disability or voluntary organisation for instance, and then they would
pass the money onto the disabled individual. It was a kind of loophole in

the law. 
<H4>Direct Payments Campaign and Lobbying</H4>
The Independent Living movement believes that Direct Payment schemes 
should
be as of right and that is why a change in the legislation is probably 
the
second most important priority in the issues of disabled people after 
comprehensive
civil rights legislation. In the early 1990s when BCODP IL group embarked

on its Direct Payments campaign, it got together with the Spinal Injuries

Association and its parliamentary officer Fidelity Simpson who was an 
expert
in lobbying tactics and parliamentary affairs. This group then drew up a
tactical strategy for bringing about Direct Payments legislation. Key 
disabled
people from both these organisations with direct experience of running 
their
own schemes worked together with Fidelity targeting possible key allies
of Members of Parliament and politicians who would support and fight our
cause. Many letters were written to local and national politicians 
seeking
support. Numerous awareness raising and briefing meetings were arranged
and relevant publicity drawn up to disseminate information in order to 
make
the issue public and clear, together with articles in both the mainstream

and disability press. 
<H4>Lobbying and the Private Members Bill</H4>
Not long after the campaign started, the group found a very keen and 
influential
care and supporter. He was Andrew Rowe, a conservative MP. He fully 
understood
what we were trying to achieve as he had first hand experience with one
of his constituents, a disabled woman who was running her own Independent

Living scheme and at the same time running her own business. This left a
deep impression on Andrew Rowe who then decided to put together a Private

Members Bill on Direct Payments Legislation. In British politics, a 
Private
Members Bill is another way of attaining legislation that is not part of
the Government's proposed agenda. It is a difficult way of achieving 
success
but over the years many innovative pieces of legislation have used this
parliamentary procedure to achieve their results. It is long and arduous
and prone to many pitfalls and political manoeuvring, especially if the
government does not support it.<BR>
<BR>
Anyway, Andrew Rowe attempted this approach twice in three years and both

attempts failed. During this time when Andrew Rowe was trying to progress

his Direct Payments Bill, the campaign group organised a number of 
meetings
with key politicians to try and influence them about the issue. These 
included
the then current Minister of Health, and the Minister for disabled 
people.
Both of these politicians expressed how much they appreciated Independent

Living schemes, but neither were prepared to take serious action and 
publicly
support them. Our understanding of the situation then was that the 
treasury
department was not in support of this kind of legislation because of the
economic argument of it costing too much. These developments exasperated
the campaign group and the Independent Living movement; the BCODP 
Independent
Living Committee then felt another course of action was needed to promote

the Direct Payments campaign and develop its strategy.<BR>
<BR>
However, all was not lost during this period as we were able to gain a 
lot
of support from a number of important national statutory organisations,
in particular the ADSS (Association of Directors of Social Services) who
passed a motion at their annual conference, supporting the need for 
Direct
Payments legislation. 
<H4>The Way Forward Through Direct Payments Research</H4>
After the failure of Andrew Rowe's Private Members Bill and the tactic of

trying to influence prominent politicians, BCODP felt that the best way
forward now would be to commission a piece of social policy research to
come up with some good evidence about the cost implications and 
effectiveness
of Direct Payment schemes and how they improved user satisfaction and 
quality
of life. BCODP drew up a workable proposal to carry out this research and

was then awarded a grant from the Rowntree Foundation to do this. The 
next
step was to contract the Policy Studies Institute who are a very notable
and influential research unit to do the work for us. We felt that by 
using
the PSI the research would have an impact on politicians and other 
important
policy makers because the PSI was highly regarded for its social research

and independence. Frances Hasler will now highlight the main features and

findings of the research. 
<H4>Direct Payments Research</H4>
Our research compared disabled people using services with disabled people

using direct payments to employ their own personal assistance. It looked
at the quality of support, at costs, and at user satisfaction.<BR>
<BR>
It found that direct payments offer disabled people a higher degree of 
choice
and control, and were more reliable than service provision. Service users

reported much higher levels of unmet need than payment users. They were
four times more likely to have difficulty in obtaining back-up for 
regular
support than payment users. They were less likely to have assistance 
delivered
in the manner they wanted. These findings are probably not news to most
people in the Independent Living movement, but it was useful to have them

documented by an independent research agency.<BR>
<BR>
On costs, our research found that support financed by direct payments was

on average between 30 to 40 percent cheaper than equivalent service based

support. At the time of the research the average hourly cost for direct
payments users was &#163;5.18; for service users it was &#163;8.52. There

was a marked difference in overhead costs - services had between 20 to 30

percent overheads, payments 5 to 15 percent.<BR>
<BR>
The research also found that people receiving direct payments had 
markedly
higher levels of overall satisfaction with their support arrangements 
than
service users. This was mainly due to the increased choice, control and
reliability offered by direct payments. Like other studies, it found that

the highest level of user satisfaction existed where users had advice 
from
an organisation of disabled people.<BR>
<BR>
Our research was the first study to combine the issues of cost and 
quality.
It showed that on both counts direct payments are preferable, both 
cheaper
and better. Information from our research was used by our allies in 
persuading
the politicians to bring in direct payments. (We could not always get 
direct
access to the Minister, but we had strong allies in the House of Commons
and among Directors of Social Services who pressed our case.) 
<H4>Official Announcement</H4>
Interestingly enough, a week before the BCODP/PSI launch of the Direct 
Payment
research findings, called &quot;Cashing in on Independence&quot;, the 
Minister
of Health announced that it was the Government's intention to bring about

Direct Payments legislation in the next parliamentary year. We were 
ecstatic!
After five years of campaigning vigorously, we had achieved the beginning

of our main goal. We were more than pleased that the research and the 
lobbying
had the impact that we were hoping for. This announcement led to an 
intense
flurry of activity around the whole issue of Direct Payments and a 
proliferation
of seminars and conferences were organised by both policy makers and the
Independent Living movement. Also, numerous research projects on 
Independent
Living issues were instigated. At one of these conferences organised by
the SSI, the Social Services Inspectorate, a number of Independent Living

advocates met up with some key civil servants, who had been delegated the

task by the Department of Health to research and work on implementing the

Direct Payments change. From now on they were crucial in our 
deliberations
and strategies. 
<H4>Technical Advisory Group (TAG)</H4>
The Government then set up the Technical Advisory Group to work on the 
research
and implementation of the Direct Payments legislation. This group then 
invited
participants from a number of professional, statutory, voluntary and 
disability
organisations. Because of its expertise in this area, BCODP was one of 
three
disability organisations invited onto the group. Jane Campbell, the 
representative
from BCODP, was the only Personal Assistance user who had been running 
her
own Direct Payment scheme that was on the TAG. The TAG group started in
June 1995 and since then has been looking at the key issues and drawing
up guidance for the appropriate civil servants and Government Ministers.
It was later partially responsible for drawing up the Government's 
consultation
document on Direct Payments which was distributed out for comment. 
<H4>Present Situation</H4>
Since the Direct Payments Bill was announced in the Queen's speech (which

is the Government's annual statement of what they intend to legislate for

the next parliamentary year) last November, there has been a tremendous
amount of activity on the political scene. BCODP has been extremely busy
lobbying and briefing the Members of Parliament with a tremendous amount
of success. The Bill has progressed very well up until now and only has
its final stage to go through. We hope that this Bill will be passed 
before
the end of July which is the end of the parliamentary year. As Frances 
has
been one of our two main persons doing this work she will now outline 
some
of the main tactics and outcomes of this time. 
<H4>The Lobby for Direct Payments</H4>
The Government Bill for direct payments is very short, what they call 
&quot;enabling
legislation&quot;. All the details are to be put into regulations, which
are published after the Bill becomes an Act. The Government has published

a consultation document setting out the sort of regulation they have in
mind.<BR>
<BR>
The most important things to be decided from our point of view were: 
<UL>
  <LI>eligibility 
  <LI>amount 
  <LI>availability 
</UL>
The Government planned to restrict eligibility to people with a physical
disability under the age of 65. This was clearly discriminatory and we 
had
to oppose it.<BR>
<BR>
The Government does not propose to set cash limits for how much can be 
paid.
They propose that authorities must give people enough to meet their legal

obligations, such as paying National Insurance. However, this is not a 
very
big concession. Workers in the UK have very few employment rights until
they have been with an employer for two years.<BR>
<BR>
The direct payments Bill is a &quot;permissive&quot;, not 
&quot;mandatory&quot;
legislation. That means that it allows authorities to make payments but
it does not compel them to. Each local authority can make its own policy
to this. We wanted the Government to set national rules.<BR>
<BR>
Other items we were concerned about were:<BR>
support services, on which the Government are not making any directives
and,<BR>
who may be employed as a personal assistant - the Government want to 
prevent
people from employing close relatives. 
<H4>The Progress of the Campaign</H4>
Our campaign has been on two levels. We have worked with Parliament, 
allying
ourselves with paid lobby workers from other organisations. And we have
worked through our networks, getting our members to approach their 
Members
of Parliament. Working with paid lobbyists has been a new venture for us.

In the UK there are a large number of charitable bodies concerned with 
disability..
Although they do nothing to promote Independent Living, they all wanted
to comment on the Bill and to influence the Government. So we had to 
educate
them about Independent Living at the same time as trying to influence 
Members
of Parliament and Members of the House of Lords.<BR>
<BR>
Our biggest victory so far has been to convince the Government that 
people
with learning difficulties (intellectual impairments) should be included
in the scope of the Bill. The organisation controlled by people with 
learning
difficulties, People First, did some very effective lobbying on this 
subject.
And then, during the &quot;Committee Stage&quot; of the Bill (where a 
small
number of MPs go through it in detail) the Government were defeated on 
key
vote over eligibility, meaning that all disabled adults, whatever age or
impairment, would be covered by the Bill.<BR>
<BR>
We have not managed to shift the Government on the same areas. They will
not make the Bill mandatory. So local authorities can choose whether or
not to have Direct Payments.<BR>
<BR>
On other areas, such as employment of relatives, we are still in 
discussion.<BR>
<BR>
Throughout the campaign we have tried to keep our supporters fully 
informed
so that they can contact MPs and Lords to press our case for change. We
have had to write lengthy briefings to assist Opposition MPs. Our 
research
was helpful here, as it gave us good background material, but having 
regular
contact with Personal Assistance Users was vital too, to get new quotes
and up-to-date facts.<BR>
<BR>
Throughout the campaign we have had to respond not just to Government but

to social work and charity professionals who were worried about direct 
payments.
Some of them support the Government approach of making Direct Payments 
available
to a small elite group. We had to argue the case for full eligibility 
over
and over. We have had to explain the principles of Independent Living 
over
and over. We have been helped by having very clear principles and a 
united
Disabled Persons Movement. 
<H4>The Future</H4>
We are now waiting to find out what further changes the Government 
proposes
to make to the Bill before its final stage in the House of Commons. We 
expect
the Bill to come into effect next April. That will be the end of stage 
one
of our campaign, to make direct payments legal. Stage two will be to make

sure that all local authorities use their power, and bring in Direct 
Payments
in their area.<BR>
<BR>
John Evans and Frances Hasler. June 1996 <BR>
<P><CENTER><HR><FONT SIZE="-1">[<A HREF="ENILhomepage.html">ENIL 
homepage]</A></FONT>
<FONT SIZE="-1">[<A HREF="ENILContents.html">ENIL Website Contents</A><A 
HREF="ENILhomepage.html">]</A></FONT><FONT SIZE="-1">[<A 
HREF="../index.html">Institute
on Independent Living Homepage</A> <A 
HREF="ENILhomepage.html">]</A></FONT></CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT23-B18-225</DOCNO>
<DOCOLDNO>IA012-000125-B023-247</DOCOLDNO>
<DOCHDR>
http://www.independentliving.org:80/ProposlPASouthAfrica.html 193.13.228.238 19970216215110 text/html 39713
HTTP/1.0 200 OK
Last-Modified: Sun, 06 Oct 1996 19:26:31 +0000
Date: Sun, 16 Feb 1997 21:51:12 +0000
Expires: Sun, 16 Feb 1997 21:49:32 +0000
Content-type: text/html
Server: RoxenEnterprise/1.0
Content-length: 39487
</DOCHDR>
<HTML>
<HEAD>
    <TITLE>Institute_on_Independent_Living</TITLE>
</HEAD>
<BODY BGCOLOR="#ffffff" TEXT="#020436" LINK="#000042">
<META NAME="description" 
CONTENT="Individuals and organizations of persons with disabilities can 
publish, free of charge,  articles, reports, training manuals, 
announcements, etc. on Independent Living, personal assistance, advocacy, 

peer support, accessibility, legislation and related subjects. "><META 
NAME="keywords" CONTENT="Independent Living, personal assistance, 
advocacy, peer support, direct payments, anti-discrimination legislation, 

accessibility, disability, disability rights"><BR>
<IMG SRC="InstLogoSmall.gif" WIDTH="198" HEIGHT="57" ALIGN="BOTTOM" 
NATURALSIZEFLAG=
"3">
<P><CENTER>People for Awareness on Disability Issues (PADI)<BR>
</CENTER>
<H3><CENTER>Personal Assistance for Independent Living Programme 
(1995-1997)</CENTER>
</H3>
<P><CENTER><BR>
Funding Proposal<BR>
</CENTER>
<P>Country: South Africa<BR>
Sector: Disability and Independent Living<BR>
Project Title: Personal Assistance for Independent Living (PAIL)<BR>
Implementing Agency: People Awareness on Disability Issues (PADI)<BR>
<BR>
<BR>
Contact Person and Address: Fadilla Lagadien, Director, PADI<BR>
74-8TH Avenue<BR>
Rondebosch East<BR>
7700 Cape Town, South Africa<BR>
Telephone: (27-21) 6973944 or 6960366<BR>
Fax: (27-21) 696 9171<BR>
<BR>
Proposed Duration of Programme: Three Years<BR>
Proposed Starting Date: As soon as funding is secured.<BR>
Proposed Level of Funding: Total Amount (Rand)<BR>
Year One 368 220<BR>
Year Two 405 040<BR>
Year Three 441 870<BR>
Total Applied For 1 215 130<BR>
<BR>
Summary of Project Proposal:<BR>
<BR>
The PAIL Project will increase by at least 20% over 1995 population 
(within
a period of ten years) the number of rural and urban severely disabled 
persons
living an independent life.<BR>
<BR>
The immediate objective of the PAIL Programme is that by the end of the
project period a minimum of five hundred severely disabled people per 
year
per operational region will have achieved greater independence than in 
1995,
through the phased implementation of comprehensive independent programmes

in South Africa.<BR>
<BR>
Some of the anticipated outputs are:
<UL>
  <LI>A single independent living unit will have been established in the
Cape Province by the end of 1995, subject to the assumptions stated 
below.
The achievement of this output will be verified by a study of minutes of
meetings of the unit and staff reports to establish whether or not the 
proposed
unit is established and operational.
  <LI>At least twelve peer support sessions per year per region will have

been implemented to benefit severely disabled people for the duration of
the project. An assessment of the number of peer support sessions (and 
the
beneficiaries of these sessions) successfully implemented each year will
be made by analysing annual narrative and peer support session reports.
</UL>
<BR>
<BR>
1. Programme Context<BR>
<BR>
1.1 Description of the Sector<BR>
Traditionally, disabled people have been thought of as a very small 
sector
of the population whose needs are best taken care of by either charity or

through the welfare sector.<BR>
<BR>
This perception began to change when - during the International Year of
Disabled Person (1981) - the World Health Organisation estimated that the

average number of disabled people in any country was as high as 10 per 
cent
of the population.<BR>
<BR>
The South African Department of Health and Welfare, usually known for its

conservatism, has put the figure of disabled people in South Africa as 
even
higher than the international average - that is, at more than 12 per 
cent.
Clearly, the myth that disabled people comprise an insignificant portion
of the population could no longer be sustained.<BR>
<BR>
An important movement which has developed within the broader struggle of
disabled people is the independent living movement.<BR>
<BR>
The Independent Living Movement was started by persons with extensive 
disabilities,
because it is this group that is exposed most to the attitudes of 
protectionism,
paternalism and pity that persons with disabilities commonly face.<BR>
<BR>
Persons with extensive disabilities are people who need assistance by 
other
persons for daily basic life supporting activities, which other people 
carry
out by themselves. The definition includes both women and men, persons 
with
mobility impairments, intellectual disabilities, persons who become 
disabled
in childhood or late in life.<BR>
<BR>
'User Rights' is a particularly appropriate theme for the PAIL project as

it reflects a change in emphasis from 'the service' to 'the user'. The 
users,
their needs and their rights form a more appropriate focus, than having
the service provision viewed in isolation from those benefiting from such

service provision.<BR>
<BR>
The main assumption behind user rights is that consumers should, whenever

possible, be able to exercise the same degree of control over their lives

as any other member of the community. In fact, they should be encouraged
to continue the exercising of rights and interests.<BR>
<BR>
The rights include attaining a level of care that is:
<UL>
  <LI>appropriate to the individual's needs;
  <LI>effective;
  <LI>responsive to varying requirements and expectations of personal 
care
users themselves; and
  <LI>respect the consumers' needs for such things as privacy and 
confidentiality.
</UL>
<BR>
The consumer has a right to know what he/she should be getting. Also, the

consumer should be able to participate in decisions that affect him/her,
including whether or not he/she receives a service.<BR>
<BR>
<BR>
1.2 Overall Government Strategy<BR>
As with so many other issues in South Africa, the undemocratic nature of
apartheid did not favour the development of 'marginal concerns', ranging
from the rights of the black majority to the protection of the 
environment.<BR>
<BR>
The current circumstances of political transition and democracy in South
Africa present a unique historical opportunity to impact upon national 
policies
to the benefit of disabled people.<BR>
<BR>
It is well known that thousands of people have died in political violence

in South Africa in recent years. What is less recognised is that, 
according
to reputable international estimates, for each person killed in such 
violence
at least three are permanently and severely blinded, paralysed or 
otherwise
disabled.<BR>
<BR>
Disabled people from disadvantaged and poor sections of the population 
face
inadequate rehabilitation and health services in hospitals, and are often

discharged back to the same conditions of deprivation and discrimination
which lead to their injuries in the first place, and there will be little

or no follow-up or aftercare.<BR>
<BR>
Although the new government of national unity has recognised the need to
support programmes in the disability sector, no practical programmes and
funding support has as yet been received from the government for personal

care users and independent living projects.<BR>
<BR>
<BR>
1.3 Prior or Ongoing Assistance<BR>
The Reconstruction and Development Programme (RDP) of the Government of
National Unity is an integrated socio-economic policy framework which 
seeks
to mobilise all of the country's people and resources toward the final 
eradication
of apartheid and the building of a democratic future. The RDP makes 
frequent
reference to disability, an acknowledgement of the suffering and neglect
of disabled people as a result of South Africa's apartheid past.<BR>
<BR>
Disabled people in South Africa (notably led by Disabled People South 
Africa
(DPSA) have succeeded in creating the potential for disabled people to 
enjoy
more equal opportunity and development through its lobbying of the main
players in the negotiations for a new South Africa.<BR>
<BR>
As a result of this advocacy, the RDP identifies disabled people as one
of four priority population groups together with women, the rural 
population
and the youth. There is a clear need to enable disabled people in the 
country
to develop the capacity to seize this opportunity. This will be achieved
through the planning and implementation of an empowering programme that
will enable disabled people (particularly those with severe disabilities)

to make use of their full potential.<BR>
<BR>
<BR>
1.4 Socio-economic Context<BR>
South Africa is often described as a country with two worlds in one. The
well developed urban infrastructure is a sharp contrast to the poor and
marginalised rural areas and urban townships, where the majority of 
disabled
people reside.<BR>
<BR>
Average per capita income of people living in the non-independent 
homelands
and on South African Development Trust land was approximately R45 a 
month.
In 1990, 42% of South Africans lived off an income below the minimum 
level,
set by Vatcom at R600 per month. By the year 2000, fourteen million 
people
will have to be accommodated in the rural areas, but only 2.5 million of
them will be able to generate an income from agriculture (Source: 
SAIRR)<BR>
<BR>
The foregoing clearly demonstrate an unfavourable scenario which affect
disabled people three times as much as able-bodied people in South 
Africa.
With the state social security programme still based on previous racial
laws, and the inadequacy of monthly disability grants (currently at about

R350 per month), disabled people in South Africa are severely affected 
and
live far below the poverty datum line.<BR>
<BR>
<BR>
1.5 Problem To Be Addressed: The Present Situation<BR>
Disabled people in South Africa, estimated at over 4.8 million, have been

among the worst victims of apartheid policies and practices. Apartheid 
has
been a direct cause of disability in terms of people injured in the 
apartheid
struggle, as well as through the structural poverty imposed on the Black
population of the country. These same circumstances have caused the lives

of disabled people to be characterised by poverty, deprivation, isolation

and gross violation of human rights.<BR>
<BR>
Until the recent change of government, the vast majority of disabled 
people
in South Africa found themselves doubly discriminated against, on the 
grounds
of their disabilities and on their race as a result of apartheid policies

and practices.<BR>
<BR>
There are chronic housing shortages in black townships, purposely created

by the previous government authorities as a means of discouraging 
urbanisation
of blacks. These townships function even worse for disabled people 
because
of the small size of houses and due to the factor of overcrowding.<BR>
<BR>
Levels of education among black disabled people are low as a result of 
the
notoriously inferior Bantu education system, and also due to the fact 
that
many have had their formal education interrupted by medical treatment and

other factors.<BR>
<BR>
When a family lives in poverty, it does not devote its scarce resources
to the education of those least likely to bring the family an income in
the future.<BR>
<BR>
Most disabled people are unemployed as a result of prejudice, inadequate
training, and the inaccessibility of transport and buildings. Disabled 
people
are thus generally excluded from such critical development inducing life
experiences as decision making and normal social interaction. Many just
sit at home alone while their peers go to school, work, fall in love and
marry.<BR>
<BR>
The net effect of all these factors is that the disabled community in 
South
Africa is the most disadvantaged in respect of education, health, 
housing,
employment, and social interaction. The level of self-esteem among 
disabled
people is very low, thus contributing to the non-participation of 
disabled
people in the decision making processes currently taking place in South
Africa.<BR>
<BR>
South Africa has one of the highest levels of social inequality in the 
world.
The majority of people live in abject poverty while a significant 
minority
enjoy high standards of living.<BR>
<BR>
Projections for future economic growth are poor. Proposed economic 
restructuring
is likely to increase marginalisation of large sectors of the population,

leading to further urbanisation and drawing resources away from rural 
areas.
The new government of national unity will be forced to use all available
resources on basic provision of education, health, and welfare. The 
backlog
in these sectors is estimated at R75 Billion.<BR>
<BR>
There has been a declining growth rate with GDP per capita down by 3% in
1990. Acute structural problems persist and serious structural 
unemployment
exist. The Development Bank of South Africa (DBSA) estimates that 41.5%
of the work force has been without formal employment since 1989.<BR>
<BR>
The current recession and limited future prospects emphasise the position

of the poorest of the poor and particularly vulnerable groups such as the

severely disabled people. The failure of the previous government to make
any meaningful provision for social welfare means that the growing 
unemployed
and homeless sector have no relief.<BR>
<BR>
According to the World Bank, in 1988 59% of the South African population
was urbanised and of these, many live in informal settlements estimated
by the South African Institute of Race Relations as ranging from 3.5 to
7 million.<BR>
<BR>
<BR>
1.6 The Reason for External Assistance.<BR>
The current transitional phase going in South Africa presents unique 
opportunities
for disabled people to participate in the decision making process, and to

secure the commitment of the new government of national unity to policies

that benefit disabled people. It is essential that disabled people should

guide the process of establishing policy instruments and mechanisms aimed

at benefiting disabled people in South Africa, particularly the severely
disabled.<BR>
<BR>
The PAIL Programme has both upstream and downstream benefits in terms of
the positive policies around Independent Living that will flow out of the

policy development process, and the participation of disabled people in
self-help oriented socio-economic activities aimed at increasing 
independence,
income and employment opportunities.<BR>
<BR>
The project was planned in a participatory manner and will be implemented

in a participatory manner involving personal care users. The availability

of technical support services is crucial to the achievement of the 
project's
objectives. Hence, it is planned that the programme will benefit from 
international
experience and expertise from consultants and resource persons who will
be identified from time to time.<BR>
<BR>
The project will provide an opportunity for the transfer of knowledge, 
experiences
and resources to South Africa to benefit disabled people.<BR>
<BR>
<BR>
2. Development Objective<BR>
The development objective of the PAIL Project is to increase (within a 
period
of ten years) the number of rural and urban severely disabled persons 
living
an independent life by at least 20% over 1995 population.<BR>
<BR>
The achievement of the development objective will be objectively verified

through an analysis of three-yearly evaluation and review reports to 
determine
annual variations in the number of severely disabled people with access
to personal assistance and other essential services and products as a 
result
of the implementation of the programme.<BR>
<BR>
<BR>
3. Immediate Objective<BR>
By the end of the project period, a minimum of five hundred severely 
disabled
people per year per operational region will have achieved greater 
independence
than in 1995, through the phased implementation of comprehensive 
independent
programmes in South Africa.<BR>
<BR>
The achievement of the immediate objective will be objectively verified
through an analysis of independent living documents and reports to 
determine
whether or not the independent living programmes are fairly comprehensive

and fully operational.<BR>
<BR>
The immediate objective will also be verified by an analysis of success
in the implementation of the initial phase of the programme planned for
the Cape Province<BR>
<BR>
<BR>
4. Outputs<BR>
The programme has both downstream and upstream benefits to rural and 
urban
disabled people. The anticipated outputs of the programme are as 
follows:<BR>
4.1 A single independent living unit will have been established in the 
Cape
Province by end of 1995, subject to the assumptions stated below. The 
achievement
of this output will be verified by a study of minutes of meetings of the
unit and staff reports to establish whether or not the proposed unit is
established and operational.<BR>
<BR>
4.2 A phased establishment of independent living units in nine provinces
of South Africa will have been completed by the end of the fifth year of
the programme. Regional and staff narrative reports will reflect the 
number
of regional independent living units/programmes established and 
operationalised
in the nine regions within the specified time frame.<BR>
<BR>
The implementation of the PAIL Programme will initially be confined to 
the
Western Cape Region with subsequent phases of the programme involving 
other
regions of South Africa. With an area of 1,223,201 sq. km., South Africa
covers a wide geographical area.<BR>
<BR>
4.3 At least twelve peer support sessions per year per region will have
been implemented to benefit severely disabled people for the duration of
the project. An assessment of the number of peer support sessions (and 
the
beneficiaries of these sessions) successfully implemented each year will
be made by analysing annual narrative and peer support session 
reports.<BR>
<BR>
4.4 Two independent living seminars will have been implemented by the end

of each twelve month period for the duration of the project. Seminar and
other reports will be analysed to determine the number of seminars 
implemented.<BR>
<BR>
4.5 Two workshops of a self-help nature for a total of sixty severely 
disabled
people will have been implemented by the end of each year. This will be
objectively ascertained by an analysis of dated workshop reports.<BR>
<BR>
4.6 By the end of the project, a single research exercise on the 
situation
of persons with spinal cord injuries and persons with other severe 
disabilities
will have been concluded. The achievement of this output will be 
objectively
verified through an analysis of research reports to ascertain the success

or otherwise, in the implementation of practical action-oriented research

on the needs of severely disabled personal care users.<BR>
<BR>
4.7 Two training sessions for forty facilitators will have been 
implemented
by the end of the project period. The number of sessions and participants

will be verified through an analysis of session reports.<BR>
<BR>
4.8 By the end of the project a comprehensive planning and resource 
mobilisation
strategy for independent living programmes to benefit severely disabled
people will have been launched. This will be verified through an 
assessment
of programme documents and funding proposals to determine progress in the

launching of the resource mobilisation campaign.<BR>
<BR>
4.9 A review exercise will have been implemented by the end of the third
year of the project. The review report will be studied to determine 
whether
or not the review will have been successfully completed.<BR>
<BR>
<BR>
5. Activities<BR>
A range of activities have been planned in order to achieve the outputs
and immediate objective referred to above thus contributing to the 
achievement
of the project's development objective. The range of activities is as 
follows:<BR>
<BR>
5.1 Personnel and Extension of Services<BR>
<BR>
An independent living unit will be established initially in the Western
Cape Province, and subsequently (subject to availability of funding) in
other regions of South Africa. A two-member staff team will be recruited
and appointed to implement the project. The completion of the appointment

process will be verified through an analysis of letters of appointment 
and
job description.<BR>
<BR>
The program team will be responsible for the day-to-day implementation of

the project, including the organisation of seminars, workshops, training
sessions and self-help initiatives of personal care users.<BR>
<BR>
The project team will initiate and facilitate the further extension of 
the
PAIL project to other regions of South Africa. The necessary planning and

fundraising work will be implemented in each region in phases.<BR>
<BR>
5.2 Regional Planning Sessions<BR>
<BR>
Regional planning sessions with personal care users and independent 
living
activists will be conducted in each region. Ideas for peer support, 
self-help
initiatives and independent living centres will be assessed and put 
through
the planning and fundraising process.<BR>
<BR>
Eight planning sessions will be planned, and this will be verified by an
analysis of session reports and other resultant documents.<BR>
<BR>
5.3 Peer Support Sessions<BR>
<BR>
Peer support sessions will be planned and implemented. Both formal and 
informal
peer support counselling will be provided to severely disabled persons,
personal care users, and independent living activists.<BR>
<BR>
The successful implementation of a peer support schedule will be verified

by analysis of peer support session reports. The sessions will serve the
useful purpose of:<BR>
providing the participants with the actual experience of formal peer 
support;<BR>
teaching basic peer support skills;<BR>
demonstrating the practical benefits of peer support to participants; 
and,<BR>
training some members in peer support group facilitation.<BR>
<BR>
5.4 Independent Living Seminars<BR>
<BR>
Two independent living seminars per year will be implemented to benefit
independent living activists, personal support users, and other severely
disabled people.<BR>
<BR>
The purpose of the seminars will be to discuss and make decisions 
relating
to the establishment of independent living centres within close proximity

to the users. Independent living centres are essential for the following
reasons:<BR>
<BR>
- they provide facilities for peer support sessions,<BR>
- they provide opportunities of discussing rights and sharing of 
self-advocacy
skills,<BR>
- they positively influence the local community in terms of accessibility

issues, inclusion in the decision making process, thus contributing to 
positive
changes in attitudes towards disabled people, and<BR>
- they provide an opportunity to develop leadership skills, and other 
essential
daily living skills (e.g. driving, appliances repairs and maintenance, 
and
sports and recreation).<BR>
<BR>
Follow-up activities will include the establishment of peer support 
groups
within the community, providing input in the disability policy 
development
process, planning and fundraising work for independent living 
centres.<BR>
<BR>
The achievement of these activities will be verified through an analysis
of seminars reports and terms of reference of task groups to determine 
success
or otherwise in the planning and implementation of the proposed seminars
and agreed follow up work.<BR>
<BR>
5.5 Self-help Initiatives Workshop<BR>
<BR>
At least two self-help oriented workshops will be planned and implemented

to benefit personal care users, independent living activists and other 
severely
disabled persons.<BR>
<BR>
The purpose of the workshops will be to determine the unsatisfied needs
of personal care users and independent living activists and to develop 
strategies
of addressing these needs. Self-help initiatives workshops will be 
planned
to address the following issues:<BR>
<BR>
- the need for employment creation and income-generating initiatives;<BR>

- training opportunities to improve business skills;<BR>
- special needs of women with severe disabilities and women who require
personal assistance,<BR>
- special needs of severely disabled children, and models for the 
provision
of personal assistance;<BR>
- the participation of severely disabled people in the reconstruction and

development process and in each sector of the community and economy.<BR>
<BR>
5.6. Practical Research and Follow-up Work - Policy Development 
Proposal<BR>
<BR>
A practical action-oriented research exercise will be undertaken to 
determine
the living conditions and work opportunities for severely disabled 
personal
care users, particularly those with spinal cord injuries or 
disorders.<BR>
<BR>
The research work will also be aimed at informing the development process

aimed at lobbying for the provision of services to personal care users 
and
independent living programmes in South Africa.<BR>
<BR>
The achievement of this activity will be determined by analysing letters
of appointment and terms of reference for the proposed research in order
to determine the completion of the recruitment and appointment of a 
research
consultant. The research report will be analysed with a view to 
determining
its usefulness in the disability policy development process.<BR>
<BR>
A follow-up policy development proposal on personal assistance 
programmes,
independent living initiatives and the service delivery mechanics to 
severely
disabled people, will be designed as a follow-up strategy to the research

exercise. The policy development proposal will be submitted to the 
relevant
national and regional government departments.<BR>
<BR>
The completion of the policy and submission to government will be 
objectively
verified through an analysis of the policy document itself and dated 
correspondence
to and from government.<BR>
<BR>
5.7 Training Sessions for Facilitators<BR>
<BR>
The program team will plan and implement two training sessions to which
severely disabled persons and personal assistance users will be 
invited.<BR>
<BR>
The purpose of training is to:<BR>
<BR>
create a group of committed and experienced peer support group 
facilitators;<BR>
increase peer support skills in the area of personal assistance;<BR>
increase the motivation and personal satisfaction of the peer group 
facilitators;
and<BR>
provide PADI with a pool of experienced peer group facilitators.<BR>
<BR>
The training will cover such areas as:
<UL>
  <LI>independent living philosophy;
  <LI>the concept of personal assistance;
  <LI>common issues of personal assistance users;
  <LI>aims of peer support groups;
  <LI>group dynamics;
  <LI>empowerment through mutual support;
  <LI>the function of role modelling;
  <LI>how to encourage all members to participate;
  <LI>how to deal with dominant members; and
  <LI>how to become a good group facilitator and still retain credibility

as a peer.
</UL>
<BR>
The training will be offered free of charge. Its format consists of a 
5-day
workshop with presentations and ample room for discussions. The major 
part
of the workshop will be made up of exercises in group facilitation, role
play and evaluation of each trainee's performance by the group. Up to 15
persons can be trained.<BR>
<BR>
Suitable trainers (to be brought in from partner organisations outside 
South
Africa) will be identified and given the task of providing training.<BR>
<BR>
After the training, the trainees are expected to form a leadership group
that takes on the responsibility for on-going peer support activities 
including
selecting suitable facilitators, scheduling meetings, establishing 
evaluation
procedures, and advertising the meetings. The group will offer peer 
support
sessions, free of charge, to the membership and other persons with 
disabilities.
PADI will assist persons with extensive disabilities with free 
transportation
to the meetings.<BR>
<BR>
The achievement of this activity will be measured by the completion on 
time
of all planning and implementation of training sessions for personal 
assistance
users and severely disabled persons.<BR>
<BR>
5.8 Resource Mobilisation Strategy<BR>
<BR>
PADI has identified a planning and fundraising consultant to undertake 
ongoing
fundraising and project planning work with programme personnel, PADI 
members,
and users of personal assistance. The achievement of this activity will
be measured by the completion of contractual arrangements with the 
consultant
and the effective launching of the resource mobilisation campaign as per
evidence from the contract for professional services and list of 
fundraising
proposals and letters of communication submitted to potential 
partners.<BR>
<BR>
5.9 Review<BR>
<BR>
The program team, PADI leaders, and users of personal assistance will be
facilitated by a consultant to review progress in the implementation of
the PAIL project and other independent living initiatives.<BR>
<BR>
The successful implementation of the review process will be verified by
analysing the review report by the consultant.<BR>
<BR>
<BR>
6. Inputs<BR>
For the successful implementation of the above activities the following
inputs are essential:<BR>
<BR>
6.1 One Project Director and one Assistant Coordinator will be recruited
to work on a full time basis. The appointments will be verifiable by 
analysing
letters of appointment.<BR>
<BR>
6.2. One planning and resource consultant will be contracted to provide
technical and fundraising back up support services.<BR>
<BR>
6.3 External facilitators (some from Sweden) will be identified and 
appointed
on a one-off basis to perform the training sessions for peer support 
counsellors.<BR>
<BR>
6.4 It is anticipated that at least a three-year budget will be approved
in order to provide funding for personnel, consultants, and other 
programme
expenses. This will be verified by studying funding agreements for this
programme.<BR>
<BR>
<BR>
7. Strategy<BR>
The initial phase of the PAIL project will initially be implemented in 
the
Western Cape Province of South Africa. It is anticipated that other 
regional
projects will be initiated as funding resources are secured, hence the 
importance
and relevance of fundraising and planning services.<BR>
<BR>
The range of services that will be provided will include the 
following:<BR>
<BR>
self-help initiatives for personal care users<BR>
practical, action-oriented research and follow-up work to inform the 
policy
development process<BR>
training sessions for facilitators<BR>
planning and resource mobilisation work, and<BR>
review and on-going monitoring.<BR>
<BR>
<BR>
8. Assumptions and Risks<BR>
8.1 The achievement of the development objective will depend on the 
assumption
that the political situation in the country will continue to be stable.
The achievement of both the development and immediate objectives will 
depend
on government continuing to be responsive to policy reform proposals on
disability issues.<BR>
<BR>
8.2 The success of fundraising and resource mobilisation strategies will
depend on the positive response from local and international funding 
partners,
and on whether the international and local fundraising climate will 
continue
to be favourable to initiatives from South Africa.<BR>
<BR>
8.3 The implementation of the activities and procurement of the inputs 
for
this project will depend on the approval of anticipated funding from 
PADI's
partners. It is also assumed that at least three-year funding will be 
provided,
and released on time in sufficient amounts, to enable the implementation
of the program to be initiated.<BR>
<BR>
<BR>
9. Organisation and Administration<BR>
PADI will take the implementation role, and will plan outreach activities

aimed at increasing the number of personal assistance users and 
independent
living activities, initially in the Western Cape and subsequently in 
other
regions.<BR>
<BR>
PADI proposes a close working relation between itself and funding 
partners
for the PAIL Programme based on close cooperation and partnership.<BR>
<BR>
The PAIL implementation team will perform the following key 
administrative
duties:<BR>
<BR>
completion and submission of narrative and financial reports<BR>
ongoing planning and fundraising work<BR>
coordination of seminars, workshops, sessions and resource mobilisation
work<BR>
facilitating communication between PADI and project partners, and<BR>
facilitating and coordinating all follow-up work and outreach 
activities.<BR>
<BR>
<BR>
10. Organisation and Financial Sustainability<BR>
By engaging the services of a fundraising and technical services 
consultant,
PADI has placed itself in a good position to have access to more 
information
and support services in terms of long term planning of its programmes and

resource mobilisation strategies. The consultant, himself a disabled 
person,
has a database of potential sources of support, and strategies for 
sustaining
project activities beyond the funding period. He has many years of 
experience
of working on disability programmes in Southern Africa.<BR>
<BR>
By increasing the resource base for its work, PADI will be able to obtain

the necessary assistance to continue to implement the programme.<BR>
<BR>
<BR>
12. Indicators and Means of Verification<BR>
All indicators and means of verification are mentioned in each section 
above
and listed in the project matrix provided.<BR>
<BR>
<BR>
13. Project Review, Reporting and Evaluation<BR>
A project review exercise will be undertaken after the end of the first
three-year cycle. The review will analyse implementation strategies, 
experiences,
opportunities and constraints. Recommendations for consideration during
the next project cycle will be made.<BR>
<BR>
The review will be jointly planned and implemented by representatives 
and/or
consultants of PADI and the funding partners, if considered 
necessary.<BR>
<BR>
Part of the monitoring process will include the preparation and 
submission
by PADI to its funding partners of at least two narrative and financial
reports per year, and a single final and evaluative report by end of the
third year.<BR>
<BR>
The evaluation of the programme will be participatory in nature and will
be completed by the end of the first five years of the programme. 
Participants
in the evaluation process will include members of PADI, personal care 
users,
representatives of funding partners (if considered necessary) and the 
PADI
Resources Consultant.<BR>
<BR>
The purpose of the evaluation will be to determine the effectiveness of
program strategies, identifying opportunities and constraints. An 
evaluation
report will be prepared and circulated as widely as possible. This stage
of the evaluation will cover the following elements (among others)<BR>
<BR>
a. whether significant progress has been/is being made towards 
accomplishing
set objectives;<BR>
b. comment on the method of implementation and exploring 
alternatives;<BR>
c. opportunities and difficulties encountered during the implementation
process; and<BR>
d. any conclusions and recommendations.<BR>
<BR>
Evaluation results will be widely circulated within the structures of 
PADI
and the international independent living movement. The results will be 
used
to plan the next phase of the programme and to secure additional 
resources
for the programme.<BR>
<BR>
<BR>
14. Budget and Financial Pattern<BR>
14.1 An activity-based financial planning method was used in the 
designing
of the budget. Historical performance and knowledge of current cost 
trends
were used in determining the figures for each budget line in the budget.
Main budget categories include the following (expressed as percentages of

three-year totals of the submitted budget):<BR>
- Workshops and Seminars 15%<BR>
- Research and Resource Mobilisation 15%<BR>
- Peer Counselling 12%<BR>
-Phasing and Outreach Visits 05%<BR>
- Programme Personnel 36%<BR>
- Information Dissemination 10%<BR>
-Administrative Costs 06%<BR>
<BR>
14.2 An extract of the master budget has been prepared. PADI proposes 
that
an initial funding partnership be formulated around the budget extract 
either
as a whole or on a contribution basis. The master budget of the PAIL 
Programme
will be made available on request. However, the annual totals reflected
in the master budget are as follows:<BR>
Rand<BR>
Year 1 - 825 870<BR>
Year 2 - 908, 450<BR>
Year 3 - 991 040<BR>
<BR>
All figures are rounded off to the nearest ten and current exchange rates

at the time of transaction will be used in converting the budget figures
to other currencies. Once approved, the budget will be maintained in 
foreign
currency to offset the effects of inflation and depreciation of the Rand
currency.<BR>
<BR>
<BR>
15. Accounting and Auditing<BR>
15.1 PADI maintains a complete set of computerised accounts. Up-to-date
financial reports will be prepared twice per year and submitted to 
funding
partners. Financial decisions will be made after the approval of two 
authorised
signatories to PADI's account.<BR>
<BR>
15.2 A receipt will be issued for all income received from funding 
partners.
PADI proposes a once-per-year disbursement plan whereby the whole budget
for a given twelve-month period will be disbursed.<BR>
<BR>
15.3 The books of accounts of PADI will be subject to an annual audit by
a firm of independent auditors after 31 March each year. Should audited
reports be required during the course of the financial year, the previous

available audited report will be submitted. A consolidated audited 
account,
reflecting all the financial details and income from all funding 
partners,
will be produced and circulated to funding partners. In order to cut down

on auditing costs, it will not be feasible to produce separate audited 
accounts
for each funding partner unless specific provision is made as an 
additional
element to the submitted budget.<BR>
<BR>
<BR>
16. Project Implementation Plan (PIP)<BR>
The project implementation plan is enclosed.<BR>
<BR>
<BR>
17. Conclusion<BR>
The right to development has now been added to the United Nations 
Universal
Declaration of Human Rights as a fundamental right that had not been 
identified
in the world movement of rights. It defines that every individual, 
including
a person with a mental, physical, or medical disability, has the right to

develop to full individual potential.<BR>
<BR>
The PAIL programme provides an opportunity for severely disabled personal

care users to take their rightful place in society, and away from the 
periphery
to the centre of development activity, and to attain increased levels of
independence. The programme fosters integration, interdependency, and 
equal
participation as opposed to isolation.<BR>
<BR>
Support to initiatives such as the PAIL programme will enable personal 
care
users to actively participate in self-help activities and in the economic

life and development of South Africa.<BR>
<BR>
This programme document and funding proposal is based on the principle of

integrating severely disabled people into the development process through

(among other things) independent living programmes, policy development,
and employment creation. The programme seeks to develop a strong 
institutional
capacity for PADI in order to generate the necessary capacity to 
implement
and sustain the programme.<BR>
<BR>
For more information on this funding proposal, please do not hesitate to
get in touch with Miss Fadilla Lagadien, Telephone 27-21 6960386 or 27-21

6973944, Rondebosch, Cape Town, RSA; or Andrew K. Dube, Tel/Fax: 
27-431-411050).<BR>
<BR>
April 1995
<P><CENTER><HR><FONT SIZE=2>[<A HREF="Contents.html">Institute on 
Independent
Living contents</A>]</FONT></CENTER>
</BODY>
</HTML>
</DOC>
